<SEC-DOCUMENT>0001144204-19-042570.txt : 20190829
<SEC-HEADER>0001144204-19-042570.hdr.sgml : 20190829
<ACCEPTANCE-DATETIME>20190829163816
ACCESSION NUMBER:		0001144204-19-042570
CONFORMED SUBMISSION TYPE:	20FR12B
PUBLIC DOCUMENT COUNT:		51
FILED AS OF DATE:		20190829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Profound Medical Corp.
		CENTRAL INDEX KEY:			0001628808
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20FR12B
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39032
		FILM NUMBER:		191066829

	BUSINESS ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5
		BUSINESS PHONE:		647-476-1350

	MAIL ADDRESS:	
		STREET 1:		2400 SKYMARK AVENUE, UNIT 6
		CITY:			MISSISSAUGA
		STATE:			A6
		ZIP:			L4W 5K5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Profound Medical Inc.
		DATE OF NAME CHANGE:	20141222
</SEC-HEADER>
<DOCUMENT>
<TYPE>20FR12B
<SEQUENCE>1
<FILENAME>tv526458_20f.htm
<DESCRIPTION>20FR12B
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 20-F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the fiscal year ended <U>_______________</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of event requiring this shell company
report <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission file number: <U>&nbsp;___________&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Profound
Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of Registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of Registrant&rsquo;s name
into English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ontario, Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Jurisdiction of incorporation or organization)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2400 Skymark Avenue, Unit 6, Mississauga,
Ontario L4W 5K5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Aaron Davidson, Chief Financial Officer
and Senior Vice-President of Corporate Development; Tel (647) 476-1350; Fax (647) 847-3739</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2400 Skymark Avenue, Unit 6, Mississauga,
Ontario L4W 5K5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name, Telephone, E-mail, and/or Facsimile
number and Address of Company Contact Person)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;Securities registered or to be
registered pursuant to Section&nbsp;12(b) of the Act:</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Title of Each Class</B></P></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 31%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Common Shares</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><B>PROF (reserved)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Nasdaq Capital Market (proposed)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered or to be registered pursuant to Section
12(g) of the Act: <B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities for which there is a reporting obligation pursuant
to Section 15(d) of the Act: <B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate the number of outstanding shares of each of the issuer&rsquo;s
classes of capital or common stock as of the close of the period covered by the annual report: <B>N/A</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether Registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. &nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this report is an annual or transition report, indicate by
check mark if Registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934. &nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the Registrant (1)&nbsp;has filed
all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing
requirements for the past 90 days.&nbsp;&nbsp; Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted&nbsp;pursuant to Rule 405 of Regulation S-T (&sect; 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
 &nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether Registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &ldquo;accelerated filer&rdquo;,
 &ldquo;large accelerated filer&rdquo;, and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 10pt">Large accelerated Filer&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 10pt">Accelerated Filer&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-size: 10pt">Non-accelerated Filer&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; width: 25%; text-align: center"><FONT STYLE="font-size: 10pt">Emerging growth company&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark which basis of accounting the Registrant
has used to prepare the financial statements included in this filing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">U.S.&nbsp;GAAP&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 58%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">International Financial Reporting Standards as issued by the International Accounting Standards Board&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD>
    <TD STYLE="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Other&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Other&rdquo; has been check in response to the previous
question, by check mark which financial statement item Registrant has elected to follow.&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;17&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;18&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this is an annual report, indicate by check mark whether
Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center; vertical-align: bottom"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_001">GENERAL MATTERS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_001">3</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_002">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_002">3</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_003">TRADEMARKS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_003">5</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_004">MARKET AND INDUSTRY DATA</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_004">5</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_005">GLOSSARY OF TERMS</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_005">5</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_006">PART I</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_006">10</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_007">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_007">10</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_008">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_008">11</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_009">ITEM 3. KEY INFORMATION</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_009">11</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_010">ITEM 4. INFORMATION ON THE COMPANY</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_010">46</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_011">&nbsp;ITEM 4A UNRESOLVED STAFF COMMENTS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_011">66</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_012">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_012">66</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_013">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_013">85</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_014">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_014">107</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_015">ITEM 8. FINANCIAL INFORMATION</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_015">109</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_016">ITEM 9. THE OFFER AND LISTING</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_016">109</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_017">ITEM 10. ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_017">110</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_018">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_018">119</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_019">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_019">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_020">PART II</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase; vertical-align: bottom"><A HREF="#a_020">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_021">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_021">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_022">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_022">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_023">ITEM 15. CONTROLS AND PROCEDURES</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in; vertical-align: bottom"><A HREF="#a_023">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_024">ITEM 16A AUDIT COMMITTEE FINANCIAL EXPERT</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_024">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_025">ITEM 16B CODE OF ETHICS</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_025">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_026">ITEM 16C PRINCIPAL ACCOUNTANT FEES AND SERVICES</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_026">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_027">ITEM 16D EXEMPTIONS FROM LISTING STANDARDS FOR AUDIT COMMITTEES</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_027">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_028">ITEM 16E PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_028">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_029">ITEM 16F CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_029">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_030">ITEM 16G CORPORATE GOVERNANCE</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_030">120</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt">&nbsp;</TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt"><A HREF="#a_031">ITEM 16H MINE SAFETY DISCLOSURE</A></TD>
    <TD STYLE="padding-left: 50.85pt; text-indent: -50.85pt; text-align: right; vertical-align: bottom"><A HREF="#a_031">120</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase"><A HREF="#a_032">PART III</A></TD>
    <TD STYLE="text-align: right; text-transform: uppercase"><A HREF="#a_032">121</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_033">ITEM 17. FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in"><A HREF="#a_033">121</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_034">ITEM 18. FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in"><A HREF="#a_034">121</A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in"><A HREF="#a_035">ITEM 19. EXHIBITS</A></TD>
    <TD STYLE="text-align: right; text-indent: 0in"><A HREF="#a_035">121</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_001"></A>GENERAL
MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Registration Statement on Form
20-F (this &ldquo;<B>Registration Statement</B>&rdquo;), all references to &ldquo;<B>Profound</B>&rdquo; are to Profound Medical
Corp., and all references to the &ldquo;<B>Company</B>&rdquo;, &ldquo;<B>our</B>&rdquo;, &ldquo;<B>us</B>&rdquo; or &ldquo;<B>we</B>&rdquo;
refer to Profound Medical Corp. and its consolidated subsidiaries, unless the context clearly requires otherwise. Certain terms
used herein are defined in the text and others are included in the glossary of terms. See &ldquo;<I>Glossary of Terms</I>&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We report under International Financial
Reporting Standards, as issued by the International Accounting Standards Board (&ldquo;<B>IFRS</B>&rdquo;). None of our financial
statements were prepared in accordance with generally accepted accounting principles in the United States (&ldquo;<B>U.S. GAAP</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We use the Canadian dollar as
our reporting currency. All references to &ldquo;<B>C$</B>&rdquo; are to Canadian dollars and references
to &ldquo;<B>US$</B>&rdquo; are to United States dollars. On August 28, 2019 the daily average exchange rate for the
conversion of Canadian dollars into U.S. dollars as reported by the Bank of Canada was C$1.00 = US$0.7518. See also
Item&nbsp;3, &ldquo;Key Information&rdquo; for more detailed currency and conversion information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_002"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement includes certain
statements that are &ldquo;forward-looking statements&rdquo; within the meaning of applicable securities laws. All statements in
this Registration Statement, other than statements of historical facts, are forward-looking statements. These statements appear
in a number of different places in this Registration Statement and can be identified by words such as &ldquo;anticipates&rdquo;,
 &ldquo;estimates&rdquo;, &ldquo;projects&rdquo;, &ldquo;expects&rdquo;, &ldquo;intends&rdquo;, &ldquo;believes&rdquo;, &ldquo;plans&rdquo;,
 &ldquo;will&rdquo;, &ldquo;could&rdquo;, &ldquo;may&rdquo;, or their negatives or other comparable words. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking
statements. Examples of such forward-looking statements include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding commercializing our approved products (particularly the TULSA-PRO system
following FDA clearance) and our ability to generate revenues and achieve profitability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding the safety, efficacy and advantages of our products over our competitors
and alternative treatment options;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding our products fulfilling unmet clinical needs and achieving market acceptance
among patients, physicians and clinicians;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding reimbursement for our approved products from third-party payers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding our relationships with Philips and Siemens, and our ability to achieve
compatibility of our systems with MRI scanners produced by other manufacturers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to attract, develop and maintain relationships with other suppliers, manufacturers,
distributors and strategic partners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding our pipeline of product development, including expanding the clinical
application of our products to cover additional indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding current and future clinical trials, including the timing and results
thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding receipt of additional regulatory approvals for our products and future
product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our mission and future growth plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to attract and retain personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our expectations regarding our competitive position for each of our products in the jurisdictions
where they are approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability to raise debt and equity capital to fund future product development, pursue regulatory
approvals and commercialize our approved products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">anticipated trends and challenges in our business and the markets in which we operate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In evaluating forward-looking statements,
current and prospective shareholders should specifically consider various factors, including the risks outlined herein under the
heading &ldquo;<I>Risk Factors</I>&rdquo; in Item&nbsp;3.D. of this Registration Statement. Some of these risks and assumptions
include, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our limited operating history and history of net losses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our ability to commercialize our approved products, including expanding our sales
and marketing capabilities, increasing our manufacturing and distribution capacity, increasing reimbursement coverage for our approved
products and achieving and maintaining market acceptance for our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the regulation of our products, including in connection with obtaining regulatory
approvals as well as post-marketing regulation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to our successful completion of clinical trials with respect to our products and
future product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to managing growth, including in respect of obtaining additional funding and establishing
and maintaining collaborative partnerships, to achieve our goals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to competition that may impact market acceptance of our products and limit our growth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks relating to fluctuating input prices and currency exchange rates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the reimbursement models in relevant jurisdictions that may not be advantageous;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to reliance on third parties, including our collaborative partners, manufacturers,
distributors and suppliers, and increasing the compatibility of our systems with MRI scanners;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to intellectual property, including license rights that are key to our business;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">risks related to the loss of key personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should one or more of these risks or uncertainties,
or a risk that is not currently known to us, materialize, or should assumptions underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the
date of this Registration Statement and we do not intend, and do not assume any obligation, to update these forward-looking statements,
except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of
future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We caution you that these cautionary remarks
expressly qualify in their entirety all forward-looking statements attributable to us or persons acting on our behalf.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_003"></A>TRADEMARKS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &ldquo;Profound Medical&rdquo; name
and design logo are our registered trademarks. Solely for convenience, the trademarks, service marks, and trade names referred
to in this Registration Statement are without the &reg; and <SUP>TM</SUP> symbols, but such references are not intended to indicate,
in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors
to these trademarks, service marks and trade names. This Registration Statement contains additional trademarks, service marks and
trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing
in this Registration Statement are, to our knowledge, the property of their respective owners. We do not intend our use or display
other companies&rsquo; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of
us by, any other companies.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_004"></A>MARKET
AND INDUSTRY DATA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement includes statistics
and other data relating to markets, market sizes and other industry data pertaining to our business that we have obtained from
industry publications and surveys and other information available to us. Industry publications and surveys generally state that
the information contained therein has been obtained from sources believed to be reliable. Market data and statistics are inherently
predictive and speculative and are not necessarily reflective of actual market conditions. Such statistics are based on market
research, which itself is based on sampling and subjective judgments by both the researchers and the respondents, including judgments
about what types of products and transactions should be included in the relevant market. In addition, the value of comparisons
of statistics for different markets is limited by many factors, including that (i)&nbsp;the markets are defined differently, (ii)&nbsp;the
underlying information was gathered by different methods and (iii)&nbsp;different assumptions were applied in compiling the data.
Accordingly, the market statistics included in this prospectus should be viewed with caution. We believe that information from
these industry publications included in this Registration Statement is reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_005"></A>GLOSSARY
OF TERMS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this Registration Statement,
the following terms have the respective meaning as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: left">2016 Bought Deal</TD>
    <TD STYLE="width: 74%; text-align: justify">has the meaning given under the heading Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought Deals&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">2017 Bought Deal</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought Deals&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">2018 Bought Deal</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought Deals&rdquo;.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: left">3D</TD>
    <TD STYLE="width: 74%; text-align: justify">means three-dimensional.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">ablation</TD>
    <TD STYLE="text-align: justify">means to remove or destroy tissue.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">ACA</TD>
    <TD STYLE="text-align: justify">means the 2010 Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">ADT</TD>
    <TD STYLE="text-align: justify">means androgen deprivation therapy.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Articles</TD>
    <TD STYLE="text-align: justify">means our Articles of Incorporation, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Audit Committee</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 6.C, &ldquo;Directors, Senior Management and Employees&mdash;Board Practices&mdash;Audit Committee&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">BDC Capital</TD>
    <TD STYLE="text-align: justify">means BDC Capital Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Board</TD>
    <TD STYLE="text-align: justify">means the Board of Directors of Profound Medical Corp.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Bought Deals</TD>
    <TD STYLE="text-align: justify">means the 2016 Bought Deal, the 2017 Bought Deal and/or the 2018 Bought Deal, as the context may require.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">BPH</TD>
    <TD STYLE="text-align: justify">means benign prostatic hyperplasia, a condition where the prostate gland is enlarged and not cancerous.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">brachytherapy</TD>
    <TD STYLE="text-align: justify">means the precise placement of short-range radiation-sources (radioisotopes) directly at the site of the cancerous tumor.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Canada MDR</TD>
    <TD STYLE="text-align: justify">means the Medical Devices Regulations issued by Health Canada&rsquo;s Therapeutic Products Directorate.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">CE Mark</TD>
    <TD STYLE="text-align: justify">means &ldquo;Conformit&eacute; Europ&eacute;enne&rdquo; and is affixed to a medical device in
    the European Union by its manufacturer or his authorized representative to declare that the medical device complies with the
    essential requirements of the Medical Device Directive (Council Directive 93/42/EEC, &ldquo;<B>MDD</B>&rdquo;) and that the
    appropriate related conformity assessment procedure as provided in the MDD and its annexes has been conducted.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">CIBC</TD>
    <TD STYLE="text-align: justify">means Canadian Imperial Bank of Commerce.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">CIBC Loan</TD>
    <TD STYLE="text-align: justify">means the initial gross proceeds of C$12,500,000, maturing on July 29, 2022, with an interest rate based on prime plus 2.5%, pursuant to the CIBC Loan Agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">CIBC Loan Agreement</TD>
    <TD STYLE="text-align: justify">means the loan agreement entered into on July 30, 2018 between PMI, as borrower; Profound, Profound Medical (U.S.) Inc and Profound Medical GmbH, as guarantors; and CIBC, as lender.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Common Shares</TD>
    <TD STYLE="text-align: justify">means the common shares in the capital of Profound Medical Corp.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">cryoablation</TD>
    <TD STYLE="text-align: justify">means a therapy that uses extreme cold temperature to destroy benign and malignant tissue by crystallizing it.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><I>de novo </I>classification</TD>
    <TD STYLE="text-align: justify">means the submission of a petition to the FDA to reclassify a novel non-predicated Class III device as a Class I or II device pursuant to Section 513(f)(2) of the United States Federal Food, Drug and Cosmetic A<I>c</I>t.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">EBRT</TD>
    <TD STYLE="text-align: justify">means external beam radiation therapy.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">EPIC</TD>
    <TD STYLE="text-align: justify">means the Expanded Prostate Cancer Index Composite.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Essential Requirements</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.B, &ldquo;Information on the Company&mdash;Business Overview&mdash;Regulation&mdash;European Union&rdquo;.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: left">European Union or EU</TD>
    <TD STYLE="width: 74%; text-align: justify">means an organization created in 1993 with the aim of achieving closer economic and political union between the member states of Europe and currently comprising Austria, Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Executive Employment Agreements</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 6.B., &ldquo;Compensation&mdash;Executive Compensation&mdash;Executive Employment Agreements &ndash; Termination and Change of Control Benefits.&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">False Claims Act</TD>
    <TD STYLE="text-align: justify">means the U.S. False Claims Act, 31 U.S.C. &sect;&sect; 3729-3733.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">FCPA</TD>
    <TD STYLE="text-align: justify">means the U.S. Foreign Corrupt Practices Act of 1977, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">FDA</TD>
    <TD STYLE="text-align: justify">means the United States Food and Drug Administration.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Federal Economic Development Agency Loan</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Federal Economic Development Agency Loan&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">FFDCA</TD>
    <TD STYLE="text-align: justify">means the Federal Food, Drug and Cosmetic Act, 21 U.S.C. &sect; 301 et seq., as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">FSCAs</TD>
    <TD STYLE="text-align: justify">means Field Safety Corrective Actions.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Genesys</TD>
    <TD STYLE="text-align: justify">means Genesys Ventures II LP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Gleason Score</TD>
    <TD STYLE="text-align: justify">means the histological assessment of prostate tissue using a tumor grading system which describes how aggressive a prostate cancer is on a scale from 1 (least aggressive) to 5 (most aggressive). The Gleason score is a combination of the two most common growth patterns observed in a biopsy specimen.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="background-color: white">Gn-RH</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: white">means gonadotrophin-releasing hormone.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">HDR</TD>
    <TD STYLE="text-align: justify">means high dose radiation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Health Technology Exchange Loan</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Health Technology Exchange Loan&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">HIFU</TD>
    <TD STYLE="text-align: justify">means high intensity focus ultrasound.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">HIPAA</TD>
    <TD STYLE="text-align: justify">means Health Insurance Portability and Accountability Act of 1996.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">IDE</TD>
    <TD STYLE="text-align: justify">means an investigational device exemption under the FFDCA and FDA regulations.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">IFRS</TD>
    <TD STYLE="text-align: justify">means the International Financial Reporting Standards as issued by the International Accounting Standards Board.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">IIEF</TD>
    <TD STYLE="text-align: justify">means the International Index of Erectile Function.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">income test</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.E, &ldquo;Additional Information&mdash;Taxation&mdash;Certain U.S. Federal Income Tax Considerations&rdquo;<I>.</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: left">Insider Participation Limits</TD>
    <TD STYLE="width: 74%; text-align: justify">has the meaning given under the heading Item 6.B., &ldquo;Compensation&mdash;Executive Compensation&mdash;Share Option Plan.&rdquo; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">IRB</TD>
    <TD STYLE="text-align: justify">means an institutional review board.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">JOBS Act</TD>
    <TD STYLE="text-align: justify">means the Jumpstart Our Business Startups Act of 2012, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Knight</TD>
    <TD STYLE="text-align: justify">means Knight Therapeutics Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Knight Loan</TD>
    <TD STYLE="text-align: justify">means the secured loan of C$4,000,000 bearing interest at 15% per annum provided by Knight pursuant to the Knight Loan Agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Knight Loan Agreement</TD>
    <TD STYLE="text-align: justify">means the loan agreement entered into on April 30, 2015 between PMI and Knight.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">MDB</TD>
    <TD STYLE="text-align: justify">means Medical Devices Bureau of Health Canada.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Medical Devices Directive</TD>
    <TD STYLE="text-align: justify">means the Council Directive 93/42/EEC concerning medical devices.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Medical Device License</TD>
    <TD STYLE="text-align: justify">means the license for marketing approval of a medical device in Canada.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">MHLW</TD>
    <TD STYLE="text-align: justify">means Japan&rsquo;s Pharmaceutical and Medical Device Agency.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Mira</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.A.1, &ldquo;History and Development of the Company&mdash;Name, Address and Incorporation; Trading Market&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Mira Subco</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.A.1, &ldquo;History and Development of the Company&mdash;Name, Address and Incorporation; Trading Market&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">MR</TD>
    <TD STYLE="text-align: justify">means magnetic resonance.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">MR-HIFU</TD>
    <TD STYLE="text-align: justify">means magnetic resonance guided high intensity focused ultrasound.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">MRI</TD>
    <TD STYLE="text-align: justify">means magnetic resonance imaging.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Nasdaq</TD>
    <TD STYLE="text-align: justify">means the Nasdaq Stock Market LLC (a U.S. national securities exchange).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">New Siemens Agreement</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">New EU MDR</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.B, &ldquo;Business Overview&mdash;Regulatory&mdash;European Union Regulation&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">NMPA </TD>
    <TD STYLE="text-align: justify">National Medical Products Administration of China.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">non-resident holder</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.E, &ldquo;Additional Information&mdash;Taxation&mdash;Canadian Federal Income Taxation&rdquo;<I>.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">OBCA</TD>
    <TD STYLE="text-align: justify">means the <I>Business Corporations Act </I>(Ontario), as amended, together with all regulations promulgated pursuant thereto.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Old PMI</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.A.1, &ldquo;History and Development of the Company&mdash;Name, Address and Incorporation; Trading Market&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Original Siemens Agreement</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.B, &ldquo;Information on the Company&mdash;Business Overview&mdash;Alliances and Partnerships&mdash;Siemens&rdquo;.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 26%">Philips</TD>
    <TD STYLE="text-align: justify; width: 74%">means Koninklijke Philips N.V.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Philips Confidentiality Agreement</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;<I>.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Philips Medical</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;<I>.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Philips Resale Purchasing Agreement</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;<I>.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Philips Share Purchase Agreement</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Philips Supply Agreement</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;<I>.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">PIRADS</TD>
    <TD STYLE="text-align: justify">means Prostate Imaging Reporting and Data System.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">PMA</TD>
    <TD STYLE="text-align: justify">means the Pre-Market Approval application process for marketing approval of medical devices in the United States.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">PMD Act</TD>
    <TD STYLE="text-align: justify">means Japan&rsquo;s Pharmaceutical and Medical Device Act.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">PMDA</TD>
    <TD STYLE="text-align: justify">means Japan&rsquo;s Pharmaceutical and Medical Device Agency.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">PMI</TD>
    <TD STYLE="text-align: justify">means Profound Medical Inc., an OBCA corporation and Profound&rsquo;s 100%-owned direct subsidiary, which serves as the holding subsidiary of our operating subsidiaries.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Profound</TD>
    <TD STYLE="text-align: justify">means Profound Medical Corp., an OBCA corporation and our TSX-traded holding company and registrant for purposes of this Registration Statement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">PSA</TD>
    <TD STYLE="text-align: justify">means prostate specific antigen.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">QMS</TD>
    <TD STYLE="text-align: justify">means quality management system.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">QSR</TD>
    <TD STYLE="text-align: justify">means the FDA&rsquo;s Quality System Regulation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">radical prostatectomy</TD>
    <TD STYLE="text-align: justify">means a surgical procedure that involves the removal of the whole prostate gland.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Registration Statement</TD>
    <TD STYLE="text-align: justify">means this registration statement on Form 20-F.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Sarbanes-Oxley</TD>
    <TD STYLE="text-align: justify">means the Sarbanes-Oxley Act of 2002, as amended.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">SEC</TD>
    <TD STYLE="text-align: justify">means the U.S. Securities and Exchange Commission.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">SEDAR</TD>
    <TD STYLE="text-align: justify">means the Canadian System for Electronic Document Analysis and Retrieval.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Share Consolidation</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 4.A.1, &ldquo;History and Development of the Company&mdash;Name, Address and Incorporation; Trading Market&rdquo;.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Share Option Plan</TD>
    <TD STYLE="text-align: justify">means our amended and restated share option plan dated July 13, 2018.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Siemens</TD>
    <TD STYLE="text-align: justify">means Siemens Healthcare GmbH.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Sonalleve</TD>
    <TD STYLE="text-align: justify">means the technology acquired from Philips in 2017 underlying our Sonalleve system, which combines real-time MRI and thermometry with focused ultrasound delivered from the outside to the patient to enable precise and incision-free ablation of diseased tissue.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; text-align: left">Sonalleve system</TD>
    <TD STYLE="width: 74%; text-align: justify">means our system utilizing Sonalleve technology.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Sonalleve Transaction </TD>
    <TD STYLE="text-align: justify">means the transaction with Philips on July 31, 2017, where we entered into the Philips Share Purchase Agreement with Philips in order to expand the existing collaboration and acquire the Sonalleve technology, which we use in our Sonalleve system.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Sunnybrook</TD>
    <TD STYLE="text-align: justify">means the Sunnybrook Health Sciences Centre.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Sunnybrook License</TD>
    <TD STYLE="text-align: justify">has the meaning given under the heading Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;<I>.</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TACT or TACT Pivotal Clinical Trial</TD>
    <TD STYLE="text-align: justify">means our TULSA-PRO Ablation Clinical Trial, a prospective, open-label, single-arm pivotal clinical study of our TULSA-PRO system.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TPD</TD>
    <TD STYLE="text-align: justify">means Health Canada&rsquo;s Therapeutic Products Directorate.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TSX</TD>
    <TD STYLE="text-align: justify">means the Toronto Stock Exchange.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TSX-V</TD>
    <TD STYLE="text-align: justify">means the TSX Venture Exchange.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TULSA</TD>
    <TD STYLE="text-align: justify">means transurethral ultrasound ablation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TULSA-PRO</TD>
    <TD STYLE="text-align: justify">means our TULSA technology, which is used in our TULSA-PRO systems.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TULSA-PRO system</TD>
    <TD STYLE="text-align: justify">means our leading product, which combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control, and is comprised of two categories of components: disposables and the capital equipment used in conjunction with a customer&rsquo;s MRI scanner.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">TURP</TD>
    <TD STYLE="text-align: justify">means a transurethral resection of the prostate, a surgical procedure that removes portions of the prostate gland via the urethra.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">UA</TD>
    <TD STYLE="text-align: justify">means ultrasound applicator.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">urinary rectal fistula</TD>
    <TD STYLE="text-align: justify">means an abnormal channel between the bladder and rectum resulting in the potential for leakage of urine from the urinary tract into surrounding tissues.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">USPTO</TD>
    <TD STYLE="text-align: justify">means the United States Patent and Trademark Office.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_006"></A>PART
I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_007"></A><FONT STYLE="text-transform: uppercase">ITEM
1. </FONT>IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Directors and
Senior Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the names, business addresses and functions
of our directors and senior management, see Item 6.A, &ldquo;Directors and Senior Management&rdquo; and Item 6.C, &ldquo;Board
Practices&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal legal advisers are Torys
LLP, 79 Wellington St. W., 33rd Floor, TD South Tower, Toronto, Ontario, Canada M5K 1N2.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Auditors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PricewaterhouseCoopers LLP audited our
consolidated financial statements for the fiscal years ended December 31, 2018, 2017 and 2016. The address of PricewaterhouseCoopers
LLP is PwC Centre, 354 Davis Road, Suite 600, Oakville, Ontario, Canada L6J 0C5.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_008"></A><FONT STYLE="text-transform: uppercase">ITEM
2. </FONT>OFFER STATISTICS AND EXPECTED TIMETABLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_009"></A><FONT STYLE="text-transform: uppercase">ITEM
3. </FONT>KEY INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Selected Financial
Data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth selected
consolidated financial information for the periods indicated, prepared in accordance with IFRS. The selected consolidated statements
of operations data and balance sheet data as of and for the years ended December 31, 2018, 2017 and 2016 are derived from our audited
consolidated financial statements set forth elsewhere in this Registration Statement. The selected consolidated statements of operations
data for the three and six months ended June 30, 2019 and 2018 and selected consolidated balance sheet data as of June 30, 2019
are derived from our unaudited consolidated financial statements included elsewhere in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selected consolidated financial information
should be read in conjunction with the financial statements and accompanying notes thereto contained elsewhere in this Registration
Statement and discussions in Item&nbsp;5, &ldquo;Operating and Financial Review and Prospects&rdquo;. The selected consolidated
financial information set out below may not be indicative of our future performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Three
    Months<BR> Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Six
    Months<BR> Ended June 30,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year
    Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD COLSPAN="5" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Unaudited)</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD COLSPAN="5" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Unaudited)</B></FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">Figures in C$ unless otherwise
    stated Consolidated Statements of Operations Data:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 37%"><FONT STYLE="font-size: 8pt">Revenues&#9;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">574,109</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">213,343</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">2,049,897</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">589,678</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">2,602,278</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">4,904,550</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Cost of sales&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">244,066</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">126,259</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">777,422</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">357,334</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,778,501</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">3,032,208</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Gross profit&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">330,043</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">87,084</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,272,475</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">232,344</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">823,777</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,872,342</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">Expenses:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Research and development expenses&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,186,355</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,347,909</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,864,101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,864,690</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,265,388</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,638,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,988,693</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">General and administrative expenses&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,586,323</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,236,529</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,100,436</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,539,733</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,656,723</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,935,215</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,369,288</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Selling and distribution expenses&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,154,869</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,113,225</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">625,524</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">2,060,127</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">4,091,347</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">3,925,804</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,282,433</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Total expenses&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">5,927,547</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">5,697,663</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">9,590,061</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">10,464,550</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">21,013,458</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">19,499,209</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">15,640,414</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Finance costs&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">337,220</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">313,606</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">651,905</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">633,569</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">826,312</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,249,084</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">829,899</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Financial income&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(110,790</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(117,357</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(252,671</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(157,161</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(483,788</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(127,732</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(157,598</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net finance costs&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">226,430</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">196,249</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">399,234</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">476,408</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">342,524</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,121,352</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">672,301</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Loss before income taxes&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,823,934</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,806,828</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,716,820</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,708,614</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,532,205</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,748,219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16,312,715</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Income tax expense&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">20,200</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">24,200</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">54,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">60,600</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">230,784</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">74,123</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">14,054</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Net loss attributable to shareholders for the
    period&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,844,134</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,831,028</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,770,820</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,769,214</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,762,989</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,822,342</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16,326,769</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Other comprehensive income&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(11,843</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">57,943</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(58,232</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">14,695</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">29,226</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(69,245</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">11,316</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Net loss and comprehensive
    loss for the period&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,832,291</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,888,971</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">8,712,588</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">10,783,909</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">20,792,215</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">18,753,097</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">16,338,085</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">Loss per share:</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Basic and diluted weighted average shares
    outstanding&#9;</FONT></TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">108,061,539</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">107,727,319</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">108,058,221</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">92,614,640</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">100,395,649</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">61,404,141</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">41,510,145</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Basic and diluted&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.08</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.12</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.21</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.31</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.39</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of<BR> December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Consolidated Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Cash<SUP>(1)</SUP>&#9;</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">20,493,470</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">30,687,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">11,103,223</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,862,711</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,549,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,879,379</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total liabilities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,443,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,923,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,738,240</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Deficit&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(119,644,062</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,033,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(90,270,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total&nbsp;shareholders&rsquo; equity&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,419,527</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,626,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,141,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Following FDA clearance of our TULSA-PRO system in August 2019, we paid a C$250,000 milestone payment to Sunnybrook under the
Sunnybrook License. See Item 4.B, &ldquo;Business Overview&mdash;Intellectual Property&mdash;Licenses&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Capitalization
and Indebtedness</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our capitalization
as of June 30, 2019. You should read this information together with our historical financial information and other information
provided in this Registration Statement, including Item 5, &ldquo;Operating and Financial Review and Prospects&rdquo; and our unaudited
consolidated financial statements as of and for the three months ended June 30, 2019 and 2018, including the notes thereto, set
forth elsewhere in this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30,<BR> 2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Figures in C$ unless otherwise stated</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Long-Term Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Long-term bank loan (secured) (non-current portion)<SUP>(1)</SUP>&#9;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">8,562,737</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">Total long-term debt&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,562,737</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Share capital&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,942,408</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contributed surplus&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,208,040</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated other comprehensive loss&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86,935</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Deficit&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(119,644,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">Total equity&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,419,527</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Capitalization (long-term debt and equity)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,982,264</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Excludes current portion of C$3,475,358.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Reasons for the
Offer and Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">D. Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>An investment in the Common Shares involves
a high degree of risk and should be considered highly speculative due to the nature and present early stage of our business. The
following risks are the material risks that we face; however, the risks below are not the only ones we face. Additional risks and
uncertainties not presently known to us or that we believe to be immaterial may also adversely affect our business. If any of the
following risks occur, our business, financial condition and results of operations could be seriously harmed and you could lose
all or part of your investment. Before deciding to invest in any Common Shares, investors should carefully consider the risk factors
described below.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors Relating to Our Operating
History and Financial Condition</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have a limited operating history and history
of operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We commenced operations in June 2008 and
have only begun generating revenues in 2017. As of June 30, 2019, we had an accumulated deficit of C$119,644,062 and had cash
and cash equivalents of approximately C$20.5 million. Since inception, we have incurred significant losses each year. For the six
months ended June 30, 2019, we recorded a net loss of C$8,770,820, and for the year ended December 31, 2018, we recorded a net
loss of C$20,762,989. We expect to incur significant operating losses even as we begin to commercialize the TULSA-PRO system in
the United States following our recent FDA clearance, which will require significant expenditures to increase our sales and marketing
capabilities and expand our manufacturing and distribution capacity, as well as other expenses related to increasing reimbursement
coverage and gaining market acceptance among patients, physicians/clinicians and others in the medical community. In addition,
we plan to continue product research and development and clinical trials and may pursue additional regulatory approvals. There
is no assurance that we will ever successfully commercialize our systems, generate significant revenues from our approved products
or achieve profitability. Even if profitability is achieved, we may not be able to sustain or increase profitability. Our failure
to achieve or maintain profitability could negatively impact the value of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business is capital intensive and requires significant
investment to increase our commercial capacity for our approved products, and the resources to do so may not be available in amounts
or on terms acceptable to us, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business requires substantial capital
investment in order to commercialize our approved products, in particular to expand our sales and marketing capabilities and increase
our manufacturing capacity, as well as to conduct research and development and to obtain regulatory approvals for existing products
and future product candidates. We will likely need additional capital to fund our current and planned business activities and to
fund any significant expansion of operations.&nbsp;In order to secure financing, if available, it is likely that we would need
to sell additional Common Shares and/or securities that are exchangeable for or convertible into Common Shares, incur additional
indebtedness and/or enter into development, manufacturing, distribution and/or licensing relationships. Any future equity financing
may be dilutive to existing shareholders. Any future debt financing arrangements we enter into (like our CIBC Loan Agreement as
described below) would likely contain restrictive covenants that would impose significant operating and, if any, financial restrictions
on us. The availability of equity or debt financing will be affected by, among other things, our commercial progress and market
acceptance in respect of the TULSA-PRO system and other approved products, as well as the results of our research and development,
our ability to obtain regulatory approvals, the state of the capital markets generally, strategic alliance agreements, and other
relevant considerations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any additional financing may not be obtained
on favorable terms, if at all. If we cannot obtain adequate funding on reasonable terms, we may not be able advance our business
strategy and/or the commercialization of our approved products, and we may need to terminate or delay clinical trials, curtail
significant regulatory initiatives, and/or sell, license or assign rights to our technologies, products or product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash outflows are expected to consist
primarily of expenditures to increase our commercial capacity, particularly in sales and marketing, as well as in manufacturing
and distribution. In addition, we intend to continue internal and external research and development efforts to develop and expand
our product pipeline, as well as incur general and administrative expenditures to support our corporate infrastructure. If we do
not obtain sufficient additional capital, there may be substantial doubt about our ability to continue as a going concern and realize
assets and pay liabilities as they become due. Depending upon the results of our research and development programs and the availability
of financial resources, we could decide to accelerate, terminate or reduce certain projects, or commence new ones. Any failure
on our part to raise additional funds on terms favorable to us, or at all, may require us to significantly change or curtail current
or planned operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated,
and could result in us not taking advantage of business opportunities, in the termination or delay of clinical trials for one or
more of our product candidates, in curtailment of our product development programs designed to identify new product candidates,
and/or in the sale or assignment of rights to our technologies, products or product candidates. Any of the foregoing could have
a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our CIBC Loan Agreement contains financial and non-financial
covenants that may impact how we operate our business. In addition, failure to comply with any of these covenants could have a
material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our CIBC Loan Agreement contains financial
and non-financial covenants, including a requirement that our unrestricted cash is at all times greater than our operating cash
expenditures during any trailing three month period. Complying with such covenants may at times necessitate that we must forego
other favorable business opportunities. Moreover, our failure to comply with any of these covenants would likely constitute a default
under any other similar facilities and agreements that we may enter into in the future, and could give rise to an acceleration
of some, if not all, of our other then outstanding indebtedness, if any, which would have a material adverse effect on our business.
Our indebtedness may grow as our business grows and/or we make acquisitions. If our income from operations underperforms, we may
have to utilize cash flow or capital resources to fund our debt service payments. If our cash flow and capital resources are insufficient
to service amounts owed under our current or any future indebtedness, we may be forced to reduce or delay capital expenditures,
dispose of assets, license or assign the rights to our technology, issue equity or incur additional debt to obtain necessary funds,
or restructure our debt, any or all of which could have a material adverse effect on our business, financial condition and results
of operations. In addition, we cannot guarantee that we would be able to take any of these actions on terms acceptable to us, or
at all; that these actions would enable us to continue to satisfy our capital requirements; or that these actions would be permitted
under the terms of our debt agreements. In particular, the CIBC Loan Agreement contains covenants with respect to capital expenditures
and other indebtedness, maintaining minimum cash balances at all times and certain financial covenants. We have granted a security
interest over all of our assets (including the shares of our subsidiaries owned by us). Events of default under the CIBC Loan Agreement
include among other things, any covenant breach (subject, in certain instances, to a cure period), insolvency of Profound or its
subsidiaries, the occurrence of certain events which would have a material adverse effect, cross defaults to other agreements,
a failure to comply with certain financial tests, and a change of control of Profound or its subsidiaries. The enforcement by CIBC
of its rights and remedies pursuant to the terms of the CIBC Loan Agreement and associated documentation could result in CIBC,
its agent or any third party purchaser thereof owning all of our assets, including the shares of our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are exposed to foreign currency risk, which exposure
will increase as we commercialize our approved products in the United States; to date, we have not hedged against risk associated
with foreign exchange rate exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we commercialize our approved products,
in particular our TULSA-PRO system in the United States, we expect that a significant portion of our revenues, expenses, current
assets and current liabilities will be denominated in United States dollars, Euros and other foreign currencies. Currently, our
financial statements are expressed in Canadian dollars. A decrease in the value of such foreign currencies relative to the Canadian
dollar could result in decreases in revenues from currency exchange rate fluctuations. To date, we have not hedged against risk
associated with foreign exchange rate exposure. Consequently, our results of operations may be negatively affected by foreign currency
exchange rate fluctuations, which could have a negative impact on the market price of our Common Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Business and
Growth Strategy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not achieve our commercialization and future
product development goals in the time frames expected, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may set goals for and makes public statements
regarding the timing of the accomplishment of objectives material to our success, such as the timing and extent of product launches
in the jurisdictions where they are approved for marketing and sale, in particular our expected commercialization of the TULSA-PRO
system following our recently obtained FDA clearance in the United States; third-party reimbursement for our approved products;
the timing and terms of any collaborations, partnerships, licenses, acquisitions or other agreements; the commencement and completion
of clinical trials, including follow-up data on our TACT Pivotal Clinical Trial; and anticipated regulatory submission and approval
dates for our products in additional jurisdictions, and for future product candidates. The actual timing of these events can vary
dramatically due to factors such as the uncertainties inherent in the arrangements sufficient to commercialize our products, including
in respect of manufacturing, distribution and marketing, as well as market competition and adverse results from our clinical trials,
and other factors and described herein, many of which are beyond our control. There can be no assurance that we will achieve our
commercialization goals in respect of the TULSA-PRO system in the United States, or that future efficacy and safety results from
our TACT Pivotal Clinical Trial will be favorable. If we fail to commercialize the TULSA-PRO system in the United States or any
other approved products in the time frame and to the extent that we anticipate, our business, results of operations and financial
condition may be materially adversely affected, and the price of the Common Shares could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our products, including the TULSA-PRO system, may
not achieve or maintain expected levels of market acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The commercial success of our approved
products, including the TULSA-PRO system which was recently FDA-cleared in the United States, is dependent upon achieving and maintaining
market acceptance. New medical devices that appear promising in development may fail to reach the market or may have only limited
or no commercial success. Levels of market acceptance for our products could be impacted by several factors, many of which are
not within our control, including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">safety, efficacy, convenience and cost-effectiveness of our systems as a method of ablation of
prostate tissue, uterine fibroids, bone metastases compared to products of our competitors or other forms of treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">scope of approved uses and marketing approval or clearance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">timing of market entry of our products versus those of our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">difficulties in, or excessive costs required in the process of, manufacturing our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">expanding compatibility of our systems to work with MRI scanners other than those made by Philips
and Siemens, and maintaining our existing relationships with Philips and Siemens;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">infringement or alleged infringement of the patents or intellectual property rights of others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance of the price of our products relative to those of our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance and adoption of our products by patients, physicians/clinicians and the medical community;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the availability of training necessary for proficient use of our products, as well as willingness
of physicians and technicians to participate in such training;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the perceived risks generally associated with the use of new products and procedures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the placement of our products in treatment guidelines published by leading medical organizations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the size and growth rate of the market for our products in the major geographies in which we operate
or intend to operate, in particular in the United States; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">acceptance of our products by government and third-party payers for adequate reimbursement coverage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the success of any new product
will depend on our ability to either successfully build our in-house sales and marketing capabilities or to maintain or secure
new, or to realize the benefits of existing or future arrangements with, third-party marketing or distribution partners. See &ldquo;&mdash;We
intend to rely primarily on our in-house sales and marketing capabilities for our commercialization strategy, which will require
substantial build-up and commitment of resources&rdquo; and &ldquo;&mdash;We currently rely on our collaborative partners, and
we may rely on additional collaborative partnerships, to assist in the sales and marketing and/or distribution of our approved
products&rdquo; below. If we are unable to commercialize new products successfully, whether through a failure to achieve market
acceptance, a failure to build our own in-house sales and marketing capabilities, a failure to maintain or secure new or existing
marketing partners or to realize the benefits of our arrangements with our marketing and distribution partners, there may be a
material adverse effect on our business, financial condition and results of operations and it could cause the market value of our
Common Shares to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market acceptance of our approved
products also depends on our ability to identify and address the relevant market. For example, our TULSA-PRO system is
FDA-cleared in the United States for transurethral ultrasound ablation (&ldquo;<B>TULSA</B>&rdquo;) of prostate tissue, and
is not specific to any particular condition or disease. For more information, see &ldquo;We may be subject to fines, penalties
or injunctions if we are determined to be promoting the use of our products for unapproved or &ldquo;off-label&rdquo; uses
or engaged in false or misleading promotion.&rdquo; below. Furthermore, our estimates of the number of patients who
have received or might have been candidates to use a specific product may not accurately reflect the true market or market
prices for such products or the extent to which such products will actually be used by patients. Our failure to
successfully introduce and market our approved products could have a material adverse effect on our business, financial
condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Successful commercialization of our approved products,
including the TULSA-PRO system, and future product development depends upon our maintaining strong working relationships with physicians/clinicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to maintain positive working
relationships with physicians/clinicians, our approved products, including our TULSA-PRO system, may not achieve the level of market
acceptance sufficient for successful commercialization of the products. It is important for us to market our approved systems successfully
to physicians/clinicians who we expect will use our approved products, and we depend on our sales and marketing personnel (and
those of our collaborative partners, e.g., Philips and Siemens) to do so in an effective manner. We can provide no assurance that
physicians/clinicians will prescribe or otherwise utilize our TULSA-PRO systems based on our existing clinical data (such as our
TACT data) or the results of any future clinical trials, or at all. See &ldquo;&mdash;Data from our clinical trials may not support
regulatory approvals or clearances and/or reimbursement coverage for our products&rdquo; below. We also rely on our relationships
with physicians/clinicians to further develop our existing products and develop future product candidates in line with the clinical
needs and expectations of the professionals who we expect will use and support the devices. These development efforts are similarly
dependent upon us and our collaborative partners maintaining working relationships with physicians/clinicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we rely on physicians/clinicians
to provide considerable knowledge and experience that assists us in the marketing and sale of our approved products and development
of our products and product candidates. Physicians/clinicians assist us as researchers, marketing and product consultants, inventors
and public speakers. If we are unable to maintain strong relationships with these professionals and continue to receive their advice
and input, the development and marketing of our products could suffer, which could have a material adverse effect on our business,
financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Physicians/clinicians misuse could result in negative
publications, negative sentiment or adverse events, thereby limiting market acceptance and future sales of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a risk that physicians/clinicians
may misuse our products, such as not following the instructions for use, not using our products on the intended patient population,
using our products with unapproved or modified hardware or software, or misuse by inadequately trained staff. Physicians/clinicians
may also initiate their own clinical studies which may be poorly designed or controlled, and may result in adverse safety or efficacy
results. Any of the foregoing could result in negative publications, negative sentiment or adverse events or regulatory actions
in respect of our products, thereby limiting market acceptance and sales of our products, which could have a material adverse effect
on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely on the compatibility of our products with
MRI scanners in the successful commercialization of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have designed our TULSA-PRO system to
be capable of integration with some of the MRI scanners from two of the major MRI manufacturers (Philips and Siemens), and the
Sonalleve system with one MRI manufacturer (Philips). Although we believe that our approved products can be used by the vast majority
of hospitals and treatment facilities, not all such facilities utilize MRI scanners that are compatible with the TULSA-PRO and
Sonalleve systems, and such facilities would be required to acquire (or outsource to other facilities that already have) compatible
MRI equipment, which may increase their costs and which could restrict or delay utilization of our systems by such facilities.
Accordingly, we intend to expand compatibility of the systems with other MRI scanners in the future, which would require design
changes to our systems, collaboration with the manufacturer of the MRI scanner and may require additional regulatory approvals.
We may be unsuccessful in making the necessary design changes and, if required, receiving the necessary regulatory approvals for
such changes, and the terms of any such arrangements that we may enter into in the future with the MRI scanner manufacturers may
not be on as favorable terms. Accordingly, we can provide no assurance that we will be successful in any such expansion of the
compatibility of our products to other MRI scanners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Successful commercialization of our approved products
will also depend on the cost of the system and the availability of coverage and adequate reimbursement coverage from third-party
payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful commercialization of our approved
products, including our TULSA-PRO system, depends largely upon the cost of the system and the availability of coverage and adequate
reimbursement for the system, and the medical procedure associated with its use, from third-party payers, such as government healthcare
programs, private health insurers and other organizations, such as health maintenance organizations and managed care organizations.
We expect that our systems will be purchased by health-care providers, including clinics and hospitals that use MRI scanners that
are compatible with our systems, and that these providers will subsequently bill various third-party payers or will be responsible
for covering the costs of the system through the provider&rsquo;s operating budget. Although we expect there to be an out-of-pocket
market for our approved products, an out-of-pocket market alone is unlikely to be sufficient to support successful commercialization
of our products. To date we have not secured significant coverage or reimbursement for any of our products from government or third-party
payors in the jurisdictions where we have regulatory approvals, including our TULSA-PRO system in the United States. We can provide
no assurance that third-party payers will provide coverage and adequate reimbursement for our TULSA-PRO system to treat our targeted
indications based on our existing clinical data (such as our TACT data) or the results of any future clinical trials, or at all.
See &ldquo;&mdash;Data from our clinical trials may not support regulatory approvals or clearances and/or coverage and reimbursement
for our products&rdquo; below. Accordingly, we likely will need to conduct additional research and successfully complete additional
clinical trials in order to obtain such coverage (e.g., follow-up data from our TACT Pivotal Clinical Trial). Such additional research
and clinical trials may require significant time and resources, and may not be successful, which could result in the postponement
of or inability to obtain coverage and reimbursement for our approved products, which could significantly delay or otherwise negatively
affect our commercialization strategy. Any of the foregoing could, in turn, have a material adverse effect on our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third-party payers carefully review and
increasingly challenge the prices charged for medical devices, procedures and services. Government healthcare programs in the United
States and the European Union may reimburse certain providers at a pre-determined all-inclusive amount for all the costs associated
with a particular procedure performed or course of treatment, based on such factors as the patient&rsquo;s principal diagnosis,
age and severity or complexity. Similarly, the surgeon or physician may be reimbursed at a pre-determined amount based on the procedure
performed, and without taking into consideration the actual costs incurred, including the actual cost of the specific devices used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New products are being increasingly scrutinized
with respect to whether or not they will be covered at all by the various health plans and at what level of reimbursement. In some
instances, economic research studies are and will be required to demonstrate whether our products and approach are superior from
a long-term cost containment standpoint. Third-party payers may determine that our products are not medically necessary, not cost-effective,
experimental, or primarily intended for non-approved indications. Such determinations could have a material adverse effect on our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, healthcare reform measures may
be adopted in the future that may impose more rigorous coverage and reimbursement standards. We are unable to predict what, if
any, additional legislation or regulation impacting the healthcare industry or third-party coverage and reimbursement may be enacted
in the future, or what effect such legislation or regulation would have on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to rely primarily on our in-house sales
and marketing capabilities for our commercialization strategy, which will require substantial build-up and commitment of resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to rely primarily on our in-house
sales and marketing capabilities in order to advance our commercialization strategy, particularly in the United States in respect
of our recently FDA-cleared TULSA-PRO system. This will require a substantial commitment of time and resources in the near-term,
and we may be unsuccessful in executing on this strategy, which could negatively impact our anticipated commercialization. We are
in the early stages of expanding our U.S. sales and marketing capabilities and can provide no assurance that we will be successful
in establishing a marketing presence and sales force sufficient to commercialize the TULSA-PRO system successfully in the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, by relying on an in-house
sales and marketing function, we may have less visibility in the U.S. market (particularly among hospitals) than we would have
if we had significant third-party distribution relationships. Any shortcomings in our in-house sales force may have a material
adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently rely on our collaborative partners,
and we may rely on additional collaborative partnerships, to assist in the sales and marketing and/or distribution of our approved
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently rely on our collaborative
partnerships for the sales and marketing and/or distribution of our approved products, in particular Philips and Siemens, who promote
our systems that are compatible with the MRI scanners produced and sold by them to end users, including hospitals and clinics.
In the future, we intend to enter into similar arrangements with other producers of MRI scanners to increase the compatibility of
our products and to promote and increase market acceptance among hospitals, clinics and other end-users. However, we can provide
no assurance that we will be successful in establishing such additional arrangements, which could negatively impact our commercialization
strategy and may have a material adverse effect on our business, results of operations and financial condition. See &ldquo;&mdash;We
rely on the compatibility of our products with MRI scanners in the successful commercialization of our products&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also seek out, evaluate and negotiate
other third-party marketing and/or distribution arrangements for our products in the jurisdictions where they are approved, which
may involve the commitment of substantial time and effort and may not ultimately result in an arrangement that is favorable to
our commercialization goals (e.g. if such third-party marketing or distribution partners are not as successful in promoting our
products as anticipated). If any of these third party collaborators are unable or unwilling to promote and/or deliver our products
to our customers in an effective manner, then our business, financial condition and operating results could be materially impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, if any of our relationships
with third-party collaborators is terminated, whether by us or the third party for any reason, there can be no assurance that we
will be able to obtain alternative sales and marketing and/or distribution channels rapidly or effectively enough to prevent disruptions
in sales generated in those markets or otherwise to ensure the success of our products in those markets. Any such termination may
have material adverse impact on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may experience manufacturing scaling issues in
connection with our commercialization strategy, as we have limited experience assembling and testing our approved products, including
the TULSA-PRO system, at a significant scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we implement our commercialization strategy,
in particular in respect of the TULSA-PRO system in the United States, we may not be able to produce sufficient quantities of systems
or maintain consistent quality control in the production of our systems. We have limited experience in assembling and testing our
approved products, including our TULSA-PRO system, on a commercial scale. To commercialize our approved products successfully and
become profitable, we must be able to assemble and test such in commercial quantities in compliance with applicable regulatory
requirements, and at an acceptable cost. Increasing our capacity to assemble and test our products on a commercial scale will require
us to improve internal efficiencies, including hiring additional experienced personnel, which may result in significant capital
expenditures. We may encounter a number of difficulties in increasing our assembly and testing capacity, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">managing production yields;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">maintaining quality control and assurance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">providing component and service availability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">maintaining adequate control policies and procedures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">hiring and retaining qualified personnel;&nbsp;and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">complying with U.S. and Canadian regulations (including at the state, provincial and/or federal
levels) and applicable foreign regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In particular, our ability to increase
our assembly and testing capacity successfully will greatly depend on our ability to hire, train and retain an adequate number
of employees, in particular employees with the appropriate level of knowledge, background and skills to assemble and test our products.
We compete with several other medical device companies to hire and retain these skilled employees, and we may be unable to hire
and retain such employees in numbers sufficient to increase our in-house capabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently intend to partner with one
or more additional QSR-compliant and FDA-registered contract manufacturers for our TULSA-PRO systems in the United States. However,
we may not be successful in establishing or maintaining such partnerships on acceptable terms or in the timeframe necessary to
commercialize our products successfully, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may encounter difficulties
in scaling our manufacturing operations, whether in-house or through third-party contract manufacturers, as a result of, among
other things, quality control and quality assurance issues and availability of components and raw material supplies. Any such quality
control issues may negatively affect production and sales of our products, and may require increased repair or re-engineering costs
due to product returns, defects and increased expenses due to switching to alternate suppliers, and reputational damage, any of
which could negatively affect our business and reputation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to satisfy commercial
demand for our products, in particular our TULSA-PRO system in the United States, due to our inability (or the inability of any
of our contract manufacturers) to assemble and test such products in sufficient quantities with consistent quality control, and
in compliance with applicable regulatory requirements (and in a cost-efficient manner), our ability to commercialize such products
successfully, and market acceptance of our products could be adversely affected as our target customers may instead purchase or
use our competitors&rsquo; products. This, in turn, could have a material adverse effect on our business, results of operations
and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely on third parties to manufacture and supply
components of our systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The TULSA-PRO and Sonalleve systems consists
of common electronic components, proprietary capital equipment and proprietary disposables. We purchase standard electronic components
for our systems from a number of third-party vendors. The capital equipment consists of custom system electronics, a treatment
delivery console, fluid circuits and an MRI compatible robotic positioning system. Printed circuit boards and assemblies and custom
mechanical parts are outsourced from approved suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that manufacturing
sources for all components will continue to be available or that we can continue to outsource the manufacturing of our components
on reasonable or acceptable terms. If we encounter delays or difficulties with contract manufacturers, delivery of our products
could be delayed. In addition, we could be forced to secure new or alternative contract manufacturers or suppliers. Securing a
replacement contract manufacturer or supplier could be difficult, and we may not be able to do so in a timely manner or without
significant expense. Any loss of a manufacturer or any difficulties that could arise in the manufacturing process could significantly
affect our ability to supply sufficient amounts of our products to our customers on a timely basis, which may negatively affect
our market share and, correspondingly, could have a material adverse effect on our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, not all of our suppliers provide
us with guaranteed minimum production levels, and we rely on single-source suppliers for some of our components. See &ldquo;&mdash;We
depend on single-source suppliers for some of the components in our systems&rdquo; below. Furthermore, we do not currently have
long-term supply contracts, and accordingly, our suppliers could terminate their services at any time without penalty within agreed
notice periods. As a result, there can be no assurance that we will be able to obtain sufficient quantities of components in the
future necessary to commercialize our approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our reliance on third-party manufacturers
and suppliers involves a number of additional risks, including, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">contract manufacturers or suppliers may fail to comply with regulatory requirements or make errors
in manufacturing that could negatively affect the efficacy or safety of our products or cause delays in shipments of products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our contract manufacturers and suppliers may not be able to respond to unanticipated changes
in customer orders, and if orders do not match forecasts, our suppliers may have excess or inadequate inventory of materials and
components;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our contract manufacturers and suppliers may be subject to price fluctuations of raw materials
and key components due to a lack of long-term supply arrangements for key components;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our contract manufacturers and suppliers may lose access to critical services and components,
resulting in an interruption in the manufacture, assembly and shipment of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we may experience delays in delivery by our contract manufacturers and suppliers due to changes
in demand from us or our other customers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">fluctuations in demand for products that our contract manufacturers and suppliers manufacture for
others may affect their ability or willingness to deliver components in a timely manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suppliers or contract manufacturers may wish to discontinue supplying components or services for
risk management reasons;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we may not be able to find new or alternative components or reconfigure our system and manufacturing
processes in a timely manner if the necessary components become unavailable; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">contract manufacturers and suppliers may encounter financial hardships unrelated to our demand,
which could inhibit their ability to fulfill orders and meet our requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of these risks materialize, it could
significantly increase costs and impact our ability to meet demand for our products, in particular in respect of our planned commercialization
of TULSA-PRO in the United States. If we are unable to satisfy commercial demand for the TULSA-PRO system or other approved products
in a timely manner, our ability to generate revenue could be impaired, market acceptance of our products could be adversely affected,
and customers may instead purchase or use competitors&rsquo; products. As a result, our business, results of operations and financial
condition may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend on single-source suppliers for some of
the components in our systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently rely on a single source for
the manufacture of some of the components of our TULSA-PRO and Sonalleve systems. Although we intend to procure alternative supply
sources for our components as our commercialization efforts increase, we can provide no assurance that we will be successful. Establishing
additional or replacement suppliers for these components will take a substantial amount of time and could result in increased costs
and impair our ability to produce our products. In addition, our products are highly technical and are required to meet exacting
specifications, and any quality control problems that we experience from such alternative supply sources could negatively affect
our reputation and market acceptance of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also have difficulty obtaining similar
components from other suppliers that are acceptable to the FDA or foreign regulatory authorities. The failure of our suppliers
to comply with strictly enforced regulatory requirements could expose us to regulatory action, including warning letters, product
recalls, termination of distribution, product seizures, or civil penalties. See &ldquo;&mdash;Risks Relating to the Regulation
of the Company and Our Products&rdquo; below for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we fail to procure alternative supply
sources on acceptable terms or at all, our planned commercialization of TULSA-PRO in the United States could be negatively affected,
which could have a material adverse effect on our business, operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We face significant competition in the markets for
our products, and in particular, there are numerous devices and procedures that compete with our TULSA-PRO system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products face significant competition
from currently available and future medical devices or surgical methodologies that are used in the same patient populations as
our products. See Item 4.B, &ldquo;Information on the Company&mdash;Business Overview&mdash;Competition&rdquo;. Some of these available
options are well-established, and our competitors have greater financial resources, development, selling and marketing capabilities
than we do. We may face further competition from medical equipment/supply companies that focus their efforts on developing and
marketing products that are similar in nature to our products, but that in some instances offer improvements over our products.
Our competitors may succeed in developing technologies and products that are more effective or less expensive to use than our products.
These developments could render our products uncompetitive, which would have a material adverse effect on our business, financial
condition and operating results. In addition, academic institutions, government agencies and other public and private organizations
conducting research may seek patent protection with respect to potentially competitive products. They may also establish exclusive
collaborative or licensing relationships with our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, our industry is also subject to
changing industry standards, market trends and customer preferences and to competitive pressures which can, among other things,
necessitate revisions in pricing strategies, price reductions and reduced profit margins. Our success will depend, in part, on
our ability to achieve technological superiority in our products and operations and maintain such superiority in the face of new
technologies. No assurance can be given that further modification of our product offerings will not be required in order to meet
demands or to make changes necessitated by developments made by competitors that might render our products less competitive. Our
future success will be influenced by our ability to continue to develop, test and market our products and future product candidates,
including increasing and/or maintaining their compatibility with MRI scanners. Although we have committed resources to these efforts,
there can be no assurance that we will be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data from our clinical trials may not support regulatory
approvals or clearances and/or reimbursement coverage for our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory clearances and approvals for
the commercial sale of any of our product candidates require that we demonstrate through clinical trials that the product candidate
is safe and effective for its intended use or, to receive 510(k) clearance in the United States, that the product candidate is
substantially equivalent to an existing predicate device for its intended use. <FONT STYLE="font-weight: normal">While we have
obtained 510(k) clearance for TULSA-PRO, additional follow-up data from our TACT Pivotal Clinical Trial may not be consistent with
our 12-month data in terms of efficacy and/or side effect profile, which in certain circumstances may result in the FDA taking
regulatory actions that are adverse to us. </FONT>In addition, our TACT Pivotal Clinical Trial involves a relatively small patient
population. Because of the small sample size, the results may not be indicative of future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that third-party payers, in
determining reimbursement coverage for our products, including the TULSA-PRO system, generally would rely upon our clinical trial
results, such as TACT, that were obtained in support of our regulatory approvals; however, we may be required to provide additional
data from our existing trials and/or conduct additional clinical trials prior to obtaining reimbursement coverage for the TULSA-PRO
system and other approved products, which would likely involve significant time and expense, and may have a material adverse effect
on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">In the
future, we may also seek regulatory approvals, which may include 510(k) clearance, for other product candidates, which likewise
could be adversely affected by insufficient clinical trial results. </FONT>Obtaining product clearance or approval and conducting
the requisite clinical trials is a long, expensive and uncertain process and is subject to delays and failures at any stage. There
can be no assurance that clinical trials will be completed successfully within any specified period of time, if at all. In addition,
a regulatory authority may disagree with our interpretation of the data from our clinical trials, or may find the clinical trial
data inadequate to support clearance or approval, and may require us to extend existing clinical trials and/or pursue additional
clinical trials, which would increase costs and could further delay regulatory approval or clearance of our products, or cause
such regulatory approvals or clearances to be denied altogether.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The data from a clinical trial may be inadequate
to support clearance or approval of an application to the regulatory authorities for numerous reasons including, but not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">prevalence and severity of adverse events and other unforeseen safety issues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes in regulatory requirements, policies or guidelines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the interim or final results are insufficient (including in respect of the time period for which
results were obtained), inconclusive or unfavorable as to the safety or efficacy of the device;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">the FDA or other regulatory authorities concluding that a clinical trial design is inadequate to demonstrate
safety and efficacy for a particular use, or to demonstrate substantial equivalence to a predicate device; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the FDA or other regulatory authorities concluding that the trial was not conducted in compliance
with regulatory requirements or lacked controls necessary to ensure the integrity of the trial data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We, the FDA or other regulatory authorities
may suspend or terminate clinical trials at any time if it is determined that patients may be or are being exposed to unacceptable
health risks, including the risk of death, that our devices are not manufactured under acceptable conditions or with acceptable
quality, or that the trial is not being conducted according the protocol and in compliance with Good Clinical Practice and regulatory
requirements. Further, success in preclinical studies and early clinical trials does not mean that future clinical trials will
be successful because medical devices and/or treatment options in later stage clinical trials may fail to demonstrate sufficient
safety and efficacy to the satisfaction of the FDA and other regulatory authorities despite having progressed through initial clinical
trials. We cannot be sure that the later trials will replicate the results of prior trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if our clinical trials are completed
as planned, there can be no certainty that trial results will support our product candidate claims or that the FDA or foreign authorities
will agree with our conclusions regarding them or agree that they are adequate to support approval or clearance. The clinical trial
process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could
cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will
delay the filing of our regulatory submissions and, ultimately, negatively affect our ability to commercialize our systems and
generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our products do not prove to be, or
continue to prove to be, safe and effective, or substantially equivalent to a predicate device, in clinical trials to the satisfaction
of the relevant regulatory authorities or third party payers, if the clinical studies do not support our product candidate claims
or if they result in the discovery of adverse side effects, then our regulatory approvals and reimbursement coverage (as applicable)
may be delayed or denied altogether, and our business, financial condition and results of operation could be materially adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may rely on third parties to perform clinical
trial planning and to facilitate obtaining regulatory approvals or clearances for our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may rely on third parties to provide
clinical trial planning and regulatory services for our product candidates. We may be unable to find suitable partners, external
consultants or service providers to provide such services or such arrangements may not be available on commercially reasonable
terms. Further, we may engage third parties that may cease to be able to provide these services or may not provide these services
in a timely or professional manner. Accordingly, we may not be able to successfully manage such services, execute clinical trials
or obtain regulatory approvals or clearances for our product candidates, which may negatively affect our business. If we fail to
establish such arrangements when, and as necessary, we could be required to undertake these activities at our own expense, which
would significantly increase capital requirements and may delay the development, approval and future commercialization of our product
candidates, which could have a material adverse effect on our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We depend on key managerial personnel for our continued
success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are highly dependent upon our small
team of managerial personnel, particularly that of our Chief Executive Officer, Arun Menawat. We do not maintain any &ldquo;key
man&rdquo; insurance policies on Mr. Menawat or any other members of senior management. Our anticipated growth will require additional
expertise and the addition of new qualified personnel. There is intense competition for qualified personnel in the medical device
field. Therefore, we may not be able to attract and retain the qualified personnel necessary for the development of our business.
We must continue to retain, motivate and recruit executives and other key employees. The failure to motivate, or the loss of the
services of, existing personnel, as well as the failure to recruit additional key managerial personnel in a timely manner, would
harm our business development programs, and our ability to manage day-to-day operations, attract collaboration partners, attract
and retain other employees, generate revenues, and could have a material adverse impact on our business, financial condition and
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development carries substantial risk
and we may not be able to expand our product portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future growth may also depend on, among
other factors, our ability to successfully develop new product candidates and make product improvements to meet evolving market
needs. We may not be able to successfully expand our product portfolio to generate new revenue opportunities in the future. Although
we believe we have the scientific and technical resources available to improve our products and develop new products, future products
will nevertheless be subject to the risks of failure inherent in the development of products based on innovative technologies.
In addition, any such research and development activities may involve significant capital expenditures. There can be no assurance
that we will be able to successfully develop future products and tests, which would prevent us from introducing new products in
the marketplace and negatively impact our ability to grow revenues and become profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the identification of new
product candidates for development may require that we enter into licensing or other collaborative agreements with others, including
medical device and pharmaceutical companies and research institutions. These collaborative agreements may require that we pay license
fees, make milestone payments or pay royalties or grant rights, including marketing rights, to one or more parties, and such amounts
may be material to our results of operations and financial condition. Moreover, these arrangements may contain covenants restricting
our product development or business efforts in the future. Any such arrangements would also increase our reliance on third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to product liability claims, which
can be expensive, difficult to defend and may result in large judgments or settlements, and/or warranty claims on our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The use of medical devices for treatment
of humans, whether in clinical trials or after marketing clearance or approval is obtained, can result in product liability claims.
Product liability claims can be expensive, difficult to defend and may result in large judgments or settlements against us. In
addition, third party collaborators and licensees may not protect us from product liability claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently maintain product liability
insurance in connection with the use of our products in clinical trials and in commercial use; however, we may not have adequate
protection against all potential liabilities under these insurance policies. If we are unable to obtain sufficient levels of insurance
at acceptable cost or otherwise protect against potential product liability claims, we will be exposed to product liability claims.
A successful product liability claim in excess of our insurance coverage could harm our financial condition, results of operations
and prevent or interfere with our commercialization efforts and future product development. In addition, any successful claim may
prevent us from obtaining adequate product liability insurance in the future on commercially desirable terms. Even if a claim is
not successful, defending such a claim may be time-consuming and expensive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also bear the risk of warranty claims
on our products, generally for one year after sale. We may not be successful in claiming recovery of the relevant components from
our suppliers in the event of a successful warranty claim against us by a customer, or that any recovery from such suppliers would
be adequate. In addition, warranty claims brought by our customers related to third-party components may arise after the expiration
of our corresponding warranty with our third-party suppliers, which would require us to bear the burden of any such warranty claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rising insurance costs could negatively impact our
profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cost of insurance, including director
and officer, worker&rsquo;s compensation, property, product liability and general liability insurance, has risen significantly
in recent years and is expected to continue to increase. In particular, our product liability insurance is subject to price increases
if we experience product liability claims. In response, we may increase deductibles and/or decrease certain coverages to mitigate
these costs. These increases, and our increased risk due to increased deductibles and reduced coverages, could have a negative
impact on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are increasingly dependent on sophisticated information
technology systems to operate our business and if we fail to properly maintain the integrity of our data or we experience a cyber-attack
or other breach of these systems, our business could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are increasingly dependent on sophisticated
information technology for our development activities, products and infrastructure. We rely on information technology systems to
process, transmit and store electronic information in our day-to-day operations. The complexity of our information technology systems
makes them vulnerable to increasingly sophisticated cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy,
or other significant disruption. Any such event could be prolonged and/or could go undetected for a significant period of time.
Our products and their information systems require an ongoing commitment of resources to maintain, protect, and enhance existing
systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and
regulatory standards, the increasing need to protect patient and customer information, and changing customer patterns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, third parties may attempt
to hack into our products or systems and may obtain data relating to patients, our products or our proprietary information. If
we fail to maintain or protect our information systems and data integrity effectively, we could lose existing customers, have difficulty
attracting new customers, have problems in determining product cost estimates and establishing appropriate pricing, have difficulty
preventing, detecting, and controlling fraud, have disputes with customers, physicians, and other health care professionals, become
subject to litigation, have regulatory sanctions or penalties imposed, experience increases in operating expenses, incur expenses
or lose revenues as a result of a data privacy breach, or suffer other adverse consequences. Any of the foregoing could have a
material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A portion of our employees are unionized, and our
good labor relations may not continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2019, 14 of our employees
in Vantaa, Finland are unionized. Currently, labor relations are good; however, the maintenance of a productive and efficient labor
environment cannot be assured. If any of our employees at our other manufacturing facilities unionize in the future, or if protracted
and extensive work stoppages occur, labor disruptions such as strikes or lockouts could have a material adverse effect on our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our facilities are damaged or destroyed, we may
experience delays that could negatively impact our revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our facilities may be affected by natural
or man-made disasters. If our facilities were affected by a disaster, we would be forced to rely on third party manufacturers or
to set up production at another manufacturing facility. In such an event, we might not be able to find a suitable alternate manufacturer
or might face significant delays in manufacturing which would prevent us from being able to sell our products. In addition, our
insurance may not be sufficient to cover all of the potential losses and may not continue to be available to us on acceptable terms,
or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We face risks associated with acquisition of businesses
and technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of our growth strategy, we intend
to evaluate and may pursue additional acquisitions of, or significant investments in, complementary companies or technologies to
increase our technological capabilities and expand our product offerings. For example, in July 2017, we acquired from Philips the
technologies and asset underlying our Sonalleve system. Acquisitions and the successful integration of new technologies, products,
assets or businesses may require significant attention from our management and could result in a diversion of resources from our
existing business, which in turn could have an adverse effect on our business operations. Other risks typically encountered with
acquisitions include disruption of our ongoing business; difficulties in integration of the acquired operations and personnel;
inability of our management to maximize our financial and strategic position by the successful implementation or integration of
the acquired technology into our product offerings; being subject to known or unknown contingent liabilities, including taxes,
expenses and litigation costs; and inability to realize expected synergies or other anticipated benefits which may, among other
things, also lead to goodwill impairments or other write-offs. For example, our ability to achieve the anticipated benefits of
the Sonalleve Transaction depends in part on our ability to realize the anticipated growth opportunities and synergies from the
acquired assets and technologies, including our further development of the Sonalleve system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will be successful
in overcoming these risks or any other problems we may encounter in connection with the Sonalleve Transaction or potential future
acquisitions. Our inability to successfully integrate the operations of an acquired business, including a successful implementation
of the technologies and assets we acquire, and realize anticipated benefits associated with an acquisition, could have a material
adverse effect on our business, financial condition, results of operations and cash flows. Acquisitions or other strategic transactions
may also result in dilution to our existing shareholders if we issue additional equity securities as consideration or partial consideration
as well as in the incurrence of indebtedness if we borrow funds to finance such transactions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Relating to Regulation of the
Company and Our Products</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business is subject to limitations imposed by
government regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preclinical testing and clinical trials
of any products developed by us and the manufacturing, labeling, sale, distribution, export or import, marketing, advertising and
promotion of any of those products are subject to rigorous regulation by U.S., Canadian, EU and other foreign regulatory authorities
at the federal, provincial, state and local governmental levels, as applicable. Our medical devices are principally regulated in
the United States by the FDA, in the European Union Notified Bodies (carrying out conformity assessment procedures) and the competent
authorities of the EU member states (supervising Notified Bodies and manufacturers of medical devices), in Canada by Health Canada
(particularly, the TPD), and by other similar regulatory authorities in other jurisdictions. Government regulation substantially
increases the cost and risk of researching, developing, manufacturing and selling products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be unable to obtain, or experience significant
delays in obtaining, FDA clearances or other regulatory approvals for our product candidates and/or enhancements to our approved
or cleared products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our products are subject to rigorous regulation
by the FDA and numerous other federal, state and foreign governmental authorities and notified bodies. The process of obtaining
FDA clearances or approvals, or equivalent third country approvals to market a medical device can be costly and time consuming,
and we may not be able to obtain these clearances or approvals on a timely basis, if at all. We expect to generate a significant
portion of our revenues from sales of our marketed systems, in particular our recently FDA-cleared TULSA-PRO system, but may be
unable to do so if the systems do not continue to prove to be safe and effective for our intended use in clinical trials to the
satisfaction of the relevant regulatory authorities in the United States, the EU, China or other countries. In addition, no assurance
can be given that our other product candidates will prove to be safe and effective in clinical trials or that we will receive regulatory
approvals in the jurisdictions where we seek to market the systems. For example, we are in discussion with the FDA regarding Sonalleve
and have submitted an application requesting designation of a regulatory pathway; however, we can provide no assurance that an
acceptable regulatory pathway will be available or that we will ever apply for or obtain FDA approval for Sonalleve in the future.
In addition, no assurance can be given that current regulations relating to regulatory approval will not change or become more
stringent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any delay in, or failure to receive or
maintain, regulatory clearance, approval or other products under development would adversely affect our ability to commercialize
our approved products, thereby adversely affecting operations and could prevent us from generating revenue from these products
or achieving profitability. Any failure to obtain regulatory approval would materially adversely affect our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If clinical trials are conducted in a manner that
fails to meet all FDA requirements, the FDA may delay our clearances or approvals, or the deficiencies may be so great that the
FDA could refuse to accept all or part of our data or trigger enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are generally required
to support PMA approval and <I>de novo</I> classification and are sometimes required to support 510(k) clearance. Such trials,
if conducted in the United States and involve a significant risk device require an IDE application to be approved in advance by
the FDA for a specified number of patients and study sites. Clinical trials involving a non-significant risk device do not require
FDA approval of an IDE application and are subject to abbreviated requirements under the IDE regulation. Further, some clinical
trials are exempted from the IDE regulation. Although we do not expect to need to obtain an additional IDE application for any
further clinical trials involving TULSA-PRO system, we may need to obtain one for any expansion to the label.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, IDE applications may be required
in support of clinical trials involving other product candidates. Clinical trials are subject to extensive monitoring, recordkeeping
and reporting requirements. Clinical trials must be conducted under the oversight of an IRB for the relevant clinical trial sites
and must comply with FDA regulations, including but not limited to those relating to good clinical practices. To conduct a clinical
trial, we must also obtain the patients&rsquo; informed consent that complies with FDA requirements, state and federal privacy
regulations and human subject protection regulations. We, the FDA or the IRB could suspend a clinical trial at any time for various
reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Additionally, we may decide at
any time, for business or other reasons, to terminate a clinical trial. Even if a clinical trial is completed, the results of clinical
testing may not adequately demonstrate the safety and efficacy of the device for its intended use or may otherwise not be sufficient
to obtain FDA clearance or approval to market the product in the United States. Following completion of a clinical trial, we would
need to collect, analyze and present the data in an appropriate submission to the FDA. Even if a study is completed and submitted
to the FDA, the results of clinical testing may not demonstrate the safety and efficacy of the device for its intended use, or
may be equivocal or otherwise not be sufficient to obtain clearance or approval of our product. In addition, the FDA may perform
a bioresearch monitoring inspection of a study and if it finds deficiencies, we will need to expend resources to correct those
deficiencies, which may delay clearance or approval or the deficiencies may be so great that the FDA could refuse to accept all
or part of the data or could trigger enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if our products are approved by regulatory
authorities, if we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements or if we
experience unanticipated problems with our products, we could be subject to restrictions or withdrawal from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any product for which we obtain regulatory
clearance or approval, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities
for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other regulatory
bodies. In particular, we and our suppliers are required to comply with the QSR and international standards for the manufacture
of products and other regulations which cover the methods and documentation of the design, testing, production, control, quality
assurance, labeling, packaging, storage and shipping of any product for which we obtain regulatory clearance or approval. Regulatory
bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. We and our contract manufacturers
have been, and anticipate in the future being, subject to such inspections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The failure by us or one of our suppliers
to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely
and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things,
any of the following enforcement actions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">customer notifications for repair, replacement or refunds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">recall, withdrawal, detention or seizure of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">operating restrictions or partial suspension or total shutdown of production;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refusing or delaying our requests for 510(k) clearance or premarket approval of new products or
modified products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">operating restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">withdrawing PMA approvals that have already been granted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">suspension, variation, or withdrawal of our CE Certificates of Conformity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refusals to allow imports and/or to issue documentation necessary to facilitate exports;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">refusal to grant export approval for our products; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">imposition of civil, administrative or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of these actions were to occur,
we may be required to expend significant time and resources to address or defend such actions, and our reputation may be harmed
and our product sales and/or profitability may be negatively affected. Furthermore, key component suppliers may not currently be,
or may not continue to be, in compliance with all applicable regulatory requirements, which could result in our failure to produce
our products on a timely basis and in the required quantities, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may be required to conduct
costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical
device reporting requirements, including the reporting of certain adverse events and malfunctions related to our products. Later
discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated
severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes
to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or
mandatory recalls, a requirement to repair, replace or refund the cost of any product we manufacture or distribute, fines, suspension
of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would have a material
adverse effect on our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our products that have received regulatory clearance
or approval are subject to extensive post-market regulation that could affect sales, marketing and profitability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to the products for which
we have obtained regulatory clearance or approval, we are subject to post-marketing regulatory obligations, including requirements
by the FDA, EU competent authorities, Health Canada and similar agencies in other jurisdictions to maintain records regarding product
safety and to report to regulatory authorities serious or unexpected adverse events. The occurrence of unanticipated serious adverse
events or other safety problems could cause the governing agencies to impose significant restrictions on the indicated uses for
which the product may be marketed, impose other restrictions on the distribution or sale of the product or require potentially
costly post-approval studies. In addition, post-market discovery of previously unknown safety problems or increased severity or
significance of a pre-existing safety signal could result in withdrawal of the product from the market and product recalls. Compliance
with extensive post-marketing record keeping and reporting requirements requires a significant commitment of time and funds, which
may limit our ability to successfully commercialize approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to fines, penalties or injunctions
if we are determined to be promoting the use of our products for unapproved or &ldquo;off-label&rdquo; uses or engaged in false
or misleading promotion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory clearances and approvals may
be subject to limitations on the intended uses for which our products may be marketed and reduce our potential to successfully
commercialize our products. While physicians/clinicians, in most jurisdictions, can use our products in ways or circumstances other
than those strictly within the scope of the regulatory clearance or approval, we are required, in many jurisdictions, to limit
our training and promotion of our products to the cleared or approved intended uses. For example, if the FDA determines that our
promotional materials, labeling, training or other marketing constitutes promotion of an uncleared or unapproved, or &ldquo;off-label&rdquo;
use, it could request that we modify or cease use of those training or promotional materials until we obtain FDA clearance or approval
for those uses or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter,
injunction, seizure, civil fine and/or criminal penalties. Discussions that may be viewed as off-label promotion by FDA include
discussions regarding treatment of a specific disease or condition when FDA has cleared or approved a device with a general tool-type
indication that does not mention any particular disease or condition. It is also possible that other federal, state or foreign
enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an
uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws
prohibiting false claims for reimbursement. In that event, our reputation could be damaged and adoption of our products would be
impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to promoting our products in
a manner consistent with our clearances and approvals, we must have adequate substantiation for the claims we make for our products.
If any of our claims are determined to be false, misleading or deceptive, we could be subject to enforcement action. In addition,
unsubstantiated claims also present a risk of consumer class action or consumer protection litigation and competitor challenges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modifications to our approved products may require
new regulatory clearances or approvals or may require us to recall or cease marketing our products until such additional clearances
or approvals are obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain modifications to our products may
require the submission of new 510(k) notifications, PMA supplements, or other regulatory agency approval applications or documents.
If a modification is implemented to address a safety concern, we may also need to initiate a recall or cease distribution of the
affected device. The FDA can review a manufacturer&rsquo;s decision not to submit a new 510(k) notification or PMA for a modification
and may disagree. The FDA may also on its own initiative determine that clearance of a new 510(k) or approval of a new PMA submission
is required. We may make additional modifications to our products in the future that we believe do not or will not require clearance
of a new 510(k) or approval of a new PMA. If we begin manufacture and distribution of the modified devices and the FDA later disagrees
with our determination and requires the submission of a new 510(k) or PMA for the modifications, we may also be required to recall
the distributed modified devices and to stop distribution of the modified devices until we have received approval or clearance
for the modified device, which could have an adverse effect on our business. If the FDA does not clear or approve the modified
devices, we may need to redesign the devices, which could also harm our business. When a device is marketed without a required
clearance or approval, the FDA has the authority to bring an enforcement action, including injunction, seizure and criminal prosecution.
The FDA considers such additional actions generally when there is a serious risk to public health or safety and the company&rsquo;s
corrective and preventive actions are inadequate to address the FDA&rsquo;s concerns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where we determine that modifications to
our products require clearance of a new 510(k) or approval of a new PMA or PMA supplement, we may not be able to obtain those additional
clearances or approvals for the modifications or additional indications in a timely manner, or at all. For those products sold
in the European Economic Area, we must notify an EU Notified Body, if significant changes are made to the products or if there
are substantial changes to our quality assurance systems affecting those products. Delays in obtaining required future clearances
or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm
its future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our contract manufacturers are subject to regulatory
compliance by the FDA, Health Canada and regulatory authorities in the EU and other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our contract manufacturers must comply
with applicable FDA, EU, Health Canada and other applicable foreign regulations, which include quality control and quality assurance
requirements, as well as the corresponding maintenance of records and documentation and manufacture of devices according to the
specifications contained in the applicable regulatory file. If our contract manufacturers do not or cannot comply with these requirements,
our ability to commercialize our approved products may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The introduction of new or alternative
manufacturers or suppliers also may require manufacturing or design changes to our products that are subject to FDA and other regulatory
clearances or approvals. Similarly, in the European Union, the introduction of new or alternative manufacturers or suppliers could
be considered to constitute a substantial change to our quality system or result in design changes to our products which could
affect compliance with the Essential Requirements. These changes must be disclosed to our notified body in the EU before implementation.
The Notified Body will then assess the changes and verify whether they affect the products&rsquo; conformity with the Essential
Requirements. If the assessment is favorable the Notified Body will issue a new CE Certificate of Conformity or an addendum to
the existing certificates attesting compliance with the Essential Requirements. We may also be required to assess the new manufacturer&rsquo;s
compliance with all applicable regulations and guidelines, which could further impede our ability to manufacture our products in
a timely manner. As a result, we could incur increased production costs, experience delays in deliveries of our products, suffer
damage to our reputation, and experience a material adverse effect on our business, financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our products may in the future be subject to product
recalls that could harm our reputation, business and financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and similar foreign governmental
authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects
in design or manufacture. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there
is a reasonable probability that the device would cause serious adverse health consequences or death. In addition, we may initiate
voluntary recalls of our products in the future to the extent we experience safety or other concerns with such products. For voluntary
corrections or removals, the FDA requires that manufacturers report to the FDA within 10 working days after the correction or removal
is initiated if the action was initiated to reduce a risk to health posed by the device or to remedy a violation of the FFDCA caused
by the device which may present a risk to health. Companies are required to maintain certain records of corrections and removals,
even if they are not reportable to the FDA. We may determine that any particular voluntary recall that we initiate does not require
notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions. A future
recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement
action for failing to report the recalls when they were conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, incidents must be
reported to the relevant authorities of the European Union Member States, and manufacturers are required to take FSCAs, to reduce
a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed
on the market. For purposes of these regulations, an &ldquo;incident&rdquo; is defined as any malfunction or deterioration in the
characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly
or indirectly, might lead to or might have led to the death of a patient or user or of other persons or to a serious deterioration
in their state of health. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. In
addition, governmental or other competent bodies or authorities have the authority to require the recall of products in the event
of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if
any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could
occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls
of the TULSA-PRO system, Sonalleve system or any future products would divert managerial and financial resources and could have
an adverse effect on our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our products cause or contribute to a death or
a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, and such events can
result in voluntary corrective actions or agency enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under FDA medical device reporting regulations,
manufacturers are required to report to the FDA information that reasonably suggests that one of their marketed devices may have
caused or contributed to a death or serious injury or has malfunctioned and that the device or a similar device marketed by the
manufacturer would likely cause or contribute to death or serious injury if the malfunction were to recur. If we fail to report
these events to the FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Similar enforcement
action could be taken by the competent authorities in the European Union if we do not comply with our medical devices vigilance
obligations. In addition, our EU notified body could decide to suspend or withdraw our CE Certificates of Conformity. Any such
adverse event involving the TULSA-PRO or Sonalleve systems also could result in future voluntary corrective actions, such as recalls
or customer notifications, or agency action, such as inspection, audit or enforcement action. Any corrective action, whether voluntary
or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of personnel time and capital, distract
management from operating the business and may harm our reputation and could have a material adverse effect on our business, financial
condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Legislative or regulatory reform of the healthcare
systems in which we intend to operate may affect our ability to sell our products profitably and could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The government and regulatory authorities
in the United States, the European Union, Canada and other markets in which we expect to sell our devices may propose and adopt
new legislation and regulatory requirements relating to medical product approval criteria, manufacturing and marketing requirements.
In addition, regulations and guidance promulgated by the FDA, the EU and other regulatory bodies are often revised or reinterpreted
by the agency in ways that may significantly affect our business and products. It is impossible to predict whether legislative
changes will be enacted or regulations, guidance or interpretations changed and what the impact of such changes, if any, may be.
Such legislation or changes in regulatory requirements, or the failure to comply with such, could adversely impact our operations
and could have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, in the United States, as part
of the Food and Drug Administration Safety and Innovation Act of 2012, Congress enacted several reforms entitled the Medical Device
Regulatory Improvements and additional miscellaneous provisions which impacted FDA medical device regulation both pre- and post-approval.
In 2016, Congress enacted the 21st Century Cures Act, which included a number of modifications to the medical device provisions
of the FFDCA, including a new priority review program for &ldquo;breakthrough devices&rdquo;. Further, the FDA Reauthorization
Act of 2017, amended certain pre- and post-market requirements for medical devices. For example, the legislation imposed a new
user fee for <I>de novo</I> classification requests. The FDA has implemented, and continues to implement, these reforms, which
could impose additional regulatory requirements upon us and delay our ability to obtain new 510(k) clearances or PMA approvals
or increase the costs of compliance. Any change in the laws or regulations that govern the clearance and approval processes relating
to our products could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market
and distribute products. Significant delays in receiving clearance or approval, or the failure to receive clearance or approval
for our products would have a material adverse effect on our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 5, 2017, the EU adopted a new
Regulation on medical devices (Regulation (EU) 2017/745 of the European Parliament and of the Council on Medical Devices (&ldquo;<B>MDR</B>&rdquo;))
and a new Regulation on <I>in vitro</I> diagnostic medical devices (Regulation (EU) 2017/746 of the European Parliament and of
the Council on <I>in vitro</I> diagnostic medical devices (&ldquo;<B>IVDR</B>&rdquo;)), which will become fully applicable on May
26, 2020 and May 26, 2022, respectively. The Regulations do not set out a substantially different regulatory system, but contemplate,
among other things, stricter controls of medical devices, including strengthening of the conformity assessment procedures, increased
expectations as regards clinical data for devices and pre-market regulatory review of high-risk devices and an extension of transparency
requirements through the establishment of a comprehensive EU database on medical devices and of a device traceability system allowing
to trace the device from its manufacturer through the supply chain to the final user. The MDR and the IVDR also introduce new classification
rules according to which manufacturers must test their products and adapt their documentation. For example, stricter clinical requirements
now apply to Class III medical devices and implants. After the expiry of the transitional periods as provided by the MDR and the
IVDR, respectively, only devices that have been CE marked under the MDR/IVDR may be placed on the market in the EU. Any notification
of Notified Bodies which are responsible for conformity assessments regarding medical devices (except for low risk medical devices
classified as Class I with no measuring function and which are not sterile) will cease to be valid from May 26, 2020. Only a few
Notified Bodies currently have a notification under the MDR. The new legislation may therefore delay the CE marking of our product
candidates under development or impact our ability to renew the CE marking our currently CE marked products on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The growth of overall healthcare costs
as a percentage of gross domestic product in many countries means that governments and payers are under intense pressure to control
healthcare spending even more tightly. As a result, our businesses and the healthcare industry in general are operating in an ever
more challenging environment with very significant pricing pressures. In recent years, national, federal, provincial, state and
local officials and legislators have proposed, or are reportedly considering proposing, a variety of price-based reforms to the
healthcare systems in the United States, the European Union and other countries. Some proposals include measures that would limit
or eliminate payments for certain medical procedures and treatments or subject pricing to government control. Furthermore, in certain
foreign markets, the pricing or profitability of healthcare products is subject to government controls and other measures that
have been prepared by legislators and government officials. While we cannot predict whether any such legislative or regulatory
proposals or reforms will be adopted, the adoption of any such proposals or reforms could adversely affect the commercial viability
of our existing and potential products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ACA was intended to expand healthcare
coverage within the United States, primarily through the imposition of health insurance mandates on employers and individuals and
expansion of the Medicaid program. The legislation imposes a number of changes to the U.S. healthcare market that are designed
to reduce the number of uninsured individuals through, among other things, expansion of certain federal and state healthcare programs
such as Medicaid, and establishment of health insurance exchanges. In addition, the legislation imposes changes directly affecting
the device industry, specifically taxes on medical device makers in the form of a 2.3% excise tax on all medical device sales in
the United States. The tax has been delayed multiple times, most recently on January 22, 2018, when President Trump signed legislation
delaying implementation through the end of 2019. The tax will go into effect on January 1, 2020, if the delay is not further extended
or the medical tax is not permanently repealed. It is uncertain whether future legislation will suspend, modify or repeal this
tax. The tax could materially and adversely affect our business, cash flows and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ACA also focuses on a number of Medicare
provisions aimed at improving quality and decreasing costs. The Medicare provisions include value-based payment programs, increased
funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and hospital acquired conditions,
and pilot programs to evaluate alternative payment methodologies that promote care coordination (such as bundled physician and
hospital payments). Additionally, the law includes a productivity adjustment, or reduction in the annual rate of inflation for
Medicare payments to a number of providers, including hospitals, that began in 2011. The United States President and certain members
of the U.S. Congress have indicated their desire to repeal and replace all or portions of the ACA and to decrease fiscal burdens.
Recently enacted legislation addresses certain ACA measures and effectively repeals the individual mandate insurance requirement.
In addition, in December 2018, a federal district court judge in Texas found the ACA to be unconstitutional, although the ruling
was stayed while the case is appealed. It is unclear whether, when and how a repeal of, or a court order enjoining, the ACA would
be effectuated and what the effect on the healthcare sector would be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other measures by the current administration
that address ACA provisions include regulatory changes to healthcare insurance exchange parameters. According to the Trump administration&rsquo;s
statements describing the changes, they are intended to increase flexibility, improve affordability, promote stability, and reduce
unnecessary burdens. We cannot predict the full effect of these new measures, what other health care laws, and regulations and
programs will be ultimately implemented at the federal or state level, or the effect of any future legislation, regulation or court
order. However, any changes that deny or restrict coverage or lower reimbursement for our products or reduce medical procedure
volumes could adversely affect our business and results of operations. Changes in the law or regulatory framework that reduce our
revenues or increase our costs would have a material adverse effect on our business, financial condition and results of operations
and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other legislation or regulatory proposals may adversely
affect our revenues and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Existing and proposed changes in the laws
and regulations affecting public companies may cause us to incur increased costs as we evaluate the implications of new rules and
responds to new requirements. Failure to comply with the new rules and regulations could result in enforcement actions or the assessment
of other penalties. The new laws and regulations could make it more difficult to obtain certain types of insurance, including directors&rsquo;
and officers&rsquo; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially
higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract
and retain qualified persons to serve on our board of directors, or as executive officers. We may be required to hire additional
personnel and utilize additional outside legal, accounting and advisory services, all of which could cause our general and administrative
costs to increase beyond what we currently have planned. Although we intend to evaluate and monitor developments with respect to
these rules, we cannot predict or estimate the amount of the additional costs we may incur or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to &ldquo;fraud and abuse&rdquo;
laws, anti-bribery laws, environmental laws and privacy and security regulations. Any violation by our employees or other agents
could expose us to severe penalties and other consequences that may have a material adverse effect on our business, financial condition
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business is subject to the FCPA in
the United States, which generally prohibits companies and company employees from engaging in bribery or other prohibited payments
to foreign officials for the purpose of obtaining or retaining business. The FCPA also requires companies to maintain accurate
books and records and internal controls. In addition, we are subject to other anti-bribery laws of the nations in which we conduct
business that apply similar prohibitions as the FCPA (e.g., The Bribery Act 2010 in the United Kingdom, Articles 299a and 299b
of the German Criminal Code specifically addressing bribery in the healthcare sector, the Corruption of Foreign Public Officials
Act in Canada and the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions of the
Organisation for Economic Co-operation and Development). Our employees or other agents may, without our knowledge and despite our
efforts, engage in prohibited conduct under our policies and procedures and the FCPA or other anti-bribery laws to which we may
be subject. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and
other consequences that may have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations may be directly or indirectly
affected by various broad United States or foreign healthcare fraud and abuse laws. In particular, the United States federal healthcare
program Anti-Kickback Statute prohibits any person from knowingly and willfully offering, paying, soliciting or receiving remuneration,
directly or indirectly, in return for or to induce the referring, ordering, leasing, purchasing or arranging for or recommending
the ordering, purchasing or leasing of an item or service, for which payment may be made under United States federal healthcare
programs, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between device
manufacturers on one hand and prescribers and purchasers on the other. For example, the United States government has sought to
apply the Anti-Kickback Statute to device manufacturers&rsquo; financial relationships with physician consultants. Among other
theories, the United States government has alleged that such relationships are payments to induce the consultants to arrange for
or recommend the ordering, purchasing or leasing of the manufacturers&rsquo; products by the hospitals, medical institutions and
other entities with whom they are affiliated. Although there are a number of statutory exemptions and regulatory safe harbors protecting
certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and
arrangements that involve remuneration that could induce prescribing, purchases, or recommendations may be subject to government
scrutiny if they do not qualify for an exemption or a safe harbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, the False Claims Act prohibits persons
from knowingly submitting, or causing to be submitted, a false claim to, or the knowing use of false statements to obtain payment
from the federal government. Suits filed under the False Claims Act can be brought by the United States government or they can
be brought by an individual on behalf of the United States government, as &ldquo;qui tam&rdquo; actions, and such individuals,
commonly known as &ldquo;whistleblowers,&rdquo; may share in any damages paid by the entity to the United States government in
fines or settlement. When an entity is determined to have violated the False Claims Act, it may be required to pay up to three
times the actual damages sustained by the United States government, plus civil penalties of up to $22,363 for each separate false
claim. Various states have also enacted laws modeled after the False Claims Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is also subject to various privacy
and security regulations, including but not limited to HIPAA in the United States. HIPAA mandates, among other things, the adoption
of uniform standards for the electronic exchange of information in common health care transactions (e.g., health care claims information
and plan eligibility, referral certification and authorization, claims status, plan enrolment, coordination of benefits and related
information), as well as standards relating to the privacy and security of individually identifiable health information, which
govern the use and disclosure of such information and require the adoption of administrative, physical and technical safeguards
to protect such information. In addition, many U.S. states, Canadian provinces and other countries have enacted comparable laws
addressing the privacy and security of health information, some of which are more stringent than HIPAA. Failure to comply with
these laws could result in the imposition of significant civil and criminal penalties. The costs of compliance with these laws
and the potential liability associated with the failure to comply with these laws could have a material adverse effect on our business,
financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compliance with environmental laws and regulations
could be expensive, and failure to comply with these laws and regulations could subject us to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may use hazardous materials in our research
and development and manufacturing processes. We are subject to various regulations governing use, storage, handling and disposal
of these materials and associated waste products. We will need one or more licenses to handle such materials, but there can be
no assurance that it will be able to retain these licenses in the future or obtain licenses under new regulations if and when they
are required by governing authorities. We cannot completely eliminate the risk of contamination or injury resulting from hazardous
materials, and we may incur liability as a result of any such contamination or injury. In the event of an accident, we could be
held liable for damages or penalized with fines, and the liability could exceed our resources and any applicable insurance. We
would also likely incur expenses related to any such incidents. Such future expenses or liability could have a significant negative
impact on its business, financial condition and results of operations. Further, we cannot assure that the cost of compliance with
these laws and regulations will not materially increase in the future. We may also be subject to liability in respect of the operations
of prior owners or operators of any properties we may own, at manufacturing sites where operations have previously resulted in
spills, discharges or other releases of hazardous substances into the environment. We could be held strictly liable under environmental
laws for contamination of property that we occupy without regard to fault or whether our actions were in compliance with law at
the time. Our liability could also increase if other responsible parties, including prior owners or operators of our facilities,
fail to complete their clean-up obligations or satisfy indemnification obligations to us. Similarly, if we fail to ensure compliance
with applicable environmental laws in foreign jurisdictions in which we operate, we may not be able to offer our products and may
be subject to civil or criminal liabilities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors Relating to Intellectual
Property</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we breach any of the agreements under which we
license rights to our technology from third parties, we could lose license rights that are important to our business. Certain of
our license agreements may not provide an adequate remedy for their breach by the licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We license certain development and commercialization
rights for certain technologies used in our systems, and expect to enter into similar licenses in the future. For instance, we
license exclusive intellectual property rights from Sunnybrook that enable us to use, manufacture, distribute and sell the TULSA-PRO
system. Under this royalty-free license, we are subject to various obligations, including the milestone payment of C$250,000 we
paid upon obtaining FDA clearance of our TULSA-PRO system, and legal costs associated with patent application preparation, filing
and maintenance. If we breach or otherwise terminate any of the agreements under which we license rights to our technology from
third parties, we could lose intellectual property rights that are important to our business, and incur other liabilities. Certain
of our license agreements may not provide an adequate remedy for their breach by the licensor. The loss or breach of any of these
license agreements could have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our proprietary rights may not adequately protect
our technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial success will depend on our
ability to obtain patents (or exclusive rights thereto) and to maintain adequate protection for our technologies in the United
States, Europe, Canada and other countries. We own or have exclusive rights to multiple issued United States patents and several
pending United States patent applications in respect of our products. For the TULSA-PRO system, our patent rights include rights
licensed to us from Sunnybrook and other intellectual property that we have developed. We acquired the patent rights for the Sonalleve
system from Philips. We or our licensors will be able to protect such proprietary rights from unauthorized use by third parties
only to the extent that our proprietary technologies and future products are covered by valid and enforceable patents or are effectively
maintained as trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We apply for patents covering our technologies
as we deem appropriate. However, we may fail to apply for patents on important technologies in a timely fashion, or at all. Our
existing patent applications and any future patents we may obtain may not be sufficiently broad to prevent others from utilizing
our technologies or from developing competing products and technologies. In addition, we cannot guarantee that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our licensors were the first to make the inventions covered by each of our licensed or issued
patents and pending patent applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we or our licensors were the first to file patent applications for these inventions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">others will not independently develop similar or alternative technologies or duplicate any of our
or our licensors&rsquo; technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any of our or our licensors&rsquo; pending patent applications will result in issued patents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any of our or our licensors&rsquo; patents will be valid or enforceable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">any patents issued to us or our licensors and collaboration partners will provide us with any competitive
advantages, or will not be challenged by third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we will develop or in-license additional proprietary technologies that are patentable; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the patents of others will not have an adverse effect on our business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The actual protection afforded by a patent
varies on an offering-by-offering basis, from country to country and depends upon many factors, including the type of patent, the
scope of our or our licensors&rsquo; coverage, the availability of regulatory related extensions, the availability of legal remedies
in a particular country and the validity and enforceability of the patents. Our or our licensors&rsquo; ability to maintain and
solidify our or our licensors&rsquo; proprietary position for our products will depend on our or our licensors&rsquo; success in
obtaining effective patent claims and enforcing those claims once granted. Our or our licensors&rsquo; issued patents and those
that may be issued in the future may be challenged, invalidated or circumvented, and the rights granted under any such issued patents
may not provide us with proprietary protection or competitive advantages against competitors with similar products or offerings.
Due to the extensive amount of time required for the development, testing and regulatory review of a medical device, it is possible
that, before our devices can be commercialized, any relevant patent may expire or remain in force for only a short period following
commercialization, thereby reducing any advantage of the patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Protection afforded by patents may be adversely
affected by recent or future changes to patent related statutes and administrative procedures, for example, such as in the laws
of the United States or to USPTO rules. Patent reform legislation could increase the uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents. For example, on September 16, 2011, the Leahy-Smith
Act was signed into law in the United States. The Leahy-Smith Act includes a number of significant changes to United States patent
law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. However,
it is not fully clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. As such, the Leahy-Smith
Act and its implementation, as well as any future changes to patent law in the United States or elsewhere, could increase the uncertainties
and costs surrounding the prosecution of our or our licensors&rsquo; patent applications and the enforcement or defense of our
or our licensors&rsquo; issued patents, all of which could have a material adverse effect on our business, financial condition
and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moreover, we or our licensors may be subject
to a third party preissuance submission of prior art to the USPTO and other patent offices, or become involved in opposition, derivation,
re-examination, <I>inter partes</I> review or interference proceedings, or other preissuance or post-grant proceedings in the United
States or other jurisdictions, challenging our or our licensors&rsquo; patent rights or the patent rights of others. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our or our licensors&rsquo;
patent rights, allow third parties to commercialize our technology or product and compete directly with us, without payment to
us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition,
if the breadth or strength of protection provided by our or our licensors&rsquo; patents and patent applications is threatened,
it could dissuade companies from collaborating with us to license, develop or commercialize current or future products. Changes
to the current patent statutes may adversely affect the protection afforded by our patents and/or open our patents up to third
party attack in non-litigation settings. The costs of patent enforcement or invalidity proceedings could be substantial, result
in adverse determinations, and divert management attention from our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets to protect
some of our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets
are difficult to maintain. While we use reasonable efforts to protect our trade secrets, our or our collaboration partners&rsquo;
employees, consultants, contractors or scientific and other advisors may unintentionally or wilfully disclose our proprietary information
to competitors. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming
and uncertain, and may divert our efforts and attention from other aspects of our business. In addition, non-U.S. courts are sometimes
less willing than courts in the United States to protect trade secrets. If our competitors independently develop equivalent knowledge,
methods and know-how, we would not be able to assert our trade secrets against them and our business could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be able to protect our intellectual property
rights throughout the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing, prosecuting and defending patents
on all of our product candidates, and products and services, when and if we have any, in every jurisdiction would be prohibitively
expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection
to develop competing products. These products may compete with our products, when and if we have any, and may not be covered by
any of our or our licensors&rsquo; patent claims or other intellectual property rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The laws of some countries do not protect
intellectual property rights to the same extent as the laws of the United States and many companies have encountered significant
problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly
certain developing countries, may not favor the enforcement of patents and other intellectual property protection, particularly
those relating to biotechnology and/or pharmaceuticals, which could make it difficult for us to stop the infringement of our patents.
Proceedings to enforce our or our licensors&rsquo; patent rights in foreign jurisdictions could result in substantial cost and
divert our efforts and attention from other aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The patent protection for our technologies may expire
before we are able to maximize our commercial value which may subject us to increased competition and reduce or eliminate our opportunity
to generate product revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patents for our technologies have varying
expiration dates; although the patents for the technologies we used are not expected to expire in the near term, when these patents
expire, we may be subject to increased competition and may not be able to recover our development costs or license fees. In some
of the larger economic territories, such as the United States and the European Union, patent term extension/restoration may be
available to compensate for time taken during aspects of a product candidate&rsquo;s regulatory review. However, we cannot be certain
that any extension will be granted or, if granted, what the applicable time period or the scope of patent protection afforded during
any extended period will be. If we or our licensors are unable to obtain patent term extension/restoration or some other exclusivity,
we could be subject to increased competition and our opportunity to establish or maintain product revenue could be substantially
reduced or eliminated. Furthermore, we may not have sufficient time to recover our development costs prior to the expiration of
our or our licensors&rsquo; patents in the United States or elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may incur substantial costs as a result of litigation
or other proceedings relating to enforcement of our or our licensors&rsquo; patent and other intellectual property rights and we
may be unable to protect our rights to, or use of, our technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we choose to go to court to try to stop
or prevent a third party from using the inventions claimed in our or our licensors&rsquo; patents, that third party has the right
to ask the court to rule that these patents are invalid and/or should not be enforced against that third party. Even if we were
successful in stopping the infringement of these patents, these lawsuits are expensive and would consume time and other resources,
and divert attention from other aspects of our business. In addition, there is a risk that the court will decide that these patents
are invalid or unenforceable and that we do not have the right to prevent the other party from using the inventions. There is also
the risk that, even if the validity of these patents is upheld, the court will refuse to prevent the other party&rsquo;s activities
on the ground that such other party&rsquo;s activities do not infringe our rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B>&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to lawsuits from, liable for damages
to, or be required to enter into license agreements with, a third party that claims we infringed its patents or otherwise misused
its proprietary information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we wish to use the technology in issued
and unexpired patents owned by others, we will need to obtain a license from the owner, enter into litigation to challenge the
validity or enforceability of these patents or incur the risk of litigation in the event that the owner asserts that we infringed
these patents. The failure to obtain a license for technology or the failure to challenge an issued patent owned by others that
we may require to develop or commercialize our product candidates may have a material adverse impact on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if a third party asserts that
we infringed its patents or other proprietary rights, we could face a number of risks that could seriously harm our results of
operations, financial condition and competitive position, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">patent infringement and other intellectual property claims, which would be costly and time consuming
to defend, whether or not the claims have merit, and which could delay the regulatory approval process and divert management&rsquo;s
attention from our business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">substantial damages for past infringement, including possible treble damages in some jurisdictions,
which we may have to pay if a court determines that our product candidates, offerings or technologies infringe a competitor&rsquo;s
patent or other proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a court prohibiting us from selling or licensing our technologies unless the third party licenses
patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">if a license is available from a third party, we may have to pay substantial royalties or lump
sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The coverage of patents is subject to interpretation
by the courts and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate
that our products or methods of use either do not infringe the patent claims of the relevant patent and/or that the patent claims
are invalid, and we may not be able to do this. Proving invalidity, in particular, is difficult since it requires a showing of
clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent laws in the United States as well
as the laws of certain other jurisdictions provide for provisional rights in published patent applications beginning on the date
of publication, including the right to obtain reasonable royalties, if a patent is subsequently issued and certain other conditions
are met. While we believe that there may be multiple grounds on which to challenge the validity of United States patents and the
counterparts filed in other jurisdictions possibly relevant to our business, we cannot predict the outcome of any invalidity challenge.
Alternatively, it is possible that we may determine it is prudent to seek a license from a patent holder to avoid potential litigation
and other potential disputes. We cannot be sure that a license would be available to us on acceptable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because some patent applications in certain
jurisdictions may be maintained in secrecy until the patents are issued, because patent applications in the United States and many
other jurisdictions are typically not published until 18 months after filing and because publications in the scientific literature
often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered
by our or our licensors&rsquo; issued patents or our pending applications or our licensors&rsquo; pending applications, or that
we or our licensors were the first to invent the technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent applications filed by third parties
that cover technology similar to ours may have priority over our or our licensors&rsquo; patent applications and could further
require us to obtain rights to issued patents covering such technologies. If another party files a United States patent application
on an invention similar to ours, we may elect to participate in or be drawn into an interference or other proceeding declared by
the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial and it is
possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such
inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also be subject to damages resulting
from claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of third parties. Many
of our employees were previously employed, and certain of our consultants are currently employed, at universities or medical device
companies, including our competitors or potential competitors. Although we have not received any claim to date, we may be subject
to claims that we, or these employees or consultants, have inadvertently or otherwise used or disclosed trade secrets or other
proprietary information of these current or former employers. Litigation may be necessary to defend against these claims. If we
fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel.
We may be subject to claims that employees of our partners or licensors of technology licensed by us have inadvertently or otherwise
used or disclosed trade secrets or other proprietary information of their former employers. We may become involved in litigation
to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable
intellectual property rights or personnel; and even if we are successful in defending such claims, they can be expensive and would
consume time and other resources, and divert attention from other aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of our competitors may be able to
sustain the costs of complex patent and other intellectual property litigation more effectively than we can because they have substantially
greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a
material adverse effect on our ability to raise the funds necessary to continue our operations. We cannot predict whether third
parties will assert these claims against us or against our licensors, or whether those claims will harm our business. If we or
our licensors are forced to defend against these claims, whether they are with or without any merit, whether they are resolved
in favor of or against us or our licensors, we may face costly litigation and diversion of management&rsquo;s attention and resources.
As a result of these disputes, we may have to develop costly non-infringing technology, or enter into licensing agreements. These
agreements, if necessary, may be unavailable on terms acceptable to us, if at all, which could have a material adverse effect on
our business, financial conditions and results of operations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risk Factors Relating to Our Common
Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future sales or the issuances of our securities
may cause the market price of our Common Shares to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our Common Shares could
decline as a result of issuances of securities (including our Common Shares) by us, exercises of outstanding options or warrants
for additional Common Shares or sales by our existing shareholders of Common Shares in the market, or the perception that these
issuances or sales could occur. Sales of Common Shares by shareholders may make it more difficult for us to sell equity securities
at a time and price that we deem appropriate. As at August 26, 2019, there were a total of 10,373,929 outstanding share options
issued under our Share Option Plan and 22,571,714 outstanding warrants issued pursuant to the Bought Deals and the CIBC Loan Agreement.
In addition, as at August 26, 2019, 3,675,553 options remain available for future grant under the Share Option Plan. Sales or issuances
of substantial numbers of Common Shares, or the perception that such sales or issuances could occur, may adversely affect prevailing
market prices of the Common Shares. With any such sale or issuance of Common Shares, investors may suffer dilution and we may experience
dilution in our earnings per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect that the price of our Common Shares may
fluctuate significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of securities of many
companies, particularly development and early commercial stage medical device companies, experience wide fluctuations in price
that are not necessarily related to the operating performance, underlying asset values or prospects of such companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our Common Shares could
be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">delays in respect of our commercialization of the TULSA-PRO system in the United States;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">adverse results or delays in our future planned data collection for the TACT Pivotal Clinical Trial
and any future clinical trials that we may conduct;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory actions with respect to our products and/or product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes in laws or regulations applicable to our products or any future product candidates, including
but not limited to clinical trial requirements for approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual or anticipated fluctuations in our financial condition and operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual or anticipated changes in our growth rate relative to our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">competition from existing products or new products that may emerge;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements by us, our collaborators or our competitors of significant acquisitions, strategic
partnerships, joint ventures, collaborations or capital commitments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">failure to meet or exceed financial estimates and projections of the investment community or that
we provide to the public;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">issuance of new or updated research or reports by securities analysts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">fluctuations in the valuation of companies perceived by investors to be comparable to us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">additions or departures of key management or scientific personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">disputes or other developments related to proprietary rights, including patents, litigation matters
and our ability to obtain patent protection for its products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcement or expectation of additional debt or equity financing efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales or issuances of our Common Shares by us, our insiders or our other shareholders, including
by exercise of outstanding options or warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">general economic and market conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These and other market and industry factors
may cause the market price and demand for our Common Shares to fluctuate substantially, regardless of our actual operating performance,
which may limit or prevent investors from readily selling their Common Shares and may otherwise negatively affect the liquidity
of our Common Shares. In addition, stock markets in general, and the TSX, the Nasdaq and the share prices of biotechnology companies
in particular, have experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating
performance of these companies. In addition, following our planned listing on Nasdaq, there may be price variations between the
TSX and Nasdaq because of our dual listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If equity research analysts do not publish research
or reports about our business or if they issue unfavorable commentary or downgrade our Common Shares, the price of our Common Shares
could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our Common Shares
will rely in part on the research and reports that equity research analysts publish about us and our business, over which we have
no control. The price of our Common Shares could decline if one or more equity analysts downgrade our Common Shares or if analysts
issue other unfavorable commentary or cease publishing reports about us or our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to securities litigation, which
is expensive and could divert management attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our Common Shares may
be volatile, and in the past companies that have experienced volatility in the market price of their shares have been subject to
securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could
result in substantial costs and diversion of management&rsquo;s attention and resources, which could adversely impact our business.
Any adverse determination in litigation could also subject us to significant liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have never paid dividends on our Common Shares
and we do not anticipate paying any dividends in the foreseeable future. Consequently, any gains from an investment in our Common
Shares will likely depend on whether the price of our Common Shares increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not paid dividends on our Common
Shares to date and we currently intend to retain our future earnings, if any, to fund the development and growth of our business.
As a result, capital appreciation, if any, of our Common Shares will be your sole source of gain for the foreseeable future. Consequently,
in the foreseeable future, you will likely only experience a gain from your investment in our Common Shares if the price of our
Common Shares increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to satisfy the requirements of
Sarbanes-Oxley, or our internal controls over financial reporting are not effective, the reliability of our financial statements
may be questioned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will become subject to the requirements
of Sarbanes-Oxley if our Common Shares are listed on Nasdaq. Section&nbsp;404 of Sarbanes-Oxley (&ldquo;<B>Section 404</B>&rdquo;)
requires companies subject to the reporting requirements of the U.S. securities laws to complete a comprehensive evaluation of
our internal controls over financial reporting. To comply with this statute, we will be required to document and test our internal
control procedures and our management will be required to assess and issue a report concerning our internal controls over financial
reporting. Pursuant to the JOBS Act, we will be classified as an &ldquo;emerging growth company.&rdquo; Under the JOBS Act, emerging
growth companies are exempt from certain reporting requirements, including the independent auditor attestation requirements of
Section 404(b) of Sarbanes-Oxley. Under this exemption, our independent auditor will not be required to attest to and report on
management&rsquo;s assessment of our internal controls over financial reporting during a five year transition period. We will need
to prepare for compliance with Section 404 by strengthening, assessing and testing our system of internal controls to provide the
basis for our report. However, the continuous process of strengthening our internal controls and complying with Section 404 is
complicated and time-consuming. Furthermore, we believe that our business will grow both domestically and internationally, in which
case our internal controls will become more complex and will require significantly more resources and attention to ensure our internal
controls remain effective overall. During the course of our testing, our management may identify material weaknesses or significant
deficiencies, which may not be remedied in a timely manner to meet the deadline imposed by Sarbanes-Oxley. If our management cannot
favorably assess the effectiveness of our internal controls over financial reporting, or our independent registered public accounting
firm identifies material weaknesses in our internal controls, investor confidence in our financial results may weaken, and the
market price of our securities may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a foreign private issuer whose shares are listed
on Nasdaq, we intend to follow certain home country corporate governance practices instead of certain Nasdaq requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a foreign private issuer whose shares
will be listed on Nasdaq, we are permitted to follow certain home country corporate governance practices instead of certain requirements
of the Nasdaq rules. We intend to adopt and approve material changes to equity incentive plans in accordance with TSX listing rules,
which do not impose a requirement of shareholder approval for such actions. In addition, we intend to follow the TSX listing rules
in respect of private placements instead of Nasdaq requirements to obtain shareholder approval for certain dilutive events (such
as issuances that will result in a change of control, certain transactions other than a public offering involving issuances of
a 20% or greater interest in us and certain acquisitions of the stock or assets of another company) and the minimum quorum requirement
for a shareholders meeting. Under Nasdaq listing rules, the required minimum quorum for a shareholders meeting is 33 1/3% of the
outstanding common shares, and our minimum quorum requirement is only 10% of the total number of voting rights attaching to all
outstanding Common Shares. See Item 10.B, &ldquo;Additional Information&mdash;Memorandum and Articles of Association&mdash;Meetings&rdquo;.
Accordingly, our shareholders may not be afforded the same protection as provided under Nasdaq corporate governance rules for domestic
issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will incur significantly increased costs and
devote substantial management time as a result of operating as a U.S. public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a U.S. public company, we will incur
significant legal, accounting and other expenses that we did not incur as a private company or as a Canadian public company. For
example, we will be subject to the reporting requirements of the U.S. Exchange Act, and will be required to comply with the applicable
requirements of Sarbanes-Oxley and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules and regulations
subsequently implemented by the SEC and the including the establishment and maintenance of effective disclosure and financial controls
and changes in corporate governance practices. We expect that compliance with these requirements will increase our legal and financial
compliance costs and will make some activities more time consuming and costly. In addition, we expect that management and other
personnel will need to divert attention from operational and other business matters to devote substantial time to these public
company requirements. In particular, we expect to incur significant expenses and devote substantial management effort toward ensuring
compliance with the requirements of Section 404, which involve annual assessments of a company&rsquo;s internal controls over financial
reporting. We may need to hire additional accounting and financial staff with appropriate public company experience and technical
accounting knowledge and may need to establish an internal audit function. We cannot predict or estimate the amount of additional
costs we may incur as a result of becoming a U.S. public company or the timing of such costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may lose foreign private issuer status in the
future, which could result in significant additional costs and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may in the future lose foreign private
issuer status if a majority of our common shares are held in the United States and we fail to meet the additional requirements
necessary to avoid loss of foreign private issuer status, such as if: (i) a majority of our directors or executive officers are
U.S. citizens or residents; (ii) a majority of our assets are located in the United States; or (iii) our business is administered
principally in the United States. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer
will be significantly more than the costs incurred as an SEC foreign private issuer. If we are not a foreign private issuer, we
would be required to file periodic and current reports and registration statements on U.S. domestic issuer forms with the SEC,
which are generally more detailed and extensive than the forms available to a foreign private issuer. In addition, we may lose
the ability to rely upon exemptions from corporate governance requirements that are available to foreign private issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">It may be difficult for United States investors
to effect services of process or enforcement of actions against us or certain of our directors and officers under U.S. federal
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is incorporated under the laws
of the Province of Ontario, Canada. A majority of our directors and officers reside in Canada. Because all or a substantial portion
of our assets and these persons are located outside the United States, it will be difficult for United States investors to effect
service of process in the United States upon us or our directors or officers, or to realize in the United States upon judgments
of United States courts predicated upon civil liabilities under the U.S. Exchange Act or other United States laws. It may also
be difficult to have a judgment rendered in a U.S. court recognized or enforced against us in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be a passive foreign investment company (&ldquo;PFIC&rdquo;)
for U.S. federal income tax purposes, which generally would result in certain adverse U.S. federal income tax consequences to our
U.S. shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, a non-U.S. corporation is a
PFIC for any taxable year in which (i) 75% or more of its gross income consists of passive income (the &ldquo;income test&rdquo;)
or (ii) 50% or more of the average quarterly value of its assets consists of assets that produce, or are held for the production
of, passive income (the &ldquo;asset test&rdquo;). Generally, &ldquo;passive income&rdquo; includes interest, dividends, rents,
royalties and certain gains, and cash is a passive asset for PFIC purposes. We have made no determination as to whether we are
classified as a PFIC for U.S. federal income tax purposes. The determination of whether we are a PFIC depends on the particular
facts and circumstances (such as the valuation of our assets, including goodwill and other intangible assets) and is also affected
by the application of the PFIC rules, which are subject to differing interpretations. The fair market value of our assets is expected
to depend, in part, upon (i) the market price of the Common Shares, which is likely to fluctuate, and (ii) the composition of our
income and assets, which will be affected by how, and how quickly, we spend any cash that is raised in any financing transaction.
If we were a PFIC for any taxable year during which a U.S. shareholder owned the Common Shares, such U.S. shareholder generally
will be subject to certain adverse U.S. federal income tax consequences, including increased tax liability on gains from dispositions
of the Common Shares and certain distributions and a requirement to file annual reports with the Internal Revenue Service. In light
of the foregoing, no assurance can be provided that we are not currently a PFIC or that we will not become a PFIC in any future
taxable year. Prospective investors should consult their own tax advisers regarding our PFIC status. See Item 10.E, &ldquo;Additional
Information&mdash;Taxation&mdash;Certain U.S. Federal Income Tax Considerations&mdash;Passive Foreign Investment Company Considerations.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_010"></A>ITEM
4. </FONT>INFORMATION ON THE COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. History and Development
of the Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">1.</TD><TD STYLE="text-align: justify">Name, Address and Incorporation; Trading Market</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is the company resulting from
a &ldquo;three-cornered&rdquo; amalgamation involving Mira, Mira Subco (a subsidiary formed to complete the amalgamation) and Profound
Medical Inc. (&ldquo;<B>Old PMI</B>&rdquo;). Old PMI was formed by articles of incorporation under the OBCA on June 13, 2008. Mira
was formed by articles of incorporation under the OBCA on July 16, 2014, and following its initial public offering in Canada, was
a &ldquo;capital pool company&rdquo; listed on the TSX-V. As a capital pool company, Mira had no assets other than cash and did
not carry on any operations. On June 3, 2015, in anticipation of the amalgamation, Mira changed its name to &ldquo;Profound Medical
Corp.&rdquo; (becoming &ldquo;Profound&rdquo;) and completed a consolidation of its share capital on the basis of one post-consolidation
common share for every 13.6363 pre-consolidation common shares. On June 4, 2015, Mira (now &ldquo;Profound&rdquo;), Mira Subco
and Old PMI completed the amalgamation, with Profound as our surviving holding company, and Mira Subco and Old PMI amalgamating
to form a new OBCA subsidiary, Profound Medical Inc. (&ldquo;<B>PMI</B>&rdquo;), to serve as the holding subsidiary of our operating
subsidiaries. Upon completion of the amalgamation, we commenced trading on the TSX-V. On July 13, 2018, we graduated from the TSX-V
and commenced trading on the TSX under the symbol &ldquo;PRN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to apply to list our Common Shares
on the Nasdaq in connection with this Registration Statement. Such a listing is dependent upon satisfaction of all necessary listing
requirements as well as this Registration Statement becoming effective with the SEC. On June 13, 2019, we received shareholder
approval for a special resolution authorizing the Board to amend our articles of incorporation to effect a consolidation of all
of the issued and outstanding Common Shares (the &ldquo;<B>Share Consolidation</B>&rdquo;), such that the trading price of the
Common Shares following the Share Consolidation would permit us to qualify for a potential listing on the Nasdaq. Although shareholder
approval for the Share Consolidation has been obtained, the exact ratio of the Share Consolidation has not yet been determined,
and will not become effective until a date in the future to be determined by the Board in order to satisfy the applicable listing
eligibility requirements of the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our head and registered office is located
at 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, Canada L4W 5K5, and its telephone number is (647) 476-1350. Our agent for
service of process in the United States is Corporation Service Company, located at 251 Little Falls Drive, Wilmington, DE 19808.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: -22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify">Summary Corporate History and Intercorporate Relationships</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intercorporate Relationships</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound operates its business through
its direct subsidiary, PMI, and its indirect subsidiaries, Profound Medical Oy, Profound Medical GmbH and Profound Medical (U.S.)
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following diagram illustrates the organizational
structure of Profound and its subsidiaries, their respective jurisdictions of incorporation and the percentage of voting and non-voting
securities owned by Profound as of the date of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;<IMG SRC="chart.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Corporate History</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">2019 Highlights (Year-to-Date)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 15, 2019, we received 510(k)
clearance from the FDA to market TULSA-PRO for transurethral ultrasound ablation of prostate tissue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 9, 2019, we announced that we sold
our first TULSA-PRO system in Japan. The system was purchased by Hokuyu Hospital in Sapporo via Japan&rsquo;s PMD Act expanded
access program. The PMD Act, regulated by Japan&rsquo;s PMDA and Ministry of Health, Labor and Welfare (&ldquo;<B>MHLW</B>&rdquo;),
allows physicians to import, with permission from the MHLW, an unapproved medical device directly from the distributor in cases
where there is a clinical urgency and there are no alternatives in Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2019, our shareholders approved
a special resolution authorizing the Board to amend our articles of incorporation to effect a consolidation of all of the issued
and outstanding Common Shares at a consolidation ratio that would permit us to qualify for a potential listing on the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2019, based on the TACT 12-month
follow-up data, we submitted an application to the FDA for clearance to market TULSA-PRO in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2019, Dr. Scott Eggener presented
12-month results of the TACT Pivotal Clinical Trial for TULSA-PRO, including the primary efficacy and safety endpoints, as well
as key secondary endpoints.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2019, we announced that the
first prostate cancer treatment using a first-of-its-kind TULSA-PRO installation had been performed in Trier, Germany.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 4, 2019, we announced positive
topline results from the TACT Pivotal Clinical Trial of TULSA-PRO in patients with prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of January 21, 2019, we entered
into and replaced our original co-marketing and co-selling agreement with Siemens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">2018 Highlights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 18, 2018, we press released
3-year clinical outcomes in prostate patients and a BPH subgroup analysis of our Phase I Clinical Trial for TULSA-PRO which was
included in a presentation at the Deutschen Gesellschaft f&uuml;r Urologie (DGU) 2018 conference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 30, 2018, we entered into the CIBC
Loan Agreement, which provided up to C$18.75 million of borrowing capacity. The first tranche of C$12.5 million was funded upon
execution of the agreement, with the option of a second tranche of up to an additional C$6.25 million available through December
31, 2019, subject to the satisfaction of certain financing and product development milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 11, 2018, we received final approval
for listing of the Common Shares on the TSX to trade under the symbol &ldquo;PRN&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 9, 2018, we obtained Chinese Food
and Drug Administration approval for Sonalleve for the non-invasive treatment of uterine fibroids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2018, we completed the 2018
Bought Deal in which we issued 34,500,000 Common Shares at a price of C$1.00 per Common Share, for total gross proceeds of C$34.5
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In February 2018, we completed patient
enrollment in the TACT Pivotal Clinical Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">2017 Highlights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 6, 2017, we announced the expanded
clinical use in Germany of TULSA-PRO in prostate care to include BPH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2017, we closed the 2017
Bought Deal in which we issued 10,000,000 Common Shares at a price of C$1.00 per Common Share, for total gross proceeds of C$10
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, we completed the acquisition
of the Sonalleve technology from Philips, and expanded our non-exclusive strategic sales relationship to include distribution of
Sonalleve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 27, 2017, we announced that the
first TULSA-PRO patient paid procedure was conducted at the ALTA Klinik in Bielefeld, Germany under the supervision of Dr. Agron
Lumiani.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">2016 Highlights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2016, we completed the
2016 Bought Deal in which we issued 15,820,000 Common Shares at a price of C$1.10 per Common Share for aggregate gross proceeds
of C$17,402,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2016, the FDA granted approval
of an IDE application for our TACT Pivotal Clinical Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2016, we announced the signing
of a sales and marketing agreement with Philips to collaborate in the commercialization of our TULSA-PRO system in Europe, Canada,
the United States and other markets, subject to regulatory clearance in those jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 28, 2016, we announced our first
commercial sale of our TULSA-PRO system in Europe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 11, 2016, we affixed the CE Mark
to the TULSA-PRO system following receipt of a CE Certificate of Conformity from our notified body in the European Union. The CE
Mark affixed to the medical device enables us to market the TULSA-PRO system in the European Union and in other jurisdictions accepting
CE marked medical devices such as Norway, Iceland, Liechtenstein and Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 26, 2016, we entered into a
strategic collaboration agreement with Siemens, aimed at advancing the commercial launch of our TULSA-PRO system.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal Capital Expenditures and
Divestitures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 5.B, &ldquo;Liquidity and Capital
Resources&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Internet Availability of Company Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC maintains an Internet site (http://www.sec.gov)
that makes available reports and other information that the Company files or furnishes electronically with it. The Company&rsquo;s
Internet site can be found at http://www.profoundmedical.com. The information on our website is not incorporated by reference into
this Registration Statement and should not be considered a part of this Registration Statement, and the reference to our website
in this Registration Statement is an inactive textual reference only.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Business Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an early commercial-stage medical
device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of
diseased tissue using our platform technology. Our leading approved product is our TULSA-PRO system, which in August 2019 received
FDA clearance as a Class II device in the United States for thermal ablation of prescribed prostate tissue, benign and malignant,
using transurethral ultrasound ablation (&ldquo;<B>TULSA</B>&rdquo;) based on our TULSA-PRO whole gland ablation clinical trial
(the &ldquo;<B>TACT Pivotal Clinical Trial</B>&rdquo; or &ldquo;<B>TACT</B>&rdquo;), and is also CE marked in the European Union
for ablation of targeted prostate tissue (benign or malignant). In addition, our Sonalleve system is CE marked in the EU for the
treatment of uterine fibroids and palliative pain relief associated with metastases in bone, and is also approved in China for
the treatment of non-invasive treatment of uterine fibroids. Our systems are designed to be used with MRI scanners and are currently
compatible with MRI scanners manufactured by Philips and Siemens. To date, we have primarily generated revenues from our limited
commercialization of our systems in the EU (principally in Germany) and Asia. We intend to commence commercialization of the TULSA-PRO
system in the United States in the near term following our recent FDA clearance. We also continue to pursue additional regulatory
approvals, research and development, clinical studies and acquisitions in order to expand the applications of our platform technology
and expand our commercial footprint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Technology Platform</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We anticipate that, based on our TACT clinical data and additional
studies conducted in the European Union, physicians may elect to use TULSA-PRO to ablate benign or malignant prostate tissue in
patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperplasia (&ldquo;<B>BPH</B>&rdquo;).
Prostate cancer is one of the most common types of cancer affecting men, with an annual incidence of newly diagnosed cases reaching
450,000 in Europe, according to the International Agency for Research on Cancer, and 175,000 in the United States according to
the American Cancer Society. The American Cancer Society further estimates that there are currently 5.8 million men living with
prostate cancer in these two geographies. Although ten-year survival outcomes for prostate cancer remain favorable, it is still
one of most common causes of cancer deaths among men. BPH is a histologic diagnosis that refers to the proliferation of smooth
muscle and epithelial cells within the prostatic transition zone. According to the American Urological Association, BPH is nearly
ubiquitous in the aging male with worldwide autopsy proven histological prevalence increases starting at ages 40 to 45 years,
reaching 60% at age 60 and 80% at age 80.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we are the only company
to provide customizable, incision-free therapies which combine real-time MRI, thermal ultrasound and closed-loop temperature feedback
control for the radiation-free and incision-free ablation of diseased tissue. We believe that our platform technology has the potential
to offer clinicians and qualified patients a better alternative to current standards of care for removing or otherwise ablating
benign or malignant prostate tissue, such as traditional surgery or radiation therapy, with respect to clinical outcomes, side
effects and recovery time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TULSA-PRO and Sonalleve share the common
technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal
ultrasound technology to heat and ablate tissue. The TULSA-PRO ablation is a catheter-based design, which is to be inserted transurethrally
into the prostate to provide a robotically driven sweeping ultrasound for continuous ablation of the surgeon defined prostate volume.
The Sonalleve ultrasound is provided through a disc located outside the patient and designed to focus the ultrasound to a specific
location inside the patient. The focal point provides the energy for ablation. We believe that Sonalleve has the potential to provide
us with a platform to expand into additional applications that may offer similar advantageous incision-free ablation related benefits
for various disease conditions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TULSA-PRO</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our TULSA-PRO System</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our TULSA-PRO system combines real-time
MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control. The combination
enables the TULSA-PRO system to provide customizable and predictable radiation-free and incision-free ablation of a surgeon-defined
prostate volume while actively protecting the urethra and rectum through water cooling to minimize the impact of ablation on the
patient&rsquo;s natural functional abilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our TULSA-PRO system is comprised of two
categories of components: disposables and the capital equipment used in conjunction with a customer&rsquo;s MRI scanner. We have
designed the TULSA-PRO system to be capable of integration with many major MRI scanners currently deployed in hospitals and treatment
facilities. That integration allows the TULSA-PRO system to display high resolution images of the prostate and surrounding anatomy.
The integrated MRI is used for treatment planning but, more importantly, to provide real-time measurement of temperature in the
prostate as the treatment is occurring to enable the physician/clinician to control and monitor tissue ablation. We have designed
our TULSA-PRO technology to work optimally with particular MRI scanners sold by Siemens and Philips and we intend to increase compatibility
of the TULSA-PRO system with models from other MRI vendors over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultrasound applicator (the &ldquo;<B>UA</B>&rdquo;)
is a sterile, single use, disposable component of the TULSA-PRO system. The UA produces directional ultrasound beams, through a
linear array of 10 independent ultrasound transducers, each of which is independently computer controlled using real-time MRI feedback
to deliver heat out to the prescribed treatment boundary. The UA is introduced into the patient via the urethra and is precisely
located within the prostate using the system&rsquo;s robotic positioning, which is controlled by the system&rsquo;s software together
with MRI feedback for guidance. The real time measurement of the temperature from the MR and the precision of transurethral ultrasound
is intended to enable the TULSA-PRO system to sculpt the ablated tissue volume to the shape of the patient&rsquo;s prostate, which
may assist in avoiding damage to sensitive structures, including the bladder neck and urethral sphincter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe there are a number of expected
clinical advantages of TULSA-PRO procedure over the existing standard of care. As described below, TULSA-PRO technology has demonstrated
accurate and precise ablation of targeted prostate tissue, while providing a well-tolerated favorable safety profile with relatively
minor impact on urinary, erectile and bowel function at 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">TACT &ndash; Our Pivotal Clinical Trial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We received FDA clearance for our TULSA-PRO
system in August 2019 based on our TACT Pivotal Clinical Trial. The TACT Pivotal Clinical Trial is a prospective, open-label, single-arm
pivotal clinical study, of 115 prostate cancer patients across 13 research sites in the United States, Canada and Europe. We commenced
our TACT Pivotal Clinical Trial in August 2016, and completed patient enrollment in February 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 5, 2019, Dr. Scott Eggener, Chief
Investigator of the TACT Pivotal Clinical Trial, presented 12-month follow-up outcomes during the American Urological Association&rsquo;s
2019 Annual Meeting Plenary Program in Chicago, IL, including the primary efficacy and safety endpoints, as well as key secondary
endpoints. The TACT Pivotal Clinical Trial met its primary Prostate-Specific Antigen (&ldquo;<B>PSA</B>&rdquo;) reduction endpoint
in 110 of 115 (approximately 96%) patients, with median interquartile range PSA reduction of approximately 95% (91-98%) and nadir
of 0.34 (0.12-0.56) ng/ml, and with low rates of severe toxicity and residual clinically significant prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The median age of enrolled patients was
65 years and the median PSA level was 6.3 ng/ml. The study focused on a clinically significant prostate cancer population, where
67.0% (77 out of 115) had NCCN (National Comprehensive Cancer Network) intermediate-risk disease, and 62.6% (72 out of 115) had
Grade Group 2 (GG2) or Gleason Score 7 (GS7) disease. Of the 43 patients with GG1 or GS6 disease, 60.5% (26 out of 43) had high-volume
disease (&ge; 3 cores positive, or &ge; 50% cancer core length). Treatment intent was whole-gland ablation with sparing of the
urethra and urinary sphincter. Median targeted prostate volume was 40 cc with treatment delivery time of 51 minutes. A median of
97.6% of the prescribed target volume was heated to ablative temperatures with spatial ablation precision of &plusmn;1.4 mm measured
on MRI thermometry during treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary efficacy endpoint of TACT is
the proportion of patients achieving a post-treatment PSA reduction &ge; 75% of their pre-treatment baseline value. The FDA-approved
protocol&rsquo;s pre-established performance goal for the success proportion was 50% of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Secondary efficacy endpoints include prostate
volume reduction on 12-month MRI and histological response on 12-month 10-core prostate biopsy. The median perfused prostate volume
of patients in TACT decreased from 41 cc to 4 cc, based on assessment from the local research sites, pending review by a central
radiology core lab. Of the 115 patients enrolled in the study, only 4 (3.5%) did not undergo follow-up biopsy, in all cases due
to patient refusal. Among 68 men with pre-treatment intermediate-risk GG2 disease, 54 (79.4%) were free of GG2 disease on one-year
biopsy. Among 94 men with pre-treatment GG2 or high-volume GG1 disease, 72 (76.6%) were free of GG2 or high-volume GG1 disease
on follow-up biopsy. Of the 111 men with one-year biopsy data, 72 (64.9%) had a complete histological response with no evidence
of any cancer, and 16 (14.4%) had low-volume GG1 disease which has virtually no potential for metastases or cancer-related mortality.
The 20.6% rate of residual clinically significant prostate cancer in an intermediate-risk patient population is similar or better
than that reported in prospective studies of modern external beam radiation therapy and other ablation technologies. In addition,
the TACT patients remain amenable to re-treatment with TULSA-PRO or standard of care therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary safety endpoint of TACT is
the frequency and severity of adverse events graded according to the Common Terminology Criteria for Adverse Events, or CTCAE.
The rate and nature of attributable adverse events were similar to the favorable safety profile reported in the Phase I Safety
 &amp; Feasibility Study of TULSA-PRO (as described below). In the TACT study, attributable serious adverse events occurred in 7.0%
of patients, including 4.3% genitourinary infection, 0.9% urinary retention, 0.9% urinoma, 0.9% ileus (related to urinary catheter),
0.9% deep vein thrombosis, and 0.9% urethral stricture, and in all cases the adverse events were resolved. Similarly, 7.8% of patients
experienced an attributable severe (Grade 3) adverse event, all resolved. There were no rectal injuries or fistulas, and no attributable
Grade &ge; 4 adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional secondary endpoints of TACT
focus on functional side effects commonly associated with current prostate cancer therapies, such as erectile dysfunction and urinary
incontinence. At 12 months, 23.5% of patients had moderate erectile dysfunction (surgeon assessed Grade 2 adverse event, intervention
such as medication indicated) and no patient experienced severe erectile dysfunction (Grade 3, intervention such as medication
not helpful). Erectile function was also evaluated using the IIEF Patient-Reported Questionnaire. The median change in IIEF-5 was
a decrease in 3 points, less than the minimal clinically important difference in erectile function. At 12 months, 75.0% (69 out
of 92) of previously potent patients were able to maintain erections sufficient for penetration (IIEF question 2 &ge; 2). With
respect to urinary function, 2.6% of patients had moderate urinary incontinence (surgeon assessed Grade 2 adverse event, pads indicated)
at 12 months. Urinary function was also evaluated using the EPIC Patient-Reported Questionnaire. At 12 months, there was 99.1%
(111 out of 112) preservation of urinary continence (&le;1 pad/day), and a 96.2% rate of leak-free continence (leak &lt;1 time/day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Multivariate predictors of GG2 disease
at one-year biopsy included presence of intraprostatic calcifications at screening, MRI thermal coverage of target volume, and
PIRADS &ge; 3 lesion at one-year post-treatment MRI (p &lt; 0.05).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on the 12-month outcomes of the TACT
Pivotal Clinical Trial, we submitted our application to the FDA in May 2019 for clearance to market the TULSA-PRO system in the
United States, and on August 15<FONT STYLE="font-weight: normal">, 2019, we received 510(k) clearance for commercial sales of TULSA-PRO
as a Class II device in the United States</FONT> for thermal ablation of prescribed prostate tissue, benign and malignant, using
transurethral ultrasound ablation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phase I Safety and Feasibility Study</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2014, we completed enrollment
and treatment of 30 patients in the Phase I TULSA multi-jurisdictional safety and feasibility study. The procedure was delivered
using our TULSA-PRO system, with the objective of determining its clinical safety and feasibility for prostate ablation in the
primary treatment setting of patients with localized prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2015, the results of our safety
and feasibility study were accepted for publication in <I>European Urology</I>, the official journal of the European Association
of Urology. We presented the successful 12-month Phase I clinical trial outcomes at the European Symposium on Focused Ultrasound
Therapy. Upon completion of the study, the clinical data was also submitted to European regulatory authorities for regulatory clearance
in Europe. Based on our Phase I clinical trial results, in April 2016, we received a CE Certificate of Conformity for the TULSA-PRO
system from our notified body in the EU, and in the fourth quarter of 2016, we initiated a pilot commercial launch of TULSA-PRO
in key European markets where the CE Mark is accepted.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sonalleve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Sonalleve system combines real-time
MRI and thermometry with focused ultrasound delivered from the outside of the patient to enable precise and incision-free ablation
of diseased tissue. We acquired the Sonalleve technology from Philips in 2017. The Sonalleve system is CE marked in the EU for
the treatment of uterine fibroids and palliative pain treatment of bone metastases. In 2018, the Sonalleve system was also approved
in China by the National Medical Products Administration (&ldquo;<B>NMPA</B>&rdquo;) for the non-invasive treatment of uterine
fibroids. We are in the early stages of exploring additional potential indications for which the Sonalleve technology has been
shown in pre-clinical studies to have the potential for clinical application, such as non-invasive ablation of abdominal cancers
and hyperthermia for cancer therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview of Uterine Fibroids</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Uterine fibroids are the most common non-cancerous
tumors in women of childbearing age. Based on data from the Agency for Healthcare Research and Quality, we estimate that uterine
fibroids occur in 70-80% of the female population, but only approximately one third of these cases will require treatment. In addition,
based on data from the Agency for Healthcare Research and Quality, we estimate that in the United States, 26 million women between
the ages of 15 and 50 have uterine fibroids, and more than 15 million of them will experience associated symptoms or health concerns
during their lifetimes. Uterine fibroids cause a variety of symptoms that can significantly reduce the quality of life for a woman,
which can include bleeding, pain, pressure and reproductive challenges including infertility, multiple miscarriages, and premature
labor. Treatment options differ in fundamental aspects such as cost, invasiveness, recovery time, risks, likelihood of long-term
resolution of symptoms, need for future care for fibroids, and influence on future childbearing potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Sonalleve System</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The procedure using the Sonalleve system
consists of imaging the uterus in an MRI scanner and heating the fibroid or adenomyosis with high-intensity focused ultrasound
energy until the tissue reaches the temperature that causes necrosis. The MRI scanner monitors the progress of the treatment. For
the patient, the technique can be much more convenient and comfortable than traditional surgical procedures, such as hysterectomy
or myomectomy. These require hospital admission on an in-patient basis and sometimes weeks of recovery. In contrast, with Sonalleve
fibroid therapy, patients can be treated on an outpatient basis without the need for anesthesia, discharged the same day and almost
fully recovered within a few days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sonalleve bone pain relief application
is indicated for palliative treatments to relieve pain associated with bone metastasis. In the later stages of their disease, many
cancer patients develop bone metastases. Bone changes and malformations irritate nerve endings, which can cause severe and debilitating
pain and become unbearable for many patients. Conventional treatment with strong medication or radiation therapy can result in
unpleasant side effects. Sonalleve provides an alternative option to alleviate this pain. Pain relief can be expected in as quickly
as 2-3 days as compared to radiation therapy which could take up to three weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultrasound energy utilized in the Sonalleve
system is MR High Intensity Focused Ultrasound (&ldquo;<B>HIFU</B>&rdquo;) or MR-HIFU. MR-HIFU therapy uses a focused transducer
to bundle ultrasound energy into a small volume at the target locations inside the body under MRI and visualization. During treatment,
the ultrasound energy beam passes through the intact skin and soft tissue, causing localized high temperatures in the focus area.
The skin and intermediate tissue are left unharmed. Within a few seconds this produces a well-defined region of coagulative necrosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sonalleve system is designed to be
integrated with Philips MRI scanners and we intend to expand this compatibility to additional MRI scanner brands in the future.
MRI can measure temperature changes within the human body non-invasively. 3D MR images provide the anatomical reference data for
treatment planning, while real-time temperature sensitive images are acquired during ablation to provide real-time information
about treatment progress and monitor critical anatomical structures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are over 200 publications from leading
institutions globally on Sonalleve technology. There are also over approximately 60 medical and scientific institutions globally
that make up the installed base of Sonalleve system.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales and Marketing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have primarily generated revenues
from our limited commercialization of our systems, including disposables and related services, in the EU (principally in Germany)
and Asia. For the year ended December 31, 2018, approximately 52% and 48% of our revenues were generated in the EU and Asia, respectively,
compared to 77%, 12% and 11% in the EU, South America and Asia, respectively, for the year ended December 31, 2017. For the year
ended December 31, 2016, we had no revenue as we only started our pilot commercial launch in 2017. We intend to commence commercialization
of the TULSA-PRO system in the United States in the near term following our recent FDA clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically treatment of conditions such
as localized prostate disease and uterine fibroids have included surgical intervention. Over time, surgery has evolved from an
 &lsquo;open&rsquo; technique, to laparoscopic, to robotic surgery. The surgeon&rsquo;s motivation behind this evolution has been
to perform procedures that reduce invasiveness, improve clinical outcomes, and reduce recovery times. We are now taking this concept
to the next level by enabling customizable, incision-free therapies for the MRI-guided ablation of diseased tissue with the TULSA-PRO
and Sonalleve systems. These incision-free and radiation-free procedures offer surgeons the option of providing predictable and
customizable procedures that eliminate invasiveness, offer the potential to improve clinical outcomes and further reduce hospital
stays and patient recovery times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the TULSA-PRO system, we generate revenue
from the sale of the capital equipment, procedure-related sales of disposable single use components of the system (which are sold
on a per patient basis), and service revenue for ongoing maintenance of the systems. The key customer segments for TULSA-PRO we
are targeting include academic/university/clinical leadership hospitals as well as private clinics with access to MRI scanners.
We are establishing our own direct sales and marketing teams for sales of TULSA-PRO systems and the disposable components related
thereto, as well as for Sonalleve systems in the jurisdictions where it is approved. The primary focus of our direct sales team
is to cultivate adoption of the TULSA-PRO technology, support clinical customers with the TULSA-PRO procedures and increase the
utilization of the systems and disposable components. We expect to generate recurring revenues from the sale of disposables and
service maintenance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also collaborate with our strategic
partners Philips and Siemens for lead generation and distribution of the capital equipment, which are currently available through
the Philips and Siemens sales catalogs. The catalogs provide access and enable the sales teams of each collaborator to provide
quotations for potential sales, in those jurisdictions where the product is approved for sale by the relevant regulatory bodies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of Sonalleve currently are primarily
a one-time capital sale with limited recurring service revenue. Given that it is currently only compatible with Philips MRI scanners,
we rely primarily on our strategic partnership with Philips for lead generation and sale of the capital units, which are available
through the Philips sales catalog. With regulatory approval for the sale of Sonalleve only in the EU and China, our current commercial
focus is limited to those jurisdictions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Competition</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">TULSA-PRO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our TULSA-PRO system is intended to ablate
benign and malignant prostate tissue. There are currently no marketed devices indicated for the treatment of prostate diseases
or prostate cancer and our FDA indication and CE mark in the European Union also do not include treatment of any particular disease
or condition. However, there are a number of devices indicated for the destruction or removal of prostate tissue and devices indicated
for use in performing surgical procedures that physicians and surgeons currently utilize when treating patients with prostate
disease, including prostate cancer. Approaches that physicians and surgeons currently use to address prostate disease include:
(1) watchful waiting/active surveillance; (2) simple prostectomy; (3) radical prostatectomy (includes open, laparoscopic and robotic
procedures); (4) radiation therapies including, external beam radiation therapy (&ldquo;<B>EBRT</B>&rdquo;), brachytherapy and
high dose radiation (&ldquo;<B>HDR</B>&rdquo;); (5) cryoablation and (6) trans-rectal high intensity focused ultrasound (&ldquo;<B>HIFU</B>&rdquo;).
In addition, certain adjunct or less common procedures are used or are under development to address prostate disease, such as
androgen deprivation therapy (&ldquo;<B>ADT</B>&rdquo;) and proton beam therapy. We anticipate that physicians may likewise elect
to use our TULSA-PRO system to ablate benign or malignant prostate tissue in patients with prostate disease such that our system
faces competition from these other options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These competing options each have their
own limitations and benefits and may be appropriate for only limited patient populations. For example, active surveillance is generally
recommended for patients who have been diagnosed with earlier stage, lower risk, disease where the possibility of side effects
from intervention may outweigh the expected benefit of the chosen procedure. For clinicians and patients, the gap between active
surveillance and the most commonly utilized options of surgery or radiation therapy impose the possibility of substantial side
effects, creating a need for a less invasive methodology to remove diseased prostate tissue that is both radiation- and incision-free
and provides a more favorable side-effect profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Watchful Waiting; Active Surveillance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Watchful waiting means no treatment until
there is an indication that the cancer has spread<B>. </B>Active surveillance is monitoring of the prostate cancer closely with
PSA tests and digital rectal exams. Prostate biopsies may also be done to see if the cancer is becoming more aggressive. Test results
will indicate whether a more aggressive treatment option should be considered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simple Prostatectomy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simple prostatectomy is recommended for
men with severe urinary symptoms caused by an obstructive prostate gland and whose symptoms are not responsive to other medical
or minimally-invasive therapies. Simple prostatectomy involves removing only the obstructive portion of the prostate gland rather
than the entire gland and surrounding tissue. A simple prostatectomy can be open or robotic. Open simple prostatectomy can be conducted
through retropubic, suprapubic, or perineal routes. Simple prostatectomy has higher morbidity and longer hospitalization in comparison
to less invasive therapies such as transurethral resection of the prostate. Simple prostatectomy is contraindicated in the presence
of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Radical Prostatectomy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Radical prostatectomy, an open surgical
removal of the entire prostate gland and some surrounding tissues, represents a current standard of care, practiced by urologists
in North America and Europe, which procedure involves the removal of the localized cancerous tissue. However, the conventional
open surgical technique has high post-surgery incidences of impotence and incontinence and long recovery time. Relatively recently,
robotic surgery systems have become more common in the market. Cited benefits of the robotic technique include improved precision
and range of motion. Risks specific to the robotic technique include longer operation time, the possible need to convert the procedure
to a non-robotic approach, and the need for additional or larger incision sites. Converting the procedure could mean a longer operation
time, resulting in a longer time under anesthesia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">External Beam Radiation Therapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EBRT requires multiple weekly clinic visits
over a period of six to eight weeks. The procedure directs a beam of radiation from outside the body to cancerous tissue inside
the body. Although such procedures are relatively costly with studies showing significant risk of collateral damage and lengthy
recovery times, it is non-invasive. It can also be used to irradiate cancer that has spread to other areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Brachytherapy and High Dose Radiation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With brachytherapy, radioactive seeds are
implanted in the prostate to irradiate the cancerous tissue. The seeds irradiate the prostate over time and decay in place to background
levels; they remain implanted and inert afterwards. Side effects of brachytherapy are similar to those of EBRT in terms of urinary,
bowel and erectile function. An alternative is high dose radiation, or HDR, in which highly radioactive seeds are temporarily inserted,
then removed during the same procedure, leaving nothing implanted afterward. HDR has the ability to target tissue, but requires
hospital stays and usually is accompanied by adjunct EBRT over several weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryoablation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cryoablation freezes cells to death by
introducing cooled liquids and gases to an area of cancerous tissue. Studies show cryoablation offers poor precision and has delivered
impotence rates that are almost as high as those for conventional radical prostatectomy. The procedure also carries a risk of potential
damage to the tissue between the urethra and rectum, potentially resulting in a urinary rectal fistulas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trans-rectal High Intensity Focused
Ultrasound (&ldquo;HIFU&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trans-rectal HIFU is used increasingly
in the European Union, United States and Canada. This technique utilizes focused ultrasound that is delivered through the rectal
wall to treat the prostate. Image guidance is generally provided by ultrasound. At an FDA urology panel meeting in 2014, the panel
indicated that HIFU can lead to complications such as rectal fistulae and rectal incontinence. Due to the focused treatment zone,
this treatment requires approximately three hours to complete. One limitation of HIFU is prostate size; the procedure is limited
to patients with prostate volume smaller than 40 cubic centimeters. Patients with larger prostates need a separate surgical procedure,
such as transurethral resection of the prostate (&ldquo;<B>TURP</B>&rdquo;) or ADT, both described below, to de-bulk or reduce
the size of the prostate prior to HIFU. This additional procedure increases costs and the risk of complications. Recent studies
have indicated positive survival outcomes and thermal ultrasound appears to be gaining traction in certain settings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Adjunct and Emerging Therapies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Androgen deprivation therapy, or ADT, uses
hormones to suppress testosterone production and alleviate symptoms, but with the primary side-effect of reduced sexual interest
and activity. Although historically used as a last line of defense for the disease (and typically in a palliative setting), it
is increasingly used as a first line treatment or in combination with other treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TURP is a surgical procedure that removes
portions of the prostate gland through the penis. This procedure is used to relieve moderate to severe urinary symptoms caused
by an enlarged prostate, a condition known as BPH. This procedure is also used in adjunct to a HIFU procedure when a prostate gland
is larger than 40 cubic centimeters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proton beam therapy is a way to deliver
radiation to tumors using tiny, sub-atomic particles (protons) instead of the photons used in conventional radiation treatment.
Proton beam therapy uses new technology to accelerate atoms to approximately 93,000 miles per second, separating the protons from
the atom. While moving at this high speed, the particles are &ldquo;fired&rdquo; at the patient&rsquo;s tumor. These charged particles
deliver a very high dose of radiation to the cancer but release very little radiation to the normal tissue in their path. In theory,
this approach minimizes damage to healthy organs and structures surrounding the cancer. The radiation beams must pass through the
skin, the bladder and the rectum on the way to the prostate gland, and once they reach the gland, they encounter normal prostate
cells and the nerves that control penile erections. Damage to these tissues can lead to complications, including bladder problems,
rectal leakage or bleeding, and erectile dysfunction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that use of the TULSA-PRO system
as a tool to ablate prostate tissue can provide a clinician and his or her patients with the following clinical advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Clinically shown to have millimeter accuracy designed to ablate prostate tissue while sparing nearby
critical structures, and that real time MR thermometry also ensures precision in ablation temperature, minimizing side effects
that can occur from overheating;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Enables clinician to define the boundaries of the tissue to be ablated, whether the whole prostate
or any of its subsections, to ensure customization of the needs of each patient;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Transurethral approach allows for ablation of even the largest prostates that may be 120&nbsp;cubic
centimeters or larger in size;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Potential to be a single outpatient procedure with a rapid recovery time; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Designed to be compatible with leading MRI platforms and could become part of a continuum of care
from MR imaging diagnosis, MR guided biopsy to MR guided treatment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the flexibility of the
TULSA-PRO system may allow us to demonstrate its use as a tool for ablating benign and malignant diseased prostate tissue with
greater speed and precisions than current options while minimizing potential side effects. We believe that the TULSA-PRO system
may overcome certain limitations of other devices and methodologies for removing or addressing disease prostate tissue including
HIFU, such as complications associated with trans-rectal delivery and limitations relating to prostate size. We believe that a
transurethral (inside out) ablation approach with millimeter accuracy has advantages over HIFU in ablating the whole gland safely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sonalleve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The treatment choices for uterine fibroids
usually depend on the symptoms of the patient, size of the fibroid, desire for future pregnancy, and preference of the treating
gynecologist.&nbsp;Most common treatment options for uterine fibroids include: (1) hormonal medications including gonadotrophin
releasing hormone agonists (&ldquo;<B>Gn-RH</B>&rdquo;); (2)&nbsp;progesterone releasing intra-uterine devices; (3) surgical procedures
such as hysterectomy and myomectomy; and (4) uterine artery embolization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the Sonalleve system may
provide a treatment option that is more convenient and comfortable with less side effects than surgical procedures, such as hysterectomy
or myomectomy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hormonal Medications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fibroids can be treated with hormonal drugs,
such as Gn-RH agonists. Gn-RH agonists can treat fibroids by blocking the production of estrogen and progesterone, putting women
into a temporary postmenopausal state. As a result, menstruation stops, fibroids shrink and anemia is often alleviated. Other hormonal
medications can also be utilized in patients with uterine fibroids. In many cases, however, medication may provide only temporary
relief from the symptoms caused by fibroids. The symptoms often return when the patient stops taking the medication. Moreover,
the side effects of some drugs may cause them to be unsuitable for some patients. Gn-RH agonists typically are used for no more
than three to six months because long-term use can cause loss of bone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Progesterone Releasing Intra-Uterine
Devices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Progesterone releasing <FONT STYLE="background-color: white">intra-uterine
devices can relieve heavy bleeding caused by fibroids. However, these devices can only provide symptom relief and do not impact
the fibroid itself.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Uterine Artery Embolization</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Uterine artery embolization involves injection
of embolic agents into the arteries that supply the uterus, thereby cutting off the blood supply to the fibroids. Many women require
at least one day of hospitalization and heavy pain medication. The prolonged pain may slow down the recovery period. Complications
may occur if the blood supply to the ovaries or other organs is compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Surgery</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Surgical options for the treatment of uterine
fibroids include hysterectomy and myomectomy. Hysterectomy is a surgical procedure which involves the complete removal of uterus
with or without removal of the cervix, ovaries and fallopian tubes. Hysterectomy can be performed abdominally in an open, laparoscopic,
robotic-assisted or vaginal method. Surgical options are associated with blood loss, hospital stays, long recovery times, pain
and scarring. Post-operative complications can include infections, urinary incontinence, vaginal prolapse, fistula formation and
chronic pain. After a hysterectomy, a woman will enter menopause and is infertile. Myomectomy is a surgical procedure to remove
uterine fibroids from the wall of the uterus. The procedure can be performed with an abdominal incision, laparoscopic, or hysteroscopic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that use of the Sonalleve system
as a tool to ablate uterine fibroids can provide a clinician and his or her patients with the following clinical advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Millimeter accuracy designed to ablate uterine fibroid while sparing nearby critical structures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Outpatient procedure with rapid recovery time, not requiring general anesthesia; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Non-invasive approach using thermal ablation designed to heat the uterine fibroid; and guided by
real-time MRI with temperature (thermometry) feedback.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alliances and Partnerships</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philips</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, we entered into the Philips
Share Purchase Agreement with Philips in order to expand the existing collaboration and acquire the Sonalleve technology, which
we use in our Sonalleve system (the &ldquo;<B>Sonalleve Transaction</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the Philips Share Purchase
Agreement, we acquired from Philips its Sonalleve assets for upfront consideration of 7,400,000 Common Shares. The Philips Share
Purchase Agreement includes earn-out provisions that require us to pay additional consideration of: (i) 5% of Net Sales (as defined
below) occurring after July 31, 2017 for the calendar year 2017; (ii) 6% of Net Sales occurring in the calendar year 2018; and
(iii) 7% of Net Sales occurring in the calendar years 2019 and 2020. To the extent that the cumulative Net Sales for the full calendar
years 2017 through 2020 exceeds &euro;45,300,000, we will be required to pay an additional earn-out equal to 7% of Net Sales for
the period beginning after July 31, 2017 through December 31, 2019. To date, we have paid &euro;99,059 (C$147,469) as part of the
earn-out provision, including &euro;80,771 (C$121,157) for the year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Net Sales&rdquo; include the revenues
(less any royalties) received by us or third parties on our behalf in respect of the sale or transfer of the Sonalleve technology,
any subsequent, successor or next-generation treatment technology of which is primarily based on Sonalleve and which utilizes intellectual
property rights acquired under the Philips Share Purchase Agreement or any future product that combines the technologies of Sonalleve
and TULSA-PRO and any amounts received by us with respect to service agreements, but does not include any revenues with respect
to consumables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Sonalleve Transaction, we
expanded our non-exclusive strategic sales relationship with Philips for our TULSA-PRO system to include distribution of Sonalleve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have also entered into several other
agreements with Philips, including (1) the Philips Supply Agreement pursuant to which Philips is required to manufacture our Sonalleve
systems for a certain period, (2) the Philips Confidentiality Agreement in which Philips agreed to certain non-competition terms,
and (3) a Philips Resale Purchasing Agreement, in which Philips is permitted to purchase and resell certain of our products to
its customers. For more details on these agreements, see Item 10.C, &ldquo;Additional Information&mdash;Material Contracts&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Siemens</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 26, 2016, we entered into a
strategic collaboration agreement with Siemens (the &ldquo;<B>Original Siemens Agreement</B>&rdquo;), aimed at advancing the commercial
launch of our TULSA-PRO system in approved jurisdictions. As of April 1, 2018, our TULSA-PRO systems are marketed by Siemens through
its electronic catalog.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2019, we entered into the
New Siemens Agreement, effective as of January 21, 2019, which replaced the Original Siemens Agreement. Under the New Siemens Agreement,
all prior financial commitments and obligations owed to Siemens were released and replaced with a one-time fixed license fee and
per annum payments calculated based on annual volume of our systems interfaced to a Siemens MRI scanner. The initial term of the
New Siemens Agreement is five years, but will be automatically extended for successive terms of one year thereafter unless terminated
earlier. We also obtained a non-exclusive license to Siemens Access I interface software and reasonable support for the term of
the New Siemens Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Knight</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Knight acts as our exclusive distributor
for TULSA-PRO in Canada pursuant to a 10-year distribution, license and supply agreement initially entered into in April 2015 (which
may be extended for successive 10-year periods at the option of either party). Currently, we are not planning any significant commercialization
efforts in Canada.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing and Supply</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely principally on third parties for
the manufacturing of the components of our system; however, we are responsible for assembly and testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have designed the TULSA-PRO system to
be capable of integration with some of the MRI scanners from two of the major MRI manufacturers (Philips and Siemens) and the Sonalleve
system with one MRI manufacturer (Philips). As not all hospital and treatment facilities utilize MRI scanners that are compatible
with the TULSA-PRO and Sonalleve systems, such facilities would be required to acquire compatible MRI technology, which may involve
additional capital expenditure and which could restrict or delay utilization of the systems by such facilities. Accordingly, we
intend to expand compatibility of the systems with other MRI scanners in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our systems are assembled from off-the-shelf
and custom-made components. We have entered into and expect to enter into additional manufacturing, licensing and distribution
arrangements with one or more QSR compliant and FDA registered contract manufacturers for the materials and components used in
our products. The TULSA-PRO and Sonalleve systems consist of common electronic components, proprietary capital equipment and proprietary
disposables. We purchase standard electronic components from a number of third party vendors. The capital equipment consists of
custom system electronics, treatment delivery console, fluid circuits and an MRI compatible robotic positioning system. Printed
circuit boards and assemblies and custom mechanical parts are outsourced to approved suppliers. TULSA-PRO disposables consist of
the UA, an endo-rectal cooling device and associated accessories. Due to sterility requirements used in connection with the TULSA-PRO
system, the UA must be manufactured under clean conditions. We have developed proprietary automated manufacturing test equipment
to improve quality and provide scalability as demand grows and this equipment is assembled and tested in-house. We assemble and
test the UA and endo-rectal cooling device in-house.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no long-term contracts with our
suppliers, and we are not bound by any minimum purchase volume undertakings with such suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently rely on single source suppliers
for certain components used in our systems. In connection with our anticipated commercialization of our approved products, we intend
to procure alternative supply arrangements for these components. See Item 3.D, &ldquo;Risk Factors&mdash;Risk Factors Relating
to Our Business and Growth Strategy&mdash;We depend on single-source suppliers for some of the components in our systems.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 15<FONT STYLE="font-weight: normal">,
2019, we</FONT> obtained 510(k) clearance for commercial sale of the TULSA-PRO as a Class II device in the United States, and have
previously received a CE Certificate of Conformity for our products in European Union, and have recently obtained regulatory approval
for Sonalleve in China. Additionally, the TULSA-PRO system has received regulatory clearances or approvals for commercial sale
in Saudi Arabia, Singapore and China, while the Sonalleve system has received regulatory clearance or approval for commercial sale
in Canada, Saudi Arabia, South Korea and Malaysia. Our long-term goal is to expand our regulatory indications in Asia and other
parts of the world where potential profitable business development opportunities warrant such investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA strictly regulates medical devices
under the authority of the FFDCA and the regulations promulgated under the FFDCA. The FFDCA and the implementing regulations govern,
among other things, the following related to our products: preclinical and clinical testing, design, manufacture, safety, efficacy,
labeling, storage, record keeping, sales and distribution, importation, post-market adverse event reporting, recalls, and advertising
and promotion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The TULSA-PRO system, and any future medical
devices that we may develop, will be classified by the FDA under the statutory framework described in the FFDCA. Medical devices
are classified into three classes from lowest risk (Class I) to highest risk (Class III). Unless an exemption applies, medical
devices require FDA clearance or approval prior to commercial sale in the United States depending on the assigned risk class. Most
Class I devices and some Class II devices are exempt from premarket review requirements. Class I devices are subject to the &ldquo;general
controls&rdquo; of the FFDCA, which include facility registration and device listing, quality system requirements, labeling requirements,
medical device reporting, and reporting of corrections and removals. Most Class II devices and some Class I devices require FDA
clearance of a 510(k) premarket notification prior to marketing. A 510(k) premarket notification must demonstrate that the device
is substantially equivalent to a previously marketed predicate device. In addition to the general controls, Class II devices are
subject to &ldquo;special controls,&rdquo; such as performance standards and guidance documents, as identified in the classification
regulation for the device type. Class III devices require FDA approval of a premarket approval application, or PMA, demonstrating
the safety and effectiveness of the device, prior to commercial distribution. Class III devices are those deemed by the FDA to
pose the greatest risk, such as life-sustaining, life-supporting or implantable devices. Class III devices are subject to the general
controls and any conditions of approval in the PMA approval order, which can include postmarket study requirements. Novel devices
that have not been classified and devices deemed not substantially equivalent to a predicate device are automatically classified
into Class III. For such low- to moderate-risk devices, the manufacturer can submit a de novo classification request to classify
the device into Class I or Class II. 510(k) premarket notifications, de novo classification requests, and PMA applications are
subject to the payment of user fees paid at the time of submission for FDA review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are generally required
to support a PMA application and are sometimes required for 510(k) clearance or de novo classification requests. Such trials, if
conducted in the United States, generally require an IDE application, approved in advance by the FDA for a specified number of
patients and study sites, unless the product is deemed a non-significant risk device eligible for more abbreviated IDE requirements
or an exemption applies. Clinical trials are subject to extensive monitoring, recordkeeping and reporting requirements as well
as a requirement to submit information regarding certain clinical trials to a public database maintained by the National Institutes
of Health. Clinical trials must be conducted under the oversight of an IRB, for the relevant clinical trial sites and must comply
with FDA regulations, including but not limited to those relating to good clinical practices and informed consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After a device is placed on the market,
numerous regulatory requirements apply. Device manufacturers and importers must register their establishments annually, list the
devices they manufacturer and pay an annual registration fee. Device manufacturers are also subject to the QSR, which includes
both design control requirements and good manufacturing practice requirements (such as requirements for purchasing controls, document
controls, production and process controls, labeling and packaging controls, control of nonconforming product, complaint handling,
corrective and preventative actions, storage, handling, distribution, and servicing). Devices must be labeled in accordance with
the FDA&rsquo;s device labeling regulations, including Unique Device Identification requirements. The FDA also regulates the promotion
of medical devices, including a requirement that all device promotion be truthful and non-misleading and a prohibition against
the promotion of devices for uncleared, unapproved or off-label use or indications. Under the medical device reporting regulations,
manufacturers and initial importers must submit a report to the FDA if they become aware of information that reasonably suggests
that one of their marketed devices may have caused or contributed to a death or serious injury or malfunctioned and the malfunction
would be likely to cause or contribute to a death or serious injury if it were to recur. Manufacturers must also report any corrections
or removals that include repairs, adjustments, relabeling, or destruction of distributed devices, if the correction or removal
was initiated to reduce a risk to health or to remedy a violation of the FFDCA caused by the device which may present a risk to
health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has broad enforcement authority
to take action against a failure to comply with the clinical trial, premarket review, or postmarket regulatory requirements discussed
above and the agency conducts routine inspections of device manufacturers to determine compliance with these requirements. FDA
enforcement typically takes the form of inspectional observations at the close of inspection, an Untitled Letter (a private letter
raising compliance questions), or a Warning Letter (a public letter alleging noncompliance). However, the FDA has authority to
take additional enforcement actions including: civil monetary penalties, criminal fines and prosecution, injunctions, mandatory
recall, and import detentions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">European Union</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, legal manufacturers
of medical devices, such as the TULSA-PRO and Sonalleve systems, are required to comply with the Essential Requirements laid down
in Annex I to the Council Directive 93/42/EEC concerning medical devices, known as the Medical Devices Directive (&ldquo;<B>MDD</B>&rdquo;).
Active implantable medical devices and in-vitro diagnostic medical devices are regulated in separate EC directives. Compliance
with these requirements entitles us to affix the CE Mark to our medical devices, without which they cannot be commercialized in
the European Union. To demonstrate compliance with the Essential Requirements and obtain the right to affix the CE Mark to our
medical devices, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its
classification. The MDD provides for four different classifications of medical devices based on their risk: Class I, Class IIa,
Class IIb and Class III. Except for low risk medical devices (Class I with no measuring function and which are not sterile), in
relation to which the manufacturer may prepare an EC Declaration of Conformity based on a self-assessment of the conformity of
its products with the Essential Requirements, a conformity assessment procedure requires the intervention of a Notified Body. A
Notified Body is a private body or company designated by the competent authorities of a European Union Member State to conduct
conformity assessments and to execute the provisions of the MDD (as implemented in the respective national legal system) in the
interest of public health. Depending on the device&rsquo;s risk category/class, the conformity assessment of the Notified Body
extends to the quality assurance system established by the manufacturer and/or the product design, as well as to the Technical
Documentation to be compiled by the manufacturer for each device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the conformity assessment process,
medical device manufacturers must carry out a clinical evaluation of their medical devices to verify that they comply with the
relevant Essential Requirements covering safety and performance. A clinical evaluation is defined as a &ldquo;methodologically
sound ongoing procedure to collect, appraise and analyze clinical data pertaining to a medical device and to evaluate whether there
is sufficient clinical evidence to confirm compliance with relevant essential requirements for safety and performance when using
the device according to the manufacturer&rsquo;s Instructions for Use&rdquo;. A clinical evaluation must address the intended purpose
of the device, clinical performance, benefits that outweigh associated risks and the usability of the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This assessment must be based on clinical
data (Annex X of the MDD), which can be obtained from (i) clinical studies conducted on the devices being assessed; (ii) scientific
literature from similar devices whose equivalence with the assessed device can be demonstrated; or (iii) both clinical studies
and scientific literature. As part of the conformity assessment procedure, depending on the type of devices, the Notified Body
will review the manufacturer&rsquo;s clinical evaluation for the medical device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Notified Body finds, as a result
of its conformity assessment, that the quality assurance system and/or the product design is compliant with the applicable legal
provisions, it issues a CE Certificate of Conformity, which is valid for a maximum of five (5) years. On the basis of these Notified
Body CE Certificates of Conformity, the manufacturer is able to draw up an EC Declaration of Conformity and affix the CE Mark to
the relevant device, followed by the ID number of the Notified Body. The CE mark allows the device to be placed on the market throughout
the EU and the European Economic Area (&ldquo;<B>EEA</B>&rdquo;), as well as in Switzerland and Turkey based on bi-lateral treaties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notified Body is obliged to perform
regular audits and, before the expiry date of a certificate of conformity, renewal audits at the manufacturer&rsquo;s site upon
prior notification. In addition to these notified audits, on the basis of a Commission Recommendation of 2012, the EU member states
were advised by the European Commission to conduct unannounced audits (including testing of product samples) on a regular basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the requirements for application of
the CE mark are not (or no longer) fulfilled, or in other cases of non-compliance with applicable medical devices law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the Notified Body has the power to withdraw, suspend or limit the scope of the applicable certificate of conformity, in accordance
with the principle of proportionality;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the competent supervisory authority of the EU member state may enforce the provisions of the MDD, e.g. by preventing the product
from being put on the market, ordering a recall or shutting down a manufacturing site;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>criminal or administrative sanctions (e.g. fines) may apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, we must establish
a medical device vigilance system, including post-marketing surveillance and adverse event reporting procedures. Under this system,
incidents occurring in the EU that might lead to or might have led to the death of a patient or user or of other persons or to
a serious deterioration in their state of health must be reported to the relevant authorities of the European Union Member States.
Manufacturers are required to take FSCAs, including product recalls and withdrawals, to reduce a risk of death or serious deterioration
in the state of health associated with the use of a medical device that is already placed on the market. Manufacturers have to
appoint a safety officer having the necessary professional qualifications to fulfil the reporting requirements and to coordinate
the necessary actions. For class I devices and certain other devices, the manufacturer of the device or its authorized representative
in the EU, must also register with the competent authority before placing the product on the market in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The advertising and promotion of our products
in the European Union is subject to the provisions of the Medical Devices Directive, Directive 2006/114/EC concerning misleading
and comparative advertising, and Directive 2005/29/EC on unfair commercial practices, as well as other national legislation in
the individual European Union Member States governing the advertising and promotion of medical devices. These laws may limit or
restrict the advertising and promotion of our products to the public and may impose limitations on our promotional activities with
healthcare professionals. In Germany, a company which advises healthcare professionals on the handling and use of medical devices
 &ndash; as may be the case for the TULSA-PRO and Sonalleve devices &ndash; has to appoint a &ldquo;medical devices advisor&rdquo;
(Medizinprodukteberater) with appropriate qualification and professional experience as set out in the German Medical Devices Act
(Medizinproduktegesetz).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 5, 2017, the EU adopted a new
Medical Devices Regulation (EU) 2017/745 (the &ldquo;<B>New EU MDR</B>&rdquo;), which will repeal and replace the Medical Device
Directive effective May 26, 2020. The New EU MDR does not set out a substantially different regulatory system, but clearly envisages,
among other things, stricter controls of medical devices, including strengthening of the conformity assessment procedures, increased
expectations as regards clinical data for devices and pre-market regulatory review of high-risk devices. The New EU MDR also envisages
greater control over Notified Bodies and their standards, increased transparency through the establishment of a comprehensive EU
database on medical devices, more robust device vigilance requirements and clarification of the rules for clinical investigations.
Further, new classification rules apply. Under transitional provisions, medical devices with notified body certificates issued
under the Medical Devices Directive prior to May 25, 2017 may continue to be placed on the market for the remaining validity of
the certificate. Certificates of conformity issued by Notified Bodies in accordance with the MDD after May 25, 2017 and prior to
May 26, 2020 will remain valid until the end of the period indicated on the certificate, but will expire on May 26, 2024 at the
latest, except for certificates issued in accordance with Annex IV to Directive 90/385/EEC or Annex IV to the MDD which shall become
void at the latest on May 27, 2022. After the expiry of any applicable transitional period, only devices that have been CE marked
under the New EU MDR may be placed on the market in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Health Canada&rsquo;s Therapeutic Products
Directorate (&ldquo;<B>TPD</B>&rdquo;) is the Canadian authority that regulates medical devices. In general, prior to being given
market authorization to sell a Class II, III or IV medical device in Canada, a manufacturer must present and/or attest to substantive
scientific evidence of a product&rsquo;s safety, efficacy and quality as required by the Food and Drugs Act and the Medical Devices
Regulations (&ldquo;<B>Canada MDR</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Medical Devices Bureau (&ldquo;<B>MDB</B>&rdquo;)
of the TPD applies the Canada MDR through a combination of pre-market review, post-approval surveillance and quality systems in
the manufacturing process. Medical devices are classified into one of four classes, where Class I represents the lowest risk and
Class IV represents the highest risk. In order to perform investigational testing in Canada for a Class II, III or IV medical device,
authorization for the testing must be granted by the MDB. A Medical Device License is a pre-market requirement for a Class II,
III and IV medical device, including for Class II, III or IV medical devices previously authorized for sale for investigational
testing now to be offered for general/commercial sale. A Medical Device License is issued to the device manufacturer, provided
the requirements of the Canada MDR are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Canada MDR requires that medical devices
be manufactured under a certified QMS that meets the criteria of the international standard, ISO 13485 Medical devices &ndash;
Quality management systems &ndash; Requirements for regulatory purposes. The MDB currently recognizes the Medical Device Single
Audit Program, a program designed to include compliance with the QMS requirements of the Canada MDR. We are manufacturing the
TULSA-PRO system under a certified ISO 13485 Quality Management System.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Current Regulatory Status</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">TULSA-PRO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 15, 2019, we received 510(k)
clearance for commercial sales of the TULSA-PRO as a Class II device in the United States for transurethral ultrasound ablation
(&ldquo;<B>TULSA</B>&rdquo;) of prostate tissue, and in April 2016 the TULSA-PRO system was CE marked in the European Union for
ablation of targeted prostate tissue (benign or malignant). Outside of these jurisdictions, the TULSA-PRO system will require country-specific
pre-market clearance or approval prior to launch.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of our Phase I safety and
feasibility study for TULSA-PRO in April 2016, we were granted CE Mark approval for the commercial sale of the TULSA-PRO system
in Europe and in other CE Mark jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2016, we initiated TACT Pivotal
Clinical Trial, which the FDA approved under an IDE application. The TACT Pivotal Clinical Trial was designed to support a 510(k)
premarket notification submission in the United States. This submission was made in May 2019 in support of clearance of the TULSA-PRO
system by the FDA for use in the ablation of prostate tissue in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In Canada, we are currently manufacturing
the TULSA-PRO system under a certified ISO 13485 Quality Management System. However, on October 26, 2017, Health Canada refused
Medical Device License approval of TULSA-PRO requiring further clinical evidence beyond the Phase I data. We are in the process
of evaluating the additional requirements with Health Canada, however, the Canadian market is not considered a lower priority from
a commercialization strategy perspective in light of its relatively small size.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sonalleve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sonalleve applications to treat uterine
fibroids and bone metastasis are CE marked and available in the European Union and its member states. The uterine fibroids application
is also available for sale in Canada. Philips Oy had registered Sonalleve in several Middle East, North African, and South Asian
countries. We are in the process of transferring existing regulatory registrations of Sonalleve from Philips Oy to us. We are also
in the process of assessing current clinical research network activities and the investigator lead studies in the United States
to form regulatory strategies for several potential indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2018, Sonalleve was also approved in
China by the NMPA for the non-invasive treatment of uterine fibroids.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reimbursement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to successfully commercialize
our products depends in large part on the extent to which coverage and reimbursement for such products and related treatments or
procedures will be available from government health administration authorities, government and private health insurers, and other
organizations or third-party payers. Pricing and reimbursement procedures and decisions vary from country to country. Many government
health authorities and private payers condition payment on the cost-effectiveness of the product. Even if a device is CE marked
or has received regulatory clearance or approval, there is no guarantee that third party payers will reimburse providers or patients
for the cost of the device and related procedures or that the amount of such reimbursement will be adequate to cover the cost of
the device. The availability of adequate coverage and reimbursement to hospitals and clinicians using our products therefore is
critical to our ability to generate revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we expect there to be an out-of-pocket
market for our approved products, an out-of-pocket market alone is unlikely to be sufficient to support successful commercialization
of our products. To date, our products do not have significant coverage or reimbursement from government or third-party payers
in the jurisdictions where they are approved. For more information, see Item 3.D, &ldquo;Risk Factors&mdash;Risks Related to Our
Business and Growth Strategy&mdash;Successful commercialization of our approved products will also depend on the cost of the system
and the availability of coverage and adequate reimbursement from third-party payers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to pursue reimbursement for our
products in these and other key markets where we have regulatory approvals.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intellectual Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our intellectual property is comprised
of a broad and world-wide portfolio of patents, patent applications, trademarks, copyrights, trade secrets and other proprietary
assets. Our intellectual property portfolio is both growing and dynamic and includes approximately 38 patent families representing
approximately 120 granted or allowed patents and 58 patent applications in various stages of review and prosecution around the
world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our patents and patent applications
claim electronic and mechanical aspects of hardware, software and methods related to ultrasonic ablation of tissue. The intellectual
property assets are largely directed to (i) using real time MRI imaging as a tool to plan, monitor or control said ultrasonic ablation;
(ii) MRI thermometry methods, especially in respect of our ultrasound therapy processes and devices; (iii) the phasing, beam-forming,
and control of acoustic arrays and similar energy sources; (iv) computational method to improve filtering, imaging and analyzing
the results of MRI-guided thermal therapy processes; and (v) secondary and support systems such as active cooling of near-target
tissues. The portfolio covers both the &ldquo;TULSA&rdquo; and the &ldquo;Sonalleve&rdquo; families of products, as well as generic
technologies and applications and extensions of our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the protection of our intellectual
property is an essential element of our business and we intend to continue our investment in the development of our intellectual
property portfolio. We have worked over the past year to pursue, maintain and expand on the intellectual property portfolio acquired
from Philips in 2017. This intellectual property has been strengthened and extended to many jurisdictions around the globe in support
of our sales, development and marketing efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We pursue a global intellectual property
strategy, registering for patent protection in all jurisdictions where we intend to carry on business, including the United States,
Canada, Japan, major European markets (e.g., Germany, France, U.K., Italy, Spain and Turkey) and the emerging markets (e.g., Brazil,
Russia, India, and China).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely upon trade secrets, know-how
and other proprietary, confidential information for the protection of our technology. We require all employees, consultants, scientific
advisors and other contractors to enter into confidentiality agreements to protect against the disclosure of such proprietary information.
Each inventor is required to execute a formal assignment specific to each invention that he or she has listed, and which is officially
recorded in the proper patent office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Licenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to developing our own intellectual
property portfolio, we have licensed and acquired intellectual property rights from third parties through exclusive licenses, collaborative
research and asset purchase agreements. Material license agreements include an exclusive license with Sunnybrook entered into on
May 16, 2011 (the &ldquo;<B>Sunnybrook License</B>&rdquo;). Under the Sunnybrook License, Sunnybrook granted us an exclusive worldwide
and royalty-free right to use certain defined Sunnybrook technology in connection with, among other things, manufacturing, marketing
and selling products such as the TULSA-PRO system, in the field of MRI-guided transurethral ultrasound therapy. Under the license,
we are subject to various obligations, including a milestone payment of C$250,000 that was paid in connection with our recent FDA
clearance of TULSA-PRO. In addition, we are required to pay legal costs associated with patent application preparation, filing
and maintenance. If either party to the Sunnybrook License breaches or fails to perform a material obligation and fails to cure
such breach or perform such obligations within a 30 day cure period, the non-breaching party may terminate the agreement. Material
obligations include our agreement not to use the technology or intellectual property outside of the license scope, not to use the
technology or intellectual property outside the field of MRI-guided transurethral ultrasound therapy (or permitting our customers
to do so) and not to breach confidentiality obligations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Organizational
Structure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the organizational structure of our
company, see Item 4.A, &ldquo;History and Development of the Company&mdash;Summary Corporate History and Intercorporate Relationships&mdash;Intercorporate
Relationships&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">D. Property, Plants
and Equipment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate from leased premises in three
different locations. We do not own any real estate property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid"><B>Location</B></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center; border-bottom: Black 1pt solid"><B>Area</B></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: center; border-bottom: Black 1pt solid"><B>Premise Use</B></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 17%; text-align: center; border-bottom: Black 1pt solid"><B>Expiry Date</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>2400 Skymark Ave, Unit 6, Mississauga, ON, Canada</TD>
    <TD>&nbsp;</TD>
    <TD>38,148 ft<SUP>2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Corporate offices and administration, Manufacturing, Research and Development</TD>
    <TD>&nbsp;</TD>
    <TD>September 30, 2026</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&Auml;yritie 4B, 01510 Vantaa, Finland</TD>
    <TD>&nbsp;</TD>
    <TD>6,372 ft<SUP>2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Manufacturing, Research and Development</TD>
    <TD>&nbsp;</TD>
    <TD>December 31, 2021</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Kehrwieder 9, 20457 Hamburg, Germany</TD>
    <TD>&nbsp;</TD>
    <TD>162 ft<SUP>2</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Sales and Marketing</TD>
    <TD>&nbsp;</TD>
    <TD>month to month</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assemble and test TULSA-PRO and Sonalleve
systems at dedicated manufacturing facilities located in Canada and Finland which are ISO 13485 certified. Our manufacturing model
consists primarily of outsourcing manufacturing of the components of our systems where it is most cost effective to do so, while
assembling and quality testing the final products in-house. Additionally, single use products are assembled entirely in the Mississauga
facility within a class 300 clean room which became operational in August 2017. Our manufacturing facilities have sufficient capacity
to meet our manufacturing needs through the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_011"></A>ITEM 4A&nbsp;UNRESOLVED STAFF COMMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_012"></A><FONT STYLE="text-transform: uppercase">ITEM
5. </FONT>OPERATING AND FINANCIAL REVIEW AND PROSPECTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Operating Results</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion and analysis
of our financial condition and results of operations should be read in conjunction with our interim unaudited financial statements
as at and for the three and six months ended June 30, 2019 and 2018 and our audited financial statements as at and for the fiscal
years ended December 31, 2018, 2017 and 2016 in each case, together with the notes thereto. The financial information contained
in this Registration Statement is derived from the financial statements prepared in accordance with IFRS.</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an early commercial-stage medical
device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of
diseased tissue using our platform technology. Our leading approved product is our TULSA-PRO system, which in August 2019 received
FDA clearance as a Class II device in the United States for thermal ablation of prescribed prostate tissue, benign and malignant,
using transurethral ultrasound ablation (&ldquo;<B>TULSA</B>&rdquo;) based on our TACT Pivotal Clinical Trial, and is also CE marked
in the European Union for ablation of targeted prostate tissue (benign or malignant). In addition, our Sonalleve system is CE marked
in the EU for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, and is also approved
in China for the treatment of non-invasive treatment of uterine fibroids. Our systems are designed to be used with MRI scanners
and are currently compatible with MRI scanners manufactured by Philips and Siemens. To date, we have primarily generated revenues
from our limited commercialization of our systems in the EU (principally in Germany) and Asia. We intend to commence commercialization
of the TULSA-PRO system in the United States in the near term following our recent FDA clearance. We also continue to pursue additional
regulatory approvals, research and development, clinical studies and acquisitions in order to expand the applications of our platform
technology and expand our commercial footprint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial strategy to date has been
to raise sufficient funds through securities offerings and bank financings in order to fund specific programs within a focused
budget, and following FDA clearance of our TULSA-PRO system that we received in August 2019, commercialization in the United States.
As our commercialization efforts increase and/or further program development costs increase, we may need to raise additional capital.
See Item 3.D, &ldquo;Risk Factors&rdquo; and Item 5.B, &ldquo;Liquidity and Capital Resources&rdquo; for more information.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trend Information and Outlook</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the following significant trends
and uncertainties are likely to influence our results of operations, cash flows and/or financial condition in the future:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We have recently obtained FDA clearance for the TULSA-PRO system in the United States, and expect
to commence commercialization in the United States in the near team.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We plan to increase our in-house sales and marketing capabilities to commercialize the TULSA-PRO
system in the United States, which we expect will increase our expenses in the near term.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We are pursuing increased compatibility of our systems, including the TULSA-PRO system, with additional
MRI scanners, and we may also pursue additional distribution relationships to facilitate our U.S. commercialization efforts; these
efforts may require significant management time and could result in increased expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We are also pursuing reimbursement coverage for the TULSA-PRO system by third-party payers, such
as private insurance plans offered by medical insurance companies; the amount of such coverage or reimbursement, however, is uncertain,
as we may be required to conduct additional research and clinical trials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We estimate that our general and administrative expenses will increase in the near term, primarily
due to the continued expansion of our management team as well as compliance costs associated with becoming subject to reporting
and other requirements under applicable U.S. securities laws and Nasdaq rules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">We also estimate that the costs for further developing our products and future product candidates
based on our platform technology may increase in future years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our ability to achieve our commercialization
goals, continue our growth and achieve profitability depends, in part, on the level of market acceptance of our products (in particular,
the TULSA-PRO system in the United States), as well as the success of our efforts to increase our U.S. sales and marketing capabilities,
increase compatibility of our systems with additional MRI scanners and procure reimbursement coverage, and also depends on changes
in trends in the standard of care for the patient populations in which our products are indicated for use. In addition, our results
may be adversely affected if, among other things, there is an economic slowdown or future clinical trial results are adverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we believe that some of the trends
and plans described above will present significant opportunities for us, they also pose significant challenges, uncertainties and
risks, including those described under Item&nbsp;3.D, &ldquo;Risk Factors&rdquo; above.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Results of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following selected financial information
as at and for the three and six month periods ended June 30, 2019 and 2018, and selected financial information as at and for the
years ended December 31, 2018, 2017 and 2016, have been derived from the interim unaudited financial statements and from the annual
audited financial statements, respectively, included elsewhere in this Registration Statement, and should be read in conjunction
with those respective financial statements and the related notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Three Months<BR> Ended June
    30,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Six Months<BR> Ended June
    30,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Year Ended<BR> December
    31,</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%"><FONT STYLE="font-size: 8pt">Revenue&#9;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">574,109</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">213,343</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">2,049,897</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">589,678</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">2,602,278</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">4,904,550</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Cost of sales&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">224,066</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">126,259</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">777,422</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">357,334</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,778,501</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">3,032,208</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Gross profit&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">330,043</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">87,084</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,272,475</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">232,344</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">823,777</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,872,342</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Operating Expenses</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 16.95pt"><FONT STYLE="font-size: 8pt">Research and development - net of investment
    tax credits&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,186,355</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,347,909</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,864,101</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,864,690</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,265,388</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,638,190</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">9,988,693</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 16.95pt"><FONT STYLE="font-size: 8pt">General and administrative&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,586,323</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,236,529</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,100,436</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,539,733</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">6,656,723</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,935,215</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,369,288</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 16.95pt"><FONT STYLE="font-size: 8pt">Selling and distribution&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,154,869</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,113,225</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">625,524</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">2,060,127</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">4,091,347</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">3,925,804</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,282,433</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Total operating expenses&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,927,547</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,697,663</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">9,590,061</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">10,464,550</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">21,013,458</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">19,499,209</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">15,640,414</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Finance costs&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">337,220</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">313,606</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">651,905</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">633,569</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">826,312</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,249,084</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">829,899</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Finance income&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(110,790</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(117,357</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(252,671</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(157,161</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(483,788</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(127,732</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(157,598</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net finance costs&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">226,430</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">196,249</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">399,234</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">476,408</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">342,524</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,121,352</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">672,301</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Loss before income taxes&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,823,934</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,806,828</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,716,820</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,708,614</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,532,205</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,748,219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16,312,715</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Income tax expense&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">20,200</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">24,200</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">54,000</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">60,600</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">230,784</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">74,123</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">14,054</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Net loss attributable to shareholders for the period&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,844,134</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,831,028</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">8,770,820</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">10,769,214</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,762,989</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,822,342</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">16,326,769</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Other comprehensive loss</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Item that may be reclassified to profit or loss</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Foreign currency translation adjustment - net
    of tax&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(11,843</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">57,943</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(58,232</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">14,695</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">29,226</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(69,245</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">11,316</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Net loss and comprehensive loss for the period&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,832,291</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,888,971</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">8,712,588</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">10,783,909</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">20,792,215</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">18,753,097</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">16,338,085</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Basic and diluted net loss per common share&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.08</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.12</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.21</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.31</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">0.39</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the TULSA-PRO system, we generate revenue
from the sale of the capital equipment, procedure-related sales of disposable single-use components of the system (which are sold
on a per patient basis), and service revenue for ongoing maintenance of the systems. Sales of Sonalleve systems are primarily a
one-time capital sale with limited recurring service revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the historical financial periods presented
herein, we have generated revenues primarily from sales of our systems and disposables through our partnerships with Siemens and
Philips in the EU and Asia. In August 2019, we received FDA clearance for our TULSA-PRO system in the United States, and accordingly
we anticipate generating future revenues in the U.S. market. As we expand our commercialization efforts, we anticipate generating
revenues through our in-house sales and marketing efforts, as well as from our collaborative partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, because we have been in our
pilot sales launch phase, our revenues for the historical periods presented herein have fluctuated significantly on a quarter-over-quarter
and year-over-year basis. We expect that our revenues will likewise fluctuate from period-to-period in the near term as we pursue
our commercialization strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of Sales</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of sales include cost of finished
goods, inventory provisions, warranties, freight and direct overhead expenses. We expect cost of sales to increase or decrease
corresponding with fluctuations in our revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operating expenses consist of three
components: research and development (&ldquo;<B>R&amp;D</B>&rdquo;), general and administrative (&ldquo;<B>G&amp;A</B>&rdquo;)
and selling, marketing and distribution expenses. Historically, our R&amp;D expenses have exceeded our selling, marketing and distribution
expenses; however, in the future we expect our selling, marketing and distribution expenses to increase as we commercialize the
TULSA-PRO system in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our R&amp;D expenses are comprised of costs
incurred in performing R&amp;D activities, including new product development, continuous product improvement, investment in clinical
trials and related clinical manufacturing costs, materials and supplies, salaries and benefits, contract research costs, patent
procurement costs, and occupancy costs related to R&amp;D activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our G&amp;A expenses are comprised of management
costs, including salaries and benefits, various management and administrative support functions, insurance and other operating
and occupancy costs related to G&amp;A activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, Marketing and
Distribution Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our selling, marketing and distribution
expenses are comprised of business development costs related to the market development activities and commercialization of our
systems, including salaries and benefits, marketing support functions, marketing-related occupancy costs and other miscellaneous
marketing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finance Costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance costs are primarily comprised of
interest and accretion expenses, among others, historically relating to the following: (i) the Federal Economic Development Agency
Loan accreting to the principal amount repayable; (ii) the Health Technology Exchange Loan accreting to the principal amount repayable
and its related interest expense; (iii) the Knight Loan accreting to the principal amount repayable and its related interest expense;
(iv) the 0.5% royalty liability to Knight accreting to the estimated amount payable; (v) the change in fair value of the contingent
consideration payable to Philips under the Philips Share Purchase Agreement; (vi) the CIBC Loan accreting to the principal amount
repayable and its related interest expense; (vii) the change in the fair value of the derivative liability warrants; (viii) the
lease liability interest expense related to the adoption of IFRS 16 and (ix) foreign exchange gains or losses. We repaid the Health
Technology Exchange Loan on March 31, 2019 and each of the Federal Economic Development Agency Loan and the Knight Loan on July
25, 2018, and the Knight royalty terminated on May 20, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparison of the Three and Six Months
Ended June 30, 2019 to the Three and Six Months Ended June 30, 2018</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended June 30, 2019,
we recorded revenue totaling C$574,109 with C$465,840 from the sale of products and C$108,269 from installation and training services
related to the commercial sales of the systems and disposables, primarily in the European Union. For the three months ended June
30, 2018, we recorded revenue totaling C$213,343, with C$170,931 from sale of products and C$42,412 from installation and training
services. The increase in revenue in the second quarter of 2019 over the second quarter of 2018 was the result of increased system
and disposable sales as well as increased service contracts<FONT STYLE="font-weight: normal">. However, our revenues in the second
quarter of 2019 were lower than in the first quarter of 2019 and the fourth quarter of 2018 because of decreased system and disposable
sales due to fluctuating revenues in our early pilot launch phase. See &ldquo;&mdash;Quarterly Results of Operations&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2019,
we recorded revenue totaling C$2,049,897, with C$1,813,621 from the sale of products and C$236,276 from installation and training
services related to the commercial sales of the systems and disposables, primarily in the European Union. For the six months ended
June 30, 2018, we recorded revenue totaling C$589,678, with C$543,425 from the sale of products and C$46,253 from installation
and training services. The increase in revenue in the six months ended June 30, 2019 was the result of increased system and disposable
sales as well as increased service contracts<FONT STYLE="font-size: 10pt; font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of Sales</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended June 30, 2019,
we recorded a cost of sales of C$244,066 related to the sale of systems and disposables, which reflects a 58% gross margin. For
the three months ended June 30, 2018, we recorded a cost of sales of C$126,259 related to the commercial sale of systems and disposables,
which reflects a 41% gross margin. The gross margin was higher in the second quarter of 2019 due to increased disposable and service
revenue, which have higher margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2019,
we recorded a cost of sales of C$777,422 related to the commercial sale of the systems and disposables, which reflects a 62% gross
margin. For the six months ended June 30, 2018, we recorded a cost of sales of C$357,334 related to the commercial sale of systems
and disposables, which reflects a 39% gross margin. The gross margin was higher in the six months ended June 30, 2019 due to increased
disposable and service revenue, which have higher margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended June 30, 2019,
R&amp;D expenses were higher by C$838,446 compared to the three months ended June 30, 2018. Clinical trial costs, materials, share
based compensation and salaries and benefits increased period-over-period by C$219,569, C$294,225, C$33,986, and C$244,263, respectively.
These increases were due to increased spending and testing for R&amp;D and activity related to pursuing U.S. regulatory approvals,
analysis of TACT clinical data, options awarded to employees, increased R&amp;D personnel and investment tax credits decreasing
by C$60,000 because of lower eligibility for refundable tax credits. Offsetting these amounts were decreases in rent of C$57,456,
due to the adoption of IFRS 16 resulting in the recognition of lower rental costs. Depreciation expenses increased by C$26,762
due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2019,
R&amp;D expenses were higher by C$999,411 compared to the six months ended June 30, 2018. Materials, share based compensation,
salaries and benefits and other expenses increased by C$777,683, C$51,238, C$214,155 and C$61,277, respectively. These costs were
higher compared to the six months ended June 30, 2018, due to increased spending and testing on R&amp;D and US regulatory projects,
options awarded to employees, increased R&amp;D personnel and investment tax credits decreasing by C$120,000 because of lower eligibility
for refundable tax credits. Offsetting these amounts was a decrease in clinical trial costs, consulting fees and rent by C$107,052,
C$67,474 and C$95,486, respectively, resulting from the completion of the TACT Pivotal Clinical Trial enrollment initiatives, insourcing
manufacturing and regulatory projects and the adoption of IFRS 16 resulting in the recognition of lower rental costs. Depreciation
expenses increased by C$54,929 due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A expenses for the three months ended
June 30, 2019 decreased by C$650,206 compared to the three months ended June 30, 2018. Salaries and benefits, consulting fees and
travel decreased by C$386,996, C$386,594 and C$24,337, respectively due to no bonuses awarded to management this quarter, lower
legal costs and decreased travel to customer sites. In addition, the second quarter of 2018 was affected by increased management
compensation due to the hiring of key management personnel. These costs were offset by an increase in share based compensation
of C$111,871 in the second quarter of 2019, due to options awarded to various employees. Depreciation expenses increased by C$59,759
due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A expenses for the six months ended
June 30, 2019 were lower by C$439,297 compared to the six months ended June 30, 2018. Salaries and benefits, consulting fees, rent
and travel decreased by C$191,845, C$400,874, C$31,289 and C$17,609, respectively, due to no bonuses awarded to management, lower
legal costs, adoption of IFRS 16 resulting in the recognition of lower rental costs and decreased travel to customer sites. Depreciation
expenses increased by C$121,191 due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, Marketing and Distribution
Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, marketing and distribution expenses
for the three months ended June 30, 2019 were higher by C$41,644 compared to the three months ended June 30, 2018. Consulting fees
increased by C$247,992 related to the additional consultants hired in various countries to help market and promote our approved
products. Marketing and salaries and benefits expenses decreased by C$49,351 and C$128,834, respectively, due to decreased tradeshow
attendance, marketing initiatives in the second quarter of 2019 a regional re-alignment of marketing personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, marketing and distribution expenses
for the six months ended June 30, 2019 were lower by C$1,434,603 compared to the six months ended June 30, 2018. Salaries and benefits,
share based compensation, marketing and travel expenses decreased by C$164,123, C$182,320, C$125,469 and C$32,220, respectively,
due to a regional re-alignment of marketing personnel, employee forfeiture of options, decreased trade show attendance, product
branding development and decreased travel. In addition, in the first quarter of 2019, our revenue share obligation decreased by
C$1,209,205 related to the replacement of the Original Siemens Agreement with the New Siemens Agreement whereby all prior financial
commitments and obligations owed to Siemens were released, resulting in a recovery of expenses recorded in the six months ended
June 30, 2019. These costs were offset by an increase in consulting fees of C$296,803 due to consultants hired in various countries
to help market and promote our approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finance Costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance costs for the three months ended
June 30, 2019 were higher by C$30,181 compared to the three months ended June 30, 2018. During the three months ended June 30,
2019, we recognized C$26,298 of foreign exchange loss and a C$25,072 gain on the change in fair value to the contingent consideration
under the Philips Share Purchase Agreement and a C$3,251 gain on the change in fair value of the derivative liability warrants,
respectively. We recognized CIBC Loan interest of C$312,050 and lease liability interest expense of C$33,556.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance costs for the six months ended
June 30, 2019 were lower by C$77,174 compared to the six months ended June 30, 2018. During the six months ended June 30, 2019,
we recognized C$34,786 of foreign exchange gain, a C$48,787 gain on the change in fair value to the contingent consideration and
a C$54,220 loss on the change in fair value of the derivative liability warrants, respectively. We recognized CIBC Loan interest
of C$617,559 and lease liability interest expense of C$67,149.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income Tax Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and six months ended June
30, 2019, we recorded an income tax expense of C$20,200 and C$54,000, respectively, compared to C$24,200 and C$60,600 for the three
and six months ended June 30, 2018, which primarily related to taxes in certain foreign jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the three months ended June
30, 2019 was C$5,844,134 or C$0.05 per Common Share, compared to a net loss of C$5,831,028 or C$0.05 per Common Share for the three
months ended June 30, 2018. The increase in net loss was primarily attributed to an increase in R&amp;D expenses of C$838,446,
an increase in selling and distribution expenses of C$41,644 and an increase in net finance costs of C$30,181. This was offset
by a decrease in G&amp;A expenses of C$650,206 and an increase in gross profits of C$242,959. <FONT STYLE="font-weight: normal">However,
our net loss in the second quarter of 2019 was greater than in the first quarter of 2019. See &ldquo;&mdash;Quarterly Results of
Operations&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the six months ended June
30, 2019 was C$8,770,820 or C$0.08 per common share, compared to a net loss of C$10,769,214 or C$0.12 per common share for the
six months ended June 30, 2018. The decrease in net loss was primarily attributed to a decrease in G&amp;A expenses of C$439,297,
a decrease in selling and distribution expenses of C$1,434,603, a decrease in net finance costs of C$77,174 and an increase in
gross profit of C$1,040,131. This was offset by an increase in R&amp;D expenses of C$999,411.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparison of the Year Ended December
31, 2018 to the Year Ended December 31, 2017</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2018, we
recorded revenue totaling C$2,602,278, with C$2,421,331 from the sale of products and C$180,947 from installation and training
services, related to the commercial sales of the systems and disposables, primarily in the EU. For the year ended December 31,
2017, we recorded revenue totaling C$4,904,550, with C$4,663,986 from sale of products and C$240,564 from installation and training
services. The decrease in revenue was the result of fewer new system and disposable sales in 2018 due to fluctuating revenues in
our early pilot launch phase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of Sales</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2018, we
recorded a cost of sales of C$1,778,501, related to the sale of the systems and disposables, which reflects a 32% gross margin.
For the year ended December 31, 2017, we recorded a cost of sales of C$3,032,208, related to the commercial sale of systems and
disposables, which reflects a 38% gross margin. The gross margin was lower in 2018 due to changes in the product mix as a result
of the Sonalleve Transaction and lower gross margin on disposables compared to the systems based on initial low volumes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2018, R&amp;D
expenses were higher by C$627,198 compared to the year ended December 31, 2017. Overall, the increase in R&amp;D spending was attributed
to the Sonalleve Transaction, which occurred in the third quarter of 2017. Materials, rent, salaries and benefits and other expenses
increased by C$125,035, C$110,756, C$1,224,691 and C$177,625, respectively. These costs were higher compared to the year ended
December 31, 2017, due to a higher number of R&amp;D personnel, new initiatives with our Sonalleve system and a new facility in
Finland. Offsetting these amounts was a decrease in clinical trial costs, travel and share based compensation by C$1,544,191, C$26,194
and C$67,403, respectively, resulting from the completion of the TACT Pivotal Clinical Trial enrollment initiatives and the forfeiture
of certain share options. Amortization of intangible assets increased by C$626,593 due to the Sonalleve Transaction which represented
12 months amortization in 2018 versus 5 months amortization in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A expenses for the year ended December
31, 2018 were higher by C$721,508 compared to the year ended December 31, 2017. Salaries and benefits, travel and office and other
increased by C$885,846, C$60,982 and C$28,879, respectively, due to increased number of G&amp;A personnel and board members, bonus
payments, salary increases, including as a result of the Sonalleve Transaction, and increased insurance expenses and travel to
customer sites. These costs were offset by a decrease in share-based compensation expense and occupancy costs (resulting in lower
utility bills and repairs to the facilities) by C$326,501 and C$106,427, respectively. Depreciation expense increased by C$167,970
primarily due to leasehold improvements for the new facility that was constructed in the latter part of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, Marketing and Distribution
Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, marketing and distribution expenses
for the year ended December 31, 2018 were higher by C$165,543 compared to the year ended December 31, 2017. Salaries and benefits,
consulting fees, travel, marketing and share based compensation increased by C$400,470, C$175,152, C$77,295, C$138,644 and C$145,229,
respectively, due to additional direct sales force personnel, awards issued to new employees, increased marketing-related efforts,
product branding development and conference attendance. These costs were offset by a reduced revenue share obligation expense of
C$787,858 related to the Siemens revenue share payments compared to the minimum amounts contractually stipulated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finance Costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance costs for the year ended December
31, 2018 were lower by C$422,772 compared to the year ended December 31, 2017. During the year ended December 31, 2018, we recognized
C$214,226 of foreign exchange loss, a C$325,253 and C$96,619 gain on the change in fair value to the contingent consideration under
the Philips Share Purchase Agreement and the change in fair value of the derivative liability warrants, respectively. We recognized
a decrease in the Health Technology Exchange Loan and Federal Economic Development Agency Loan and Knight Loan interest and accretion
expense of C$57,149 and C$752,358, respectively and an increase in CIBC Loan interest and accretion expense of C$517,409.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income Tax Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2018,
we recorded an income tax expense of C$230,784, compared to C$74,123 for the year ended December 31, 2017 which primarily related
to taxes in certain foreign jurisdictions. The increase was a direct result of increased commercial efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the year ended December 31,
2018 was C$20,762,989 or C$0.21 per Common Share, compared to a net loss of C$18,822,342 or C$0.31 per Common Share for the year
ended December 31, 2017. The increase in net loss was primarily attributed to an increase in R&amp;D expenses of C$627,198, an
increase in G&amp;A expenses of C$721,508, an increase selling and distribution expenses of C$165,543, and a decrease in gross
profit of C$1,048,565. These were offset by a decrease in net finance costs of C$778,828.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparison of the Year Ended December
31, 2017 to the Year Ended December 31, 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2017, we
recorded revenues totaling C$4,904,550, with C$4,663,986 from sale of products and C$240,564 from installation and training services,
related to the commercial sales of the systems and disposables, primarily in the EU. In 2016, we had no revenues as we were in
the pre-commercial stage of our development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of Sales</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2017, we
recorded cost of sales of C$3,032,208, related to the sales of the systems and disposables. In 2016, we had no revenues or related
cost of sales as we were in the pre-commercial stage of our development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2017, R&amp;D
expenses were lower by C$350,503 compared to the year ended December 31, 2016. Overall, the decrease in R&amp;D spending reflected
the advanced stages of development of our products and the ramp-up of commercial operations in approved jurisdictions. Materials,
contractors and other expenses were lower by C$2,523,608, C$136,386 and C$204,711, respectively due to lower material costs and
R&amp;D initiatives associated with our TACT Pivotal Clinical Trials. Offsetting this amount was an increase in clinical trial
costs, salaries and benefits, amortization of intangible assets, consulting fees and travel by C$1,311,878, C$562,626, C$458,980,
C$80,763 and C$66,248, respectively, resulting from ongoing activities related to the initiation of clinical site visits, enrollment
initiatives, patient treatment and workforce costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">G&amp;A expenses for the year ended December
31, 2017 were higher by C$1,565,927 compared to the year ended December 31, 2016. Salaries and benefit expenses increased by C$88,190,
primarily related to a separation payment to a former executive officer and the addition of key executives. In addition, professional
and consulting fees increased by C$976,380 due to legal fees associated with the Sonalleve Transaction and the inclusion of Sonalleve-related
operations. Share-based compensation and rent increased by C$289,689 and C$20,364, respectively, due to new options issued to executive
officers while rent was due to relocation to a larger facility in July 2016. Depreciation expense increased by C$195,218 primarily
due to the new property and equipment for the new facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling, Marketing and Distribution
Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling and distribution expenses for the
year ended December 31, 2017 were higher by C$2,643,371 compared to the year ended December 31, 2016. The increase is largely attributable
to recognizing commissions payable on commercial sales of C$73,046 and a provision of C$953,429 related to the estimated shortfall
of revenue share payments compared to the minimum amounts contractually required. In addition, shared based compensation and salaries
and benefits increased by C$32,820 and C$650,391, respectively, resulting from additional direct sales force personnel. Professional
and consulting fees, marketing, office and other and travel expenses increased by C$353,974, C$257,074, C$90,676 and C$231,961,
respectively. These increases relate directly to marketing-related efforts and an increased direct sales force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finance Costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Finance costs for the year ended December
31, 2017 were higher by C$419,185 compared to the year ended December 31, 2016. During the year ended December 31, 2017, we revised
the fair value of the royalty payable to Knight, using future revenue forecasts for the term of the Knight Loan and recognized
an interest accretion recovery of C$36,438. As part of the Sonalleve Transaction, we were required to repay the Knight Loan at
an accelerated rate and therefore recognized C$333,997 of accelerated accretion expense. During the year, we revised the fair value
of the contingent consideration under the Philips Share Purchase Agreement and recognized a change in fair value of C$82,578.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income Tax Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2017,
we recorded an income tax expense C$74,123, compared to the year ended December 31, 2016 of C$14,054 with the increase primarily
related to the Sonalleve Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss for the year ended December 31,
2017 was C$18,822,342 or C$0.31 per common share, compared to a net loss of C$16,326,769 or C$0.39 per Common Share for the year
ended December 31, 2016. The increase in net loss was primarily attributed to an increase in selling and distribution expenses
of C$2,643,371, G&amp;A expenses of C$1,565,927 and an increase in financing costs of C$419,185. These increases were offset by
a gross profit of C$1,872,342.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quarterly Results of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes selected
unaudited consolidated financial data for each of the last eight quarters. The summary financial information provided below is
derived from our interim financial statements for each of the last eight quarters that are prepared under IFRS in Canadian dollars.
These quarterly operating results are not necessarily indicative of our operating results for a full year or any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2019</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q2</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q1</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q4</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q3</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q2</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q1</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Q4</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-size: 8pt"><B>Q3</B><SUP>(1)</SUP></FONT></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">C$</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 8pt">Revenue<SUP>(3)</SUP>&#9;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">574,109</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">1,475,788</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">1,708,936</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">303,664</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">213,343</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">376,335</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">1,890,482</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 8pt">1,465,412</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Cost of Sales&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">244,066</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">533,356</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,180,481</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">240,686</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">126,259</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">231,075</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,063,950</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">1,185,674</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Gross profit&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">330,043</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">942,432</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">528,455</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">62,978</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">87,084</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">145,260</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">826,532</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">279,738</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Operating expenses&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,927,547</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">3,662,514</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,309,931</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,238,977</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,697,663</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,766,887</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,155,423</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,148,434</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Net finance costs<SUP>(2)</SUP>&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">226,430</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">172,804</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(60,151</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(73,733</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">196,249</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">280,159</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">130,632</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">651,378</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Loss before income taxes&#9;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,823,934</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,892,886</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,721,325</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,102,266</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,806,828</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,901,786</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,459,523</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">5,520,074</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">Income taxes&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">20,200</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">33,800</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">136,884</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">32,700</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">24,200</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">36,400</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">69,470</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">Net loss for the period&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,844,134</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">2,926,686</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">4,858,809</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,134,966</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,831,028</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">4,938,186</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">4,528,993</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">5,520,074</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">Loss per common share</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><FONT STYLE="font-size: 8pt">Basic and diluted&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.03</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.04</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.05</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.06</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.06</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-size: 8pt">0.09</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>The fourth quarter of 2018 was impacted by increased commercial sales of systems primarily in Germany and Asia, resulting in
increased revenues.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>The third and fourth quarters of 2018 net finance costs were lower due to a gain on the change in fair value of contingent
consideration under the Philips Share Purchase Agreement and share warrants being recognized.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently Issued Accounting Pronouncements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In conjunction with the transition to the
new IFRS 16, Leases and IFRIC 23, Uncertainty over Income Tax Treatments, we have determined that the adoption of these new accounting
standards did not have a significant impact on our control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
in conformity with IFRS requires management to make estimates and judgements that affect the reported amounts of assets and liabilities
at the date of the financial statements, and the reported amounts of revenue and expenses during the period. Actual results could
differ from these estimates. As additional information becomes available or actual amounts are determinable, the recorded estimates
are revised and reflected in operating results in the period in which they are determined.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical Accounting Policies and Estimates</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for arrangements
we performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in
the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the
contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts
when it is probable that we will collect the consideration it is entitled to in exchange for the goods or services it transfers
to the customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue is recognized when a contractual
promise to a customer (performance obligation) has been fulfilled by transferring control over the promised goods or services,
generally at the point in time of shipment to or receipt of the products by the customer or when the services are performed. When
contracts contain customer acceptance provisions, revenue is recognized on the satisfaction of the specific acceptance criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The amount of revenue to be recognized
is based on the consideration we expect to receive in exchange for its goods and services. For contracts that contain multiple
performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on
relative standalone selling prices and we recognize the related revenue when or as control of each individual performance obligation
is transferred to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Service revenue related to installation
and training is recognized over the period in which the services are performed. Service revenue related to extended warranty service
is deferred and recognized on a straight-line basis over the extended warranty period covered by the respective customer contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of certain of our partnership
agreements with Philips and Siemens, we retain a percentage of all amounts earned with the remaining percentage due to the partner.
Accordingly, associated revenue is recognized net of the consideration due to the partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Complex financial instruments and provisions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We make various judgments when determining
the accounting for certain complex financial instruments. We have concluded that the contingent consideration in a business combination
represents a financial liability measured at fair value through profit or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts receivable and allowance for credit losses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are generally non-interest
bearing, unsecured obligations due from customers. We make a provision to allow for potentially uncollectible amounts owed from
customers. The allowance is reviewed by management periodically based on an analysis of the age of the outstanding accounts receivable.
The balance of accounts receivable after the allowance for credit losses represents management&rsquo;s estimate of the net realizable
value of receivables after discounts and contractual adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Impairment of goodwill and long-lived assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management tests at least annually whether
goodwill suffered any impairment. Property and equipment are reviewed for impairment whenever events or changes in circumstances
indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which the asset&rsquo;s
carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&rsquo;s fair value less costs
to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are
separately identifiable cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management makes key assumptions and estimates
in determining the recoverable amount of our cash generating units (&ldquo;<B>CGUs</B>&rdquo;) or groups of CGUs, including future
cash flows based on historical and budgeted operating results, growth rates, tax rates and appropriate after-tax discount rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We evaluate our long-lived assets (property
and equipment) and intangible assets, other than goodwill, for impairment whenever indicators of impairment exist. The accounting
standards require that if the sum of the undiscounted expected future cash flows from a long-lived asset or definite-lived intangible
asset is less than the carrying value of that asset, an asset impairment charge must be recognized. The amount of the impairment
charge is calculated as the excess of the asset&rsquo;s carrying value over its fair value, which generally represents the discounted
future cash flows from that asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Impairment of non-financial assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review amortized non-financial assets
for impairment whenever events or changes in circumstances indicate the carrying amount of the assets may be impaired. We also
review goodwill annually for impairment. If the recoverable amount of the respective non-financial asset is less than our carrying
amount, it is considered to be impaired. In the process of measuring the recoverable amount, management makes assumptions about
future events and circumstances. The actual results may vary and may cause significant adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounting for acquisitions and contingent consideration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Areas of estimation include the determination
and fair value measurement of the contingent consideration, which include us developing our best estimate of projected revenue,
the probability of the contingency being achieved and the discount rate. Management is also required to make estimates of the fair
value of assets acquired and liabilities assumed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clinical trial expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trial expenses are accrued based
on the services received and efforts expended pursuant to agreements with clinical trial sites and other vendors. In the normal
course of business we contract third parties to perform various clinical trial activities. The financial terms of these agreements
vary from contract to contract, are subject to negotiation and may result in uneven payment flows. Payments under the contracts
depend on factors such as the achievement of certain events, the successful enrollment of patients or the completion of certain
portions of a clinical trial. We determine the accrual by reviewing contracts, vendor agreements and through discussions with internal
personnel and external clinical trial sites as to the progress or stage of completion of the clinical trial and the agreed-upon
fees to be paid for such services. Actual costs and timing of the clinical trial is uncertain, subject to risks and may change
depending on a number of factors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JOBS Act</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a company with less than US$1.07 billion
in revenue during the last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo; pursuant to the JOBS Act. An emerging
growth company may take advantage of specified exemptions from various requirements that are otherwise applicable generally to
public companies in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JOBS Act also permits an emerging growth
company such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable
to public companies. We will not take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
Act for complying with new or revised accounting standards. This election is irrevocable. We will remain an emerging growth company
until the earliest of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the last day of our fiscal year during which we have total annual gross revenues of at least US$1.07
billion;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the last day of our fiscal year following the fifth anniversary of the completion of an initial
public offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which we have, during the previous three-year period, issued more than US$1 billion
in non-convertible debt securities; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; under the Exchange
Act, which would occur if the market value of our Common Shares that are held by non-affiliates exceeds US$700 million as of the
last business day of our most recently completed second fiscal quarter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our status as an emerging
growth company, the information that we provide shareholders may be less comprehensive than what you might receive from other public
companies that are not emerging growth companies. When we are no longer deemed to be an emerging growth company, we will not be
entitled to the exemptions provided in the JOBS Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Liquidity and
Capital Resources</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary sources of capital to date
have been from securities offerings and bank financings, including the Bought Deals and CIBC Loan as described below. At June 30,
2019, we had cash of C$20,493,470 compared to C$30,687,183 at December 31, 2018. Following FDA clearance of our TULSA-PRO system
in August 2019, we paid a C$250,000 milestone payment to Sunnybrook under the Sunnybrook License. See Item 4.B, &ldquo;Business
Overview&mdash;Intellectual Property&mdash;Licenses&rdquo;. As of June 30, 2019, our total borrowings were C$12,500,000, related
to the CIBC Loan described below. Our funding and treasury activities are conducted within corporate practices to maximize investment
returns while maintaining appropriate liquidity for both our short and long-term needs. Cash is held primarily in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the six months ended June 30, 2019
and for the year ended December 31, 2018, we had no capital expenditures, compared to C$430,569 for the year ended December 31,
2017 and C$863,991 for the year ended December 31, 2016, most of which were used for the purchase of production and research and
development equipment, office furniture and equipment and computers and self-manufactured equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our working capital has decreased by C$9,825,322
with a surplus of C$20,215,107 at June 30, 2019 compared to the surplus of C$30,040,429 at December 31, 2018. For a calculation
of working capital, see &ldquo;Working Capital&rdquo; below. The change in working capital was due to a decrease in current assets
of C$10,239,005, which was primarily the result of the decreased cash balance of C$20,493,470 resulting from general working capital
payments. We believe that our working capital is sufficient for our present requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may require additional capital to fund
our commercialization efforts in the United States and future clinical trials and/or R&amp;D activities. Potential sources of capital
could include equity and/or debt financings, development agreements or marketing agreements, the collection of revenue resulting
from future commercialization activities and/or new strategic partnership agreements to fund some or all costs of development.
There can be no assurance that we will be able to obtain the capital sufficient to meet any or all of our needs. The availability
of equity or debt financing will be affected by, among other things, the success of our commercialization efforts, the follow-up
results of our clinical trials and our future R&amp;D activity, our ability to obtain additional regulatory approvals, the state
of the capital markets generally, strategic alliance agreements and other relevant considerations. See Item 3.D., &ldquo;Risk Factors&rdquo;
elsewhere in this Registration Statement. In addition, if we raise additional funds by issuing equity securities, existing security
holders will likely experience dilution, and any additional incurrence of indebtedness would result in increased debt service obligations
and could require us to agree to additional operating and financial covenants that could further restrict our operations. Any failure
to raise additional funds on terms favorable to us or at all may require us to significantly change or curtail our current or planned
operations in order to conserve cash until such time, if ever, that sufficient proceeds from operations are generated, and could
result in us not being in a position to advance our commercialization strategy or take advantage of business opportunities, and
may results in the termination or delay of clinical trial results for our products or future clinical trials for other product
candidates, in the curtailment of product development programs designed to improve our existing products or identify new product
candidates, in the sale or assignment of rights to our intellectual property, and/or cause us to delay or suspend applications
for regulatory approvals at all or in time to competitively market our products and future product candidates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recent Sources and Uses of Financing</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bought Deals</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2018, we closed a bought deal
financing, resulting in the issuance of 34,500,000 units at a price of C$1.00 per unit, for gross proceeds of C$34,500,000 (C$32,027,502,
net of cash transaction costs) (the &ldquo;<B>2018 Bought Deal</B>&rdquo;). Each unit consisted of one Common Share and one-half
of one Common Share purchase warrant, resulting in the issuance of 34,500,000 Common Shares and 17,250,000 warrants. Each whole
warrant has a five-year term and entitles the holder thereof to acquire one Common Share at an exercise price of C$1.40 per Common
Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have allocated the net proceeds of the
2018 Bought Deal to (i) support certain costs and expenses of other clinical trial support and the ongoing TACT Pivotal Clinical
Trial follow-up and finalization; (ii) ongoing expansion of infrastructure to execute on global sales and marketing plans with
respect to the TULSA-PRO system and the Sonalleve system; (iii) support ongoing research and development and continue to invest
in additional research and development and acquisitions in order to expand the applications for current and future platforms; (iv)
scheduled repayment under the Knight Loan and other indebtedness; and (v) other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 20, 2017, we closed a bought
deal financing, resulting in the issuance of 10,000,000 units at a price of C$1.00 per unit, for gross proceeds of C$10,000,000
(C$8,913,868, net of cash transaction costs) (the &ldquo;<B>2017 Bought Deal</B>&rdquo;). Each unit consisted of one Common Share
and one-half of one Common Share purchase warrant, resulting in the issuance of 10,000,000 Common Shares and 5,000,000 warrants.
Each whole warrant has a three-year term and entitles the holder thereof to acquire one Common Share at a price of C$1.40 per Common
Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2016, we closed a bought
deal financing, resulting in the issuance of 15,820,000 Common Shares at a price of C$1.10 per Common Share for gross proceeds
of C$17,402,000 (C$16,182,997, net of cash transaction costs) (the &ldquo;<B>2016 Bought Deal</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIBC Loan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PMI entered into the CIBC Loan Agreement,
for initial gross proceeds of C$12,500,000, maturing on July 29, 2022, with an interest rate based on prime plus 2.5% (the &ldquo;<B>CIBC
Loan</B>&rdquo;). PMI is required to make interest only payments for the first 15 months (until October 31, 2019) and monthly repayments
on the principal of C$378,788 plus accrued interest afterwards for 33 months. All obligations of PMI under the CIBC Loan Agreement
are guaranteed by Profound and certain of its current and future subsidiaries, and are secured by first priority security interests
in the assets of Profound and such subsidiaries. PMI has the ability to draw an additional C$6,250,000 subject to the achievement
of certain financing and FDA approval milestones. The CIBC Loan Agreement also contains a financial covenant that requires our
unrestricted cash to be greater than operating cash expenditures for a trailing three-month period, reportable to CIBC on a monthly
basis. We are currently in compliance with this financial covenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the CIBC Loan Agreement,
we also issued 321,714 Common Share purchase warrants to CIBC, with each warrant entitling the holder to acquire one Common Share
at a price of C$0.97 per Common Share until the date that is 60 months from the closing of the CIBC Loan Agreement, with a cashless
exercise feature. The cashless exercise feature causes the conversion ratio to be variable and the warrants are therefore classified
as a financial liability. Gains and losses on the warrants are recorded within finance costs on the consolidated statements of
loss and comprehensive loss. A pricing model with observable market-based inputs was used to estimate the fair value of the warrants
issued. The estimated fair value of the warrants at June 30, 2019 and December 31, 2018 was C$152,423 and C$98,203, respectively.
As at June 30, 2019, the principal balance outstanding on the CIBC Loan Agreement was C$12,500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Knight Loan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2015, Knight provided us with
a secured loan of C$4,000,000 bearing interest at 15% per annum (the &ldquo;<B>Knight Loan</B>&rdquo;) under the Knight Loan Agreement.
On July 25, 2018, the full amount of the Knight Loan, including prepayment fees, was repaid for a total payment of C$3,188,023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also granted Knight a 0.5% royalty on
global net sales of our products until the original maturity date of the Knight Loan on May 20, 2019. The royalty was initially
recorded at fair value and subsequently carried at amortized cost using the effective interest rate method. The initial fair value
of the royalty was determined using future revenue forecasts for the term of the Knight Loan and a discount rate of 18%. During
the three and six months ended June 30, 2019, we revised the fair value of the royalty to reflect that the royalty had expired
during the period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Knight Loan Agreement,
in April 2015 we also entered into a distribution, license and supply agreement with Knight pursuant to which Knight will act as
our exclusive distributor in Canada for an initial 10-year term, renewable for successive 10-year terms by either party. In connection
with these arrangements in April 2015, we issued Knight a total of 1,717,450 Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Federal Economic Development Agency Loan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a loan agreement dated December
16, 2011, the Federal Economic Development Agency provided us with an unsecured and non-interest bearing loan of $867,000 (the
 &ldquo;<B>Federal Economic Development Agency Loan</B>&rdquo;) with the final repayment of $563,550 made on July 25, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Health Technology Exchange Loan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to a loan agreement dated May
25, 2011, as amended April 1, 2012, and a loan agreement dated May 31, 2014, the Health Technology Exchange provided us with an
unsecured loan of $1,500,000 bearing interest at 4.5% per annum (the &ldquo;<B>Health Technology Exchange Loan</B>&rdquo;). The
final payment of $1,094,698 including accrued interest was made on March 31, 2018.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manage liquidity risk by monitoring
actual and projected cash flows. A cash flow forecast is performed regularly to ensure that we have sufficient cash to meet operational
needs while maintaining sufficient liquidity. We do not use any financial instruments for hedging currencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash flows for the three and six months
ended June 30, 2019 and 2018 are summarized in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six months ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">June 30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Cash provided by (used in) operating activities&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(6,286,215</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(5,414,430</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(9,504,257</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(9,135,773</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash provided by (used in) investing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash provided by (used in) financing activities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(269,152</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(604,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(689,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,028,469</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,555,367</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,019,044</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,193,713</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,892,696</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) operating
activities for the three months ended June 30, 2019 was C$(6,286,215) versus C$(5,414,430) for the three months ended June 30,
2018. The principal use of the operating cash flows during this period related to increased workforce costs and expenses associated
with seeking U.S. regulatory approval for the TULSA-PRO system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) operating
activities for the six months ended June 30, 2019 was C$(9,504,257) versus C$(9,135,773) for the six months ended June 30, 2018.
The principal uses of the operating cash flows during this period related to additional costs associated with increased workforce
and seeking U.S. regulatory approval for the TULSA-PRO system and consultant costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) financing
activities for the three months ended June 30, 2019 were C$(269,152) versus C$(604,614) for the three months ended June 30, 2018.
These cash flows related to the CIBC Loan interest payments in 2019 which had a lower interest rate versus the Health Technology
Exchange Loan, and the Knight Loan interest payments in 2018 which had a higher cost of borrowing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) financing
activities for the six months ended June 30, 2019 were C$(689,456) versus C$30,028,469 for the six months ended June 30, 2018.
These cash flows related to the CIBC Loan interest payments in 2019 versus the Health Technology Exchange Loan, and the Knight
Loan and gross proceeds from the 2018 Bought Deal, less cash transactions costs paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash flows for the years ended December
31, 2018, 2017 and 2016 are summarized in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">December 31</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Cash provided by (used in) operating activities&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(18,294,637</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(15,571,227</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(14,502,266</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash provided by (used in) investing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(280,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,912,835</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash provided by (used in) financing activities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,878,597</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,122,050</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,899,972</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">Net increase (decrease) in cash&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,583,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,729,838</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,310,541</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) operating
activities for the year ended December 31, 2018 was C$(18,294,637) versus C$(15,571,227) for the year ended December 31, 2017 and
C$(14,502,266) for the year ended December 31, 2016. The principal uses of the operating cash flows during 2018 related to additional
costs associated with Sonalleve that were only present for 5 months in 2017, increased TACT expenses and increased workforce costs,.
In the year ended December 31, 2016, the principal uses of operating cash flows were related to the preparations for the IDE submission
and the TACT Pivotal Trial in 14 clinical sites, designed to support the 510(k) submission in the United States to provide a pathway
for Class II classification for the TULSA-PRO system and increased employee headcount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) investing
activities for the year ended December 31, 2018 was C$nil versus C$(280,661) for the year ended December 31, 2017 and C$8,912,835
for the year ended December 31, 2016. The change in the year ended December 31, 2018 compared to the year ended December 31, 2017
related to no purchases of property and equipment and intangible assets during the year ended December 31, 2018 compared to the
year ended December 31, 2017. The change in the year ended December 31, 2017 compared to the year ended December 31, 2016 related
to the redemption of short term investments, offset by cash outflows related to purchase of enterprise resource planning implementation
and leasehold improvements at the new office building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) financing
activities for the year ended December 31, 2018 were C$37,878,597 versus C$6,122,050 for the year ended December 31, 2017 and C$15,899,972
for the year ended December 31, 2016. These cash flows in 2018 related to the CIBC Loan, 2018 Bought Deal proceeds less cash transactions
costs paid and debt repayments of the Health Technology Exchange Loan, Federal Economic Development Agency Loan and the Knight
Loan. Cash flows provided by financing activities in 2017 related to 2017 Bought Deal proceeds and were offset by the repayment
of long term debt. Cash flows provided by financing activities in 2016 related to 2016 Bought Deal proceeds and were offset by
the repayment of long term debt.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Working Capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our working capital as at June 30, 2019
and December 31, 2018, with reconciliations to current assets are set forth in the table below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>June 30,</B></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 31,</B></P></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Current assets&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">27,680,784</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">37,919,789</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: Current liabilities&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,465,677</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,879,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">Working capital&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,215,107</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">30,040,429</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Research and
Development, Patents and Licenses, etc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our R&amp;D expenses are comprised of costs
incurred in performing R&amp;D activities, including new product development, continuous product improvement, investment in clinical
trials and related clinical manufacturing costs, materials and supplies, salaries and benefits, contract research costs, patent
procurement costs, and R&amp;D-related occupancy costs. Since January 1, 2016, the majority of these expenses have related to the
TACT Pivotal Clinical Trial and development costs of our systems, primarily our TULSA-PRO system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For information regarding our intellectual
property, see Item 4.B, &ldquo;Business Overview&mdash;Intellectual Property&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">D. Trend Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See <FONT STYLE="font-weight: normal">5.A,
 &ldquo;Operating Results&mdash;Trend Information and Outlook&rdquo;.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">E. Off-Balance Sheet
Arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have no off-balance sheet arrangements
within the meaning of U.S. or Canadian securities laws.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">F. Tabular Disclosure
of Contractual Obligations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our significant
contractual obligations as of December 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less than 1&nbsp;Year</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Between<BR> 1&nbsp;year and<BR> 5&nbsp;years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Greater than <BR>
5&nbsp;years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">C$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Accounts payables and accrued liabilities&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,912,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,912,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term debt<SUP>(1)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,497,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,936,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,560,587</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other liabilities<SUP>(2)</SUP>&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,365,217</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">429,426</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">935,791</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total<SUP>(3)</SUP></B>&#9;</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,774,609</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,278,231</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,496,378</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Represents the CIBC Loan. Carrying amount: C$11,955,245. See Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent
Sources and Uses of Financing&mdash;CIBC Loan&rdquo; and note 10 to our audited annual financial statements included in this Registration
Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Represents contingent consideration under the Philips Share Purchase Agreement, which is valued based on estimated projected
net sales, the likelihood of certain levels being reached and a discount rate of 15%, and warranty liability relating to warrants
issued in the 2017 Bought Deal and 2018 Bought Deal, and to CIBC in connection with the CIBC Loan. Carrying amount: C$1,275,394.
For information regarding the Philips Share Purchase Agreement and our recorded contingent consideration thereunder, see Item 4.B,
 &ldquo;Business Overview&mdash;Alliances and Partnerships&mdash;Philips&rdquo; and note 4 to our audited annual financial statements
included in this Registration Statement. For information regarding the warrants and warranty liability, see Item 5.B, &ldquo;Liquidity
and Capital Resources&mdash;Recent Sources and Uses of Financing&rdquo; and note 12 to our audited annual financial statements
included in this Registration Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Carrying amount: C$17,142,989. In addition, following FDA clearance of our TULSA-PRO system in August 2019, we were required
to pay a C$250,000 milestone payment to Sunnybrook under the Sunnybrook License, which we have paid as of the date of this Registration
Statement. See Item 4.B, &ldquo;Business Overview&mdash;Intellectual Property&mdash;Licenses&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">G. Safe Harbor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;<I>Cautionary Note Regarding
Forward-Looking Statements</I>&rdquo; in the introduction to this Registration Statement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_013"></A>ITEM
6. </FONT>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Directors and
Senior Management</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set out below is information with respect
to our directors. Our directors are elected by our shareholders at each annual general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 25%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name, Age
    and</B></FONT><B><BR>
    <FONT STYLE="font-size: 10pt">Residence</FONT></B></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; width: 15%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Positions
    with</B></FONT><B><BR>
    <FONT STYLE="font-size: 10pt">the Company</FONT></B></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: top; width: 15%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Date
    First Appointed to the Board</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; width: 39%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Principal
    Occupation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Arun Menawat</I><BR>
Age: 64<BR>
Oakville, Ontario, Canada</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer and Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 4, 2015</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer and Director of the Company (since August 2016); Chairman, President and Chief Executive Officer of Novadaq Technologies Inc. (from 2003 to 2016).</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Brian Ellacott</I><SUP>(1)</SUP><BR>
Age: 62<BR>
Sanibel Island, Florida, USA</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">June 14, 2018</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer Belmont Instrument Corporation, a medical device company (since 2017); President and Chief Executive Officer Laborie Medical Technologies, a medical device company (from 2013 to 2017).</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"><I>Steve Forte</I></FONT><B><SUP>(</SUP></B><SUP>1)</SUP></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Age: 40</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Montr&eacute;al, Qu&eacute;bec,
        Canada</FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-weight: normal">August 6, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer Clementia Pharmaceutical (from August 2018 to July 2019); Chief Financial Officer Thinking First (from September 2015 to August 2018); Executive Director of Finance (from September 2014 to September 2015); Vice-President, Financial Reporting Aptalis Pharma Inc. (from April 2011 to May 2014)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 25%; border-bottom: Black 1pt solid; text-align: left; vertical-align: bottom"><FONT STYLE="font-style: normal"><B>Name,
Age and <BR>
Residence</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; padding-bottom: 1pt; vertical-align: bottom"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; width: 15%; border-bottom: Black 1pt solid; vertical-align: bottom"><B>Positions with<BR>
    the Company</B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; width: 15%; text-align: center; border-bottom: Black 1pt solid"><B>Date First Appointed
    to the Board</B></TD>
    <TD STYLE="text-align: center; width: 2%; padding-bottom: 1pt; vertical-align: bottom"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center; width: 39%; border-bottom: Black 1pt solid; vertical-align: bottom"><B>Principal Occupation</B></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: bottom"><I>Kenneth Galbraith</I><SUP>(1)(2)(3)</SUP><BR>
Age: 56<BR>
Vancouver, British Columbia, Canada</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">Director</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">January 17, 2017</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">Chief Executive Officer Prometic Life Sciences (since April 2019); Founder of Five Corners Capital, a venture capital management company (since 2013).</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><I>Linda Maxwell</I> <SUP>(2)</SUP><BR>
Age: 45<BR>
Toronto, Ontario, Canada </TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">Director</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">October 9, 2018</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">Surgeon (since 2005); Executive Director, Biomedical Zone at Ryerson University (since June 2015); Technology Transfer Manager University of Oxford (from June 2013 to July 2014)</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><I>Jean-Fran&ccedil;ois Pariseau</I><SUP>(2)</SUP><BR>
Age: 50<BR>
Montr&eacute;al, Qu&eacute;bec, Canada</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">Director</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">June 4, 2015</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">Co-Founder and Partner at Amplitude Ventures (since July 2018); Partner, BDC Capital Healthcare Fund, a venture capital company (since July 2001 to June 2018).</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><I>Arthur Rosenthal</I><SUP>(4)</SUP> <BR>
Age: 72 <BR>
Oro Valley, Arizona, USA</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">Director</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">June 14, 2018</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">Professor of Practice in the Biomedical Engineering Department at Boston University (since 2010); Chief Executive Officer of gEyeCue, Ltd., a medical technology company (since 2011).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Member of the Audit Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Member of the Human Resources and Corporate Governance Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Chair of the Audit Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Chair of the Human Resources and Corporate Governance Committee.</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B>&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director Biographies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Arun Menawat </I>&ndash; Chief Executive
Officer and Director &ndash; Dr. Menawat has an accomplished history of executive leadership success in the healthcare industry.
Since April 2003 until to joining Profound, he served as the Chairman, President and CEO of Novadaq Technologies Inc., a TSX and
Nasdaq listed company that marketed medical imaging and therapeutic devices for use in the operating room. Previously, he was President
and Chief Operating Officer and Director of another publicly listed medical imaging software company, Cedara Software. His educational
background includes a Bachelor of Science in Biology, University of District of Columbia, Washington, D.C., and a Ph.D. in Chemical
Engineering, from the University of Maryland, College Park, MD, including graduate research in Biomedical Engineering from the
National Institute of Health, Bethesda, MD. He also earned an Executive M.B.A. from the J.L. Kellogg School of Management, Northwestern
University, Evanston, IL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Brian Ellacott &ndash; </I>Director
 &ndash; Mr. Ellacott is an experienced global medical device executive. Mr. Ellacott joined Belmont Instrument as Chief Executive
Officer in December 2017. Belmont Instrument is a Boston based private equity owned medical device company with a leading global
position in fluid warming and infusion systems. Prior to Belmont Instrument, Mr.&nbsp;Ellacott was the President and CEO of Laborie.
Laborie is a Urology and Gastroenterology medical device company based in Toronto with manufacturing facilities in Toronto, Montreal,
Enschede NL, Attikon Switzerland and Portsmouth New Hampshire. Mr. Ellacott joined private equity owned Laborie as President and
CEO in July 2013 and in four years completed 14 global acquisitions tripling Laborie&rsquo;s revenue and increasing EBITDA eight
fold. The company was ranked as one of the fastest growing and most profitable medical device companies in the world. Prior to
joining Laborie Medical Technologies (&ldquo;<B>Laborie</B>&rdquo;), Mr. Ellacott served as Executive Vice President and General
Manager of Invacare&rsquo;s (NYSE: IVC) $1 billion North and South American homecare and rehabilitation business. Mr. Ellacott
has also held executive positions with Baxter International and American Hospital Supply, with assignments in Canada, Australia
and the United States. Mr. Ellacott serves on the board of Belmont Instrument and is the past Chairman of the board of the Canadian
Assistive Devices Association. Mr. Ellacott holds a Bachelor of Business Administration Degree from Wilfrid Laurier University,
Waterloo, Ontario, Canada and is a dual United States and Canadian citizen.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal"><I>Steve
Forte </I>&ndash; Director &ndash; Mr. Forte is a senior finance leader with broad experience managing complex, large-scale finance
environments. Mr. Forte was most recently CFO of Clementia Pharmaceuticals (NASDAQ: CMTA), which was sold earlier this year to
Ipsen S.A. in a transaction valued at US$1.3 billion. His experience includes nearly a decade at Aptalis Pharma Inc., where he
was responsible for the overall corporate controllership function of a multinational pharmaceutical company with approximately
$700 million in annual revenue. At Aptalis, Mr. Forte was responsible for SEC reporting and led the preparation of an SEC S-1 registration
statement for a U.S. IPO on Nasdaq prior to the successful sale of the company to Forest Labs. Mr. Forte&rsquo;s prior experience
also includes Chief Financial Officer of Thinking Capital Financial Corporation, a leading Canadian financial technology firm.
Mr. Forte received his Bachelor of Commerce in Accountacy from Concordia University and is a Certified Professional Accountant
in the Province of Quebec and a Certified Information Systems Auditor with ISACA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Kenneth Galbraith &ndash; </I>Director
 &ndash; Mr. Galbraith is an accomplished life sciences industry veteran with over 30 years of experience acting as an executive,
director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr. Galbraith
currently serves as the Chief Executive Officer of Prometic Life Sciences Inc. (TSX: PLI), a biotechnology company. Mr. Galbraith
joined Ventures West as a General Partner in 2007 and led the firm&rsquo;s biotechnology practice prior to founding Five Corners
Capital in 2013 to continue management of the Ventures West investment portfolio. Previously, he served as the Chairman and Interim
CEO of AnorMED until its sale to Genzyme Corp. in a cash transaction worth almost US$600 million. Starting his career in the life
sciences sector in 1987, Mr. Galbraith spent 13 years in senior management with QLT Inc., retiring in 2000 from his position as
Executive VP and CFO when QLT Inc.&rsquo;s market capitalization exceeded US$5 billion. He has served on the board of directors
of several public and private companies, including Angiotech Pharmaceuticals, Arbutus Biopharma and Cardiome Pharma. Mr. Galbraith
currently serves on the board of directors of Macrogenics and Prometic Life Sciences Inc. Mr. Galbraith earned a Bachelor of Commerce
(Honors) degree from the University of British Columbia in 1985 and was appointed a Fellow of the Chartered Accountants of British
Columbia in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 89; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Linda Maxwell</I> &ndash; Director &ndash;
Dr. Maxwell, a seasoned surgeon and entrepreneur, is the Founding and Executive Director of the Biomedical Zone, a business incubator
for emerging health technology companies. It is an innovative strategic partnership between St. Michael&rsquo;s Hospital and Ryerson
University. Under Dr. Maxwell&rsquo;s stewardship, the Biomedical Zone has gone from concept to creation to going concern, supporting
Toronto&rsquo;s leading health technology businesses and driving disruption and innovation adoption in the clinical setting. Dr.
Maxwell&rsquo;s breadth of experience and scope of expertise is founded on over a decade and a half as an accomplished head and
neck/facial plastic surgeon. Her academic medical career is distinguished by university appointments as a clinical instructor,
medical school faculty member, and published scientific author. A frequent public speaker and panelist, Dr. Maxwell has addressed
national and international communities on scientific research, innovation, and entrepreneurship. Additionally, Dr. Maxwell has
worked internationally as a senior tech transfer manager and partnership leader for innovation and commercialization for the National
Health Service and University of Oxford. She also worked for Medtronic on business strategy for South America (Brazil) and continues
to consult to Medtronic on international clinical trials as an external medical monitor. In addition to her professional endeavors,
Dr. Maxwell is a member of the Institute of Corporate Directors. She serves as a director for Profound, Gardiner Museum, and the
Economic Club of Canada. She serves as an innovation and health technology subject matter expert for the Federal government&rsquo;s
Canadian Space Agency, Canadian Medical Association, and the Ontario Chief Innovation Strategist. Dr. Maxwell earned a Bachelor&rsquo;s
degree with honors from Harvard University (Biology, <I>cum laude</I>), M.D. from Yale University, and M.B.A. from University of
Oxford. She completed six years of residency and fellowship training in surgery at the University of Toronto. Additionally, Dr.
Maxwell successfully completed the Royal College of Canada, American College of Surgery, and American Board of Facial Plastic Reconstructive
Surgery certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Jean-Fran&ccedil;ois Pariseau</I> &ndash;
Director &ndash; Mr. Pariseau is co-founder and Partner at Amplitude Ventures. Amplitude Ventures is a capital catalyst for highly
innovative companies at the point of value acceleration. Amplitude Ventures works with Canada&rsquo;s most promising healthcare
companies, with a shared vision of bringing groundbreaking technologies to patients. Amplitude Ventures is focused on building
world-class Canadian companies in precision medicine and next-generation medical devices. Before co-founding Amplitude Ventures,
Mr. Pariseau was Partner at the Healthcare Fund of BDC Capital and an investment manager with CDP Capital Technology Ventures,
a $2 billion global fund investing in healthcare, information technology and advanced technologies, where he was responsible for
healthcare investments in Canada and the United States. Prior to joining the investment world, Jean-Francois was CEO of a consulting
company specializing in regulatory affairs, and VP, R&amp;D for a pharmaceutical-product distribution company, both of which he
founded. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Universit&eacute; de Sherbrooke, a Master of Science in
Biomedical Sciences from Universit&eacute; de Montr&eacute;al, and an M.B.A. from HEC&nbsp;Montr&eacute;al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Arthur L. Rosenthal</I>&nbsp;&ndash;
Director &ndash; Dr. Rosenthal is director and Chair of Compensation Committee for LivaNova PLC, a UK global medical technology
company. Prior, Dr. Rosenthal served on the Cyberonics board of directors as a non-executive director and Chair of the Compensation
Committee from January 2007 to October 2015. Since June 2010, Dr. Rosenthal has served as Professor of Practice in the Biomedical
Engineering Department at Boston University. Since December 2011, Dr. Rosenthal has also served as CEO of gEyeCue, Ltd., which
he co-founded, a development stage medical device company working on a guided biopsy for lower and upper gastrointestinal cancer
screening. From June 2011 until July 2012, Dr. Rosenthal served as executive vice chairman of Cappella Medical Devices Ltd. (now
ArraVasc Ltd.), a development-stage company focused on novel device solutions for coronary artery disease. From June 2009 until
June 2011, Dr. Rosenthal served as President and CEO of Cappella, Inc. Dr. Rosenthal served as chairman, from January 2002, and
CEO, commencing in January 2005, of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From
January 1994 to May 2000, Dr. Rosenthal was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston
Scientific, and from May 2000 until his retirement in January 2005, he was a Senior Vice President, Chief Scientific Officer, and
Executive Committee Member of Boston Scientific. From 2000 until 2010, Dr. Rosenthal served as a non-executive director, and from
2006 through 2009, as chairman of the Remuneration Committee, of Renovo, Ltd., a U.K. based pharmaceutical company that became
publicly traded in 2006. In July 2009, Dr. Rosenthal joined the board of Interface Biologics, Inc., a Toronto-based development
stage company focused on drug delivery devices, as a non-executive director. In April 2011, Dr. Rosenthal was elected Chairman
at Interface Biologics, Inc. From April 2013 to May 2015, Dr. Rosenthal served as non-executive director and Member of the Compensation
Committee of Arch Technologies, Inc. and is currently a member of Arch&rsquo;s Clinical Advisory Board. In 2015, Dr. Rosenthal
was appointed to the Industrial Advisory Committee, CURAM (National University in Galway, Ireland). Since 2003, Dr. Rosenthal has
been a Fellow of the American Institute of Medical and Biological Engineering.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Senior Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Set out below is information with respect
to our senior management. Our officers serve for an indefinite term, subject to the terms of their employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date Appointed</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Arun Menawat</I></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">August 15, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Mathieu Burtnyk</I></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Vice-President of Clinical Affairs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">July 7, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Aaron Davidson</I></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Senior Vice-President of Corporate Development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">May 1, 2018</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Rashed Dewan</I></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Vice President of Finance, Manufacturing and Service</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">July 5, 2016</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><I>Guruprit (Goldy) Singh</I></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Vice President of Regulatory Affairs and Product Management</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">December 1<B>, </B>2011</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Management Biographies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Arun Menawat &ndash; </I>Chief Executive
Officer and Director &ndash; see &ldquo;Director Biographies&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Mathieu Burtnyk &ndash; </I>Vice President
of Clinical Affairs &ndash; Dr. Mathieu Burtnyk has over 15 years of experience creating and developing imaging technologies and
therapeutic ultrasound solutions, from benchtop to bedside, with a focus on prostate disease. He started his career in academia,
obtaining his PhD in Medical Biophysics at the University of Toronto and Sunnybrook Health Sciences Center. He is the inventor
of the patented closed-loop temperature feedback control algorithm used by the TULSA-PRO today in clinic. Mathieu joined Profound
in 2011 as Scientist progressing to Clinical Scientist, Director of Clinical Affairs and now VP Clinical Affairs, where he has
led the scientific design and execution of pre-clinical, Phase I and TACT Pivotal clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Aaron Davidson </I>&ndash; Chief Financial
Officer and Senior Vice-President of Corporate Development &ndash; Mr. Aaron Davidson has been the CFO and Senior Vice President
of Corporate Development of Profound since May 2018, a medical technology company that is developing real-time MRI-guided thermal
ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Before joining Profound, Mr. Davidson served as
Co-Head and Managing Director of H.I.G. BioHealth Partners from January 2004 through May 2018, where he focused on investment opportunities
with emerging life sciences companies. Mr. Davidson began his career with Eli Lilly and Company, where he spent a decade in various
operating management roles in the United States and Canada, including financial management, business development, strategic planning,
market research and general management. Mr. Davidson continues to serve as a Venture Partner at H.I.G. Previously, Mr. Davidson
led investments in, worked with the management teams of, and represented H.I.G. as a board member of several successful companies,
including Alder Biopharmaceuticals (public), Forsight Vision5 (acquired), Gemin X Pharmaceuticals (acquired), HyperBranch Medical
Technology (acquired), Intact Vascular, OnTarget Laboratories, Novadaq Technologies (public/acquired), and Salmedix (acquired).
Mr. Davidson earned his M.B.A. from Harvard Business School and a Bachelor&rsquo;s Degree in Finance from McGill University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 91; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Rashed Dewan </I>&ndash; Vice President
of Finance, Manufacturing and Service &ndash; Mr. Dewan joined Profound in 2015 as Director of Finance and Corporate Controller.
He has also served as Vice President, Finance and Interim Chief Financial Officer, and most recently, since 2018, as our Vice President
of Finance, Manufacturing and Service. Prior to joining us, Mr. Dewan previously held senior finance and management roles with
Xylem Canada from September 2013 to June 2015, Natus Medical from March 2010 to August 2013 and Psion Teklogix from 2001 to 2009.
Mr. Dewan has over 20 years of finance and accounting experience in public and private companies, with expertise in the medical
device sector. Mr. Dewan has extensive experience with systems design and implementation and a strong track record of success in
accounting, finance, sales and operations management. Mr. Dewan is a Certified Public Accountant, and has a Bachelor of Science
Degree with a concentration in Accounting from the University of Southern California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Guruprit (Goldy) Singh &ndash; </I>Vice
President of Regulatory Affairs and Product Management &ndash; Ms. Singh is Vice President Regulatory Affairs &amp; Product Management
of Profound. She joined the Company in December 2011 as a VP Quality Assurance and Regulatory Affairs. In this role, she provided
strategic direction on regulatory affairs, quality assurance, risk management, and clinical trials ensuring the product is introduced
to markets efficiently and effectively. In 2019, she was given responsibility for the overall product management process of a particular
product line. She works closely with internal and external stakeholders such as researchers, engineers, clinicians, hospital administrations,
regulatory bodies etc. to ensure that the strategies are executable and achieve desired results. Before joining Profound, Ms. Singh
spent 22 years in medical device companies in the Greater Toronto Area. Prior to Profound, she worked for Natus, as Director Quality
Assurance and Regulatory Affairs, managed compliance and day-to-day operations through a substantial growth period including six
acquisitions and commercialization of high-tech medical devices. She also worked for Philips and C.R. Bard. Ms. Singh has a Bachelor&rsquo;s
Degree with a major in Biology and Physics from Ranchi University, India.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Executive Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compensation Discussion and Analysis</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Objectives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have relied on the experience of the
Board and the Human Resources and Corporate Governance Committee in setting executive compensation. In considering compensation
awards, the Human Resources and Corporate Governance Committee has considered the skill level of its executives as well as comparable
levels of compensation for individuals with similar capabilities and experience. In regard to our current executive compensation
arrangements, the Human Resources and Corporate Governance Committee has considered such factors as our current financial situation,
our estimated financial situation in the mid-term and the need to attract and retain the key executives necessary for our long
term success. The Human Resources and Corporate Governance Committee has determined that at this stage of the Company&rsquo;s development
it is appropriate that compensation be in the form of base salary, options, a potential bonus award and certain benefits plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compensation Philosophy and Objectives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The executive compensation program adopted
by us and applied to our executive officers is designed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">attract and retain qualified and experienced executives who have international business and operations
experience and will contribute to our success;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">ensure that the compensation of the executive officers provides a competitive base compensation
package, with additional compensation to reward success and create a strong link between corporate performance and compensation;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">motivate executive officers to enhance long term shareholder value, with current compensation being
weighted toward at-risk long-term incentives in the form of options and other security based incentives so as to foster alignment
with the interests of our shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The goals of the compensation program are
to attract and retain the most qualified people with relevant experience, to motivate and reward such individuals on a short term
and long term basis, and to create alignment between corporate performance and compensation. The Human Resources and Corporate
Governance Committee and the Board intend that the total cash components of compensation (base salary plus discretionary cash bonus)
target the median of a benchmark group in comparable industries with similar market capitalization (the &ldquo;<B>Compensation
Peer Group</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not believe that our compensation
programs encourage excessive or inappropriate risk taking as: (i) our employees receive both fixed and variable compensation, and
the fixed (salary) portion provides a steady income regardless of Common Share value which allows employees to focus on our business;
and (ii) the Share Option Plan encourages a long term perspective due to the vesting provisions of the options (see &ldquo;&mdash;Share
Option Plan&rdquo; below). We believe that our compensation program is appropriately structured and balanced to motivate our executives
and reward the achievement of annual performance goals, as well as the achievement of long term growth in shareholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elements of Compensation</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Base Salary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Base salary is intended to reflect an executive
officer&rsquo;s position within the corporate structure, his or her years of experience and level of responsibility, and salary
norms in the sector and the general marketplace. As such, decisions with respect to base salary levels for executive officers are
not based on objective identifiable performance measures but for the most part are determined by reference to competitive market
information for similar roles and levels of responsibility, as well as more subjective performance factors such as leadership,
commitment, accountability, industry experience and contribution. Our view is that a competitive base salary is a necessary element
for retaining qualified executive officers, as it creates a meaningful incentive for individuals to remain with us and not be unreasonably
susceptible to recruiting efforts by our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In determining the base salary compensation
of the Named Executive Officers (as defined herein), the Board considered: (i) recruiting and retaining executives critical to
the success of the Company and the enhancement of shareholder value; (ii) providing fair and competitive compensation; (iii) balancing
the interests of management and our shareholders; and (iv) rewarding performance, both on an individual basis and with respect
to operations in general.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 93; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-Term Incentives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-term incentives, in the form of options,
are intended to align the interests of our directors and our executive officers with those of our shareholders, to provide a long-term
incentive that rewards these individuals for their contribution to the creation of shareholder value and to reduce the cash compensation
we would otherwise have to pay. The Share Option Plan is administered by the Board. In establishing the number of options to be
granted to any particular executive officer, reference was made to the number of options granted to officers of other companies
involved in similar businesses. The Board also considers previous grants of options and the overall number of options that are
outstanding relative to the number of outstanding Common Shares in determining whether to make any new grants of options and the
size and terms of any such grants, as well as the level of effort, time, responsibility, ability, experience and level of commitment
of the executive officer in determining the level of incentive stock option compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bonus Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board will consider whether it is appropriate
and in our best interests to award a discretionary cash bonus to executive officers for the most recently completed financial year
and if so, in what amount. A cash bonus may be awarded to reward extraordinary performance that has led to increased value for
our shareholders through property acquisitions or divestitures, the formation of new strategic or joint venture relationships and/or
capital raising efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Quantitative performance objectives include
the achievement of our revenue targets, departmental and individual goals, which may be quantitative or qualitative in nature.
These have been established for each individual executive officer by the Board with alignment of such corporate/individual goals
with the CEO and include objectives such as research and product development, company productivity, revenue growth and our long-term
strategic guidance. These corporate, departmental and individual goals form the basis for the review of the executive officers
and the determination of cash bonuses at the end of each year with the Board. These awards are reviewed yearly to ensure that corporate
performance metrics and individual goals are consistent from year to year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bonus award payments are based on the following
assessment of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">whether or not the executive officers have successfully met or exceeded the established corporate,
departmental and individual performance metrics and goals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">the executive officers&rsquo; decisions and actions and whether or not they are aligned with our
long-term growth strategy and have created value for our shareholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">whether any near-term goals and objectives were not met because the executive officers made decisions
in our best long-term interests or due to factors outside of the executive officers&rsquo; control; and/or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">additional initiatives undertaken by the executive officers, which were not contemplated in the
initial objectives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following targets, as a percentage
of base salary, were approved for each NEO for the fiscal year ending December&nbsp;31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Target</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">CEO&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">65%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other NEOs&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-45%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Benefits Plans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Named Executive Officers, as defined
below, are entitled to life insurance, health and dental benefits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Performance Graph</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following graph illustrates the cumulative
return to shareholders of a C$100 investment in Common Shares from June 8, 2015 to December 31, 2018, as compared to the cumulative
total return on the Standard &amp; Poor&rsquo;s/TSX Index and Standard &amp; Poor&rsquo;s/TSX Venture Index for the same period,
assuming the reinvestment of cash distributions and/or dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">June&nbsp;8,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2015</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">December&nbsp;31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2015</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">December&nbsp;31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2016</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">December&nbsp;31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2017</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">December&nbsp;31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2018</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left">Profound Medical</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">100.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">53.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">74.67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">56.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">36.67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">S&amp;P/TSX Composite Index</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">88.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">103.69</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">109.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">97.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">S&amp;P/TSX Venture Composite Index</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">100.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">76.68</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">111.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">124.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">81.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv526458_img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trend shown in the above graph does
not necessarily correspond to our trend of compensation for the NEOs (as defined herein) for the period disclosed above. We consider
a number of factors in connection with our determination of appropriate levels of compensation including, but not limited to, the
demand for and supply of skilled professionals with experience in the medical device industry, individual performance, our performance
(which is not necessarily tied exclusively to the trading price of the Common Shares on the TSX or any other stock exchanges on
which our Common Shares are listed and other factors discussed under &ldquo;Compensation Discussion and Analysis&rdquo; above).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Named Executive Officers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following individuals are considered
the &ldquo;<B>Named Executive Officers</B>&rdquo; or &ldquo;<B>NEOs</B>&rdquo; for the purposes of the disclosure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">each individual who, during any part of the most recently completed financial year, served as our
Chief Executive Officer (&ldquo;<B>CEO</B>&rdquo;), including an individual performing functions similar to a CEO;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">each individual who, during any part of the most recently completed financial year, served as our
Chief Financial Officer (&ldquo;<B>CFO</B>&rdquo;), including an individual performing functions similar to a CFO;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">each of our three most highly compensated executive officers, or the three highly compensated officers
acting in a similar capacity, other than the CEO and CFO, at the end of the most recently completed financial year whose total
compensation was more than C$150,000 for the fiscal year ended December 31, 2018; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">each individual who would be a Named Executive Officer under paragraph (c) but for the fact the
individual was not one of our executive officers and was not acting in a similar capacity as of December 31, 2018.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summary Compensation Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
concerning the total compensation for the three most recently completed financial years paid to the Named Executive Officers for
the year ended December 31, 2018. Dr. Menawat is our only officer who also serves as one of our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="4" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Non-Equity
    Incentive<BR>
Plan Compensation</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Name and Principal Position</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Salary</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Option-<BR>
Based<BR>
Awards</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Annual<BR>
Incentive<BR>
Plan</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Long<BR>
Term<BR>
Incentive<BR>
Plan</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Pension<BR>
Value</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">All
    Other<BR>
Compensation</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">Total<BR>
Compensation</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(C$)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(C$)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="4" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(C$)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(C$)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(C$)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">(C$)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 16%; font-weight: bold"><FONT STYLE="font-size: 8pt"><B>Arun Menawat</B><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">647,665</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">208,000</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="width: 1%; font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">855,665</FONT></TD><TD STYLE="width: 1%; font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Chief Executive Officer and Director</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">331,500</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">331,500</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">125,370</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">2,197,221</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(5)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">24,363</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">2,346,954</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>Aaron Davidson</B><SUP>(2)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">209,446</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">913,015</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">1,122,461</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Chief Financial Officer and Senior Vice-</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">President of Corporate Development</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt"><B>Ian Heynen</B><SUP>(3)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">200,976</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">730,412</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(6)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">931,388</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Senior Vice-President of Sales and</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">Marketing</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">Rashed Dewan</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">190,102</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">26,010</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">216,112</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">Vice-President of Finance</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">184,301</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">23,598</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(7)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">207,899</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">178,500</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">124,513</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>(8)</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">12,888</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">315,901</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">Guruprit (Goldy) Singh</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2018</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">209,131</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">15,604</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">224,735</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Vice-President of Regulatory Affairs and</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2017</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">205,020</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">205,020</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Product Management</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">2016</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">204,000</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt"><SUP>&nbsp;</SUP></FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">14,800</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt; font-weight: normal">Nil</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: center"><FONT STYLE="font-size: 8pt">Nil</FONT></TD><TD STYLE="font-weight: normal"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-size: 8pt">218,800</FONT></TD><TD STYLE="font-weight: normal; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Dr. Menawat was appointed CEO on August 15, 2016, as such he no longer receives any Director or Committee fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Mr. Davidson was hired as CFO and Senior Vice-President of Corporate Development on May 1, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Mr. Heynen was hired as Senior Vice-President Sales &amp; Marketing on April 23, 2018 and resigned on January 7, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Nil indicates that perquisites and other personal benefits did not exceed C$50,000 or 10% of the total salary of the NEO for
the financial year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>Option based awards granted utilize the Black-Scholes model to determine the fair value. The input factors to determine the
fair value were volatility 99%, exercise price C$1.23, interest rate 1.35% and expected life of 6 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>Option based awards granted utilize the Black-Scholes model to determine the fair value. The input factors to determine the
fair value were volatility 82%, exercise price C$1.06, interest rate 2.30% and expected life of 6 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD>Option based awards granted utilize the Black-Scholes model to determine the fair value. The input factors to determine the
fair value were volatility 135%, exercise price C$0.85, interest rate 1.90% and expected life of 6 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(8)</TD><TD>Option based awards granted utilize the Black-Scholes model to determine the fair value. The input factors to determine the
fair value were volatility 99%, exercise price C$1.20, interest rate 0.94% and expected life of 6 years.</TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option-Based Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
with respect to the unexercised options granted under the Share Option Plan to the NEOs that were outstanding as of December 31,
2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="8" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option-Based Awards</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Principal Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR>
Common Shares<BR>
Underlying<BR>
Unexercised<BR>
Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Exercise<BR>
Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR>
Expiration Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value of<BR>
Unexercised In-<BR>
the-Money<BR>
Options<SUP>(6)</SUP></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Arun Menawat</B><SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">33,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">1.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%">Nov 12, 2024</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Executive Officer and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">934,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Aug 22, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Sep 15, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">364,141</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Nov 24, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,417,583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Dec 21, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>May 16, 2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aaron Davidson</B><SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>May 22, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chief Financial Officer and Senior Vice-</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Aug 23, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">President of Corporate Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>May 16, 2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ian Heynen</B><SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>May 22, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Senior Vice-President of Sales and Marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Aug 23, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rashed Dewan</B><SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Sept 8, 2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Vice-President of Finance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>July 19, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Nov 24, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Nov 16, 2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>May 16, 2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guruprit (Goldy) Singh</B><SUP>(5)</SUP></FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">0.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%">Dec 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">15,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Vice-President of Regulatory Affairs and</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Sept 12, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Product Management</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Sept 8, 2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 16, 2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>As of December 31, 2018, Dr. Menawat held 2,765,279 options, with 1,549,389 of these options exercisable and the remaining
balance vesting over a three-year period. In addition, Dr. Menawat was granted 2,000,000 additional options on May 16, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>As of December 31, 2018, Mr. Davidson held 1,000,000 options, all options remain unvested and will vest over a three-year period.
In addition, Mr. Davidson was granted 1,000,000 additional options on May 16, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Mr. Heynen was hired as Senior Vice-President Sales &amp; Marketing on April 23, 2018 and resigned on January 7, 2019. All
of these options expired upon his resignation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>As of December 31, 2018, Mr. Dewan held 200,000 options, with 110,003 of these options exercisable and the remaining balance
vesting over a three-year period. In addition, Mr. Dewan was granted 25,000 additional options on May 16, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>As of December 31, 2018, Ms. Singh held 375,000 options, with 325,000 of these options exercisable and the remaining balance
vesting over a three-year period. In addition, Ms. Singh was granted 200,000 additional options on May 16, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>The value shown is the product of the number of Common Shares underlying the option multiplied by the difference between the
Common Share TSX closing price on December 31, 2018 of C$0.55 and the exercise price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Employment Agreements &ndash; Termination
and Change of Control Benefits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of Dr. Menawat, Mr. Davidson, Mr.
Dewan, Ms. Singh and D<FONT STYLE="font-size: 10pt; font-weight: normal">r. Burtnyk</FONT> are party to executive employment agreements
(the &ldquo;<B>Executive Employment Agreements</B>&rdquo;) with us. The Executive Employment Agreements have an indefinite term
and contain standard confidentiality and non-solicitation provisions. We have agreed pursuant to the Executive Employment Agreements
that each of Dr. Menawat, Mr. Davidson, Mr. Dewan, Ms. Singh and D<FONT STYLE="font-weight: normal">r. Burtnyk</FONT> will receive
base salaries determined by the Board and may receive discretionary bonuses, grants of options, reimbursement of expenses, benefits
and certain perquisites as set forth in the Executive Employment Agreements, copies of which are filed as exhibits to this Registration
Statement. The amounts paid in 2018 with respect to the applicable Executive Employment Agreements are set forth in the Summary
Compensation Table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
with respect to the estimated aggregate dollar amount to which each current NEO would have been entitled under his or her Executive
Employment Agreement if an event resulting in termination of employment occurred on December&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 16%; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Triggering Event</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash Payment</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value of Bonus and other Benefits</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 14%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value of Option Awards</B></FONT></TD><TD STYLE="width: 1%; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total Payout</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Arun Menawat</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination with cause/resignation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination without cause</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$682,100<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$446,472<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<SUP>(4)</SUP></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1,128,572<SUP>(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Change of control</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1,364,200<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$443,365<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$1,807,565<SUP>(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Aaron Davidson</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination with cause/resignation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination without cause</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$158,500</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$95,100<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<SUP>(4)</SUP></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$253,600</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Change of control</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$317,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$142,650</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$459,650</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Rashed Dewan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination with cause/resignation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<B><SUP>(1)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<SUP>(4)</SUP></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination without cause</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$95,051<SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$12,966<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$108,017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Change of control</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Guruprit (Goldy) Singh</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination with cause/resignation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$23,250<B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$23,250</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Termination without cause</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$106,110<SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$10,135<B><SUP>(3)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$23,250 <B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$147,658</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>Change of control</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C$23,250 <B><SUP>(5)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">C$23,250</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>In the event of a termination for just cause or resignation, we will have no further obligation to Dr. Menawat, Mr. Davidson,
Mr. Dewan or Ms. Singh, as applicable, other than the payment of unpaid base salary, any bonus declared but not yet paid, plus
all outstanding vacation pay and expense reimbursement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Amounts paid in United States dollars and converted to Canadian dollars for reporting purposes. On December 31, 2018, the exchange
rate for United States dollars expressed in Canadian dollars (as reported by the Bank of Canada) was US$1.00 = C$1.3642.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>The value shown is a multiple of the annual cost of benefits and the average cash bonus paid in respect of the years ended
December&nbsp;31, 2018, 2017 and 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>The value shown is the product of the number of Common Shares underlying the vested options multiplied by the difference between
the Common Share TSX closing price on December&nbsp;31, 2018 of C$0.55 and the exercise price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>The value shown is the product of the number of Common Shares underlying the options multiplied by the difference between the
Common Share TSX closing price on December&nbsp;31, 2018 of C$0.55 and the exercise price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>If Mr. Dewan&rsquo;s employment is terminated without cause, he is entitled to the greater of: (i) six months&rsquo; notice;
or (ii) the minimum notice (or pay in lieu) and minimum severance, if any, to which he would be entitled under employments standards
legislation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD>If Ms. Singh&rsquo;s employment is terminated without cause, she is entitled to six months&rsquo; notice and minimum severance,
if any, to which she would be entitled under employments standards legislation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director Compensation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors were paid an annual fee of
C$20,000 for their services in the year ended December 31, 2018, other than Dr. Menawat, who was compensated as CEO and Mr. Damian
Lamb and Mr. Jean-Fran&ccedil;ois Pariseau, who were compensated by their employers (affiliates of the Company). Members of the
Audit Committee received an additional C$5,000 for the year. Members of the Human Resources and Corporate Governance Committee
received an additional C$2,500 for the year, and the Chair of the Audit Committee received an additional C$10,000 and the Chair
of the Human Resources and Corporate Governance Committee received an additional C$5,000 for the year. Director and committee fees
were prorated for partial year terms of service. Our directors are also eligible to receive an initial grant of options when joining
the Board and additional grants on an annual basis. During 2018, each of Ms. Samira Sakhia, Mr. Kenneth Galbraith and Mr. William
Curran were granted 16,500 options. Mr. Brian Ellacott, Dr. Arthur Rosenthal and Dr. Linda Maxwell were granted 33,000 options
for joining the Board in 2018. Except as set out above, Directors are not eligible to receive any other compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Summary Compensation Table</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
concerning compensation paid to the non-executive directors for the year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fees Earned</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option-based<BR>
awards</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">All Other<BR>
Compensation</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Damian Lamb<SUP>(3)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jean-Fran&ccedil;ois Pariseau&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">William Curran<SUP>(3)</SUP>&#9;</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">32,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">11,960</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">Nil</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">44,460</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Kenneth Galbraith&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,625</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,960</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,585</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Samira Sakhia<SUP>(3)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,960</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,835</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Brian Ellacott<SUP>(4)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,920</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,170</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Arthur Rosenthal<SUP>(4)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,920</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,170</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Linda Maxwell<SUP>(5)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,793</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,793</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Option based awards granted utilize the Black-Scholes model to determine the fair value. The input factors to determine the
fair value were volatility 83%, exercise price C$1.02, interest rate 2.19% and expected life of 6 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Option based awards granted utilize the Black-Scholes model to determine the fair value. The input factors to determine the
fair value were volatility 80%, exercise price C$0.60, interest rate 2.47% and expected life of 6 years.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Mr. Lamb, Mr. Curran, and Ms. Sakhia stepped down from the Board on June 13, 2019<FONT STYLE="font-weight: normal">. Ms. Sakhia&rsquo;s
options will expire 90 days after the date of such resignation, and Mr. Curran&rsquo;s options will expire as indicated in the
table under &ldquo;Option-Based Awards&rdquo; below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">(4)</FONT></TD><TD><FONT STYLE="font-weight: normal">Mr. Ellacott and Mr. Rosenthal joined the Board on June 14, 2018.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">(5)</FONT></TD><TD><FONT STYLE="font-weight: normal">Ms. Maxwell joined the Board on October 9, 2018. </FONT></TD></TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B>&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option-Based Awards</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
with respect to the unexercised options granted under the Share Option Plan to the non-executive directors that were outstanding
as of December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="8" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option-Based Awards</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR>
Common Shares<BR>
Underlying<BR>
Unexercised<BR>
Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Exercise<BR>
Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option<BR>
Expiration Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Value of<BR>
Unexercised In-<BR>
the-Money<BR>
Options<SUP>(7)</SUP></B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">(C$)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samira Sakhia<SUP>(1)(8)</SUP>&#9;</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">16,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">0.97</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center">Apr 25, 2027</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 15, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth Galbraith<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Apr 25, 2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 15, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Curran<SUP>(3)(8)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Mar 16, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,230</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Sep 15, 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Apr 24, 2027</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 15, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Ellacott<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 15, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arthur Rosenthal<SUP>(5)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 15, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda Maxwell<SUP>(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nov 19, 2028</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damian Lamb<SUP>(8)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Jean-Fran&ccedil;ois Pariseau</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Nil</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nil</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>As of December 31, 2018, Ms. Sakhia held 33,000 options, with 16,500 of these options exercisable and the remaining balance
vesting over a three-year period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>As of December 31, 2018, Mr. Galbraith held 49,500 options, with 11,000 of these options exercisable and the remaining balance
vesting over a three-year period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>As of December 31, 2018, Mr. Curran held 82,500 options, with 66,000 of these options exercisable and the remaining balance
vesting over a three-year period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>As of December 31, 2018, Mr. Ellacott held 33,000 options, all options remain unvested and will vest over a three-year period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>As of December 31, 2018, Dr. Rosenthal held 33,000 options, all options remain unvested and will vest over a three-year period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>As of December 31, 2018, Dr. Maxwell held 33,000 options, all options remain unvested and will vest over a three-year period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD>The value shown is the product of the number of Common Shares underlying the Option multiplied by the difference between the
Common Share TSX closing price on December 31, 2018 of C$0.55 and the exercise price.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(8)</TD><TD>Mr. Lamb, Mr. Curran, and Ms. Sakhia stepped down from the board on June 13, 2019<FONT STYLE="font-weight: normal">. Ms. Sakhia&rsquo;s
options will expire 90 days after the date of such resignation, and Mr. Curran&rsquo;s options will expire as indicated in the
table above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Share Option Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Option Plan is administered by
the Board which may, from time to time, delegate to a committee of the Board, all or any of the powers conferred to the Board under
the Share Option Plan. The Share Option Plan was originally adopted by the Board on June 4, 2015, and then amended and restated
on December 8, 2016 effective January 26, 2017 and again on July 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Option Plan provides that the
Board may from time to time, in its discretion, grant to directors, officers, employees, consultants and any other person or entity
engaged to provide ongoing services to the Company non-transferable options to purchase Common Shares, provided that the maximum
number of Common Shares reserved for issuance under the Share Option Plan is equal to 13% of the issued and outstanding shares
in the capital of the Company at the time of any option grant. If any option is exercised, cancelled, expired, surrendered or otherwise
terminated for any reason, the number of Common Shares in respect of which the option is exercised, cancelled, expired, surrendered
or otherwise terminated, as the case may be, will again be available for purchase pursuant to options granted under the plan. As
at August&nbsp;26, 2019, 10,373,929 options have been granted under the Share Option Plan, and 3,675,553 options are available
for future grant under the Share Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate number of Common Shares that
may be (i) issued to insiders of the Company within any one-year period, or (ii) issuable to insiders of the Company at any time,
in each case, under the Share Option Plan alone or when combined with all other security-based compensation arrangements of the
Company, cannot exceed 10% of the outstanding Common Shares (the &ldquo;<B>Insider Participation Limits</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board shall determine the exercise
price of the options, provided that, it cannot be less than the Market Price of the Common Shares on the date of grant. For the
purposes of the Share Option Plan, &ldquo;Market Price&rdquo; means the volume-weighted average price of the Common Shares on the
stock exchange where the majority of trading volume and value of the Common Shares occurs (currently, the TSX), for the five trading
days immediately preceding the relevant date on which the Market Price is to be determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The expiry date for an option under the
Share Option Plan shall not be later than the 10th anniversary of the date such option is granted, subject to the expiry date falling
with a corporate blackout period or within 5 business days following the expiry of such a blackout period, in which case the expiry
date will be extended to the 10th business day following the expiry of the blackout period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified by the Board,
each option under the Share Option Plan generally vests and becomes exercisable as to 1/4 on the first anniversary of the date
of grant and as to 1/36 on the first day of each calendar month thereafter. The Board has the discretion to permit accelerated
vesting of options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not provide any financial assistance
to optionees to facilitate the purchase of Common Shares issued pursuant to the exercise of options under the Share Option Plan.
Options granted under the Share Option Plan are not transferable or assignable (except to an optionee&rsquo;s estate) and no options
may be exercised by anyone other than the optionee or his or her legal representative during the lifetime of the optionee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to adopt and approve material
changes to the Share Option Plan, and any other equity incentive plans that we may have in the future, in accordance with TSX listing
rules, which do not impose a requirement of shareholder approval for such actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, following our proposed listing
on Nasdaq, we plan to file a registration statement on Form S-8 to register the Common Shares issuable upon exercise of options
granted under the Share Option Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Board Practices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors are elected by shareholders
at each annual general meeting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit committee (the &ldquo;<B>Audit
Committee</B>&rdquo;) consists of all independent directors within the meaning of Nasdaq listing standards and Rule 10A-3 under
the U.S. Exchange Act. Currently, the members of the Audit Committee are Kenneth Galbraith (Chair), Brian Ellacott and <FONT STYLE="font-size: 10pt; font-weight: normal">Steve
Forte</FONT>. The Audit Committee oversees the accounting and financial reporting practices and procedures of our financial statements.
The principal responsibilities of the Audit Committee include: (i)&nbsp;overseeing the quality and integrity of our internal controls
and accounting procedures, including reviewing our procedures for internal control with our external auditor and CFO; (ii) reviewing
and assessing the quality and integrity of our annual and quarterly financial statements and related management discussion and
analysis, as well as all other material continuous disclosure documents; (iii) monitoring compliance with legal and regulatory
requirements related to financial reporting; (iv) reviewing and approving the engagement of our external auditor and independent
audit fees; (v) reviewing the qualifications, performance and independence of our external auditor, considering the external auditor&rsquo;s
recommendations and managing the relationship with the external auditor, including meeting with the external auditor as required
in connection with the audit services provided to us; (vi) assessing our financial and accounting personnel; (vii) reviewing our
risk management procedures; (viii) reviewing any significant transactions outside of our ordinary course of business and any pending
litigation involving us; and (ix) examining improprieties or suspected improprieties with respect to accounting and other matters
that affect financial reporting.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee Charter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee reviews and reassesses
the adequacy of its charter periodically as it deems appropriate and recommend changes to the Board. The performance of the Audit
Committee is evaluated with reference to its charter annually or otherwise periodically as deemed appropriate by the Board. A copy
of our Audit Committee&rsquo;s charter is available on our website at https://profoundmedical.com/investors/#governance. The information
on our website is not incorporated by reference into this Registration Statement and should not be considered a part of this Registration
Statement, and the reference to our website in this Registration Statement is an inactive textual reference only.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Audit Committee Oversight</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At no time since the commencement of our
most recently completed financial period was a recommendation of the Audit Committee to nominate or compensate an external auditor
not adopted by the Board.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">External Auditor Service Fees by Category</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate fees billed (excluding out-of-pocket
expenses) by our external auditor in the last two fiscal years are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Financial Year Ending</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Audit<BR>
Fees<SUP>(1)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Audit<BR>
Related<BR>
Fees<SUP>(2)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Tax Fees<SUP>(3)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>All Other<BR>
Fees<SUP>(4)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 47%; text-align: left"><FONT STYLE="font-size: 10pt">December&nbsp;31, 2018&#9;</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">365,776</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">C$</TD><TD STYLE="width: 10%; text-align: right">61,215</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">December&nbsp;31, 2017&#9;</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">313,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">29,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">C$</TD><TD STYLE="text-align: right">186,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 103; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Audit fees include annual audit, quarterly reviews and work performed in relation to the 2018 Bought Deal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Audit related fees includes work performed on acquisitions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Tax fees includes fees related to annual tax returns and scientific research credit return along with tax and transfer pricing
advice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human Resources and Corporate Governance
Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Human Resources and Corporate Governance
Committee is comprised of four independent directors; currently, Arthur Rosenthal (Chair), Kenneth Galbraith, Jean-Francois Pariseau
and Linda Maxwell. The Human Resources and Corporate Governance Committee oversees our remuneration policies and practices. The
principal responsibilities of the Human Resources and Corporate Governance Committee include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">with respect to human resources: (i) assist the Board in ensuring that the necessary policies and
processes are in place by which all of our employees, with special attention to the executive group, will be fairly and competitively
compensated; and (ii) produce a report on executive compensation for inclusion in our proxy statement as required by applicable
rules and regulations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">with respect to corporate governance: (i) identify individuals qualified to become Board members,
and recommend that the Board select the director nominees for the next annual meeting of shareholders; and (ii) develop and recommend
to the Board the corporate governance guidelines and processes applicable to us, review these guidelines and processes at least
annually and recommend changes to the Board.<B>&nbsp;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A copy of our Human Resources and Corporate
Governance Committee&rsquo;s charter is available on our website at https://profoundmedical.com/investors/#governance. The information
on our website is not incorporated by reference into this Registration Statement and should not be considered a part of this Registration
Statement, and the reference to our website in this Registration Statement is an inactive textual reference only.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Statement of Corporate Governance
Practices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board is committed to a high standard
of corporate governance practices. The Board believes that this commitment is not only in the best interests of our shareholders
but that it also promotes effective decision making at the Board level. The Board is of the view that its approach to corporate
governance is appropriate and continues to work to align with the recommendations currently in effect and contained in <I>National
Policy 58-201 - Corporate Governance Guidelines </I>which are addressed below. In connection with our Nasdaq listing, we will become
subject to certain U.S. corporate governance requirements. However, we intend to comply with home country jurisdiction rules, including
the rules of the TSX, instead of certain applicable Nasdaq rules, including with respect to shareholder approvals of equity compensation
plans and additional issuances of our Common Shares and the minimum quorum requirement for a shareholders meeting. Under Nasdaq
listing rules, the required minimum quorum for a shareholders meeting is 33 1/3% of the outstanding common shares, and our minimum
quorum requirement is only 10% of the total number of voting rights attaching to all outstanding Common Shares. See Item 10.B,
 &ldquo;Additional Information&mdash;Memorandum and Articles of Association&mdash;Meetings&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mandate of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has responsibility for stewardship
of the Company. The Board has adopted a written mandate for the Board (the &ldquo;<B>Mandate</B>&rdquo;) to confirm and enhance
the Board&rsquo;s ongoing duty and responsibility for stewardship of the Company, a copy of which is available on our website at
www.profoundmedical.com. The information on our website is not incorporated by reference into this Registration Statement and should
not be considered a part of this Registration Statement, and the reference to our website in this Registration Statement is an
inactive textual reference only. The Board is ultimately responsible for supervising the management of our business and affairs
and, in doing so, is required to act in our best interests. The Board generally discharges its responsibilities either directly
or through the Audit Committee and the Human Resources and Corporate Governance Committee. Specific responsibilities of the Board
set out in the Mandate include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Appointing Management &ndash; including approval of the CEO, the compensation of the executive
officers and the oversight of succession planning programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Board Organization &ndash; including responding to recommendations received from the Human Resources
and Corporate Governance Committee, but the Board retains the responsibility for managing its own affairs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Strategic Planning &ndash; including the review and approval of our business, financial and strategic
plans on at least an annual basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Monitoring of Financial Performance and Other Financial Reporting Matters &ndash; including the
review of our ongoing financial performance and results of operations and review and approval of our audited and interim consolidated
financial statements and management&rsquo;s discussion and analysis of financial conditions and results of operations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">Risk Management &ndash; including the identification of our principal business risks and the implementation
of appropriate systems to effectively monitor and manage such risks;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Policies and Procedures &ndash; including the approval and monitoring of all policies and procedures
including those related to corporate governance, ethics and confidentiality;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">Communication and Reporting &ndash; including the oversight of the timely and accurate disclosure
of financial reports and other material corporate developments; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify">Other Responsibilities &ndash; including those related to position descriptions, orientation and
continuing education, nomination of directors and Board evaluations and matters in respect of any disposition, material commitment
or venture, or significant expenditure in either monetary or business terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Composition of the Board</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director Independence</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jean-Fran&ccedil;ois Pariseau, Brian Ellacott,
Arthur Rosenthal, Linda Maxwell, Kenneth Galbraith and Steve Forte are all &ldquo;independent&rdquo; as such term is defined by
<I>National Instrument 58-101 &ndash; Disclosure of Corporate Governance Practices</I> and applicable Nasdaq listing rules. Arun
Menawat is non-independent as he is our CEO. Each of the independent directors has no direct or indirect material relationship
with us, including any business or other relationship, which could reasonably be expected to interfere with the director&rsquo;s
ability to act with a view to our best interests or which could reasonably be expected to interfere with the exercise of the director&rsquo;s
independent judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Chairman is not independent, the
independent directors may select one of their members to be appointed Lead Director of the Board for such term as the independent
directors may determine. The Lead Director is responsible for chairing regular meetings of the independent directors and seeking
to ensure that the Board is able to carry out its role.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Arun Menawat acts as Chairman of the
Board. Since Dr. Menawat is not independent, Brian Ellacott has been appointed Lead Director of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below shows the current Board
and committee membership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="5">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Committees</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 46%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; padding-bottom: 1pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Year
        Appointed</B></P></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; padding-bottom: 1pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Audit</B></P></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-bottom: 1pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Human
        Resources and<BR>
Corporate Governance<BR>
Committee</B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B>Not Independent &ndash; Management</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Arun Menawat (Chairman)&#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2019 (2015 as director)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><B>Independent Board Members</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Jean-Fran&ccedil;ois Pariseau&#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Member</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Kenneth Galbraith&#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chair</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Member</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Arthur Rosenthal&#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Chair</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Brian Ellacott&#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Member</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Linda Maxwell&#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Member</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Steve Forte &#9;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Member</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Meetings of Independent Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All independent directors on the Board
and each of the committees meet regularly without management present. The Chairman of the Board conducts these sessions at Board
meetings and the Chair of each committee conducts them at committee meetings. During the year ended December 31, 2018, there were
7 such meetings of the independent directors.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chairman of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Chairman, Dr. Arun Menawat, is our
Chief Executive Officer and as a result does not meet the Board&rsquo;s independence standards. The primary functions of the Chairman
are to facilitate the operations and deliberations of the Board and the satisfaction of the Board&rsquo;s responsibilities under
its mandate. The Chairman&rsquo;s key responsibilities include duties relating to providing overall leadership to the Board, chairing
Board and shareholder meetings, acting as a liaison between management, the members of the Board and the Chairs of the various
committees of the Board, and communicating with shareholders and regulators. The responsibilities of the Chairman are reviewed
by the Human Resources and Corporate Governance Committee and considered by the Board for approval each year.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Director Term Limits and Other Mechanics
of Board Renewal</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board has not established any term
limits for directors, as the Board takes the view that term limits are an arbitrary mechanism for removing directors which can
result in valuable, experienced directors being forced to leave the Board solely because of length of service. The Board&rsquo;s
priorities continue to be ensuring the appropriate skill sets are present amongst the Board to optimize the benefit to us. The
Board conducts annual evaluations of the individual directors, the committees of the Board and the Chairman of the Board, which
are overseen by the Human Resources and Corporate Governance Committee, to ensure these objectives are met.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other Reporting Issuer Experience</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets out our current
directors who are presently directors of other issuers that are public companies in the United States, Canada or a foreign jurisdiction,
the name of such public companies and the name of the exchange or market applicable to such public companies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Public Company</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Exchange or Market</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(if applicable)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Kenneth Galbraith&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Macrogenics, Inc., Prometic Life Sciences Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Nasdaq, Toronto Stock Exchange</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Arthur Rosenthal&#9;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LivaNova PLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Nasdaq</FONT></TD></TR>
</TABLE>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board Meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board holds a minimum of one regular
meeting per quarter and a corporate strategy session each year, as well as additional meetings as required. An <I>in&nbsp;camera</I>
session of the directors is held at each regularly scheduled Board and committee meeting so that the independent members of the
Board have an opportunity to meet without the presence of management members of the Board.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Meeting Attendance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="5" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Board Meetings Attended<BR>
in 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Committee Meetings<BR>
Attended in 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damian Lamb<SUP>(5)</SUP>&#9;</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">7 of 7</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">100</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: center">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jean-Fran&ccedil;ois Pariseau&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7 of 7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4 of 4<B><SUP>(3)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Arun Menawat&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7 of 7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Curran<SUP>(5)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7 of 7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8 of 8<B><SUP>(3) (4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Kenneth Galbraith&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 of 7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 of 8<B><SUP>(3) (4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samira Sakhia<SUP>(5)</SUP>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 of 7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 of 2<B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Arthur Rosenthal&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 of 5<B><SUP>(1)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 of 2<B><SUP>(3)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Brian Ellacott&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 of 5<B><SUP>(1)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 of 2<B><SUP>(4)</SUP></B></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Linda Maxwell&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 of 2<B><SUP>(2)</SUP></B></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Dr. Rosenthal and Mr. Ellacott joined the Board on June 14, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Dr. Maxwell joined the Board on October 9, 2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Human Resources and Compensation Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>Audit Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>Mr. Lamb, Mr. Curran, and Ms. Sakhia stepped down from the board on June 13, 2019<FONT STYLE="font-size: 10pt; font-weight: normal">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Orientation and Education</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide new directors with copies
of relevant financial, technical and other information regarding our programs. Board members are also encouraged to communicate
with management and the external auditor and, to keep themselves current with industry trends and developments. Board members have
full access to our records.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">D. Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2019, we had 67 full-time
employees, 14 of whom in Vantaa, Finland that were unionized. We believe that our relations with our employees are positive. We
intend to add staff and consulting resources in order to support product development, market access, field support and additional
clinical trials.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">E. Share Ownership</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 26, 2019, our NEOs and directors
in 2018, as a group, beneficially owned a total of 18,547,317 Common Shares, representing beneficial ownership of 17.2% of the
Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table states the number of
Common Shares beneficially owned by each of our NEOs and directors in 2018 as of August 26, 2019. The persons listed below are
deemed to be the beneficial owners of Common Shares underlying options and/or warrants that are exercisable within 60 days from
the above date. The percentages shown below are based on an aggregate total of 108,027,939 outstanding Common Shares as of August
26, 2019, plus the number of Common Shares underlying options and warrants that are exercisable within 60 days for the indicated
beneficial owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Number of<BR>
Common Shares<BR>
Beneficially Owned</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Percent of<BR>
Outstanding<BR>
Common Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Named Executive Officers (2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%"><FONT STYLE="font-size: 10pt">Arun Menawat<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT>&#9;</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,006,862</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2.7</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Aaron Davidson&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rashed Dewan&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Ian Heynen<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP></FONT>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Guruprit (Goldy) Singh&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; text-align: left">Non-Executive Directors (2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">William Curran<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Brian Ellacott&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Kenneth Galbraith&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Damian Lamb<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)(4)</SUP></FONT>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,828,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Linda Maxwell&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jean-Francois Pariseau&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Arthur Rosenthal&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Samira Sakhia<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(3)</SUP></FONT>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents
less than 1% beneficial ownership of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Includes 1,888,862 Common Shares underlying
options issued under our Share Option Plan (see Item 6.B, &ldquo;Compensation&mdash;Director Compensation&rdquo; and Item 6.B,
 &ldquo;Compensation&mdash;Share Option Plan&rdquo;) and pursuant to a shareholder-approved option grant in January 2017 (see Item
7.B, &ldquo;Related Party Transactions&rdquo;) and 150,000 Common Shares underlying warrants purchased in connection with the 2017
Bought Deal and the 2018 Bought Deal (see Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought
Deals&rdquo; and Item 7.B, &ldquo;Related Party Transactions&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) Mr. Heynen resigned on January 7, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) Mr. Curran, Mr. Lamb and Ms. Sakhia
stepped down from the Board on June 13, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(4) Represents beneficial ownership of
13,328,144 Common Shares and 750,000 Common Shares underlying warrants directly held by Genesys, of which entity Mr. Lamb is an
officer. See Item 7.A, &ldquo;Major Shareholders&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_014"></A>ITEM
7. </FONT>MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Major Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 26, 2019, we had 108,027,939
issued and outstanding Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table states the number of
Common Shares beneficially owned by each person known to us who beneficially owns more than 5% of our issued and outstanding Common
Shares as of August 26, 2019. The persons listed below are deemed to be the beneficial owners of Common Shares underlying options
and/or warrants that are exercisable within 60 days from the above date. The percentages shown below are based on an aggregate
total of 108,027,939 outstanding Common Shares as of August 26, 2019, plus the number of Common Shares underlying options or warrants
that are exercisable within 60 days for the indicated beneficial owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Number of<BR>
Common Shares<BR>
Beneficially Owned</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Percent of<BR>
Outstanding<BR>
Common Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left"><FONT STYLE="font-size: 10pt">BDC Capital Inc. (&ldquo;<B>BDC Capital</B>&rdquo;)&#9;</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">13,441,792</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">12.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Genesys Ventures II LP (&ldquo;<B>Genesys</B>&rdquo;) <FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(1)</SUP></FONT>&#9;</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,828,144</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gagnon Securities LLC&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,305,534</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.5</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes
750,000 Common Shares underlying warrants purchased in connection with the 2018 Bought Deal. See also Item 5.B, &ldquo;Liquidity
and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought Deals&rdquo; and Item 7.B, &ldquo;Related Party Transactions&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Significant Changes in the Ownership
of Major Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">During
the past three years, to our knowledge, the significant changes in the percentage ownership of our major shareholders were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-weight: normal">On January 8, 2019, Gagnon Securities LLC reported that it became the beneficial owner of
more than 10% of our Common Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-weight: normal">On March 20, 2018, Genesys acquired 1,500,000 Common Shares and 750,000 warrants to purchase
Common Shares in the 2018 Bought Deal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-weight: normal">On November 14, 2016, Genesys acquired 2,727,272 Common Shares in the 2016 Bought Deal.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-weight: normal">&middot;</FONT></TD><TD><FONT STYLE="font-weight: normal">On November 14, 2016, BDC Capital acquired 3,636,363 Common Shares in the 2016 Bought Deal.</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Major Shareholders Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Our major
shareholders do not have different voting rights from other holders of our Common Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Record Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Based
on our records and a review of the information provided to us by the TSX, as of August 2, 2019, there were 2,420 holders of record
of our ordinary shares, of which 896 record holders, holding approximately 36% of our outstanding ordinary shares, had registered
addresses in the United States. These numbers are not representative of the number of beneficial holders of our ordinary shares
nor is it representative of where such beneficial holders reside primarily because many of these ordinary shares may be held of
record by brokers or other nominees.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Related Party
Transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed below, none of our
directors or officers, nor any of our proposed nominees for election as a director, nor any of our other insiders, nor any associate
or affiliate of any one of them, has or has had, at any time since the beginning of our financial year ended December 31, 2016,
any material interest, direct or indirect, in any transaction or proposed transaction that has materially affected or would materially
affect us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2018, Genesys, of which entity
Mr. Lamb (our former director) is an officer, purchased 1,500,000 of units in the 2018 Bought Deal at a price of C$1.00 per unit,
for total consideration of C$1,500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Three members of our senior management,
Dr. Menawat, Mr. Davidson and Mr. Dewan, also purchased our units in the 2018 Bought Deal, in the amounts of 150,000 units (150,000
Common Shares and 75,000 warrants), 125,000 units (125,000 Common Shares and 62,500 warrants) and 50,000 units (50,000 Common Shares
and 25,000 warrants), respectively, at a price of C$1.00 per unit, for total consideration of C$150,000, C$125,000 and C$50,000
respectively. The units were issued on the same terms as the units issued in the 2018 Bought Deal. For more information, see Item
5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought Deals&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2017, three members of our
senior management, Dr. Menawat, Mr. Dewan and Ms. Singh, purchased our units in the 2017 Bought Deal, in the amounts of 150,000
units (150,000 Common Shares and 75,000 warrants), 100,000 units (100,000 Common Shares and 50,000 warrants) and 100,000 units
(100,000 Common Shares and 50,000 warrants), respectively, at a price of C$1.00 per unit, for total consideration of C$150,000,
C$100,000 and C$100,000, respectively. The units were issued on the same terms as the units issued in the 2017 Bought Deal. For
more information, see Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and Uses of Financing&mdash;Bought
Deals&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Special Meeting of Shareholders
of the Company held in January 2017, the disinterested shareholders approved the grant of an option to purchase 1,417,583 Common
Shares for an exercise price of C$1.10 to Arun Menawat.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2016, Genesys, of which entity
Mr. Lamb is an officer, purchased 2,727,272 Common Shares in the 2016 Bought Deal at a price of C$1.10 per Common Share, representing
aggregate consideration of C$2,999,999.20. Genesys acquired the Common Shares for investment purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2016, BDC Capital purchased
3,636,363 Common Shares in the 2016 Bought Deal at a price of C$1.10 per Common Share, representing aggregate consideration of
C$3,999,999.30. BDC Capital acquired the Common Shares for investment purposes.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Agreements with Directors and Officers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have employment agreements in place
with our Chief Executive Officer, Arun Menawat; our Chief Financial Officer, Aaron Davidson; our Vice President, Finance, Rashed
Dewan and our Vice-President of Regulatory Affairs and Product Management, Guruprit (Goldy) Singh and Mathieu Burtnyk, our Vice
President Clinical Affairs. See Item 6.B, &ldquo;Compensation&mdash;Named Executive Officers&mdash;Executive Employment Agreements
 &ndash; Termination and Change of Control Benefits&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Interests of
Experts and Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_015"></A>ITEM
8. </FONT>FINANCIAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Consolidated
Statements and Other Financial Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our unaudited consolidated financial statements
as at and for the three and six months ended June 30, 2019 and 2018 and our audited consolidated financial statements as at and
for the years ended December 31, 2018, 2017 and 2016 are attached hereto and found immediately following the text of this Registration
Statement, beginning on page F-1. The audit report of PwC is included herein immediately preceding the audited consolidated financial
statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may become involved
in legal or regulatory proceedings arising in the ordinary course of business. During the most recently completed fiscal year:
(a) there were no legal proceedings to which we were a party, or by which any of our property was subject, which would be material
to it and are not aware of any such proceedings being contemplated, (b) there were no penalties or sanctions imposed by a court
relating to securities legislation, or other penalties or sanctions imposed by a court or regulatory body against us that would
likely be considered important to a reasonable investor making an investment decision and (c) we have not entered into any settlement
agreements before a court relating to securities legislation or with a securities regulatory authority.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividend Policy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not declared or paid any dividends
since incorporation and we have no present intention to declare or pay any dividends in the foreseeable future. Any decision to
declare or pay dividends on the Common Shares will be made by the board of directors based upon our earnings, financial requirements
and other conditions existing at such future time.&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Significant Changes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise disclosed in this Registration
Statement, there have been no significant changes in our financial condition since the most recent consolidated financial statements
for the three and six months ended June 30, 2019.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_016"></A>ITEM
9. </FONT>THE OFFER AND LISTING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Offer and Listing
Details</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Shares are listed and posted
for trading on the TSX under the trading symbol &ldquo;PRN&rdquo;. We intend to apply for our Common Shares to be listed on Nasdaq
under the trading symbol &ldquo;PROF&rdquo;. Such a listing is dependent upon this Registration Statement being declared effective
as well as our meeting all the necessary listing requirements of the Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this Registration Statement,
our authorized capital consisted of an unlimited number of Common Shares without par value. Our issued and outstanding Common Shares
are fully paid. We have no other authorized class of equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Common Shares are in registered form
and the transfer of our common shares is managed by our transfer agent, TSX Trust Company, 301 &ndash; 100 Adelaide St. W., Toronto,
ON, M5H 4H1 (Tel: (416) 342-1091). Our transfer agent in the United States will be Computershare Trust Company, N.A., Canton, MA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For additional details regarding our Common
Shares, see Item 10.A, &ldquo;Share Capital&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Plan of Distribution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Markets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 9.A, &ldquo;Offer and Listing
Details&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">D. Selling Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">E. Dilution</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">F. Expenses of the
Issue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_017"></A>ITEM
10. </FONT>ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">A. Share Capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital consists of an unlimited
number of Common Shares without par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at August 26, 2019, there were a total
of 108,027,939 Common Shares issued and outstanding. The holders of the Common Shares are entitled to receive notice of and to
attend <FONT STYLE="font-weight: normal">all</FONT> annual and special meetings of our shareholders and to one vote in respect
of each common share held at such meetings. Since January 1, 2016, we have issued a total of 68,599,612 Common Shares, principally
in connection with the Bought Deals and issuances upon exercise of options and warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As at August 26, 2019, there were a total
of 10,373,929 outstanding share options issued under our Share Option Plan and 22,571,714 outstanding warrants issued pursuant
to the Bought Deals and the CIBC Loan Agreement. See Item 5.B, &ldquo;Liquidity and Capital Resources&mdash;Recent Sources and
Uses of Financing&rdquo;. In addition, as at August 26, 2019, 3,675,553 options remain available for future grant under the Share
Option Plan. See Item 6.B, &ldquo;Compensation&mdash;Share Option Plan&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">B. Memorandum and
Articles of Association</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Set out below is a description of our
articles of incorporation (our &ldquo;<B>Articles</B>&rdquo;) and of the Business Corporations Act (Ontario) (as currently in effect)
related to our articles of incorporation. Our articles of incorporation are filed as an exhibit to this Registration Statement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Incorporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Profound is organized under the <I>Business
Corporations Act </I>(Ontario) (&ldquo;<B>OBCA</B>&rdquo;). Profound&rsquo;s Ontario corporation number is 2426652<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Objects and Purposes of our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Our Articles
do not contain and are not required to contain a description of our objects and purposes. There is no restriction contained in
our Articles of the business that we may carry on.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting on Certain Proposal, Arrangement, Contract
or Compensation by Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither our Articles nor our by-laws restrict
our directors&rsquo; power to: (a) vote on a proposal, arrangement or contract in which the directors are materially interested;
(b) to vote with regard to compensation payable to themselves or any other members of their body in the absence of an independent
quorum; or (c) borrow money. Additionally, a director is not required to hold a share in our capital as qualification for his or
her office but must be qualified as required by the OBCA to become, act or continue to act as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Common Shares are entitled
to receive notice of and to attend all annual and special meetings of the shareholders of the Company and to one vote in respect
of each common share held at such meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Procedures to Change the Rights of Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The rights, privileges, restrictions and
conditions attaching to the Common Shares are contained in our Articles and such rights, privileges, restrictions and conditions
may be changed by amending our Articles. In order to amend such Articles, the OBCA requires a resolution to be passed by a majority
of not less than two-thirds of the votes cast by the shareholders entitled to vote thereon. In addition, if we resolve to make
certain amendments to its Articles, a holder of Common Shares may dissent with regard to such resolution and, if such shareholder
so elects, we would have to pay such shareholder the fair value of the Common Shares so held. The types of amendment that would
be subject to dissent rights include without limitation: (a) to add, remove or change restrictions on the issue, transfer or ownership
of shares of a class or series of our shares; and (b) to add, remove or change any restriction upon the business that we may carry
on or upon the powers we may exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each director holds office until our next
annual general meeting or until his or her office is earlier vacated in accordance with the provisions of the OBCA. A director
appointed or elected to fill a vacancy on our board of directors also holds office until our next annual general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual meetings of our shareholders must
be held at such time in each year not more than fifteen (15) months after the last annual meeting, as the board of directors may
determine. Pursuant to our by-laws, notice of the time and place of a meeting of shareholders must be sent not less than twenty-one
(21) days and not more than fifty (50) days, before such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The only persons entitled to attend a meeting
of our shareholders are voting persons, the directors, the auditor and, if any, the chairperson, the managing director and the
President, as well as others permitted by the chairperson of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The OBCA provides that our shareholders
may requisition a special meeting in accordance with the OBCA. The OBCA provides that the holders of not less than five (5) percent
of our issued shares that carry the right to vote at a meeting may requisition our directors to call a special meeting of shareholders
for the purposes stated in the requisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under our by-laws, the quorum for the transaction
of business at a meeting of our shareholders is two or more voting persons present in person and authorized to cast in the aggregate
not less than ten (10) percent of the total number of votes attaching to all Common Shares. Under Nasdaq listing rules, the required
minimum quorum for a shareholders meeting is 33 1/3% of the outstanding common shares; however, we are relying on an exception
for &ldquo;foreign private issuers&rdquo; to this quorum requirement insofar as the provisions of our Articles are permitted under
the OBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Limitations on Ownership of Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as provided in the <I>Investment
Canada Act</I> (Canada), there are no limitations specific to the rights of non-Canadians to hold or vote the Common Shares under
the laws of Canada or Ontario, or in our Articles or by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Change in Control</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no provisions in our Articles
or by-laws that would have the effect of delaying, deferring or preventing a change in control of us, and that would operate only
with respect to a merger, acquisition or corporate restructuring involving us or any of our subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ownership Threshold</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither our by-laws nor our Articles contain
any provisions governing the ownership threshold above which shareholder ownership must be disclosed. In addition, securities legislation
in Canada requires that we disclose in our proxy information circular for our annual meeting and certain other disclosure documents
filed by us under such legislation, holders who beneficially own more than ten (10) percent of our issued and outstanding Common
Shares.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">C. Material Contracts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for contracts entered into in the
ordinary course of business, the following are our only material agreements (the &ldquo;<B>Material Contracts</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Amended and Restated Technology License Agreement dated May 16, 2011 between PMI and Sunnybrook
(the &ldquo;<B>Sunnybrook License</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Loan Agreement with Canadian Imperial Bank of Commerce dated July 30, 2018 (the &ldquo;<B>CIBC
Loan Agreement</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Asset and Share Purchase Agreement dated July 31, 2017 between Philips and PMI (the &ldquo;<B>Philips
Share Purchase Agreement</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Supply Agreement dated July 31, 2017 between PMI and Philips Medical Systems Nederland B.V. (the
 &ldquo;<B>Philips Supply Agreement</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Noncompetition, Nonsolicitation and Confidentiality Agreement dated July 31, 2017 between Philips
and PMI (the &ldquo;<B>Philips Confidentiality Agreement</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Resale Purchasing Agreement dated July 31, 2017 between Philips Medical and PMI (the &ldquo;<B>Philips
Resale Purchasing Agreement</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Agreement between PMI and Siemens, dated February 11, 2019 (the &ldquo;<B>New Siemens Agreement</B>&rdquo;)
and effective as of January 21, 2019.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunnybrook License</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 4.B, &ldquo;Business Overview&mdash;Intellectual
Property&mdash;Licenses&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIBC Loan Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 5.B, &ldquo;Liquidity and Capital
Resources&mdash;Recent Sources and Uses of Financing&mdash;CIBC Loan&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Philips Share Purchase Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 4.A, &ldquo;Business Overview&mdash;Alliances
and Partnerships&mdash;Philips&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Philips Supply Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, we entered into the Philips
Supply Agreement with Philips Medical Systems Nederland B.V. (&ldquo;<B>Philips Medical</B>&rdquo;) in connection with the Sonalleve
Transaction. Under the terms of the Philips Supply Agreement and until such time as the manufacturing of our Sonalleve systems
is assumed by us, Philips Medical agrees to serve as a contract manufacturer to us for our Sonalleve systems. We work together
with Philips Medical to ensure that production capacity and delivery times are appropriate to meet our sales forecasts.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Philips Confidentiality Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, we entered into the Philips
Confidentiality Agreement with Philips in connection with the Sonalleve Transaction. Under the terms of the Philips Confidentiality
Agreement, Philips has agreed to (i) not compete in related lines of business, anywhere in the world, for period of three years
after closing; (ii) not solicit any of our employees for so long as agreements related to the Sonalleve Transaction are in force,
plus an additional two years; and (iii) maintain in confidence any confidential information that if disseminated would be detrimental
to our business, for a period of ten years after closing.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Philips Resale Purchasing Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, we entered into the Philips
Resale Purchasing Agreement with Philips Medical in connection with the Sonalleve Transaction. Under the terms of the agreement,
Philips Medical is permitted to purchase certain of our products for the purpose of reselling such products to its customers. In
addition, we are permitted to sell additional products directly to customers of Philips Medical upon an initial sale of the Philips
products to such customers.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Siemens Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item 4.A, &ldquo;Business Overview&mdash;Alliances
and Partnerships&mdash;Siemens&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">D. Exchange Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not aware of any Canadian federal
or provincial laws, decrees, or regulations that restrict the export or import of capital, including foreign exchange controls,
or that affect the remittance of dividends, interest or other payments to non-Canadian holders of the Common Shares. There are
no limitations under the laws of Canada or by the charter or our other constituent documents, except the Investment Canada Act
which may require review and approval by the Minister of Industry (Canada) of certain acquisition of control of us by non-Canadians.
The threshold for acquisitions of control is generally defined as being one-third or more of our voting shares. If the investment
is potentially injurious to national security it may be subject to review under the Investment Canada Act notwithstanding the percentage
interest acquired or amount of the investment. &ldquo;Non-Canadian&rdquo; generally means an individual who is not a Canadian citizen,
or a corporation, partnership, trust or joint venture that is ultimately controlled by non-Canadians.&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">E. Taxation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Canadian Federal Income Taxation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consider that the following general
summary fairly describes the principal Canadian federal income tax consequences applicable to a holder of our Common Shares who
is a resident of the United States, who is not, will not be and will not be deemed to be a resident of Canada for purposes of the
<I>Income Tax Act </I>(Canada) and any applicable tax treaty and who does not use or hold, and is not deemed to use or hold, his,
her or its Common Shares in the capital of our Company in connection with carrying on a business in Canada (a &ldquo;<B>non-resident
holder</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is based upon the current
provisions of the <I>Income Tax Act </I>(Canada), the regulations thereunder (the &ldquo;<B>Regulations</B>&rdquo;), the current
publicly announced administrative and assessing policies of the Canada Revenue Agency and the Canada-United States Tax Convention
as amended by the Protocols thereto (the &ldquo;<B>Treaty</B>&rdquo;). This summary also takes into account the amendments to the
<I>Income Tax Act </I>(Canada) and the Regulations publicly announced by the Minister of Finance (Canada) prior to the date hereof
(the &ldquo;<B>Tax Proposals</B>&rdquo;) and assumes that all such Tax Proposals will be enacted in their present form. However,
no assurances can be given that the Tax Proposals will be enacted in the form proposed, or at all. This summary is not exhaustive
of all possible Canadian federal income tax consequences applicable to a holder of our Common Shares and, except for the foregoing,
this summary does not take into account or anticipate any changes in law, whether by legislative, administrative or judicial decision
or action, nor does it take into account provincial, territorial or foreign income tax legislation or considerations, which may
differ from the Canadian federal income tax consequences described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This summary is of a general nature
only and is not intended to be, and should not be construed to be, legal, business or tax advice to any particular holder or prospective
holder of our Common Shares, and no opinion or representation with respect to the tax consequences to any holder or prospective
holder of our Common Shares is made. Accordingly, holders and prospective holders of our Common Shares should consult their own
tax advisors with respect to the income tax consequences of purchasing, owning and disposing of our Common Shares in their particular
circumstances. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends paid on our Common Shares to
a non-resident holder will be subject under the <I>Income Tax Act </I>(Canada) to withholding tax at a rate of 25% subject to a
reduction under the provisions of an applicable tax treaty, which tax is deducted at source by our Company. The Treaty provides
that the <I>Income Tax Act </I>(Canada) standard 25% withholding tax rate is reduced to 15% on dividends paid on shares of a corporation
resident in Canada (such as our Company) to residents of the United States who are entitled to the benefits of the Treaty, and
also provides for a further reduction of this rate to 5% where the beneficial owner of the dividends is a corporation resident
in the United States entitled to the benefits of the Treaty that owns at least 10% of the voting shares of the corporation paying
the dividend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Capital Gains</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A non-resident holder is not subject to
tax under the <I>Income Tax Act</I> (Canada) in respect of a capital gain realized upon the disposition of a common share of our
Company unless such share represents &ldquo;taxable Canadian property&rdquo;, as defined in the <I>Income Tax Act</I> (Canada),
to the holder thereof. Our Common Shares generally will not be considered taxable Canadian property to a non-resident holder provided
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the non-resident holder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">persons with whom the non-resident holder did not deal at arm&rsquo;s length;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the non-resident holder and persons with whom such non-resident holder did not deal at arm&rsquo;s
length; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">partnerships in which the non-resident holder or a person with whom the non-resident holder did
not deal at arm&rsquo;s length holds a membership interest directly or indirectly through one or more partnerships,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">did not own, or have
an interest in, or an option in, respect of, 25% or more of the issued shares of any class of our capital stock at any time during
the 60 month period immediately preceding the disposition of such shares. In the case of a non-resident holder to whom shares of
our Company represent taxable Canadian property and who is resident in the United States and entitled to the benefits of the Treaty,
no Canadian taxes will generally be payable on a capital gain realized on such shares by reason of the Treaty unless the value
of such shares is derived principally from real property situated in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain U.S. Federal Income Tax Considerations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the U.S.
federal income tax considerations generally applicable to a U.S. Holder (as defined below) of the acquisition, ownership, and disposition
of Common Shares. This summary does not purport to address all U.S. federal income tax matters that may be relevant to a particular
U.S. Holder of Common Shares, nor is it a complete analysis of all potential U.S. federal income tax consequences. This summary
does not address any tax consequences arising under any state, local or non-U.S. tax laws or U.S. federal estate or gift tax laws.
This summary is based on the provisions of the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), the Treasury
regulations thereunder, and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of
which are subject to change, possibly with retroactive effect. This summary applies only to a U.S. Holder that acquires Common
Shares and holds Common Shares as capital assets for U.S. federal income tax purposes (generally, property held for investment).
This summary does not address all U.S. federal income tax considerations that may be relevant to shareholders that are subject
to special tax rules, including, without limitation, expatriates and certain former citizens of the United States, partnerships
and other pass-through entities, financial institutions, insurance companies, brokers, dealers or traders in securities, commodities
or currencies, tax-exempt organizations, tax qualified retirement plans and individual retirement accounts, regulated investment
companies, real estate investment trusts, persons subject to the alternative minimum tax, persons whose functional currency for
U.S. federal income tax purposes is not the U.S. dollar, persons holding Common Shares as part of a hedge, straddle or other risk
reduction strategy or as part of a hedging or conversion transaction or other integrated investment, persons that own or have owned
(directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares (including
Common Shares) of the Company, and persons who acquired Common Shares through stock option or shares purchase plan programs or
in other compensatory arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a partnership (or other entity taxed
as a partnership for U.S. federal income tax purposes) holds Common Shares, the tax treatment of a partner in the partnership generally
will depend upon the status of the partner and the activities of the partnership. Partnerships and partners in such a partnership
are urged to consult their tax advisers regarding the tax consequences of acquiring, owning, and disposing of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this discussion, a &ldquo;<B>U.S.
Holder</B>&rdquo; is a beneficial owner of Common Shares that is: (i) a citizen or an individual who is a resident of the United
States as determined for U.S. federal income tax purposes; (ii) a corporation (or other entity taxable as a corporation for U.S.
federal income tax purposes) created or organized under the laws of the United States, any State or political subdivision thereof
or the District of Columbia; (iii) an estate, the income of which is subject to U.S. federal income taxation regardless of its
source; or (iv) a trust (1) if a court within the United States is able to exercise primary supervision over its administration
and one or more U.S. persons has the authority to control all of the substantial decisions of the trust; or (2) that has a valid
election in effect under applicable Treasury regulations to be treated as a U.S. person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary is of a general nature only
and is not intended to be tax advice to any prospective investor, and no representation with respect to the tax consequences to
any particular investor is made. Prospective investors are urged to consult their tax advisers with respect to the U.S. federal,
state, local and non-U.S. income and other tax considerations relevant to them, having regard to their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Distributions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion under &ldquo;&mdash;
Passive Foreign Investment Company Considerations&rdquo; below, the gross amount of a distribution paid to a U.S. Holder with respect
to Common Shares (including amounts withheld to pay Canadian withholding taxes) will be included in such holder&rsquo;s gross income
as dividend income to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined
under U.S. federal income tax principles). To the extent that the amount of a distribution exceeds our current and accumulated
earnings and profits, it will be treated first as a tax-free return of a U.S. Holder&rsquo;s tax basis in Common Shares, and to
the extent the amount of the distribution exceeds such U.S. Holder&rsquo;s tax basis, the excess will be taxed as capital gain.
Because we do not expect to calculate our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders
should expect that a distribution generally will be treated as a dividend for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends received by individuals and other
non-corporate U.S. Holders of Common Shares generally will be subject to tax at preferential rates applicable to long-term capital
gains, provided that such holders meet certain holding period and other requirements and that the Company is not treated as a PFIC
(as defined below) for the taxable year in which the dividend is paid or for the preceding taxable year. Dividends on Common Shares
generally will not be eligible for the dividends-received deduction allowed to corporations. U.S. Holders are urged to consult
their tax advisers regarding the application of the relevant rules to their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dividends paid on Common Shares generally
will constitute foreign-source income classified as &ldquo;passive category&rdquo; income for foreign tax credit limitation purposes.
A U.S. Holder may be entitled to deduct or credit any Canadian withholding taxes on dividends in determining its U.S. income tax
liability, subject to certain limitations (including that the election to deduct or credit foreign taxes applies to all of such
U.S. Holder&rsquo;s foreign taxes for a particular taxable year). The rules governing the foreign tax credit are complex. U.S.
Holders are urged to consult their tax advisers regarding the availability of the foreign tax credit under their particular circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receipt of Foreign Currency</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. dollar value of any distribution
on Common Shares made in Canadian dollars generally will be calculated by reference to the exchange rate between U.S. dollars and
Canadian dollars in effect on the date of actual or constructive receipt of such distribution by the U.S. Holder, regardless of
whether the Canadian dollars so received are in fact converted into U.S. dollars. If the Canadian dollars so received are converted
into U.S. dollars on the date of receipt, then a U.S. Holder generally will not recognize foreign currency gain or loss on such
conversion. If the Canadian dollars so received are not converted into U.S. dollars on the date of receipt, then a U.S. Holder
generally will have a tax basis in the Canadian dollars equal to the U.S. dollar value of such Canadian dollars on the date of
receipt. Any gain or loss on a subsequent conversion or other disposition of the Canadian dollars generally will be treated as
ordinary income or loss to a U.S. Holder and generally will be U.S.-source income or loss for U.S. foreign tax credit purposes.
U.S. Holders are urged to consult their tax advisers regarding the U.S. federal income tax consequences of receiving distributions
on Common Shares in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sale or Other Disposition of Common
Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the discussion under &ldquo;&mdash;Passive
Foreign Investment Company Considerations&rdquo; below, a U.S. Holder will recognize taxable gain or loss upon the sale, exchange,
or other taxable disposition of Common Shares equal to the difference, if any, between the amount realized for Common Shares and
the U.S. Holder&rsquo;s tax basis in such Common Shares. The gain or loss will be capital gain or loss. Non-corporate U.S. Holders,
including individual U.S. Holders that have held Common Shares for more than one year, currently are eligible for reduced tax rates.
The deductibility of capital losses is subject to limitations. Any such gain or loss recognized by a U.S. Holder generally will
be treated as U.S.-source gain or loss for foreign tax credit limitation purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Passive Foreign Investment Company
Considerations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain adverse tax consequences could
apply to a U.S. Holder if we are treated as a &ldquo;passive foreign investment company&rdquo; (a &ldquo;<B>PFIC</B>&rdquo;) for
any taxable year during which the U.S. Holder holds Common Shares. In general, a non-U.S. corporation is a PFIC for any taxable
year in which (i) 75% or more of its gross income consists of passive income (the &ldquo;<B>income test</B>&rdquo;) or (ii) 50%
or more of the average quarterly value of its assets consists of assets that produce, or are held for the production of, passive
income (the &ldquo;<B>asset test</B>&rdquo;). Generally, &ldquo;passive income&rdquo; includes interest, dividends, rents, royalties
and certain gains, and cash is a passive asset for PFIC purposes. For purposes of the asset test and income test, a non-U.S. corporation
that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate
share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have made no determination as to whether
we are classified as a PFIC for U.S. federal income tax purposes. The determination of whether we are a PFIC depends on the particular
facts and circumstances (such as the valuation of our assets, including goodwill and other intangible assets) and is also affected
by the application of the PFIC rules, which are subject to differing interpretations. The fair market value of our assets is expected
to depend, in part, upon (i) the market price of Common Shares, which is likely to fluctuate, and (ii) the composition of our income
and assets, which will be affected by how, and how quickly, we spend any cash that is raised in any financing transaction. Moreover,
our PFIC status is determined on an annual basis after the end of each taxable year. In light of the foregoing, no assurance can
be provided that we are not currently a PFIC or that we will not become a PFIC in any future taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, if we were a PFIC for any taxable
year during which a U.S. Holder held Common Shares, gain recognized upon a disposition of Common Shares by the U.S. Holder would
be allocated ratably over the U.S. Holder&rsquo;s holding period for such Common Shares. The amounts allocated to the taxable year
of disposition and to taxable years prior to the first taxable year in which we were a PFIC would be taxed as ordinary income.
The amount allocated to each other taxable year would be subject to tax at the highest tax rate in effect for that taxable year
for individuals or corporations, as appropriate, and an interest charge would be imposed on the resulting tax liability for each
such year. Further, to the extent that any distribution received by a U.S. Holder on Common Shares exceeded 125% of the average
of the annual distributions received on such Common Shares during the preceding three years or the U.S. Holder&rsquo;s holding
period, whichever is shorter, that distribution would be subject to taxation in the same manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alternatively, if we were a PFIC and if
Common Shares were &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange,&rdquo; a U.S. Holder might be able to make a
mark-to-market election with respect to Common Shares that would result in tax treatment different from the general tax treatment
for PFICs described above. The Common Shares would be treated as &ldquo;regularly traded&rdquo; in any calendar year in which more
than a de minimis quantity of Common Shares were traded on a qualified exchange on at least 15 days during each calendar quarter.
Nasdaq, where Common Shares are expected to be listed, is a qualified exchange for this purpose. If a U.S. Holder makes the mark-to-market
election, in each year that we are a PFIC the U.S. Holder generally will recognize as ordinary income any excess of the fair market
value of Common Shares at the end of the taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect
of any excess of the adjusted tax basis of Common Shares over their fair market value at the end of the taxable year (but only
to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes
the election, the U.S. Holder&rsquo;s tax basis in Common Shares will be adjusted to reflect these income or loss amounts. In addition,
if a U.S. Holder makes the mark-to-market election, any gain that the U.S. Holder recognizes on the sale or other disposition of
Common Shares in a year in which we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss
(but only to the extent of the net amount of income previously included as a result of the mark-to-market election). U.S. Holders
should consult their tax advisers regarding the availability and advisability of making a mark-to-market election in their particular
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not intend to provide information
necessary for U.S. Holders to make qualified electing fund elections, which, if available, would result in a further alternative
tax treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we were a PFIC for any year during which
a U.S. Holder owned Common Shares, we generally would continue to be treated as a PFIC with respect to such U.S. Holder&rsquo;s
Common Shares unless (i) we ceased to be a PFIC and (ii) the U.S. Holder had made a &ldquo;deemed sale&rdquo; election under the
PFIC rules to recognize gain (but not loss) under the PFIC rules described above, without the receipt of corresponding cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we were a PFIC or, with respect to a
particular U.S. Holder, we were treated as a PFIC for the taxable year in which we pay a dividend or for the prior taxable year,
the preferential rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply. In
addition, if we were a PFIC for any taxable year during which a U.S. Holder owns Common Shares, the U.S. Holder would be required
to file annual reports with the Internal Revenue Service, subject to certain exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The application of the PFIC rules to U.S.
Holders is uncertain in certain respects, and the PFIC rules remain subject to recently proposed Treasury Regulations yet to be
made final. Each U.S. Holder should consult its own tax adviser regarding the application of the PFIC rules, including the foregoing
filing requirements and the recently proposed Treasury Regulations, as well as the advisability of making any available election
under the PFIC rules, with regard to such holder&rsquo;s ownership and disposition of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional Tax on Net Investment
Income</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain U.S. Holders that are individuals,
estates or trusts are subject to a 3.8% tax on all or a portion of their &ldquo;net investment income,&rdquo; which may include
all or a portion of their dividend income and net gains from the disposition of Common Shares. Each U.S. Holder that is an individual,
estate or trust is urged to consult its tax advisers regarding the applicability of this tax to its income and gains in respect
of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign Financial Asset Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citizens or individual residents of the
United States holding &ldquo;specified foreign financial assets&rdquo; (which generally include shares and other securities issued
by a foreign person unless held in an account maintained by a financial institution) that exceed certain U.S. dollar thresholds
are required to report information relating to such assets, which could include Common Shares, by filing a completed Internal Revenue
Service Form 8938 (Statement of Specified Foreign Financial Assets) with their tax returns. Significant penalties may apply for
the failure to satisfy this reporting obligation. U.S. Holders are urged to consult their tax advisers regarding the foregoing
reporting obligation with regard to their ownership of Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information Reporting and Backup
Withholding</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Distributions with respect to Common Shares
and proceeds from the sale, exchange, or other taxable disposition of Common Shares may be subject to information reporting to
the Internal Revenue Service and U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes
a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding
and properly establishes such exempt status. Backup withholding is not an additional tax. Amounts withheld as backup withholding
may be credited against a U.S. Holder&rsquo;s U.S. federal income tax liability, and a U.S. Holder generally may obtain a refund
of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the Internal
Revenue Service and furnishing any required information.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">F. Dividends and
Paying Agents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">G. Statement by
Experts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements as
of December 31, 2018, 2017 and 2016 and the related consolidated statements of loss and comprehensive loss, changes in shareholders&rsquo;
equity, and cash flows for each of the three years in the period ended December 31, 2018 and a summary of significant accounting
policies and other explanatory information included in this Registration Statement have been audited by PricewaterhouseCoopers
LLP, 354 Davis Road, Suite 600, Oakville, ON, Canada L6J 0C5, an independent registered public accounting firm, as stated in their
report appearing herein. Such consolidated financial statements are included in reliance upon the report of such firm given upon
their consent and authority as experts in accounting and auditing.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">H. Documents on
Display</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement and the related
exhibits are available for viewing at the offices of Profound Medical Corp., 2400 Skymark Avenue, Unit 6, Mississauga, Ontario
L4W 5K5, telephone: (647) 476-1350. Copies of our financial statements and other continuous disclosure documents required under
the Securities Act (Ontario) are available for viewing on SEDAR at www.sedar.com. All of the documents referred to are in English.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC maintains an Internet site (<I>http://www.sec.gov</I>)
that makes available reports and other information that the Company files or furnishes electronically with it. The Company&rsquo;s
Internet site can be found at http://www.profoundmedical.com. The information on our website is not incorporated by reference into
this Registration Statement and should not be considered a part of this Registration Statement, and the reference to our website
in this Registration Statement is an inactive textual reference only.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">I. Subsidiary Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase"><A NAME="a_018"></A>ITEM
11. </FONT>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to various risks associated
with our assets, liabilities and anticipated transactions, including credit risk, market risk (including interest rate price risk
and foreign currency risk) and liquidity risk. See note 18 of our audited consolidated financial statements for the years ended
December 31, 2018, 2017 and 2016 for a qualitative and quantitative discussion of our exposure to these market risks. There were
no material changes in these risks for the three and six months ended June 30, 2019.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_019"></A><FONT STYLE="text-transform: uppercase">ITEM
12. </FONT>DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_020"></A>PART
II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_021"></A><FONT STYLE="text-transform: uppercase">ITEM
13. </FONT>DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_022"></A><FONT STYLE="text-transform: uppercase">ITEM
14. </FONT>MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_023"></A><FONT STYLE="text-transform: uppercase">ITEM
15. </FONT>CONTROLS AND PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_024"></A>ITEM 16A AUDIT COMMITTEE FINANCIAL
EXPERT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_025"></A>ITEM 16B CODE OF ETHICS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_026"></A>ITEM 16C PRINCIPAL ACCOUNTANT
FEES AND SERVICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_027"></A>ITEM 16D EXEMPTIONS FROM LISTING
STANDARDS FOR AUDIT COMMITTEES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_028"></A>ITEM 16E PURCHASES OF EQUITY
SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_029"></A>ITEM 16F CHANGE IN REGISTRANT'S
CERTIFYING ACCOUNTANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_030"></A>ITEM 16G CORPORATE GOVERNANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not Applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_031"></A>ITEM 16H MINE SAFETY DISCLOSURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"></P>


<!-- Field: Page; Sequence: 122; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="a_032"></A>PART
III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_033"></A><FONT STYLE="text-transform: uppercase">ITEM
17. </FONT>FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See Item&nbsp;18, &ldquo;Financial Statements&rdquo;.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><A NAME="a_034"></A><FONT STYLE="text-transform: uppercase">ITEM
18. </FONT>FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following financial statements are
attached hereto, incorporated herein and found immediately following the text of this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Our audited consolidated financial statements as at and for the years ended December 31, 2018,
2017 and 2016, together with the notes thereto and our independent auditor&rsquo;s report thereon.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Our unaudited interim condensed consolidated financial statements as at and for the three and six
months ended June 30, 2019 and 2018, together with the notes thereto.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><A NAME="a_035"></A><FONT STYLE="text-transform: uppercase">ITEM
19. </FONT>EXHIBITS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex1-1.htm" STYLE="-sec-extract: exhibit">1.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex1-1.htm" STYLE="-sec-extract: exhibit">Articles of Incorporation</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex1-2.htm" STYLE="-sec-extract: exhibit">1.2</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex1-2.htm" STYLE="-sec-extract: exhibit">Articles of Amendment</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex1-3.htm" STYLE="-sec-extract: exhibit">1.3</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex1-3.htm" STYLE="-sec-extract: exhibit">Articles of Amalgamation</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex1-4.htm" STYLE="-sec-extract: exhibit">1.4</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex1-4.htm" STYLE="-sec-extract: exhibit">Bylaws</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex2-1.htm" STYLE="-sec-extract: exhibit">2.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex2-1.htm" STYLE="-sec-extract: exhibit">Form of Common Share Certificate</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-1.htm" STYLE="-sec-extract: exhibit">4.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Technology License Agreement between Sunnybrook Health Sciences Centre and
Profound Medical Inc., dated May 16, 2011</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-2.htm" STYLE="-sec-extract: exhibit">4.2</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-2.htm" STYLE="-sec-extract: exhibit">Asset and Share Purchase Agreement between Profound Medical Corp. and Koninklijke Philips N.V.,
dated July 31, 2017</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-3.htm" STYLE="-sec-extract: exhibit">4.3</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-3.htm" STYLE="-sec-extract: exhibit">Noncompetition, Nonsolicitation and Confidentiality Agreement among Koninklijke Philips NV and
Profound Medical Inc., dated July 31, 2017</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-4.htm" STYLE="-sec-extract: exhibit">4.4</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-4.htm" STYLE="-sec-extract: exhibit">Resale Purchasing Agreement between Philips Medical Systems Nederland B.V. and Profound Medical
Inc., dated July 31, 2017</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-5.htm" STYLE="-sec-extract: exhibit">4.5</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-5.htm" STYLE="-sec-extract: exhibit">Supply Agreement between Profound Medical Inc. and Philips Medical Systems Nederland B.V., dated
July 31, 2017</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-6.htm" STYLE="-sec-extract: exhibit">4.6</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-6.htm" STYLE="-sec-extract: exhibit">Agreement between Profound Medical Inc. and Siemens Healthcare GmbH, dated February 11, 2019</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-7.htm" STYLE="-sec-extract: exhibit">4.7</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-7.htm" STYLE="-sec-extract: exhibit">Credit Agreement among Profound Medical Inc., Profound Medical Corp, Profound Medical GMBH, Profound
Medical (U.S.) Inc. and Canadian Imperial Bank of Commerce, dated July 30, 2018</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-8.htm" STYLE="-sec-extract: exhibit">4.8</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-8.htm" STYLE="-sec-extract: exhibit">Common Share Purchase Warrant Indenture between Profound Medical Corp. and TSX Trust Company, dated
September 20, 2017</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 123; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-9.htm" STYLE="-sec-extract: exhibit">4.9</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-9.htm" STYLE="-sec-extract: exhibit">Common Share Purchase Warrant Indenture between Profound Medical Corp. and TSX Trust Company, dated
March 20, 2018</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex4-10.htm" STYLE="-sec-extract: exhibit">4.10</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-10.htm" STYLE="-sec-extract: exhibit">Amended and Restated Share Option Plan, dated July 13,
2018</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-11.htm" STYLE="-sec-extract: exhibit">4.11</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-11.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement between Profound Medical Corp. and Arun Menawat, dated
January 1, 2018</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-12.htm" STYLE="-sec-extract: exhibit">4.12</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-12.htm" STYLE="-sec-extract: exhibit">Employment Agreement between Profound Medical Corp. and Aaron Davidson, dated April 10, 2018</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-13.htm" STYLE="-sec-extract: exhibit">4.13</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-13.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement between Profound Medical Corp. and Rashed Dewan, dated
August 23, 2019</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-14.htm" STYLE="-sec-extract: exhibit">4.14</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-14.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement between Profound Medical Corp. and Goldy Singh, dated
August 20, 2019</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><A HREF="tv526458_ex4-15.htm" STYLE="-sec-extract: exhibit">4.15</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex4-15.htm" STYLE="-sec-extract: exhibit">Amended and Restated Employment Agreement between Profound Medical Corp. and Mathieu Burtnyk, dated
August 20, 2019</A></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex8-1.htm" STYLE="-sec-extract: exhibit">8.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex8-1.htm" STYLE="-sec-extract: exhibit">List of Subsidiaries</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><A HREF="tv526458_ex15-1.htm" STYLE="-sec-extract: exhibit">15.1</A></TD><TD STYLE="text-align: justify"><A HREF="tv526458_ex15-1.htm" STYLE="-sec-extract: exhibit">Consent of PricewaterhouseCoopers LLP</A></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant hereby certifies that it
meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Registration
Statement on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">DATED:</TD>
    <TD STYLE="width: 41%; text-align: justify">August 29, 2019</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; text-align: justify">/s/ Aaron Davidson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Aaron Davidson</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Chief Financial Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt; text-align: right; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center; background-color: White"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: right; background-color: White">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#f_001">Our audited consolidated financial statements as at and for the years ended December 31, 2018, 2017 and 2016, together with the notes thereto and the auditor&rsquo;s report thereon.</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#f_001">F-2</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><A HREF="#f_002">Our unaudited interim condensed consolidated financial statements as at and for the three and six months ended June 30, 2019 and 2018, together with the notes thereto.</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#f_002">F-42</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="f_001"></A><IMG SRC="tv526458_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2018,
<BR>
2017 AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRESENTED IN CANADIAN DOLLARS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="tv526458_img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Report of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>To the Board of Directors and Shareholders of Profound Medical
Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Opinion on the financial statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have audited the accompanying consolidated balance sheets of
Profound Medical Corp. and its subsidiaries (together, the company) as of December 31, 2018 and 2017, and the related consolidated
statements of loss and comprehensive loss, shareholders&rsquo; equity and cash flows for each of the three years in the period
ended December 31, 2018, including the related notes (collectively referred to as the consolidated financial statements). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the company
as of December 31, 2018 and 2017, and their financial performance and their cash flows for each of the three years in the period
ended December 31, 2018 in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board (IFRS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Basis for opinion</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These consolidated financial statements are the responsibility of
the company&rsquo;s management. Our responsibility is to express an opinion on the company&rsquo;s consolidated financial statements
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted our audits of these
consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement,
whether due to error or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>PricewaterhouseCoopers LLP</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>PwC Centre, 354 Davis Road, Suite 600, Oakville, Ontario, Canada
L6J 0C5</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>T: +1 905 815 6300, F: +1 905 815 6499</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;PwC&rdquo; refers to PricewaterhouseCoopers LLP, an Ontario
limited liability partnership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><IMG SRC="tv526458_img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our audits included performing procedures to assess the risks of
material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>/s/ PricewaterhouseCoopers LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chartered Professional Accountants, Licensed Public Accountants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Oakville, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">August 14, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have served as the company&rsquo;s auditor since 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidated Balance Sheets</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">As at December 31, 2018 and
2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2017</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in"><B>Assets</B> (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-indent: 0in; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">30,687,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">11,103,223</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Trade and other receivables (note 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,686,112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,251,658</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Investment tax credits receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">240,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Inventory (note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,631,623</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,431,157</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Prepaid expenses and deposits (note 20)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">434,871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">576,028</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,919,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,602,066</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Property and equipment (note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,726,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Intangible assets (note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,013,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,141,998</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Goodwill (note 8)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,409,165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,409,165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,549,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,879,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,912,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,081,704</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Deferred revenue (note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,364</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Long-term debt (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,339,583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,701,214</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Provisions (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,017</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,222</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Other liabilities (notes 10 and 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">567,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Derivative financial instrument (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,203</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Income taxes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">297,353</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72,779</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,879,360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,616,241</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Long-term debt (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,615,662</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Deferred revenue (note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">379,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,952</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Provisions (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">988,239</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt; text-indent: 0in">Other liabilities (notes 10 and 11)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000,153</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,580,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,923,538</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,738,240</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-indent: 0in">Share capital (note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,932,404</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,365,770</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Contributed surplus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,756,294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,103,970</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,703</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(57,929</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; padding-bottom: 1pt; text-indent: 0in">Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(111,033,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(90,270,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,626,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,141,139</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,549,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,879,379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: 0in">Commitments and contingencies (note 20)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The accompanying
notes are an integral part of these consolidated financial statements</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidated Statements of Loss and Comprehensive Loss</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">For the years ended December
31, 2018 and 2017 and 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2018</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2017</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-indent: -0.1in; padding-left: 16.2pt">Products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,421,331</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,663,986</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">180,947</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">240,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,602,278</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,904,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cost of sales</B> <FONT STYLE="font-weight: normal">(note 14)</FONT></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,778,501</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,032,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">823,777</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,872,342</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Operating expenses</B> (note 14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Research and development &ndash; net of investment tax credits of $240,000 (2017 &ndash; $240,000, 2016 &ndash; $240,000)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,265,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,638,190</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,988,693</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,656,723</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,935,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,369,288</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,091,347</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,925,804</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,282,433</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,013,458</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,499,209</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,640,414</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Operating Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,189,681</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,626,867</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,640,414</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other income and expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Finance costs (note 15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">826,312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,249,084</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">829,899</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(483,788</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,732</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(157,598</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">342,524</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,121,352</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">672,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Loss before taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,532,205</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,748,219</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,312,715</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income taxes (note 16)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">230,784</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,054</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for the year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,762,989</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,822,342</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,326,769</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other comprehensive loss (income)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Item that may be reclassified to profit or loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Foreign currency translation adjustment &ndash; net of tax</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,226</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(69,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss and comprehensive loss for the year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,792,215</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,753,097</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,338,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><B>Loss per share</B> (note&nbsp;17)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic and diluted loss per common share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The accompanying
notes are an integral part of these consolidated financial statements</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidated Statements of Changes in Shareholders&rsquo; Equity</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">For the years ended December
31, 2018 and 2017 and 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number<BR> of&nbsp;shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share<BR> capital<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contributed<BR> surplus<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated<BR> other<BR> comprehensive<BR> income&nbsp;(loss)<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Balance </B></FONT><B><FONT STYLE="font: 10pt Symbol">-</FONT></B><B> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">January&nbsp;1, 2016</FONT></B></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">39,473,327</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">67,082,821</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">2,002,190</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">(55,121,561</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">13,963,450</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,326,769</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,326,769</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cumulative translation adjustment &ndash; net of tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,316</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,185</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,675</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation (note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,001,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,001,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Issuance of units on bought deal financing (note 12)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,820,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,182,997</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,182,997</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Balance </B></FONT><B><FONT STYLE="font: 10pt Symbol">-</FONT></B><B> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 31, 2016</FONT></B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">55,305,577</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,272,678</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,000,563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(71,448,330</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,836,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,822,342</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,822,342</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cumulative translation adjustment &ndash; net of tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,245</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69,245</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">411,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(171,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,301</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation (note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,338,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,338,330</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of common shares on acquisition (note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,844,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,844,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Issuance of units on bought deal financing (note 12)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,977,621</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,936,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,913,868</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Balance </B></FONT><B><FONT STYLE="font: 10pt Symbol">-</FONT></B><B> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;31, 2017</FONT></B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">73,117,377</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">98,365,770</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,103,970</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(90,270,672</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,141,139</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,762,989</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,762,989</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cumulative translation adjustment &ndash; net of tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">437,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,625</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,257</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation (note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086,199</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Issuance of units on bought deal financing (note 12)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,259,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,767,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,027,502</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Balance </B></FONT><B><FONT STYLE="font: 10pt Symbol">-</FONT></B><B> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">December&nbsp;31, 2018</FONT></B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,054,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,932,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,756,294</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,703</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(111,033,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,626,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying notes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Consolidated Statements of Cash Flows</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">For the years ended December
31, 2018 and 2017 and 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2018 <BR>$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2017 <BR>$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">2016<BR>
$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(20,762,989</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(18,822,342</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">(16,326,769</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Adjustment to reconcile net loss to net cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Depreciation of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,320</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,335</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,437</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,673</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Loss on disposal of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,338,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,001,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Interest and accretion expense (note 15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,028,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,347,825</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">829,899</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Change in deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">241,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Change in fair value of derivative financial instrument</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(96,619</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(325,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in non-cash working capital balances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investment tax credits receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(240,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(91,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,565,546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,985,322</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173,857</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(557,604</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,200,466</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,014,334</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(416,823</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,167,336</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,245,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">775,781</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Provisions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">319,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,041,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Customer deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(259,293</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">259,293</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Income taxes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">224,574</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72,779</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(18,294,637</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,571,227</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,502,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cash acquired in business acquisition (note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sale of short-term investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Purchase of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(34,080</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(223,174</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(430,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(863,991</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total cash (used in) from investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(280,661</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,912,835</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,402,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Transaction costs paid on issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,472,498</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,086,132</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,219,003</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Proceeds from bank loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Bank loan costs paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(735,698</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Payment of long-term debt and interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,851,489</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,877,050</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(286,700</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Payment of other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(166,975</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Proceeds from share options exercised</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,257</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,675</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total cash from financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,878,597</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,122,050</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,899,972</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net change in cash during the year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,583,960</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,729,838</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,310,541</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Cash &ndash; Beginning of year </FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,103,223</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,833,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,522,520</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash &ndash; End of year</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,687,183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,103,223</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,833,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying notes are an integral part of these consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">1</TD><TD>Description of business</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Profound Medical Corp. (Profound)
and its subsidiaries (together, the Company) were incorporated under the Ontario Business Corporations Act on July 16, 2014. The
Company is a medical technology company developing treatments to ablate the prostate gland, uterine fibroids and nerves for palliative
pain relief for patients with metastatic bone disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company&rsquo;s registered address
is 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, L4W 5K5.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">2</TD><TD STYLE="text-align: justify">Summary of significant accounting policies and basis of preparation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Basis of preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company prepares its consolidated
financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards
Board (IFRS). The Board of Directors approved these consolidated financial statements on August 14, 2019. These consolidated financial
statements comply with IFRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Adoption of new accounting standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A number of new amended standards
became applicable for the current reporting period and the Company had to change its accounting policies as a result. The impact
of the adoption of these standards is disclosed below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43.9pt; text-align: justify; text-indent: -18.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.2pt"></TD><TD STYLE="width: 18.7pt"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IFRS 9, Financial Instruments</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">IFRS 9, Financial Instruments (IFRS
9) replaces the provisions of International Accounting Standard (IAS) 39, Financial Instruments &ndash; Recognition and Measurement
(IAS 39) that relate to the recognition, classification and measurement of financial assets and financial liabilities, derecognition
of financial instruments, impairment of financial assets and hedge accounting. The adoption of IFRS 9 from January 1, 2018 resulted
in changes in the Company&rsquo;s accounting policies but it did not result in any adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company has applied IFRS 9 retrospectively,
but has elected not to restate comparative information. As a result, the comparative information provided continues to be accounted
for in accordance with the Company&rsquo;s previous accounting policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company has one type of financial asset that is subject to IFRS
9&rsquo;s new expected credit loss model, which is trade and other receivables. The Company was required to revise its impairment
methodology under IFRS 9 for trade and other receivables and this resulted in no adjustments as at January 1, 2018. The Company
applies the IFRS 9 simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance for all
trade and other receivables. To measure the expected credit losses, trade and other receivables have been grouped based on shared
credit risk characteristics and the days past due. On that basis, the loss allowance as at January 1, 2018 and December 31, 2018
is nominal as the Company only transacts with hospitals and private clinics and has not incurred any credit losses since revenue
began.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">Trade and other receivables are written
off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include,
among others, failure to make contractual payments for an extended period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">There was no impact on the Company&rsquo;s
financial liabilities as a result of the adoption of IFRS 9 and no material change to the Company&rsquo;s accounting policies for
financial liabilities. All historical changes to the Company&rsquo;s debt agreements were accounted for as extinguishments under
IAS 39, which is consistent with the required treatment under IFRS 9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.35in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IFRS 15, Revenue from Contracts with Customers</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">IFRS 15, Revenue from Contracts with
Customers (IFRS 15) amends revenue recognition requirements and establishes principles for reporting information about the nature,
amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The adoption of IFRS 15 from January
1, 2018 resulted in changes in the Company&rsquo;s revenue recognition accounting policy but it did not result in any adjustments.
In accordance with the transitional provisions in IFRS 15, the Company has adopted the new rules on a full retrospective basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company sells separately priced
extended warranty service contracts that extend maintenance coverage beyond the base warranty for its medical devices. The separately
priced service contracts typically range from 12 to 24 months. As at December 31, 2018, the Company had $691,602 (2017 &ndash;
$241,316) of deferred revenue related to unfulfilled performance obligations associated with these extended warranty service contracts.
The Company expects to recognize the revenue associated with the unfulfilled performance obligations over the following annual
periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.6in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2017 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">132,364</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">249,808</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,042</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,618</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">2022</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">64,618</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">691,602</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">241,316</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Use of estimates and judgments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The preparation of consolidated financial
statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise
its judgment in the process of applying the Company&rsquo;s accounting policies. The areas involving a higher degree of judgment
or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed
in note&nbsp;3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Subsidiaries are all entities over
which the Company has control. The Company controls an entity when it is exposed to, or has rights to, variable returns from its
involvement with the entity and has the ability to affect those returns through its power over the entity. The wholly owned subsidiaries
of Profound are consolidated from the date control is obtained. All intercompany transactions, balances, income and expenses on
transactions with the subsidiaries are fully eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">These consolidated financial statements
include the following wholly owned subsidiaries of the Company: Profound Medical Inc., Profound Medical Oy, Profound Medical GmbH
and Profound Medical (U.S.) Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Business combinations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The acquisition method of accounting
is used to account for business combinations. The consideration transferred in a business combination is measured at fair value
at the date of acquisition. Acquisition-related transaction costs are recognized in the consolidated statements of loss and comprehensive
loss as incurred. At the acquisition date, the identifiable assets acquired and the liabilities assumed are initially recognized
at their fair value. Goodwill is measured as the excess of the sum of the consideration transferred and the fair value of the acquirer&rsquo;s
previously held equity interest in the acquiree (if any) over the net of the acquisition date amounts of the identifiable assets
acquired and liabilities assumed. When the consideration transferred by the Company in a business combination includes assets or
liabilities resulting from a contingent consideration arrangement, the contingent consideration is measured at its acquisition
date fair value and is included as part of the consideration transferred in a business combination. Changes in the acquisition
date fair values of the identifiable assets, liabilities and contingent consideration that qualify as measurement period adjustments
are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that
arise from additional information obtained during the measurement period (which cannot exceed one year from the acquisition date)
about facts and circumstances that existed at the acquisition date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Other than measurement period adjustments,
contingent consideration that is classified as a financial liability is remeasured at subsequent reporting dates, with the corresponding
gain or loss recognized in the consolidated statements of loss and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Segment reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Operating segments are reported in
a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker
has been identified as the chief executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Foreign currency translation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has a functional currency
of Canadian dollars and the functional currency of each subsidiary is determined based on facts and circumstances relevant for
each subsidiary. Where the Company&rsquo;s presentation currency of Canadian dollars differs from the functional currency of a
subsidiary, the assets and liabilities of the subsidiary are translated from the functional currency into the presentation currency
at the exchange rates as at the reporting date. The income and expenses of the subsidiaries are translated at rates approximating
the exchange rates at the dates of the transactions. Exchange differences arising on the translation of the financial statements
of the Company&rsquo;s subsidiaries are recognized in other comprehensive loss (income).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Foreign currency transactions are
translated into the functional currency of the Company or its subsidiaries, using the exchange rates prevailing at the dates of
these transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the
translation at year-end exchange rates of monetary assets and liabilities denominated in currencies other than an entity&rsquo;s
functional currency are recognized in the consolidated statements of loss and comprehensive loss, within finance costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Investment tax credits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The benefits of refundable investment
tax credits (ITCs) for scientific research and experimental development (SR&amp;ED) expenditures are recognized in the year the
qualifying expenditure is made providing there is reasonable assurance of recoverability. The refundable ITCs recorded are based
on management&rsquo;s estimates of amounts expected to be recovered and are subject to audit by taxation authorities. The refundable
ITCs reduce the research and development expenses to which they relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Accounting policy applied from
January 1, 2018 &ndash; financial assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">From January 1, 2018, the Company
classifies its financial assets in the following measurement categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">those to be measured subsequently at fair
value (either through other comprehensive income, or through profit or loss); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.55in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">those to be measured at amortized cost.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The classification depends on the
Company&rsquo;s business model for managing the financial assets and the contractual terms of the cash flows. The Company does
not currently have any assets measured subsequently at fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">At initial recognition, the Company
measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction
costs that are directly attributable to the acquisition of the financial asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Financial assets are derecognized
when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred
substantially all the risks and rewards of ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company assesses on a forward-looking
basis the expected credit losses associated with its financial assets carried at amortized cost. For trade and other receivables,
the Company applies the simplified approach permitted by IFRS 9, which requires lifetime expected credit losses to be recognized
at the time of initial recognition of the receivables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Inventories</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Inventories are valued at the lower
of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business less the
estimated costs of completion and the estimated costs necessary to make the sale. Cost is determined using the first-in, first-out
method for finished goods and weighted average cost for raw materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Property and equipment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Property and equipment are stated
at cost, less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable
to the acquisition of the asset. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance
costs are charged to the consolidated statements of loss and comprehensive loss during the year in which they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The major categories of property
and equipment are depreciated on a straight-line basis as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Furniture and fittings</TD>
    <TD STYLE="width: 6%; padding-left: 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: right">20% per year</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Research and manufacturing equipment</TD>
    <TD STYLE="padding-left: 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</TD>
    <TD STYLE="text-align: right">30% per year</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Computer equipment</TD>
    <TD STYLE="padding-left: 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</TD>
    <TD STYLE="text-align: right">45% per year</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Computer software</TD>
    <TD STYLE="padding-left: 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</TD>
    <TD STYLE="text-align: right">100% per year</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Leasehold improvements</TD>
    <TD STYLE="padding-left: 0.3in; text-align: justify; text-indent: -0.3in">&nbsp;</TD>
    <TD STYLE="text-align: right">over the term of the lease</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Residual values, methods of depreciation
and useful lives of the assets are reviewed annually and adjusted if appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Goodwill</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Goodwill represents the excess fair
value of the consideration transferred over the fair value of the underlying net assets in a business combination and is measured
at cost less accumulated impairment losses. Goodwill is not amortized but is tested for impairment on an annual basis or more frequently
if there are indications the goodwill may be impaired. For the purposes of impairment testing, goodwill is allocated to each of
the Company&rsquo;s cash generating units (CGUs) or group of CGUs that are expected to benefit from the synergies of the acquisition.
If the recoverable amount of the CGU or group of CGUs is less than the carrying amount, the impairment loss is allocated first
to reduce the carrying amount of any goodwill and then to other assets of the CGU or group of CGUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Identifiable intangible assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company&rsquo;s intangible assets
are stated at cost, less accumulated amortization and are amortized on a straight-line basis in the consolidated statements of
loss and comprehensive loss over their estimated useful lives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The major categories of intangible
assets are amortized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: justify">Exclusive licence agreement </TD>
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 34%; text-align: right">20 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Software </TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Brand</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">Proprietary technology</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">5 years</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Impairment of non-financial assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Property and equipment and intangible
assets are tested for impairment when events or changes in circumstances indicate the carrying amount may not be recoverable. For
the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable
cash flow CGUs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The recoverable amount is the higher
of an asset&rsquo;s fair value, less costs of disposal and value in use (which is the present value of the expected future cash
flows of the relevant asset or CGU). An impairment loss is recognized as the amount by which the asset&rsquo;s carrying amount
exceeds its recoverable amount. The Company evaluates impairment losses for potential reversals when events or circumstances warrant
such consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Accounts payable and accrued liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">These amounts represent liabilities
for goods and services provided to the Company before the end of the financial year, which are unpaid. Accounts payable and accrued
liabilities are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are
recognized initially at their fair value and subsequently measured at amortized cost using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Long-term debt</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Long-term debt is initially recognized
at fair value, net of transaction costs incurred. Long-term debt is subsequently measured at amortized cost. Any difference between
the proceeds (net of transaction costs) and the redemption amount is recognized in the consolidated statements of loss and comprehensive
loss over the period of the long-term debt using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Long-term debt is removed from the
consolidated balance sheets when the obligation specified in the contract is discharged, cancelled or expired. The difference between
the carrying amount of a financial liability that has been extinguished and the consideration paid is recognized in the consolidated
statements of loss and comprehensive loss within finance costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Financial liabilities and equity
instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Classification as debt or equity</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">Instruments issued by the Company
are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and
the definitions of a financial liability and an equity instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Knight Loan </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Knight Loan contained a financial
liability in accordance with the terms of the contractual arrangements. At the date of issue, the host financial liability was
recorded at fair value. The financial liability was measured on an amortized cost basis using the effective interest method over
the expected life and was subsequently remeasured at fair value through profit or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A provision is recognized when the
Company has a legal or constructive obligation as result of a past event, it is probable that an outflow of economic benefits will
be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the effect is material,
provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments
of the time value of money and, where appropriate, the risks specific to the liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">To determine revenue recognition
for arrangements the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the
performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company
only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company derives its revenues
primarily from the sale of medical devices. Revenue is recognized when a contractual promise to a customer (performance obligation)
has been fulfilled by transferring control over the promised goods or services, generally at the point in time of shipment to or
receipt of the products by the customer or when the services are performed. When contracts contain customer acceptance provisions,
revenue is recognized on the satisfaction of the specific acceptance criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The amount of revenue to be recognized
is based on the consideration the Company expects to receive in exchange for its goods and services. For contracts that contain
multiple performance obligations, the Company allocates the consideration to which it expects to be entitled to each performance
obligation based on relative standalone selling prices and recognizes the related revenue when or as control of each individual
performance obligation is transferred to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Service revenue related to installation
and training is recognized over the period in which the services are performed. Service revenue related to extended warranty service
is deferred and recognized on a straight-line basis over the extended warranty period covered by the respective customer contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Under the terms of certain of the
Company&rsquo;s partnership agreements, the Company retains a percentage of all amounts earned with the remaining percentage due
to the partner. Accordingly, associated revenue is recognized net of the consideration due to the partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Cost of sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Cost of sales primarily includes
the cost of finished goods, inventory provisions, royalties, warranty expense, freight and direct overhead expenses necessary to
acquire or manufacture the finished goods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Income taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Income taxes are accounted for using
the liability method. Deferred tax assets and liabilities are recognized for the differences between the tax basis and carrying
amounts of assets and liabilities, for operating losses and for tax credit carry-forwards. Deferred tax assets are recognized to
the extent that it is probable that future taxable income will be available against which temporary differences can be utilized.
Deferred tax assets and liabilities are measured using enacted or substantively enacted tax rates and laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Share-based compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company grants share options
periodically to certain employees, directors, officers and advisers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Options currently outstanding vest
over four years and have a contractual life of ten years. Each tranche in an award is considered a separate award with its own
vesting period and grant date fair value. The fair value of each tranche is measured at the date of grant using the Black-Scholes
option pricing model. Compensation expense is recognized over the tranche&rsquo;s vesting period using the graded vesting method
by increasing contributed surplus based on the number of awards expected to vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Leases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Leases are classified as finance
leases when the lease arrangement transfers substantially all of the risks and rewards related to the ownership of the leased asset.
All other leases are treated as operating leases. Payments on operating lease agreements are recognized as an expense on a straight-line
basis over the lease term. Associated costs, such as maintenance and insurance, are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Research and development costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Research costs are charged to expense
as incurred. Development costs are capitalized and amortized when the criteria for capitalization are met, otherwise they are expensed
as incurred. No development costs have been capitalized to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Clinical trial expenses result from
obligations under contracts with vendors, consultants and clinical site agreements in connection with conducting clinical trials.
The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment
flows that do not match the periods over which materials or services are provided to the Company. The appropriate level of clinical
trial expenses is reflected in the Company&rsquo;s consolidated financial statements by matching period expenses with period services
and efforts expended. These expenses are recorded according to the progress of the clinical trial as measured by patient progression
and the timing of various aspects of the clinical trial. Clinical trial accrual estimates are determined through discussions with
internal clinical personnel and outside service providers as to the progress or state of completion of clinical trials, or the
services completed. Service provider status is then compared to the contractually obligated fees to be paid for such services.
During the course of a clinical trial, the Company may adjust the rate of clinical expense recognized if actual results differ
from management&rsquo;s estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Loss per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Basic loss per share is calculated
by dividing the net loss by the weighted average number of common shares outstanding during the year. Diluted loss per share is
calculated by dividing the applicable net loss by the sum of the weighted average number of shares outstanding during the year
and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during
the year. The computation of diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect of the
share options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Reclassification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Certain prior year figures have been
reclassified to conform with the current year presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Accounting standards issued but
not yet adopted</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IFRS 16, Leases (IFRS 16)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">IFRS 16 sets out the principles for
the recognition, measurement and disclosure of leases. IFRS 16 provides revised guidance on identifying a lease and for separating
lease and non-lease components of a contract. IFRS 16 introduces a single accounting model for all lessees, thereby removing the
distinction between operating and finance leases. IFRS 16 requires a lessee to recognize an asset (right-to-use the leased item)
and a financial liability to pay rentals on the interim condensed consolidated balance sheets with terms of more than 12 months,
unless the underlying asset is of low value. The standard permits either a full retrospective or a modified retrospective approach
for the adoption. IFRS 16 was effective for annual periods beginning on or after January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company has adopted IFRS 16 retrospectively
from January 1, 2019, but did not restate comparative information, as permitted under the specific transitional provisions in the
standard in accordance with the modified retrospective approach for adoption. The reclassifications and the adjustments arising
from the new leasing standard were therefore recognized in the opening consolidated balance sheet on January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>Adjustments recognized on adoption
of IFRS 16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">On adoption of IFRS 16, the Company
recognized lease liabilities in relation to leases, which had previously been classified as operating leases under the principles
of IAS 17, Leases (IAS 17). These liabilities were measured at the present value of the remaining lease payments, discounted using
the incremental borrowing rate as of January 1, 2019. The weighted average lessee&rsquo;s incremental borrowing rate applied to
the lease liabilities on January 1, 2019 was 4%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.6in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Operating lease commitments as at December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,313,292</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Asset retirement obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Discounted using the Company&rsquo;s average incremental borrowing rate of 4.0%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(836,665</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Lease liabilities recognized as at January 1, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,587,727</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The change in accounting policy affected
the following items in the consolidated balance sheet on January 1, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.6in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase <BR>(decrease) <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; text-indent: 0in">Right-of-use assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,616,773</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,587,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(210,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Provisions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,319</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(292,054</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,419</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>Practical expedients applied</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company elected to apply the
practical expedient not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of
12 months or less and leases of low value assets. The lease payments associated with these leases are recognized as an expense
on a straight-line basis over the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company also elected not to reassess
whether a contract is, or contains a lease at the date of initial application. Instead, for contracts entered into before the transition
date, the Company has relied on its assessment made applying IAS 17 and IFRIC 4, Determining whether an Arrangement contains a
Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IFRIC 23, Uncertainty over Income Tax
Treatments (IFRIC 23)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">In June 2017, the IASB issued IFRIC
23, with a mandatory effective date of January 1, 2019. The interpretations provide guidance on how to value uncertain income tax
positions based on the probability of whether the relevant tax authorities will accept the Company&rsquo;s tax treatments. A Company
is to assume that a taxation authority with the right to examine any amounts reported to it will examine those amounts and will
have full knowledge of all relevant information when doing so. IFRIC 23 is to be applied by recognizing the cumulative effect of
initially applying these guidelines in opening deficit without adjusting comparative information. There was no impact in applying
the new standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">3</TD><TD STYLE="text-align: justify">Critical accounting estimates and judgments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Critical accounting judgments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Complex financial instruments and provisions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company makes various judgments
when determining the accounting for certain complex financial instruments and provisions. The Company has concluded that the contingent
consideration in a business combination represents a financial liability measured at fair value through profit or loss. The revenue
share obligation represents an executory contract and is accounted for as a best estimate provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting for acquisitions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company assesses whether an acquisition
should be accounted for as an asset acquisition or a business combination under IFRS 3. This assessment requires management to
assess whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set
of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company
obtains control of the business. The Company&rsquo;s acquisition has been accounted for as a business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Critical accounting estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company makes estimates and assumptions
concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates
and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities
within the next financial year are addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue share obligation</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The revenue share obligation provision
was determined using certain assumptions described in note&nbsp;9. The Company uses its judgment to select a variety of methods
and make assumptions that are mainly based on conditions existing at the end of each reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Impairment of non-financial assets</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company reviews amortized non-financial
assets for impairment whenever events or changes in circumstances indicate the carrying amount of the assets may be impaired. It
also reviews goodwill annually for impairment. If the recoverable amount of the respective non-financial asset is less than its
carrying amount, it is considered to be impaired. In the process of measuring the recoverable amount, management makes assumptions
about future events and circumstances. The actual results may vary and may cause significant adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounting for acquisitions and contingent
consideration</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">Areas of estimation include the determination
and fair value measurement of the contingent consideration, which includes the Company developing its best estimate of projected
revenue, the probability of the contingency being achieved and the discount rate. Management is also required to make estimates
of the fair value of assets acquired and liabilities assumed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical trial expenses</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">Clinical trial expenses are accrued
based on the services received and efforts expended pursuant to agreements with clinical trial sites and other vendors. In the
normal course of business, the Company contracts third parties to perform various clinical trial activities. The financial terms
of these agreements vary from contract to contract, are subject to negotiation and may result in uneven payment flows. Payments
under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients or the completion
of certain portions of a clinical trial. The Company determines the accrual by reviewing contracts, vendor agreements and through
discussions with internal personnel and external clinical trial sites as to the progress or stage of completion of the clinical
trial and the agreed on fees to be paid for such services. Actual costs and timing of the clinical trial are uncertain, subject
to risks and may change depending on a number of factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">4</TD><TD STYLE="text-align: justify">Business combination</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On July 31, 2017, the Company entered
into an Asset and Share Purchase Agreement (the agreement) to acquire all of the issued and outstanding shares and certain assets
of Royal Philips&rsquo; (Philips) Sonalleve MR-HIFU business (Sonalleve). Under the terms of the agreement, Philips transferred
its Sonalleve assets to the Company for an upfront consideration of 7,400,000 common shares of the Company. The agreement includes
certain contingent consideration payments payable monthly in euro tied to future revenue levels of the Sonalleve business summarized
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5% of revenue between the date of acquisition
and December 31, 2017;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6% of revenue during the year ending December
31, 2018;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">7% of revenue during the years ending
December 31, 2019 and 2020; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">if total revenues are in excess of
a defined amount from the date of acquisition to December 31, 2020, then the Company will be required to pay 7% of revenue from
the date of acquisition to December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As part of closing the agreement,
the Company committed to repay all amounts outstanding under the Knight Loan (note 10) on or before December 31, 2018. The Knight
Loan was repaid on July 25, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The non-exclusive strategic sales
relationship with Philips was expanded to include distribution of Sonalleve. Under the terms of the agreement, Philips will also
provide other services, including, but not limited to, manufacturing and installation of Sonalleve MR-HIFU for a certain period
of time at market rates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The contingent consideration (note
11) is classified as a Level 3 financial liability within the fair value hierarchy given its fair value is estimated using the
discounted value of estimated future payments. The key assumptions in valuing the contingent consideration include: estimated projected
net sales; the likelihood of certain levels being reached; and a discount rate of 15%. During the year ended December 31, 2018,
the change in fair value of the contingent consideration was a gain of $325,253 (2017 &ndash; loss of $82,578, 2016 - $nil).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company accounted for this transaction
as a business combination and has applied the acquisition method of accounting. The purchase price allocation of assets acquired
and liabilities assumed and the fair value of the total consideration transferred is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in">Assets acquired and liabilities assumed</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: justify; text-indent: 0in; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">183,988</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 9pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(183,988</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 9pt">Property and equipment (note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,872</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 9pt">Intangible assets (note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,372,435</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 9pt; padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,409,165</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">9,495,472</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in">Consideration paid or payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 9pt">Common shares issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,844,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-left: 9pt; padding-bottom: 1pt">Fair value of contingent consideration (note 11)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,651,472</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">9,495,472</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Goodwill of $3,409,165 arising from
the acquisition is attributable to the acquired workforce and synergies expected from combining the operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Had the Sonalleve MR-HIFU business
been consolidated from January 1, 2017, the consolidated statements of loss and comprehensive loss would be pro forma revenue of
$6,883,850 and a pro forma net loss and comprehensive loss of $21,657,797 for the year ended December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During the period from July 31, 2017
to December 31, 2017, there was revenue of $2,484,804 and a net loss and comprehensive loss of $1,166,582 recorded in the consolidated
statements of loss and comprehensive loss related to the former Sonalleve MR-HIFU business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Acquisition related costs of $716,767
have been charged to general and administrative expenses in the consolidated statements of loss and comprehensive loss.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">5</TD><TD>Trade and other receivables</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The trade and other receivables balance comprises the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: 0in">Trade receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,791,688</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,971,768</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Interest receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Indirect tax receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,832</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">279,890</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Other receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">272,862</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Total trade and other receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,686,112</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,251,658</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Trade receivables include the gross
revenue amount billed to customers and certain amounts that are included in deferred revenue. Included in&nbsp;accounts payable
and accrued liabilities&nbsp;is an amount of $nil (2017 &ndash; $2,534,259) payable to the same counterparty as the corresponding
trade receivable balance of $nil (2017 &ndash;$3,505,423) as there is no legal right of offset with respect to the receivable and
payable balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">An aging of trade receivable balances
past due is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Past due 1 &ndash; 30 days</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">16,057</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Past due 31 &ndash; 60 days</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,553,215</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.3in; padding-left: 0.6in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,569,272</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Amounts past due represent trade receivables past due
based on the customer&rsquo;s contractual terms. The Company applies the simplified approach to providing for expected credit losses
prescribed by IFRS 9, which permits the use of the lifetime expected loss provision for all trade receivables (note 18).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">6</TD><TD>Inventory</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Finished goods</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,305,746</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">715,193</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Raw materials</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,383,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">799,589</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Inventory provision</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57,695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(83,625</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,631,623</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,431,157</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">During the year ended December 31, 2018, $1,648,728 (2017
 &ndash; $2,255,727, 2016 &ndash; $nil) of inventory was recognized in cost of sales. The Company decreased its inventory provision
by $25,930 during the year ended December 31, 2018 (2017 &ndash; $44,603). There were no other inventory writedowns charged to
cost of sales during the year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">7</TD><TD>Property and equipment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Property and equipment consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Furniture <BR>and <BR>
fittings <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Research <BR>and <BR>manufact-<BR>
uring <BR>equipment <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leasehold <BR>Improve-<BR>
ments <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computer <BR>equipment <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Computer <BR>software <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font-weight: bold">Year ended December&nbsp;31, 2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">173,201</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">180,395</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">530,148</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">69,285</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">953,029</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,181</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">414,419</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Acquisition (note 4)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,872</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Foreign exchange</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(38,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(217,207</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(64,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(51,255</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(371,320</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">134,883</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">947,588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">605,789</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">37,890</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,726,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: 0in">At December&nbsp;31, 2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Cost</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,169</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,386,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">718,742</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">212,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,729,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(100,286</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(439,104</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(112,953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(174,651</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(176,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,003,456</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">134,883</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">947,588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">605,789</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">37,890</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,726,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: 0in">Year ended December&nbsp;31, 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,883</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">947,588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">605,789</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,890</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,726,150</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Foreign exchange</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(38,318</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(403,554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(69,282</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(34,847</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(546,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">96,565</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">571,242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">536,507</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,207,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: 0in">At December&nbsp;31, 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Cost</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,169</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,386,692</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">718,742</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">212,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,729,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(138,604</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(815,450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(182,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(209,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(176,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,522,249</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">96,565</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">571,242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">536,507</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,207,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">8</TD><TD>Intangible assets</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Intangible assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exclusive <BR>licence <BR>agreement <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Software <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proprietary <BR>technology <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Brand <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">Year ended December&nbsp;31, 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 45%; text-align: left; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: normal; text-align: right">30,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: normal; text-align: right">232,685</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: normal; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: normal; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: normal; text-align: right">262,685</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Additions</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">34,080</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">34,080</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Acquisition (note 4)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,489,295</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">883,140</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,372,435</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Disposals</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(26,684</TD><TD STYLE="font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(26,684</TD><TD STYLE="font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Amortization</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(2,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(50,315</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(374,108</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(73,595</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(500,518</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">27,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">189,766</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,115,187</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">809,545</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">5,141,998</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at December&nbsp;31, 2017</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Cost</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">50,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">257,254</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,489,295</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">883,140</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,679,689</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated amortization</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(22,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(67,488</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(374,108</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(73,595</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(537,691</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">27,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">189,766</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,115,187</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">809,545</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">5,141,998</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">Year ended December&nbsp;31, 2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">27,500</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">189,766</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,115,187</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">809,545</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,141,998</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Amortization</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(2,500</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(51,450</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(897,859</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(176,628</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(1,128,437</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">138,316</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">3,217,328</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">632,917</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,013,561</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at December&nbsp;31, 2018</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Cost</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">50,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">257,254</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">4,489,295</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">883,140</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,679,689</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated amortization</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(25,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(118,938</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(1,271,967</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(250,223</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(1,666,128</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">138,316</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">3,217,328</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">632,917</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,013,561</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has a licence agreement
(the licence) with Sunnybrook Health Sciences Centre (Sunnybrook), pursuant to which Sunnybrook licenses to the Company certain
intellectual property. Pursuant to the licence, the Company has exclusively licenced-in rights that enable the Company to use Sunnybrook&rsquo;s
technology for MRI-guided trans-urethral ultrasound therapy. Under the licence, the Company is subject to various obligations,
including milestone payments of up to $250,000 (on FDA approval) and legal costs associated with patent application preparation,
filing and maintenance. Subject to certain buyout provisions as defined in the licence, the Company has the option to acquire ownership
of the licensed technology and intellectual property. In addition, the Company has a further option to acquire rights to improvements
to the relevant technology and intellectual property. If the Company fails to comply with any of its obligations or otherwise breaches
this agreement, Sunnybrook may have the right to terminate the licence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">In accordance with the Company&rsquo;s
accounting policy, the carrying value of goodwill is assessed annually as well as assessed for impairment triggers at each reporting
date to determine whether there exists any indicators of impairment. When there is an indicator of impairment of non-current assets
within a CGU or group of CGUs containing goodwill, the Company tests the non-current assets for impairment first and recognizes
any impairment loss on goodwill before applying any remaining impairment loss against the non-current assets within the CGU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company completed its
annual goodwill impairment testing on the goodwill related to the Sonalleve MR-HIFU&nbsp;CGU,&nbsp;which comprises all of the
goodwill of the Company, on December 31, 2018. The recoverable amount of the Sonalleve MR-HIFU CGU was calculated using fair
value less costs of disposal (FVLCD).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The calculation of the recoverable
amount of the Sonalleve MR-HIFU CGU was determined using discounted cash flow projections based on financial forecasts approved
by management covering a four-year period (Level 3 of the fair value hierarchy) and a terminal growth assumption of 4%. The key
assumptions and estimates used in determining the FVLCD are related to revenue and EBITDA assumptions, which are based on the financial
forecast and assumed growth rates, working capital assumptions, the effective tax rate of 26.5% and the discount rate of 20.3%
applied to the cash flow projections. As a result of the impairment testing performed, it was determined that the recoverable amount
of the Sonalleve MR-HIFU CGU of $13,864,000 exceeded the carrying value of $7,659,000 and no impairment writedown was required.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">9</TD><TD>Provisions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Asset <BR>retirement <BR>obligation <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue <BR>share <BR>obligation <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warranty <BR>provision <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: 0in">As at January 1, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">39,619</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">39,619</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">921,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,351</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,037,257</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Accretion expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,585</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,585</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">921,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,351</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,081,461</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,079</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">273,321</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Expiry</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(74,582</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(74,582</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,509</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,512</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,021</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Accretion expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,115</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,115</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,241,657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,401,336</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,241,657</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,352,017</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">49,319</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Asset retirement obligation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The asset retirement obligation is related to the Company&rsquo;s
leasehold improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Revenue share obligation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has certain minimum amounts
payable under a co-marketing and co-selling agreement with Siemens Healthcare GmbH (Siemens). The provision was determined using
the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.8in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">estimated probability of a new agreement
being signed based on the facts and circumstances in place as at December 31, 2018 that eliminated these minimum amounts payable;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.8in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">future revenue forecasts related to the
revenue share agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.8in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.55in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a discount rate of 11%.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The amount has been included in selling
and distribution expenses in the consolidated statements of loss and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Subsequent to year-end, the Company
replaced the original co-marketing and co-selling agreement with Siemens with a new agreement. Under the new agreement, all prior
financial commitments and obligations owed to Siemens are released and replaced with a non-exclusive licence resulting in a one-time
fixed licence fee and a per annum payment per device interfaced to a Siemens MRI scanner. In exchange for the one-time fixed licence
fee and per annum payments, the Company obtained a non-exclusive licence and reasonable support for the term of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Warranty provision</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The warranty provision is related
to the Company&rsquo;s estimate of future warranty obligations on product sales, which generally have a term of 12 to 24 months.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">10</TD><TD>Long-term debt</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A summary of the long-term debt is
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify; text-indent: 0in">CIBC loan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">11,955,245</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">FedDev and HTX loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,607,195</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">Knight Loan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">3,537,894</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">Balance &ndash; End of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,955,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,145,089</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,339,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">4,701,214</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,615,662</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">443,875</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Federal Economic Development
Agency (FedDev) loan with total proceeds of $867,000 was unsecured and non-interest bearing. The final repayment of $563,550 was
made on July 25, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During the year ended December 31,
2018, the Company recognized $90,775 of interest and accretion expense on this loan (2017&nbsp;&ndash; $54,024, 2016 &ndash; $57,076).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Health Technology Exchange (HTX)
loans with total proceeds of $1,500,000 were unsecured and bearing interest at 4.50% per annum. The final repayment of $1,094,698,
including accrued interest, was made on March&nbsp;31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During the year, the Company recognized
$18,078 of interest and accretion expense on this loan (2017&nbsp;&ndash; $111,978, 2016&nbsp;&ndash; $107,046).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A reconciliation of the FedDev and
HTX loans is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: 0in">Balance &ndash; Beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,607,195</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,027,893</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Repayment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,716,048</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(586,700</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Interest and accretion expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">108,853</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">166,002</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Balance &ndash; End of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,607,195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,163,320</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">443,875</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On April 30, 2015, Profound Medical
Inc. signed an agreement with Knight Therapeutics Inc. (Knight) to provide a secured loan of $4,000,000 (the Knight Loan) for an
initial period of four years with an interest rate of 15% per annum, with payments of interest and principal deferred until June
30, 2017. As part of the agreement, Knight was also granted a royalty of 0.5% on net sales resulting from global sales of the Company&rsquo;s
products until May 20, 2019 (the royalty).&nbsp;In addition, the Company also entered into a distribution, licence and supply agreement
with Knight pursuant to which Knight will act as the exclusive distributor of the Company&rsquo;s product in Canada for an initial
ten-year term, renewable for successive ten-year terms by either party. In connection with these arrangements, the Company issued
to Knight 4% of the common shares of the Company (1,717,450 common shares). On July 25, 2018, the full amount of the Knight Loan,
including prepayment fees, was repaid for a total payment of $3,188,023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A reconciliation of the Knight Loan
balance is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: justify; text-indent: 0in">Balance &ndash; Beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,537,894</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,609,983</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">Repayment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,003,797</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,290,350</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">Interest and accretion expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">465,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,218,261</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: 0in">Balance &ndash; End of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,537,894</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,537,894</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The royalty was initially recorded
at fair value and was subsequently carried at amortized cost using the effective interest rate method. The initial fair value of
the royalty was determined using future revenue forecasts for the term of the loan and a discount rate of 18%. During the year,
the Company revised the fair value of the royalty, using future revenue forecasts for the term of the loan and a discount rate
of 18%, and recognized an interest accretion recovery of $63,322 (2017 &ndash; $36,438, 2016&nbsp;&ndash; $249,413). This liability
is included within other liabilities on the consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On July 30, 2018, the Company signed
a term loan agreement with CIBC Innovation Banking (CIBC) to provide a secured loan for total initial gross proceeds of $12,500,000
maturing on July 29, 2022 with an interest rate based on prime plus 2.5%. The Company is required to make interest only payments
until October 31, 2019 and monthly repayments on the principal of $378,788 plus accrued interest commencing on October 31, 2019.
All obligations of the Company under the term loan agreement are guaranteed by current and future subsidiaries of the Company and
include security of first priority interests in the assets of the Company and its subsidiaries. The Company has the ability to
draw an additional $6,250,000 subject to the achievement of certain financing and product development milestones. The Company has
a financial covenant in relation to the CIBC loan where unrestricted cash is required to be greater than operating cash expenditures
for a trailing three-month period, reported on a monthly basis. The Company is in compliance with this financial covenant as at
December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Balance &ndash; Beginning of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left; text-indent: 0in">Proceeds received</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">12,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(930,520</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Interest and accretion expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,409</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">Repayment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(131,644</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Balance &ndash; End of year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,955,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,339,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,615,662</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">In connection with this term loan
agreement, on July 31, 2018 the Company also issued 321,714 common share purchase warrants to CIBC, with each warrant entitling
the holder to acquire one common share at a price of $0.97 per common share until the date that is 60 months from the closing of
the term loan agreement, with a cashless exercise feature. The cashless exercise feature causes the conversion ratio to be variable
and the warrants are therefore classified as a financial liability. Gains and losses on the warrants are recorded within finance
costs on the consolidated statements of loss and comprehensive loss. A pricing model with observable market based inputs was used
to estimate the fair value of the warrants issued. The estimated fair value of the warrants as at July 31, 2018 and December 31,
2018 was $194,822 and $98,203, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The variables used to determine the
fair values are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">July 31, <BR>2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-indent: 0in">Share price</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">0.55</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Volatility</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">86</TD><TD STYLE="font-weight: normal; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Expected life of warrants</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-weight: normal">4.6 years</FONT></TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&#9;5 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Risk-free interest rate</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1.88</TD><TD STYLE="font-weight: normal; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.19</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Dividend yield</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">11</TD><TD>Other liabilities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Knight <BR>royalty <BR>payable <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contingent <BR>consideration <BR>(note 4) <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deferred <BR>rent <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: 0in">As at January 1, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">148,401</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">161,320</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">309,721</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,651,472</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,775,099</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Amounts paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,069</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,069</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Change in fair value (note 15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Accretion recovery (note 15)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,438</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,438</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,734,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,115,891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Amounts paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,919</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(153,056</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(166,975</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Change in fair value (note 15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(325,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(325,253</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Accretion recovery (note 15)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(63,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(63,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at December 31, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,255,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">292,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,567,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,653</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">547,643</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">567,296</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">708,098</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">292,055</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000,153</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Knight royalty payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As part of the Knight Loan, Knight
was granted a royalty of 0.5% on net sales resulting from global sales of the Company&rsquo;s products until May 20, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Deferred rent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The deferred rent obligation is related
to the Company&rsquo;s straight-line rent accrual for its current premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">12</TD><TD>Share capital</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Common shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The Company is authorized to issue an unlimited number
of common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Issued and outstanding (with no par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">108,054,939 (2017&nbsp;&ndash; 73,117,377, 2016 &ndash; 55,305,577) common shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,932,404</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">98,365,770</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">83,272,678</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On March 20, 2018, the Company closed
a bought deal financing, resulting in the issuance of 34,500,000 units at a price of $1.00 per unit, for gross proceeds of $34,500,000
($32,027,502, net of cash transaction costs). Each unit consisted of one common share of the Company and one-half of one warrant,
with each whole warrant entitling the holder to acquire one common share at a price of $1.40 per common share until the date that
is 60&nbsp;months from the closing of the bought deal financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On September 20, 2017, the Company
closed a bought deal financing, resulting in the issuance of 10,000,000 units at a price of $1.00 per unit for gross proceeds of
$10,000,000 ($8,913,868, net of cash transaction costs). Each unit consisted of one common share of the Company and one-half of
one warrant, with each whole warrant entitling the holder to acquire one common share at a price of $1.40 per common share until
the date that is 36 months from the closing of the bought deal financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On November 14, 2016, the Company
closed a bought deal financing, resulting in the issuance of 15,820,000 common shares at a price of $1.10 per common share for
gross proceeds of $17,402,000 ($16,182,997, net of transaction costs).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As a result of the March 20, 2018
bought deal financing, 17,250,000 warrants were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As a result of the July 30, 2018
CIBC loan, 321,714 warrants were issued on July 31, 2018 (note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As a result of the September 20,
2017 bought deal financing, 5,000,000 warrants were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A summary of warrants outstanding
is shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> warrants</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> average<BR> exercise price<BR> $</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> average<BR> remaining<BR> contractual life<BR> (years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance&nbsp;</B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">January 1, 2017 </FONT></B></TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; padding-bottom: 1pt">Granted</TD><TD STYLE="width: 1%; font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">5,000,000</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">1.40</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">2.72</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance&nbsp;</B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2017</FONT></B></TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,000,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Granted</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">17,571,714</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.39</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4.23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2018</FONT></B></TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">22,571,714</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.39</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3.67</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The Company estimated the fair value of the warrants issued
using the Black-Scholes option pricing model with the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 20,<BR>
 2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>September 20,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2017</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Share price on date of issuance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1.06</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.95</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected life of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.56</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Due to the absence of company specific
volatility rates for the expected life of the warrants, the Company chose comparable companies in the medical device industry.
The fair value of the warrants issued as part of the March&nbsp;20, 2018 bought deal financing was $9,767,750, or $0.57 per warrant,
and was recorded in contributed surplus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The estimated fair value of the warrants
issued as part of the September 20, 2017 bought deal financing was $1,936,247 or $0.39 per warrant and was recorded in contributed
surplus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">13</TD><TD>Share-based payments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Share options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Effective January 26, 2017, the Company
adopted amendments to the share option plan (the Share Option Plan). The maximum number of common shares reserved for issuance
under this plan is 14,047,142 common shares or such other number as may be approved by the holders of the voting shares of the
Company. As at December&nbsp;31, 2018, 6,244,779 (2017 &ndash; 5,318,279, 2016 &ndash; 4,689,839) options are outstanding. Each
option granted allows the holder to purchase one common share, at an exercise price not less than the lesser of the closing trading
price of the common shares on the TSX, on the date a share option is granted and the volume-weighted average price of the common
shares for the five trading shares immediately preceding the date the share option is granted. Share options granted under the
Share Option Plan generally have a maximum term of ten years and vest over a period of up to four years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A summary of the share option changes
during the years presented and the total number of share options outstanding as at those dates are set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Number</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>of options</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>exercise</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">January 1, 2016</FONT></B></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,407,283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.05</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,650,696</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.33</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,250</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(355,890</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.44</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2016</FONT></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,689,839</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,141,583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(411,800</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,101,343</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.42</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2017</FONT></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,318,279</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,999,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(436,562</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(636,438</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.12</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">December 31, 2018</FONT></B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,244,779</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.13</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The following table summarizes information about the share
options outstanding as at December&nbsp;31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Exercise price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>options</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>outstanding</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>remaining</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>contractual life</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(years)</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>options</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>exercisable</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 23%; text-align: right">0.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">213,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">3.69</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">213,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.85</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">340,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,076</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.02</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,971,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">997,411</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.19</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">918,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">934,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">544,865</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">1.50</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">575,000</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6.67</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">470,240</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,244,779</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">8.17</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,481,304</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The Company estimated the fair value of the share options
granted during the year using the Black-Scholes option pricing model with the weighted average assumptions below. Due to the absence
of company specific volatility rates for the expected life of the share options, the Company chose comparable companies in the
medical device industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>May 4,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2016</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>July 19,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2016</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>August 22,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2016</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 15, <BR>2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">November 24, <BR>2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-indent: -0.1in; padding-left: 0.1in">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">73</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">73</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">101</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">99</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">99</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Expected life of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.89</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.86</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.82</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.94</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Number of share options issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">934,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">554,141</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">January 26, <BR>2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">April 25, <BR>2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">November 16, <BR>2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-indent: -0.1in; padding-left: 0.1in">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">99</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">97</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">135</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Expected life of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-weight: normal">6 years</FONT></TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.35</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.37</TD><TD STYLE="text-align: left">%</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1.90</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Number of share options issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,417,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">658,000</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>March 28,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2018</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>May 22,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2018</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>June 15,</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>2018</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">August 23, <BR>2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">November 19, <BR>2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-indent: -0.1in; padding-left: 0.1in">Volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">96</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">82</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">83</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">70</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">80</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Expected life of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.14</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.30</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.19</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.47</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Number of share options issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">918,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Compensation expense related to share options recorded
in the consolidated statements of loss and comprehensive loss for the year was $1,086,199 (2017&nbsp;&ndash; $1,338,330, 2016&nbsp;&ndash;
$1,001,558).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">14</TD><TD>Nature of expenses</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Production and manufacturing costs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,303,246</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,561,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Salaries and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,692,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,131,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,642,202</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,041,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,506,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">3,783,832</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,005,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">3,125,364</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sales and marketing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,236,712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,644,971</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">129,461</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Amortization and depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,674,438</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">871,838</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">187,008</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,086,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,338,330</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1,001,558</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">738,198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">591,243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">555,759</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,012,901</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">934,764</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">1,215,230</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">22,791,959</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">22,531,417</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">15,640,414</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">15</TD><TD>Finance costs</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 13pt 0.3in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">HTX and FedDev loans (note 10)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">108,853</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">166,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">164,122</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Knight Loan (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">465,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,218,261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">913,080</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">CIBC loan (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,409</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Royalty interest recovery (notes 10 and 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(63,322</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,438</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(249,413</TD><TD STYLE="font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in fair value of contingent consideration (note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(325,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,578</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in fair value of derivative financial instrument (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(96,619</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Provisions (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,115</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,585</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">2,110</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Foreign exchange loss (gain)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">214,226</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(185,904</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.6in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">826,312</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,249,084</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">829,899</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">16</TD><TD>Income taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Income tax expense differs from the
tax recovery amount that would be obtained by applying the statutory income tax rate to the respective year&rsquo;s loss before
income taxes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Loss before income taxes</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">20,532,205</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">18,748,219</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">16,312,715</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recovery based on combined federal and provincial statutory rate of 26.5% (2017 &ndash; 26.5%, 2016 &ndash; 26.5%)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,441,034</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,968,278</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(4,322,869</TD><TD STYLE="font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(770,593</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(301,808</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">(802,664</TD><TD STYLE="font-weight: normal; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in deferred tax assets not recognized</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,460,542</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,334,312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">5,132,948</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Effect of tax rates in foreign jurisdictions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(18,131</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">9,897</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">6,639</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Net income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">230,784</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">74,123</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">14,054</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Deferred tax assets are recognized
for tax loss carry-forwards and unused tax credits to the extent that the realization of the related tax benefit through future
taxable profits is probable. The Company has not recognized deferred tax assets that can be carried forward against future taxable
income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Permanent differences are primarily
comprised of non-refundable tax credits and deductible finance fees not recorded in the consolidated statements of loss and comprehensive
loss, offset by non-deductible share-based compensation and accretion expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has non-capital loss
carry-forwards of approximately $55,564,000 as at December 31, 2018 that expire in varying amounts from 2028 to 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has SR&amp;ED expenditures
of approximately $15,806,000 as at December 31, 2018, which can be carried forward indefinitely to reduce future years&rsquo; taxable
income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has approximately $2,890,000
of federal and provincial tax credits that are available to be applied against federal and provincial taxes otherwise payable in
future years and that expire in varying amounts from 2028 to 2038.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">17</TD><TD>Loss per share</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The following table shows the calculation
of basic and diluted loss per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Net loss for the year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">20,762,989</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,822,342</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">16,326,769</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average number of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,395,649</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,404,141</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">41,510,145</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Basic and diluted loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.31</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">0.39</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">For the years noted above, the computation
of diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect on the share options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Of the 6,244,779 (2017&nbsp;&ndash;
5,318,279, 2016&nbsp;&ndash; 4,689,839) share options and 22,571,714 (2017 &ndash; 5,000,000, 2016&nbsp;&ndash; nil) warrants not
included in the calculation of diluted loss per share for the year ended December 31, 2018, 25,053,018 (2017 &ndash; 7,052,894,
2016&nbsp;&ndash; 2,315,602) were exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">18</TD><TD>Financial assets and liabilities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Classification of financial instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On January 1, 2018 (the date of initial
application of IFRS 9), the Company assessed which business models to apply to the financial assets held by the Company and has
classified its financial instruments into the appropriate IFRS 9 categories. A summary of the classifications under IFRS 9 as at
December 31, 2018 and under IAS 39 as at December 31, 2017 is shown below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 &ndash; IFRS 9</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair value <BR>through <BR>profit or<BR>
loss <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Financial <BR>assets at <BR>amortized <BR>cost <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Financial <BR>liabilities at <BR>amortized <BR>cost <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-indent: 0in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">30,687,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,686,112</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,912,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,955,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,255,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,653</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Derivative financial instrument</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">98,203</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,353,944</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,373,295</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,887,248</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 &ndash; IAS 39</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair value <BR>through <BR>profit or loss <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loans and <BR>receivables <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Other <BR>financial <BR>liabilities <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-indent: 0in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">11,103,223</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,251,658</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,081,704</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,145,089</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,734,050</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">96,894</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,734,050</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">15,354,881</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10,323,687</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Credit risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Credit risk is the risk of a financial
loss to the Company if a counterparty to a financial instrument fails to meet its contractual obligation. The Company is exposed
to credit risk on its cash and trade and other receivable balances. The Company&rsquo;s cash management policies include ensuring
cash is deposited in Canadian chartered banks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company applies the IFRS 9 simplified
approach to measuring expected credit losses, which uses a lifetime expected loss allowance for all trade and other receivables.
To measure the expected credit losses, trade and other receivables are grouped based on shared credit risk characteristics and
the days past due. On that basis, the loss allowance as at January 1, 2018 and December 31, 2018 is nominal as the Company only
transacts with hospitals and private clinics and has not incurred any credit losses since revenue began.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Trade and other receivables are written
off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include,
amongst others, failure to make contractual payments for a period of greater than 120 days past due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Market risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Market risk is the risk the fair
value or future cash flows of a financial instrument will fluctuate because of changes in market prices, including interest rate
risk and foreign currency risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest rate price risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">Interest rate price risk is the risk
the cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Company is exposed to such
fluctuations relating to the long-term debt, as it bears interest at a floating rate, whose interest rates are based on the prime
rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">If interest rates had been 1% higher
on the average long-term debt balance, with all other variables held constant, loss before income taxes would have been $52,083
higher for the year ended December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign currency risk</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">Foreign currency risk occurs as a
result of foreign exchange rate fluctuations between the time a transaction is recorded and the time it is settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company purchases goods and services
denominated in foreign currencies and, accordingly, is subject to foreign currency risk. The Company&rsquo;s financial instruments
denominated in foreign currencies are shown below in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US <BR>dollars <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Euro <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canadian <BR>dollars <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-indent: 0in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">136,879</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,039,205</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">29,511,099</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">30,687,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">613,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,450,661</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,686,112</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(472,431</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,758,294</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(681,625</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,912,350</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Other liabilities (excluding deferred rent)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,255,741</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,653</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,275,394</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">US <BR>dollars <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Euro <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canadian <BR>dollars <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-indent: 0in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,479</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">338,743</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">10,746,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">11,103,223</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">747,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,396,317</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,161</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,251,658</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(774,814</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,156,360</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,150,530</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,081,704</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Other liabilities (excluding deferred rent)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,734,050</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(96,894</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,830,944</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">As at December 31, 2018, if foreign
exchange rates had been 5% higher, with all other variables held constant, loss before income taxes would have been $62,292 (2017&nbsp;&ndash;
$8,225) higher, mainly as a result of the translation of foreign currency denominated cash, trade and other receivables, accounts
payable and accrued liabilities and other liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company does not use derivatives
to reduce exposure to foreign currency risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Liquidity risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Liquidity risk is the risk the Company
may encounter difficulties in meeting its financial liability obligations as they come due. The Company has a planning and budgeting
process in place to help determine the funds required to support the Company&rsquo;s normal operating requirements on an ongoing
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company controls liquidity risk
through management of working capital, cash flows and the availability and sourcing of financing. The Company&rsquo;s ability to
accomplish all of its future strategic plans is dependent on obtaining additional financing or executing other strategic options;
however, there is no assurance the Company will achieve these objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The following table summarizes the
Company&rsquo;s significant contractual, undiscounted cash flows related to its financial liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-transform: uppercase; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 18pt; font-weight: bold; text-transform: uppercase; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Carrying <BR>amount <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Future <BR>cash <BR>flows <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Less than <BR>1 year <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Between <BR>1 year and <BR>5 years <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Greater <BR>than 5 <BR>years <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accounts payable and accrued liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,912,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,912,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,912,350</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,955,245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,497,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,936,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,560,587</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Other liabilities (excluding deferred rent)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,275,394</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,365,217</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">429,426</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">935,791</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">17,142,989</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">19,774,609</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,278,231</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">13,496,378</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 18pt; font-weight: bold; text-transform: uppercase; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">2017</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 18pt; font-weight: bold; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Carrying
    <BR>amount <BR>$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Future
    <BR>cash <BR>flows <BR>$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Less
    than <BR>1 year <BR>$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Between
    <BR>1 year and <BR>5 years <BR>$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Greater
    <BR>than 5 <BR>years <BR>$</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accounts payable and accrued liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,081,704</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,081,704</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,081,704</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,145,089</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,802,658</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,268,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">534,647</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other liabilities (excluding deferred rent)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,830,944</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,161,552</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">419,121</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,742,431</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,057,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,045,914</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,768,836</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,277,078</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Fair value</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The fair values of cash, trade and
other receivables and accounts payable and accrued liabilities approximate their carrying values, due to their relatively short
periods to maturity. The fair value of long-term debt approximates its carrying amount as it has a floating interest rate.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">19</TD><TD>Related party transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Key management includes the Company&rsquo;s
directors and senior management team. The remuneration of directors and the senior management team was as follows during the years
ended December 31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Salaries and employee benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,746,024</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,021,568</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">1,247,563</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Termination benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Directors&rsquo; fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,132</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">63,616</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">959,234</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,220,655</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">862,798</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Total related party transactions</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,933,140</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,468,580</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">2,173,977</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Executive employment agreements allow for additional payments
in the event of a liquidity event, or if the executive is terminated without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">20</TD><TD>Commitments and contingencies</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has commitments under
operating leases for the rental of office space. On March 28, 2016, the Company signed a lease for office space and took possession
of this office space effective July 1, 2016. Included in prepaid expenses and deposits as at December 31, 2018 is an amount of
$210,000 (2017 &ndash; $330,000) related to prepaid rent for this lease that is drawn down at $10,000 per month starting October
1, 2016. The future minimum obligations, including prepaid rent, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; text-indent: 0in">No later than 1 year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">452,574</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Later than 1 year and no later than 5 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,775,583</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Later than 5 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,085,135</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Total commitments and contingencies</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,313,292</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">All directors and officers of the
Company are indemnified by the Company for various items including, but not limited to, all costs to settle lawsuits or actions
due to their association with the Company, subject to certain restrictions. The Company has purchased directors&rsquo; and officers&rsquo;
liability insurance to mitigate the cost of any potential future lawsuits or actions. The term of the indemnification is not explicitly
defined, but is limited to events for the period during which the indemnified party served as a director or officer of the Company.
The maximum amount of any potential future payment cannot be reasonably estimated but could have a material adverse effect on the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company has also indemnified
certain lenders and underwriters in relation to certain debt and equity offerings and their respective affiliates and directors,
officers, employees, shareholders, partners, advisers and agents and each other person, if any, controlling any of the underwriters
or lenders or their affiliates against certain liabilities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">21</TD><TD>Capital management</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company&rsquo;s capital management
objectives are to safeguard its ability to continue as a going concern and to provide returns for shareholders and benefits for
other stakeholders by ensuring it has sufficient cash resources to fund its research and development activities, to pursue its
commercialization efforts and to maintain its ongoing operations. The Company includes its share capital, deficit and long-term
debt in the definition of capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A summary of the Company&rsquo;s
capital structure is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 18pt; font-weight: bold; text-transform: uppercase; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017<BR>
$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-indent: 0in">Common shares</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">120,932,404</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">98,365,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,033,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(90,270,672</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Long-term debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">11,955,245</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">5,145,089</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">21,853,988</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">13,240,187</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">22</TD><TD>Segment reporting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company&rsquo;s operations are
categorized into one industry segment, which is medical technology focused on magnetic resonance guided ablation procedures for
the treatment of prostate disease, uterine fibroids and palliative pain treatment for patients with metastatic bone disease. The
Company is managed geographically in Canada, Germany and Finland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">For the year ended December 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: 0in">Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,436,654</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,165,624</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,602,278</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in; padding-bottom: 1pt">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">844,015</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">934,486</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,778,501</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">592,639</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">231,138</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">823,777</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,844,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,421,263</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,265,388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,256,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,656,723</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0.125in; padding-bottom: 1pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,004,143</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,676,389</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">410,815</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">4,091,347</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">16,105,014</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,676,389</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,232,055</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">21,013,458</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,512,375</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,445,251</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,232,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,189,681</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Net finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">342,524</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Loss for the year before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">20,532,205</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 12pt"><B>Profound Medical Corp.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Consolidated Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 1pt solid">December 31, 2018 and 2017
and 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">For the year ended December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: 0in">Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,331,606</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,572,944</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">4,904,550</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in; padding-bottom: 1pt">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,967,677</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,064,531</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,032,208</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,363,929</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">508,413</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,872,342</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,952,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">685,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,638,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,617,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,935,215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt; padding-bottom: 1pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,950,204</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,819,814</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">155,786</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,925,804</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">16,520,308</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,819,814</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,159,087</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">19,499,209</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,156,379</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,311,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,159,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,626,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Net finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,121,352</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Loss for the year before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">18,748,219</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Other financial information by segment as at December
31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: 0in">Total assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">42,437,691</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,093,184</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,018,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">46,549,872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Goodwill and intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,422,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,422,726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">797,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">409,795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,357</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,437</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,437</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Depreciation of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">296,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246,808</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Other financial information by segment as at December
31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Total assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">25,546,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,227,216</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,105,980</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">27,879,379</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Goodwill and intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,551,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,551,163</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,093,389</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,366</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">629,395</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,726,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,518</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Depreciation of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,290</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Intangible assets and goodwill additions or acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,815,680</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,815,680</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property and equipment additions or acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">409,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,984</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,144,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="f_002"></A>&nbsp;<IMG SRC="tv526458_img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>INTERIM CONDENSED CONSOLIDATED <BR>
FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>June 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PRESENTED IN CANADIAN DOLLARS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim Condensed Consolidated Balance Sheet</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.3in; padding-left: 0.3in">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-indent: -9.25pt; padding-left: 0.3in">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">20,493,470</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">30,687,183</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Trade and other receivables (note 3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,934,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,686,112</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Investment tax credits receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Inventory (note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,611,346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,631,623</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in; padding-bottom: 1pt">Prepaid expenses and deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">161,685</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">434,871</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,680,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,919,789</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Property and equipment (note 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">914,848</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,357</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Intangible assets (note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,449,342</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,013,561</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Right-of-use assets (notes 2 and 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,408,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,409,165</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,409,165</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Total assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">37,862,711</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">46,549,872</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.3in; padding-left: 0.3in">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,339,451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,912,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,558</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Long-term debt (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,475,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,339,583</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Provisions (note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,017</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Other liabilities (notes 9 and 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">614,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">567,296</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Derivative financial instrument (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,203</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.25pt; padding-left: 0.3in">Lease liabilities (notes 2 and 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">211,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 12.35pt; padding-bottom: 1pt">Income taxes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">164,079</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">297,353</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7,465,677</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7,879,360</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Long-term debt (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,562,737</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,615,662</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">658,026</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">379,044</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Provisions (note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in">Other liabilities (notes 9 and 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">432,545</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Lease liabilities (notes 2 and 11)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,279,037</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">19,443,184</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">19,923,538</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-indent: -0.3in; padding-left: 0.3in">Share capital (note 12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,942,484</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,932,404</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: -0.3in; padding-left: 0.3in">Contributed surplus</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,208,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,756,294</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; text-align: left; text-indent: -0.3in; padding-left: 0.3in">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86,935</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,703</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(119,644,062</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(111,033,661</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Total Shareholders&rsquo; Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">18,419,527</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">26,626,334</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.3in; padding-left: 0.3in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.3in; padding-left: 0.3in; padding-bottom: 1pt">Total Liabilities and Shareholders&rsquo; Equity</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">37,862,711</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right; border-bottom: Black 1pt solid">46,549,872</TD><TD STYLE="font-weight: normal; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying notes are an integral part of these interim condensed
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim Condensed Consolidated Statement of Loss and Comprehensive
Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three <BR>months <BR>ended <BR>June 30, <BR>2019 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three <BR>months <BR>ended <BR>June 30, <BR>2018 <BR>$</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-indent: -0.1in; padding-left: 16.2pt">Products</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">465,840</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">170,931</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,813,621</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">543,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,269</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,412</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">236,276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">574,109</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,049,897</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">589,678</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><B>Cost of sales</B> (note 14)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">244,066</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">126,259</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">777,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">357,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">330,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,272,475</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">232,344</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in"><B>Operating Expenses</B> (note 14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Research and development &ndash; net of investment tax credits of $nil (2018 &ndash; $120,000)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,186,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,347,909</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,864,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,864,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,586,323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,236,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,100,436</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,539,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Selling and distribution &ndash; net of revenue share obligation reversal (note&nbsp;8)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,154,869</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,113,225</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">625,524</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,060,127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,927,547</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,697,663</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,590,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,464,550</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Operating Loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,597,504</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,610,579</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,317,586</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,232,206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other income and expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Finance costs (note 15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313,606</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">651,905</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">633,569</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Finance income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(110,790</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(117,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(252,671</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(157,161</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">226,430</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">196,249</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">399,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">476,408</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Loss before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,823,934</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,806,828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,716,820</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,708,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,200</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60,600</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,844,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,831,028</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,770,820</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,769,214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Item that may be reclassified to profit or loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Foreign currency translation adjustment - net of tax</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,843</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,943</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(58,232</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net loss and comprehensive loss for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,832,291</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,888,971</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,712,588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,783,909</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in"><B>Loss per share</B> (note 16)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Basic and diluted net loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying notes are an integral part of these interim condensed
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim Condensed Consolidated Statement of Changes in Shareholders&rsquo;
Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number <BR>of shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Share <BR>capital <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contributed <BR>surplus <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <BR>other <BR>comprehensive <BR>income (loss) <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance &ndash; January 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">73,117,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">98,365,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">6,103,970</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(57,929</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(90,270,672</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">14,141,139</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,769,214</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,769,214</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cumulative translation adjustment &ndash; net of tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">426,562</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">295,781</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(193,406</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation (note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">476,931</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">476,931</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Issuance of units on bought deal financing (note&nbsp;12)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,276,555</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,767,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,044,305</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Balance &ndash; June 30, 2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,043,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,938,106</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,155,245</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(101,039,886</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,010,231</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance &ndash; January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,054,939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,932,404</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,756,294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,703</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,033,661</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,626,334</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in accounting policy for IFRS 16 (note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,419</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,419</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Restated balance &ndash; January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,054,939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,932,404</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,756,294</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(28,703</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(110,873,242</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,786,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,770,820</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,770,820</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Cumulative translation adjustment &ndash; net of tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,232</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(58,232</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,080</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,681</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,399</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation (note 13)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">456,427</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">456,427</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Balance &ndash; June 30, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,072,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120,942,484</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,208,040</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(86,935</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(119,644,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,419,527</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying notes are an integral part of these interim condensed
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Interim Condensed Consolidated Statement of Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six months <BR>ended <BR>June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six months <BR>ended <BR>June 30, <BR>2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(8,770,820</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(10,769,214</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Adjustments to reconcile net loss to net cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Depreciation of property and equipment (note 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,299</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">284,167</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Amortization of intangible assets (note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">564,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">564,219</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Depreciation of right-of-use assets (note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Share-based compensation (note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">456,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">476,931</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Interest and accretion expense (note 15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">681,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">522,215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Change in deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,670</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Change in fair value of derivative financial instrument (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Change in fair value of contingent consideration (note 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(208,911</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,546</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Changes in non-cash working capital balances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investment tax credits receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(248,171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,227,089</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,186</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(93,660</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,277</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,144,721</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,612,144</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,320,795</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Provisions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,219,114</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,263</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Income taxes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(133,274</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">62,089</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Net cash flow used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(9,504,257</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(9,135,773</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Transaction costs paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,455,695</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Payment of other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,203</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(164,389</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Payment of long-term debt and interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(534,709</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,953,822</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Proceeds from share options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Payment of lease liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(143,943</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Total cash (used in) from financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(689,456</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">30,028,469</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net change in cash during the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,193,713</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,892,696</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Cash &ndash; Beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">30,687,183</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">11,103,223</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Cash &ndash; End of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">20,493,470</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">31,995,919</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying notes are an integral part of these interim condensed
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">1</TD><TD>Description of business</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Profound Medical Corp. (Profound)
and its subsidiaries (together, the Company) were incorporated under the Ontario Business Corporations Act on July 16, 2014. The
Company is a medical technology company developing treatments to ablate the prostate gland, uterine fibroids and nerves for palliative
pain relief for patients with metastatic bone disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company&rsquo;s registered address
is 2400 Skymark Avenue, Unit 6, Mississauga, Ontario, L4W 5K5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">2</TD><TD>Summary of significant accounting policies and basis of preparation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Basis of preparation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">These interim condensed consolidated
financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International
Accounting Standards Board (IFRS), applicable to the preparation of interim condensed consolidated financial statements, including
International Accounting Standard (IAS) 34, Interim Financial Reporting. These interim condensed consolidated financial statements
are presented in Canadian dollars and should be read in conjunction with the Company&rsquo;s annual financial statements for the
year ended December 31, 2018, which were prepared in accordance with IFRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">These interim condensed consolidated
financial statements were authorized for issue by the Board of Directors on August 14, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The interim condensed consolidated
financial statements were prepared on a going concern basis under the historical cost convention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The accounting policies adopted are
consistent with those of the previous financial year except as noted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A new standard became applicable
for the current reporting period and the Company had to change its accounting policies as a result. The impact of the adoption
of this standard and the new accounting policy is disclosed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IFRS 16, Leases (IFRS 16)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">IFRS 16 sets out the principles for the recognition, measurement
and disclosure of leases. IFRS 16 provides revised guidance on identifying a lease and for separating lease and non-lease components
of a contract. IFRS 16 introduces a single accounting model for all lessees, thereby removing the distinction between operating
and finance leases. IFRS 16 requires a lessee to recognize an asset (right-to-use the leased item) and a financial liability to
pay rentals on the interim condensed consolidated balance sheets with terms of more than 12 months, unless the underlying asset
is of low value. The standard permits either a full retrospective or a modified retrospective approach for the adoption. IFRS 16
was effective for annual periods beginning on or after January 1, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company has adopted IFRS 16 retrospectively
from January 1, 2019, but has not restated comparative information, as permitted under the specific transitional provisions in
the standard in accordance with the modified retrospective approach for adoption. The reclassifications and the adjustments arising
from the new leasing standard are therefore recognized in the opening interim condensed consolidated balance sheet on January 1,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>Adjustments recognized on adoption
of IFRS 16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">On adoption of IFRS 16, the Company
recognized lease liabilities in relation to leases, which had previously been classified as operating leases under the principles
of IAS 17, Leases (IAS 17). These liabilities were measured at the present value of the remaining lease payments, discounted using
the incremental borrowing rate as of January 1, 2019. The weighted average lessee&rsquo;s incremental borrowing rate applied to
the lease liabilities on January 1, 2019 was 4%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.6in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-indent: -0.1in; padding-left: 0.1in">Operating lease commitments as at December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,313,292</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Asset retirement obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Discounted using the Company&rsquo;s average incremental borrowing rate of 4.0%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(836,665</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Lease liabilities recognized as at January 1, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,587,727</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The change in accounting policy affected
the following items in the interim condensed consolidated balance sheet on January 1, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.6in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Increase <BR>(decrease) <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left; text-indent: 0in">Right-of-use assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,616,773</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,587,727</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Prepaid expenses and deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(210,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Provisions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,319</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(292,054</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,419</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>Practical expedients applied</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company has elected to apply
the practical expedient not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term
of 12 months or less and leases of low value assets. The lease payments associated with these leases are recognized as an expense
on a straight-line basis over the lease term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company has also elected not
to reassess whether a contract is, or contains a lease at the date of initial application. Instead, for contracts entered into
before the transition date, the Company has relied on its assessment made applying IAS 17 and IFRIC 4, Determining whether an Arrangement
contains a Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify"><B>Accounting policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">At inception of a contract, the Company
assesses whether a contract is, or contains, a lease based on whether the contract conveys the right to control the use of an identified
asset for a period of time in exchange for consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The Company recognizes a right-of-use
asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured based on the initial amount
of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred
and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it
is located, less any lease incentives received. The assets are depreciated to the earlier of the end of the useful life of the
right-of-use asset or the lease term using the straight-line method as this most closely reflects the expected pattern of consumption
of the future economic benefits. The lease term includes periods covered by an option to extend if the Company is reasonably certain
to exercise that option. Lease terms range from four to ten years for offices. In addition, the right-of-use asset is periodically
reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The lease liability is initially
measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate
implicit in the lease or, if that rate cannot be readily determined, the Company&rsquo;s incremental borrowing rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">The lease liability is measured at
amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from
a change in an index or rate, if there is a change in the Company&rsquo;s estimate of the amount expected to be payable under a
residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension or termination
option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify">When the lease liability is remeasured
in this way, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss
if the carrying amount of the right-of-use asset has been reduced to zero.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">3</TD><TD>Trade and other receivables</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The trade and other receivables balance comprises the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: 0in">Trade receivables</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,350,477</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,791,688</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Interest receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,877</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Indirect tax receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">510,851</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">565,832</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Other receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,078</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">272,862</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total trade and other receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,934,283</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,686,112</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Amounts past due represent trade
receivables past due based on the customer&rsquo;s contractual terms. The Company applies the simplified approach to providing
for expected credit losses prescribed by IFRS 9, which permits the use of the lifetime expected loss provision for all trade receivables.
At June 30, 2019 and December 31, 2018, there were no trade receivables that are past due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">4</TD><TD>Inventory</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Finished goods</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,017,634</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,305,746</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Raw materials</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,633,565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,383,572</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Inventory provision</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(39,853</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(57,695</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,611,346</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,631,623</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During the three and six months ended
June 30, 2019, $254,319 and $726,402 (three and six months ended June 30, 2018, $61,198 and $330,696, respectively) of inventory
was recognized in cost of sales. The Company decreased its inventory provision by $3,606 and $17,842 during the three and six months
ended June 30, 2019 (three and six months ended June 30, 2018 &ndash; decrease of $2,198 and $40,549). There were no other inventory
writedowns charged to cost of sales during the period ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">5</TD><TD>Property and equipment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Property and equipment consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Furniture</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">and</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">fittings</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Research</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">and</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">manufact-<BR>
uring</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">equipment</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Leasehold</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">improve-<BR>
ments</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Computer</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">equipment</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Computer</P> <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">software</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Total</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">At January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 34%; text-indent: 0in; padding-left: 9pt">Cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">235,169</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,386,692</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">718,742</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">212,541</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">176,462</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,729,606</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(138,604</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(815,450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(182,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(209,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(176,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,522,249</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">96,565</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">571,242</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">536,507</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,207,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">Six months ended June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571,242</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">536,507</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,357</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,210</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,210</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,159</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(200,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(34,641</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,765</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(257,299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77,406</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">335,298</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">501,866</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">914,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">At June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,169</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,388,922</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">718,742</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">212,541</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,462</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,731,836</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(157,763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,053,624</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(216,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(212,263</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(176,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,816,988</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77,406</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">335,298</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">501,866</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">278</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">914,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">6</TD><TD>Intangible assets</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Intangible assets consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exclusive <BR>licence <BR>agreement <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Software <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Proprietary <BR>technology <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Brand <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 45%; text-indent: 0in; padding-left: 9pt">Cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">257,254</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">4,489,295</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">883,140</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">5,679,689</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(118,938</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,271,967</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(250,223</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,666,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">138,316</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,217,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">632,917</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,013,561</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">Six months ended June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,217,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">632,917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,013,561</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,725</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(448,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(88,315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(564,219</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">112,591</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,768,399</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">544,602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,449,342</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,254</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,489,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">883,140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,679,689</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(144,663</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,720,896</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(338,538</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,230,347</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">112,591</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,768,399</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">544,602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,449,342</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">7</TD><TD>Right-of-use assets</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Leased <BR>
premises <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-indent: 0in; padding-left: 0.125in">Cost</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,616,773</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 0.125in">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 0.125in">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,616,773</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">Six months ended June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Opening net book value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,616,773</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,075</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(204,126</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Closing net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,408,572</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: 0in">As at June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,616,773</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(208,201</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Net book value</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,408,572</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company leases office premises
in Mississauga, Canada and Vantaa, Finland. These lease agreements are typically entered into for four to ten-year periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">8</TD><TD>Provisions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Asset <BR>retirement <BR>obligation <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue <BR>share <BR>obligation <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warranty <BR>provision <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">As at January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">49,319</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,241,657</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">110,360</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,401,336</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in accounting policy for IFRS 16 (note 2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,319</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49,319</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Restated balance as at January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,241,657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,352,017</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Additions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,922</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,922</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Expiry</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,241,657</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,998</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,282,655</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Foreign exchange</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,381</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,381</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">As at June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,903</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,903</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,162</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">45,162</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Asset retirement obligation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The asset retirement obligation was
related to the Company&rsquo;s leasehold improvements. This amount was transferred as part of the adoption of IFRS 16 (note 2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Revenue share obligation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During January 2019, the Company
replaced the original co-marketing and co-selling agreement with Siemens with a new agreement. Under the new agreement, all prior
financial commitments and obligations owed to Siemens are released and replaced with a non-exclusive licence resulting in a one-time
fixed licence fee of US$100,000 and a per annum payment per device interfaced to a Siemens MRI scanner. In exchange for the one-time
fixed licence fee and per annum payments, the Company obtained a non-exclusive licence and reasonable support for the term of the
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Warranty provision</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The warranty provision is related
to the Company&rsquo;s estimate of future warranty obligations on product sales, which generally have a term of 12 to 24 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">9</TD><TD>Long-term debt</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">A summary of the long-term debt is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: 0in">CIBC loan</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">12,038,095</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">11,955,245</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,475,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,339,583</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,562,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">10,615,662</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On July 30, 2018, the Company signed
a term loan agreement with CIBC Innovation Banking (CIBC) to provide a secured loan for total initial gross proceeds of $12,500,000
maturing on July 29, 2022 with an interest rate based on prime plus 2.5%. The Company is required to make interest only payments
until October 31, 2019 and monthly repayments on the principal of $378,788 plus accrued interest commencing on October 31, 2019.
All obligations of the Company under the term loan agreement are guaranteed by current and future subsidiaries of the Company and
include security of first priority interests in the assets of the Company and its subsidiaries. The Company has the ability to
draw an additional $6,250,000 subject to the achievement of certain financing and product development milestones. The Company has
a financial covenant in relation to the CIBC loan where unrestricted cash is required to be greater than operating cash expenditures
for a trailing three-month period, reported on a monthly basis. The Company is in compliance with this financial covenant as at
June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-indent: 0in">Balance &ndash; Beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">11,955,245</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Proceeds received</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(930,520</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Interest and accretion expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617,559</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,409</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">Repayment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(534,709</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(131,644</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Balance &ndash; End of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,038,095</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,955,245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,475,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,339,583</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,562,737</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,615,662</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">In connection with this term loan
agreement on July 31, 2018, the Company also issued 321,714 common share purchase warrants to CIBC, with each warrant entitling
the holder to acquire one common share at a price of $0.97 per common share until the date that is 60 months from the closing of
the term loan agreement, with a cashless exercise feature. The cashless exercise feature causes the conversion ratio to be variable
and the warrants are therefore classified as a financial liability. Gains and losses on the warrants are recorded within finance
costs on the interim condensed consolidated statements of loss and comprehensive loss. A pricing model with observable market based
inputs was used to estimate the fair value of the warrants issued. The estimated fair value of the warrants as at June 30, 2019
and December 31, 2018 was $152,423 and $98,203, respectively. The variables used to determine the fair values are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-indent: 0in">Share price</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">0.79</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: normal">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: normal; text-align: left">$</TD><TD STYLE="width: 10%; font-weight: normal; text-align: right">0.55</TD><TD STYLE="width: 1%; font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">Volatility</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">88</TD><TD STYLE="font-weight: normal; text-align: left">%</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">86</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Expected life of warrants</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-weight: normal">4.1&nbsp;years</FONT></TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right"><FONT STYLE="font-weight: normal">4.6&nbsp;years</FONT></TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Risk free interest rate</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1.41</TD><TD STYLE="font-weight: normal; text-align: left">%</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">1.88</TD><TD STYLE="font-weight: normal; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Dividend yield</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal">&nbsp;</TD>
    <TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD><TD STYLE="font-weight: normal; text-align: right">-</TD><TD STYLE="font-weight: normal; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Federal Economic Development
Agency (FedDev) loan with total proceeds of $867,000 was unsecured and non-interest bearing. The final repayment of $563,550 was
made on July 25, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During the three and six months ended
June 30, 2019 and 2018, the Company recognized $nil of interest and accretion expense on this loan (three and six months ended
June 30, 2018 - $77,783 and $90,775, respectively).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Health Technology Exchange (HTX)
loans with total proceeds of $1,500,000 were unsecured and bore interest at 4.50% per annum. The final repayment of $1,094,698,
including accrued interest, was made on March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">During the three and six months ended
June 30, 2019 and 2018, the Company recognized $nil of interest and accretion expense on these loans (three and six months ended
June 30, 2018 - $nil and $18,078, respectively).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On April 30, 2015, Profound Medical
Inc. signed an agreement with Knight Therapeutics Inc. (Knight) to provide a secured loan of $4,000,000 (the Knight Loan) for an
initial period of four years with an interest rate of 15% per annum, with payments of interest and principal deferred until June
30, 2017. As part of the agreement, Knight was also granted a royalty of 0.5% on net sales resulting from global sales of the Company&rsquo;s
products until May 20, 2019 (the royalty). In addition, the Company also entered into a distribution, licence and supply agreement
with Knight pursuant to which Knight will act as the exclusive distributor of the Company&rsquo;s product in Canada for an initial
ten-year term, renewable for successive ten-year terms by either party. In connection with these arrangements, the Company issued
to Knight 4% of the common shares of the Company (1,717,450 common shares). On July 25, 2018, the full amount of the Knight Loan,
including prepayment fees, was repaid for a total payment of $3,188,023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The royalty was initially recorded
at fair value and was subsequently carried at amortized cost using the effective interest rate method. The initial fair value of
the royalty was determined using future revenue forecasts for the term of the loan and a discount rate of 18%. During the three
and six months ended June 30, 2019, the Company revised the fair value of the royalty, using future revenue forecasts for the term
of the loan and a discount rate of 18%, and recognized an interest accretion recovery of $6,361 and $3,450, respectively (three
and six months ended June 30, 2018&nbsp;- accretion recovery of $7,931 and $3,383, respectively). This liability is included within
other liabilities on the interim condensed consolidated balance sheets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">10</TD><TD>Other liabilities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Knight <BR>royalty <BR>payable <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Contingent <BR>consideration <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deferred <BR>rent <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">As at January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">19,653</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,255,741</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">292,055</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,567,449</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Change in accounting policy for IFRS 16 (note 2)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(292,055</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(292,055</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Restated balance as at January 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,653</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,255,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,275,394</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Amounts paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,203</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,203</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(208,911</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(208,911</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Accretion recovery (note 15)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,450</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">As at June 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,046,830</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,046,830</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">614,285</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">614,285</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">432,545</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">432,545</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Knight royalty payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As part of the Knight Loan, Knight
was granted a royalty of 0.5% on net sales resulting from global sales of the Company&rsquo;s products until May 20, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Contingent consideration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">On July 31, 2017, the Company entered
into an Asset and Share Purchase Agreement (the agreement) to acquire all of the issued and outstanding shares and certain assets
of Royal Philips&rsquo; (Philips) Sonalleve MR-HIFU business (Sonalleve). The agreement includes certain contingent consideration
payments payable monthly in euro tied to future revenue levels of the Sonalleve business summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">5% of revenue between the date of acquisition
and December 31, 2017;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">6% of revenue during the year ending December
31, 2018;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">7% of revenue during the years ending
December 31, 2019 and 2020; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-align: justify; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.3in"></TD><TD STYLE="width: 0.3in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if total revenues are in excess of a defined
amount from the date of acquisition to December 31, 2020, then the Company will be required to pay 7% of revenue from the date
of acquisition to December 31, 2019.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The contingent consideration is classified
as a Level 3 financial liability within the fair value hierarchy given its fair value is estimated using the discounted value of
estimated future payments. The key assumptions in valuing the contingent consideration include: estimated projected net sales;
the likelihood of certain levels being reached; and a discount rate of 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Deferred rent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The deferred rent obligation was
related to the Company&rsquo;s straight-line rent accrual for its current premises. This amount was transferred as part of the
adoption of IFRS 16 (note 2).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">11</TD><TD>Lease liabilities</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">As at January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,587,727</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Repayments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(143,943</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Foreign exchange</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,297</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Interest and accretion expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">67,149</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Balance &ndash; End of period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,490,636</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Less: Current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">211,599</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Long-term portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,279,037</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">12</TD><TD>Share capital</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Common shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The Company is authorized to issue an unlimited number
of common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Issued and outstanding (with no par value)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, <BR>2019 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2018 <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">108,072,939 (December 31, 2018 &ndash; 108,054,939) common shares</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">120,942,484</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">120,932,404</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">As a result of the March 20, 2018
bought deal financing, 17,250,000 warrants were issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A summary of warrants outstanding
is shown below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR>warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted <BR>average <BR>exercise <BR>price <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>remaining</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>contractual</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>life</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(years)</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 61%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance
 &ndash; January 1, 2019 and June 30, 2019</B></FONT></TD><TD STYLE="font-weight: normal; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-align: right; width: 10%">22,571,714</TD><TD STYLE="padding-bottom: 1pt; font-weight: normal; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; width: 10%">1.39</TD><TD STYLE="padding-bottom: 1pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; width: 10%">3.17</TD><TD STYLE="padding-bottom: 1pt; text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">13</TD><TD>Share-based payments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in"><B>Share options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Compensation expense related to share
options for the three and six months ended June 30, 2019 was $383,789 and $456,427, respectively (three and six months ended June
30, 2018 - $235,873 and $476,931, respectively).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">A summary of the share option changes
during the period presented and the total number of share options outstanding as at those dates are set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Number</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>of options</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>exercise</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">January 1, 2019</FONT></B></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,244,779</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1.13</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,982,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.92</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Forfeited/expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(835,250</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.06</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Balance </B></FONT><B>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">June 30, 2019</FONT></B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,373,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.04</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The company estimated the fair value
of the share options granted during the period using the Black-Scholes option pricing model with the weighted average assumptions
below. Due to the absence of company-specific volatility rates for the expected life of the share options, the company chose comparable
companies in the medical device industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">May 15, <BR>2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">May 16, <BR>2019</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Share price on date of issuance</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.91</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">0.94</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Expected life of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6&nbsp;years</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6&nbsp;years</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.59</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Number of share options issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,849,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The following table summarizes information
about the share options outstanding as at June 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Exercise price</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>$</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>options</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>outstanding</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Weighted</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>remaining</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>contractual life</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(years)</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>options</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>exercisable</B></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: center">0.24</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">212,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">3.19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">212,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">0.60</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">0.85</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,663</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">0.91</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">0.92</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,849,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.88</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">0.93</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">0.97</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.82</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">0.99</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,747</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1.02</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">1.10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,971,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,243,874</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1.19</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">518,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,291</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">1.35</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">132,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,961</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1.46</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">934,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">661,622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; padding-bottom: 1pt">1.50</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">565,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6.17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">528,621</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,373,929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8.64</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,155,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">14</TD><TD>Nature of expenses</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Production and manufacturing costs</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">68,171</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">45,537</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">464,477</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">237,590</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Salaries and benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,473,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,657,601</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,012,176</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,095,979</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,378,418</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,286,739</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,297,765</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,552,083</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Research and development expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">613,821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266,463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,096,785</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320,255</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Sales and marketing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">368,339</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">427,721</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(696,955</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">685,885</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Amortization and depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">516,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">424,548</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,026,028</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">848,386</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">383,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">456,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">476,931</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,974</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">193,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">216,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">348,741</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Other expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">242,782</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">286,365</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">494,647</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">256,035</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">6,171,613</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">5,823,922</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10,367,483</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">10,821,885</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">15</TD><TD>Finance costs</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three<BR> months<BR> ended<BR> June 30,<BR> 2019<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three<BR> months<BR> ended<BR> June 30,<BR> 2018<BR> $</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months<BR> ended<BR> June 30,<BR> 2019<BR> $</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months<BR> ended<BR> June 30,<BR> 2018<BR> $</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Knight loan (note 9)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">264,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">416,745</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in fair value of contingent consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(185,197</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(73,193</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(208,911</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,546</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">CIBC loan (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">617,559</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">HTX and FedDev loans (note&nbsp;9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,783</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,853</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Change in fair value of derivative financial instrument (note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,251</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Lease liability interest expense (note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,556</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Royalty interest accretion recovery (note 9 and 10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,361</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,931</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,450</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,383</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Provisions (note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,488</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Foreign exchange (gain) loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">186,423</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,920</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">125,338</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">133,412</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">337,220</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">313,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">651,905</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">633,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">16</TD><TD>Loss per share</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">The following table shows the calculation of basic and
diluted loss per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss for the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,844,134</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,831,028</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8,770,820</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">10,769,214</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Weighted average number of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,061,539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">107,727,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108,058,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">92,614,640</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Basic and diluted loss per share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">For the periods noted above, the
computation of diluted loss per share is equal to the basic loss per share due to the anti-dilutive effect of the share options
and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Of the 10,373,929 (June 30, 2018
 &ndash; 5,535,029) share options and 22,571,714 (June 30, 2018 &ndash; 22,250,000) warrants not included in the calculation of
diluted loss per share for the period ended June 30, 2019, 25,726,743 (June 30, 2018 &ndash; 24,347,875) were exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">17</TD><TD STYLE="text-align: justify">Related party transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Key management includes the Company&rsquo;s
directors and senior management team. The remuneration of directors and the senior management team was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Three</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2019 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">Six</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">months <BR>ended <BR>June 30, <BR>2018 <BR>$</P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Salaries and employee benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">347,258</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">705,127</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">696,848</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">908,853</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Termination benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Directors&rsquo; fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,084</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,031</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">Share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">315,536</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">228,792</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">372,170</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">401,596</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">700,294</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">954,003</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,144,018</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,456,230</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">Executive employment agreements allow
for additional payments in the event of a liquidity event, or if the executive is terminated without cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">18</TD><TD>Segment reporting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">The Company&rsquo;s operations are
categorized into one industry segment, which is medical technology focused on magnetic resonance guided ablation procedures for
the treatment of prostate disease, uterine fibroids and palliative pain treatment for patients with metastatic bone disease. The
Company is managed geographically in Canada, Germany and Finland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">For the three-month period ended June 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-indent: 0in; padding-left: 9pt">Product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">351,822</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">114,018</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">465,840</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,590</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">88,679</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,269</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">371,412</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">202,697</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">574,109</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: 0in">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,698</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">184,368</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">244,066</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">311,714</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">330,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,548,997</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">637,358</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,186,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,507,414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,909</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,586,323</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">659,343</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">412,861</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,665</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,154,869</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,715,754</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">412,861</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">798,932</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,927,547</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,404,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">394,532</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798,932</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,597,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-bottom: 1pt">Net finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">226,430</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in; padding-bottom: 1pt">Loss for the period before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">5,823,934</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">For the six-month period ended June 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-indent: 0in; padding-left: 9pt">Product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,289,131</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">524,490</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,813,621</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,768</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">204,508</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">236,276</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,320,899</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">728,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,049,897</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: 0in">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">215,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">562,282</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">777,422</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,105,759</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">166,716</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,272,475</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,444,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,419,885</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,864,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,908,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,100,436</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(332,591</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">789,449</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">168,666</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">625,524</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,020,035</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">789,449</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,780,577</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,590,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,914,276</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">622,733</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,780,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,317,586</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Net finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">399,234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Loss for the period before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,716,820</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">For the three-month period ended June 30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-indent: 0in; padding-left: 9pt">Product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">170,931</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">170,931</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,412</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">201,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">126,259</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">126,259</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74,965</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">87,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,009,586</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">338,323</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,347,909</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,236,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,236,529</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">599,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">333,040</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">180,187</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,113,225</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,846,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">333,040</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">518,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,697,663</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,833,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">258,075</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">518,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,610,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Net finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">196,249</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Loss for the period before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,806,828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 12pt">Profound Medical Corp.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes to Interim Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Unaudited)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid">June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">For the six-month period ended June
30, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-indent: 0in">Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-indent: 0in; padding-left: 9pt">Product</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">543,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">543,425</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Services</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">34,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">577,559</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">589,678</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-indent: 0in">Cost of sales</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">357,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">357,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">220,225</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">232,344</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: 0in">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,835,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,029,379</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,864,690</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 9pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,359,195</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,538</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,539,733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in; padding-left: 9pt">Selling and distribution</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,003,598</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">726,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">330,205</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,060,127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Total operating expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,198,104</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">726,324</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,540,122</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,464,550</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Operating loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,185,985</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">506,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,540,122</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,232,206</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 0in">Net finance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">476,408</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0in">Loss for the period before income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,708,614</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Other financial information by segment as at June 30,
2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: 0in">Total assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">34,015,086</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">896,755</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,950,871</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">37,862,711</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Goodwill and intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,858,507</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,858,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">662,624</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">252,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">914,848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,127,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">281,471</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,408,572</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">564,219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">564,219</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Depreciation of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134,672</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">267</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">122,360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,299</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Depreciation of right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,697</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,126</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">Other financial information by segment as at December
31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.3in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Canada <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Germany <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Finland <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total <BR>$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; text-indent: 0in">Total assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">42,437,691</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,093,184</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3,018,997</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">46,549,872</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Goodwill and intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,422,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,422,726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">797,296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">409,795</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207,357</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,437</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,437</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in">Depreciation of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">296,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246,808</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">546,001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 187; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tv526458_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID:</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">016652025</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Province of Ontario</FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date Report Produced: 2014/07/16</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demande n&deg;:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Province de l'Ontario</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Document produit le:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction ID:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">054818438</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ministry of Government Services</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time Report Produced: 10:25:28</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transaction n&deg;:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ministers des Services gouvernementaux</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imprim&eacute; &agrave;:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Category ID: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cat&eacute;gorie:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Certificate
of Incorporation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Certificat
de constitution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3pt; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This is to certify that</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ceci certifie que</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>MIRA IV ACQUISITION CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation No.</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Num&eacute;ro matricule de la personne morale en Ontario</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>002426652</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is a corporation incorporated, </FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">est une soci&eacute;t&eacute; constitu&eacute;e aux termes</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under the laws of the Province of Ontario.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">des lois de la province de l'Ontario.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These articles of incorporation</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Les pr&eacute;sents statuts constitutifs</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are effective on </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entrent en vigueur le</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JULY 16 JUILLET, 2014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="tv526458_ex1-1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Director/Directeur</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Business Corporations Act/Loi sur les societes
par actions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM 1</FONT></TD>
    <TD STYLE="width: 3%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>FORMULE NUMERO 1</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BUSINESS CORPORATIONS ACT</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LOI <I>SUR LES SOCIETES PAR ACTIONS</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: center">ARTICLES OF INCORPORATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: center"><I>STATUTS CONSTITUTIFS</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The name of the corporation is:</FONT></TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denomination socials <I>de</I> la <I>compagnie:</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MIRA IV ACQUISITION CORP.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The address of the registered office is:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adresse du <I>si&egrave;ge social:</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5</B></FONT></TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HAZELTON AVENUE </B></FONT></TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Suite 300</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Street &amp; Number, or R.R. Number &amp; if Multi-Office Building give Room No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><I>&nbsp;</I></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Rue et num&eacute;ro,
    ou num&eacute;ro de la R.R. et, s'il s'agit edifice a bureau, numero du bureau)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TORONTO</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ONTARIO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CANADA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M5R 2E1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Name of Municipality or Post Office)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>(Nom da la municipalit</I>&eacute; ou du bureau de <I>poste)</I></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Postal Code/<I>Code postal</I>)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number (or minimum and maximum number) of directors is:</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Nombre (ou nombres minimal et maximal)</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>d'administrateurs :</I></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum 3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximum 11</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first director(s) is/are:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Premier (a) administrateur (s) :</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First name, initials and surname</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Pr</I>&eacute;<I>nom, initiales et</I> nom de <I>famille</I></FONT></P></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resident Canadian State Yes or No</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Resident Canadien <I>Oui/Non</I></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for service, giving Street &amp; No.</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">or R.R. No., Municipality and Postal Code</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Domicile &eacute;1u, y compris la</I> rue et <I>le num</I>&eacute;<I>ro, le num</I>&eacute;<I>ro de la R.R., ou le nom de la municipalit&eacute; et le code postal</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">The first director(s) is/are:</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Premier <I>(a) administrateur(s):</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First name, initials and surname <I></I></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Pr</I>&eacute;<I>nom, initiales at nom do famille</I></FONT></P></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resident Canadian State Yes or No</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Resident
Canadien Oui/Non</I></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for service, giving Street &amp; No.
    or R.R. No., Municipality and Postal Code</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Domicile </I>&eacute;<I>1u, y compris la
    rue et le num</I>&eacute;<I>ro, le</I> num&eacute;ro <I>de la R.R.,</I> ou <I>le nom de la</I> municipalit&eacute; et le <I>code
    postal</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RONALD</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YES</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHMEICHEL</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 HAZELTON AVENUE Suite 300</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TORONTO ONTARIO</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CANADA M5R 2E1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEVIN</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NO</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TAYLOR</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2456 NE 27TH AVENUE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORT LAUDERDALE FLORIDA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED STATES OF AMERICA 33305</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JORDAN</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">YES</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KUPINSKY</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 HAZELTON AVENUE Suite 300</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TORONTO ONTARIO</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CANADA M5R 2E1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 95%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restrictions, if any, on business the corporation
        may carry on or on powers the corporation may exercise.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Limites, s'il y a lieu, impos&eacute;es
        aux activit&eacute;s commerciales ou aux pouvoirs de la conpagnie.</I></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no restrictions on the business the Corporation may carry on or on the powers the Corporation may exercise.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The classes and any maximum number of shares that the corporation is authorized to issue:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cat&eacute;gories
    et nombre maximal, s'il y a lieu, d'actions que la compagnie est autoris&eacute;e &agrave; &eacute;mettre;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Corporation is authorized to issue an unlimited number of shares of one class designated as common shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights, privileges, restrictions and conditions (if any) attaching to each class of shares and directors authority with respect to any class of shares which may be issued in series: <I>Droits, privil&egrave;ges, restrictions et conditions, s'il y </I>a lieu, <I>rattach&eacute;s &aacute; chaque cat&eacute;gorie d'actions et pouvoirs des administrateurs relatifs </I>&agrave; chague <I>cat&eacute;gorie d'actions que peut &ecirc;tre &eacute;mise en s&eacute;rie:</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-indent: -19pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issue, transfer or ownership of shares is/is not restricted and the restrictions (if any) are as follows:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>L'</I>&eacute;<I>mission, le</I> transfert ou <I>la propri</I>&eacute;<I>t</I>&eacute; <I>d'actions eat/n'est pas</I> restraints. <I>Les </I>restrictions, s<I>'il y a</I> lieu, sont <I>lea suivantes:</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other provisions, (if any, are):</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Autres <I>dispositions, s'il y</I> a <I>lie</I>u:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page: 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario Corporation Number</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request ID / <I>Demande n&deg;</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Num&eacute;ro de la compagnie en Ontario</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16652025</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2426652</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The names and addresses of the incorporators are <I><BR>
Nam et adresse des fondateurs</I></FONT></TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First name, initials and last name</FONT></TD>
    <TD STYLE="width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pr</I>&eacute; <I>nom,</I> initiale et nom da</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or corporate name</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>famille</I> ou <I>d</I>&eacute; <I>nomination sociale</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full address for service or
    address of registered office or of principal place of business giving street  &amp; No. or R.R. No., municipality and postal
    code</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Domicile &eacute;lu, adresse du si&egrave;ge social </I>au <I>adresse de l'&eacute;tablissement principal, </I>y <I>compris la rue et le num&eacute;ro, le num&eacute;ro de la R.R., le nom de la municipalit&eacute; et le code postal</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 23pt; text-indent: -20pt"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>*</I></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RUBIN RAPUCH</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333 BAY STREET Suite 2400</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TORONTO ONTARIO </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CANADA M5H 2T6</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="tv526458_ex1-1img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="tv526458_ex1-1img03.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><IMG SRC="tv526458_ex1-1img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"><IMG SRC="tv526458_ex1-1img05.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tv526458_ex1-1img06.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;<IMG SRC="tv526458_ex1-1img07.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>tv526458_ex1-2.htm
<DESCRIPTION>EXHIBIT 1.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="tv526458_ex1-2img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<IMG SRC="tv526458_ex1-2img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.3
<SEQUENCE>4
<FILENAME>tv526458_ex1-3.htm
<DESCRIPTION>EXHIBIT 1.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><B>Exhibit 1.3</B></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img01.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img02.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img03.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img04.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img05.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img06.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><IMG SRC="tv526458_ex1-3img07.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;A&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">STATEMENT OF A DIRECTOR OR OFFICER OF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MIRA IV SUBCO INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SUBSECTION 178(2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF THE <I>BUSINESS CORPORATIONS ACT</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">I, Elena Masters, of the City of Toronto,
in the Province of Ontario, state that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">1.</TD><TD STYLE="text-align: justify">this Statement is made pursuant to subsection 178(2) of
the <I>Business Corporations Act</I> (the <B>&ldquo;Act&rdquo;);</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">2.</TD><TD STYLE="text-align: justify">I am the director, President and Secretary of Mira IV Subco
Inc. and as such have knowledge of its affairs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">3.</TD><TD STYLE="text-align: justify">I have conducted such examinations of the books and records
of Mira IV Subco Inc. (the <B>&ldquo;Corporation&rdquo;), </B>and have made such enquiries and investigations as are necessary
to enable me to make this Statement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left">4.</TD><TD STYLE="text-align: justify">There are reasonable grounds for believing that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Corporation is, and the corporation to be formed
by its amalgamation with Profound Medical Inc. will, be able to pay its liabilities as they become due;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the realizable value of such amalgamated corporation&rsquo;s
assets will not be less than the aggregate of its liabilities and stated capital of all classes;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">no creditor of the Corporation will be prejudiced
by the amalgamation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">adequate notice has been given to all known creditors
of the Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">This Statement is made this 4th day of
June, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">/s/ Elena Masters</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><B>Elena Masters</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Statement of Director of Mira IV Subco]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;A&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>STATEMENT OF DIRECTOR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Steven Plymale, of the City of Toronto,
in the Province of Ontario, solemnly state that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">I am a director of Profound Medical Inc. (the <B>&ldquo;Corporation&rdquo;)
</B>and as such have personal knowledge of the matters herein deposed to.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">There are reasonable grounds for believing that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Corporation is and the amalgamated corporation
will be able to pay its liabilities as they become due;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the realizable value of the assets of the amalgamated corporation
will not be less than the aggregate of its liabilities and stated capital of all classes; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">no creditor of the Corporation will be prejudiced by the
amalgamation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>DATED </B>June 4, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: center">/s/ Steven Plymale</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">Steven Plymale</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE &ldquo;B&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>EXECUTION VERSION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMALGAMATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>BETWEEN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MIRA IV ACQUISITION CORP.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROFOUND MEDICAL INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MIRA IV SUBCO INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>April 29, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="width: 86%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: center"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify">ARTICLE 1 INTERPRETATION</TD>
    <TD STYLE="text-align: right">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Definitions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">2</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.2</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Interpretation Not Affected by Headings, etc</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.3</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Number, etc</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.4</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Date for Any Action</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.5</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Rounding</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.6</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Currency</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.7</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Knowledge</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">1.8</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Meanings</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">13</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 2 AMALGAMATION</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">14</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Amalgamation</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">14</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.2</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Amalco</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">14</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.3</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Resulting Issuer</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">15</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.4</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Effect of Certificate of Amalgamation</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">16</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.5</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Manner of Conversion of Issued Securities</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">17</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.6</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Certificates</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">18</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.7</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Fractional Securities</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.8</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Stock Option Plan</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.9</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Cancellation of Certain Options</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">2.10</TD>
    <TD STYLE="vertical-align: top; text-align: justify">U.S. Securities Law Compliance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 3 COVENANTS</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">3.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Covenants of Mira</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">3.2</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Further Covenants of Mira</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">3.3</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Covenants of Profound</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">23</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">3.4</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Further Covenants of Profound</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">25</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">3.5</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Profound Shareholder Approval</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 4 REPRESENTATIONS AND WARRANTIES</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">27</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">4.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Representations and Warranties of Mira</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">27</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">4.2</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Representations and Warranties of Profound</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">32</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 5 CONDITIONS PRECEDENT AND OTHER MATTERS</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">5.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Conditions to Obligations of Profound</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 8%; text-align: justify; padding-left: 9pt">5.2</TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify">Conditions to Obligations of Mira</TD>
    <TD STYLE="vertical-align: bottom; width: 6%; text-align: right">47</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">5.3</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Merger of Conditions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">5.4</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Alternative Transactions - Mira</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">5.5</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Alternative Transactions - Profound</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">49</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 6 NOTICES</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">6.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Notices</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 7 AMENDMENT AND TERMINATION OF AGREEMENT</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">51</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">7.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Amendment</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">51</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">7.2</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Rights of Termination</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">51</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">7.3</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Notice of Unfulfilled Conditions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">52</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">ARTICLE 8 GENERAL</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">52</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.1</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Entire Agreement</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">52</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.2</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Binding Effect</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">52</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.3</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Waiver and Modification</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.4</TD>
    <TD STYLE="vertical-align: top; text-align: justify">No Personal Liability</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.5</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Assignment</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.6</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Confidentiality</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.7</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Costs</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.8</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Time of Essence</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.9</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Survival</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.10</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 0.125in">Governing Law</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.11</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 0.125in">Severability</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">54</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.12</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 0.125in">Further Assurances</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 9pt">8.13</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-left: 0.125in">Counterparts and Electronic Copies</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">55</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMALGAMATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS AMALGAMATION AGREEMENT</B> made
as of the 29<SUP>th</SUP> day of April, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BETWEEN:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>MIRA IV ACQUISITION CORP.,</B> a body
corporate incorporated under the laws of the Province of Ontario (hereinafter called &ldquo;<B>Mira</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>OF THE FIRST PART</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- and -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>PROFOUND MEDICAL INC.,</B> a body corporate
incorporated under the laws of the Province of Ontario (hereinafter called &ldquo;<B>Profound</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>OF THE SECOND PART</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- and -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>MIRA IV SUBCO INC.,</B> a body corporate
incorporated under the laws of the Province of Ontario (hereinafter called &ldquo;<B>Mira Subco</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>OF THE THIRD PART</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B> Profound
and Mira, among others, are parties to a letter agreement dated November 5, 2014, as amended (the &ldquo;<B>Letter Agreement</B>&rdquo;)
whereby the parties have agreed to complete a business combination;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>AND WHEREAS</B>
Profound and Mira have agreed to structure the business combination contemplated in the Letter Agreement by way of a three-cornered
amalgamation in accordance with the provisions of the <I>Business Corporations Act</I> (Ontario);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>AND WHEREAS</B>
the parties have entered into this Agreement to provide for the matters referred to in the foregoing recitals and for other matters
relating to the proposed amalgamation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW THEREFORE THIS
AGREEMENT WITNESSETH</B> that in consideration of the above premises and of the covenants, agreements, representations and warranties
hereinafter contained, the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INTERPRETATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.1</B></TD><TD STYLE="text-align: justify"><B>Definitions</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In this Agreement, unless there
is something in the context or subject matter inconsistent therewith, the following defined terms shall have the meanings hereinafter
set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Agency Agreement&rdquo;
</B>means the agency agreement to be entered into among the Agents, Profound and Mira in respect of the Profound Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Agents&rdquo; </B>means
GMP, Cormark Securities Inc., Bloom Burton &amp; Co. and Mackie Research Capital Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Agents&rsquo; Option
Certificates&rdquo; </B>means, collectively, the definitive certificates issued to the Agents representing the Profound Agents&rsquo;
Options or the Resulting Issuer Agents&rsquo; Options, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Agreement&rdquo;, &ldquo;this
Agreement&rdquo;, &ldquo;herein&rdquo;, &ldquo;hereby&rdquo;, &ldquo;hereof&rsquo;, &ldquo;hereunder&rdquo; </B>and similar expressions
mean or refer to this agreement and any amendments hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Amalco&rdquo; </B>means
the amalgamated corporation to be constituted upon completion of the Amalgamation, to be named Profound Medical Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Amalco Shares&rdquo;
</B>means the common shares in the capital of Amalco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Amalgamation&rdquo;
</B>means the amalgamation of Profound and Mira Subco pursuant to Section 174 of the OBCA provided for herein to form Amalco
to be effective at the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Applicable Anti-Corruption
Laws and Regulations&rdquo; </B>has the meaning ascribed thereto in Section 4.2(pp).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Applicable Anti-Money
Laundering Laws&rdquo; </B>has the meaning ascribed thereto in Section 4.2(qq).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Articles of Amalgamation&rdquo;
</B>means the Articles of Amalgamation with respect to the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Assessment&rdquo; </B>has
the meaning ascribed thereto in Subsection 3.2(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Assets and Properties&rdquo;
</B>with respect to any Person means all assets and properties of every kind, nature, character and description (whether real,
personal or mixed, tangible or intangible, choate or inchoate, absolute, accrued, contingent, fixed or otherwise, and, in each
case, wherever situated), including the goodwill related thereto, operated, owned or leased by or in the possession of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;associate&rdquo;
</B>and <B>&ldquo;affiliate&rdquo; </B>have the respective meanings ascribed thereto in the <I>Securities Act</I> (Ontario).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Auditors&rdquo; </B>means
such firm of chartered accountants as a company may have appointed or may from time to time appoint as auditors of such company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;BDC Secured Convertible
Note&rdquo; </B>means the secured convertible note dated January 27, 2015, between Profound and BDC Capital Inc. pursuant to which
BDC Capital Inc. has advanced $1,000,000 to Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Business Day&rdquo;
</B>means any day other than a Saturday or Sunday or a day when banks in the City of Toronto are not generally open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;CDS&rdquo; </B>means
CDS Clearing &amp; Depository Services Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Certificate of Amalgamation&rdquo;
</B>means the certificate of amalgamation for the Amalgamation issued pursuant to Section 178 of the OBCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Clinical Trials&rdquo;
</B>has the meaning ascribed thereto in Section 4.2(yy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Closing&rdquo; </B>means
the completion of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Closing Date&rdquo;
</B>means the date of the Closing, which shall be within three (3) Business Days following the later of the satisfaction or waiver
of all conditions precedent to the Amalgamation or such other date as Profound and Mira may collectively agree, acting reasonably,
and in any event not later than June 12, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;CMS&rdquo; </B>means
the Centers for Medicare and Medicaid Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Confidential Information&rdquo;
</B>means any information concerning a party to this Agreement (the <B>&ldquo;Disclosing Party&rdquo;) </B>or its business, properties
and assets made available to another party or its representatives (the <B>&ldquo;Receiving Party&rdquo;); </B>provided that it
does not include information which (i) is generally available to or known by the public other than as a result of improper disclosure
by the Receiving Party, or (ii) is obtained by the Receiving Party from a source other than the Disclosing Party, provided that
such source was not bound by a duty of confidentiality to the Disclosing Party or another party with respect to such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Consolidation&rdquo;
</B>means a consolidation of the Mira Common Shares on the basis of one (1) post-consolidation Mira Common Share for every 13.6363
pre-consolidation Mira Common Shares, which Consolidation shall occur prior to completion of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Contract&rdquo; </B>means
all agreements, contracts or commitments of any nature, written or oral, including, for greater certainty and without limitation,
leases, purchase agreements, manufacturing, supply and distribution agreements, loan documents and security documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Convertible Notes&rdquo;</B>
means, collectively, the BDC Secured Convertible Note and the Genesys Secured Convertible Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;CPC Policy&rdquo;</B>
means Policy 2.4 of the TSX Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Disclosing Party&rdquo;
</B>has the meaning ascribed thereto in the definition of <B>&ldquo;Confidential Information&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Disclosure Documents&rdquo;
</B>has the meaning ascribed thereto in Subsection 4.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Effective Date&rdquo;
</B>means the effective date of the Amalgamation, which shall be the date of the Certificate of Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Effective Time&rdquo;
</B>means the effective time at which the articles of amalgamation in respect of the Amalgamation are filed on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Employee Plans&rdquo;
</B>has the meaning ascribed thereto in Section 4.2(ff).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Encumbrance&rdquo;
</B>means any charge, mortgage, lien, pledge, claim, restriction, security interest or other encumbrance whether created or arising
by agreement, statute or otherwise pursuant to any applicable law, attaching to property, interests or rights and shall be construed
in the widest possible terms and principles known under the laws applicable to such property, interests or rights and whether or
not they constitute specific or floating charges as those terms are understood under the laws of the Province of Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Environmental Laws&rdquo;
</B>means all applicable laws currently in existence in the United States and Canada (whether federal, state, provincial or municipal)
relating to the protection and preservation of the environment, occupational health and safety, product safety, product liability
or hazardous substances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Environmental Permits&rdquo;
</B>includes all orders, permits, certificates, approvals, consents, registrations and licences issued by any authority of competent
jurisdiction under any Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Escrow Release Conditions&rdquo;
</B>has the meaning ascribed thereto in the Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Escrow Release Date&rdquo;
</B>has the meaning ascribed thereto in the Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;FDA&rdquo; </B>means
the U.S. Food and Drug Administration of the U.S. Department of Health &amp; Human Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Final Exchange Bulletin&rdquo;
</B>means the exchange bulletin which is issued following the Closing and the submission of all documentation and that evidences
final TSX Venture acceptance of the Qualifying Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Final Filing Statement&rdquo;
</B>means the final filing statement of Mira in the form prescribed by the TSX Venture pertaining to the Qualifying Transaction
which shall be filed on SEDAR at least seven (7) Business Days prior to the Closing, unless abridged by the TSX Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Final Offering Memorandum&rdquo;
</B>means the final confidential offering memorandum of Profound, dated April 24, 2015, in respect of the Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Genesys Secured Convertible
Note&rdquo; </B>means the secured convertible note dated January 27 2015, between Profound and Genesys Ventures II L.P., pursuant
to which Genesys Ventures II L.P. has advanced $500,000 to Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;GMP&rdquo; </B>means
GMP Securities L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Governmental Authority&rdquo;
</B>means any governmental authority and includes, without limitation, any national or federal government, province, state, municipality
or other political subdivision of any of the foregoing, any entity or agency exercising executive, legislative, judicial, regulatory
or administrative functions of or pertaining to government and any corporation or other entity owned or controlled (through stock
or capital ownership or otherwise) by any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Government Health Care
Program&rdquo; </B>means any federal, provincial, state or other publicly funded healthcare insurance or reimbursement program,
including but not limited to a federal healthcare program as defined in Section 1128B(f) of the United States federal Social Security
Act and includes the United States Medicare, Medicaid and TRICARE programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Health Care Laws&rdquo;
</B>means any international, federal, state, provincial or local statutes, regulations, directives guidelines, ordinances, orders,
standards, requirements, approvals, or consents, including but not limited to: the United States Federal Food, Drug and Cosmetic
Act and similar foreign health product legislation; any implementing regulations pursuant to any of the foregoing, and all similar
or related international, federal, state provincial or local healthcare statutes, regulations and directives applicable to the
Profound Business, including but not limited to state and provincial laws concerning fee-splitting, kickbacks, corporate practice
of medicine, disclosure of ownership, related party requirements, survey, certification, licensing, civil monetary penalties, self-referrals,
or laws concerning the privacy and/or security of personal health information and breach notification requirements concerning personal
health information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;IFRS&rdquo; </B>means
International Financial Reporting Standards as issued by the International Accounting Standards Board, as applicable in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Indebtedness&rdquo;
</B>of any Person means all obligations of such Person:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">for borrowed money;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">evidenced by notes, bonds, debentures or similar instruments;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">for the deferred purchase price of goods or services (other
than trade payables or accruals incurred in the ordinary course of business);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">under capital and operating leases;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">under &ldquo;vendor take-back&rdquo; financing or deferred
payments in connection with any acquisition; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">which are guarantees of the obligations described in clauses
(a) through (e) above of any other Person if secured by any or all of the Assets and Properties of the guarantor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Intellectual Property&rdquo;
</B>means all of the following which is currently owned by, issued to or licensed to Profound, or other rights of Profound to use
the following: (i) patent rights, issued patents, patent applications, patent disclosures, and registrations, inventions, discoveries,
developments, concepts, ideas, improvements, processes and methods, whether or not such inventions, discoveries, developments,
concepts, ideas, improvements, processes, or methods are patentable or registrable under patent or similar laws anywhere in the
world; (ii) copyrights (including performance rights) to any original works of art or authorship, including source code and graphics,
which are fixed in any medium of expression, including copyright registrations and applications therefor, anywhere in the world,
whether or not registered or registrable; (iii) any and all common law or registered trade-mark rights, trade names, business names,
trade-marks, proposed trade-marks, certification marks, service marks, distinguishing marks and guises, logos, slogans, goodwill,
domain names and any registrations and applications therefor, anywhere in the world, whether or not registered or registrable;
(iv) know-how, show-how, confidential information, trade secrets; (v) any and all industrial design rights, industrial designs,
design patents, industrial design or design patent registrations and applications therefor, anywhere in the world, whether or not
registered or registrable; (vi) any and all integrated circuit topography rights, integrated circuit topographies and integrated
circuit topography applications, anywhere in the world, whether or not registered or registrable, (vii) any reissues, divisions,
continuations, continuations-in-part, renewals, improvements, translations, derivatives, modifications and extensions of any of
the foregoing; (viii) any other industrial, proprietary or intellectual property rights, anywhere in the world; and (ix) proprietary
computer software (including but not limited to data, data bases and documentation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Knight&rdquo; </B>means
Knight Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Knight Loan&rdquo;
</B>means the loan agreement to be entered into between Profound and Knight on the closing of the Profound Private Placement, pursuant
to which Knight will agree to provide Amalco a four-year secured loan bearing interest at an effective annual rate of 15.0% per
annum and in connection with which Profound will grant to Knight a 0.5% royalty on net sales of Profound for the duration of the
loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Knight Share Issuance&rdquo;
</B>means the issuance, for nominal consideration immediately prior to the Closing, by Profound of that number of Profound Common
Shares to Knight as will equal four percent (4%) of the issued and outstanding Resulting Issuer Shares, on a fully-diluted basis,
after giving effect to the Qualifying Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Leased Premises&rdquo;
</B>has the meaning ascribed thereto in Section 4.2(cc).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Letter Agreement&rdquo;
</B>has the meaning ascribed thereto in the first recital of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Material Adverse Change&rdquo;
</B>or <B>&ldquo;Material Adverse Effect&rdquo; </B>with respect to Mira or Profound, as the case may be, means any change (including
a decision to implement such a change made by the board of directors or by senior management), event, violation, inaccuracy, circumstance
or effect that is materially adverse to the business, assets (including intangible assets), liabilities, capitalization, ownership,
financial condition or results of operations of Mira or Profound, as the case may be, on a consolidated basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Material Permits&rdquo;
</B>has the meaning ascribed thereto in Section 4.2(tt).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira&rdquo; </B>means
Mira IV Acquisition Corp., a body corporate incorporated under the OBCA with its head office located in Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Alternative Transaction&rdquo;
</B>has the meaning ascribed thereto in Section 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Alternative Transaction
Agreement&rdquo; </B>has the meaning ascribed thereto in Section 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Business&rdquo;
</B>means the identification and evaluation of businesses and assets with a view to completing a Qualifying Transaction and, having
identified and evaluated such opportunities, to negotiate an acquisition subject to acceptance by the TSX Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Circular&rdquo;
</B>means the management information circular dated November 19, 2014 in respect of the Mira Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Common Shares&rdquo;
</B>means the issued and outstanding common shares in the capital of Mira.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Escrow Agreement&rdquo;
</B>means an escrow agreement dated as of August 12, 2014 among Mira, Equity Financial Trust Company (now operating as TMX Equity
Transfer Services), and certain securityholders of Mira.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Event&rdquo; </B>has
the meaning ascribed thereto in Section 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira IPO Agent Options&rdquo;
</B>means the stock options of Mira currently outstanding to acquire 1,000,000 Mira Common Shares issued to GMP Securities L.P.
in connection with Mira&rsquo;s initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Loan&rdquo; </B>means
the loan agreement entered into between Profound and Mira, pursuant to which Mira will provide Profound a three-month secured loan
in the principal amount of $225,000, bearing interest at an effective annual rate of 15% per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Management Options&rdquo;
</B>means the management stock options of Mira currently outstanding to acquire collectively 3,000,000 Mira Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Material Contract&rdquo;
</B>has the meaning ascribed thereto in Subsection 4.1(t).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Meeting&rdquo;
</B>means the special meeting of holders of Mira Common Shares held on December 22, 2014 approving the Mira Meeting Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Meeting Matters&rdquo;
</B>means the following matters: (i) the election of the directors set out in Subsection 2.3(e); (ii) the appointment of PricewaterhouseCoopers
LLP as the auditor and the authorization of the board of directors of Mira to fix the remuneration thereof; (iii) the approval
of the stock option plan of the Resulting Issuer; (iv) the amendment of the articles of Mira to effect the Consolidation; and (v)
the amendment of the articles of Mira to change its name to &ldquo;Profound Medical Inc.&rdquo; or such other name as the board
of directors of Mira, in its sole discretion, deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Offer&rdquo; </B>has
the meaning ascribed thereto in Section 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Shareholders&rsquo;
Approval&rdquo; </B>means the approval of the Mira Meeting Matters by the holders of Mira Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Subco&rdquo; </B>means
Mira IV Subco Inc., a wholly-owned subsidiary of Mira, incorporated under the OBCA for the sole purpose of effecting the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Mira Termination&rdquo;
</B>has the meaning ascribed thereto in Section 5.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;OBCA&rdquo; </B>means
the <I>Business Corporations Act</I> (Ontario), as from time to time amended or re-enacted and includes any regulations heretofore
or hereafter made pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;OIG&rdquo; </B>means
the United States Department of Health and Human Services Office of Inspector General.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Person&rdquo; </B>shall
be broadly interpreted and shall include any individual, corporation, partnership, joint venture, association, trust or other legal
entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Private Placement Shareholders&rdquo;
</B>means holders of Profound Common Shares that obtained such shares upon the automatic conversion of Profound Subscription Receipts
acquired under the Profound Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Product&rdquo; </B>means
the medical device currently being developed by Profound in the United States, Canada and the European Union, known as the Transurethral
ULtraSound Ablation (TULSA-PRO) device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Product Distribution
Agreement&rdquo; </B>means the product distribution agreement to be entered into by Knight and Profound prior to the Closing pursuant
to which Profound will grant to Knight certain product distribution rights in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound&rdquo; </B>means
Profound Medical Inc., a body corporate incorporated under the OBCA with its registered office located at 3080 Yonge Street, Suite
4040, Toronto, ON M4N 3N1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Agents&rsquo;
Options&rdquo; </B>means the options entitling the Agents to subscribe for that number of Profound Common Shares as is equal to
the following percentages of the total number of Profound Common Shares issued pursuant to the exercise of Profound Subscription
Receipts under the Profound Private Placement, including those Profound Subscription Receipts issued in respect of the Profound
Over-allotment Option: (i) for Profound Common Shares issued to persons or entities on the president&rsquo;s list of Profound,
2%; and (ii) for all other persons or entities, 4%, each such option exercisable for one Profound Common Share for a period of
24 months from the release of the proceeds of the Profound Private Placement at the offering price of the Profound Subscription
Receipts under the Profound Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Alternative
Transaction&rdquo; </B>has the meaning ascribed thereto in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Alternative
Transaction Agreement&rdquo; </B>has the meaning ascribed thereto in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound&rsquo;s Auditors&rdquo;
</B>means PricewaterhouseCoopers LLP or such other firm of chartered accountants as Profound may have appointed or may from time
to time appoint as auditors of Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Business&rdquo;
</B>means the development and commercialization of a unique, minimally invasive treatment for prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Common Shares&rdquo;
</B>means the common shares in the capital of Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Event&rdquo;
</B>has the meaning ascribed thereto in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Financial
Statements&rdquo; </B>means audited financial statements for Profound for the years ended December 31, 2014 and 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Management
Options&rdquo; </B>means (i) options granted to Mr. Shameze Rampertab, in connection with his employment as Chief Financial Officer
of Profound, to purchase that number of Profound Common Shares upon completion of the Profound Private Placement as is equal to
1.00% of the total fully-diluted share capital of Profound after giving effect to the Profound Private Placement and the Knight
Share Issuance and (ii) options granted to Mr. Steven Plymale, in connection with an amended and restated employment agreement,
to purchase that number of Profound Common Shares upon completion of the Profound Private Placement that, when combined with the
Profound Options he holds as at the date of this Agreement, would result in Mr. Plymale holding options to purchase that number
of Profound Common Shares as is equal to 4.45% of the total fully-diluted share capital of Profound after giving effect to the
Profound Private Placement and the Knight Share Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Material Agreements&rdquo;
</B>means, collectively, this Agreement, the Agency Agreement, the Subscription Receipt Indenture, the Subscription Agreements,
the Profound Agents&rsquo; Options, the Resulting Issuer Agents&rsquo; Options, the Agents&rsquo; Option Certificates, the certificates
(if any) representing the Profound Subscription Receipts and the Sunnybrook License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Offer&rdquo;
</B>has the meaning ascribed thereto in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Options&rdquo;
</B>means the 501,250 issued and outstanding options of Profound exercisable into Profound Common Shares, in addition to the Profound
Management Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Over-allotment
Option&rdquo; </B>means an option exercisable by the Agents up to 48 hours prior to the closing of the Profound Private Placement,
to arrange for the purchase of up to an additional 15% of the number of Profound Subscription Receipts sold under the Profound
Private Placement on the same terms as under the Profound Private Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Principals&rdquo;
</B>means BDC Capital Inc. and Genesys Ventures II LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Private Placement&rdquo;
</B>means the brokered private placement by Profound of Profound Subscription Receipts for gross proceeds of up to $25,012,500,
assuming the exercise of the Profound Over-allotment Option in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Shareholder
Approval&rdquo; </B>means the unanimous shareholders resolution of the shareholders of Profound approving, among other things,
the Amalgamation and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Shareholders
Agreement&rdquo; </B>means the amended and restated shareholders agreement of Profound dated May 25, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Subscription
Receipts&rdquo; </B>means the up to 16,675,000 subscription receipts of Profound to be issued in connection with the Profound Private
Placement, each exchangeable into one Profound Common Share, subject to adjustment, without additional consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Termination&rdquo;
</B>has the meaning ascribed thereto in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Purchasers&rdquo; </B>means
the Persons (which may include the Agents) who, as purchasers, acquire the Profound Subscription Receipts by duly completing, executing
and delivering the Subscription Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Qualifying Transaction&rdquo;
</B>has the meaning ascribed thereto under the policies of the TSX Venture Corporate Finance Manual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Receiving Party&rdquo;
</B>has the meaning ascribed thereto in the definition of <B>&ldquo;Confidential Information&rdquo;.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Registrar and Transfer
Agent&rdquo; </B>means Equity Financial Trust Company, and any other Person which may be appointed as registrar and transfer agent
of Mira, as applicable, from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Regulatory Authority&rdquo;
</B>means the Governmental Authority authorized under applicable laws to protect and promote public health through regulation and
supervision of medical products, including, without limitation, the FDA, Health Canada and similar foreign regulatory agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Resulting Issuer&rdquo;
</B>means Mira as it exists upon completion of the Amalgamation to be known as Profound Medical Corp., or such other name determined
by the board of directors of Mira.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Resulting Issuer Agents&rsquo;
Options&rdquo; </B>means the compensation options of the Resulting Issuer that will be outstanding upon completion of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Resulting Issuer Common
Shares&rdquo; </B>means common shares of the Resulting Issuer including those issued upon the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Resulting Issuer Options&rdquo;
</B>means the stock options of the Resulting Issuer that will be outstanding upon completion of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Resulting Issuer Registrar
and Transfer Agent&rdquo; </B>means Equity Financial Trust Company and any other Person which may be appointed as registrar and
transfer agent of the Resulting Issuer from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Resulting Issuer Stock
Option Plan&rdquo; </B>means the stock option plan of the Resulting Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Securities Laws&rdquo;
</B>means all applicable securities laws, the respective regulations made thereunder, together with applicable published fee schedules,
prescribed forms, policy statements, multilateral and national instruments, orders, blanket rulings, notices and other regulatory
instruments of the securities regulatory authorities in applicable jurisdictions, including the rules and published policies of
the TSX Venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;SEDAR&rdquo; </B>means
the System for Electronic Document Analysis and Retrieval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Series A1</B> <B>Preferred
Shares&rdquo; </B>means the first series of preferred shares in the capital of Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Series A2 Preferred
Shares&rdquo; </B>means the second series of preferred shares in the capital of Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Subscription Agreements&rdquo;
</B>means the subscription agreements in the forms agreed upon by the Agents and Profound pursuant to which Purchasers agree to
subscribe for and purchase the Profound Subscription Receipts and shall include, for greater certainty, all schedules and exhibits
thereto.<B>&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Subscription Receipt Indenture&rdquo;
</B>means the subscription receipt indenture to be entered into on the closing date of the Profound Private Placement among Profound,
GMP, on behalf of the Agents, and Equity Financial Trust Company, in its capacity as subscription receipt agent thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Sunnybrook License
Agreement&rdquo; </B>has the meaning ascribed thereto in Section 4.2(q)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Support Agreements&rdquo;
</B>means the support agreements of the Profound Principals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Taxes&rdquo; </B>means
all taxes (including income tax, sales tax, value add tax, capital tax, payroll taxes, employer health tax, workers&rsquo; compensation
payments, property taxes and land transfer taxes), duties, royalties, levies, imposts, assessments, deductions, charges or withholdings
and all liabilities with respect thereto including any penalty and interest payable with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Termination Date&rdquo;
</B>means June 12, 2015 or such other date as the parties may agree upon in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;TSX Venture&rdquo;
</B>means the TSX Venture Exchange Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;United States&rdquo;
</B>means the United States of America, its territories and possessions, any State of the United States and the District of Columbia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;U.S. Investment Company
Act&rdquo; </B>means the United States Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;U.S. Person&rdquo;
</B>means a U.S. person as defined in Rule 902(k) of Regulation S under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;U.S. Private Placement
Accredited Investor&rdquo; </B>means a holder of Profound Common Shares in the United States or that is a U.S. Person that: (i)
obtained such shares upon the automatic conversion of Profound Subscription Receipts that were acquired by such holder as a subscriber
in the Profound Private Placement; and (ii) did not execute and deliver a copy of Appendix II to Schedule C (United States Qualified
Institutional Buyer Acknowledgement, Agreement and Undertaking) to the Profound Private Placement subscription agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;U.S. Private Placement
QIB&rdquo; </B>means a holder of Profound Common Shares in the United States or that is a U.S. Person that: (i) obtained such
shares upon the automatic conversion of Profound Subscription Receipts that were acquired by such holder as a subscriber in the
Profound Private Placement; and (ii) executed and delivered a copy of Appendix II to Schedule C (United States Qualified Institutional
Buyer Acknowledgement, Agreement and Undertaking) to the Profound Private Placement subscription agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;U.S. Securities Act&rdquo;
</B>means the United States Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.2</B></TD><TD STYLE="text-align: justify"><B>Interpretation Not Affected by Headings, etc.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The division of this Agreement into articles,
sections and subsections is for convenience of reference only and shall not affect the construction or interpretation of this Agreement.
The terms &ldquo;this Agreement&rdquo;, &ldquo;hereof&rsquo;, &ldquo;herein&rdquo;, and &ldquo;hereunder&rdquo; and similar expressions
refer to this Agreement and not to any particular article, section or other portion hereof and include any Agreement or instrument
supplementary or ancillary hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.3</B></TD><TD STYLE="text-align: justify"><B>Number, etc.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Words importing the singular number shall
include the plural and vice versa, words importing the use of any gender shall include all genders and words importing persons
shall include firms and corporations and vice versa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.4</B></TD><TD STYLE="text-align: justify"><B>Date for Any Action</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event that any date on which any
action is required to be taken hereunder by any of the parties is not a Business Day such action shall be required to be taken
on the next succeeding day which is a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.5</B></TD><TD STYLE="text-align: justify"><B>Rounding</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In performing the various mathematical
calculations required to be performed hereunder, all numbers shall be rounded to the nearest four (4) decimal places.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.6</B></TD><TD STYLE="text-align: justify"><B>Currency</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All sums of money which are referred to
in this Agreement are expressed in lawful money of Canada, unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.7</B></TD><TD STYLE="text-align: justify"><B>Knowledge</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Where any representation or warranty contained
in this Agreement is expressly qualified by reference to the knowledge of Mira or Profound, as applicable, it shall be deemed to
refer to the actual knowledge after having made due inquiry of the officers of the particular company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.8</B></TD><TD STYLE="text-align: justify"><B>Meanings</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Words and phrases defined in the OBCA shall
have the same meaning herein as in the OBCA, unless otherwise defined herein or the context otherwise requires. Unless otherwise
specifically indicated or the context otherwise requires &ldquo;include&rdquo;, &ldquo;includes&rdquo; and &ldquo;including&rdquo;
shall be deemed to be followed by the words &ldquo;without limitation&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMALGAMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.1</B></TD><TD STYLE="text-align: justify"><B>Amalgamation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On or before the Closing Date, subject
to the terms and conditions of this Agreement and receipt of necessary approvals, Profound, Mira and Mira Subco shall take all
steps required to complete the Amalgamation and, without limitation, to apply for and obtain all consents, orders or approvals
as are necessary or desirable for the implementation of the Amalgamation and the filing of the Articles of Amalgamation with the
registrar pursuant to the OBCA, and Profound shall use all reasonable efforts to obtain the Profound Shareholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.2</B></TD><TD STYLE="text-align: justify"><B>Amalco</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><B>Name. </B>The name of Amalco shall be Profound Medical
Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><B>Registered Office. </B>The registered office of Amalco
shall be situated at 3080 Yonge Street, Suite 4040, Toronto, ON M4N 3N1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><B>Authorized Capital. </B>Amalco shall be authorized to
issue an unlimited number of Amalco Shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><B>Restrictions on Share Transfer. </B>The transfer of
shares of Amalco shall not be subject to any restrictions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify"><B>Number of Directors. </B>The minimum number of directors
of Amalco shall be one and the maximum number of directors of Amalco shall be 10.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify"><B>First Directors. </B>The number of first directors of
Amalco shall be one. The first director of Amalco shall be:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify; border-bottom: Black 1pt solid"><B>Name</B></TD>
    <TD STYLE="width: 4%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1pt solid"><B>Address</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Steven Plymale</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">1 Ripley Avenue, Unit 509</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Toronto, Ontario M6S 4Z6</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify"><B>Officers. </B>The officers of Amalco, until changed
or added to by the board of directors of Amalco, shall be as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: left; border-bottom: Black 1pt solid"><B>Office</B></TD>
    <TD STYLE="width: 4%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1pt solid"><B>Name</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Chief Executive Officer and President</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Steven Plymale</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify; border-bottom: Black 1pt solid"><B>Office</B></TD>
    <TD STYLE="width: 4%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1pt solid"><B>Name</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Chief Financial Officer, Secretary and Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Shameze Rampertab</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vice-President of Quality and Regulatory Affairs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Guruprit Singh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Vice-President of Engineering</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Ronald Kurtz</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify"><B>First Auditors. </B>The Auditors of Amalco shall be
PricewaterhouseCoopers LLP. The Auditors of Amalco shall hold office until the first annual meeting of shareholders of Amalco
following the Amalgamation, or until their successor is appointed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify"><B>Fiscal Year. </B>The fiscal year end of Amalco shall
be December 31.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify"><B>Restrictions on Business. </B>There shall be no restrictions
on the business that Amalco may carry on.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify"><B>By-laws. </B>The by-laws of Amalco shall be the current
by-laws of Profound. A copy of such by-laws may be examined at the current address of Profound set out in Section 6.1 hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.3</B></TD><TD STYLE="text-align: justify"><B>Resulting Issuer</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><B>Name. </B>The name of the Resulting Issuer shall be
Profound Medical Corp.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><B>Registered Office. </B>The registered office of the
Resulting Issuer shall be situated at 3080 Yonge Street, Suite 4040, Toronto, ON M4N 3N1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><B>Authorized Capital. </B>The Resulting Issuer shall be
authorized to issue an unlimited number of Resulting Issuer Common Shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><B>Number of Directors. </B>The minimum number of directors
of the Resulting Issuer shall be three and the maximum number of directors of the Resulting Issuer shall be 11.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify"><B>First Directors. </B>The number of first directors of
the Resulting Issuer shall be 5. Subject to the receipt of all necessary approvals, the first directors of the Resulting Issuer
shall be:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify; border-bottom: Black 1pt solid"><B>Name</B></TD>
    <TD STYLE="width: 4%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1pt solid"><B>Address</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Steven Plymale</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">1 Ripley Avenue, Unit 509</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Toronto, Ontario M6S 4Z6</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Damian Peter Lamb</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">3 Orchard Crest Road</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Toronto, Ontario M6S 4N2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Jean-Fran&ccedil;ois Pariseau</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">1772 Cecile-L.-Dagenais</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Laval, Quebec H3L 2X7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: justify; border-bottom: Black 1pt solid"><B>Name</B></TD>
    <TD STYLE="width: 4%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1pt solid"><B>Address</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">William Edward Curran</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">28 Jean Street </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Rye, New York 10580</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Arun Swarup Menawat</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2412 Eighth Line</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oakville, Ontario L6H 6S9</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The first directors shall hold office until
the first annual meeting of the shareholders of the Resulting Issuer, or until their successors are duly appointed or elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify"><B>Officers. </B>The officers of the Resulting Issuer,
until changed or added to by the board of directors of the Resulting Issuer, shall be as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; text-align: left; border-bottom: Black 1pt solid"><B>Office</B></TD>
    <TD STYLE="width: 4%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: center; border-bottom: Black 1pt solid"><B>Name</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Chief Executive Officer and President</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Steven Plymale</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Chief Financial Officer, Secretary and Treasurer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Shameze Rampertab</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Vice-President of Quality and Regulatory Affairs</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Guruprit Singh</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Vice-President of Engineering</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Ronald Kurtz</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify"><B>First Auditors. </B>The Auditors of the Resulting
Issuer shall be PricewaterhouseCoopers LLP. The Auditors of the Resulting Issuer shall hold office until the first annual meeting
of shareholders of the Resulting Issuer following the Amalgamation or until their successor is appointed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify"><B>Fiscal Year. </B>The fiscal year end of the Resulting
Issuer shall be December 31.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify"><B>Restrictions on Business. </B>There shall be no restrictions
on the business that the Resulting Issuer may carry on.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify"><B>By-laws. </B>The by-laws of the Resulting Issuer shall
be the current by-laws of Mira.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.4</B></TD><TD STYLE="text-align: justify"><B>Effect of Certificate of Amalgamation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon the issuance of the Certificate of
Amalgamation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Amalgamation of Profound and Mira Subco and their continuation
as one corporation becomes irrevocable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Amalco shall possess all the property, rights, privileges
and franchises and interests of each of Profound and Mira Subco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Amalco shall be subject to all liabilities, including civil,
criminal and quasicriminal and all contracts, disabilities and debts of each of Profound and Mira Subco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">a conviction against, or ruling, order or judgment in favour
of or against, either Profound or Mira Subco may be enforced by or against Amalco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Amalco shall be a wholly-owned subsidiary of Mira;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">the aggregate stated capital of the common shares of Amalco
shall become an amount equal to the paid-up capital for purposes of the <I>Income Tax Act</I> (Canada) of the common shares of
Mira Subco immediately prior to the Amalgamation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">the aggregate stated capital of the Resulting Issuer Common
Shares shall be an amount equal to the aggregate paid-up capital for purposes of the <I>Income Tax Act </I>(Canada) immediately
prior to the Amalgamation of (i) the Mira Common Shares and (ii) the Profound Common Shares that are exchanged, or deemed to be
exchanged, for Mira Common Shares on the Amalgamation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.5</B></TD><TD STYLE="text-align: justify"><B>Manner of Conversion of Issued Securities</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon the terms and subject to the conditions
set forth herein, at the time of the Amalgamation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">each outstanding Profound Common Share (except for Profound
Common Shares held by holders that have validly exercised their dissent rights in connection with the Profound Shareholder Approval)
shall be exchanged for one fully paid and non-assessable Resulting Issuer Common Share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">each outstanding share of Mira Subco shall be exchanged
for one fully paid and non-assessable share of Amalco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">subject to receipt of all required regulatory approvals,
each outstanding Profound Option shall be exchanged for a Resulting Issuer Option to purchase the corresponding number of Resulting
Issuer Common Shares on the same terms as those contained in the Profound Option immediately prior to the Amalgamation and each
such Profound Option shall be cancelled. The exercise price for each Resulting Issuer Common Share underlying a Resulting Issuer
Option will be equal to the exercise price per Profound Common Share under the Profound Option in effect immediately prior to
the Amalgamation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">subject to receipt of all required regulatory approvals, each outstanding Profound
                                                                                 Agents&rsquo; Option shall be exchanged for a Resulting Issuer Agents&rsquo; Option to purchase the corresponding number of
                                                                                 Resulting Issuer Common Shares on the same terms as those contained in the Profound Agents&rsquo; Option immediately prior to
                                                                                 the Amalgamation and each such Profound Agents&rsquo; Option shall be cancelled. The exercise price for each Resulting Issuer
                                                                                 Common Share underlying a Resulting Issuer Agents&rsquo; Option will be equal to the exercise price per Profound Common Share
                                                                                 under the Profound Agents&rsquo; Option in effect immediately prior to the Amalgamation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Profound Common Shares held by holders
who have validly exercised their dissent rights in connection with the applicable shareholder resolution to approve the Amalgamation
in accordance with the OBCA will not be exchanged pursuant to this Section 2.5. However, if any such dissenting holder fails to
perfect or effectively withdraws its claim pursuant to the OBCA or forfeits its right to make a claim under the OBCA or if its
rights as a shareholder of Profound are otherwise reinstated, the Profound Common Shares held by such holders shall thereupon be
deemed to have been exchanged as of the time of the Amalgamation in accordance with this Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.6</B></TD><TD STYLE="text-align: justify"><B>Certificates</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At the time of the Amalgamation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the registered holders of Profound Common Shares shall
cease to be holders of Profound Common Shares, and shall be deemed to be registered holders of the Resulting Issuer Common Shares
to which they are entitled in accordance with Section 2.5 hereof, all certificates evidencing Profound Common Shares shall be
null and void and, on or after the Effective Time, subject to the provisions of any escrow requirement, if applicable, and subject
to Section 2.10 hereof, the Resulting Issuer shall provide instructions to the Resulting Issuer Registrar and Transfer Agent to
deliver such certificates or other evidence of ownership representing the number of Resulting Issuer Common Shares to which they
are so entitled and/or register the holders thereof in book-entry only format in CDS&rsquo; name in accordance with the following:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">holders of Profound Common Shares immediately prior to
the Amalgamation (other than Private Placement Shareholders and holders of Profound Common Shares that are either in the United
States or are U.S. Persons) will be issued physical certificates representing the Resulting Issuer Common Shares exchanged therefor;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">holders of Profound Common Shares immediately prior to
the Amalgamation that are either in the United States or U.S. Persons (other than U.S. Private Placement Accredited Investors
and U.S. Private Placement QIBs) will not be entitled to receive delivery of any Resulting Issuer Common Shares unless and until
such holder provides any and all such representations, warranties, covenants or agreements as may be required by the Resulting
Issuer, in its sole discretion, in order to establish the availability of an exemption from the registration requirements of the
U.S. Securities Act and any applicable state securities laws in connection with the distribution of the Resulting Issuer Common
Shares to be exchanged for their Profound Common Shares, and in order to ensure compliance by the Resulting Issuer with the requirements
of the U.S. Investment Company Act, failing which the Company shall appoint an agent to sell the Resulting Issuer Shares of such
a holder on behalf of that holder and that holder shall be entitled to receive an amount of cash representing the proceeds of
the sale of the Resulting Issuer Common Shares, net of expenses of sale; if and to the extent that the Resulting Issuer determines
in its sole discretion that Resulting Issuer Common Shares may otherwise be delivered to any such holder, such holder will be
issued physical certificates representing the Resulting Issuer Common Shares, each bearing such legend or legends with respect
to United States securities laws matters as the Resulting Issuer determines to be necessary or appropriate, in its sole discretion;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">each Private Placement Shareholder that is neither in the
United States nor a U.S. Person and holds Profound Common Shares immediately prior to the Amalgamation will have the Resulting
Issuer Common Shares they are entitled to receive pursuant to this Agreement registered in book-entry only with CDS;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">each Private Placement Shareholder that is a U.S. Private
Placement Accredited Investor and holds Profound Common Shares immediately prior to the Amalgamation will be issued a physical
certificate representing the Resulting Issuer Common Shares they are entitled to receive pursuant to this Agreement bearing the
following legend:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;U.S. SECURITIES ACT&rdquo;).
THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO THE CORPORATION OR
(B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT AND IN COMPLIANCE WITH
APPLICABLE LOCAL LAWS AND REGULATIONS;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">each Private Placement Shareholder that is a U.S. Private
Placement QIB and holds Profound Common Shares immediately prior to the Amalgamation will have the Resulting Issuer Common Shares
they are entitled to receive pursuant to this Agreement registered in book-entry only with CDS;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the registered holders of the Profound Options and Profound Agents&rsquo; Options shall be
                                                                                 deemed to be the registered holders of the Resulting Issuer Options and Resulting Issuer Agents&rsquo; Options, respectively,
                                                                                 to which they are entitled in accordance with Section 2.5 hereof, all certificates and/or agreements evidencing
                                                                                 such securities shall, in accordance with their terms, evidence such securities of the Resulting Issuer and the Resulting
                                                                                 Issuer shall deliver notice to the holders of such options of the foregoing or deliver amended certificates or agreements
                                                                                 evidencing such securities of the Resulting Issuer as required; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">notwithstanding the foregoing, all certificates representing
Profound Common Shares held by persons who have validly exercised their dissent rights in connection with the Profound Shareholder
Approval shall represent only the right to receive fair value of the Profound Common Shares formerly represented by such certificates
in accordance with the OBCA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.7</B></TD><TD STYLE="text-align: justify"><B>Fractional Securities</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No fractional securities of the Resulting
Issuer will be issued. If a securityholder of Profound would otherwise be entitled to a fractional security upon the Amalgamation,
the number of securities of the Resulting Issuer issued to such securityholder shall be rounded down to the next lesser whole number
of such security. In calculating such fractional interests, all securities of the Resulting Issuer, as the case may be, registered
in the name of or beneficially held by a Resulting Issuer securityholder or their nominee shall be aggregated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.8</B></TD><TD STYLE="text-align: justify"><B>Stock Option Plan</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The stock option plan of the Resulting
Issuer shall be substantially in the form approved at the Mira Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.9</B></TD><TD STYLE="text-align: justify"><B>Cancellation of Certain Options</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Immediately prior to the time of the Amalgamation,
Mira shall cancel one-third (1/3) of the Mira Management Options, being 1,000,000 of such Mira Management Options on a pre-Consolidation
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.10</B></TD><TD STYLE="text-align: justify"><B>U.S. Securities Law Compliance</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Notwithstanding anything to the contrary
in this Agreement, no Resulting Issuer Common Shares, Resulting Issuer Options or Resulting Issuer Agents&rsquo; Options shall
be delivered to any person in the United States or to any U.S. Person if the Resulting Issuer determines, in its sole discretion,
that doing so may result in any contravention of the U.S. Securities Act or any applicable state securities laws, or the U.S. Investment
Company Act, and the Resulting Issuer may instead, in the case of Resulting Issuer Shares, appoint an agent to sell the Resulting
Issuer Shares of such person on behalf of that person and deliver an amount of cash representing the proceeds of the sale of such
Resulting Issuer Shares, net of expenses of sale, or, in the case of Resulting Issuer Options or Resulting Issuer Agents&rsquo;
Options, deliver an amount of cash representing the fair market value of the Resulting Issuer Options or Resulting Issuer Agents&rsquo;
Options, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.1</B></TD><TD STYLE="text-align: justify"><B>Covenants of Mira</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mira covenants and agrees with Profound
from the date of execution hereof to and including the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">not to, directly or indirectly, solicit, initiate, knowingly
encourage, co-operate with or facilitate (including by way of furnishing any non-public information or entering into any form
of agreement, arrangement or understanding) the submission, initiation or continuation of any oral or written inquiries or proposals
or expressions of interest regarding, constituting or that may reasonably be expected to lead to any activity, arrangement or
transaction or propose any activities or solicitations in opposition to or in competition with the Amalgamation, and without limiting
the generality of the foregoing, not to induce or attempt to induce any other Person to initiate any shareholder proposal or &ldquo;take-over
bid,&rdquo; exempt or otherwise, within the meaning of the <I>Securities Act </I>(Ontario), for securities of Mira, nor to undertake
any transaction or negotiate any transaction which would be or potentially could be in conflict with the Amalgamation, including
allowing access to any third party (other than its representatives) to conduct due diligence, nor to permit any of its officers
or directors to do so, except as required by statutory obligations. In the event Mira or any of its affiliates, including any
of their officers or directors, receives any form of offer or inquiry in respect of any of the foregoing, Mira shall forthwith
(in any event within one Business Day following receipt) notify Profound of such offer or inquiry and provide Profound with such
details as it may request;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to co-operate fully with Profound and to use all reasonable
commercial efforts to assist Profound in its efforts to complete the Amalgamation, unless such co-operation and/or efforts would
subject Mira to liability or would be in breach of applicable statutory or regulatory requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">to operate its business in a prudent and business-like
manner in the ordinary course and in a manner consistent with past practice;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">not to, without Profound&rsquo;s prior written consent
(such consent not to be unreasonably withheld, conditioned or delayed):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">issue any debt, equity or other securities, except the
issuance of Mira Common Shares (or options to acquire Mira Common Shares) pursuant to the Amalgamation or pursuant to any securities
exercisable to acquire Mira Common Shares outstanding as of the date hereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">borrow money or incur any indebtedness for money borrowed;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">make any capital expenditures;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">make loans, advances, or any other payments out of the
ordinary course, other than the Mira Loan and payment of professional fees in connection with or ancillary to the Amalgamation,
not to exceed $250,000, which amount excludes professional fees in connection with annual shareholder meeting requirements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">declare or pay any dividends or distribute any of Mira&rsquo;s
properties or assets to shareholders or otherwise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">alter or amend Mira&rsquo;s articles or by-laws in any
manner which may adversely affect the success of the Amalgamation, except as required to give effect to the matters contemplated
herein; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">except as otherwise permitted or contemplated herein, enter
into any transaction or material Contract which is not in the ordinary course of business or engage in any business enterprise
or activity materially different from that carried on by Mira as of the date hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.2</B></TD><TD STYLE="text-align: justify"><B>Further Covenants of Mira</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mira covenants and agrees with Profound
that Mira will from the date of execution hereof to and including the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to obtain all necessary
consents, assignments or waivers from third parties and amendments or terminations to any instrument or agreement and take such
other measures as may be necessary to fulfil its obligations under and to carry out the transactions contemplated by this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">make necessary filings and applications under applicable
federal and provincial laws and regulations required on the part of it in connection with the transactions contemplated herein,
and take all reasonable action necessary to be in compliance with such laws and regulations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to conduct its
affairs so that all of its representations and warranties contained herein shall be true and correct on and as of the Effective
Date as if made on the Effective Date, except to the extent that such representations and warranties require modification to give
effect to the transactions contemplated herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">immediately notify Profound of any legal or governmental actions, suits, judgments,
                                                                                 investigations, injunction, complaint, motion, regulatory investigation, regulatory proceeding or similar proceeding by any
                                                                                 Person, Governmental Authority or other regulatory body, whether actual or threatened, with respect to the Amalgamation or
                                                                                 which could otherwise delay or impede the transactions contemplated hereby or would result in a Material Adverse Effect; </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">                                                                                                                                                                                                                                                                                                                                                                                                                  <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">(e)</TD><TD STYLE="text-align: justify">notify Profound immediately upon becoming aware that any of the representations and warranties of Mira contained herein
                                                                                 are no longer true and correct in any material respect;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">immediately upon
                                         receipt of any written audit inquiry, assessment, reassessment, confirmation or variation
                                         of an assessment, indication that an assessment is being considered, request for filing
                                         of a waiver or extension of time or any other notice in writing relating to Taxes (an
                                         &ldquo;<B>Assessment</B>&rdquo;) of Mira, deliver to Profound a copy thereof together
                                         with a statement setting out, to the extent then determinable, an estimate of the obligations,
                                         if any, of Mira on the assumption that such Assessment is valid and binding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to cause each of
the conditions precedent set forth in Section 5.1 hereof to be complied with;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">effect the Consolidation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">subject to the satisfaction of the conditions in Section
5.2 hereof thereafter cause Mira Subco to file together with Profound with the registrar the Articles of Amalgamation and such
other documents as may be required to give effect to the Amalgamation on or before the Termination Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.3</B></TD><TD STYLE="text-align: justify"><B>Covenants of Profound</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Profound covenants and agrees with Mira
from the date of execution hereof to and including the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">not to, directly or indirectly, solicit, initiate, knowingly
encourage, co-operate with or facilitate (including by way of furnishing any non-public information or entering into any form
of agreement, arrangement or understanding) the submission, initiation or continuation of any oral or written inquiries or proposals
or expressions of interest regarding, constituting or that may reasonably be expected to lead to any activity, arrangement or
transaction or propose any activities or solicitations in opposition to or in competition with the Amalgamation, and without limiting
the generality of the foregoing, not to induce or attempt to induce any other Person to initiate any shareholder proposal or &ldquo;take-over
bid,&rdquo; exempt or otherwise, within the meaning of the <I>Securities Act </I>(Ontario) for securities or assets of Profound,
nor to undertake any transaction or negotiate any transaction which would be or potentially could be in conflict with the Amalgamation,
including allowing access to any third party (other than its representatives) to conduct due diligence, nor to permit any of its
officers or directors to do so, except as required by statutory obligations or in respect of which the board of directors of Profound
determines, in its good faith judgement, after receiving advice from its legal advisors, that failure to recommend such alternative
transaction to its shareholders would be a breach of its fiduciary duties under applicable law. In the event Profound or any of
its affiliates, including any of their officers or directors, receives any form of offer or inquiry in respect of any of the foregoing,
Profound shall forthwith (in any event within one Business Day following receipt) notify Mira of such offer or inquiry and provide
Mira with such details as it may request;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to co-operate fully with Mira and to use all reasonable
commercial efforts to assist Mira in its efforts to complete the Amalgamation unless such co-operation and efforts would subject
Profound to liability or would be in breach of applicable statutory or regulatory requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">to operate its business in a prudent and business-like
manner in the ordinary course and in a manner consistent with past practice;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">that Profound shall not, without Mira&rsquo;s prior written
consent (such consent not to be unreasonably withheld, conditioned or delayed):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">issue any equity or convertible debt securities, except
in connection with the Knight Share Issuance, the Profound Private Placement or the issuance of Profound Common Shares pursuant
to any securities exercisable to acquire common shares of Profound (including the Profound Subscription Receipts, Profound Agents&rsquo;
Options, and Profound Options (including without limitation, the Profound Management Options)) outstanding as of the date hereof
or in connection with any short-term convertible note bridge financing (not to exceed $5 million), from shareholders of Profound
prior to the Profound Private Placement (including, for greater certainty, the Convertible Notes), which notes are convertible
into securities issuable in the Profound Private Placement or into Profound Common Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">make loans, advances, or any other payments, excluding
salaries and bonuses at current rates or routine advances to employees of Profound for expenses incurred in the ordinary course
or as contemplated pursuant to or in conjunction with the Amalgamation; and excluding the Knight Loan and the Mira Loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">declare or pay any dividends or distribute any properties
or assets of Profound to shareholders or otherwise dispose of any of such properties or assets;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">alter or amend the articles or by-laws of Profound in any
manner which may adversely affect the success of the Amalgamation, except as required to give effect to the matters contemplated
herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">except as otherwise permitted or contemplated herein, enter
into any transaction or material Contract which is not in the ordinary course of business or engage in any business enterprise
or activity materially different from that carried on by Profound as at the date hereof; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">make capital expenditures, other than in the ordinary course
of business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.4</B></TD><TD STYLE="text-align: justify"><B>Further Covenants of Profound</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Profound covenants and agrees with Mira
that it will from the date of execution hereof to and including the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to obtain all necessary
consents, assignments or waivers from third parties and amendments or terminations to any instrument or agreement, to provide
all notices required in connection with the Amalgamation and take such other measures as may be necessary to fulfil its obligations
under and to carry out the transactions contemplated by this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to complete the
Profound Private Placement prior to the Effective Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">circulate to its shareholders materials required in connection
with the Profound Shareholder Approval in accordance with its constating documents and applicable laws as soon as reasonably practicable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">use its commercially reasonable efforts to have the Profound
Shareholder Approval approved by the required percentage of shareholders of Profound;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">advise Mira once it receives the Profound Shareholder Approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">promptly advise Mira of any written notice of dissent or
purported exercise by any Profound shareholder of dissent rights under the OBCA received by Profound in relation to the Amalgamation
and any withdrawal of dissent rights received by Profound and, subject to applicable law, any written communications sent by or
on behalf of Profound to any Profound shareholder exercising or purporting to exercise dissent rights in relation to the Amalgamation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">make necessary filings and applications under applicable
federal, state and provincial laws and regulations required on the part of Profound in connection with the transactions contemplated
herein, and take all reasonable action necessary to be in compliance with such laws and regulations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to conduct its
affairs so that Profound&rsquo;s representations and warranties contained herein shall be true and correct on and as of the Effective
Date as if made on the Effective Date, except to the extent that such representations and warranties require modification to give
effect to the transactions contemplated herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">immediately notify Mira of any legal or governmental actions,
suits, judgments, investigations, injunction, complaint, motion, regulatory investigation, regulatory proceeding or similar proceeding
by any Person, Governmental Authority or other regulatory body, whether actual or threatened, with respect to the Amalgamation
or which could otherwise delay or impede the transactions contemplated hereby or result in a Material Adverse Effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">notify Mira immediately upon becoming aware that any of
the representations and warranties of Profound contained herein are no longer true and correct in any material respect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">immediately upon receipt of any Assessment relating to
Profound, deliver to Mira a copy thereof together with a statement setting out, to the extent then determinable, an estimate of
the obligations, if any, of Profound on the assumption that such Assessment is valid and binding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">use all commercially reasonable efforts to cause each of
the conditions precedent set forth in Section 5.2 hereof to be complied with; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">subject to the satisfaction of the conditions precedent
in Section 5.1 hereof thereafter together with Mira Subco file with the registrar the Articles of Amalgamation and such other
documents as may be required to give effect to the Amalgamation on or before the Termination Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.5</B></TD><TD STYLE="text-align: justify"><B>Profound Shareholder Approval</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Promptly after the execution of this Agreement, Profound
shall prepare and complete the Profound Shareholder Approval, together with any other documents required by the OBCA and other
applicable laws in connection with the Amalgamation, and Profound shall cause the Profound Shareholder Approval to be sent to
each shareholder of Profound and other Persons as required by its constating documents and applicable laws, as soon as is practicable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Profound shall furnish to Mira all such information concerning
Profound, as may be reasonably required by Mira in the preparation of the Final Filing Statement and other documents related thereto,
and Profound shall ensure that no such information provided by Profound for inclusion in the Final Filing Statement shall contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein in order to make any information
so furnished by Profound not misleading in light of the circumstances in which it is disclosed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Profound shall indemnify and save harmless Mira and Mira
Subco and their respective directors, officers, employees, agents, advisors and representatives from and against any and all respective
liabilities, claims, demands, losses, costs, damages and expenses to which Mira or Mira Subco or their respective directors, officers,
employees, agents, advisors or representatives may be subject or may suffer, in any way caused by, or arising, directly or indirectly,
from or in consequence of:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">any misrepresentation or alleged misrepresentation in any
information included in the Final Filing Statement that is provided by Profound for inclusion therein; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">any order made, or any inquiry, investigation or proceeding
by any securities regulatory authority or other Governmental Authority, to the extent based on any misrepresentation or any alleged
misrepresentation in any information related to Profound and provided for inclusion in the Final Filing Statement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Profound shall promptly notify Mira if, at any time before
the Closing, the Final Filing Statement contains an untrue statement of a material fact or omits to state a material fact required
to be stated therein or necessary to make the statements contained therein not misleading in light of the circumstances in which
they are made, or that otherwise requires an amendment or supplement to the Final Filing Statement and the parties shall co-operate
in the preparation of any amendment or supplement as required or as appropriate. Mira shall, subject to compliance by Profound
with this Subsection 3.5(d), and, if required by the TSX Venture or applicable laws, file any amendment or supplement to the Final
Filing Statement with the applicable securities regulatory authority and as otherwise required.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 4 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.1</B></TD><TD STYLE="text-align: justify"><B>Representations and Warranties of Mira</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mira represents and warrants to and in
favour of Profound as follows, and acknowledges that Profound is relying upon such representations and warranties in connection
with the completion of the transactions contemplated herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Each of Mira and Mira Subco is a corporation incorporated
and validly existing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and corporate
authority and is duly qualified and holds all material permits, licences, registrations, qualifications, consents and authorizations
necessary or required to carry on the Mira Business as now conducted and to own, lease or operate its Assets and Properties and
neither Mira nor, to the knowledge of Mira, any other Person, has taken any steps or proceedings, voluntary or otherwise, requiring
or authorizing Mira&rsquo;s dissolution or winding up of Mira or Mira Subco, and each of Mira and Mira Subco has all requisite
corporate power and corporate authority to enter into this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The authorized capital of Mira consists of an unlimited
number of Mira Common Shares, of which 30,000,000 Mira Common Shares are issued and outstanding as at the date hereof as fully
paid and non-assessable shares in the capital of Mira. Mira also has the Mira Management Options and the Mira IPO Agent Options
outstanding. Immediately prior to the Effective Time, Mira shall cancel 1,000,000 of the Mira Management Options (on a pre-Consolidation
basis).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Other than Mira Subco, Mira has no direct or indirect subsidiaries
nor any investment in any Person or any agreement, option or commitment to acquire any such investment. All of the issued and
outstanding securities of Mira Subco (being one common share of Mira Subco) are held by Mira. Mira Subco is not a party to any
contract and has nominal assets and no liabilities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Mira became a &ldquo;reporting issuer&rdquo; (as that term
is defined under applicable Securities Laws in each of the provinces of Ontario, Alberta and British Columbia) on August 13, 2014,
is a reporting issuer as at the date hereof, and is not in default of the requirements of the applicable Securities Laws in such
jurisdictions in any material respect as at the date hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">As at November 17, 2014, Mira had at least 200 shareholders
each holding a Board Lot (as such term is defined in TSX Venture Policy 1.1 - <I>Interpretation).</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">Mira has filed all material documents and information required
to be filed by it, whether pursuant to applicable Securities Laws or otherwise, with the applicable securities commissions (the
<B>&ldquo;Disclosure Documents&rdquo;), </B>except where non-compliance has not had, and would not reasonably be expected to
have, a Material Adverse Effect, and Mira does not have any confidential filings with any securities authorities. As of the time
the Disclosure Documents were filed with the applicable securities regulators and on SEDAR (System for Electronic Document Analysis
and Retrieval) (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing):
(i) each of the Disclosure Documents complied in all material respects with the requirements of the applicable Securities Laws
in the jurisdictions they were filed; and (ii) none of the Disclosure Documents contained any untrue statement of a material fact
regarding Mira or omitted to state a material fact regarding Mira required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">Mira has been conducting the Mira Business in compliance
in all material respects with all applicable laws and regulations of each jurisdiction in which it carries on the Mira Business
and has not received a notice of material non-compliance, and, to the knowledge of Mira, there are no facts that would give rise
to a notice of material non-compliance with any such laws and regulations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">No consent, approval, order or authorization of, or registration,
declaration or filing with, any third party or Governmental Authority is required by or with respect to Mira or Mira Subco in
connection with the execution and delivery of this Agreement by Mira or Mira Subco, the performance of their obligations hereunder
or the consummation by Mira or Mira Subco of the transactions contemplated hereby other than: (i) the approval of the Amalgamation
as Mira&rsquo;s Qualifying Transaction by the TSX Venture and the listing of the Resulting Issuer Common Shares on the TSX Venture;
(ii) the filing of Articles of Amendment to effect the applicable Mira Meeting Matters; (iii) the filing of the Articles of Amalgamation
under the OBCA and the issuance of a certificate in respect thereof; (iv) such registrations and other actions required under
applicable Securities Laws as are contemplated by this Agreement and registrations and applications required as a result of the
formation of a new corporation on the Amalgamation; and (v) any filings with the registrar under the OBCA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Each of the execution and delivery of this Agreement, the performance by each of Mira and
                                                                                 Mira Subco of its obligations hereunder, the issue of the Resulting Issuer Common Shares and the consummation of the
                                                                                 transactions contemplated in this Agreement, including the Amalgamation, do not and will not conflict with or result in a
                                                                                 breach or violation of any of the terms or provisions of, or constitute a default under, (whether after notice or lapse of
                                                                                 time or both), (i) any law, statute, rule or regulation applicable to Mira or Mira Subco including applicable
                                                                                 Securities Laws; (ii) the constating documents, by-laws or resolutions of Mira or Mira Subco, which are in effect as at the
                                                                                 date hereof; (iii) any mortgage, note, indenture, contract, agreement, joint venture, partnership, instrument, lease or other
                                                                                 document to which Mira or Mira Subco is a party or by which it is bound; or (iv) any judgment, decree or order binding upon
                                                                                 Mira or Mira Subco or either&rsquo;s Assets and Properties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">This Agreement has been duly authorized and executed by
Mira and Mira Subco and constitutes a valid and binding obligation of Mira and Mira Subco and shall be enforceable against each
of Mira and Mira Subco in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium and other laws relating to or affecting the rights of creditors generally and except as limited by the application
of equitable principals when equitable remedies are sought, and by the fact that rights to indemnity, contribution and waiver,
and the ability to sever unenforceable terms, may be limited by applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">Other than this Agreement, neither Mira nor Mira Subco
is currently party to any agreement in respect of: (i) the purchase of any material property or assets or any interest therein
or the sale, transfer or other disposition of any material property or assets or any interest therein currently owned, directly
or indirectly, by Mira or Mira Subco whether by asset sale, transfer of shares or otherwise; or (ii) the change of control of
Mira or Mira Subco (whether by sale or transfer of shares or otherwise).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">The audited financial statements of Mira from the period
from the date of incorporation (July 16, 2014) to December 31, 2014 have been prepared in accordance with IFRS and present fairly,
in all material respects, the financial position (including the assets and liabilities, whether absolute, contingent or otherwise
as required by IFRS) of Mira as at such date and the results of its operations and its cash flows for the period then ended and
contain and reflect adequate provisions for all reasonably anticipated liabilities, expenses and losses of Mira in accordance
with IFRS and there has been no change in accounting policies or practices of Mira since December 31, 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">Mira is a taxable Canadian corporation and all Taxes due
and payable or required to be collected or withheld and remitted by Mira have been paid, collected or withheld and remitted as
applicable, except for where the failure to pay such Taxes would not have a Material Adverse Effect. Except to the extent that
failure to do so would not have a Material Adverse Effect, all tax returns, declarations, remittances and filings required to
be filed by Mira have been filed with all appropriate Governmental Authorities and all such returns, declarations, remittances
and filings are complete and accurate and no material fact or facts have been omitted therefrom which would make any of them misleading.
To the knowledge of Mira, no examination of any tax return of Mira is currently in progress by any Governmental Authority and
there are no issues or disputes outstanding with any Governmental Authority respecting any Taxes that have been paid, or may be
payable, by Mira. There are no agreements, waivers or other arrangements with any taxation authority providing for an extension
of time for any assessment or reassessment of Taxes with respect to Mira.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(n)</TD><TD STYLE="text-align: justify">Mira has established on its books and records reserves
that are adequate for the payment of all material Taxes not yet due and payable and there are no liens for Taxes on the assets
of Mira that are material, and there are no audits pending of the tax returns of Mira (whether federal, state, provincial, local
or foreign) and there are no claims which have been asserted relating to any such tax returns, which audits and claims, if determined
adversely, would result in the assertion by any governmental agency of any deficiency that would result in a Material Adverse
Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(o)</TD><TD STYLE="text-align: justify">Mira&rsquo;s Auditors are independent public accountants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(p)</TD><TD STYLE="text-align: justify">No holder of outstanding shares in the capital of Mira
is entitled to any pre-emptive or any similar rights to subscribe for any Mira Common Shares or other securities of Mira and,
other than pursuant to the Mira Management Options, Mira IPO Agent Options and this Agreement, there are no rights to acquire,
or instruments convertible into or exchangeable for, any shares in the capital of Mira or Mira Subco.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(q)</TD><TD STYLE="text-align: justify">No third party has any ownership right, title, interest
in, claim in, lien against or any other right to the Assets and Properties purported to be owned by Mira or Mira Subco.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(r)</TD><TD STYLE="text-align: justify">No legal or governmental actions, suits, judgments, investigations
or proceedings are pending to which Mira or Mira Subco, or to the knowledge of Mira, the directors, officers or employees of Mira
are a party or to which the Assets and Properties of Mira or Mira Subco are subject that would result in&rsquo; a Material Adverse
Effect and, to the knowledge of Mira, no such proceedings have been threatened against or are pending with respect to Mira or
Mira Subco, or with respect to its Assets and Properties and neither Mira nor Mira Subco is subject to any judgment, order, writ,
injunction, decree or award of any Governmental Authority, which, either individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(s)</TD><TD STYLE="text-align: justify">Neither Mira nor Mira Subco is in violation of its constating
documents or in default in the performance or observance of any material obligation, agreement, covenant or condition contained
in any Contract to which it is a party or by which it or its property may be bound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(t)</TD><TD STYLE="text-align: justify">Mira is not party to any material Contract, written or
oral, other than:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a registrar and transfer agency and disbursing agent agreement
dated as of August 12, 2014 between Mira and Equity Financial Trust Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">an agency agreement dated as of August 12, 2014 between
Mira and Richardson GMP Limited in connection with the initial public offering of Mira; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">the Mira Escrow Agreement,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(collectively, the &ldquo;<B>Mira
Material Contracts</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(u)</TD><TD STYLE="text-align: justify">All Mira Material Contracts are in good standing in all
material respects and in full force and effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">Neither Mira nor, to the knowledge of Mira, any other party
thereto is in material default or breach of any Mira Material Contract and there exists no condition, event or act which, with
the giving of notice or lapse of time or both, would constitute a material default or breach under any Mira Material Contract
which would give rise to a right of termination on the part of any other party to a Mira Material Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(w)</TD><TD STYLE="text-align: justify">Except for the trading halt imposed by the TSX Venture
on November 5, 2014 following disclosure by Mira of the Letter Agreement, no order, ruling or determination having the effect
of suspending the sale or ceasing the trading in any securities of Mira (including the Mira Common Shares) has been issued by
any regulatory authority and is continuing in effect and no proceedings for that purpose have been instituted or, to the knowledge
of Mira, are pending, contemplated or threatened by any regulatory authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(x)</TD><TD STYLE="text-align: justify">Mira is not party to any agreement, nor, to the knowledge
of Mira, is there any shareholders agreement or other Contract which in any manner affects the voting control of any of the securities
of Mira.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(y)</TD><TD STYLE="text-align: justify">There is no agreement, plan or practice of Mira relating
to the payment of any management, consulting, service or other fee or any bonus, pensions, share of profits or retirement allowance,
insurance, health or other employee benefit other than in the ordinary course of business or in respect of professional service
fees.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(z)</TD><TD STYLE="text-align: justify">Mira has no, and since incorporation has not had any, employees.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(aa)</TD><TD STYLE="text-align: justify">Except for the Mira Management Options, Mira IPO Agent
Options and the stock option plan of the Resulting Issuer approved by the shareholders of Mira at the Mira Meeting, Mira does
not have any plan for retirement, bonus, stock purchase, profit sharing, stock option, deferred compensation, severance or termination
pay, insurance, medical, hospital, dental, vision care, drug, sick leave, disability, salary continuation, legal benefits, unemployment
benefits, vacation, incentive or otherwise contributed to, or required to be contributed to, by Mira for the benefit of any current
or former director, officer, employee or consultant of Mira, each of which has been maintained in all material respects with its
terms and with the requirements prescribed by any and all applicable statutes, orders, rules and regulations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(bb)</TD><TD STYLE="text-align: justify">None of the directors or officers of Mira has any material
interest, direct or indirect, in any material transaction or any proposed material transaction with Mira that materially affects,
is material to or will materially affect Mira. Mira is not indebted to: (i) any director, officer or shareholder of Mira; (ii)
any individual related to any of the foregoing by blood, marriage or adoption; or (iii) any corporation controlled, directly or
indirectly, by any one or more of those Persons referred to in this Subsection 4.1(bb). None of those Persons referred to in this
Subsection 4.1(bb) is indebted to Mira. Mira is not currently a party to any material Contract, agreement or understanding with
any officer, director, employee, shareholder or any other Person not dealing at arm&rsquo;s length with Mira.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(cc)</TD><TD STYLE="text-align: justify">Mira has no insurance policies in place.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(dd)</TD><TD STYLE="text-align: justify">The minute books and records of Mira made available to
counsel for Profound in connection with the due diligence investigation of Mira for the period from the date of incorporation
to the date hereof are all of the minute books of Mira and contain copies of all material proceedings (or certified copies thereof)
of the shareholders, the directors and all committees of directors of Mira to the date hereof and there have been no other meetings,
resolutions or proceedings of the shareholders, directors or any committees of the directors of Mira to the date hereof not reflected
in such minute books.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ee)</TD><TD STYLE="text-align: justify">There is no Person acting at the request or on behalf of
Mira that is entitled to any brokerage or finder&rsquo;s fee or other compensation in connection with the transactions contemplated
by this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.2</B></TD><TD STYLE="text-align: justify"><B>Representations and Warranties of Profound</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Profound represents and warrants to and
in favour of Mira and Mira Subco as follows, and acknowledges that Mira and Mira Subco are relying upon such representations and
warranties in connection with the completion of the transactions contemplated herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Profound is a corporation incorporated and validly existing
under the laws of the Province of Ontario and has all requisite corporate power and corporate authority and is duly qualified
and holds all permits, licences, registrations, qualifications, consents and authorizations necessary or required to carry on
the Profound Business as now conducted in each of the jurisdictions it carries on business and to own, lease or operate its Assets
and Properties and neither Profound nor, to the knowledge of Profound, any other Person, has taken any steps or proceedings, voluntary
or otherwise, requiring or authorizing Profound&rsquo;s dissolution or winding up, and Profound has all requisite corporate power
and corporate authority to enter into each of the Profound Material Agreements and to carry out its obligations hereunder and
thereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Profound has no direct or indirect subsidiaries nor any
investment in any Person or any agreement, option or commitment to acquire any such investment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Profound has been conducting the Profound Business in compliance
in all respects with all applicable laws, rules, regulations, orders and directions of Governmental Authorities of each jurisdiction
in which it carries on the Profound Business and has not received a notice of material noncompliance, and, to the knowledge of
Profound, there are no facts that would give rise to a notice of material non-compliance with any such laws, rules, regulations,
orders and directions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">No consent, approval, order or authorization of, or registration,
declaration or filing with, any third party or Governmental Authority is required by or with respect to Profound in connection
with the execution and delivery of this Agreement by Profound, the performance of its obligations hereunder or the consummation
by Profound of the transactions contemplated hereby other than the approvals set out in Schedule 4.2(d).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">The execution and delivery of this Agreement, the performance
by Profound of its obligations hereunder, and the consummation of the transactions contemplated in this Agreement do not and will
not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (whether
after notice or lapse of time or both), (i) any statute, rule or regulation applicable to Profound including Securities Laws;
(ii) the constating documents, by-laws or resolutions of Profound which are in effect at the date hereof; (iii) any mortgage,
note, indenture, contract, agreement, joint venture, partnership, instrument, lease or other document to which Profound is a party
or by which it is bound; or (iv) any judgment, decree or order binding Profound of its Assets and Properties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">This Agreement has been duly authorized and executed by
Profound and constitutes a valid and binding obligation of Profound and is enforceable against Profound in accordance with its
terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium and other laws relating
to or affecting the rights of creditors generally and except as limited by the application of equitable principals when equitable
remedies are sought, and by the fact that rights to indemnity, contribution and waiver, and the ability to sever unenforceable
terms, may be limited by applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">Other than this Agreement and as stated in this Section
4.2(g), Profound is not currently party to any agreement in respect of: (A) the purchase of any material Assets and Properties
or any interest therein or the sale, transfer or other disposition of any material Assets and Properties or any interest therein
currently owned, directly or indirectly, by Profound whether by asset sale, transfer of shares or otherwise; or (B) the change
of control of Profound (whether by sale or transfer of shares or sale of all or substantially all of the Assets and Properties
of Profound or otherwise). Profound expects to enter into the Profound Distribution Agreement at or prior to Closing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">The Profound Financial Statements have been prepared in
accordance with IFRS consistently applied throughout the periods referred to therein and present fairly, in all material respects,
the financial position (including the assets and liabilities, whether absolute, contingent or otherwise as required by IFRS) of
Profound as at such dates and the results of its operations and its cash flows for the periods then ended and contain and reflect
adequate provisions or allowance for all reasonably anticipated liabilities, expenses and losses of Profound in accordance with
IFRS and there has been no change in accounting policies or practices of Profound since incorporation. Except as set out in the
Profound Financial Statements, and other than the Convertible Notes, Profound does not have any outstanding indebtedness or any
liabilities or obligations including any unfunded obligation under any employee plan, whether accrued, absolute, contingent or
otherwise as of the date of the applicable financial statements. Profound expects to enter into the Mira Loan at or prior to the
closing of the Profound Private Placement and the Knight Loan at or prior to the Closing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">All Taxes due and payable or required to be collected or
withheld and remitted, by Profound have been paid, collected or withheld and remitted as applicable. All tax returns, declarations,
remittances and filings required to be filed by Profound have been filed with all appropriate Governmental Authorities and all
such returns, declarations, remittances and filings are complete and accurate and no material feet or facts have been omitted
therefrom which would make any of them misleading. To the knowledge of Profound, no examination of any tax return of Profound
is currently in progress and there are no issues or disputes outstanding with any Governmental Authority respecting any taxes
that have been paid, or may be payable, by Profound. There are no agreements, waivers or other arrangements with any taxation
authority providing for an extension of time for any assessment or reassessment of taxes with respect to Profound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">Profound has established on its books and records reserves
that are adequate for the payment of all Taxes not yet due and payable and there are no liens for Taxes on the Assets and Properties
of Profound (other than liens for Taxes that are not yet due and payable), and there are no audits pending of the tax returns
of Profound (whether federal, state, provincial, local or foreign) and there are no claims which have been asserted relating to
any such tax returns, which audits and claims, if determined adversely, would result in the assertion by any governmental agency
of any material deficiency.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">Profound maintains a system of internal accounting controls
sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&rsquo;s general or
specific authorization; and (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with IFRS and to maintain accountability for assets.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">Profound&rsquo;s Auditors who audited the audited consolidated
financial statements of Profound for the financial year ended December 31, 2014 are independent public accountants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">No Person has any agreement, option, right or privilege
(whether pre-emptive, contractual or otherwise) capable of becoming an agreement for the purchase, acquisition, subscription for
or issue of any of the unissued Profound Common Shares or other securities of Profound and, other than the (i) the Profound Subscription
Receipts; (ii) options to purchase 1,268,312 Profound Common Shares; (iii) 2,500,000 Series A1 Preferred Shares; (iv) 10,812,500
Series A2 Preferred Shares; (v) the Convertible Notes; (vi) the Profound Management Options; and (vii) the Knight Share Issuance;
and except for pre-emptive rights and rights of first refusal as provided for in the Profound Shareholders Agreement with respect
to Profound, no other rights to acquire, or instruments convertible into or exchangeable for, any shares in the capital of Profound
are outstanding.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(n)</TD><TD STYLE="text-align: justify">No legal or governmental actions, suits, judgments, investigations
or proceedings are pending to which Profound, or to the knowledge of Profound, the directors, officers or employees of Profound
are a party or to which the Assets and Properties of Profound is subject and, to the knowledge of Profound, no such proceedings
have been threatened against or are pending with respect to Profound, or with respect to its Assets and Properties and Profound
is not subject to any judgment, order, writ, injunction, decree or award of any Governmental Authority, which, either individually
or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(o)</TD><TD STYLE="text-align: justify">Profound is not in violation of its constating documents
or in default in the performance or observance of any obligation, agreement, covenant or condition contained in any Contract to
which it is a party or by which it or its Assets and Properties may be bound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(p)</TD><TD STYLE="text-align: justify">Profound owns or has the right to full use of all Assets
and Properties owned or used in the Business (other than Intellectual Property, with respect to which the representations and
warranties in Sections 4.2(s)-(y) apply) free and clear of any actual, pending or, to the knowledge of Profound, threatened claims,
liens, charges, options, set-offs, free-carried interests, royalties, encumbrances, security interests or other interests whatsoever,
including: (a) all Contracts that are material to the Profound Business; and (b) all Assets and Properties necessary to enable
Profound to carry on the Profound Business as now conducted and as presently proposed to be conducted.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(q)</TD><TD STYLE="text-align: justify">All Contracts to which Profound is a party are in good
standing in all respects and in full force and effect, including, without limitation:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the amended and restated technology license agreement (the
<B>&ldquo;Sunnybrook License Agreement&rdquo;) </B>entered into on May 16, 2011 between Profound and Sunnybrook Health Sciences
Centre, pursuant to which Sunnybrook Health Sciences Centre licenses to Profound certain intellectual property on the terms and
conditions set forth therein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the Convertible Notes;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the lease extending and amending agreement entered into
on August 30, 2012, between Profound and Yonge &amp; Lawrence Inc., pursuant to which Profound leases the premises at 3080 Yonge
Street for a term ending December 31, 2016;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">the agreement entered into on February 27, 2012, between
Profound and TDC Medical, Inc. for the manufacture and supply of the disposal portion of the Product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">the loan agreement entered into on May 25, 2011, between
Profound and The Health Technology Exchange, as amended by the amending agreement dated April 1, 2012, for a non-revolving term
performance based loan of up to $750,000 for a project relating to the commercialization of the Product, with annual repayments
commencing upon commercialization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">the loan agreement entered into on March 31, 2014, between
Profound and The Health Technology Exchange for a non-revolving performance based loan of up to $750,000 for a project relating
to the commercialization of the Product, with annual repayments commencing upon commercialization; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">the loan agreement entered into on December 16, 2011, between
Profound and the Federal Economic Development Agency for a non-interest bearing loan of up to $867,000, to be repaid in 60 monthly
instalments commencing April 1, 2015 and finishing on April 1, 2020.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(r)</TD><TD STYLE="text-align: justify">Neither Profound nor, to the knowledge of Profound, any
other party thereto is in default or breach of any Contract and, to the knowledge of Profound, there exists no condition, event
or act which, with the giving of notice or lapse of time or both would constitute a default or breach under any Contract which
would give rise to a right of termination on the part of any other party to a Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(s)</TD><TD STYLE="text-align: justify">(i) Profound owns, or has obtained valid and enforceable
licenses for, or other rights to use, the Intellectual Property including the Intellectual Property described in the Final Offering
Memorandum; (ii) Profound has no knowledge that Profound lacks any rights or licenses to use all Intellectual Property necessary
and material for the conduct of the Profound Business; (iii) no third parties have rights to any Intellectual Property that is
owned by or licensed to Profound, except as disclosed in the Final Offering Memorandum, other than rights acquired pursuant to
non-exclusive licenses granted by Profound in the ordinary course of business or Intellectual Property licensed to Profound; (iv)
all of the applied for or registered Intellectual Property that is owned by or licensed to Profound and necessary and material
in the operation of the Profound Business is in full force and effect and, to the knowledge of Profound, Profound has not failed
to take any actions with respect to such applied for or registered Intellectual Property in a manner which would result in the
abandonment, opposition, re-examination, rejection, impeachment, cancellation, termination, lapsing, limitation, expungement or
unenforceability of any of such applied for or registered Intellectual Property; (v) all applications, registrations, filings,
renewals and payments necessary to preserve the rights in and to the applied for or registered Intellectual Property that is owned
by or licensed to Profound and necessary and material to the operation of the Profound Business have been duly filed, made, prosecuted
and maintained, are in good standing or substantially reinstatable and are, if owned by Profound, recorded in the name of Profound,
and Profound has not received any written notice indicating that any application for registration of the Intellectual Property
that is owned by Profound has been finally rejected or denied by the applicable reviewing authority, except as would not, individually
or in the aggregate, have or would reasonably be expected to have a Material Adverse Effect; and (vi) there is no pending or threatened
action, suit, proceeding or claim by any other Person challenging the validity or enforceability of any Intellectual Property,
and Profound has no knowledge of any finding of unenforceability or invalidity of any issued or registered Intellectual Property
that is owned by Profound or licensed to Profound pursuant to the Sunnybrook License Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(t)</TD><TD STYLE="text-align: justify">(i) Profound is the sole and exclusive legal and/or beneficial
owner, as applicable, of, has good and marketable title to, and owns all right, title and interest in all material Intellectual
Property that is owned by Profound, free and clear of all encumbrances, liens, mortgages, hypothecations, security interests,
charges or adverse interests whatsoever, options to purchase and restrictions or other adverse claims of any kind or nature, and
Profound has no knowledge of any claim of adverse ownership in respect thereof; (ii) no consent of any person is necessary to
make, use, reproduce, license, sell, modify, update, enhance or otherwise exploit any Intellectual Property that is owned by Profound;
and (iii) other than the Intellectual Property licensed to Profound pursuant to the Sunnybrook License Agreement, none of the
Intellectual Property that is owned by or licensed to Profound comprises an improvement to any Intellectual Property that would
give any third Person any rights to any such Intellectual Property, including, without limitation, rights to license any such
Intellectual Property; except as would not, individually or in the aggregate, have or would reasonably be expected to have a Material
Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(u)</TD><TD STYLE="text-align: justify">The Company has no knowledge of any pending or threatened,
action, suit, proceeding or claim by others challenging Profound&rsquo;s rights in or to any Intellectual Property, and Profound
has no knowledge of any facts which form a reasonable basis for any such claim; Profound has not received any written notice or
claim challenging its ownership or right to use any of the Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">(i) To Profound&rsquo;s knowledge, the conduct of the Profound
Business (including, without limitation, the use or other exploitation of the Intellectual Property by Profound) has not infringed,
violated, misappropriated or otherwise conflicted with any intellectual property right of any third Person; and (ii) to the knowledge
of Profound, there is no pending or threatened action, suit, proceeding or claim by any other person that Profound infringes or
otherwise violates (or would infringe or otherwise violate upon commercialization of Profound&rsquo;s products or services under
development) any intellectual property right owned by any other Person, and Profound has no knowledge of any facts which form
a reasonable basis for any such claim.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(w)</TD><TD STYLE="text-align: justify">To&#9;Profound&rsquo;s knowledge, no person has infringed
or misappropriated, or is infringing or misappropriating, any rights of Profound in or to any of the Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(x)</TD><TD STYLE="text-align: justify">To&#9;the extent that any of the Intellectual Property
that is owned by Profound is licensed or disclosed to any other Person by Profound, Profound has entered into a valid and subsisting
written agreement with any such Person which contains terms and conditions prohibiting the unauthorized use or transfer of such
Intellectual Property by such Person. Other than such agreements that have expired in accordance with their respective terms,
all such agreements are in full force and effect and, to the knowledge of Profound, none of Profound or, any other Person, is
in material default or material breach of its obligations thereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(y)</TD><TD STYLE="text-align: justify">To Profound&rsquo;s knowledge, all moral rights as defined
under the <I>Copyright Act </I>(Canada) or any other applicable legislation or by operation of law in any applicable jurisdiction
have been waived in writing in favour of Profound and its successors or assignees with respect to the copyrightable works that
are owned by Profound, except as would not, individually or in the aggregate, have or would reasonably be expected to have a Material
Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(z)</TD><TD STYLE="text-align: justify">No order, ruling or determination having the effect of
suspending the sale or ceasing the trading in any securities of Profound has been issued by any regulatory authority and is continuing
in effect and no proceedings for that purpose have been instituted or, to the knowledge of Profound, are pending, contemplated
or threatened by any Governmental Authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(aa)</TD><TD STYLE="text-align: justify">The authorized capital of Profound consists of: (i) an
unlimited number of Profound Common Shares of which 2,166,766 Profound Common Shares are issued and outstanding as fully paid
and non-assessable shares in the capital of Profound as of the date hereof; and (ii) an unlimited number of preferred shares,
issuable in series, the first series of which is designated as Series A1 Preferred Shares, of which 2,500,000 Series A1 Preferred
Shares are issued and outstanding as fully paid and non-assessable shares in the capital of Profound as of the date hereof, and
the second series of which is designated as Series A2 Preferred Shares, of which 10,812,500 Series A2 Preferred Shares are issued
and outstanding as fully paid and non-assessable shares in the capital of Profound as of the date hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(bb)</TD><TD STYLE="text-align: justify">at the Effective Time, there will be no securityholders&rsquo;
agreements to which Profound is a party and, to the knowledge of Profound, there will not be, at the time of the Qualifying Transaction
Closing, any pooling agreements, voting trusts or other similar agreements with respect to the ownership or voting of any of the
securities of Profound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(cc)</TD><TD STYLE="text-align: justify">Profound owns
                                         no real property; and with respect to each premises of Profound which is material to
                                         the Profound Business and which Profound occupies as tenant (the <B>&ldquo;Leased Premises&rdquo;),
                                         </B>Profound occupies the Leased Premises and has the exclusive right to occupy and use
                                         the Leased Premises and each of the leases pursuant to which Profound occupies the Leased
                                         Premises is in good standing and in full force and effect in all respects.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(dd)</TD><TD STYLE="text-align: justify">Profound is not a party to or bound by any collective agreement
and is not currently conducting negotiations with any labour union or employee association.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ee)</TD><TD STYLE="text-align: justify">Profound is in compliance with all laws respecting employment
and employment practices, terms and conditions of employment, pay equity and wages and has not and is not engaged in any unfair
labour practice.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ff)</TD><TD STYLE="text-align: justify">Other than (i)
                                         Profound&rsquo;s Amended and Restated Stock Option Plan dated September 26, 2008, as
                                         amended and restated on March 16, 2012 and on September 12, 2012; and (ii) the Encon
                                         Group Benefits Plan as renewed on March 1, 2014, Profound does not have any agreements,
                                         plans or practices relating to the payment of any management, consulting, service or
                                         other fees or any bonuses, pensions, share of profits or retirement allowance, insurance,
                                         health or other employee benefits or any plan for retirement, stock purchase, profit
                                         sharing, stock option, deferred compensation, severance or termination pay, insurance,
                                         medical, hospital, dental, vision care, drug, sick leave, disability, salary continuation,
                                         legal benefits, unemployment benefits, vacation, incentive or otherwise contributed to,
                                         or required to be contributed to, by Profound for the benefit of any current or former
                                         director, officer, employee or consultant of Profound (the <B>&ldquo;Employee Plans&rdquo;).
                                         </B>The Company has made available to Mira IV the opportunity to review true and complete
                                         copies of documents, contracts and arrangements relating to the Employee Plans. The Employee
                                         Plans have been established, operated in the ordinary course and administered in all
                                         material respects in accordance with their terms and applicable laws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(gg)</TD><TD STYLE="text-align: justify">There has not been in the last two years and there is not
currently any labour disruption that would reasonably be expected to have a Material Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(hh)</TD><TD STYLE="text-align: justify">To Profound&rsquo;s knowledge, none of the directors, officers
or employees of Profound or any associate or affiliate of any of the foregoing has any interest, direct or indirect, in any transaction
with Profound that materially affects, is material to or would reasonably be expected to materially affect Profound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Other than the Convertible Notes, Profound is not indebted
to: (i) any director, officer or shareholder of Profound; (ii) any individual related to any of the foregoing by blood, marriage
or adoption; or (iii) any corporation controlled, directly or indirectly, by any one or more of those Persons referred to in this
Section 4.2(ii). None of those Persons referred to in this Section 4.2(ii) is indebted to Profound. Profound is not currently
a party to any material Contract, agreement or understanding with any officer, director, employee, shareholder or any other Person
not dealing at arm&rsquo;s length with Profound other than employment agreements and the Convertible Notes.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(jj)</TD><TD STYLE="text-align: justify">Profound&rsquo;s insurance policies are valid and enforceable
and in full force and effect, are underwritten by unaffiliated and reputable insurers, are sufficient for all applicable requirements
of law and provide insurance, including liability and product liability insurance, in such amounts and against such risks as is
customary for corporations engaged in businesses similar to that carried on by Profound. Profound is not in default in any respect
with respect to the payment of any premium or compliance with any of the provisions contained in any such insurance policy and
has not failed to give any notice or present any claim within the appropriate time therefor. There are no circumstances under
which Profound would be required to or, in order to maintain its coverage, should give any notice to the insurers under any such
insurance policy which has not been given. Profound has not received notice from any of the insurers regarding cancellation of
such insurance policy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(kk)</TD><TD STYLE="text-align: justify">Copies of the minute books and records of Profound made
available to counsel for Mira IV in connection with the due diligence investigation of Profound for the period from the date of
incorporation to the date hereof are all of the minute books of Profound and contain copies of all proceedings (or certified copies
thereof) of the shareholders, the directors and all committees of directors of Profound to the date hereof to the extent that
minutes exist and there have been no other meetings, resolutions or proceedings of the shareholders, directors or any committees
of the directors of Profound to the date hereof not reflected in such minute books.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ll)</TD><TD STYLE="text-align: justify">(A) Profound and each of its Assets and Properties and
the operation of the Profound Business have been and are, to the knowledge of Profound, in compliance in all respects with all
Environmental Laws; (B) Profound has complied in all respects with all reporting and monitoring requirements under all Environmental
Laws; (C) Profound has not ever received any notice of any non-compliance in respect of any Environmental Laws; and (D) there
are no Environmental Permits necessary to conduct the Profound Business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(mm)</TD><TD STYLE="text-align: justify">Other than the Agents, there is no Person acting or purporting
to act at the request or on behalf of Profound that is entitled to any brokerage or finder&rsquo;s fee or other compensation in
connection with the transactions contemplated hereby or by the Agency Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(nn)</TD><TD STYLE="text-align: justify">Since December 31, 2014, there has not occurred any Material
Adverse Change (actual, anticipated, contemplated or threatened, whether financial or otherwise) in the assets, liabilities (contingent
or otherwise), properties, capital, affairs, prospects, business, operations or condition (financial or otherwise) of Profound
which has not been disclosed in the Final Offering Memorandum.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(oo)</TD><TD STYLE="text-align: justify">Other than the Profound Private Placement and other than
as disclosed in the Final Offering Memorandum, Profound has not:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">paid or declared any dividend or incurred any material
capital expenditure or made any commitment therefor;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">incurred any obligation or liability, direct or indirect,
contingent or otherwise, except in the ordinary course of business and which is not, and which in the aggregate are not, material;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">entered into any material transaction other than as contemplated
herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(pp)</TD><TD STYLE="text-align: justify">Profound has conducted all transactions, negotiations,
discussions and dealings in full compliance with anti-bribery and anti-corruption laws and regulations applicable in any jurisdiction
in which they are located or conducting business (collectively <B>&ldquo;Applicable Anti-Corruption Laws and Regulations&rdquo;).
</B>The Company has not made any offer, payment, promise to pay or authorization of payment of money or anything of value to any
government official, or any other person while having reasonable grounds to believe that all or a portion of such money or thing
of value will be offered, given or promised, directly or indirectly, to a government official, for the purpose of (i) assisting
the parties in obtaining, retaining or directing business; (ii) influencing any act or decision of a government official in his
or its official capacity; (iii) inducing a government official to do or omit to do any act in violation of his or its lawful duty,
or to use his or its influence with a government or instrumentality thereof to affect or influence any act or decision of such
government or department, agency, instrumentality or entity thereof; or (iv) securing any improper advantage.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(qq)</TD><TD STYLE="text-align: justify">The operations of Profound are and have been conducted
at all times in compliance with applicable financial recordkeeping and reporting requirements of the anti-money laundering statutes
of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any Governmental Authority (collectively, the <B>&ldquo;Applicable Anti-Money Laundering Laws&rdquo;)
</B>and no action, suit or proceeding by or before any Governmental Authority involving Profound with respect to Applicable Anti-Money
Laundering Laws is, to the knowledge of Profound, pending or threatened.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(rr)</TD><TD STYLE="text-align: justify">All forward-looking information and statements of Profound
contained in the Final Offering Memorandum and that will be contained in the Final Filing Statement and the assumptions underlying
such information and statements, subject to any qualifications contained therein, are reasonable in the circumstances, or will
be reasonable in the circumstances, as applicable, as at the date on which such assumptions were made.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ss)</TD><TD STYLE="text-align: justify">The statistical, industry and market related data included
in the Final Offering Memorandum and that will be contained in the Final Filing Statement are derived from sources which Profound
reasonably believes to be accurate, reasonable and reliable, and such data is consistent, or will be consistent, as applicable,
with the sources from which it was derived.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(tt)</TD><TD STYLE="text-align: justify">Profound holds all of the permits, licenses, approvals,
consents, orders, markings, certificates and like authorizations necessary for it to own, lease and license its Assets and Properties
and carry on the Profound Business, as now carried on as of the date of this Agreement, in each jurisdiction where such business
is carried on that are material to the conduct of the Profound Business, as now carried on as of the date of this Agreement, including,
but not limited to, permits, licenses, approvals, consents, orders, certificates and like authorizations from Regulatory Authorities
(collectively, the &ldquo;<B>Material Permits</B>&rdquo;); all such Material Permits are valid and subsisting and in good standing
and none of the same contains any term, provision, condition or limitation which has or would reasonably be expected to affect
or restrict in an adverse manner the operation of the Profound Business, as now carried on as of the date of this Agreement or
proposed to be carried on, as set out in the Final Offering Memorandum, and Profound is not in breach thereof or in default with
respect to filings to be effected or conditions to be fulfilled in order to maintain such Material Permits in good standing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(uu)</TD><TD STYLE="text-align: justify">No Material Permits issued by a Regulatory Authority have
been limited, suspended, or revoked, and nor is a Regulatory Authority considering such action.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(vv)</TD><TD STYLE="text-align: justify">Profound is in compliance in all material respects with
each Material Permit held by it and is not in violation of, or in default under applicable Health Care Laws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ww)</TD><TD STYLE="text-align: justify">There is no false or misleading information or significant
omission in any submission to a Regulatory Authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(xx)</TD><TD STYLE="text-align: justify">The Product has been and is being developed, tested, investigated,
manufactured, stored, distributed and marketed in compliance with applicable Health Care Laws or any other applicable legal requirement,
including those regarding non-clinical testing, clinical research, establishment registration, device listing, pre-market notification,
good manufacturing practices, labeling, advertising, record-keeping, adverse event reporting and reporting of corrections and
removals.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(yy)</TD><TD STYLE="text-align: justify">The clinical,
                                         pre-clinical and other studies and tests conducted by or on behalf of or sponsored by
                                         Profound that are described or referred to in the Final Offering Memorandum (collectively,
                                         the &ldquo;<B>Clinical Trials</B>&rdquo;) were and, if still pending, are being conducted,
                                         in all material respects, in accordance with all experimental protocols; procedures and
                                         controls; accepted professional scientific standards; accepted standards of ethical research
                                         involving humans; and applicable laws, including applicable laws administered by Regulatory
                                         Authorities. The descriptions of the result of the Clinical Trials described or referred
                                         to in the Final Offering Memorandum are accurate and complete in all respects and fairly
                                         present the published data derived from the Clinical Trials and Profound has no knowledge
                                         of other studies or tests the results of which are inconsistent with or would otherwise
                                         call into question the results described or referred to in the Final Offering Memorandum.
                                         The Company has not received any notices or written correspondence from any Regulatory
                                         Authority with respect to any Clinical Trial requesting information about or requiring
                                         the termination or suspension of such Clinical Trial.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(zz)</TD><TD STYLE="text-align: justify">Profound has filed with applicable Regulatory Authorities
all filings, declarations, listings, registrations, reports, updates and submissions that are required to be so filed under applicable
Health Care Laws. All such filings were in compliance with applicable Health Care Laws when filed and no deficiencies have been
asserted by any Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports, updates
or submissions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(aaa)</TD><TD STYLE="text-align: justify">Profound has not received any Form FDA-483, notice of adverse
finding, FDA warning letters, notice of violation or &ldquo;untitled letters,&rdquo; or notice of FDA action for import detentions
or refusals or any other written correspondence from the FDA or similar communications from another Regulatory Authority alleging
or asserting noncompliance with any applicable Health Care Laws. Profound is not subject to any obligation arising under an administrative
or regulatory action, inspection, warning letter, notice of violation letter, or other written notice, response or commitment
made to or with the FDA or any other Regulatory Authority, and, to Profound&rsquo;s knowledge, no such proceedings have been threatened.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(bbb)</TD><TD STYLE="text-align: justify">Profound and its officers, directors, and employees and,
to Profound&rsquo;s knowledge, their respective representatives, contractors and agents, have been and are currently in compliance
with all applicable Health Care Laws and neither Profound nor its officers, directors or employees have engaged in any act or
omission that violates or would violate any Health Care Laws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ccc)</TD><TD STYLE="text-align: justify">Profound and, to Profound&rsquo;s knowledge, none of its
officers, directors, and employees (i) are not and have not been a party to, or bound by, any order, individual integrity agreement,
corporate integrity agreement or other formal agreement or settlement with any Governmental Authority concerning compliance with
Health Care Laws; (ii) has not made any filings in the United States pursuant to the OIG or CMS self-disclosure protocol; (iii)
has not been a defendant in any action, or received a threat of any action, brought under a United States federal or state whistleblower
statute, including without limitation the False Claims Act of 1863 (31 U.S.C. &sect; 3729 et seq.); and (iv) has not been served
with or received any written search warrant, subpoena (other than those related to actions against third parties), civil investigative
demand or contact letter from a Governmental Authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ddd)</TD><TD STYLE="text-align: justify">Profound has not received notice of any action pending
or recommended by any Governmental Authority (including a Regulatory Authority) either to revoke, withdraw, suspend or limit any
Material Permit, or to terminate, suspend, limit, withdraw, or forfeit the participation of Profound in any government program.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(eee)</TD><TD STYLE="text-align: justify">To Profound&rsquo;s knowledge, Profound is not the target
or subject of any current or potential investigation relating to any Government Health Care Program-related offense.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(fff)</TD><TD STYLE="text-align: justify">Profound has not (i) offered, authorized, promised, made
or agreed to make gifts of money, other property, other value or similar benefits or contributions to, or entered into any fee-splitting
arrangement with, any actual or potential patient, health care provider, actual or potential business partner, governmental employee,
or other Person in a position to assist or hinder Profound in connection with any actual or proposed transaction, or to any political
party, political party official or candidate for federal, state, provincial or local public office in violation of any applicable
law or (ii) maintained any unrecorded fund or asset of Profound for any improper purpose or made any false entries on its books
and records for any reason.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ggg)</TD><TD STYLE="text-align: justify">To Profound&rsquo;s knowledge, no Persons who have engaged
in any activity that is in violation of or have been convicted of, charged with, or investigated for, a felony or a criminal offense
under any Health Care Law; or who are excluded, suspended, debarred, prohibited from providing services under, or otherwise ineligible
to participate in any Government Health Care Program; or who have been threatened with exclusion, debarment or being otherwise
ineligible to participate in any Government Health Care Program; or who have committed any act or have engaged in any activity
that is permissive or mandatory grounds for exclusion, debarment, suspension, or other ineligibility to so participate, are either
employed by, under Contract with, or agents of Profound or provide items or services on behalf of Profound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(hhh)</TD><TD STYLE="text-align: justify">Profound has not unlawfully disclosed the protected health
information of any person, nor committed any other breach of applicable Health Care Laws concerning the privacy and/or security
of personal health information; nor is Profound aware of any investigation by any Governmental Authority for a violation of applicable
Health Care Laws concerning the privacy and/or security of personal health information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">Profound has not notified, either voluntarily or as required
by Health Care Law or other applicable law, any affected individual, any Governmental Authority or the media of any breach of
protected health information. To the knowledge of Profound, Profound has not suffered any unauthorized acquisition, access, use
or disclosure of any personal information that, individually or in the aggregate, materially compromises the security or privacy
of such personal information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(jjj)</TD><TD STYLE="text-align: justify">Profound does not participate in, directly or through any
broker, distributor or similar party, any arrangement pursuant to which customers of the Profound Business receive, directly or
indirectly, a reduction in the purchase or other benefits, monetary or otherwise, other than normal and legal customary trade
practices and incidental business-related entertainment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(kkk)</TD><TD STYLE="text-align: justify">Subject only to the terms of the Sunnybrook License Agreement,
Profound is the sole legal and beneficial owner of, has good and marketable title to, and owns all right, title and interest in
the Product. Profound intends to grant Knight the exclusive right to market, sell, distribute and commercialize the Product in
Canada, and any future product of Profound to be approved in Canada;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(lll)</TD><TD STYLE="text-align: justify">There is no actual or, to Profound&rsquo;s knowledge, threatened
enforcement actions by any Regulatory Authority against Profound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(mmm)</TD><TD STYLE="text-align: justify">Except for ordinary course inquiries by Regulatory Authorities,
no Regulatory Authority is presently alleging or asserting, or, to Profound&rsquo;s knowledge, threatening to allege or assert,
noncompliance with any applicable legal requirement or registration in respect of the Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDITIONS PRECEDENT AND OTHER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.1</B></TD><TD STYLE="text-align: justify"><B>Conditions to Obligations of Profound</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The obligation of Profound to consummate
the transactions contemplated herein is subject to the satisfaction, on or before the Closing Date, of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">except as affected by the transactions contemplated herein,
including the Mira Loan, the representations and warranties of Mira contained in Section 4.1 hereof shall be true in all material
respects on the Closing Date with the same effect as though such representations and warranties had been made at and as of such
time, other than in respect of representations and warranties qualified by materiality which representations and warranties shall
be true and correct, and Profound shall have received a certificate to that effect, dated the Closing Date, from an officer or
director of Mira acceptable to Profound, to the best of his or her knowledge, having made reasonable inquiry;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Mira and Mira Subco shall have performed, fulfilled or
complied with, in all material respects, all of their obligations, covenants and agreements contained in this Agreement to be
fulfilled or complied with by them at or prior to the Closing and Profound shall have received a certificate of an officer or
director of Mira to such effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Mira shall have furnished Profound with:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">a certified copy of the resolutions passed by the board
of directors of Mira approving this Agreement and the consummation of the transactions contemplated herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a certified copy of the special resolution of the sole
shareholder of Mira Subco authorizing and approving the Amalgamation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">a certified copy of the resolutions of shareholders of
Mira approving the Mira Meeting Matters; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">written approval of the TSX Venture of the Amalgamation
as a Qualifying Transaction under the TSX Venture rules and policies and such other matters as may require TSX Venture approval
in order to give effect to the transactions contemplated hereby.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">receipt of all regulatory and third party approvals, authorizations
and consents as are required to be obtained by Mira or Profound in connection with the Amalgamation, including the approval of
the TSX Venture and any other applicable regulatory authorities and specifically including approval of the TSX Venture with respect
to the Knight Share Issuance;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">completion of the Consolidation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">the shareholders of Profound approving the Amalgamation
and this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">the Resulting Issuer Common Shares that are issued as consideration
for the Profound Common Shares shall be issued as fully paid and non-assessable Resulting Issuer Common Shares in the capital
of the Resulting Issuer, free and clear of any and all encumbrances, liens, charges and demands of whatsoever nature, except those
imposed pursuant to escrow restrictions of the TSX Venture and/or applicable securities laws;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">no Material Adverse Change shall have occurred with respect
to Mira since the date of this Agreement, other than a reduction of its cash position in order to pay its ongoing operating expenses
and professional fees, such fees not to exceed $250,000 except in accordance with Section 3.1(d)(iv) or with Profound&rsquo;s
written consent;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">there being no legal proceeding or regulatory actions or
proceedings against any Person to enjoin, restrict or prohibit the Amalgamation or which could reasonably be expected to result
in a Material Adverse Effect on Mira;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">there being no prohibition at law against completion of
Amalgamation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">Mira shall be in compliance, in all material respects,
with applicable Securities Laws and the rules and policies of the TSX Venture and there shall be no cease-trade order made or
threatened by a Governmental Authority in respect of the Mira Common Shares except pursuant to the CPC Policy; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">completion of the Profound Private Placement for gross
proceeds of not less than $21,750,000.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The conditions described above are for
the exclusive benefit of Profound and may be asserted by Profound regardless of the circumstances, or may be waived by Profound
in its sole discretion, in whole or in part, at any time and from time to time prior to the Amalgamation without prejudice to any
other rights which Profound may have hereunder or at law and notwithstanding the approval of this Agreement by the shareholders
of Mira Subco and/or Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.2</B></TD><TD STYLE="text-align: justify"><B>Conditions to Obligations of Mira</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The obligations of Mira and Mira Subco
to consummate the transactions contemplated herein are subject to the satisfaction, on or before the Closing Date, of the following
conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">except as affected by the transactions contemplated herein,
the representations and warranties of Profound contained in Section 4.2 hereof shall be true in all material respects on the Closing
Date with the same effect as though such representations and warranties had been made at and as of such time, other than in respect
of representations and warranties qualified by materiality which representations and warranties shall be true and correct, and
Mira shall have received a certificate to such effect, dated the Closing Date, of a senior officer of Profound to the best of
his knowledge having made reasonable inquiry;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Profound shall have performed, fulfilled or complied with,
in all material respects, all of its obligations, covenants and agreements contained in this Agreement to be fulfilled or complied
with by it at or prior to the time of the Closing and Mira shall have received a certificate of an officer of Profound to such
effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Profound shall have furnished Mira with:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">certified copies of the directors&rsquo; resolutions passed
by the board of directors of Profound approving this Agreement, as well as the consummation of the transactions contemplated therein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">certified copies of the special resolution of the shareholders
of Profound authorizing and approving the Amalgamation and this Agreement; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">a certificate of Profound, or Profound&rsquo;s registrar
and transfer agent, setting forth the number of issued and outstanding Profound securities immediately prior to the Amalgamation
and confirming that there are no issued and outstanding preferred shares in the capital of Profound;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">receipt of all regulatory or third party approvals, authorizations
and consents as are required to be obtained by Mira or Profound in connection with the Amalgamation, including the approval of
the TSX Venture and any other applicable regulatory authorities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">no Material Adverse Change shall have occurred in the business,
results of operations, assets, liabilities, financial condition or affairs of Profound since the date of this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">each of the Profound Principals shall have entered into
a Support Agreement on or prior to the date hereof with Mira and Profound and shall not be in default of any term thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">the shareholders of Profound approving the Amalgamation
and this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">there being no legal proceeding or regulatory actions or
proceedings against any Person to enjoin, restrict or prohibit the Amalgamation or which could reasonably be expected to result
in a Material Adverse Effect on Profound;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">there being no prohibition at law against the completion
of the transactions contemplated hereby; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">the completion of the Profound Private Placement for gross
proceeds of not less than $21,750,000 million.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The conditions described above are for
the exclusive benefit of Mira and Mira Subco and may be asserted by Mira and Mira Subco, acting together, regardless of the circumstances,
or may be waived by Mira and Mira Subco, acting together, in their sole discretion, in whole or in part, at any time and from time
to time prior to the Amalgamation without prejudice to any other rights which Mira and Mira Subco may have hereunder or at law
and notwithstanding the approval of this Agreement by the shareholders of Mira Subco and/or Profound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.3</B></TD><TD STYLE="text-align: justify"><B>Merger of Conditions</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The conditions set out in Sections 5.1
and 5.2 hereof shall be conclusively deemed to have been satisfied, waived or released on the filing by Profound and Mira Subco
of the Articles of Amalgamation with the registrar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.4</B></TD><TD STYLE="text-align: justify"><B>Alternative Transactions &ndash; Mira</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event that Mira receives
a <I>bona fide</I> offer, whether written or oral (a &ldquo;<B>Mira Offer</B>&rdquo;), from a third party to acquire the assets
or shares of Mira or to enter into an arrangement or agreement which would materially interfere with the Amalgamation which Mira
wishes to pursue at the instruction of its board of directors or a committee thereof, including without in any way limiting the
generality of the foregoing, any such arrangement or agreement resulting from an unsolicited offer or proposal from a third party
(a &ldquo;<B>Mira Alternative Transaction</B>&rdquo;), then Mira shall provide forthwith a copy of the Mira Offer to Profound
or, if made orally, a written summary of the Mira Offer (and in any event within one Business Day following receipt thereof) and
Mira may terminate this Agreement upon written notice to Profound. Upon termination of this Agreement by Mira by written notice
to Profound (the &ldquo;<B>Mira Termination</B>&rdquo;) or upon Mira entering into an agreement, including a letter of intent,
whether or not binding (the &ldquo;<B>Mira Alternative Transaction Agreement</B>&rdquo;), prior to the termination of this Agreement,
with respect to the Mira Alternative Transaction, Mira shall forthwith provide Profound with a copy of the Mira Alternative Transaction
Agreement and shall, within ten (10) Business Days following the earlier of the Mira Termination and the entering into of the
Mira Alternative Transaction Agreement (collectively and individually referred to as a &ldquo;<B>Mira Event</B>&rdquo;), as applicable,
make a cash payment to Profound in the amount of: (a) $100,000 if the Mira Event occurs after the entering into of this Agreement
but prior to the filing of the Final Filing Statement on SEDAR; and (b) $200,000 if the Mira Event occurs on or after the filing
of the Final Filing Statement on SEDAR, which payment shall constitute full and final compensation and remedy to Profound for
any breach or the non-performance of this Agreement and any and all fees and expenses associated therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.5</B></TD><TD STYLE="text-align: justify"><B>Alternative Transactions &ndash; Profound</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event that Profound or
any of the Profound Principals receives a <I>bona fide</I> offer, whether written or oral, (a &ldquo;<B>Profound Offer</B>&rdquo;),
from a third party to acquire the assets or shares of Profound or to enter into an arrangement or agreement which would materially
interfere with the Amalgamation which Profound wishes to pursue at the instruction of its board of directors or a committee thereof,
including without in any way limiting the generality of the foregoing, any such arrangement or agreement resulting from an unsolicited
offer or proposal from a third party (a &ldquo;<B>Profound Alternative Transaction</B>&rdquo;), then Profound shall provide forthwith
a copy of the Profound Offer to Mira or if made orally, a written summary of the Profound Offer (and in any event within one Business
Day following receipt thereof) and Profound may terminate this Agreement upon written notice to Mira. Upon termination of this
Agreement by Profound by written notice to Mira (the &ldquo;<B>Profound Termination</B>&rdquo;) or upon Profound entering into
an agreement, including a letter of intent, whether or not binding (the &ldquo;<B>Profound Alternative Transaction Agreement</B>&rdquo;)
prior to the termination of this Agreement, with respect to the Profound Alternative Transaction, Profound shall forthwith provide
Mira with a copy of the Profound Alternative Transaction Agreement and shall, within ten (10) Business Days following the earlier
of the Profound Termination and the entering into of the Profound Alternative Transaction Agreement (collectively and individually
referred to as a &ldquo;<B>Profound Event</B>&rdquo;), as applicable, make a cash payment to Mira in the amount of: (a) $100,000
if the Profound Event occurs after the entering into of this Agreement but prior to the filing of the Final Filing Statement on
SEDAR; and (b) $200,000 if the Profound Event occurs on or after the filing of the Final Filing Statement on SEDAR, which payment
shall constitute full and final compensation and remedy to Mira for any breach or the non-performance of this Agreement and any
and all fees and expenses associated therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 6 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.1</B></TD><TD STYLE="text-align: justify"><B>Notices</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">All notices, requests and demands hereunder,
which may or are required to be given pursuant to any provision of this Agreement, shall be given or made in writing and shall
be delivered by courier, facsimile or e-mail as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">to Mira, addressed to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Mira IV Acquisition Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Suite 300, 5 Hazelton Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Toronto, ON M5R 2E1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">Attn:</TD>
    <TD STYLE="width: 93%; text-align: justify">Jordan Kupinsky</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Fax:</TD>
    <TD STYLE="text-align: justify">(416) 972-6208</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email:</TD>
    <TD STYLE="text-align: justify">jkupinsky@jjrcapital.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">with a copy to (such copy shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Fasken Martineau DuMoulin LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">333 Bay Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Suite 2400, Bay Adelaide Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Toronto, ON M5H 2T6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">Attn:</TD>
    <TD STYLE="width: 93%; text-align: justify">Tracy Hooey</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Fax:</TD>
    <TD STYLE="text-align: justify">(416)364 7813</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email:</TD>
    <TD STYLE="text-align: justify">thooey@fasken.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to Profound, addressed to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Profound Medical Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">3080 Yonge Street, Suite 4040</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Toronto, ON M4N 3N1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">Attn:</TD>
    <TD STYLE="width: 93%; text-align: justify">Steven Plymale</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Fax:</TD>
    <TD STYLE="text-align: justify">(647) 847-3739</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email:</TD>
    <TD STYLE="text-align: justify">splymale@profoundmedical.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">with a copy to (such copy shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Osier Hoskin &amp; Harcourt LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">100 King Street West, Suite 6200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">First Canadian Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Toronto, ON M5X 1B8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; text-align: justify">Attn:</TD>
    <TD STYLE="width: 93%; text-align: justify">GeoffTaber</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Fax:</TD>
    <TD STYLE="text-align: justify">(416) 862-6666</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email:</TD>
    <TD STYLE="text-align: justify">gtaber@osler.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">or to such other addresses and facsimile
numbers or e-mail addresses as the parties may, from time to time, advise to the other parties hereto by notice in writing. All
notices, requests and demands hereunder shall be deemed to have been received, if delivered personally or by prepaid courier on
the date of delivery and if sent by facsimile or e-mail, on the next Business Day after the facsimile or e-mail was sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT AND TERMINATION OF AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.1</B></TD><TD STYLE="text-align: justify"><B>Amendment</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement may, at any time and from
time to time before or after the holding of the Mira Meeting or obtaining the Profound Shareholder Approval, be amended by written
agreement of the parties hereto without, subject to applicable law, further notice to or authorization on the part of their respective
shareholders and any such amendment may, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">change the time for performance of any of the obligations
or acts of the parties hereto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">waive any inaccuracies or modify any representation or
warranty contained herein or in any document delivered pursuant hereto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">waive compliance with or modify any of the covenants herein
contained and waive or modify performance of any of the obligations of the parties hereto; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">waive compliance with or modify any other conditions precedent
contained herein,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">provided that no such amendment shall change
the provisions hereof regarding the consideration to be received by securityholders of Profound without approval by such securityholders
of Profound given in the same manner as required for the approval of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.2</B></TD><TD STYLE="text-align: justify"><B>Rights of Termination</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement may be terminated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by mutual agreement of the parties hereto in writing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">upon provision of notice in accordance with Section 5.4
or 5.5;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">by Profound (i) by notice to Mira if any of the conditions
contained in Section 5.1 hereof shall not be fulfilled or performed by the Termination Date or (ii) upon a breach by Mira of Subsection
3.1(a) hereof that could reasonably result in a condition set forth in Section 5.1 which condition has not been waived to be incapable
of being satisfied on or before the Termination Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">by Mira (i) by notice to Profound if any of the conditions
contained in Section 5.2 hereof shall not be fulfilled or performed by the Termination Date or (ii) upon a breach by Profound
of Subsection 3.3(a) hereof that could reasonably result in a condition set forth in Section 5.2 which condition has not been
waived to be incapable of being satisfied on or before the Termination Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">by any party if the Amalgamation is not completed by the
Termination Date; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">by any party if any applicable regulatory or Governmental
Authority has notified any of Mira, Mira Subco or Profound that it will not permit the Amalgamation to proceed, in whole or in
part.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If this Agreement is terminated as aforesaid,
the party terminating this Agreement shall be released from all obligations under this Agreement other than the obligations that
by their terms survive the termination of this Agreement (including the obligation to make payments under Section 5.4 and 5.5,
the obligations with respect to confidentiality under Section 8.6 and the obligations with respect to expenses under Section 8.7),
all rights of specific performance against such party shall terminate and, unless such party can show that the condition or conditions
the non-performance of which has caused such party to terminate this Agreement were reasonably capable of being performed by the
other party, then the other party shall also be released from all obligations hereunder, except any liability expressly contemplated
hereby; and further provided that any of such conditions may be waived in full or in part by either of the parties without prejudice
to its rights of termination in the event of the non-fulfilment or non-performance of any other condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.3</B></TD><TD STYLE="text-align: justify"><B>Notice of Unfulfilled Conditions</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If either of Profound or Mira shall determine
at any time prior to the Effective Date that it intends to refuse to consummate the Amalgamation or any of the other transactions
contemplated hereby because of any unfulfilled or unperformed condition contained in this Agreement on the part of the other of
them to be fulfilled or performed, Profound or Mira, as the case may be, shall so notify the other of them forthwith upon making
such determination in order that such other of them shall have the right and opportunity to take such steps, at its own expense,
as may be necessary for the purpose of fulfilling or performing such condition within a reasonable period of time, but in no event
later than the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.1</B></TD><TD STYLE="text-align: justify"><B>Entire Agreement</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The terms and provisions herein contained
constitute the entire agreement between the parties with respect to the subject matter herein and shall supersede all previous
oral or written communications, representations, undertakings and agreements with respect to such subject matter, including the
Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.2</B></TD><TD STYLE="text-align: justify"><B>Binding Effect</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement shall be binding upon and
enure to the benefit of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.3</B></TD><TD STYLE="text-align: justify"><B>Waiver and Modification</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Mira and Profound may waive or consent
to the modification of, in whole or in part, any inaccuracy of any representation or warranty made to them hereunder or in any
document to be delivered pursuant hereto and may waive or consent to the modification of any of the covenants or agreements herein
contained for their respective benefit or waive or consent to the modification of any of the obligations of the other parties hereto.
No waiver, or consent to the modification of any inaccuracy of any provision of this Agreement constitutes a waiver of or consent
to any proceeding, continuing or succeeding inaccuracy of such provision or of any other provision of this Agreement. Any waiver
or consent to the modification of any of the provisions of this Agreement, to be effective, must be in writing executed by the
party granting such waiver or consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.4</B></TD><TD STYLE="text-align: justify"><B>No Personal Liability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">No director, officer, employee or agent of either Profound
shall have any personal liability whatsoever to Mira under this Agreement, or under any other document delivered in connection
with the Amalgamation on behalf of Profound.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">No director, officer, employee or agent of either Mira
or Mira Subco shall have any personal liability whatsoever to Profound under this Agreement, or under any other document delivered
in connection with the Amalgamation on behalf of Mira.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.5</B></TD><TD STYLE="text-align: justify"><B>Assignment</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">No party to this Agreement may assign any
of its rights or obligations under this Agreement without the prior written consent of the other party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.6</B></TD><TD STYLE="text-align: justify"><B>Confidentiality</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">No disclosure or announcement, public or otherwise, in
respect of this Agreement or the transactions contemplated hereby will be made by Mira, Mira Subco, Profound or their representatives
without the prior agreement of the other parties hereto as to timing, content and method, provided that the obligations herein
will not prevent a party from making, after consultation with the other parties, such disclosure as its counsel advises is required
by applicable law or the rules and policies of the TSX Venture.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Except as and only to the extent required, by applicable
law, a Receiving Party will not disclose or use, and it will cause its representatives not to disclose or use, any Confidential
Information furnished, or to be furnished, by a Disclosing Party or its representatives to the Receiving Party or its representatives
at any time or in any manner other than for purposes of evaluating the transactions proposed in this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If this Agreement is terminated pursuant to Article 7,
each Receiving Party will promptly return to the Disclosing Party or destroy any Confidential Information and any work product
produced from such Confidential Information in its possession or in the possession of any of its representatives.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.7</B></TD><TD STYLE="text-align: justify"><B>Costs</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each of the parties hereto shall be responsible
for their own costs and charges incurred with respect to the transactions contemplated herein, including all costs and charges
incurred prior to the date of this Agreement and all legal and accounting fees and disbursements relating to preparing the documents
relating to the transactions contemplated herein or otherwise relating to the transactions contemplated herein. For the purposes
of clarity, Profound shall be responsible for paying the costs and fees payable to the TSX Venture regarding their review of the
personal information forms to be submitted by the proposed executive officers, directors and promoters and insiders of the Resulting
Issuer following completion of the Amalgamation and all listing fees payable in connection with any securities issued pursuant
to the Amalgamation and/or any application fees payable to the TSX Venture in connection with the transactions contemplated herein.
The legal fees of Mira shall also be the responsibility of the Resulting Issuer following completion of the Amalgamation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.8</B></TD><TD STYLE="text-align: justify"><B>Time of Essence</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Time shall be of the essence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.9</B></TD><TD STYLE="text-align: justify"><B>Survival</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The representations and warranties of each
of Profound, Mira and Mira Subco contained herein shall survive the execution and delivery of this Agreement and shall terminate
on the earlier of the termination of this Agreement in accordance with its terms and the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.10</B></TD><TD STYLE="text-align: justify"><B>Governing Law</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement shall be governed by and
construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein, without giving
effect to the principles of conflicts of laws thereof, and the parties hereto irrevocably attorn to the non-exclusive jurisdiction
of the courts of the Province of Ontario in respect of any matter arising hereunder or in connection herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.11</B></TD><TD STYLE="text-align: justify"><B>Severability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event that any provisions contained
in this Agreement shall be declared invalid, illegal or unenforceable by a court or other lawful authority of competent jurisdiction,
this Agreement shall continue in force with respect to the enforceable provisions and all rights and remedies accrued under the
enforceable provisions shall survive any such declaration, and any non-enforceable provision shall, to the extent permitted by
law, be replaced by a provision which, being valid, comes closest to the intention underlying the invalid, illegal and unenforceable
provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.12</B></TD><TD STYLE="text-align: justify"><B>Further Assurances</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Each party hereto shall, from time to time,
and at all times hereafter, at the request of the other parties hereto, but without further consideration, do all such further
acts and execute and deliver all such further documents and instruments as shall be reasonably required in order to fully perform
and carry out the terms and intent hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.13</B></TD><TD STYLE="text-align: justify"><B>Counterparts and Electronic Copies</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">This Agreement may be executed in separate
counterparts, and all such counterparts when taken together shall constitute one (1) agreement. The parties shall be entitled to
rely on delivery of a facsimile, email in pdf or other electronic copy of the executed Agreement and such copy shall be legally
effective to create a valid and binding Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Remainder of Page Intentionally Left
Blank]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF </B>the parties have executed this Agreement
as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><B>MIRA IV ACQUISITION CORP.</B></TD>
    <TD STYLE="width: 50%; text-align: justify"><B>PROFOUND MEDICAL INC.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">Per:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: justify">/s/ Jordan Kupinsky</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">Per:</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; text-align: justify">/s/ Steven Plymale</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Jordan Kupinsky</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Steven Plymale</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Director</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><B>MIRA IV SUBCO INC.</B></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 52%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Elena Masters</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: Elena Masters</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: Director</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[Signature Page - Amalgamation Agreement]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 4.2(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Written consent of the landlord prior to effecting a transfer
that results in a change in the effective voting control of the tenant (Sections. 13.1 and 13.21), under a lease agreement between
3080 Yonge Street Inc. and Profound Medical Inc. dated September 27, 2011, as may be amended from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Written consent of the Minister before effecting change
of control (Section 8.2(b)), under Investing in Business Innovation Contribution Agreement between Her Majesty the Queen in Right
of Canada and Profound Medical Inc. dated December 16, 2011 as amended February 29, 2012.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Written consent of the lender before change of control
(Section 8.1(d)), under the Performance-Based Loan Agreement between The Health Technology Exchange and Profound Medical Inc.
dated March 31, 2014.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Written consent of the lender before change of control
(Section 8.1(d)), under the Performance-Based Loan Agreement between The Health Technology Exchange and Profound Medical Inc.
dated May 25, 2011.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 69; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.4
<SEQUENCE>5
<FILENAME>tv526458_ex1-4.htm
<DESCRIPTION>EXHIBIT 1.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">BY-LAW NUMBER 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>A BY-LAW RELATING TO THE BUSINESS AND AFFAIRS
OF<BR>
MIRA IV ACQUISITION CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ARTICLE 1<BR>
INTERPRETATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.1</TD><TD STYLE="text-align: justify"><B>Definitions</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">In this by-law:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;Act&rdquo;
means the <I>Business Corporations Act</I> (Ontario) and the regulations enacted pursuant to it and any statute and regulations
that may be substituted for them, as amended from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;articles&rdquo;
means the articles, as that term is defined in the Act, of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;auditor&rdquo; means the auditor of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;board&rdquo;
means the board of directors of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;by-law&rdquo; means a by-law of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;Corporation&rdquo;
means the corporation incorporated on July 16, 2014 under the name &ldquo;Mira IV Acquisition Corp.&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;director&rdquo;
means a director of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;officer&rdquo;
means an officer of the Corporation, and reference to any specific officer is to the individual holding that office of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;person&rdquo;
means an individual, body corporate, partnership, joint venture, trust, unincorporated organization, association, the Crown or
any agency or instrumentality thereof, or any entity recognized by law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;proxyholder&rdquo;
means an individual holding a valid proxy for a shareholder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;resident Canadian&rdquo; has the meaning ascribed to that phrase
in the Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;shareholder&rdquo; means a shareholder of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;telephonic
or electronic means&rdquo; means telephone calls or messages, facsimile messages, electronic mail, transmission of data or information
through automated touch-tone telephone systems, transmission of data or information through computer networks, any other similar
means or any other means prescribed by the Act; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">&ldquo;voting person&rdquo;
means, in respect of a meeting of shareholders, an individual who is either a shareholder entitled to vote at that meeting, a duly
authorized representative of a shareholder entitled to vote at the meeting or a proxyholder entitled to vote at that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">1.2</FONT></TD><TD STYLE="text-align: justify">Number, Gender and Headings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">In this by-law,
words in the singular include the plural and vice-versa and words in one gender include all genders. The insertion of headings
in this by-law and its division into articles, sections and other subdivisions are for convenience of reference only, and shall
not affect the interpretation of this by-law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">1.3</FONT></TD><TD STYLE="text-align: justify">By-Law Subordinate to Other Documents</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">This by-law is
subordinate to, and should be read in conjunction with, the Act, the articles and any unanimous shareholder agreement of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">1.4</FONT></TD><TD STYLE="text-align: justify">Computation of Time</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The computation
of time and any period of days shall be determined in accordance with the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE 2<BR>
DIRECTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">2.1</TD><TD STYLE="text-align: justify"><B>Notice of Meeting</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Any director or
the president may call a meeting of the board by giving notice stating the date, time and place of the meeting to each of the directors
other than the director giving that notice. Notices sent by delivery or by telephonic or electronic means shall be sent no less
than 48 hours before the time of the meeting. Notices sent by mail shall be sent no less than 5 days before the day of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The board may appoint,
by resolution, dates, time and places for meetings of the board. A copy of any such resolution shall be sent to each director forthwith
after being passed, but no other notice is required for any such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.2</FONT></TD><TD STYLE="text-align: justify">Meetings Without Notice</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">A meeting of the
board may be held without notice immediately following the first or any annual meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.3</FONT></TD><TD STYLE="text-align: justify">Place of Meeting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">A meeting of the
board may be held at any place within or outside Ontario, and no such meeting need be held at a place within Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.4</FONT></TD><TD STYLE="text-align: justify">No Notice to Newly Appointed Director</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">An individual need
not be given notice of the meeting at which that individual is appointed by the other directors to fill a vacancy on the board,
if that individual is present at that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.5</FONT></TD><TD STYLE="text-align: justify">Quorum for Board Meetings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">If there are 1 or
2 directors, all of the directors constitute a quorum at a meeting of the board. If there are 3, 4 or 5 directors, a majority of
the directors constitute a quorum at a meeting of the board. Otherwise, such a quorum consists of the next whole number not less
than 2/5ths of the number of directors. In this section, the &ldquo;number of directors&rdquo; is either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify">the number of directors specified in the articles; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">if a minimum and maximum number of directors is provided for in the articles, the number determined
from time to time by special resolution or, if the special resolution empowers the directors to determine the number, by resolution
of the directors, or if no such resolution has been passed, the number of directors named in the articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.6</FONT></TD><TD STYLE="text-align: justify">Chairman of Board Meetings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The chairman of a
meeting of the board must be a director present at the meeting who consents to preside as chairman. The first-mentioned of the
chairman of the board, the managing director or the president who so qualifies shall preside as chairman of the meeting. If none
of them is so qualified, the directors present at the meeting shall choose a director to preside as chairman of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.7</FONT></TD><TD STYLE="text-align: justify">Votes at Board Meetings</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Each director present
at a meeting of the board shall have 1 vote on each motion arising. Motions arising at meetings of the board shall be decided by
a majority vote. The chairman of the meeting shall not have a second or casting vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">2.8</FONT></TD><TD STYLE="text-align: justify">Officers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Each officer shall
hold office during the pleasure of the board. Any officer may, however, resign at any time by giving notice to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE 3<BR>
MEETINGS OF SHAREHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">3.1</TD><TD STYLE="text-align: justify"><B>Notice of Shareholders&rsquo; Meetings</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The board may call
a meeting of shareholders by causing notice of the date, time and place of the meeting to be sent to each shareholder entitled
to vote at the meeting, each director and the auditor. Such notice shall be sent no less than 21 days and no more than 50 days
before the meeting, if the Corporation is an offering corporation (as defined in the Act), or no less than 10 days and no more
than 50 days before the meeting if the Corporation is not an offering corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">3.2</FONT></TD><TD STYLE="text-align: justify">Quorum at Meetings of Shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">If the Corporation
has only 1 shareholder entitled to vote at a meeting of shareholders, that shareholder constitutes a quorum. Otherwise, any 2 voting
persons present shall constitute a quorum, but only to appoint a chairman and adjourn the meeting. For all other purposes, a quorum
consists of at least 2 voting persons present and authorized to cast in the aggregate not less than 10% of the total number of
votes attaching to all shares carrying the right to vote at that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">3.3</FONT></TD><TD STYLE="text-align: justify">Chairman&rsquo;s Vote</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The chairman of
any meeting of shareholders shall not have a second or casting vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">3.4</FONT></TD><TD STYLE="text-align: justify">Voting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Unless the chairman
of a meeting of shareholders directs a ballot, or a voting person demands one, each motion shall be voted upon by a show of hands.
Each voting person has 1 vote in a vote by show of hands. A ballot may be directed or demanded either before or after a vote by
show of hands. If a ballot is taken, a prior vote by show of hands has no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">3.5</FONT></TD><TD STYLE="text-align: justify">Scrutineers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The chairman of
a meeting of shareholders may appoint for that meeting 1 or more scrutineers, who need not be voting persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">3.6</FONT></TD><TD STYLE="text-align: justify">Who May Attend Shareholders&rsquo; Meeting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The only persons
entitled to attend a meeting of shareholders are voting persons, the directors, the auditor and, if any, the chairman, the managing
director and the President, as well as others permitted by the chairman of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">3.7</FONT></TD><TD STYLE="text-align: justify">Meeting by Telephonic or Electronic Means</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">A meeting of the
shareholders may be held by telephonic or electronic means and a shareholder who, through those means, votes at the meeting or
establishes a communications link to the meeting shall be deemed for the purposes of the Act to be present at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITY CERTIFICATES, PAYMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">4.1</TD><TD STYLE="text-align: justify"><B>Certificates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Subject to Section 4.1(b), security certificates shall
be in such form as the board may approve or the Corporation adopt. The president or the board may order the cancellation of any
security certificate that has become defaced and the issuance of a replacement certificate for it when the defaced certificate
is delivered to the Corporation or to a transfer agent or branch transfer agent of the Corporation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Unless otherwise provided in the articles, the board may provide by resolution that any or all
classes and series of shares or other securities shall be uncertificated securities, provided that such resolution shall not apply
to securities represented by a certificate until such certificate is surrendered to the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">4.2</FONT></TD><TD STYLE="text-align: justify">Cheques</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Any amount payable
in cash to shareholders (including dividends payable in cash) may be paid by cheque drawn on any of the Corporation&rsquo;s bankers
to the order of each registered holder of shares of the class or series in respect of which such amount is to be paid. Cheques
may be sent by delivery or first class mail to such registered holder at that holder&rsquo;s address appearing on the register
of shareholders, unless that holder otherwise directs in writing. By sending a cheque, as provided in this by-law, in the amount
of the dividend less any tax that the Corporation is required to withhold, the Corporation discharges its liability to pay the
amount of that dividend, unless the cheque is not paid on due presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">4.3</FONT></TD><TD STYLE="text-align: justify">Cheques to Joint Shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Cheques payable
to joint shareholders shall be made payable to the order of all such joint shareholders unless such joint shareholders direct otherwise.
Such cheques may be sent to the joint shareholders at the address appearing on the register of shareholders in respect of that
joint holding, to the first address so appearing if there is more than one, or to such other address as those joint shareholders
direct in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">4.4</FONT></TD><TD STYLE="text-align: justify">Non-Receipt of Cheques</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The Corporation
shall issue a replacement cheque in the same amount to any person who does not receive a cheque sent as provided in this by-law,
if that person has satisfied the conditions regarding indemnity, evidence of non-receipt and title set by the board from time to
time, either generally or for that particular case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">4.5</FONT></TD><TD STYLE="text-align: justify">Currency of Dividends</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Dividends or other
distributions payable in cash may be paid to some shareholders in Canadian currency and to other shareholders in equivalent amounts
of a currency or currencies other than Canadian currency. The board may declare dividends or other distributions in any currency
or in alternative currencies and make such provisions as it deems advisable for the payment of such dividends or other distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">ARTICLE 5<BR>
SIGNATORIES, INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">5.1</TD><TD STYLE="text-align: justify"><B>Signatories</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Except for documents
executed in the usual and ordinary course of the Corporation&rsquo;s business, which may be signed by any officer or employee of
the Corporation acting within the scope of his or her authority, the following are the only persons authorized to sign any document
on behalf of the Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">any individual appointed by resolution of the board to
sign the specific document, that type of document or documents generally on behalf of the Corporation; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any director or any officer appointed to office by the board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 0in">Any document so signed
may, but need not, have the corporate seal of the Corporation applied, if there is one.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">5.2</FONT></TD><TD STYLE="text-align: justify">Facsimile or Electronic Signatures</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The signature of
any individual authorized to sign on behalf of the Corporation may, if specifically authorized by resolution of the board, be written,
printed, stamped, engraved, lithographed or otherwise mechanically reproduced or may be an electronic signature. Anything so signed
shall be as valid as if it had been signed manually, even if that individual has ceased to hold office when anything so signed
is issued or delivered, until revoked by resolution of the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">5.3</FONT></TD><TD STYLE="text-align: justify">Restriction on Information Disclosed</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Except as required
by the Act or authorized by the board, no shareholder is entitled by virtue of being a shareholder to disclosure of any information,
document or records respecting the Corporation or its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">ARTICLE 6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">PROTECTION AND INDEMNITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">6.1</TD><TD STYLE="text-align: justify"><B>Transactions with the Corporation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">No director or officer
shall be disqualified, by virtue of being a director, or by holding any other office of, or place of profit under, the Corporation
or any body corporate in which the Corporation is a shareholder or is otherwise interested, from entering into, or from being concerned
or interested in any manner in, any contract, transaction or arrangement made, or proposed to be made, with the Corporation or
any body corporate in which the Corporation is interested and no such contract, transaction or arrangement shall be void or voidable
for any such reason. No director or officer shall be liable to account to the Corporation for any profit arising from any such
office or place of profit or realized in respect of any such contract, transaction or arrangement. Except as required by the Act,
no director or officer must make any declaration or disclosure of interest or, in the case of a director, refrain from voting in
respect of any such contract, transaction or arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">6.2</FONT></TD><TD STYLE="text-align: justify">Limitation of Liability</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in">Subject to the Act,
no director or officer shall be liable for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the acts, receipts, neglects or defaults of any other
person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">joining in any receipt or act for conformity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any loss, damage or expense to the Corporation arising from the insufficiency or deficiency of
title to any property acquired by or on behalf of the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the insufficiency or deficiency of any security in or upon which any moneys of the Corporation
are invested;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">any loss, damage or expense arising from the bankruptcy, insolvency, act or omission of any person
with whom any monies, securities or other property of the Corporation are lodged or deposited;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">any loss, damage or expense occasioned by any error of judgment or oversight; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">any other loss, damage or expense related to the performance or non-performance of the duties of
that individual&rsquo;s office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">6.3</FONT></TD><TD STYLE="text-align: justify">Contracts on Behalf of the Corporation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Subject to the Act,
any contract entered into, or action taken or omitted, by or on behalf of the Corporation shall, if duly approved by a resolution
of the shareholders, be deemed for all purposes to have had the prior authorization of the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">6.4</FONT></TD><TD STYLE="text-align: justify">Indemnity of Directors and Officers</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">As required or
permitted by the Act, the Corporation shall indemnify each Indemnified Person (as defined in this section) against all costs, charges
and expenses, including an amount paid to settle an action or satisfy a judgment, which that Indemnified Person reasonably incurs
in respect of any civil, criminal, administrative, investigative or other proceeding to which that Indemnified Person is made a
party by reason of being or having been a director or officer of the Corporation or of a body corporate or by reason of having
acted in a similar capacity for an entity if:</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Indemnified Person acted honestly and in good faith with a view to the best interests of the
Corporation or as the case may be, to the best interests of the other entity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in the case of a criminal or administrative action or proceeding that is enforced by a monetary
penalty, the Indemnified Person had reasonable grounds for believing that the conduct was lawful; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;Indemnified Person&rdquo; means:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">each director and former director of the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">each officer and former officer of the Corporation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">each individual who acts or acted at the Corporation&rsquo;s request as a director or officer of
a body corporate or an individual acting in a similar capacity of another entity; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the respective heirs and legal representatives of each of the persons designated in the preceding
paragraphs (i) through (iii) of this section 6.4(c).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">6.5</FONT></TD><TD STYLE="text-align: justify">Advances by the Corporation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The Corporation shall
advance monies to an Indemnified Person for the costs, charges and expenses of a proceeding referred to in Section 6.4 provided
the Indemnified Person shall repay such monies if the Indemnified Person does not fulfil the duties of Subsections 6.4 (a) and
(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">6.6</FONT></TD><TD STYLE="text-align: justify">Indemnities Not Limiting</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The provisions
of this Article 6 shall be in addition to and not in substitution for any rights, immunities and protections to which an Indemnified
Person is otherwise entitled under the Act or as the law may permit or require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">6.7</FONT></TD><TD STYLE="text-align: justify">Insurance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Subject to the
Act, the Corporation may purchase and maintain such insurance for the benefit of any individual referred to in Subsection 6.4 as
the board may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE 7<BR>
NOTICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">7.1</TD><TD STYLE="text-align: justify"><B>Procedure for Sending Notices</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Notice shall be
deemed to have been sufficiently sent if sent in writing to the address of the addressee on the books of the Corporation and delivered
in person, sent by prepaid first class mail or sent by any telephonic or electronic means of sending messages, including telex
or facsimile transmission, which produces a paper record. Notice shall not be sent by mail if there is any general interruption
of postal services in the municipality in which or to which it is mailed. Each notice so sent shall be deemed to have been received
on the day it was delivered or sent by telephonic or electronic means or on the fifth day after it was mailed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">7.2</FONT></TD><TD STYLE="text-align: justify">Notices to Successors in Title</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Notice to a shareholder
is sufficient notice to each successor in title to that shareholder until the name and address of that successor have been entered
on the Corporation&rsquo;s share register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">7.3</FONT></TD><TD STYLE="text-align: justify">Notice to Joint Shareholders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Notice to one joint
shareholder is sufficient notice to all of them. Such notice shall be addressed to all such joint shareholders and sent to the
address for them on the Corporation&rsquo;s register of shareholders, or to the first such address if there is more than one.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">7.4</FONT></TD><TD STYLE="text-align: justify">Signatures on Notices</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The signature on
any notice or other communication or document to be sent by the Corporation may be written, printed, stamped, engraved, lithographed
or otherwise mechanically reproduced or may be an electronic signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">7.5</FONT></TD><TD STYLE="text-align: justify">Omission of Notice Does Not Invalidate Actions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">All actions taken
at a meeting in respect of which a notice has been sent shall be valid even if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">by accident, notice was not sent to any person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">notice was not received by any person; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">there was an error in a notice that did not affect the substance of that notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">7.6</FONT></TD><TD STYLE="text-align: justify">Waiver of Notice</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">Any person entitled
to notice under the Act, the articles or the by-laws may waive that notice. Waiver, either before or after the event referred to
in the notice, shall cure any default in sending that notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE 8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REPEAL OF FORMER BY-LAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt">8.1</TD><TD STYLE="text-align: justify"><B>Former By-Laws May be Repealed</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The board may repeal
one or more by-laws by passing a by-law that contains provisions to that effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 72pt"><FONT STYLE="font-weight: normal">8.2</FONT></TD><TD STYLE="text-align: justify">Effect of Repeal of By-Laws</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 1in">The repeal of any
by-law in whole or part shall not in any way affect the validity of any act done or right, privilege, obligation or liability acquired
or incurred thereunder prior to such repeal. All directors, officers and other persons acting under any by-law repealed in whole
or part shall continue to act as if elected or appointed under the provisions of this by-law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 77pt; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><B>MADE</B> by the
board on the 16<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT> day of July, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 77pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;Ronald D. Schmeichel&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">President and Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 92.2pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>BY-LAWS RESOLUTION (ADVANCE NOTICE REQUIREMENT)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify"><B>BE IT HEREBY RESOLVED</B> that<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">the following amendment to By-Law No. 1 of the Corporation,
which shall be added to Section 1.1 of By-Law No. 1 of the Corporation in the appropriate alphabetical sequence is hereby ratified,
confirmed and approved:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&ldquo;<B>Nominating Shareholder</B>&rdquo;
has the meaning ascribed to that phrase in section 2.1A(c);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&ldquo;<B>Nomination Notice</B>&rdquo; has the meaning ascribed to
that phrase in section 2.2A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&ldquo;<B>Nominee</B>&rdquo; has the meaning ascribed to that phrase in section 2.3A(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">the following amendment to By-Law No. 1 of the Corporation, which shall be inserted following Article
2 and preceding Article 3 of By-Law No. 1 of the Corporation, is hereby ratified, confirmed and approved:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&ldquo;<B>ARTICLE 2A </B><BR>
<B>NOMINATION OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>2.1A</B></TD><TD STYLE="text-align: justify"><B>Nomination of Directors</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 71.95pt">Subject to the
Act and the articles, only persons who are nominated in accordance with the following procedures shall be eligible for election
as directors of the Corporation. Nominations of persons for election to the board may be made:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 35.9pt">(a)</TD><TD STYLE="text-align: justify">by or at the direction of the board, including pursuant to a notice of meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 35.9pt">(b)</TD><TD STYLE="text-align: justify">by or at the direction or request of one or more shareholders pursuant to a proposal made in accordance
with the provisions of the Act or a requisition of the shareholders made in accordance with the provisions of the Act; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 35.9pt">(c)</TD><TD STYLE="text-align: justify">by any person (a &ldquo;<B>Nominating Shareholder</B>&rdquo;) who: (i) at the close of business
on the date of the giving of the notice provided described in section 0A and on the record date for notice of such meeting of shareholders
is a registered holder of one or more shares carrying the right to vote at such meeting of shareholders; and (ii) complies with
the provisions set forth in this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>2.2A</B></TD><TD STYLE="text-align: justify"><B>Timely Notice</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 71.95pt">A Nominating
Shareholder must give notice of a nomination (a &ldquo;<B>Nomination Notice</B>&rdquo;) in proper form to the chairman of the board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in the case of an annual meeting
                                         of shareholders, not less than 30 days before the date of the annual meeting of shareholders,
                                         unless such meeting of shareholders is called for a date that is less than 50 days after
                                         the date on which the first public filing or announcement of the date of such meeting
                                         was made, in which case a Nomination Notice must be given not later than the close of
                                         business on the 10<SUP>th</SUP> day following the date of such public filing or announcement;
                                         and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">in the case of a special meeting
                                         of shareholders (which is not also an annual meeting of shareholders) called for the
                                         purpose of electing directors (whether or not called for other purposes), not later than
                                         the close of business on the 15<SUP>th</SUP> day following the day on which the first
                                         public filing or announcement of the date of such meeting of shareholders was made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify">In the event of any adjournment or
postponement of a meeting of shareholders, or an announcement thereof, the required time periods for the giving of a Nomination
Notice as described above shall apply using the date of the adjourned or postponed meeting, or the date of announcement thereof,
as the case may be. This means that a Nominating Shareholder who failed to deliver a timely Nomination Notice in proper written
form to the chairman of the board for purposes of the originally scheduled meeting of shareholders shall nonetheless be entitled
to provide a Nomination Notice for purposes of any adjourned or postponed meeting of shareholders as the determination as to whether
a Nomination Notice is timely is to be determined based off of the adjourned or postponed meeting of shareholders date and not
the original meeting of shareholders date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>2.3A</B></TD><TD><B>Proper Written Form</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 71.95pt">To be in proper
written form, a Nomination Notice must set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">disclose or include, as applicable, as to each person
whom the Nominating Shareholder proposes to nominate for election as a director (a &ldquo;<B>Nominee</B>&rdquo;):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(i)</TD><TD STYLE="text-align: justify">their name, age, business and residential address, principal occupation or employment for the past
five years, status as a &ldquo;resident Canadian&rdquo; (as such term is defined in the Act);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(ii)</TD><TD STYLE="text-align: justify">their direct or indirect beneficial ownership in, or control or direction over, any class or series
of securities of the Corporation, including the number or principal amount;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(iii)</TD><TD STYLE="text-align: justify">any relationships, agreements or arrangements, including financial, compensation and indemnity
related relationships, agreements or arrangements, between the Nominee or any affiliates or associates of, or any person or entity
acting jointly or in concert with, the Nominee and the Nominating Shareholder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(iv)</TD><TD STYLE="text-align: justify">any other information that would be required to be disclosed in a dissident proxy circular or other
filings required to be made in connection with the solicitation of proxies for election of directors pursuant to the Act or applicable
securities law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">disclose or include, as applicable, as to each Nominating
Shareholder giving the notice and each beneficial owner, if any, on whose behalf the nomination is made:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(i)</TD><TD STYLE="text-align: justify">their name, business and residential address, direct or indirect beneficial ownership in, or control
or direction over, any class or series of securities of the Corporation, including the number or principal amount;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(ii)</TD><TD STYLE="text-align: justify">their interests in, or rights or obligations associated with, an agreement, arrangement or understanding,
the purpose or effect of which is to alter, directly or indirectly, the person&rsquo;s economic interest in a security of the Corporation
or the person&rsquo;s economic exposure to the Corporation, including any derivative or hedging arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(iii)</TD><TD STYLE="text-align: justify">any proxy, contract, arrangement, agreement or understanding pursuant to which such person, or
any of its affiliates or associates, or any person acting jointly or in concert with such person, has any interests, rights or
obligations relating to the voting of any securities of the Corporation or the nomination of directors to the Board; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 35.9pt">(iv)</TD><TD STYLE="text-align: justify">any other information relating to such person that would be required to be included in a dissident
proxy circular or other filings required to be made in connection with solicitations of proxies for election of directors pursuant
to the Act or as required by applicable securities laws;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Such notice shall include a written consent duly signed by each Nominee to being named as a nominee
and to serve as a director of the Corporation, if elected, and that the Nominee is eligible to serve as a director under the Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">All information to be provided in a Nomination Notice shall be provided as of the date of such
notice. The Nominating Shareholder shall update such information forthwith so that it is true and correct in all material respects
as of the date that is 10 business days prior to the date of the meeting of shareholders, or any adjournment or postponement thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in"><B>2.4</B></TD><TD STYLE="text-align: justify"><B>Further Information</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 71.95pt">The Corporation
may require that any Nominee furnish such other information as may be required to be contained in a dissident proxy circular or
by applicable law or regulation to determine the independence of the Nominee or his or her eligibility to serve as a director of
the Corporation or a member of any committee of the board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in"><B>2.5</B></TD><TD STYLE="text-align: justify"><B>Discussion Permitted</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 71.95pt">Nothing in this
section shall be deemed to preclude discussion by a shareholder (as distinct from nominating directors) at a meeting of shareholders
of any matter in respect of which such shareholder would have been entitled to submit a proposal pursuant to the provisions of
the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in"><B>2.6</B></TD><TD STYLE="text-align: justify"><B>Notice</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in; text-align: justify; text-indent: 71.95pt">A Nomination
Notice may only be given by personal delivery, facsimile transmission or by e-mail at such e-mail address as may be stipulated
from time to time by the Corporation for purposes of this notice, and shall be deemed to have been given and made only at the time
it is served by personal delivery to the chairman of the board at the registered address of the Corporation, sent by facsimile
transmission (provided that receipt of confirmation of such transmission has been received) or sent by e-mail (at the address as
aforesaid); provided that if such delivery or electronic communication is made on a day which is a not a business day or later
than 5:00 p.m. (Toronto time) on a day which is a business day, then such delivery or electronic communication shall be deemed
to have been made on the next following day that is a business day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in"><B>2.7</B></TD><TD STYLE="text-align: justify"><B>Additional Matters</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The chairman of any meeting of shareholders shall have
the power to determine whether any proposed nomination is made in accordance with this section, and if any proposed nomination
is not in compliance with such provisions, must declare that such defective nomination shall not be considered at any meeting
of shareholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding the foregoing, the board may, in its sole discretion, waive any requirement in
this section.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">any one director or officer of the Corporation is hereby
authorized and directed for and in the name of and on behalf of the Corporation to execute or cause to be executed and to deliver
or cause to be delivered all such documents, and to do or cause to be done all such acts and things, as in the opinion of such
director or officer may be necessary or desirable in order to carry out the terms of this resolution, such determination to be
conclusively evidenced by the execution and delivery of such documents or the doing of any such act or thing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>6
<FILENAME>tv526458_ex2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tv526458_ex2-1img1.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tv526458_ex2-1img2.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 1pt; color: White">FOR VALUE RECEIVED, hereby sell, assign and transfer unto (PLEASE
INSERT SOCIAL INSURANCE NUMBER OF TRANSFEREE) - - (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS OF ASSIGNEE) Shares of the Capital
Stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said Stock
on the Books of the within named Corporation, with full power of substitution in the premises. Dated: Signature: NOTICE: THE SIGNATURE
TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE, IN EVERY PARTICULAR, WITHOUT ALTERATION
OR ENLARGEMENT, OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A SCHEDULE 1 CANADIAN CHARTERED BANK OR AN ELIGIBLE GUARANTOR
INSTITUTION WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM. Guaranteed by: 999999 TIR5405 CERT.9999 RESTRICTIONS
SECURITY INSTRUCTIONS - INSTRUCTIONS DE S&Eacute;CURIT&Eacute; THIS IS WATERMARKED PAPER, DO NOT ACCEPT WITHOUT NOTING WATERMARK.
HOLD TO LIGHT TO VERIFY WATERMARK. PAPIER FILIGRAN&Eacute;, NE PAS ACCEPTER SANS V&Eacute;RIFIER LA PR&Eacute;SENCE DU FILIGRANE.
POUR CE FAIRE, PLACER &Agrave; LA LUMI&Eacute;RE.</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>7
<FILENAME>tv526458_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>AMENDED AND
RESTATED TECHNOLOGY LICENCE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>THIS AMENDED AND RESTATED TECHNOLOGY
LICENCE AGREEMENT</B> is made as of May 16, 2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BETWEEN:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>SUNNYBROOK HEALTH SCIENCES CENTRE</B>, with offices
located at 2075 Bayview Avenue in Toronto, Ontario (the &ldquo;<B>Licensor</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">- and -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><B>PROFOUND MEDICAL INC.</B>,
a company governed by the laws of the Province of Ontario (the &ldquo;<B>Licensee</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RECITALS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">A.</TD><TD STYLE="text-align: justify">The Inventors, while employed by Licensor, have made inventions,
as described in the patent applications and disclosures listed on Schedules B and C hereto (collectively, the &ldquo;<B>Inventions</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">B.</TD><TD STYLE="text-align: justify">Each of the Inventors has assigned all of his respective
right, title and interest in the Inventions to Licensor;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">C.</TD><TD STYLE="text-align: justify">Licensor has filed or is filing patent applications for
such Inventions, as listed and described in Schedules B and <FONT STYLE="font-variant: small-caps">C;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">D.</TD><TD STYLE="text-align: justify">Licensee wishes to commercialize, develop, manufacture,
market, distribute and sell Products which may be derived in whole or in part from the practice of the Technology and, therefore,
desires to obtain a licence from Licensor for rights to the Technology in the Field of Use;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">E.</TD><TD STYLE="text-align: justify">Licensor is willing
                                         to grant Licensee such licence upon the terms and conditions in this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">F.</TD><TD STYLE="text-align: justify">The Licensor and Licensee
entered into a technology licence agreement dated June 16, 2008, as amended March 22, 2010 (the &ldquo;<B>Original Technology
Licence Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">G.</TD><TD STYLE="text-align: justify">Licensee wishes to complete a financing through the issuance
of preferred shares (the &ldquo;<B>Financing</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">H.</TD><TD STYLE="text-align: justify">A shareholders meeting has been called to amend the constating
documents of Licensee in satisfaction of a condition of the Financing and Licensor has agreed to support and vote in favour of
the amendment to those constating documents and otherwise to support that preferred share financing transaction; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">I.</TD><TD STYLE="text-align: justify">In connection with the Financing the parties have agreed
to amend and restate the Original Technology Licence Agreement as set forth in this Agreement, the terms of which shall supersede
any and all licence agreements between the Licensor and Licensee, including the Original Technology Licence Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW THEREFORE,</B> in consideration
of the mutual premises set forth herein (the receipt and sufficiency of which are hereby acknowledged), the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.1</B></TD><TD STYLE="text-align: justify">The following capitalized terms, and other capitalized
terms defined elsewhere in this Agreement, will have the meanings ascribed thereto wherever used in this Agreement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>Acceptance Period</B>&rdquo; has the meaning
set forth in Section 4.1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Affiliate</B>&rdquo; means any legal entity (such
as a corporation, partnership or limited liability company) that controls, is controlled by or is under common control with a
Party hereto. The term &ldquo;control&rdquo; means the ability to direct the management and policies of said entity, whether through
ownership of equity, by contract or otherwise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>Agreement</B>&rdquo; means this agreement and
all schedules attached hereto, as the same may be amended from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>Business Day</B>&rdquo; means any day other than
a Saturday, Sunday or a day which is a statutory or civic holiday in Toronto, Ontario.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>Buy Out IP</B>&rdquo; has the meaning set forth
in Section 8.3.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>Buy Out Milestones</B>&rdquo; means the milestones
set out in Part 1  of Schedule D.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Calendar
                                         Quarter</B>&rdquo; means the following periods of time for each year that this Agreement
                                         is in effect: January 1<SUP>st</SUP> through March 31<SUP>st</SUP> (1<SUP>st </SUP>Calendar
                                         Quarter); April l<SUP>st</SUP> through June 30<SUP>th</SUP> (2<SUP>nd </SUP>Calendar
                                         Quarter); July 1<SUP>st</SUP> through September 30<SUP>th</SUP> (3<SUP>rd </SUP>Calendar
                                         Quarter); and October 1<SUP>st</SUP> through December 31<SUP>st</SUP> (4<SUP>th </SUP>Calendar
                                         Quarter).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B>Confidential Information</B>&rdquo; means any business, marketing, technical,
                                                                                 scientific or other information disclosed by either Party which, at the time of disclosure, is designated as confidential (or
                                                                                 like designation), is disclosed in circumstances of confidence, or would be understood by the Parties, upon exercising
                                                                                 reasonable business judgment, to be confidential. Confidential Information includes, without limitation, all technical
                                                                                 information, all design documentation and all implementation details relating to the Technology, and all Licensee Updates,
                                                                                 and all Licensor Updates and all Trade Secrets.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>Copyright</B>&rdquo; means the rights prescribed
in the <I>Copyright Act</I> (Canada), including those copyright registrations and applications relating to the Technology identified
in Schedules B and C.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B>Effective Date</B>&rdquo; means June 16, 2008.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">&ldquo;<B>End User</B>&rdquo; means an individual, body corporate, unincorporated
                                                                                 organization or any other entity recognized by law to whom or to which, as the case may be, Products are sold or otherwise
                                                                                 transferred.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B>Fees</B>&rdquo; means all amounts payable to
Licensor under this Agreement for the sale of Products and Services.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">&ldquo;<B>Field of Use</B>&rdquo; means MRI-guided trans-urethral
ultrasound therapy throughout the world.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(n)</TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property Rights</B>&rdquo; means
all Patents, Copyrights, trade-names and other intellectual property rights relating to the Technology, whether registered or
not, owned by or licensed to Licensor, including any and all proprietary rights provided under patent law, copyright law, trademark
law or any other statutory provision or applicable common law principles which may provide a right in either ideas, formulae,
algorithms, concepts, inventions or know-how relating to the Technology, including Trade Secrets, or the expression or use thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(o)</TD><TD STYLE="text-align: justify">&ldquo;<B>Inventors</B>&rdquo;
                                         means, collectively, Michael Bronskill, Rajiv Chopra, Kee Tang and Mathieu Burtynk and
                                         &ldquo;<B>Inventor</B>&rdquo; means any one of them.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(p)</TD><TD STYLE="text-align: justify">&ldquo;<B>Know-how</B>&rdquo; means any and all trade secrets,
technical expertise, knowledge, confidential information and know-how, whether patentable or unpatentable, relating to the Technology
and/or the Inventions, whether in written, machine readable, drawing or oral form, including, without limitation, all technical
information, raw material data, product specifications, processes and designs, operating and production data, calculations, computer
programs, instructions and techniques, quality control, and other standards and drawings relating thereto developed by an Inventor
and which exists as at the Effective Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(q)</TD><TD STYLE="text-align: justify">&ldquo;<B>Licensee Updates</B>&rdquo; means any update,
correction, improvement, enhancement or modification of the Technology created, produced or developed by the Licensee (without
the active participation of Licensor personnel) in the Field of Use during the Term.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(r)</TD><TD STYLE="text-align: justify">&ldquo;<B>Licensor Updates</B>&rdquo; means any update,
correction, improvement, enhancement or modification of the Technology created, produced or developed by the Inventors (or any
of them) or Licensor in the Field of Use during the Term.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(s)</TD><TD STYLE="text-align: justify">&ldquo;<B>Milestones</B>&rdquo; means the milestones set
out in Part 2 of Schedule D.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(t)</TD><TD STYLE="text-align: justify">&ldquo;<B>Notice of Offer</B>&rdquo; has the meaning set
forth in Section 4.1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(u)</TD><TD STYLE="text-align: justify">&ldquo;<B>Party</B>&rdquo;
                                         means either Licensee or Licensor, and &ldquo;<B>Parties</B>&rdquo; means both of them,
                                         collectively.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">&ldquo;<B>Patents</B>&rdquo; means the patents, patent
applications and patent disclosures listed on Schedules B and C and any continuations, continuations in part, divisionals, reissues,
re-examinations, renewals or extensions of such foregoing patents and patent applications and any patents which may issue on,
from or as a result of any of the foregoing. For greater clarity, Patents does not include patented Licensor Updates or patented
Licensee Updates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(w)</TD><TD STYLE="text-align: justify">&ldquo;<B>Person</B>&rdquo; means any individual, sole proprietorship, partnership,
                                                                                 unincorporated association, unincorporated syndicate, unincorporated organization, trust, body corporate and a natural person
                                                                                 in his or her capacity as trustee, executor, administrator or other legal representative.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(x)</TD><TD STYLE="text-align: justify">&ldquo;<B>Prime Rate</B>&rdquo; means the published
prime rate of interest per annum that the Royal Bank of Canada offers to its most credit-worthy commercial customers for Canadian
dollar loans, adjusted monthly on the last business day of each month that any amount remains outstanding hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(y)</TD><TD STYLE="text-align: justify">&ldquo;<B>Product</B>&rdquo; means any product derived
from the Technology or that results from practising or using the Technology, in whole or in part.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(z)</TD><TD STYLE="text-align: justify">&ldquo;<B>Service</B>&rdquo; means any service to Third
Parties, not provided for free, that is provided by using the Technology, by using a Product or that relates to a Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(aa)</TD><TD STYLE="text-align: justify">&ldquo;<B>Sponsored Research Agreement</B>&rdquo; means
any sponsored research agreement entered into between Licensor and Licensee with respect to the Technology, including the Sponsored
Research Agreement entered into between the Parties as of the Effective Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(bb)</TD><TD STYLE="text-align: justify">&ldquo;<B>Technology</B>&rdquo; means: (i) all existing
technology relating to the Field of Use that is described and claimed in the Patents and possessed as at the Effective Date by
Licensor that is not (other than as contained in any patent application or patent disclosure) presently available to the public
by publication, and (ii) all Know-How and all Intellectual Property Rights relating to such existing technology.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(cc)</TD><TD STYLE="text-align: justify">&ldquo;<B>Term</B>&rdquo; has the meaning set forth in
Section 13.1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(dd)</TD><TD STYLE="text-align: justify">&ldquo;<B>Third Party</B>&rdquo; means a Person who deals
with a Party to this Agreement at arm&rsquo;s length, which for these purposes has the meaning that it has for purposes of the
<I>Income Tax Act</I> (Canada), as in effect on the Effective Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ee)</TD><TD STYLE="text-align: justify">&ldquo;<B>Trade Secrets</B>&rdquo; means information and/or
knowledge which derives economic value, actual or potential, from not being generally known to, or readily ascertainable by proper
means by, other persons who can obtain economic value from its disclosure or use, and which is the subject of efforts that are
reasonable under the circumstances to maintain its secrecy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(ff)</TD><TD STYLE="text-align: justify">&ldquo;<B>Update Interest</B>&rdquo; has the meaning set
forth in Section 4.1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LICENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.1</B></TD><TD STYLE="text-align: justify"><B>Grant of Licences.</B> Subject to the terms and conditions
of this Agreement, Licensor hereby grants to Licensee and Licensee hereby accepts an exclusive, royalty-free, worldwide right
and licence under the Intellectual Property Rights to use the Technology in the Field of Use, with no right to sublicense except
as specifically provided in this Section 2.1:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">to use, copy, display, create derivative works of and integrate
the Technology and any such derivative works into the Products and otherwise to use, copy and practice the Technology (including
making Licensee Updates and other improvements to the Technology);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">to engage contractors and collaborators to (i) market and
sell the Products and (ii) reproduce, develop and make components and any parts thereof incorporated into any Products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">to make any Licensee Updates and derivative works thereof,
and incorporate Licensee Updates and any such derivative works into the Products, provided that: (i) Licensee provides notification
to Licensor of such Licensee Updates, and (ii) Licensee grants Licensor the licence described in Section 3.2(b);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">to make, have made, use, lease, sell, offer for sale and
import Products and to make, have made, use, copy, display, sell and distribute Technology (solely for the purpose to be incorporated
into Products) to End Users as components of other products intended for Sale to End Users;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">to sell any Service(s); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">to provide technical support to End Users; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">to grant sub-licences of all rights set out above and to
disclose Confidential Information to sub-licensees, provided that sub-licensees are: (i), with respect to Licensee, a Third Party
(ii) bound by terms and conditions no less onerous than set forth in this Agreement (it being understood that no further amount
shall be payable to Licensor or the Inventors in connection with any such sub-licence), provided that Licensee shall provide at
least five (5) days prior written notice to Licensor of Licensee&rsquo;s intent to enter into any such sub-license.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.2</B></TD><TD STYLE="text-align: justify"><B>Prohibited Uses.</B> Licensee may not provide the Technology
to any Third Party without Licensor&rsquo;s prior written permission, except as expressly provided in this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.3</B></TD><TD STYLE="text-align: justify"><B>Validity. </B>Licensee agrees that, during the Term,
it will not, either directly or indirectly, challenge the validity of the Technology and any Intellectual Property Rights associated
therewith, including any patents issuing in relation to Licensor Updates, or the ownership rights of Licensor in the Technology
or Licensor Updates, and shall not assist any person or entity to do so, provided such obligations are not contrary to law, in
which case this Section shall be read down only as necessary to make the obligation valid and enforceable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.4</B></TD><TD STYLE="text-align: justify"><B>Retained Rights.</B> Subject to the provisions set forth
in Section 2.5, Licensor expressly reserves from the licence rights granted above:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the right of Licensor to publish or disclose research results
arising from performance of the Technology; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the right to use any and all of the Patents and Technology
for the purpose of non-commercial research and teaching, educational and administrative purposes.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">provided
that Licensor Updates that result from such research are subject to the right of first refusal set out in Section 4.1 and the obligation
to disclose set out in Section 3.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.5</B></TD><TD STYLE="text-align: justify"><B>Publications.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Each Party (the &ldquo;<B>First Party</B>&rdquo;) will
provide a copy of any proposed publication or disclosure related to the Technology to the other Party for its review at least
thirty (30) days before submission for publication or disclosure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Upon the other Party&rsquo;s written request, to be delivered
to the First Party within twenty (20) days of the other Party&rsquo;s receipt of such proposed publication or disclosure, the
First Party will, at the other Party&rsquo;s Sole option: (i) delay publication up to sixty (60) additional days to enable the
other Party to secure intellectual property protection of any intellectual property that would be publicly disclosed by such publication,
and/or (ii) delete any Confidential Information provided by the other Party from the manuscript or proposed disclosure.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Licensor agrees to acknowledge the support of Licensee
in all publications and disclosure related to the Technology that have been funded by Licensee under the Sponsored Research Agreement,
unless otherwise agreed in writing by the Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.6</B></TD><TD STYLE="text-align: justify"><B>Know-how.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Licensor shall give to Licensee a copy
of all relevant Know-how that has been reduced to written form, including all Patents, together with all documentation that is
reasonably necessary for understanding the Technology, to the extent that it exists and is within the control of Licensor or any
of the Inventors, along with oral explanations of the Know-how and of unwritten Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OWNERSHIP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.1</B></TD><TD STYLE="text-align: justify"><B>Ownership of Technology.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Except for the rights expressly granted under this Agreement, all right, title and interest
                                                                                 in and to the Technology and Licensor Updates, including the Technology incorporated in the Products, are and shall at all
                                                                                 times remain the property of Licensor, the entity from whom the Licensor has licensed such Technology or any permitted
                                                                                 transferee to whom the Technology has been transferred.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Except for the rights expressly granted under this Agreement,
all right, title and interest in and to the Licensee Updates are and shall at all times remain the property of Licensee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.2</B></TD><TD STYLE="text-align: justify"><B>Ownership of Improvements.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If Licensor receives
from any third party (the &ldquo;<B>Third Party</B>&rdquo;) a <I>bona fide</I> written offer (the &ldquo;<B>Third Party Offer</B>&rdquo;)
with respect to a Licensor Update or if Licensor (or any Inventor) proposes to in any other way take any steps to commercialise
any Licensor Update, then Licensor shall, except as provided otherwise in Section 3.2(e), promptly inform Licensee and Licensee
shall have a right of first refusal to obtain an exclusive licence to use such Licensor Update in accordance with Article 4. Any
disclosure of Licensor Updates shall constitute Licensor&rsquo;s Confidential Information and be treated in strict confidence
by Licensee in accordance with Article 11. For greater clarity, &ldquo;steps to commercialise&rdquo; does not include actions
to obtain intellectual property rights with respect to any Licensor Update in the absence of any Third Party Offer with respect
to such Licensor Update.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Within 10 days of the end of each calendar year during
the Term, Licensor shall disclose (on a confidential basis) to Licensee all Licensor Updates (if any) that were generated during
the twelve (12) months preceding the end of such calendar year.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Within 10 days
                                         of the end of each year during the Term, Licensee shall disclose (on a confidential basis)
                                         to Licensor all Licensee Updates (if any) that were generated during the twelve (12)
                                         months preceding the end of such calendar year and Licensee shall provide to Licensor
                                         a licence, without cost, to use all such Licensee Updates exclusively for the purposes
                                         set out in Section 2.4(b), on the same terms and conditions as set out therein, and Licensee
                                         Updates shall be deemed to form part of the Technology for the purposes of Section 2.4(b).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Where Licensee exercises its Right of First Refusal in
accordance with Article 4, Licensee shall have the right (and Licensor, for greater certainty, shall have no obligation) to file
patent applications on any such Licensor Updates, provided that Licensee agrees to pay for all expenses associated with the filing
and prosecution of such patent applications. If Licensee elects not to file patent applications for such additions or changes,
Licensor shall have the right to apply for patents at its own expense. It is understood that Licensor shall not be obligated to
undertake responsibility with respect to any such additions or changes unless it elects to do so.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Notwithstanding Subsections 3.2(a), (b), (c) and (d), any
Licensee Updates or Licensor Updates to the Technology which qualify as New Intellectual Property under the terms of the Sponsored
Research Agreement shall be treated in accordance with the provisions of such research agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.3</B></TD><TD STYLE="text-align: justify"><B>Reservation of Rights.</B> Licensor reserves all rights
not expressly granted in this Agreement, and nothing in this Agreement, including any grant or reservation of rights set forth
herein, shall be construed as implying or giving rise to any implied grant or licence of any right, or as implying any limitation
of any reservation of rights, except as expressly set forth in this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RIGHT OF FIRST REFUSAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.1</B></TD><TD STYLE="text-align: justify"><B>Right of First Refusal.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensor may not license, convey, transfer or otherwise
grant an interest in or to a Licensor Update (an &ldquo;<B>Update Interest</B>&rdquo;) to any person or entity and shall
not take any action or proceed in any manner with a view to commercialising any Licensor Update except in accordance with the
provisions of this Section 4.1 and pursuant to a Third Party Offer that is subject to the right of first refusal set out in this
Section 4.1. For greater clarity, &ldquo;View to commercialising&rdquo; does not include actions to obtain intellectual property
rights with respect to any Licensor Update in the absence of a Third Party Offer with respect to such Licensor Update.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If Licensor receives from any Third Party (including without
limitation (i) any entity in which Licensor, any Inventor or any member of Licensor&rsquo;s faculty or staff has any equity or similar
interest and (ii) any entity proposed to receive any rights or interest in or to a Licensor Update in connection with a spin-out
or similar transaction with respect to a Licensor Update) a Third Party Offer with respect to an Update Interest, Licensor shall
only accept such Third Party Offer subject to compliance with the provisions of this Section 4.1. Upon such conditional acceptance,
Licensor shall deliver a written notice (the &ldquo;<B>Notice of Offer</B>&rdquo;) to Licensee irrevocably offering the Update
Interest at the same price and in all other material respects on the same terms and conditions as provided in the Third Party
Offer, <I>provided that</I> if the applicable Licensor Update was developed pursuant to a sponsored research or similar agreement,
the price in the Notice of Offer shall not include or account for any funding (whether made in the form of cash or otherwise)
previously advanced or otherwise made available to Licensor or any Inventor. Licensor shall deliver, with the Notice of Offer,
a true copy of the Third Party Offer, The offer contained in the Notice of Offer shall be irrevocable except with the Licensee&rsquo;s
consent and shall be open for acceptance for a period of 30 Business Days after the date upon which the Notice of Offer is received
by the Licensee (the &ldquo;<B>Acceptance Period</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Within the Acceptance
                                         Period, Licensee may accept the offer contained in the Notice of Offer by delivering
                                         to Licensor a written notice to such effect (an &ldquo;<B>Acceptance Notice</B>&rdquo;).
                                         To permit the practical implementation of this Section 4.11, no Update Interest may be
                                         provided by Licensor to any Third Party for consideration other than cash or publicly
                                         traded common shares of a corporation with a public float in excess of $250 million,
                                         the common shares of which are listed and posted for trading on a recognised North American
                                         stock exchange. Where the Third Party Offer contemplates consideration in the form of
                                         such publicly traded common shares, then Licensee may, in its Acceptance Notice, specify
                                         that it shall pay, on the Same terms and timelines, the cash equivalent of the market
                                         price of such shares. For the purposes of this Section 4.1, &ldquo;market price&rdquo;
                                         shall have the meaning ascribed to such term in Section 1.3 of OSC Rule 62-504 as in
                                         effect on May 16, 2011 and where the relevant date for determination of such market price
                                         is the date of the Third Party Offer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">If Licensor does not receive an Acceptance Notice from
Licensee within the Acceptance Period confirming its acceptance of the offer contained in the Notice of Offer, Licensee&rsquo;s
right to acquire the Update Interest under this Section 4.1 shall cease as at the end of the Acceptance Period and Licensor may
thereafter provide the Update Interest to the Third Party at the price and upon the terms and conditions specified in the Third
Party Offer, provided that in any event the agreement with the Third Party is on the same terms as contained in the Third Party
Offer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Any provision of an Update Interest to a Third Party pursuant  to this Section 4.1 must be
                                                                                 completed within 60 days following the expiry of the Acceptance Period, failing which the provisions of this Section 4.1
                                                                                 shall again apply to any proposed provision of an Update Interest, and so on from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PAYMENTS; LEASED PREMISES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.1</B></TD><TD STYLE="text-align: justify"><B>Execution
                                         Payments; Leased Premises.</B> Licensee has paid to Licensor $37,500 ($25,000 on December
                                         30, 2009 and 12,500 in February 2010) and agrees to pay to Licensor a further $62,500
                                         (collectively, the &ldquo;<B>Execution Payments</B>&rdquo;) on the following dates: $12,500
                                         on April 1, 2010 and $50,000 on June 1, 2010. The Parties acknowledge the lease of Suite
                                         4040, 3080 Yonge Street, Toronto, ON, M4N 3N1 from September 1, 2008 to August 31, 2009
                                         and further acknowledge that there are no outstanding payment obligations in respect
                                         thereof. If the Sponsored Research Agreement executed on June 17, 2008, between the Parties,
                                         continues to a mutually agreed-upon level beyond June 30, 2010, Licensor will consider
                                         extending the payment dates of the unpaid Execution Payments, with any extension to be
                                         agreed to by Licensor in writing at least forty-five (45) days prior to the due date.
                                         The Lease Term shall not be less than the aggregate Execution Payments divided by the
                                         Lease Rate. For greater certainty, Licensor agrees that the location of the rental space
                                         described in the Lease Agreement will not change during the Lease Term without Licensee&rsquo;s
                                         prior written consent, such consent not to be unreasonably withheld or delayed. Licensor
                                         will provide to Licensee a draft of the lease agreement with respect to such premises
                                         (the &ldquo;<B>Lease Agreement</B>&rdquo;) within sixty (60) days of the Effective Date.
                                         The Execution Payments shall be credited against any payments owing by Licensee to Licensor
                                         under the Lease Agreement. If Licensee vacates the rental space provided by Licensor
                                         prior to expiry of the Lease Term (in circumstances where Licensor is in full compliance
                                         with its obligations under the Lease Agreement), all remaining Execution Payments shall
                                         accelerate and immediately become due and payable and Licensor, subject to compliance
                                         with the terms of the Lease Agreement, may re-let such premises without deduction against
                                         the Execution Payments.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.2</B></TD><TD STYLE="text-align: justify"><B>Milestone
                                         Payment.</B> Licensee shall pay to Licensor the amount of Cdn.$250,000 (the &ldquo;<B>Milestone
                                         Payment</B>&rdquo;) within fifteen (15) days of notification of clearance by the United
                                         States Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;) of Licensee&rsquo;s first
                                         Product for sale for human use, including any U.S. 510k or pre-market approval (&ldquo;<B>PMA</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.3</B></TD><TD STYLE="text-align: justify"><B>Payment.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Parties acknowledge that Fees payable
within Canada are subject to Harmonized Sales Tax (&ldquo;<B>HST</B>&rdquo;). Licensee shall provide to Licensor a statement as
to Licensee&rsquo;s HST status and shall remit such amounts to Licensor as are required under Canadian HST legislation. Licensor
is registered to collect HST under registration number 10809 1281 RT0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensee shall pay promptly all Fees to Licensor, free
and clear of all taxes or other charges, including income taxes<SUB></SUB> except such taxes as Licensee shall be required by
law to withhold. Any withholding taxes or like charges which Licensee shall be required by law to withhold on remittance of the
Fees shall be deducted from Fees paid to Licensor. Licensee shall furnish Licensor with copies of official receipts for such taxes
or other charges. If any currency conversion shall be required in connection with the payment of Fees hereunder, such conversion
shall be made quarterly by using the published closing exchange rate (as published by the Bank of Canada) for the purchase of
Canadian Dollars for the day preceding the date of payment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If Licensee does not pay any amount owing to Licensor within thirty (30) days of such amount
                                                                                 becoming due, it shall pay such amount, plus interest calculated at the Prime Rate plus three percent, compounded monthly.
                                                                                 The payment of interest shall not be deemed an alternative to the payment of amounts owing on the due date, which payment,
                                                                                 shall be deemed to be in default and Licensor may terminate this Agreement as provided in Section 13.4 if Licensee fails to
                                                                                 remedy the default within the time period set out therein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LICENSOR REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.1</B></TD><TD STYLE="text-align: justify"><B>Right and Authority Warranty.</B> Licensor represents
and warrants that it has the right and authority to grant the rights and licences granted herein, that it has not previously granted
any rights with respect to the Technology or the Intellectual Property Rights that would conflict with the rights granted hereunder
and further that each of the Inventors has assigned his respective right, title and interest in and to the Inventions and the
Technology to Licensor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.2</B></TD><TD STYLE="text-align: justify"><B>No Lien on Intellectual Property Rights. </B>Licensor
represents and warrants that, to its knowledge, the Technology is not subject to any outstanding order, ruling, decree, court
judgment or stipulation by or with any court, arbitrator or administrative agency. Licensor further represents and warrants that
it has proceeded with reasonable due diligence prior to filing for the Patents and that, to its actual knowledge, the Technology
docs not infringe on any patent or any other intellectual property rights of any Third Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.3</B></TD><TD STYLE="text-align: justify"><B>Validity.</B> Nothing in this Agreement shall constitute
a representation or warranty by Licensor that any Patent pertaining to the Technology is valid or enforceable in any country.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.4</B></TD><TD STYLE="text-align: justify"><B>Exclusion.</B> Except as expressly otherwise set forth
herein or provided by applicable law, any liability of the Parties and their respective directors, officers, employees, agents
or advisers for any misrepresentation or other act or omission made or committed in the preparation of this Agreement, but rot
included in this Agreement (including any liability in tort, for breach of pre-contractual obligations or under any implied representations
and warranties), shall be excluded.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.5</B></TD><TD STYLE="text-align: justify"><B>Inventors.</B> Licensor confirms that, other than as
provided below in this Section 6.5, Nicolas Yak and each of the Inventors is currently, and has been since June 17, 2008, a member
of Licensor&rsquo;s faculty and/or staff. Licensor and Licensee confirm and acknowledge that Kee Tang ceased to be a member of
Licensor&rsquo;s faculty and/or staff on October 31, 2008 and that Dr. Bronskill ceased to be a member of Licensor&rsquo;s faculty
and/or staff on June 30, 2009. Each of the Inventors and Nicolas Yak, to the extent that he contributed to the development of
Licensor Updates (including Licensor Updates which qualify as New Intellectual Property under the terms of the Sponsored Research
Agreement) while a member of Licensor&rsquo;s faculty and/or staff, assigned to Licensor all of his respective right, title and
interest in and to all such Licensor Updates and New Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE 7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LICENSEE WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.1</B></TD><TD STYLE="text-align: justify"><B>Development and Use of Technology.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensee shall diligently proceed with the integration of the Technology into, and the
                                                                                 development and manufacture of, Products in order to make them readily available to End Users for sale and use as soon as is
                                                                                 commercially reasonable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Licensee shall market the Products. All marketing and promotion
of Products and decisions with respect thereto shall be made by Licensee in the exercise of its absolute discretion.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Licensee shall spend sufficient funds on the development
and sale of Products to reasonably carry out its obligations hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Licensee shall use its commercially reasonable efforts, consistent with reasonable business
                                                                                 practices, <B STYLE="font-style: normal; font-weight: normal; text-decoration: none"> to </B>perform the Milestones within the established timelines set forth on Schedule D.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">The Parties hereby agree that, upon the written request
of either of them, they will enter into good faith discussions with respect to the Milestones to be achieved after January 1,
2014 and, in particular, whether the Milestones remain appropriate in the context of Licensee&rsquo;s progress and the state of
development of the Technology, it being understood that there shall be no change to the Milestones unless each of the Parties
agree to such change.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.2</B></TD><TD STYLE="text-align: justify"><B>Reports and Other Deliveries.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Within forty-five (45) days of each calendar year end,
Licensee shall provide Licensor with a written report with respect to the Technology that sets out: (i) the amount of money spent
by Licensee on research and development, (ii) the amount of money spent by Licensee on operations, (iii) a summary of technological
and clinical progress achieved in the previous calendar year, and (iv) the regulatory status of any Products under development.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Within forty-five (45) days of the calendar year end in
which Products are first sold to an End User, and within forty-five (45) days of each subsequent calendar year end thereafter,
Licensee shall provide Licensor with a written report with respect to the Technology that sets out: (i) a summary of all sales
and uses, if any, made of Products during the preceding Calendar Quarter, and (ii) the number and dollar amount of sales made
during such Calendar Quarter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Each written report delivered to Licensor shall include
at least the following:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the number of Products manufactured;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the number of Products sold by Licensee;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">an accounting for all Products used or sold by Licensee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Unless otherwise provided under the Sponsored Research
Agreement, Licensee shall provide Licensor with two copies of software and documentation for all major releases of Products developed
throughout the Term, which deliverables shall constitute Licensee&rsquo;s Confidential Information and shall be treated in strict
confidence by Licensor in accordance with Article 11.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Within forty-five (45) days of the date of this Amended and Restated Technology Licence
                                                                                 Agreement, Licensor will complete filing all remaining disclosure(s) contemplated pursuant to the terms of the Original
                                                                                 Technology Licence Agreement, including disclosing all Updates generated since the Effective Date and prior to May 16, 2011,
                                                                                 together with such assistance, advice and correspondence contemplated under Sections 8.2(a) and 8.2(b) of the Original
                                                                                 Technology License Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.3</B></TD><TD STYLE="text-align: justify"><B>Books and Records.</B> Licensee shall keep complete,
true and accurate books of account containing the particulars that may be necessary for the purpose of showing the amounts payable
to Licensor hereunder, which books of account shall be kept at Licensee&rsquo;s principal place of business or the principal place
of business of the appropriate division of Licensee to which this Agreement relates. Upon at least 24 hours advance notice to
Licensee and during regular working hours, all applicable books and the supporting data shall be available for inspection by Licensor
or its agents, on a confidential basis, not more than once during any calendar year during the term of this Agreement, unless
there is a discrepancy of greater than two percent (2%) from the amounts reported under Section 7.2, for the purpose of verifying
compliance with this Agreement, provided that any such inspection shall be conducted in a manner that does not unreasonably interfere
with Licensee&rsquo;s normal operations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.4</B></TD><TD STYLE="text-align: justify"><B>Good Faith.</B> Licensee shall act reasonably and in
good faith in all respects regarding the Fees and Milestones, and Licensee shall not participate in any scheme, alliance, partnership
or other business arrangement or activity that has the effect of evading or reducing the Fees that would otherwise be payable.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INTELLECTUAL PROPERTY PROSECUTION AND
MAINTENANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.1</B></TD><TD STYLE="text-align: justify"><B>Patent Fees.</B> Licensee shall pay all future costs and legal fees incurred in the
                                                                                    preparation, filing and maintenance of United States patent applications US 2007/0239062 and US 2006/0206105. United States
                                                                                    patent US 6,589,174, or any issued patents thereof and any United States patents or patent applications derived from
                                                                                    confidential disclosure forms as listed in Schedule C, including any taxes payable with respect thereto. The parties hereby
                                                                                    confirm and agree that Licensee has paid to Licensor the amount of Cdn.$50,000 as reimbursement for Licensor&rsquo;s
                                                                                    work and expenses incurred in connection with the Patents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.2</B></TD><TD STYLE="text-align: justify"><B>Filings.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensee shall, as between Licensor and Licensee, be responsible
for filing, prosecuting and maintaining the Patents and any subsequent patent applications relating to the Technology under this
Agreement. Licensee shall use reasonable efforts to obtain such patents and shall not allow such patents to lapse for failure
to comply with maintenance obligations. Licensor shall provide to Licensee all such assistance, at Licensee&rsquo;s cost and expense,
as Licensee may reasonably request in connection with Licensee&rsquo;s efforts to obtain and maintain such patents. Licensee shall
consult with Licensor (whose consent shall not be required) in order to determine in which countries other than the United States
to pursue any patent applications relating to the Technology, provided that, if Licensee elects not to pursue a patent application
in any country, Licensor shall be entitled to do so and (i) Licensee&rsquo;s license for the Technology for such jurisdiction
shall promptly terminate; (ii) Licensor may license the Technology to a Third Party in such jurisdiction; and (iii) Licensee shall
provide such assistance to Licensor, at Licensor&rsquo;s cost and expense, in this regard as Licensor may reasonably request.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Licensee will keep Licensor reasonably advised of the progress
of prosecution and of any actions Licensee proposes to take or has taken in connection with the prosecution or maintenance of
the Patents or any patent application included in the definition of Patents. Licensee will provide Licensor with copies of correspondence
and all actions issued by patent authorities and shall consider, but is not obligated to incorporate, any comments, remarks or
suggestions Licensor may promptly provide to Licensee in writing at least (30) days prior to any patent office due dates of which
it becomes aware.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Unless otherwise agreed, for all Technology and any Licensor
Updates thereof, the Parties agree that, if necessary, inventorship shall  be defined according to Title 35 of the United States
Code.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.3</B></TD><TD STYLE="text-align: justify"><B>Assignment of Rights.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensor hereby
                                         grants to Licensee an option (the &ldquo;<B>Buy Out</B>&rdquo;) to acquire ownership
                                         of the Technology, including, without limitation, the Patents (the &ldquo;<B>Buy Out
                                         IP</B>&rdquo;) upon Licensee having satisfied or otherwise achieved the Buy Out Milestones
                                         and paying to Licensor the amount of Cdn $200,000, which amount shall be in addition
                                         to any Fees owing or already paid.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Licensor shall assign to Licensee all of its (and of the Inventors&rsquo;) right, title and
                                                                                 interest in and to the Buy Out IP, all pursuant to a written agreement prepared by Licensee and to be entered into by the
                                                                                 Parties, which agreement shall contain terms reasonable and customary in similar transactions (it being understood and agreed
                                                                                 that no consideration or amount other than the Cdn $200,000 amount noted in Section 8.3(a) plus reimbursement by Licensee for
                                                                                 all reasonable costs incurred by Licensor in connection with necessary third party consents or assistance (as notified to
                                                                                 Licensee in advance of the Buy Out becoming final) incurred in connection with meeting the Licensor&rsquo;s obligations under
                                                                                 this Section 8.3(a) shall be payable in connection with such assignment). To the extent any rights to the Buy Out IP,
                                                                                 including any moral rights, are not capable of assignment under applicable law, Licensor hereby irrevocably and
                                                                                 unconditionally waives all enforcement of those rights to the maximum extent permitted under applicable law and agrees to
                                                                                 obtain such a waiver in writing from each Licensor personnel, each Inventor and any other personnel involved in the
                                                                                 development or creation of any part of the Buy Out IP. Upon Licensee&rsquo;s request and at Licensee&rsquo;s expense,
                                                                                 Licensor shall execute and deliver to Licensee all instruments and other documents, and shall take such other actions as may
                                                                                 be necessary or reasonably requested by Licensee, so that Licensee may protect and defend its rights in and to such Buy Out
                                                                                 IP.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Licensee shall, in connection with any Buy Out, provide
to Licensor, upon completion of such Buy Out transaction, a license to use the Buy Out IP, without cost, for the purposes set
out in Section 2.4(b), on the same terms and conditions as set out therein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.4</B></TD><TD STYLE="text-align: justify"><B>Infringement.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Each Party will notify the other Party promptly upon becoming
aware of any claim or assertion by a Third Party that the Intellectual Property Rights infringe or otherwise are in violation
of a Third Party&rsquo;s patents or intellectual property. The Parties shall promptly enter into discussions with the Third Party
to determine the existence and extent of the infringement and the Parties&rsquo; mutually agreed course of action. Each Party
will absorb its own costs of the discussions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Licensee and Licensor may agree to jointly defend or pursue litigation, but neither of them
                                                                                 shall bind or commit the other to any course of action which involves liability for legal costs, expenses or damages. If
                                                                                 Licensee and Licensor fail to agree, within a reasonable time, having regard to the normal progress of litigation, as to any
                                                                                 course of action which might be jointly taken, then either of them may take or defend proceedings alone, if legally entitled
                                                                                 to act alone, and shall be entitled to retain anything awarded to it by a court or paid to it as a settlement by the Third
                                                                                 Party. Where either Licensee or Licensor wishes to act alone or is unable to agree on a joint defence, but
                                                                                 formalities require participation of the other, then the other shall join in the proceeding to the extent necessary for
                                                                                 formalities. Each will cooperate with the other in making available all necessary documents and witnesses for any legal
                                                                                 proceedings. The Party acting alone will reimburse the other for its time and all costs associated with participation in the
                                                                                 proceedings, and making available of documents. If either Licensee or Licensor proceeds alone (or with the other as a
                                                                                 formality), it shall indemnify the other for reasonable legal costs for representation that is reasonably necessary and for
                                                                                 any court-ordered payments. Neither Licensee nor Licensor shall settle any such claim without the consent of the other, such
                                                                                 consent not to be unreasonably withheld.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The Parties may negotiate with a Third Party to obtain any
additional rights required such as may arise if a Third Party&rsquo;s patent emerges. Each Party shall absorb its own costs of
negotiation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PATENT MARKING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.1</B></TD><TD STYLE="text-align: justify"><B>Technology Patent.</B> Licensor covenants to provide
issued patent numbers pertaining to the Technology to Licensee and such information will be set forth on Schedule B, as may be
amended from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.2</B></TD><TD STYLE="text-align: justify"><B>Patent Marking.</B> Licensee shall mark all Products
made, used or sold pursuant to the terms of this Agreement, in accordance with all applicable patent marking laws and, prior to
marketing the Product, will obtain written confirmation from Licensor that all applicable patent numbers are set forth on Schedule
B. Thereafter, Licensor shall keep Licensee apprised of further Patents it wishes to have marked on Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEMNIFICATION AND INSURANCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.1</B></TD><TD STYLE="text-align: justify"><B>Disclaimer.</B> Except as otherwise set forth in this Agreement, all Technology, Licensor
                                                                                     Updates and Intellectual Property Rights arc provided on an &ldquo;as is&rdquo; basis.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.2</B></TD><TD STYLE="text-align: justify"><B>Indemnification by Licensee.</B> Licensee shall save, defend and hold Licensor and its
                                                                                     officers, directors, employees, consultants and agents harmless from and against any and all suits, claims, actions, demands,
                                                                                     liabilities, expenses and losses, including reasonable legal expenses and attorneys&rsquo; fees, resulting directly or
                                                                                     indirectly from this Agreement or the development or sale of Products (save and except for any and all suits, claims,
                                                                                     actions, demands, liabilities, expenses and losses to the extent caused by the gross negligence or wilful misconduct
                                                                                     of Licensor or arising directly or indirectly out of or in connection with the breach of this Agreement by Licensor). This
                                                                                     provision shall survive expiration or other termination of the Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.3</B></TD><TD STYLE="text-align: justify"><B>Insurance.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensee, at  its own expense, shall maintain in full force and effect throughout the term of
                                                                                 this Agreement (and following termination thereof to cover any claims arising from the performance of this Agreement), a
                                                                                 policy of insurance at levels sufficient for the conduct of Licensee&rsquo;s business and the services contemplated by this
                                                                                 Agreement, including the indemnification obligations hereunder, in such amounts and on terms as are customary in the
                                                                                 industry for the activities to be conducted by the License under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Upon Licensor&rsquo;s reasonable request, the amount of insurance coverage shall be increased
                                                                                 as may be reasonably necessary.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The coming into force of this Agreement is conditional upon Licensor having reviewed a
                                                                                 certificate of insurance from the relevant insurance company, in a form acceptable to Licensor, acting reasonably, evidencing
                                                                                 Licensee&rsquo;s compliance with the provisions of this Section 10.3. Such policy shall contain an endorsement by the insurer
                                                                                 providing that it shall not be cancelled or amended without thirty (30) days&rsquo; prior notice to Licensor. Licensee shall
                                                                                 provide any further certificates of such insurance to Licensor upon Licensor&rsquo;s written request.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.4</B></TD><TD STYLE="text-align: justify"><B>No Consequential Damages.</B> Except with respect to
each Party&rsquo;s obligations under Article 11, Licensor&rsquo;s representations under Section 6.2 and Licensee&rsquo;s obligations
under Sections 10.2, neither Party shall be liable for consequential damages or indirect loss of whatever nature hereunder including,
but not limited to, lost profits, unless such damage was caused by the gross negligence or wilful misconduct of the breaching
party or others for whom such Party is responsible.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIALITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.1</B></TD><TD STYLE="text-align: justify"><B>Confidential Information.</B> Any Confidential Information
received by one Party (the &ldquo;<B>Recipient</B>&rdquo;) from the other Party (the &ldquo;<B>Disclosing Party</B>&rdquo;) pursuant
to this Agreement shall be used, disclosed or copied only for the purposes of, and only in accordance with, this Agreement. The
Recipient shall use, at a minimum, the same degree of care as it uses to protect its own Confidential Information of a similar
nature, but no less than reasonable care, to prevent the unauthorized use, disclosure or publication of the Disclosing Party&rsquo;s
Confidential Information. Without limiting the generality of the foregoing:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Recipient shall only disclose the Disclosing Party&rsquo;s
Confidential Information to Recipient&rsquo;s employees or any individual or entity which (i) has entered into a written agreement
with Recipient containing obligations of confidence substantially similar to (but no less protective of the Confidential Information
than) those contained in this Agreement and (b) needs access to the Disclosing Party&rsquo;s Confidential Information consistent
with the Recipient&rsquo;s rights under this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Recipient shall not make or have made any copies of the
Disclosing Party&rsquo;s Confidential Information, except those copies which are reasonable for the purposes of this Agreement;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Recipient shall affix to any copies it makes of the Disclosing
Party&rsquo;s Confidential Information, to the extent reasonably practicable, all proprietary notices or legends affixed to the
Confidential Information as they appear on the copies of the Confidential Information originally received from the Disclosing
Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.2</B></TD><TD STYLE="text-align: justify"><B>Exclusions.</B> Recipient shall not be bound by obligations
restricting disclosure set forth in this Agreement with respect to any Confidential Information which:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">was known by the Recipient prior to disclosure, as evidenced
by its written records;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">was lawfully in the public domain prior to its disclosure,
or lawfully becomes publicly available other than through a breach of this Agreement or any other confidentiality obligation on
behalf of any Third Party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">was disclosed to the Recipient by a Third Party provided
such Third Party, or any other party from whom such Third Party receives such information, is not in breach of any confidentiality
obligation in respect of such information;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">is independently developed by the Recipient, as evidenced
by its written records; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">is required to be disclosed for patient safety reason.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, Disclosing Party&rsquo;s Confidential
Information may be disclosed by a Recipient when such disclosure is compelled pursuant to legal, judicial or administrative proceedings,
or otherwise required by law<SUB>,</SUB> provided that Recipient advises the Disclosing Party of any such compelled disclosure
in a timely manner prior to making any such disclosure (so that Disclosing Party can apply for such legal protection as may be
available with respect to the confidentiality of the information which is to be disclosed), and provided that Recipient shall apply
for such legal protection as may be available with respect to the confidentiality of the Disclosing Party&rsquo;s Confidential
Information which is required to be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.3</B></TD><TD STYLE="text-align: justify"><B>Notice of Disclosures.</B> Except for disclosures authorized
under the terms of this Agreement, each Party shall notify the other immediately upon learning of any unauthorized disclosure
of the other Party&rsquo;s Confidential Information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>12.1</B></TD><TD STYLE="text-align: justify"><B>Assignment.</B> This Agreement may not be assigned by
a Party except that a Party may assign this Agreement in connection with the sale of all or substantially all of the assets of
such Party provided that such Party provides at least sixty (60) days&rsquo; prior written notice to the other Party of the intent
to assign this Agreement and executes an instrument agreeing to remain bound by the terms of this Agreement and further provided
that, where such sale is by Licensee, such sale is a <I>bona fide</I> transaction entered into with a third party that deals at
arm&rsquo;s length with Licensee and also with each of the holders of preferred shares in the capital of Licensee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERM AND TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.1</B></TD><TD STYLE="text-align: justify"><B>Term.
</B>Subject to Sections 13.2, 13.3 and 13.6, the term of this Agreement (the &ldquo;<B>Term</B>&rdquo;) shall commence on the Effective
Date and will continue until the earlier of: (i) expiration of the last of the Patents to expire and (ii) the effective date of
the Buy Out.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.2</B></TD><TD STYLE="text-align: justify"><B>Breach.</B> Subject to Section 13.4, if a Party is in
breach of, or fails to perform, a material obligation under this Agreement, and fails to cure such breach or perform such obligation
to the non-breaching Party&rsquo;s satisfaction, acting reasonably, within thirty (30) days after the date of written notice thereof,
the non-breaching Party may, upon thirty (30) days&rsquo; additional written notice, terminate this Agreement. For the purposes
of this Agreement, breach of a &ldquo;material obligation&rdquo; shall include, but not be limited to; (a) use of the Technology
and/or Intellectual Property Rights outside of, or otherwise committing or causing to be committed a material act that is outside
of the scope of, the licences set forth in Article 2 of this Agreement, (b) authorizing or knowingly acquiescing in an End User&rsquo;s
use of the Product for a purpose other than specified in Section 2.1 of this Agreement, or (c) committing or causing to be committed
an act that is a material breach of Article 11 (Confidentiality).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.3</B></TD><TD STYLE="text-align: justify"><B>Termination
                                         on Bankruptcy, Insolvency.</B> In the event that (a) a Party ceases to operate as a going
                                         concern, or (b) a decree or order of a competent court is entered finally (i) winding
                                         up all the affairs of such Party and its Affiliates under the <I>Companies Creditors
                                         Arrangement Act</I> (Canada), the <I>Bankruptcy and Insolvency Act</I> (Canada) or the
                                         <I>Winding-Up and Restructuring Act</I> (Canada), <I>United States Bankruptcy Code</I>,
                                         or any other bankruptcy, insolvency or analogous law, or (ii) ordering the winding-up
                                         or liquidation of such Party, and any such decree or order continues and is in effect
                                         for a period of thirty (30) days from its issuance and is not withdrawn or discharged
                                         within such thirty (30) days of issuance, the other Party shall have the right to terminate
                                         this Agreement after the relevant cure period, if any.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.4</B></TD><TD STYLE="text-align: justify"><B>Non-Performance Termination.</B> Licensor may terminate
this Agreement, effective immediately, if Licensee is determined to be in non-performance (as set out in Schedule D) of any of
the Milestones or if it defaults in any of its payment obligations hereunder and does not: (i) in the case of achievement of Milestones,
cure such non-performance within thirty (30) days of receipt of written notice from Licensor as to such non-performance, all as
stipulated and in accordance with the description of the Milestones in Schedule D; and (ii) in the case of a payment obligation,
cure such default within thirty (30) days of receipt of written notice from Licensor as to such default.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.5</B></TD><TD STYLE="text-align: justify"><B>Conduct on Termination of this Agreement.</B> On termination
of this Agreement other than in connection with the Buy Out or expiry of the Term:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Licensee shall cease to initiate any new sale of Products.
Licensee may complete the sale of all Products with respect to (i) written purchase orders that require delivery within ninety
(90) days of such termination, or (ii) outstanding quotations to actual and prospective customers, provided these quotations expire
within thirty (30) days of such termination;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Licensee shall, within thirty (30) days of such termination,
return to Licensor or, if so requested by Licensor, certify in writing to Licensor that all copies of the Technology, Licensor
Updates and Confidential Information in the possession or under the legal control of Licensee have been destroyed; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">all existing obligations that have accrued to the date of such termination shall be
                                                                                 honoured.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.6</B></TD><TD STYLE="text-align: justify"><B>Survival.</B> The following provisions shall survive termination or expiry of this
                                                                                     Agreement: Article 1 (Definitions), Article 3 (Ownership) (except in the case of termination in connection with the Buy Out,
                                                                                     in which case Article 3 shall not survive), Article 10 (Indemnification), Article 11 (Confidentiality), Section 13.5 (Conduct
                                                                                     on Termination of this Agreement), Section 13.6 (Survival), Article 14 (Arbitration) and Article 15 (General).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 14</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARBITRATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>14.1</B></TD><TD STYLE="text-align: justify"><B>Arbitration.</B> Subject to either Party&rsquo;s right
to seek injunctive or other temporary relief in any court or other tribunal of competent jurisdiction, any controversy, dispute,
difference of opinion or failure to agree which shall arise between the Parties concerning this Agreement or its construction
or application, or the rights, duties and obligations of any Party to this Agreement, shall be resolved in the following listed
order as needed:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Direct negotiation
                                         between Licensee and Licensor with specific regard to the disputed item and reconciliation
                                         thereof in good faith, to continue for a maximum period of fifteen (15) days from the
                                         &ldquo;<B>date of initial dispute</B>&rdquo;, which shall mean the date of notice under
                                         Section 14.1 of a dispute initialed by a Party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Mediation between Licensee and Licensor through an independent
individual (&ldquo;<B>Mediator</B>&rdquo;), selected upon mutual agreement by the Parties, who has at least ten (10) years experience
in the practice of law relating to the subject matter of the dispute, is familiar with details of the disputed item and can assist
in reconciliation thereof in good faith, to continue for a maximum period of thirty (30) days from the date of initial dispute;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Arbitration before a sole arbitrator (&ldquo;<B>Arbitrator</B>&rdquo;), selected upon mutual
                                                                                 agreement by the Parties, the award and determination for which shall be final and binding upon the Parties. If the Parties
                                                                                 do not agree upon the Arbitrator, each Party may apply to a judge of the Ontario Court, General Division under the <I>Arbitration
                                                                                 Act.</I> 1991 (Ontario) (the &ldquo;<B>Arbitration Act</B>&rdquo;) for the appointment of the Arbitrator. The rules and
                                                                                 procedures of the Arbitration Act shall apply to any arbitration conducted hereunder. Unless otherwise agreed to by the
                                                                                 Parties in writing, the arbitration shall take place in Toronto in the English language. The Parties shall jointly pay and be
                                                                                 responsible for the costs of the arbitration, provided that the Arbitrator may make an award of costs upon the conclusion of
                                                                                 the arbitration making one of the Parties liable to pay the costs of the other Party.</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>14.2</B></TD><TD STYLE="text-align: justify">Notwithstanding Section 14.1, the individual selected as
Mediator or Arbitrator shall be (a) qualified by education and experience to decide the matter in dispute and, in the case of
any dispute regarding the performance of the Milestones, an expert in the Field of Use; and (b) at arm&rsquo;s length from the Parties
and shall not be a member of the audit or legal firm or firms who advise the Parties, nor shall the Mediator or Arbitrator be
an individual who is, or is a member of a firm, otherwise regularly retained by each of the Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.1</B></TD><TD STYLE="text-align: justify"><B>Notices.</B> All notices shall be in writing and sent
by certified or registered mail, return receipt requested, or by hand delivery to the other Party at the following address or
fax number:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If to Licensor:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Sunnybrook Health Sciences Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2075 Bayview Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, Ontario M4N 3M5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: </FONT></TD>
    <TD STYLE="width: 88%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leslie Boehm, Director of Operations and Business Development</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(416) 480-5814</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If to Licensee:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Profound Medical Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">c/o Genesys Ventures II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">200 Front Street West, Ste 3004</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, Ontario M5V 3K2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Chipperton, Chief Operating Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(416) 598-3328</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Such notices shall be deemed to have been
received five (5) Business Days after mailing if forwarded by mail or on the day of receipt if delivered by hand or fax. The address
of either Party may be changed by giving notice to the other Party in accordance with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.2</B></TD><TD STYLE="text-align: justify"><B>Independent Contractors.</B> No agency, partnership,
joint venture or employment relationship is or shall be created by virtue of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.3</B></TD><TD STYLE="text-align: justify"><B>Publicity.</B> Neither Party shall use the name of the
other Party or make any reference to the terms of this Agreement in any advertising, public relations, promotional materials or
media releases without the prior written consent of such other Party, except that Licensee may state that it has licensed Technology
from Licensor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.4</B></TD><TD STYLE="text-align: justify"><B>Entire Agreement.</B> The attached Schedules form part
of this Agreement and are incorporated by reference herein. This Agreement and the Sponsored Research Agreement, entered into
between the Parties as of the same effective date constitute the entire agreement between the Parties as to the subject matter
contained herein and supersedes all other agreements between the Parties concerning such subject matter. This Agreement may only
be modified by an instrument in writing executed by each Party&rsquo;s duty authorized representative.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.5</B></TD><TD STYLE="text-align: justify"><B>Headings.</B> The headings, sections and articles are
inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of
this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.6</B></TD><TD STYLE="text-align: justify"><B>Waiver.</B> Any waiver of, or consent to depart from,
the requirements of any provision of this Agreement shall be effective only if it is in writing and signed by the Party giving
it, and only in the specific instance and for the specific purpose for which it has been given. No failure on the part of any
Party to exercise, and no delay in exercising, any right under this Agreement shall operate as a waiver of such right. No single
or partial exercise of any such right shall preclude any other or further exercise of such right or the exercise of any other
right.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.7</B></TD><TD STYLE="text-align: justify"><B>Governing Law.</B> This Agreement shall be governed
by, and interpreted and enforced in accordance with, the laws in force in the Province of Ontario (excluding any conflict of laws
rule or principle which might refer such questions to the laws of another jurisdiction). Each Party irrevocably attorns to and
submits to the non-exclusive jurisdiction of the courts of Ontario with respect to any matter arising hereunder or related hereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.8</B></TD><TD STYLE="text-align: justify"><B>Severability.</B> If any one or more of the provisions
contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity,
illegality or unenforceability shall not affect any other provisions of this Agreement. All other provisions shall remain in full
force and effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.9</B></TD><TD STYLE="text-align: justify"><B>Due Authority.</B> The persons executing this Agreement
on behalf of Licensor and Licensee represent and warrant that they are duly authorized to legally bind Licensor and Licensee,
respectively, to the terms and conditions of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.10</B></TD><TD STYLE="text-align: justify"><B>Gender and Number.</B> Any reference in this Agreement
to gender includes all genders and words importing the singular number only shall include the plural and vice versa.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.11</B></TD><TD STYLE="text-align: justify"><B>Currency.</B> All dollar amounts referred to herein
are in Canadian currency, unless otherwise indicated.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.12</B></TD><TD STYLE="text-align: justify"><B>Further Assurances.</B> Each Party shall from time to
time promptly execute and deliver and take all further action as may be reasonably necessary or appropriate to give effect to
the provisions and intent of this Agreement and to complete the transactions contemplated by this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.13</B></TD><TD STYLE="text-align: justify"><B>Counterparts; Facsimile.</B> This Agreement may be executed
in counterparts and transmitted by facsimile, each of which shall be deemed an original and all of which, taken together, shall
constitute one and the same instrument.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUNNYBROOK HEALTH SCIENCES CENTRE</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    Julius</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 18, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ahsan
    Welch</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 18, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROFOUND MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Chipperton</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signature</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 25, 2011</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TECHNOLOGY DESCRIPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MRI-guided transurethral ultrasound therapy
is an image-guided, minimally-invasive treatment for localized prostate cancer performed within a standard clinical MR imager.
High-intensity ultrasound energy is delivered from a device in the urethra using rotational control to generate a precise region
of thermal coagulation in the prostate gland. Real-time temperature maps acquired with MRI during heating are used as active feedback
to ensure a precise region of thermal damage is generated within the prostate gland. The nature of the heating applicator enables
a high degree of spatial control over tissue heating which improves targeting within the prostate gland while reducing damage to
surrounding tissues, the main limitation of existing treatments for prostate cancer. The hardware, software and medical devices
that make up this technology have been developed within the Imaging Research group at Sunnybrook Health Sciences Centre over the
past eight years through peer-reviewed grant support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The technology is designed to treat low-
to moderate-risk localized prostate cancer which is the most rapidly growing segment in this patient population due to widespread
use of PSA testing and ultrasound-guided transrectal biopsy. In this population, a minimally invasive treatment that can be delivered
efficiently with high precision and minimal recovery time would be highly desirable from the perspective of patients, clinicians
and healthcare providers due to the significant complications and lengthy recovery times that accompany conventional radical treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The potential features of this technology
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">the minimally-invasive transurethral approach;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">the incorporation of real-time quantitative MR temperature
imaging for precise control of treatment</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">short treatment time (~30 minutes);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">rapid recovery; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">the capability to perform multiple treatments in  the case of recurrent disease or deliberate
                                                                            focal therapy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PATENT APPLICATIONS; PATENTS; AND COPYRIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chopra and Bronskill: US 6589174 Technique
and apparatus for ultrasound therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chopra, Bronskill <I>&amp;</I> Burtnyk:
US20060206105 Treatment of diseased tissue using controlled ultrasonic heating.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chopra, Bronskill &amp; Tang: US20070239062
Method and apparatus for obtaining quantitative temperature measurements in prostate and other tissue undergoing thermal therapy
treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONFIDENTIAL INVENTION FORMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunnybrook Research Institute Confidential Invention Disclosures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Chopra, Bronskill <I>&amp;</I> Burtnyk:
3D algorithm to control transurethral ultrasound heating including temperature noise reduction and extrapolation techniques.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Chopra &amp; Bronskill: Rectal cooling device for use with transurethral
thermal therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE D</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Part 1.</B></TD><TD STYLE="text-align: justify"><B>BUY OUT MILESTONES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Event</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0 0 1pt">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-top: 0; padding-right: 0; border-bottom: Black 1pt solid; padding-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sunset
    Dale</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatment of first human patient using the Technology</FONT></TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2010</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total direct Third Party investment in Licensee (whether through equity or debt financing, government grants, refundable tax credits or other sources of non-dilutive financing) of at least Cdn $7.5 million or such lesser amount as the Board of Directors of Licensee determines (acting in good faith) is sufficient to fund Licensee&rsquo;s business plan and to enable Licensee to develop a Product.</FONT></TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PMA or 510k regulatory approval</FONT></TD>
    <TD STYLE="padding: 0">&nbsp;</TD>
    <TD STYLE="padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2018</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in; text-align: left"><B>Part 2.</B></TD><TD STYLE="text-align: justify"><B>MILESTONES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensee will use its commercially reasonable
efforts to develop and commercialize the Technology as it extends to all other intellectual property and technology under its control.
Formal performance reviews may be performed by Licensor every six (6) months from the Effective Date to the termination or expiry
of this Agreement. At each review, Licensee will provide a full description of the research and development being performed and
to be performed with the Technology by the Licensee, including copies of relevant internal disclosures, reports and memos.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-performance will be regarded as two
(2) consecutive reviews in which Licensor, acting reasonably, determines that the progress of the research and development that
the Licensee has performed up to the relevant date, in the context of Licensee&rsquo;s goal to achieve 510k regulatory approval
from the U.S. Food and Drug Administration or a PMA from it or any similar regulatory authority by the Sunset Date noted above,
is not satisfactory, provided that Licensor shall provide written notice to Licensee of the results of each such investigation.
Any conclusion as to non-performance shall be conclusive, subject only to the dispute resolution provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LEASED PREMISES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Up to 1000 square feet at 3080 Yonge St. Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Space can be increased by mutual consent, such consent not to
be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>8
<FILENAME>tv526458_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSET AND SHARE PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROFOUND MEDICAL CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">KONINKLIJKE PHILIPS N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of June 30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 1 DEFINITIONS AND INTERPRETATION</TD>
    <TD STYLE="text-align: right; font-weight: bold">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 14%; text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="width: 78%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 1.1</TD>
    <TD STYLE="text-align: justify">Definitions</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 1.2</TD>
    <TD STYLE="text-align: justify">Knowledge of the Vendor</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 1.3</TD>
    <TD STYLE="text-align: justify">Generally Accepted Accounting Principles</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 1.4</TD>
    <TD STYLE="text-align: justify">Calculations in Euros</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 1.5</TD>
    <TD STYLE="text-align: justify">Interpretation</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 1.6</TD>
    <TD STYLE="text-align: justify">Schedules</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 2 PURCHASE AND SALE; PURCHASE PRICE</TD>
    <TD STYLE="text-align: right; font-weight: bold">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.1</TD>
    <TD STYLE="text-align: justify">Purchase and Sale of Subco Shares and Class A Patents and Trademarks</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.2</TD>
    <TD STYLE="text-align: justify">Assumption of Liabilities</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.3</TD>
    <TD STYLE="text-align: justify">Purchase Price</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.4</TD>
    <TD STYLE="text-align: justify">Accounting</TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.5</TD>
    <TD STYLE="text-align: justify">Payment of Purchase Price and Closing Deliverables</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.6</TD>
    <TD STYLE="text-align: justify">Payment and Location of Closing</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.7</TD>
    <TD STYLE="text-align: justify">Allocation of Purchase Price</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 2.8</TD>
    <TD STYLE="text-align: justify">Third Party Consents</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF VENDOR</TD>
    <TD STYLE="text-align: right; font-weight: bold">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.1</TD>
    <TD STYLE="text-align: justify">Authority of the Vendor and Subco and Enforceability</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.2</TD>
    <TD STYLE="text-align: justify">Organization and Qualification of the Vendor and Subco</TD>
    <TD STYLE="text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.3</TD>
    <TD STYLE="text-align: justify">Subco Shares</TD>
    <TD STYLE="text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.4</TD>
    <TD STYLE="text-align: justify">Corporate Records and Documentation</TD>
    <TD STYLE="text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.5</TD>
    <TD STYLE="text-align: justify">Government Approvals, Notices and Filings</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.6</TD>
    <TD STYLE="text-align: justify">Third Party Consents, Approvals and Notices</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.7</TD>
    <TD STYLE="text-align: justify">Absence of Breach; Non-Contravention.</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.8</TD>
    <TD STYLE="text-align: justify">Financial Information</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.9</TD>
    <TD STYLE="text-align: justify">Absence of Other Liabilities</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.10</TD>
    <TD STYLE="text-align: justify">Title to Assets</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.11</TD>
    <TD STYLE="text-align: justify">Absence of Changes</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.12</TD>
    <TD STYLE="text-align: justify">Leased Real Property</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.13</TD>
    <TD STYLE="text-align: justify">Owned Real Property</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.14</TD>
    <TD STYLE="text-align: justify">Contracts</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.15</TD>
    <TD STYLE="text-align: justify">Intellectual Property Rights</TD>
    <TD STYLE="text-align: right">28</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: justify; padding-left: 0.125in">Section 3.16</TD>
    <TD STYLE="width: 78%; text-align: justify">Employee Benefit Plans </TD>
    <TD STYLE="width: 8%; text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.17</TD>
    <TD STYLE="text-align: justify">Employees; Labor Relations</TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.18</TD>
    <TD STYLE="text-align: justify">Taxes and Tax Returns</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.19</TD>
    <TD STYLE="text-align: justify">Insurance </TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.20</TD>
    <TD STYLE="text-align: justify">Environmental Matters</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.21</TD>
    <TD STYLE="text-align: justify">Permits</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.22</TD>
    <TD STYLE="text-align: justify">Compliance with Laws</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.23</TD>
    <TD STYLE="text-align: justify">Litigation</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.24</TD>
    <TD STYLE="text-align: justify">Affiliate Transactions</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.25</TD>
    <TD STYLE="text-align: justify">Suppliers</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.26</TD>
    <TD STYLE="text-align: justify">Customers</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.27</TD>
    <TD STYLE="text-align: justify">Inventory </TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.28</TD>
    <TD STYLE="text-align: justify">Product Warranties; Product Liability </TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.29</TD>
    <TD STYLE="text-align: justify">Regulatory Matters</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.30</TD>
    <TD STYLE="text-align: justify">Financial Services Relations</TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.31</TD>
    <TD STYLE="text-align: justify">Representations Regarding Investment in the Purchaser Common Shares</TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.32</TD>
    <TD STYLE="text-align: justify">Brokers </TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.33</TD>
    <TD STYLE="text-align: justify">Bankruptcy </TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 3.34</TD>
    <TD STYLE="text-align: justify">No Misrepresentations</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF PURCHASER </TD>
    <TD STYLE="text-align: right; font-weight: bold">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.1</TD>
    <TD STYLE="text-align: justify">Organization and Qualification of the Purchaser </TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.2</TD>
    <TD STYLE="text-align: justify">Authority of the Purchaser and Enforceability </TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.3</TD>
    <TD STYLE="text-align: justify">Government Approvals, Notices and Filings</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.4</TD>
    <TD STYLE="text-align: justify">Third Party Consents, Approvals and Notices</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.5</TD>
    <TD STYLE="text-align: justify">Absence of Breach; Non-Contravention</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.6</TD>
    <TD STYLE="text-align: justify">Litigation</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.7</TD>
    <TD STYLE="text-align: justify">Securities Filings</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.8</TD>
    <TD STYLE="text-align: justify">Brokers </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.9</TD>
    <TD STYLE="text-align: justify">Bankruptcy </TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.10</TD>
    <TD STYLE="text-align: justify">Profound Subsidiaries</TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.11</TD>
    <TD STYLE="text-align: justify">Compliance with Laws</TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.12</TD>
    <TD STYLE="text-align: justify">No Default </TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.13</TD>
    <TD STYLE="text-align: justify">No Acquisitions, etc </TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.14</TD>
    <TD STYLE="text-align: justify">Financial Statements</TD>
    <TD STYLE="text-align: right">45</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: justify; padding-left: 0.125in">Section 4.15</TD>
    <TD STYLE="width: 78%; text-align: justify">Taxes</TD>
    <TD STYLE="width: 8%; text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.16</TD>
    <TD STYLE="text-align: justify">Disclosure Controls</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.17</TD>
    <TD STYLE="text-align: justify">Auditors</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.18</TD>
    <TD STYLE="text-align: justify">Share Capital, etc</TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.19</TD>
    <TD STYLE="text-align: justify">Proceedings</TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.20</TD>
    <TD STYLE="text-align: justify">Constating Documents</TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.21</TD>
    <TD STYLE="text-align: justify">Liens</TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.22</TD>
    <TD STYLE="text-align: justify">Ownership of Assets</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.23</TD>
    <TD STYLE="text-align: justify">Contracts</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.24</TD>
    <TD STYLE="text-align: justify">No Breach or Default</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.25</TD>
    <TD STYLE="text-align: justify">Purchaser Intellectual Property</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.26</TD>
    <TD STYLE="text-align: justify">Real Property</TD>
    <TD STYLE="text-align: right">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.27</TD>
    <TD STYLE="text-align: justify">Employees</TD>
    <TD STYLE="text-align: right">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.28</TD>
    <TD STYLE="text-align: justify">Insurance</TD>
    <TD STYLE="text-align: right">51</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.29</TD>
    <TD STYLE="text-align: justify">Minute Books</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.30</TD>
    <TD STYLE="text-align: justify">Environmental Laws</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.31</TD>
    <TD STYLE="text-align: justify">No Material Adverse Change</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.32</TD>
    <TD STYLE="text-align: justify">No Dividends</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.33</TD>
    <TD STYLE="text-align: justify">Anti-Bribery, etc</TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.34</TD>
    <TD STYLE="text-align: justify">Continuous Disclosure Obligations</TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.35</TD>
    <TD STYLE="text-align: justify">Share Certificates</TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.36</TD>
    <TD STYLE="text-align: justify">Transfer Agent</TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.37</TD>
    <TD STYLE="text-align: justify">Permits</TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.38</TD>
    <TD STYLE="text-align: justify">Regulatory Matters</TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.39</TD>
    <TD STYLE="text-align: justify">Acquisitions/Dispositions</TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 4.40</TD>
    <TD STYLE="text-align: justify">No Misrepresentations</TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 5 COVENANTS OF THE VENDOR</TD>
    <TD STYLE="text-align: right; font-weight: bold">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.1</TD>
    <TD STYLE="text-align: justify">Restrictions</TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.2</TD>
    <TD STYLE="text-align: justify">Retention and Access to Books and Records</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.3</TD>
    <TD STYLE="text-align: justify">Regulatory and Third Party Approvals</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.4</TD>
    <TD STYLE="text-align: justify">Material Supplier Contracts</TD>
    <TD STYLE="text-align: right">61</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.5</TD>
    <TD STYLE="text-align: justify">Transferred Contracts</TD>
    <TD STYLE="text-align: right">61</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.6</TD>
    <TD STYLE="text-align: justify">Fulfillment of Conditions</TD>
    <TD STYLE="text-align: right">61</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.7</TD>
    <TD STYLE="text-align: justify">Restrictions on Transfer</TD>
    <TD STYLE="text-align: right">62</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: justify; padding-left: 0.125in">Section 5.8</TD>
    <TD STYLE="width: 78%; text-align: justify">Updates</TD>
    <TD STYLE="width: 8%; text-align: right">62</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.9</TD>
    <TD STYLE="text-align: justify">Exclusivity </TD>
    <TD STYLE="text-align: right">62</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.10</TD>
    <TD STYLE="text-align: justify">Purchased Assets </TD>
    <TD STYLE="text-align: right">63</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.11</TD>
    <TD STYLE="text-align: justify">Affiliate Transactions</TD>
    <TD STYLE="text-align: right">63</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.12</TD>
    <TD STYLE="text-align: justify">Disentanglement </TD>
    <TD STYLE="text-align: right">63</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.13</TD>
    <TD STYLE="text-align: justify">[Redacted &ndash; Prejudicial Disclosure] </TD>
    <TD STYLE="text-align: right">63</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.14</TD>
    <TD STYLE="text-align: justify">Regulatory Correspondence </TD>
    <TD STYLE="text-align: right">63</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 5.15</TD>
    <TD STYLE="text-align: justify">Access to the MR System </TD>
    <TD STYLE="text-align: right">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 6 COVENANTS OF PURCHASER </TD>
    <TD STYLE="text-align: right; font-weight: bold">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 6.1</TD>
    <TD STYLE="text-align: justify">Confidentiality </TD>
    <TD STYLE="text-align: right">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 6.2</TD>
    <TD STYLE="text-align: justify">Regulatory and Third Party Approvals </TD>
    <TD STYLE="text-align: right">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 6.3</TD>
    <TD STYLE="text-align: justify">Fulfillment of Conditions </TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 6.4</TD>
    <TD STYLE="text-align: justify">Retention of Books and Records</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 6.5</TD>
    <TD STYLE="text-align: justify">Use of Philips Names and Marks</TD>
    <TD STYLE="text-align: right">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 6.6</TD>
    <TD STYLE="text-align: justify">[Redacted &ndash; Prejudicial Disclosure] </TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 7 MUTUAL COVENANTS OF THE VENDOR AND PURCHASER </TD>
    <TD STYLE="text-align: right; font-weight: bold">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 7.1</TD>
    <TD STYLE="text-align: justify">Regulatory Filings and Other Actions</TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 7.2</TD>
    <TD STYLE="text-align: justify">Further Assurances</TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 7.3</TD>
    <TD STYLE="text-align: justify">Tax Matters</TD>
    <TD STYLE="text-align: right">66</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 7.4</TD>
    <TD STYLE="text-align: justify">Employees</TD>
    <TD STYLE="text-align: right">67</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 8 CONDITIONS PRECEDENT TO THE OBLIGATIONS OF PURCHASER</TD>
    <TD STYLE="text-align: right; font-weight: bold">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.1</TD>
    <TD STYLE="text-align: justify">Representations and Warranties</TD>
    <TD STYLE="text-align: right">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.2</TD>
    <TD STYLE="text-align: justify">Performance of Covenants</TD>
    <TD STYLE="text-align: right">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.3</TD>
    <TD STYLE="text-align: justify">Orders and Laws</TD>
    <TD STYLE="text-align: right">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.4</TD>
    <TD STYLE="text-align: justify">Consents, Approvals and Notices</TD>
    <TD STYLE="text-align: right">68</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.5</TD>
    <TD STYLE="text-align: justify">Cooperation with Business Acquisition Report </TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.6</TD>
    <TD STYLE="text-align: justify">Officer&rsquo;s Certificate </TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.7</TD>
    <TD STYLE="text-align: justify">Operating Agreements</TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 8.8</TD>
    <TD STYLE="text-align: justify">No Material Adverse Effect </TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 9 CONDITIONS PRECEDENT TO OBLIGATIONS OF VENDOR </TD>
    <TD STYLE="text-align: right; font-weight: bold">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 9.1</TD>
    <TD STYLE="text-align: justify">Representations and Warranties</TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 9.2</TD>
    <TD STYLE="text-align: justify">Performance of Covenants</TD>
    <TD STYLE="text-align: right">69</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 9.3</TD>
    <TD STYLE="text-align: justify">Orders and Laws</TD>
    <TD STYLE="text-align: right">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 9.4</TD>
    <TD STYLE="text-align: justify">Consents, Approvals and Notices</TD>
    <TD STYLE="text-align: right">70</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: justify; padding-left: 0.125in">Section 9.5</TD>
    <TD STYLE="width: 78%; text-align: justify">Officer&rsquo;s Certificate </TD>
    <TD STYLE="width: 8%; text-align: right">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 9.6</TD>
    <TD STYLE="text-align: justify">Operating Agreements</TD>
    <TD STYLE="text-align: right">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 9.7</TD>
    <TD STYLE="text-align: justify">Knight Loan Agreement </TD>
    <TD STYLE="text-align: right">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 10 SURVIVAL; INDEMNIFICATION </TD>
    <TD STYLE="text-align: right; font-weight: bold">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.1</TD>
    <TD STYLE="text-align: justify">Survival of Representations, Warranties, Covenants and Agreements</TD>
    <TD STYLE="text-align: right">70</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.2</TD>
    <TD STYLE="text-align: justify">Indemnification by Vendor </TD>
    <TD STYLE="text-align: right">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.3</TD>
    <TD STYLE="text-align: justify">Limitations on Amount of Indemnification by Vendor </TD>
    <TD STYLE="text-align: right">71</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.4</TD>
    <TD STYLE="text-align: justify">Indemnification by Purchaser </TD>
    <TD STYLE="text-align: right">72</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.5</TD>
    <TD STYLE="text-align: justify">Limitations on Amount of Indemnification by Purchaser </TD>
    <TD STYLE="text-align: right">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.6</TD>
    <TD STYLE="text-align: justify">Notice and Defense of Claims</TD>
    <TD STYLE="text-align: right">73</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 10.7</TD>
    <TD STYLE="text-align: justify">Further Limitations and Qualifications on Indemnification</TD>
    <TD STYLE="text-align: right">75</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 11 TERMINATION OF AGREEMENT </TD>
    <TD STYLE="text-align: right; font-weight: bold">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 11.1</TD>
    <TD STYLE="text-align: justify">Termination</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 11.2</TD>
    <TD STYLE="text-align: justify">Notice of Termination</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 11.3</TD>
    <TD STYLE="text-align: justify">Effect of Termination</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 12 [REDACTED &ndash; COMMERCIALLY SENSITIVE]; DISPUTE RESOLUTION </TD>
    <TD STYLE="text-align: right; font-weight: bold">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 12.1</TD>
    <TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive] </TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 12.2</TD>
    <TD STYLE="text-align: justify">Dispute Resolution</TD>
    <TD STYLE="text-align: right">76</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: justify; font-weight: bold">ARTICLE 13 MISCELLANEOUS </TD>
    <TD STYLE="text-align: right; font-weight: bold">77</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.1</TD>
    <TD STYLE="text-align: justify">Expenses</TD>
    <TD STYLE="text-align: right">77</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.2</TD>
    <TD STYLE="text-align: justify">Notices</TD>
    <TD STYLE="text-align: right">77</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.3</TD>
    <TD STYLE="text-align: justify">Amendment </TD>
    <TD STYLE="text-align: right">78</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.4</TD>
    <TD STYLE="text-align: justify">Schedules and Exhibits</TD>
    <TD STYLE="text-align: right">78</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.5</TD>
    <TD STYLE="text-align: justify">Enforcement of Agreement </TD>
    <TD STYLE="text-align: right">79</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.6</TD>
    <TD STYLE="text-align: justify">Severability </TD>
    <TD STYLE="text-align: right">79</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.7</TD>
    <TD STYLE="text-align: justify">Entire Understanding </TD>
    <TD STYLE="text-align: right">79</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.8</TD>
    <TD STYLE="text-align: justify">Binding Effect; No Third Party Beneficiaries</TD>
    <TD STYLE="text-align: right">79</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.9</TD>
    <TD STYLE="text-align: justify">Governing Law </TD>
    <TD STYLE="text-align: right">80</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.10</TD>
    <TD STYLE="text-align: justify">Waiver of Trial by Jury </TD>
    <TD STYLE="text-align: right">80</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.11</TD>
    <TD STYLE="text-align: justify">Assignability </TD>
    <TD STYLE="text-align: right">80</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.12</TD>
    <TD STYLE="text-align: justify">Counterparts; Delivery by Electronic Transmission</TD>
    <TD STYLE="text-align: right">80</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.13</TD>
    <TD STYLE="text-align: justify">Public Announcements</TD>
    <TD STYLE="text-align: right">81</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in">Section 13.14</TD>
    <TD STYLE="text-align: justify">Restrictive Covenants</TD>
    <TD STYLE="text-align: right">81</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17pt; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit A</B></FONT></TD>
    <TD STYLE="width: 87%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resale Purchasing Agreement</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit B-1</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual Property Assignment Agreement </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit B-2</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual Property License Agreement</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit C</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Noncompetition and Confidentiality Agreement</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit D</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class A Patents and Trademarks</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASSET AND SHARE PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS ASSET AND SHARE
PURCHASE AGREEMENT </B>dated as of the 30th day of June, 2017 by and between Profound Medical Corp., a company organized and existing
under the laws of the Province of Ontario (the &ldquo;<B>Purchaser</B>&rdquo;) and Koninklijke Philips N.V., a company organized
and existing under the laws of the Netherlands (the &ldquo;<B>Vendor</B>&rdquo;). The Purchaser and the Vendor are sometimes referred
to in this Agreement, individually, as a &ldquo;<B>Party</B>&rdquo; and, collectively, as the &ldquo;<B>Parties</B>&rdquo;, unless
otherwise stated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">RECITALS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS </B>the
Vendor owns, directly or indirectly, all of the Purchased Assets, owns the Class A Patents and Trademarks and conducts the operations
of the Vendor&rsquo;s business relating to the magnetic resonance image-guided high intensity focused ultrasound, including Sonalleve
MR-HIFU and related assets (the &ldquo;<B>Business</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS </B>the
Vendor owns all of the issued and outstanding securities (the &ldquo;<B>Subco Shares</B>&rdquo;) of Wing Medical Oy <B>(&ldquo;Subco&rdquo;)</B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>immediately
prior to Closing (the &ldquo;<B>Transfer Time</B>&rdquo;), the Vendor intends to transfer, or cause its Affiliates, Philips Oy
and Philips Medical Systems Nederland B.V. to transfer, the Purchased Assets to Subco and Subco will assume the Assumed Liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS </B>the
Purchaser desires to purchase from the Vendor and the Vendor desires to sell to the Purchaser, the Class A Patents and Trademarks
and the Subco Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE 1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DEFINITIONS AND INTERPRETATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 1.1</TD><TD STYLE="text-align: justify">Definitions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As used in this Agreement, the
following terms have the meanings ascribed thereto below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Accounts Receivable</B>&rdquo;
means all accounts receivable, bills receivable, trade accounts, book debts and insurance claims and proceeds of the Vendor and
its Affiliates relating to the Business or the Purchased Assets and any other amount due to the Vendor and its Affiliates relating
to the Business or the Purchased Assets, including any refunds and rebates receivable relating to the Business or the Purchased
Assets, and the benefit of all security, guarantees and other collateral held by the Vendor and its Affiliates relating to the
Business or the Purchased Assets, recorded as receivables in the Business Books and Records in accordance with generally accepted
accounting principles as of any date prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Additional Earnout
Amount</B>&rdquo; has the meaning set forth in Section 2.3(a)(iii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Affiliates</B>&rdquo;
means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with the specified Person. As used in this definition, &ldquo;<B>control</B>&rdquo;,
 &ldquo;<B>controlled by</B>&rdquo; and &ldquo;<B>under common control with</B>&rdquo; means possession, directly or indirectly,
of power to direct or cause the direction of management or policies of such Person (whether through ownership of securities or
other partnership or ownership interests, as trustee, personal representative or executive or by contract, credit agreement or
otherwise), provided that in any event, any Person which owns directly, indirectly or beneficially more than 50% of the securities
having voting power for the election of directors or other governing body of a corporation more than 50% of the partnership interests
or other ownership interests of any other Person will be deemed to control such Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Agreement</B>&rdquo;
means this asset and share purchase agreement, the Disclosure Schedule and all other Schedules and Exhibits attached to this Agreement
and the expressions &ldquo;<B>hereof</B>&rdquo;, &ldquo;<B>herein</B>&rdquo;, &ldquo;<B>hereto</B>&rdquo;, &ldquo;<B>hereunder</B>&rdquo;,
 &ldquo;<B>hereby</B>&rdquo; and similar expressions refer to this Agreement and unless otherwise indicated, references to Sections,
Articles or Exhibits are to sections, articles or exhibits, as applicable, in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Alternate Transaction</B>&rdquo;
has the meaning set forth in Section 5.9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Applicable Anti-Money
Laundering Laws&rdquo; </B>has the meaning set forth in Section 4.33(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Applicable Securities
Laws&rdquo; </B>means, collectively, the applicable securities Laws of each of the provinces of Canada and the respective regulations
and rules made under those securities Laws together with all applicable policy statements, instruments, notices, blanket orders
and rulings of the Canadian Securities Administrators and the Securities Commissions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Appurtenances</B>&rdquo;
means, with respect to any real property:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
buildings, structures, fixtures, improvements and appurtenances located on or forming part of that real property, including those
under construction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
rights of way, licenses, rights of occupation, easements or other similar rights appurtenant to and for the benefit of that real
property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Asset Acquisition Statement</B>&rdquo;
has the meaning set forth in Section 2.7;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Asset Transfer Agreements</B>&rdquo;
means the asset transfer agreements to be entered into between each of Philips Oy and Philips Medical Systems Nederland B.V. and
Subco immediately prior to Closing pursuant to which the Vendor and its Affiliates will transfer the Purchased Assets to Subco
and Subco will assume the Assumed Liabilities, in each case, as of the Transfer Time, which will each be in a form to be mutually
agreed by the Parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Assets and Properties</B>&rdquo;
with respect to any Person means all assets and properties of every kind, nature, character and description (whether real, personal
or mixed, tangible or intangible, choate or inchoate, absolute, accrued, contingent, fixed or otherwise, and, in each case, wherever
situated), including the goodwill related thereto, operated, owned, licensed or leased by or in the possession of such Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Assumed Liabilities</B>&rdquo;
means all Liabilities relating to or arising out of the Business or the Purchased Assets incurred after the Transfer Time. For
clarity, the Assumed Liabilities exclude the Retained Liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Base Purchase
Price Shares</B>&rdquo; has the meaning set forth in Section 2.3(a)(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Business</B>&rdquo; has the meaning set forth
in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Business Benefit Plan</B>&rdquo;
and &ldquo;<B>Business Benefit Plans</B>&rdquo; have the meaning set forth in Section 3.16(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Business Books and
Records</B>&rdquo; means the books and records of the Vendor relating to the Business, the Purchased Assets and the Assumed Liabilities
in the possession or control of the Vendor, including financial, corporate, operations and sales books, records, books of account,
sales and purchase records, formulae, production data, equipment maintenance data, sales promotional data, advertising materials,
cost and pricing information, accounting records, business reports, plans and projections and all other documents, surveys, plans
files, records, correspondence and other data and information, financial or otherwise, including all data and information stored
on computer-related or other electronic media, the share registry and minute books of Subco but excluding Excluded Books and Records;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Business Day</B>&rdquo;
means any day other than a Saturday, Sunday or statutory holiday, in the Province of Ontario or the Netherlands;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Business Intellectual
Property</B>&rdquo; means all of the Intellectual Property and Intellectual Property Rights, whether registered or not, used in,
or relating to, the operation of the Business owned or used by the Vendor, its Affiliates or Subco;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Claims</B>&rdquo; means
any claims, demands, actions, suits, causes of action, assessments or reassessments, charges, judgments, liabilities, expenses,
costs, damages or Losses, contingent or otherwise, including loss of value, reasonable professional fees and all costs incurred
in investigating or pursuing any of the foregoing or any proceeding relating to any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Class A Patents and
Trademarks</B>&rdquo; means the patents and trademarks listed in Exhibit D hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Clinical Trials</B>&rdquo;
has the meaning set forth in Section 4.38(c);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Closing</B>&rdquo;
means the closing of the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Closing Date</B>&rdquo;
means the day which is three (3) Business Days after the day on which the conditions set forth in Article 8 and Article 9 have
been satisfied or waived (other than conditions that, by their terms, are to be satisfied at the Closing), or at such other date
as the Purchaser and the Vendor shall mutually agree;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Collective Bargaining
Agreements</B>&rdquo; means any collective bargaining agreement or collective agreement and related documents including all benefit
agreements, letters of understanding, letters of intent and other written agreements with bargaining agents or trade unions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Common Shares&rdquo;
</B>means the common shares in the capital of the Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Confidentiality Agreement</B>&rdquo; has the meaning set
forth in Section 6.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Contracts</B>&rdquo;
means any written or oral agreement, lease, license, mortgage, indenture, note, debenture, credit agreement, security agreement
or other contract or arrangement, including all customer and supplier purchase orders or other similar Contracts arising therefrom
or related thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Designated Officers</B>&rdquo;
has the meaning set forth in <B>Error! Reference source not found.</B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Determined Amount</B>&rdquo;
has the meaning set forth in Section 2.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Disclosure Record</B>&rdquo;
means the Purchaser&rsquo;s prospectuses, annual reports, annual and interim financial statements, annual information forms, business
acquisition reports, management discussion and analysis of financial condition and results of operations, information circulars,
material change reports, press releases and all other information or documents required to be filed or furnished by the Purchaser
under Applicable Securities Laws which have been publicly filed or otherwise publicly disseminated by the Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Disclosure Schedule</B>&rdquo;
means the disclosure schedule of the Vendor attached to this Agreement including all exhibits thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Disentanglement</B>&rdquo;
has the meaning set forth in Section 5.12(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Dispute Period</B>&rdquo;
has the meaning set forth in Section 10.6(c);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Effective Time</B>&rdquo;
has the meaning set forth in Section 2.6;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Eligible Issuer&rdquo;
</B>means an issuer which meets the criteria and has complied with the requirements of NI 44-101 so as to be qualified to offer
securities by way of a short form prospectus under Applicable Securities Laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Employee Liabilities</B>&rdquo;
means any unpaid amounts payable and any undischarged obligations and liabilities of the Vendor and its Affiliates related to the
employees of the Business and the Employees transferring to Subco by operation of law in accordance with Chapter 1, Section 10
of the Finnish Act on Employment Contracts (55/2001, as amended), to the extent accrued under the terms and conditions of the employees&rsquo;
of the Business or the Employees&rsquo;, as the case may be, employment contract, under any law, collective agreement or otherwise
being considered as an entitlement under the terms of the employees&rsquo; of the Business or the Employees&rsquo;, as the case
may be, employment with the Vendor or its Affiliates, whether due for payment thereon or not (including but not limited to any
salaries, fringe benefits, holiday pay (including but not limited to holiday bonuses, and all social and pension costs related
thereto), compensation for overtime and flexible work time settlement, and any payroll taxes, withholding taxes, social security
contributions, pension insurance contributions arising thereupon).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Employees</B>&rdquo;
means those individuals employed or retained by the Vendor or its Affiliates listed on Section 1.1-1 of the Disclosure Schedule
hereto and transferring to Subco by operation of law in accordance with Chapter 1, Section 10 of the Finnish Act on Employment
Contracts (55/2001, as amended);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Environmental Laws</B>&rdquo;
means any and all common law and federal, provincial, municipal or local statutes, regulations, orders, by-laws or ordinances relating
to occupational health and safety, pollution or protection of the environment (including natural resource damages), including those
relating to emissions, discharges or releases of Hazardous Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Environmental Permits&rdquo;
</B>includes all orders, permits. certificates, approvals, consents, registrations and licences issued by any authority of competent
jurisdiction under any Environmental Law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Environmental Release</B>&rdquo;
means any discharge, emission, spilling, leaking, pumping, pouring, injecting, dumping, burying, leaching, migrating, abandoning
or disposing into or through the environment of any Hazardous Material, including the abandonment of barrels, containers and other
closed receptacles containing any Hazardous Material;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Excluded Assets</B>&rdquo;
means (i) the Patents listed in Exhibit A to the Intellectual Property License Agreement, (ii) any used or refurbished Product
units of the Vendor or its Affiliates, (iii) the Accounts Receivable; (iv) the Inventory; (v) the Excluded Books and Records, (vi)
all amounts receivable for Taxes, including all Tax refunds, in respect of any Vendor Tax Period relating to the Business or the
Purchased Assets, together with any interest due thereon, (vii) the rights of the Vendor in, to and under all Excluded Contracts,
and (viii) any Permits exclusively relating to an Excluded Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Excluded Books and
Records</B>&rdquo; means all corporate, financial, taxation, Tax Returns and other books and records of the Vendor not related
to the Business, the Purchased Assets, the Subco Shares or the Assumed Liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Excluded Contracts</B>&rdquo;
means those Contracts relating to the Business, except for the Transferred Contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Exhibits</B>&rdquo;
means the exhibits to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>FDA</B>&rdquo;
has the meaning set forth in the definition of &ldquo;<B>Governmental Authority</B>&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Financial Statements&rdquo;
</B>means, collectively, the (i) audited consolidated financial statements of the Purchaser as at and for the financial year ended
December 31, 2016 (which financial statements include comparative financial information for the 2015 financial year), together
with the report of PricewaterhouseCoopers LLP on those financial statements, and including the notes with respect to those financial
statements; and (ii) the unaudited condensed consolidated interim financial statements of the Purchaser as at and for the three
months ended March 31, 2017 (which financial statements include comparative financial information for the comparable period in
2015), and including the notes with respect to those financial statements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">[Redacted &ndash;
Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Finnish GAAP</B>&rdquo;
has the meaning set forth in Section 1.3;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Form 44-101&rdquo;
</B>means Form 44-101 &mdash; Short Form Prospectus;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Full Disputed
Amount</B>&rdquo; has the meaning set forth in Section 2.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Fundamental Representations</B>&rdquo;
has the meaning set forth in Section 10.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>generally accepted
accounting principles</B>&rdquo; has the meaning set forth in Section 1.3;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Goodwill</B>&rdquo;
means the goodwill of the Business, including lists of customers and suppliers, credit information, research materials, and the
exclusive right of the Purchaser to represent itself as carrying on the Business in succession to the Vendor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Governmental Authority</B>&rdquo;
means any federal, national, supranational, state, provincial or local government, any court, tribunal, arbitrator, authority,
agency, commission, stock exchange, official, any minister or the crown or foreign equivalent or any non-governmental self-regulatory
agency or other instrumentality of any government that, in each case, has jurisdiction over the matter in question, including the
U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;), the European Commission, and Health Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Hazardous Materials</B>&rdquo;
means any substance that is listed or regulated pursuant to any applicable Environmental Law as a &ldquo;pollutant&rdquo;, &ldquo;deleterious
substance&rdquo;, &ldquo;toxic substance&rdquo;, &ldquo;hazardous substance&rdquo; or &ldquo;hazardous waste&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Health Care Laws&rdquo;
</B>means any international, federal, state, provincial or local statutes, regulations, directives guidelines, ordinances, orders,
standards, requirements, approvals, or consents, including but not limited to: the United States Federal Food, Drug and Cosmetic
Act and similar foreign health product legislation; any implementing regulations pursuant to any of the foregoing, and all similar
or related international, federal, state, provincial or local healthcare statutes, regulations and directives applicable to the
business of the Purchaser or the Profound Subsidiaries, including but not limited to state and provincial laws concerning fee-splitting,
kickbacks, corporate practice of medicine, disclosure of ownership, related party requirements, survey, certification, licensing,
civil monetary penalties, self-referrals, or laws concerning the privacy and/or security of personal health information and breach
notification requirements concerning personal health information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Hold Period</B>&rdquo;
has the meaning set forth in Section 5.7(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>ICC Arbitration Rules</B>&rdquo;
has the meaning set forth in Section 12.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indebtedness</B>&rdquo;
of any Person means all obligations of such Person (a) for money borrowed, whether or not evidenced by bonds, debentures, notes
or other similar instruments (including obligations to reimburse any other Person under any letter of credit, banker&rsquo;s acceptance
or related reimbursement agreement, to the extent drawn and not repaid, and any notes issued by such Person in connection with
any acquisition undertaken by such Person); (b) relating to any lease that is required to be classified as a capital lease in
accordance with generally accepted accounting principles; (c) for amounts owing or due under any interest rate protection agreement,
derivative instrument, &ldquo;swap&rdquo; agreement or similar agreement (valued on a fair market value basis); (d) in respect
of the deferred purchase price of property (other than trade accounts payable and other accrued current liabilities arising in
the ordinary course of business); (e) to guarantee or be liable for obligations of the types described in clauses (a) to (d) above,
of any other Person; and (f) for any accrued interest, prepayment premium or penalty or other costs, fees or expenses related
to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indemnified Party</B>&rdquo;
has the meaning set forth in Section 10.6(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indemnifying Party</B>&rdquo;
has the meaning set forth in Section 10.6(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indemnity Cap</B>&rdquo;
has the meaning set forth in Section 10.3(iii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Independent Auditor</B>&rdquo;
means an internationally recognized accounting firm that does not provide material accounting, auditing or tax services to any
of the Parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Independent CPA</B>&rdquo;
has the meaning set forth in Section 2.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo;
means, in any and all jurisdictions, all: (a) patents and applications therefor, including all continuations, divisionals, continuations-in-part
and provisionals and patents issuing thereon, and all reissues, reexaminations, substitutions, renewals and extensions thereof
(collectively, &ldquo;<B>Patents</B>&rdquo;); (b) trademarks, service marks, trade names, trade dress, logos, corporate names,
Internet domain names or uniform resource locators used in connection with any global computer or electronic network, together
with all translations, adaptations, derivations and combinations thereof, and other source or business identifiers, together with
the goodwill associated with any of the foregoing, and all applications, registrations, renewals and extensions thereof; (c) industrial
designs, designs and design rights; (d) copyrights, works of authorship and moral rights, and all registrations, applications,
renewals, extensions and reversions thereof; (e) trade secrets, discoveries, concepts, ideas, research and development, know-how,
formulae, inventions, compositions, manufacturing and production processes and techniques, technical data, quality data, procedures,
designs, drawings, specifications, databases, and other proprietary or confidential information, including customer lists, supplier
lists, pricing and cost information, and business and marketing plans and proposals, which would constitute a &ldquo;trade secret&rdquo;
under applicable Law, in each case excluding any rights in respect of any of the foregoing that comprise or are protected by Patents
(&ldquo;<B>Trade Secrets</B>&rdquo;); (f) inventions, processes and designs; and (g) software, and all source code, object code,
data and documentation relating thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property
Assignment Agreement</B>&rdquo; has the meaning set forth in Section 2.5(a)(i)(C)(4);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property
License Agreement</B>&rdquo; has the meaning set forth in Section 2.5(a)(i)(C)(4);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property
Rights</B>&rdquo; means all rights in Intellectual Property, and all related priority rights and goodwill arising from or in respect
of Intellectual Property, whether protected, created or arising under applicable Laws or under any international convention, and
all rights to sue for past, present and future infringement in any jurisdiction in which a right to sue for past, present and future
infringement may be transferred with Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property
Rights Agreements</B>&rdquo; has the meaning set forth in Section 2.5(a)(i)(C)(4);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Instrument of
Conveyance</B>&rdquo; has the meaning set forth in Section 2.5(a)(ii)(L);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Inventory</B>&rdquo;
means all inventory (including raw materials, work in progress and finished goods), packaging, supplies and parts used in the
conduct of the manufacturing of the Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">[Redacted &ndash; Commercially
Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Knowledge of the Vendor</B>&rdquo;
has the meaning set forth in Section 1.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Laws</B>&rdquo; means
all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of laws of Finland, the Netherlands
or any other country or any domestic or foreign province, state, county, city or other political subdivision or of any Governmental
Authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Leased Premises&rdquo;
</B>has the meaning set forth in Section 4.26;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Legal Proceeding</B>&rdquo;
means any judicial, administrative or arbitral actions, suits, proceedings (public or private) or claims or other proceedings,
investigations or audits by or before a Governmental Authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Liability</B>&rdquo;
means any debt, liability or obligation (whether direct or indirect, known or unknown, absolute or contingent, accrued or unaccrued,
liquidated or unliquidated, or due or to become due), and including all costs and expenses relating thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Licensed Intellectual
Property</B>&rdquo; has the meaning set forth in Section 3.15(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Liens</B>&rdquo;
means any encumbrance, lien, pledge, charge, mortgage or security interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Line of Business</B>&rdquo;
means [Redacted &ndash; Commercially Sensitive];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Loan Agreement</B>&rdquo;
has the meaning set forth in Section 2.5(a)(i)(C)(5);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Local Counsel Review</B>&rdquo;
means review and comment by Purchaser local Netherlands counsel with respect to Netherlands law issues;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Loss</B>&rdquo; or
 &ldquo;<B>Losses</B>&rdquo; have the meaning set forth in Section 10.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Adverse Effect</B>&rdquo;
means any change, effect, event, occurrence or condition that, individually or in the aggregate with any other changes, effects,
events or conditions, has or would reasonably be expected to have a materially adverse effect upon the business, assets, Liabilities,
results of operations or financial condition of the Business taken as a whole, except that none of the following, either alone
or in combination, shall be considered in determining whether there has been a &ldquo;Material Adverse Effect&rdquo; or a breach
of a representation, warranty, covenant or agreement that is qualified by the term &ldquo;Material Adverse Effect&rdquo;: (i) changes,
effects, events or conditions affecting the Finish, Netherlands, Canadian or other financial or securities markets or general economic
or political conditions, including changes in the credit, interest rate, commodity and currency markets or in the availability
of financing, except to the extent any such change disproportionately impacts the Business relative to other companies operating
in the industries in which the Business operates; (ii) changes, effects, events or conditions that result from the execution, announcement
or performance of this Agreement or the identity of the Purchaser or the consummation of the transactions contemplated hereby;
(iii) changes, effects, events or conditions that result from any action or omission required to be taken pursuant to this Agreement
or at the request of or with the prior written consent of the Purchaser; and (iv) changes in the revenue forecast for the Business
from January 1, 2017 to the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Supplier Contract</B>&rdquo;
means each supplier Contract set forth on Section 1.1-2 of the Disclosure Schedule hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Net Sales</B>&rdquo;
means the revenues (less any royalties), as reported in accordance with generally accepted accounting principles, received by the
Purchaser, and/or its parent, the Profound Subsidiaries and Affiliate(s), or others on their behalf in respect of the sale or transfer
of the Product, which, for greater clarity, includes any amounts received with respect to service agreements. For clarity, any
revenues with respect to consumables are not included in Net Sales;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;NI 44-101&rdquo; </B>means
National Instrument 44-101 &mdash; Short Form Prospectus Distributions of the Canadian Securities Administrators;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;NI 51-102&rdquo; </B>means
National Instrument 51-102 - Continuous Disclosure Obligations of the Canadian Securities Administrators;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Noncompetition and
Confidentiality Agreement</B>&rdquo; has the meaning set forth in Section 2.5(a)(ii)(H);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Notice</B>&rdquo; has
the meaning set forth in Section 10.6(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Order</B>&rdquo; means
any writ, judgment, injunction, decree, determination, award or similar order of any Governmental Authority (whether preliminary
or final);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Other Transaction Documents</B>&rdquo;
means, collectively, the Transition Services Agreement, the Resale Purchasing Agreement, the Intellectual Property Rights Agreements,
the Loan Agreement, the Supply Agreement, the Noncompetition and Confidentiality Agreement, the Subscription Agreement, and each
Instrument of Conveyance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Outside Date</B>&rdquo;
has the meaning set forth in Section 11.1(iii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Party</B>&rdquo;
and &ldquo;<B>Parties</B>&rdquo; have the meanings set forth in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Patents</B>&rdquo;
has the meaning set forth in the definition of Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Permits</B>&rdquo;
means all permits, licenses, certificates of authority, authorizations, approvals, registrations, variances, franchises or similar
consents granted or issued by any Governmental Authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Permitted Liens</B>&rdquo;
means, with respect to any Person, (i) any statutory Lien for Taxes not yet due or delinquent or being contested in good faith
by appropriate proceedings, (ii) any Liens for a judgment rendered or claim filed against such Person which is being contested
in good faith by appropriate Legal Proceedings, (iii) mechanics&rsquo;, carriers&rsquo;, workmen&rsquo;s, repairmen&rsquo;s or
other like Liens and Liens imposed by Law, in each case arising or incurred in the ordinary course of business and where the underlying
obligations are not delinquent, (iv) any minor defect or irregularity in title, easement, right of way, zoning, land use, bylaw
regulation or other similar restriction, (v) any Lien granted to a public utility or Governmental Authority, (vi) the rights of
any landlord or any Person under any lease of real property occupied by such Person as tenant and Liens, reservations and renewals
of freehold interest in any such property having priority to any such leases, and (vii) any Lien that will be satisfied and released
at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Person</B>&rdquo; means
any individual, partnership, limited partnership, joint venture, syndicate, sole proprietorship, company or corporation with or
without share capital, unincorporated association, trust, trustee, executor, administrator or other legal personal representative
or Governmental Authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Philips Group</B>&rdquo;
means the Vendor and its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Prior Commitments</B>&rdquo;
has the meaning as defined in the Intellectual Property Assignment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Product</B>&rdquo;
means (i) Sonalleve MR-HIFU or any subsequent, successor or next-generation product the treatment technology of which is primarily
based on MR-HIFU and which utilizes the Business Intellectual Property or (ii) any future product that combines the technologies
of Sonalleve MR-HIFU and Transurethral UltraSound Ablation (TULSA-PRO), provided, however, that Product shall not include any consumables;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Profound Subsidiaries&rdquo;
</B>means: (i) Profound Medical GmbH, (ii) Profound Medical US Inc. and, following Closing, Subco, and &quot;Profound Subsidiary&quot;
means any one of them, as the context requires or permits;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchase Price</B>&rdquo;
has the meaning set forth in Section 2.3(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchased Assets</B>&rdquo;
means all of the Vendor&rsquo;s and its Affiliates&rsquo; right, title and/or interest in, to and under, or relating to, the assets,
properties and undertakings relating to the operation of the Business and including, for greater certainty and without limitation,
(i) the Business Books and Records, (ii) the Tangible Assets, (iii) the Goodwill, (iv) the Business Intellectual Property, (v)
all prepaid expenses and deposits of the Vendor and any of its Subsidiaries relating to or arising out of the operation of the
Business, (vi) subject to Section 2.8, the Transferred Contracts; (vii) subject to Section 2.8 and to the extent transferable under
applicable Law, all Transferred Permits (including applications therefor); (viii) all rights of the Vendor and its Affiliates under
or pursuant to all warranties, representations and guarantees made by suppliers and manufacturers to the extent relating to the
Purchased Assets, (ix) all open and unfulfilled purchase orders of customers with respect to the Product, (x) all marketing assets
relating to the operation of the Business, including those listed in Section 1.1-4 of the Disclosure Schedule, and (xi) all other
rights, properties and assets of the Vendor or its Affiliates owned by the Vendor or its Affiliates for use in or relating to the
operation of the Business of whatsoever nature or kind and wherever situated, but excluding the Excluded Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchaser</B>&rdquo;
has the meaning set forth in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchaser Common Shares</B>&rdquo;
has the meaning set forth in Section 2.3(a)(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Purchaser Employee
Plans&rdquo; </B>has the meaning set forth in Section 4.27(c);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchaser Indemnified
Parties</B>&rdquo; has the meaning set forth in Section 10.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Purchaser Intellectual
Property&rdquo; </B>means all of the following which is currently owned by, issued to or licensed to the Purchaser or a Profound
Subsidiary, or other rights of the Purchaser or a Profound Subsidiary to use the following (i) patent rights, issued patents, patent
applications, patent disclosures., and registrations, inventions, discoveries, developments, concepts, ideas, improvements, processes
and methods, whether or not such inventions, discoveries, developments, concepts, ideas, improvements, processes, or methods are
patentable or registrable, anywhere in the world, (ii) copyrights (including performance rights) to any original works of art or
authorship, including source code and graphics, which are fixed in any medium of expression, including copyright registrations
and applications therefor, anywhere in the world, whether or not registered or registrable, (iii) any and all common law or registered
trade-mark rights, trade names, business names, trade-marks, proposed trade-marks, certification marks, service marks, distinguishing
marks and guises, logos, slogans, goodwill, domain names and any registrations and applications therefor, anywhere in the world,
whether or not registered or registrable, (iv) know-how, show-how, confidential information, trade secrets, (v) any and all industrial
design rights, industrial designs, design patents, industrial design or design patent registrations and applications therefor,
anywhere in the world, whether or not registered or registrable, (vi) any and all integrated circuit topography rights, integrated
circuit topographies and integrated circuit topography applications, anywhere in the world, whether or not registered or registrable,
(vii) any reissues, divisions, continuations, continuations-in-part, renewals, improvements, translations, derivatives, modifications
and extensions of any of the foregoing, (viii) any other industrial, proprietary or intellectual property rights, anywhere in the
world, and (ix) proprietary computer software (including but not limited to data, data bases and documentation);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Purchaser Material
Adverse Effect&rdquo; </B>means any change (including a decision to implement such a change made by the board of directors or by
senior management who believe that confirmation of the decision by the board of directors is probable), fact, event, violation,
inaccuracy, circumstance, state of being or effect that is materially adverse (actually or anticipated, whether financial or otherwise)
to the business, assets (including intangible assets), affairs, operations, prospects, liabilities (contingent or otherwise), capital,
properties, condition (financial or otherwise), results of operations or control of the Purchaser and the Profound Subsidiaries,
on a consolidated basis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Purchaser Product&rdquo;
</B>means the medical device currently being developed by the Purchaser and its Subsidiaries, known as the Transurethral UltraSound
Ablation (TULSA-PRO) device;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchaser Proposed
Amount</B>&rdquo; has the meaning set forth in Section 2.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Purchaser&rsquo;s Disclosure
Schedule&rdquo; </B>means the disclosure schedule of the Purchaser attached to this Agreement, including all exhibits thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Qualifying Jurisdictions&rdquo;
</B>means all of the Provinces of Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Refund</B>&rdquo;
has the meaning set forth in Section 7.3(d);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Registered Business
Intellectual Property</B>&rdquo; has the meaning set forth in Section 3.15(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regular Earn-out
Payments</B>&rdquo; has the meaning set forth in Section 2.3(a)(ii)(C);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regulatory Approvals</B>&rdquo; has the meaning
set forth in Section 3.29(a);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Regulatory Authority&rdquo;
</B>means the Governmental Authority authorized under applicable Laws to protect and promote public health through regulation and
supervision of medical products, including, without limitation, the FDA, Health Canada and similar regulatory agencies outside
of Canada and the United States;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Representatives</B>&rdquo;
has the meaning set forth in Section 5.2(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Resale Purchasing
Agreement</B>&rdquo; has the meaning set forth in Section 2.5(a)(i)(C)(3);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Resolution Period</B>&rdquo; has the meaning
set forth in Section 2.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Restrictive Covenants</B>&rdquo;
has the meaning set forth in Section 13.14;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Retained Liabilities</B>&rdquo;
means all Liabilities relating to or arising out of the Business or the Purchased Assets, other than the Assumed Liabilities, including,
for greater certainty: (i) any Indebtedness of the Vendor and its Affiliates, (ii) all Liabilities and obligations relating to
the Excluded Assets and the Excluded Contracts, (iii) all Liabilities and obligations relating to Taxes related to, or arising
out of, ownership of the Purchased Assets or operation of the Business in respect of a Vendor Tax Period, (iv) all Transaction
Expenses, (v) all Liabilities related to the termination of any individual on or prior to the Closing Date that was employed or
retained by the Vendor and its Affiliates prior to the Closing Date, including any termination or severance payment, (vi) all Employee
Liabilities (a) accruing on or prior to the Closing Date in respect of all Employees and all employees of the Business and (b)
after the Closing Date in respect of the employees of the Business other than the Employees; (vii) all accounts payable arising
with respect to goods and services of the Business incurred prior to the Closing Date; and (viii) all Liabilities known or unknown
to the Vendor to the extent related to the Business prior to the Transfer Time, including Liabilities relating to recalls for the
Product sold prior to the Transfer Time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Royalty Payments&rdquo;
</B>has the meaning set forth in Section 2.3(a)(ii)(D);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Schedules</B>&rdquo;
means the schedules to this Agreement, including, for greater certainty, the Disclosure Schedule;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Securities Commission&rdquo;
</B>means the applicable securities commission or regulatory authority in each of the Qualifying Jurisdictions and &ldquo;<B>Securities
Commissions</B>&rdquo; means all of them;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;SR&amp;ED&rdquo; </B>has
the meaning set forth in Section 4.15(c);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Straddle Period</B>&rdquo;
means any period that includes, but does not end on or before, the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Subco</B>&rdquo;
has the meaning set forth in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Subco Shares</B>&rdquo;
has the meaning set forth in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Subscription Agreement</B>&rdquo;
means the subscription agreement to be entered into between the Purchaser and the Vendor pursuant to which the Vendor will receive
the Purchaser Common Shares by way of a prospectus-exempt private placement offering, substantially in the form annexed hereto
as Exhibit I;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Subject Laws</B>&rdquo;
has the meaning set forth in Section 3.22;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to any Person, any other Person in which such Person, directly or indirectly through Subsidiaries or otherwise,
beneficially owns more than fifty percent (50%) of either the equity interests in, or the voting control of, such other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;Sunnybrook License
Agreement&rdquo; </B>means the amended and restated technology license agreement entered into on May 16, 2011 between the Purchaser
and Sunnybrook Health Sciences Centre, pursuant to which Sunnybrook Health Sciences Centre licenses to the Purchaser certain intellectual
property on the terms and conditions set forth therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Supply Agreement</B>&rdquo;
has the meaning set forth in Section 2.5(a)(i)(C)(6);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Tangible Assets</B>&rdquo;
means the machinery, equipment (including manufacturing equipment), computers (other than leased computers), fixtures, furniture,
furnishings, tools, office equipment, supplies, telephones and other tangible personal property (other than Inventory) used primarily
in the conduct of the Business at the locations at which the Business is conducted, or otherwise used by the Vendor and its Affiliates
primarily in the conduct of the Business, as more fully set forth on Section 1.1-5 of the Disclosure Schedule, which Schedule shall
be updated at Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Tax Act</B>&rdquo;
means the <I>Income Tax Act </I>(Canada).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Tax Returns</B>&rdquo;
has the meaning set forth in Section 3.18(a)(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Taxes</B>&rdquo;
has the meaning set forth in Section 3.18(a)(i);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Third Party</B>&rdquo;
means any Person other than the Parties and their Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Threshold</B>&rdquo;
has the meaning set forth in Section 10.3(ii);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Trade Secrets</B>&rdquo;
has the meaning set forth in the definition of Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Transaction</B>&rdquo; has the meaning set forth
in <B>Error! Reference source not found.</B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Transaction Expenses</B>&rdquo;
means: (i) the legal, accounting, financial advisory and other Third Party advisory or consulting fees of the Vendor or its Affiliates
incurred in connection with the transactions contemplated by this Agreement; and (ii) all transaction or stay bonuses or similar
amounts payable to officers, directors or employees of the Vendor or its Affiliates to the extent arising as a result of the execution
and delivery of this Agreement or the Other Transaction Documents or the consummation of the transactions contemplated hereby or
thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Transfer Time</B>&rdquo;
has the meaning set forth in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Transferred Contracts</B>&rdquo;
means those Contracts listed on Section 1.1-3 of the Disclosure Schedule;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Transferred Permits</B>&rdquo;
means the import Permits necessary for operation of the Business and transfer of the Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Transition Services
Agreement</B>&rdquo; means the Transition Services Agreement to be entered into by the Purchaser and the Vendor in a form to be
mutually agreed by the Parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Treaty</B>&rdquo;
has the meaning set forth in Section 2.3(b);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&ldquo;TSXV&rdquo; </B>means
the TSX Venture Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Vendor</B>&rdquo;
has the meaning set forth in the Preamble;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Vendor Indemnified
Parties</B>&rdquo; has the meaning set forth in Section 10.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Vendor Proposed
Amount</B>&rdquo; has the meaning set forth in Section 2.4;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Vendor Tax Period</B>&rdquo;
means and includes any and all periods ending before the Closing Date and, in addition, the portion of any Straddle Period that
consists of a partial period deemed to end immediately before the Closing Date; <U>provided, </U>that in the case of any Straddle
Period, for purposes hereof, the Business Books and Records shall be deemed to have been closed at and as of the beginning of the
Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Vendor Update</B>&rdquo;
has the meaning set forth in Section 5.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 1.2</TD><TD STYLE="text-align: justify">Knowledge of the Vendor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">For purposes
of this Agreement, the term or phrase &ldquo;<B>Knowledge of the Vendor</B>&rdquo; shall mean and be limited to the actual knowledge,
after reasonable inquiry, of the individuals set forth in Section 1.2 of the Disclosure Schedule, in each case after reasonable
inquiry of each senior management level Person who reports directly to such Person, and without personal liability for any such
knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 1.3</TD><TD STYLE="text-align: justify">Generally Accepted Accounting Principles.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">In this Agreement,
except to the extent otherwise expressly provided, references to &ldquo;<B>generally accepted accounting principles</B>&rdquo;
means International Financial Reporting Standards adopted by the International Accounting Standards Board in effect from time to
time, consistently applied. References to &ldquo;<B>Finnish GAAP</B>&rdquo; means generally accepted accounting principles in Finland,
which are subject to the Finnish Accountancy Act (1336/1997, as amended) and the Finnish Accountancy Regulation (1339/1997, as
amended), as consistently applied by Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 1.4</TD><TD STYLE="text-align: justify">Calculations in Euros.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except to the
extent expressly provided, all amounts in this Agreement are stated and shall be paid in Euros.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 1.5</TD><TD STYLE="text-align: justify">Interpretation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Unless otherwise expressly provided,
the following rules of interpretation shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table of contents and headings set forth in this Agreement are for convenience of reference purposes only and shall not affect
or be deemed to affect in any way the meaning or interpretation of this Agreement or any term or provision hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, all references herein to sections, articles, exhibits or schedules, shall be deemed to refer to Sections,
Articles, Exhibits or Schedules of or to this Agreement, as applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
use in this Agreement of the masculine pronoun in reference to a Person shall be deemed to include the feminine or neuter, and
vice versa, as the context may require;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
reference to the singular in this Agreement shall also include the plural and vice versa, as the context may require;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References
to any Law shall be construed as a reference to the same as in effect on the date of this Agreement, unless the context otherwise
requires;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
reference to a number of days shall refer to calendar days unless Business Days are specified;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties agree that they have been represented by counsel during the negotiation and execution of this Agreement and, therefore,
waive the application of any Law, holding or rule of construction providing that ambiguities in an agreement or other document
will be construed against the Party drafting such agreement or document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
words &ldquo;include&rdquo;, &ldquo;<B>includes</B>&rdquo; and &ldquo;<B>including</B>&rdquo; mean &ldquo;<B>include</B>&rdquo;,
 &ldquo;<B>includes</B>&rdquo; and &ldquo;<B>including</B>&rdquo;, in each case, &ldquo;<B>without limitation</B>&rdquo;; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
words &ldquo;<B>ordinary course of business</B>&rdquo; mean, with respect to an action taken by a Person, the action is consistent
with the past practices of the Person and is taken in the normal day-to-day operations of the Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 1.6</TD><TD STYLE="text-align: justify">Schedules.</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The following are the schedules
attached to this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify">Section 1.1-1</TD>
    <TD STYLE="width: 60%; text-align: justify">Employees</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Section 1.1-2</TD>
    <TD STYLE="text-align: justify">Material Supplier Contracts</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Section 1.1-3</TD>
    <TD STYLE="text-align: justify">Contracts</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Section 1.1-4</TD>
    <TD STYLE="text-align: justify">Purchased Assets</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Section 1.1-5</TD>
    <TD STYLE="text-align: justify">Tangible Assets</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Section 1.2</TD>
    <TD STYLE="text-align: justify">Individuals with Knowledge of the Vendor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Section 2.7</TD>
    <TD STYLE="text-align: justify">Allocation of Purchase Price </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Disclosure Schedule</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Purchaser Disclosure Schedule</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center">ARTICLE 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURCHASE AND SALE; PURCHASE PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.1</TD><TD STYLE="text-align: justify">Purchase and Sale of Subco Shares and Class A Patents
and Trademarks.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Subject to
the terms of this Agreement, the Vendor shall sell, transfer, assign, convey and deliver the Class A Patents and Trademarks and
the Subco Shares, free and clear of all Liens, other than restrictions on transfer contained in Subco&rsquo;s constituting documents
and applicable securities Laws and other than as set forth herein, to the Purchaser or, at the direction of the Purchaser, to the
Purchaser and/or a permitted assignee of the Purchaser in accordance with Section 13.11, and the Purchaser or such permitted assignee
shall purchase, accept and receive, all right, title and interest in or to the Class A Patents and Trademarks and the Subco Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.2</TD><TD STYLE="text-align: justify">Assumption of Liabilities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Assumed
Liabilities shall be assumed by Subco pursuant to the Asset Transfer Agreements and shall be timely paid, performed and discharged,
as the case may be, by Subco in accordance with their terms. The Retained Liabilities shall be timely paid, performed and discharged,
as the case may be, by the Philips Group, in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.3</TD><TD STYLE="text-align: justify">Purchase Price.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate purchase price (the &ldquo;<B>Purchase Price</B>&rdquo;) payable by the Purchaser to the Vendor for the Subco Shares
and the Class A Patents and Trademarks shall be equal to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">7,400,000 common shares of the Purchaser (the &ldquo;<B>Purchaser Common Shares</B>&rdquo;), issued
by way of prospectus-exempt private placement offering (the &ldquo;<B>Base Purchase Price Shares</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the earn-out payments payable as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.35in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">5% of Net Sales occurring only after the Closing in the calendar year 2017;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.35in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">6% of Net Sales occurring in the calendar year 2018; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.35in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">7% of Net Sales occurring in calendar years 2019 and 2020 (the payments referred to in clauses
(A), (B) and (C) collectively, &ldquo;<B>Regular Earnout Payment</B>s&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.35in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">To the extent the Purchaser sublicenses out the Business Intellectual Property to a Third Party,
the Purchaser shall pay the Vendor [Redacted &ndash; Commercially Sensitive] of royalties in respect of sales received by the Purchaser
under such license agreements during 48 months after Closing Date the (&ldquo;<B>Royalty Payments</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-align: justify">The Regular Earnout Payments and
Royalty Payments shall be made on a monthly basis within 30 days after the end of each applicable calendar month; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the cumulative Net Sales for the full calendar years 2017 through 2020 exceeds &euro;45,300,000,
a single additional earn-out payment will be payable by the Purchaser to the Vendor (the &ldquo;<B>Additional Earnout Amount</B>&rdquo;).
The Additional Earnout Amount shall be equal to 7% of Net Sales for the period beginning after the Closing Date and through December
31, 2019. The Additional Earnout Amount, if any, shall be paid on the later of (a) March 31, 2021 or (b) once the annual confirmation
with respect to Net Sales and Royalty Payments for the calendar year ending 2020 is final, binding and conclusive on the Parties
in accordance with Section 2.4.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">For greater
certainty, all amounts payable in Section 2.3(a)(ii) and Section 2.3(a)(iii) shall be paid in Euros.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser shall be entitled to deduct or withhold from the cash components of the Purchase Price any amounts required to be deducted
or withheld under applicable Law with respect to Taxes. Provided the Vendor will provide any further documentation reasonably requested
by the Purchaser from time to time in relation to the Vendor&rsquo;s residency status and entitlement to the full benefits under
the Canada-Netherlands Income Tax Convention (1986) as amended (the &ldquo;<B>Treaty</B>&rdquo;), the Purchaser shall (i) consider
in good faith such status and entitlement to full benefits of the Vendor under the Treaty when determining the amount of Canadian
taxes to be withheld from payments by the Purchaser to the Vendor and (ii) use commercially reasonable efforts to cooperate with
the Vendor to minimize the amounts of such Canadian taxes it withholds, including, to the extent applicable and necessary or desirable,
negotiating with the Vendor in good faith to agree on an allocation of payments into categories that (A) are not subject to Canadian
withholding tax pursuant to the Tax Act, or (B) are subject to Canadian withholding tax pursuant to the Tax Act and (I) are eligible
for a full exemption from Canadian withholding tax under the Treaty, or (II) are eligible for a reduction in the rate of Canadian
withholding tax under the Treaty, or (III) are not eligible for any Treaty relief. The Vendor agrees to indemnify and hold the
Purchaser Indemnified Parties harmless against any Canadian withholding tax and related interest and penalties that are assessed
against the Vendor by the Canada Revenue Agency and reasonable third party costs and expenses incurred in connection with any audit
by or dispute with the Canada Revenue Agency, as a result of the Purchaser and the Vendor agreeing that Treaty relief is available
to the Vendor pursuant to clause (ii)(B)(I) or (ii)(B)(II) above. Any amount deducted and withheld pursuant to this Section 2.3(b)
shall be remitted by the Purchaser to the relevant Governmental Authority and shall be treated for all purposes of this Agreement
as having been paid to the Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.4</TD><TD STYLE="text-align: justify">Accounting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
shall calculate the Regular Earnout Payments and the Royalty Payments and provide the Vendor with an accounting (including a schedule
summarizing Net Sales) simultaneously on the date on which they are due. Such calculations and schedules shall set forth the applicable
information on a country-by-country basis and shall further set forth all applicable calculations of currency exchange rates (based
upon the average of the daily average exchange rate published by the Bank of Canada on the last Business Day of each month) and
detail supporting any calculations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Within three
months after the end of each of calendar years 2017, 2018, 2019, 2020 and 2021, the Purchaser shall provide the Vendor with a written
confirmation of the actual annual Royalty Payments for the relevant calendar year, as such Royalty Payments are reported by the
Purchaser&rsquo;s accountants in Purchaser&rsquo;s annual accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">If, after completion
of its review of the annual confirmation, the Vendor disagrees as to the Regular Earnout Payments, the Additional Earnout Amount
or the Royalty Payments, as applicable (the &ldquo;<B>Purchaser Proposed Amount</B>&rdquo;), the Vendor shall provide the Purchaser
with written notice of each disputed item and a description of the Vendor&rsquo;s dispute with such item (such description to be
in sufficient detail for an auditor to understand the Vendor&rsquo;s disagreement(s)) as well as the amount which it believes it
is owed (the &ldquo;<B>Vendor Proposed Amount</B>&rdquo;), such notice to be provided to the Purchaser within fifteen (15) Business
Days after completion of its review. In the event of such a dispute, the Parties shall attempt to reconcile in good faith their
differences as to such items within thirty (30) days of the Purchaser&rsquo;s receipt of such notice or such longer period as may
be mutually agreed upon by the Parties (the &ldquo;<B>Resolution Period</B>&rdquo;), and any resolution by the Parties as to any
disputed items shall be final, binding and conclusive on the Parties, except with respect to fraud. If the Parties are unable to
reach a resolution with such effect within the Resolution Period, the Parties shall submit the dispute to the Designated Officers
who shall submit the dispute to an independent, nationally recognized accounting firm jointly selected by the Parties (an &ldquo;<B>Independent
CPA</B>&rdquo;). The determination of such dispute by the Independent CPA (the &ldquo;<B>Determined Amount</B>&rdquo;) shall be
final, binding and conclusive on the Parties, except with respect to fraud. The fees and expenses of the Independent CPA shall
be allocated between the Purchaser, on the one hand, and the Vendor, on the other hand, as follows: (i) the Vendor shall pay a
fraction of such fees and expenses equal to (a) the difference between the Vendor Proposed Amount and the Determined Amount divided
by (b) the difference between the Vendor Proposed Amount and the Purchaser Proposed Amount (the &ldquo;<B>Full Disputed Amount</B>&rdquo;)
and (ii) the Purchaser shall pay a fraction of such fees and expenses equal to (a) the difference between the Purchaser Proposed
Amount and the Determined Amount divided by (b) the Full Disputed Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Once the annual
confirmation is final, binding and conclusive on the Parties, either as mutually agreed by the Parties, as determined by the Independent
CPA or by the Vendor not issuing (in time) a notification of dispute, each in accordance with above paragraphs, the Parties shall
balance the Regular Earnout Payments and Royalty Payments as paid by the Purchaser to the Vendor in the relevant calendar year
against the amounts as included in the annual confirmation and settle accordingly in one payment by the Purchaser to the Vendor,
or vice versa (in case the monthly payments exceeded the amounts due under the finally determined annual confirmation). Settlement
shall be paid within thirty (30) days from the date the annual confirmation is finally determined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.5</TD><TD STYLE="text-align: justify">Payment of Purchase Price and Closing Deliverables.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">At the Closing,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the Purchaser shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">or shall cause its permitted assignee to, as promptly as practicable at or after the Effective
Time, deliver to the Vendor the Base Purchase Price Shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">cause Subco to, pay, discharge and perform, as the case may be, from and after the Closing Date,
the Assumed Liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">deliver to the Vendor:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">an officer&rsquo;s certificate required to be delivered pursuant to Section 9.5;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">a Transition Services Agreement, duly executed by the Purchaser and the applicable permitted assignees
of the Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">a resale purchasing agreement, substantially in the form attached hereto as Exhibit A, but subject
to Local Counsel Review (the &ldquo;<B>Resale Purchasing Agreement</B>&rdquo;), duly executed by the Purchaser and the applicable
permitted assignees of the Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">the intellectual property assignment agreement (the &ldquo;<B>Intellectual Property Assignment
Agreement</B>&rdquo;) and the intellectual property license agreement (the &ldquo;<B>Intellectual Property License Agreement</B>&rdquo;),
each in the forms attached hereto as Exhibit B-1 and Exhibit B-2, respectively, but subject to Local Counsel Review in each case
(collectively, the &ldquo;<B>Intellectual Property Rights Agreements</B>&rdquo;), duly executed by the Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">a loan agreement, in a form to be mutually agreed by the Parties (the &ldquo;<B>Loan Agreement</B>&rdquo;),
duly executed by the Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">a supply agreement, in a form to be mutually agreed by the Parties (the &ldquo;<B>Supply Agreement</B>&rdquo;),
duly executed by the Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">a non-competition and confidentiality agreement, in the form attached hereto as Exhibit C (the
 &ldquo;<B>Noncompetition and Confidentiality Agreement</B>&rdquo;), duly executed by the Purchaser;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">a Subscription Agreement, in a form to be mutually agreed by the Parties, duly executed by the
Purchaser, together with the documents deliverable thereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(9)</TD><TD STYLE="text-align: justify">such other documents, instruments and certificates as the Vendor may reasonably request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Vendor shall deliver to the Purchaser:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">officer&rsquo;s certificates required to be delivered pursuant to Section 8.4;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Asset Transfer Agreements duly executed by each of Philips Oy and Philips Medical Systems Nederland
B.V. and Subco;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(C)</TD><TD STYLE="text-align: justify">the Transition Services Agreement duly executed by the Vendor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(D)</TD><TD STYLE="text-align: justify">the Resale Purchasing Agreement duly executed by the Vendor or an Affiliate of a Vendor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(E)</TD><TD STYLE="text-align: justify">the Intellectual Property Rights Agreements, duly executed by the Vendor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(F)</TD><TD STYLE="text-align: justify">the Loan Agreement, duly executed by Philips Medical Systems Nederland B.V.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(G)</TD><TD STYLE="text-align: justify">the Supply Agreement, duly executed by Philips Medical Systems Nederland B.V.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(H)</TD><TD STYLE="text-align: justify">the Noncompetition and Confidentiality Agreement, duly executed by the Vendor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(I)</TD><TD STYLE="text-align: justify">a Subscription Agreement, substantially in the form attached hereto as Exhibit I, duly executed
by the Vendor, together with the documents deliverable thereunder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(J)</TD><TD STYLE="text-align: justify">share certificates representing the Subco Shares duly endorsed in blank for transfer or accompanied
by duly signed powers of attorney for transfer in blank;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(K)</TD><TD STYLE="text-align: justify">all such release documentation as the Purchaser reasonably deems necessary to effectuate, or reflect
on the public record, the release and discharge of any security interests, mortgages and Liens on the Purchased Assets, Subco Shares,
or any assets of Subco;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(L)</TD><TD STYLE="text-align: justify">all other instruments of conveyance and transfer, in form and substance reasonably acceptable to
the Purchaser, as may be necessary to transfer the Purchased Assets to Subco and the Subco Shares to the Purchaser or a permitted
assignee of the Purchaser in accordance with Section 13.11 (each an &ldquo;<B>Instrument of Conveyance</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(M)</TD><TD STYLE="text-align: justify">resignation letters executed by the members of the board of directors of Subco whereby each such
director waives any claims against Subco before the resignation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(N)</TD><TD STYLE="text-align: justify">the list of supplier Contracts of the Business pursuant to Section 5.4;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(O)</TD><TD STYLE="text-align: justify">the material correspondence set forth in Section 5.14;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(P)</TD><TD STYLE="text-align: justify">a payment made out to the Purchaser in an amount equal to the accrued Liability relating to any
remaining Employee holidays existing prior to the Closing Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(Q)</TD><TD STYLE="text-align: justify">such other documents, instruments and certificates as the Purchaser may reasonably request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.6</TD><TD STYLE="text-align: justify">Payment and Location of Closing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Any reference
in this Agreement to payment shall mean payment by wire transfer of immediately available funds to the bank account or accounts
designated by the recipient of such payment in writing to the Purchaser or to the Vendor, as the case may be, not less than two
(2) Business Days prior to the date of such payment. The Closing shall be held at the offices of Torys LLP at 79 Wellington Street
West, Suite 3000, Toronto, Ontario, M5K 1N2 on the Closing Date or such other place or time as may be agreed by the Purchaser and
the Vendor and shall be effective at the close of business of the Vendor on the Closing Date (the &ldquo;<B>Effective Time</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.7</TD><TD STYLE="text-align: justify">Allocation of Purchase Price.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
and the Purchaser shall allocate the Purchase Price among the Class A Patents and Trademarks and the Subco Shares as specified
in Schedule 2.7 (the &ldquo;<B>Asset Acquisition Statement</B>&rdquo;). The Purchase Price for the Class A Patents and Trademarks
and the Subco Shares shall be allocated in accordance with the Asset Acquisition Statement, as updated, and all Tax Returns and
reports filed by the Purchaser and the Vendor and its Affiliates shall be prepared consistently with such allocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 2.8</TD><TD STYLE="text-align: justify">Third Party Consents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">To the extent
that any Transferred Contract or Transferred Permit is not, as a matter of Law or by its terms, (i) assignable or transferable
or (ii) assignable or transferable without the consent of another party, this Agreement shall not constitute an assignment or an
attempted assignment thereof if such assignment or attempted assignment would constitute a breach thereof or a default thereunder.
To the extent that any Transferred Contract is not transferred to the Purchaser in compliance with Section 5.5, then such Transferred
Contract shall not be transferred or assigned to the Purchaser pursuant to this Agreement. The Vendor shall use its commercially
reasonable efforts to obtain the consent of such other party to the assignment of any such Transferred Contracts or Transferred
Permits to Subco in all cases in which such consent is or may be required for such assignment and at its sole cost and expense.
If and to the extent that such consent cannot be obtained (except where such consent is implied to have been obtained), the Purchaser
shall have no obligation pursuant to Section 2.2 or otherwise with respect to any Transferred Contract or Transferred Permit and
the Purchase Price shall not be adjusted. Any increase in fees, charges or other payments resulting after the assignment or transfer
shall be borne by the Purchaser and/or Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.65pt; text-align: center">ARTICLE 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES OF VENDOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
represents and warrants to the Purchaser, subject to such exceptions as are disclosed in the Disclosure Schedule, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.1</TD><TD STYLE="text-align: justify">Authority of the Vendor and Subco and Enforceability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution, delivery and performance of this Agreement and the Other Transaction Documents to which it is a party has been duly
authorized by all necessary corporate or other action of the Vendor and Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement has been, or in the case of the Other Transaction Documents to which it is a party to be executed and delivered at the
Closing such Other Transaction Documents will be, duly executed and delivered by the Vendor and Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement constitutes, and upon the execution and delivery of the Other Transaction Documents to which it is a party such Other
Transaction Documents will constitute, a legal, valid and binding obligation of the Vendor and Subco and each is, or on Closing
in the case of the Other Transaction Documents will be, enforceable in accordance with its terms, subject to bankruptcy, insolvency,
reorganization, moratorium or similar laws now or hereinafter in effect relating to creditors&rsquo; rights generally and to the
application of equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Vendor and its Affiliates in each case has all necessary corporate power, authority and capacity to enter into and carry
out its obligations under this Agreement and the Other Transaction Documents to which each is a party and all other agreements
and instruments to be executed by the Vendor and its Affiliates as contemplated by this Agreement and the Other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Section 3.2</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Organization and Qualification
of the Vendor and </B></FONT><B>Subco.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Each of the
Vendor, its Affiliates and Subco is duly incorporated and validly existing under the laws of the jurisdiction of its incorporation,
and has full corporate power and authority to conduct the Business as and to the extent now conducted and to own, use and lease
the assets and properties of the Business. Each of the Vendor, its Affiliates and Subco is duly qualified, licensed and authorized
to do business as a foreign corporation or an extra-provincial corporation, as applicable, and is in good standing as a corporation,
foreign corporation or an extra-provincial corporation, as applicable, with respect to the Business, except where the failure to
be so licensed, qualified or authorized would not be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.3</TD><TD STYLE="text-align: justify">Subco Shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
owns the Subco Shares free and clear of all Liens other than any restrictions on transfer contained in the constituting documents
of Subco. The Subco Shares constitutes all of the issued and outstanding shares of Subco. The Subco Shares are validly issued and
fully paid and there are no options, warrants, conversion privileges or other rights, agreements, arrangements or commitments (pre-emptive,
contingent or otherwise) for the purchase or sale of securities of Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.4</TD><TD STYLE="text-align: justify">Corporate Records and Documentation</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;True,
complete and current copies of the Articles of Association and registration certificate of Subco have been delivered to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;True,
complete and current copies of the share and shareholder register of Subco have been delivered to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
corporate documentation of Subco including minutes of the board meetings and shareholders&rsquo; meetings exists, is safely stored
and is correct, except as would not be material. All such documentation has been provided to Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
filings required by applicable Law to be delivered or made by Subco to company registries have been duly delivered or made on a
timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
registration filings for Subco are pending and no resolutions have been passed which should be, but have not yet been filed for
registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.5</TD><TD STYLE="text-align: justify">Government Approvals, Notices and Filings.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 3.5 of the Disclosure Schedule, no consent, approval or authorization of, giving of notice to, making filings
with or taking of any action in respect of or by any Governmental Authority is required to be obtained or given by the Vendor or
Subco with respect to the execution, delivery or performance by the Vendor and Subco of this Agreement or the Other Transaction
Documents to which such entity is a party or the consummation of the transactions contemplated hereunder or thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.6</TD><TD STYLE="text-align: justify">Third Party Consents, Approvals and Notices.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 3.6 of the Disclosure Schedule, no consent or approval of, or notice to, any Person (other than any Governmental
Authority) is required to be obtained or given by the Vendor or Subco with respect to the execution, delivery or performance by
the Vendor and Subco of this Agreement or the Other Transaction Documents to which such entity is a party or the consummation of
the transactions hereunder or thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.7</TD><TD STYLE="text-align: justify">Absence of Breach; Non-Contravention.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 3.7 of the Disclosure Schedule, the execution, delivery and performance of this Agreement and the Other Transaction
Documents and the consummation of the transactions contemplated herein and therein by the Vendor and Subco does not and will not
with the passage of time or the giving of notice or both:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">subject to obtaining the consents and approvals and giving the notices set forth in Section 3.6
of the Disclosure Schedule, result in a breach of or constitute a default by the Vendor or Subco or result in any right of termination,
payment or acceleration under any Transferred Contract;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">subject to obtaining the consents and approvals, making the filings and giving the notices disclosed
in Section 3.5 of the Disclosure Schedule, result, except on account of facts or circumstances concerning the Purchaser and/or
its Affiliates, in a violation of or default under any Law, any Order or any Permit, now in effect having applicability to the
Business, the Purchased Assets or Subco, except for any such violation or default which would not be material; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">violate any provisions of any charter document or by-law of the Vendor or Subco.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.8</TD><TD STYLE="text-align: justify">Financial Information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The carve-out
financial statements for the Business provided by the Vendor in folder 2.1.1 of the Vendor&rsquo;s electronic data room on the
Merrill website at https://eu1.merrillcorp.com, as in effect at 5:00 p.m. (Toronto time) on June 29, 2017 (the &ldquo;<B>Data Room</B>&rdquo;)
has been prepared in good faith by using assumptions that the Vendor considered were reasonable at the time they were made and
have been prepared based upon the Business Books and Records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.9</TD><TD STYLE="text-align: justify">Absence of Other Liabilities</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except Liabilities that are
(i) disclosed in Section 3.9 of the Disclosure Schedule, (ii) incurred in
connection with the transactions contemplated by this Agreement, (iii) incurred in the ordinary course of the Business, none
of the Vendor or Subco have any Liabilities with respect to the Business. Except as set forth in Section 3.9 of the
Disclosure Schedule, Subco has no Indebtedness. Subco has not declared any dividend or distribution that has not yet been
paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.10</TD><TD STYLE="text-align: justify">Title to Assets</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.10 of the Disclosure Schedule, the Vendor, Philips Oy or Philips Medical Systems Nederland B.V. is the
sole legal and beneficial owner and, where its interests are registrable, the sole record owner, of the Purchased Assets, with
good and valid title thereto, free and clear of any Liens other than Permitted Liens, and the Vendor is exclusively entitled to
possess and dispose of same (subject only, in the case of the Transferred Contracts and the Transferred Permits, to the extent
assignable and transferable under Law and the necessity of obtaining consents to their assignment or otherwise to the transactions
contemplated hereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchased Assets, the assets for which Subco has a valid and enforceable right under Contract to use, and the services contemplated
by the Transition Services Agreement, the Intellectual Property License Agreement, the Supply Agreement and the Resale Purchasing
Agreement constitute all of the assets, properties, rights, undertakings and goodwill (i) necessary to conduct the Business as
currently conducted and as conducted during the prior twelve months and (ii) sufficient, except for the third party software to
be licensed to the Purchaser or its Affiliate pursuant to provisions of the IT Transitional Service Level Agreement to be entered
between Philips Electronics Nederland B.V. and the Purchaser or an Affiliate on the Closing Date, for the continued conduct of
the Business after the Closing in substantially the same manner as conducted during the prior twelve months. The Purchased Assets
to be owned by Subco as of the Closing Date, having regard to their age and use, are in good operating condition and repair, and
are adequate for the uses to which they are being put, and none of them is in need of maintenance or repairs except for ordinary,
routine maintenance and repairs that are not material in nature or cost. None of the Excluded Assets are material to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.10 of the Disclosure Schedule, neither Vendor nor Subco leases any tangible assets used to conduct the
Business, except for those assets that are not material. Each Contract providing Subco the right to use a Tangible Asset is a legal,
valid and binding Contract, enforceable in accordance with its terms against Subco and, to the Knowledge of the Vendor, of each
other Person that is party thereto, subject to bankruptcy, insolvency, reorganization, moratorium or similar laws now or hereinafter
in effect relating to creditors&rsquo; rights generally and to the application of equitable principles. Subco has not received
any written notice since the date of its formation that it is in default in payment or in performance of its material obligations
under any such Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.11</TD><TD STYLE="text-align: justify">Absence of Changes.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in or contemplated or permitted by this Agreement or in Section 3.11 of the Disclosure Schedule, since December 31, 2016,
(i) the Business has been conducted in all material respects in the ordinary course, (ii) there has not occurred a Material Adverse
Effect, (iii) there has not been any material change in any method of accounting or accounting practice for the Business, except
as required by generally accepted accounting principles, and (iv) no action has been taken which, if such action had been taken
after the date of this Agreement, would require consent pursuant to Section 5.1 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.12</TD><TD STYLE="text-align: justify">Leased Real Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
or an Affiliate of the Vendor has a lease for the premises used by Subco in the operation of the Business, which lease is a legal,
valid and binding agreement, enforceable in accordance with its terms, of the Vendor or an Affiliate of the Vendor, and to the
Knowledge of the Vendor, of each other Person that is a party thereto, subject to bankruptcy, insolvency, reorganization, moratorium
or similar laws now or hereinafter in effect relating to creditors&rsquo; rights generally and to the application of equitable
principles. The Vendor or an Affiliate of the Vendor shall provide access to Subco to the premises used by Subco in the operation
of the Business following the Closing under the transitional services level agreement and subject to the relevant terms and conditions
of the transitional services level agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.13</TD><TD STYLE="text-align: justify">Owned Real Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Vendor, any of its Affiliates or Subco owns any real property that is used in connection with the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.14</TD><TD STYLE="text-align: justify">Contracts.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no Contracts that are material to the Business except for the Transferred Contracts and the Material Supplier Contracts and,
as of the Closing, the Other Transaction Documents. All Transferred Contracts are in full force and effect and constitute valid
and binding obligations of the Vendor and Subco, as applicable, and, to the Knowledge of the Vendor, the other parties thereto
in accordance with their respective terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as disclosed in Section 3.14(b) of the Disclosure Schedule, (i) none of the Vendor or Subco, nor, to the Knowledge of the Vendor,
any other party thereto, is in breach or default of any material provision of any Transferred Contract to which it is a party,
and (ii) to the Knowledge of the Vendor, no event or circumstance has occurred which with lapse of time or the giving of notice
or both would constitute a material breach or default by the Vendor, Subco or any other party thereto with respect to any Transferred
Contract to which it is a party. None of the Vendor or Subco have received any written notice within the preceding two (2) years
of any material default under any Transferred Contract that has not been cured or any written termination notice regarding any
Transferred Contract that has not been resolved with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.15</TD><TD STYLE="text-align: justify">Intellectual Property Rights.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.15(a) of the Disclosure Schedule lists all Business Intellectual Property owned by the Vendor and used in or related to the operation
of the Business, that is applied for or registered (the &ldquo;<B>Registered Business Intellectual Property</B>&rdquo;), each of
which the Vendor or its Affiliates has all right, title and interest in, free and clear of all Liens except Permitted Liens and
for Prior Commitments, and all of such right, title and interest in will not be adversely affected by the transactions contemplated
by this Agreement. Section 3.15(a) of the Disclosure Schedule additionally lists in a separate section all Business Intellectual
Property that is not owned by the Vendor or its Affiliates, but used in or related to the operation of the Business (the &ldquo;<B>Licensed
Intellectual Property</B>&rdquo;), each of which the Vendor or an Affiliate has a valid and binding right under Contract to use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
respect of the Business Intellectual Property, all registrations with and applications to Governmental Authorities are valid,
enforceable and in full force and effect, all necessary filing, maintenance, and renewal fees have been timely paid, and all necessary
documents, certificates, and other relevant filings have been timely filed with the relevant Governmental Authorities for the
purpose of maintaining all issuances, registrations and applications and for recording title in the name of the Vendor and the
co-owner of the Class A Patents and Trademarks that are the subject of the Prior Commitments, each inventor or author has assigned
all Intellectual Property Rights in any said registration or application to the Vendor or Subco, and no inventor or author has
any outstanding right to compensation for Intellectual Property Rights in any said registration or application. Except as set
forth in Section 3.15(b) of the Disclosure Schedule and to the Knowledge of the Vendor: (i) the making, using, selling or practice
of any products, methods, or services under the Business Intellectual Property does not infringe, constitute an unauthorized use
or misappropriation of or violate any Intellectual Property Rights of any Third Party; (ii) the operation of the Business as currently
conducted does not infringe or misappropriate any Intellectual Property of any other Person; and (iii) no other Person is infringing
or misappropriating any of the Business Intellectual Property. None of the Vendor, its Affiliates or Subco has received any written
notice within the past six (6) years: (i) of allegations that the conduct of the Business has violated any Intellectual Property
Rights of any Person; (ii) of any default or any event that with notice or lapse of time, or both, would constitute a default
under any Business Intellectual Property license, assignment, grant, agreement, or contract which the Vendor, any of its Affiliates
or Subco is a party or by which it is bound; and (iii) challenging use, the right to use, or ownership by the Vendor, any of its
Affiliates or Subco of any Business Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no restrictions on the right to sell goods or offer services in connection with the Business, or to transfer, license, use,
modify or otherwise exploit any Business Intellectual Property, except for the Prior Commitments. None of the Vendor, any of its
Affiliates or Subco have entered into any agreement to indemnify any other person against any charge of infringement of any Third
Party Intellectual Property by the Business conducted by the Vendor, any of its Affiliates and Subco or otherwise. Each of the
Vendor, its Affiliates and Subco has taken commercially reasonable measures to protect the secrecy, confidentiality and value of
all Trade Secrets and confidential information of the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.15(d) of the Disclosure Schedule, all current and former employees, contractors, agents and consultants
of the Vendor and its Affiliates with respect to the Business and Subco have executed a nondisclosure and assignment of inventions
agreement in the form reasonably sufficient to protect the confidentiality and to vest in the Vendor or Subco exclusive ownership
of the Business Intellectual Property. To the Knowledge of the Vendor, no employee, contractor, agent or consultant of the Vendor
or its Affiliates with respect to the Business or Subco has used any Trade Secrets or other confidential information of any other
person in the course of their work for the Vendor, its Affiliates or Subco. Except as set forth in Section 3.15(d) of the Disclosure
Schedule, none of the Vendor, its Affiliates or Subco have any written or oral agreements with employees, contractors, agents or
consultants with respect to the ownership of Intellectual Property or other works created by them as a result of which any such
employee, contractor, agent or consultant may have any rights whatsoever to the portions of the Business Intellectual Property
so created by such individual, except as required by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Knowledge of the Vendor, no Employee is, or is now expected to be, in violation of any term of any employment contract, patent
disclosure agreement, proprietary information agreement, noncompetition agreement, nonsolicitation agreement, confidentiality agreement,
or any other similar contract or agreement or any restrictive covenant relating to the right of any such Employee to be employed
or engaged by Subco because of the nature of the business conducted or to be conducted by Subco or relating to the use of Intellectual
Property of others, and to the Knowledge of the Vendor, the continued employment or retention of the Employees does not subject
the Vendor, its Affiliates, Subco or the Business to any liability with respect to any of the foregoing matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
of the Vendor nor Subco is aware that any of the Employees is (i) subject to confidentiality restrictions in favor of any Third
Person the breach of which could subject Subco or the Business to any material liability, or (ii) obligated under any contract
(including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of
any court or administrative agency, that would interfere with their duties to Subco or the Business, or that would conflict with
the Business as presently conducted. No Employee is in default or breach of any term of any employment agreement, non-disclosure
agreement, assignment of invention agreement or similar agreement or contract that could reasonably be expected to have an adverse
effect on the protection, ownership, development, use or transfer of any Business Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
of the Vendor nor Subco has deposited, nor is obligated to deposit, any item of any Business Intellectual Property into any escrow
or similar arrangement and neither of the Vendor nor Subco is under any contractual or other obligation to disclose any material
proprietary information included in or relating to the Products of the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.16</TD><TD STYLE="text-align: justify">Employee Benefit Plans.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
3.16(a) of the Disclosure Schedule lists all employee benefit plans relating to the Employees (individually, referred to as a &ldquo;<B>Business
Benefit Plan</B>&rdquo; and, collectively, referred to as the &ldquo;<B>Business Benefit Plans</B>&rdquo;), including all plans,
agreements, arrangements or policies relating to employment, sick pay, retirement or leave, vacation pay or severance pay, deferred
or incentive compensation, pension, profit sharing, retirement income or other benefits, stock purchase and stock option plans,
bonuses, severance arrangements, health benefits, disability benefits, insurance benefits and all other employee benefits or fringe
benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
of each Business Benefit Plan and the most recent summary plan description for each Business Benefit Plan for which a summary plan
description is required by Law, have been provided to the Purchaser prior to the date hereof. True, accurate and complete copies
of all material documents relating to each of the Business Benefit Plans have been provided to the Purchaser prior to the date
hereof, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">all material documents establishing, creating or amending each Business Benefit Plan, including
all prior versions of those documents and amendments thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">all trust agreements and funding agreements relating to the Business Benefit Plans, including all
prior versions of those documents and amendments thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">all material Contracts relating to the Business Benefit Plans, including insurance Contracts, investment
management agreements, subscription agreements and participation agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">to the Knowledge of the Vendor, all material booklets, summaries, notices or manuals prepared for
or circulated to employees generally concerning each Business Benefit Plan; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all material data, Books and Records required to administer the Business Benefit Plans.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Business Benefit Plan has been registered, administered, operated and funded, where applicable, in accordance with the terms thereof
and all applicable Laws, except where such failure to be registered, administered, operated or funded is not material. Other than
claims in the ordinary course of business with respect to the Business Benefit Plans, there are no actions, suits or claims pending
with respect to any Business Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Knowledge of the Vendor, no default or violation by any other Person in respect of the Business Benefit Plans has occurred.
No Taxes, non-Tax related interest, penalties or fees are owing or exigible under any of the Business Benefit Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as disclosed in Section 3.16(e) of the Disclosure Schedule, there are no improvements, increases or changes promised to the benefits
provided under the Business Benefit Plans nor is there any pattern of ad hoc benefit increases and none of the Business Benefit
Plans provide for benefit increases or the acceleration of funding obligations that are contingent on, or will be triggered by,
the entering into of this Agreement or the completion of the transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no Claim by any applicable Governmental Authority, or by any Person (other than routine Claims for payment of benefits) pending
or, to the Knowledge of the Vendor, threatened in respect of any of the Business Benefit Plans or its assets and, to the Knowledge
of the Vendor, no facts exist which could reasonably be expected to give rise to any such Claim (other than routine Claims for
payment of benefits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to any of the Business Benefit Plans which are registered under any applicable Law, no event has occurred respecting that
Business Benefit Plan which could result in the revocation of that registration or entitle any Person (without the consent of the
Vendor) to wind up or terminate the Business Benefit Plan, in whole or in part, or which could otherwise reasonably be expected
to adversely affect the Tax-favoured status thereof or its qualification as a particular type of plan under applicable tax Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
material changes have occurred in respect of each of the Business Benefit Plans since the date of its most recent financial, accounting,
actuarial or other report, as applicable, filed with any applicable Governmental Authority (where applicable) in connection with
that Business Benefit Plan, nor have there been any events occurring prior to the most recent financial, accounting, actuarial
or other report which are not disclosed in that report which could reasonably be expected to adversely affect the relevant report
or to have materially affected the financial status of that Business Benefit Plan. No Business Benefit Plan is subject to any retroactive
adjustment of premiums, contributions or payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Business Benefit Plans, which purports to qualify as a particular type of plan under applicable tax Law or which has or
purports to have Tax-favoured treatment, to the Knowledge of the Vendor, meets all requirements in effect under applicable tax
Law for such qualification or treatment, and has complied with the provisions of applicable tax Law and the administrative practices
of the applicable tax authority applicable to that type of plan or treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Vendor or Subco maintains any Business Benefit Plan, as applicable, which provides post-retirement benefits to the Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any provision of this Agreement to the contrary, this Section 3.16, Section 3.17 and Section 3.15(d), (e) and (f) shall be the
exclusive representations and warranties in respect of all matters respecting employment, incentives, labour and benefits (including
the Business Benefit Plans) and conditions, liabilities or Losses arising from any such matters relating to the Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 1in; text-align: left">Section 3.17</TD><TD STYLE="text-align: justify">Employees; Labor Relations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to Section 6.1 hereof, set forth in Section 3.17(a) of the Disclosure Schedule is a list setting forth each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the identification number and titles of all Employees, together with their location of employment
and name of employer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the date that each Employee was hired and their age;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the effective and expiry date of any written employment, engagement, severance, consulting, temporary,
fixed-term or indefinite agreement respecting each Employee, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">the rate of annual remuneration or hourly wage rate of each Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">all additional compensation paid to the Employee or to which the employee is entitled (i.e. bonuses,
incentive or performance payments, profit-sharing or stock options, premiums, allowances, etc.);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">whether or not the Employee is actively employed or inactive and if inactive, the reason they are
inactive, their last day worked, and the nature of any benefits to which they are entitled; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.85in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">the particulars of any other non-customary terms and conditions of employment or engagement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor has provided the Purchaser with true, complete and correct copies of all written Contracts of employment with any Employee.
Except as provided in Section 3.17(b) of the Disclosure Schedule, none of the Vendor, its Affiliates or Subco has (i) any written
severance agreement with any Employee, (ii) any written &ldquo;golden parachute&rdquo; agreement, &ldquo;golden handcuffs&rdquo;
agreement or similar Contract to provide a severance, termination, retirement or post-retirement or stay-on bonus to any Employee
following a change in control of any such Party, or (iii) any other written Contract that provides benefits of any type to any
Employee conditioned on any change in control of any such Party. Except as set forth in Section 3.17(b) of the Disclosure Schedule,
none of the Vendor, its Affiliates or Subco has a severance policy that provides for any severance benefits to any Employee (i)
simply as a consequence of the occurrence of a change in control of such Party or (ii) who leaves the employ of a Party voluntarily
following the occurrence of any change in control of such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
accruals for unpaid vacation pay, premiums and contributions, accrued wages, salaries, bonuses, commissions and other forms of
performance or incentive based compensation have been reflected in the books and records of the Vendor or Subco as applicable.
The Vendor, its Affiliates and Subco have paid when due all contributions required to be paid in respect of pension plans or undertakings
(including liabilities for part-time, unemployment and disability retirement) to the extent required by relevant plan or undertaking,
applicable laws or collective bargaining agreement. There are no unfunded or underfunded pension liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such employees of the Business whose employment has been terminated prior to the date of this Agreement and that will as at Closing
be subject to any re-employment duty under the Employment Contract Act (55/2001) are listed in Section 3.17(d) of the Disclosure
Schedule (including true and complete information of their overall remuneration, i.e. salaries, fringe benefits and other material
employment benefits, as at the moment of termination of employment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor, its Affiliates and Subco have fulfilled all obligations concerning employee inventions in respect of the Business and there
are no pending, or to Knowledge of Vendor, threatened Claims against the Vendor, its Affiliates or Subco under an agreement or
Law providing an Employee any compensation or ownership in respect of any rights or interests in such Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as provided in Section 3.17(f) of the Disclosure Schedule, there are no outstanding, pending, or, to the Knowledge of Vendor, threatened,
Claims, Legal Proceedings or settlements, concerning service and employment contracts, profit-sharing, bonus schemes and incentive
programs binding upon the Vendor, its Affiliates or Subco regarding the Business or any Employee, Collective Bargaining Agreements,
working conditions or the relationship between the Vendor, its Affiliates or Subco and any employee of the Business (whether current
or former). To the Knowledge of the Vendor, the Business is currently being performed in accordance with all such applicable labour
and employment Laws, except as not material. All costs, charges, surcharges, penalties, fines, Liens (other than Permitted Liens),
experience rating assessments or other assessments or other liabilities, contingent or otherwise, under workers&rsquo; compensation
legislation or other legislation relating to industrial accidents and/or occupational health and safety claims applicable to the
Vendor, its Affiliates or Subco have been paid or accrued and there has not been any special or penalty charge or assessment under
those legislation against the Vendor, its Affiliates or Subco that has not been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no labour proceedings pending or unfair labour practice complaints or, to the Knowledge of the Vendor, threatened before any
Governmental Authority in any jurisdiction with respect to the Business against Subco, the Vendor or its Affiliates that would
be material. There is no labour strike, work stoppage or lockout pending or, to the Knowledge of the Vendor, threatened against
the operations of the Business. Except as disclosed in Section 3.17(g) of the Disclosure Schedule, none of the Vendor or Subco
is a party to or bound by any Collective Bargaining Agreement with respect to the Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
1.1-1 of the Disclosure Schedule is true and correct and exhaustively lists any and all employees that will transfer from Vendor
or its Affiliates to Subco prior to Closing pursuant to the Chapter 1, Section 10 of the Finnish Act on Employment Contracts or
otherwise. Subco does not have and will not have any other employees other than the Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes
and Tax Returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.18 of the Disclosure Schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">each of the Vendor, its Affiliates with respect to the Business and Subco has filed or caused
                                                                               to be filed on a timely basis all Tax and information returns, reports or other declarations relating to Taxes required to be
                                                                               filed by it (collectively, the &ldquo;<B>Tax Returns</B>&rdquo;) and all such Tax Returns are complete and correct in all
                                                                               material respects and no material fact or facts have been omitted therefrom which would make any of them misleading, and each
                                                                               of the Vendor, its Affiliates and Subco has paid or caused to be paid, except where any failure to so pay would be immaterial
                                                                               (A) all federal, provincial, state, local and foreign taxes, direct or indirect Taxes, including, but not limited to, income,
                                                                               profits, franchise, property (real, tangible and intangible), sales, use, value added, goods and services, unemployment,
                                                                               withholding, gross receipts, business license, transfer, capital, net worth, gains, excise, social security and estimated
                                                                               income and franchise tax payments, and penalties, interest and fines with respect to any thereof and (B) any Liability in
                                                                               respect of any items described in the preceding clause (A) payable by reason of Contract, assumption, transferee liability
                                                                               or operation of legal requirements (items listed in (A) and (B) are collectively referred to as &ldquo;Taxes&rdquo;) due and
                                                                               payable by it;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">there are no Legal Proceedings now pending or, to the Knowledge
of the Vendor, threatened against the Vendor or its Affiliates with respect to the Business or Subco in respect of any Taxes;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">none of the Vendor or its Affiliates with respect to the
Business or Subco has executed any waiver of any statute of limitations on the assessment or collection of Taxes or executed any
agreement now in effect extending the period of time of the filing of any Tax Return, or to assess, pay or collect any Taxes;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">neither the Subco Shares nor the Class A Patents and Trademarks
is &ldquo;taxable Canadian property&rdquo; of the Vendor for purposes of the Tax Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">there are no Liens for Taxes (other than Permitted Liens)
upon, pending against or, to the Knowledge of the Vendor, threatened against any Purchased Asset, the Class A Patents and Trademarks
or any Subco Shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">each of the Vendor with respect to the Business and Subco
has withheld or collected all Taxes required to be withheld or collected by it and has remitted the same to the proper Tax or
other receiving authority within the time required under applicable Law; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">it is a resident of Netherlands for purposes of the Treaty
and is entitled to the full benefits of the Treaty.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">There is no
material claim pending under any insurance policies as to which coverage has been questioned, denied or disputed in relation to
the Business. No written notice of default, cancellation, termination or increase in premium has been received within the preceding
three (3) years with respect to any such policy which has not been replaced on substantially similar terms prior to the date of
such cancellation or termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Environmental
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Except as set forth in Section 3.20 of the Disclosure
Schedule:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
operations of the Vendor, its Affiliates and Subco with respect to the Business and the Purchased Assets, as applicable, are in
compliance in all material respects with applicable Environmental Laws, and the Vendor, its Affiliates and Subco, as applicable,
possesses all material Permits required under applicable Environmental Laws for the conduct of the Business and the operation of
the Purchased Assets as currently conducted and operated and all such Permits are valid and in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of the Vendor, its Affiliates and Subco has not within the past three (3) years received any written notice from any Governmental
Authority alleging non-compliance with any applicable Environmental Law with respect to the Business or the Purchased Assets, as
applicable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
the Knowledge of the Vendor, no Environmental Release or threatened Environmental Release has occurred in the last two (2) years
or is occurring at, under or from, and no condition or circumstance exists at any real property currently or previously owned or
operated by the Vendor or its Affiliates in connection with the Business or by Subco for which applicable Environmental Law requires
as of the date hereof (i) notice to any public or private entity or Person, (ii) further investigation, or (iii) any form of remediation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
are no Legal Proceedings of any kind or nature pending or, to the Knowledge of the Vendor, threatened against the Vendor, its
Affiliates or Subco with respect to the Business, the Purchased Assets or the Assumed Liabilities, as applicable, that
pertain or relate to (i) any obligations or Liabilities arising under any applicable Environmental Law, (ii) violations or
alleged violations of any applicable Environmental Law, or (iii) personal injury or property damage Claims relating to the
use or Environmental Release of Hazardous Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;none
of the Vendor, its Affiliates or Subco is subject to any outstanding Order with any Governmental Authority respecting any Environmental
Law with respect to the Business or the Purchased Assets, as applicable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;each
of the Vendor, its Affiliates and Subco has made available to the Purchaser all environmental investigation reports, studies, audits,
tests or other analyses conducted by it within the last two (2) years or in its possession in relation to the Business or the Purchased
Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as disclosed
in Section 3.21 of the Disclosure Schedule, for the Transferred Permits, the CE Mark and the VAT registration, no Permits are necessary
for the lawful operation of the Business and possession of the Purchased Assets, as presently conducted and held. The only material
Permit is the CE Mark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 3.22 of the Disclosure Schedule, each of the Vendor, its Affiliates and Subco is in compliance with the requirements
of all applicable Laws and Orders which affect the Business or the Purchased Assets, as applicable (the &ldquo;<B>Subject Laws</B>&rdquo;),
except as would not be material. None of the Vendor, its Affiliates or Subco has received within the last thirty-six (36) months
any written notice or other written communication from any Governmental Authority with respect to an alleged violation and/or failure
to comply with the Subject Laws. Without limiting the foregoing, none of the Vendor, its Affiliates or Subco, or, to the Knowledge
of the Vendor, any director, officer, employee, agent or representative of the Vendor, its Affiliates or Subco, acting on behalf
of any of them has paid or received any bribes or kickbacks to or from any Person in violation of any applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 3.23 of the Disclosure Schedule, there are no (i) Legal Proceedings pending for which the Vendor, its Affiliates
or Subco has been served or given written notice or, to the Knowledge of the Vendor, threatened against the Vendor, its Affiliates
or Subco with respect to the Business, the Subco Shares or the Purchased Assets, as applicable, or (ii) Orders outstanding against
the Vendor, its Affiliates or Subco with respect to the Business, the Subco Shares or the Purchased Assets, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliate
Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No officer,
director or Affiliate of the Vendor or Subco provides or causes to be provided any assets, services or facilities used in connection
with the Business (ii) the Business does not provide or cause to be provided any assets, services or facilities to such officer,
director or Affiliate and (iii) no officer, director or Affiliate of the Vendor is party to a Transferred Contract with Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">None of the
Vendor, its Affiliates or Subco has received written notice within the past three (3) years from any counterparty to a Material
Supplier Contract to the effect, to the Knowledge of the Vendor, no such supplier intends to (a) stop supplying materials, products
or services to the Business, (b) reduce the volume of sales such supplier is willing to make to the Business where such reduction
is material, (c) decrease the rebates, discounts, customer support payments or similar economic benefits provided to the Business
or increase the prices charged to the Business where such decrease or increase, as applicable, is material (d) otherwise adversely
alter the terms on which it conducts business with the Business where such alteration is material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Section 3.26
of the Disclosure Schedule sets forth, for the twelve months ended March 31, 2017, the names of the customers of the Business.
As of the Closing Date, none of the Vendor, its Affiliates or Subco has received written notice within the past three (3) years
from any customer set forth in Section 3.26 of the Disclosure Schedule to the effect, and to the Knowledge of the Vendor no such
customer intends to (a) stop buying products or services of the Business or (b) otherwise adversely alter the terms on which it
conducts business with the Business where such alternation is material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Subco does
not have any purchase orders (i) outstanding for raw materials or parts that may not be cancelled or otherwise modified or reduced
without penalty and that (ii) obligate Subco or the Business to purchase raw materials or parts for a period longer than six (6)
months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product
Warranties; Product Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
has provided the Purchaser with true, complete and correct copies of the standard terms and conditions of sale for the Product
containing applicable guaranty, warranty and indemnity provisions. Except as set forth in Section 3.28 of the Disclosure Schedule,
there are no existing or threatened Claims, against the Vendor, its Affiliates or Subco for services or merchandise with respect
to the Product or the Business which are defective or fail to meet any service or product warranties. The Product is free from
known defects and conforms substantially to the specifications, documentation and sample demonstration furnished to the Vendor&rsquo;s,
its Affiliates&rsquo; or Subco&rsquo;s customers of the Business, including the representations and warranties made to the Vendor&rsquo;s,
its Affiliates&rsquo; or Subco&rsquo;s customers on the Vendor&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the Product: (i) (A) the Vendor, its Affiliates and Subco have obtained all necessary and applicable approvals, clearances,
authorizations, licenses and registrations required by the applicable Governmental Authorities, including, without limitation,
the CE Mark, to permit the design, development, pre-clinical and clinical testing, manufacture, labeling, sale, distribution and
promotion of the Product in jurisdictions where it currently conducts such activities with respect to the Product (collectively,
the &ldquo;<B>Regulatory Approvals</B>&rdquo;), (B) the Vendor, its Affiliates and Subco are in compliance in all material respects
with all terms and conditions of each Regulatory Approval, (C) the Vendor, its Affiliates and Subco are in compliance in all material
respects with all applicable Laws regarding registration, license and certification for each jurisdiction at which the Product
is labeled, sold, or distributed, and (D) to the extent that the Product has been exported, it has only been exported in compliance
in all material respects with applicable Law; (ii) all manufacturing operations performed by or on behalf of the Vendor, its Affiliates
and Subco have been and are being conducted in all material respects in compliance with applicable Laws relating to quality systems
in each country where compliance is required; (iii) all non-clinical laboratory studies of the Product sponsored by the Vendor,
its Affiliates and/or Subco used or intended to be used to support regulatory clearance or approval, have been and are being conducted
in compliance with the applicable Laws, including Health Care Laws; and (iv) the Vendor, its Affiliates and Subco are in compliance
in all material respects with all applicable reporting requirements for all Regulatory Approvals or plant registrations described
in clause (i) above, including, but not limited to, applicable adverse event reporting requirements in each country where compliance
is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor, its Affiliates and Subco are in compliance in all material respects with all applicable Governmental Authority (in each
country where compliance is required) and similar provincial, state and local Laws applicable to the maintenance, compilation and
filing of reports, including medical device reports, with regard to the Product. Section 3.29(b) of the Disclosure Schedule sets
forth a list of all applicable adverse event reports related to the Product. Set forth on Section 3.29(b) of the Disclosure Schedule
are complaint review and analysis reports of the Vendor, its Affiliates and Subco with respect to the Business through the date
hereof, including information regarding complaints, categorized by root cause analysis of closed complaints, which reports are
correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in Section 3.29(c) of the Disclosure Schedule, none of the Vendor, its Affiliates or Subco have received any written
notice or other written communication from any Governmental Authority: (i) contesting the approval of, the uses of or the labeling
and promotion of the Product; or (ii) otherwise alleging any violation of any Laws by the Vendor, its Affiliates or Subco with
respect to the use, sale or manufacture of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as disclosed in Section 3.29(d) of the Disclosure Schedule, there have been no recalls, field notifications or seizures ordered
or adverse regulatory actions taken (or, to the Knowledge of the Vendor, threatened) by any Governmental Authority with respect
to the Product, including any facilities where the Product is produced, processed, packaged or stored and none of the Vendor, its
Affiliates or Subco have within the last three (3) years, either voluntarily or at the request of any Governmental Authority, initiated
or participated in a recall of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
filings with and submissions to any Governmental Authority made by the Vendor, its Affiliates and/or Subco with regard to the Product,
whether oral, written or electronically delivered, were true, accurate and complete in all material respects as of the date made
and, to the extent required to be updated, have been updated to be true, accurate and complete in all material respects as of the
date of such update, and such filings, submissions and updates comply with all regulations of such Governmental Authorities in
all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Vendor, its Affiliates nor Subco is the subject, officially or otherwise, of any pending or, to the Knowledge of the Vendor,
threatened investigation by any Governmental Authority pursuant to any anti-bribery Law related to the Business, the Purchased
Assets, or the Product. None of the Vendor, its Affiliates nor, to the Knowledge of the Vendor, any officer, employee or agent
of the Vendor or its Affilites, has (A) made an untrue statement of a material fact or fraudulent statement to any Governmental
Authority, (B) failed to disclose a material fact required to be disclosed to any Governmental Authority, or (C) committed an act,
made a statement, or failed to make a statement that, at the time such disclosure was made, that would reasonably be expected to
provide a basis for any Governmental Authority to invoke its policy related to such Laws, in each case, related to the Business,
the Purchased Assets, or the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Vendor, its Affiliates or Subco, or, to the Knowledge of the Vendor, any officer, employee or agent of the Vendor, its Affiliates
or Subco, has been convicted of any crime or engaged in any conduct for which debarment is mandated by applicable Law or authorized
by applicable Law with respect to the Business. None of the Vendor, its Affiliates or Subco, or, to the Knowledge of the Vendor,
any officer, employee or agent of the Vendor, its Affiliates or Subco, has been convicted of any crime or engaged in any conduct
for which such person or entity could be excluded from participating in any aspect of the Business under applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the Vendor, its Affiliates or Subco has received any written notice that any Governmental Authority has (a) commenced, or threatened
to initiate, any action to withdraw its approval or request the recall of the Product, or (b) commenced, or threatened to initiate,
any action to enjoin production of the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor and its Affiliates with respect to the Business are and at all times have been in material compliance with: (i)
the provisions of applicable Laws relating to investigational use, premarket clearance or marketing approval (or
exemptions thereto) to market a product, good manufacturing practices, labeling, advertising, record keeping, filing of
reports and security; (ii) the applicable provisions relating to the privacy and security of individually identifiable
health information, and all regulations thereunder; (iii) any applicable antikickback Laws; and (iv) health care fraud Laws.
Since January 1, 2011, none of the Vendor or its Affiliates has received any written notice or other communication from any
Governmental Authority regarding any actual or possible violation of, or failure to comply with, any legal requirement set
forth in this Section 3.29(i) with respect to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Employee has been excluded from participation in any health care program or, to the Knowledge of the Vendor, committed any offense
that would be the basis for such exclusion in a health care program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Services Relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Details of
the bank account that Subco has with any bank depository institution or other financial services entity are described on Section
3.30 of the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23pt; text-indent: 1in">Section 3.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
Regarding Investment in the Purchaser Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser Common Shares to be received by the Vendor will be issued to the Vendor as principal for its own account, not as a nominee
or agent, and not with a view to the distribution of any part thereof, and the Vendor has no present intention of selling, granting
any participation in, or otherwise distributing the same. The Vendor does not currently have any contract, undertaking, agreement
or arrangement with any Person to sell, transfer or grant participations to such Person or to any Third Party, with respect to
any of the Purchaser Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor is an &ldquo;accredited investor&rdquo; as defined in paragraph m of the definition of &ldquo;accredited investor&rdquo;
in section 1.1 of National Instrument 45-106 &ndash; <I>Prospectus Exemptions</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor recognizes that the Purchaser Common Shares are being offered for sale only on a &ldquo;private placement&rdquo; basis and
are being sold pursuant to exemptions under applicable Canadian securities laws and will be subject to resale restrictions under
applicable Canadian securities laws and that the certificates evidencing the Purchaser Common Shares shall bear the following restricted
legend: &ldquo;UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE [<B>insert
the date that is fourth months and one day after the Closing Date</B>].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
the Vendor recognizes that the certificates representing the Purchaser Common Shares will be endorsed with a legend setting out
resale restrictions pursuant to policies of the TSX Venture Exchange in substantially the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Without prior written approval
of the TSX Venture Exchange and compliance with all applicable securities legislation, the securities represented by this certificate
may not be sold, transferred, hypothecated or otherwise traded on or through the facilities of the TSX Venture Exchange or otherwise
in Canada or to or for the benefit of a Canadian resident until <B>[insert the date that is fourth months and one day after the
Closing Date]</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
office or offices of the Vendor in which its principal place of business is identified is Eindhoven, the Netherlands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor is (i) capable of assessing the proposed issuance of the Purchaser Common Shares, (ii) aware of the characteristics of the
Purchaser Common Shares and the risks relating to an investment therein, and (iii) able to bear the economic risk of loss of its
investment in the Purchaser Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Neither the
Vendor nor Subco has dealt with any broker or finder in connection with the transactions contemplated herein who would be entitled
to a fee or commission in connection with the transactions contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">There are no
bankruptcy, reorganization or arrangement proceedings or similar proceedings pending against, being contemplated by, or to the
Knowledge of the Vendor, threatened against the Vendor or Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 3.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Misrepresentations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No representation
or warranty made by the Vendor or Subco in this Agreement and no statement contained in the Disclosure Schedule or any certificate
or other document furnished or to be furnished to the Purchaser pursuant to this Agreement contains any untrue statement of material
fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which
they are made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPRESENTATIONS AND WARRANTIES OF PURCHASER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Purchaser represents and warrants to
the Vendor, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization
and Qualification of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
is duly incorporated, amalgamated or organized, validly existing and in good standing under the laws of the jurisdiction of its
incorporation, amalgamation or organization, as the case may be. The Purchaser is duly qualified, licensed and authorized to do
business as a foreign corporation or an extra-provincial corporation, as applicable, and is in good standing as a foreign corporation
or an extra-provincial corporation, as applicable, in the jurisdictions, if any, where it is required to be so licensed, qualified
or authorized to conduct its business or own its property, except for jurisdictions in which the failure to be so licensed, qualified
or authorized would not reasonably be expected to have a material adverse effect on the business, results of operations, properties
or financial condition of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authority
of the Purchaser and Enforceability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
execution, delivery and performance of this Agreement and the Other Transaction Documents to which it is a party has been, or will
be prior to the Closing Date in the case of the Other Transaction Documents to which it is a party, duly authorized, by all necessary
corporate or other action of the Purchaser (including, if applicable, its investment committee).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement has been, or in the case of the Other Transaction Documents to which it is a party to be executed and delivered at the
Closing such Other Transaction Documents will be, duly executed and delivered by the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement constitutes, and upon the execution and delivery of the Other Transaction Documents to which it is a party such Other
Transaction Documents will constitute, a legal, valid and binding obligation of the Purchaser and is, or on Closing in the case
of the Other Transaction Documents to which it is a party will be, enforceable against the Purchaser in accordance with its terms,
subject to bankruptcy, insolvency, reorganization, moratorium or similar Laws now or hereinafter in effect relating to creditors&rsquo;
rights generally and to the application of equitable principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has all necessary corporate power, authority and capacity to enter into and carry out its obligations under this Agreement
(including the issuance of the Purchaser Common Shares) and the Other Transaction Documents to which it is a party and all other
agreements and instruments to be executed by the Purchaser as contemplated by this Agreement and the Other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser Common Shares have been duly authorized for issuance and upon issuance pursuant to the provisions hereof will be validly
issued and fully paid as non-assessable common shares in the capital of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser is a &ldquo;reporting issuer&rdquo; in all of the Canadian provinces, is not in default of any of the material requirements
of the Applicable Securities Laws of those jurisdictions and is not on the list of defaulting issuers maintained by the applicable
Securities Commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Common Shares are listed and posted for trading on the TSXV and, to the best of its knowledge, the Purchaser is not in default
of any of the material listing or filing requirements of the TSXV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser Common Shares will not have been issued in violation of or subject to any pre-emptive or contractual rights to purchase
securities issued or granted by the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government
Approvals, Notices and Filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 4.3 of Schedule 4, no consent, approval or authorization of, giving of notice to, making filings with, or taking
of any action in respect of or by, any Governmental Authority is required of the Purchaser with respect to the execution, delivery
or performance by the Purchaser of this Agreement or such Other Transaction Documents to which the Purchaser is a party or the
consummation of the transactions contemplated hereunder or thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third
Party Consents, Approvals and Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 4.4 of Schedule 4, no authorization, consent or approval of, or notice to, any Person (other than any Governmental
Authority) is required to be obtained or given by the Purchaser with respect to the execution, delivery or performance by the Purchaser
of this Agreement or such Other Transaction Documents to which the Purchaser is a party or the consummation of the transactions
hereunder or thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absence
of Breach; Non-Contravention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The execution,
delivery and performance of this Agreement or such Other Transaction Documents to which the Purchaser is a party, the issuance
of the Purchaser Common Shares and the consummation of the transactions contemplated herein and therein by the Purchaser does not
and will not with the passage of time or the giving of notice or both:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">result in a breach of or constitute a default by the Purchaser
or result in any right of termination or acceleration under any Contract to which the Purchaser is a party or by which the property
of the Purchaser is bound or affected, except for any such breach or default which would not materially impair or delay the ability
of the Purchaser to perform its obligations hereunder or consummate the transactions contemplated hereby;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">subject to obtaining the consents and approvals, making
the filings and giving the notices disclosed in Section 4.3 of Schedule 4, result in a violation of or default under any Law or
Order now in effect having applicability to the Purchaser, except for any such violation or default which would not materially
impair or delay the ability of the Purchaser to perform its obligations hereunder or consummate the transactions contemplated
hereby, or adversely affect the validity or enforceability of this Agreement or prohibit, make illegal, enjoin or restrict in
any manner the transactions contemplated hereby; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">violate any provisions of any charter document or by-law
restriction of the Purchaser.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">There are no
(i) Legal Proceedings pending or, to the Purchaser&rsquo;s knowledge, threatened against the Purchaser, and (ii) outstanding Orders
against the Purchaser or any of its Affiliates which, in either case, prohibit, make illegal or seeks to enjoin or restrain the
transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
Filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
is in material compliance with its timely and continuous disclosure requirements under applicable securities laws and the disclosures
made by the Purchaser in its securities filings with the Ontario Securities Commission are true and complete in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
has not dealt with any broker or finder in connection with the transactions contemplated herein who would be entitled to a fee
or commission in connection with the transactions contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">There are no
bankruptcy, reorganization or arrangement proceedings pending against, being contemplated by, or to the knowledge of the Purchaser,
threatened against the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Profound
Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
than the Profound Subsidiaries, the Purchaser has no direct or indirect Subsidiaries nor any investment in any person or any agreement,
option or commitment to acquire any such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser is the direct or indirect registered and beneficial owner of all of the issued and outstanding shares and other voting
securities of each Profound Subsidiary, in each case, except as set out in the constating documents of a Profound Subsidiary, free
and clear of all encumbrances, liens, mortgages, hypothecations, security interests, charges or adverse interests whatsoever, and
no Person, firm, corporation or entity has any agreement, option, right or privilege (whether pre-emptive or contractual) capable
of becoming an agreement or option, for the purchase from the Purchaser or any Profound Subsidiary of any of the shares or other
securities of any Profound Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Profound Subsidiary is a corporation incorporated, amalgamated, continued or organized and validly existing under the laws of its
jurisdiction of incorporation. amalgamation, continuation or organization and has all requisite power, capacity and authority and
is duly qualified and holds all permits, licences, registrations, qualifications, consents and authorizations necessary or required
to carry on its business as now conducted in each of the jurisdictions it carries on business and to own, lease or operate its
Assets and Properties and none of the Profound Subsidiaries nor, to the knowledge of the Purchaser, any other Person, has taken
any steps or proceedings, voluntary or otherwise, requiring or authorizing such Profound Subsidiaries' dissolution or winding up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Each of the
Purchaser and the Profound Subsidiaries has been conducting its business in compliance in all material respects with all applicable
Laws of each jurisdiction in which it carries on such business and has not received a notice of material noncompliance, and, to
the knowledge of the Purchaser, there are no facts that would give rise to a notice of material non-compliance with any such applicable
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No default
exists under and no event has occurred which, after notice or lapse of time or both, or otherwise, constitutes a default under
or breach, by the Purchaser, any Profound Subsidiary, or any other Person, of any material obligation, agreement, covenant or condition
contained in any material Contract to which the Purchaser or any Profound Subsidiary is a party or by which it or any of its properties
may be bound; and no order, ruling or determination having the effect of suspending the sale or ceasing the trading of the Common
Shares or any other security of the Purchaser has been issued or made by any Securities Commission or stock exchange or any other
regulatory authority and is continuing in effect and no proceedings for that purpose have been instituted or are pending or, to
the knowledge of the Purchaser, are contemplated or threatened by any such authority or under any Applicable Securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Acquisitions, etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except for
discussions or negotiations in the ordinary course of business and the transaction contemplated hereby, the Purchaser is not currently
party to any agreement in respect on (A) the purchase of any material Assets and Properties or any interest therein or the sale,
transfer or other disposition of any material Assets and Properties or any interest therein currently owned, directly or indirectly,
by the Purchaser whether by asset sale, transfer of shares or otherwise; or (B) the change of control of the Purchaser (whether
by sale or transfer of shares or sale of all or substantially all of the Assets and Properties of the Purchaser or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Financial
Statements (i) have been prepared in accordance with generally accepted accounting principles consistently applied throughout the
periods referred to therein, (ii) present fairly, in all material respects, the financial position (including the assets and liabilities,
whether absolute, contingent or otherwise as required by generally accepted accounting principles) of the Purchaser and the Profound
Subsidiaries on a consolidated basis as at such dates and the results of its operations and its cash flows for the periods then
ended and contain and reflect adequate provisions or allowance for all reasonably anticipated liabilities, expenses and losses
of the Purchaser and the Profound Subsidiaries on a consolidated basis in accordance with generally accepted accounting principles,
and (iii) have been audited (in the case of the annual financial statements comprising the Financial Statements) or have been reviewed
(in the case of the interim financial statements comprising the Financial Statements) by independent public accountants within
the meaning of Applicable Securities Laws and the rules of the Chartered Professional Accountants of Canada, and there has been
no change in accounting policies or practices of the Purchaser since incorporation. Except as set out in the Financial Statements,
the Purchaser does not have any outstanding indebtedness or any liabilities or obligations including any unfunded obligation under
any employee plan, whether accrued, absolute, contingent or otherwise as of the date of the applicable financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Taxes due and payable or required to be collected or withheld and remitted, by the Purchaser and the Profound Subsidiaries have
been paid, collected or withheld and remitted as applicable, except for any failure to so pay that would be immaterial. All Tax
Returns required to be filed by the Purchaser and the Profound Subsidiaries have been filed with all appropriate Governmental Authorities
and all such Tax Returns are complete and accurate in all material respects and no material fact or facts have been omitted therefrom
which would make any of them misleading. To the knowledge of the Purchaser, there are no issues or disputes outstanding with any
Governmental Authority respecting any Taxes that have been paid, or may be payable, by the Purchaser or any Profound Subsidiary.
There are no agreements, waivers or other arrangements with any taxation authority providing for an extension of time for any assessment
or reassessment of Taxes with respect to the Purchaser or any Profound Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser and the Profound Subsidiaries have each established on their books and records reserves that are adequate for the payment
of all Taxes not yet due and payable and there are no liens for Taxes on the Assets and Properties of the Purchaser or the Profound
Subsidiaries (other than Permitted Liens), and, to the knowledge of the Purchaser, there are no audits pending of the tax returns
of the Purchaser or any Profound Subsidiary (whether federal, state, provincial, local or foreign) and there are no claims which
have been asserted relating to any such tax returns, which audits and claims, if determined adversely, would result in the assertion
by any governmental agency of any material deficiency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
scientific research and experimental development (&ldquo;<B>SR&amp;ED</B>&rdquo;) tax incentives pursuant to the Tax Act have been
applied for by the Purchaser or a Profound Subsidiary in good faith and the Purchaser has no knowledge that the Canada Revenue
Agency will disallow, reassess or reduce any SR&amp;ED incentives applied for by or previously granted to the Purchaser or a Profound
Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosure
Controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
has established and maintains a system of disclosure controls and procedures and internal control over financial reporting, and
has: (i) designed such disclosure controls and procedures, or caused them to be designed under management's supervision, to provide
reasonable assurance that material information relating to each of the Purchaser and the Profound Subsidiaries is made known to
management by others, particularly during the period in which the financial statements are being prepared; and (ii) designed such
internal control over financial reporting, or caused it to be designed under management's supervision, to provide reasonable assurance
regarding the reliability financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">PricewaterhouseCoopers
LLP, who audited the audited consolidated financial statements of the Purchaser for the financial year ended December 31, 2016,
are independent public accountants and there has not been any &quot;disagreement&quot; or &ldquo;reportable event&rdquo; (within
the respective meanings of NI 51-102) with the current auditors or any former auditors of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
Capital, etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
authorized capital of the Purchaser consists of an unlimited number of Common Shares of which 55,417,377 Common Shares are issued
and outstanding as fully paid and non-assessable shares in the capital of the Purchaser as of June 29, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June 29, 2017, no person has any agreement, option, right or privilege (whether pre-emptive, contractual or otherwise) capable
of becoming an agreement for the purchase, acquisition, subscription for or issue of any of the unissued Common Shares or other
securities of the Purchaser or any Profound Subsidiary or any other security convertible into or exchangeable for any such shares,
or to require the Purchaser or any Profound Subsidiary to purchase, redeem or otherwise acquire any of the outstanding securities
in the capital of the Purchaser or any Profound Subsidiary, except as disclosed in Section 4.18(b) of Schedule 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the knowledge of the Purchaser, no agreement is in force or effect which in any manner affects the voting or control of any of
the securities of the Purchaser or any Profound Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.19&nbsp;&nbsp;
 &nbsp;&nbsp;&nbsp;&nbsp;Proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No legal or
governmental actions, suits, judgments, investigations or proceedings are pending to which the Purchaser or any Profound Subsidiary,
or to the knowledge of the Purchaser, the directors, officers or employees of the Purchaser or a Profound Subsidiary are a party
or to which the Assets and Properties of the Purchaser or a Profound Subsidiary is subject and, to the knowledge of the Purchaser,
no such proceedings have been threatened against or are pending with respect to the Purchaser or any Profound Subsidiary, or with
respect to their Assets and Properties and none of the Purchaser or any Profound Subsidiary is subject to any judgment, order,
writ, injunction, decree or award of any Governmental Authority, which, either individually or in the aggregate, could reasonably
be expected to have a Purchaser Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Constating
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Neither the
Purchaser nor any Profound Subsidiary is in violation of its constating documents or in default in the performance or observance
of any obligation, agreement, covenant or condition contained in any Contract to which it is a party or by which it or its Assets
and Properties may be bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as
described in Section 4.21 of Schedule 4, other than liens arising in the ordinary course of business which, individually or
in the aggregate, do not and will not have a Purchaser Material Adverse Effect, the Purchaser and each Profound Subsidiary
owns or has the right to full use of all Assets and Properties owned or used in its Business (other than the Purchaser
Intellectual Property, with respect to which the representations and warranties contained in Section 4.25 applies) free and
clear of any actual, pending or, to the knowledge of the Purchaser, threatened claims, liens, charges, options, set-offs,
free-carried interests, royalties, encumbrances, security interests or other interests whatsoever, including (i) all
Contracts that are material to its business, and (ii) all Assets and Properties necessary to enable the Purchaser and the
Profound Subsidiaries to carry on their business as now conducted and as presently proposed to be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as described
in Section 4.22 of Schedule 4, no third party has any ownership right, title, interest in, claim in, lien against or any other
right to the Assets and Properties owned by the Purchaser or any Profound Subsidiary or any written or oral agreement, option,
understanding or privilege capable of becoming such (other than liens and/or encumbrances arising in the ordinary course of business
which, individually or in the aggregate, do not and will not have a Purchaser Material Adverse Effect).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">All Contracts
to which the Purchaser and/or any Profound Subsidiary is a party are, to the knowledge of the Purchaser in good standing in all
material respects and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Breach or Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">None of the
Purchaser, any Profound Subsidiary or, to the knowledge of the Purchaser, any other party thereto is in default or breach of any
Contract to which it is a party and, to the knowledge of the Purchaser, there exists no condition, event, circumstances or act
which, with the giving of notice or lapse of time or both would constitute a default or breach under any such Contract which would
give rise to a right of termination on the part of any other party to any such Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchaser
Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)
The Purchaser and/or the Profound Subsidiaries, as applicable, own, or have obtained valid and enforceable licenses for, or other
rights to use, the Purchaser Intellectual Property; (ii) the Purchaser has no knowledge that the Purchaser and/or the Profound
Subsidiaries, as applicable, lack any rights or licenses to use all Purchaser Intellectual Property necessary and material for
the conduct of their business; (iii) no third parties have rights to any Purchaser Intellectual Property that is owned by or licensed
to the Purchaser or the Profound Subsidiaries, other than rights acquired pursuant to non-exclusive licenses granted by the Purchaser
or a Profound Subsidiary in the ordinary course of business or Purchaser Intellectual Property licensed to the Purchaser or a Profound
Subsidiary; (iv) all of the applied for or registered Purchaser Intellectual Property that is owned by or licensed to the Purchaser
or a Profound Subsidiary and necessary and material in the operation of its business is in full force and effect and, to the knowledge
of the Purchaser, none of the Purchaser or the Profound Subsidiaries have failed to take any actions with respect to such applied
for or registered Purchaser Intellectual Property in a manner which would result in the abandonment, opposition, re-examination,
rejection, impeachment, cancellation, termination, lapsing, limitation, expungement or unenforceability of any of such applied
for or registered Purchaser Intellectual Property; (v) all applications, registrations, filings, renewals and payments necessary
to preserve the rights in and to the applied for or registered Purchaser Intellectual Property that is owned by or licensed to
the Purchaser or a Profound Subsidiary and necessary and material to the operation of its business have been duly filed, made,
prosecuted and maintained, are in good standing or substantially reinstatable and are, if owned by the Purchaser or a Profound
Subsidiary, recorded in the name of the Purchaser or such Profound Subsidiary, as applicable, and none of the Purchaser or the
Profound Subsidiaries have received any written notice indicating that any application for registration of the Purchaser Intellectual
Property that is owned by the Purchaser or a Profound Subsidiary has been finally rejected or denied by the applicable reviewing
authority, except as would not, individually or in the aggregate, have a Purchaser Material Adverse Effect; and (vi) there is no
pending or threatened action, suit, proceeding or claim by any other person challenging the validity or enforceability of any Purchaser
Intellectual Property, and the Purchaser has no knowledge of any finding of unenforceability or invalidity of any issued or registered
Purchaser Intellectual Property that is owned by the Purchaser or a Profound Subsidiary or licensed to the Purchaser or a Profound
Subsidiary, including pursuant to the Sunnybrook License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described in Section 4.25(b) of Schedule 4, either the Purchaser or a Profound Subsidiary is the sole and exclusive legal and/or
beneficial owner, as applicable, of, has good and marketable title to, and owns all right, title and interest in all material Purchaser
Intellectual Property, free and clear of all encumbrances, liens, mortgages, hypothecations, security interests, charges or adverse
interests whatsoever, options to purchase and restrictions or other adverse claims of any kind or nature, and the Purchaser has
no knowledge of any claim of adverse ownership in respect thereof; (ii) no consent of any person is necessary to make, use, reproduce,
license, sell, modify, update, enhance or otherwise exploit any Purchaser Intellectual Property that is owned by the Purchaser
or a Profound Subsidiary; and (iii) other than the Purchaser Intellectual Property licensed to the Purchaser or a Profound Subsidiary
pursuant to the Sunnybrook License Agreement, none of the Purchaser Intellectual Property that is owned by the Purchaser or a Profound
Subsidiary comprises an improvement to any Purchaser Intellectual Property that would give any third person any rights to any such
Purchaser Intellectual Property, including, without limitation, rights to license any such Purchaser Intellectual Property; except
as would not, individually or in the aggregate, have a Purchaser Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has no knowledge of any pending or threatened, action, suit, proceeding or claim by others challenging the Purchaser's
or a Profound Subsidiaries' rights in or to any Purchaser Intellectual Property, and the Purchaser has no knowledge of any facts
which form a reasonable basis for any such claim; none of the Purchaser or the Profound Subsidiaries have received any written
notice or claim challenging its ownership or right to use any of the Purchaser Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Purchaser's knowledge, the conduct of its business (including, without limitation, the use or other exploitation of the Purchaser
Intellectual Property by the Purchaser or a Profound Subsidiary) has not infringed, violated, misappropriated or otherwise conflicted
with any intellectual property right of any third person; and (ii) to the knowledge of the Purchaser, there is no pending or threatened
action, suit, proceeding or claim by any other person that the Purchaser or any Profound Subsidiary infringes or otherwise violates
(or would infringe or otherwise violate upon commercialization of the Purchaser's products or services under development) any intellectual
property right owned by any other person, and the Purchaser has no knowledge of any facts which form a reasonable basis for any
such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Purchaser's knowledge, no person has infringed or misappropriated, or is infringing or misappropriating, any rights of the
Purchaser or a Profound Subsidiary in or to any of the Purchaser Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that (i) any of the Purchaser Intellectual Property that is owned by the Purchaser or a Profound Subsidiary is licensed
or (ii) any of the Purchaser Intellectual Property that is owned by the Purchaser or a Profound Subsidiary and that is treated
by the Purchaser or a Profound Subsidiary as confidential is disclosed, in either case, to any other Person by the Purchaser or
a Profound Subsidiary, the Purchaser or such Profound Subsidiary. as applicable, has entered into a valid and subsisting written
agreement with any such Person which contains terms and conditions prohibiting the unauthorized use, disclosure or transfer of
such Purchaser Intellectual Property by such Person. Other than such agreements that have expired in accordance with their respective
terms, all such agreements are in full force and effect and, to the knowledge of the Purchaser, none of the Purchaser, the Profound
Subsidiaries or any other Person is in material default or material breach of its obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Purchaser's knowledge, all moral rights as defined under the <I>Copyright Act </I>(Canada) or any other applicable legislation
or by operation of law in any applicable jurisdiction have been waived in writing in favour of any of the Purchaser, the Profound
Subsidiaries and their successors or assignees with respect to the copyrightable works that are owned by the Purchaser or a Profound
Subsidiary, except as would not, individually or in the aggregate, have a Purchaser Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Real
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Neither the
Purchaser nor the Profound Subsidiaries own any real property; and with respect to each premises of the Purchaser and each of the
Profound Subsidiaries which is material to the business of the Purchaser and which the Purchaser or a Profound Subsidiary occupies
as tenant (the &ldquo;<B>Leased Premises</B>&rdquo;), the Purchaser or a Profound Subsidiary occupies the Leased Premises and has
the exclusive right to occupy and use the Leased Premises and each of the leases pursuant to which the Purchaser or a Profound
Subsidiary occupies the Leased Premises is, to the knowledge of the Purchaser, in good standing and in full force and effect in
all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor any Profound Subsidiary is a party to or bound by any collective agreement and is not currently conducting negotiations
with any labour union or employee association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser and each Profound Subsidiary is in compliance in all material respects with all laws respecting employment and employment
practices, terms and conditions of employment, pay equity and wages and has not and is not engaged in any unfair labour practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
than (i) the Purchaser's Share Option Plan dated June 4, 2015; and (ii) the Encon Group Benefits Plan as renewed on March 1, 2014,
neither the Purchaser nor the Profound Subsidiaries have agreements, plans or practices relating to the payment of any management,
consulting, service or other fees or any bonuses, pensions, share of profits or retirement allowance, insurance, health or other
employee benefits or any plan for retirement, stock purchase, profit sharing, stock option, deferred compensation, severance or
termination pay, insurance, medical, hospital, dental, vision care, drug, sick leave, disability, salary continuation, legal benefits,
unemployment benefits, vacation, incentive or otherwise contributed to, or required to be contributed to, by the Purchaser or a
Profound Subsidiary for the benefit of any current or former director, officer, employee or consultant of the Purchaser or a Profound
Subsidiary (&ldquo;<B>Purchaser Employee Plans</B>&rdquo;). The Purchaser has made available to the Vendor true and complete copies
of documents, contracts and arrangements relating to the Purchaser Employee Plans. The Purchaser Employee Plans have been established,
operated in the ordinary course and administered in all material respects in accordance with their terms and applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
has not been in the last two years and there is not currently any labour disruption with respect to the Purchaser that would reasonably
be expected to have a Purchaser Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Purchaser&rsquo;s knowledge, none of the directors, officers or employees of the Purchaser, the Profound Subsidiaries or any
associate or Affiliate of any of the foregoing has any interest, direct or indirect, in any transaction with the Purchaser or any
Profound Subsidiary that materially affects, is material to or would reasonably be expected to materially affect the Purchaser
or any Profound Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for wages, salaries and other compensation-related payments in the ordinary course, neither the Purchaser nor any Profound Subsidiary
is indebted to: (i) any director, officer or shareholder of the Purchaser; any individual related to any of the foregoing by blood,
marriage or adoption; or any corporation controlled, directly or indirectly, by any one or more of those Persons referred to in
this Section 4.27(f). None of those Persons referred to in this Section 4.27(f) is indebted to the Purchaser or any Profound Subsidiary.
Neither the Purchaser nor a Profound Subsidiary is currently a party to any material Contract, agreement or understanding with
any officer, director, employee, shareholder or any other Person not dealing at arm's length with the Purchaser or the Profound
Subsidiaries, other than employment agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
and each Profound Subsidiary's insurance policies are valid and enforceable and in full force and effect, are underwritten by unaffiliated
and reputable insurers, are sufficient for all applicable requirements of applicable Law and provide insurance, including liability
and product liability insurance, in such amounts and against such risks as is customary for corporations engaged in businesses
similar to that carried on by the Purchaser and the Profound Subsidiaries. Neither the Purchaser nor any Profound Subsidiary is
in default in any respect with respect to the payment of any premium or compliance with any of the provisions contained in any
such insurance policy and has not failed to give any notice or present any claim within the appropriate time therefor. There are
no circumstances under which the Purchaser or any Profound Subsidiary would be required to or, in order to maintain its coverage,
should give any notice to the insurers under any such insurance policy which has not been given. Neither the Purchaser nor any
Profound Subsidiary has received notice from any of the insurers regarding cancellation of such insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minute
Books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Copies of the
minute books and records of the Purchaser and the Profound Subsidiaries made available to counsel for the Vendor in connection
with the due diligence investigation of the Purchaser and the Profound Subsidiaries for the period from the date of incorporation
to the date hereof are all of the minute books of the Purchaser and the Profound Subsidiaries and contain copies of all proceedings
(or certified copies thereof or drafts thereof pending approval) of the shareholders, the directors and all committees of directors
of the Purchaser and the Profound Subsidiaries to the date hereof to the extent that minutes exist and there have been no other
meetings, resolutions or proceedings of the shareholders. directors or any committees of the directors of the Purchaser or the
Profound Subsidiaries to the date hereof not reflected in such minute books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Environmental
Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i) The Purchaser,
the Profound Subsidiaries and each of their respective Assets and Properties and the operation of their respective businesses have
been and are, to the knowledge of the Purchaser, in compliance in all material respects with all Environmental Laws; (ii) the Purchaser
and each of the Profound Subsidiaries has complied in all respects with all reporting and monitoring requirements under all Environmental
Laws; (iii) neither the Purchaser nor any Profound Subsidiary has ever received any notice of any non-compliance in respect of
any Environmental Laws; and (iii) there are no Environmental Permits necessary to conduct the business of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Since December
31, 2016, there has not occurred any material adverse change (actual, anticipated, contemplated or, to the knowledge of the Purchaser,
threatened, whether financial or otherwise) in the assets, liabilities (contingent or otherwise), properties, capital, affairs,
prospects, business, operations or condition (financial or otherwise) of the Purchaser and the Profound Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Neither the Purchaser nor any Profound Subsidiary
has:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;paid
or declared any dividend or incurred any material capital expenditure or made any commitment therefor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;incurred
any obligation or liability, direct or indirect, contingent or otherwise, except in the ordinary course of business and which is
not, and which in the aggregate are not, material; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;entered
into any material transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Bribery,
etc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser and the Profound Subsidiaries and their directors, officers, employees and other representatives are familiar with and
have conducted all transactions, negotiations, discussions and dealings in full compliance with anti-bribery and anti-corruption
laws and regulations applicable in any jurisdiction in which they are located or conducting business. Neither the Purchaser nor
any Profound Subsidiary has made any offer, payment, promise to pay, or authorization of payment of money or anything of value
to any government official, or any other Person while having reasonable grounds to believe that all or a portion of such money
or thing of value will be offered, given or promised, directly or indirectly, to a government official, for the purpose of (i)
assisting the parties in. obtaining, retaining or directing business; (ii) influencing any act or decision of a government official
in his or its official capacity; (iii) inducing a government official to do or omit to do any act in violation of his or its lawful
duty, or to use his or its influence with .a government or instrumentality thereof to affect or influence any act or decision of
such government or department, agency, instrumentality or entity thereof; or (iv) securing any improper advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
operations of the Purchaser and the Profound Subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the money laundering statutes of all applicable jurisdictions, the rules
and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any
Governmental Authority (collectively, the &ldquo;<B>Applicable Anti- Money Laundering Laws</B>&rdquo;) and no action, suit or proceeding
by or before any Governmental Authority involving the Purchaser with respect to Applicable Anti-Money Laundering Laws is, to the
knowledge of the Purchaser, pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuous
Disclosure Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser is in material compliance with its timely and continuous disclosure obligations under the Applicable Securities Laws
and the policies, rules and regulations of the TSXV and, without limiting the generality of the foregoing, there are no material
facts and there has not occurred any material change (actual, anticipated, contemplated, or to the knowledge of the Purchaser,
threatened, financial or otherwise) in the business, assets (including intangible assets), affairs, operations, liabilities (contingent
or otherwise), capital, properties, condition (financial or otherwise), results of operations or control of the Purchaser and the
Profound Subsidiaries taken as a whole since December 31, 2016 which has not been publicly disclosed on a non-confidential basis,
and the Purchaser has not filed any confidential material change report which remains confidential as at the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has filed a current annual information form in the form prescribed by NI 51-102 in each of the
Qualifying Jurisdictions prior to the date hereof; the Purchaser is as of the date hereof an Eligible Issuer in the
Qualifying Jurisdictions and there will be no documents required to be filed under the
Applicable Securities Laws of the Qualifying Jurisdictions in connection with the issuance of the Purchaser Common Shares
that will not have been filed as required as at those respective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has filed all documents forming the Disclosure Record on a timely basis, except for any failure to file on a timely basis
which is not material. As of their respective dates, the documents forming the Disclosure Record complied in all material respects
with the requirements of the Applicable Securities Laws of the Qualifying Jurisdictions, and none of the documents forming the
Disclosure Record, when filed, contained any misrepresentation or contained an untrue statement of a material fact, or an omission
to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the
circumstances in which it was made, which has not been corrected by the filing on a public basis of a subsequent document which
forms part of the Disclosure Record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The form and
terms of the certificate representing the Common Shares have been approved and adopted by the board of directors of the Purchaser
and the form and terms of the certificate representing the Common Shares do not and will not conflict with any applicable Laws
or the rules and by-laws of the TSXV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">TMX Equity
Transfer Services, at its principal offices in Toronto, Ontario, has been duly appointed as the registrar and transfer agent for
the Common Shares and Globex Transfer LLC is a co-transfer agent for the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser and the Profound Subsidiaries hold all of the permits, licenses, approvals, consents, orders, markings, certificates
and like authorizations necessary for it to own, lease and license their Assets and Properties and carry on their businesses, as
now carried on as of the date of this Agreement, in each jurisdiction where such business is carried on that are material to the
conduct of such business, as now carried on as of the date of this Agreement, including, but not limited to, permits, licenses,
approvals, consents, orders, certificates and like authorizations from Regulatory Authorities (collectively, the &ldquo;<B>Material
Permits</B>&rdquo;); all such Material Permits are valid and subsisting and in good standing and none of the same contains any
term, provision, condition or limitation which has or would reasonably be expected to affect or restrict in an adverse manner the
operation of the Purchaser&rsquo;s business, as now carried on as of the date of this Agreement or proposed to be carried on and
neither the Purchaser nor any Profound Subsidiary is in breach thereof or in default with respect to filings to be effected or
conditions to be fulfilled in order to maintain such Material Permits in good standing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Material Permits issued by a Regulatory Authority have been limited, suspended, or revoked, and, to the knowledge of the Purchaser,
no Regulatory Authority is considering such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Purchaser and the Profound Subsidiaries is in material compliance in all material respects with each Material Permit held
by it and is not in violation of; or in default under, applicable Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no false or misleading information or significant omission in any submission made by or on behalf of the Purchaser or any Profound
Subsidiary to a Regulatory Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser Product has been and is being developed, tested, investigated, manufactured, stored, distributed and marketed in compliance
in all material respects with applicable Health Care Laws and all other applicable legal requirements, including those regarding
non-clinical testing, clinical research, establishment registration, device listing, pre-market notification, good manufacturing
practices, labeling, advertising, record-keeping, adverse event reporting and reporting of corrections and removals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Purchaser or any Profound Subsidiary
that are described or referred to in the Disclosure Record (collectively, the &ldquo;<B>Clinical Trials</B>&rdquo;) were and, if
still ongoing or pending, are being conducted, in all material respects, in accordance with all experimental protocols; procedures
and controls; accepted professional scientific standards; accepted standards for good clinical practices and ethical research involving
humans; and applicable Laws, including applicable Laws administered by Regulatory Authorities. The descriptions of the result of
the Clinical Trials described or referred to in the Disclosure Record are accurate and complete in all material respects and fairly
present the published data derived from the Clinical Trials and the Purchaser has no knowledge of other studies or tests the results
of which are inconsistent with or would otherwise call into question the results described or referred to in the Disclosure Record.
Neither the Purchaser nor any Profound Subsidiary has received any notices or written correspondence from any Regulatory Authority
with respect to any Clinical Trial requesting information about or requiring the termination or suspension of such Clinical Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser and the Profound Subsidiaries have filed with applicable Regulatory Authorities all filings, declarations, listings,
registrations, reports, updates and submissions that are required to be so filed under applicable Health Care Laws. All such filings
were in compliance in all material respects with applicable Health Care Laws when filed and no deficiencies have been asserted
by any Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports, updates or submissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor any Profound Subsidiary has received any Form FDA- 483 Notice of Inspectional Observations, notice of adverse
finding, FDA warning letters, notice of violation or &quot;untitled letters,&quot; or notice of FDA action for import detentions
or refusals or any other written correspondence from the FDA or similar communications from another Regulatory Authority alleging
or asserting noncompliance with any applicable Health Care Laws. Neither the Purchaser nor any Profound Subsidiary is subject to
any obligation arising under an administrative or regulatory action, inspection, warning letter, notice of violation letter or
other written notice, response or commitment made to or with the FDA or any other Regulatory Authority, and, to the Purchaser's
knowledge, no such proceedings have been threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser, each Profound Subsidiary and their respective officers, directors, and employees and, to the Purchaser&rsquo;s knowledge,
their respective representatives, contractors and agents, have been and are currently in compliance with all applicable Health
Care Laws, except where such non-compliance would be immaterial to the Purchaser or the Profound Subsidiaries, and neither the
Purchaser, the Profound Subsidiaries nor their officers, directors or employees have engaged in any act or omission that violates
or would violate any Health Care Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor the Profound Subsidiaries and, to the Purchaser&rsquo;s knowledge, none of their respective officers, directors
and employees (i) are or have been a party to, or bound by, any order, individual integrity agreement, corporate integrity agreement
or other formal agreement or settlement with any Governmental Authority concerning compliance with Health Care Laws; (ii) has made
any filings in the United States pursuant to the OIG or CMS self-disclosure protocol; (iii) has been a defendant in any action,
or received a threat of any action, brought under a United States federal or state whistleblower statute, including without limitation
the False Claims Act of 1863 (31 U.S.C. &sect; 3729 et seq.); and (iv) has been served with or received any written search warrant,
subpoena (other than those related to actions against third parties), civil investigative demand or contact letter from a Governmental
Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor any Profound Subsidiary has received notice of any action pending or recommended by any Governmental Authority
(including a Regulatory Authority) either to revoke, withdraw, suspend or limit any Material Permit, or to terminate, suspend,
limit, withdraw, or forfeit the participation of the Purchaser or any Profound Subsidiary in any government program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Purchaser&rsquo;s knowledge, neither the Purchaser nor any Profound Subsidiary is the target or subject of any current or potential
investigation relating to any Government Health Care Program-related offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor the Profound Subsidiaries have (i) offered, authorized, promised, made or agreed to make gifts of money, other
property, other value or similar benefits or contributions to, or entered into any fee-splitting arrangement with, any actual or
potential patient, health care provider, actual or potential business partner, governmental employee, or other Person in a position
to assist or hinder the Purchaser or the Profound Subsidiaries in connection with any actual or proposed transaction, or to any
political party, political party official or candidate for federal, state, provincial or local public office in violation of any
applicable Law or (ii) maintained any unrecorded fund or asset of the Purchaser or any Profound Subsidiary for any improper purpose
or made any false entries on its books and records for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Purchaser&rsquo;s knowledge, no Persons who have engaged in any activity that is in violation of, or have been
convicted of, charged with, or investigated for, a felony or a criminal offense under any Health Care Law; or
who are excluded, suspended, debarred, prohibited from providing services under, or otherwise ineligible to participate in
any Government Health Care Program; or who have been threatened with exclusion, debarment or being otherwise ineligible to
participate in any Government Health Care Program; or who have committed any act or have engaged in any activity that is
permissive or mandatory grounds for exclusion, debarment, suspension, or other ineligibility to so participate, are either
employed by, under Contract with, or agents of the Purchaser or any Profound Subsidiary or provide items or services on
behalf of the Purchaser or any Profound Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor any Profound Subsidiary has unlawfully disclosed the protected health information of any Person, nor committed
any other breach of applicable Health Care Laws concerning the privacy and/or security of personal health information; nor, to
the knowledge of the Purchaser, is there any investigation of the Purchaser or any Profound Subsidiary by any Governmental Authority
for a violation of applicable Health Care Laws concerning the privacy and/or security of personal health information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Purchaser nor any Profound Subsidiary has notified, either voluntarily or as required by Health Care Law or other applicable
Law, any affected individual, any Governmental Authority or the media of any breach of protected health information. To the knowledge
of the Purchaser, neither the Purchaser nor any Profound Subsidiary has suffered any unauthorized acquisition, access, use or disclosure
of any personal information that, individually or in the aggregate, materially compromises the security or privacy of such personal
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the Purchaser and the Profound Subsidiaries, in conducting their business, does not participate in, directly or through any
broker, distributor or similar party, any arrangement pursuant to which customers of such business receive, directly or indirectly,
a reduction in the purchase or other benefits, monetary or otherwise, other than normal and legal customary trade practices and
incidental business-related entertainment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
only to the terms of the Sunnybrook License Agreement, the Purchaser is the sole legal and beneficial owner of, has good and marketable
title to, and owns all right, title and interest in the Purchaser Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is no actual or pending or to the Purchaser&rsquo;s knowledge, threatened enforcement actions by any Regulatory Authority against
the Purchaser or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for ordinary course inquiries by Regulatory Authorities, no Regulatory Authority is presently alleging or asserting, or, to the
Purchaser&rsquo;s knowledge, threatening to allege or assert, noncompliance with any applicable legal requirement or registration
in respect of the Purchaser Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
and all operations of the Purchaser and the Profound Subsidiaries, and to the Purchaser&rsquo;s knowledge, any and all operations
by predecessors, on or in respect of the Assets and Properties of the Purchaser and the Profound Subsidiaries have been conducted
substantially in accordance with good industry practices in the jurisdiction of operation and in material compliance with applicable
Laws and orders, judgments, decrees and directions of Governmental Authorities and other competent authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions/Dispositions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has not completed any &ldquo;significant acquisition&rdquo;, &ldquo;significant disposition&rdquo; nor is it proposing
any &ldquo;probable acquisitions&rdquo; (as such terms are used in NI 44-101 and NI 51-102), other than the transaction contemplated
hereby, that would require the inclusion of any additional financial statements or any pro forma financial statements pursuant
to the Applicable Securities Laws of the Qualifying Jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser has not entered into any agreement or arrangement in respect of a transaction that would be a &ldquo;significant acquisition&rdquo;
for purposes of Part 8 of NI 51-102 and there are no proposed acquisitions by the Purchaser that have progressed to the state where
a reasonable person would believe that the likelihood of the Purchaser completing the acquisition is high and would be a &ldquo;significant
acquisition&rdquo; for the purposes of Part 8 of NI 51-102 if completed as of the date hereof, other than the transaction contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 4.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Misrepresentations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No representation
or warranty made by the Purchaser in this Agreement and no statement contained in the Disclosure Schedule or any certificate or
other document furnished or to be furnished to the Vendor pursuant to this Agreement contains any untrue statement of material
fact, or omits to state a material fact necessary to make the statements contained therein, in light of the circumstances in which
they are made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 5</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">COVENANTS OF THE VENDOR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except (i)
as contemplated by this Agreement, (ii) set forth in Section 5.1 of the Disclosure Schedule, or (iii) with the prior written consent
of the Purchaser (which consent shall not be unreasonably withheld, conditioned or delayed), from the date hereof until the Closing
Date, the Vendor shall, and shall cause its Affiliates to, conduct the Business in the ordinary course of business and the Vendor
shall not, and shall cause its Affiliates and Subco, as applicable, not to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">sell, lease, license, transfer or otherwise dispose
of, or suffer a Lien (other than Permitted Liens) to exist on, the Purchased Assets;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">incur any Indebtedness that would constitute an Assumed
Liability or a Liability of Subco, other than trade accounts payable and other current liabilities arising in the ordinary course
of business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">transfer, assign or grant any license or sublicense or
any rights under or with respect to the Business Intellectual Property;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">hire or terminate any employee of the Business that would
be an Employee;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">enter into any employee benefit plan relating to the Employees,
except as required by Law;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">amend in any respect any Business Benefit Plan or Contract
with respect to Employees or employees of Subco, or increase the compensation of any Employee or employee of Subco, except, in
each case, as required by Law or the terms of any Business Benefit Plan or Contract in existence on the date hereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">enter into any Contract that would constitute a Transferred
Contract or terminate or amend in any material respect any Transferred Contract, except in the ordinary course of business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(viii)</TD><TD STYLE="text-align: justify">make capital expenditures that would constitute an Assumed
Liability or a Liability of Subco, or fail to make any scheduled capital expenditures relating to the Business required to be
made in the ordinary course of business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ix)</TD><TD STYLE="text-align: justify">with respect to Subco, authorize, issue or sell any shares
of capital stock or other equity of Subco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(x)</TD><TD STYLE="text-align: justify">with respect to the Business, make, amend or revoke any
Tax elections or designations or take any discretionary positions with respect to any Taxes owed by or affecting Subco, amend
any Tax Return (other than as required by Law), or fail to withhold, accrue and pay when due any Taxes and penalties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(xi)</TD><TD STYLE="text-align: justify">delay or postpone the payment of accounts payable or other
Liabilities that would constitute an Assumed Liability or a Liability of Subco, in each case outside the ordinary course of business,
except where a valid business rationale exists for such delay or postponement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(xii)</TD><TD STYLE="text-align: justify">make or authorize any change to the organizational or constituent documents of Subco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(xiii)</TD><TD STYLE="text-align: justify">with respect to Subco, merge or amalgamate into or with
or consolidate with any other Person or acquire all or substantially all of the business or assets of any other Person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(xiv)</TD><TD STYLE="text-align: justify">with respect to Subco, make any change to the accounting (including Tax accounting) methods,
                                                                                 principles, classifications or practices, except as may be required by Finnish GAAP;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(xv)</TD><TD STYLE="text-align: justify">initiate, compromise or settle any litigation or arbitration
proceeding with respect to the Business; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(xvi)</TD><TD STYLE="text-align: justify">enter into any Contract to do or engage in any of the foregoing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retention
and Access to Books and Records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor shall retain for a period of seven (7) years from the Closing Date, or such longer period as may be prescribed by applicable
Law, all books, records and other written information relating to the Business and not delivered to the Purchaser in connection
with the consummation of the transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof and during such period of seven (7) years from the Closing Date, the Vendor shall allow the Purchaser and its officers,
directors, employees, accountants, auditors, counsel, legal and financial advisors, consultants and other agents and representatives
(&ldquo;<B>Representatives</B>&rdquo;), upon reasonable written notice, access during normal business hours to such books, records
and other information, including the right to inspect and take copies (at the Purchaser&rsquo;s expense) and make its employees
available, as may be reasonably required by the Purchaser in connection with the transactions contemplated by this Agreement and
the Other Transaction Documents, an administrative or internal procedure, investigation or inquiry, or to enable the Purchaser
to comply with its statutory and contractual obligations under this Agreement, provided that the foregoing does not (i) unduly
disrupt the conduct of the operations of the Vendor and its Affiliates, (ii) violate any Law, fiduciary duty, Order, Contract or
Permit applicable to the Vendor and its Affiliates, or (iii) jeopardize any attorney-client or other legal privilege, and subject
to existing confidentiality and non-disclosure obligations of the Vendor and its Affiliates..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
and Third Party Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor shall as promptly as practicable after the date hereof (i) use commercially reasonable efforts to give all notices to, make
all filings and applications with, obtain all consents, clearances and approvals of, and take any action in respect of, any Persons
and Governmental Authorities required of the Vendor, its Affiliates and Subco to consummate the transactions contemplated by this
Agreement, including those described in Section 3.4 and Section 3.6 of the Disclosure Schedule, (ii) provide such other information
and communications to such Governmental Authorities or other Persons as such Governmental Authorities or other Persons may reasonably
request in connection therewith, and (iii) provide such necessary information and reasonable cooperation to the Purchaser or its
outside counsel as reasonably requested by the Purchaser in connection with the performance of the Purchaser&rsquo;s obligations
under Section 6.2. The Vendor shall provide prompt notification to the Purchaser when any such consent, clearance, approval, action,
filing or notice referred to in clause (i) above is obtained, taken, made or given, as applicable, and shall advise the Purchaser
of any communications (and, unless precluded by Law, provide copies of any such communications that are in writing to the Purchaser
or its outside counsel) with any Governmental Authority or other Person regarding any of the transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the generality of the foregoing, the Vendor shall consult and cooperate with the Purchaser in connection with
all notices, filings, applications, analyses, appearances, presentations, memoranda, briefs, arguments, opinions and
proposals made or submitted by or on behalf of the Vendor, its Affiliates or Subco in connection with obtaining all consents
and approvals from any Governmental Authorities necessary to consummate the transactions contemplated hereby. None of the
Vendor or its Affiliates will make any notification, filing, application or other submission in relation to the
transactions contemplated hereby without first providing the Purchaser with a copy of such notification, filing, application
or other submission in draft form and giving the Purchaser a reasonable opportunity to consider its content before it is
filed with the relevant Governmental Authority, and shall consider and take account of all reasonable comments timely made in
this respect. The Vendor shall promptly notify the Purchaser of any substantive communications from or with any Governmental
Authority with respect to the transactions contemplated by this Agreement and will use its reasonable commercial efforts to
ensure, to the extent permitted by Law, that the Purchaser, or its outside counsel where appropriate, are involved in any
substantive communications or invited to attend meetings with, or other appearances before, any Governmental Authority with
respect to the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Material
Supplier Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Until one (1)
year following the termination of the Supply Agreement, the Vendor shall facilitate an orderly transition of the Material Supplier
Contracts from the Vendor to the Purchaser following termination of the Supply Agreement by using commercially reasonable best
efforts to assist the Purchaser in entering into supply agreements directly with the counterparties to the Material Supplier Contracts
on terms that are satisfactory to the Purchaser, acting reasonably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
shall provide a list of supplier Contracts of the Business to the Purchaser on or prior to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferred
Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
shall take, and shall cause its Affiliates and Subco to take, all commercially reasonable steps necessary or desirable in order
to arrange for the transfer of the Transferred Contracts to Subco on terms that are satisfactory to the Purchaser, acting reasonably.
For clarity, assignment of a Transferred Contract on the same terms as are existing on the date hereof without the incurring of
additional obligations or conditions by the Purchaser is considered satisfactory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fulfillment
of Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
shall take, and shall cause its Affiliates and Subco to take, all commercially reasonable steps necessary or desirable and proceed
diligently in good faith to satisfy each condition to the obligations of the Purchaser contained in this Agreement and shall not
take or fail to take any action that could reasonably be expected to result in the non-fulfillment of any such condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions
on Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor shall not, directly or indirectly, transfer, sell, assign, gift, pledge, encumber, hypothecate, mortgage, exchange or otherwise
dispose of (including through the sale or purchase of options or other derivative instruments with respect to the Base Purchase
Price Shares) (any such occurrence a &ldquo;disposition&rdquo;), all or any portion of the Base Purchase Price Shares, or its economic
interest therein, after the Closing Date for a period of one (1) year following the Closing Date (the &ldquo;<B>Hold Period</B>&rdquo;)
without the prior written consent of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the Hold Period, the Vendor shall be permitted to dispose no more than 25% of the Base Purchase Price Shares in any calendar quarter,
provided that following the Hold Period the Vendor shall be permitted to dispose any amount of Base Purchase Price shares on a
prospectus-exempt private placement basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing restrictions in this Section 5.7, the Vendor or a nominee of the Vendor shall be permitted to (i) transfer its Base
Purchase Price Shares to any of its Affiliates, provided that (A) the transferee agrees in writing in favour of the Purchaser and
in form and substance reasonably satisfactory to the Purchaser to be bound by the terms and conditions of this Agreement applicable
to the Vendor, (B) the Vendor shall remain bound and subject to its obligations hereunder and shall be responsible for ensuring
such Affiliate complies with its obligations under this Agreement, and (C) if the transferee ceases at any time to be an Affiliate
of the Vendor, the Vendor shall cause the transferee to transfer the Base Purchase Price Shares to the Vendor or any of its Affiliates,
provided that the transferee complies with (A) above; and (ii) tender its Base Purchase Price Shares to a takeover bid made for
more than 50% of the Purchaser&rsquo;s common shares or participate in a plan of arrangement or similar reorganization in respect
of the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Updates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">From and after
the date of this Agreement and until Closing, the Vendor will notify the Purchaser in writing (each such notification, a &ldquo;<B>Vendor
Update</B>&rdquo;) in a reasonably prompt manner upon the Vendor&rsquo;s determination of any matter arising or discovered after
the date of this Agreement which, if existing or known to the Vendor or its Affiliates as of the execution of this Agreement would
have been required to be set forth in the Disclosure Schedule; provided, however, that no Vendor Update shall be deemed to amend
the Disclosure Schedule for purposes of Article 8 or Article 10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">From the date
hereof until the earlier of the Closing or the date on which this Agreement terminates or is terminated pursuant to Section 11.1,
the Vendor agrees that it and its Affiliates shall not, and the Vendor shall cause Subco not to, directly or indirectly through
any of their respective Representatives, (i) discuss or pursue a possible sale, recapitalization, merger or other disposition of
any interest in the Business, any securities of Subco, or any Purchased Assets with any Person other than the Purchaser or its
Representatives (&ldquo;<B>Alternate Transaction</B>&rdquo;) or provide any information to any Person other than the Purchaser
or its Representatives in connection therewith, or (ii) except as required by Law or for disclosures to the Representatives and
Affiliates of the Vendor and Subco who reasonably need to know such information in connection with the performance of this Agreement,
disclose the terms of this Agreement to any Person; <U>provided, however</U>, that an Alternate Transaction shall not include any
such transaction which does not involve any of the assets or equity included in the transactions contemplated by this Agreement
or related to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchased
Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">If any monies
or other assets are received by the Vendor after the Closing to which any of Subco, the Purchaser or any of its permitted assignees
in accordance with Section 13.11 is entitled in accordance with the terms hereof and that are included in the Purchased Assets,
the Vendor shall hold such monies and assets received in trust for Subco, the Purchaser or such permitted assignee and shall account
for and pay the same to Subco, the Purchaser or such permitted assignee within 30 days after receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Affiliate
Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as set
forth in Section 5.11 of the Disclosure Schedule and other than the Transferred Contracts and the Other Transaction Documents,
all Contracts and arrangements between the Philips Group on the one hand and Subco or the Business on the other hand (including
services provided by the Philips Group to the Business, other than under the Other Transaction Documents) shall, to the extent
they relate to the Business, be terminated as at the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disentanglement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Closing Date, the Vendor will procure the transfer of the Purchased Assets (excluding the Class A Patents and Trademarks)
and Assumed Liabilities from the relevant members of the Philips Group in which they are currently held to Subco (such process
hereinafter referred to as the &ldquo;<B>Disentanglement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor undertakes to procure that between the date of this Agreement and the Closing Date the Philips Group will complete the Disentanglement.
The Disentanglement shall take place in coordination with the Purchaser and reasonable requests of the Purchaser and in particular,
documentation of the Disentanglement, material tax issues, shall be taken into account if the fulfilment of such requests (i) do
not materially hamper the planning of the Disentanglement and (ii) are not commercially unfavourable to the Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Redacted
 &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
Correspondence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
will provide to the Purchaser on or prior to Closing Date, true and correct copies of any and all material correspondence to the
Vendor, its Affiliates or Subco relating to the Business from any Governmental Authority and all material correspondence relating
to the Business from the Vendor, its Affiliates or Subco to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Access
to the MR System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
shall procure that Philips Oy will grant Subco access to its MR system in Helsinki at a hourly rate of [REDACTED &ndash; Pricing
Terms] per hour and on such other terms and conditions to be mutually agreed in the relevant transitional service level agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">COVENANTS OF PURCHASER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
acknowledges that the provisions of the confidentiality agreement dated November 1, 2016 (the &ldquo;<B>Confidentiality Agreement</B>&rdquo;)
between the Purchaser and Philips International B.V. shall continue to apply notwithstanding the execution of this Agreement by
the Parties or the announcement of this Agreement, and agrees to fulfill its obligations thereunder in accordance with the terms
thereof; provided, however, that the Confidentiality Agreement shall terminate effective as of the Closing Date. For the avoidance
of doubt, if this Agreement is, for any reason, terminated prior to the Closing Date, the Confidentiality Agreement shall nonetheless
continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
and Third Party Approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser shall, as promptly as practicable after the date hereof (i) use its commercially reasonable efforts to give all notices
to, make all filings and applications with, obtain all consents, clearances and approvals of and take any action in respect of,
any Persons and Governmental Authorities that are required of the Purchaser to consummate the transactions contemplated by this
Agreement, including those described in Section 4.3 and Section 4.4 of Schedule 4; (ii) provide such other information and communications
to such Governmental Authorities or other Persons as such Governmental Authorities or other Persons may reasonably request in connection
therewith and (iii) provide such necessary information and reasonable cooperation to the Vendor and its outside counsel as reasonably
requested by the Vendor in connection with the performance of the Vendor&rsquo;s obligations under Section 5.3. The Purchaser shall
provide prompt notification to the Vendor when any such consent, clearance, approval, action, filing or notice referred to in clause
(i) above is obtained, taken, made or given, as applicable, and shall advise the Vendor of any communications (and, unless precluded
by Law, provide copies of any such communications that are in writing to the Vendor and its outside counsel) with any Governmental
Authority or other Person regarding any of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the generality of the foregoing, the Purchaser shall consult and cooperate with the Vendor in connection with
all notices, filings, applications, analyses, appearances, presentations, memoranda, briefs, arguments, opinions and
proposals made or submitted by or on behalf of the Purchaser in connection with obtaining all consents and approvals from any
Governmental Authorities necessary to consummate the transactions contemplated hereby. The Purchaser will not make
any notification, filing, application or other submission in relation to the transactions contemplated hereby without
first providing the Vendor with a copy of such notification, filing, application or other submission in draft form (subject
to reasonable redactions or limiting the sharing of such draft, or parts thereof, to an outside-counsel-only basis
where appropriate) and giving the Vendor a reasonable opportunity to consider its content before it is filed with
the relevant Governmental Authority, and the Purchaser shall consider and take account of all reasonable comments timely made
in this respect. The Purchaser shall promptly notify the Vendor of any substantive communications from or with any
Government Authority with respect to the transactions contemplated by this Agreement and will use its reasonable commercial
efforts to ensure, to the extent permitted by Law, that the Vendor, or its outside counsel where appropriate, are involved in
any substantive communications or invited to attend meetings with, or other appearances before, any Government Authority
with respect to the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fulfillment
of Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
shall take all commercially reasonable steps necessary or desirable and proceed diligently in good faith to satisfy each condition
to the obligations of the Vendor contained in this Agreement and shall not take or fail to take any action that could reasonably
be expected to result in the non-fulfillment of any such condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retention
of Books and Records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser shall, and shall cause Subco to, retain for a period of seven (7) years from the Closing Date, or such longer period
as may be prescribed by applicable Law, all books, records and other written information relating to the Business delivered to
the Purchaser or Subco in connection with the consummation of the transaction contemplated hereby or held by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
such period, the Purchaser shall, and shall cause Subco to, allow the Vendor and its Representatives, upon reasonable written notice,
access during normal business hours to such books, records and other information, including the right to inspect and take copies
(at the Vendor&rsquo;s expense) and make the Employees available, as may be reasonably required by the Vendor in connection with
an administrative or internal procedure, investigation or inquiry, or to enable the Vendor to comply with its statutory and contractual
obligations under this Agreement, provided that the foregoing does not (i) unduly disrupt the conduct of the operations of the
Purchaser and its Affiliates, (ii) violate any Law, fiduciary duty, Order, Contract or Permit applicable to the Purchaser and its
Affiliates, or (iii) jeopardize any attorney-client or other legal privilege, and subject to existing confidentiality and non-disclosure
obligations of the Vendor and its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of Philips Names and Marks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as explicitly agreed otherwise in the Other Transaction Documents, the Purchaser shall not, and shall cause Subco not to, after
Closing Date, use in any way whatsoever, by means of trading names, domain names, registered or unregistered trademarks, logos
or otherwise, the name Philips, or any abbreviation thereof or any name or lettering which is confusingly similar to the same,
provided that nothing in this Section 6.5 shall prevent Purchaser or its Affiliates from referencing the name Philips, or any abbreviation
thereof in order to describe or refer to the sale of Subco and the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
Section 6.5(a), the Purchaser shall, as soon as practicable after the Closing, but in any event within six (6) months after the
Closing Date, procure that the name Philips, or any abbreviations thereof, is removed from all business stationery and other assets
held or used by Subco or acquired by the Purchaser pursuant to this Agreement, and from all premises o<B>c</B>cupied by Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"><FONT STYLE="font-size: 10pt"><B>Section 6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>[Redacted
&ndash; Commercially Sensitive]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">[Redacted &ndash; Commercially
Sensitive]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MUTUAL COVENANTS OF THE VENDOR AND PURCHASER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
Filings and Other Actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Parties
shall prepare and file, as promptly as practicable and in any event within twenty (20) Business Days after the execution of this
Agreement, such other filings, notices and applications required to obtain the consents, clearances, approvals and authorizations
from Persons and Governmental Authorities that are necessary to consummate the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
Assurances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">From time to
time after the date hereof, including after the Closing, and without further consideration, the Parties shall execute and deliver,
or arrange for the execution and delivery of, such other instruments of conveyance, transfer or assumption and take or arrange
for such other actions as may be reasonably requested by the other Party to more effectively complete any of the transactions provided
for in this Agreement or any document contemplated hereby. Without limiting the foregoing, to the extent an allocation of the Purchase
Price attributable to transferred rights and assets in a particular jurisdiction hereby is requested by either Party in order to
minimize transfer taxes, the other Party will cooperate and use commercially reasonable efforts to enter into and deliver such
documents provided it is not commercially unfavourable to such other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall pay the applicable transfer Taxes payable upon and in connection with the sale, assignment, conveyance and transfer
of the Subco Shares and Class A Patents and Trademarks to the Purchaser as required and imposed on such Party by applicable Law.
The Purchaser shall, at its own expense, timely file any Tax Return with respect to such Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor and the Purchaser shall cooperate fully with each other and make available to each other in a timely fashion such data,
personnel or other information as may reasonably be required for the preparation of any Tax Return with respect to any Vendor Tax
Period relating to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting the generality of the foregoing, the Purchaser shall prepare, or cause to be prepared, all Tax Returns required to be
filed by Subco after the Closing Date. The Vendor shall be given the opportunity to review, comment upon and suggest changes or
corrections to, any Tax Returns required to be filed by Subco after the Closing Date which include any Vendor Tax Period and any
amendments to such Tax Returns or any Tax Returns filed by Subco, as applicable, prior to the Closing (and the work papers of Subco
and its respective accountants used in the preparation thereof), in each case, prior to the filing thereof (but in no event less
than thirty (30) days prior to such filing). Except as required by Law, without the Vendor&rsquo;s prior written consent, none
of the Purchaser or Subco shall take any position on any Tax Return (including any amendment thereto) for, or agree to any settlement
relating to, any taxable period which might result in any increase in Tax (over accruals therefor on the books and records of Subco
as of the end of the day prior to the Closing Date) for any Vendor Tax Period. The Vendor shall pay all Taxes owing by Subco in
respect of a Vendor Tax Period and shall remit to the Purchaser all such amounts not less than five (5) Business Days before the
date on which such Taxes are required under applicable Law to be remitted to the applicable Tax authority or other receiving Governmental
Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a refund of Taxes (the &ldquo;<B>Refund</B>&rdquo;) is received by or credited to the account of Subco in respect of any Vendor
Tax Period, the Purchaser shall pay, or cause Subco, as applicable, to pay, within thirty (30) days of receipt, the amount of the
Refund to the Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties acknowledge that the Employees will transfer to Subco on the basis of their existing employment terms, existing
benefits and compensation plans and other employment rights and obligations by operation of law in accordance with Chapter 1,
Section 10 of the Finnish Act on Employment Contracts (55/2001 as amended). Subco shall assume all Liabilities accruing after
the Closing Date in respect of all such Employees. The Vendor shall reimburse Subco for any form of payment, incentive or
bonus to be received by or paid to any Employees in connection with the Closing of the transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
the date hereof to the Closing Date, the Vendor and its Affiliates shall not, and the Vendor shall cause Subco not to, take any
action to offer Employees alternate employment with the Vendor, its Affiliates or otherwise and the Vendor and its Affiliates shall
not, and the Vendor shall cause Subco not to, otherwise interfere with the continuance of the employment of the Employees with
Subco.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor shall be responsible for all success or other bonuses accrued by the Vendor, its Affiliates and Subco in respect of all
Employees&rsquo; employment or retention by the Vendor, its Affiliates and Subco for any and all periods ending on the Closing
Date even if payable after the Closing Date and the Vendor shall indemnify and save harmless the Purchaser in respect of all such
obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall be responsible for and shall indemnify and hold harmless the other Party against any liability arising from a failure
by it to comply with requirements of or obligations under any law regarding the transfer of undertaking (including, but not limited
to, any information duties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDITIONS PRECEDENT TO THE OBLIGATIONS
OF PURCHASER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The obligation
of the Purchaser to acquire the Subco Shares and the Class A Patents and Trademarks and assume the Assumed Liabilities as contemplated
hereby and to perform its other obligations hereunder to be performed on or after the Closing shall be subject to the fulfillment,
on or prior to the Closing Date, unless otherwise waived in writing by the Purchaser, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
and Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The representations
and warranties of the Vendor set forth in Article 3 shall be true and correct in all material respects, except to the extent qualified
by materiality (including the word &ldquo;material&rdquo; and words of similar import) or Material Adverse Effect which shall be
true and correct in all respects, in each case, on the Closing Date as if made on and as of such date (or, to the extent any such
representations and warranties, by their terms, are made expressly as of the date hereof or another date, as of such other date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
of Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
shall have and shall have caused its Affiliates and Subco to have performed and complied with in all material respects all of their
covenants, agreements and obligations contained in this Agreement to be performed on or prior to the Closing Date. The Vendor shall
have delivered, or caused to be delivered, to the Purchaser all the deliveries set forth in Section 2.5(a)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Orders
and Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">There shall
not be in effect on the Closing Date any Order or Law restraining, enjoining or otherwise prohibiting or making illegal the consummation
of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consents,
Approvals and Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The consents,
clearances and approvals of, filings with and notices and applications to the Governmental Authorities and other third Persons
listed in Schedule 8.4 shall have been duly obtained, made or given (or in lieu thereof waivers) and shall be in full force and
effect, and all terminations or expirations of waiting periods listed in Schedule 8.4 imposed by any Governmental Authority necessary
for the consummation of the transactions contemplated hereunder shall have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cooperation
with Business Acquisition Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
shall have received from the Vendor the financial statement disclosure for a significant acquisition (as such term is defined in
Part 8 of NI 51-102) required pursuant to section 8.4 of NI 51-102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Officer&rsquo;s
Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Vendor
shall have delivered to the Purchaser a certificate dated as of the Closing Date and executed by a duly authorized officer of the
Vendor, in a form reasonably acceptable to the Purchaser, confirming the matters applicable to the Vendor in Section 8.1 and Section
8.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Parties
shall have mutually agreed on the terms and conditions of the Transition Services Agreement, the Loan Agreement, the Supply Agreement
and the Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Since the date hereof, there
shall not have occurred a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDITIONS PRECEDENT TO OBLIGATIONS OF
VENDOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The obligation
of the Vendor to sell the Subco Shares as contemplated hereby and to perform its other obligations hereunder to be performed on
or after the Closing shall be subject to the fulfillment, on or prior to the Closing Date, unless otherwise waived in writing by
the Vendor, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations
and Warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The representations
and warranties of the Purchaser set forth in Article 4 shall be true and correct in all material respects, except to the extent
qualified by materiality (including the word &ldquo;material&rdquo; and words of similar import) which shall be true and correct
in all respects, in each case, on the Closing Date as if made on and as of such date (or, to the extent that any such representations
and warranties, by their terms, are made expressly as of the date hereof or another date, as of such other date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
of Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
shall have performed and complied with in all material respects all of its covenants, agreements and obligations contained in this
Agreement to be performed on or prior to the Closing Date. The Purchaser shall have delivered, or caused to be delivered, to the
Vendor all the deliveries set forth in Section 2.5(a)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Orders
and Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">There shall
not be in effect on the Closing Date any Order or Law restraining, enjoining or otherwise prohibiting or making illegal the consummation
of the transactions contemplated herby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consents,
Approvals and Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The consents,
clearances and approvals of, filings with and notices and applications to the Governmental Authorities and other third Persons
listed in Section 9.4 shall have been duly obtained, made or given (or in lieu thereof waivers) and shall be in full force and
effect, and all terminations or expirations of waiting periods listed in Schedule 10.4 imposed by any Governmental Authority necessary
for the consummation of the transactions contemplated hereunder shall have occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Officer&rsquo;s
Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
shall have delivered to the Vendor a certificate dated as of the Closing Date and executed by a duly authorized officer of the
Purchaser, in a form reasonably acceptable to the Vendor, confirming the matters in Section 9.1 and Section 9.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Parties
shall have mutually agreed on the terms and conditions of the Transition Services Agreement, the Loan Agreement, the Supply Agreement
and the Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Knight
Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Purchaser
shall have obtained the consent of Knight Therapeutics Inc. to the transactions contemplated hereby, including payment of the amounts
contemplated by Section 2.3(a)(ii) and (iii) hereof, pursuant to the loan agreement dated April 30, 2015, as amended, between the
Purchaser and Knight Therapeutics Inc. and shall have provided the Vendor with evidence of same satisfactory to the Vendor, acting
reasonably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 10</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SURVIVAL; INDEMNIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Survival
of Representations, Warranties, Covenants and Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">All representations,
warranties, covenants and agreements contained herein, or in any other certificate executed and delivered by any Party to another
Party in connection with this Agreement shall survive the execution and delivery of this Agreement and consummation of the transactions
contemplated hereunder. Notwithstanding the foregoing, (i) all such representations and warranties shall expire and terminate on
the date that is two years after the Closing Date, except that (A) the representations and warranties of (x) the Vendor contained
in Section 3.1 (Authority of the Vendor and Subco and Enforceability), Section 3.2 (Organization and Qualification of the Vendor
and Subco), Section 3.3 (Subco Shares), Section 3.10 (Title to Assets), Section 3.15(a), (b), (c) and (g) (Intellectual Property
Rights), Section 3.29 (Regulatory Matters), and Section 3.32 (Brokers) (collectively, the &ldquo;<B>Fundamental Representations</B>&rdquo;)
and (y) the Purchaser contained in Section 4.1 (Organization and Qualification of the Purchaser), Section 4.2 (Authority of the
Purchaser and Enforceability), Section 4.8 (Brokers), shall, in each case, survive indefinitely, and (B) the representations and
warranties of the Vendor contained in Section 3.18 (Taxes) shall survive until sixty (60) days after the expiration of all applicable
statutes of limitation under applicable Law (including all periods of extension, whether automatic or permissive), (ii) to the
extent not fully performed by the Closing, the covenants and agreements of the Parties contained in this Agreement shall survive
until fully performed in accordance with their respective terms. Notwithstanding anything contained in this Article 10, nothing
herein shall limit claims and remedies for fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification
by Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Subject to
the provisions of this Article 10, from and after Closing, the Vendor agrees to indemnify and hold the Purchaser and its Representatives
and Affiliates (the &ldquo;<B>Purchaser Indemnified Parties</B>&rdquo;) harmless from and against any actual damages, liabilities,
losses and expenses (including, but not limited to, reasonable attorney&rsquo;s fees incurred in defending any claim by a Third
Person, and amounts paid in settlement of any claim or suit), fines, penalties and interest (collectively, the &ldquo;<B>Loss</B>&rdquo;
or &ldquo;<B>Losses</B>&rdquo;) which are sustained or suffered by the Purchaser Indemnified Parties to the extent caused by, arising
from or pursuant to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">any misrepresentation or a breach of any representation
or warranty made by the Vendor, its Affiliates or Subco herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a failure to perform any covenant or agreement made by
the Vendor, its Affiliates or Subco (in the case of Subco, in respect of covenants or agreements to be performed prior to the
Closing Date) herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">a Retained Liability;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">any Taxes in respect of a Vendor Tax Period of (A) the
Vendor or its Affiliates with respect to the Business or (B) Subco;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">any Indebtedness of Subco existing prior to Closing; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">the Disentanglement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in">Section 10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations
on Amount of Indemnification by Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
anything provided in this Agreement to the contrary, the indemnification obligations of the Vendor pursuant to Section 10.2(i)
shall be limited as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">no indemnification shall be payable by the Vendor with
respect to any claim for breach of any representation or warranty made by the Vendor, its Affiliates or Subco or failure by the
Vendor its Affiliates or Subco to perform any covenant or agreement asserted by the Purchaser after the expiration of the survival
period, if any, prescribed for such representation, warranty, covenant or agreement in Section 10.1;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">no indemnification shall be payable by the Vendor hereunder
until the total amount of recoverable claims for indemnification against the Vendor shall exceed in the aggregate an amount equal
to <FONT STYLE="font-family: Times New Roman, Times, Serif">&euro;</FONT>250,000 (the &ldquo;<B>Threshold</B>&rdquo;) whereby
the total amount of each individual recoverable claim shall not be less than <FONT STYLE="font-family: Times New Roman, Times, Serif">&euro;</FONT>10,000,
in which event the Purchaser Indemnified Parties shall then be entitled to recover the aggregate amount of such recoverable claims
back to Euro one, provided, however, that the Threshold shall not apply to Losses arising from a breach of a Fundamental Representation
or a breach of a representation or warranty contained in Section 3.18 (Taxes and Tax Returns);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">the aggregate liability of the Vendor for indemnification
payable under this Agreement shall not exceed an amount equal to <FONT STYLE="font-family: Times New Roman, Times, Serif">&euro;</FONT>5,000,000
(the &ldquo;<B>Indemnity Cap</B>&rdquo;), provided, however, that the Indemnity Cap shall not apply to Losses arising from a breach
of a Fundamental Representation or a breach of a representation or warranty contained in Section 3.18 (Taxes and Tax Returns);
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">for purposes of determining the existence of a misrepresentation
or breach of any representation or warranty made by the Vendor, its Affiliates or Subco and, in each case, the Losses related
thereto, the representations and warranties in this Agreement shall be read without regard to any qualifications therein referencing
the terms &ldquo;material&rdquo;, &ldquo;materially&rdquo;, &ldquo;Material Adverse Effect&rdquo; or other terms of similar import
or effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification
by Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Subject to
the provisions of this Article 10, from and after Closing, the Purchaser agrees to indemnify and hold the Vendor and each of its
shareholders, officers, directors, employees, representatives, agents and Affiliates (the &ldquo;<B>Vendor Indemnified Parties</B>&rdquo;)
harmless from and against, any Losses sustained or suffered by the Vendor Indemnified Parties to the extent caused by, arising
from or pursuant to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">any misrepresentation or a breach of any representation
or warranty made by the Purchaser herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a failure to perform any covenant or agreement made by
the Purchaser herein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">an Assumed Liability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations
on Amount of Indemnification by Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
anything provided in this Agreement to the contrary, no indemnification shall be payable by the Purchaser pursuant to Section 10.4
with respect to any claim for breach of any representation or warranty made by the Purchaser or failure to perform any covenant
or agreement asserted by a Vendor Indemnified Party after the expiration of the survival period, if any, prescribed for such representation,
warranty or covenant in Section 10.1. The aggregate liability of the Purchaser for indemnification payable under this Agreement
shall not exceed an amount equal to the Indemnity Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
and Defense of Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that any Person shall incur or suffer any Losses in respect of which indemnification may be sought by such Person pursuant
to the provisions of this Article 10 (including any application of the Threshold), the Person seeking to be indemnified hereunder
(the &ldquo;<B>Indemnified Party</B>&rdquo;) shall assert a claim for indemnification by written notice to the Person from whom
indemnification is sought (the &ldquo;<B>Indemnifying Party</B>&rdquo;) stating with reasonable specificity the nature and basis
of such claim (including the breach, inaccuracy, nonperformance or provision of this Agreement to which such claim relates), a
reasonable estimate of the amount of such claim and including copies of all relevant pleadings and other demands (a &ldquo;<B>Notice</B>&rdquo;).
In the case of Losses arising by reason of any Third Party claim, the Notice shall be given within fifteen (15) days of the filing
or other written assertion of any such claim against the Indemnified Party, but the failure of the Indemnified Party to give the
Notice within such time period shall not relieve the Indemnifying Party of any liability that the Indemnifying Party may have to
the Indemnified Party unless the Indemnifying Party can demonstrate actual loss or prejudice as a result of such failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Indemnified Party shall provide to the Indemnifying Party on request all information and documentation reasonably necessary to
support and verify any Losses which the Indemnified Party believes give rise to a claim for indemnification hereunder and shall
give the Indemnifying Party reasonable access to all premises, books, records and personnel in the possession or under the control
of the Indemnified Party which would have bearing on such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of any Third Party claims for which indemnification is sought, the Indemnifying Party shall have the right to: (i) conduct
and control any proceedings or negotiations; (ii) take steps to settle or defend any such claim (provided that the Indemnifying
Party shall not settle any such claim without the consent of the Indemnified Party unless the settlement includes a complete release
of the Indemnified Party with respect to the claim and provides that any amount to be paid shall be fully indemnified by the Indemnifying
Party); and (iii) employ counsel to contest any such claim or liability. In the event the Indemnifying Party is permitted to and
elects to conduct and control any proceedings itself, the Indemnified Party shall be entitled to fully participate at its own expense
(to the extent the Indemnifying Party is diligently conducting the defense of such Third Party claim) and by its own counsel in
any proceedings relating to any Third Party claim, provided, however, that the Indemnifying Party shall pay as incurred the reasonable
fees and expenses of such counsel of the Indemnified Party incurred in connection with any Third Party claim if (i) a Third Party
claim seeks an injunction or other equitable remedies in respect of the Indemnified Party or (ii) the Indemnified Party shall have
been advised by counsel that the representation of an Indemnifying Party and the Indemnified Party by the same counsel would be
inappropriate due to actual or potential differing interests between them, including a situation in which (A) one or more legal
defenses may be available to any Indemnified Party that are inconsistent with, different from or in addition to those available
to the Indemnifying Party and (B) material Liabilities would result which, in the good faith determination of the Indemnified Party,
if taken with other Losses relating to then existing indemnifiable claims would not be fully indemnified hereunder. The Indemnifying
Party shall, within thirty (30) days after delivery of the Notice to Indemnifying Party (the &ldquo;<B>Dispute Period</B>&rdquo;),
notify the Indemnified Party of its intention as to the conduct and control of the defense of such claim, provided that the Indemnified
Party and its counsel shall cooperate with the Indemnifying Party and its counsel. If the Indemnifying Party shall decline to assume
the defense of any such claim, or the Indemnifying Party shall fail to notify the Indemnified Party within the Dispute Period of
the Indemnifying Party&rsquo;s election to defend such claim, the Indemnified Party shall defend against such claim (provided that
the Indemnified Party shall not settle such claim without the consent of the Indemnifying Party (which consent shall not be unreasonably
withheld, conditioned or delayed)). The expenses of all proceedings, contests or lawsuits in respect of such claims shall be borne
by the Indemnifying Party but only if the Indemnifying Party is responsible pursuant hereto to indemnify the Indemnified Party
in respect of the Third Party claim and, if applicable, only to the extent required by Section 10.3 and Section 10.5, as the case
may be, and subject to the limitations of this Section 10.6 and Section 10.7. Regardless of whether the Indemnified Party or the
Indemnifying Party shall assume the defense of the claim, the Indemnified Party and the Indemnifying Party agree to cooperate fully
with one another in connection therewith and to keep each other reasonably informed of the status of the claim and any related
proceeding and the Indemnified Party shall take no action or make any admissions or statements not required by applicable Law which
would adversely affect the defense of any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Indemnifying Party notifies the Indemnified Party that it does not dispute its liability to the Indemnified Party with respect
to any claim under this Article 10 or fails to notify the Indemnified Party within the Dispute Period, the Losses arising from
any such claim shall, subject to the provisions of Section 10.3, Section 10.5 and Section 10.7, be conclusively deemed a liability
of the Indemnifying Party and the Indemnifying Party shall, subject to the provisions of Section 10.3, Section 10.5 and Section
10.7, pay the amount of such Loss to the Indemnified Party on demand following the final determination thereof. If the Indemnifying
Party has timely disputed its liability with respect to such claim, the Indemnifying Party and the Indemnified Party shall proceed
in good faith to negotiate a resolution of such dispute and, if not resolved through negotiations, any Party may seek a resolution
of such dispute by litigation in a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
Limitations and Qualifications on Indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein to the contrary, the Indemnified Party shall have no right to indemnification with respect to any punitive, exemplary
or indirect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Indemnifying Party shall make any indemnification payments determined to be payable to the Indemnified Party hereunder without
regard to any expectation that the Indemnified Party will recover insurance proceeds or other amounts as a result of the matter
giving rise to the claim for which indemnification payments are to be made. If the Indemnified Party receives any insurance proceeds
or other amounts as a result of the matter giving rise to any indemnification claim of the Indemnified Party prior to the date
upon which the Indemnifying Party is given notice of the claim, the Indemnifying Party&rsquo;s indemnification obligation with
respect to such claim shall be reduced by the amount of any such insurance proceeds actually received by the Indemnified Party,
net of the reasonable costs of recovery incurred by the Indemnified Party. If the Indemnified Party receives any insurance proceeds
or other amounts as a result of the matter giving rise to any indemnification claim of the Indemnified Party against the Indemnifying
Party after the Indemnifying Party has paid such indemnification claim to the Indemnified Party, then the Indemnified Party shall
promptly turn over any such insurance proceeds or other amounts received to the Indemnifying Party to the extent of the payments
made by the Indemnifying Party to the Indemnified Party on the claim, net of the reasonable costs of recovery incurred by the Indemnified
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the amount of the Losses for which an Indemnified Party is entitled to indemnification, the amount of any Taxes required
to be paid by the Indemnified Party with respect to the receipt of any indemnification payment and/or the amount of any Taxes that
otherwise would have been required to be paid by the Indemnified Party save for the utilisation of any Tax deductions, Tax losses,
Tax credits, Tax overpayments or similar attributes or items to reduce the Tax liability that otherwise would have been incurred
by the Indemnified Party with respect to the receipt of the indemnification payment will be taken into account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
indemnification obligations of the Indemnifying Party pursuant to this Agreement with respect to a specific claim for which indemnification
is provided under this Agreement shall extend beyond the time period for indemnification set forth herein with respect to such
specific claim until it has been fully discharged or resolved or settled; <U>provided, however</U>, a Notice shall have been given
to the Indemnifying Party on or prior to the end of such time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Indemnified Party shall take reasonable steps to mitigate in accordance with applicable Law any Losses for which such Indemnified
Party seeks indemnification under this Agreement. If the Indemnified Party shall fail to take such steps, then the Indemnifying
Party shall not be required to indemnify any Indemnified Party for the Losses that could have been avoided if the Indemnified Party
had taken such steps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 11</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TERMINATION OF AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">At any time prior to the Closing, this Agreement may
be terminated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">by the mutual written agreement of the Purchaser and the
Vendor;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">by the Purchaser or the Vendor at any time prior to the
Closing in the event that any Order or Law becomes effective restraining, enjoining or otherwise prohibiting or making illegal
the consummation of the transactions contemplated hereunder, and such Order or Law has become final and/or non-appealable; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">by the Purchaser or the Vendor if the Closing has not occurred
before the close of business on 120 days from the date of signing this Agreement (the &ldquo;<B>Outside Date</B>&rdquo;) unless,
in the case of the Purchaser, such Purchaser&rsquo;s breach of this Agreement results in the failure of the Closing to occur by
such date or, in the case of the Vendor, any such Vendor&rsquo;s breach of this Agreement results in the failure to close by such
date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">In the event
of termination by any Party pursuant to Section 11.1, written notice setting forth the reasons therefor shall be given by the terminating
Party to the other Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">If this Agreement
shall be validly terminated as above provided, this Agreement shall forthwith become null and void and all obligations of the
Parties hereunder shall terminate without liability of any Party to the other (or any of their respective Representatives or Affiliates),
other than Section 6.1, Section 11.3, Section 13.1, Section 13.2, and Section 13.5 to Section 13.13; <U>provided</U>, <U>however</U>,
that nothing in this Article 11 shall prevent any Party from seeking or obtaining damages or appropriate equitable relief for
the willful breach of this Agreement by any other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>[REDACTED &ndash; COMMERCIALLY SENSITIVE];
DISPUTE RESOLUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Redacted
 &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dispute
Resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">All disputes
arising out of or relating to this Agreement and the Other Transaction Documents, including, without limitation, the interpretation,
breach, termination or invalidity thereof, shall be determined by and in accordance with the ICC Arbitration Rules, and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
place of the arbitration shall be held in Toronto, Ontario in the English language;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall be three arbitrators; each Party shall be entitled to choose one of the arbitrators upon notice to the other Party, the third
arbitrator shall be chosen by the first two arbitrators and shall be an experienced lawyer with expertise in the commercialization
of medical devices or technology, and if the first two arbitrators cannot agree upon the third arbitrator, then the third arbitrator
shall be selected in accordance with the ICC Arbitration Rules;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
arbitrator may grant any remedy that a judge of the Province of Ontario or federal court may grant, including without limitation
equitable and injunctive relief, but may not award punitive damages; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Parties and participants in the arbitration shall keep confidential the fact of arbitration proceedings, all awards in their arbitration,
all materials in the proceedings created for the purpose of the arbitration, and all other documents produced by another Party
in the proceedings not otherwise in the public domain, save, and to the extent that, disclosure is required of a Party (i) by legal
duty, (ii) to protect or pursue a legal right, or (iii) to enforce or challenge an award in legal proceedings before a court or
other judicial authority, in which event the Parties shall use their reasonable commercial efforts to obtain a confidentiality
or sealing order with respect to any court proceeding related to the arbitration or award. In addition, as a condition to participating
in such arbitration, all participants, including any witnesses, must agree to abide by the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE 13</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except as otherwise
provided in this Agreement (including Section 7.3(a)), each Party shall pay its own costs and expenses, including the fees and
expenses of its accountants, financial advisors (including those described in Section 3.32 and Section 4.8) and legal counsel,
incurred in connection with the negotiation, execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Any
notice or other communication required or permitted to be given to any Party hereunder shall be in writing and shall be given
to such Party at such Party&rsquo;s address set forth below, or such other address as such Party may hereafter specify by
notice in writing to the other Party. Any such notice or other communication shall be addressed as aforesaid and given by:
(i) hand delivery; (ii) international overnight courier; or (iii) e-mail transmission. Any notice or other communication will
be deemed to have been duly given: (A) on the date of service if served personally; (B) on the Business Day after delivery to
an international overnight courier service, provided receipt of delivery has been confirmed; or (C) on the date of
transmission if sent via e-mail transmission, provided confirmation of receipt is obtained promptly after completion of
transmission and provided that transmission via e-mail is followed promptly by delivery via one of the methods in Section
14.2(i) or (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">To the Vendor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Koninklijke Philips N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Amstelplein 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">1096 BC Amsterdam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="width: 85%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Head of M&amp;A</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to: Head of Legal M&amp;A and Alliances</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Blake, Cassels &amp; Graydon LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">199 Bay Street, Suite 4000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, Ontario M5L 1A9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="width: 85%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ken Pearce</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>kenneth.pearce@blakes.com</U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">To the Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2400 Skymark Avenue, Unit 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Mississauga, ON L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="width: 85%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arun Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amenawat@profoundmedical.com</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Torys LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Suite 3000, P.O. Box 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">79 Wellington Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">TD Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, ON M5K 1N2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="width: 85%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cheryl Reicin and Leah Frank</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>creicin@torys.com
    </U>and <U>lfrank@torys.com</U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">No amendment to this Agreement may be made unless agreed
to by the Parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Schedules
and Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">The Schedules and Exhibits
shall be deemed to be attached hereto and made a part hereof. All references herein to this Agreement shall include the
Schedules and the Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement
of Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Parties
agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy would occur in the
event that any of the provisions of this Agreement (including the failure by any Party to take such actions as are required of
it hereunder to consummate the transactions contemplated by this Agreement) was not performed in accordance with its specified
terms or was otherwise breached. It is accordingly agreed that the Vendor and the Purchaser, as applicable, shall be entitled to
an injunction or other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions
hereof in any court of competent jurisdiction, this being in addition to any other remedy to which the Vendor and the Purchaser,
as applicable, are entitled at Law or in equity, and any requirement for the securing or posting of any bond in connection with
the obtaining of any such injunctive or other equitable relief is hereby waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Wherever possible,
each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable Law. If any
portion of this Agreement is declared invalid for any reason in any jurisdiction, such declaration shall have no effect upon the
remaining portions of this Agreement which shall continue in full force and effect as if this Agreement had been executed with
the invalid portions thereof deleted; provided, however, if such severability will negate in any material respect the monetary
terms of this Agreement, then the Parties shall negotiate in good faith to amend the invalid terms in a manner so that such terms
shall not be invalid and will not modify in any material respect the monetary terms of this Agreement unless otherwise agreed to
by the Parties. Furthermore, the entirety of this Agreement shall continue in full force and effect in all other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire
Understanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">This Agreement,
including the Schedules and Exhibits hereto, sets forth the entire agreement and understanding between the Parties with respect
to the subject matter hereof and supersedes any and all prior discussions, negotiations, letters of intent or agreements in principle
between them, other than the Confidentiality Agreement which shall survive the execution and delivery of this Agreement in accordance
with its terms; provided, that the Confidentiality Agreement shall terminate effective as of Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Binding
Effect; No Third Party Beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except for
the provisions of Article 10 relating to the Vendor Indemnified Parties and the Purchaser Indemnified Parties, this Agreement shall
be binding upon and shall inure to the exclusive benefit of the Parties and their respective heirs, executors, administrators,
legal representatives, successors and permitted assigns and nothing herein, express or implied, is intended to, nor shall it, confer
on any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
The Parties agree that, for the purpose of giving enforceable rights under this Agreement (i) to the Vendor Indemnified Parties
who are not party to this Agreement, the Vendor is contracting as the agent of such Persons and will hold the rights of such Persons
in trust for them, and (ii) to the Purchaser Indemnified Parties who are not party to this Agreement, the Purchaser is contracting
as the agent of such Persons and will hold the rights of such Persons in trust for them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">This Agreement
is and shall be deemed to be a contract entered into and made pursuant to the laws of the Province of Ontario and shall in all
respects be governed, construed, applied and enforced in accordance with said laws, without reference to applicable conflict of
laws rules or principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver
of Trial by Jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">EACH PARTY
HERETO HEREBY EXPRESSLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ALL RIGHTS TO TRIAL BY JURY WITH RESPECT TO ANY CLAIM,
SUIT, LITIGATION, ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED UPON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING
TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. THE PARTIES AGREE THAT ANY OF THEM MAY FILE A COPY OF THIS PROVISION
WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED FOR AGREEMENT BETWEEN THE PARTIES IRREVOCABLY TO WAIVE
TRIAL BY JURY, AND THAT SUCH PROCEEDING WHATSOEVER BETWEEN THEM SHALL INSTEAD BE TRIED BY A COURT OF COMPETENT JURISDICTION BY
A JUDGE SITTING WITHOUT A JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No Party hereto
shall sell, pledge, assign or otherwise transfer its rights or obligations under this Agreement without the prior written consent
of the other Party and any attempt to do so shall be void; <U>provided</U>, <U>however</U>, that: (i) no such consent will be required
for an assignment of all or any part of this Agreement by the Purchaser to an Affiliate provided the Purchaser continues to be
obligated hereunder; and (ii) without the consent of the other Party hereto, the Purchaser may pledge, grant a security interest
in or assign as collateral all or any portion of its interest in, or rights under, this Agreement to any one or more financial
institutions or Persons providing financing to the Purchaser and that upon foreclosure or sale or deed in lieu of foreclosure by
or to any such financial institutions or Persons, the rights of the Purchaser hereunder may be assigned to any such financial institutions
or any purchaser upon such foreclosure or sale or deed in lieu of foreclosure; <U>provided</U>, <U>further</U>, that any such permitted
assignee agrees in writing to be bound by all of the terms and conditions contained herein relating to such rights or obligations
assigned, but no such assignment shall relieve the Purchaser of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.75in">Section 13.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts;
Delivery by Electronic Transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">This Agreement
may be executed in counterparts, all of which when so executed shall be deemed to be an original and all of which taken together
shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile
transmission or other electronic transmission shall be as effective as delivery of a manually executed counterpart of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Public
Announcements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">No public announcements
or other publicity regarding the transactions referred to herein shall be made by the Purchaser, the Vendor or Subco at any time
prior to the Closing without the prior written consent of the other Party (which consent shall not be unreasonably withheld, conditioned
or delayed) as to form, timing and manner of distribution or publication, except (i) to the extent otherwise required by Law, and
(ii) the Parties may disclose to their current and prospective lender and investors and their representatives and agents. The Parties
shall also obtain the other Parties&rsquo; prior written consent (which consent shall not be unreasonably withheld, conditioned
or delayed) of any press release to be issued immediately following the Closing announcing the consummation of the transactions
contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">Section 13.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictive
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Parties
intend that the conditions set forth in subsection 56.4(7) of the Tax Act have been met such that subsection 56.4(5) of the Tax
Act applies to any &ldquo;restrictive covenants&rdquo; (as defined in subsection 56.4(1) of the Tax Act) granted by the Vendor
pursuant to this Agreement (the &ldquo;<B>Restrictive Covenants</B>&rdquo;). For greater certainty, the Parties hereto agree and
acknowledge that: (i) no proceeds shall be received or receivable by the Vendor for granting the Restrictive Covenants; and (ii)
the Restrictive Covenants are integral to this Agreement and have been granted to maintain or preserve the fair market value of
the Subco Shares and the Class A Patents and Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 89; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --> - </TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify"><B>IN
WITNESS WHEREOF</B>, each of the Parties has caused this Agreement to be executed by its duly authorized officer as of the
date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">PROFOUND
    MEDICAL CORP.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Arun
Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Arun S. Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">KONINKLIJKE
    PHILIPS N.V.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">/s/
<FONT STYLE="font-family: Times New Roman, Times, Serif">Iwald Mons</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Iwald Mons</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Title: Authorized Representative</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-left: 0; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">/s/
<FONT STYLE="font-family: Times New Roman, Times, Serif">Leonie Starmans</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    Leonie Starmans</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Title: Authorized Representative</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>RESALE PURCHASING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">This Resale Purchasing Agreement
is effective as of&nbsp;______, 2017 (&quot;<B>Effective Date</B>&quot;) by and between <B>Philips Medical Systems Nederland B.V.</B>
having a place of business at Veenpluis 4-6, 5684 PC Best, the Netherlands (&ldquo;<B>Philips</B>&rdquo;); and <B>Profound Medical
Corp.</B>, having a place of business at 3080 Yonge Street, Suite 4040, Toronto, ON, M4N 3N1, Canada (&ldquo;<B>Supplier</B>&rdquo;)
(individually, a &ldquo;<B>Party</B>&rdquo; and jointly, the &ldquo;<B>Parties</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PREAMBLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, Philips is engaged in the development, design,
engineering, manufacturing, marketing, sale and delivery of medical equipment and systems;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, Supplier is engaged in the development,
design, engineering, manufacturing, sale, delivery and support of Products (as defined herein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, Buyer (as defined herein) desires to purchase
from Supplier a varying volume of Products for the purpose of reselling such Products to Customers and Supplier desires to sell
such Products to Buyer for its resale activities under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHERAS, on the date hereof, the Parties have entered
into a Supply Agreement, pursuant to which, for the term specified therein, Philips will manufacture and supply, as a contract
manufacturer to Supplier, the Products (the &ldquo;<B>Supply Agreement</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, the Parties hereto
wish to set forth in this Agreement the terms and conditions under which Buyer will purchase from Supplier and Supplier will
sell and deliver to Buyer the Products and Consumables; provided, for greater certainty, subsequent to the initial sale of
Consumables by Buyer to a Customer, and outside the scope of this Agreement, Supplier may sell and deliver directly
to Customers additional Consumables beyond those delivered in connection with the initial sale of the Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">NOW, THEREFORE, in consideration of the mutual promises,
and of the representations, warranties, covenants and agreements contained herein the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 1:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>DEFINITIONS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">For purposes of this Agreement, the following terms
have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.1</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Affiliates&rdquo;</B> means, with respect to
any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is
under common control with the specified Person. As used in this definition, &ldquo;control&rdquo;, &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo; means possession, directly or indirectly, of power to direct or cause the direction
of management or policies of such Person (whether through ownership of securities or other partnership or ownership interests,
as trustee, personal representative or executive or by contract, credit agreement or otherwise), provided that in any event, any
Person which owns directly, indirectly or beneficially fifty percent (50%) or more of the securities having voting power for the
election of directors or other governing body of a corporation or fifty percent (50%) or more of the partnership interests or
other ownership interests of any other Person will be deemed to control such Person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.2</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Agreement&rdquo;</B> means this Agreement,as the same may be amended or
                                                                                      supplemented and/or restated from time to time in accordance with the terms hereof, including all Attachments, exhibits and
                                                                                      other documents referred to herein or therein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.3</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Buyer&rdquo;</B> means Philips or any of its
Affiliates that has issued a Purchase Order under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.4</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Buyer Indemnitees&rdquo;</B> has the meaning
given to such term in clause 9.1.4.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.5</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Change of Control&rdquo;</B> means with respect
to Supplier (i) the sale of all or substantially all of the assets of Supplier, or (ii) a merger, consolidation or other reorganization
of Supplier which results in more than fifty percent (50%) of the voting stock of the resulting or surviving entity being owned
or held by persons other than those owning or holding the voting stock in Supplier on the date of this Agreement, or (iii) the
sale by one or more stockholders of Supplier, in a single transaction or series of related transactions, of more than fifty percent
(50%) of the voting stock of Supplier to one or more third parties who are at the time of such sale unaffiliated with any shareholders
of Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.6</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Confidential Information&rdquo;</B> means any
information, provided in whatever form (including in written, electronic or oral form) or medium, which relates to either Party&rsquo;s
or its Affiliates&rsquo; business, products (hardware and software), technology, business plans, product plans, customers, customer
information, specifications, designs, costs, prices, business opportunities, Know How, trade secrets, inventions, techniques,
processes, algorithms, software programs, schematics and any other business or technical information disclosed by the disclosing
Party to the receiving Party in connection with this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.7</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Consumables&rdquo;</B> means the consumables
that function with the Product as identified in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.8</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Customer</B>&rdquo; means any customer of Buyer
that purchases and/or uses Philips Equipment together with any of the Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.9</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Factory Test Report</B>&rdquo; means the report
attached as <U>Attachment 5</U> hereto during the term of Supply Agreement and thereafter a similar document with the same content
and modified signatures and introduction language.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.10</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Force Majeure Event&rdquo;</B> means any prevention,
delay, stoppage or interruption in the performance of any obligations or the occcurance of any event due to an act of God, the
occurrence of enemy or hostile actions, sabotage, war, blockades, terrorist attacks, insurrections, riots, epidemics, nuclear
and radiation activity or fall-out, civil disturbances, explosions, fire or other casualty, failure of energy sources, any industry-wide
material shortage and changes in governmental or regulatory action or legislation or regulation, third party labour disputes or
strikes or any other similar causes beyond the control of the Party seeking relief from its obligations as a result of such event,
but not including, for clarity, any financial inability of a Party or any of its Affiliates or the failure of any subcontractor
to perform obligations owed to a Party (unless such failure by a subcontractor in turn was caused by a Force Majeure Event).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.11</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property Rights</B>&rdquo; (or &ldquo;<B>IPR</B>&rdquo;)
means, in any and all jurisdictions, all: (a) patents and applications therefor, including all continuations, continuations-in-part
and provisionals and patents issuing thereon, and all reissues, re-examinations, substitutions, renewals and extensions thereof
(collectively, &ldquo;<B>Patents</B>&rdquo;); (b) trademarks, service marks, trade names, trade dress, logos, corporate names,
Internet domain names or uniform resource locators used in connection with any global computer or electronic network, together
with all translations, adaptations, derivations and combinations thereof, and other source or business identifiers, together with
the goodwill associated with any of the foregoing, and all applications, registrations, renewals and extensions thereof; (c) industrial
designs, designs and design rights; (d) copyrights, works of authorship and moral rights, and all registrations, applications,
renewals, extensions and reversions thereof; (e) trade secrets, discoveries, concepts, ideas, research and development, Know How,
formulae, inventions, compositions, manufacturing and production processes and techniques, technical data, quality data, procedures,
designs, drawings, specifications, databases, and other proprietary or confidential information, including customer lists, supplier
lists, pricing and cost information, and business and marketing plans and proposals, which would constitute a &ldquo;trade secret&rdquo;
under applicable law, in each case excluding any rights in respect of any of the foregoing that comprise or are protected by Patents
(&ldquo;<B>Trade Secrets</B>&rdquo;); (f) inventions, processes and designs; and (g) software, and all source code, object code,
data and documentation relating thereto.</TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.12</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Know How</B>&rdquo; means any and all concepts,
ideas, information, data and documents of whatever nature, including, without limitation, drawings, methods, techniques, designs,
specifications, photographs, samples, models, processes, procedures, reports, particulars of a technical nature (including, without
limitation, any know how related to the manufacturing or design of Products and technical and commercial know how).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.13</B></TD><TD STYLE="text-align: justify">&ldquo;<B>OEM Quality Agreement&rdquo;</B> means the OEM
Quality Agreement signed as a supplementary agreement to this Agreement by Buyer and Supplier on the Effective Date of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.14</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Open Source Software&rdquo;</B> means any software
that is licensed under terms that require as a condition of use, modification and/or distribution of a work: (i) the making available
of source code or other materials preferred for modification; (ii) the granting of permission for creating derivative works; (iii)
the reproduction of certain notices or license terms in derivative works or accompanying documentation; or (iv) the granting of
a royalty-free license to any party under Intellectual Property Rights regarding the work and/or any work that contains, is combined
with, requires or otherwise is based on the work.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.15</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Philips Equipment</B>&rdquo; means the various
versions of the Philips Achieva 3.0T and 1.5T and Ingenia 3.0T and 1.5T MRI systems with which Products will be used by Philips
and Customers.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.16</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Person</B>&rdquo; means any individual, partnership,
limited partnership, joint venture, syndicate, sole proprietorship, Supplier or corporation with or without share capital, unincorporated
association, trust, trustee, executor, administrator or other legal personal representative or governmental authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.17</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Price&rdquo;</B> means the price for the Product
as specified in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.18</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Product&rdquo;</B> means the products delivered
by Supplier to Buyer as further identified in the respective <U>Attachment 1</U>, including if so specificied in <U>Attachment
1</U>: service parts as well as any materials, sub-assemblies, accessories or software incorporated in the Product and any other
items supplied by Supplier to Buyer (in respect of the Product), including Consumables or any incidental services provided by
Supplier, in their form existing as of the Effective Date and as the same may be modified, enhanced or improved by or on behalf of Supplier and its Affiliates, unless otherwise agreed
by the Parties.</TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.19</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Production Plan</B>&rdquo; means the production
plan as defined in the Supply Agreement, or after the termination of the Supply Agreement, a production plan to be mutually agreed
by the Parties, acting reasonably and in good faith, in writing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.20</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Purchase Agreement</B>&rdquo; means the Asset
and Share Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) entered into on June 30, 2017 by Supplier and Koninklijke
Philips NV (&ldquo;<B>Philips NV</B>&rdquo;) N.V. (an Affiliate of Buyer).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.21</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Purchase Order&rdquo; </B>means any written or
electronic purchase order issued by Buyer to Supplier for a Product, each of which will be governed by and be subject to the terms
of this Agreement, unless explicitly agreed otherwise in writing in the respective Purchase Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.22</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Specifications&rdquo;</B> means the specifications,
descriptions, design criteria, drawings, samples, prototypes and other requirements relating to the Products provided in writing
by Supplier to Buyer from time to time to define Productst.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.23</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Supplier&rdquo;</B> means Profound Medical Corp.
and its Affiliates that provide Products hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.24</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Territory&rdquo;</B> means for each Product the
area or country as listed in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.25</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Third Party</B>&rdquo; means any Person other
than the Parties and their Affiliates.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE: 2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCOPE
AND INTENT</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.1</B></TD><TD STYLE="text-align: justify">Supplier will manufacture and on a non-exclusive basis
sell and deliver to Buyer for resale in combination with or separately from Philips Equipment to Customer the quantities of Products
as may be ordered, subject to any restrictions on forecasts and orders contained herein, by Buyer under this Agreement and the
OEM Quality Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.2</B></TD><TD STYLE="text-align: justify">Buyer shall use commercially reasonable efforts to sell
Products to Customers in the Territory for use in combination with Philips Equipment and under the brand name(s) as indicated
in <U>Attachment 1</U>. Buyer shall not distribute, sell or export any Products outside of the Territory. Buyer shall not solicit
orders for Products outside the Territory.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.3</B></TD><TD STYLE="text-align: justify">Nothing in this Agreement, shall prevent Supplier from
selling Products to other customers, or prevent Buyer from selling Philips Equipment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.4</B></TD><TD STYLE="text-align: justify">Supplier shall be responsible for the design, engineering,
manufacture, quality control and sourcing of Products, as set forth in the OEM Quality Agreemet, and is entitled to outsource
or subcontract these activities without the consent of the Buyer being required. Such outsourcing or subcontracting shall not
release Supplier from any of its duties and obligations in or in relation to this Agreement or under applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.5</B></TD><TD STYLE="text-align: justify">Supplier shall deliver the Products and any other deliverables
to the Buyer at the agreed point of delivery as specified in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.6</B></TD><TD STYLE="text-align: justify">Installation, application support, training, maintenance
and service to the Customer (for the avoidance of doubt, including the remedies for non-compliance with Product warranties as
set forth in clause 9.3) will be provided by Supplier as set forth in <U>Attachment 2</U>, it being understood that Supplier may
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subcontract these activities to Buyer and/or its Affiliates,
subject to the parties written agreement, on the basis of the scope and service fees as set out in <U>Attachment 2</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.7</B></TD><TD STYLE="text-align: justify">The Parties may agree in writing on additional terms and
conditions defined for certain parts of the Territory in local agreements, if any (hereinafter &ldquo;<B>Local Agreements</B>&rdquo;).
This Agreement sets out the principles and framework for the underlying Local Agreements. In case of conflict between the Local
Agreements and this Agreement, this Agreement will prevail, unless explicitly agreed otherwise in writing in a Local Agreement
(using the words &ldquo;notwithstanding the terms of the Resale Purchase Agreement, the Parties expressly agree&rdquo;), it being
understood that quality, sustainability and liability in respect of the Product cannot be deviated locally from the terms of this
Agreement. As of the Effective Date, there are no local agreements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.8</B></TD><TD STYLE="text-align: justify">The Parties will meet from time to time (but not less than
one time per year) as mutually agreed by the parties to discuss efficiency increases, product and technology roadmaps, price/performance
ratio of Products, cost and quality issues, Supplier&rsquo;s and Buyers performance hereunder, market conditions, and all other
issues which the Parties may deem appropriate, including, conducting meetings of the Joint Steering Committee (as defined in the
Purchase Agreement) in accordance with the schedule for meetings of the Joint Steering Committee as contemplated by the Purchase
Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.9</B></TD><TD STYLE="text-align: justify">Buyer will use commercially reasonable efforts to engage
in the marketing and promotion of the Products in the Territory, through such means as personal contact with prospective customers,
distribution of Product literature and the like in accordance with <U>Attachment 4</U>. Supplier will use commercially reasonable
efforts cooperate with Buyer in the promotion of the Products in accordance with <U>Attachment 4</U>. Each Party agrees to adhere
to the COCIR Code of Conduct in its efforts to promote the Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.10</B></TD><TD STYLE="text-align: justify">Except for connecting the Product to Philips Equipment,
Buyer shall not modify, reverse engineer, disassemble, decompile, decode, copy, duplicate, change or alter the Product or any
parts or components thereof unless with Supplier&rsquo;s prior written consent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 124.8pt; text-indent: -50.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 3:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TERM</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.1</B></TD><TD STYLE="text-align: justify">This Agreement shall come into effect on the Effective
Date, and unless terminated earlier, shall continue in full force until the <B>[Redacted &ndash; Commercially Sensitive]</B> of
the Effective Date (the &ldquo;<B>Initial Term</B>&rdquo;), <B>[Redacted &ndash; Commercially Sensitive]</B>. The Initial Term
shall thereafter automatically renew for additional one (1) year periods (the Initial Term and any renewal thereof being collectively
referred to herein as the &ldquo;<B>Term</B>&rdquo;), unless either Party terminates this Agreement by no less than ninety (90)
days written notice prior to the end of the then current Term. If the end of the Term does not coincide with the end of the term
of any Purchase Order (other than due to termination upon notice), then this Agreement shall automatically renew with respect
only to the open Purchase Order for additional one (1) week periods until such time as the Purchase Order has been fully completed
in accordance with the terms of such Purchase Order and this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 4:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>COMPONENTS,
CHANGES AND DISCONTINUATION OF PRODUCT</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.1</B></TD><TD STYLE="text-align: justify"><B><U>Changes</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1.1</TD><TD STYLE="text-align: justify">Any changes to the Product including those changes and
modifications referred to in the OEM Quality Agreement shall be discussed in the Joint Steering Committee (as such is established
under the Share Purchase Agreement) prior to the change being implemented.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.2</B></TD><TD STYLE="text-align: justify"><B><U>Discontinuation of Production.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">4.2.1</TD><TD STYLE="text-align: justify">Subject to the forecasting and delivery requirements and
obligations outlined in this Agreement, Supplier agrees to provide the Product in accordance with the terms of this Agreement
of (i) in respect of the Product during the Term of this Agreement, unless the Agreement is partially terminated pursuant to clause
14.1.1 with respect to that Product, to the extent such partial termination is provided for hereunder; and (ii) during the Term,
in respect of Consumables, for a period of two (2) years after last shipment of the relevant Product to Buyer under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 124.8pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 5:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PRICE,
PAYMENT, SET OFF, CURRENCY</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.1</B></TD><TD STYLE="text-align: justify"><B><U>Price.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.1</TD><TD STYLE="text-align: justify">Parties have agreed upon the Price and payment terms which
apply and against which Buyer may order Products (and if so specified in <U>Attachment 1</U> for the relevant Product: Consumables
and/or services) from Supplier as well as the period of validity of such Price, all as specified in <U>Attachment 1</U> (as may
be adjusted from time to time if mutually agreed in writing by the Parties).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.2</TD><TD STYLE="text-align: justify">[<B>Redacted &ndash; Pricing Information - Commercially
Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 124.8pt; text-indent: -50.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.3</TD><TD STYLE="text-align: justify">Subject to applicable law, Supplier and Philips agree to
discuss purchase prices and other terms whenever market conditions so require, including possible price reductions and anything
else considered materially relevant for the performance of this Agreement by either Party. Such discussions may include the average
price for the Product received by Buyer in each jurisdiction in the Territory (in the previous year), at most once per year. The
prevailing prices and other terms agreed upon in <U>Attachment 1</U> will remain in effect until the Parties have reached a mutual
written agreement on new prices and other terms.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.4</TD><TD STYLE="text-align: justify">In respect of any sale of a Product to a Customer, if Buyer
wishes to offer a discount on the price of such Product to such Customer, Philips may discuss such discount with Supplier. If
Supplier does not agree, in its sole discretion, to provide Buyer a further discount in respect of such sale, Buyer will then
decide, in its sole discretion, as to whether it wishes to provide the originally proposed discount to such Customer (without
receiving a corresponding discount from Supplier) and Supplier will have no further obligations to discuss further discounts in
respect of such sale.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.5</TD><TD STYLE="text-align: justify">Prices are exclusive of any federal, state or local sales,
use or excise taxes and any, value added tax (VAT). Supplier will list separately on its invoice any tax lawfully applicable to
the relevant Purchase Order and payable by Buyer, if any, w<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ith
respect to which Buyer does not furnish evidence of exemption. Supplier is responsible for remitting any applicable VAT, sales
tax, consumption tax, or any other similar tax, in each instance, that were charged to Buyer under an applicable Purchase Order,
to the appropriate tax authorities in accordance with applicable laws and required timelines. Supplier will issue an invoice containing
wording that will allow Buyer to take advantage of any applicable &ldquo;input&rdquo; tax deduction.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.2</B></TD><TD STYLE="text-align: justify"><B><U>Payment.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.2.1</TD><TD STYLE="text-align: justify">Supplier invoices, compliant with the requirements of this
Agreement, will be payable within <B>[Redacted &ndash; Payment Terms]</B>. Buyer shall make all payments in Euros by check, wire
transfer or automated clearing house to the bank account designated by Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.2.2</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Payment Terms]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.3</B></TD><TD STYLE="text-align: justify"><B><U>Offset.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.3.1</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Payment Terms]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>5.4</B></TD><TD STYLE="text-align: justify"><B><U>Currency.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.4.1</TD><TD STYLE="text-align: justify">All invoicing and payment obligations under this Agreement
will be satisfied in the same currency as the currency of the Price as specified in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 124.8pt; text-indent: -50.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>PLANNING
AND ORDERING</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.1</B></TD><TD STYLE="text-align: justify"><B><U>Planning.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.1.1</TD><TD STYLE="text-align: justify">Buyer shall provide Supplier in good faith on a monthly
basis, on the later of (i) seven (7) days prior to the beginning of each calendar month a rolling twelve (12) month forecast for
the Products (including the major configuration of each Product such as field strength and Consummables) (&ldquo;<B>Forecast</B>&rdquo;)
it expects to purchase during such 12-month period. Such Forecast shall be provided in writing or in any other mutually agreed
manner of communication (e.g., EDI or email). Notwithstanding any other obligation set forth herein, Buyer shall give Supplier
at least six (6) months prior written notice if, during the Term, it intends to discontinue the purchase of any Products hereunder,
or if it intends to substantially decrease, versus the Forecast, its purchase demand hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.1.2</TD><TD STYLE="text-align: justify">Notwithstanding Buyer&rsquo;s obligations pursuant to clause
6, the first two (2) months of each Forecast shall constitute a binding commitment of Buyer to purchase the quantities of Products
set forth in the relevant Forecast for such two (2) month period. The Forecast for the period beyond this two (2) month period
shall be non-binding except to the extent otherwise provided in this clause 6. Only Purchase Orders as accepted by Supplier constitute
an obligation for Supplier to actually produce the so ordered Products and no quantities of Products in the Forecast provided
by Buyer shall constitute an accepted Purchase Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.1.3</TD><TD STYLE="text-align: justify">Buyer shall have the right to increase or decrease, as
the case may be, the 12-month Forecast only within the limitations set forth in the Production Plan per quarter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.2</B></TD><TD STYLE="text-align: justify"><B><U>Ordering.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.1</TD><TD STYLE="text-align: justify">Only Purchase Orders placed by Buyer (except for blanket
purchase orders placed for estimated annual purposes, which are non binding) and accepted by Supplier will create a binding obligation
on Buyer to take delivery and make payment for Products delivered under such Purchase Order. Supplier will accept a Purchase Order
to Buyer by returning a signed confirmation of the Purchase Order to Buyer. Order acknowledgement may be made by Supplier if so
agreed with Buyer using customary means as email or other electronic transmission.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.2</TD><TD STYLE="text-align: justify">Any Purchase Order issued by Buyer under this Agreement
to Supplier shall constitute a contractual relationship between that respective Buyer and Supplier. Supplier shall not hold any
Buyer liable for any damages or losses arising from any act, default, omission or negligence of another Buyer, including but not
limited to any default payment; provided that Philips shall be responsible for the obligations of all Buyers, solely to the extent
that the applicable Purchase Orders of such Buyers are delivered by Philips to Supplier. Notwithstanding anything to the contrary
herein, Supplier warrants also towards Philips the proper fulfilment of any and all obligations and warranties in the supply of
any Products hereunder to Buyer. As a result any breach by Supplier against Buyer under this Agreement shall also be regarded
a breach by Supplier against Philips under this Agreement, in which case Philips shall be entitled to claim any and all damage
that it and/or Buyer has incurred in connection with such breach, it being understood that the same damage can only be claimed
once by Philips and/or Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.3</TD><TD STYLE="text-align: justify">No Purchase Order shall be deemed to be accepted by Supplier
until accepted in writing (including by email or another agreed manner of communication) by Supplier. Supplier shall not reject
any Purchase Order which is placed in accordance with the Forecast, the applicable lead time for such Product (set forth in <U>Attachment
1</U>) and otherwise in accordance with this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.4</TD><TD STYLE="text-align: justify">Supplier shall confirm to Buyer the receipt of each Purchase
Order issued hereunder (each, a &ldquo;<B>Confirmation</B>&rdquo;) within seven (7) days following Supplier&rsquo;s receipt thereof
in writing or in any other mutually agreed manner of communication (e.g., EDI or email). Each Confirmation must reference Buyer&rsquo;s
Purchase Order number, confirm acceptance of the Purchase Order, include a confirmed Delivery Date (which may differ from the
requested one in the Purchase Order)or, solely if permitted under this clause 6.2.4, advise Buyer of Supplier&rsquo;s rejection
of such Purchase Order, the date of acceptance or rejection and the basis for rejection, if applicable. If Supplier commences
performance under such Purchase Order, Supplier will be deemed to have accepted the Purchase Order. Buyer may withdraw any Purchase
Order prior to Supplier&rsquo;s acceptance thereof. Supplier may only reject a Purchase Order if (a) the quantity ordered by Buyer
in such Purchase Order is inconsistent with the quantity in the applicable Forecast in accordance with clause 6, (b) Supplier
has sent Philips of termination pursuant to clause 14 or (c) the applicable Purchase Order includes terms and conditions that
supplement those contained in this Agreement, which Supplier is unwilling to accept. Supplier may not cancel any previously accepted
Purchase Order hereunder. Buyer may not cancel a previously accepted Purchase Order .</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 7:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>DELIVERY</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.1</B></TD><TD STYLE="text-align: justify"><B><U>Delivery</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.1</TD><TD STYLE="text-align: justify">Delivery of Products to Buyer shall be made in accordance
with the Incoterms as referred to in <U>Attachment 1</U>. Incoterms 2010, shall apply to the interpretation of the delivery terms
mentioned in this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.2</TD><TD STYLE="text-align: justify">Supplier shall make the agreed deliveries by making the
Products and any other deliverables available to the Buyer at the agreed point of delivery as specified in <U>Attachment 1</U>.
<B>[Redacted &ndash; Commercially Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.3</TD><TD STYLE="text-align: justify">Supplier shall use commercially reasonable efforts to deliver Products on the delivery date
                                                                                 specified in the Confirmation (the &ldquo;<B>Delivery Date</B>&rdquo;). <B>[Redacted &ndash; Commercially
                                                                                 Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.4</TD><TD STYLE="text-align: justify">Buyer shall inspect shipments for freight damages at time
of receipt of the Product at the named place of delivery specified in the Purchase Order and promptly notify Supplier of any freight
damage.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.5</TD><TD STYLE="text-align: justify">Should Supplier wish to deliver Products before the Delivery
Date, than Buyer may choose, at its option to (i) return such Products in order to have them delivered at the Delivery Date, in
which case transportation charges shall be for Supplier&rsquo;s costs, (ii) accept delivery but withhold payment for such Products
until the Delivery Date, or (iii) keep the Products in storage at Supplier&rsquo;s costs until the Delivery Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.2</B></TD><TD STYLE="text-align: justify"><B><U>Complete Delivery.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.2.1</TD><TD STYLE="text-align: justify">Supplier may not over ship or under ship Products. In either
case, Supplier will alert Buyer in a timely manner. Supplier will recover any over shipments or ship additional Products to cover
under shipments. All over shipments returned to Supplier, and all additional Products shipped by Supplier to cover under shipments,
will be at Supplier&rsquo;s risk and expense, including transportation charges.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.3</B></TD><TD STYLE="text-align: justify"><B><U>Acceptance.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.3.1</B></TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Acceptance Criteria &ndash; Commercially
Sensitive]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.4</B></TD><TD STYLE="text-align: justify"><B><U>Buyer&rsquo;s subcontractors.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.4.1</TD><TD STYLE="text-align: justify">Buyer may appoint a third party to handle logistics, administration,
integration, assembling or other activities relating to Products or Philips Equipment, in which case Buyer shall inform Supplier
hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 124.8pt; text-align: justify; text-indent: -50.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 8:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>DOCUMENTS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.1</B></TD><TD STYLE="text-align: justify"><B><U>Supplier&rsquo;s Documents</U></B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.1.1</TD><TD STYLE="text-align: justify">Supplier will provide end-user documentation in the language
of the anticipated end users as per the legal requirements of the relevant countries, such countries as initially forecasted in
<U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.1.2</TD><TD STYLE="text-align: justify">Buyer may reproduce, create and disseminate derivative
works from such technical data and other Supplier&rsquo;s Documents and use, in any manner the technical data and other Supplier&rsquo;s
Documents, without a license fee or other payment to Supplier or third parties. Such derivative works shall be true and accurate.
Buyer shall obtain Supplier&rsquo;s prior written approval over such derivative works. Buyer shall provide Supplier with copies
of such derivative works.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.2</B></TD><TD STYLE="text-align: justify"><B><U>Updates of Supplier&rsquo;s Documents.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.2.1</TD><TD STYLE="text-align: justify">Supplier shall update and maintain its Documents relating
to the Product, during the Term of this Agreement including the continuing maintenance and service support period as provided
herein. Updates will be made available to reflect any changes and modifications implemented to the Products. Any corrections or
updates to Supplier&rsquo;s Documents will be promptly furnished to Buyer at no charge to Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.3</B></TD><TD STYLE="text-align: justify"><B><U>Promotional Materials</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.3.1</TD><TD STYLE="text-align: justify">All advertisements, promotions and other descriptive matters
(together referred to as &ldquo;<B>Promotional Material</B>&rdquo;) provided by Supplier shall be consistent with the labelling
of the Product. At Buyer&rsquo;s request, Supplier shall review any Promotional Material created by the Buyer that refers to the
clinical use, safety or effectiveness of the Product and shall confirm to Buyer in writing within ten (10) days of submission
that such Promotional Material is consistent with the labelling of the Product and complies with all applicable regulatory requirements
for the Product under applicable law. If Supplier cannot so confirm, it shall within ten (10) days of the submission, identify
in detail the provisions of the Promotional Material that are non-compliant or inconsistent with labeling. Supplier shall defend,
indemnify and hold Buyer and its Affiliated Companies harmless from any and all claims, direct losses, demands, direct costs and/or
liabilities, including reasonable attorney fees, alleging that Promotional Material provided or confirmed by Supplier promotes
use inconsistent with the Product labelling or causes the Product to be misbranded or adulterated.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 124.8pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.75in; text-align: left">ARTICLE 9:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>REPRESENTATIONS
AND WARRANTIES</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.1</B></TD><TD STYLE="text-align: justify"><B><U>Representations and Warranties.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants to Buyer that all Products
delivered and any services provided hereunder:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">conform to the Specifications on the Delivery Date, as
[<B>Redacted &ndash; Commercially Sensitive]</B>;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">unless otherwise agreed with Buyer in writing, are new
(do not contain any used or reconditioned parts or materials) and fit for the purposes for which they are intended;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">are of sound workmanship, good quality and free from defects
in design, construction, manufacture and material, [<B>Redacted &ndash; Commercially Sensitive]</B>;;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">comply in all respects with applicable laws, regulations,
certification requirements, including health and safety standards and all other applicable regulatory requirements for the design,
manufacture and shipment of Products;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">v.</TD><TD STYLE="text-align: justify">do not contain any of the restricted substances as listed
in the Sustainability Declaration;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vi.</TD><TD STYLE="text-align: justify">are free and clear of all liens, encumbrances, and other
claims against title; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vii.</TD><TD STYLE="text-align: justify">comply in all respects with the terms of this Agreement
and the applicable Purchase Orders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.2</TD><TD STYLE="text-align: justify">Supplier&rsquo;s representations and warranties do not
apply to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">Philips Equipment;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">damage to Products resulting from misuse, abuse, accident,
neglect, impacts and/or abrasions and failure to use or store Products as provided for in the Specifications;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">damages resulting from any modifications or alterations
made by Buyer or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a</TD><TD STYLE="text-align: justify">Customer to Products, including those resulting from the
repair or service of Products by anyone other than Supplier approved personnel or in a manner not approved by Supplier; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">damage resulting from Customer&rsquo;s application of cleaners,
germicides or other chemicals not approved by Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">For the avoidance of doubt, clause 9.1.2(iii) shall
not apply to damages to the Product resulting from the connection of the Product to Philips Equipment by Supplier upon installation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.3</TD><TD STYLE="text-align: justify">[<B>Redacted &ndash; Limitation on Warranties - Commercially
Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.4</TD><TD STYLE="text-align: justify">[<B>Redacted &ndash; Limitation on Warranties - Commercially
Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.5</TD><TD STYLE="text-align: justify">Subject to the limitations applied (including the ability
to bring a claim) [<B>Redacted &ndash; Commercially Sensitive]</B>, the foregoing warranties will survive any inspection, delivery,
acceptance, or payment by Buyer and will be enforceable by Buyer and its Affiliates, and their successors, assigns, subcontractors,
distributors, dealers, agents and Customers and all other entities combining, selling or using Products or goods into which Products
have been incorporated (together, the &ldquo;<B>Buyer Indemnitees</B>&rdquo;), for the period set forth in clause 9.2.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.2</B></TD><TD STYLE="text-align: justify"><B><U>Warranty Term.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.2.1</TD><TD STYLE="text-align: justify">Without prejudice to any other rights accruing under this
Agreement or law, the warranties set forth in clause 9.1 will extend for a period of [<B>Redacted &ndash; Warranty Term - Commercially
Sensitive]</B>; (the &ldquo;<B>Warranty Term</B>&rdquo;); provided that such Warranty Term shall not extend beyond [<B>Redacted
 &ndash; Warranty Term - Commercially Sensitive]</B>. Products repaired or replaced by Supplier within the Warranty Term are warranted
for the remainder of the original Warranty Term of said Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>9.3</B></TD><TD STYLE="text-align: justify"><B><U>Buyer&rsquo;s Remedies.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.3.1</TD><TD STYLE="text-align: justify">Subject to the remedies in clause 7.3 in respect of failure to meet the Specifications, if
                                                                                 Products do not comply with the warranties set forth in clause 9.1, Buyer may then, after having consulted Supplier as to the
                                                                                 most appropriate remedy, elect reasonably to have Products:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">returned to Supplier for repair or replacement;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">repaired or replaced by Supplier in the field; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">repaired or replaced by Buyer in the field, including Products
in distributor inventory and Buyer&rsquo;s installed base; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">returned to Supplier in exchange for a full refund of the
purchase price for the non-conforming Products paid under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.3.2</TD><TD STYLE="text-align: justify">Supplier will bear all costs, including transportation
and labor costs, in connection with the repair or replacement of, and all other costs or damages Buyer may incur as a result of
Products not complying with clause 9.1. If Supplier agrees that Buyer performs the repair, Supplier will provide Buyer free of
charge with any replacement Product or upgrade necessary, and will reimburse Buyer for all costs relating to such repair, including
any related labor <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD NOWRAP STYLE="width: 1in"></TD><TD NOWRAP STYLE="width: 1in; text-align: left">ARTICLE 10:</TD><TD NOWRAP STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONFIDENTIALITY</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.1</TD><TD STYLE="text-align: justify">Confidential Information may be disclosed by or on behalf
of a Party or its Affiliates (the &ldquo;Disclosing Party&rdquo;) to the other Party or its Affiliates (the &ldquo;Receiving Party&rdquo;)
in connection with this Agreement. Each Party agrees to keep the other Party&rsquo;s (and its Affiliates) Confidential Information
confidential and not to reproduce or disclose such Confidential Information to any third party, or to use it for any purpose other
purpose than for the purposes of this Agreement. Each Party shall protect any Confidential Information of the other Party (and
its Affiliates) with the same degree of care used in protecting its own Confidential Information, but no less than a reasonable
degree of care. Unless otherwise mutually agreed in writing, the Confidential Information shall remain the property of the Disclosing
Party. Each party&rsquo;s obligation to protect the Confidential Information of the other Party shall continue for a period of
<B>[Redacted - Confidentiality Term &ndash; Commercially Sensitive]</B> following the date of termination of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.2</TD><TD STYLE="text-align: justify">Each Party may disclose the other Party&rsquo;s Confidential
Information to its and its Affiliates&rsquo; employees, officers, lawyers, accountants, sub-contractors (collectively, &ldquo;<B>Representatives</B>&rdquo;)
or financing sources (both debt and equity) or any prospective acquirer of of Party (or substantially all of the assets related
to the Products)(collectively, &ldquo;<B>Other Recipients</B>&rdquo;&rdquo;) on a strict need to know basis, provided that such
Representatives and Other Recipients are subject to confidentiality obligations and/or agreements at least as stringent as the
confidentiality restrictions imposed by this clause 10 on the Receiving Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.3</TD><TD STYLE="text-align: justify">The confidentiality obligations set out in this clause
10 shall not apply to any information (but only to the extent that such information). and the definition of &ldquo;Confidential
Information&rdquo; shall not be deemed to include any information that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">is generally available from public sources or in the public
domain through no fault or breach of the Receiving Party or any of its Representatives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">becomes available to the Receiving Party (or any of its Affiliates) unless the Receiving
                                                                              Party (or such Affiliate) is aware that such source was bound by a confidentiality agreement with the Disclosing Party or
                                                                              any                                                                               or its Representatives or otherwise under a
                                                                              contractual, legal, fiduciary or other obligation of confidentiality with respect
                                                                              such information;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">developed independently by the receiving Party or any of
its Affiliates without use of or reliance on the Disclosing Party&rsquo;s (or any of its Affiliates&rsquo;) Confidential Information
as demonstrated by written records; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">was known or in the possession of the Receiving Party (or any of its Affiliates) prior to
                                                                              its                                                                               disclosure by the Disclosing Party unless
                                                                              the receiving Party (or such Affiliate) is aware that the source of such information
                                                                              was bound by a confidentiality undertaking to the disclosing Party (or its Affiliates) or any or its Representatives or
                                                                              otherwise under a contractual, legal, fiduciary or other obligation of confidentiality with respect to such
                                                                              information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.4</TD><TD STYLE="text-align: justify">This clause 10 does not prohibit disclosure or use of any
Confidential Information if and to the extent that the disclosure or use is required by applicable law, any judicial or administrative
proceedings, or the rules of any <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognized stock exchange
on which the shares of any Party (or its parent entity) are listed, provided that prior to such disclosure, the Receiving Party
promptly notifies the Disclosing Party of such requirement with a view to providing the Disclosing Party with the opportunity
to contest such disclosure or use and/or to obtain a protective order or otherwise to agree to the timing and content of such
disclosure or use and the Receiving Party shall at the request of the Disclosing Party, assist the Disclosing Party in contesting
such disclosure and/or obtaining a protective order; provided further that the Receiving Party shall only disclose such portions
of the Confidential Information that are strictly required to be disclosed by applicable law, and if permitted by applicable law,
the Disclosing Party shall be provided with the opportunity to review and comment on the disclosure to be made.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.5</TD><TD STYLE="text-align: justify">Notwithstanding any of the carve outs to the definition
of &ldquo;Confidential Information&rdquo; contained in clause 10.3, any Confidential Information in respect of the &ldquo;Purchased
Assets&rdquo; and the &ldquo;Business&rdquo; (each, as defined under the Purchase Agreement) shall be deemed the Confidential
Information of Supplier (the &ldquo;<B>Transferred Confidential Information</B>&rdquo;), and, in respect of Philips, the carve
out to the definition of &ldquo;Confidential Information&rdquo; contained in clause 10.3 shall not apply to any Transferred Confidential
Information, notwithstanding the fact that Philips was aware of, had possession of, or independently developed any such Transferred
Confidential Information prior to the date of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.6</TD><TD STYLE="text-align: justify">Each Party reserves all rights in its and its Affiliates&rsquo;
Confidential Information. No rights or obligations in respect of a Party&rsquo;s Confidential Information other than those expressly
stated in this Agreement are granted to the other Party or to be implied from this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 129.15pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 11:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INTELLECTUAL
PROPERTY RIGHTS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.1</B></TD><TD STYLE="text-align: justify"><B><U>Intellectual Property Warranty and Indemnification.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.1.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants to Buyer that: (x) it
has not received any notice claiming that any of Products and services directly or indirectly infringes any third party IPR; and
(y) to the best of its knowledge, all Products delivered hereunder do not directly or indirectly infringe, misappropriate, or
otherwise violate any third party IPR. Supplier shall defend, indemnify and hold harmless Buyer Indemnitees from and against all
liabilities, costs, damages and expenses, including reasonable attorneys&rsquo; fees, arising from or related to any claim that
Products, in whole or in part, directly or indirectly infringe, misappropriate, or otherwise violate any IPR of a Third Party.
If Supplier does not diligently pursue resolution of the claim against Buyer Indemnitees or provide reasonable assurances that
it shall diligently pursue resolution, then the Buyer Indemnitee against who such claim has been advanced may, without in any
way limiting its other rights and remedies, defend against the claim at Supplier&rsquo;s expense. If the use of a Product is found
to (or believed by Supplier to) directly or indirectly infringe, misappropriate, or otherwise violate any Third Party IPR, Supplier
shall, without in any way limiting its foregoing obligations, and at its sole expense:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">procure the necessary rights so that Products are not subject
to any such claim;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">replace or modify Product with a product of equivalent
performance so that it avoids such claim; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">if the options under subclasses a) or b) above are not
possible, refund to Buyer in full all costs paid by Buyer for the relevant Products and pay all reasonable additional costs incurred
by Buyer as a result of Supplier&rsquo;s action under sub clauses a), b) or c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">If the Parties foresee that the Parties will jointly
develop any Intellectual Property Rights in connection with this Agreement, such development will be reviewed by the joint streering
committee (as contemplated by the Purchase Agreement) and appropriate legal documentation will be put in place to address such
joint development, in a form approved by such joint steering committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.2</B></TD><TD STYLE="text-align: justify"><B><U>Open Source Software Warranty and Indemnification.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.2.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants that Products do not include
and are not accompanied by any portion of Open Source Software that has not been approved by Buyer in writing. As a condition
for such approval, Supplier shall provide to Buyer a full specification of such Open Source Software together with a copy of the
license conditions associated therewith. Supplier shall deliver all necessary information to enable Buyer to comply fully with
the licenses of all Open Source Software, including but not limited to any required notices to be reproduced by Buyer and the
source code if such licenses requires as a condition of distribution the making available of source code.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.2.2</TD><TD STYLE="text-align: justify">Supplier represents and warrants that any use of any Open
Source Software in Products, when used as anticipated by this Agreement, does not require Philips&rsquo; Equipment or any other
product of Buyer to be licensed under terms set forth in the definition of Open Source Software. Supplier shall defend, indemnify
and hold harmless Buyer Indemnitees against any and all losses, damages, costs and expenses, including reasonable attorneys&rsquo;
fees. arising from any inclusion, or claims related to the inclusion, of Open Source Software in Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.3</B></TD><TD STYLE="text-align: justify"><B><U>False Patent Marking</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.1</TD><TD STYLE="text-align: justify">False Patent Marking. Supplier shall defend, indemnify
and hold harmless the other Party against any and all claims arising from Markings on Marked Products alleged to be false or otherwise
in violation of the law. As used herein, (a)&nbsp;&rdquo;Markings&rdquo; means one or more patent numbers and/or the words or
phrases &ldquo;Patent&rdquo;, &ldquo;Patented&rdquo;, &ldquo;Patent Pending&rdquo;, &ldquo;patent applied for&rdquo;, &ldquo;covered
by one or more of the following patents&rdquo;, &ldquo;may be covered by patent number&rdquo;, &ldquo;covered by at least patent
number&rdquo;, or any derivations thereof, or any word or number importing, implying, indicating, or suggesting that the same
is or is in the process of being patented, and (b) &rdquo;Marked Products&rdquo; means Markings on or in connection with various
products, product components, product packaging, materials accompanying Product, and product advertising, including web-based
advertising/marketing materials, having, including, or referencing such Markings.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.4</B></TD><TD STYLE="text-align: justify"><B><U>License.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.1</TD><TD STYLE="text-align: justify">The purchase of a Product shall confer on Buyer and on
Buyer Indemnitees an irrevocable, world-wide, royalty-free and fully paid up, non-exclusive, license under all IPR owned or controlled,
directly or indirectly, by Supplier related to the Product to use, market, sell, lease, license, distribute or otherwise dispose
of Product acquired by Buyer under this Agreement throughout the Territory.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 104; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.2</TD><TD STYLE="text-align: justify">Nothing in this Agreement shall be construed as limiting the Parties rights and obligations
                                                                                  under the Joint Development Agreement <B>[Redacted &ndash; Commercially Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.3</TD><TD STYLE="text-align: justify">This Agreement and the supply of Products by Supplier to
Buyer does not grant Supplier either explicitly or by implication any right, title or interest in or to any of Buyer&rsquo;s or
any of its Affiliates&rsquo; Confidential Information and/or Intellectual Property Rights OR GRANT TO BUYER EITHER EXPLICITLY
OR BY IMPLICATION ANY RIGHT, TITLE OR INTEREST IN OR TO ANY OF SUPPLIER&rsquo;S OR ANY OF ITS AFFILIATES CONFIDENTIAL INFORMATION
AND INTELLECTUAL PROPERTY RIGHTS OTHER THAN THE LICENSED RIGHTS CONFERRED UNDER CLAUSE 11.4.1, AND THAT BUYER SHALL NOT SEEK TO
OBTAIN (OTHER THAN FROM SUPPLIER) ANY INTELLECTUAL PROPERTY RIGHTS IN THE PRODUCTS.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.4</TD><TD STYLE="text-align: justify">Buyer hereby assigns and transfers and, to the extent any
such assignment or transfer cannot be made at present, will assign and transfer to Supplier and its successors and assigns or
Supplier&rsquo;s designee, all Buyer&rsquo;s right, title and interest in and to all Intellectual Property Rights that are created,
developed, made, conceived or reduced to practice by Buyer or under Buyer&rsquo;s direction in connection with the services provided
under this Agreement (the &ldquo;<B>Developed Intellectual Property</B>&rdquo;) and waives any moral rights with respect to such
Developed Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.5</B></TD><TD STYLE="text-align: justify"><B><U>Trademarks.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.1</TD><TD STYLE="text-align: justify">Except as set forth in this clause 11.5, this Agreement
and the manufacture and supply of Products by Supplier does not grant to Supplier any rights in or license to the word mark Philips
or any other trademark, trade name or other indicia of Buyer or its Affiliates (hereinafter, individually and collectively referred
to as &ldquo;<B>Buyer&rsquo;s Marks</B>&rdquo;) or to the use of the Buyer&rsquo;s Marks, whether to Products alone or in any
combination in press releases, advertisements, sales literature or otherwise without Buyer&rsquo;s prior written consent. Supplier
will not copy or imitate the content or material style of Buyer&rsquo;s websites onto its own web site or sections of it to avoid
confusion to Internet users.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.2</TD><TD STYLE="text-align: justify">Buyer may use the name of Supplier and the name of Products
only for the purpose of advertising and marketing Products or Buyer&rsquo;s medical products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.3</TD><TD STYLE="text-align: justify">Buyer acknowledges and agrees that the all Supplier trademarks
associated with Products are the trademarks of Supplier and Buyer shall not rebrand Products for resale, seek to obtain any rights
in Supplier trademarks through the filing of trademark applications. Buyer shall leave in place all trade-marks, labels and other
trade designations placed by Supplier on Products and their packaging (including designations indicating manufacture by Supplier)
and shall not alter any such trade-marks, labels or other trade designations without the prior written consent of Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.4</TD><TD STYLE="text-align: justify">All goodwill associated with Buyer&rsquo;s use of Supplier&rsquo;s
trademarks shall enure exclusively to the benefit of Supplier. Buyer shall not take any action which may constitute an infringement
of such rights without prior written authorization from Supplier. Furthermore, Buyer shall not use or make reference to Supplier&rsquo;s
trademarks or trade name (or any derivation thereof) in connection with Buyer&rsquo;s own products or trade name without prior
written authorization from Supplier. Buyer shall not take any action, or omit to take any action, the result of which is to depreciate
or dilute the goodwill in any trademark or trade name used or adopted by Supplier or to damage or bring into disrepute the reputation
of Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.5</TD><TD STYLE="text-align: justify"><U>Branding of TULSA-PRO.</U> Without limiting the provisions
of clause 11.5, Buyer may use the name of Supplier and the name of &ldquo;TULSA&rdquo; or &ldquo;TULSA-PRO&rdquo; for the purpose
of advertising and marketing TULSA-PRO. Buyer acknowledges and agrees that Supplier trademarks associated with TULSA-PRO and related
Consumables are the trademarks of Supplier and Buyer shall not rebrand Products for resale or seek to obtain any rights in Supplier
trademarks through the filing of trademark applications. Buyer shall leave in place all trademarks, labels and other trade designations
placed by Supplier on Products and their packaging (including designations indicating manufacture by Supplier) and shall not alter
any such trade marks, labels or other trade designations without the prior written consent of Supplier. Buyer acknowledges and
agrees that all intellectual property rights in the TULSA-PRO, including the aesthetic and functional designs of the Product,
are the property of Supplier and that Buyer shall not seek to obtain any intellectual property rights in the &ldquo;TULSA-PRO&rdquo;
and related Consumables.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.6</TD><TD STYLE="text-align: justify"><U>Branding of the &ldquo;SONALLEVE&rdquo; Product.</U>
Without limiting the provisions of clause 11.5, the Parties agree to negotiate in good faith and sign a detailed, written branding
policy in relation to Sonalleve (&ldquo;<B>Branding Policy</B>&rdquo;). Each Party will nominate appropriate Buyers (including
cover in the event of holiday or sickness) to participate in discussions and workshops to produce the Branding Policy. Once agreed
the Branding Policy shall be signed off by authorised Buyers of each Party and shall then become binding on both Parties and shall
form part of this Agreement. The Parties shall use all reasonable endeavours to agree the Branding Policy within <B>[Redacted
- timing for Branding Policy &ndash; Commercially Sensitive]</B>. The Parties agree that the following principles are agreed and
shall, unless agreed otherwise in the Branding Policy, be reflected in the Branding Policy:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.7</TD><TD STYLE="text-align: justify">The Parties agree that the following principles are agreed
and shall, unless agreed otherwise in the Branding Policy, be reflected in the Branding Policy:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Supplier will ensure that Sonalleve will be re-branded,
with Supplier&rsquo;s brand represented on Sonalleve as the lead brand.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Supplier is entitled, but not the obliged, to add a Philips
co-branding label to Sonalleve (including future generations of Sonalleve) and to related product literature, presentations, brochures
and webpages.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The scope of such co-branding will be limited to generations/versions
of Sonalleve that are exclusively compatible with Philips&rsquo; Equipment and are not compatible with, or sold to work with,
MRI systems from other vendors than Philips.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">The possibility to add a co-branding label to Sonalleve
will be jointly evaluated by both Parties. Supplier wishes to re-brand Sonalleve, the usefulness of adding co-branding will be
evaluated by the Parties jointly.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">In case both Parties agree to co-brand a generation of
Sonalleve, the most recent applicable Philips co-branding guidelines at that time will be taken as starting point to agree the
actual co-branding expression on Sonalleve and marketing collaterals.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">The co-branding label to be used shall include &ldquo;Powered
by Philips [Descriptor]&rdquo;, with [Descriptor] being an appropriate description of the contribution made by Buyer to Sonalleve
or shall include &ldquo;Works with Philips [Descriptor]&rdquo;, with [Descriptor] being an appropriate description of the contribution
made by Buyer to Sonalleve, to be agreed upon jointly.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">The co-branding label shall also appear in related product
literature, presentations, brochures, videos and webpages.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 106; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.8</TD><TD STYLE="text-align: justify"><U>Notice</U>. Buyer shall, when using or making reference
to a trademark of Supplier (as may be permitted by clause 11.5.4 above, or elsewhere in this Agreement), clearly identify (whether
through use of an asterisk, footnote or otherwise) such trademark as a &ldquo;Trademark of Profound Medical Corp. or its affiliates&rdquo;
or otherwise as Supplier may instruct from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 12:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INDEMNITY
AND LIMITATION OF LIABILITY</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>12.1</B></TD><TD STYLE="text-align: justify"><B><U>Indemnity.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.1.1</TD><TD STYLE="text-align: justify">Buyer will defend, indemnify and hold harmless Supplier
and its Affiliates and their respective directors, officers, employees and agents, and their successors, heirs and assigns (the
 &ldquo;<B>Supplier Indemnitees</B>&rdquo;) from and against all liabilities, costs, damages, claims and expenses, including reasonable
attorney&rsquo;s fees, arising from or related to any actual or alleged <B>[Redacted &ndash; Scope of Indemnity &ndash; Commercially
Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.1.2</TD><TD STYLE="text-align: justify">Supplier will defend, indemnify and hold harmless Buyer
and its Affiliates and their respective directors, officers, employees and agents and their respective successors, heirs and assigns
(the <B>&ldquo;Buyer Indemnitees</B>&rdquo;) from and against all liabilities, costs, damages, claims and expenses, including
reasonable attorney&rsquo;s fees, arising from or related to any actual or alleged <B>[Redacted &ndash; Scope of Indemnity &ndash;
Commercially Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>12.2</B></TD><TD STYLE="text-align: justify"><B><U>Limitations of Liability.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.2.1</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Limitations on Liability &ndash; Commercially
Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>12.3</B></TD><TD STYLE="text-align: justify"><B><U>Lower Tier.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.3.1</TD><TD STYLE="text-align: justify">Supplier as legal manufacturer of Product will be responsible
for its participating Affiliates, subcontractors and vendors through the lowest tier. Supplier will ensure that each lower tier
subcontract contains all applicable Specifications and obligations needed to fully comply with this Agreement. Supplier will indemnify,
defend and hold harmless the Buyer Indemnitees from and against any and all claims and liabilities, including all costs and expenses,
arising out of or in any way connected with any actual or alleged action or failure to act by Supplier&rsquo;s Affiliates, subcontractors
or vendors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 13:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>INSURANCE</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.1</B></TD><TD STYLE="text-align: justify"><B><U>Supplier&rsquo;s Insurance.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1.1</TD><TD STYLE="text-align: justify">Supplier will maintain comprehensive or commercial general
liability insurance (including premises and operations, products and completed operations, broad form contractual liability, broad
form property damage and personal injury liability) with a minimum limit of <B>[Redacted &ndash; Minimum Insurance Requirements
- Commercially Sensitive]</B> combined single limit per occurrence and <B>[Redacted &ndash; Minimum Insurance Requirements - Commercially
Sensitive]</B> in the aggregate, for claims of bodily injury, including death, and property damage that may arise from use of
Products. Supplier shall also maintain professional liability insuring the acts or omissions of Supplier under this Agreement
in an amount of <B>[Redacted &ndash; Minimum Insurance Requirements - Commercially Sensitive]</B> per occurrence and aggregate.
Supplier will also maintain excess liability in an amount of not less than <B>[Redacted &ndash; Minimum Insurance Requirements
- Commercially Sensitive]</B> per occurrence. The commercial general liability policy obtained by Supplier will name Buyer, its
officers, directors and employees as additional insured. Such insurance will apply as primary insurance and no other <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance
will be called upon to contribute to a loss covered there under. In addition, such policies will permit Supplier to waive, on
its own behalf and on behalf of its insurers, any rights of subrogation against Buyer. Such insurance policies will be written
with appropriately licensed and financially responsible insurers, and will provide for a minimum of 30 days written notice to
Buyer of any cancellation or reduction in coverage. Certificates of insurance evidencing the required coverage and limits will
be furnished to Buyer before any work is commenced hereunder, and Supplier will deliver copies of policies or certificates to
the Buyer contact designated by Buyer.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 107; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1.2</TD><TD STYLE="text-align: justify">If any policies have &ldquo;claims made&rdquo; coverage,
Supplier will maintain such coverage with Buyer named as an additional insured for a minimum of <B>[Redacted &ndash; Minimum Insurance
Requirements - Commercially Sensitive]</B>. Any such coverage must have a retroactive date no later than the date upon which work
commenced under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1.3</TD><TD STYLE="text-align: justify">All deductibles on policies providing coverage will be
paid by Supplier. If Supplier is self-insured for matters described above, Supplier agrees to respond to any claims or losses
made against or incurred by Buyer in the same fashion as if insurance had been purchased with the same or broader coverage terms
than what is generally available to similar Suppliers. In no event will the coverage or limits of any insurance required under
this clause, or the lack or unavailability of any other insurance, be deemed to limit or diminish Supplier&rsquo;s obligations
or liability to Buyer under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 14:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TERMINATION</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>14.1</B></TD><TD STYLE="text-align: justify"><B><U>Termination for Cause.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">14.1.1</TD><TD STYLE="text-align: justify">Each Party may suspend performance of its obligations under
the Agreement or terminate this Agreement upon written notice to the other Party if:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the other Party files a voluntary petition in bankruptcy
or any voluntary proceeding relating to insolvency, receivership, liquidation, assignment for the benefit of creditors or similar
proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the other Party becomes the subject of a petition in bankruptcy
or any proceeding relating to insolvency, receivership, liquidation, assignment for the benefit of creditors or similar proceeding
and such petition or proceeding is not dismissed within thirty (30) days from filing of such petition or proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the other Party ceases or threatens to cease to carry on
business in the ordinary course or a Change of Control with respect to Supplier to a Buyer&rsquo;s direct competitor occurs; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the other Party materially breaches any of its obligations
under the Agreement, and the breaching failures to cure such breach within <B>[Redacted &ndash; Time Period &ndash; Commercially
Sensitive]</B> days after it receives written notice from the non-breaching Party to cure same;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Termination Right for Non-Performance
 &ndash; Commercially Sensitive]</B>; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">conviction of, or commission by, the other Party or any
principal officer, shareholder, employee or any partner of the other Party of any crime or immoral act which may adversely affect
the goodwill or reputation of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buyer or Supplier;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">For greater certainty, if a Party is provided,
pursuant to one of the termination rights contemplated by this clause 14.1.1, with the right to elect to terminate this Agreement,
such Party may do so in respect of the entire Agreement, or to terminate the Agreement on a Product-by-Product basis (in which
instance, this Agreement will continue in respect of those Products not terminated by such Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>14.2</B></TD><TD STYLE="text-align: justify"><B><U>Consequences of Termination.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">14.2.1</TD><TD STYLE="text-align: justify">In the event that the Agreement is terminated as provided
for in clause 14.1:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All Purchase Orders that are outstanding on the date this
Agreement shall terminate, for any reason, shall be fulfilled regardless of such termination, unless Buyer indicates otherwise.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Buyer shall no longer have the right to sell Product to Customers, and shall return all
                                                                                  Products in inventory to Supplier in the manner directed by Supplier and, at the Buyer&rsquo;s sole cost and expense. Buyer
                                                                                  shall cease holding itself out to be an authorized Supplier sales Buyer and shall cease all use of Supplier trademarks and
                                                                                  trade names.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Supplier shall continue the service obligation as per the
regulations in the jurisdiction where the Product is sold.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">All Confidential Information supplied by one Party to the
other to assist in carrying out the obligations hereunder shall remain the property of the supplying Party and, subject to any
express provisions hereof to the contrary, shall be returned to the supplying Party upon termination or expiration of this Agreement.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Buyer will ship, F.O.B. Buyer&rsquo;s principal place of
business, within (30) days following the date of expiration or the effective date of termination of this Agreement, to the destination
specified by Supplier in writing, all sample Products, catalogs, circulars, folders, and other Marketing Materials, all price
sheets, bulletins, official communications, technical information, confidential data and all other materials owned or provided
by Supplier to Buyer which are in the possession or control of Buyer, its employees or agents on such date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 150.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 15:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>FORCE
MAJEURE</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.1</B></TD><TD STYLE="text-align: justify">Neither Party will be liable for any failure to perform
solely caused by a Force Majeure Event and if that either Party is prevented from performing or is unable to perform any of its
obligations under this Agreement due to a Force Majeure Event, its performance will be excused, and the time for performance will
be extended for the period of delay or inability to perform due to such Force Majeure Event, provided that such Party will give
promptly written notice thereof to the other Party:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">describing the Force Majeure Event;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">describing the obligations which it is unable to perform
due to the Force Majeure Event; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">giving a projection of the expected period of delay or
inability to perform due to the Force Majeure Event, and such Party will have used reasonable commercial efforts to mitigate its
effects and to cure any non-performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 109; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.2</B></TD><TD STYLE="text-align: justify">Force majeure on the part of Supplier shall in any event
not include shortage of personnel or production materials or resources, breach of contract by third parties contracted by Supplier,
financial problems of Supplier, nor the inability <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
Supplier to secure the necessary licenses in respect of software to be supplied or the necessary legal or administrative permits
or authorizations in relation to Products to be supplied.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.3</B></TD><TD STYLE="text-align: justify">If a Party is not or is not expected to be able to perform
any material obligation under this Agreement due to a Force Majeure Event for a period of <B>[Redacted &ndash; Commercially Sensitive]
</B>or more, the other Party may terminate this Agreement without liability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.4</B></TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Rights during continuation of Force
Majeure Event - Commercially Sensitive]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">15.5</TD><TD STYLE="text-align: justify">For greater certainty, during the term of the Supply Agreement,
if there is a &ldquo;force majeure event&rdquo; outstanding under the Supply Agreement (claimed by Philips or one of its Affiliates
under the Supply Agreement), Buyer may not exercise the remedies in clause 15.3 and 15.4 hereunder if Supplier exercises a corresponding
Force Majeure Event under this Agreement in response to the Force Majeure Event exercised under the Suppply Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 129.15pt; text-indent: -38.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 16:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>RECALL</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">16.1</TD><TD STYLE="text-align: justify">If Supplier or any relevant Governmental Authority determines
that a recall campaign is necessary, Supplier will implement such recall campaign and Buyer will have the right to return the
affected Products to Supplier or destroy such Products, as determined by Supplier in its reasonable discretion, at Supplier&rsquo;s
sole cost and risk. Supplier hereby covenants and agrees that it shall be responsible for all costs and expenses related to the
implementation of any such recall. In case of a recall of the Product, Philips shall at its sole cost provide full cooperation
to Supplier in order to achieve an efficient and effective recall by Supplier. For greater certainty, the obligations of the Parties
pursuant to this clause 16 shall only apply in respect of Products sold or distributed on or after the Effective Date, and for
clarity, to the extent there is a recall that involves any Product sold or distributed prior to the Effective Date, the covenants
and obligations of the Parties pursuant to this clause 16 shall not apply (and shall be addressed by the terms of the Purchase
Agreement).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 1in; text-align: left">ARTICLE 17:</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>GENERAL
                                                                                        PROVISIONS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.1</B></TD><TD STYLE="text-align: justify"><B><U>Amendments.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.1.1</TD><TD STYLE="text-align: justify">This Agreement may be amended only by a written instrument explicitly referring to this
                                                                                  Agreement, duly executed by authorized representatives of both Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.2</B></TD><TD STYLE="text-align: justify"><B><U>Binding Agreement and Assignment.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.2.1</TD><TD STYLE="text-align: justify">This Agreement will be binding upon and inure to the benefit
of the Parties and their respective successors and permitted assigns. This Agreement may not be assigned by either Party, in whole
or in part, to any Third Party without the prior written consent of the other Party, except that either Patrty may assign this
Agreement as a whole, and all of its rights and obligations hereunder, without the consent of the other Party but subject to prior
written notice to the other Party (a) to an Affiliate, or (b) in case of a transfer of all, or substantially all, stock or assets
of such Party or the relevant business activity through which such Party <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acts
in this Agreement to a Third Party or to any partnership or other venture in which such business activity is to participate. Except
as provided above, without prior written consent of the other Party, any assignment or pledge of rights under this Agreement by
a Party to a Third Party shall have no effect vis-&agrave;-vis such Third Party.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.3</B></TD><TD STYLE="text-align: justify"><B><U>Agreement.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.3.1</TD><TD STYLE="text-align: justify">This Agreement, any Purchase Order issued hereunder and
the OEM Quality Agreement constitute the entire agreement and understanding of the Parties and merges all prior discussions and
negotiations between them and supersedes any previous agreement whether oral or written. Course of performance, course of dealing
and usage of trade will not apply to this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.3.2</TD><TD STYLE="text-align: justify">This Agreement also constitute a complete restatement of
the Resale Purchase Agreement between the Parties, dated January 1, 2016, and the Parties hereby terminate said Agreement as of
the the Effective Date of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.3.3</TD><TD STYLE="text-align: justify">The following attachments form an integral part of this
Agreement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><B>[Redacted &ndash; List of Schedules &ndash;
Commercially Sensitive]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 120.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">In the event of any conflict
between any provision of this Agreement and any provision of Attachment 1, 2 or 4, the provisions of this Agreement shall prevail.
In the event of any conflict between any provision of this Agreement and any provision of Attachment 3, 5, 6, 7 or 8 the provisions
of Attachment 3, 5, 6, 7 or 8, as applicable, shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">In the event of any conflict between any provision
of this Agreement and any provision of the OEM Quality Agreement, the provisions of the OEM Quality Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.4</B></TD><TD STYLE="text-align: justify"><B><U>Customs Compliance/ Country of Origin/ Export Control</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.1</TD><TD STYLE="text-align: justify">Upon Buyer&rsquo;s request, Supplier will provide Buyer
with an acceptable and auditable certification stating the country of origin for Products, sufficient to satisfy the requirements
of (i) customs authorities of the country of receipt, and (ii) applicable export licensing regulations. Supplier will mark each
Product (or Product&rsquo;s container if there is no room on Product) with the country of origin. Supplier will, in marking Products,
comply with the requirements of the customs authorities of the country of receipt.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.2</TD><TD STYLE="text-align: justify">If Products delivered under this Agreement are imported,
Supplier will when possible allow Buyer to be the importer of record. If Buyer is not the importer of record and Supplier obtains
duty drawback rights to Products, Supplier will, upon Buyer&rsquo;s request, provide Buyer with documents required by the customs
authorities of the country of receipt to prove importation and to transfer duty drawback rights to Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.3</TD><TD STYLE="text-align: justify">Supplier will: organize its administration and manufacturing in such a way, that Products
                                                                                  can                                                                                   be supplied with preferential origin
                                                                                  status and supply Products with the appropriate documentary evidence of the preferential
                                                                                  origin status. Supplier will provide the appropriate customs documentation for Products which may be imported and/or
                                                                                  exported                                                                                   by Buyer, including Certificate of
                                                                                  Origin (renewed on a two (2)-year basis), and Harmonized Tariff System Classification
                                                                                  Codes. Supplier will support Buyer with import and export regulatory issues so that regulatory compliance will be met.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.4</TD><TD STYLE="text-align: justify">This Agreement has been executed taking into consideration
the asserted origin of Products as well as the delivery by Supplier of the appropriate documentary evidence of the preferential
origin status requested by custom authorities. It is expressly understood that the preferential origin status of Product and the
accuracy thereof for any supplied Product hereunder are essential under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.5</TD><TD STYLE="text-align: justify">Each Party agrees and warrants that it will comply with
all applicable international and national export control laws and regulations and that it will not export or re-export, directly
or indirectly, any information, goods, software and/or technology, including any Products or Philips&rsquo; Equipment, to any
country for which the European Union or the United States of America or any other country, at the time of export or re-export,
requires an export license or other governmental approval, without first obtaining such license or approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.6</TD><TD STYLE="text-align: justify">Supplier agrees to inform Buyer in writing whether or not
Products are controlled and/or controlled under the export control laws of its own country, and if so, Supplier will inform Buyer
about the extent of the restrictions (including but not limited to export control legal jurisdiction, export control classification
numbers, export control licenses and/or CCATS as applicable).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.7</TD><TD STYLE="text-align: justify">Supplier shall obtain all international and national export
licenses or similar permits required under all applicable export control laws and regulations and shall provide Buyer with all
information required to enable Buyer and its Customers to comply with such laws and regulations. Supplier agrees to indemnify
and hold Buyer harmless from any claims, liabilities, penalties, forfeitures, and associated costs and expenses (including attorneys&rsquo;
fees) which Buyer may incur due to Supplier&rsquo;s non-compliance with applicable export control laws, rules and regulations.
Supplier agrees to promptly notify Buyer of Supplier&rsquo;s receipt of any such notice of a violation of any export control related
law, rule or regulation, which may affect Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.8</TD><TD STYLE="text-align: justify">If Products are export controlled, Supplier will inform
Buyer accordingly and to indicate the applicable export control classification number (&ldquo;ECCN&rdquo;)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.5</B></TD><TD STYLE="text-align: justify"><B><U>Governing Law; Jurisdiction</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.5.1</TD><TD STYLE="text-align: justify">This Agreement will be governed by and construed in accordance
with the laws of the Netherlands. The United Nations Convention on Contracts for the International Sale of Goods (the Vienna Sales
Convention) is not applicable to this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.5.2</TD><TD STYLE="text-align: justify">Any dispute arising out of or in connection with this Agreement
shall be resolved in the manner provided in Sections 12.1 and 12.2 of the Purchase Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.6</B></TD><TD STYLE="text-align: justify"><B><U>Compliance with Laws</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.6.1</TD><TD STYLE="text-align: justify">Each of the Parties will at all times comply with all laws,
rules, regulations and ordinances applicable to the Agreement and each Purchase Order, including but not limited to all fair labor,
equal opportunity and environmental compliance laws, rules, regulations and ordinances. Supplier will furnish to Buyer any information
required to enable Buyer to comply with such laws, rules, and regulations in its use of Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.7</B></TD><TD STYLE="text-align: justify"><B><U>[Redacted &ndash; Privacy Requirements &ndash; Commercially
Sensitive]</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 203.9pt; text-indent: -50.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.8</B></TD><TD STYLE="text-align: justify"><B><U>Waivers.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.8.1</TD><TD STYLE="text-align: justify">Neither the failure nor delay of any Party to this Agreement
to assert or exercise any right, power, privilege or remedy under this Agreement or to enforce any term or provision hereof or
thereof, will constitute a waiver of such right, power, privilege or remedy, and no single or partial exercise of any such right,
power, privilege or remedy will preclude any other or further exercise of such right, power, privilege or remedy or the exercise
of any other right, power, privilege or remedy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.9</B></TD><TD STYLE="text-align: justify"><B><U>Notices.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.9.1</TD><TD STYLE="text-align: justify">Any notice or other communication required or permitted to be given to any Party hereunder
                                                                                  shall be in writing and shall be given to such Party at such Party&rsquo;s address set forth below, or such other address as
                                                                                  such Party may hereafter specify by notice in writing to the other Party. Any such notice or other communication shall be
                                                                                  addressed as aforesaid and given by: (i) hand delivery; (ii) international overnight courier; or (iii) e-mail transmission.
                                                                                  Any notice or other communication will be deemed to have been duly given: (A) on the date of service if served personally;
                                                                                  (B) on the Business Day after delivery to an international overnight courier service, provided receipt of delivery has been
                                                                                  confirmed; or (C) on the date of transmission if sent via e-mail transmission, provided confirmation of receipt is
                                                                                  obtained promptly after completion of transmission and provided that transmission via e-mail is followed promptly by delivery
                                                                                  via one of the methods in clause 16.9 (i) or (ii) above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to Buyer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">P.O. Box 10.000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">5680 DA Best, The Netherlands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: <B>[Redacted &ndash; Individual&rsquo;s
Name]</B>, General Manager MR Therapy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Legal Department PMSN BV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Veenpluis 4-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">5684 PC Best</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Building QX2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to Supplier:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2400 Skymark Avenue, Unit #6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Mississauga, ON, L4W 5K5, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:<B>[Redacted &ndash; Personal Email Address]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 113; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Torys LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Suite 3000, P.O. Box 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">79 Wellington Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">TD Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, ON M5K 1N2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Cheryl Reicin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: <U>creicin@torys.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.10</B></TD><TD STYLE="text-align: justify"><B><U>Publicity.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.10.1</TD><TD STYLE="text-align: justify">Any public announcements or press releases relating to
this Agreement shall be governed by the provisions of clause 14.13 of the Purchase Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.11</B></TD><TD STYLE="text-align: justify"><B><U>Independent Contractors</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.11.1</TD><TD STYLE="text-align: justify">Each Party is an independent contractor, not an agent,
employee or Buyer of the other. Neither Party has authority to make any statement, representation or commitment of any kind or
to take any action binding upon the other, without the other Party&rsquo;s prior, written authorization.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.12</B></TD><TD STYLE="text-align: justify"><B><U>Excluded Provider</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.12.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants that it, and, to the best
of its knowledge, its employees and subcontractors providing the Products are not debarred, excluded, suspended or otherwise neligible
to participate in a U.S. federal health care program, nor have they been convicted of any U.S. health care related crime (an &quot;Excluded
Provider&quot;). Supplier will promptly notify Buyer in writing if it becomes aware that any of its employees or subcontractors
providing the Products has become an Excluded Provider. Buyer may terminate this Agreement upon written notice to Supplier if
upplier or any of its employees or subcontractors providing the Products becomes an Excluded Provider.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.13</B></TD><TD STYLE="text-align: justify"><B><U>Authority; Due Execution.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.13.1</TD><TD STYLE="text-align: justify">Each Party represents and warrants to the other, that (a) it has full power and authority to
                                                                                   enter into this Agreement and any agreements related hereto and, subject to the terms and conditions hereof, this Agreement,
                                                                                   when executed, will be a valid and legally binding obligation of such Party according to its provisions, (b) the execution
                                                                                   and performance of this Agreement will not constitute a breach of or an event of default under any agreement, contract, law
                                                                                   or regulation to which such Party is or may be bound, and (c) the execution and performance of this Agreement has been duly
                                                                                   authorized by all necessary corporate action.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.14</B></TD><TD STYLE="text-align: justify"><B><U>Severability.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.14.1</TD><TD STYLE="text-align: justify">The provisions of this Agreement are severable and the
invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof.
If any provision of this Agreement, or the application thereof to any person or entity or any circumstance, is invalid or unenforceable,
(a) a suitable and equitable provision will be substituted therefor in order to carry out, so far as may be valid and enforceable,
the intent and purpose of such invalid or unenforceable provision, and (b) the remainder of this Agreement and the application
of such provision to other persons or <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entities or circumstances
will not be affected by such invalidity or unenforceability, nor will such invalidity or unenforceability affect the validity
or enforceability of such provision, or the application thereof, in any other jurisdiction.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.15</B></TD><TD STYLE="text-align: justify"><B><U>Supply Chain Security</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.15.1</TD><TD STYLE="text-align: justify">Supplier will comply with the supply chain security requirements
outlined in <U>Attachment 7</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.16</B></TD><TD STYLE="text-align: justify"><B><U>Supply Agreement Matters</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.16.1</TD><TD STYLE="text-align: justify">The Parties acknowledge and agree that during the term
of the Supply Agreement, that Supplier will not be liable for any breach of this Agreement by it to the extent that such breach
of this Agreement primarily and directly results from a breach of the Supply Agreement by Philips or any of its Affiliates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>17.17</B></TD><TD STYLE="text-align: justify"><B><U>Survival.</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.17.1</TD><TD STYLE="text-align: justify">All terms and conditions of this Agreement which are intended
(whether expressed or not) to survive the duration or termination of this Agreement will so survive.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="text-align: left; width: 0.5in"><B>17.18</B></TD><TD STYLE="text-align: justify"><B><U>Attachments.</U></B></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.18.1</TD><TD STYLE="text-align: justify">The Parties hereby acknowledge and agree that Attachments
1-7, as applicable, will be updated and amended by the Parties prior to the closing contemplated by the Purchase Agreement, to
reflect the principles, pricing and terms outlined in Attachment 8 hereto, and in respect of items not listed in Attachment 8,
the Parties will discuss and make such additional modifications as mutually agreed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Include reference to the attachments as part of
this agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><B>[Redacted &ndash; List of Schedules &ndash;
Commercially Sensitive]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Remainder of Page Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">IN WITNESS WHEREOF, this Resale Purchase Agreement
has been duly executed by the duly authorized officers of the Parties hereto as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Philips Medical Systems Nederland B.V.</B></FONT></TD>
    <TD STYLE="width: 49%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Profound Medical Corp.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 9%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 9%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 44%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 45%; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 116; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">Philips &amp; Profound</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Redacted &ndash; Contents of Schedules
 &ndash; including, pricing, shipping terms, product specifications, scope of services, co-marketing obligations, product testing
criteria, data privacy, supply chain requirements &ndash; Commercially Sensitive]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> of 27 -&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT B-1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INTELLECTUAL PROPERTY ASSIGNMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">This Intellectual Property
Assignment Agreement (the &ldquo;<B>Assignment</B>&rdquo;), dated as of the &#9632; day of &#9632;, 2017 (the
 &ldquo;<B>Effective Date</B>&rdquo;), is made by and between <B>Koninklijke Philips N.V. </B>(the
 &ldquo;<B>Assignor</B>&rdquo;) and Profound Medical Corp. (the &ldquo;<B>Assignee</B>&rdquo;). In the event of a conflict
between the terms set forth herein and the Purchase Agreement (defined below), the Purchase Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">WHEREAS Assignee and Assignor have
entered into that certain Asset and Share Purchase Agreement, dated as of the &#9632; day of &#9632;, 2017 by and among Assignor
and Assignee, (the &ldquo;<B>Purchase Agreement</B>&rdquo;), pursuant to which Assignor agreed to sell to Assignee, and Assignee
agreed to purchase from Assignor certain assets, including certain intellectual property assets listed on the attached Schedule
 &ldquo;A&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">WHEREAS Assignor wishes to assign
to Assignee, and Assignee wishes to acquire from Assignor, the rights, title, and interest in and to the intellectual property
assets, including applications and registrations for patents (the &ldquo;<B>Patents</B>&rdquo;) and trademarks (the &ldquo;<B>Trademarks</B>&rdquo;)
listed on the attached Schedule &ldquo;A&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">NOW THEREFORE, in consideration of
the premises, the mutual covenants, agreements and respective representations and warranties contained herein and in the Purchase
Agreement, and other good and valuable consideration, the receipt and sufficiency for which are hereby acknowledged, the Parties
hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>ARTICLE I</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>DEFINITIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><U>1.</U></TD><TD STYLE="text-align: justify"><U>Defined Terms.</U> Capitalized terms used in this Agreement but not otherwise defined
                                                                                        herein shall have the meanings ascribed thereto in the Purchase Agreement. As used in this Agreement, the following
                                                                                        capitalized terms shall have the meanings set forth below.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&ldquo;<B>Line of Business</B>&rdquo; shall mean [Redacted
 &ndash; Commercially Sensitive].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&ldquo;<B>Prior Commitments</B>&rdquo; shall mean,
for Assignor as well as its Affiliates, any and all encumbrances as existing on the Closing Date listed on the attached Schedule
 &ldquo;B&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ARTICLE II</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>TRANSFER OF RIGHTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Assignor hereby sells, assigns and transfers unto the Assignee,
its successors and assigns, subject to Assignor&rsquo;s Prior Commitments, all of Assignor&rsquo;s right, title and interest in
and to the Patents and inventions disclosed therein, along with (a) all applications for patents for such inventions or based
on the Patents in all countries, now filed or to be filed, including all divisional, renewal, substitute, continuation, continuation-in-part
and convention applications based in whole or in part upon the inventions or upon the Patents, (b) all patents which may issue
on the inventions and on any application transferred by this Assignment in all countries, and any and all reissues, extensions,
divisions, renewals, substitutes, continuations or continuations-in-part of patents granted for the inventions or upon such applications
or Patents, for the full term or terms for which the patents may be issued, and (c) every priority right that is or may be predicated
upon or arise from the inventions, the Patents and the foregoing applications and patents under any applicable international or
bilateral treaty, agreement or convention.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Assignor hereby sells, assigns and transfers, and confirms
that it has sold, assigned and transferred, to Assignee all of Assignor&rsquo;s right, title and interest in the Trademarks, including
all registrations and applications thereof, all registrations which may be granted in respect of such applications, all renewals
of such registrations, along with all common law rights therein, together with the goodwill associated with the Trademarks, the
same to be held and enjoyed by Assignee for its own use and enjoyment and the use and enjoyment of its successors, assigns or
other legal representatives, including the right, throughout the world, to use, register, and sell wares and services thereunder,
as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made, and including its entire
right, title and interest in and to all income, royalties, damages and payments now or hereafter due or payable with respect to
the Trademarks.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Assignor will, upon request of Assignee and without further
consideration but at the expense of the Assignee, cooperate with and take all reasonably necessary steps to record Assignee as
the assignee and owner of the Patents and Trademarks at the relevant patent and trademark offices.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">Assignee and its Affiliates hereby grants Assignor and
its Affiliates a non-exclusive, non-transferable, irrevocable, world-wide, fully paid-up license, without the right to grant sub-licenses,
under all Patents, to use, make, have made, sell, lease, import, export, distribute, repair, refurbish, service or commercialize
in any other way products and services outside the Line of Business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">After expiration of the Noncompetition Period (defined
in the Noncompetition, Nonsolicitation and Confidentiality Agreement entered between the Assignor and Assignee) and at Assignor&rsquo;s
or any of its Affiliates&rsquo; request, Assignee and its Affiliates may consider, in their sole and absolute discretion, providing
Assignor and its Affiliates with access to the Patents within the Line of Business [Redacted &ndash; Commercially Sensitive].</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: justify">Assignor and Assignee acknowledge and agree that nothing
contained in this Assignment shall in any way supersede, modify, replace, amend, rescind, waive narrow or broaden any provision
set forth in the Purchase Agreement or any of the rights, remedies or obligations arising therefrom.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">7.</TD><TD STYLE="text-align: justify">This Assignment is binding upon, and enures to the benefit
of, the parties and their respective legal representatives, successors and assigns.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: justify">This Assignment is and shall be deemed to be a contract
entered into and made pursuant to the laws of the Province of Ontario and shall in all respects be governed, construed, applied
and enforced in accordance with said laws, without reference to applicable conflict of laws rules or principles. Any action or
proceeding in respect of any claim arising out of or related to this Assignment shall be solely conducted by the Parties in accordance
with the procedure provided in Sections 12.2, 13.5 and 13.10 of the Purchase Agreement, including the right to pursue equitable
or injunctive relief in a court in any jurisdiction.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">9.</TD><TD STYLE="text-align: justify">This Assignment may be executed in counterparts, all of
which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.
Delivery of an executed counterpart of a signature page to this Assignment by facsimile transmission or other electronic transmission
shall be as effective as delivery of a manually executed counterpart of this Assignment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify"><B>IN WITNESS WHEREOF</B> Assignor
and Assignee have caused this Assignment to be executed by their duly authorized officer as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><U>Assignor:</U></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>Assignee:</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold">KONINKLIJKE PHILIPS N.V.</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Name: Brian Hinman</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Title: Chief Intellectual Property Officer</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><U>Witness:</U></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>Witness:</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 120; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SCHEDULE A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INTELLECTUAL PROPERTY RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Patents:</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 121; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><U>2.</U></TD><TD STYLE="text-align: justify"><U>Trademarks:</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 122; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SCHEDULE B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Encumbrances</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 156.3pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">PATENTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 123; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Definitions:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Collaborator</B>&rdquo; means Philips.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>CRADA Software</B>&rdquo; means an application-level
part of a computer program or an applications-level computer program (including both the source code and object code, as appropriate)
for graphics and image processing or user interface developed and written in whole or in part <I>solely by</I> PHS employee(s)
or PHS contractor(s) and/or jointly by PHS employee(s) or PHS contractor(s) and Collaborator personnel pursuant to the Research
Plan and not already existing as of the Effective Date, together with any documentation pertaining to the structure, function,
or use of the computer code, or pertaining to the interoperation of the computer code with other software. A computer program that
is in a format readable by a human is referred to as &ldquo;source code,&rdquo; and one in a format that is executable by a computer
is referred to as &ldquo;object code.&rdquo; &ldquo;CRADA Software&rdquo; encompasses works of authorship, and does not include
Inventions relating to software or computer-related processes. &ldquo;CRADA Software&rdquo; also does not include commercially
available software procured or supplied by either Party for use in conducting research under the CRADA, even if the commercial
software is tailored or adapted to the particular needs of the Research Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Government</B>&rdquo; means the Government
of the United States as represented through the PHS agency that is a Party to this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Identifiable Private Information</B>&rdquo;
means patient-identifying data from medical records or attached to patient specimens, to be obtained prospectively or from stored
medical records or specimens, that can be linked to individual human subjects, either directly or indirectly through codes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>IP</B>&rdquo; means intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Proprietary/Confidential Information</B>&rdquo;
means confidential scientific, business, or financial information provided that such information does not include:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">information that is publicly known or available from
other sources who are not under a confidentiality obligation to the source of the information;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">information which has been made available by its owners
to others without a confidentiality obligation;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">information which is already known by or available
to the receiving Party without a confidentiality obligation; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">information which relates to potential hazards or
cautionary warnings associated with the production, handling or use of the subject matter of the Research Plan of this CRADA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Research Plan</B>&rdquo; or &ldquo;<B>RP&rdquo;</B>
means the statement in Appendix A of the respective research and development plan commitments of the Parties of this CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Subject Data</B>&rdquo; means all recorded
information first produced in the performance of this CRADA by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&ldquo;<B>Subject Invention</B>&rdquo;
means any Invention of the Parties, conceived or first actually reduced to practice in the performance of the Research Plan of
this CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Article 6. Patent Applications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Reporting</B>.
The Parties shall promptly report to each other in writing each Subject Invention and any patent applications filed thereon resulting
from the research conducted under this CRADA that is reported to them by their respective employees. Each Party shall report all
Subject Inventions to the other Party in sufficient detail to determine inventorship. Such reports shall be treated as Proprietary/Confidential
Information in accordance with Article 8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>There is an obligation for Profound
to report the filing of any new patent application to PHS. If Profound files a continuation, divisional, or continuation-in-part
application, Profound would need to report the filing of such application to the NIH. This requirement is fulfilled by sending
a note containing the NIH docket number and the response or Office Action to <U>ottrecordssupervisor@mail.nih.gov</U>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 124; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Filing
of Patent Applications</B>. Each party shall be responsible for filing patent or other IP applications in a timely manner and at
its own expense and after consultation with the other Party. The Parties will consult and mutually determine a filing strategy
for jointly owned subject inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>There is an obligation to consult
and mutually determine a filing strategy for jointly owned inventions. The expense of the filing is to be assumed by the party
filing the application. A filing strategy has already been executed for these jointly owned inventions.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent
Expenses</B>. The expenses attendant to the filing of patent or other IP applications generally shall be paid by the Party filing
such application. If an exclusive license to any Subject Invention is granted to the Collaborator, the Collaborator shall be responsible
for all past and future out-of-pocket expenses in connection with the preparation, filing, prosecution and maintenance of any applications
claiming such exclusively licensed inventions and any patents or other IP grants that may issue on such applications. The Collaborator
may waive its exclusive license rights on any application, patent or other IP grant at any time, and incur no subsequent compensation
obligation for that application, patent or IP grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>The expenses for filing a patent
or other is to be paid by the Party filing such application. The subject applications were filed by Philips. Accordingly, further
prosecution expenses would be assumed by Profound.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prosecution
of Intellectual Property Applications</B>. Within one month of receipt or filing, each Party shall use reasonable efforts to
provide the other Party with copies of the applications and all documents received from or filed with the relevant patent or
other IP office in connection with the prosecution of such applications. Each Party shall also provide the other Party with
the power to inspect and make copies of all documents retained in the patent or other IP application files by the applicable
patent or other IP office. The party filing the patent application shall have the right to control the prosecution of the
application. The parties agree to cooperate with each other in the preparing and prosecution of patent applications. If the
Parties agree that Collaborator shall file and prosecute IP applications on Subject Inventions, the Collaborator agrees to
Customer Number Practice and/or granting of power(s) of attorney (or its equivalent) necessary to assure PHS access to its
United States, international, and foreign intellectual property rights on said applications. If the Parties agree that PHS
shall file and prosecute IP applications on joint Subject Inventions, the PHS agrees to grant Collaborator power(s) of
attorney (or its equivalent) necessary to assure Collaborator access to such IP application(s) per 37 C.F.R.
 &sect;1.32(c)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Within one month, the filing party
must provide the other Party with copies of the applications and all documents received from or filed with the relevant patent
or other IP office in connection with the prosecution of such applications. In addition, each Party shall also provide the other
Party with the power to inspect and make copies of all documents retained in the patent or other IP application files by the applicable
patent or other IP office. Since Philips filed the subject applications, Profound would assume this role and be obligated to provide
copies of all documents received from or filed with the relevant patent office to PHS.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Maintenance
Fees</B>. The fees payable to a patent office in order to maintain a jointly owned or exclusively licensed patent's enforcement
will be paid by the party owning the patent subject to reimbursement from Collaborator if Collaborator is the exclusive licensee
of that patent. If that party decides not to pay the maintenance fees, it shall promptly notify the other party, who may pay the
maintenance fees if it desires to maintain the enforceability of the patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Maintenance fees for the subject
applications would be assumed by Profound.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Article 7. Licensing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>License
for PHS Employee Inventions and Joint Inventions</B>. Pursuant to 15 U.S.C. &sect;3710a(b)(1)(A), for Subject Inventions made under
this CRADA by a PHS employee(s) or jointly by such employee(s) and employees of the Collaborator and licensed pursuant to the option
of Article 7.1, the Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid- up license to practice
the invention or have the invention practiced throughout the world by or on behalf of the Government. In the exercise of such license,
the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential
with the meaning of 5 U.S.C. &sect;552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Profound grants to the Government
a nonexclusive, nontransferable, irrevocable, paid- up license to practice the invention or have the invention practiced throughout
the world by or on behalf of the Government.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>License
in Collaborator Inventions</B>. Pursuant to 15 U.S.C. &sect; 3710a(b)(2), for inventions made solely by Collaborator employees
under this CRADA, the Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid -up license to practice
the invention or have the invention practiced throughout the world by or on behalf of the Government for research or other Government
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Profound grants
to the Government a nonexclusive, nontransferable, irrevocable, paid- up license to practice the invention or have the invention
practiced throughout the world by or on behalf of the Government for research or other Government purposes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Third
Party License</B>. Pursuant to 15 U.S.C. &sect;3710a(b)(l)(B), if PHS grants an exclusive license to a Subject Invention made
wholly by PHS employees or jointly with a Collaborator under this CRADA, the Government shall retain the right to require the
Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the
invention in Collaborator's licensed field of use on terms that are reasonable under the circumstances; or if the
Collaborator fails to grant such a license, to grant the license itself. The exercise of such rights by the Government shall
only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or
safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to meet requirements for public
use specified by Federal regulations, and such requirements are not reasonably satisfied by the Collaborator; or (iii) the
Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C. &sect;3710a(c)(4)(B). The
determination made by the Government under this Article is subject to administrative appeal and judicial review under 35 U
S.C. &sect; 203(2). <B>Comments:</B> <I>This provision is the &ldquo;march-in&rdquo; provision. If the Government has health
or safety needs that are not reasonably satisfied by Collaborator, the Government may grant a license to use in the invention
in order to meet its requirements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Joint
Inventions Not Exclusively Licensed</B>. In the event that the Collaborator does not acquire an exclusive commercialization license
to IP rights in all fields in joint Subject Inventions then each Party shall have the right to use the joint Subject Invention
and to license its use to others in all fields not exclusively licensed to Collaborator. The Parties may agree to a joint licensing
approach for such IP rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>No exclusive commercialization license
was acquired for the subject patent families. Accordingly, Profound has the right use the Subject Invention and to license its
use to others in all fields.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Ownership
of Inventions</B>. Title to Subject Inventions made jointly by employees of PHS and Collaborator will be held jointly by PHS and
Collaborator, and title to Subject Inventions made solely by employees of the respective parties will be held by the respective
parties. Collaborator will have the initial option to file patent applications on joint Inventions at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments: </B><I>Title to
the subject patent families will be held jointly between PHS and Profound.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Research
License for PHS Inventions</B>. PHS grants to Collaborator a nonexclusive, nontransferable (but sublicensable) to Collaborator's
Affiliates), irrevocable, paid-up, license to practice Subject Inventions owned by the Government and to have Subject Inventions
owned by the Government practiced throughout the world by or on behalf of the Collaborator solely for research, development or
other internal Collaborator purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Profound receives a license to practice
Subject Inventions owned by the Government for research, development, other internal Profound purposes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">7.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>License
in CRADA Software</B>. To the extent CRADA Software made in whole or in part by PHS employees under this CRADA is governed by 17
U.S.C. &sect;105, Collaborator shall have the unrestricted right to duplicate, distribute, prepare derivative works from, and publicly
run such CRADA Software in the United States. For all CRADA Software, the Government shall have a nonexclusive, nontransferable,
irrevocable, royalty-free, worldwide license in the CRADA Software to duplicate it, to prepare derivative works, to run it publicly,
to authorize others working on behalf of the Government to do the same, and otherwise to use, run or utilize it for Government
purposes. In the exercise of this license, the Government shall remain mindful of Collaborator&rsquo;s possible interest in commercializing
the CRADA Software, and shall attempt to minimize any adverse impact the Government&rsquo;s use may have on the market for the
CRADA Software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>If CRADA Software was made in whole
or in part by PHS employees under this CRADA, Profound shall have the unrestricted right to duplicate, distribute, prepare, derivative
works from, and publicly run such CRADA Software in the United States. There is not expected to be any significant CRADA Software
to be transferred.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 126; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Government
Copyright Notice</B>. If Collaborator obtains a copyright registration in CRADA Software, Collaborator shall affix the applicable
copyright notice of 17 U.S.C. &sect; 401, 402, and 403, and an acknowledgement of the scientific and technical contributions of
the Public Health Service, to any product containing the CRADA Software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>If Profound obtains a Copyright
registration in the CRADA Software, Profound must include an acknowledgement of the scientific and technical contributions of the
PHS to any product containing the CRADA Software.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Article 8. Proprietary Rights and Publications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Proprietary
/Confidential Information</B>. Each Party agrees to limit disclosure of Proprietary/Confidential Information to the amount necessary
to carry out the Research Plan of this CRADA and shall place a confidentiality notice on all such information. Confidential oral
communications shall be reduced to writing within 30 days by the disclosing Party. Each Party receiving Proprietary/Confidential
Information agrees that any information so designated shall be used by it only for the purposes described in the attached Research
Plan. Any Party may object to the designation of information as Proprietary/Confidential Information by another Party. Subject
Data and Research Materials developed solely by the Collaborator may be designated as Proprietary/Confidential Information when
they are wholly separable from the Subject Data and Research Materials developed jointly with PHS investigators, and advance designation
of such data and material categories is set forth in the RP. The exchange of other confidential information, e.g., Identifiable
Private Information, shall be subject to term of Article 8.9. Jointly developed Subject Data and Research Material derived from
the Research Plan may be disclosed by Collaborator to a third party under a confidentiality agreement for the purpose of possible
sublicensing pursuant to the Licensing Agreement and subject to Article 8.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Restricted and Confidential/Proprietary Computer Software
of Collaborator is provided under this Article for use in executing the Research Plan, except that the Restricted and Confidential/Proprietary
Computer Software shall not be subject to the three year duration of confidentiality obligation set forth in Article 8.6. Restricted
and Confidential/Proprietary Computer Software is provided to PHS with restricted rights as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted
and Confidential/Proprietary Computer Software may not be used, reproduced, or disclosed by PHS except as provided in (b) of this
paragraph or as otherwise expressly stated in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
computer software may be&mdash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Used
or copied for use with the computer(s) for which it was acquired, including use at any PHS installation to which such computers
may be transferred for use in carrying out the Research Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Used
or copied for use with a backup computer if any computer for which it was acquired is inoperative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reproduced
for safekeeping (archives) or backup purposes;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Modified,
adapted, or combined with other computer software, provided that such modification, adaptation or design is done only using standard
user input features and provided that the modified, adapted, or combined portions of the derivative software incorporating any
of the delivered, restricted computer software shall be subject to the same restricted rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
to and reproduced for use by support service contractors or their subcontractors in accordance with paragraphs (b)(1) through
(b)(4) of this notice; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Used or copied for use with a replacement computer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
right is granted to PHS to modify, adapt, translate, reverse engineer, decompile, disassemble, or create derivative works
based on Restricted and Confidential/Proprietary Computer Software. Any modification, adaptation or combination of Restricted
and Confidential/Proprietary Computer Software, whether made by Collaborator's personnel for the purposes of this Agreement
or made by Collaborator's personnel for any other purpose, shall be solely owned by Collaborator. Restricted and
Confidential/Proprietary Computer Software of Philips is not Computer Software or other data first produced in the
performance of this CRADA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Provided for background purposes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Publication</B>.
The Parties are encouraged to make publicly available the results of their research. Before either Party submits a paper or abstract
for publication or otherwise intends to publicly disclose information about a Subject Invention, Subject Data or Research Materials,
the other Patty shall be provided thirty (30) days to review the proposed publication or disclosure to assure that Proprietary/Confidential
Information is protected. The publication or other disclosure shall be delayed for up to thirty (30) additional days upon written
request by any Party as necessary to preserve U.S. or foreign patent or other IP rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Provided for background purposes.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 127; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Article 12. Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Indemnification</B>.
The Collaborator agrees to hold the U.S. Government harmless and to indemnify the Government for all liabilities, demands, damages,
expenses and losses arising out of the use by the Collaborator for any purpose of the Subject Data, Research Materials and/or Subject
Inventions produced in whole or part by PHS employees under this CRADA, unless due to the negligence or willful misconduct of PHS,
its employees, or agents. The Collaborator shall be liable for any claims or damages it incurs in connection with this CRADA. PHS
has no authority to indemnify the Collaborator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>Comments:</B> <I>Profound agrees to indemnify the
Government for any liabilities arising out of Profound&rsquo;s use of the Subject Invention, unless due to the negligence or willful
misconduct of PHS, its employees, or agents.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT B-2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM OF LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">This <B>LICENSE AGREEMENT</B> (this
 &ldquo;<U>Agreement</U>&rdquo;) dated as of the &#9632; day of &#9632;, 2017 (the &ldquo;<B>Effective Dates</B>&rdquo;) by and
among Profound Medical Corp. (the &ldquo;<B>Licensee</B>&rdquo;) and Koninklijke Philips N.V. (the &ldquo;<B>Licensor</B>&rdquo;).
Licensor and Licensee are hereinafter referred to collectively as the &ldquo;<B>Parties</B>&rdquo; or individually as a &ldquo;<B>Party</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">WHEREAS the Licensee acquired the
Subco Shares and the Purchased Assets (each as defined in the Purchase Agreement) from Licensor and its affiliates, pursuant to
and on the terms and conditions set forth in that certain Asset and Share Purchase Agreement, dated as of the &#9632; day of &#9632;,
2017 by and among Licensee and Licensor (the &ldquo;<B>Purchase Agreement</B>&rdquo;), and such Purchase Agreement requires the
Parties to enter into this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">WHEREAS, Licensor is the owner of
the Licensed Patents (as defined below); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">WHEREAS, Licensee desires to obtain
from Licensor, and Licensor desires to grant to Licensee, a license to the Licensed Patents under the terms and conditions of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">NOW THEREFORE, in consideration of
the premises, the mutual covenants, agreements and respective representations and warranties contained herein and in the Purchase
Agreement, and other good and valuable consideration, the receipt and sufficiency for which are hereby acknowledged, the Parties
hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>DEFINITIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Defined
Terms.</U> Capitalized terms used in this Agreement but not otherwise defined herein shall have the meanings ascribed
thereto in the Asset and Share Purchase Agreement. As used in this Agreement, the following capitalized terms shall have the
meanings set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;<B>Licensed Patents</B>&rdquo;
shall mean the patent applications and patents listed on Exhibit A hereto, along with any and all divisionals, re-issues, renewals,
re-examinations, continuations, continuations-in-part, priorities and foreign counterparts of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;<B>Line of Business</B>&rdquo; shall mean [Redacted
 &ndash; Commercially Sensitive].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 129 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>LICENSES AND OTHER RIGHTS OF LICENSOR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">2.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Scope
of License.</U> Subject to the terms and conditions of this Agreement, Licensor, on behalf of itself and its applicable Affiliates,
hereby grants to Licensee and its Affiliates a non-exclusive (subject to Section 2.02), irrevocable, worldwide, and fully paid-up
license, with a right to sublicense, under the Licensed Patents to manufacture, use, sell, lease, import, export, distribute, repair,
refurbish, service or otherwise dispose of Products (as defined in the Purchase Agreement) solely within the Line of Business (the
 &ldquo;<B>License</B>&rdquo;); provided that any sublicense relates to Products that are manufactured pursuant to and based on
the design and specifications owned by Licensee and/or its Affliates. The License shall run with title to the Licensed Patents,
and Licensor shall provide and ensure that the License remains in effect and irrevocably bind any transferee notwithstanding any
sale, assignment, hypothecation, lease, or any other transfer whatsoever of any of the Licensed Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">2.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limited
Exclusivity.</U> Notwithstanding anything to the contrary, the License granted herein shall be exclusive (including as to Licensor
and its Affiliates) to Licensee and its Affiliates within the Line of Business for a period of three (3) years from the date hereof,
followed by a sole license for an additional two (2) year period in which the Licensor and its Affiliates are permitted to exercise
the Licensed Patents in the Line of Business, but not license third parties under the Licensed Patents in the Line of Business
during this period; and thereafter the License shall continue on a non-exclusive basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in; text-align: justify">2.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
License granted hereunder may be assigned by Licensee to a Third Party acquirer of the Business or a substantial portion of the
assets thereof, provided that such Third Party acquirer will have informed Licensor in writing of its commitment to be bound by
the provisions of this Agreement prior to such acquisition and further subject to the condition that the license assigned shall
only be for the Business and not for any existing or other acquired business of such third party acquirer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(b)<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
Licensed Patents may be assigned by Licensor or the applicable Affiliate of Licensor to a Third Party acquirer of the Licensed
Patents, provided that such Third Party acquirer will have informed Licensee in writing of its commitment to be bound by the provisions
of this Agreement concurrently with or prior to such acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>MISCELLANEOUS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">3.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
contained in Agreement shall be deemed or construed to constitute or create a partnership, association, joint venture or other
agency between the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
amendment to this Agreement may be made unless agreed to by the Parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
notices or other communications hereunder shall be given in accordance with the notices provision of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise explicitly provided herein, Licensee may not assign any right or obligations under this Agreement to any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
headings of this Agreement are for convenience purposes only and do not constitute a part of this Agreement and shall not be construed
to limit or change any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party shall pay its own costs and expenses, including the fees and expenses of its accountants, financial advisors and legal counsel,
incurred in connection with the negotiation, execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement is and shall be deemed to be a contract entered into and made pursuant to the laws of the Province of Ontario and shall
in all respects be governed, construed, applied and enforced in accordance with said laws, without reference to applicable conflict
of laws rules or principles. Any action or proceeding in respect of any claim arising out of or related to this Agreement shall
be solely conducted by the Parties in accordance with the procedure provided in Sections 12.2, 13.5 and 13.10 of the Purchase Agreement,
including the right to pursue equitable or injunctive relief in a court in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement may be executed in counterparts, all of which when so executed shall be deemed to be an original and all of which
taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this
Agreement by facsimile transmission or other electronic transmission shall be as effective as delivery of a manually executed
counterpart of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement, together with the Purchase Agreement and the Other Transaction Documents constitutes the entire agreement and
understanding between the Parties with respect to the subject matter hereof and supersedes any and all prior discussions,
negotiations, letters of intent or agreements in principle between them. In the event of a conflict between this Agreement
and the Purchase Agreement with respect to the subject matter of this Agreement, this Agreement shall control.</P>


<!-- Field: Page; Sequence: 131; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify"><B>IN WITNESS WHEREOF</B>, each
of the Parties has caused this Agreement to be executed by its duly authorized officer as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">KONINKLIJKE PHILIPS N.V.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Brian Hinman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Chief Intellectual Property Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Exhibit A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 133; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NONCOMPETITION, NONSOLICITATION AND CONFIDENTIALITY
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">This
Noncompetition, Nonsolicitation and Confidentiality Agreement (this &quot;<B>Agreement</B>&quot;), effective as of the
Closing Date (as defined in the Purchase Agreement which is defined below), is made by and among Koninklijke Philips NV (the
 &ldquo;Vendor&rdquo;), and Profound Medical Corp. (the &ldquo;<B>Purchaser</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Vendor and the Purchaser entered into that certain Asset and Share Purchase Agreement dated as of &#9632;, 2017 (the &quot;<B>Purchase
Agreement</B>&quot;) pursuant to which the Purchaser purchased certain assets and equity from the Vendor as more fully set forth
in the Purchase Agreement (the &quot;<B>Transaction</B>&quot;). Capitalized terms used but not defined herein shall have the meanings
ascribed to such terms in the Purchase Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, prior
to the Closing Date, the Vendor was the owner of the Business, the Purchased Assets and the Subco Shares that will be sold as more
fully set forth in the Purchase Agreement, and will receive significant consideration in the Transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Vendor is in possession of certain confidential information regarding the Business which it has obtained in its capacity as owner
of the Business, the Purchased Assets and the Subco Shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Purchaser has determined that the Vendor competing in the Business, the use or disclosure of the confidential information in the
Vendor&rsquo;s possession, or the solicitation by the Vendor of employees or customers of the Business would be detrimental to
the Business, and would fundamentally undermine the parties' purpose and intent in effecting the Transaction under its terms; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Purchaser is unwilling to consummate the Transaction without the benefit of the covenants and obligations of the Vendor contained
in this Agreement and has, therefore, required that it is an express condition of the Purchaser&rsquo;s obligation to consummate
the Transaction that the Vendor execute and deliver this Agreement and acknowledge that the Purchaser is relying on this Agreement
in entering into the Transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, because
the closing of the Transaction, including, without limitation, the sale by the Vendor under the Purchase Agreement of the Class
A Patents and Subco Shares as more fully set forth in the Purchase Agreement, will not occur without the execution and delivery
of this Agreement by the Vendor, the Vendor agrees hereby to be bound by the noncompetition, nonsolicitation and confidentiality
terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
in consideration of the foregoing and of the respective covenants and agreements set forth below the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 134 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncompetition;
Non-Solicitation<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor agrees that during the three (3) year period beginning on the date of the Closing Date (the &quot;<B>Noncompetition Period</B>&quot;)
the Vendor will not, and will not permit any of its directors, officers, employees or agents to, directly or indirectly through
any of its Affiliates, (i) (A) engage or participate in any business in the Line of Business, anywhere in the Territory, or (B)
take any action to invest in, own, manage, operate, control or participate in any Person engaging in any business that competes
within the Line of Business anywhere in the Territory, if that Person&rsquo;s revenues attributable to the Line of Business amount
to more than 10% of such entity&rsquo;s total annual revenues; provided that if such revenue threshold is exceeded the Vendor shall
have twelve months from the date of completion of the corresponding transaction to divest that portion of the entity engaged in
the Line of Business, or (ii) (A) solicit, sell, call upon, advise, do or attempt to do business with or otherwise contact in regard
to diverting business away from the Business, any customer or supplier of the Business as of the Closing Date, or (B) solicit,
encourage or induce any customer or supplier of the Business to terminate or materially and adversely alter its relationship with
Subco, the Purchaser or the Business. The Vendor shall not be in violation of this Section 1(a) solely as a result of (x) Vendor
and its Affiliates, as applicable, fulfilling its obligations under the Other Transaction Documents, or (y) an investment in stock
or other securities of any publicly held entity if the Vendor or any of its Affiliates does not, directly or indirectly, hold in
the aggregate more than a total of three (3%) of all such shares of stock or other securities issued and outstanding. For purposes
hereof, &ldquo;<B>Line of Business</B>&rdquo; means [Redacted &ndash; Commercially Sensitive].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the period which any of Other Transaction Documents are in effect and for two (2) years thereafter, the Vendor will not permit
any of its directors, officers, employees or agents to, directly or indirectly through any of its Affiliates, whether on the Vendor&rsquo;s
own behalf or on behalf of any other Person, (i) solicit, induce, persuade, entice or endeavor to solicit, induce, persuade or
entice an Employee or any current (meaning at date of this Agreement) member of management of Purchaser or any of its Affiliates
to leave employment or cease performing services for Subco, the Business, or the Purchaser following the Closing, (ii) hire or
retain the services of, or attempt to hire or retain the services of, an Employee or any current member of management of Purchaser
or any of its Affiliates, (iii) assist in the hiring or attempted hiring of an Employee or any member of management of Purchaser
or any of its Affiliates by any Person, other than, in each case, any Employee or any current member of management of Purchaser
or any of its Affiliates who (A) responds to advertising placed in a newspaper, trade journal, through a website or via other
media of general circulation or an executive search firm acting on the Vendor&rsquo;s behalf whose effort were not directed at
the Employees or any current member of management of Purchaser or any of its Affiliates, (B) who has terminated his/her employment
with, or has been terminated by, Subco or the Purchaser, or (C)&nbsp;who initiates
contact with the Vendor with no encouragement or inducement on the part of the Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used in this Agreement, (i) &quot;<B>Person</B>&quot; shall mean any natural person, firm, partnership, association, corporation,
company, trust, business trust, or other such entity (ii) &quot;<B>Territory</B>&quot; shall mean worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 135; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Vendor or any Affiliate of the Vendor is acquired (whether by merger, acquisition or otherwise) by any Person who is not an
Affiliate of the Vendor (such Person, the &ldquo;<B>Acquiror</B>&rdquo;), this Section 1 shall not apply in respect of any activities
of the Acquiror or any of its Affiliates (including the acquired entity or entities) following such acquisition, to the extent,
and only to the extent, (i) that such activities are carried out by such entities prior to such acquisition, and (ii) none of the
employees, officers or directors of the Vendor or any Affiliate of the Vendor who devoted 50% or more of his/her time to matters
relating to Line of Business at any time within 24 months prior to such acquisition, shall participate in any manner whatsoever
with such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
there is a conflict between this Section 1 and the provisions of any of the Other Transaction Documents, the provisions of this
Section 1 shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nondisclosure
of Confidential Information<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor hereby acknowledges that during the course of the Vendor&rsquo;s association with the Business, the Vendor and its Affiliates
have gained certain confidential and proprietary information and trade secrets of the Business including, without limitation, some
or all of the following: information pertaining to the products and business operations of the Business, including, without limitation,
customer lists and prices, methods of manufacture, operation and distribution of the Products, which may be confidential or a trade
secret, or both; processes; protocols; ideas; designs, inventions; business practices; potential customers and suppliers; marketing
methods; costs; contractual relationships; regulatory status; compensation paid to Employees or other terms of employment; dealers;
distributors; sales; costs; pricing; strategies; forecasts and long range plans; financial and tax matters; manufacturing strategies
and techniques; personnel; business, marketing and operational matters; projections; plans and opportunities; product formulas;
and customer, vendor, and supplier data (collectively, &quot;<B>Confidential Information</B>&quot;). For a period of ten (10) years
following the Closing, the Vendor and its Affiliates shall maintain in confidence and shall not directly or indirectly disseminate,
disclose or publish, or use in any manner detrimental to the Business, any Confidential Information or deliver to any Person any
document, record, notebook, computer program or similar repository of or containing any Confidential Information. Notwithstanding
anything to the contrary set forth herein, &quot;<B>Confidential Information</B>&quot; shall not include: (i) any information which
is in the public domain (other than by means of the Vendor&rsquo;s (or the Vendor&rsquo;s directors', officers', employees', agents'
or Affiliates&rsquo;) direct or indirect disclosure of such Confidential Information in violation of the Vendor&rsquo;s obligations
under this Section 2(a); (ii) any information which enters the public domain (other than by means of the Vendor&rsquo;s (or the
Vendor&rsquo;s directors', officers', employees', agents' or Affiliates&rsquo;) direct or indirect disclosure of such Confidential
Information in violation of its obligations under this Section 2(a)) or (iii) any information subsequently developed by the Vendor
without reference to or use of the Confidential Information or (iv) any information disclosed to the Vendor (provided it is disclosed
to Vendor not in its capacity as an agent, distributor or manufacturer of the Purchaser or its Affiliates) from any Third Party
on a non-confidential basis provided that such Third Party is not, to the knowledge of the Vendor, in violation of any other obligation
of confidentiality or non-use. Without limiting the foregoing, nothing herein shall limit the confidentiality obligations of the
Vendor and its Affiliates under the Other Transaction Documents. The parties hereby stipulate and agree that, as among them, the
Confidential Information identified herein is important, material and affects the successful conduct of the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, the Vendor may disclose Confidential Information if legally required (in response to a lawful and valid subpoena,
oral questions, requests for information or documents, civil investigative demand or other legal process) but (i) shall, to the
extent legally permitted, give the Purchaser notice thereof as promptly as practicable, (ii) shall, as much in advance of the
return date as reasonably possible and to the extent legally permitted, make available to the Purchaser and its counsel the documents
and other information sought, (iii) shall use reasonable commercial efforts to assist such counsel in resisting or otherwise responding
to such process at the Purchaser&rsquo;s sole cost and expense, and (iv)&nbsp;in any
event, only disclose the minimum information that is required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reasonable Restraint; Injunctive Relief.</B> It is
recognized and acknowledged by the Vendor that a breach of the covenants contained in Section 1 and Section 2 will cause
irreparable damage to the Business, Subco and the Purchaser and the goodwill of the Business, Subco and the Purchaser, the
exact amount of which will be difficult or impossible to ascertain, and that the remedies at law for any such breach will be
inadequate. It is also recognized and acknowledged by the Vendor that (i) for the reasons set forth in the Recitals of this
Agreement, the Purchaser will not consummate the Transaction without the execution of this Agreement by the Vendor, (ii) the
covenants contained in Section 1 and Section 2 impose a reasonable restraint on the Vendor in light of the requirement by the
Purchaser that the Vendor execute this Agreement as a condition to the consummation of the Transaction and the
significant benefits received by the Vendor in the Transaction, and (iii) the Vendor has received good and valuable
consideration in exchange for the Vendor&rsquo;s agreement to be bound by such covenants. Accordingly, the Vendor agrees that
in the event of a breach of any of the covenants contained in Section 1 and Section 2, in addition to any other remedy which
may be available at law or in equity, Subco and the Purchaser will be entitled to apply for specific performance and
injunctive relief in any court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Binding Effect; Successors and Assigns.</B>
This Agreement shall be binding upon and shall inure to the exclusive benefit of the parties and their respective heirs,
executors, administrators, legal representatives, successors and permitted assigns and nothing herein, express or implied, is
intended to, nor shall it, confer on any other Person any legal or equitable right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement. The Purchaser may, upon written notice to the Vendor, assign its rights
under this Agreement to any entity, including any successors to all, substantially all or a material portion of the assets of
the Purchaser&rsquo;s business, by merger or otherwise, and may assign or encumber this Agreement and its rights hereunder as
security for indebtedness of the Purchaser and its Affiliates, and any such assignee or secured party may foreclose
upon, assign or encumber this Agreement or such rights. The Vendor may not assign the Vendor&rsquo;s rights or obligations
under this Agreement to any individual or entity except by operation of law or to the estate or legal representatives of the
Vendor with respect to obligations the Vendor may have under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</B>. This Agreement is and shall be deemed to be a contract entered into and made pursuant to the laws of the
Province of Ontario and the laws of Canada applicable in such Province and shall in all respects be governed, construed, applied
and enforced in accordance with said laws, without reference to applicable conflict of laws rules or principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 137; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>. Any notice or other communication required or permitted to be given to any party hereunder shall be in writing
and shall be given to such party at such party&rsquo;s address set forth below, or such other address as such party may hereafter
specify by notice in writing to the other Person. Any such notice or other communication shall be addressed as aforesaid and given
by: (i) hand delivery; (ii) international overnight courier; or (iii) e-mail transmission. Any notice or other communication will
be deemed to have been duly given: (A) on the date of service if served personally; (B) on the Business Day after delivery to an
international overnight courier service, provided receipt of delivery has been confirmed; or (C) on the date of transmission if
sent via e-mail transmission, provided confirmation of receipt is obtained promptly after completion of transmission and provided
that transmission via e-mail is followed promptly by delivery via one of the methods in Section 6(i) or (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">To the Vendor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Koninklijke Philips NV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Amstelplein 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">1096 BC Amsterdam</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">Attention:</TD>
    <TD STYLE="width: 87%">Philips Group Legal &ndash; Head of Legal M&amp;A and Alliances</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>Gregory.hatfield@philips.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Blake, Cassels &amp; Graydon LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">199 Bay Street, Suite 4000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, Ontario M5L 1A9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">Attention:</TD>
    <TD STYLE="width: 87%">Ken Pearce</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>kenneth.pearce@blakes.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">To the Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2400 Skymark Avenue, Unit 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Mississauga, ON L4W 5K5</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">Attention:</TD>
    <TD STYLE="width: 87%">Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>amenawat@profoundmedical.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Torys LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Suite 3000, P.O. Box 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">79 Wellington Street West TD Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, ON M5K 1N2</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">Attention:</TD>
    <TD STYLE="width: 87%">Cheryl Reicin and Leah Frank</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>creicin@torys.com and lfrank@torys.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 138; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts; Electronic Delivery.</B> This Agreement may be executed
in counterparts, all of which when so executed shall be deemed to be an original and all of which taken together shall constitute
one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission
or other electronic transmission shall be as effective as delivery of a manually executed counterpart of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement</B>. The terms of this
Agreement, together with the Purchase Agreement of which this Agreement is a part of, are intended by the parties to be the
entire agreement of the parties with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments; Waivers</B>. No amendment to this Agreement may be made
unless agreed to by the parties in writing. By an instrument in writing similarly executed, the Vendor or the Purchaser may waive
compliance by the other party or parties with any provision of this Agreement that such other party was or is obligated to comply
with or perform, provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or
subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any
other or further exercise of any other right, remedy, or power provided herein or by law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction</B>. The parties agree that they have been
represented by counsel during the negotiation and execution of this Agreement and, therefore, waive the application of
any Law, holding or rule of construction providing that ambiguities in an agreement or other document will be construed
against the party drafting such agreement or document. The headings in this Agreement are only for convenience and are not
intended to affect construction or interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement</B>. Wherever possible, each provision of this Agreement
shall be interpreted in such a manner as to be effective and valid under applicable Law. If any portion of this Agreement is
declared invalid for any reason in any jurisdiction, such declaration shall have no effect upon the remaining portions of
this Agreement which shall continue in full force and effect as if this Agreement had been executed with the invalid portions
thereof deleted; provided, however, if such severability will negate in any material respect the monetary terms of this
Agreement, then the parties shall negotiate in good faith to amend the invalid terms in a manner so that such terms shall not
be invalid and will not modify in any material respect the monetary terms of this Agreement unless otherwise agreed to by the
parties. Furthermore, the entirety of this Agreement shall continue in full force and effect in all other jurisdictions.
Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically as part of this
Agreement a provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and be
legal, valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 139; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vendor&rsquo;s Acknowledgement</B>. The Vendor acknowledges that
the Vendor (i) has read and understands this Agreement, (ii) has, to the extent the Vendor so desires and as recommended by
the Purchaser, consulted with legal counsel with respect to the terms and condition hereof, (iii) is fully aware of its
legal effect, (iv) has not acted in reliance upon any representations or promises made by any Person other than those
contained in writing herein and in the Purchase Agreement, (v) has entered into this Agreement freely based on the
Vendor&rsquo;s own judgment with the advice of legal counsel and other advisers as the Vendor has deemed necessary or
advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 140; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">IN WITNESS WHEREOF, the parties
have executed this Agreement on the date and year first above referenced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">KONINKLIJKE PHILIPS NV</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 3%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 47%; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Authorized Representative</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to Non-Competition and
Non-Disclosure Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 141 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INTELLECTUAL PROPERTY RIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Patents:</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">[Redacted &ndash; Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 142 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><U>1.</U></TD><TD STYLE="text-align: justify"><U>Trademarks:</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 143; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PURCHASER DISCLOSURE SCHEDULE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASSET AND SHARE PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PROFOUND MEDICAL CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">KONINKLIJKE PHILIPS N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Dated as of June
30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 144 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">The
Disclosure Schedule, dated as of June 30, 2017, is being delivered by the Purchaser pursuant to the Asset and Share Purchase
Agreement, dated as of June 30, 2017, by and among the Purchaser and the Vendor (the &ldquo;<B>Agreement</B>&rdquo;).
Capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Agreement. References to
 &ldquo;Data Room&rdquo; shall mean the Company&rsquo;s electronic data room on the on the Merrill website at <U>https://eu1.merrillcorp.com</U>
as in effect at 5:00 p.m. (Toronto time), June 29, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">The
headings, sub-headings and captions herein are included for convenience of reference only and shall be ignored in the
construction or interpretation hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 145; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><U>Schedules</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.3</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Approvals, Notices and Filings</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Party Consents, Approvals and Notices</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.18(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.21</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liens</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ownership of Assets</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section 4.25(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser Intellectual Property</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 146; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 4.3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Government Approvals, Notices and Filings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Receipt of final approval from TSX Venture Exchange
for the issuance of the Purchaser Common Shares and the listing of such Common Shares on the TSX Venture Exchange, including but
not limited to, the clearance of the personal information form of the Vendor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 147 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 4.4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Third Party Consents, Approvals and Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Consent from Knight Therapeutics Inc. under the loan
agreement between the Purchaser and Knight Therapeutics Inc. dated April 30, 2015.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 148 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 4.18(b)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Share Capital, etc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Omitted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 149 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 4.21</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Liens</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Knight Therapeutics Inc. has a lien on all of the assets
of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 150 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 4.22</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ownership of Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">See Section 4.21 of the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 4.25(b)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Purchaser Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Sunnybrook License Agreement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 152 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">VENDOR DISCLOSURE SCHEDULE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASSET AND SHARE PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PROFOUND MEDICAL CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">KONINKLIJKE PHILIPS N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Dated as of June
30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 153 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">The
Disclosure Schedule, dated as of June 30, 2017, is being delivered by the Vendor pursuant to the Asset and Share Purchase
Agreement, dated as of June 30, 2017, by and among the Purchaser and the Vendor (the &ldquo;<B>Agreement</B>&rdquo;).
Capitalized terms used herein but not otherwise defined shall have the meanings set forth in the Agreement. References to
 &ldquo;Data Room&rdquo; shall mean the Company&rsquo;s electronic data room on the on the Merrill website at <U>https://eu1.merrillcorp.com</U>
as in effect at 5:00 p.m. (Toronto time), June 29, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in; text-align: justify">The
headings, sub-headings and captions herein are included for convenience of reference only and shall be ignored in the
construction or interpretation hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 154; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Schedules</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">Section 1.1-1</TD>
    <TD STYLE="width: 75%">Employees</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 1.1-2</TD>
    <TD>Material Supplier Contracts</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 1.1-3</TD>
    <TD>Transferred Contracts</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 1.1-4</TD>
    <TD>Purchased Assets &ndash; Marketing Assets</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 1.1-5</TD>
    <TD>Tangible Assets</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 1.2</TD>
    <TD>Individuals with Knowledge of the Vendor</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 2.7</TD>
    <TD>Allocation of Purchase Price</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.5</TD>
    <TD>Government Approvals, Notices and Filings</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.6</TD>
    <TD>Third Party Consents, Approvals and Notices</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.7</TD>
    <TD>Absence of Breach; Non-Contravention</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.9</TD>
    <TD>Absence of Other Liabilities</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.10</TD>
    <TD>Title to Assets</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.11</TD>
    <TD>Absence of Changes</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.14(b)</TD>
    <TD>Contracts</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.15(a)</TD>
    <TD>Intellectual Property Rights</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.15(b) and (d)</TD>
    <TD>Intellectual Property Rights</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.16(a)</TD>
    <TD>Employee Benefit Plans</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.16(e)</TD>
    <TD>Employee Benefit Plans</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.17(a)</TD>
    <TD>Employees; Labour Relations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.17(b)</TD>
    <TD>Employees; Labour Relations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.17(d)</TD>
    <TD>Employees; Labour Relations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.17(g)</TD>
    <TD>Employees; Labour Relations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Sections 3.18(a)</TD>
    <TD>Taxes and Tax Returns</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.20</TD>
    <TD>Environmental Matters</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.21</TD>
    <TD>Permits</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.22</TD>
    <TD>Compliance with Laws</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Sections 3.23</TD>
    <TD>Litigation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.26</TD>
    <TD>Customers</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.29(b),(c) and (d)</TD>
    <TD>Regulatory Matters</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 3.30</TD>
    <TD>Financial Services Relations</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 5.1</TD>
    <TD>Restrictions</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 5.11</TD>
    <TD>Affiliate Transactions</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 8.4</TD>
    <TD>Consents, Approvals and Notices</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Section 9.4</TD>
    <TD>Consents, Approvals and Notices</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>


<!-- Field: Page; Sequence: 155; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 1.1-1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Redacted - Personal Information]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 156; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 1.1-2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Material Supplier Contracts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Omitted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 157; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 1.1-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Transferred Contracts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Research Agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 158; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Employee Agreements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted - Personal Information]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 159; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 1.1-4</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Purchased Assets &ndash; Marketing Assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">All of the following items with respect to the Business:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Logos</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Update of product logos on Sonalleve</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Product powerpoints</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Product brochures, flyers and other promotional material</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Product pictures</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Any clinical whitepapers</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Studies where distribution to customer rights were
purchased</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Website (uterine fibroid and Philips Sonalleve)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Catalogue &ndash; remains in Philips catalogue</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Packaging and any changes</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Conference and booth hardware/materials</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify">Demo Units, including Sonalleve products and any accessories
and TULSA-PRO and any accessories</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 160; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 1.1-5</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Tangible Assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">HIFU assets Helsinki</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">HIFU assets Best</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Demo Units</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 161; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 1.2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Individuals with Knowledge of the Vendor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted - Personal Information]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 162; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 2.7</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Allocation of Purchase Price</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">The purchase
price under section 4.1 of the asset transfer agreement between Philips Oy and Subco and the purchase price under section 4.1 of
the asset transfer agreement between Philips Medical Systems Nederland B.V. and Subco, in each case, to be entered into upon Closing,
will be allocated to the Subco Shares, and the remainder of the Purchase Price will be allocated to the Class A Patents and Trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 163; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.5</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Government Approvals, Notices and Filings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 164; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.6</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Third Party Consents, Approvals and Notices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Any consent, approval or notice required to transfer
the Transferred Contracts or Transferred Permits to Subco on the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 165; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.7</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Absense of Breach; Non-Contravention</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 138.15pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 166; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.9</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Absence of Other Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 167.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>


<!-- Field: Page; Sequence: 167; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.10</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Title to Assets</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Certain leased computers.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Patents:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Redacted
- Commercially Sensitive]</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are all co-owned.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">See item 3 of Schedule 3.15(a).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 168; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.11</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Absence of Changes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 169; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.14(b)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 170; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.15(a)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Intellectual Property Rights</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 171; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Disclosure Schedule Section 3.15(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Owned Registered Business Intellectual Property</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Reference is made to Schedule A of the Intellectual
Property Assignment Agreement and Exhibit A of the Intellectual Property License Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Non-owned Registered Business Intellectual Property </TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.5in">Nil</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Other non-owned Business Intellectual Property</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Open Source Software</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-left: -4.5in">[Redacted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 172; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Non-open Source Software</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">[Redacted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 173; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.15(b) and (d)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Intellectual Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;"><B>Section 3.15(b):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Section 3.15(d):</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 174; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.16(a)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employee Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.85pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 175; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Disclosure Schedule Section 3.16(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Collective Agreement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Benefit List</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Equality Policy</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">Employee Handbook</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">Manager Handbook</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.</TD><TD STYLE="text-align: justify">Sample Employment Contract</TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">7.</TD><TD STYLE="text-align: justify">Aava document</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify">Scope of occupational healthcare</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Remainder Omitted - Commercially Sensitive and Personal
Information]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 176; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.16(e)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employee Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The bonuses and holidays as listed in Schedule 3.17(a).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 177; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.17(a)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employees; Labour Relations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 162.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 178; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Disclosure Schedule Section
3.17(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employee Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.55pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Redacted - Personal Information]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.3pt; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 179; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.17(b)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Employees; Labour Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Redacted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 180; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.17(d)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employees; Labour Relations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 162.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 181; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.17(g)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Employees; Labour Relations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 162.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 182; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.18(a)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Taxes and Tax Returns</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 107.35pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 183; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.20</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Environmental Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.85pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 184; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.21</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Permits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Omitted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>


<!-- Field: Page; Sequence: 185; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.22</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Compliance with Laws</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.1pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>


<!-- Field: Page; Sequence: 186; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.23</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Litigation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 131.25pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">&nbsp;</P>


<!-- Field: Page; Sequence: 187; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Section
3.26</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Customers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 188.15pt; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Omitted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 188; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 3.29(b),(c) and (d)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">[Omitted - Commercially Sensitive]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 189; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 3.30</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Financial Services Relations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 169pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See attached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Redacted - Personal Information]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 190; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Disclosure Schedule Section 3.30</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 151.25pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 191; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 5.1</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Restrictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 192; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Section 5.11</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Affiliate Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">Nil.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 193; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 8.4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consents, Approvals and Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt;">See Sections 4.3 and 4.4 of the Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 194; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Section 9.4</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consents, Approvals and Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Receipt of final approval from TSX Venture Exchange for
the issuance of the Purchaser Common Shares and the list of such Common Shares on the TSX Venture Exchange, including but not
limited to, the clearance of the personal information form of the Vendor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23pt; text-indent: -0.25in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 195; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>9
<FILENAME>tv526458_ex4-3.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: #20262D"><B>Exhibit 4.3</B></FONT></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NONCOMPETITION, NONSOLICITATION AND
CONFIDENTIALITY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">This Noncompetition,
Nonsolicitation and Confidentiality Agreement (this &quot;<B>Agreement</B>&quot;), effective as of the Closing Date (as defined
in the Purchase Agreement which is defined below), is made by and among Koninklijke Philips NV (the &ldquo;Vendor&rdquo;), and
Profound Medical Inc. (the &ldquo;<B>Purchaser</B>&rdquo;), a wholly-owned subsidiary of Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Vendor and Profound Medical Corp. entered into that certain Asset and Share Purchase Agreement dated as of June 30, 2017 (the &quot;<B>Purchase
Agreement</B>&quot;) pursuant to which the Purchaser purchased certain assets and equity from the Vendor as more fully set forth
in the Purchase Agreement (the &quot;<B>Transaction</B>&quot;). Capitalized terms used but not defined herein shall have the meanings
ascribed to such terms in the Purchase Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, prior
to the Closing Date, the Vendor was the owner of the Business, the Purchased Assets and the Subco Shares that will be sold as more
fully set forth in the Purchase Agreement, and will receive significant consideration in the Transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Vendor is in possession of certain confidential information regarding the Business which it has obtained in its capacity as owner
of the Business, the Purchased Assets and the Subco Shares; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Purchaser has determined that the Vendor competing in the Business, the use or disclosure of the confidential information in the
Vendor&rsquo;s possession, or the solicitation by the Vendor of employees or customers of the Business would be detrimental to
the Business, and would fundamentally undermine the parties' purpose and intent in effecting the Transaction under its terms; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, the
Purchaser is unwilling to consummate the Transaction without the benefit of the covenants and obligations of the Vendor contained
in this Agreement and has, therefore, required that it is an express condition of the Purchaser&rsquo;s obligation to consummate
the Transaction that the Vendor execute and deliver this Agreement and acknowledge that the Purchaser is relying on this Agreement
in entering into the Transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, because
the closing of the Transaction, including, without limitation, the sale by the Vendor under the Purchase Agreement of the Class
A Patents and Subco Shares as more fully set forth in the Purchase Agreement, will not occur without the execution and delivery
of this Agreement by the Vendor, the Vendor agrees hereby to be bound by the noncompetition, nonsolicitation and confidentiality
terms and conditions set forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
in consideration of the foregoing and of the respective covenants and agreements set forth below the parties hereto agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncompetition;
Non-Solicitation<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor agrees that during the three (3) year period beginning on the date of the Closing Date (the &quot;<B>Noncompetition Period</B>&quot;)
the Vendor will not, and will not permit any of its directors, officers, employees or agents to, directly or indirectly through
any of its Affiliates, (i) (A) engage or participate in any business in the Line of Business, anywhere in the Territory, or (B)
take any action to invest in, own, manage, operate, control or participate in any Person engaging in any business that competes
within the Line of Business anywhere in the Territory, if that Person&rsquo;s revenues attributable to the Line of Business amount
to more than 10% of such entity&rsquo;s total annual revenues; provided that if such revenue threshold is exceeded the Vendor shall
have twelve months from the date of completion of the corresponding transaction to divest that portion of the entity engaged in
the Line of Business, or (ii) (A) solicit, sell, call upon, advise, do or attempt to do business with or otherwise contact in regard
to diverting business away from the Business, any customer or supplier of the Business as of the Closing Date, or (B) solicit,
encourage or induce any customer or supplier of the Business to terminate or materially and adversely alter its relationship with
Subco, the Purchaser or the Business. The Vendor shall not be in violation of this Section 1(a) solely as a result of (x) Vendor
and its Affiliates, as applicable, fulfilling its obligations under the Other Transaction Documents, or (y) an investment in stock
or other securities of any publicly held entity if the Vendor or any of its Affiliates does not, directly or indirectly, hold in
the aggregate more than a total of three (3%) of all such shares of stock or other securities issued and outstanding. For purposes
hereof, &ldquo;<B>Line of Business</B>&rdquo; means [Redacted &ndash; Commercially Sensitive].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the period which any of Other Transaction Documents are in effect and for two (2) years thereafter, the Vendor will not
permit any of its directors, officers, employees or agents to, directly or indirectly through any of its Affiliates, whether
on the Vendor&rsquo;s own behalf or on behalf of any other Person, (i) solicit, induce, persuade, entice or endeavor to
solicit, induce, persuade or entice an Employee or any current (meaning at date of this Agreement) member of management of
Purchaser or any of its Affiliates to leave employment or cease performing services for Subco, the Business, or the Purchaser
following the Closing, (ii) hire or retain the services of, or attempt to hire or retain the services of, an Employee or any
current member of management of Purchaser or any of its Affiliates, (iii) assist in the hiring or attempted hiring of an
Employee or any member of management of Purchaser or any of its Affiliates by any Person, other than, in each case, any
Employee or any current member of management of Purchaser or any of its Affiliates who (A) responds to advertising placed in
a newspaper, trade journal, through a website or via other media of general circulation or an executive search firm acting on
the Vendor&rsquo;s behalf whose effort were not directed at the Employees or any current member of management of Purchaser or
any of its Affiliates, (B) who has terminated his/her employment with, or has been terminated by, Subco or the Purchaser, or
(C) who initiates contact with the Vendor with no encouragement or inducement on the part of the Vendor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
used in this Agreement, (i) &quot;<B>Person</B>&quot; shall mean any natural person, firm, partnership, association, corporation,
company, trust, business trust, or other such entity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">(ii) &quot;<B>Territory</B>&quot; shall mean worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Vendor or any Affiliate of the Vendor is acquired (whether by merger, acquisition or otherwise) by any Person who is not an
Affiliate of the Vendor (such Person, the &ldquo;<B>Acquiror</B>&rdquo;), this Section 1 shall not apply in respect of any activities
of the Acquiror or any of its Affiliates (including the acquired entity or entities) following such acquisition, to the extent,
and only to the extent, (i) that such activities are carried out by such entities prior to such acquisition, and (ii) none of the
employees, officers or directors of the Vendor or any Affiliate of the Vendor who devoted 50% or more of his/her time to matters
relating to Line of Business at any time within 24 months prior to such acquisition, shall participate in any manner whatsoever
with such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
there is a conflict between this Section 1 and the provisions of any of the Other Transaction Documents, the provisions of this
Section 1 shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nondisclosure
of Confidential Information<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Vendor hereby acknowledges that during the course of the Vendor&rsquo;s association with the Business, the Vendor and its Affiliates
have gained certain confidential and proprietary information and trade secrets of the Business including, without limitation, some
or all of the following: information pertaining to the products and business operations of the Business, including, without limitation,
customer lists and prices, methods of manufacture, operation and distribution of the Products, which may be confidential or a trade
secret, or both; processes; protocols; ideas; designs, inventions; business practices; potential customers and suppliers; marketing
methods; costs; contractual relationships; regulatory status; compensation paid to Employees or other terms of employment; dealers;
distributors; sales; costs; pricing; strategies; forecasts and long range plans; financial and tax matters; manufacturing strategies
and techniques; personnel; business, marketing and operational matters; projections; plans and opportunities; product formulas;
and customer, vendor, and supplier data (collectively, &quot;<B>Confidential Information</B>&quot;). For a period of ten (10) years
following the Closing, the Vendor and its Affiliates shall maintain in confidence and shall not directly or indirectly disseminate,
disclose or publish, or use in any manner detrimental to the Business, any Confidential Information or deliver to any Person any
document, record, notebook, computer program or similar repository of or containing any Confidential Information. Notwithstanding
anything to the contrary set forth herein, &quot;<B>Confidential Information</B>&quot; shall not include: (i) any information which
is in the public domain (other than by means of the Vendor&rsquo;s (or the Vendor&rsquo;s directors', officers', employees', agents'
or Affiliates&rsquo;) direct or indirect disclosure of such Confidential Information in violation of the Vendor&rsquo;s obligations
under this Section 2(a); (ii) any information which enters the public domain (other than by means of the Vendor&rsquo;s (or the
Vendor&rsquo;s directors', officers', employees', agents' or Affiliates&rsquo;) direct or indirect disclosure of such Confidential
Information in violation of its obligations under this Section 2(a)) or (iii) any information subsequently developed by the Vendor
without reference to or use of the Confidential Information or (iv) any information disclosed to the Vendor (provided it is disclosed
to Vendor not in its capacity as an agent, distributor or manufacturer of the Purchaser or its Affiliates) from any Third Party
on a non-confidential basis provided that such Third Party is not, to the knowledge of the Vendor, in violation of any other obligation
of confidentiality or non-use. Without limiting the foregoing, nothing herein shall limit the confidentiality obligations of the
Vendor and its Affiliates under the Other Transaction Documents. The parties hereby stipulate and agree that, as among them, the
Confidential Information identified herein is important, material and affects the successful conduct of the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 1in; text-align: justify">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, the Vendor may disclose Confidential Information if legally required (in response to a lawful and valid
subpoena, oral questions, requests for information or documents, civil investigative demand or other legal process) but (i)
shall, to the extent legally permitted, give the Purchaser notice thereof as promptly as practicable, (ii) shall, as much in
advance of the return date as reasonably possible and to the extent legally permitted, make available to the Purchaser and
its counsel the documents and other information sought, (iii) shall use reasonable commercial efforts to assist such counsel
in resisting or otherwise responding to such process at the Purchaser&rsquo;s sole cost and expense, and
(iv) in any event, only disclose the minimum information that is required by
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reasonable Restraint; Injunctive Relief.</B> It is recognized and
acknowledged by the Vendor that a breach of the covenants contained in Section 1 and Section 2 will cause irreparable damage to
the Business, Subco and the Purchaser and the goodwill of the Business, Subco and the Purchaser, the exact amount of which will
be difficult or impossible to ascertain, and that the remedies at law for any such breach will be inadequate. It is also recognized
and acknowledged by the Vendor that (i) for the reasons set forth in the Recitals of this Agreement, the Purchaser will not consummate
the Transaction without the execution of this Agreement by the Vendor, (ii) the covenants contained in Section 1 and Section 2
impose a reasonable restraint on the Vendor in light of the requirement by the Purchaser that the Vendor execute this Agreement
as a condition to the consummation of the Transaction and the significant benefits received by the Vendor in the Transaction, and
(iii) the Vendor has received good and valuable consideration in exchange for the Vendor&rsquo;s agreement to be bound by such
covenants. Accordingly, the Vendor agrees that in the event of a breach of any of the covenants contained in Section 1 and Section
2, in addition to any other remedy which may be available at law or in equity, Subco and the Purchaser will be entitled to apply
for specific performance and injunctive relief in any court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Binding Effect; Successors and Assigns.</B> This Agreement shall
be binding upon and shall inure to the exclusive benefit of the parties and their respective heirs, executors, administrators,
legal representatives, successors and permitted assigns and nothing herein, express or implied, is intended to, nor shall it, confer
on any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
The Purchaser may, upon written notice to the Vendor, assign its rights under this Agreement to any entity, including any successors
to all, substantially all or a material portion of the assets of the Purchaser&rsquo;s business, by merger or otherwise, and may
assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Purchaser and its Affiliates, and
any such assignee or secured party may foreclose upon, assign or encumber this Agreement or such rights. The Vendor may not assign
the Vendor&rsquo;s rights or obligations under this Agreement to any individual or entity except by operation of law or to the
estate or legal representatives of the Vendor with respect to obligations the Vendor may have under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</B>. This Agreement is and shall be deemed to be a
contract entered into and made pursuant to the laws of the Province of Ontario and the laws of Canada applicable in such Province
and shall in all respects be governed, construed, applied and enforced in accordance with said laws, without reference to applicable
conflict of laws rules or principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</B>. Any notice or other communication required or permitted
to be given to any party hereunder shall be in writing and shall be given to such party at such party&rsquo;s address set forth
below, or such other address as such party may hereafter specify by notice in writing to the other Person. Any such notice or other
communication shall be addressed as aforesaid and given by: (i) hand delivery; (ii) international overnight courier; or (iii) e-mail
transmission. Any notice or other communication will be deemed to have been duly given: (A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;on
the date of service if served personally; (B) on the Business Day after delivery to an international overnight courier service,
provided receipt of delivery has been confirmed; or (C) on the date of transmission if sent via e-mail transmission, provided confirmation
of receipt is obtained promptly after completion of transmission and provided that transmission via e-mail is followed promptly
by delivery via one of the methods in Section 6(i) or (ii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">To the Vendor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Koninklijke Philips NV</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Amstelplein 2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">1096 BC Amsterdam</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-size: 10pt">Attention:</TD>
    <TD STYLE="width: 88%; font-size: 10pt">Philips Group Legal &ndash; Head of Legal M&amp;A and Alliances</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">E-mail:</TD>
    <TD STYLE="font-size: 10pt"><U>Gregory.hatfield@philips.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Blake, Cassels &amp; Graydon LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">199 Bay Street, Suite 4000</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Toronto, Ontario&nbsp;&nbsp;M5L 1A9</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 88%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Attention:</TD>
    <TD>Ken Pearce</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>kenneth.pearce@blakes.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt">To the Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Profound Medical Corp.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">2400 Skymark Avenue, Unit 6 Mississauga, ON L4W 5K5</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">Attention:</TD>
    <TD STYLE="width: 88%">Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>amenawat@profoundmedical.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">Torys LLP</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Suite 3000, P.O. Box 270</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">79 Wellington Street West TD Centre</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Toronto, ON M5K 1N2</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">Attention:</TD>
    <TD STYLE="width: 88%">Cheryl Reicin and Leah Frank</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>E-mail:</TD>
    <TD><U>creicin@torys.com</U> and <U>lfrank@torys.com</U></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts; Electronic Delivery.</B> This Agreement may be executed
in counterparts, all of which when so executed shall be deemed to be an original and all of which taken together shall constitute
one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission
or other electronic transmission shall be as effective as delivery of a manually executed counterpart of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement</B>. The terms of this Agreement, together with
the Purchase Agreement of which this Agreement is a part of, are intended by the parties to be the entire agreement of the parties
with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments; Waivers</B>. No amendment to this Agreement may be made
unless agreed to by the parties in writing. By an instrument in writing similarly executed, the Vendor or the Purchaser may waive
compliance by the other party or parties with any provision of this Agreement that such other party was or is obligated to comply
with or perform, provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or
subsequent failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any
other or further exercise of any other right, remedy, or power provided herein or by law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction</B>. The parties agree that they have been represented by
counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any Law, holding or rule
of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such
agreement or document. The headings in this Agreement are only for convenience and are not intended to affect construction or interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcement</B>. Wherever possible, each provision of this Agreement shall
be interpreted in such a manner as to be effective and valid under applicable Law. If any portion of this Agreement is declared
invalid for any reason in any jurisdiction, such declaration shall have no effect upon the remaining portions of this Agreement
which shall continue in full force and effect as if this Agreement had been executed with the invalid portions thereof deleted;
provided, however, if such severability will negate in any material respect the monetary terms of this Agreement, then the parties
shall negotiate in good faith to amend the invalid terms in a manner so that such terms shall not be invalid and will not modify
in any material respect the monetary terms of this Agreement unless otherwise agreed to by the parties. Furthermore, the entirety
of this Agreement shall continue in full force and effect in all other jurisdictions. Furthermore, in lieu of such illegal, invalid
or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such
illegal, invalid or unenforceable provision as may be possible and be legal, valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><B>Section
12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vendor&rsquo;s Acknowledgement</B>. The Vendor acknowledges that the Vendor (i) has read
and understands this Agreement, (ii) has, to the extent the Vendor so desires and as recommended by the Purchaser, consulted
with legal counsel with respect to the terms and condition hereof, (iii) is fully aware of its legal effect, (iv) has not
acted in reliance upon any representations or promises made by any Person other than those contained in writing herein and in
the Purchase Agreement, (v) has entered into this Agreement freely based on the Vendor&rsquo;s own judgment with the advice
of legal counsel and other advisers as the Vendor has deemed necessary or advisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
have executed this Agreement on the date and year first above referenced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">KONINKLIJKE PHILIPS NV</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iwald
    Mons</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 40%">Iwald Mons</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Authorized Representative</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arun
    Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD> Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 232.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>[Signature Page to Non-Competition and Non-Disclosure
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 98.35pt"><I>&nbsp;</I></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>10
<FILENAME>tv526458_ex4-4.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: #20262D"><B>Exhibit 4.4</B></FONT></P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: #20262D"><B></B></FONT>&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">RESALE PURCHASING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">This Resale Purchasing Agreement
is effective as of July 31, 2017 (&quot;<B>Effective Date</B>&quot;) by and between <B>Philips Medical Systems Nederland B.V.</B>
having a place of business at Veenpluis 4-6, 5684 PC Best, the Netherlands (&ldquo;<B>Philips</B>&rdquo;); and <B>Profound Medical
Inc.</B>, having a place of business at 2400 Skymark Avenue, Unit #6, Mississauga, ON, L4W 5K5, Canada (&ldquo;<B>Supplier</B>&rdquo;)
(individually, a &ldquo;<B>Party</B>&rdquo; and jointly, the &ldquo;<B>Parties</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PREAMBLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, Philips is engaged in the development, design,
engineering, manufacturing, marketing, sale and delivery of medical equipment and systems;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, Supplier is engaged in the development, design,
engineering, manufacturing, sale, delivery and support of Products (as defined herein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, Buyer (as defined herein) desires to purchase
from Supplier a varying volume of Products for the purpose of reselling such Products to Customers and Supplier desires to sell
such Products to Buyer for its resale activities under this Agreement<FONT STYLE="font-size: 10pt">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHERAS, on the date hereof, the Parties have entered
into a Supply Agreement, pursuant to which, for the term specified therein, Philips will manufacture and supply, as a contract
manufacturer to Supplier, the Products (the &ldquo;<B>Supply Agreement</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">WHEREAS, the Parties hereto wish
to set forth in this Agreement the terms and conditions under which Buyer will purchase from Supplier and Supplier will sell and
deliver to Buyer the Products and Consumables; provided, for greater certainty, subsequent to the initial sale of Consumables by
Buyer to a Customer, and outside the scope of this Agreement, Supplier may sell and deliver directly to Customers additional Consumables
beyond those delivered in connection with the initial sale of the Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">NOW, THEREFORE, in consideration of the mutual promises,
and of the representations, warranties, covenants and agreements contained herein the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>ARTICLE 1:&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>DEFINITIONS</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">For purposes of this Agreement, the following terms
have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.1</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Affiliates&rdquo;</B> means, with respect to
any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is
under common control with the specified Person. As used in this definition, &ldquo;control&rdquo;, &ldquo;controlled by&rdquo;
and &ldquo;under common control with&rdquo; means possession, directly or indirectly, of power to direct or cause the direction
of management or policies of such Person (whether through ownership of securities or other partnership or ownership interests,
as trustee, personal representative or executive or by contract, credit agreement or otherwise), provided that in any event, any
Person which owns directly, indirectly or beneficially fifty percent (50%) or more of the securities having voting power for the
election of directors or other governing body of a corporation or fifty percent (50%) or more of the partnership interests or
other ownership interests of any other Person will be deemed to control such Person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.2</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Agreement&rdquo; </B> means this Agreement, as
the same may be amended or supplemented and/or restated from time to time in accordance with the terms hereof, including all Attachments,
exhibits and other documents referred to herein or therein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philips &amp; Profound</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.3</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Buyer&rdquo;</B> means Philips or any of its
Affiliates that has issued a Purchase Order under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.4</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Buyer Indemnitees&rdquo;</B> has the meaning
given to such term in clause 9.1.4.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.5</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Change of Control&rdquo;</B> means with respect
to Supplier (i) the sale of all or substantially all of the assets of Supplier, or (ii) a merger, consolidation or other reorganization
of Supplier which results in more than fifty percent (50%) of the voting stock of the resulting or surviving entity being owned
or held by persons other than those owning or holding the voting stock in Supplier on the date of this Agreement, or (iii) the
sale by one or more stockholders of Supplier, in a single transaction or series of related transactions, of more than fifty percent
(50%) of the voting stock of Supplier to one or more third parties who are at the time of such sale unaffiliated with any shareholders
of Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.6</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Confidential Information&rdquo;</B> means any
information, provided in whatever form (including in written, electronic or oral form) or medium, which relates to either Party&rsquo;s
or its Affiliates&rsquo; business, products (hardware and software), technology, business plans, product plans, customers, customer
information, specifications, designs, costs, prices, business opportunities, Know How, trade secrets, inventions, techniques,
processes, algorithms, software programs, schematics and any other business or technical information disclosed by the disclosing
Party to the receiving Party in connection with this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.7</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Consumables&rdquo;</B> means the consumables
that function with the Product as identified in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.8</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Customer</B>&rdquo; means any customer of Buyer
that purchases and/or uses Philips Equipment together with any of the Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.9</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Factory Test Report</B>&rdquo; means the report
attached as <U>Attachment 5</U> hereto during the term of Supply Agreement and thereafter a similar document with the same content
and modified signatures and introduction language.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.10</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Force Majeure Event&rdquo;</B> means any prevention,
delay, stoppage or interruption in the performance of any obligations or the occcurance of any event due to an act of God, the
occurrence of enemy or hostile actions, sabotage, war, blockades, terrorist attacks, insurrections, riots, epidemics, nuclear
and radiation activity or fall-out, civil disturbances, explosions, fire or other casualty, failure of energy sources, any industry-wide
material shortage and changes in governmental or regulatory action or legislation or regulation, third party labour disputes or
strikes or any other similar causes beyond the control of the Party seeking relief from its obligations as a result of such event,
but not including, for clarity, any financial inability of a Party or any of its Affiliates or the failure of any subcontractor
to perform obligations owed to a Party (unless such failure by a subcontractor in turn was caused by a Force Majeure Event).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.11</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Intellectual Property Rights</B>&rdquo; (or &ldquo;<B>IPR</B>&rdquo;)
means, in any and all jurisdictions, all: (a) patents and applications therefor, including all continuations, continuations-in-part
and provisionals and patents issuing thereon, and all reissues, re-examinations, substitutions, renewals and extensions thereof
(collectively, &ldquo;<B>Patents</B>&rdquo;); (b) trademarks, service marks, trade names, trade dress, logos, corporate names,
Internet domain names or uniform resource locators used in connection with any global computer or electronic network, together
with all translations, adaptations, derivations and combinations thereof, and other source or business identifiers, together with
the goodwill associated with any of the foregoing, and all applications, registrations, renewals and extensions thereof; (c) industrial
designs, designs and design rights; (d) copyrights, works of authorship and moral rights, and all registrations, applications,
renewals, extensions and reversions thereof; (e) trade secrets, discoveries, concepts, ideas, research and development, Know How,
formulae, inventions, compositions, manufacturing and production processes and techniques, technical data, quality data, procedures,
designs, drawings, specifications, databases, and other proprietary or confidential information, including customer lists, supplier
lists, pricing and cost information, and business and marketing plans and proposals, which would constitute a &ldquo;trade secret&rdquo;
under applicable law, in each case excluding any rights in respect of any of the foregoing that comprise or are protected by Patents
(&ldquo;<B>Trade Secrets</B>&rdquo;); (f) inventions, processes and designs; and (g) software, and all source code, object code,
data and documentation relating thereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.12</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Know How</B>&rdquo; means any and all concepts,
ideas, information, data and documents of whatever nature, including, without limitation, drawings, methods, techniques, designs,
specifications, photographs, samples, models, processes, procedures, reports, particulars of a technical nature (including, without
limitation, any know how related to the manufacturing or design of Products and technical and commercial know how).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.13</B></TD><TD STYLE="text-align: justify">&ldquo;<B>OEM Quality Agreement&rdquo;</B> means the OEM
Quality Agreement signed as a supplementary agreement to this Agreement by Buyer and Supplier on the Effective Date of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.14</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Open Source Software&rdquo;</B> means any software
that is licensed under terms that require as a condition of use, modification and/or distribution of a work: (i) the making available
of source code or other materials preferred for modification;(ii) the granting of permission for creating derivative works; (iii)
the reproduction of certain notices or license terms in derivative works or accompanying documentation; or (iv) the granting of
a royalty-free license to any party under Intellectual Property Rights regarding the work and/or any work that contains,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt">is combined with, requires or otherwise is based on
the work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.15</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Philips Equipment</B>&rdquo; means the various
versions of the Philips Achieva 3.0T and 1.5T and Ingenia 3.0T and 1.5T MRI systems with which Products will be used by Philips
and Customers.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.16</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Person</B>&rdquo; means any individual, partnership,
limited partnership, joint venture, syndicate, sole proprietorship, Supplier or corporation with or without share capital, unincorporated
association, trust, trustee, executor, administrator or other legal personal representative or governmental authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.17</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Price&rdquo;</B> means the price for the Product
as specified in <U>Attachment 1.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.18</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Product&rdquo;</B> means the products delivered
by Supplier to Buyer as further identified in the respective <U>Attachment 1,</U> including if so specificied in <U>Attachment
1</U>: service parts as well as any materials, sub-assemblies, accessories or software incorporated in the Product and any other
items supplied by Supplier to Buyer (in respect of the Product), including Consumables or any incidental services provided by
Supplier, in their form existing as of the Effective Date and as the same may be modified, enhanced or improved by or on behalf
of Supplier and its Affiliates, unless otherwise agreed by the Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.19</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Production Plan</B>&rdquo; means the production
plan as defined in the Supply Agreement, or after the termination of the Supply Agreement, a production plan to be mutually agreed
by the Parties, acting reasonably and in good faith, in writing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.20</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Purchase Agreement</B>&rdquo; means the Asset
and Share Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) entered into on June 30, 2017 by Supplier and Koninklijke
Philips NV (&ldquo;<B>Philips NV</B>&rdquo;) N.V. (an Affiliate of Buyer).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.21</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Purchase Order&rdquo;</B> means any written or
electronic purchase order issued by Buyer to Supplier for a Product, each of which will be governed by and be subject to the terms
of this Agreement, unless explicitly agreed otherwise in writing in the respective Purchase Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.22</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Specifications&rdquo;</B> means the specifications,
descriptions, design criteria, drawings, samples, prototypes and other requirements relating to the Products provided in writing
by Supplier to Buyer from time to time to define Productst.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.23</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Supplier&rdquo;</B> means Profound Medical Inc.
and its Affiliates that provide Products hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.24</B></TD><TD STYLE="text-align: justify"><B>&ldquo;Territory&rdquo;</B> means for each Product the
area or country as listed in <U>Attachment 1</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.25</B></TD><TD STYLE="text-align: justify">&ldquo;<B>Third Party</B>&rdquo; means any Person other
than the Parties and their Affiliates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><B>ARTICLE
2:&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>SCOPE AND INTENT</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.1</B></TD><TD STYLE="text-align: justify">Supplier will manufacture and on a non-exclusive basis
sell and deliver to Buyer for resale in combination with or separately from Philips Equipment to Customer the quantities of Products
as may be ordered, subject to any restrictions on forecasts and orders contained herein, by Buyer under this Agreement and the
OEM Quality Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.2</B></TD><TD STYLE="text-align: justify">Buyer shall use commercially reasonable efforts to sell
Products to Customers in the Territory for use in combination with Philips Equipment and under the brand name(s) as indicated
in <U>Attachment 1</U>. Buyer shall not distribute, sell or export any Products outside of the Territory. Buyer shall not solicit
orders for Products outside the Territory.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.3</B></TD><TD STYLE="text-align: justify">Nothing in this Agreement, shall prevent Supplier from
selling Products to other customers, or prevent Buyer from selling Philips Equipment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.4</B></TD><TD STYLE="text-align: justify">Supplier shall be responsible for the design, engineering,
manufacture, quality control and sourcing of Products, as set forth in the OEM Quality Agreemet, and is entitled to outsource
or subcontract these activities without the consent of the Buyer being required. Such outsourcing or subcontracting shall not
release Supplier from any of its duties and obligations in or in relation to this Agreement or under applicable law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.5</B></TD><TD STYLE="text-align: justify">Supplier shall deliver the Products and any other deliverables
to the Buyer at the agreed point of delivery as specified in <U>Attachment 1.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.6</B></TD><TD STYLE="text-align: justify">Installation, application support, training, maintenance
and service to the Customer (for the avoidance of doubt, including the remedies for non-compliance with Product warranties as
set forth in clause 9.3) will be provided by Supplier as set forth in <U>Attachment 2</U>, it being understood that Supplier may
subcontract these activities to Buyer and/or its Affiliates, subject to the parties written agreement, on the basis of the scope
and service fees as set out in <U>Attachment 2</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.7</B></TD><TD STYLE="text-align: justify">The Parties may agree in writing on additional terms and
conditions defined for certain parts of the Territory in local agreements, if any (hereinafter &ldquo;<B>Local Agreements</B>&rdquo;).
This Agreement sets out the principles and framework for the underlying Local Agreements. In case of conflict between the Local
Agreements and this Agreement, this Agreement will prevail, unless explicitly agreed otherwise in writing in a Local Agreement
(using the words &ldquo;notwithstanding the terms of the Resale Purchase Agreement, the Parties expressly agree&rdquo;), it being
understood that quality, sustainability and liability in respect of the Product cannot be deviated locally from the terms of this
Agreement. As of the Effective Date, there are no local agreements.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.8</B></TD><TD STYLE="text-align: justify">The Parties will meet from time to time (but not less than
one time per year) as mutually agreed by the parties to discuss efficiency increases, product and technology roadmaps, price/performance
ratio of Products, cost and quality issues, Supplier&rsquo;s and Buyers performance hereunder, market conditions, and all other
issues which the Parties may deem appropriate, including, conducting meetings of the Joint Steering Committee (as defined in the
Purchase Agreement) in accordance with the schedule for meetings of the Joint Steering Committee as contemplated by the Purchase
Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.9</B></TD><TD STYLE="text-align: justify">Buyer will use commercially reasonable efforts to engage
in the marketing and promotion of the Products in the Territory, through such means as personal contact with prospective customers,
distribution of Product literature and the like in accordance with <U>Attachment 4.</U> Supplier will use commercially reasonable
efforts cooperate with Buyer in the promotion of the Products in accordance with <U>Attachment 4</U>. Each Party agrees to adhere
to the COCIR Code of Conduct in its efforts to promote the Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.10</B></TD><TD STYLE="text-align: justify">Except for connecting the Product to Philips Equipment,
Buyer shall not modify, reverse engineer, disassemble, decompile, decode, copy, duplicate, change or alter the Product or any
parts or components thereof unless with Supplier&rsquo;s prior written consent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE
3:&nbsp;<U>TERM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>3.1</B></TD><TD STYLE="text-align: justify">This Agreement shall come into effect on the Effective
Date, and unless terminated earlier, shall continue in full force until <B>[Redacted &ndash; Commercially Sensitive &ndash; Term]
</B>anniversary of the Effective Date (the &ldquo;<B>Initial Term</B>&rdquo;), provided <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Term]</B>. The Initial Term shall thereafter automatically renew for additional <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Term]</B> (the Initial Term and any renewal thereof being collectively referred to herein as the &ldquo;<B>Term</B>&rdquo;),
unless either Party terminates this Agreement by no less than ninety (90) days written notice prior to the end of the then current
Term. If the end of the Term does not coincide with the end of the term of any Purchase Order (other than due to termination upon
notice), then this Agreement shall automatically renew with respect only to the open Purchase Order for additional one (1) week
periods until such time as the Purchase Order has been fully completed in accordance with the terms of such Purchase Order and
this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>ARTICLE 4:&nbsp;<U>COMPONENTS, CHANGES AND
DISCONTINUATION OF PRODUCT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">4.1.1</TD><TD STYLE="text-align: justify">Any changes to the Product including those changes and
modifications referred to in the OEM Quality Agreement shall be discussed in the Joint Steering Committee (as such is established
under the Share Purchase Agreement) prior to the change being implemented.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Discontinuation
of Production.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">4.2.1</TD><TD STYLE="text-align: justify">Subject to the forecasting and delivery requirements and
obligations outlined in this Agreement, Supplier agrees to provide the Product in accordance with the terms of this Agreement
of (i) in respect of the Product during the Term of this Agreement, unless the Agreement is partially terminated pursuant to clause
14.1.1 with respect to that Product, to the extent such partial termination is provided for hereunder; and (ii) during the Term,
in respect of Consumables, for a period of two (2) years after last shipment of the relevant Product to Buyer under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>ARTICLE 5:&nbsp;&nbsp;<U>PRICE, PAYMENT, SET OFF, CURRENCY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Price.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.1</TD><TD STYLE="text-align: justify">Parties have agreed upon the Price and payment terms which
apply and against which Buyer may order Products (and if so specified in <U>Attachment 1</U> for the relevant Product: Consumables
and/or services) from Supplier as well as the period of validity of such Price, all as specified in <U>Attachment 1</U> (as may
be adjusted from time to time if mutually agreed in writing by the Parties).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.2</TD><TD STYLE="text-align: justify">Supplier shall at all times offer the most favorable prices,
for similar quantities of Products purchased, for the Products to Buyer, meaning that such prices shall be no less favorable than
those currently and in the future extended to the customers of Supplier, in each instance, based on an similar quantities of purchases.
Accordingly, Buyer shall automatically have the benefit of any lower prices, charges or fees Supplier offers to third parties
and Supplier shall notify Buyer immediately at its own initiative of such more favorable terms offered to third parties for similar
quantities of Products of like kind and quality.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.3</TD><TD STYLE="text-align: justify">Subject to applicable law, Supplier and Philips agree to
discuss purchase prices and other terms whenever market conditions so require, including possible price reductions and anything
else considered materially relevant for the performance of this Agreement by either Party. Such discussions may include the average
price for the Product received by Buyer in each jurisdiction in the Territory (in the previous year), at most once per year. The
prevailing prices and other terms agreed upon in <U>Attachment 1</U> will remain in effect until the Parties have reached a mutual
written agreement on new prices and other terms.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.4</TD><TD STYLE="text-align: justify">In respect of any sale of a Product to a Customer, if Buyer
wishes to offer a discount on the price of such Product to such Customer, Philips may discuss such discount with Supplier. If
Supplier does not agree, in its sole discretion, to provide Buyer a further discount in respect of such sale, Buyer will then
decide, in its sole discretion, as to whether it wishes to provide the originally proposed discount to such Customer (without
receiving a corresponding discount from Supplier) and Supplier will have no further obligations to discuss further discounts in
respect of such sale.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.1.5</TD><TD STYLE="text-align: justify">Prices are exclusive of any federal, state or local sales,
use or excise taxes and any, value added tax (VAT). Supplier will list separately on its invoice any tax lawfully applicable to
the relevant Purchase Order and payable by Buyer, if any, with respect to which Buyer does not furnish evidence of exemption.
Supplier is responsible for remitting any applicable VAT, sales tax, consumption tax, or any other similar tax, in each instance,
that were charged to Buyer under an applicable Purchase Order, to the appropriate tax authorities in accordance with applicable
laws and required timelines. Supplier will issue an invoice containing wording that will allow Buyer to take advantage of any
applicable &ldquo;input&rdquo; tax deduction.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.2.1</TD><TD STYLE="text-align: justify">Supplier invoices, compliant with the requirements of this
Agreement, will be payable within <B>[Redacted &ndash; Commercially Sensitive &ndash; Payment Terms] </B>following the end of
the month of the date of invoice. Buyer shall make all payments in Euros by check, wire transfer or automated clearing house to
the bank account designated by Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">5.2.2</FONT></TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive &ndash; Payment
Terms]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.3</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive &ndash; Payment
Terms]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Currency.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">5.4.1</TD><TD STYLE="text-align: justify">All invoicing and payment obligations under this Agreement
will be satisfied in the same currency as the currency of the Price as specified in <U>Attachment 1.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE
6:&nbsp;&nbsp;<U>PLANNING AND ORDERING</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Planning.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.1.1</TD><TD STYLE="text-align: justify">Buyer shall provide Supplier in good faith on a monthly
basis, on the later of (i) seven (7) days prior to the beginning of each calendar month a rolling twelve (12) month forecast for
the Products (including the major configuration of each Product such as field strength and Consummables) (&ldquo;<B>Forecast</B>&rdquo;)
it expects to purchase during such 12-month period. Such Forecast shall be provided in writing or in any other mutually agreed
manner of communication (e.g., EDI or email). Notwithstanding any other obligation set forth herein, Buyer shall give Supplier
at least six (6) months prior written notice if, during the Term, it intends to discontinue the purchase of any Products hereunder,
or if it intends to substantially decrease, versus the Forecast, its purchase demand hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.1.2</TD><TD STYLE="text-align: justify">Notwithstanding Buyer&rsquo;s obligations pursuant to clause
6, the first two (2) months of each Forecast shall constitute a binding commitment of Buyer to purchase the quantities of Products
set forth in the relevant Forecast for such two (2) month period. The Forecast for the period beyond this two (2) month period
shall be non-binding except to the extent otherwise provided in this clause 6. Only Purchase Orders as accepted by Supplier constitute
an obligation for Supplier to actually produce the so ordered Products and no quantities of Products in the Forecast provided
by Buyer shall constitute an accepted Purchase Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.1.3</TD><TD STYLE="text-align: justify">Buyer shall have the right to increase or decrease, as
the case may be, the 12-month Forecast only within the limitations set forth in the Production Plan per quarter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Ordering.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.1</TD><TD STYLE="text-align: justify">Only Purchase Orders placed by Buyer (except for blanket
purchase orders placed for estimated annual purposes, which are non binding) and accepted by Supplier will create a binding obligation
on Buyer to take delivery and make payment for Products delivered under such Purchase Order. Supplier will accept a Purchase Order
to Buyer by returning a signed confirmation of the Purchase Order to Buyer. Order acknowledgement may be made by Supplier if so
agreed with Buyer using customary means as email or other electronic transmission.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.2</TD><TD STYLE="text-align: justify">Any Purchase Order issued by Buyer under this Agreement
to Supplier shall constitute a contractual relationship between that respective Buyer and Supplier. Supplier shall not hold any
Buyer liable for any damages or losses arising from any act, default, omission or negligence of another Buyer, including but not
limited to any default payment; provided that Philips shall be responsible for the obligations of all Buyers, solely to the extent
that the applicable Purchase Orders of such Buyers are delivered by Philips to Supplier. Notwithstanding anything to the contrary
herein, Supplier warrants also towards Philips the proper fulfilment of any and all obligations and warranties in the supply of
any Products hereunder to Buyer. As a result any breach by Supplier against Buyer under this Agreement shall also be regarded
a breach by Supplier against Philips under this Agreement, in which case Philips shall be entitled to claim any and all damage
that it and/or Buyer has incurred in connection with such breach, it being understood that the same damage can only be claimed
once by Philips and/or Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.3</TD><TD STYLE="text-align: justify">No Purchase Order shall be deemed to be accepted by Supplier
until accepted in writing (including by email or another agreed manner of communication) by Supplier. Supplier shall not reject
any Purchase Order which is placed in accordance with the Forecast, the applicable lead time for such Product (set forth in <U>Attachment
1</U>) and otherwise in accordance with this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">6.2.4</TD><TD STYLE="text-align: justify">Supplier shall confirm to Buyer the receipt of each Purchase
Order issued hereunder (each, a &ldquo;<B>Confirmation</B>&rdquo;) within seven (7) days following Supplier&rsquo;s receipt thereof
in writing or in any other mutually agreed manner of communication (e.g., EDI or email). Each Confirmation must reference Buyer&rsquo;s
Purchase Order number, confirm acceptance of the Purchase Order, include a confirmed Delivery Date (which may differ from the
requested one in the Purchase Order)or, solely if permitted under this clause 6.2.4, advise Buyer of Supplier&rsquo;s rejection
of such Purchase Order, the date of acceptance or rejection and the basis for rejection, if applicable. If Supplier commences
performance under such Purchase Order, Supplier will be deemed to have accepted the Purchase Order. Buyer may withdraw any Purchase
Order prior to Supplier&rsquo;s acceptance thereof. Supplier may only reject a Purchase Order if (a) the quantity ordered by Buyer
in such Purchase Order is inconsistent with the quantity in the applicable Forecast in accordance with clause 6, (b) Supplier
has sent Philips of termination pursuant to clause 14 or (c) the applicable Purchase Order includes terms and conditions that
supplement those contained in this Agreement, which Supplier is unwilling to accept. Supplier may not cancel any previously accepted
Purchase Order hereunder. Buyer may not cancel a previously accepted Purchase Order .</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE
7:&nbsp;&nbsp;<U>DELIVERY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.1</TD><TD STYLE="text-align: justify">Delivery of Products to Buyer shall be made in accordance
with the Incoterms as referred to in <U>Attachment 1</U>. Incoterms 2010, shall apply to the interpretation of the delivery terms
mentioned in this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.2</TD><TD STYLE="text-align: justify">Supplier shall make the agreed deliveries by making the
Products and any other deliverables available to the Buyer at the agreed point of delivery as specified in <U>Attachment 1</U>.
The risk in the Products shall pass to Buyer on Delivery Date in accordance with the Incoterms set forth in <U>Attachment 1</U>.
<B>[Redacted &ndash; Commercially Sensitive &ndash;Shipping Terms]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.3</TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive &ndash; Shipping
Terms]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.4</TD><TD STYLE="text-align: justify">Buyer shall inspect shipments for freight damages at time
of receipt of the Product at the named place of delivery specified in the Purchase Order and promptly notify Supplier of any freight
damage.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.1.5</TD><TD STYLE="text-align: justify">Should Supplier wish to deliver Products before the Delivery
Date, than Buyer may choose, at its option to (i) return such Products in order to have them delivered at the Delivery Date, in
which case transportation charges shall be for Supplier&rsquo;s costs, (ii) accept delivery but withhold payment for such Products
until the Delivery Date, or (iii) keep the Products in storage at Supplier&rsquo;s costs until the Delivery Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Complete
Delivery.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.2.1</TD><TD STYLE="text-align: justify">Supplier may not over ship or under ship Products. In either
case, Supplier will alert Buyer in a timely manner. Supplier will recover any over shipments or ship additional Products to cover
under shipments. All over shipments returned to Supplier, and all additional Products shipped by Supplier to cover under shipments,
will be at Supplier&rsquo;s risk and expense, including transportation charges.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acceptance.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.3.1</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive &ndash; Delivery
and Acceptance Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Buyer&rsquo;s
subcontractors.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">7.4.1</TD><TD STYLE="text-align: justify">Buyer may appoint a third party to handle logistics, administration,
integration, assembling or other activities relating to Products or Philips Equipment, in which case Buyer shall inform Supplier
hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE
8:&nbsp;&nbsp;<U>DOCUMENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supplier&rsquo;s
Documents</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.1.1</TD><TD STYLE="text-align: justify">Supplier will provide end-user documentation in the language
of the anticipated end users as per the legal requirements of the relevant countries, such countries as initially forecasted in
<U>Attachment 1.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.1.2</TD><TD STYLE="text-align: justify">Buyer may reproduce, create and disseminate derivative
works from such technical data and other Supplier&rsquo;s Documents and use, in any manner the technical data and other Supplier&rsquo;s
Documents, without a license fee or other payment to Supplier or third parties. Such derivative works shall be true and accurate.
Buyer shall obtain Supplier&rsquo;s prior written approval over such derivative works. Buyer shall provide Supplier with copies
of such derivative works.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Updates
of Supplier&rsquo;s Documents.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.2.1</TD><TD STYLE="text-align: justify">Supplier shall update and maintain its Documents relating
to the Product, during the Term of this Agreement including the continuing maintenance and service support period as provided
herein. Updates will be made available to reflect any changes and modifications implemented to the Products. Any corrections or
updates to Supplier&rsquo;s Documents will be promptly furnished to Buyer at no charge to Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Promotional
Materials</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">8.3.1</TD><TD STYLE="text-align: justify">All advertisements, promotions and other descriptive matters
(together referred to as &ldquo;<B>Promotional Material</B>&rdquo;) provided by Supplier shall be consistent with the labelling
of the Product. At Buyer&rsquo;s request, Supplier shall review any Promotional Material created by the Buyer that refers to the
clinical use, safety or effectiveness of the Product and shall confirm to Buyer in writing within ten (10) days of submission
that such Promotional Material is consistent with the labelling of the Product and complies with all applicable regulatory requirements
for the Product under applicable law. If Supplier cannot so confirm, it shall within ten (10) days of the submission, identify
in detail the provisions of the Promotional Material that are non-compliant or inconsistent with labeling. Supplier shall defend,
indemnify and hold Buyer and its Affiliated Companies harmless from any and all claims, direct losses, demands, direct costs and/or
liabilities, including reasonable attorney fees, alleging that Promotional Material provided or confirmed by Supplier promotes
use inconsistent with the Product labelling or causes the Product to be misbranded or adulterated.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>ARTICLE 9:&nbsp;&nbsp;<U>REPRESENTATIONS AND
WARRANTIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants to Buyer that all Products
delivered and any services provided hereunder:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">conform to the Specifications on the Delivery Date <B>[Redacted
 &ndash; Commercially Sensitive]</B>;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">unless otherwise agreed with Buyer in writing, are new
(do not contain any used or reconditioned parts or materials) and fit for the purposes for which they are intended;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">are of sound workmanship, good quality and free from defects
in design, construction, manufacture and material <B>[Redacted &ndash; Commercially Sensitive]</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD>comply in all respects with applicable laws, regulations,
certification requirements, including health and safety standards and all other applicable regulatory requirements for the design,
manufacture and shipment of Products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">v.</TD><TD STYLE="text-align: justify">do not contain any of the restricted substances as listed
in the Sustainability Declaration;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vi.</TD><TD STYLE="text-align: justify">are free and clear of all liens, encumbrances, and other
claims against title; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vii.</TD><TD STYLE="text-align: justify">comply in all respects with the terms of this Agreement
and the applicable Purchase Orders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.2</TD><TD STYLE="text-align: justify">Supplier&rsquo;s representations and warranties do not
apply to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">Philips Equipment;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">damage to Products resulting from misuse, abuse, accident,
neglect, impacts and/or abrasions and failure to use or store Products as provided for in the Specifications;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">damages resulting from any modifications or alterations
made by Buyer or a Customer to Products, including those resulting from the repair or service of Products by anyone other than
Supplier approved personnel or in a manner not approved by Supplier; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">damage resulting from Customer&rsquo;s application of cleaners,
germicides or other chemicals not approved by Supplier. For the avoidance of doubt, clause 9.1.2(iii) shall not apply to damages
to the Product resulting from the connection of the Product to Philips Equipment by Supplier upon installation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 150pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">9.1.3</FONT></TD><TD STYLE="text-align: justify"><B>[Redacted
                                         &ndash; Commercially Sensitive &ndash; Warranty]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.4</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive &ndash; Warranty]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1.5</TD><TD STYLE="text-align: justify">Subject to the limitations applied (including the ability
to bring a claim) in respect of the Factory Test Report pursuant to clause 7.3 and 9.1.4, the foregoing warranties will survive
any inspection, delivery, acceptance, or payment by Buyer and will be enforceable by Buyer and its Affiliates, and their successors,
assigns, subcontractors, distributors, dealers, agents and Customers and all other entities combining, selling or using Products
or goods into which Products have been incorporated (together, the &ldquo;<B>Buyer Indemnitees</B>&rdquo;), for the period set
forth in clause 9.2.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warranty
Term.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.2.1</TD><TD STYLE="text-align: justify">Without prejudice to any other rights accruing under this
Agreement or law, the warranties set forth in clause 9.1 will extend for <B>[Redacted &ndash; Commercially Sensitive &ndash; Warranty
Term]</B>. Products repaired or replaced by Supplier within the Warranty Term are warranted for the remainder of the original
Warranty Term of said Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Buyer&rsquo;s
Remedies.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.3.1</TD><TD STYLE="text-align: justify">Subject to the remedies in clause 7.3 in respect of failure
to meet the Specifications, if Products do not comply with the warranties set forth in clause 9.1, Buyer may then, after having
consulted Supplier as to the most appropriate remedy, elect reasonably to have Products:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">returned to Supplier for repair or replacement;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">repaired or replaced by Supplier in the field; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">repaired or replaced by Buyer in the field, including Products
in distributor inventory and Buyer&rsquo;s installed base; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">returned to Supplier in exchange for a full refund of the
purchase price for the non-conforming Products paid under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">9.3.2</TD><TD STYLE="text-align: justify">Supplier will bear all costs, including transportation
and labor costs, in connection with the repair or replacement of, and all other costs or damages Buyer may incur as a result of
Products not complying with clause 9.1. If Supplier agrees that Buyer performs the repair, Supplier will provide Buyer free of
charge with any replacement Product or upgrade necessary, and will reimburse Buyer for all costs relating to such repair, including
any related labor costs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>ARTICLE 10: <U>CONFIDENTIALITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.1</TD><TD STYLE="text-align: justify">Confidential Information may be disclosed by or on behalf
of a Party or its Affiliates (the &ldquo;Disclosing Party&rdquo;) to the other Party or its Affiliates (the &ldquo;Receiving Party&rdquo;)
in connection with this Agreement. Each Party agrees to keep the other Party&rsquo;s (and its Affiliates) Confidential Information
confidential and not to reproduce or disclose such Confidential Information to any third party, or to use it for any purpose other
purpose than for the purposes of this Agreement. Each Party shall protect any Confidential Information of the other Party (and
its Affiliates) with the same degree of care used in protecting its own Confidential Information, but no less than a reasonable
degree of care. Unless otherwise mutually agreed in writing, the Confidential Information shall remain the property of the Disclosing
Party. Each party&rsquo;s obligation to protect the Confidential Information of the other Party shall continue for a period of
<B>[Redacted &ndash; Commercially Sensitive &ndash; Confidentiality Term] </B>following the date of termination of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.2</TD><TD STYLE="text-align: justify">Each Party may disclose the other Party&rsquo;s Confidential
Information to its and its Affiliates&rsquo; employees, officers, lawyers, accountants, sub-contractors (collectively, &ldquo;<B>Representatives</B>&rdquo;)
or financing sources (both debt and equity) or any prospective acquirer of of Party (or substantially all of the assets related
to the Products)(collectively, &ldquo;<B>Other Recipients</B>&rdquo;&rdquo;) on a strict need to know basis, provided that such
Representatives and Other Recipients are subject to confidentiality obligations and/or agreements at least as stringent as the
confidentiality restrictions imposed by this clause 10 on the Receiving Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.3</TD><TD STYLE="text-align: justify">The confidentiality obligations set out in this clause
10 shall not apply to any information (but only to the extent that such information). and the definition of &ldquo;Confidential
Information&rdquo; shall not be deemed to include any information that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">is generally available from public sources or in the public
domain through no fault or breach of the Receiving Party or any of its Representatives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">becomes available to the Receiving Party (or any of its
Affiliates) unless the Receiving Party (or such Affiliate) is aware that such source was bound by a confidentiality agreement
with the Disclosing Party or any or its Representatives or otherwise under a contractual, legal, fiduciary or other obligation
of confidentiality with respect such information;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">developed independently by the receiving Party or any of
its Affiliates without use of or reliance on the Disclosing Party&rsquo;s (or any of its Affiliates&rsquo;) Confidential Information
as demonstrated by written records; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">was known or in the possession of the Receiving Party (or
any of its Affiliates) prior to its disclosure by the Disclosing Party unless the receiving Party (or such Affiliate) is aware
that the source of such information was bound by a confidentiality undertaking to the disclosing Party (or its Affiliates) or
any or its Representatives or otherwise under a contractual, legal, fiduciary or other obligation of confidentiality with respect
to such information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.4</TD><TD STYLE="text-align: justify">This clause 10 does not prohibit disclosure or use of any
Confidential Information if and to the extent that the disclosure or use is required by applicable law, any judicial or administrative
proceedings, or the rules of any recognized stock exchange on which the shares of any Party (or its parent entity) are listed,
provided that prior to such disclosure, the Receiving Party promptly notifies the Disclosing Party of such requirement with a
view to providing the Disclosing Party with the opportunity to contest such disclosure or use and/or to obtain a protective order
or otherwise to agree to the timing and content of such disclosure or use and the Receiving Party shall at the request of the
Disclosing Party, assist the Disclosing Party in contesting such disclosure and/or obtaining a protective order; provided further
that the Receiving Party shall only disclose such portions of the Confidential Information that are strictly required to be disclosed
by applicable law, and if permitted by applicable law, the Disclosing Party shall be provided with the opportunity to review and
comment on the disclosure to be made.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.5</TD><TD STYLE="text-align: justify">Notwithstanding any of the carve outs to the definition
of &ldquo;Confidential Information&rdquo; contained in clause 10.3, any Confidential Information in respect of the &ldquo;Purchased
Assets&rdquo; and the &ldquo;Business&rdquo; (each, as defined under the Purchase Agreement) shall be deemed the Confidential
Information of Supplier (the &ldquo;<B>Transferred Confidential Information</B>&rdquo;), and, in respect of Philips, the carve
out to the definition of &ldquo;Confidential Information&rdquo; contained in clause 10.3 shall not apply to any Transferred Confidential
Information, notwithstanding the fact that Philips was aware of, had possession of, or independently developed any such Transferred
Confidential Information prior to the date of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">10.6</TD><TD STYLE="text-align: justify">Each Party reserves all rights in its and its Affiliates&rsquo;
Confidential Information. No rights or obligations in respect of a Party&rsquo;s Confidential Information other than those expressly
stated in this Agreement are granted to the other Party or to be implied from this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 136.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>ARTICLE 11: <U>INTELLECTUAL PROPERTY
RIGHTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property Warranty and Indemnification.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.1.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants to Buyer that: (x) it
has not received any notice claiming that any of Products and services directly or indirectly infringes any third party IPR; and
(y) to the best of its knowledge, all Products delivered hereunder do not directly or indirectly infringe, misappropriate, or
otherwise violate any third party IPR. Supplier shall defend, indemnify and hold harmless Buyer Indemnitees from and against all
liabilities, costs, damages and expenses, including reasonable attorneys&rsquo; fees, arising from or related to any claim that
Products, in whole or in part, directly or indirectly infringe, misappropriate, or otherwise violate any IPR of a Third Party.
If Supplier does not diligently pursue resolution of the claim against Buyer Indemnitees or provide reasonable assurances that
it shall diligently pursue resolution, then the Buyer Indemnitee against who such claim has been advanced may, without in any
way limiting its other rights and remedies, defend against the claim at Supplier&rsquo;s expense. If the use of a Product is found
to (or believed by Supplier to) directly or indirectly infringe, misappropriate, or otherwise violate any Third Party IPR, Supplier
shall, without in any way limiting its foregoing obligations, and at its sole expense:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">procure the necessary rights so that Products are not subject
to any such claim;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">replace or modify Product with a product of equivalent
performance so that it avoids such claim; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">if the options under subclasses a) or b) above are not
possible, refund to Buyer in full all costs paid by Buyer for the relevant Products and pay all reasonable additional costs incurred
by Buyer as a result of Supplier&rsquo;s action under sub clauses a), b) or c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">If the Parties foresee that the Parties will jointly
develop any Intellectual Property Rights in connection with this Agreement, such development will be reviewed by the joint streering
committee (as contemplated by the Purchase Agreement) and appropriate legal documentation will be put in place to address such
joint development, in a form approved by such joint steering committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>11.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Open
Source Software Warranty and Indemnification.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.2.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants that Products do not include
and are not accompanied by any portion of Open Source Software that has not been approved by Buyer in writing. As a condition
for such approval, Supplier shall provide to Buyer a full specification of such Open Source Software together with a copy of the
license conditions associated therewith. Supplier shall deliver all necessary information to enable Buyer to comply fully with
the licenses of all Open Source Software, including but not limited to any required notices to be reproduced by Buyer and the
source code if such licenses requires as a condition of distribution the making available of source code.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.2.2</TD><TD STYLE="text-align: justify">Supplier represents and warrants that any use of any Open
Source Software in Products, when used as anticipated by this Agreement, does not require Philips&rsquo; Equipment or any other
product of Buyer to be licensed under terms set forth in the definition of Open Source Software. Supplier shall defend, indemnify
and hold harmless Buyer Indemnitees against any and all losses, damages, costs and expenses, including reasonable attorneys&rsquo;
fees. arising from any inclusion, or claims related to the inclusion, of Open Source Software in Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>11.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>False
Patent Marking</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.3.1</TD><TD STYLE="text-align: justify">False Patent Marking. Supplier shall defend, indemnify
and hold harmless the other Party against any and all claims arising from Markings on Marked Products alleged to be false or otherwise
in violation of the law. As used herein, (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&rdquo;Markings&rdquo;
means one or more patent numbers and/or the words or phrases &ldquo;Patent&rdquo;, &ldquo;Patented&rdquo;, &ldquo;Patent Pending&rdquo;,
 &ldquo;patent applied for&rdquo;, &ldquo;covered by one or more of the following patents&rdquo;, &ldquo;may be covered by patent
number&rdquo;, &ldquo;covered by at least patent number&rdquo;, or any derivations thereof, or any word or number importing, implying,
indicating, or suggesting that the same is or is in the process of being patented, and (b) &rdquo;Marked Products&rdquo; means
Markings on or in connection with various products, product components, product packaging, materials accompanying Product, and
product advertising, including web-based advertising/marketing materials, having, including, or referencing such Markings.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>11.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>License.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.1</TD><TD STYLE="text-align: justify">The purchase of a Product shall confer on Buyer and on
Buyer Indemnitees an irrevocable, world-wide, royalty-free and fully paid up, non-exclusive, license under all IPR owned or controlled,
directly or indirectly, by Supplier related to the Product to use, market, sell, lease, license, distribute or otherwise dispose
of Product acquired by Buyer under this Agreement throughout the Territory.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.2</TD><TD STYLE="text-align: justify">Nothing in this Agreement shall be construed as limiting
the Parties rights and obligations under the <B>[Redacted &ndash; Commercially Sensitive &ndash; Reference to external agreement]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.3</TD><TD STYLE="text-align: justify">This Agreement and the supply of Products by Supplier to
Buyer does not grant Supplier either explicitly or by implication any right, title or interest in or to any of Buyer&rsquo;s or
any of its Affiliates&rsquo; Confidential Information and/or Intellectual Property Rights OR GRANT TO BUYER EITHER EXPLICITLY
OR BY IMPLICATION ANY RIGHT, TITLE OR INTEREST IN OR TO ANY OF SUPPLIER&rsquo;S OR ANY OF ITS AFFILIATES CONFIDENTIAL INFORMATION
AND INTELLECTUAL PROPERTY RIGHTS OTHER THAN THE LICENSED RIGHTS CONFERRED UNDER CLAUSE 11.4.1, AND THAT BUYER SHALL NOT SEEK TO
OBTAIN (OTHER THAN FROM SUPPLIER) ANY INTELLECTUAL PROPERTY RIGHTS IN THE PRODUCTS.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.4.4</TD><TD STYLE="text-align: justify">Buyer hereby assigns and transfers and, to the extent any
such assignment or transfer cannot be made at present, will assign and transfer to Supplier and its successors and assigns or
Supplier&rsquo;s designee, all Buyer&rsquo;s right, title and interest in and to all Intellectual Property Rights that are created,
developed, made, conceived or reduced to practice by Buyer or under Buyer&rsquo;s direction in connection with the services provided
under this Agreement (the &ldquo;<B>Developed Intellectual Property</B>&rdquo;) and waives any moral rights with respect to such
Developed Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>11.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Trademarks.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.1</TD><TD STYLE="text-align: justify">Except as set forth in this clause 11.5, this Agreement
and the manufacture and supply of Products by Supplier does not grant to Supplier any rights in or license to the word mark Philips
or any other trademark, trade name or other indicia of Buyer or its Affiliates (hereinafter, individually and collectively referred
to as &ldquo;<B>Buyer&rsquo;s Marks</B>&rdquo;) or to the use of the Buyer&rsquo;s Marks, whether to Products alone or in any
combination in press releases, advertisements, sales literature or otherwise without Buyer&rsquo;s prior written consent. Supplier
will not copy or imitate the content or material style of Buyer&rsquo;s websites onto its own web site or sections of it to avoid
confusion to Internet users.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.2</TD><TD STYLE="text-align: justify">Buyer may use the name of Supplier and the name of Products
only for the purpose of advertising and marketing Products or Buyer&rsquo;s medical products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.3</TD><TD STYLE="text-align: justify">Buyer acknowledges and agrees that the all Supplier trademarks
associated with Products are the trademarks of Supplier and Buyer shall not rebrand Products for resale, seek to obtain any rights
in Supplier trademarks through the filing of trademark applications. Buyer shall leave in place all trade-marks, labels and other
trade designations placed by Supplier on Products and their packaging (including designations indicating manufacture by Supplier)
and shall not alter any such trade-marks, labels or other trade designations without the prior written consent of Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.4</TD><TD STYLE="text-align: justify">All goodwill associated with Buyer&rsquo;s use of Supplier&rsquo;s
trademarks shall enure exclusively to the benefit of Supplier. Buyer shall not take any action which may constitute an infringement
of such rights without prior written authorization from Supplier. Furthermore, Buyer shall not use or make reference to Supplier&rsquo;s
trademarks or trade name (or any derivation thereof) in connection with Buyer&rsquo;s own products or trade name without prior
written authorization from Supplier. Buyer shall not take any action, or omit to take any action, the result of which is to depreciate
or dilute the goodwill in any trademark or trade name used or adopted by Supplier or to damage or bring into disrepute the reputation
of Supplier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.5</TD><TD STYLE="text-align: justify"><U>Branding of TULSA-PRO.</U> Without limiting the provisions
of clause 11.5, Buyer may use the name of Supplier and the name of &ldquo;TULSA&rdquo; or &ldquo;TULSA-PRO&rdquo; for the purpose
of advertising and marketing TULSA-PRO. Buyer acknowledges and agrees that Supplier trademarks associated with TULSA-PRO and related
Consumables are the trademarks of Supplier and Buyer shall not rebrand Products for resale or seek to obtain any rights in Supplier
trademarks through the filing of trademark applications. Buyer shall leave in place all trademarks, labels and other trade designations
placed by Supplier on Products and their packaging (including designations indicating manufacture by Supplier) and shall not alter
any such trade marks, labels or other trade designations without the prior written consent of Supplier. Buyer acknowledges and
agrees that all intellectual property rights in the TULSA-PRO, including the aesthetic and functional designs of the Product,
are the property of Supplier and that Buyer shall not seek to obtain any intellectual property rights in the &ldquo;TULSA-PRO&rdquo;
and related Consumables.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.6</TD><TD STYLE="text-align: justify"><U>Branding of the &ldquo;SONALLEVE&rdquo; Product</U>.
Without limiting the provisions of clause 11.5, the Parties agree to negotiate in good faith and sign a detailed, written branding
policy in relation to Sonalleve (&ldquo;<B>Branding Policy</B>&rdquo;). Each Party will nominate appropriate Buyers (including
cover in the event of holiday or sickness) to participate in discussions and workshops to produce the Branding Policy. Once agreed
the Branding Policy shall be signed off by authorised Buyers of each Party and shall then become binding on both Parties and shall
form part of this Agreement. The Parties shall use all reasonable endeavours to agree the Branding Policy within <B>[Redacted
 &ndash; Commercially Sensitive &ndash; Time Period]</B> from the Effective Date. The Parties agree that the following principles
are agreed and shall, unless agreed otherwise in the Branding Policy, be reflected in the Branding Policy:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.7</TD><TD STYLE="text-align: justify">The Parties agree that the following principles are agreed
and shall, unless agreed otherwise in the Branding Policy, be reflected in the Branding Policy:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Supplier will ensure that Sonalleve will be re-branded,
with Supplier&rsquo;s brand represented on Sonalleve as the lead brand.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Supplier is entitled, but not the obliged, to add a Philips
co-branding label to Sonalleve (including future generations of Sonalleve) and to related product literature, presentations, brochures
and webpages.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The scope of such co-branding will be limited to generations/versions
of Sonalleve that are exclusively compatible with Philips&rsquo; Equipment and are not compatible with, or sold to work with,
MRI systems from other vendors than Philips.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">The possibility to add a co-branding label to Sonalleve
will be jointly evaluated by both Parties. Supplier wishes to re-brand Sonalleve, the usefulness of adding co-branding will be
evaluated by the Parties jointly.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">In case both Parties agree to co-brand a generation of
Sonalleve, the most recent applicable Philips co-branding guidelines at that time will be taken as starting point to agree the
actual co-branding expression on Sonalleve and marketing collaterals.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">The co-branding label to be used shall include &ldquo;Powered
by Philips [Descriptor]&rdquo;, with [Descriptor] being an appropriate description of the contribution made by Buyer to Sonalleve
or shall include &ldquo;Works with Philips [Descriptor]&rdquo;, with [Descriptor] being an appropriate description of the contribution
made by Buyer to Sonalleve, to be agreed upon jointly.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 168pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">The co-branding label shall also appear in related product
literature, presentations, brochures, videos and webpages.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">11.5.8</TD><TD STYLE="text-align: justify"><U>Notice.</U> Buyer shall, when using or making reference
to a trademark of Supplier (as may be permitted by clause 11.5.4 above, or elsewhere in this Agreement), clearly identify (whether
through use of an asterisk, footnote or otherwise) such trademark as a &ldquo;Trademark of Profound Medical Inc. or its affiliates&rdquo;
or otherwise as Supplier may instruct from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>ARTICLE 12: <U>INDEMNITY AND LIMITATION
OF LIABILITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>12.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnity.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.1.1</TD><TD STYLE="text-align: justify">Buyer will defend, indemnify and hold harmless Supplier
and its Affiliates and their respective directors, officers, employees and agents, and their successors, heirs and assigns (the
 &ldquo;<B>Supplier Indemnitees</B>&rdquo;) from and against all liabilities, costs, damages, claims and expenses, including reasonable
attorney&rsquo;s fees, arising from or related to any actual or alleged <B>[Redacted &ndash; Commercially Sensitive &ndash; Indemnity
Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.1.2</TD><TD STYLE="text-align: justify">Supplier will defend, indemnify and hold harmless Buyer
and its Affiliates and their respective directors, officers, employees and agents and their respective successors, heirs and assigns
(the <B>&ldquo;Buyer Indemnitees</B>&rdquo;) from and against all liabilities, costs, damages, claims and expenses, including
reasonable attorney&rsquo;s fees, arising from or related to any actual or alleged <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Indemnity Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>12.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitations
of Liability.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.2.1</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive &ndash; Indemnity
Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>12.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Lower
Tier.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">12.3.1</TD><TD STYLE="text-align: justify">Supplier as legal manufacturer of Product will be responsible
for its participating Affiliates, subcontractors and vendors through the lowest tier. Supplier will ensure that each lower tier
subcontract contains all applicable Specifications and obligations needed to fully comply with this Agreement. Supplier will indemnify,
defend and hold harmless the Buyer Indemnitees from and against any and all claims and liabilities, including all costs and expenses,
arising out of or in any way connected with any actual or alleged action or failure to act by Supplier&rsquo;s Affiliates, subcontractors
or vendors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><B>ARTICLE
13: </B><U>INSURANCE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supplier&rsquo;s
Insurance.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1.1</TD><TD STYLE="text-align: justify">Supplier will maintain comprehensive or commercial general
liability insurance (including premises and operations, products and completed operations, broad form contractual liability, broad
form property damage and personal injury liability) with a minimum limit of <B>[Redacted &ndash; Commercially Sensitive &ndash;
Insurance Details]</B> combined single limit per occurrence and <B>[Redacted &ndash; Commercially Sensitive &ndash; Insurance
Details]</B> in the aggregate, for claims of bodily injury, including death, and property damage that may arise from use of Products.
Supplier shall also maintain professional liability insuring the acts or omissions of Supplier under this Agreement in an amount
of <B>[Redacted &ndash; Commercially Sensitive &ndash; Insurance Details] </B>per occurrence and aggregate. Supplier will also
maintain excess liability in an amount of not less than &euro;10 million per occurrence. The commercial general liability policy
obtained by Supplier will name Buyer, its officers, directors and employees as additional insured. Such insurance will apply as
primary insurance and no other insurance will be called upon to contribute to a loss covered there under. In addition, such policies
will permit Supplier to waive, on its own behalf and on behalf of its insurers, any rights of subrogation against Buyer. Such
insurance policies will be written with appropriately licensed and financially responsible insurers, and will provide for a minimum
of 30 days written notice to Buyer of any cancellation or reduction in coverage. Certificates of insurance evidencing the required
coverage and limits will be furnished to Buyer before any work is commenced hereunder, and Supplier will deliver copies of policies
or certificates to the Buyer contact designated by Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1.2</TD><TD STYLE="text-align: justify">If any policies have &ldquo;claims made&rdquo; coverage,
Supplier will maintain such coverage with Buyer named as an additional insured for a minimum of <B>[Redacted &ndash; Commercially
Sensitive &ndash; Insurance Details] </B>after termination of this Agreement. Any such coverage must have a retroactive date no
later than the date upon which work commenced under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">13.1.3</TD><TD STYLE="text-align: justify">All deductibles on policies providing coverage will be
paid by Supplier. If Supplier is self-insured for matters described above, Supplier agrees to respond to any claims or losses
made against or incurred by Buyer in the same fashion as if insurance had been purchased with the same or broader coverage terms
than what is generally available to similar Suppliers. In no event will the coverage or limits of any insurance required under
this clause, or the lack or unavailability of any other insurance, be deemed to limit or diminish Supplier&rsquo;s obligations
or liability to Buyer under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><B>ARTICLE
14:</B><B> <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>TERMINATION</U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination
for Cause.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">14.1.1</TD><TD STYLE="text-align: justify">Each Party may suspend performance of its obligations under
the Agreement or terminate this Agreement upon written notice to the other Party if:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the other Party files a voluntary petition in bankruptcy
or any voluntary proceeding relating to insolvency, receivership, liquidation, assignment for the benefit of creditors or similar
proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the other Party becomes the subject of a petition in bankruptcy
or any proceeding relating to insolvency, receivership, liquidation, assignment for the benefit of creditors or similar proceeding
and such petition or proceeding is not dismissed within thirty (30) days from filing of such petition or proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the other Party ceases or threatens to cease to carry on
business in the ordinary course or a Change of Control with respect to Supplier to a Buyer&rsquo;s direct competitor occurs; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the other Party materially breaches any of its obligations
under the Agreement, and the breaching failures to cure such breach within sixty <B>[Redacted &ndash; Commercially Sensitive &ndash;
Termination Details] </B>after it receives written notice from the non-breaching Party to cure same;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-weight: normal">(e)</FONT></TD><TD STYLE="text-align: justify"><B>[Redacted
                                         &ndash; Commercially Sensitive &ndash; Termination Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">conviction of, or commission by, the other Party or any
principal officer, shareholder, employee or any partner of the other Party of any crime or immoral act which may adversely affect
the goodwill or reputation of Buyer or Supplier;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">For greater certainty, if a Party is provided,
pursuant to one of the termination rights contemplated by this clause 14.1.1, with the right to elect to terminate this Agreement,
such Party may do so in respect of the entire Agreement, or to terminate the Agreement on a Product-by-Product basis (in which
instance, this Agreement will continue in respect of those Products not terminated by such Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>14.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Consequences
of Termination.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">14.2.1</TD><TD STYLE="text-align: justify">In the event that the Agreement is terminated as provided
for in clause 14.1:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">All Purchase Orders that are outstanding on the date this
Agreement shall terminate, for any reason, shall be fulfilled regardless of such termination, unless Buyer indicates otherwise.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Buyer shall no longer have the right to sell Product to
Customers, and shall return all Products in inventory to Supplier in the manner directed by Supplier and, at the Buyer&rsquo;s
sole cost and expense. Buyer shall cease holding itself out to be an authorized Supplier sales Buyer and shall cease all use of
Supplier trademarks and trade names.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Supplier shall continue the service obligation as per the
regulations in the jurisdiction where the Product is sold.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">All Confidential Information supplied by one Party to the
other to assist in carrying out the obligations hereunder shall remain the property of the supplying Party and, subject to any
express provisions hereof to the contrary, shall be returned to the supplying Party upon termination or expiration of this Agreement.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Buyer will ship, <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Delivery Details]</B> Buyer&rsquo;s principal place of business, within (30) days following the date of expiration or
the effective date of termination of this Agreement, to the destination specified by Supplier in writing, all sample Products,
catalogs, circulars, folders, and other Marketing Materials, all price sheets, bulletins, official communications, technical information,
confidential data and all other materials owned or provided by Supplier to Buyer which are in the possession or control of Buyer,
its employees or agents on such date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 159pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>ARTICLE 15: <U>FORCE MAJEURE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.1</B></TD><TD STYLE="text-align: justify">Neither Party will be liable for any failure to perform
solely caused by a Force Majeure Event and if that either Party is prevented from performing or is unable to perform any of its
obligations under this Agreement due to a Force Majeure Event, its performance will be excused, and the time for performance will
be extended for the period of delay or inability to perform due to such Force Majeure Event, provided that such Party will give
promptly written notice thereof to the other Party:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">describing the Force Majeure Event;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">describing the obligations which it is unable to perform
due to the Force Majeure Event; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">giving a projection of the expected period of delay or
inability to perform due to the Force Majeure Event, and such Party will have used&nbsp;reasonable commercial efforts to mitigate
its effects and to cure any non-performance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 163.55pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.2</B></TD><TD STYLE="text-align: justify">Force majeure on the part of Supplier shall in any event
not include shortage of personnel or production materials or resources, breach of contract by third parties contracted by Supplier,
financial problems of Supplier, nor the inability of Supplier to secure the necessary licenses in respect of software to be supplied
or the necessary legal or administrative permits or authorizations in relation to Products to be supplied.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.3</B></TD><TD STYLE="text-align: justify">If a Party is not or is not expected to be able to perform
any material obligation under this Agreement due to a Force Majeure Event for a period of <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Time Period Details] </B>or more, the other Party may terminate this Agreement without liability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>15.4</B></TD><TD STYLE="text-align: justify"><B>[Redacted &ndash;
                                         Commercially Sensitive &ndash; Timing Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">15.5</TD><TD STYLE="text-align: justify">For greater certainty, during the term of the Supply Agreement,
if there is a &ldquo;force majeure event&rdquo; outstanding under the Supply Agreement (claimed by Philips or one of its Affiliates
under the Supply Agreement), Buyer may not exercise the remedies in clause 15.3 and 15.4 hereunder if Supplier exercises a corresponding
Force Majeure Event under this Agreement in response to the Force Majeure Event exercised under the Suppply Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 136.55pt; text-indent: -40.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARTICLE
16: <U>RECALL</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">16.1</TD><TD STYLE="text-align: justify">If Supplier or any relevant Governmental Authority determines
that a recall campaign is necessary, Supplier will implement such recall campaign and Buyer will have the right to return the
affected Products to Supplier or destroy such Products, as determined by Supplier in its reasonable discretion, at Supplier&rsquo;s
sole cost and risk. Supplier hereby covenants and agrees that it shall be responsible for all costs and expenses related to the
implementation of any such recall. In case of a recall of the Product, Philips shall at its sole cost provide full cooperation
to Supplier in order to achieve an efficient and effective recall by Supplier. For greater certainty, the obligations of the Parties
pursuant to this clause 16 shall only apply in respect of Products sold or distributed on or after the Effective Date, and for
clarity, to the extent there is a recall that involves any Product sold or distributed prior to the Effective Date, the covenants
and obligations of the Parties pursuant to this clause 16 shall not apply (and shall be addressed by the terms of the Purchase
Agreement).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>ARTICLE 17: <U>GENERAL PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.1.1</TD><TD STYLE="text-align: justify">This Agreement may be amended only by a written instrument
explicitly referring to this Agreement, duly executed by authorized representatives of both Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding
Agreement and Assignment.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.2.1</TD><TD STYLE="text-align: justify">This Agreement will be binding upon and inure to the benefit
of the Parties and their respective successors and permitted assigns. This Agreement may not be assigned by either Party, in whole
or in part, to any Third Party without the prior written consent of the other Party, except that either Patrty may assign this
Agreement as a whole, and all of its rights and obligations hereunder, without the consent of the other Party but subject to prior
written notice to the other Party (a) to an Affiliate, or (b) in case of a transfer of all, or substantially all, stock or assets
of such Party or the relevant business activity through which such Party acts in this Agreement to a Third Party or to any partnership
or other venture in which such business activity is to participate. Except as provided above, without prior written consent of
the other Party, any assignment or pledge of rights under this Agreement by a Party to a Third Party shall have no effect vis-&agrave;-vis
such Third Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.3.1</TD><TD STYLE="text-align: justify">This Agreement, any Purchase Order issued hereunder and
the OEM Quality Agreement constitute the entire agreement and understanding of the Parties and merges all prior discussions and
negotiations between them and supersedes any previous agreement whether oral or written. Course of performance, course of dealing
and usage of trade will not apply to this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.3.2</TD><TD STYLE="text-align: justify">This Agreement also constitute a complete restatement of
the Resale Purchase Agreement between the Parties, dated January 1, 2016, and the Parties hereby terminate said Agreement as of
the the Effective Date of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.3.3</TD><TD STYLE="text-align: justify">The following attachments form an integral part of this
Agreement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[Redacted &ndash; Commercially Sensitive &ndash;
List of Schedules]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.55pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">In the event of any conflict
between any provision of this Agreement and any provision of Attachment 1, 2 or 4, the provisions of this Agreement shall prevail.
In the event of any conflict between any provision of this Agreement and any provision of Attachment 3, 5, 6, 7 or 8 the provisions
of Attachment 3, 5, 6, 7 or 8, as applicable, shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">In the event of any conflict between any provision
of this Agreement and any provision of the OEM Quality Agreement, the provisions of the OEM Quality Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Customs
Compliance/ Country of Origin/ Export Control</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.1</TD><TD STYLE="text-align: justify">Upon Buyer&rsquo;s request, Supplier will provide Buyer
with an acceptable and auditable certification stating the country of origin for Products, sufficient to satisfy the requirements
of (i) customs authorities of the country of receipt, and (ii) applicable export licensing regulations. Supplier will mark each
Product (or Product&rsquo;s container if there is no room on Product) with the country of origin. Supplier will, in marking Products,
comply with the requirements of the customs authorities of the country of receipt.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.2</TD><TD STYLE="text-align: justify">If Products delivered under this Agreement are imported,
Supplier will when possible allow Buyer to be the importer of record. If Buyer is not the importer of record and Supplier obtains
duty drawback rights to Products, Supplier will, upon Buyer&rsquo;s request, provide Buyer with documents required by the customs
authorities of the country of receipt to prove importation and to transfer duty drawback rights to Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.3</TD><TD STYLE="text-align: justify">Supplier will: organize its administration and manufacturing
in such a way, that Products can be supplied with preferential origin status and supply Products with the appropriate documentary
evidence of the preferential origin status. Supplier will provide the appropriate customs documentation for Products which may
be imported and/or exported by Buyer, including Certificate of Origin (renewed on a two (2)-year basis), and Harmonized Tariff
System Classification Codes. Supplier will support Buyer with import and export regulatory issues so that regulatory compliance
will be met.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.4</TD><TD STYLE="text-align: justify">This Agreement has been executed taking into consideration
the asserted origin of Products as well as the delivery by Supplier of the appropriate documentary evidence of the preferential
origin status requested by custom authorities. It is expressly understood that the preferential origin status of Product and the
accuracy thereof for any supplied Product hereunder are essential under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.5</TD><TD STYLE="text-align: justify">Each Party agrees and warrants that it will comply with
all applicable international and national export control laws and regulations and that it will not export or re-export, directly
or indirectly, any information, goods, software and/or technology, including any Products or Philips&rsquo; Equipment, to any
country for which the European Union or the United States of America or any other country, at the time of export or re-export,
requires an export license or other governmental approval, without first obtaining such license or approval.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.6</TD><TD STYLE="text-align: justify">Supplier agrees to inform Buyer in writing whether or not
Products are controlled and/or controlled under the export control laws of its own country, and if so, Supplier will inform Buyer
about the extent of the restrictions (including but not limited to export control legal jurisdiction, export control classification
numbers, export control licenses and/or CCATS as applicable).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.7</TD><TD STYLE="text-align: justify">Supplier shall obtain all international and national export
licenses or similar permits required under all applicable export control laws and regulations and shall provide Buyer with all
information required to enable Buyer and its Customers to comply with such laws and regulations. Supplier agrees to indemnify
and hold Buyer harmless from any claims, liabilities, penalties, forfeitures, and associated costs and expenses (including attorneys&rsquo;
fees) which Buyer may incur due to Supplier&rsquo;s non-compliance with applicable export control laws, rules and regulations.
Supplier agrees to promptly notify Buyer of Supplier&rsquo;s receipt of any such notice of a violation of any export control related
law, rule or regulation, which may affect Buyer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.4.8</TD><TD STYLE="text-align: justify">If Products are export controlled, Supplier will inform
Buyer accordingly and to indicate the applicable export control classification number (&ldquo;ECCN&rdquo;)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Jurisdiction</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.5.1</TD><TD STYLE="text-align: justify">This Agreement will be governed by and construed in accordance
with the laws of the Netherlands. The United Nations Convention on Contracts for the International Sale of Goods (the Vienna Sales
Convention) is not applicable to this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.5.2</TD><TD STYLE="text-align: justify">Any dispute arising out of or in connection with this Agreement
shall be resolved in the manner provided in Sections 12.1 and 12.2 of the Purchase Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Laws</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.6.1</TD><TD STYLE="text-align: justify">Each of the Parties will at all times comply with all laws,
rules, regulations and ordinances applicable to the Agreement and each Purchase Order, including but not limited to all fair labor,
equal opportunity and environmental compliance laws, rules, regulations and ordinances. Supplier will furnish to Buyer any information
required to enable Buyer to comply with such laws, rules, and regulations in its use of Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Personal
Data</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.7.1</TD><TD STYLE="text-align: justify">The Parties will have the obligations of patient privacy
and data as set forth <U>Attachment 6.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.55pt; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waivers.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.8.1</TD><TD STYLE="text-align: justify">Neither the failure nor delay of any Party to this Agreement
to assert or exercise any right, power, privilege or remedy under this Agreement or to enforce any term or provision hereof or
thereof, will constitute a waiver of such right, power, privilege or remedy, and no single or partial exercise of any such right,
power, privilege or remedy will preclude any other or further exercise of such right, power, privilege or remedy or the exercise
of any other right, power, privilege or remedy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.9.1</TD><TD STYLE="text-align: justify">Any notice or other communication required or permitted
to be given to any Party hereunder shall be in writing and shall be given to such Party at such Party&rsquo;s address set forth
below, or such other address as such Party may hereafter specify by notice in writing to the other Party. Any such notice or other
communication shall be addressed as aforesaid and given by: (i) hand delivery; (ii) international overnight courier; or (iii)
e-mail transmission. Any notice or other communication will be deemed to have been duly given: (A) on the date of service if served
personally; (B) on the Business Day after delivery to an international overnight courier service, provided receipt of delivery
has been confirmed; or (C) on the date of transmission if sent via e-mail transmission, provided confirmation of receipt is obtained
promptly after completion of transmission and provided that transmission via e-mail is followed promptly by delivery via one of
the methods in clause 16.9 (i) or (ii) above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to Buyer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">P.O. Box 10.000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">5680 DA Best, The Netherlands</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn:&nbsp;&nbsp;&nbsp; <FONT STYLE="font-size: 10pt"><B>[Redacted
 &ndash; Personal Information]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Legal Department PMSN BV Veenpluis 4-6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">5684 PC Best Building QX2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to Supplier:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Profound Medical Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2400 Skymark Avenue, Unit #6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Mississauga, ON, L4W 5K5, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email:<B>[Redacted &ndash; Personal Information]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Torys LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Suite 3000, P.O. Box 270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">79
Wellington Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">TD Centre</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Toronto, ON M5K 1N2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Cheryl Reicin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: <U>creicin@torys.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 82.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Publicity.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.10.1</TD><TD STYLE="text-align: justify">Any public announcements or press releases relating to
this Agreement shall be governed by the provisions of clause 14.13 of the Purchase Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Contractors</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.11.1</TD><TD STYLE="text-align: justify">Each Party is an independent contractor, not an agent,
employee or Buyer of the other. Neither Party has authority to make any statement, representation or commitment of any kind or
to take any action binding upon the other, without the other Party&rsquo;s prior, written authorization.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Excluded
Provider</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.12.1</TD><TD STYLE="text-align: justify">Supplier represents and warrants that it, and, to the best
of its knowledge, its employees and subcontractors providing the Products are not debarred, excluded, suspended or otherwise neligible
to participate in a U.S. federal health care program, nor have they been convicted of any U.S. health care related crime (an &quot;Excluded
Provider&quot;). Supplier will promptly notify Buyer in writing if it becomes aware that any of its employees or subcontractors
providing the Products has become an Excluded Provider. Buyer may terminate this Agreement upon written notice to Supplier if
upplier or any of its employees or subcontractors providing the Products becomes an Excluded Provider.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.55pt; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authority;
Due Execution.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.13.1</TD><TD STYLE="text-align: justify">Each Party represents and warrants to the other, that (a)
it has full power and authority to enter into this Agreement and any agreements related hereto and, subject to the terms and conditions
hereof, this Agreement, when executed, will be a valid and legally binding obligation of such Party according to its provisions,
(b) the execution and performance of this Agreement will not constitute a breach of or an event of default under any agreement,
contract, law or regulation to which such Party is or may be bound, and (c) the execution and performance of this Agreement has
been duly authorized by all necessary corporate action.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.14.1</TD><TD STYLE="text-align: justify">The provisions of this Agreement are severable and the
invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof.
If any provision of this Agreement, or the application thereof to any person or entity or any circumstance, is invalid or unenforceable,
(a) a suitable and equitable provision will be substituted therefor in order to carry out, so far as may be valid and enforceable,
the intent and purpose of such invalid or unenforceable provision, and (b) the remainder of this Agreement and the application
of such provision to other persons or entities or circumstances will not be affected by such invalidity or unenforceability, nor
will such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof,
in any other jurisdiction.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
Chain Security</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.15.1</TD><TD STYLE="text-align: justify">Supplier will comply with the supply chain security requirements
outlined in <U>Attachment 7.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
Agreement Matters</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.16.1</TD><TD STYLE="text-align: justify">The Parties acknowledge and agree that during the term
of the Supply Agreement, that Supplier will not be liable for any breach of this Agreement by it to the extent that such breach
of this Agreement primarily and directly results from a breach of the Supply Agreement by Philips or any of its Affiliates.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">17.17.1</TD><TD STYLE="text-align: justify">All terms and conditions of this Agreement which are intended
(whether expressed or not) to survive the duration or termination of this Agreement will so survive.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in"><B>17.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Attachments.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Include reference to the attachments as part of this
agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">[Redacted &ndash; Commercially Sensitive &ndash;
List of Schedules]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 132pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">[Remainder of Page Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">IN WITNESS WHEREOF, this Resale Purchase Agreement
has been duly executed by the duly authorized officers of the Parties hereto as of the date first written above.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Philips Medical Systems
    Nederland B.V.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Profound Medical Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature:</FONT></TD>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; font-size: 10pt">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Iwald
    Mons</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature: </FONT></TD>
    <TD STYLE="width: 41%; border-bottom: Black 1pt solid; font-size: 10pt">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Arun
    Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Iwald
    Mons </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Arun
    Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">M&amp;A
    Project</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief
    Executive</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leader</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">July
    31, 2017</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: </FONT></TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">July
    31, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">And</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Philips &amp; Profound</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">[REDACTED &ndash; Commercially Sensitive &ndash;
Schedules, including pricing, shipping terms, product specifications, scope of services, co-marketing obligations, product testing
criteria, data privacy, supply chain requirements]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">- Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> of 27 -</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>11
<FILENAME>tv526458_ex4-5.htm
<DESCRIPTION>EXHIBIT 4.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="color: #20262D"><B>Exhibit 4.5</B></FONT></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SUPPLY AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 57.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROFOUND MEDICAL
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>THIS AGREEMENT </B>is made July 31, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">BETWEEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%">&nbsp;</TD>
    <TD STYLE="width: 82%; text-align: justify; text-indent: 0in; font-size: 10pt"><B>PROFOUND MEDICAL INC.</B>, a company
    incorporated under the laws of &nbsp;the &nbsp;province &nbsp;of &nbsp;Ontario &nbsp;and &nbsp;having
    &nbsp;its registered address at 2400 Skymark, Unit 6, Mississauga, Ontario L4W 5K5,
    Canada</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hereinafter referred to as &ldquo;<B>Customer</B>&rdquo;)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">- and -</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PHILIPS &nbsp;MEDICAL &nbsp;SYSTEMS &nbsp;NEDERLAND &nbsp;B.V.</B>, &nbsp;a &nbsp;company</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">incorporated under the laws of the Netherlands with its principal place of business at Veenpluis 4-6 5684 PC Best, the Netherlands</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">(hereinafter referred to as &ldquo;<B>Philips</B>&rdquo;)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Customer and Philips hereinafter also collectively referred to as the &ldquo;<B>Parties</B>&rdquo; and individually as a &ldquo;<B>Party</B>&rdquo;.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">WHEREAS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">A.</TD><TD STYLE="text-align: justify">Pursuant to the Asset and Share Purchase Agreement (the
 &ldquo;<B>Purchase Agreement</B>&rdquo;) entered into on June 30, 2017 by Customer, Koninklijke Philips NV (&ldquo;<B>Philips
NV</B>&rdquo;) N.V. and Customer agreed to execute and deliver (or cause to be executed and delivered) certain ancillary agreements
one of which is this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">B.</TD><TD STYLE="text-align: justify">Prior to the consummation of the transactions contemplated
by the Purchase Agreement, Philips manufactured the Product in-house and did not outsource the manufacturing to an independent
facility, and as a result, Philips has intimate knowledge of the manufacturing process and requirements for the Product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">C.</TD><TD STYLE="text-align: justify">Customer originally desired to take over responsibility
for the manufacture of the Product immediately upon closing of the transactions contemplated by the Purchase Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">D.</TD><TD STYLE="text-align: justify">As Philips historically manufactured the Product in-house,
to enable Customer to prepare for and realize the transition of the manufacturing of the Product to Customer&rsquo;s organization,
Customer requires the assistance of Philips to continue manufacturing the Product until such time as the manufacturing process
can be transitioned to Customer hereunder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">E.</TD><TD STYLE="text-align: justify">Until such time as the manufacturing of the Product can
be transitioned to Customer in accordance with the terms of this Agreement, Philips agrees to supply, as a contract manufacturer
to Customer, on a temporary basis for the Term (as defined herein), the Product, and Customer wishes to buy such Products from
Philips under this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center"> </TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">F.</TD><TD STYLE="text-align: justify">Customer acknowledges and agrees that it assumes all obligations
and liabilities as the legal manufacturer of the Product as from the Effective Date, on the terms and conditions set out in this
Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><B>NOW IT IS HEREBY AGREED</B> as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">DEFINITIONS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The following
terms used in this Agreement shall have the meaning set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries,
controls, is controlled by or is under common control with the specified Person. As used in this definition,
 &ldquo;control&rdquo;, &ldquo;controlled by&rdquo; and &ldquo;under common control with&rdquo; means possession, directly or
indirectly, of power to direct or cause the direction of management or policies of such Person (whether through ownership of
securities or other partnership or ownership interests, as trustee, personal representative or executive or by contract,
credit agreement or otherwise), provided that in any event, any Person which owns directly, indirectly or beneficially 50% or
more of the securities having voting power for the election of directors or other governing body of a corporation or 50% or
more of the partnership interests or other ownership interests of any other Person will be deemed to control such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Agreement</B>&rdquo;
means this Supply Agreement including any and all of its Schedules as attached hereto and as may be amended or supplemented from
time to time in accordance with the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Business
Day</B>&rdquo; means any day other than a Saturday, Sunday or statutory holiday, in the Province of Ontario or the Netherlands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Claim</B>&rdquo;
means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation,
citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or other, whether at Law,
in equity or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Confidential
Information</B>&rdquo; means any information, provided in whatever form (including in written, electronic or oral form) or medium,
which relates to either Party&rsquo;s or its Affiliates&rsquo; business, products (hardware and software), technology, business
plans, product plans, customers, customer information, specifications, designs, costs, prices, business opportunities, Know How,
trade secrets, inventions, techniques, processes, algorithms, software programs, schematics and any other business or technical
information disclosed by the Disclosing Party to the Receiving Party in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Confirmation</B>&rdquo;
has the meaning ascribed thereto in clause 4.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Contract
Year</B>&rdquo; means the twelve (12) month period beginning on the Effective Date, and each subsequent twelve (12) month period
during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Customer</B>&rdquo;
has the meaning ascribed thereto in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Customer Indemnified
Parties</B>&rdquo; has the meaning ascribed thereto in clause 10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Delivery</B>&rdquo;
means the actual delivery of the Product to Customer and the acceptance by Customer of the Product in accordance with clause
7.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Disclosing Party</B>&rdquo;
as the meaning ascribed thereto in clause 14.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>DMR</B>&rdquo; has the meaning ascribed thereto in clause 5.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>EDI</B>&rdquo;
means electronic data interchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Effective
Date</B>&rdquo; means the Completion Date as defined in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Encumbrance</B>&rdquo;
means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option,
security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including
any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Export Regulations</B>&rdquo;
has the meaning ascribed thereto in clause 16.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Factory
Test Report</B>&rdquo; means the report, the content of which is set forth in Schedule 4, that Philips shall prepare and maintain,
identifying the factory tests Philips completes on the Product prior to Delivery to support its compliance with the Specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Force Majeure</B>&rdquo;
has the meaning ascribed thereto in clause 0.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Forecasts</B>&rdquo;
means those documents setting out anticipated demand for the Product as to be more particularly described in clause 3.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Governmental
Authority</B>&rdquo; means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality
of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority
or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the
force of Law), or any arbitrator, court or tribunal of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Intellectual
Property Rights</B>&rdquo; means, in any and all jurisdictions, all: (a) patents and applications therefor, including all
continuations, continuations-in-part and provisionals and patents issuing thereon, and all reissues, re-examinations,
substitutions, renewals and extensions thereof (collectively, &ldquo;<B>Patents</B>&rdquo;); (b) trademarks, service marks,
trade names, trade dress, logos, corporate names, Internet domain names or uniform resource locators used in connection with
any global computer or electronic network, together with all translations, adaptations, derivations and combinations thereof,
and other source or business identifiers, together with the goodwill associated with any of the foregoing, and all
applications, registrations, renewals and extensions thereof; (c) industrial designs, designs and design rights; (d)
copyrights, works of authorship and moral rights, and all registrations, applications, renewals, extensions and reversions
thereof; (e) trade secrets, discoveries, concepts, ideas, research and development, Know How, formulae, inventions,
compositions, manufacturing and production processes and techniques, technical data, quality data, procedures, designs,
drawings, specifications, databases, and other proprietary or confidential information, including customer lists, supplier
lists, pricing and cost information, and business and marketing plans and proposals, which would constitute a &ldquo;trade
secret&rdquo; under applicable Law, in each case excluding any rights in respect of any of the foregoing that comprise or are
protected by Patents (&ldquo;<B>Trade Secrets</B>&rdquo;); (f) inventions, processes and designs; and (g) software, and all
source code, object code, data and documentation relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Know
How</B>&rdquo; means any and all concepts, ideas, information, data and documents of whatever nature, including, without limitation,
drawings, methods, techniques, designs, specifications, photographs, samples, models, processes, procedures, reports, particulars
of a technical nature (including, without limitation, any know how related to the manufacturing or design of Products and technical
and commercial know how).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 3pt">&ldquo;<B>Law</B>&rdquo;
means all laws, statutes, ordinances, decrees, judgments, codes, standards, acts, orders, by-laws, rules, regulations, permits,
legally binding policies and guidelines and legally binding requirements of all Governmental Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Lead-Time</B>&rdquo;
means, as applicable, the minimum number of days required between the date of the Purchase Order and the date of Delivery requested
in a Purchase Order as such number is listed in Schedule 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Losses</B>&rdquo;
has the meaning ascribed thereto in clause 10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>New Technology</B>&rdquo;
has the meaning ascribed thereto in clause 13.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Other Transaction Documents</B>&rdquo; has
the meaning ascribed thereto in clause 6.6. <B>&ldquo;Parties</B>&rdquo; and &ldquo;<B>Party</B>&rdquo; have the meaning ascribed
thereto in the Preamble. &ldquo;<B>Permit</B>&rdquo; has the meaning ascribed thereto in clause 8.2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Person</B>&rdquo;
includes any individual, sole proprietorship, partnership, unincorporated association, unincorporated syndicate, unincorporated
organization, trust, body corporate and a natural person in his or her capacity as trustee, executor, administrator or other legal
representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Project Manager</B>&rdquo;
has the meaning ascribed thereto in clause 12.8(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Project Team</B>&rdquo;
has the meaning ascribed thereto in clause 12.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Quality Agreement</B>&rdquo;
has the meaning ascribed thereto in clause 8.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Philips</B>&rdquo; has
the meaning ascribed thereto in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Philips Indemnitees</B>&rdquo; has the meaning
ascribed thereto in clause 10.1(ii)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Product</B>&rdquo; means
the Sonalleve MR-guided HIFU device which Philips shall manufacture and supply according to this Agreement as specified in Schedule
1,including spare parts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 3pt">&ldquo;<B>Production Plan</B>&rdquo;
means the production plan setting forth the delivery limitations as specified in Schedule 3, and as may be updated in accordance
with clause 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Purchase Order</B>&rdquo;
means an order for Products as may be submitted by Customer in accordance with clause 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Quality
Agreement</B>&rdquo; means the Quality Agreement as described further in clause 8.1 of this Agreement, as the same may be amended
or supplemented from time to time in accordance with the terms thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Receiving Party</B>&rdquo; as the meaning
ascribed thereto in clause 14.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Regulatory Transfer Date</B>&rdquo; has the
meaning ascribed to such term in clause 2.3. &ldquo;<B>Representatives</B>&rdquo; has the meaning ascribed to such term in clause
14.2. &ldquo;<B>Required Jurisdictions</B>&rdquo; <B>[Redacted &ndash; Commercially Sensitive]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>RPA</B>&rdquo; means the
resale purchasing agreement between the Parties, dated as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<B>Specifications</B>&rdquo;
means the specifications for the Product as set out in Schedule 1, as such specifications be amended from time to time in accordance
with the terms of the quality agreement (the &ldquo;<B>Quality Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>Term</B>&rdquo; has the
meaning ascribed thereto in clause 12.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Third Parties</B>&rdquo; means a Person who
is not a Party or an Affiliate of a Party. &ldquo;<B>Transferred Confidential Information</B>&rdquo; has the meaning ascribed thereto
in clause 14.4. &ldquo;<B>Transition Plan</B>&rdquo; has the meaning ascribed thereto in clause 12.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&ldquo;<B>VAT</B>&rdquo; has the
meaning ascribed thereto in clause 6.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">GENERAL, SCOPE</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.1</TD><TD STYLE="text-align: justify">During the Term, Philips shall manufacture and supply and
Customer shall purchase the Products ordered by Customer pursuant to Purchase Orders (issued by Customer and accepted by Philips)
in accordance with the terms and conditions of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.2</TD><TD STYLE="text-align: justify">The Parties intend for the express terms and conditions
contained in this Agreement, including the Quality Agreement and any Schedules and Exhibits hereto or thereto, and in any Purchase
Order that are consistent with the terms and conditions of this Agreement to exclusively govern and control each of the Parties&rsquo;
respective rights and obligations regarding the manufacture, purchase and sale of the Products, and the Parties&rsquo; agreement
is expressly limited to such terms and conditions. Notwithstanding the foregoing, if any terms and conditions contained in a Purchase
Order conflict with any terms and conditions contained in this Agreement, the applicable term or condition of this Agreement will
prevail and such additional, contrary or different terms will have no force or effect. Except for such additional and contrary
terms, the terms and conditions of all Purchase Orders are incorporated by reference into this Agreement for all applicable purposes
hereunder. Without limitation of anything contained in this clause 2.2, any additional, contrary or different terms contained
in any Confirmation (as defined below) or any of Philips&rsquo;s invoices or other communications between the Parties, and any
other attempt to modify, supersede, supplement or otherwise alter this Agreement, are deemed rejected by Customer and will not
modify this Agreement or be binding on the Parties unless such terms have been fully approved in a signed writing by authorized
by both Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.3</TD><TD STYLE="text-align: justify">On the Effective Date, Philips (or its Affiliate, Philips
Oy) is the legal manufacturer of the Product. Customer hereby covenants and agrees to file with all applicable notified bodies
and Governmental Authorities, including but not limited to BSI, Notified Body and ISO Registrar, on a jurisdiction-by-jurisdiction
basis, within the applicable time periods for each jurisdiction outlined in the &ldquo;Transitional Service Level Agreement&rdquo;
(TSLA Number: QR01, TSLA Title: Transfer of Legal Manufacturers), all documentation required or necessary to change the legal
manufacturer of the Product in each Required Jurisdiction from Philips Oy to Customer for all applicable regulatory purposes.
In order to expedite and achieve such change of legal manufacturer and to achieve the required changes outlined in such Transitional
Service Level Agreement, Customer shall fully cooperate with as required by and actively facilitate the above registration process
by the applicable notified bodies and Governmental Authorities in each Required Jurisdiction. On a jurisdiction-by-jurisdiction
basis, from the date that the legal manufacturer is updated to Customer in such jurisdiction, Philips will supply the Products
in such jurisdiction as contract manufacturer of Customer under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.4</TD><TD STYLE="text-align: justify">Philips shall provide such reasonable support, assistance
and information reasonably requested by Customer and as outlined in the above referenced Transitional Service Level Agreement
(including, to achieve the required changes outlined in such Transitional Service Level Agreement) in connection with Customer&rsquo;s
transfer of the registrations in respect of the Product from Philips to Customer (as contemplated by clause 2.3 above), including,
those services outlined in the Transitional Service Level Agreement, participating in any meeting with the applicable Governmental
Authority reasonably requested by Customer and subject to the limitations and the obligations of the Parties under the &ldquo;Transitional
Service Level Agreement&rdquo; (TSLA Number: QR01, TSLA Title: Transfer of Legal Manufacturers) concluded by the Parties in conjunction
with the Purchasing Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">DELIVERY CAPACITY, FORECAST</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.1</TD><TD STYLE="text-align: justify">Philips shall maintain a delivery capacity, which allows
Philips to deliver the Products in accordance with the Lead Times, Forecasts and Purchase Orders, but always subject to the supply
limitations, if any, outlined in the Production Plan. Such Production Plan may be updated, and the production capacity may be
increased only by the Parties&rsquo; written agreement and any reasonable additional incremental (and documented) investment required
to exclusively satisfy such increase shall be borne by Customer. Philips shall not be held liable for rejecting any Purchase Order
through which the volume in any Contract Year or the relevant quarter exceeds the volume indicated in the Production Plan.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.2</TD><TD STYLE="text-align: justify">Customer shall provide Philips in good faith on a monthly
basis, on the later of (i) seven (7) days prior to the beginning of each calendar month a rolling <B>[Redacted &ndash; Commercially
Sensitive]</B> forecast for the Products (including the major configuration of each Product such as field strength) (&ldquo;<B>Forecast</B>&rdquo;)
it expects to purchase during such <B>[Redacted &ndash; Commercially Sensitive]</B> period. Such Forecast shall be provided in
writing or in any other mutually agreed manner of communication (e.g., EDI or email). Notwithstanding any other obligation set
forth herein, Customer shall give Philips at least <B>[Redacted &ndash; Commercially Sensitive]</B> prior written notice if, during
the Term, it intends to discontinue the purchase of any Products hereunder, or if it intends to substantially decrease, versus
the Forecast, its purchase demand hereunder. For greater certainty, if Philips (or an Affiliate of Philips) is delayed in delivering
any &ldquo;Forecast&rdquo; contemplated by the RPA, the Customer&rsquo;s obligations to deliver the Forecast hereunder (solely
in respect of that portion of the Forecast that corresponds to the volume of Product to be sold to Philips (or an Affiliate of
Philips) pursuant to the RPA) shall be tolled until Philips (or an Affiliate of Philips) delivers the corresponding &ldquo;Forecast&rdquo;
under the RPA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.3</TD><TD STYLE="text-align: justify">Notwithstanding Customer&rsquo;s obligations pursuant to
clauses 3.1 and 3.4, the first <B>[Redacted &ndash; Commercially Sensitive]</B> of each Forecast shall constitute a binding commitment
of Customer to purchase the quantities of Products set forth in the relevant Forecast for such <B>[Redacted &ndash; Commercially
Sensitive]</B> period. The Forecast for the period beyond this two (2) month period shall be non-binding except to the extent
otherwise provided in clause 3.4. Only Purchase Orders as accepted by Philips, as set forth in clause 3.4 below, constitute an
obligation for Philips to actually produce the so ordered Products and no quantities of Products in the Forecast provided by Customer
shall constitute an accepted Purchase Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.4</TD><TD STYLE="text-align: justify">Customer shall have the right to increase or decrease,
as the case may be, the <B>[Redacted&ndash; Commercially Sensitive]</B> Forecast only within the limitations set forth in the
Production Plan per quarter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.5</TD><TD STYLE="text-align: justify">The reasonable and documented costs of all materials, parts
and components which have been purchased and paid for by Philips in order to meet Customer&rsquo;s demand as may be concluded,
based on the historical operations of Philips in the ordinary course of business, on the basis of Customer&rsquo;s Forecast, shall
be reimbursed, at inventory value without additional mark up by Customer against invoice in accordance with the payment terms
of this Agreement in such instance where any such materials are not used in the production of any Products to meet any Purchase
Orders of Customer within <B>[Redacted &ndash; Commercially Sensitive]</B> of the purchase of such materials. The same reimbursement
obligation shall apply at the end of the Term for materials, parts and components then available at Philips. Such materials, parts
and/or components shall be delivered to Customer <B>[Redacted &ndash; Commercially Sensitive]</B>. Upon payment the title of the
materials, parts and/or components shall transfer to Customer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>PURCHASE ORDERS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.1</TD><TD STYLE="text-align: justify">Customer shall place Purchase Orders in writing (or any
other mutually agreed manner of communication, e.g. email or EDI) within the Lead-Time and in accordance with the Forecast provided
to Philips in accordance with clause 3.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.2</TD><TD STYLE="text-align: justify">Each Purchase Order shall be given in writing (or such
other manner of communication (e-mail) as may be mutually agreed from time to time) and shall specify:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Purchase Order number;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the type (including Product name and codes) and quantity
of Products ordered;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the requested date of Delivery;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">destination &ndash; ship to address;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the services ordered for the ordered Product; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">such other information as Philips may reasonably request
from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.3</TD><TD STYLE="text-align: justify">No Purchase Order shall be deemed to be accepted by Philips
until accepted in writing (including by email or another agreed manner of communication) by Philips or as otherwise contemplated
by clause 4.4 below. Philips shall not reject any Purchase Order which is placed in accordance with the Forecast, the Lead Time
and otherwise in accordance with this Agreement, unless Philips is entitled to reject on the basis of clause 3.1 or 4.4.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.4</TD><TD STYLE="text-align: justify">Philips shall confirm to Customer the receipt of each Purchase
Order issued hereunder (each, a &ldquo;<B>Confirmation</B>&rdquo;) within seven (7) days following Philips&rsquo;s receipt thereof
in writing or in any other mutually agreed manner of communication (e.g., EDI or email). Each Confirmation must reference Customer&rsquo;s
Purchase Order number, confirm acceptance of the Purchase Order, include a confirmed date of Delivery (which may differ from the
requested one in the Purchase Order) or, solely if permitted under this clause 4.4, advise Customer of Philips&rsquo;s rejection
of such Purchase Order, the date of acceptance or rejection and the basis for rejection, if applicable. If Philips commences performance
under such Purchase Order, Philips will be deemed to have accepted the Purchase Order. Customer may withdraw any Purchase Order
prior to Philips&rsquo; acceptance thereof. Philips may only reject a Purchase Order if (a) the quantity ordered by Customer in
such Purchase Order is inconsistent with the quantity in the applicable Forecast in accordance with clause 3.2 (as amended pursuant
to clause 3.4), (b) Philips has sent Customer a Notice of termination pursuant to clause 12 or (c) the applicable Purchase Order
includes terms and conditions that supplement those contained in this Agreement, which Philips is unwilling to accept. Philips
may not cancel any previously accepted Purchase Order hereunder. Customer may not cancel a previously accepted Purchase Order
..</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">DELIVERY, TRANSFER OF RISK AND OWNERSHIP</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.1</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive &ndash; Delivery
Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.2</TD><TD STYLE="text-align: justify">If Customer fails to take Delivery of ordered Products
at the date of Delivery acknowledged by Philips, then Philips may deliver the Products in consignment and at Customer&rsquo;s
risk and cost.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.3</TD><TD STYLE="text-align: justify">Philips will manufacture, handle, properly pack, mark and
ship the Products in accordance with Customer&rsquo;s instructions provided to Philips in writing as part of the Device Master
Record (&ldquo;<B>DMR</B>&rdquo;) or as otherwise set forth in the Quality Agreement. The purchase price for the Product includes
the costs of packaging as defined in the DMR, but any additional costs resulting from compliance with non-standard packaging specifications
(<I>i.e.</I>, different from as defined in the DMR) shall be added to the Price.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">5.4</FONT></TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive &ndash; Delivery
Details]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>PRICE AND PAYMENT</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.1</TD><TD STYLE="text-align: justify">Prices are exclusive of any federal, state or local sales,
use or excise taxes and any, value added tax imposed solely as a result of the sale and transfer of the Products (VAT). Philips
will list separately on its invoice any tax lawfully applicable to the relevant Purchase Order and payable by Customer, if any,
with respect to which Customer does not furnish evidence of exemption. Philips is responsible for remitting any applicable VAT,
sales tax, consumption tax, or any other similar tax, in each instance, that were charged to Customer under an applicable Purchase
Order, to the appropriate tax authorities in accordance with applicable Laws and required timelines. Philips will issue an invoice
containing wording that will allow Customer to take advantage of any applicable &ldquo;input&rdquo; tax deduction.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.2</TD><TD STYLE="text-align: justify">Purchase prices for the Products are set out in Schedule
1. Prices are firm and fixed for the Term and shall include all costs for work performed, Delivery according to this Agreement
and packaging as set forth in clause 5.3 above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.3</TD><TD STYLE="text-align: justify">Any invoices provided by Philips shall refer to the Purchase
Order number and any other details required by applicable Law. Philips shall invoice for the purchase prices set out in Schedule
1 on or at any time after Delivery.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.4</TD><TD STYLE="text-align: justify">Philips invoices, compliant with the requirements of this
Agreement, will be payable within <B>[Redacted &ndash; Commercially Sensitive]</B> following the end of the month of the date
of invoice. Customer shall make all payments in Euros by check, wire transfer or automated clearing house to the bank account
designated by Philips.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">6.5</FONT></TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive &ndash; Late Payment
Details]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.6</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>CONFORMITY OF PRODUCTS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.1</TD><TD STYLE="text-align: justify">Philips represents and warrants to Customer that all Products
delivered and any services provided hereunder:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">conform to the Specifications
on the Delivery Date </FONT><B>[Redacted &ndash; Commercially Sensitive]</B><FONT STYLE="font-size: 10pt">;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">unless otherwise agreed with Customer in writing, are new
(do not contain any used or reconditioned parts or materials) and fit for the purposes for which they are intended;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">iii.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">are of sound workmanship,
good quality and free from defects in construction, manufacture and material</FONT> <B>[Redacted &ndash; Commercially Sensitive]</B><FONT STYLE="font-size: 10pt">;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">the manufacturing and shipment of the Product comply in
all respects with applicable Laws, regulations, certification requirements, including health and safety standards and all other
applicable regulatory requirements for the manufacture and shipment of Products;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">v.</TD><TD STYLE="text-align: justify">are free and clear of all liens, encumbrances, and other
Claims against title; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">vii.</TD><TD STYLE="text-align: justify">comply in all respects with the terms of this Agreement
and the applicable Purchase Orders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 149pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">7.2</FONT></TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.3</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive]</B> the foregoing
warranties will survive any inspection, delivery, acceptance, or payment by Customer and will be enforceable by Customer and its
Affiliates, and their successors, assigns, subcontractors, distributors, dealers, agents and customers and all other entities
combining, selling or using Products or goods into which Products have been incorporated (together, the &ldquo;<B>Customer Parties</B>&rdquo;),
for the period set forth in clause 7.4<B>.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.4</TD><TD STYLE="text-align: justify">Without prejudice to any other rights accruing under this
Agreement or law, the warranties set forth in clause 7.1 will extend for a period of <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Warranty Details]</B>. Products repaired or replaced by Philips within the Warranty Term are warranted for the remainder
of the original Warranty Term of said Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.5</TD><TD STYLE="text-align: justify">In respect of failure to meet the Specifications, if Products
do not comply with the warranties set forth in clause 7.1, Customer may then, after having consulted Philips as to the most appropriate
remedy, elect reasonably to have Products:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">i.</TD><TD STYLE="text-align: justify">returned to Philips for repair or replacement;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">ii.</TD><TD STYLE="text-align: justify">repaired or replaced by Philips in the field; or</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iii.</TD><TD STYLE="text-align: justify">repaired or replaced by Customer in the field, including
Products in distributor inventory and Customer&rsquo;s installed base; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">iv.</TD><TD STYLE="text-align: justify">returned to Philips in exchange for a full refund of the
purchase price for the non-conforming Products paid under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.6</TD><TD STYLE="text-align: justify">Philips will bear all costs, including transportation and
labor costs, in connection with the repair or replacement of, and all other costs or damages Customer may incur as a result of
Products not complying with clause 7.1. If Philips agrees that Customer performs the repair, Philips will provide Customer free
of charge with any replacement Product or upgrade necessary, and will reimburse Customer for all costs relating to such repair,
including any related labor costs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.7</TD><TD STYLE="text-align: justify">If Customer or any relevant Governmental Authority determines
that a recall campaign is necessary, Customer will implement such recall campaign at Customer&rsquo;s sole cost and risk. Customer
hereby covenants and agrees that it shall bear all costs and expenses related to the implementation of any such recall. In case
of a recall of the Product, Philips shall at its sole cost provide full cooperation to Customer in order to achieve an efficient
and effective recall by Customer. Philips shall provide such cooperation at its own costs, including internal organizational costs
but not including the costs of repair, replacement, installation of Products and logistics related to the recall <B>[Redacted
 &ndash; Commercially Sensitive]</B>. For greater certainty, the obligations of the Parties pursuant to this clause 7.6 shall only
apply in respect of Products sold or distributed on or after the Effective Date, and for clarity, to thwe extent there is a recall
that involves any Product sold or distributed prior to the Effective Date, the covenants and obligations of the Parties pursuant
to this clause 7.6 shall not apply (and shall be addressed by the terms of the Purchase Agreement).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">7.8</FONT></TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive &ndash; Warranty
Details]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>QUALITY AND REGULATORY AND COMPLIANCE WITH LAWS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.1</TD><TD STYLE="text-align: justify">The Parties have entered into a Quality Agreement on or
around the Effective Date, detailing Customer&rsquo;s requirements, as the legal manufacturer of the Product, with respect to
the manufacturing of the Product by Philips as the contract manufacturer. . The Quality Agreement is deemed to be incorporated
into this Agreement by reference and made a part hereof, and to the extent of a conflict between the terms of the Quality Agreement
and this Agreement, the terms and provisions of this Agreement shall prevail.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.2</TD><TD STYLE="text-align: justify">Until, on a jurisdiction by jurisdiction basis, the Regulatory
Transfer Date, Philips shall</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">remain the legal manufacturer of the Product according
to its own quality management systems.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">comply, in all material respects, with all applicable Laws,
Philips&rsquo; operation of its business and the exercise of its rights and performance of its obligations hereunder (including,
the manufacture of the Product). Without limitation of the foregoing, Philips shall ensure the Product is manufactured in accordance
with applicable Laws.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">obtain and maintain all Permits necessary for the exercise
of its rights and performance of Philips&rsquo; obligations under this Agreement, including any Permits required for the manufacture
of the Product and the import or any materials and other manufacturing parts used in the production and manufacture of the Product,
and the shipment of hazardous materials, as applicable. For purposes of this Agreement, &ldquo;<B>Permit</B>&rdquo; means any
permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained or
required to be obtained, from any Governmental Authority.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.</TD><TD STYLE="text-align: justify">CHANGES TO PRODUCT</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.1</TD><TD STYLE="text-align: justify">Any changes to the Product proposed by Philips shall be
discussed and handled by the Parties as described in the Quality Agreement. Until execution of the Quality Agreement, the provisions
of this clause 9 shall apply.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.2</TD><TD STYLE="text-align: justify">Philips shall be entitled to make changes to the Products
to comply only with any applicable Laws. Without prejudice to the foregoing, it is understood and agreed that Customer (and not
Philips) shall be responsible to notify Philips of any changes required to comply with any applicable Laws, as long as such applicable
Laws concern the Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.3</TD><TD STYLE="text-align: justify">Customer may reasonably request and Philips may propose,
in writing, that Philips makes a change to the method of packing, a change to the packaging, or the Products. Such request or
proposal (as applicable) will include a description of the requested/proposed change sufficient to allow Philips, using commercially
reasonable efforts, to evaluate the feasibility and impact on costs and other terms of such requested change, it being understood
that Customer shall pay for any reasonable incremental and documented costs incurred by Philips in connection with such evaluation.
All such changes are subject to Philips&rsquo;s written approval (and in case of a change proposal by Philips, Customer&rsquo;s
written approval), which cannot unreasonably withheld, conditioned or delayed, it being understood that, if technically feasible
and commercially reasonable, Philips shall make any changes required to comply with any applicable Laws upon Customer&rsquo;s
written request. Philips will not be obligated to agree or accept any such request for a change nor to proceed with the requested
change until the Parties have mutually agreed upon the changes to the Product&rsquo;s Specifications, the price, the implementation
costs to be borne by Customer including, without limitation, development and other non-recurring expenses, the cost of inventory
and materials that may become obsolete, and any other terms of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.4</TD><TD STYLE="text-align: justify">The incremental and documented costs of any changes (including
any non-recurring costs such as development and re-engineering costs, as well as costs of changes to the tools used to manufacture
the changed Products) shall be borne by Customer. All such charges will be charged to Customer at cost, without any additional
markup.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.</TD><TD STYLE="text-align: justify">INDEMNIFICATION AND LIMITATION OF LIABILITY</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.1</TD><TD STYLE="text-align: justify"><B>Indemnification by Philips</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Philips will defend, indemnify and hold harmless Customer
and its Affiliates and their respective directors, officers, employees and agents, and their successors, heirs and assigns (the
 &ldquo;<B>Customer Indemnitees</B>&rdquo;) from and against all liabilities, costs, damages, Claims and expenses, including&nbsp;
reasonable attorney&rsquo;s fees, arising from or related to any actual or alleged <B>[Redacted &ndash; Commercially Sensitive
 &ndash; Indemnification Details]</B><FONT STYLE="font-weight: normal">.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Customer will defend, indemnify and hold harmless Philips
and its Affiliates and their respective directors, officers, employees and agents, and their successors, heirs and assigns (the
 &ldquo;<B>Philips Indemnitees</B>&rdquo;) from and against all liabilities, costs, damages, Claims and expenses, including reasonable
attorney&rsquo;s fees, arising from or related to any actual or alleged <B>[Redacted &ndash; Commercially Sensitive &ndash; Indemnification
Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">10.2</FONT></TD><TD STYLE="text-align: justify">[Redacted &ndash; Commercially Sensitive &ndash; Indemnification
Details]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.3</TD><TD STYLE="text-align: justify"><B>[Redacted &ndash; Commercially Sensitive &ndash; Indemnification
Details]</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.4</TD><TD STYLE="text-align: justify">The limitations and exclusions set forth above in this
clause 10 shall apply to the fullest extent permitted by applicable Law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify">TOOLS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">11.1</TD><TD STYLE="text-align: justify">The Parties will conclude contract(s) managing the ownership
and use of tools and equipment needed for the manufacturing of the Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.</TD><TD STYLE="text-align: justify">TERM AND TERMINATION AND TRANSITION</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.1</TD><TD STYLE="text-align: justify">This Agreement shall come into force on the Effective Date
and shall remain in force and effect for a period of <B>[Redacted &ndash; Commercially Sensitive &ndash; Term Details]</B> , unless
this Agreement is extended or previously terminated in accordance with this clause 12, pursuant to clause 15.1 (Force Majeure),
or (ii) by the mutual written consent of the Parties (the &ldquo;<B>Term</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.2</TD><TD STYLE="text-align: justify">Customer, in its sole discretion, may terminate this Agreement,
without cause, by providing six (6) months prior written notice to Philips. Philips may terminate this Agreement with immediate
effect by written notice to Customer, should Customer not have filed with the specified bodies to transfer the applicable registrations
within the time period specified in clause 2.3.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.3</TD><TD STYLE="text-align: justify">Without prejudice to any other right or remedy a Party
may have against the other Party for breach or non-performance of this Agreement, Each Party may suspend performance of its obligations
under the Agreement or terminate this Agreement upon written notice to the other Party if:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the other Party files a voluntary petition in bankruptcy
or any voluntary proceeding relating to insolvency, receivership, liquidation, assignment for the benefit of creditors or similar
proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the other Party becomes the subject of a petition in bankruptcy
or any proceeding relating to insolvency, receivership, liquidation, assignment for the benefit of creditors or similar proceeding
and such petition or proceeding is not dismissed within thirty (30) days from filing of such petition or proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the other Party materially breaches any of its obligations
under the Agreement, and the breaching failures to cure such breach within [<B>Redacted &ndash; Commercial Sensitive &ndash; Termination
Timing] </B>after it receives written notice from the non-breaching Party to cure same;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-weight: normal">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">[</FONT>Redacted &ndash;
Commercially Sensitive &ndash; Termination Timing]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify">conviction of, or commission by, the other Party or any
principal officer, shareholder, employee or any partner of the other Party of any crime or immoral act which may adversely affect
the goodwill or reputation of Customer or Philips;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.4</TD><TD STYLE="text-align: justify">If Philips causes the Agreement to be terminated, directly
or indirectly, then Philips undertakes to sell all Products which have been ordered by Customer but not yet delivered at the date
of termination upon the terms and conditions of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.5</TD><TD STYLE="text-align: justify">On termination or expiry of this Agreement, each Party
shall promptly:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">return to the other Party all equipment, materials and
property belonging to the other Party that the other Party had supplied to the other Party (or its Affiliates) in connection with
the supply and purchase of the Products under this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">cooperate with the other Party to arrange for the sale
and purchase of the materials, parts and components as referred to in clause 3.4;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">return to the other Party all documents and materials (and
any copies) containing the other party&rsquo;s Confidential Information;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">erase all the other party&rsquo;s Confidential Information
from its computer systems (to the extent possible); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">on request, certify in writing to the other Party that
it has complied with the requirements of this clause.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">On
termination or expiry of this Agreement Philips shall facilitate an orderly transition of suppliers from Philips to Customer
in accordance with the requirements outlined in Section 5.4 (Material Supplier Contracts) of the Purchase Agreement,
including using commercially reasonable best efforts to assist Customer to enter into supply agreements directly with the
counterparties to the Material Supplier Contracts (as defined in the Purchase Agreement) on terms that are satisfactory to
the Customer, acting reasonably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.6</TD><TD STYLE="text-align: justify">Termination of this Agreement in accordance with this clause
12, is without prejudice to any right to claim for amounts or interest accrued prior to the date of such termination under this
Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.7</TD><TD STYLE="text-align: justify">All terms and conditions of this Agreement which are intended
(whether expressed or not) to survive the duration or termination of this Agreement will so survive, including, for greater certainty,
clauses 2.3, 2.4, 6, 10, 12, 13, 14, and 18.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.8</TD><TD STYLE="text-align: justify">Within <B>[Redacted &ndash; Commercially Sensitive &ndash;
Time Period]</B> of the Effective Date, the parties shall negotiate, acting reasonably and in good faith, a transition plan (the
 &ldquo;<B>Transition Plan</B>&rdquo;) to provide for a smooth transfer and transition of the manufacturing activities under this
Agreement to Customer, an Affiliate of Customer or a third party manufacturer designated by Customer. The Transition Plan shall
be negotiated based on the key transition terms outlined in Schedule 5 hereto (the &ldquo;<B>Transition Plan Term Sheet</B>&rdquo;).
In connection with the negotiation and ultimately implementation of the Transition Plan, Parties shall install a project team
which:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">shall have a manager (&ldquo;<B>Project Manager</B>&rdquo;),
one from Philips, who has experience in transferring manufacturing actives, and one from Customer, who has experience in setting
up manufacturing activities;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">shall be committed with sufficient capacity &ndash; made
available by both Parties &ndash; to execute the Transition Plan within the given time frame (quantity), and the Parties shall
ensure that sufficient and reasonable organizational resources are provided to each such Project Manager to ensure a smooth, uninterrupted
and efficient transition of the manufacturing of the Product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">shall be sufficiently skilled and experienced with the
activities under this Agreement (quality);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">shall be fully dedicated to the timely and adequate execution
of the Transition Plan.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.9</TD><TD STYLE="text-align: justify">The Parties shall perform such activities as set forth
in the Transition Plan and shall otherwise perform all such obligations in good faith to ensure a smooth transfer of the manufacturing
activities under this Agreement to Customer. In connection with the Transition Plan, Customer will pay all reasonable freight
cost and any Philips&rsquo; employee (or third parties engaged by Philips) at [<B>Redacted &ndash; Commercial Sensitive &ndash;
Billing Rate]</B>, as needed, in connection with the implementation of the Transition Plan. For greater certainty, Philips will
only engage third party support to assist with the transition if such additional support is required in order to implement the
Transition Plan and such additional support is previously approved by Customer in writing (not to be unreasonably withheld). If
to the opinion of the Project Team, circumstances occur in which the timely and/or proper execution of the Transition Plan is
obstructed, this shall be immediately reported to the relevant executive officers of both Parties for immediate resolution.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.</TD><TD STYLE="text-align: justify">INTELLECTUAL PROPERTY RIGHTS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.1</TD><TD STYLE="text-align: justify">Customer grants to Philips, during the Term, a non-exclusive,
royalty-free, non-transferrable right to make, have made, use, sell, reproduce, adapt, distribute, or otherwise use or practice
Customer&rsquo;s Intellectual Property Rights solely in connection with manufacturing of the Products and packaging to Customer
pursuant to this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.2</TD><TD STYLE="text-align: justify">Customer represents and warrants that any Product manufactured
by Philips under this Agreement in accordance with the Specifications does not infringe, misappropriate, or otherwise violate
any third party Intellectual Property Rights.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.3</TD><TD STYLE="text-align: justify">All right, title and interest in any and all Intellectual
Property Rights and Know How resulting or based on any services by Philips or its Affiliates hereunder or enhancements carried
out or technology developed during manufacture of the Products and that relate specifically and solely to the manufacture of the
Product (&ldquo;<B>New Technology</B>&rdquo;), in each case, that were developed for the Product, will be owned exclusively by
Customer. Philips hereby assigns and shall cause its Affiliates to assign all right title and interest in New Technology to Customer,
and shall cause all employees or service providers to assign all right title and interest and waive any moral rights in New Technology.
For greater certainty, &ldquo;New Technology&rdquo; shall exclude any (x) modification to Philips pre-existing Intellectual Property
Rights (which, shall exclude any Intellectual Property Rights forming part of the &ldquo;Purchased Assets&rdquo; under the Purchase
Agreement) and (y) developments developed not for the Products (collectively, &ldquo;<B>Philips Retained Product IP</B>&rsquo;),
provided that Philips and its Affiliates hereby grant to Customer under any such Intellectual Property Rights, which are applicable
or used for the manufacturing of the Product, a non-exclusive, non-transferable (except in accordance with clause 18.4 (Assignment)),
irrevocable, world-wide, fully paid-up license, without the right to grant sub-licenses, to make, have made, sell or commercialize
in any other way the Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.4</TD><TD STYLE="text-align: justify">The sale of any Products under this Agreement shall not
constitute the transfer of any ownership rights or title in any Intellectual Property Rights or Know How in or to such Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.</TD><TD STYLE="text-align: justify">CONFIDENTIALITY</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.1</TD><TD STYLE="text-align: justify">Confidential Information may be disclosed by or on behalf
of a Party or its Affiliates (the &ldquo;<B>Disclosing Party</B>&rdquo;) to the other Party or its Affiliates (the &ldquo;<B>Receiving
Party</B>&rdquo;) in connection with this Agreement. Each Party agrees to keep the other Party&rsquo;s (and its Affiliates) Confidential
Information confidential and not to reproduce or disclose such Confidential Information to any third party, or to use it for any
purpose other purpose than for the purposes of this Agreement. Each Party shall protect any Confidential Information of the other
Party (and its Affiliates) with the same degree of care used in protecting its own Confidential Information, but no less than
a reasonable degree of care. Unless otherwise mutually agreed in writing, the Confidential Information shall remain the property
of the Disclosing Party. Each party&rsquo;s obligation to protect the Confidential Information of the other Party shall continue
for a period of [<B>Redacted &ndash; Commercial Sensitive &ndash; Time Period]</B> following the date of termination of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.2</TD><TD STYLE="text-align: justify">Each Party may disclose the other Party&rsquo;s Confidential
Information to its and its Affiliates&rsquo; employees, officers, lawyers, accountants, professional advisers, consultants and
sub-contractors (collectively, &ldquo;<B>Representatives</B>&rdquo;) or financing sources (both debt and equity) or any prospective
acquirer of a Party (or substantially all of the assets related to the Products)(collectively, &ldquo;<B>Other Recipients</B>&rdquo;)
on a strict need to know basis, provided that such Representatives and Other Recipients are subject to confidentiality obligations
and/or agreements at least as stringent as the confidentiality restrictions imposed by this clause 14 on the Receiving Party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.3</TD><TD STYLE="text-align: justify">The confidentiality obligations set out in this clause
14 shall not apply to any information (but only to the extent that such information) and the definition of &ldquo;Confidential
Information&rdquo; shall not be deemed to include any information that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">is generally available from public sources or in the public
domain through no fault or breach of the Receiving Party or any of its Representatives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">becomes available to the Receiving Party (or any of its
Affiliates) unless the Receiving Party (or such Affiliate) is aware that such source was bound by a confidentiality agreement
with the Disclosing Party or any or its Representatives or otherwise under a contractual, legal, fiduciary or other obligation
of confidentiality with respect such information;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">developed independently by the Receiving Party or any of
its Affiliates without use of or reliance on the Disclosing Party&rsquo;s (or any of its Affiliates&rsquo;) Confidential Information
as demonstrated by written records; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">was known or in the possession of the Receiving Party (or
any of its Affiliates) prior to its disclosure by the Disclosing Party unless the Receiving Party (or such Affiliate) is aware
that the source of such information was bound by a confidentiality undertaking to the Disclosing Party (or its Affiliates) or
any or its Representatives or otherwise under a contractual, legal, fiduciary or other obligation of confidentiality with respect
to such information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.4</TD><TD STYLE="text-align: justify">Notwithstanding any of the carve outs to the definition
of &ldquo;Confidential Information&rdquo; contained in clause 14.3, any Confidential Information in respect of the &ldquo;Purchased
Assets&rdquo; and the &ldquo;Business&rdquo; (each, as defined under the Purchase Agreement) shall be deemed the Confidential
Information of Customer (the &ldquo;<B>Transferred Confidential Information</B>&rdquo;), and, in respect of Philips, the carve
out to the definition of &ldquo;Confidential Information&rdquo; contained in clause 14.3 shall not apply to any Transferred Confidential
Information, notwithstanding the fact that Philips was aware, had possession of, or independently developed any such Transferred
Confidential Information prior to the Effective Date</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.5</TD><TD STYLE="text-align: justify">Clause 14 does not prohibit disclosure or use of any Confidential
Information if and to the extent that the disclosure or use is required by applicable Law, any judicial or administrative proceedings,
or the rules of any recognized stock exchange on which the shares of any Party are listed, provided that prior to such disclosure,
the Receiving Party promptly notifies the Disclosing Party of such requirement with a view to providing the Disclosing Party with
the opportunity to contest such disclosure or use and/or to obtain a protective order or otherwise to agree to the timing and
content of such disclosure or use and the Receiving Party shall at the request of the Disclosing Party, assist the Disclosing
Party in contesting such disclosure and/or obtaining a protective order; provided further that the Receiving Party shall only
disclose such portions of the Confidential Information that are strictly required to be disclosed by applicable Law, and if permitted
by applicable Law, the Disclosing Party shall be provided with the opportunity to review and comment on the disclosure to be made.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.6</TD><TD STYLE="text-align: justify">Each Party reserves all rights in its and its Affiliates&rsquo;
Confidential Information. No rights or obligations in respect of a Party&rsquo;s Confidential Information other than those expressly
stated in this Agreement are granted to the other Party or to be implied from this Agreement. Each Party, and its Representatives
shall protect and keep confidential and shall not use, publish or otherwise disclose to any Third Party, except as permitted by
this Agreement, or with the other Party&rsquo;s written consent, the other Disclosing Party&rsquo;s Confidential Information.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">15.</TD><TD STYLE="text-align: justify">FORCE MAJEURE</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding
any provision to the contrary contained in this Agreement, the Parties shall be excused from the consequences of any breach
of this Agreement if and to the extent that such breach was caused in whole or in part by a Force Majeure event, provided
that (a) the affected Party shall not in any material way have caused or contributed to such Force Majeure event, (b) the
Force Majeure event could not have been prevented by reasonable and ordinary precautions (as would be employed by a
reasonably prudent person in the position of the affected party), and (c) the Force Majeure event could not reasonably have
been circumvented by the affected Party by reasonable and ordinary commercial means, such as the use of alternate suppliers
or subcontractors. Notwithstanding the foregoing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the existence or occurrence of a Force Majeure event shall
excuse a breach of this Agreement only for such period of time as the Force Majeure event remains in existence and only to the
extent that such Force Majeure event has caused in whole or in part the breach of this Agreement;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the existence of a Force Majeure event that has caused
a breach of this Agreement shall not prevent a Party from asserting and acting upon a breach of this Agreement that has not been
caused by a Force Majeure event;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If a Party is not or is not expected to be able to perform
any material obligation under this Agreement due to a Force Majeure event for a period of [<B>Redacted &ndash; Commercial Sensitive
 &ndash; Time Period]</B> or more, the other Party may terminate this Agreement without liability.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Notwithstanding the foregoing, Customer may cancel without
liability any affected Purchase Orders if the Force Majeure event would result in a delay in delivery of more than [<B>Redacted
 &ndash; Commercial Sensitive &ndash; Time Period]</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">For the purposes
of this clause 15, &ldquo;<B>Force Majeure</B>&rdquo; means any prevention, delay, stoppage or interruption in the performance
of any obligation or the occurrence of any event due to an act of God, the occurrence of enemy or hostile actions, sabotage, war,
blockades, terrorist attacks, insurrections, riots, epidemics, nuclear and radiation activity or fall-out, civil disturbances,
explosions, fire or other casualty, failure of energy sources, any industry-wide material shortage and changes in governmental
or regulatory action or legislation or regulation, third party labour disputes or strikes or any other similar causes beyond the
control of the Party seeking relief from its obligations as a result of such event, but not including, for clarity, any financial
inability of Philips or any of its Affiliates or the failure of any subcontractor to perform obligations owed to Philips unless
when those are caused by Force Majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.</TD><TD STYLE="text-align: justify">EXPORT CONTROL</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.1</TD><TD STYLE="text-align: justify">Customer understands that certain transactions of Philips
are subject to export control Laws and regulations, such as but not limited to the UN, EU and the USA export control Laws and
regulations, (&ldquo;<B>Export Regulations</B>&rdquo;) which prohibit export or diversion of certain products and technology to
certain countries. Any and all obligations of Philips to export, re-export or transfer Products as well as any technical assistance,
training, investments, financial assistance, financing and brokering will be subject in all respects to such Export Regulations
and will from time to time govern the license and Delivery of Products and technology abroad by persons subject to the jurisdiction
of the relevant authorities responsible for such Export Regulations. If the Delivery of Products, services and/or documentation
is subject to the granting of an export or import license by certain governmental authorities or otherwise restricted or prohibited
due to export/import control regulations, Philips may suspend its obligations and Customer&rsquo;s and/or end-user&rsquo;s rights
until such license is granted or for the duration of such restrictions or prohibitions. Furthermore, Philips may even terminate
the relevant order in all cases without incurring any liability towards Customer or end-user.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.2</TD><TD STYLE="text-align: justify">Philips undertakes to provide Customer on request and in
a timely fashion, with the following information in relation to the Products:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The country of origin of items to be supplied; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The applicable export control classification number of
items known by Philips to be so subject to control.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.3</TD><TD STYLE="text-align: justify">Each Party will provide the other with reasonable assistance
when applying for export licences for the Product.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.4</TD><TD STYLE="text-align: justify">Customer warrants that it will comply in all respects with
the export, re-export and transfer restrictions set forth in such Export Regulations or in export licenses (if any) for every
Product. Customer will not re-export the Product to any Third Parties unless Customer first obtains the same warranty as Customer
is providing in the first sentence of this clause 16.4 from such third party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.5</TD><TD STYLE="text-align: justify">Customer shall take all commercially reasonable actions
in a manner consistent with industry practice, that are within its reasonable control to help minimize the risk of a customer/purchaser
or end-user contravening such Export Regulations.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">17.</TD><TD STYLE="text-align: justify">REGULATORY MATTERS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Until execution
of the Quality Agreement, the following provision shall govern the regulatory aspects of the activities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.1</FONT></TD><TD STYLE="text-align: justify">Regulatory Actions</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Customer and
Philips agree to notify each other within two (2) Business Days of any regulatory action affecting the Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.2</FONT></TD><TD STYLE="text-align: justify">Government Inspections, Compliance Review and Inquiries</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Upon
request of any Governmental Authority or any third party entity authorized by a Governmental Authority, such entity shall,
for the purpose of regulatory review and compliance, have access to observe and inspect the: (i) facilities of Philips; and
(ii) manufacturing, testing, storage and preparation for shipment of Product, including development operations in respect of
manufacturing, and auditing the Philips facility for compliance with applicable Laws. Philips shall give Customer prompt
written notice of any upcoming inspections or audits by a Governmental Authority, governmental entity or any third party
entity authorized by a Governmental Authority of the Philips facility or any of the foregoing, shall provide Customer with a
written summary of such inspection or audit within five (5) Business Days following completion thereof. Philips agrees to use
commercially reasonable efforts to promptly rectify or resolve any deficiencies (consisting of any failure to meet applicable
regulatory requirements under applicable Law then in force) noted by a Governmental Authority, governmental entity or any
third party entity authorized by a Governmental Authority in a report or correspondence issued to Philips or Customer.
Subject to any specific arrangements agreed upon by the parties and subject to any limitations due to the fact (and until)
Philips is the legal manufacturer, Customer shall be responsible for communicating with any Governmental Authority concerning
the Product or the marketing, distribution, sale use of the Product, and Philips shall provide Customer with such assistance
as Customer may reasonably require to assist it in such communications. Philips shall have no such communications
specifically related to the Product, except to the extent (and notwithstanding its confidentiality undertakings in this
Agreement) that they relate to Philips&rsquo;s manufacture, testing, storage and preparation for shipment of Product
under this Agreement or as required of Philips directly by the Governmental Authority (including but not limited to due to
the fact (and until) Philips is the legal manufacturer of the Product), in which case Philips shall be responsible for such
communications. Notwithstanding the foregoing and except to the extent that an immediate or urgent communication is necessary
under the circumstances or required by applicable Law, Philips in good faith shall consult in advance with Customer regarding
all communications with any Governmental Authority that relate to Product or to Philips&rsquo; ability to manufacture the
Product pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.3</FONT></TD><TD STYLE="text-align: justify">Complaints and Adverse Events</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Philips and
Customer shall fully comply with the terms of the Quality Agreement regarding their respective obligations and responsibilities
with respect to any complaints or adverse events regarding the Product and other activities related to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.4</FONT></TD><TD STYLE="text-align: justify">Records</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Philips shall
maintain, and provide Customer reasonable access to, all records, both during and after the termination or expiration of this Agreement,
in accordance with the Quality Agreement. The cost of any off-site storage of such records after the Term of this Agreement shall
be borne by Customer and invoiced on a calendar quarter basis. After the Term, Customer may elect to have such records delivered
to it upon reimbursing Philips for its reasonable costs of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.5</FONT></TD><TD STYLE="text-align: justify">Testing, Documentation, and Quality Assurance</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Philips shall
maintain, and provide Customer reasonable access to, accurate and complete production records with respect to the manufacture of
the Product in accordance with the Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Parties
agree to execute, and shall comply with their respective obligations and duties set forth in, the Quality Agreement. To the extent
that there is any conflict between the terms of this Agreement and the Quality Agreement, the terms of this Agreement shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.6</FONT></TD><TD STYLE="text-align: justify">Cooperation as to Adverse Events, Product Inquiries and
Recalls</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Each Party shall
provide to each other in a timely manner all information which the other party reasonably requests regarding the Product in order
to enable the other party to comply with all applicable Laws. Without limiting the foregoing, each Party will cooperate fully with
the other party in connection with any recall efforts and mandatory problem reporting to Governmental Authorities as more fully
detailed in the Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">18.</TD><TD STYLE="text-align: justify">MISCELLANEOUS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">18.1</TD><TD STYLE="text-align: justify"><B>Entire Agreement</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">This Agreement,
together with the Quality Agreement and the Purchase Order, contains the entire agreement between the Parties relating to the subject
matter of this Agreement, to the exclusion of any terms implied by applicable Law which may be excluded by contract, and supersedes
any previous written or oral agreement between the Parties in relation to the matters dealt with in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Each Party acknowledges
that it has not been induced to enter into this Agreement by any representation, warranty or undertaking not expressly set out
in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.2</FONT></TD><TD STYLE="text-align: justify">Severability</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">If any provision
in this Agreement is held to be illegal, invalid or unenforceable, in whole or in part, under any applicable Law, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">such provision or part shall to that extent be deemed not
to form part of this Agreement but the legality, validity or enforceability of the remainder of this Agreement shall not be affected;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Parties shall use reasonable efforts to agree a replacement
provision that is legal, valid and enforceable to achieve so far as possible the intended effect of the illegal, invalid or unenforceable
provision.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.3</FONT></TD><TD STYLE="text-align: justify">Notices</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Any notice or
other communication required or permitted to be given to any Party hereunder shall be in writing and shall be given to such Party
at such Party&rsquo;s address set forth below, or such other address as such Party may hereafter specify by notice in writing to
the other Party. Any such notice or other communication shall be addressed as aforesaid and given by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">delivered personally;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">sent by an internationally recognized overnight courier
service such as Federal Express; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">e-mail transmission,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Philips&rsquo;
details:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="width: 80%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">P.O. Box 10.000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">5680 DA Best, The Netherlands</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="width: 80%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<B>Redacted &ndash; Personal Information]</B>, Operations Manager MR Best</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[Redacted &ndash; Personal Information]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">With copy to:</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Legal Department PMSN BV <BR>
Veenpluis 4-6</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">5684 PC Best<BR>
 Building QX2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Email:</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38.8pt"><B>The Company&rsquo;s details:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROFOUND MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="width: 80%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Profound Medical Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">2400 Skymark Avenue, Unit #6</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Mississauga, ON, L4W
        5K5, Canada</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Arun Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">E-mail:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[Redacted &ndash; Personal Information]</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">With copy to:</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Torys LLP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Suite 3000, P.O. Box 270</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">79 Wellington Street West</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">TD Centre</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Toronto, ON M5K 1N2</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Attention: Cheryl Reicin</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Any
notice or other communication will be deemed to have been duly given: (A) on the date of service if served personally; (B) on
the Business Day after delivery to an international overnight courier service, provided receipt of delivery has been
confirmed; or (C) on the date of transmission if sent via e-mail transmission, provided confirmation of receipt is obtained
promptly after completion of transmission and provided that transmission via e-mail is followed promptly by delivery via one
of the methods in Clause 18.3(a) or (b) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.4</FONT></TD><TD STYLE="text-align: justify">Assignment</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">This
Agreement will be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns.
This Agreement may not be assigned by either Party, in whole or in part, to any Third Party without the prior written consent
of the other Party, except that either Party may assign this Agreement as a whole, and all of its rights and obligations
hereunder, without the consent of the other Party, but upon written notice to the other Party (a) to an Affiliate, or (b) in
case of a transfer of all, or substantially all, stock or assets of such Party or the relevant business activity through
which such Party acts in this Agreement to a Third Party or to any partnership or other venture in which such business
activity is to participate. Except as provided above, without prior written consent of the other Party, any assignment or
pledge of rights under this Agreement by a Party to a Third Party shall have no effect vis-&agrave;-vis such Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.5</FONT></TD><TD STYLE="text-align: justify">Independent Contractors</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Parties
to this Agreement are independent contractors and nothing in this Agreement shall operate to create a relationship of agency, partnership
or employment between the Parties and neither Party shall have any right or authority to act on behalf of the other nor to bind
the other by contract or otherwise (except as expressly permitted by the terms of this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.6</FONT></TD><TD STYLE="text-align: justify">Headings</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Headings used
in this Agreement are for convenience only and shall not affect the interpretation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.7</FONT></TD><TD STYLE="text-align: justify">Amendments and Waiver</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">No amendment
of this Agreement shall be effective unless such amendment is in writing and signed by or on behalf of each of the Parties. No
waiver of any provision of this Agreement shall be effective unless such waiver is in writing and signed by or on behalf of the
Party entitled to give such waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.8</FONT></TD><TD STYLE="text-align: justify">Disputes and Applicable Law</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">This Agreement
(including any dispute hereunder) and the documents to be entered into pursuant to it, save as expressly otherwise provided therein,
will be governed by and construed in accordance with the Laws of the Netherlands. The applicability of the UN Convention on Contracts
for the International Sale of Goods (Vienna convention) is explicitly excluded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Any dispute
arising out of or in connection with this Agreement shall be resolved in the manner provided in Sections 12.1 and 12.2 of the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.9</FONT></TD><TD STYLE="text-align: justify">Counterparts</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">This Agreement
may be executed in multiple counterparts, each of which shall be deemed an original. Signatures submitted by facsimile and electronically
transmitted signatures as to which authenticity can reasonably be confirmed, shall be valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.10</FONT></TD><TD STYLE="text-align: justify">Third Party Rights</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Save as expressly
otherwise stated, this Agreement does not contain a stipulation in favour of a Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.11</FONT></TD><TD STYLE="text-align: justify">Costs</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Except as otherwise
provided in this Agreement, all costs which a Party has incurred or shall incur in preparing, concluding or performing this Agreement
are for that Party&rsquo;s own account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.12</FONT></TD><TD STYLE="text-align: justify">Insurance</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Philips shall
fully comply with the terms of the Quality Agreement regarding its obligations and responsibilities with respect to maintaining
the required level of insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.13</FONT></TD><TD STYLE="text-align: justify">Further Assurances</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Each Party shall
at its own costs and expenses from time to time execute such documents and perform such acts and things as the other Party may
reasonably require to give the other Party the full benefit of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0in"><B>IN WITNESS WHEREOF</B>, this Agreement
has been duly executed and delivered by the duly authorized representatives of the parties as of the dates set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PHILIPS MEDICAL SYSTEMS</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROFOUND MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>NEDERLAND B.V.</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Iwald
    Mons</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Arun Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Iwald Mons</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Arun Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">M&amp;A Project Leader</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">July 31, 2017</FONT></TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Date:</TD>
    <TD STYLE="text-indent: 0in; border-bottom: Black 1pt solid">July 31, 2017</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">[Redacted &ndash; Commercially
Sensitive &ndash; Schedules concerning Product specifications, details, pricing, lead times, production plan and transition details]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-indent: -33pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>12
<FILENAME>tv526458_ex4-6.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SIEMENS ID</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by and between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Profound
Medical Inc</B></FONT><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(</FONT>-
<FONT STYLE="font-family: Times New Roman, Times, Serif">hereinafter referred to as &ldquo;the Receiver&rdquo; -)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIEMENS Healthcare GmbH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(-
hereinafter referred to as &ldquo;SIEMENS&rdquo;</FONT> -<FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver and SIEMENS hereinafter referred to individually </FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif">as &ldquo;PARTY&rdquo; or collectively as &ldquo;PARTIES&rdquo;</FONT>
-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>on the provision of information regarding
SIEMENS&rsquo; interface</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preamble </FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 1</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Definitions </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 2</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">License </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 3</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Obligations of the PARTIES </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 4</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">INTERFACE </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 5</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Provision of DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">INFORMATION and the SDK </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 6</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Pricing </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 7</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Limitations: Permits</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory Approvals and Standards </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 8</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Billing </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 9</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Marketing </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 1</FONT>0 - <FONT STYLE="font-family: Times New Roman, Times, Serif">Monitoring of Usage Data </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 11</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Revocation of the AUTHORIZATION KEY and LICENSE KEY </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 12</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Notification Page </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 13</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Support </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 14</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Liability </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 15</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Confidentiality </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 16</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement Term</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Notification and CHANGE</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">OF</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">CONTROL </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 17</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Force Majeure </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">22</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 18</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">23</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Article 19</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Arbitration and Substantive Law </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">24</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annex 1</B> &ndash; Specification of
INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annex 2</B> &ndash; Specification of
PRODUCTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Annex 3</B> &ndash; Agreement for risks
exported in using Access-i</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preamble</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PARTIES entered in a co</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">marketing and co</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">selling
agreement on February 26, 2016 (the &ldquo;<B>Original Agreement</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PARTIES now wish to substitute and replace the Original Agreement with this Agreement in connection with all sales and other activities
as of the Effective Date</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">such that all prior financial commitments
and obligations are released and replaced with the financial commitments and obligations of this Agreement</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
is prepared to supply certain interface information and/or other documentation to the Receiver to enable the Receiver to use the
Access</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">I interface for interfacing PRODUCTS to certain SIEMENS
MAGNETOM Scanners pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The PARTIES therefore agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
1</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Definitions</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">INFORMATION hereinafter refers to know</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">how</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">information and/or documentation supplied by SIEMENS to the Receiver as
detailed in Annex 1.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">1.2</TD><TD STYLE="text-align: justify">PRODUCTS hereinafter refer to Receiver&rsquo;s products developed for the ablation of soft tissue
in conjunction with MRI scanners.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS MAGNETOM SCANNERS hereinafter
refer to certain SIEMENS MAGNETOM Scanners which the Receiver intends to interface to its PRODUCTS using the INFORMATION and
which are equipped with the INTERFACE</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CHANGE OF CONTROL hereinafter means, with
respect to the Receiver</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">one of the following events or series
of related events: a) a sale of all or substantially all of the Receiver&rsquo;s assets, voting stock or securities or business
relating to this Agreement; b) a merger</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">reorganization or consolidation
involving the Receiver in which the stockholders of the Receiver immediately prior to such transaction cease to own collectively
a majority of the voting equity securities of the successor entity; or c) a person or group of persons acting in concert acquire
fifty percent (5</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">%) or more of the voting equity securities of
the Receiver.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AFFILIATE shall mean</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">with
respect to a PARTY</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">a subsidiary</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">meaning
a company in which such PARTY owns or controls, directly or indirectly</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">more
than fifty percent (5</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">%) of the stock or voting rights</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or a parent company</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">meaning
a company which owns or controls</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">directly or indirectly</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">more than fifty percent (5</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">%)
of the stock or voting rights of the relevant PARTY</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or a company
which is a subsidiary of such PARTY&rsquo;s parent company</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPETITOR hereinafter refers to any entity
which has a product line that competes with SIEMENS MAGNETOM SCANNERS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">END USER hereinafter refers to an individual</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">company</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">institution
or other legal entity other than the PARTIES or an AFFILIATE of SIEMENS that uses or intends to use the PRODUCTS in combination
with a SIEMENS MAGNETOM SCANNER to treat patients or to conduct any form of research</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">OTHERS hereinafter refers to any individual</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">company</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">institution
or other legal entity other than the PARTIES or any AFFILIATE of either of the PARTIES or END USERS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">IP hereinafter refers to intellectual
property</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">which is patents</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">rights
to inventions, copyright and related rights, trademarks, trade names and domain names, rights to sue for passing off, rights in
designs, rights in computer software</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">database rights, rights in
confidential information (including know</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">how and trade secrets)
and any other equivalent intellectual property rights</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in each
case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions
of</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">such rights or and all similar or equivalent rights or forms
of protection which subsist now or in the future</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in any part of
the world</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.10</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">INTERFACE hereinafter refers to the Access-i
(Scanner Remote Control) Interface for 3rd party device integration developed and provided through SIEMENS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.11</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">DEVELOPER SERVICES hereinafter refers
to the activities conducted by SIEMENS to support the development efforts of the Receiver to achieve compatibility of the Receiver&rsquo;s
PRODUCTS with the INTERFACE; this does not include any other development efforts in the Receiver&rsquo;s PRODUCTS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.12</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOFTWARE DEVELOPER KIT (SDK) hereinafter
refers to a software tool developed and provided through SIEMENS to support the development efforts of the Receiver to achieve
compatibility of the Receiver&rsquo;s PRODUCTS with the INTERFACE</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.13</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AUTHORIZATION KEY hereinafter refers to
an authorization key file installed on the Receiver&rsquo;s PRODUCTS enabling the use of the PRODUCTS in connection with the INTERFACE
by End Users. The AUTHORIZATION KEY is time limited and unique to each individual MAGNETOM SCANNER</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.14</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">LICENSE KEY hereinafter refers to a software
license and license key file installed on the SIEMENS MAGNETOM SCANNERS enabling the INTERFACE on SIEMENS MAGNETOM SCANNERS</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">The LICENSE KEY has to be purchased by the END USER (at no additional
cost to Receiver) from Siemens as a one</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">time purchase</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
provision and the cost of this LICENSE KEY are not covered by this agreement</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.15</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">EFFECTIVE DATE hereinafter means January
21<FONT STYLE="font-size: 10pt">st</FONT></FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
2</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">License</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to the terms and conditions set
out in this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS shall make available and provide
to the Receiver (and its personnel and subcontractors) the INFORMATION</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">DEVELOPER
SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the SDK and the AUTHORIZATION KEY and herewith grants
to the Receiver under this Agreement the following rights:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A non</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">exclusive</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">non-transferable</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">worldwide
right and license to use the INFORMATION</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">DEVELOPER SERVICES</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the SDK and the AUTHORIZATION KEY for the sole purpose of interfacing
PRODUCTS to certain SIEMENS MAGNETOM SCANNERS and to make available and deliver such adapted PRODUCTS for use by END USERS for
use in connection with SIEMENS MAGNETOM SCANNERS for research and/or development purposes and/or for medical treatment</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">The license granted herein includes the right to grant sublicenses to
Receiver&rsquo;s AFFILIATES and service providers to Profound carrying out Profounds business and shall exclusively apply to the
Receiver&rsquo;s PRODUCTS and any successor product to the Receiver&rsquo;s PRODUCTS which replaces the PRODUCT in question</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">but not cover any other product of the Receiver. Receiver will not reverse
engineer the SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the INTERFACE or the AUTHORIZATION KEY for the
purpose of the development of adaptations of the Receiver&rsquo;s PRODUCTS to any other customer other than SIEMENS customers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the above</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">nothing in this Agreement shall limit the Receiver from
developing PRODUCTS that can interface with scanners from multiple suppliers (i.e. that can interface with both SIEMENS MAGNETOM
SCANNERS and scanners from other manufacturers) as long as Receiver does not use or disclose to such other manufacturers any CONFIDENTIAL
INFORMATION provided to the Receiver under this Agreement in the development of interfaces for such other manufacturers&rsquo;
scanners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
3</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Obligations of the PARTIES</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obligations
of SIEMENS:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will provide the Receiver with
information on the related product risks as referred to in Annex 3 and inform the Receiver of any updates during the lifetime of
the INTERFACE</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will provide the Receiver with
AUTHORIZATION KEYS on a perpetual basis for each individual SIEMENS MAGNETOM SCANNER enabling the use of the INTERFACE according
to the INTERFACE description</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will provide the END USER with
the LICENSE KEY to enable use of the SDK with the INTERFACE</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will use commercially reasonable
efforts to notify the Receiver of any actual or planned change regarding the INTERFACE that might compromise the compatible use
of the Receivers PRODUCTS with the SIEMENS INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and to provide
the Receiver with such INFORMATION and/or collaborative testing as may be reasonably required in order for the Receiver to sufficiently
maintain or update the Receiver&rsquo;s PRODUCTS and</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">if applicable</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the Technical Documentation and/or clinical dossier of such PRODUCTS in
accordance with Directive 93/42/EEC or Regulation (EU) 2017/745 on medical devices, as applicable</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">to
ensure continued compatible use with the INTERFACE in view of such change no less than 12</FONT>0 <FONT STYLE="font-family: Times New Roman, Times, Serif">days
in advance of the time at which the change becomes effective for End Users SIEMENS MAGNETOM SCANNERs. More generally Siemens
will aid reasonable requests to support the attainment of data for validation runs</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">compatibility
testing and other such assistance; however the determination of reasonable will be at Siemens discreation</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will use commercially reasonable
efforts to provide the DEVELOPER SERVICES and the SDK to the Receiver</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS shall not have any other obligations
than those expressly described in this Agreement</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">For the sake
of clarity</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS shall not be obligated to disclose any further
information than the INFORMATION described in <B>Annex 1</B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Obligations
of the Receiver:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver acknowledges and agrees that
the AUTHORIZATION KEY enables the use of the INTERFACE according to the INTERFACE description and that its improper use could cause
damage to the system and patient injury</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">It is the responsibility
of the Receiver to comply with all applicable legal requirements related to the PRODUCTS, to understand all consequences of using
the PRODUCTS or the INTERFACE on the basis of the INFORMATION provided by SIEMENS in Annex 1 and the product risk information provided
in Annex 3</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and to refrain from such use if there is any reasonable
question of legality</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">hardware or other property damage, or patient
injury</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
the use of the INTERFACE is for the purpose of research conducted or sponsored by the Receiver involving human subjects</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">it requires appropriate documentation</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">review
and approval by an appropriate Ethics Committee or by the Receiver&rsquo;s Institutional Review Board (&ldquo;IRB&rdquo;) according
to applicable medical device law and compliance with all Ethics Committee/IRB recommendations and requirements. No human subject
research may be commenced by Receiver or a party sponsored by Receiver before Ethics Committee/IRB approval has been granted</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver accepts the exported product
risks described in <B>Annex 3</B> to this contract and any risks as updated by SIEMENS according to Article 3</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">It is the responsibility of the Receiver to assess the measures defined
in <B>Annex 3</B> within their processes and to ensure that reasonable measures are in place to mitigate these risks in using the
INTERFACE&rsquo;s functionality</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the issuance of an AUTHORIZATION KEY</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver has to provide to SIEMENS the serial number of the SIEMENS
MAGNETOM SCANNER the PRODUCT will be interfaced with and the duration the PRODUCT is intended to be compatible with the SIEMENS
MAGNETOM SCANNER</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">whereas AUTHORIZATION KEYS can be deactivated
on request</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The AUTHORIZATION KEY mentioned in Article
3</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1.2 (and any other information provided by SIEMENS) shall be
(i) used by the Receiver exclusively to use the INTERFACE for interfacing PRODUCTS to certain SIEMENS MAGNETOM SCANNERS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">unless otherwise expressly agreed to in writing by SIEMENS and (ii)
kept strictly confidential and encrypted or in some secure fashion by the Receiver with the same degree of care as is used with
respect to the Receiver&rsquo;s own equally important confidential information to avoid disclosure to any third party</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">but
at least with reasonable care</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Without limiting use of the PRODUCTS
by END USERS the AUTHORIZATION KEY shall not be made available to OTHERs and shall be made available to AFFILIATES, Receiver&rsquo;s
personnel</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">contractors for the sole purpose of interfacing and
using the PRODUCTS with the dedicated SIEMENS MAGNETOM SCANNER according to the terms and conditions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver has the sole responsibility
for the combined products and it is the Receiver&rsquo;s responsibility to ensure that all legal and country specific requirements
for such a combination are adhered to</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">following the obligations
of the country in which the combination is used</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">This includes,
for example, that no unacceptable risks can be caused by the combination to patients or users. SIEMENS takes no responsibility
regarding the combination of the products even though SIEMENS supports the connectivity to the INTERFACE; provided that any damage
occurred</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">if any</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">was
not caused by a gross negligent act or omission of SIEMENS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
4</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">INTERFACE</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">4.1</TD><TD STYLE="text-align: justify">Update Cycles</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
is prepared to continuously develop new functionalities and features for the INTERFACE at no additional cost to Receiver. Such
new features and functionalities are intended to be released in up to two application updates per year in accordance with Section
3</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">4.
Security related updates and patches can be introduced whenever deemed necessary by SIEMENS</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
will use commercially reason</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">able efforts to maintain the compatibility
of the PRODUCT with the SIEMENS MAGNETOM SCANNER and provide all necessary information and assistance to Receiver as outlined
in Section 3.1.4</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">4.2</TD><TD STYLE="text-align: justify">Changes to Requirements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
may change and/or issue additional technical requirements for the combination of the PRODUCT with the SIEMENS MAGNETOM SCANNER
using the INTERFACE at any time by using commercially reasonable efforts to notifying the Receiver at SIEMENS&rsquo; earliest
convenience</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">but no less than 12</FONT>0 <FONT STYLE="font-family: Times New Roman, Times, Serif">days
before the changed technical requirements become effective, provided that SIEMENS will endeavor to maintain compatibility of the
INTERFACE with any of the Receiver&rsquo;s PRODUCTS compliant with the requirements at the time of their submission during next
two (2) update cycles of the INTERFACE following the submission of the respective PRODUCT at minimum</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver has to ensure that the combination
of its PRODUCTS to the SIEMENS MAGNETOM SCANNER is still working with the changes in the requirement and SIEMENS shall provide
all necessary information and assistance in this respect</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">as outlined
in Section 3</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1.4. Such notice period may be shortened by SIEMENS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">and the requirements regarding maintenance of compatibility will not apply
only to the extent that</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">based on SIEMENS&rsquo; reasonable judgment</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS believes that a shorter notice period or incompatibility is
necessary in order to avoid any: (i) threat to the security or functionality of the INTERFACE or the DEVELOPER SERVICES; (ii) adverse
impact on the Receiver</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver&rsquo;s or SIEMENS&rsquo; AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">END USERS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including,
without limitation, any risk of personal injury; and/or (iii) subject the Receiver, SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver&rsquo;s or SIEMENS&rsquo; AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">END USERS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party to material liability for personal injury or IP infringement;
in each case, so long as SIEMENS takes commercially reasonable efforts to maintain the compatibility of the PRODUCT with the SIEMENS
MAGNETOM SCANNER</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">To the extent the Receiver is</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">due
to such changes</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">materially deprived of the benefits of the INTERFACE or the SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver is entitled to terminate the Agreement
in writing with effect upon effectiveness of the change at the earliest and the Receiver will be entitled to a refund of all amounts
paid with regards to the affected AUTHORIZATION KEYs by Receiver to SIEMENS over the period of incompatability</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">4.3</TD><TD STYLE="text-align: justify">Changes to the INTERFACE</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
updates and further develops the technology, features and functionalities of the INTERFACE and is under no obligation to maintain
prior versions thereof. Upon the provision of a modified or new version of the INTERFACE, the Receiver is no longer entitled to
use previous versions. Should material changes to the INTERFACE be implemented which have an impact on the Receiver&rsquo;s use,
whereas these impacts are known to SIEMENS, or should agreed functionalities be restricted or disabled, SIEMENS will use commercially
reasonable efforts to notify the Receiver at SIEMENS&rsquo; earliest convenience, but no less than 120 days before the changes
become effective. Such notice period may be shortened by SIEMENS only to the extent that, based on SIEMENS&rsquo; reasonable judgment,
SIEMENS believes that a shorter notice period is necessary in order to avoid any: (i) threat to the security or functionality
of the INTERFACE; (ii) adverse impact on the Receiver, SIEMENS, the Receiver&rsquo;s or SIEMENS&rsquo; Affiliates, END USERS,
or any third party, including, without limitation, any risk of personal injury; and/or (iii) subject the Receiver, SIEMENS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver&rsquo;s or SIEMENS&rsquo; Affiliates</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">END
USERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party to material liability for personal injury
or IP infringement; in each case</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">so long as SIEMENS takes commercially
reasonable efforts to maintain the compatibility of the PRODUCT with the SIEMENS MAGNETOM SCANNER</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">To
the extent the Receiver is, due to such changes, materially deprived of the benefits of the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver is entitled to terminate the Agreement in writing with effect upon effectiveness of the change at the earliest and Receiver
will be entitled to a refund of all amounts with regards to the affected AUTHORIZATION KEYs paid by Receiver to SIEMENS over the
period of incompatability</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">4.4</TD><TD STYLE="text-align: justify">Freedom from Defects in Title</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
represents, warrants and covenants that during the term of this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver&rsquo;s use of the INTERFACE as permitted under the Agreement does not infringe upon a patent, copyright, trade secret</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or other intellectual property right in or to such INTERFACE in the country
where SIEMENS has its seat or in countries where SIEMENS have put SIEMENS MAGNETOM SCANNERS on the market</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
Receiver acknowledges that SIEMENS and/or its AFFILIATES is not responsible for an infringement of any such intellectual property
rights to the extent it is due to: (i) the Receiver&rsquo;s failure to use the most current version of or a defect correction or
patch supplied by SIEMENS; (ii) the combination</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">operation</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or use of the INTERFACE in conjunction with any non-SIEMENS information
or with any third</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">party software, equipment</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">materials,
or products other than as contemplated by the INFORMATION; or (iii) an adjustment or configuration of the INTERFACE not made by
SIEMENS (or on its behalf)</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding any deviating and/or
additional obligations expressly set forth in the Agreement, SIEMENS will neither assume any additional obligation nor responsibility
that Receiver&rsquo;s use of the INTERFACE complies with applicable law</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
5</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Provision of DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">INFORMATION
and the SDK</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">5.1</TD><TD STYLE="text-align: justify">Service Standards</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the term of the Agreement and subject to Article 5</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">2 to Article
5</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
will provide DEVELOPER SERVICES as a service in conformance with the features and functionalities as described in the Agreement
and the INFORMATION</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will provide the Receiver with information
and make the SDK available in a manner suitable for adapting the Receiver&rsquo;s PRODUCTS to the INTERFACE</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">This
service will include providing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Technical descriptions</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SDK including</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">INTERFACE Simulator</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in">o</TD><TD STYLE="text-align: justify">Test Client for the INTERFACE</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Library of examples to demonstrate programming
and/ or usage of certain functionalities</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Introductory webinar support/ conference
call (up to one hour)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email support to answer basic questions</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Up to two follow</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">up
conference calls to discuss questions (up to one hour each)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">One introduction call for each regular
update (up to one hour)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
service does not include code check or any development work</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">neither
software nor hardware related</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">5.2</TD><TD STYLE="text-align: justify">Limitations</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">Except as set forth in the
Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
SIEMENS assumes no obligations to the Receiver in connection with</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
any statements about the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the DEVELOPER SERVICES</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the SDK and the INFORMATION</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">It
does constitute merely technical information and not obligations of SIEMENS</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify">(b) None of the PARTIES&rsquo;
obligations under the Agreement shall be deemed to constitute a guaranteed quality (zugesicherte Eigenschaft) or other guarantee
(Garantie); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
Each of the PARTIES disclaims any strict liability (verschuldensunabh&auml;ngige Haftung) for defects and non-conformance already
existing when the Agreement was concluded</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">5.3</TD><TD STYLE="text-align: justify">Changes to DEVELOPER SERVICES</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
expressly agreed otherwise, SIEMENS provides the DEVELOPER SERVICES and the SDK as standard services and enables the Receiver
to use the agreed DEVELOPER SERVICES and the SDK made generally available by SIEMENS to its other receivers. SIEMENS will update
and further develop the technology</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">features and functionalities
of the DEVELOPER SERVICES and the SDK and is under no obligation to maintain prior versions thereof</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the provision of a modified or new version of the DEVELOPER SERVICES and the SDK or any other content</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver is no longer entitled to use previous versions. Should material changes to the DEVELOPER SERVICES or the SDK be implemented
which have an impact on the Receivers use or should agreed DEVELOPER SERVICES or SDK functionalities be restricted or disabled,
SIEMENS will notify the Receiver at least one hundred eighty (180) days before the changes become effective</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Such
notice period may be shortened only to the extent that</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">based on
SIEMENS reasonable judgment</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS believes that changes are
necessary in order to avoid any: (i) threat to the security or functionality of the INTERFACE or the DEVELOPER SERVICES or the
SDK; (ii) adverse impact on the Receiver, SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver&rsquo;s
or SIEMENS&rsquo; Affiliates, END USERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">including</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">without
limitation</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">any risk of personal injury; and/or (iii) subject the
Receiver, SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver&rsquo;s or SIEMENS&rsquo; Affiliates,
END USERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party to material liability for personal
injury or IP infringement; in each case</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">so long as SIEMENS takes
commercially reasonable efforts to maintain the compatibility of the PRODUCT with the SIEMENS MAGNETOM SCANNER</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">To
the extent the Receiver is, due to such changes</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">materially deprived
of the benefits of the DEVELOPER SERVICES or SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver
is entitled to terminate the Agreement in writing with effect upon effectiveness of the change at the earliest and Receiver will
be entitled to a refund of all amounts paid by Receiver with regards to the affected AUTHORIZATION KEYs to SIEMENS over the period
of incompatability</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">5.4</TD><TD STYLE="text-align: justify">Discontinuation of Services</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
may discontinue the provision of DEVELOPER SERVICES or the SDK in relation to a PRODUCT for use by an END USER at any time if the
respective AUTHORIZATION KEY or LICENSE KEY has been revoked by SIEMENS according to Article 11</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Suspension
of the AUTHORIZATION KEY and LICENSE KEY or the Agreement has been terminated according to Article16</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">5.5</TD><TD STYLE="text-align: justify">Place of Performance</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
provides the Receiver access to the DEVELOPER SERVICES and the SDK to be provided over the internet at the WAN exit of the data
center used by SIEMENS</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Unless otherwise agreed</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
will use a data center in Germany to provide the DEVELOPER SERVICES and the SDK</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
reserves the right to change the data center location and use additional data centers at any time and will inform the Receiver
of this in due time</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">provided that any such data centers will be
within the European Union</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will ensure that AUTHORIZATION
KEYS are generated</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">transferred, and/or revoked from the SIEMENS
Headquarter only</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">5.6</TD><TD STYLE="text-align: justify">Freedom from Defects in Title</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
represents</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">warrants and covenants that during the term of this
Agreement, the Receiver&rsquo;s use of the DEVELOPER SERVICES and SDK as permitted under the Agreement does not infringe upon a
patent, copyright</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">trade secret</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or
other intellectual property right in or to such DEVELOPER SERVICES and SDK in the country where SIEMENS has its seat or in countries
where SIEMENS have put SIEMENS MAGNETOM SCANNERS on the market</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
Receiver acknowledges that SIEMENS and/or its AFFILIATES is not responsible for an infringement of any such intellectual property
rights to the extent it is due to: (i) the Receiver&rsquo;s failure to use the most current version of or a defect correction
or patch supplied by SIEMENS for DEVELOPER SERVICES or the SDK; (ii) the combination</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">operation</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or use of the DEVELOPER SERVICES or the SDK in conjunction with any non-SIEMENS
information or with any third-party software, equipment</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">materials,
or products other than as contemplated by the INFORMATION; or (iii) an adjustment or configuration of the DEVELOPER SERVICES
or SDK not made by SIEMENS (or on its behalf). Notwithstanding any deviating and/or additional obligations expressly set forth
in the Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will neither assume any additional obligation
nor responsibility that Receiver&rsquo;s use of the DEVELOPER SERVICES or the SDK comply with applicable law</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
6</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Pricing</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As consideration that SIEMENS fulfills
the described obligations and provides the described support the PARTIES agree upon a one</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">time
fixed license fee of $1</FONT>00,000 <FONT STYLE="font-family: Times New Roman, Times, Serif">USD to be paid to SIEMENS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS shall be entitled to invoice the
Receiver the one</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">time fixed license fee ten (1</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">)
days after the effective date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">6.3</TD><TD STYLE="text-align: justify">As consideration for the licenses granted under this Agreement the PARTIES agree upon a yearly
license fee calculated based on the number of SIEMENS MAGNETOM SCANNERS being used for patient treatment:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[pricing information redacted]</I>
USD per scanner per year for the first 1</FONT>0 <FONT STYLE="font-family: Times New Roman, Times, Serif">connected SIEMENS MAGNETOM
SCANNERS (Scanner 1 &ndash; <FONT STYLE="font-size: 10pt">10)</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[pricing information redacted]</I>
USD per scanner per year for additional 2</FONT>0 <FONT STYLE="font-family: Times New Roman, Times, Serif">connected SIEMENS MAGNETOM
SCANNERS (Scanner 11 &ndash; 30)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><I>[pricing information redacted]</I> USD per scanner per year for additional 70 connected SIEMENS
MAGNETOM SCANNERS (Scanner 31 &ndash; 100)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>[pricing information redacted]</I>
USD per scanner for additional SIEMENS MAGNETOM SCANNERS exceeding 100</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
yearly license fee shall be prorated based on the number of days that elapsed during the year during which the SIEMENS MAGNETOM
SCANNERS are in use during the applicable year</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">There shall be
no yearly license fees due in respect of SIEMENS MAGNETOM SCANNERS which are already in use as of the Effective Date until the
beginning of the second year of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
SIEMENS MAGNETOM SCANNERS which are in any year used solely for the purpose of pre</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">clinical
or clinical research, whereas the Receiver is not getting any revenue from the END USER</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">will
not be subject to any license fees</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Receiver will advise SIEMENS
of the specific SIEMENS MAGNETOM SCANNERS being used solely for pre-clinical or clinical research and</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">upon
request</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Receiver will provide an annual attestation as to the
number and location of any such SIEMENS MAGNETOM SCANNERS</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
7</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Limitations: Permits, Regulatory Approvals and Standards</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Receiver acknowledges and agrees that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operation of SIEMENS MAGNETOM SCANNERS
demands observance of the applicable statutory provisions (e</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">g</FONT>.,
<FONT STYLE="font-family: Times New Roman, Times, Serif">in the EU</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Directive
93/42/EEC on medical devices (&ldquo;MDD&rdquo;) and Regulation (EU) 2017/745 on medical devices (&ldquo;MDR&rdquo;), to become
fully applicable on 26 May 202</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">) or any future revisions / successor
requirements and is limited to particular indicated uses</FONT><B><I>.</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any changes to SIEMENS MAGNETOM SCANNERS
by the Receiver, its AFFILIATES or OTHERS are not covered by CE labeling or regulatory approval or other applicable statutory provisions
and can be relevant for patient safety</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As part of the INFORMATION</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
shall only provide the documentation outlined in Annex 1 and does not foresee providing customized documentation, in particular
not any part of the END USER documentation for the PRODUCTS and the combination of the PRODUCTS to the SIEMENS MAGNETOM SCANNER</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">Upon Receiver&rsquo;s request, SIEMENS shall however provide reasonable
assistance and information needed for testing and documenting such combination as related to the INTERFACE only and not for MR
compatability in general. However, more generally Siemens will aid reasonable requests to support the attainment of data for validation
runs, compatibility testing and other such assistance; however the determination of reasonable will be at Siemens discreation</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS does not assume any responsibility
for the proper or safe functioning of the Receiver&rsquo;s PRODUCTS and/or its combination with SIEMENS MAGNETOM SCANNERS</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver will remain fully responsible for their PRODUCTS including
the combination with the SIEMENS MAGNETOM SCANNER</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and the manufacture</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">sale, marketing and service of the PRODUCTS</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
however endeavors to provide complete and accurate INFORMATION</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS is not responsible for an infringement
of any third party intellectual property rights due to: (i) The Receiver&rsquo;s failure to use the most current version of or
a defect correction or patch supplied by SIEMENS for the DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
SDK or the INTERFACE; (ii) the combination</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">operation</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or
use of the DEVELOPER SERVICES; the SDK or the INTERFACE in conjunction with any Receiver content or with any third</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">party
software</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">equipment</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">materials,
or products; or (iii) an adjustment or configuration of the DEVELOPER SERVICES; the SDK or the INTERFACE not made by</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or
on behalf of, SIEMENS or its AFFILIATES (or as contemplated by Section 7</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">7);
provided always that the DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SDK or the INTERFACE
as supplied by SIEMENS are not the root cause for such infringement</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
any deviating and/or additional obligations expressly set forth in the Agreement, SIEMENS will neither assume any additional obligation
nor responsibility that the DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the SDK or the
INTERFACE and/or the Receiver&rsquo;s use of the DEVELOPER SERVICES, the SDK or the INTERFACE comply with applicable law</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This Agreement does not cover service
related issues for either party at the Receiver&rsquo;s site or at the END USER&rsquo;s site and SIEMENS is not responsible for
any service or support related to the Receiver&rsquo;s PRODUCTS and the combination of the PRODUCTS to the SIEMENS MAGNETOM SCANNER
unless otherwise agreed upon in writing</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS may engage any of its AFFILIATES
and any other business partners for and in connection with the provision of DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
AUTHORIZATION KEY</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">billing
or payment</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver agrees to provide all reasonable cooperation
required by SIEMENS should it become necessary or desirable</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in
SIEMENS&rsquo; sole discretion</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">for SIEMENS to use a new or different
service providers. SIEMENS will be responsible for any of its obligations hereunder which are performed by its AFFILIATES</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">business partners and other service providers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver may</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">without
accounting to SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">use and modify information and documentation
in order to generate its END USER documentation of the PRODUCTS and the combination of the PRODUCTS to the SIEMENS MAGNETOM SCANNER,
provided this is done:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">at the Receiver&rsquo;s own cost, responsibility and risk,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ensuring that the documentation conforms
to the regulations applicable in the target countries and continuously updating it to the newest revision level</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in
particular as such information and documentation provided by SIEMENS may be country or region</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">specific
and subject to change</FONT>,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">without in any way portraying SIEMENS
as responsible for the content of the END USER documentation</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
clearly identifying the Receiver as responsible for marketing</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">sale</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">market</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">observation
and service, subject to customary disclaimers and limitation on liability</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                         Receiver agrees to:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generate
                                         and provide all END USER documentation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Complete risk assessments, risk mitigation</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">integration and system testing</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">compatibility
testing</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">etc. for their PRODUCTS and comply with all applicable
statutory provisions and regulations (e</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">g</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">those
stipulated by the FDA or the European Commission or Japanese equivalent regulatory bodies) of the target country in which the combined
product will be operated before releasing the PRODUCT into the market</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
SIEMENS discretion which will not be unreasonably withheld</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
will use commercially reasonable efforts to provide standard documentation and reasonable support in connection with such activities
upon request</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensure that the Receiver&rsquo;s END</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">USER&rsquo;s
are provided with all reasonably relevant instructions, warnings and</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">if
required</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">training for the Receiver&rsquo;s PRODUCTS and its combination
with the SIEMENS MAGNETOM SCANNERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">particularly if these are safety</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">relevant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver is responsible for post market
surveillance (as required by applicable laws and regulations where Receiver&rsquo;s PRODUCTS are approved and in use) of their
PRODUCTS and the combination of their PRODUCTS with SIEMENS MAGENTOM SCANNERS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore,
the Receiver has the responsibility for the proper handling and, in case of adverse events, reporting to regulatory bodies customer
complaints related to the combination of their PRODUCTS to the SIEMENS MAGNETOM SCANNERS (as required by applicable laws and regulations
where Receiver&rsquo;s PRODUCTS are approved and in use)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Receiver has the obligation to inform SIEMENS without undue delay about material adverse events in relation to the combination
of their PRODUCTS and the SIEMENS MAGNETOM SCANNER to the best of the Receiver&rsquo;s knowledge</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Receiver has the responsibility
to perform field updates and recalls, if necessary conduct reporting to reduce a risk to health and bring back the combination
into specification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">SIEMENS will not take any responsibility
related to post market surveillance / vigilance of the combination of the Receiver&rsquo;s PRODUCTS with the SIEMENS MAGNETOM
SCANNERS other than as set out in Section 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver shall indemnify</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">defend
and hold harmless SIEMENS and its AFFILIATES from any and all proceedings</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">costs,
expenses, damages, fees, penalties, and losses (including reasonable attorney fees)</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in
each case arising from a third party claim</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">that result from:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt">7.3.1</TD><TD STYLE="text-align: justify">A culpable breach of an obligation under this Agreement by the Receiver, Receiver&rsquo;s AFFILIATES
and their respective employees and agents; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">failures of the SIEMENS MAGNETOM SCANNERS
to function in accordance with their INFORMATION to the extent caused by the combination of the Receiver&rsquo;s PRODUCTS with
SIEMENS MAGNETOM SCANNERS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS shall indemnify</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">defend
and hold harmless Receiver and its AFFILIATES from any and all proceedings</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">costs,
expenses, damages, fees, penalties</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and losses (including reasonable
attorney fees)</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in each case arising from a third party claim,
that result from:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A non</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">fulfillment</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">wrongful act or omission or a culpable breach of an obligation under this
Agreement by SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS AFFILIATES and their respective employees
and agents; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">failures of the SIEMENS MAGNETOM SCANNERS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or
the SDK to function in accordance with their INFORMATION to the extent they are not caused by the combination of the Receiver&rsquo;s
PRODUCTS with SIEMENS MAGNETOM SCANNERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the INTERFACE</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or the SDK; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a claim that the SIEMENS MAGNETOM SCANNERS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or
the SDK infringe or misappropriate an OTHER&rsquo;s IP other than where such infringement or misappropriation would not have occurred
but for the combination of the SIEMENS MAGNETOM SCANNERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the INTERFACE</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or the SDK with the PRODUCT</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
8</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Billing</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
services and responsibilities described under this Agreement make SIEMENS eligible to receive a yearly license fee calculated as
outlined in Article 6</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
invoices will refer to an applicable timeframe</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Receiver will pay
all properly invoiced amounts within 3</FONT>0 <FONT STYLE="font-family: Times New Roman, Times, Serif">days of its receipt of
the applicable invoice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
license fee will be paid in US currency to SIEMENS or its respective AFFILIATES</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each
PARTY will ensure that its AFFILIATES adopt and comply with the provisions of this Agreement applicable to such transactions to
the extent allowed under local law</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Within
thirty (30) business days after the end of each calendar quarter</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
will invoice the Receiver the license fee for the applicable quarter as defined in Article 6</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Pricing
based on all connected SIEMENS MAGNETOM SCANNERS and based on the analysis of the received customer data; the number of issued
AUTHORIZATION KEYS and the resulting license fee and prorated for the applicable portion of the quarter</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">lf
the Receiver is required by law to make any deduction or to withhold from any sum payable directly to SIEMENS or any of its AFFILIATES
hereunder</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver shall promptly effect payment thereof to
the applicable tax authorities, and shall also promptly provide SIEMENS or any of its AFFILIATES with official tax receipts or
other evidence sufficient to establish that the taxes have been paid and to enable SIEMENS or any of its AFFILIATES to support
a claim for income tax credits for such payments. Failure to provide official tax receipts or other evidence of payment shall
result in the Receiver paying directly to SIEMENS or any of its AFFILIATES such amounts deducted or withheld from the original
payment. The Receiver shall also assist SIEMENS or any of its AFFILIATES in minimizing the withholding rate available under an
applicable tax treaty</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or otherwise, by supplying SIEMENS or any
of its AFFILIATES with any appropriate documentation upon reasonable request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
9</B></FONT><B> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Marketing</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
may</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">but is not obligated to</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">advertise
the PRODUCTS offered by the Receiver. For this purpose, the Receiver grants SIEMENS a non</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">exclusive</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">non</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">transferable</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">sub</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">licensable,
and royalty</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">free worldwide license to use all trademarks or trade
names of the Receiver&rsquo;s PRODUCTS</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">RECEIVER
may, but is not obligated to</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">advertise the combination of SIEMENS
MAGNETOM SCANNERS and the Receiver&rsquo;s PRODUCTS</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
such advertising materials created by either PARTY using any trademark or trade names of the other PARTY will be subject to prior
approval</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">not to be unreasonably withheld or delayed</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PARTIES will discuss in good faith the possibilities for a joint marketing collaboration between the PARTIES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">aiming
towards each of the PARTIES being able to market a joint offering of the PRODUCTS together with SIEMENS MAGNETOM SCANNERS</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">Any such expanded collaboration shall be agreed upon separately between
the PARTIES</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 10 - Monitoring of Usage Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
may and will use reasonable efforts to monitor the usage of the INTERFACE by END USERS, e.g</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">,
the number of users</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">for SIEMENS&rsquo; internal business purposes,
in particular: (i) for security and availability reasons; (ii) to the extent required to ensure compliance of the END USER with
the applicable END USER agreement and of the Receiver with this Agreement; and (iii) to detect</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">prevent,
and suspend any use of the INTERFACE exceeding the permitted use under the END USER agreement as well as this Agreement</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">to charge for such excess use, and otherwise as necessary for payment
and billing related tasks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 11 - Suspension of the AUTHORIZATION
KEY and LICENSE KEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
is entitled to suspend the AUTHORIZATION KEY for the INTERFACE issued to the Receiver at any time</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">resulting
in the END USER no longer being able to use the Receiver&rsquo;s PRODUCTS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">if
in SIEMENS&rsquo; reasonable judgment there is a risk that the use of the Receiver&rsquo;s PRODUCT by the END USER will: (i) constitute
a threat to the security or functionality of the END USER&rsquo;S systems;(ii) adversely impact the END USER</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver, SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver&rsquo;s or SIEMENS&rsquo; AFFILIATES</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including,
without limitation</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">any risk of personal injury; [or (iii) subject
the END USER</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver, SIEMENS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
Receiver&rsquo;s or SIEMENS&rsquo; AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or any third party
to liability for personal injury or IP infringement]. Furthermore</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
is entitled to suspend the LICENSE KEY if such revocation is required by law</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">a
court decision, or a request from a governmental body; and (iii) SIEMENS is entitled to revoke the END USER LICENSE KEY for the
relevant END USER if</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in each case for security or compliance reasons
or requests from a governmental body</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">its access to the INTERFACE has been suspended or the agreement between SIEMENS and the END USER has been terminated by SIEMENS or the END USER</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">whenever
reasonably possible</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">consult with Receiver in advance of the revocation
of a LICENSE KEY</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will inform the Receiver about any revocation
of a LICENSE KEY as soon as possible</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will reinstate any
suspended AUTHORIZATION KEY or LICENSE KEY once the circumstances giving rise to such suspension have been remedied</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 12 - Notification Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
is entitled to notify the Receiver</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">END USERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
authorities in a suitable form at any time</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">if: (i) in SIEMENS&rsquo;
reasonable judgment there is a risk that the use of the Receiver&rsquo;s PRODUCTS by the END USER will: (a) threaten the security
or functionality of the END USER&rsquo;s systems; (b) adversely impact the END USER or any third party</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">without limitation</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">any
risk of personal injury; or (c) subject the END USER or any third party to liability for personal injury or IP infringement; or
(ii) such notification is required by law</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">a court decision, or
a request from a governmental body; provided that SIEMENS will notify Receiver prior to providing any such notice to END USERS
or authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Receiver acknowledges that a revocation of the AUTHORIZATION KEY or the LICENSE KEY pursuant to and in compliance with the conditions
of Article 11</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">or a notification pursuant to and in compliance
with this Article by SIEMENS does not lead to any responsibility of SIEMENS</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 13 - Support</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where
END USERS contact SIEMENS for support queries</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS will: (i)
process queries concerning the SIEMENS MAGNETOM SCANNERS and provide all support with respect to the SIEMENS MAGNETOM SCANNERS;
and (ii) forward queries concerning the Receiver&rsquo;s PRODUCT to the Receiver within a reasonable period of time and the Receiver
(and not SIEMENS) will have responsibility for providing the support</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
receipt</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Receiver will forward support queries from END USERS
concerning the SIEMENS MAGNETOM SCANNER to SIEMENS within a reasonable period of time</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each
PARTY may notify the other PARTY of changes to its point of contact at least two (2) weeks in advance, e</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">mail
being sufficient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 14 - Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The PARTIES agree that other than as set
out in this Agreement: any information is made available &ldquo;as is&rdquo; and no warranties are given or liabilities of any
kind are assumed with respect to the quality of such information, including</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">but
not limited</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">to its fitness for the purpose, non</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">infringement
of third</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">party rights, its correctness or completeness. Furthermore</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">none of the Parties&rsquo; obligations under this Agreement shall be deemed
to constitute a guaranteed quality or other guarantee. In addition</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">other
than as expressly set out in this agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">each of the Parties
disclaims any strict liability for defects and non-conformance already existing when this contract was concluded</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This clause 14 sets out the entire financial
liability of each of the PARTIES (including any liability for the acts or omissions of its AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">employees,
agents, consultants and subcontractors) under this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including
in respect of any breach and any representation, statement or tortious act or omission (including negligence), indemnity</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">warranty</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or
strict liability arising under or in connection with this Agreement</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to clause 14</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">4
the liability of each PARTY under this Agreement shall be limited to direct losses and only to an amount of EUR 250</FONT>,000-
<FONT STYLE="font-family: Times New Roman, Times, Serif">for each single damage event and subject to a maximum of EUR 1</FONT>,000,000-
<FONT STYLE="font-family: Times New Roman, Times, Serif">for all such events. Claims for other indirect losses</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including
but not limited to claims for business stoppage, indirect lost profit</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">loss
of information or data as well as consequential</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">special or incidental
losses shall be excluded regardless of their legal grounds</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This disclaimer of liability shall not
apply in cases involving intent or gross negligence, or where liability is mandatory by law</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Receiver will</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in
its sole responsibility</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">decide on the use of the INTERFACE</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the INFORMATION or any other material provided
through SIEMENS</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS does not assume any liability for defects
of or damages to the END USER&rsquo;S systems resulting from the use of the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
INFORMATION or any other material provided through SIEMENS and hereby waives and excludes any and all liability arising out of
or in connection with the use of the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the SDK</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">the DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
INFORMATION or any other material provided through SIEMENS beyond the intended use whether based on contract</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">tort,
negligence</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">under an indemnity</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">warranty</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">strict liability or otherwise except to the extent such defect or damage
is caused or contributed to by a negligent act or negligent omission of SIEMENS, or a breach of this Agreement</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">14.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to of the INTERFACE</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the DEVELOPER SERVICES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
INFORMATION or any other material provided through SIEMENS or its AFFILIATES is the responsibility of the Receiver.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 15 - Confidentiality</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CONFIDENTIAL INFORMATION&rdquo;
shall mean any information and data</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including without limitation</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">any kind of business</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">commercial
or technical information and data disclosed by the Receiver to SIEMENS or SIEMENS to the Receiver in connection with the execution
or performance of this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">irrespective of the medium in
which such information or data is embedded</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">which is:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">when disclosed in tangible form &ndash;
marked &ldquo;Confidential&rdquo; by the disclosing PARTY</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">or when disclosed orally or visually &ndash;
identified as such prior to disclosure and summarized in writing by the disclosing PARTY and said summary is given to the receiving
PARTY within thirty (30) days after such disclosure marked &ldquo;Confidential&rdquo;. In case of disagreement regarding orally
or visually disclosed information</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the receiving PARTY must present
its objections to the summary in writing within thirty (3</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">) days
of receipt</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL
INFORMATION shall also include any copies or abstracts made thereof as well as any apparatus</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">data</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">modules, samples, prototypes or parts thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the avoidance of doubt</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the pricing information described in Article
6.1 and Article 6.3</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the library of examples, the SDK</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
INTERFACE description shall deemed to be SIEMENS CONFIDENTIAL INFORMATION irrespective of the fact if they are marked or not</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">All information about the PRODUCTS or Receiver&rsquo;s business practices
which is not made generally available to the public and <B><I>t</I></B>he pricing information described in Article 6</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1
and Article 6.3 shall be deemed Receiver CONFIDENTIAL INFORMATION</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The receiving PARTY shall maintain CONFIDENTIAL
INFORMATION received from the disclosing PARTY in confidence and will use such CONFIDENTIAL INFORMATION solely for the purposes
of this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and shall not distribute or disclose it</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">provided</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">however</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">that the receiving PARTY may disclose such information to its officers,
AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and those of its employees and subcontractors who need
to know it for the purposes of this Agreement</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Each PARTY shall
impose on its officers, AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and its employees and subcontractors
confidentiality obligations no less stringent than its own confidentiality obligations under this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
the receiving PARTY will be responsible for any violation of the confidentiality obligations under this Agreement by any of its
officers</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">AFFILIATES</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">employees
or subcontractors</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The obligations of Article 15.2 shall
remain in force for a period of five (5) years after the termination of this Agreement</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL
INFORMATION (as defined in the Original Agreement) disclosed by either PARTY under the Original Agreement shall be deemed CONFIDENTIAL
INFORMATION disclosed under this Agreement and shall be subject to the provisions of this Article 15</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The obligations of Article 15</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">2
shall not apply to information which is or becomes generally known to the public or which has been obtained independently as evidenced
by a PARTY&rsquo;S business records or acquired legitimately from OTHERS who are to the knowledge of the receiving PARTY free to
lawfully disclose the information</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The provisions of Article 15</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">2
hereof shall apply to copies of electronically exchanged CONFIDENTIAL INFORMATION made as a matter of routine information technology
backup and to CONFIDENTIAL INFORMATION or copies thereof which must be stored by the receiving PARTY or its advisers according
to provisions of mandatory law or as required by regulatory bodies such as the FDA</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
such CONFIDENTIAL INFORMATION or copies thereof shall be subject to an indefinite confidentiality obligation according to the terms
and conditions set forth herein</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">15.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Save as set out in Article 15</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">5
above</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">within ninety (90) calendar days after termination of this
Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the receiving PARTY shall destroy or, as may be requested
by the disclosing PARTY</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">return all CONFIDENTIAL INFORMATION received
and stored electronically and/or on record</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">bearing media as well
as any copies thereof. The receiving PARTY shall confirm in writing such destruction to the disclosing PARTY</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Excluded
from the obligations set out in this Article 15.6 is information that the Receiver is required to retain in his technical files
relating to the PRODUCTS or information that: (a) is required to enforce or comply with the terms of this Agreement or Receiver&rsquo;s
agreements with End Users; or (b) is stored in accordance with a Party&rsquo;s back-up and disaster recovery systems.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Article
16 - Agreement Term, Notification and CHANGE</B></FONT><B>-<FONT STYLE="font-family: Times New Roman, Times, Serif">OF</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">CONTROL</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This Agreement shall come into force when
signed by both PARTIES and shall have a term for sixty (6</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">) months.
Unless earlier terminated</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the Agreement shall be extended for
successive terms of one (1) year each unless written notice to terminate is given by either PARTY at least three (3) months before
the end of the respective contract term</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each PARTY shall be entitled to terminate
this Agreement prematurely by means of written notice</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">if the other
PARTY breaches a material obligation and fails to rectify the aforesaid breach within ninety (9</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">)
calendar days of the non-breaching PARTY&rsquo;s notice</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">16.3</TD><TD STYLE="text-align: justify">If there is a CHANGE-OF-CONTROL to a COMPETITOR of SIEMENS:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 18pt">&bull;</TD><TD STYLE="text-align: justify">the Receiver shall inform SIEMENS in writing within fifteen (15) calendar days, but under no circumstance
later than any public announcement by the Receiver,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The PARTIES shall discuss in good faith
within thirty (3</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">) calendar days after SIEMENS has been informed
in writing by the Receiver,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In particular</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">it
shall be discussed how such CHANGE OF CONTROL would impact the relationship contemplated by this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">including
whether the Receiver or such COMPETITOR will terminate this Agreement after the closing of such CHANGE OF CONTROL transaction</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS shall be entitled to terminate
with immediate effect this Agreement within sixty (6</FONT>0<FONT STYLE="font-family: Times New Roman, Times, Serif">) calendar
days after SIEMENS has been informed in writing by the Receiver of such CHANGE OF CONTROL involving a COMPETITOR of SIEMENS</FONT>,
<FONT STYLE="font-family: Times New Roman, Times, Serif">provided that SIEMENS, acting reasonably, shall only terminate this Agreement
if such CHANGE OF CONTROL transaction involving a COMPETITOR of SIEMENS will have a detrimental impact on the PARTIES collaboration
hereunder relating to the PRODUCTS and SIEMENS MAGNETOM SCANNERS</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">16.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The provisions in Article 7</FONT> - ,
<FONT STYLE="font-family: Times New Roman, Times, Serif">Article 1</FONT>0 - <FONT STYLE="font-family: Times New Roman, Times, Serif">Article
11</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Article 12</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">Article
14</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">this Article 16</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">4
and Article 19</FONT> - <FONT STYLE="font-family: Times New Roman, Times, Serif">shall survive the expiration or termination of
this Agreement. With regards to the PRODUCTS which have already been connected to SIEMENS MAGNETOM SCANNERS before expiration or
termination of this agreement the licenses granted for the AUTHORIZATION KEY shall be unaffected as well as the corresponding obligation
to pay the license fee as set forth in Article 2</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Article 6 and
Article 8 for all granted AUTHORIZATION KEYs</FONT>., <FONT STYLE="font-family: Times New Roman, Times, Serif">unless and until
such time as Receiver specifies which individual or all such AUTHORIZATION KEYS are no longer in use. Then the Receiver only has
the obligation to pay the license fee for all the AUTHORIZATION KEYs still in use</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 17 - Force Majeure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A PARTY shall not be in breach of this
Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">nor liable for any failure or delay in the performance
of any of its obligations under this Agreement as a result of force majeure event provided that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt">17.1.1</TD><TD STYLE="text-align: justify">it promptly notifies the other PARTY in writing of the nature and extent of the force majeure event
causing its failure or delay in performance; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.1.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">it has used reasonable endeavors to mitigate
the effect of the force majeure event</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">to carry out its obligations
under this Agreement in any way that is reasonably practicable and to resume the performance of its obligations as soon as reasonably
possible</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">17.2</TD><TD STYLE="text-align: justify">&lsquo;<U>Force majeure event</U>&rsquo; in the sense of this Agreement shall be one of the following
events which is outside the control of a PARTY and its suppliers and contractors and prevents that PARTY from meeting its contractual
obligations:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">acts of God, fires</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">floods,
earthquakes or other natural disasters;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">war, embargo</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">terrorist
attack, riots;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt">17.2.3</TD><TD STYLE="text-align: justify">explosion or building collapse;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 45.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">failure of plant machinery</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">interruption
or failure of utility service, including but not limited to electric power</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">gas
or water</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">17.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If either PARTY is prevented from meeting
its obligations under this Agreement for a continuous period of more than six (6) months as a result of a &lsquo;force majeure
event&rsquo;, the other PARTY shall be entitled</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">at its sole discretion,
to terminate the Agreement with one (1) month&rsquo;s written notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 18 - Miscellaneous</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neither PARTY shall be entitled, without
the prior written consent of the other</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">to transfer or assign this
Agreement or any rights and obligations arising from it to OTHERS</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">except
a transfer or assignment to an AFFILIATE or a purchaser of substantially all of the assets of a PARTY</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">provided
that the transferring or assigning PARTY shall remain responsible for the fulfilment of the obligations it originally incurred
under the Agreement. Consent hereto shall not be unreasonably withheld</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">18.2</TD><TD STYLE="text-align: justify">SIEMENS&rsquo; obligation to fulfill this Agreement is subject to the proviso that the fulfillment
is not prevented by any impediments arising out of national and international foreign trade and customs requirements or any embargos
or other sanctions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The PARTIES shall comply with all applicable
export control</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">customs and foreign trade regulations (&ldquo;Foreign
Trade Regulations&rdquo;) and shall obtain all necessary export licenses, if any</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any amendments as well as supplements
to this Agreement must be in writing and signed by the PARTY to be bound in order to be effective</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">A
waiver of form shall be effective only if agreed upon in writing and signed by the PARTY to be bound</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If this Agreement requires a notice or
a document to be &bdquo;in writing&rdquo; or &bdquo;in written form&rdquo;, such notice or document shall be duly signed by the
sender and the signed notice or document shall be delivered</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">sent
or transmitted to the other PARTY in its original form or as a telefax copy or a PDF. For the avoidance of doubt</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">electronic
communication shall not qualify as a written notice or document unless confirmed as received by the receiving PARTY</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any general terms and conditions of the
PARTIES in addition to this Agreement shall be excluded</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">This shall
particularly apply if there is any reference to such terms in correspondence or other documentation of the PARTIES (e</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">g</FONT>.,
<FONT STYLE="font-family: Times New Roman, Times, Serif">printed</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">stamped
and electronically reproduced).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If any provisions of this Agreement should
be held to be illegal</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">invalid or unenforceable</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the
validity</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">legality and enforceability of the remaining provisions
shall not in any way be affected or impaired thereby</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The PARTIES
shall substitute the illegal, invalid</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">or unenforceable provision
by a legal</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">valid or enforceable one</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">approximating
as closely as possible the original commercial intent of the PARTIES</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If provisions of this Agreement conflict
with the Annexes or other agreements</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the provisions of this Agreement
shall have precedence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">18.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Original Agreement and the PARTIES&rsquo;
obligations thereunder are hereby terminated and replaced by this Agreement</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">[Article
7</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">2 of the Original Agreement shall continue to apply after the
Effective Date of this Agreement; provided that Art</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">8 of the Original
Agreement shall not survive termination of the Original Agreement according to this section 18</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">9</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Article 19 - Arbitration and Substantive
Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If a dispute arises in connection with
this Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">the responsible representatives of the PARTIES
shall attempt</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">in fair dealing and good faith, to settle such dispute.
Upon request of a PARTY a senior management representative of each PARTY shall participate in the negotiations. Each PARTY shall
be entitled to terminate these negotiations by written notification to the other PARTY at any time</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The PARTIES shall attempt to agree on
a procedure for Alternative Dispute Resolution (ADR) and the applicable procedural rules (including time limits) within fourteen
days after a termination notice under Article 19.1 has been received by the other side. If the PARTIES fail to agree on such procedure
within this time limit each PARTY shall be entitled to refer the dispute to arbitration pursuant to Article 19</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">19.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All disputes arising in connection with
this Agreement which are not resolved pursuant to Article 19</FONT>.<FONT STYLE="font-family: Times New Roman, Times, Serif">1
or an ADR procedure, including any question regarding the termination or any subsequent amendment of the Agreement</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">shall
be finally settled in accordance with the Rules of Arbitration (&ldquo;Rules&rdquo;) of the International Chamber of Commerce (&ldquo;ICC&rdquo;)</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">The seat of arbitration shall be Zurich Switzerland</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
language to be used in the ADR and the arbitration proceeding shall be English</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Any
production of documents shall be limited to the documents on which each PARTY specifically relies in its submission(s). Consolidation
of arbitrations pending under the Rules into a single arbitration shall only be possible if the PARTIES have agreed to consolidation</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">The unsuccessful PARTY shall bear the costs of the arbitral proceedings</FONT>.
<FONT STYLE="font-family: Times New Roman, Times, Serif">However, the arbitral tribunal may take into account the extent to which
each PARTY has conducted the arbitration in an expeditious and cost</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">effective
manner</FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9.35pt"></TD><TD STYLE="width: 36pt">19.4</TD><TD STYLE="text-align: justify">This Agreement shall be subject to the substantive law in force in Germany without reference to
any of its conflict of law rules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;/&nbsp;26</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&hellip;&hellip;&hellip;&hellip;</B></FONT><B>..</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Place</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Mississauga, Ontario</U></FONT><U>, <FONT STYLE="font-family: Times New Roman, Times, Serif">February 11, 2019</FONT></U></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Aaron Davidson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Arun Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name <FONT STYLE="font-size: 10pt">(Print)</FONT>:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name <FONT STYLE="font-size: 10pt">(Print)</FONT>:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aaron Davidson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Arun Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SIEMENS Healthcare GmbH</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Place</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Erlangen</U></FONT><U>, <FONT STYLE="font-family: Times New Roman, Times, Serif">Germany</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">January 23, 2019</FONT></U></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Robert Krieg</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif">Peter
    Horn</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name <FONT STYLE="font-size: 10pt">(Print)</FONT>:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name <FONT STYLE="font-size: 10pt">(Print)</FONT>:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr</FONT>. <FONT STYLE="font-family: Times New Roman, Times, Serif">Robert Krieg</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Peter Horn</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">VP MR Advanced Solutions &amp; Therapy</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Senior Vice President Finance</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Magnetic Resonance</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.35pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font-size: 10pt"><B>CONFIDENTIAL</B></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Specification of INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preamble</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIEMENS provides the INFORMATION to the Receiver for the sole
purpose of interfacing the PRODUCTS to certain SIEMENS MAGNETOM SCANNERS and to deliver such adapted PRODUCTS to END USERS for
interworking with SIEMENS MAGNETOM SCANNERS. The INFORMATION in scope are described in this Annex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Interface description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Access-I
developer guide with comprehensive documentation of the interface, intended for a developer to integrate against this interface.
Includes descriptions of the setup, configuration,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">methods of
the interface with examples.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Software Development Kit (SDK)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
test environment is provided to ease the development, integration and testing of remote clients with Access-i. It comprises
an Access</FONT>-I <FONT STYLE="font-family: Times New Roman, Times, Serif">Simulator and a Test Client, which are designed
for a Windows PC environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The <B>Access-i Simulator</B> enables the remote client implementation
and testing without the need for physical access to an MR scanner. It mimics the Access-I related functionality of the MR host</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The <B>Access</B></FONT><B>-<FONT STYLE="font-family: Times New Roman, Times, Serif">i
Test Client</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> provides an example implementation of a
remote client, and also serves as a reference to verify the functionality of the Access-i interface</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Source Code toolbox</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As part of the SDK, some source code toolboxes are included
to provide an example implementation of a remote client. These can be used in the development of the remote client to enable faster
development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Specification of PRODUCTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preamble</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIEMENS
provides the INFORMATION to the Receiver for the sole purpose of interfacing the PRODUCTS to certain SIEMENS MAGNETOM SCANNERS
and to deliver such adapted PRODUCTS to END USERS for interworking with SIEMENS MAGNETOM SCANNERS. The PRODUCTS in scope are described
in this Annex</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Product Name</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TULSA-PRO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sonalleve</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Product Description</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TULSA-PRO: MRI guided directional ultrasound ablation of soft
tissue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sonalleve:
MRI guided high</FONT>-<FONT STYLE="font-family: Times New Roman, Times, Serif">intensity focused ultrasound of soft tissue, bone
and nerves</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intended Use</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TULSA-PRO: MRI guided directional ultrasound ablation of soft
tissue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sonalleve: MRI guided high-intensity focused ultrasound of soft
tissue, bone and nerves</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulatory Status and Regulatory Roadmap</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TULSA-PRO: Approved in EU and soon to be in registration in
the US</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sonalleve:
Approved in the EU</FONT>, <FONT STYLE="font-family: Times New Roman, Times, Serif">and several Asian countries including
China and soon to be in registration in the US</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MR-Compatibility Status</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">TULSA</FONT>
-<FONT STYLE="font-family: Times New Roman, Times, Serif">PRO: Intention is to be compatible with all Siemens scanners upon which
Access I can be operational</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sonalleve: Intention is to be compatible with all Siemens scanners
upon which Access I can be operational</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Agreement for risks exported in using
Access-i</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preamble</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Siemens Healthcare GmbH has created a risk analysis according
to their risk management process fulfilling the requirements given by IS014971:2012. Listed below are the residual risks related
to the use of &ldquo;Access-i&rdquo; interface that cannot be further mitigated by Siemens Healthcare GmbH and which the Receiver
accepts in using this interface functionality. It is the responsibility of the Receiver to ensure that the appropriate measures
are in place to mitigate these risks in using this&rsquo; interface functionality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks exported to the Receiver using the Access-i interface:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: left; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Function </B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Error</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cause</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hazard</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Measure(s)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUMARIS/4 product SW crash or instability, loss
    in performance.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SW hang-up / Side effects / secondary effects on NUMARIS/4 product SW</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed diagnosis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It must be ensured, that the status of the MR system always corresponds to the required status (e.g. sequence is running) during safety relevant interventions</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: middle">Remote PC- control session active</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No fast way to stop the MR measurement and/or patient table
        movement in an emergency situation.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Visual and audio contact to the patient (window / video / Intercom
        system (cf. above)) not possible.</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patient intercom system / video supervision remains at the MR AWP and is not available at the remote PC.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various!</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients must be monitored, always and it needs to be ensured that MR measurement can be stopped in emergency situations.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Connection between MR AWP and remote PC gets lost.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Technical defect; Forced control take over at the MR AWP (e.g. by User); Remote session is aborted (intended or unintended)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Burns up to 2nd degree; misdiagnosis; Jamming or injection / infusion needles pulled out &ndash; minor or moderate injury</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A termination or a break of the connection between the MR AWP and the remote PC must be recognized. In this case the procedure (e.g. intervention) must be handled appropriately (e.g. stopped).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parameters are accidently changed on the MR AWP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to MR System by MR AWP between two remote control sessions possible.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delayed diagnosis</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It must be ensured that the protocol parameters are not changed unintentionally before each procedure (e.g. intervention). Only Personnel that are trained must use the MR-Device and the remote PC. It is recommended to have at least two persons for the workflow.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">5</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 13%">Remote PC &ndash; Untrained Personnel</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%">MR device not used correctly</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%">Untrained personnel are using the MR Device (via remote control)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%">Various!</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%">Only Personnel which are trained must use the MR-Device and the remote PC. It is recommended to have two persons for the workflow.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>6</TD>
    <TD>&nbsp;</TD>
    <TD>Remote PC &ndash; Popup Issue service</TD>
    <TD>&nbsp;</TD>
    <TD>Popup confirmed (automatically) by remote PC SW</TD>
    <TD>&nbsp;</TD>
    <TD>Malfunction of remote PC software or intended automated popup confirmation.</TD>
    <TD>&nbsp;</TD>
    <TD>Misdiagnosis</TD>
    <TD>&nbsp;</TD>
    <TD>The remote PC SW must consider all popup related information provided by MR AWP via the issue service for safe and proper use of the MR Device; e.g. automatic table movement. Popups can be handled automatically by SW, if the consequences are known and measures are implemented to prevent resulting hazards.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>7</TD>
    <TD>&nbsp;</TD>
    <TD>Remote PC &ndash; Debugging service</TD>
    <TD>&nbsp;</TD>
    <TD>Start of savelog generation shortly before a sequence is started</TD>
    <TD>&nbsp;</TD>
    <TD>Savelog generation can take up to 5 minutes and can lead to a longer reconstruction time</TD>
    <TD>&nbsp;</TD>
    <TD>Delayed diagnosis</TD>
    <TD>&nbsp;</TD>
    <TD>If update rate of date is not sufficient for the required application the procedure (e.g. intervention) must be handled appropriately (e.g. stopped).</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>8</TD>
    <TD>&nbsp;</TD>
    <TD>Remote PC &ndash; Image Service</TD>
    <TD>&nbsp;</TD>
    <TD>Image service and/or projection service not available</TD>
    <TD>&nbsp;</TD>
    <TD>Automatic receive of images via websocket functionality</TD>
    <TD>&nbsp;</TD>
    <TD>Delayed diagnosis</TD>
    <TD>&nbsp;</TD>
    <TD>If update rate of date is not sufficient for the required application the procedure (e.g. intervention) must be handled appropriately (e.g. stopped).</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>13
<FILENAME>tv526458_ex4-7.htm
<DESCRIPTION>EXHIBIT 4.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.7</B></P>

<P STYLE="margin: 0; text-align: right"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXECUTION COPY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CREDIT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>between </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROFOUND MEDICAL INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Borrower</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROFOUND MEDICAL CORP. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROFOUND MEDICAL GMBH </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROFOUND MEDICAL (U.S.) INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Guarantors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CANADIAN IMPERIAL BANK OF COMMERCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Lender</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>dated as of </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>July 30, 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GOODMANS LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE I. INTERPRETATION</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">1</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 20%; padding-left: 0.5in">Section 1.01</TD>
    <TD STYLE="vertical-align: top; width: 70%">Definitions</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right">1</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.02</TD>
    <TD STYLE="vertical-align: top">PPSA</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.03</TD>
    <TD STYLE="vertical-align: top">Headings</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.04</TD>
    <TD STYLE="vertical-align: top">References to Sections</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.05</TD>
    <TD STYLE="vertical-align: top">Currency</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.06</TD>
    <TD STYLE="vertical-align: top">Gender and Number</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.07</TD>
    <TD STYLE="vertical-align: top">Invalidity of Provisions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.08</TD>
    <TD STYLE="vertical-align: top">Transition from GAAP to US GAAP</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">20</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.09</TD>
    <TD STYLE="vertical-align: top">Amendment or Waiver</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.10</TD>
    <TD STYLE="vertical-align: top">Non-Business Days</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.11</TD>
    <TD STYLE="vertical-align: top">Currency Equivalents</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 1.12</TD>
    <TD STYLE="vertical-align: top">German Terms</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">21</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE II. THE LOANS</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">22</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 2.01</TD>
    <TD STYLE="vertical-align: top">The Commitments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">22</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 2.02</TD>
    <TD STYLE="vertical-align: top">Loans</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">22</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 2.03</TD>
    <TD STYLE="vertical-align: top">Fees</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">23</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 2.04</TD>
    <TD STYLE="vertical-align: top">Payment; Computation</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">24</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 2.05</TD>
    <TD STYLE="vertical-align: top">Loan Account</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">24</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE III. PAYMENTS AND PREPAYMENTS</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">24</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.01</TD>
    <TD STYLE="vertical-align: top">Repayment of Loans</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">24</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.02</TD>
    <TD STYLE="vertical-align: top">Interest</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">24</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.03</TD>
    <TD STYLE="vertical-align: top">End of Term Payment</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.04</TD>
    <TD STYLE="vertical-align: top">Optional Prepayments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.05</TD>
    <TD STYLE="vertical-align: top">Mandatory Prepayments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">26</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.06</TD>
    <TD STYLE="vertical-align: top">Application of Prepayments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">27</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.07</TD>
    <TD STYLE="vertical-align: top">Notice of Prepayments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">27</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.08</TD>
    <TD STYLE="vertical-align: top">Payments Generally</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">28</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.09</TD>
    <TD STYLE="vertical-align: top">Change in Law and Increased Costs</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">28</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.10</TD>
    <TD STYLE="vertical-align: top">Taxes</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">29</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 3.11</TD>
    <TD STYLE="vertical-align: top">Illegality</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">31</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE IV. SECURITY</TD>
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: right">31</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 4.01</TD>
    <TD STYLE="vertical-align: top">Security Documents</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">31</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 4.02</TD>
    <TD STYLE="vertical-align: top">Control of Collateral; Control Agreements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">32</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 4.03</TD>
    <TD STYLE="vertical-align: top">Guarantors</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">33</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 4.04</TD>
    <TD STYLE="vertical-align: top">Real Estate</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">33</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 4.05</TD>
    <TD STYLE="vertical-align: top">Delivery of Additional Documentation Required</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">33</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 4.06</TD>
    <TD STYLE="vertical-align: top">Right to Inspect</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">34</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE V. REPRESENTATIONS AND WARRANTIES </TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">34</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 20%; padding-left: 0.5in">Section 5.01</TD>
    <TD STYLE="vertical-align: top; width: 70%">Incorporation and Status</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right">34</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.02</TD>
    <TD STYLE="vertical-align: top">Corporate Power and Due Authorization</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">34</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.03</TD>
    <TD STYLE="vertical-align: top">Business of the Loan Parties</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">34</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.04</TD>
    <TD STYLE="vertical-align: top">No Contravention</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">35</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.05</TD>
    <TD STYLE="vertical-align: top">Not Insolvent</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">35</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.06</TD>
    <TD STYLE="vertical-align: top">Approvals and Consents</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">35</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.07</TD>
    <TD STYLE="vertical-align: top">Welfare and Pension Plans</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">35</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.08</TD>
    <TD STYLE="vertical-align: top">Changes Since Date of Financial Statements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">35</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.09</TD>
    <TD STYLE="vertical-align: top">No Default Under Agreements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">36</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.10</TD>
    <TD STYLE="vertical-align: top">Title to Assets</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">37</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.11</TD>
    <TD STYLE="vertical-align: top">Financial Matters</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">37</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.12</TD>
    <TD STYLE="vertical-align: top">No Material Adverse Change</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">37</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.13</TD>
    <TD STYLE="vertical-align: top">Environmental Matters</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">37</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.14</TD>
    <TD STYLE="vertical-align: top">Assets in Good Condition</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">38</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.15</TD>
    <TD STYLE="vertical-align: top">Licenses and Agreements</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">38</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.16</TD>
    <TD STYLE="vertical-align: top">Tax Matters</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">38</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.17</TD>
    <TD STYLE="vertical-align: top">Insurance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">38</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.18</TD>
    <TD STYLE="vertical-align: top">Intellectual Property</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">39</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.19</TD>
    <TD STYLE="vertical-align: top">Permits</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">39</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.20</TD>
    <TD STYLE="vertical-align: top">Regulatory Required Permits</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">39</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.21</TD>
    <TD STYLE="vertical-align: top">Compliance with Laws and Litigation</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.22</TD>
    <TD STYLE="vertical-align: top">Material Facts Disclosed</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.23</TD>
    <TD STYLE="vertical-align: top">No Rights to Acquire Assets</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.24</TD>
    <TD STYLE="vertical-align: top">No Rights to Provide Financial Advisory Services</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.25</TD>
    <TD STYLE="vertical-align: top">Chief Executive Office and Location of Assets</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">40</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.26</TD>
    <TD STYLE="vertical-align: top">Minute Books</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.27</TD>
    <TD STYLE="vertical-align: top">Use of Proceeds; Margin Stock</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.28</TD>
    <TD STYLE="vertical-align: top">Investment Company Act</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.29</TD>
    <TD STYLE="vertical-align: top">Bank Accounts</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.30</TD>
    <TD STYLE="vertical-align: top">Shares and Corporate Structure</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">41</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.31</TD>
    <TD STYLE="vertical-align: top">Liabilities</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">42</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.32</TD>
    <TD STYLE="vertical-align: top">Employee Matters</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">42</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.33</TD>
    <TD STYLE="vertical-align: top">Non-Arm&rsquo;s Length Transactions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">43</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.34</TD>
    <TD STYLE="vertical-align: top">Description of Real Property</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">43</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 5.35</TD>
    <TD STYLE="vertical-align: top">Application of Section to New Subsidiaries</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">43</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE VI. COVENANTS </TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">43</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.01</TD>
    <TD STYLE="vertical-align: top">Use of Proceeds</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">43</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.02</TD>
    <TD STYLE="vertical-align: top">Payment of Principal and Interest; Secured Obligations</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">43</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.03</TD>
    <TD STYLE="vertical-align: top">Lender Expenses</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.04</TD>
    <TD STYLE="vertical-align: top">Compliance with Laws; Permits; Corporate Existence</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.05</TD>
    <TD STYLE="vertical-align: top">Delivery of Collateral and Perfection</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.06</TD>
    <TD STYLE="vertical-align: top">Collateral</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 20%; padding-left: 0.5in">Section 6.07</TD>
    <TD STYLE="vertical-align: top; width: 70%">Operating Leases</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right">44</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.08</TD>
    <TD STYLE="vertical-align: top">Insurance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">44</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.09</TD>
    <TD STYLE="vertical-align: top">Transactions with Affiliates</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.10</TD>
    <TD STYLE="vertical-align: top">Material Agreement</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.11</TD>
    <TD STYLE="vertical-align: top">Reporting</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.12</TD>
    <TD STYLE="vertical-align: top">Healthcare Regulatory Matters</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">45</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.13</TD>
    <TD STYLE="vertical-align: top">Accounts</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">46</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.14</TD>
    <TD STYLE="vertical-align: top">Negative Covenants</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">46</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.15</TD>
    <TD STYLE="vertical-align: top">Maintenance of Records</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">47</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.16</TD>
    <TD STYLE="vertical-align: top">Notices</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.17</TD>
    <TD STYLE="vertical-align: top">Limitations on Modifications, Waivers, Extensions</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.18</TD>
    <TD STYLE="vertical-align: top">Financial Covenant</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">48</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.19</TD>
    <TD STYLE="vertical-align: top">Intellectual Property</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">49</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.20</TD>
    <TD STYLE="vertical-align: top">Pension Plans</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.21</TD>
    <TD STYLE="vertical-align: top">Material Subsidiaries</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 6.22</TD>
    <TD STYLE="vertical-align: top">Centre of Main Interests</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">50</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE VII. CONDITIONS </TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">51</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 7.01</TD>
    <TD STYLE="vertical-align: top">Conditions Precedent to the Initial Extension of Credit</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">51</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 7.02</TD>
    <TD STYLE="vertical-align: top">Conditions Precedent to all Extensions of Credit</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE VIII. EVENTS OF DEFAULT </TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">53</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.01</TD>
    <TD STYLE="vertical-align: top">Events of Default</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">53</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.02</TD>
    <TD STYLE="vertical-align: top">Lender&rsquo;s Remedies Upon Default</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">56</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.03</TD>
    <TD STYLE="vertical-align: top">Lender Protective Payments</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">57</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.04</TD>
    <TD STYLE="vertical-align: top">Remedies Cumulative</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">57</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.05</TD>
    <TD STYLE="vertical-align: top">Power of Attorney</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">57</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.06</TD>
    <TD STYLE="vertical-align: top">Notice of Event of Default</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">58</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.07</TD>
    <TD STYLE="vertical-align: top">Default under Other Encumbrances</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">58</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.08</TD>
    <TD STYLE="vertical-align: top">Judgment</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">58</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.09</TD>
    <TD STYLE="vertical-align: top">Application of Proceeds</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">58</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.10</TD>
    <TD STYLE="vertical-align: top">Limitation of Liability</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">59</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 8.11</TD>
    <TD STYLE="vertical-align: top">Borrower Liable</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">59</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-weight: bold; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-weight: bold">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; font-weight: bold">ARTICLE IX. GENERAL </TD>
    <TD STYLE="vertical-align: bottom; text-align: right; font-weight: bold">59</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.01</TD>
    <TD STYLE="vertical-align: top">Releases</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">59</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.02</TD>
    <TD STYLE="vertical-align: top">Governing Law; Jurisdiction; Jury Trial Waiver and Judicial&nbsp;&nbsp;Reference</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">60</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.03</TD>
    <TD STYLE="vertical-align: top">Whole Agreement</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">60</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.04</TD>
    <TD STYLE="vertical-align: top">Time</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">60</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.05</TD>
    <TD STYLE="vertical-align: top">Notices</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">60</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.06</TD>
    <TD STYLE="vertical-align: top">Successors and Assigns</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">62</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.07</TD>
    <TD STYLE="vertical-align: top">Indemnification</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">62</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.08</TD>
    <TD STYLE="vertical-align: top">No Set-Off</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0.5in">Section 9.09</TD>
    <TD STYLE="vertical-align: top">Permitted Encumbrance</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">63</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; padding-left: 0.5in">Section 9.10</TD>
    <TD STYLE="width: 70%">Press Releases</TD>
    <TD STYLE="width: 10%; text-align: right; vertical-align: bottom">63</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">Section 9.11</TD>
    <TD>Confidentiality</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">63</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in">Section 9.12</TD>
    <TD>Judgment Currency</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">63</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in">Section 9.13</TD>
    <TD>Anti-Money Laundering Legislation</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">64</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in">Section 9.14</TD>
    <TD>Counterparts</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">65</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CREDIT AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>CREDIT AGREEMENT</B>
(as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Agreement</B>&rdquo;) dated as of July
30, 2018, by and among Profound Medical Inc., an Ontario corporation, as borrower (&ldquo;<B>Borrower</B>&rdquo;), Profound Medical
Corp., an Ontario corporation, as a guarantor (&ldquo;<B>Parent</B>&rdquo;), Profound Medical GmbH, a German limited liability
company (<I>Gesellschaft mit beschr&auml;nkter Haftung</I>), as a guarantor (&ldquo;<B>PM Germany</B>&rdquo;) and Profound Medical
(U.S.) Inc., a Delaware corporation, as a guarantor (&ldquo;<B>PM USA</B>&rdquo;) and Canadian Imperial Bank of Commerce, as lender
(&ldquo;<B>Lender</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B> the
Borrower has requested that Lender extend credit to it in a maximum aggregate principal amount of up to $18,750,000 for the various
purposes set out herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B> the
Borrower is a wholly-owned subsidiary of Parent and PM Germany and PM USA are each a wholly-owned subsidiary of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B> Parent,
PM Germany and PM USA have agreed to guarantee the obligations of the Borrower hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>AND WHEREAS</B>
Lender is willing to extend such credit on and subject to the terms and conditions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW THEREFORE</B>
in consideration of the covenants and agreements herein the parties hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE
I.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INTERPRETATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">In this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Account Debtor</B>&rdquo; means a person
obligated on an Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Accounts</B>&rdquo; has the meaning given
to such term in the PPSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Acquisition</B>&rdquo;
means, with respect to any Person, any purchase or other acquisition by such Person, regardless of how accomplished or effected
(including any such purchase or other acquisition effected by way of amalgamation, merger, arrangement, business combination or
other form of corporate reorganization or by way of purchase, lease or other acquisition arrangements), of (a) any other Person
(including any purchase or acquisition of such number of the issued and outstanding securities of, or such portion of an Equity
Interest in, such other Person so that such other Person becomes a Subsidiary of the purchaser or of any of its Affiliates) or
of all or a material portion of of the Property of any other Person, or (b) any division, business, operation or undertaking of
any other Person or of all or a material portion of the Property of any division, business, operation or undertaking of any other
Person or (c) any material real estate asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Additional Documents</B>&rdquo; has the
meaning set forth in <U>Section 4.05.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, another Person that directly, or indirectly through one or more intermediaries, Controls or
is Controlled by or is under common Control with the Person specified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Agreement</B>,&rdquo;
 &ldquo;<B>hereto</B>,&rdquo; &ldquo;<B>herein</B>,&rdquo; &ldquo;<B>hereof</B>,&rdquo; &ldquo;<B>hereby</B>,&rdquo; &ldquo;<B>hereunder</B>,&rdquo;
and any similar expressions refer to this Agreement and the schedules attached hereto and not to any particular article, section
or other portion hereof, and include any and every instrument supplemental hereto or amending or replacing any part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Applicable Law</B>&rdquo;
means, in respect of any Person, property, transaction, event or other matter, as applicable, all Laws relating or applicable to
such Person, property, transaction, event or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Board</B>&rdquo; means
a Person&rsquo;s board of directors, board of managers, board of members or similar governing body, provided that, unless otherwise
specified, &ldquo;Board&rdquo; shall refer to the applicable Loan Party&rsquo;s Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Borrower</B>&rdquo;
has the meaning set forth in the preamble to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Budget</B>&rdquo; means
the consolidated and consolidating projections and budget, prepared annually on a monthly basis, for Parent and its Subsidiaries
adopted and approved by Parent&rsquo;s Board for the given period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Business Day</B>&rdquo;
means a day other than a Saturday, Sunday or any other day on which banks located in the City of Toronto, Province of Ontario are
not open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Canadian Dollars</B>&rdquo; and &ldquo;<B>$</B>&rdquo;
mean lawful money of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Canadian Guarantee</B>&rdquo; has the meaning set forth in <U>Section 4.01(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Canadian IP Security Agreement</B>&rdquo;
has the meaning set forth in <U>Section 4.01(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Canadian Pension Plan</B>&rdquo;
means any &ldquo;pension plan&rdquo; that is subject to the funding requirements of the <I>Pension Benefits Act</I> (Ontario) or
applicable pension benefits legislation in any other Canadian jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Canadian Security Agreement</B>&rdquo;
has the meaning set forth in <U>Section 4.01(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Capital Lease</B>&rdquo;
means any lease that would be considered to be a capital lease in accordance with GAAP; provided, that any lease that would be
considered to be an operating lease in accordance with GAAP on the date of this agreement shall not be considered to be a Capital
Lease notwithstanding any change in GAAP after such date that may reclassify it as a capital lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Cash Equivalents</B>&rdquo;
means (a) marketable direct obligations issued or unconditionally guaranteed by the United States, the Government of Canada or
any agency or any State or Province, as applicable, thereof having maturities of not more than one (1) year from the date of acquisition;
(b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &amp;
Poor&rsquo;s Ratings Group or Moody&rsquo;s Investors Service, Inc.; (c) certificates of deposit issued maturing no more than one
(1) year after issue; (d) money market funds at least ninety-five percent (95%) of the assets of which constitute Cash Equivalents
of the kinds described in <U>clauses (a) through (c)</U> of this definition; and (e) comparable instruments as those described
in <U>clauses (a) through (d)</U> for any Loan Party that is not formed under the federal or provincial laws of Canada and operates
in a jurisdiction outside of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Casualty Event</B>&rdquo;
means, with respect to any Property of any Person, any loss of or damage to, or any condemnation or other taking of, such Property
for which such Person or any of its Subsidiaries receives insurance proceeds, or proceeds of a condemnation award or other compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>CDOR</B>&rdquo; means,
on any date, the annual rate of interest which is the rate based on an average rate applicable to Canadian Dollar bankers&rsquo;
acceptances for a specified term appearing on the &ldquo;Reuters Screen CDOR Page&rdquo; (as defined in the International Swaps
and Derivatives Association, Inc., definitions, as modified and amended from time to time) at approximately 10:00 a.m. (Toronto
time), on such date, or if such date is not a Business Day, then on the immediately preceding Business Day, <I>provided</I> that
if such rate does not appear on the Reuters Screen CDOR Page on such date as contemplated, then CDOR on such date shall be the
rate for the term referred to above applicable to Canadian Dollar bankers&rsquo; acceptances quoted by the Lender as of 10:00 a.m.
(Toronto time) on such date or, if such date is not a Business Day, then on the immediately preceding Business Day; <I>provided
further</I>, that if CDOR is less than zero, it shall be deemed to be zero hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Centre of Main Interests</B>&rdquo;
means the &ldquo;centre of main interests&rdquo; of a Loan Party incorporated in a member state of the European Union as that term
is used in Article 3(1) of Regulation (EU) 2015/848 of the European Parliament and of the Council of 20 May 2015 on insolvency
proceedings (recast).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Change of Control</B>&rdquo;
means, unless otherwise waived in writing by Lender, (a) the consummation of any transaction (including, without limitation, any
plan of arrangement, merger, amalgamation or consolidation) the result of which is that any Person or group of Persons acquires
or otherwise beneficially owns, directly or indirectly, or acquires or has the voting power and/or investment power in respect
of, 50% or more of the Shares of Parent; (b) the first day on which a majority of the members of the Board of the Parent are not
Continuing Directors; (c) if any Loan Party that is a Subsidiary of Parent ceases to be a wholly-owned Subsidiary of Parent or
any Subsidiary thereof, or any other Subsidiary ceases to be Controlled by Parent, other than as a result of an amalgamation with
a Loan Party or any other Subsidiary permitted hereunder; or (d) if there is an indirect event or transaction similar to the events
or transactions described above which has the same result or effect as the events or transactions described above whereby: (i)
with respect to any Loan Party other than the Parent, any Person or group of Persons other than an Existing Shareholder shall acquire
the right or ability to effectively Control any such Loan Party, and (ii) with respect to the Parent, any Person or group of Persons
shall acquire the right or ability to effectively Control the Parent. &ldquo;<B>Existing Shareholder</B>&rdquo; shall mean the
shareholders of each Loan Party as of the Closing Date set forth on Schedule 5.31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Change in Law</B>&rdquo;
means the occurrence, after the date of this Agreement, of any of the following: (a) the adoption or taking effect of any Law,
(b) any change in any Law or in the administration, interpretation, implementation or application thereof by any Governmental Authority
or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law, but in the
case of a request, rule, guideline or directive not having the force of law, being a request, rule, guideline or directive with
which Persons customarily, and are expected by the relevant Governmental Authority to, comply and nevertheless are considered to
be binding on such Person or its property) by any Governmental Authority; <U>provided</U> that notwithstanding anything herein
to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives
thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for
International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States,
European or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &ldquo;Change
in Law&rdquo;, regardless of the date enacted, adopted or issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Closing Date</B>&rdquo; means the date of
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Closing Fee</B>&rdquo; has the meaning set forth in <U>Section 2.03(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Collateral</B>&rdquo;
means all assets, property (both real and personal) and undertaking that is subject to grant of security pursuant to a Security
Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Collateral Access Agreement</B>&rdquo;
means an agreement, in form and substance reasonably satisfactory to Lender, executed and delivered by a Loan Party and the landlord
with respect to any applicable leased facility, which agreement is sufficient to give Lender access to any Collateral located at
such leased facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Commitment Fee</B>&rdquo;
has the meaning set forth in <U>Section 2.03(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Compliance Certificate</B>&rdquo; means
a certificate in the form of <U>Exhibit B</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Continuing Directors</B>&rdquo;
means, as of any date of determination, any member of the Board of any Loan Party or any of their respective Subsidiaries (1) who
was a member of such Board on the Closing Date or (2) whose election or nomination for election to such Board has been approved
by a majority of the Continuing Directors who were at the time of such nomination or election members of such Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Control</B>&rdquo;
means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a
Person, whether through the ability to exercise voting power by contract or otherwise; &ldquo;<B>Controlling</B>&rdquo;, &ldquo;<B>Controlled</B>&rdquo;
and &ldquo;<B>Controls</B>&rdquo; have meanings correlative thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Control Agreement</B>&rdquo;
means an agreement, in form and substance reasonably satisfactory to Lender, executed and delivered by a Loan Party and the applicable
securities intermediary or bank, which agreement is sufficient to give Lender &ldquo;control&rdquo; over the subject Securities
Account, Deposit Account or Investment Property under the PPSA or applicable foreign Law, as applicable, and in the case of a Deposit
Account governed by Canadian laws, shall include a blocked account agreement the effect of which would be similar to a control
agreement even though it may not be required for &ldquo;control&rdquo; under Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Default</B>&rdquo;
means any event specified in <U>Section 8.01</U> hereof, whether or not any requirement in connection with such event for the giving
of notice, lapse of time or happening of any further condition has been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Deposit Account</B>&rdquo;
means any checking account, demand deposit account or other deposit or bank account maintained by a Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Disposition</B>&rdquo;
means any sale, assignment, transfer or other disposition of any Property (whether now owned or hereafter acquired) by a Loan Party
or any of its Subsidiaries to any other Person excluding any sale, assignment, transfer or other disposition of any Property sold
or disposed of in the ordinary course of business and on ordinary business terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>End of Term Payment</B>&rdquo;
has the meaning set forth in <U>Section 3.03.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Environmental Laws</B>&rdquo;
means any and all present and future federal, provincial, state, local and foreign laws, rules or regulations, and any orders or
decrees, in each case as now or hereafter in effect, relating to the regulation or protection of human health, safety or the environment
or to emissions, discharges, releases or threatened releases of pollutants, contaminants, chemicals or toxic or hazardous substances
or wastes into the indoor or outdoor environment, including, without limitation, ambient air, soil, surface water, ground water,
wetlands, land or subsurface strata, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage,
disposal, transport or handling of pollutants, contaminants, chemicals or toxic or hazardous substances or wastes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Equipment</B>&rdquo;
has the meaning given to such term in the PPSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Equity Interests</B>&rdquo;
means (a) in the case of any corporation or company, all shares or capital stock and any securities exchangeable for or convertible
into shares or capital stock, (b) in the case of an association or business entity, any and all shares, interests, participation
rights or other equivalents of corporate stock (however designated) in or to such association or entity, (c) in the case of a partnership,
limited liability company or unlimited liability company, partnership or membership interests (whether general or limited), as
applicable, and (d) any other interest or participation that confers on a Person the right to receive a share of the profits and
losses of, or distribution of assets of, the issuing Person, and including, in all of the foregoing cases described in <U>clauses
(a), (b), (c) or (d)</U>, any warrants, rights or other options to purchase or otherwise acquire any of the interests described
in any of the foregoing cases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Establishment</B>&rdquo;
has the meaning as used in Article 2(10) of Regulation (EU) 2015/848 of the European Parliament and of the Council of 20 May 2015
on insolvency proceedings (recast).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Event of Default</B>&rdquo;
has the meaning set forth in <U>Section 8.01.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Exchange Rate</B>&rdquo;
means, in relation to the conversion of one currency into another currency, the spot rate of exchange quoted for by the Lender
in accordance with its usual practice at 11:00am Toronto time on the Business Day such conversion is to be made in accordance with
its normal practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Excluded Accounts</B>&rdquo;
means collectively (a) non-collection Deposit Accounts that collectively hold an aggregate of no more than $500,000, (b) for the
period beginning on the Closing Date and terminating 90 days thereafter, Deposit Accounts that are located in Canada and collectively
hold an aggregate of no more than $2,000,000 and (c) Deposit Accounts that are located in Canada and maintained with the Lender
or an Affiliate of the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Excluded Taxes</B>&rdquo;
means, any of the following Taxes imposed on or with respect to the Lender or required to be withheld or deducted from a payment
to the Lender, (a) Taxes imposed on or measured by net income (however denominated), franchise or capital Taxes, and branch profits
Taxes, in each case, imposed as a result of the Lender being organized under the laws of, or having its principal office or its
applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof), (b) withholding
Taxes of the United States imposed on amounts payable to or for the account of the Lender with respect to an applicable interest
in a Loan pursuant to a Law in effect on the date on which (i) the Lender acquires by assignment such interest in a Loan or (ii)
the Lender changes its lending office, except in each case to the extent that, pursuant to <U>Section 3.10(c)</U>, amounts with
respect to such Taxes were payable either to the Lender&rsquo;s assignor immediately before the Lender became a party hereto or
to the Lender immediately before it changed its lending office, and (c) Taxes imposed under FATCA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Existing Loan Facility</B>&rdquo;
means the loan by Knight Therapeutics Inc. in favour of Borrower established pursuant to the loan agreement dated as of April 30,
2015 among Knight Therapeutics Inc. and Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>FATCA</B>&rdquo; means
sections 1471 through 1474 of the Internal Revenue Code (U.S.), as of the date of this Agreement (or any amended or successor version
that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official
interpretations thereof, any intergovernmental agreement or foreign legislation (including official administrative rules or practices)
implemented to give effect to any intergovernmental agreements entered into thereunder and any agreements entered into pursuant
to section 1471(b) of the Internal Revenue Code (U.S.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Financing Documents</B>&rdquo;
means this Agreement, the Canadian Guarantee, any other Guarantee, the Security Documents, all Additional Documents and any other
document, instrument or agreement now or hereafter entered into in connection with the Secured Obligations or the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>GAAP</B>&rdquo; means
generally accepted accounting principles which are in effect from time to time in Canada, and which on the Closing Date encompass
International Financial Reporting Standards adopted by the Canadian Accounting Standards Board provided that if the Loan Parties
convert its consolidated financial reporting to US GAAP, in accordance with <U>Section 1.08, </U>then GAAP shall mean US GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>German Security Agreements</B>&rdquo;
has the meaning set forth in Section 4.01(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Governing Documents</B>&rdquo;
means, for any Person, such Person&rsquo;s formation documents, as certified by the applicable governmental agency of such Person&rsquo;s
jurisdiction of organization (provided that in case of any later updates to such certified documents a print-out from the electronic
commercial register will be sufficient), and, (a) if such Person is a corporation, its certificate of incorporation or formation
and bylaws, (b) if such Person is a limited liability company, its certificate of incorporation and/or limited liability company
agreement (or similar agreement), and (c) if such Person is a partnership or limited partnership, its partnership agreement (or
similar agreement), in each case, including all amendments or modifications thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Governmental Authority</B>&rdquo;
means any nation or government, any provincial, state or other political subdivision thereof, any agency, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
functions of or pertaining to government, any securities exchange and any self-regulatory organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Guarantee</B>&rdquo;
means any guarantee of the Secured Obligations entered into on or after the Closing Date by any Person required to provide a Guarantee
in accordance with the terms of this Agreement (including, without limitation, pursuant to <U>Section 4.01 </U> and <U>Section
4.03</U> hereof) and which for greater certainty shall include the Canadian Guarantee, which shall be in form and substance satisfactory
to the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Guarantor</B>&rdquo;
means, collectively, (i) Parent, PM Germany and PM USA, and (ii) any person providing a Guarantee in favor of Lender under the
terms of <U>Section 4.03.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Hazardous Materials</B>&rdquo; has the meaning
set forth in <U>Section 5.13.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Healthcare Laws</B>&rdquo;
means, collectively, any and all federal, state, provincial or local laws, rules, regulations and administrative manuals, orders,
guidelines and requirements issued under or in connection with any government payment program or any law governing the establishment,
certification, licensure of or regulating healthcare providers, professionals, facilities (including nursing facilities), medical
devices, medications or payors or otherwise governing or regulating the provision of, or payment for, medical and healthcare services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Hedge Arrangement</B>&rdquo;
means, for any period, for any Person, any arrangement or transaction between such Person and any other Person which is an interest
rate swap transaction, basis swap, forward interest rate transaction, commodity swap, interest rate option, forward foreign exchange
transaction, cap transaction, floor transaction, collar transaction, currency swap transaction, cross-currency interest rate swap
transaction, currency option or any other similar transaction (including any option with respect to any of such transactions or
arrangements) designed to protect or mitigate against risks in interest, currency exchange or commodity price fluctuations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indebtedness</B>&rdquo;
of a Loan Party or any of its Subsidiaries, as the case may be, means, without duplication:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all of its indebtedness for or in respect of borrowed
money, credit or other financial accommodation, including liabilities and obligations with respect to letters of credit, letters
of guarantee, bankers&rsquo; acceptances or similar instruments issued or accepted by banks and other financial institutions for
the account of such Loan Party or any of its Subsidiaries and all obligations evidenced by notes, bonds, debentures or other similar
instruments;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">all obligations for or in respect of the deferred purchase
or acquisition price of Property or services, whether or not recourse is limited to the repossession and sale of any such Property;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">all obligations under any lease entered into as lessee
which would be classified as a capital lease in accordance with GAAP;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">all obligations of it to purchase, redeem, retract or
otherwise acquire any securities issued by such Loan Party or any of its Subsidiaries where such obligation has been exercised
or otherwise become payable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">all obligations under Hedge Arrangements; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">all guarantees by such Loan Party or any of its Subsidiaries
or any of its Subsidiaries of any of the foregoing, or obligations of such Loan Party or any of its Subsidiaries to purchase or
acquire any of the foregoing, or any other assurance given by such Loan Party or any of its Subsidiaries to a creditor of another
Person against loss in connection with any of the foregoing incurred by such other Person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">but &ldquo;Indebtedness&rdquo;
shall not include unsecured trade debt incurred in the ordinary course of business, issued share capital or surplus, reserves (including,
for certainty, reserves in connection with purchase orders) for deferred taxes or general contingencies, minority interests in
Subsidiaries, operating leases, nor any contingent liabilities in connection with contracts entered into in the ordinary course
of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indemnified Claim</B>&rdquo;
has the meaning set forth in <U>Section 9.05.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Indemnified Person</B>&rdquo; has the meaning
set forth in <U>Section 9.07.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Indemnified Taxes</B>&rdquo;
means Taxes, other than Excluded Taxes imposed on or with respect to any payment made by or on account of any obligation of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Insolvency Legislation</B>&rdquo;
means legislation in any applicable jurisdiction relating to reorganization, arrangement, compromise or re-adjustment of debt,
dissolution or winding-up, or any similar legislation, and specifically includes for greater certainty the <I>BIA</I>, the <I>Companies&rsquo;
Creditors Arrangement Act</I> (Canada), the <I>German Insolvency Code (Insolvenzordnung)</I> (Germany), the <I>Winding-Up and Restructuring
Act</I> (Canada) and the <I>Bankruptcy Code</I> (United States), together with any other similar statutes (including corporate
statutes) in Canada or any other applicable jurisdiction in which any Loan Party operates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Insolvency Proceeding</B>&rdquo;
is any proceeding by or against any Person under any Insolvency Legislation, or any other bankruptcy or insolvency law, including
assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization,
arrangement, or other relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Instruments</B>&rdquo;
has the meaning given to such term in the PPSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property</B>&rdquo;
means the following properties and assets owned or held or in which the applicable Person otherwise has any interest, now existing
or hereafter acquired or arising:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">all patents and patent applications, domestic or foreign,
all licenses relating to any of the foregoing and all income and royalties with respect to any licenses, all rights to sue for
past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions,
continuations, renewals, extensions and continuations-in-part thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">all copyrights and applications for copyright, domestic
or foreign, together with the underlying works of authorship (including titles), whether or not the underlying works of authorship
have been published and whether said copyrights are statutory or arise under the common law, and all other rights and works of
authorship, all computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible
Property embodying or incorporating any copyrights, all licenses relating to any of the foregoing and all income and royalties
with respect to any licenses, and all other rights, claims and demands in any way relating to any such copyrights or works, including
royalties and rights to sue for past, present or future infringement, and all rights of renewal and extension of copyright;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">all state and provincial (including common law), federal
and foreign trade-marks, service marks and trade names, and applications for registration of such trademarks, service marks and
tradenames, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses, whether registered
or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof,
all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">all technology created, developed or acquired by such
Person, trade secrets, trade dress, trade styles, logos, other sources of business identifiers, mask-works, mask-work registrations,
mask-work applications, software, proprietary or confidential information, customer lists, license rights, advertising materials,
operating manuals, methods, processes, know-how, techniques, research, studies, algorithms, formulae, databases, quality control
procedures, product, service and technical specifications and data, operating, production and quality control manuals, sales literature,
drawings, specifications, blue prints, descriptions, inventions, name plates and catalogs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">all domain names, internet protocol addresses and uniform
resource locators used in the business and all applications, registrations and rights therein and thereto;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">the entire goodwill of or associated with the businesses
now or hereafter conducted connected with and symbolized by any of the aforementioned properties and assets; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">all accounts, all intangible intellectual or other similar
Property and other general intangibles associated with or arising out of any of the aforementioned properties and assets and not
otherwise described above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Intellectual Property
Security Agreements</B>&rdquo; means (i) the Canadian IP Security Agreement, the (ii) US IP Security Agreement, and (iii) any other
security agreement covering the Intellectual Property of the Loan Parties, in each case as amended, restated, supplemented or otherwise
modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Investment</B>&rdquo; means any direct or
indirect:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">purchase or other acquisition of Equity Interest or other
securities of any other Person or any beneficial interest therein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">purchase or other acquisition of bonds, notes, debentures
or other debt securities of any other Person or beneficial interest therein;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">loan or advance to any other Person; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">capital contribution to any other Person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Investment Property</B>&rdquo; has the meaning
given to such term in the PPSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>ITA</B>&rdquo; means the <I>Income Tax Act
</I>(Canada), as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Law</B>&rdquo; means any statute, law, ordinance,
regulation, rule, order, writ, injunction, policies, practices, directives, guidelines or decree of any Tribunal, and which for
greater certainty shall include Healthcare Laws and any policies, practices, directives or guidelines of the TSX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Lender</B>&rdquo; has
the meaning set forth in the preamble to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Lender Expenses</B>&rdquo;
means all reasonable fees, costs, expenses (including, without limitation, reasonable attorneys&rsquo; and other legal fees, costs
and expenses and audit fees), or any other reasonable charges incurred by Lender in the negotiation, preparation, amendment, administration,
monitoring, defense, enforcement and restructuring of the Financing Documents (including without limitation, those incurred after
appeal or in Insolvency Proceedings) or the exercise of remedies pursuant thereto, or otherwise incurred by Lender with respect
to any Loan Party or the Financing Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Lien</B>&rdquo; means
any lien, mortgage, charge, hypothecation, pledge, security interest, prior assignment, option, warrant, lease, sublease, right
to possession, right of distress, encumbrance, claim, right or restriction which affects, by way of a conflicting ownership interest
or otherwise, the right, title or interest in or to any particular property. For purposes of the Financing Documents, a Person
shall be deemed to own subject to a Lien any property that it has acquired or holds subject to the interest of a vendor or lessor
under any conditional sale agreement, capital lease or other title retention agreement relating to such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Loan Account</B>&rdquo;
has the meaning set forth in <U>Section 2.05.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Loan Parties</B>&rdquo;
means Borrower, Parent and each Guarantor from time to time party hereto or any other Financing Document, collectively, and &ldquo;<B>Loan
Party</B>&rdquo; means any one of such parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Loans</B>&rdquo; means
the Term Loans and any other amounts owing to Lender by Borrower under the Financing Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Adverse Change</B>&rdquo;
means a material adverse change in the business, assets, operations, prospects or condition, financial or otherwise, of the Borrower
or any other Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Adverse Effect</B>&rdquo;
means a material adverse effect on (a) the business, assets, liabilities (actual or contingent), financial condition, operations,
performance or properties of the Loan Parties and their Subsidiaries taken as a whole, (b) the ability of the Loan Parties to perform
their obligations under the Financing Documents, (c) the validity or enforceability of the Financing Documents or the Lien granted
to Lender thereunder, or (d) the rights and remedies of Lender under the Financing Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Agreements</B>&rdquo;
any contract, agreement, license, sublicense, supply agreement, permit, lease or other instrument, the termination of which would
reasonably be expected to have a Material Adverse Effect, including, without limitation, the agreements set forth on <U>Schedule
5.09.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Intellectual
Property</B>&rdquo; means all Intellectual Property and license or sublicense agreements or other agreements with respect to rights
in Intellectual Property, of any Loan Party or any of its Subsidiaries, that is material to the business or operations of the Loan
Parties on a consolidated basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Material Subsidiary</B>&rdquo;
means (i) each present and future Subsidiary of Parent that at any time individually accounts for more than 7.5% of either the
revenue or assets of Parent on a consolidated basis, (ii) each present and future Subsidiary of Parent that at any time, when aggregated
with all other Subsidiaries that are not Loan Parties, accounts for more than 15% of either the revenue or assets of Parent on
a consolidated basis and (iii) each other present and future Subsidiary of Parent that is a party to a Material Agreement or holds
any Intellectual Property that is material to Parent&rsquo;s or Borrower&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Maturity Date</B>&rdquo;
means July 29, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Monthly Interest Amount</B>&rdquo;
has the meaning set forth in the defined term &ldquo;Term Loan Interest Rate&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Net Available Proceeds</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">in the case of any Disposition, the amount of Net Cash
Payments received in connection with such Disposition; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in the case of any Casualty Event, the aggregate amount
of proceeds of insurance, condemnation awards and other compensation received by a Loan Party or any of its Subsidiaries in respect
of such Casualty Event net of (A) reasonable expenses incurred by a Loan Party or any of its Subsidiaries in connection therewith
and (B) contractually required repayments of Indebtedness to the extent secured by a Lien on such property and any income and
transfer taxes payable by a Loan Party or any of its Subsidiaries in respect of such Casualty Event.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Net Cash Payments</B>&rdquo;
means, with respect to any Disposition, the aggregate amount of all cash payments, and the fair market value of any non-cash consideration,
received by a Loan Party or any of its Subsidiaries directly or indirectly in connection with such Disposition; provided that Net
Cash Payments shall be net of (i) the amount of any legal, title and recording tax expenses, commissions and other fees and expenses
paid by a Loan Party or any of its Subsidiaries in connection with such Disposition and (ii) any federal, provincial, state and
local income or other taxes estimated to be payable by a Loan Party or any of its Subsidiaries as a result of such Disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Non-Canadian Pension
Plan</B>&rdquo; means any &ldquo;pension plan&rdquo;, scheme, fund (including any superannuation fund) or other similar program
established, sponsored or maintained outside of Canada by any Loan Party primarily for the benefit of employees of such Loan Party
residing outside Canada, which is subject to statutory funding requirements in advance of the payment of pension benefits thereunder,
and which plan is not subject to the funding requirements of the <I>Pension Benefits Act</I> (Ontario) or applicable pension benefits
legislation in any other Canadian jurisdiction. For clarity Non-Canadian Pension Plan shall include, without limitation, any such
plan maintained in Germany.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Operating Cash Expenditures</B>&rdquo;
means the aggregate of all operating expenses of the Loan Parties on a consolidated basis, including, without limitation, all expenditures
associated with the maintenance, administration and operation of the Loan Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Parent</B>&rdquo; has
the meaning set forth in the preamble to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Pension Plan</B>&rdquo;
means a Canadian Pension Plan or a Non-Canadian Pension Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Pension Plan Event</B>&rdquo;
means, to the extent a Loan Party or a Subsidiary forms or acquires a Pension Plan after the Closing Date, (i) the institution
of any steps by any Loan Party or any applicable regulatory authority to terminate a Pension Plan if, as a result of such termination,
any such Loan Party shall be required to make an additional contribution to such Pension Plan or to incur an additional liability
or obligation to such Pension Plan equal to or in excess of $250,000; or (ii) the taking of any steps to establish, fund or otherwise
contribute to a Canadian Pension Plan that contains a &ldquo;defined benefit provision&rdquo; as such term is defined under the
ITA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Permit</B>&rdquo; has
the meaning set forth in <U>Section 5.19.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Acquisition</B>&rdquo; means any
Acquisition that complies with the following criteria:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">no Event of Default exists at the time of such Acquisition
or would exist after giving effect to such Acquisition;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Acquisition is non-hostile in nature;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the person, division, product line of business acquired
in such Acquisition shall be in the same or substantially similar line of business as Borrower or in an adjacent line of business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the total aggregate consideration for the Acquisition,
together with all other Acquisitions hereunder, is not greater than $10,000,000;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">if the Acquisition is of a Material Subsidiary, it shall
provide a Guarantee and deliver such Security Documents and certificates as are consistent with the documentation provided to
the Lender by a Loan Party and comply with the requirements of <U>Section 4.01</U> and <U>Section 4.03,</U> and if it is an Acquisition
of assets it shall otherwise comply with <U>Article IV</U>; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">the Loan Parties (i) demonstrate pro forma compliance
with the financial covenant set out in <U>Section 6.19</U> for the trailing three month period ending immediately prior to the
date of the proposed Acquisition before giving effect to such Acquisition and, (ii) reasonably project that the Loan Parties will
remain in compliance for the following two (2) fiscal quarters with such financial covenant after giving effect to such Acquisition.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Distribution</B>&rdquo; means
any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the conversion of any convertible securities into other
securities pursuant to the terms of such convertible securities as long as the conversion does not involve any payment of cash;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the payment of dividends solely in equity securities
a Loan Party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the payment of dividends or other distributions in cash
from any Loan Party to any other Loan Party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">payment of dividends by the Parent pursuant to the then
most recent Budget in an amount up to 115% of the amount set forth in such Budget provided that no Event of Default exists and
is continuing;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the repurchase of stock, with the exception of preferred
stock, of former employees, independent directors or consultants pursuant to stock repurchase agreements up to an aggregate of
$250,000 per fiscal year or in connection with a normal course issuer bid.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Encumbrances</B>&rdquo; means
any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Liens set forth on <U>Schedule 1.01 </U>hereto existing
as of the Closing Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Liens for Taxes not at the time due unless contested
in good faith by all necessary proceedings and reserves satisfactory to Lender acting reasonably have been taken;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">rights reserved to or vested in any municipality or governmental
or other public authority by the terms of any lease, license, franchise, grant or permit, or by any statutory provision, to terminate
the same or to require annual or other periodic payments as a condition to the continuance thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">reservations, limitations, provisos and conditions expressed
in any original grants from the Crown or other grants of real or immovable property, or interests therein, which do not materially
affect the use of the affected land for the purpose for which it is used by that Person, and title defects, encroachments or irregularities
or other matters relating to title which are of a minor nature and which in the aggregate do not materially impair the use of
the affected property for the purpose for which it is used by that Person;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">a security interest in cash or governmental obligations
deposited in the ordinary course of business to secure worker&rsquo;s compensation, unemployment insurance, public and statutory
obligations, mechanics&rsquo;, warehousemen&rsquo;s, carriers&rsquo; and other similar liens arising by operation of law in the
ordinary course of business and which are not registered or enforceable against any property of any Loan Party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">Lien created by a judgment of a court of competent jurisdiction,
as long as the judgment is being contested diligently and in good faith by appropriate proceedings or is promptly satisfied by
that Person and does not result in an Event of Default;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">Liens on Equipment securing the unpaid purchase price
thereof and/or Liens securing Capital Leases; provided that the Indebtedness secured thereby (plus any Indebtedness for equipment
financings and Capital Leases as may be set forth on <U>Schedule 1.01</U> hereto) does not exceed $500,000 and such security interest
is limited to the Equipment so leased or acquired;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">Liens granted to Lender to secure the Secured Obligations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">inchoate liens or any rights of distress reserved in
or exercisable under any real property lease or sublease to which any Loan Party is a lessee which secure the payment of rent
or compliance with the terms of such lease or sublease, provided that such rent is not then overdue and such Loan Party is then
in compliance in all material respects with such terms;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">any Lien which does not secure Indebtedness, the satisfaction
of which has been provided for by deposit with the Lender of cash or a surety bond or other security satisfactory to the Lender
in an amount sufficient to pay the liability in respect of such Lien in full; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">any other encumbrances Lender declares in writing to
be Permitted Encumbrance.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&ldquo;<B>Permitted Indebtedness</B>&rdquo;
means any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Indebtedness set forth on <U>Schedule 1.01, </U>existing
as of the Closing Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Secured Obligations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Indebtedness in connection with Capital Leases in an
amount not to exceed $500,000; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">unsecured Indebtedness not otherwise permitted in an
aggregate amount not to exceed $500,000 outstanding in the aggregate at any given time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Investments</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Investments set forth on the <U>Schedule 1.01, </U>existing
as of the Closing Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Investments consisting of Cash Equivalents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Investments in a Loan Party or any Subsidiary, provided
that Investments of the Loan Parties in a Subsidiary that is not a Loan Party shall not exceed $500,000 per fiscal year;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Investments consisting of (a) travel advances and employee
relocation loans and other employee loans and advances in the ordinary course of business, and (a) loans to employees, officers
or directors relating to the purchase of equity securities of any Loan Party pursuant to employee stock purchase plans or agreements
approved by such Loan Party&rsquo;s Board, up to a maximum of $500,000 per annum; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Investments consisting of Securities Accounts (and the
Investment Property therein) in which Lender has a Control Agreement covering such Securities Account.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Person</B>&rdquo; is
to be interpreted broadly and includes any individual, partnership, limited partnership, joint venture, syndicate, sole proprietorship,
company, limited liability company or corporation with or without share capital, unincorporated association, trust, trustee, executor,
administrator or other legal personal representative, regulatory body or agency, government or governmental agency, authority or
entity however designated or constituted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Plan</B>&rdquo; means an employee benefit
or other plan established or maintained by a Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>PM Germany</B>&rdquo; has the meaning set
forth in the preamble to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>PM USA</B>&rdquo; has the meaning set forth
in the preamble to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Post-Default Rate</B>&rdquo; has the meaning
set forth in <U>Section 3.02(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>PPSA</B>&rdquo; means
the <I>Personal Property Security Act</I> (Ontario) as in effect from time to time and the regulations and orders made thereunder,
or, in respect of Collateral located in a Canadian province other than Ontario, the personal property security act, regulations
and orders in effect in such other province from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Prime Rate</B>&rdquo;
means a fluctuating rate of interest per annum, expressed on the basis of a year of 365 or 366 days, as applicable, which is equal
at all times to the greater of (i) the base rate of interest (however designated) of the Lender for determining interest chargeable
by it on Canadian Dollar commercial loans made in Canada; and (ii) 1.00% above CDOR from time to time for one month Canadian Dollar
bankers&rsquo; acceptances having a face amount comparable to the face amount in respect of which the applicable Prime Rate calculation
is being made. Any change in the Prime Rate due to a change in the applicable base rate or CDOR from time to time shall be effective
from and including the effective date of such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Proceedings</B>&rdquo;
has the meaning set forth in <U>Section 5.21.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Product</B>&rdquo;
means each product, process or service under development, developed, manufactured, licensed, distributed, marketed or sold by any
Loan Party and any other similar products or services in which any Loan Party has any proprietary rights or beneficial interests,
which for greater certainty shall include the TULSA-PRO and Sonalleve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Property</B>&rdquo;
means any interest in any kind of property or asset, whether real, personal or mixed, or tangible or intangible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regulatory Authority</B>&rdquo;
means any Governmental Authority that has responsibility in any country or group of countries over the development, manufacture
or commercialization of a Product, including the U.S. Food and Drug Administration, Health Canada and the European Medicines Agency,
and any successor agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regulatory Reporting
Event</B>&rdquo; has the meaning set forth in <U>Section 6.12.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Regulatory Required
Permit</B>&rdquo; means any and all licenses, approvals and permits issues by any Regulatory Authority or any other Governmental
Authority necessary for the testing, manufacture, marketing or sale of any Product by any Loan Party and their respective Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Responsible Officer</B>&rdquo;
means a Loan Party&rsquo;s chief executive officer or chief financial officer. Any document delivered hereunder that is signed
by a Responsible Officer shall be conclusively presumed to have been authorized by all necessary corporate or other action on the
part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Secured Obligations</B>&rdquo;
means all advances to, and debts, liabilities, obligations, covenants and duties of each Loan Party arising under this Agreement
or any other Financing Document or otherwise with respect to any Loan, including, without limitation, Lender Expenses, whether
direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter
arising and including interest and fees that accrue after the commencement by or against any Loan Party of any Insolvency Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Securities Account</B>&rdquo;
has the meaning given to such term in the PPSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Security Agreements</B>&rdquo;
means the Canadian Security Agreement, the German Security Agreements and the USA Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Security Documents</B>&rdquo;
means each Security Agreement, any Collateral Access Agreements, any Control Agreement, the Intellectual Property Security Agreements,
all PPSA and applicable foreign Law financing statements required thereby to be filed with respect to the security interests in
personal Property and fixtures created pursuant thereto, and any and all other agreements or instruments now or hereafter executed
and delivered to Lender by any Loan Party or any other Person as security for the Secured Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Shares</B>&rdquo; means
the issued and outstanding capital stock, membership units or other securities owned or held of record at any time by any Loan
Party in any Subsidiary of such Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Sonalleve</B>&rdquo;
means the innovative therapeutic platform combining real time MR imaging and thermometry with thermal ultrasound to enable precise
and incision-free ablation of diseased tissue, CE marked for the treatment of uterine fibroids and palliative pain treatment of
bone metastases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo;
means, with respect to any Person, any corporation, limited corporation, limited liability company, partnership, limited partnership
or other entity of which at least a majority of the securities or other ownership interests having by the terms thereof ordinary
voting power to elect a majority of the board of directors or other persons performing similar functions of such corporation, limited
corporation, limited liability company, partnership, limited partnership or other entity (irrespective of whether or not at the
time securities or other ownership interests of any other class or classes of such corporation, limited corporation, limited liability
company, partnership, limited partnership or other entity shall have or might have voting power by reason of the happening of any
contingency) is at the time directly or indirectly owned or Controlled by such Person or one or more Subsidiaries of such Person
or by such Person and one or more Subsidiaries of such Person. Unless otherwise specified herein, &ldquo;Subsidiary&rdquo; means
a direct or indirect Subsidiary of a Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Taxes</B>&rdquo; or
 &ldquo;<B>Tax</B>&rdquo; means all present and future taxes, charges, fees, levies, imposts, surtaxes, duties and other assessments,
including all income, sales, use, goods and services, value added, capital, capital gains, alternative, net worth, transfer, profits,
withholding, payroll, employer health, excise, real property and personal property taxes, and any other taxes, customs duties,
fees, assessments, or similar charges of any nature, including Canada Pension Plan or similar plan in any other jurisdiction, and
provincial pension plan contributions, unemployment insurance payments and workers&rsquo; compensation premiums and including all
present or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies arising from any
payment made hereunder or under any other Financing Document or from the execution, delivery of enforcement of, or otherwise with
respect to, any Financing Document, together with any instalments with respect thereto, and any interest, fines and penalties with
respect thereto, imposed by any Governmental Authority (including federal, state, provincial, municipal and foreign Governmental
Authorities), and whether disputed or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Term Loan</B>&rdquo;
has the meaning set forth in <U>Section 2.01(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Term Loan Interest
Rate</B>&rdquo; means for each of the Tranche A Term Loan and the Tranche B Term Loan, a rate equal to the Prime Rate plus 2.5%
per annum, which shall be payable monthly in cash in arrears (the &ldquo;<B>Monthly Interest Amount</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Term Sheet</B>&rdquo;
means the term debt financing term sheet issued on May 25, 2018 by Lender and accepted on May 28, 2018 by Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Tranche A Closing Fee</B>&rdquo;
has the meaning set forth in <U>Section 2.03(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche A Commitment Fee</B>&rdquo; has
the meaning set forth in <U>Section 2.03(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche A Term Loan</B>&rdquo; has the meaning
set forth in <U>Section 2.01(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Availability Period</B>&rdquo;
means the period commencing on the Closing Date and ending on December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Closing Fee</B>&rdquo; has the
meaning set forth in <U>Section 2.03(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Commitment Fee</B>&rdquo; has
the meaning set forth in <U>Section 2.03(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Conditions</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">no Default or Event of Default has occurred and is continuing
since the Closing Date or will occur as a result of a drawdown under the Tranche B Term Loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the company has raised not less than $20,000,000 in new
equity since the Closing Date and has provided satisfactory evidence of same to the Lender; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">TULSA-PRO has received approval from the U.S. Food and
Drug Administration under Section 510(k) of the <I>Food, Drug and Cosmetic Act </I>(United States).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Initial Drawdown</B>&rdquo; means
the first advance of the Tranche B Term Loan after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Term Loan</B>&rdquo; has the meaning
set forth in <U>Section 2.01(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Tranche B Term Loan Request</B>&rdquo; is
a request pursuant to <U>Section 2.02(b)</U> in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Tribunal</B>&rdquo;
means any state, commonwealth, federal, foreign, territorial or other court or government body, subdivision, agency, department,
commission, board, bureau or instrumentality of a governmental body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>TSX</B>&rdquo; means
the Toronto Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>TULSA-PRO</B>&rdquo;
is a therapy that combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and
closed-loop thermal feedback control to provide precise ablation of the prostate while simultaneously actively protecting critical
surrounding anatomy from potential side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Unrestricted Cash</B>&rdquo;
means cash and Cash Equivalents of Borrower that do not appear on Borrower&rsquo;s balance sheet as &ldquo;restricted cash&rdquo;
and that (i) are deposited in Canada, Germany or the United States of America in a Deposit Account with the Lender or with an Affiliate
of the Lender or (ii) otherwise deposited in Deposit Accounts or Securities Accounts subject to a Control Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>US GAAP</B>&rdquo;
means generally accepted accounting principles that are in effect from time to time in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>US IP Security Agreement</B>&rdquo;
has the meaning set forth in Section 4.01(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Warrants</B>&rdquo; means the warrants granted
by the Parent in favour of Lender the from time to time exercisable for one common share in the capital of the Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Welfare Plan</B>&rdquo;
means any medical, health, hospitalization, insurance or other employee benefit or welfare plan or arrangement applicable to employees
resident in Canada, Germany or any other jurisdiction in which any Loan Party operates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 1.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PPSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any terms used in this
Agreement that are defined in the PPSA shall be construed and defined as set forth from time to time in the PPSA unless otherwise
defined herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The inclusion of headings
in this Agreement is for convenience of reference only and shall not affect the construction or interpretation hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References
to Sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever in this Agreement
a particular article, section or other portion thereof is referred to, such reference pertains to the particular article, section
or portion thereof contained herein, unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except where otherwise
expressly provided, all amounts in this Agreement are stated and shall be paid in Canadian Dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gender
and Number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this Agreement,
unless the context otherwise requires, words importing the singular include the plural and vice versa and words importing gender
include all genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Invalidity
of Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the provisions
contained in this Agreement is distinct and severable and a declaration of invalidity or unenforceability of any such provision
or part thereof by a court of competent jurisdiction shall not affect the validity or enforceability of any other provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transition
from GAAP to US GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Loan Parties
shall elect as of the end of financial reporting period to prepare their financial statements in accordance with US GAAP, rather
than GAAP, then, following delivery to the Lender of a completed Compliance Certificate attaching the information required to be
delivered for such financial reporting period, the parties hereto shall use their best efforts to amend (in a manner mutually satisfactory
to Lender and Loan Parties) the thresholds or methods of calculation required by <U>Section 6.18</U> (including any definitions
or components applicable thereto) such that compliance therewith is neither more nor less burdensome (as determined by the Lender
in its sole discretion) to Loan Parties as a result of such conversion to US GAAP and, thereafter, all references in the Loan Documents
to GAAP shall be deemed references to US GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment
or Waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No amendment or waiver
of this Agreement shall be binding unless executed in writing by the party to be bound thereby. No waiver of any provision of this
Agreement shall constitute a waiver of any other provision nor shall any waiver of any provision of this Agreement constitute a
continuing waiver unless otherwise expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Business
Days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any date on which
any payment is due or any action is required to be taken is not a Business Day, the date for payment or taking such action shall
be the next Business Day following the date specified for such payment or action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currency
Equivalents</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of calculation
and compliance with any limit set forth in <U>Section 6.14</U> with respect to the amount of Indebtedness, Investment or any other
amount subject to a basket that is incurred or made in a currency other than Canadian Dollars, the equivalent amount in Canadian
Dollars shall be calculated based on the rate of exchange quoted by the Bank of Canada at the close of business on the Business
Day preceding the date the transaction was completed. For purposes of calculation and compliance with the financial covenant set
forth in <U>Section 6.18</U> with respect to any Unrestricted Cash or Operating Cash Expenditures denominated in a currency other
than Canadian Dollars, the equivalent amount in Canadian Dollars shall be calculated as of the date of determination based on the
rate of exchange used in preparing the applicable financials statements delivered hereunder (or if there is no such rate, the rate
of exchange quoted by the Bank of Canada at the close of business on the Business Day preceding the date of calculation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;German
Terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this Agreement,
where it relates to a company incorporated or established under the laws of Germany or a Transaction Security Document governed
by German law, a reference to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">&ldquo;receiver&rdquo;, &ldquo;manager&rdquo;, &ldquo;conservator&rdquo;,
 &ldquo;trustee&rdquo;, &ldquo;agent&rdquo;, &ldquo;custodian&rdquo;, &ldquo;monitor&rdquo;, &ldquo;liquidator&rdquo; or other
similar officer includes a reference to an <I>Insolvenzverwalter, vorl&auml;ufiger Insolvenzverwalter, Sachwalter</I> or <I>vorl&auml;ufiger
Sachwalter</I>;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">seeking to adjudicate a Loan Party or Subsidiary bankrupt
or insolvent or seeking the &ldquo;liquidation&rdquo;, &ldquo;dissolution&rdquo;, &ldquo;winding-up&rdquo;, reorganization&rdquo;,
 &ldquo;arrangement&rdquo;, &ldquo;protection&rdquo;, &ldquo;relief&rdquo; or &ldquo;composition&rdquo; or initiating or taking
steps to initiate any &ldquo;Insolvency Proceedings&rdquo; includes an application or filing for, or an institution of, insolvency
proceedings (<I>Antrag auf Er&ouml;ffnung eines Insolvenzverfahrens</I>) (including, without limitation, by way of <I>(vorl&auml;ufige)
Eigenverwaltung</I> or <I>Schutz-schirmverfahren</I>), an ordering of provisional measures according to section 21 of the German
Insolvency Code (<I>Insolvenzordnung</I>) (<I>Anordnung vorl&auml;ufiger Ma&szlig;nahmen</I>) or a rejection of insolvency proceedings
on grounds of insufficiency of assets (<I>Abweisung mangels Masse</I>);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">a person being &ldquo;unable to pay its debts&rdquo;
or &ldquo;unable to pay its debts as they fall due&rdquo;, includes that person being in a state of <I>Zahlungsunf&auml;higkeit
</I>within the meaning of section 17 of the German Insolvency Code (<I>Insolvenzordnung</I>) and a person&rsquo;s &ldquo;assets
being less than the aggregate sum of its liabilities&rdquo; includes that person being in a state of <I>&Uuml;berschuldung</I>
within the meaning of section 19 of the German Insolvency Code (<I>Insolvenzordnung</I>);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;management&rdquo;
of a person includes reference to its <I>Gesch&auml;ftsf&uuml;hrung</I> or <I>Vorstand </I></FONT>(as applicable); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">the &ldquo;Governing Documents&rdquo; includes an excerpt
from the competent commercial register (Ausdruck aus dem Handelsregister) of most recent date (not older than 14 days), an up-to-date
copy of the articles of association (Satzung) (as filed with the competent commercial register) or partnership agreement (Gesellschafts-vertrag) and, as applicable, an up-to-date copy of the list of shareholders (Gesellschafterliste) as filed with the competent
commercial register.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE II.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE LOANS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 2.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Commitments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><U>Term Loans</U>.
                                         Subject to the terms and conditions of this Agreement, Lender agrees to make (i) a term
                                         loan in Canadian Dollars on the Closing Date in the original principal amount of $12,500,000
                                         (the &ldquo;<B>Tranche A Term Loan</B>&rdquo;), and (ii) subject to the Tranche B Conditions
                                         and compliance with all terms, conditions and covenants of this Agreement, at any time
                                         during the Tranche B Availability Period, additional term loans in minimum draws of $1,000,000
                                         in Canadian Dollars after the Closing Date in the original principal amount of up to
                                         $6,250,000 (the &ldquo;<B>Tranche B Term Loans</B>&rdquo; and each a &ldquo;<B>Tranche
                                         B Term Loan</B>&rdquo;, and together with the Tranche A Term Loan, the &ldquo;<B>Term
                                         Loans</B>&rdquo;, and each, a &ldquo;<B>Term Loan</B>&rdquo;). Amounts prepaid or repaid
                                         in respect of the Term Loans may not be reborrowed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 2.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><U>Funding of Term Loans</U>. The Tranche A Term Loan
shall be fully funded on the Closing Date. The Tranche B Term Loans, if made, shall be funded in advances after the Closing Date
and during the Tranche B Availability Period. Each advance made under the Tranche B Term Loan shall be added to and form part
of the aggregate amount outstanding under the Term Loans.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Request for Tranche B Term Loan.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">To request Lender to make the Tranche B Term Loan, Borrower
shall notify Lender of such request by email not later than 1:00 p.m., Toronto, Ontario time, two (2) Business Days before the
date of the proposed Tranche B Term Loan. Such request (a) shall be irrevocable, (b) may be made by a Responsible Officer, and
(c) shall be confirmed promptly by hand delivery or facsimile to Lender of a written Tranche B Term Loan Request, in substantially
the form of <U>Exhibit A</U> and signed by a Responsible Officer (a &ldquo;<B>Tranche B Term Loan Request</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Such Tranche B Term Loan Request shall include:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(A)</TD><TD STYLE="text-align: justify">the date the Tranche B Term Loan is requested to be made;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(B)</TD><TD STYLE="text-align: justify">a certification that each of the Tranche B Conditions
have been met;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(C)</TD><TD STYLE="text-align: justify">an authorization to deduct the Tranche B Closing Fee
from the proceeds of the Loan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(D)</TD><TD STYLE="text-align: justify">the conditions set forth in <U>Section 7.02 </U>are
satisfied; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(E)</TD><TD STYLE="text-align: justify">the account to which funds are to be disbursed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 2.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><U>Commitment Fees.</U> Borrower (i) has paid to Lender
prior to the date of this Agreement a commitment fee with respect to the Tranche A Term Loan equal to 0.50% of $12,500,000, which
fee has been fully earned and has been paid on signing the Term Sheet (the &ldquo;<B>Tranche A Commitment Fee</B>&rdquo;), and
(ii) agrees to pay to the Lender a commitment fee with respect to the Tranche B Term Loan equal to 0.50% of $6,250,000, which
fee shall be fully earned and payable on the date of the Tranche B Initial Drawdown, if any (the &ldquo;<B>Tranche B Commitment
Fee</B>&rdquo;, and together with the Tranche A Commitment Fee, the &ldquo;<B>Commitment Fee</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Closing Fees.</U> Borrower hereby agrees to pay
Lender (i) a closing fee equal to 1.00% of $12,500,000 on the Closing Date, in respect of the Tranche A Term Loan, which fee shall
be fully earned and payable on the Closing Date (the &ldquo;<B>Tranche A Closing Fee</B>&rdquo;), and (ii) a closing fee equal
to 1.00% of $6,250,000 payable as a condition to the Tranche B Initial Drawdown, which fee shall be fully earned and payable as
of the date of the Tranche B Initial Drawdown, if any (the &ldquo;<B>Tranche B Closing Fee</B>&rdquo;, and collectively with the
Tranche A Closing Fee, the &ldquo;<B>Closing Fee</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 2.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment;
Computation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All fees payable under
this Agreement shall be paid on the dates due, in immediately available Canadian Dollars, to Lender. Fees shall be fully earned
on the dates set forth in this Agreement and shall not be refundable under any circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 2.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loan
Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lender shall maintain,
in accordance with its usual practice, an account on its books in the name of Borrower (the &ldquo;<B>Loan Account</B>&rdquo;)
on which Borrower will be charged with all Loans made by Lender to Borrower or for Borrower&rsquo;s account and with all other
Secured Obligations hereunder or under the other Financing Documents, including, the date, amount and interest rate of each Loan
made to Borrower, accrued interest, fees and expenses, Lender Expenses, and the amount of any sum received by Lender on account
of the Secured Obligations. The entries made in lender&rsquo;s records with respect to the Loan Account pursuant to this <U>Section
2.05</U> shall be conclusive evidence (absent manifest error) of the existence and amounts of the obligations recorded therein;
provided that the failure of Lender to maintain such records or any error therein shall not affect in any manner the obligations
of the Borrower to repay the Loans and other Secured Obligations in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE III.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PAYMENTS AND PREPAYMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 3.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Repayment
of Loans.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Borrower hereby
unconditionally promises to make a monthly repayment of the Term Loans in the principal amount of $378,787.88 on the last Business
Day of each month commencing in October, 2019. Notwithstanding the foregoing and provided that Borrower provides evidence thereof
satisfactory to Lender, if Borrower raises not less than $20,000,000 in new equity prior to the last Business Day of October, 2019,
the first monthly amortization payment may be deferred until the last Business Day of April 2020, and in such case the monthly
repayment amount shall be $462,962.96 payable on the last Business Day of April 2020 and each month thereafter. The principal amounts
drawn, if any, under the Tranche B Term Loan following the Closing Date shall be added to the applicable aforementioned monthly
repayment amounts and repaid in the same manner equally over the number of months remaining until the Maturity Date, and the Lender
shall advise the Borrower of such new monthly repayment amount. The Borrower hereby unconditionally promises to pay to the Lender
the remaining outstanding principal amount of the Term Loans on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><U>Term Loans.</U> The Borrower hereby unconditionally
promises to pay to Lender interest on the unpaid principal amount of the Term Loans for the period from and including the date
of each Term Loan to but excluding the date such Term Loan shall be paid in full, at a rate equal to the Term Loan Interest Rate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Post-Default Rate.</U> Notwithstanding the foregoing,
the Borrower acknowledges and agrees that if an Event of Default shall have occurred and be continuing, then at the option of
Lender for as long as such Event of Default exists, the unpaid balance of all Loans shall bear interest, to the fullest extent
permitted by law, at a rate equal to 12% per annum (the &ldquo;<B>Post-Default Rate</B>&rdquo;), from the date of the Event of
Default has occurred until such Event of Default is cured or waived. The Borrower hereby unconditionally agrees to pay to Lender
interest at the Post- Default Rate, as specified in this paragraph from time to time on demand.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><U>Payment</U>. The Monthly Interest Amount accrued
on each applicable Term Loan shall be payable monthly in arrears on the last Business Day of each month. Notwithstanding the foregoing,
(i) accrued interest on the principal amount of any Loan repaid or prepaid shall be payable on the date of the payment or prepayment
thereof, and (ii) interest payable at the Post-Default Rate shall be payable on demand.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">For the purposes of the <I>Interest Act</I> (Canada)
and disclosure thereunder, whenever any interest or any fee to be paid hereunder or in connection herewith is to be calculated
on the basis of any period of time that is less than a calendar year, the yearly rate of interest to which the rate used in such
calculation is equivalent is the rate so used multiplied by the actual number of days in the calendar year in which the same is
to be ascertained and divided by 360 or 365, as applicable. The rates of interest under this Agreement are nominal rates, and
not effective rates or yields. The principle of deemed reinvestment of interest does not apply to any interest calculation under
this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">If any provision of this Agreement would oblige Borrower
to make any payment of interest or other amount payable to the Lender in an amount or calculated at a rate which would be prohibited
by law or would result in a receipt by that Lender of &ldquo;interest&rdquo; at a &ldquo;criminal rate&rdquo; (as such terms are
construed under the <I>Criminal Code</I> (Canada)), then, notwithstanding such provision, such amount or rate shall be deemed
to have been adjusted with retroactive effect to the maximum amount or rate of interest, as the case may be, as would not be so
prohibited by Law or so result in a receipt by that Lender of &ldquo;interest&rdquo; at a &ldquo;criminal rate&rdquo;, such adjustment
to be effected, to the extent necessary (but only to the extent necessary), as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">first, by reducing the amount or rate of interest
required to be paid to the Lender; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">thereafter, by reducing any fees, commissions, premiums
and other amounts required to be paid to the Lender which would constitute interest for purposes of section 347 of the <I>Criminal
Code</I> (Canada).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify"><U>Calculation of Interest Rate</U>. EACH OF THE LOAN
PARTIES CONFIRMS THAT IT FULLY UNDERSTANDS AND IS ABLE TO CALCULATE THE RATE OF INTEREST APPLICABLE TO EACH OF THE LOANS AND OTHER
SECURED OBLIGATIONS BASED ON THE METHODOLOGY FOR CALCULATING PER ANNUM RATES PROVIDED FOR IN THIS AGREEMENT. Lender agrees that
if requested in writing by a Loan Party it shall calculate the nominal and effective per annum rate of interest on any Loans or
other Secured Obligations outstanding at any time and provide such information to such Loan Party promptly following such request;
provided that any error in any such calculation, or any failure to provide such information on request, shall not relieve such
Loan Party of any of its obligations under this Agreement or any other Financing Document, nor result in any liability to the
Lender. EACH LOAN PARTY HEREBY IRREVOCABLY AGREES NOT TO PLEAD OR ASSERT, WHETHER BY WAY OF DEFENCE OR OTHERWISE, IN ANY PROCEEDING
RELATING TO THE FINANCING DOCUMENTS, THAT THE INTEREST PAYABLE UNDER THE FINANCING DOCUMENTS AND THE CALCULATION THEREOF HAS NOT
BEEN ADEQUATELY DISCLOSED TO THE LOAN PARTIES, WHETHER PURSUANT TO SECTION 4 OF THE INTEREST ACT (CANADA) OR ANY OTHER APPLICABLE
LAW OR LEGAL PRINCIPLE.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;End
of Term Payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts advanced
under the Term Loans, including for greater certainty all amounts advanced under the Tranche B Term Loan, shall be subject to an
additional payment in the amount of 2% of the aggregate principal amount of the Term Loans that were advanced (the &ldquo;<B>End
of Term Payment</B>&rdquo;) due upon the earlier of (i) the Maturity Date, (ii) the date of prepayment of the Term Loans in full,
(iii) the acceleration of the Term Loan or (iv) the occurrence of a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Optional
Prepayments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower may prepay
the Term Loans, in whole or in part, which prepayments shall be in increments of $500,000 except in connection with prepayment
of all Term Loans in full (including in connection with a prepayment required as a result of a Change of Control, but excepting
prepayments required pursuant to <U>Section 3.05(a)</U> or <U>Section 3.05(b)</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mandatory
Prepayments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><U>Asset Sales.</U> Without limiting the restrictions
pursuant to <U>Section 6.14</U> with respect to Dispositions, on or before ten (10) days after the receipt of the Net Available
Proceeds from a Disposition, Borrower shall (i) deliver to Lender a certificate of a Responsible Officer, in form and substance
reasonably satisfactory to Lender, containing a statement of the amounts of the cash and non-cash portions of the Net Available
Proceeds of such Disposition and (ii) prepay the Loans in an aggregate amount equal to 100% of the cash portion of the Net Available
Proceeds of the Dispositions, except where such Net Available Proceeds do not exceed $250,000 and are reinvested by a Loan Party
in additional Collateral within 360 days after receipt of such proceeds, provided that any portion of such Disposition proceeds
that has not been reinvested within 360 days after the date of making the Disposition (a &ldquo;<B>Reinvestment Period</B>&rdquo;)
shall (x) be deemed to be Net Available Proceeds of a Disposition occurring on the last day of such Reinvestment Period; and (y)
within three (3) Business Days after the last day of such Reinvestment Period, unless otherwise agreed to by the Lender, be used
to prepay the Loans in an aggregate amount equal to 100% of the cash portion of the Net Available Proceeds of the Dispositions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Insurance Proceeds.</U> Borrower shall prepay the
Loans in an aggregate amount equal to 100% of the Net Available Proceeds of any Casualty Event, provided that if no Event of Default
has occurred and is continuing and the Loan Parties otherwise haven&rsquo;t suffered a material impact to the operation of their
business that would take longer than 90 days to remedy, the Loan Parties shall be permitted to apply proceeds of up to $3,500,000
per fiscal year of any insurance, condemnation award or other compensation in respect of a Casualty Event within 90 days after
the receipt thereof by the Loan Parties to repair or replace the affected property, subject to Borrower&rsquo;s written notice
thereof to Lender promptly upon the occurrence of the Casualty Event. Any proceeds remaining and not used to repair or replace
the affected property within such 90 days shall be applied to prepay the Loans at the Lender&rsquo;s discretion.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><U>Change of Control</U>. Upon the occurrence of a
Change of Control, Borrower shall prepay the Loans in full, together with (i) accrued and unpaid interest thereon, and (ii) the
End of Term Payment, together with all other amounts payable under this Agreement, and Lender shall cease to have any commitment
to make Loans under this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Application
of Prepayments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except as otherwise provided in this Agreement,
prepayments pursuant to this <U>Article III</U> shall be applied as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">First, to pay outstanding fees or Lender Expenses;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Second, to prepay accrued and unpaid interest accrued
on the Term Loans;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Third, to prepay outstanding principal outstanding
in respect of the Term Loans;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Fourth, to the payment in full in cash of all other
Secured Obligations; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Fifth, to whomsoever is legally entitled thereto or
as a court of competent jurisdiction may direct.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Prepayments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall notify
Lender by telephone, confirmed by facsimile, of any optional prepayment under this <U>Article III</U> not later than noon Toronto
time, five (5) Business Days before the proposed date of prepayment. Each such notice shall be irrevocable (unless, if Lender so
consents in its reasonable discretion, such notice is a notice of a prepayment which is contingent on the consummation of another
transaction) and shall specify the prepayment date, the principal amount of each Loan or part thereof to be prepaid and (for a
mandatory prepayment) a reasonably detailed calculation of the amount of such prepayment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments
Generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All payments to be
made by any Loan Party shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff. Except
to the extent otherwise provided herein or in any other Financing Document, the Borrower shall make all payments of principal,
interest and other amounts to be made by any Loan Party under the Financing Documents in immediately available funds, without deduction,
set-off or counterclaim, to Lender at Lender&rsquo;s Account (except as otherwise expressly provided in this Agreement), prior
to 1:00 p.m. Toronto, Ontario time on the date when due. Any amounts received after such time on any date may, in the discretion
of Lender, be deemed to have been received on the next succeeding Business Day for purposes of calculating interest thereon. All
amounts owing under any Financing Document are payable in Canadian Dollars unless otherwise specified herein. Except to the extent
otherwise provided herein, if any payment under any Financing Document shall be due on a day that is not a Business Day, the date
for payment shall be extended to the next succeeding Business Day and interest thereon shall be payable for the period of such
extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change
in Law and Increased Costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If any Change in Law shall:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">impose, modify or deem applicable any reserve, special
deposit, additional capital, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for
the account of, or credit extended by, the Lender;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">subject the Lender to any Taxes (other than (A) Indemnified
Taxes or (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes) on its loans, loan principal, letters
of credit, commitments, or other obligations, or its deposits, reserves or other liabilities or capital attributable thereto;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">impose on the Lender any other condition, cost or
charge (other than Taxes) affecting this Agreement or any Loan hereunder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">and the result of any of the foregoing
shall be to increase the cost to the Lender of making, continuing, converting to or maintaining any Loan (or of maintaining its
obligation to make any such Loan) or to reduce the amount of any sum received or receivable by the Lender hereunder (whether of
principal, interest or otherwise), then from time to time Borrower will pay to the Lender such additional amount or amounts as
will compensate the Lender for such additional costs incurred or reduction suffered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If the Lender determines that any Change in Law affecting
the Lender or any of its lending offices or its holding company, if any, regarding capital or liquidity requirements, has or would
have the effect of reducing the rate of return on the Lender&rsquo;s capital or on the capital of its holding company, if any,
as a consequence of this Agreement, its commitment hereunder or the Loans made by the Lender, to a level below that which the
Lender or its holding company would have achieved but for such Change in Law (taking into consideration the Lender&rsquo;s policies
and the policies of its holding company with respect to capital adequacy or liquidity, as applicable), then from time to time
the Borrower will pay to the Lender in Canadian Dollars such additional amount or amounts as will compensate the Lender or its
holding company for any such reduction suffered.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">A certificate of the Lender setting forth the amount
or amounts necessary to compensate the Lender as specified in <U>clause (a) or (b)</U>, as applicable, shall be delivered to Borrower,
and any such certificate shall include a brief description of the Change in Law and a calculation of the amount or amounts necessary
to compensate the Lender and shall, absent manifest error, be <I>prima facie</I> evidence of the amount of such compensation.
In determining such amount, the Lender may use any reasonable method of averaging and attribution that it shall deem applicable.
Borrower shall pay the Lender the amount shown as due on any such certificate within 30 days after receipt thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Failure or delay on the part of the Lender to demand
compensation pursuant to this section shall not constitute a waiver of the Lender&rsquo;s right to demand such compensation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Section 3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Any and all payments by or on account of any obligation
of a Loan Party under any Financing Document shall be made without deduction or withholding for any Taxes, except as required
by Applicable Law. If any Applicable Law (as determined in the good faith discretion of the applicable Loan Party) requires the
deduction or withholding of any Tax from any such payment by such Loan Party, then the applicable Loan Party shall be entitled
to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority
in accordance with ApplicableLaw and, if such Tax is an Indemnified, then the sum payable by such Loan Party shall be increased
as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable
to additional sums payable under this <U>Section 3.10)</U> the Lender receives an amount equal to the sum it would have received
had no such deduction or withholding been made.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><U>Payment of Other Taxes by the Borrower</U>: The
Loan Parties shall pay to the relevant Governmental Authority in accordance with Applicable Law, or at the option of the Lender
timely reimburse it for the payment of, any present or future stamp, court or documentary, intangible, recording, filing or similar
Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from
the receipt or perfection of a security interest under, or otherwise with respect to, any Financing Document, except any such
Taxes imposed as a result of a present or former connection between an assignee and the jurisdiction imposing such Taxes (other
than a connection arising from an assignee having executed, delivered, become a party to, performed its obligations under, received
payments under, received or perfected a security interest under, engaged in any transaction pursuant to or enforced any Financing
Document) with respect to an assignment of this Agreement (other than an assignment requested by a Loan Party).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><U>Indemnification by the Loan Parties.</U> The Loan
Parties shall, jointly and severally, indemnify the Lender, within 10 days after written demand therefor, for the full amount
of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this <U>Section
3.10</U> payable or paid by the Lender or required to be withheld or deducted from a payment to the Lender and any reasonable
expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or
asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the
applicable Loan Party by the Lender shall be conclusive, absent manifest error.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><U>Evidence of Payments.</U> As soon as practicable
after any payment of Taxes by any Loan Party to a Governmental Authority pursuant to this <U>Section 3.10,</U> such Loan Party
shall deliver to the Lender the original or certified copy of a receipt issued by such Governmental Authority evidencing such
payment or other evidence of such payment reasonably satisfactory to the Lender.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify"><U>Status of Lender</U>. If the Lender is entitled
to an exemption from or reduction of withholding Tax with respect to payments made under any Financing Document, it shall deliver
to the applicable Loan Party, at the time or times reasonably requested in writing by such Loan Party, such properly completed
and executed documentation so requested as will permit such payments to be made without withholding or at a reduced rate of withholding.
In addition, the Lender, if reasonably requested in writing by any Loan Party, shall deliver such other documentation prescribed
by Applicable Law or so requested by such Loan Party as will enable such Loan Party to determine whether or not the Lender is
subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding
two sentences, the completion, execution and submission of such documentation shall not be required if in the Lender&rsquo;s reasonable
judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would
materially prejudice the legal or commercial position of the Lender.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify"><U>Treatment of Certain Refunds.</U> If, following
the imposition of any Taxes on any payment by any Loan Party to the Lender in respect of which any Loan Party is required to make
an additional payment pursuant to this <U>Section 3.10,</U> the Lender receives a refund of Taxes as to which it has been reimbursed,
made whole or indemnified pursuant to this <U>Section 3.10,</U> the Lender will reimburse the Loan Parties an amount equal to
such refund, but only to the extent of indemnity payments made or additional amounts paid by the Loan Parties under this <U>Section
3.10</U> with respect to Taxes giving rise to such refund, net of all out of pocket expenses (including Taxes) of the Lender and
without interest (other than any net after-tax interest paid by the relevant Governmental Authority with respect to such refund).
Notwithstanding anything to the contrary in this <U>Section 3.10,</U> in no event will the Lender be required to pay any amount
to the Loan Parties pursuant to this <U>Section 3.10,</U> the payment of which would place the Lender in a less favorable net
after-tax position than the Lender would have been in if the indemnification payments or additional amounts giving rise to such
refund had never been paid. Each Loan Party, upon the request of the Lender, agrees to repay to the Lender the amount paid over
to the Loan Parties (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) if the Lender
is required to repay such refund or reduction to such Governmental Authority. This <U>Section 3.10</U> shall not be construed
to require the Lender to make available its tax returns (or any other information relating to its taxes which it deems confidential)
to the Loan Parties or any other Person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illegality</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Lender determines that any Law has made
it unlawful, or that any Governmental Authority has asserted that it is unlawful, for Lender or its applicable lending office to
make or maintain any Loan (or to maintain its obligation to make any Loan), or to determine or charge interest rates based upon
any particular rate, then, on notice thereof by such Lender to Borrower, any obligation of such Lender with respect to the activity
that is unlawful shall be suspended until Lender notifies Borrower that the circumstances giving rise to such determination no
longer exist. Upon receipt of such notice, Borrower shall, upon demand from Lender, prepay in order to avoid the activity that
is unlawful. Upon any such prepayment, Borrower shall also pay accrued interest on the amount so prepaid or converted. Lender agrees
to designate a different lending office if such designation will avoid the need for such notice and will not, in the good faith
judgment of Lender, otherwise be materially disadvantageous to Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IV.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 4.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security
Documents.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the Closing Date
or, as the case may be, on such later date stated in Section 6.23, as general and continuing security for the due payment and performance
of the Secured Obligations, the following Security Documents will be provided to the Lender:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">a pledge and general security agreement from Borrower
and Parent governed by the laws of Ontario and granting security over all of Borrower&rsquo;s and Parent&rsquo;s personal property
and undertaking in Canada (the &ldquo;<B>Canadian Security Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">a Guarantee by Parent, PM Germany and PM USA governed
by the laws of Ontario guaranteeing the Secured Obligations (the &ldquo;<B>Canadian Guarantee</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">a global assignment agreement from PM Germany governed
by the laws of Germany and granting security over PM Germany&rsquo;s intragroup receivables and trade receivables (the &ldquo;<B>German
Global Assignment Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">a pledge agreement from PM Germany governed by the
laws of Germany and granting security over PM Germany&rsquo;s accounts balances (the &ldquo;<B>German Account Pledge Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">a pledge agreement from Borrower governed by the laws
of Germany and granting security over all of the Borrower&rsquo;s equity interest in PM Germany (the &ldquo;<B>German Share Pledge
Agreement</B>&rdquo; and collectively with the German Global Assignment&rdquo; and the German Account Pledge Agreement, the &ldquo;<B>German
Security Agreements</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">a pledge and security agreement from the Borrower
and PM USA governed by the laws of New York and granting security over (i) all of the Borrower&rsquo;s shares in PM USA and (ii)
PM USA&rsquo;s personal property and undertaking in the United States of America (the &ldquo;<B>USA Security Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">an intellectual property security agreement for all
Canadian Intellectual Property (the &ldquo;<B>Canadian IP Security Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">an intellectual property security agreement for all
United States Intellectual Property (the &ldquo;<B>US IP Security Agreement</B>&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">a Collateral Access Agreement for the Borrower&rsquo;s
Mississauga, Ontario location;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">a Control Agreement for all Securities Accounts, Deposit
Accounts and other Investment Property held by each Loan Party on the Closing Date, in each case other than in respect of Excluded
Accounts; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">any other Security Documents reasonably requested
by the Lender.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Control
of Collateral; Control Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall maintain
all Deposit Accounts with financial institutions that are acceptable to the Lender. If from time to time any Collateral consists
of property or rights of any Loan Party in which the perfection or priority of Lender&rsquo;s security interest is dependent upon
Lender&rsquo;s gaining control of such Collateral (including Securities Accounts, other Investment Property or Deposit Accounts)
or otherwise consists of a Deposit Account located in a jurisdiction for which control is not required for perfection, in each
case other than Excluded Accounts, Borrower shall notify Lender and deliver the appropriate Control Agreements, and each Loan Party
shall do the same with respect to any property securing the applicable Guarantee. No Control Agreement in respect of any Deposit
Account, Securities Accounts or other Investment Property shall be modified by any Loan Party without the prior written consent
of Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 4.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Guarantors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time Borrower
owns, establishes or acquires a wholly-owned Material Subsidiary (including without limitation any wholly-owned Subsidiary that
exists on the Closing Date and becomes a Material Subsidiary), Borrower shall immediately cause such Subsidiary to become a Guarantor
hereunder, and deliver such Guarantee and other Security Documents so as to reflect and replicate the security delivered by Borrower
on the Closing Date and the intent of <U>Section 4.05(b)</U>. The Borrower shall also deliver or cause the delivery of a pledge
of all of the issued and outstanding equity of such new Guarantor concurrently therewith, together with any certificates representing
such equity and corresponding powers of attorney in respect of such certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 4.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Real
Estate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Borrower shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">notify the Lender within ten Business Days of any
Loan Party acquiring any freehold, leasehold, licence or other similar interest in real property after the Closing Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in the case of any freehold interest in real property
located in Canada, Europe or the United States with a value in excess of $500,000, grant a fixed charge to the Lender on any such
real property interest (together with any title opinions or title insurance relating thereto in form and substance acceptable
to the Lender); and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">in the case of any leasehold interest in real property,
use commercially reasonable efforts to obtain a Collateral Access Agreement if requested by the Lender.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 4.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery
of Additional Documentation Required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">At any time upon the written request of Lender, each
Loan Party shall execute and deliver to Lender, any and all security agreements, pledges, assignments, endorsements of certificates
of title, bailee acknowledgments and all other documents (the &ldquo;<B>Additional Documents</B>&rdquo;) that Lender may request
in its sole discretion, each in form and substance satisfactory to Lender, to maintain perfection and protect the priority of
Lender&rsquo;s Liens in the Collateral (whether now owned or hereafter arising or acquired), to create and perfect Liens in favor
of Lender in any real property acquired after the Closing Date, and in order to fully consummate all of the transactions contemplated
hereby and under the other Financing Documents. Each Loan Party authorizes Lender to execute any such Additional Documents in
such Loan Party&rsquo;s name and authorize Lender to file such executed Additional Documents in any appropriate filing office.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">It is the intention of the parties hereunder that
Borrower and each Material Subsidiary shall grant security over all present and after-acquired personal property and material
real estate described in <U>Section 4.05</U> in the applicable jurisdiction(s) as determined by the Lender, and agree to promptly
deliver all to the Lender all Additional Documents that may be required from time to time to effect such intention.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 4.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Right
to Inspect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lender (through any
of its officers, employees, or agents) shall have the right, from time to time hereafter (but, provided no Event of Default has
occurred and is continuing, not more than once per fiscal year), at reasonable times and upon reasonable notice, during business
hours, to inspect the books and records of each Loan Party and to check, test, and appraise the Collateral in order to verify the
Loan Parties&rsquo; financial condition or the amount, quality, value, condition of, or any other matter relating to, the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE V.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each Loan Party represents and warrants
to Lender that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation
and Status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party is
duly incorporated and organized, and is validly existing under its jurisdiction of organization. Such Loan Party is duly registered,
licensed or qualified as a foreign corporation, and is up to date in the filing of all corporate and similar returns and is in
good standing under the laws of those jurisdictions where it operates and where failure to be so registered, licensed, qualified
or up to date would have a Material Adverse Effect on it. . For the purposes of Regulation (EU) 2015/848 of the European Parliament
and of the Council of 20 May 2015 on insolvency proceedings (recast), the Centre of Main Interests of each Loan Party incorporated
in a member state of the European Union is situated in its jurisdiction of organization and each Loan Party incorporated in a member
state of the European Union has, and at all times during the three (3) month period prior, had, no Establishment in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate
Power and Due Authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party has
the corporate power and capacity to enter into, and to perform its obligations under this Agreement and the Financing Documents,
to which it is a party, as applicable. Each of this Agreement and the Financing Documents to which it is a party has been duly
authorized, executed and delivered by such Loan Party (including, without limitation, receipt of all requisite board, stockholder
and member approvals) and is a valid and binding obligation of such Loan Party enforceable in accordance with its terms, subject
to the usual exceptions as to bankruptcy and the availability of equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business
of the Loan Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties has
the corporate or other applicable power and capacity to own, lease or license its assets and to carry on its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Contravention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the entering
into and performing under this Agreement or the Financing Documents or the performance by each Loan Party of any of its respective
obligations hereunder or thereunder will contravene, breach, result in any default or result in any acceleration, bonus or benefit
to any other party under Governing Documents of such Loan Party or under any mortgage, lease, license agreement, supply agreement,
contract, agreement, other legally binding instrument, license, permit, Regulatory Required Permit, statute, regulation, order,
judgment, decree or law to which it is a party or by which it may be bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
Insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Loan Party nor any
of their predecessors where applicable (a) has committed any act of bankruptcy or initiated or taken steps to initiate any Insolvency
Proceeding, (b) (i) is insolvent, (ii) is unable for any reason to unable to meet its obligations as they generally become due,
(iii) has ceased paying its current obligations or (iv) is a Person the aggregate of whose property is not, at fair valuation,
sufficient, or, if disposed of at a fairly conducted sale under legal process, would not be sufficient to pay all its obligations
due and accruing due, (c) has proposed, or given notice of its intention to propose, a compromise or arrangement to its creditors
generally, including pursuant to any Insolvency Legislation, or (d) has any petition for a receiving order in bankruptcy filed
against it, made a voluntary assignment in bankruptcy, taken any proceeding with respect to any compromise or arrangement, taken
any proceeding to have itself declared bankrupt or wound-up, taken any proceeding to have a receiver appointed of any part of its
assets, has had any encumbrancer take possession of any of its property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approvals
and Consents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No authorization, consent
or approval of, or filing with or notice to, any governmental agency, regulatory body, court or other person is required in connection
with the execution, delivery or performance and compliance with the terms of this Agreement and the Financing Documents to which
any Loan Party is a party nor will such performance and compliance contravene any statute, rule or regulation binding on any Loan
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Welfare
and Pension Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party has
adopted all Welfare Plans required by Law and each of such plans has been maintained in compliance with such laws in all material
respects including, without limitation, all requirements relating to employee participation, funding, investment of funds, benefits
and transactions with Loan Parties and persons related to them. No Loan Party has a material contingent liability with respect
to any post-retirement benefit under a Welfare Plan. No Loan Party maintains a Pension Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
Since Date of Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Loan Party is a
party to nor is bound by any contract, agreement or commitment that materially adversely affects or could reasonably be expected
to materially adversely affect such Loan Party&rsquo;s business or its financial condition or any of its assets. Additionally,
since December 31, 2017, no event has (or would reasonably be expected to) give rise to a Material Adverse Effect, and no Loan
Party has (except as set forth on <U>Schedule 5.08)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">other than in the ordinary course and consistent with
past practices of the Loan Parties, sold, transferred or otherwise disposed of, or created, assumed or permitted any encumbrance
on or in respect of, its property or assets or any part thereof other than Permitted Encumbrances;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">incurred, assumed or become subject to any material
liability except in the ordinary course of business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">suffered a change in assets, liabilities, financial
condition, prospects or operations of the Loan Parties, from that reflected in the financial statements as of the date set forth
above, other than changes in the ordinary course, which individually or in the aggregate has had or could reasonably be expected
to have a Material Adverse Effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">suffered any damage, destruction or loss, whether
or not covered by insurance, which would materially and adversely affecting the properties, business or prospects or financial
condition of the Loan Parties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">cancelled or released any debts or claims or waived
or surrendered any rights which, in the aggregate, are material;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">suffered the resignation or termination of any officer,
key employee or group of employees thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">made any material change to any material compensation
agreement or other Material Agreement with any employee, officer, director or stockholder;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">assigned or granted any exclusive license or transferred
any Material Intellectual Property or material Regulatory Required Permit;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">made any change to any Material Agreement to which
any Loan Party is a party or by which it is bound which materially and adversely affects the business, assets, liabilities, financial
condition, operations or prospects of the Loan Parties; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">except as described in the Loan Parties&rsquo; consolidated
financial statements, made any change in its accounting principles and practices as theretofore applied including, without limitation,
the basis upon which its assets and liabilities are recorded on its books and its earnings, profits and losses are ascertained.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Default Under Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Loan Party is in
default or breach of any Material Agreement to which it is a party which default or breach has had or could reasonably be expected
to have a Material Adverse Effect, no event has occurred that after notice or the passage of time, or both, would constitute such
a default or breach, and all Material Agreements are in good standing in all material respects. A list of all Material Agreements,
including all material supply agreements, is set forth on <U>Schedule 5.09.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title
to Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties are
the absolute beneficial owners of and have good and marketable title, free of all charges except for Permitted Encumbrances, to
all the material assets owned by them and used in connection with the Loan Parties&rsquo; business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The audited consolidated
financial statements of Borrower for the fiscal year ended 2017 and the unaudited consolidated financial statements of Borrower
for the periods through March 31, 2018 present fairly in all material respects the consolidated financial position of Borrower
on a consolidated basis as at the dates indicated and the results of its operations and changes in its financial position for the
periods specified and reflect all material liabilities (absolute, accrued, contingent or otherwise) of Borrower as of the dates
thereof and such financial statements have been prepared in conformity with GAAP applied, except as otherwise stated therein, on
a consistent basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Material Adverse Change</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since December 31, 2017, there has been
no Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Environmental
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The assets of each
Loan Party have not been used by a Loan Party in the disposal of, or to produce, store, handle, treat, release, or transport, any
Hazardous Materials, where such production, storage, handling, treatment, release or transport was in violation, in any material
respect, of applicable Environmental Law, (b) to Borrower&rsquo;s knowledge, no properties or assets of any Loan Party has ever
been designated or identified in any manner pursuant to any environmental protection statute as a Hazardous Materials disposal
site, (c) no Loan Party has received notice that a Lien arising under any Environmental Law has attached to any revenues or to
any Property owned or operated by a Loan Party, and (d) no Loan Party has received a summons, citation, notice, or directive from
any federal or state governmental agency concerning any action or omission by any Loan Party resulting in the releasing or disposing
of Hazardous Materials into the environment. As used herein, &ldquo;Hazardous Materials&rdquo; means (A) substances that are defined
or listed in, or otherwise classified pursuant to, any Applicable Laws or regulations as &ldquo;hazardous substances,&rdquo; &ldquo;hazardous
materials,&rdquo; &ldquo;hazardous wastes,&rdquo; &ldquo;toxic substances,&rdquo; or any other formulation intended to define,
list, or classify substances by reason of deleterious properties such as ignitability, corrosivity, reactivity, carcinogenicity,
reproductive toxicity, or &ldquo;EP toxicity&rdquo;, (B) oil, petroleum, or petroleum derived substances, natural gas, natural
gas liquids, synthetic gas, drilling fluids, produced waters, and other wastes associated with the exploration, development, or
production of crude oil, natural gas, or geothermal resources, (C) any flammable substances or explosives or any radioactive materials,
and (D) asbestos in any form or electrical equipment that contains any oil or dielectric fluid containing levels of polychlorinated
biphenyls in excess of 50 parts per million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets
in Good Condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All the material physical
assets of each Loan Party are in good operating condition and in a state of good maintenance and repair subject to the usual wear
and tear for assets of that age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licenses
and Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the material
licenses and agreements to which any Loan Party are a party is in good standing and in full force and effect, and neither a Loan
Party nor, to the best of the knowledge, information and belief of the Loan Parties, after due inquiry, any other party thereto,
is in breach of any material covenants, conditions or obligations contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party has
filed all federal, provincial, state and other (including foreign) Tax returns which are required to be filed, and have paid all
Taxes as shown on said returns, as well as all other Taxes to the extent that they have become due, unless being contested in good
faith with appropriate reserves. All Tax liabilities of each Loan Party are adequately provided for on such Loan Party&rsquo;s
books, including interest and penalties. No Tax liability has been asserted by taxing authorities for Taxes in excess of those
already paid, and no taxing authority has notified any Loan Party of any material deficiency in any federal, state and other Tax
returns. Notwithstanding the foregoing, each of the representations set forth in this Section 5.16 shall be deemed to be satisfied
where the potential liability does not exceed, and could not reasonably be expected to exceed, $20,000.00; provided that any such
liability under such threshold known to the Loan Parties as of the Closing Date is set forth on Schedule 5.16 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party maintains
insurance for risks and in amounts customary for prudent companies in the Loan Parties&rsquo; industry and owners of comparable
assets with responsible insurers against such risks. No Loan Party is in default with respect to any of the material provisions
contained in any current insurance policy or has failed to give any notice or pay any premium or present any unsettled claim under
any current insurance policy in a due and timely fashion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties own
or possess all their Material Intellectual Property without any known conflict with, or infringement of, the rights of others.
To the knowledge of the Loan Parties, no Product or service marketed or sold (or proposed to be marketed or sold) by any Loan Party
violates or will violate any license or infringes or will infringe in any material manner any intellectual property rights of any
other party. <U>Schedule 5.18</U> lists (i) all applications and registrations of Intellectual Property of the Loan Parties as
of the date hereof and identifies which of such Intellectual Property is Material Intellectual Property as of the date hereof,
(ii) all in-bound license or sublicense agreements for Material Intellectual Property to which a Loan Party is a party as of the
date hereof, and (iii) all material out-bound license or sublicense agreements to which a Loan Party is a party as of the date
hereof (in the case of (ii) and (iii) except for licenses of commercially available software or information technology services).
Other than as set forth on <U>Schedule 5.18,</U> or with respect to commercially available software products or information technology
services, as of the date hereof there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership
interests of any kind relating to the Material Intellectual Property owned by any Loan Party, nor is any Loan Party bound by or
a party to any options, licenses or agreements of any kind with respect to any patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information, proprietary rights and processes of any other Person. With respect to any Material
Intellectual Property that is a license agreement, <U>Schedule 5.18</U> indicates as of the date hereof (A) the name of the licensor,
(B) the name and date of the agreement pursuant to which such item of Material Intellectual Property is licensed, and (C) whether
or not such license agreement grants an exclusive license to any Loan Party. No Loan Party has received any written communications
alleging that such Loan Party has violated or, by conducting its business, would violate any of the patents, trademarks, service
marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person. It will
not be necessary to use any inventions of any of such Loan Party&rsquo;s employees or consultants (or Persons it currently intends
to hire) made prior to their employment by such Loan Party. Each employee or consultant engaged in research and development has
entered into an invention assignment agreement or similar agreement with such Loan Party with respect to all intellectual property
rights he or she develops pursuant to his or her employment or engagement to the applicable Loan Party. No Subsidiary that is not
a Loan Party owns any Material Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties hold
all permits (including Regulatory Required Permits), licenses, approvals, consents, authorizations, registrations, certificates
and franchises of governmental agencies or regulatory bodies required to own its properties and assets and to carry on its business,
except for any of the foregoing where the failure to hold the same would not have a Material Adverse Effect (the &ldquo;<B>Permits</B>&rdquo;),
and a list of all such Permits is set forth on <U>Schedule 5.19. </U>All the Permits are in full force and effect; each Loan Party
is in compliance in all material respects with all the terms and conditions relating to the Permits; and there are no proceedings
in progress, pending or, to such Loan Party&rsquo;s knowledge, threatened, that may result in revocation, cancellation, suspension,
rescission or any adverse modification of any of the Permits nor, to the best of the knowledge, information and belief of such
Loan Party, after due inquiry, are there any facts upon which proceedings could reasonably be based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory
Required Permits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to any
Product or service of any Loan Party, (i) each Loan Party has received, and such Product or service is the subject of, all Regulatory
Required Permits needed in connection with the testing, manufacture, marketing or sale of such Product or conduct of such service
as currently being conducted by or on behalf of such Loan Party, and (ii) such Product is being tested, manufactured, marketed
or sold, as the case may be, in material compliance with all Applicable Laws and Regulatory Required Permits, and such Loan Party
has not received any notice from any applicable Regulatory Authority or any other Governmental Authority that such Regulatory Authority
or Governmental Authority is conducting a material investigation or review of such Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 5.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Laws and Litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Each Loan Party is each conducting its business in compliance with all Applicable Laws,
                                                                                 including for greater certainty all Healthcare Laws, of each jurisdiction in which its business is carried on, except where
                                                                                 the failure to be in such compliance would not have a Material Adverse Effect; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">There is no court, administrative, regulatory or similar
proceeding (whether civil, quasi-criminal or criminal); arbitration or other dispute settlement procedure; investigation or enquiry
by any governmental, administrative, regulatory or similar body; or any similar matter or proceeding (collectively, &ldquo;<B>Proceedings</B>&rdquo;)
against or involving any Loan Party or any of their officers or directors (whether in progress, pending or, to the best of the
knowledge, information and belief of such Loan Party after due inquiry, threatened); no event has occurred that might give rise
to any Proceedings and such Loan Party is not aware of any existing grounds on which such Proceedings might be commenced and there
is no judgment, decree, injunction, rule, award or order of any court, government department, board, commission, agency, arbitrator
or similar body outstanding against such Loan Party or its officers or directors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Material
Facts Disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the statements,
documents, certificates or other items prepared or supplied by any Loan Party with respect to the transactions contemplated hereby
contains an untrue statement of a material fact, or fails to disclose a fact that is necessary to be made in order for any material
statement not to be misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Rights to Acquire Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person has any agreement
or option or right or privilege (whether pre-emptive or contractual) capable of becoming an agreement for the purchase of any assets
of any Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Rights to Provide Financial Advisory Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No person has any agreement
or option, or right or privilege (whether pre-emptive or contractual) capable of becoming an agreement for the provision of financial
advisory services to any Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief
Executive Office and Location of Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no location
at which any Loan Party has any assets (except for Products in transit) other than those locations listed on <U>Schedule 5.25.</U>
The chief executive office, registered office, principal place of business and the place where each Loan Party keeps its books
and records is located and specifically identified on <U>Schedule 5.25.</U> The locations of any assets stored with a bailee or
similar entity are located on <U>Schedule 5.25.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minute
Books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The minute books, stock
certificate books and stock transfer ledgers of each Loan Party are true, correct, complete and up-to-date and contain the minutes
of all meetings, and all resolutions, of the board of directors thereof (and all committees thereof) and shareholders thereof,
except that minutes of the most recent meeting of the directors may not be included or may be included in such minute books in
draft form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 5.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of Proceeds; Margin Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The proceeds of any
of the Loans will be used solely as provided in this Agreement, and none of such proceeds will be used (i) for the purpose of purchasing
or carrying any &ldquo;margin stock&rdquo; as defined in Regulations T, U or X of the Board of Governors of the Federal Reserve
System (12 C.F.R. Parts 220, 221 and 224), (ii) for the purpose of maintaining, reducing or retiring any indebtedness which was
originally incurred to purchase or carry a &ldquo;margin stock,&rdquo; or (iii) for any other purpose which might constitute this
transaction a &ldquo;purpose credit&rdquo; within the meaning of Regulations T, U or X. No Loan Party is engaged in the business
of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying &ldquo;margin stock.&rdquo;
No Loan Party nor any Person acting on behalf of any Loan Party has taken or will take any action which might cause any of the
Financing Documents to violate Regulations T, U or X, or any other regulations of the Board of Governors of the Federal Reserve
System or to violate the Securities Exchange Act of 1934, as amended, or any rule or regulation thereunder, in each case as now
in effect or as the same may hereafter be in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment
Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither any Loan Party
or any Person Controlling a Loan Party is or is required to be registered as an &ldquo;investment company&rdquo; under the Investment
Company Act of 1940.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bank
Accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Schedule 5.27</U>
lists, as of the Closing Date, all banks and other financial institutions at which any Loan Party maintains Deposit Account or
Securities Accounts, and such Schedule correctly identifies the name and address of each depository or intermediary, the name in
which such account is held, a description of the purpose of the account and the complete account number of such account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
and Corporate Structure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The corporate structure of the Loan Parties and their
Subsidiaries and shareholders is, as at the Closing Date, as set out in <U>Schedule 5.30,</U> which Schedule contains the authorized
capital of the Parent, Borrower and their respective Subsidiaries and the number of issued and outstanding shares and the beneficial
owners thereof at such time. Each of the Subsidiaries is, directly or indirectly, wholly-owned by one or more a Loan Party or
a Subsidiary. No Loan Party is a participant in any joint venture, partnership, limited liability company or similar arrangement.
Except as set forth on Schedule since its inception, no Loan Party has consolidated or merged with, or acquired assets outside
the ordinary course of, or acquired the stock of or any interest in any Person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">No Person (other than the Lender) will have an agreement
or option or any other right or privilege (whether by law, pre-emptive or contractual) capable of becoming an agreement or option,
including convertible securities, warrants or convertible obligations of any nature, for the purchase, subscription, allotment
or issuance of any unissued shares in the capital of the Borrower except as described in <U>Schedule 5.30.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">To the extent applicable and subject to satisfaction
of all obligations pursuant to Section 6.23, each Loan Party has full power and authority to create a lien on the Shares and no
disability or contractual obligation or restriction exists, that would prohibit such Loan Party from pledging the Shares pursuant
to this Agreement or the Security Agreements. There are no subscriptions, warrants, rights of first refusal or other restrictions
on transfer relative to, or options exercisable with respect to the Shares. The Shares have been and will be duly authorized and
(to the extent such concepts are applicable under the laws under which the applicable entity was formed) validly issued, fully
paid and non-assessable. The Shares are not the subject of any present or threatened (in writing) suit, action, arbitration, administrative
or other proceeding, and no Loan Party knows of any reasonable grounds for the institution of any such proceedings.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 5.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Loan Party has any
material liabilities and, to the best of its knowledge no material contingent liabilities, not disclosed in the financial statements
of such Loan Party, except (i) current liabilities incurred in the ordinary course of business to the date of the financial statements,
which have not been, either in any individual case or in the aggregate, materially adverse and (ii) liabilities of a type not required
by GAAP to be reflected in financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 5.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Loan Party is a
party to or bound by any currently effective employment contract, deferred compensation arrangement, bonus plan, incentive plan,
profit sharing plan, retirement agreement or other employee compensation plan or agreement, except as set forth on <U>Schedule
5.32.</U> No employee of a Loan Party has been granted the right to continued employment by such Loan Party or to any material
compensation following termination of employment with such Loan Party, except as set forth on <U>Schedule 5.32.</U> To each Loan
Party&rsquo;s knowledge, no employee of any Loan Party, nor any consultant with whom such Loan Party has contracted, is in violation
of any term of any employment contract, proprietary information agreement or any other agreement relating to the right of any such
individual to be employed by, or to contract with, such Loan Party; and to each Loan Party&rsquo;s knowledge the continued employment
by such Loan Party of its respective present employees, and the performance of such Loan Party&rsquo;s contracts with its independent
contractors, will not result in any such violation, and no such Loan Party has received any notice alleging that such violation
has occurred. No Loan Party is aware that any officer, key employee or group of employees of such Loan Party intends to terminate
his, her or their employment with any Loan Party, as applicable, nor does any Loan Party have a present intention to terminate
the employment of any such officer, key employee or group of employees. Each former employee of each Loan Party whose employment
was terminated by such Loan Party has entered into an agreement with such Loan Party providing for the full release of any claims
against such Loan Party or any related party arising out of such employment. There are no actions pending, or to such Loan Party&rsquo;s
knowledge, threatened, by any former or current employee concerning such person&rsquo;s employment by such Loan Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Arm&rsquo;s
Length Transactions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All agreements, arrangement
or transactions between any Loan Party, on the one hand, and any Affiliate of or other Person not dealing at arm&rsquo;s length
with the Borrower (other than ordinary course arrangements with any employee, management or director of the Borrower), on the other
hand, in existence as of the Closing Date are set forth on <U>Schedule 5.33.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description
of Real Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Schedule 5.34</U>
contains a description as of the Closing Date of (a) all real property owned by the Loan Parties (including municipal addresses,
legal description (to the extent available), a brief description of such property and its use), and (b) all real property leased
by the Loan Parties (including municipal addresses, legal description (to the extent available), the name of the landlord, the
term and any renewal rights under the applicable lease and a brief description of such property and its use).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Application
of Section to New Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent any Loan
Party forms or acquires any Subsidiary that becomes a Loan Party after the Closing Date, the representations and warranties in
this section shall be made with respect to such Subsidiary as if it were a Loan Party for purposes hereof from and after the date
of such formation or acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VI.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COVENANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For as long as the
Secured Obligations remain outstanding or Lender has any commitment to extend credit, each Loan Party agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of Proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Borrower shall
only use the proceeds of the Loans to refinance the Existing Loan Facility and for general corporate and working capital purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
of Principal and Interest; Secured Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Loan Parties
will duly and punctually pay the Secured Obligations, including, without limitation, the principal and interest accrued on the
Loans at the time and in the manner specified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the Loan Parties shall pay all Lender
Expenses on demand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Laws; Permits; Corporate Existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Loan Parties
shall (and shall cause its Subsidiaries, if any, to) maintain its corporate existence (other than in accordance with <U>Section
6.14(d)</U> or <U>Section 6.14(e)</U>), carry on and conduct its business in a proper and business-like manner, take all reasonable
action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business, including
all Permits, and comply with all Applicable Laws, in each case in all material respects. Each of the Loan Parties shall also forthwith
notify Lender in writing of the dissolution or wind-up of any existing Loan Party or Subsidiary or the creation or acquisition
of any new Subsidiary after the date hereof (and whether such Subsidiary is a Material Subsidiary).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delivery
of Collateral and Perfection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party shall
take such actions at the sole cost and expense of such Loan Party, as may be required or desirable and as requested by Lender,
to preserve, protect or perfect the security interests of Lender with respect to the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party will
defend the Collateral against, and will take such other action as is necessary to remove, any and all security interests on and
claims in respect of the Collateral other than the security interests created by this Agreement and Permitted Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
Leases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither a Loan Party
nor any of its Subsidiaries will enter into or maintain operating leases (other than real property leases) such that the aggregate
annual consolidated expenditure on such operating leases would be greater than $500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party shall
(and shall cause each of its Subsidiaries to) maintain insurance for risks and in amounts customary for prudent companies in the
Loan Parties&rsquo; industry and owners of comparable assets with responsible insurers against such risks, which insurance shall
be satisfactory to Lender, including but not limited to, business interruption, with Lender being named as a lender first loss
payee and mortgagee with respect to any commercial property insurance of each Loan Party and as additional insured with respect
to any general liability insurance of each Loan Party, and shall provide appropriate endorsements. Borrower shall promptly notify
Lender of the occurrence of any event which would negatively affect any insurance coverage. If a Loan Party does not maintain insurance
as required under this <U>Section 6.08</U> or pay any amount or furnish required proof of payment to Lender, Lender may make all
or part of such payment or obtain such insurance policies required in this <U>Section 6.08.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transactions
with Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Loan Party shall
or shall permit any of its Subsidiaries to enter into any transaction with any officer, director, employee, shareholder or any
Person not dealing at arm&rsquo;s length or any Affiliate of any of the foregoing (specifically excluding any employment or option
agreement or intercompany indebtedness or transactions between a Loan Party and any of its Subsidiaries) unless such transaction
is on terms no less favorable to such Loan Party than would be obtainable in an arm&rsquo;s length transaction. The Loan Parties
shall provide the Lender with evidence of compliance with this covenant upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Material
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party shall
observe each term, covenant and agreement contained in the Material Agreements, except to the extent that any non-compliance could
not reasonably be expected to result in Material Adverse Effect. At Lender&rsquo;s request, each Loan Party shall provide copies
of any Material Agreements entered into after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Parent shall prepare and provide to Lender
with respect to Parent and its Subsidiaries (a) monthly unaudited consolidated financial statements within 30 days of the end of
each month accompanied by a Compliance Certificate as referred to in Section 6.18, (b) quarterly unaudited consolidated financial
statements within the earlier of fourty-five (45) days of the end of each fiscal quarter (including, without limitation, the last
fiscal quarter) or the date that such financial statements are filed publicly, (c) audited consolidated financial statements within
the earlier of one hundred and twenty (120) days of the Parent&rsquo;s fiscal year end or the date such financial statements are
filed publicly, such audited financial statements to be accompanied by a report and opinion of an independent certified public
accountant acceptable to Lender, which report and opinion shall be prepared in accordance with GAAP and shall not be subject to
any qualification or exception, and (d) as soon as available, but in any event not later the last day of each fiscal year, the
Budget for the next fiscal year. Parent shall provide, upon request by the Lender, general ledger accounts and any board and board
subcommittee materials and shall provide online access to the Lender to quarterly board materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare
Regulatory Matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each Loan Party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">shall notify Lender promptly, and in any event within
ten (10) Business Days, after receiving a written notice of or otherwise becoming aware of or determining that any of the following
has occurred and would reasonably be expected to cause a Material Adverse Effect (each, a &ldquo;<B>Regulatory Reporting Event</B>&rdquo;
and collectively, the &ldquo;<B>Regulatory Reporting Events</B>&rdquo;): (i) any Governmental Authority or Regulatory Authority
is conducting or has conducted (A) if applicable, an investigation of any of the Loan Parties&rsquo; or their respective Subsidiaries&rsquo;
manufacturing facilities and processes for any Product which investigation has disclosed any material deficiencies or violations
of Laws and/or the Regulatory Required Permits related thereto or (B) an investigation or review of any Regulatory Required Permit
(other than routine reviews in the ordinary course of business associated with the renewal of a Regulatory Required Permit), (ii)
development, testing, and/or manufacturing of any Product that is material to the Loan Parties business (taken as a whole) should
cease, (iii) if a Product that is material to the Loan Parties business (taken as a whole) has been approved for marketing and
sale, any marketing or sales of such Product should cease or such Product should be withdrawn from the marketplace, or (iv) any
Regulatory Required Permit has been revoked or withdrawn. Each Loan Party shall provide to Lender such further information (including
copies of such documentation) as Lender may reasonably request with respect to any such Regulatory Reporting Event; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">shall and shall cause each other Loan Party to, obtain
all Regulatory Required Permits necessary for compliance in all material respects with Laws with respect to testing, manufacturing,
developing, selling or marketing of Products and shall, and shall cause each Loan Party to, maintain and comply in all material
respects with all such Regulatory Required Permits, the noncompliance with which could have a Material Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower shall cause
all of its Deposit Accounts in Canada to be held with the Lender within 90 days of the Closing Date, provided that, for certainty,
all banking services offered to the Borrower will be subject to fees comparable with customers similar to the Borrower and in accordance
with the Lender&rsquo;s standard practice in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Negative
Covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without the prior written
consent of Lender, no Loan Party shall (or shall permit any of its Subsidiaries, if any, to):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">incur, issue or make any request for or permit to
exist Indebtedness, except for the Permitted Indebtedness;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">grant or permit the existence of any Lien other than
Permitted Encumbrances, or enter into any agreement which prohibits the granting of any Lien or assignment by way of security
in the assets of any Loan Party or any Subsidiary (including a Lien in such instrument, contract, document or agreement);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">make any Disposition of material Property (including
Intellectual Property) except for:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Dispositions of obsolete or worn-out Equipment;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Dispositions that comply with <U>Section 3.05(a)</U>;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">Dispositions among Loan Parties;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">wind-up or liquidate any Loan Party unless the assets
thereof are transferred to another Loan Party and all documents reasonably requested by Lender are delivered in order to preserve
the Liens under the Security Documents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">merge, amalgamate or enter into another form of business
combination or reorganization (including any joint venture or partnership), except that (i) any Loan Party may merge, amalgamation
or consolidated with any other Loan Party, and (ii) any Subsidiary may merge, amalgamate or consolidate into a Loan Party or another
Subsidiary, provided that such merger, amalgamation or consolidation does not result in assets being transferred from a Loan Party
to a Subsidiary that is not a Loan Party, in each case so long as all documents reasonably requested by the Lender are delivered
in order to preserve the Liens under the Security Documents,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">make any payment of any dividend, distribution, redemption
or other payment (either cash or non-cash) in respect of any Loan Party&rsquo;s Equity Interests, other than Permitted Distributions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">make any Investment other than Permitted Investments;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">make any Acquisition other than Permitted Acquisitions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">change the jurisdiction of organization of any Loan
Party, or amend any Loan Party&rsquo;s Governing Documents in a manner which could reasonably be expected to have a Material Adverse
Effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">engage in any business other than the business engaged
in as of the Closing Date or substantially any substantially similar line of business as Borrower or in an adjacent line of business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">permit a Change of Control, except if Lender will
be paid in full in cash at the closing of such Change of Control in accordance with <U>Section 3.05(c)</U>;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">make or incur any capital expenditures in any fiscal
year in the aggregate in an amount which exceeds the amount set forth in the Budget for such a period by more than 15%; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">agree or otherwise commit to take any action described
in <U>paragraphs (a) through (l)</U> above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 6.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintenance
of Records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Loan Parties will keep and maintain accurate and
complete records of the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 6.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Borrower shall provide written notice to Lender at
least 30 days prior to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">any change in legal name, or jurisdiction of organization,
or chief executive office of any Loan Party, or commencing operations in a new province in Canada; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">any amendment to the Governing Documents of any Loan
Party; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Promptly upon becoming aware of same, Borrower shall
provide prompt written notice to Lender, of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">any Lien (other than Permitted Encumbrances) on, or
claim asserted against, any of the Collateral;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the occurrence of any event, claim or occurrence that
is or could reasonably be expected to have a Material Adverse Effect, including without limitation, any notice of default pursuant
to any license, Permit or other agreement pursuant to which a Loan Party or any of its Subsidiaries licenses, Material Intellectual
Property or the commencement of any litigation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">any change in the location of material Collateral
(including additional locations);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">any material loss of or damage to any of the Collateral;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">any material communication with or notice from the
TSX; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">any Material Adverse Change.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations
on Modifications, Waivers, Extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than in the ordinary
course of business, no Loan Party will (or will permit any of its Subsidiaries, if any, to): (i) amend, modify, terminate or waive
any provision of any Permit, contract, license or any agreement giving rise to a material Account except in the ordinary course
of business and which would not result in a Material Adverse Effect; or (ii) fail to exercise promptly and diligently its rights
under each Permit, contract and agreement giving rise to an Account except in the ordinary course of business and if such failure
is or could not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Covenant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties shall
ensure that Unrestricted Cash at all times is greater than aggregate Operating Cash Expenditures during any given trailing three
(3) month period, to be tested as of the last day of each month based on the most recently reported consolidated financial statements
delivered pursuant to <U>Section 6.11(a)</U> of this Agreement and reported on in the most recent Compliance Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 6.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intellectual
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Each of the Loan Parties shall protect, defend and
maintain the validity and enforceability of the Material Intellectual Property and shall not allow any Material Intellectual Property
to be abandoned, forfeited or dedicated to the public without Lender&rsquo;s consent. No Subsidiary that is not a Loan Party shall
own any Material Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">No Loan Party shall, or shall permit any of its Subsidiaries
to, enter into a license with respect to Material Intellectual Property with respect to which any Loan Party or such Subsidiary
is the licensee that prohibits or otherwise restricts a Loan Party or any Subsidiary from granting a security interest in a Loan
Party&rsquo;s or any Subsidiary&rsquo;s interest in such license or agreement or would adversely affect Lender&rsquo;s ability
to exercise remedies pursuant to any Financing Documents with respect to Collateral without prior notice to Lender and obtaining
such modifications to such license or agreement to ensure Lender&rsquo;s rights and remedies pursuant to the Financing Documents
are not materially impaired as Lender may request. The Loan Parties shall not be in material breach of any licenses and agreements
pursuant to which any Loan Party licenses Material Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Together with each Compliance Certificate for the
months ending March, June, September and December, Borrower shall provide Lender with a report of patents, patent applications,
copyright registrations, copyright applications, trademark registrations and trademark applications acquired by any Loan Party
or any of its Subsidiaries since the last such report delivered including a report regarding any new in-bound licenses or sublicense
agreements pertaining to Material Intellectual Property or new material out-bound license or sublicense agreements to which a
Loan Party is a party (in each case except for licenses of commercially available software or information technology services),
together with all copies of such applications, licenses, agreements or registrations as Lender may request. With respect to any
Intellectual Property registered in Canada, the United States or any other applicable jurisdiction and acquired by any Loan Party
or changed after the Closing Date, each of the Loan Parties hereby agrees to give notice of same to the Lender and upon Lender&rsquo;s
request, to deliver, or cause any other Guarantor to deliver, to Lender an Intellectual Property Security Agreements or other
documents as Lender may reasonably require to perfect its Lien therein or protect its interest with respect thereto, and authorizes
Lender to amend any previously delivered Intellectual Property Security Agreement to amend any schedule thereto to reflect such
addition or change. Borrower shall promptly notify Lender of the institution of any action, suit, litigation or proceeding pertaining
to the Material Intellectual Property of any Loan Party or a claim of infringement by any Loan Party or any of its Subsidiaries
on the intellectual property rights of a third party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension
Plans</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties shall
fund and maintain all Pension Plans and Welfare Plans, if any, in compliance with all Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Material
Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Loan Parties shall
cause each Material Subsidiary to promptly comply with <U>Section 4.03.</U> The Loan Parties shall ensure that all Material Agreements
are entered into by and all Material Intellectual Property is held through entities that are Loan Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Centre
of Main Interests</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party incorporated
in a member state of the European Union must not cause or allow its registered office or Centre of Main Interests to be in, or
maintain an Establishment in, any jurisdiction other than its jurisdiction of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Post-Closing
Obligations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Loan Parties shall satisfy the following
obligations after the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">within 10 Business Days after the Closing Date, the
Loan Parties shall deliver the German Security Agreements together with all customary officer&rsquo;s certificates, resolutions
and opinions required by the Lender related to PM Germany and such Financing Documents to which it will have become a party and
the Borrower&rsquo;s pledge of PM Germany (including, for the avoidance of doubt, legal opinions from Borrower&rsquo;s and Lender&rsquo;s
counsel in Germany), in each case in form and substance satisfactory to Lender;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">within 20 Business Days after the Closing Date, the
Borrower as sole shareholder of PM Germany shall take all required action to amend the articles of association (<I>Satzung</I>)
of PM Germany with the effect that the creation of pledges over, and the transfer of, shares in PM Germany are not subject to
any restriction of any kind (in particular to procure that paragraph 6 of the articles of association of PM Germany is deleted),
and promptly provide evidence thereof to Lender; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">when available after the Closing Date, but in no event
later than 30 days thereafter, the Loan Parties shall deliver formal evidence of the repayment and termination of the unsecured
Investment in Business Innovation Business Start-ups Contribution Agreement dated December 16, 2011 among Her Majesty the Queen
in Right of Canada and Profound Medical Inc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VII.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONDITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions
Precedent to the Initial Extension of Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of
Lender on the Closing Date, are subject to the fulfillment, to the satisfaction of Lender, of each of the conditions precedent
set forth below (unless provided on such later date stated in Section 6.23:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Lender shall have received this Agreement and each
of the other Financing Documents, in form and substance satisfactory to Lender, duly executed by each Person party thereto, and
each such document shall be in full force and effect, and no Default or Event of Default shall exist as of the execution of such
documents;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Lender shall have received confirmation that the Security
Documents (to the extent applicable) have been registered in the applicable jurisdictions so as to result in perfected of security
in all jurisdictions required by the Lender on the Closing Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Lender shall have received the Warrants on the terms
described in the Term Sheet;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Lender shall have received the applicable fees outlined
in <U>Section 2.03(b)</U> together with any other fees contemplated by this Agreement and payable on the Closing Date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">Lender shall have received a payoff letter with respect
to the Existing Loan Facility together with all documents as Lender may reasonably require in connection with the payoff of the
Existing Loan Facility to evidence the payoff and release of all Liens pursuant to the Existing Loan Facility;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">Lender shall have received Collateral Access Agreements
for the Borrower&rsquo;s Mississauga, Ontario location;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">Lender shall have received a certificate from an officer
of each Loan Party attesting to (i) the resolutions of such Loan Party&rsquo;s applicable Board authorizing its execution, delivery,
and performance of this Agreement and the other Financing Documents to which it is a party, (ii) the resolutions of such Loan
Party&rsquo;s stockholders, shareholders or members, as applicable, to the extent required pursuant to such Loan Party&rsquo;s
Governing Documents, (iii) such Loan Party&rsquo;s Governing Documents, certified by the applicable jurisdiction of organization,
and (iv) to the extent applicable in the relevant jurisdiction of incorporation, incumbency of the officers of such Loan Party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">to the extent applicable in the relevant jurisdiction
of incorporation, Lender shall have received a certificate of existence or good standing (or equivalent) with respect to each
Loan Party, dated within 10 days of the Closing Date, which certificate shall indicate the good standing in the applicable jurisdiction
of organization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Lender shall have received the Budget, together with
such financial statements as Lender may require;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">Lender shall have received a legal opinion letter
of (i) Borrower&rsquo;s counsel in Canada and the United States of America;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">Each of the Loan Parties shall have received all licenses,
approvals, consents or evidence of other actions required by any Person in connection with the execution and delivery by such
Loan Party of this Agreement or any other Financing Document or with the consummation of the transactions contemplated hereby
and thereby;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">Lender shall have received one or more certificates
of insurance, together with the endorsements thereto, as are required by <U>Section 6.08,</U> the form and substance of which
shall be satisfactory to Lender;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">No action, suit, investigation, litigation or proceeding
before any arbitrator or Tribunal that could reasonably be expected to have a Material Adverse Effect if adversely determined
shall be pending or threatened against any Loan Party or any Subsidiary;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(n)</TD><TD STYLE="text-align: justify">Lender shall have completed its business, legal, and
Collateral due diligence, the results of which shall be satisfactory to Lender in its sole discretion;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(o)</TD><TD STYLE="text-align: justify">No Material Adverse Effect shall have occurred;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(p)</TD><TD STYLE="text-align: justify">The Borrower&rsquo;s Deposit Account and operating
Account with the Lender shall have been opened;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(q)</TD><TD STYLE="text-align: justify">No Material Adverse Change shall have occurred since
the date of the Term Sheet.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(r)</TD><TD STYLE="text-align: justify">The Loan Parties shall have paid all Lender Expenses
incurred in connection with the transactions evidenced by this Agreement; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(s)</TD><TD STYLE="text-align: justify">All other documents and legal matters in connection
with the transactions contemplated by this Agreement shall have been delivered, executed, or recorded and shall be in form and
substance satisfactory to Lender.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 7.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions
Precedent to all Extensions of Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The obligation of Lender to make any Loans
or other credit extensions under this Agreement shall be subject to the following conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the representations and warranties contained in this
Agreement and the other Financing Documents shall be true and correct in all material respects on and as of the date of such extension
of credit, as though made on and as of such date (except to the extent that such representations and warranties relate solely
to an earlier date);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">(i) no Default or Event of Default shall have occurred
and be continuing on the date of such extension of credit, nor shall either result from the making thereof, (ii) no Material Adverse
Effect shall have occurred, and (iii) there has been no material deterioration in the consolidated financial condition of the
Loan Parties since the date of the most recent financial statements submitted to Lender;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">as a condition to the Tranche B Term Loan, (i) Borrower
shall have delivered the Tranche B Term Loan Request, (ii) Borrower shall have satisfied each of the Tranche B Conditions, and
(iii) Lender shall have received the Tranche B Commitment Fee and the Tranche B Closing Fee;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">no injunction, writ, restraining order, or other order
of any nature prohibiting, directly or indirectly, the extending of such credit shall have been issued and remain in force by
any Tribunal against any Loan Party, Lender, or any of their Affiliates; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">in the case of the initial draw under the Tranche
B Term Loans only, the Lender shall have received additional Warrants on the terms described in the Term Sheet.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VIII.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EVENTS OF DEFAULT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Section 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Events
of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any of the following shall constitute
an Event of Default under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">failure by any Loan Party to pay in cash all or any
part of the Secured Obligations (including, without limitation, principal and interest payments due hereunder) when due and payable
hereunder, and in the case of any amount other than principal (which shall not be subject to a cure period) such default shall
remain unremedied for a period of 2 Business Days after the due date;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Any Loan Party ceases or threatens to cease to carry
on business in the ordinary course or any material part of its business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Any Loan Party or any Subsidiary becomes unable to
satisfy its liabilities as they become due, or at any time the realizable value of the Loan Parties&rsquo; assets is less than
the aggregate sum of its liabilities, or any of them otherwise commit an act of bankruptcy or admits that it is &ldquo;insolvent;&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Any Loan Party or any Subsidiary, any creditor of
such a party, or any other Person institutes any proceeding or takes any action or executes any agreement in connection with the
commencement of any proceeding:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">seeking to adjudicate any Loan Party or any Subsidiary
bankrupt or insolvent;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">seeking liquidation, dissolution, winding-up, reorganization,
arrangement, protection, relief or composition of any Loan Party or Subsidiary or any material part of its property or debt, or
making a proposal with respect to any Loan Party or Subsidiary under any law relating to bankruptcy, insolvency, reorganization
or compromise of debts or other similar laws including, without limitation, all Insolvency Legislation, unless any such proceeding
or other action is successfully contested by the applicable Loan Party or Subsidiary in good faith and is dismissed or stayed
within 45 days;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">seeking appointment of a receiver, receiver and manager,
trustee, agent, custodian, monitor, liquidator or similar official for any Loan Party or Subsidiary or for any part of their properties
and assets or for any part of the Collateral; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">takes any other action or steps to institute an Insolvency
Proceeding;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">a receiver, conservator, trustee, custodian, monitor,
liquidator or similar official is appointed in respect of any Loan Party or Subsidiary or any of the Collateral;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify">a failure by any Loan Party or Subsidiary to make
payments of principal, interest or other amounts when due with respect to any other Indebtedness, or the occurrence of any default,
or any event or condition which, with the giving of notice or passage of time, or both, would constitute a default or event of
default by any Loan Party or Subsidiary under the terms of any Indebtedness in excess of Two Hundred and Fifty Thousand ($250,000);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(g)</TD><TD STYLE="text-align: justify">if any representation or warranty made by any Loan
Party in any of the Financing Documents or any other document, instrument or agreement executed and delivered by any Loan Party
at any time to or in favor of Lender is untrue or incorrect in any material respect as of the date on which it is made;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(h)</TD><TD STYLE="text-align: justify">any Loan Party breaches or fails to duly perform or
observe any covenant contained in <U>Section 6.14</U> or Section 6.23;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">any Loan Party fails to observe the covenants set
forth in <U>Article VI</U> (other than those contained in <U>Section 6.14</U> and Section 6.23) of this Agreement or any other
term, covenant or agreement contained herein or in any of the Financing Documents or any other document, instrument or agreement
executed and delivered by any Loan Party at any time to or in favor of Lender and such failure is not cured to the satisfaction
of the Lender, acting reasonably, within 10 Business Days after the earlier of (i) written notice thereof by the Lender to the
Borrower and (ii) actual knowledge of the Borrower of the same;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(j)</TD><TD STYLE="text-align: justify">any Loan Party challenges or threatens to challenge
the validity or enforceability of any of the Financing Documents or terminates or repudiates any of them or attempts to do so,
or such Financing Documents or any other document, instrument, agreement or certificate executed and delivered by any Loan Party
to Lender shall cease to be in full force and effect or fail, in whole or in part, to constitute a legal, valid, binding and enforceable
obligation of any Loan Party, as the case may be;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(k)</TD><TD STYLE="text-align: justify">any Security Document shall cease to create a valid
Lien in favor of Lender or Lender&rsquo;s Lien ceases to be a perfected, first priority Lien in the Collateral (subject to Permitted
Encumbrances), or any occurrence, development or change shall occur, which has resulted or is reasonably expected to result in
impairment in the perfection or priority of the Liens granted to Lender other than pursuant to Permitted Encumbrances, or there
is a material impairment of the Collateral;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(l)</TD><TD STYLE="text-align: justify">any part of the Collateral is attached, seized, levied
on or becomes subject to any similar process, or any Governmental Authority (including an administrative body or taxation authority)
issues a demand in respect of any Loan Party on any part of the Collateral, or any creditor enforces a Lien on the Collateral
or otherwise takes possession of property of any Loan Party, or gives written notice of its intent to do any of the foregoing
(unless such notice contested in good faith by appropriate legal proceedings and appropriate reserves satisfactory to Lender have
been taken);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(m)</TD><TD STYLE="text-align: justify">any resolution is passed for the winding up, dissolution
or liquidation or amalgamation of any Loan Party other than as permitted by <U>Section 6.14(d)</U> or <U>Section 6.14(e)</U> or
if any Loan Party loses its charter by expiration, cancellation, forfeiture or otherwise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(n)</TD><TD STYLE="text-align: justify">there is entered into against any Loan Party or Subsidiary
a judgment or order for the payment of money in an aggregate amount in excess of $250,000 or for equitable relief to enjoin, restrain
or prevent any Loan Party or Subsidiary from conducting any material part of its business, or which would otherwise reasonably
be expected to have a Material Adverse Effect;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(o)</TD><TD STYLE="text-align: justify">a Change of Control occurs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(p)</TD><TD STYLE="text-align: justify">any Permit (including any Regulatory Required Permit)
shall have been revoked, rescinded, suspended, modified in an adverse manner or not renewed for a full term, and such revocation,
rescission, suspension, modification or non-renewal has, or could reasonably be expected to have, a Material Adverse Effect.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(q)</TD><TD STYLE="text-align: justify">a Pension Plan Event occurs;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(r)</TD><TD STYLE="text-align: justify">if the common shares of the Parent cease to be listed
for trading on the TSX, the Parent ceases to be a reporting issuer in good standing in the Province of Ontario, a cease trade
order is issued by a Governmental Authority with respect to the common shares of the Parent which order is in effect for more
than twenty (20) Business Days or if the Parent appears on the list of defaulting issuers maintained by the Ontario Securities
Commission available for consultation on its website;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(s)</TD><TD STYLE="text-align: justify">the occurrence of a Material Adverse Change; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(t)</TD><TD STYLE="text-align: justify">any other event or circumstance occurs that could
reasonably give rise to a Material Adverse Effect.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 8.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender&rsquo;s
Remedies Upon Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Upon the occurrence, and during the continuation,
of an Event of Default, Lender may exercise any of the rights and remedies of a secured party under the PPSA or other similar
applicable foreign Law, and any other rights and remedies provided for in this Agreement or any other Financing Document or otherwise
available to it at law or in equity, such rights and remedies to include, without limitation, the following, all of which are
authorized by each Loan Party:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">Declare all Secured Obligations, whether evidenced
by this Agreement, by any of the other Financing Documents, or otherwise, immediately due and payable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Cease advancing money or extending credit to or for
the benefit of Borrower under this Agreement, under any of the Financing Documents, or under any other agreement between any Loan
Party, and Lender;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">Terminate this Agreement and any of the other Financing
Documents as to any future liability or obligation of Lender, but without affecting any of Lender&rsquo;s Liens in the Collateral
and without affecting the Secured Obligations;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">Settle or adjust disputes and claims directly with
Account Debtors for amounts and upon terms which Lender in its sole discretion considers advisable, and in such cases, Lender
will credit Borrower&rsquo;s Loan Account with only the net amounts received by Lender in payment of such Accounts after deducting
all Lender Expenses incurred or expended in connection therewith;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(v)</TD><TD STYLE="text-align: justify">Without notice to any Loan Party (such notice being
expressly waived), and without constituting a retention of any collateral in satisfaction of an obligation (within the meaning
of the PPSA or other similar applicable foreign Law), set off and apply to the Secured Obligations any and all (i) funds coming
into possession of Lender, or (ii) Indebtedness at any time owing to or for the credit or the account of any Loan Party held by
Lender;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vi)</TD><TD STYLE="text-align: justify">Deliver a notice of exclusive control, any entitlement
order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">take any and all other remedies at Law or provided
for under the applicable Security Documents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
Protective Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without notice to or
demand upon any Loan Party, make such payments and do such acts as Lender considers necessary or reasonable to protect its security
interests in the Collateral, enhance the likelihood of repayment of the Secured Obligations, or pay any other amount payable by
or chargeable to any Loan Party pursuant to the terms of this Agreement, including costs, fees, and expenses, and Lender Expenses.
All such amounts shall be added to the principal of the Term Loan outstanding hereunder, and be repayable on demand and secured
by the Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remedies
Cumulative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights and remedies
of Lender under this Agreement, the other Financing Documents, and all other agreements shall be cumulative. Lender shall have
all other rights and remedies not inconsistent herewith as provided under the PPSA or other similar applicable foreign Law, by
law, or in equity. No exercise by Lender of one right or remedy shall be deemed an election, and no waiver by Lender of any Event
of Default shall be deemed a continuing waiver. No delay by Lender shall constitute a waiver, election, or acquiescence by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Power
of Attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party hereby
irrevocably makes, constitutes, and appoints Lender (and any of Lender&rsquo;s officers, employees, or agents designated by Lender)
as such Loan Party&rsquo;s true and lawful attorney, during the existence of an Event of Default, with power to (a) sign the name
of such Loan Party on any Additional Documents, (b) sign such Loan Party&rsquo;s name on any invoice or bill of lading relating
to the Collateral, drafts against Account Debtors, or notices to Account Debtors, (c) send requests for verification of Accounts,
(d) endorse such Loan Party&rsquo;s name on any collection item that may come into Lender&rsquo;s possession, (e) make, settle,
and adjust all claims under such Loan Party&rsquo;s policies of insurance and make all determinations and decisions with respect
to such policies of insurance, and (f) pay, contest or settle any Lien or other encumbrance or adverse claim in or to the Collateral
or any judgment based thereon. The appointment of Lender as each such Loan Party&rsquo;s attorney, and each and every one of its
rights and powers, being coupled with an interest, is irrevocable until all of the Secured Obligations have been fully and finally
repaid and performed and any obligation of Lender to extend credit hereunder is terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party hereby
releases Lender (and any of Lender&rsquo;s officers, employees, or agents designated by Lender) from the restrictions (to the extent
that such restrictions would otherwise apply) on self-dealing and multi-representation pursuant to section 181 of the German Civil
Code (<I>B&uuml;rgerliches Gesetzbuch</I>) and similar restrictions (if any) applicable to it pursuant to any other applicable
laws, in each case to the extent legally possible to such Loan Party. For the avoidance of doubt, if and to the extent that Lender
is authorised to sub-delegate (by power of attorney or otherwise) any powers granted to it under the Financing Documents (or any
of them), this shall extend to include such release. Each Loan Party which is barred by its constitutional documents, by-laws or
otherwise from validly granting such release will inform Lender accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notice
of Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party shall
promptly give notice in writing to Lender of the occurrence of any Event of Default or other event which, with the lapse of time
or giving of notice or otherwise, would be an Event of Default, forthwith upon becoming aware thereof. Such written notice shall
specify the nature of such default or Event of Default and the steps taken to remedy the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Default
under Other Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amount paid by
Lender before or after the occurrence of an Event of Default on account of monies payable under any Lien upon the Collateral or
any part thereof shall be repaid by the Loan Parties to Lender on demand and shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">be added to the Secured Obligations and constitute
a charge upon the Collateral; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">bear interest at the rate equal to the Post-Default
Rate as a reasonable and genuine pre-estimate of damages and not as a penalty.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the taking
of any judgment nor the exercise of any power of seizure or sale shall operate to extinguish the liability of the Loan Parties
to perform the Secured Obligations nor shall such operate as a merger of any covenant or affect the right of Lender to receive
interest at the specified rate, and any judgment shall bear interest at such rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Application
of Proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the existence
of an Event of Default, Lender may apply in any order all payments received or funds coming into its possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation
of Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lender shall not be
liable by reason of any entry into or taking possession of any of the Collateral charged or intended to be charged by the Security
Documents or any part thereof, to account as mortgagee in possession or for anything except actual receipts or be liable for any
loss on realization or any act or omission for which a secured party in possession might be liable. Lender shall not, by virtue
of these presents, be deemed to be a mortgagee in possession of the Collateral. Lender shall not be liable or accountable for any
failure to exercise its remedies, take possession of, seize, collect, realize, sell, lease or otherwise dispose of or obtain payment
for the Collateral and shall not be bound to institute proceedings for such purposes or for the purpose of preserving any rights,
remedies or powers of Lender, any Loan Party or any other person in respect of same. Each Loan Party hereby releases and discharges
Lender from every claim of every nature, whether sounding in damages or not, which may arise or be caused to any Loan Party or
any person claiming through any Loan Party by reason or as a result of anything done or omitted to be done, as the case may be,
by Lender or any successor or assign claiming through or under Lender under the provisions of this Agreement, unless such claim
is the result of Lender&rsquo;s gross negligence or willful misconduct as determined by a final, non-appealable judgment. The guarantee
limitations set forth in clause 4.10 of the Canadian Guarantee shall apply <I>mutatis mutandis</I> to any indemnity granted by
or other secondary liability of a Loan Party incorporated as limited liability company (<I>GmbH</I>) in Germany to the Lender pursuant
to this Section 8.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower
Liable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrower hereby waives
any requirement that the Lender protect, secure, perfect or insure any security interest or Lien, or any property subject thereto,
or exhaust any right or take any action against any other Loan Party or other entity. Borrower agrees not to seek payment directly
or indirectly from another Loan Party through a claim of indemnity, contribution, or otherwise with respect to the Secured Obligations,
until the Secured Obligations have been repaid in full and this Agreement has terminated. Any agreement providing for indemnification,
reimbursement or any other arrangement prohibited under this Section shall be null and void. If any payment is made to a Loan Party
in contravention of this Section, such Loan Party to hold such payment in trust for Lender and such payment shall be promptly delivered
to Lender for application to the Secured Obligations, whether matured or unmatured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IX.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GENERAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Releases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lender may in its discretion
from time to time release any part of the Collateral or any other security either with or without any sufficient consideration
therefor, without responsibility therefor and without thereby releasing any other part of the Collateral or any other security
or any Person from the security created by this Agreement or any of the Financing Documents or from any of the covenants herein
contained. Each and every portion into which the Collateral is or may hereafter be divided does and shall stay subject to the Lien
pursuant to this Agreement. No Person shall have the right to require the Secured Obligations to be apportioned and Lender shall
not be accountable to any Loan Party for any moneys except those actually received by Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 9.02 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law; Jurisdiction; Jury Trial Waiver and Judicial Reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Financing Documents,
except if expressly provided otherwise therein, shall be exclusively (without regard to any rules or principles relating to conflicts
of laws) governed by, enforced and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada
applicable therein. Each Loan Party hereby irrevocably and unconditionally consents, for itself and its property, to the exclusive
jurisdiction of the courts of the Province of Ontario with respect to any matter arising under or relating to this Agreement or
any of the other Financing Documents, except if expressly provided otherwise therein. Each Loan Party expressly submits and consents
in advance to such jurisdiction in any action or suit commenced in any such court, and such Loan Party hereby waives any objection
that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting
of such legal or equitable relief as is deemed appropriate by such court. Nothing in this Agreement shall affect any right that
Lender may otherwise have to bring any action or proceeding relating to any Financing Document against a Loan Party or its properties
in the courts of any jurisdiction. Each Loan Party hereby waives personal service of the summons, complaints and other process
issued in such action or suit and agrees that service of such summons, complains and other process may be made by registered or
certified mail addressed to Borrower as its duly appointed process agent at the address set forth in, or subsequently provided
to Lender in accordance with this Agreement, and that service so made shall be deemed completed upon the earlier to occur of Borrower&rsquo;s
actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage paid. TO THE FULLEST EXTENT PERMITTED
BY APPLICABLE LAW, EACH LOAN PARTY AND LENDER WAIVES THEIR RIGHT TO A JURY TRIAL OF ANY CLAIMS OR CAUSE OF ACTION ARISING OUT OF
OR BASED UPON THIS AGREEMENT, THE FINANCING DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY
AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED
THIS WAIVER WITH ITS COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whole
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and
other Financing Documents and any and all other documents ancillary thereto and executed and delivered in connection therewith,
constitute the entire agreement between the parties hereto with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Time shall be of the
essence of all provisions of this Agreement and the other Financing Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any notice or other
communication required or permitted to be given hereunder shall be in writing and shall be given by prepaid first-class mail, or
means of electronic communication or by hand-delivery as hereinafter provided. Any such notice or other communication, if mailed
by prepaid first-class mail at any time other than during, or within three (3) Business Days prior to, a general discontinuance
of postal service due to strike, lockout or otherwise, shall be deemed to have been received on the fourth Business Day after the
postmarked date thereof, or if sent or by means of electronic communication, shall be deemed to have been received on the Business
Day of the sending (provided it was sent before 4:30 p.m. Toronto, Ontario time), or if delivered by hand shall be deemed to have
been received at the time it is delivered to the applicable address noted below either to the individual designated below or to
an employee of the addressee at such address with responsibility for matters to which the information relates. Notice of change
of address shall also be governed by this <U>Section 9.05.</U> In the event of a general discontinuance of postal service due to
strike, lock-out or otherwise, notices or other communications shall be delivered by hand or any means of electronic communication
and shall be deemed to have been received in accordance with the foregoing. Notices and other communications shall be addressed
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">if to the Loan Parties:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Profound Medical Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2400 Skymark Ave. Unit #6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Mississauga, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Aaron Davidson, Chief Financial Officer
and Senior VP Corporate Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: ADavidson@profoundmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with a copy (that does not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Torys LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">79 Wellington St W #3000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Toronto, ON M5K 1N2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Amanda Balasubramanian</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: abalasubramanian@torys.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">if to Lender:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">for any borrowing request:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Canadian Imperial Bank of Commerce</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Credit Processing Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">595 Bay Street, 5<FONT STYLE="font-size: 10pt"><SUP>th
</SUP></FONT>floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Toronto, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">M5H 2C2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">e-mail: gregory.mcdonald@cibc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Gregory McDonald</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">for all other notices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">CIBC Innovation Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">40 King S. West, Suite 5702</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Toronto, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">M5H 3Y2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">facsimile: 416-682-1160</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">e-mail: jeff.chapman@cibc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jeff Chapman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with a copy (that does not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Goodmans LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">333 Bay Street, Suite 3400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Toronto, Ontario M5H 2S7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Facsimile: 416-979-1234</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">e-mail: mbertrand@goodmans.ca</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Michael Bertrand</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successors
and Assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall
be binding on each Loan Party and its successors and assigns and shall inure to the benefit of Lender and its successors and permitted
assigns. Each Loan Party agrees not assign, transfer or delegate any of its rights or obligations under this Agreement without
the prior written consent of Lender which it may exercise in its sole and absolute discretion. Lender shall be entitled to assign
this Agreement to any other party (with, so long as no Default or Event of Default has occurred, the consent of Borrower); provided,
that so long as no Default or Event has occurred, such assignment shall not increase the relevant Loan Party&rsquo;s obligation
to reimburse, indemnify or make whole the Lender pursuant to <U>Section 3.09 </U> or <U>Section 3.10</U> as a result of such assignment.
Notwithstanding the foregoing, an assignment to an Affiliate of Lender may be made at any time without consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party hereby
agrees to indemnify, defend and hold Lender and its principals, employees, agents, attorneys, or any other Person affiliated with
or representing Lender (each, an &ldquo;<B>Indemnified Person</B>&rdquo;) harmless against: (i) all obligations, demands, claims,
and liabilities (collectively, &ldquo;<B>Indemnified Claims</B>&rdquo;) claimed or asserted by any other party in connection with
the transactions contemplated by the Financing Documents; and (ii) all losses or expenses (including Lender Expenses) in any way
suffered, incurred, or paid by such Indemnified Person as a result of, following from, consequential to, or arising from transactions
between Lender and any Loan Party (including attorneys&rsquo; and other legal fees and expenses), except for Indemnified Claims
or losses finally determined by a court of competent jurisdiction to have been directly caused by such Indemnified Person&rsquo;s
gross negligence or willful misconduct. This provision shall survive the termination of this Agreement and the repayment of the
Secured Obligations. The guarantee limitations set forth in clause 4.10 of the Canadian Guarantee shall apply <I>mutatis mutandis</I>
to any indemnity granted by or other secondary liability of a Loan Party incorporated as limited liability company (<I>GmbH</I>)
in Germany to the Lender pursuant to this Section 9.07.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Set-Off.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Secured Obligations
shall be paid by the Loan Parties without regard to any set-off, withholding, counterclaim or equities between any Loan Party and
Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted
Encumbrance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any
other provision in this Agreement, the parties confirm their intent that the references to Permitted Encumbrances herein are not
intended to imply the subordination by Lender to any Person whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press
Releases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Loan Party agrees
that Lender may issue press releases announcing the fact and extension of the financing under this Agreement and further agrees
that Lender may display any Loan Party&rsquo;s logo on its website and collateral material consistent with its other portfolio
companies. Lender&rsquo;s use of such logo shall be subject to such Loan Party&rsquo;s approval, which shall not be unreasonably
withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 9.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lender agrees to use
the same degree of care that it exercises with respect to its own proprietary information to maintain the confidentiality of any
and all proprietary, trade secret or confidential information provided to or received by Lender from or on behalf of the Loan Parties,
which indicates that it is confidential or would reasonably be understood to be confidential, including business plans and forecasts,
non-public financial information, confidential or secret processes, formulae, devices and contractual information, customer lists,
and employee relation matters, provided that Lender may disclose such information to its officers, directors, employees, attorneys,
accountants and affiliates, and such other Persons to whom Lender shall at any time be required to make such disclosure in accordance
with Applicable Law and in connection with the exercise of remedies, and provided that the foregoing shall not apply to information
that is in the public domain or becomes part of the public domain (other than as a result of its disclosure by Lender in violation
of this Agreement) after disclosure to Lender. The confidentiality agreement in this Section supersedes any prior confidentiality
agreement of Lender relating to the Loan Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 9.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Judgment
Currency</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If for the purpose of obtaining or enforcing judgment
against any Loan Party in any court in any jurisdiction, it becomes necessary to convert into any other currency (such other currency
being hereinafter in this <U>Section 9.12</U> referred to as the &ldquo;<B>Judgement Currency</B>&rdquo;) an amount due in into
another currency (referred to as the &ldquo;<B>Required Currency</B>&rdquo;), the conversion shall be made at the Exchange Rate
prevailing on the Business Day immediately preceding:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(i)</TD><TD STYLE="text-align: justify">the date of actual payment of the amount due, in the
case of any proceeding in the courts of the Province of Ontario or in the courts of any other jurisdiction that will give effect
to such conversion being made on such date; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">the date on which the judgment is given, in the case
of any proceeding in the courts of any other jurisdiction (the date as of which such conversion is made pursuant to this <U>Section
9.12(a)(ii)</U> being hereinafter in this Section referred to as the &ldquo;<B>Judgement Conversion Date</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If, in the case of any proceeding in the court of
any jurisdiction referred to in <U>clause (a)(ii)</U> of this section, there is a change in the rate of exchange prevailing between
the Judgement Conversion Date and the date of actual payment of the amount due, the Loan Parties, jointly and severally, shall
pay such additional or lesser amount as may be necessary to ensure that the amount paid in the Judgement Currency, when converted
at the rate of exchange prevailing on the date of payment, will produce the amount of the Required Currency, which could have
been purchased with the amount of Judgement Currency stipulated in the judgment or judicial order at the rate of exchange prevailing
on the Judgement Conversion Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Any amount due from any Loan Party under the provisions
of Section (b) shall be due as a separate debt and shall not be affected by judgment being obtained for any other amounts due
under or in respect of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Section 9.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Money
Laundering Legislation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Each Loan Party acknowledges that, pursuant to the
<I>Proceeds of Crime (Money Laundering) and Terrorist Financing Act</I> (Canada) and other applicable anti-money laundering,
anti-terrorist financing, government sanction and &ldquo;know your client&rdquo; laws (collectively, including any guidelines
or orders thereunder, &ldquo;<B>AML Legislation</B>&rdquo;), Lender may be required to obtain, verify and record information regarding
the Loan Parties, their directors, authorized signing officers, direct or indirect shareholders or other Persons in control of
such Loan Party, and the transactions contemplated hereby. Each Loan Party shall promptly provide all such information, including
supporting documentation and other evidence, as may be reasonably requested by Lender, or any prospective assignee or participant
of Lender, in order to comply with any applicable AML Legislation, whether now or hereafter in existence.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Each Loan Party acknowledges and agrees that pursuant
to the provisions of the <I>USA Patriot Act</I> (Title III of the Pub. L. 107-56) signed into law October 26, 2001 (the &ldquo;<B><I>Patriot
Act</I></B>&rdquo;), Lender may be required to obtain, verify and record information with respect to the Loan Parties, and each
Loan Party hereby agrees to cooperate with Lender and provide them with all information that may be required in order to fulfil
its obligations under the Patriot Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Section 9.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may
be executed in several counterparts, each of which, when so executed, shall be deemed to be an original and which counterparts
taken together shall constitute one and the same Agreement. This Agreement may be executed by facsimile or pdf, and any signature
contained hereon by facsimile or pdf shall be deemed to be equivalent to an original signature for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85pt">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF, each of the parties hereto have duly executed
this Agreement as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">PROFOUND MEDICAL INC., as Borrower</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arun
    Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%">Name:</TD>
    <TD STYLE="width: 38%">Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rashed
    Dewan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Rashed Dewan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>VP Finance</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">PROFOUND MEDICAL CORP., as a</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guarantor</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arun
Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aaron
    Davidson</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Aaron Davidson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">PROFOUND MEDICAL GMBH, as a</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guarantor</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hartmut
Warnken</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Hartmut Warnken</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>VP, Int. Sales</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Per:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>Signature Page &ndash; Credit Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 72 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">PROFOUND MEDICAL (U.S.) INC., as a</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guarantor</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arun
    Menawat</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%">Name: &nbsp;</TD>
    <TD STYLE="width: 38%">Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rashed
    Dewan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: &nbsp;</TD>
    <TD>Rashed Dewan</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 252.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 252.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">CANADIAN IMPERIAL BANK OF</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMERCE, as Lender</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Usher</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 7%">Name: &nbsp;</TD>
    <TD STYLE="width: 38%">Mark Usher</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Per:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>Signature Page &ndash; Credit Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Exhibit A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TRANCHE B TERM LOAN REQUEST</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CIBC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentleman:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned, a Responsible Officer
of Profound Medical Inc., an Ontario corporation (&ldquo;<B>Borrower</B>&rdquo;), refer to the Credit Agreement, dated as of July
30, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Credit Agreement</B>&rdquo;,
the terms defined therein being used herein as therein defined), among Borrower, the other Loan Parties party thereto and CIBC
(&ldquo;<B>Lender</B>&rdquo;), and hereby give you notice, irrevocably, pursuant to and as required by <U>Section 2.02(b)(i)</U>
of the Credit Agreement, that Borrower hereby requests a Tranche B Term Loan under the Credit Agreement, and confirms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">The requested date of the Tranche B Term Loan, which
is a Business Day, is [<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>].</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">The amount of the Tranche B Term Loan is $[<FONT STYLE="font-family: Wingdings">l</FONT>].</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Each of the Tranche B Conditions have been met.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">4.</TD><TD STYLE="text-align: justify">The Tranche B Closing Fee shall be [deducted from
the proceeds of the Loan] [has been paid separately as of the date hereof.]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.</TD><TD STYLE="text-align: justify">The bank name, location and number of the account
to which funds are to be disbursed is attached.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby represents and warrants
that, as of the date of this Tranche B Term Loan Request, the conditions set forth in <U>Section 7.02</U> have been satisfied as
if such conditions were set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE TO TRANCHE B TERM LOAN REQUEST]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very yours truly,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 238pt">&nbsp;</P>


<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Exhibit B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B><U>COMPLIANCE CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 201<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIBC Innovation Banking</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">40 King S. West, Suite 5702</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Toronto, Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M5H 3Y2, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Jeff Chapman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Re:&#9;Credit Agreement, dated as of July
30, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the &ldquo;<B>Credit Agreement</B>&rdquo;),
among Profound Medical Inc., an Ontario corporation (the &ldquo;<B>Borrower</B>&rdquo;), the other Loan Parties from time to time
party thereto, and CIBC (&ldquo;<B>Lender</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently herewith
Borrower delivers to Lender the <B><I>[monthly/quarterly/annual] </I></B>financial statements for the period ending<U>&#9;</U>.
Any capitalized terms used herein but not defined shall have the meaning set forth in the Credit Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter shall serve
as certification by or on behalf of the Borrower to Lender of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with <U>Section 6.10</U> of the Credit Agreement, (i) all financial statements delivered herewith have been prepared
in accordance with GAAP (except for the lack of footnotes and being subject to year-end audit adjustments) and fairly present in
all material respects the financial condition of the Loan Parties and each of its Subsidiaries at the close of, and results of
Borrower&rsquo;s and each of its Subsidiaries&rsquo; operations and cash flows for, the periods covered, (ii) the Borrower has
properly made all statutory withholdings, (iii) the representations and warranties of the Loan Parties set forth in the Credit
Agreement are true and correct in all material respects as of the date hereof with the same force and effect as if such representations
and warranties had been made on and as of such time except for (A) such representations and warranties stated to be true as of
a specific date and (B) any changes to the schedules to such representations and warranties that arise in the ordinary course of
business and are not prohibited under the Credit Agreement and attached hereto, (iv) the Borrower has complied with all covenants,
conditions and other requirements contained in any Financing Document, (v) there has not occurred any Default or Event of Default,
and there has not occurred any breach or default under any other document, instrument or agreement (including any Material Agreement)
which would reasonably be expected to have a Material Adverse Effect and (vi) there has been no material deterioration in the consolidated
financial condition of the Loan Parties since the date of the most recent financial statements submitted to Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with <U>Section 6.18</U> of the Credit Agreement, the Loan Parties are in compliance with the following financial covenants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">For the month ended<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrestricted
Cash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trailing
3 Month Operating Cash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Expenditures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Required:</U>&nbsp;(A) must be greater than (B)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Complies:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;Yes&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
confirmations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">Any change in the legal name, jurisdiction of organization
or location of chief executive office or registered office of any Loan Party or new Canadian Provinces in which they operate?</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;Yes,
details listed below&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>
No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD STYLE="text-align: justify">Are there any new Deposit Accounts or Securities Accounts
opened by any Loan Party (not previously disclosed on a Compliance Certificate)?</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;Yes,
details listed below&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>
No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Account </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holder</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Depository
/</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intermediary</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Account </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 16%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Control </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Agreement</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify">Have any Subsidiaries been formed, acquired other
than Subsidiaries set forth on <U>Schedule 5.31 </U>to the Agreement or as previously disclosed on a Compliance Certificate? Are
any of them Material Subsidiaries?</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>Yes,
details listed below, together with updated organizational chart</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Wingdings">&uml;</FONT>No</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organization</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 20%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ownership of </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiary </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(indicating </B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>percentage)</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attached
hereto are any updates to the schedules to the Agreement to give effect to the statement in <U>clause (a)(iii)(B)</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>[For
the certificate for March, June, September and December only to comply with the statement in Section 6.19(c) of the Credit Agreement]</B>:
Attached is a list of new Intellectual Property acquired and not previously disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE TO COMPLIANCE CERTIFICATE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">This Compliance Certificate is a Financing Document.
Such certification is made as of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
201<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">BORROWER:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>][[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>]]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 257pt">&nbsp;</P>


<!-- Field: Page; Sequence: 80 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE OF EXCEPTIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SCHEDULE OF EXCEPTIONS REDACTED]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 81; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>14
<FILENAME>tv526458_ex4-8.htm
<DESCRIPTION>EXHIBIT 4.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-variant: normal">Exhibit
4.8</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">PROFOUND
MEDICAL CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- and -</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TSX TRUST
COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">COMMON SHARE
PURCHASE WARRANT INDENTURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Providing for the Issue of<BR>
up to 5,750,000 Common Share Purchase Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">September 20, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 0; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt 0pt 0; text-align: right"><B></B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 1 INTERPRETATION</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%; padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.1</TD>
    <TD STYLE="text-indent: 0in">Definitions</TD>
    <TD STYLE="text-align: right; text-indent: 0in">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.2</TD>
    <TD STYLE="text-indent: 0in">Words Importing the Singular</TD>
    <TD STYLE="text-align: right; text-indent: 0in">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.3</TD>
    <TD STYLE="text-indent: 0in">Interpretation not Affected by Headings</TD>
    <TD STYLE="text-align: right; text-indent: 0in">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.4</TD>
    <TD STYLE="text-indent: 0in">Day not a Business Day</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.5</TD>
    <TD STYLE="text-indent: 0in">Time of the Essence</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.6</TD>
    <TD STYLE="text-indent: 0in">Governing Law</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.7</TD>
    <TD STYLE="text-indent: 0in">Meaning of &ldquo;outstanding&rdquo; for Certain Purposes</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.8</TD>
    <TD STYLE="text-indent: 0in">Currency</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.9</TD>
    <TD STYLE="text-indent: 0in">Termination</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 2 ISSUE OF WARRANTS</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.1</TD>
    <TD STYLE="text-indent: 0in">Issue of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.2</TD>
    <TD STYLE="text-indent: 0in">Form and Terms of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.3</TD>
    <TD STYLE="text-indent: 0in">Signing of Warrant Certificates</TD>
    <TD STYLE="text-align: right; text-indent: 0in">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.4</TD>
    <TD STYLE="text-indent: 0in">Authentication or Certification by the Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.5</TD>
    <TD STYLE="text-indent: 0in">Warrantholder not a Shareholder, etc.</TD>
    <TD STYLE="text-align: right; text-indent: 0in">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.6</TD>
    <TD STYLE="text-indent: 0in">Issue in Substitution for Lost Warrant Certificates</TD>
    <TD STYLE="text-align: right; text-indent: 0in">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.7</TD>
    <TD STYLE="text-indent: 0in">Warrants to Rank <I>Pari Passu</I></TD>
    <TD STYLE="text-align: right; text-indent: 0in">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.8</TD>
    <TD STYLE="text-indent: 0in">Registration and Transfer of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.9</TD>
    <TD STYLE="text-indent: 0in">Registers Open for Inspection</TD>
    <TD STYLE="text-align: right; text-indent: 0in">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.10</TD>
    <TD STYLE="text-indent: 0in">Exchange of Warrant Certificates</TD>
    <TD STYLE="text-align: right; text-indent: 0in">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.11</TD>
    <TD STYLE="text-indent: 0in">Ownership of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.12</TD>
    <TD STYLE="text-indent: 0in">Book-Based System Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.13</TD>
    <TD STYLE="text-indent: 0in">Adjustment of Exchange Basis</TD>
    <TD STYLE="text-align: right; text-indent: 0in">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.14</TD>
    <TD STYLE="text-indent: 0in">Rules Regarding Calculation of Adjustment of Exchange Basis</TD>
    <TD STYLE="text-align: right; text-indent: 0in">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.15</TD>
    <TD STYLE="text-indent: 0in">Postponement of Subscription</TD>
    <TD STYLE="text-align: right; text-indent: 0in">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.16</TD>
    <TD STYLE="text-indent: 0in">Notice of Adjustment</TD>
    <TD STYLE="text-align: right; text-indent: 0in">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.17</TD>
    <TD STYLE="text-indent: 0in">No Action after Notice</TD>
    <TD STYLE="text-align: right; text-indent: 0in">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.18</TD>
    <TD STYLE="text-indent: 0in">Optional Purchases by the Company</TD>
    <TD STYLE="text-align: right; text-indent: 0in">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.19</TD>
    <TD STYLE="text-indent: 0in">Protection of Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.20</TD>
    <TD STYLE="text-indent: 0in">U.S. Legend on Warrant Certificates and Warrant Share certificates</TD>
    <TD STYLE="text-align: right; text-indent: 0in">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 3 EXERCISE OF WARRANTS</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.1</TD>
    <TD STYLE="text-indent: 0in">Method of Exercise of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.2</TD>
    <TD STYLE="text-indent: 0in">No Fractional Warrant Shares</TD>
    <TD STYLE="text-align: right; text-indent: 0in">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.3</TD>
    <TD STYLE="text-indent: 0in">Effect of Exercise of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.4</TD>
    <TD STYLE="text-indent: 0in">Cancellation of Warrants</TD>
    <TD STYLE="text-align: right; text-indent: 0in">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.5</TD>
    <TD STYLE="text-indent: 0in">Subscription for less than Entitlement</TD>
    <TD STYLE="text-align: right; text-indent: 0in">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.6</TD>
    <TD STYLE="text-indent: 0in">Expiration of Warrant</TD>
    <TD STYLE="text-align: right; text-indent: 0in">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.7</TD>
    <TD STYLE="text-indent: 0in">Prohibition on Exercise by U.S. Persons; Exception</TD>
    <TD STYLE="text-align: right; text-indent: 0in">26</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 4 COVENANTS</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%; padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.1</TD>
    <TD STYLE="text-indent: 0in">General Covenants of the Company</TD>
    <TD STYLE="text-align: right; text-indent: 0in">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.2</TD>
    <TD STYLE="text-indent: 0in">Securities Qualification Requirements</TD>
    <TD STYLE="text-align: right; text-indent: 0in">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.3</TD>
    <TD STYLE="text-indent: 0in">Warrant Agent&rsquo;s Remuneration and Expenses</TD>
    <TD STYLE="text-align: right; text-indent: 0in">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.4</TD>
    <TD STYLE="text-indent: 0in">Performance of Covenants by Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 5 ENFORCEMENT</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">5.1</TD>
    <TD STYLE="text-indent: 0in">Suits by Warrantholders</TD>
    <TD STYLE="text-align: right; text-indent: 0in">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">5.2</TD>
    <TD STYLE="text-indent: 0in">Limitation of Liability</TD>
    <TD STYLE="text-align: right; text-indent: 0in">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 6 MEETINGS OF WARRANTHOLDERS</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.1</TD>
    <TD STYLE="text-indent: 0in">Right to Convene Meetings</TD>
    <TD STYLE="text-align: right; text-indent: 0in">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.2</TD>
    <TD STYLE="text-indent: 0in">Notice</TD>
    <TD STYLE="text-align: right; text-indent: 0in">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.3</TD>
    <TD STYLE="text-indent: 0in">Chairman</TD>
    <TD STYLE="text-align: right; text-indent: 0in">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.4</TD>
    <TD STYLE="text-indent: 0in">Quorum</TD>
    <TD STYLE="text-align: right; text-indent: 0in">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.5</TD>
    <TD STYLE="text-indent: 0in">Power to Adjourn</TD>
    <TD STYLE="text-align: right; text-indent: 0in">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.6</TD>
    <TD STYLE="text-indent: 0in">Show of Hands</TD>
    <TD STYLE="text-align: right; text-indent: 0in">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.7</TD>
    <TD STYLE="text-indent: 0in">Poll and Voting</TD>
    <TD STYLE="text-align: right; text-indent: 0in">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.8</TD>
    <TD STYLE="text-indent: 0in">Regulations</TD>
    <TD STYLE="text-align: right; text-indent: 0in">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.9</TD>
    <TD STYLE="text-indent: 0in">Company, Warrant Agent and Counsel may be Represented</TD>
    <TD STYLE="text-align: right; text-indent: 0in">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.10</TD>
    <TD STYLE="text-indent: 0in">Powers Exercisable by Extraordinary Resolution</TD>
    <TD STYLE="text-align: right; text-indent: 0in">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.11</TD>
    <TD STYLE="text-indent: 0in">Meaning of &ldquo;Extraordinary Resolution&rdquo;</TD>
    <TD STYLE="text-align: right; text-indent: 0in">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.12</TD>
    <TD STYLE="text-indent: 0in">Powers Cumulative</TD>
    <TD STYLE="text-align: right; text-indent: 0in">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.13</TD>
    <TD STYLE="text-indent: 0in">Minutes</TD>
    <TD STYLE="text-align: right; text-indent: 0in">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.14</TD>
    <TD STYLE="text-indent: 0in">Instruments in Writing</TD>
    <TD STYLE="text-align: right; text-indent: 0in">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.15</TD>
    <TD STYLE="text-indent: 0in">Binding Effect of Resolutions</TD>
    <TD STYLE="text-align: right; text-indent: 0in">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.16</TD>
    <TD STYLE="text-indent: 0in">Holdings by the Company or Subsidiaries of the Company Disregarded</TD>
    <TD STYLE="text-align: right; text-indent: 0in">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 7 SUPPLEMENTAL INDENTURES AND SUCCESSOR COMPANIES</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">7.1</TD>
    <TD STYLE="text-indent: 0in">Provision for Supplemental Indentures for Certain Purposes</TD>
    <TD STYLE="text-align: right; text-indent: 0in">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">7.2</TD>
    <TD STYLE="text-indent: 0in">Successor Companies</TD>
    <TD STYLE="text-align: right; text-indent: 0in">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 8 CONCERNING THE WARRANT AGENT</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.1</TD>
    <TD STYLE="text-indent: 0in">Indenture Legislation</TD>
    <TD STYLE="text-align: right; text-indent: 0in">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.2</TD>
    <TD STYLE="text-indent: 0in">Rights and Duties of Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.3</TD>
    <TD STYLE="text-indent: 0in">Evidence, Experts and Advisers</TD>
    <TD STYLE="text-align: right; text-indent: 0in">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.4</TD>
    <TD STYLE="text-indent: 0in">Securities, Documents and Monies Held by Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.5</TD>
    <TD STYLE="text-indent: 0in">Actions by Warrant Agent to Protect Interests</TD>
    <TD STYLE="text-align: right; text-indent: 0in">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.6</TD>
    <TD STYLE="text-indent: 0in">Warrant Agent not Required to Give Security</TD>
    <TD STYLE="text-align: right; text-indent: 0in">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.7</TD>
    <TD STYLE="text-indent: 0in">Protection of Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">39</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.8</TD>
    <TD STYLE="text-indent: 0in">Replacement of Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.9</TD>
    <TD STYLE="text-indent: 0in">Conflict of Interest</TD>
    <TD STYLE="text-align: right; text-indent: 0in">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.10</TD>
    <TD STYLE="text-indent: 0in">Acceptance of Duties and Obligations</TD>
    <TD STYLE="text-align: right; text-indent: 0in">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.11</TD>
    <TD STYLE="text-indent: 0in">Warrant Agent not to be Appointed Receiver</TD>
    <TD STYLE="text-align: right; text-indent: 0in">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.12</TD>
    <TD STYLE="text-indent: 0in">Authorization to Carry on Business</TD>
    <TD STYLE="text-align: right; text-indent: 0in">42</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right"><B></B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article 9 GENERAL</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%; padding-right: 0.5in; padding-left: 0.125in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.5in; text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.1</TD>
    <TD STYLE="text-indent: 0in">Notice to the Company and the Warrant Agent</TD>
    <TD STYLE="text-align: right; text-indent: 0in">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.2</TD>
    <TD STYLE="text-indent: 0in">Notice to the Warrantholders</TD>
    <TD STYLE="text-align: right; text-indent: 0in">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.3</TD>
    <TD STYLE="text-indent: 0in">Privacy</TD>
    <TD STYLE="text-align: right; text-indent: 0in">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.4</TD>
    <TD STYLE="text-indent: 0in">Third Party Interests</TD>
    <TD STYLE="text-align: right; text-indent: 0in">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.5</TD>
    <TD STYLE="text-indent: 0in">Discretion of Directors</TD>
    <TD STYLE="text-align: right; text-indent: 0in">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.6</TD>
    <TD STYLE="text-indent: 0in">Satisfaction and Discharge of Indenture</TD>
    <TD STYLE="text-align: right; text-indent: 0in">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.7</TD>
    <TD STYLE="text-indent: 0in">Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders</TD>
    <TD STYLE="text-align: right; text-indent: 0in">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.8</TD>
    <TD STYLE="text-indent: 0in">Indenture to Prevail</TD>
    <TD STYLE="text-align: right; text-indent: 0in">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.9</TD>
    <TD STYLE="text-indent: 0in">Assignment</TD>
    <TD STYLE="text-align: right; text-indent: 0in">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.10</TD>
    <TD STYLE="text-indent: 0in">Counterparts and Formal Date</TD>
    <TD STYLE="text-align: right; text-indent: 0in">46</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Schedule A FORM OF WARRANT CERTIFICATE</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">A-1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Schedule B FORM OF DECLARATION FOR REMOVAL OF LEGEND</TD>
    <TD STYLE="text-align: right; text-indent: 0in; text-transform: uppercase">B-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>THIS WARRANT INDENTURE</B>
dated as of September 20, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BETWEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>PROFOUND MEDICAL CORP.</B><BR>
a corporation incorporated under the laws of Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(hereinafter called the &ldquo;<B>Company</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>TSX TRUST COMPANY</B><BR>
a trust company continued under the laws of Canada and registered to carry on business in the Province of Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(hereinafter called the &ldquo;<B>Warrant
Agent</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>RECITALS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">WHEREAS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">In connection with a public offering in Canada (and concurrent private offering in the United States)
by the Company of up to an aggregate of 11,500,000 Units (the &ldquo;<B>Offering</B>&rdquo;), the Company proposes to issue up
to 5,750,000 Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">Each whole Warrant entitles the holder thereof to purchase, subject to adjustment in certain events,
one Warrant Share at a price of $1.40 at any time prior to 5:00&nbsp;p.m. (Toronto time) on September 20, 2020, subject to earlier
expiry in accordance with this Indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">For such purpose the Company deems it necessary to create and issue Warrants and Warrant Certificates
to be constituted and issued in the manner hereinafter set forth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">The Company is duly authorized to create and issue the Warrants to be issued as herein provided;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify">All things necessary have been done and performed to make the Warrants, when Authenticated or certified
by the Warrant Agent and issued as provided in this Indenture, legal, valid and binding upon and obligations of the Company that
are entitled to the benefits of and subject to the terms of this Indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: justify">The foregoing recitals are made as statements of fact by the Company and not by the Warrant Agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: justify">The Warrant Agent has agreed to enter into this Indenture and to hold all rights, interests and
benefits contained herein for and on behalf of those persons who become holders of Warrants issued pursuant to this Indenture from
time to time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>NOW THEREFORE THIS
INDENTURE WITNESSES</B> that for good and valuable consideration mutually given and received, the receipt and sufficiency of which
are hereby acknowledged, it is hereby agreed and declared as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;1<BR>
INTERPRETATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.1</TD><TD STYLE="text-align: justify"><U>Definitions</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In this Indenture, unless
there is something in the subject matter or context inconsistent therewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Accredited Investor</B>&rdquo;
means an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Acceleration Notice</B>&rdquo;
has the meaning ascribed to that term in subsection 2.2(3);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Applicable Legislation</B>&rdquo;
means the provisions of the statutes of Canada and its provinces and the regulations under those statutes relating to warrant indentures
and/or the rights, duties or obligations of issuers and warrant agents under warrant indentures as are from time to time in force
and applicable to this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Authenticated</B>&rdquo; means
with respect to the issuance of an Uncertificated Warrant, one in respect of which the Warrant Agent has completed all Internal
Procedures such that the particulars of such Uncertificated Warrant are entered in the register of Warrantholders, and &ldquo;<B>Authenticate</B>&rdquo;,
 &ldquo;<B>Authenticating</B>&rdquo; and &ldquo;<B>Authentication</B>&rdquo; have the appropriate correlative meanings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Beneficial Owner</B>&rdquo; means
a person that has a beneficial interest in a Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Book-Based System</B>&rdquo;
means the book-based securities system administered by CDS in accordance with its operating rules and procedures in force from
time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Business Day</B>&rdquo; means
a day that is not a Saturday, Sunday, or a day on which banks are closed or which is a civic or statutory holiday in the City of
Toronto, Ontario;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Capital Reorganization</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.13(4);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>CDS</B>&rdquo; means CDS Clearing
and Depository Services Inc. and its successors in interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>CDS Participant</B>&rdquo; means
a person recognized by CDS as a participant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Closing Date</B>&rdquo; means
September 20, 2017;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Common Shares</B>&rdquo; means
the common shares in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Common Share Reorganization</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.13(1);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Company</B>&rdquo; means Profound
Medical Corp., a corporation incorporated under the laws of Ontario, and its lawful successors from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Company&rsquo;s Auditors</B>&rdquo;
means the chartered (professional) accountant or firm of chartered (professional) accountants duly appointed as auditor or auditors
of the Company from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Confirmation</B>&rdquo; means
that CDS shall deliver to the Warrant Agent confirmation of its intention to exercise Warrants in a manner acceptable to the Warrant
Agent, including by electronic means through the Book-Based System;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>counsel</B>&rdquo; means a barrister
and solicitor or lawyer or a firm of barristers and solicitors or lawyers (who may be counsel to the Company), in both cases acceptable
to the Warrant Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Current Market Price</B>&rdquo;
means, at any date, the volume weighted average price per share at which the Common Shares have traded:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">on the TSXV;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Common Shares are not listed on the TSXV, on any stock exchange upon which the Common Shares
are listed as may be selected for this purpose by the board of directors of the Company, acting reasonably; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Common Shares are not listed on any stock exchange, on any over-the-counter market on which
the Common Shares are trading, as may be selected for this purpose by the board of directors of the Company, acting reasonably;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">during the 10&nbsp;consecutive trading
days (on each of which at least 100&nbsp;Common Shares are traded in board lots) ending the third trading day before such date
and the weighted average price shall be determined by dividing the aggregate sale price of all Common Shares sold in board lots
on the exchange or market, as the case may be, during the 10&nbsp;consecutive trading days by the number of Common Shares sold
or, if not traded on any recognized exchange or market, as determined by the directors of the Company, acting reasonably;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>director</B>&rdquo; means a member
of the board of directors of the Company for the time being, and unless otherwise specified herein, reference to &ldquo;<B>action
by the board of directors</B>&rdquo; means action by the board of directors of the Company as a board or, whenever duly empowered,
action by a committee of the board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exchange Basis</B>&rdquo; means,
at any time, the number of Warrant Shares or other classes of shares or securities which a Warrantholder is entitled to receive
upon the exercise of the rights attached to the Warrants pursuant to the terms of this Indenture, as the number may be adjusted
pursuant to Section 2.13 hereof, such number being equal to one Warrant Share per Warrant as of the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exercise Date</B>&rdquo; with
respect to any Warrant means the date on which such Warrant is duly surrendered for exercise in accordance with the provisions
of Article&nbsp;3 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exercise Price</B>&rdquo; means
$1.40 for each Warrant Share, subject to adjustment in accordance with the provisions of this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>extraordinary resolution</B>&rdquo;
has the meaning ascribed to that term in sections&nbsp;6.11 and&nbsp;6.14;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Internal Procedures</B>&rdquo;
means in respect of the making of any one or more entries to, changes in or deletions of any one or more entries in the register
at any time (including without limitation, original issuance or registration of transfer of ownership) the minimum number of the
Warrant Agent&rsquo;s internal procedures customary at such time for the entry, change or deletion made to be complete under the
operating procedures followed at the time by the Warrant Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>NCI</B>&rdquo; has the meaning
ascribed to that term in subsection 2.12(1);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Offering</B>&rdquo; the public
offering in Canada (and concurrent private offering in the United States) by the Company of up to an aggregate of 11,500,000 Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>person</B>&rdquo; means an individual,
a corporation, a partnership, a syndicate, a trustee or any unincorporated organization and words importing persons that are intended
to have a similarly extended meaning;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Purchaser</B>&rdquo; means a
purchaser of Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Qualified Institutional Buyer</B>&rdquo;
means a &ldquo;qualified institutional buyer&rdquo; within the meaning of Rule&nbsp;144A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>QIB Letter</B>&rdquo; means a
representation letter signed by Qualified Institutional Buyer(s) in connection with the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Regulation&nbsp;D</B>&rdquo;
means Regulation&nbsp;D as promulgated under the U.S.&nbsp;Securities&nbsp;Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Regulation&nbsp;S</B>&rdquo;
means Regulation&nbsp;S as promulgated under the U.S.&nbsp;Securities&nbsp;Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Rights Offering</B>&rdquo; has
the meaning ascribed to that term in subsection&nbsp;2.13(2);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Rights Offering Price</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.14(8);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Rule&nbsp;144A</B>&rdquo; means
Rule&nbsp;144A as promulgated under the U.S.&nbsp;Securities&nbsp;Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Securities Laws</B>&rdquo; means,
collectively, the applicable securities laws of each of the provinces of Canada, the United States and each of the states of the
United States, as applicable, and the respective regulations made and forms prescribed thereunder together with all applicable
published rules, policy statements, notices and blanket orders and rulings of the securities commissions or similar regulatory
authorities in each of the provinces of Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>shareholder</B>&rdquo; means
an owner of record of one or more Common Shares or shares of any other class or series of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Special Distribution</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.13(3);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo; means a
corporation, a majority of the outstanding voting shares of which are owned, directly or indirectly, by the Company or by one or
more subsidiaries of the Company and, as used in this definition, &ldquo;<B>voting shares</B>&rdquo; means shares of a class or
classes ordinarily entitled to vote for the election of the majority of the directors of a corporation irrespective of whether
or not shares of any other class or classes shall have or might have the right to vote for directors by reason of the happening
of any contingency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>successor company</B>&rdquo;
has the meaning ascribed to that term in section&nbsp;7.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>this Indenture</B>&rdquo;, &ldquo;<B>herein</B>&rdquo;,
 &ldquo;<B>hereby</B>&rdquo; and similar expressions mean or refer to this common share purchase warrant indenture and any indenture,
deed or instrument supplemental or ancillary hereto; and the expressions &ldquo;<B>Article</B>&rdquo;, &ldquo;<B>section</B>&rdquo;,
 &ldquo;<B>subsection</B>&rdquo; or &ldquo;<B>paragraph</B>&rdquo; followed by a number or letter mean and refer to the specified
Article, section, subsection or paragraph of this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Time of Expiry</B>&rdquo; means
5:00&nbsp;p.m. (Toronto time) on September 20, 2020, unless the term of the Warrants shall be accelerated as provided for in subsection
2.2(3), in which case the Time of Expiry shall be the earlier of (i) 5:00 p.m. (Toronto time) on the date that is 20 days following
delivery of the Acceleration Notice and (ii) 5:00&nbsp;p.m. (Toronto time) on September 20, 2020;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>trading day</B>&rdquo; means
a day on which the TSXV (or such other exchange on which the Common Shares are listed and which forms the primary trading market
for such shares) is open for trading, and if the Common Shares are not listed on a stock exchange, a day on which an over-the-counter
market where such shares are traded is open for business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>transaction instruction</B>&rdquo;
means a written order signed by the holder or CDS, entitled to request that one or more actions be taken, or such other form as
may be reasonably acceptable to the Warrant Agent, requesting one or more such actions to be taken in respect of an Uncertificated
Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Transfer Agent</B>&rdquo; means
the transfer agent or agents for the time being for the Common Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>TSXV</B>&rdquo; means the TSX
Venture Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S.&nbsp;Person</B>&rdquo; means
a U.S. person as that term is defined in Regulation&nbsp;S;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S.&nbsp;Securities&nbsp;Act</B>&rdquo;
means the United States Securities Act of 1933, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S. Subscription Agreement</B>&rdquo;
means a subscription agreement for Units in the Offering signed by an Accredited Investor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Uncertificated Warrant</B>&rdquo;
means any Warrant which is issued under the Book-Based System;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Unit Share</B>&rdquo; means a
Common Share comprising part of each Unit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>United States</B>&rdquo; means
the United States as that term is defined in Regulation&nbsp;S;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Units</B>&rdquo; means the units
of the Company, each Unit being comprised of one Unit Share and one-half of one Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant Agent</B>&rdquo; means
TSX Trust Company, a trust company existing under the laws of Canada, or any lawful successor thereto including through the operation
of section&nbsp;8.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant Certificates</B>&rdquo;
means the certificates representing Warrants substantially in the form attached as Schedule A hereto or such other form as may
be approved by the Company and the Warrant Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant Shares</B>&rdquo; means
the Common Shares or other securities or property issuable upon the exercise of the Warrants as a result of any adjustment to the
subscription rights pursuant to Section 2.13 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrantholders</B>&rdquo; or
 &ldquo;<B>holders</B>&rdquo; means the persons whose names are entered for the time being in the register maintained pursuant to
section&nbsp;2.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrantholders&rsquo; Request</B>&rdquo;
means an instrument, signed in one or more counterparts by Warrantholders representing, in the aggregate, at least 25% of the aggregate
number of Warrants then outstanding, which requests the Warrant Agent to take some action or proceeding specified therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrants</B>&rdquo; means the
common share purchase warrants of the Company issued and Authenticated hereunder as Uncertificated Warrants or to be issued and
countersigned in the form of Warrant Certificates, in either case, entitling the holders thereof to purchase Warrant Shares on
the basis of one Warrant Share for each whole Warrant upon payment of the Exercise Price at any time prior to the Time of Expiry;
provided that in each case the number and/or class of shares or securities receivable on the exercise of the Warrants may be subject
to increase or decrease or change in accordance with the terms and provisions hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>written direction of the Company</B>&rdquo;,
 &ldquo;<B>written request of the Company</B>&rdquo;, &ldquo;<B>written consent of the Company</B>&rdquo; and &ldquo;<B>certificate
of the Company</B>&rdquo; and any other document required to be signed by the Company, means, respectively, a written direction,
request, consent, certificate or other document signed in the name of the Company by any executive officer or director and may
consist of one or more instruments so executed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.2</TD><TD STYLE="text-align: justify"><U>Words Importing the Singular</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless elsewhere otherwise
expressly provided, or unless the context otherwise requires, words importing the singular include the plural and <I>vice versa</I>
and words importing the masculine gender include the feminine and neuter genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.3</TD><TD STYLE="text-align: justify"><U>Interpretation not Affected by Headings</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The division of this
Indenture into Articles, sections, subsections and paragraphs, the provision of a table of contents and the insertion of headings
are for convenience of reference only and shall not affect the construction or interpretation of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.4</TD><TD STYLE="text-align: justify"><U>Day not a Business Day</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If any day on or before
which any action is required or permitted to be taken hereunder is not a Business Day, then such action shall be required or permitted
to be taken on or before the requisite time on the next succeeding day that is a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.5</TD><TD STYLE="text-align: justify"><U>Time of the Essence</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Time shall be of the
essence in all respects of this Indenture and the Warrants issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.6</TD><TD STYLE="text-align: justify"><U>Governing Law</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Indenture and the
Warrants issued hereunder shall be construed and enforced in accordance with the laws of the Province of Ontario and the federal
laws of Canada applicable therein and shall be treated in all respects as Ontario contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.7</TD><TD STYLE="text-align: justify"><U>Meaning of &ldquo;outstanding&rdquo; for Certain Purposes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Every Warrant Authenticated
or certified by the Warrant Agent hereunder shall be deemed to be outstanding until it shall be cancelled or delivered to the Warrant
Agent for cancellation, exercised pursuant to section&nbsp;3.1 or until the Time of Expiry; provided that where a new Warrant Certificate
has been issued pursuant to section&nbsp;2.6 hereof to replace one which is lost, mutilated, stolen or destroyed, the Warrants
represented by only one of such Warrant Certificates shall be counted for the purpose of determining the aggregate number of Warrants
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.8</TD><TD STYLE="text-align: justify"><U>Currency</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless otherwise stated,
all dollar amounts referred to in this Indenture are in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.9</TD><TD STYLE="text-align: justify"><U>Termination</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Indenture shall
continue in full force and effect until the earlier of: (a) the Time of Expiry; and (b) the date that no Warrants are outstanding
hereunder; provided that this Indenture shall continue in effect thereafter, if applicable, until the Company and the Warrant Agent
have fulfilled all of their respective obligations under this Indenture.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;2<BR>
ISSUE OF WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.1</TD><TD STYLE="text-align: justify"><U>Issue of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A maximum of 5,750,000
Warrants are hereby created and authorized to be issued hereunder entitling the registered holders thereof to acquire an aggregate
of 5,750,000 Warrant Shares (subject to adjustment in accordance with Section 2.13) at the Exercise Price upon the terms and conditions
herein set forth. Uncertificated Warrants shall be Authenticated by the Warrant Agent and deposited in CDS and Warrant Certificates
evidencing the Warrants, if any, shall be executed by the Company, certified by or on behalf of the Warrant Agent and delivered
by the Warrant Agent to the Company, as applicable, in accordance with a written direction of the Company, all in accordance with
sections&nbsp;2.3 and&nbsp;2.4. Subject to adjustment in accordance with the provisions of this Indenture, each of the Warrants
issued hereunder shall entitle the holder thereof to receive from the Company, at the Exercise Price, the number of Warrant Shares
equal to the Exchange Basis in effect on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.2</TD><TD STYLE="text-align: justify"><U>Form and Terms of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrants may be issued in either certificated or uncertificated form. Notwithstanding the foregoing, all Warrants issued in the
United States or to, or for the account or benefit of, a person in the United States or U.S.&nbsp;Persons that are Accredited Investors
shall be in certificated form only. The Warrant Certificates shall be substantially in the form attached as Schedule A hereto and
dated as of the date of issue, subject to the provisions of this Indenture, with such additions, variations and changes as may
be required or permitted by the terms of this Indenture, and to give effect to any Warrants not being issued as Uncertificated
Warrants, and which may from time to time be agreed upon by the Warrant Agent and the Company, and shall have such distinguishing
letters and numbers as the Company may, with the approval of the Warrant Agent, prescribe. Except as hereinafter provided in this
Article&nbsp;2, all Warrants shall, save as to denominations, be of like tenor and effect. The Warrant Certificates may be engraved,
printed, lithographed, photocopied or be partially in one form or another, as the Company may determine. No change in the form
of the Warrant Certificate shall be required by reason of any adjustment made pursuant to this Article&nbsp;2 in the number and/or
class of securities or type of securities that may be acquired pursuant to the exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Warrant authorized to be issued hereunder shall entitle the registered holder thereof to acquire (subject to sections&nbsp;2.13,
2.14 and&nbsp;2.15) upon due exercise and upon the transaction instruction or due execution of the exercise form endorsed on the
Warrant Certificate, as applicable, or other instrument of exercise in such form as the Warrant Agent and/or the Company may from
time to time prescribe and upon payment of the Exercise Price, one Warrant Share or such other kind and amount of shares or securities
or property, calculated pursuant to the provisions of sections&nbsp;2.13 and&nbsp;2.14, as the case may be, at any time after the
date of issuance of such Warrants and prior to the Time of Expiry, in accordance with the provisions of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fractional
Warrants shall not be issued or otherwise provided for and shall be disregarded for all purposes and no cash amount will be payable
in lieu thereof. If the exercise of any Warrant would result in a fraction of a Common Share being issued to any person, any such
fraction shall be rounded down to the next whole number of Common Shares and no cash amount will be payable in lieu thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any other provision herein, if at any time on or after the date that is 18 months after September 20, 2017, the closing trading
price of the Common Shares on the TSXV (or if the Common Shares are not listed on the TSXV, then on such other recognized Canadian
stock exchange on which the Common Shares are then listed and primarily traded) equals or exceeds $2.50 for a period of at least
10 consecutive trading days, the Company shall be entitled, within 15 days of the occurrence of such event, to accelerate the Time
of Expiry of the Warrants to a period ending on the date that is 20 days from the date that notice of such acceleration (the &ldquo;<B>Acceleration
Notice</B>&rdquo;) is given to the Warrant Agent and to the Warrantholders pursuant to a press release issued by the Company, with
the new Time of Expiry specified in such Acceleration Notice. From and after the new Time of Expiry specified in such Acceleration
Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect following the new Time
of Expiry. For greater certainty, the new Time of Expiry specified in an Acceleration Notice shall not be later than 5:00 p.m.
(Toronto Time) on September 20, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.3</TD><TD STYLE="text-align: justify"><U>Signing of Warrant Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Warrant Certificates
shall be signed by any one of the directors or executive officers of the Company and may, but need not be under the corporate seal
of the Company or a reproduction thereof. The signature of any such director or officer may be mechanically reproduced in facsimile
or other electronic format and Warrant Certificates bearing such facsimile or other electronic format signatures shall be binding
upon the Company as if they had been manually signed by such director or officer. Notwithstanding that the person whose manual
or electronic signature appears on any Warrant Certificate as a director or executive officer may no longer hold office at the
date of issue of the Warrant Certificate or at the date of certification or delivery thereof, any Warrant Certificate signed as
aforesaid shall, subject to section&nbsp;2.4, be valid and binding upon the Company and the registered holder thereof will be entitled
to the benefits of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.4</TD><TD STYLE="text-align: justify"><U>Authentication or Certification by the Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Warrant Certificate shall be issued or, if issued, shall be valid for any purpose or entitle the registered holder to the benefit
hereof or thereof until it has been certified by manual signature by or on behalf of the Warrant Agent and such certification by
the Warrant Agent shall be conclusive evidence as against the Company that the Warrant so certified has been duly issued hereunder
and the holder is entitled to the benefits hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
NCI deposit in the Book-Based System shall be made or, if made, shall be valid for any purposes or entitle the holder to the benefits
hereof and thereof until it has been Authenticated by the Warrant Agent and such Authentication shall be conclusive evidence as
against the Company that the NCI deposit so made has been duly issued hereunder and that the holder is entitled to the benefits
hereof and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
certification of the Warrant Agent on the Warrant Certificates issued hereunder, or the Authentication of the Warrant Agent of
the NCI deposit in the Book-Based System made hereunder, as applicable, shall not be construed as a representation or warranty
by the Warrant Agent as to the validity of this Indenture or the Warrant Certificates (except the due certification thereof) or
the NCI deposit (except the due Authentication thereof) as applicable, and the Warrant Agent shall in no respect be liable or answerable
for the use made of the Warrant Certificate or NCI deposit, as applicable, or any of them or of the consideration therefor except
as otherwise specified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.5</TD><TD STYLE="text-align: justify"><U>Warrantholder not a Shareholder,&nbsp;etc.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Nothing in this Indenture
or the holding of a Warrant evidenced by a Warrant Certificate shall be construed as conferring upon a Warrantholder any right
or interest whatsoever as a shareholder, including but not limited to the right to vote at, to receive notice of, or to attend
meetings of shareholders or any other proceedings of the Company, nor entitle the holder to any right or interest in respect thereof
except as herein and in the Warrants expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.6</TD><TD STYLE="text-align: justify"><U>Issue in Substitution for Lost Warrant Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any Warrant Certificates issued and certified under this Indenture shall become mutilated or be lost, destroyed or stolen, the
Company, subject to applicable law, and subsection&nbsp;2.6(2), shall issue and thereupon the Warrant Agent shall certify and deliver
a new Warrant Certificate of like denomination, date and tenor as the one mutilated, lost, destroyed or stolen in exchange for,
in place of and upon cancellation of such mutilated Warrant Certificate, or in lieu of and in substitution for such lost, destroyed
or stolen Warrant Certificate, and the substituted Warrant Certificate shall be substantially in the form set out in Schedule A
hereto and Warrants evidenced by it will entitle the holder thereof to the benefits hereof and shall rank equally in accordance
with its terms with all other Warrant Certificates issued or to be issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicant for the issue of a new Warrant Certificate pursuant to this section&nbsp;2.6 shall bear the reasonable cost of the issue
thereof and in the case of mutilation shall, as a condition precedent to the issue thereof, deliver to the Warrant Agent the mutilated
Warrant Certificate, and in the case of loss, destruction or theft shall, as a condition precedent to the issue thereof, furnish
to the Company and to the Warrant Agent such evidence of ownership and of the loss, destruction or theft of the Warrant Certificate
so lost, destroyed or stolen as shall be satisfactory to the Company and to the Warrant Agent in their sole discretion and such
applicant may be required to furnish an indemnity and surety bond in amount and form satisfactory to the Company and the Warrant
Agent in their sole discretion and shall pay the reasonable charges of the Company and the Warrant Agent in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.7</TD><TD STYLE="text-align: justify"><U>Warrants to Rank <I>Pari Passu</I></U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All Warrants shall rank
<I>pari passu</I> with all other Warrants, whatever may be the actual date of issue of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.8</TD><TD STYLE="text-align: justify"><U>Registration and Transfer of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent will create and keep at the principal stock transfer offices of the Warrant Agent in the City of Toronto, Ontario:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a register of holders in which shall be entered in alphabetical order the names and addresses of
the holders of Warrants and particulars of the Warrants held by them and the Warrant Agent shall be entitled to rely on such register
in connection with the exchange, transfer or exercise of any Warrant(s) pursuant to the terms of this Indenture or the terms thereof;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a register of transfers in which all transfers of Warrants and the date and other particulars of
each such transfer shall be entered.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
transfer of any Warrant will be valid unless entered on the register of transfers referred to in subsection&nbsp;2.8(1), and, in
the case of a Warrant Certificate, upon surrender to the Warrant Agent of the Warrant Certificate evidencing such Warrant, and
a duly completed and executed transfer form endorsed on the Warrant Certificate executed by the registered holder or his executors,
administrators or other legal representatives or his attorney duly appointed by an instrument in writing in form and execution
satisfactory to the Warrant Agent, if applicable, and, upon compliance with such requirements and such other reasonable requirements
as the Warrant Agent may prescribe, such transfer will be recorded on the register of transfers by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of a Warrant Certificate, the transferee of any Warrant will, after surrender to the Warrant Agent of the Warrant Certificate
evidencing such Warrant as required by subsection&nbsp;2.8(2) and upon compliance with all other conditions in respect thereof
required by this Indenture or by law, be entitled to be entered on the register of holders referred to in subsection&nbsp;2.8(1)
as the owner of such Warrant free from all equities or rights of set-off or counterclaim between the Company and the transferor
or any previous holder of such Warrant, except in respect of equities or rights of which the Company is required to take notice
by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will be entitled, and may direct the Warrant Agent, to refuse to recognize any transfer, or enter the name of any transferee,
of any Warrant on the registers referred to in subsection&nbsp;2.8(1), if such transfer would constitute a violation of (a) the
Securities Laws of any applicable jurisdiction or the rules, regulations or policies of any regulatory authority having jurisdiction,
(b) any restrictive legend on such Warrant or (c) any applicable representations and warranties made by the Warrantholder in a
QIB Letter executed by such Warrantholder in connection with the Offering. The Warrant Agent is entitled to assume compliance with
all applicable Securities Laws unless otherwise notified in writing by the Company. No duty shall rest with the Warrant Agent to
determine compliance of the transferee or transferor of any Warrant with applicable Securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Warrant issued to a transferee upon transfers contemplated by this section&nbsp;2.8 shall bear the appropriate legend(s) as set
forth in subsection&nbsp;2.20(2), if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Warrant tendered for transfer bears the legend set forth in subsection&nbsp;2.20(2), the Warrant Agent shall not register such
transfer unless the transferor has provided the Warrant Agent with the Warrant Certificate and complies with the requirements of
the said subsection&nbsp;2.20(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants,
in certificated form, bearing the legend set forth in subsection&nbsp;2.20(2) shall not be offered, sold or otherwise transferred
except (A)&nbsp;to the Company, (B)&nbsp;outside the United States in accordance with Rule&nbsp;904 of Regulation&nbsp;S and in
compliance with applicable local securities laws and regulations, (C)&nbsp;in compliance with the exemption from the registration
requirements under the U.S.&nbsp;Securities&nbsp;Act provided by (i) Rule 144A, if available, or (ii)&nbsp;Rule&nbsp;144 under
the U.S.&nbsp;Securities&nbsp;Act, if available, (D)&nbsp;in another transaction that does not require registration under the U.S.&nbsp;Securities&nbsp;Act,
and in each case, in accordance with any applicable state securities laws in the United States, provided that in the case of transfers
pursuant to&nbsp;(C)(ii) or&nbsp;(D)&nbsp;above, the Company has received, prior to such transfer, an opinion of counsel or other
evidence of exemption reasonably satisfactory to the Company. Warrants, in uncertificated form, held by a Warrantholder in the
United States or a U.S.&nbsp;Person that is a Qualified Institutional Buyer may be offered, sold or otherwise transferred only
in accordance with this section&nbsp;2.8(7)(A) or (B), as provided for in the QIB Letter for such Warrantholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.9</TD><TD STYLE="text-align: justify"><U>Registers Open for Inspection</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The registers referred
to in subsection&nbsp;2.8(1) shall be open at all reasonable times during business hours on a Business Day for inspection by the
Company or any Warrantholder. The Warrant Agent shall, from time to time when requested to do so in writing by the Company and
upon payment of its reasonable fees, furnish the Company with a list of the names and addresses of holders of Warrants entered
in the register of holders kept by the Warrant Agent and showing the number of Warrants held by each such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.10</TD><TD STYLE="text-align: justify"><U>Exchange of Warrant Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant
Certificates may, upon compliance with the reasonable requirements of the Warrant Agent, be exchanged for Warrant Certificates
in any other authorized denomination representing in the aggregate an equal number of Warrants as the number of Warrants represented
by the Warrant Certificates being exchanged. The Company shall sign and the Warrant Agent shall certify, in accordance with sections&nbsp;2.3
and&nbsp;2.4, all Warrant Certificates necessary to carry out the exchanges contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant
Certificates may be exchanged only at the principal stock transfer offices of the Warrant Agent in the City of Toronto, Ontario
or at any other place that is designated by the Company with the approval of the Warrant Agent. Any Warrant Certificates tendered
for exchange shall be surrendered to the Warrant Agent and cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise herein provided, the Warrant Agent may charge Warrantholders requesting an exchange a reasonable sum for each Warrant
Certificate issued; and payment of such charges and reimbursement of the Warrant Agent or the Company for any and all taxes or
governmental or other charges required to be paid shall be made by the party requesting such exchange as a condition precedent
to such exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.11</TD><TD STYLE="text-align: justify"><U>Ownership of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company and the Warrant
Agent and their respective agents may deem and treat the registered holder of any Warrant as the absolute owner of the Warrant
represented thereby for all purposes and the Company and the Warrant Agent and their respective agents shall not be affected by
any notice or knowledge to the contrary except as required by statute or order of a court of competent jurisdiction. The holder
of any Warrant shall be entitled to the rights evidenced by that Warrant free from all equities or rights of set-off or counterclaim
between the Company and the original or any intermediate holder thereof and all persons may act accordingly and the receipt by
any holder of the Warrant Shares or monies obtainable pursuant to the exercise of the Warrant shall be a good discharge to the
Company and the Warrant Agent for the same and neither the Company nor the Warrant Agent shall be bound to inquire into the title
of any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.12</TD><TD STYLE="text-align: justify"><U>Book-Based System Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described above, and except for Warrants issued in the United States or to, or for the account or benefit of, a person in the
United States or U.S. Persons that are Accredited Investors, or as may be directed by the Company, registration of interests in
and transfers of Warrants shall be made only through the Book-Based System. Other than for those Warrants issued in the United
States or to, or for the account or benefit of, a person in the United States or U.S. Persons that are Accredited Investors, or
as may be directed by the Company, the Warrants will be evidenced by a non-certificated inventory (&ldquo;<B>NCI</B>&rdquo;) deposit
though the Book-Based System for an amount representing the aggregate number of such Warrants outstanding from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfers
of beneficial ownership in any Warrant represented by an NCI deposit will be effected only (i) with respect to the interest of
a CDS Participant, through records maintained by CDS or its nominee for such Warrants, and (ii) with respect to the interest of
any person other than a CDS Participant, through records maintained by CDS Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
rights of Beneficial Owners who hold security entitlements in respect of Warrants through the Book-Based System shall be limited
to those established by applicable law and agreements between CDS and CDS Participants and between such CDS Participants and Beneficial
Owners who hold security entitlements in respect of Warrants through the Book-Based System and must be exercised through a CDS
Participant in accordance with the rules and procedures of CDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of the following events occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">CDS or the Company has notified the Warrant Agent that (A) CDS is unwilling or unable to continue
as depository or (B) CDS ceases to be a clearing agency in good standing under applicable laws and, in either case, the Company
is unable to locate a qualified successor depository within 90&nbsp;days of delivery of such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Company has determined, in its sole discretion, to terminate the Book-Based System in respect
of such Uncertificated Warrants and has communicated such determination to the Warrant Agent in writing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Company or CDS is required by applicable law to take the action contemplated in this subsection;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Book-Based System administered by CDS ceases to exist,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then one or more definitive fully registered
Warrant Certificates shall be executed by the Company and certified and delivered by the Warrant Agent to CDS in exchange for the
Uncertificated Warrants form held by CDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fully registered Warrant
Certificates issued and exchanged pursuant to this subsection shall be registered in such names and in such denominations as CDS
shall instruct the Warrant Agent, provided that the aggregate number of Warrants represented by such Warrant Certificates shall
be equal to the aggregate number of Uncertificated Warrants so exchanged. Upon exchange of Uncertificated Warrants for one or more
Warrant Certificates in definitive form, such Uncertificated Warrants shall be cancelled by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in this Indenture in terms of an NCI deposit, neither the Company nor the Warrant Agent nor any agent thereof shall have
any responsibility or liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the records maintained by CDS relating to any ownership interests or any other interests in the
Warrants or the depository system maintained by CDS, or payments made on account of any ownership interest or any other interest
of any person in any Warrant represented by any NCI deposit (other than CDS or its nominee);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">maintaining, supervising or reviewing any records of CDS or any CDS Participant relating to any
such interest; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any advice or representation made or given by CDS or those contained in this Indenture that relate
to the rules and regulations of CDS or any action to be taken by CDS on its own direction or at the direction of any CDS Participant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.13</TD><TD STYLE="text-align: justify"><U>Adjustment of Exchange Basis</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to section&nbsp;2.14,
the Exchange Basis shall be subject to adjustment from time to time in the events and in the manner provided as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">issue Common Shares or securities exchangeable for or convertible into Common Shares to all or
substantially all the holders of the Common Shares as a stock dividend or other distribution (other than a distribution of Warrant
Shares upon exercise of the Warrants or pursuant to the exercise, conversion or exchange of securities of the Company outstanding
as of the date hereof), or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">subdivide, redivide or change its then outstanding Common Shares into a greater number of Common
Shares, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">reduce, combine or consolidate its then outstanding Common Shares into a lesser number of Common
Shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events in these paragraphs&nbsp;(i),
(ii) or&nbsp;(iii) being called a &ldquo;<B>Common Share Reorganization</B>&rdquo;), then the Exchange Basis in effect on the effective
date of such subdivision, redivision or change, or reduction, combination or consolidation, or on the record date of such stock
dividend or other distribution, as the case may be, shall be adjusted by multiplying the Exchange Basis in effect immediately prior
to such effective or record date by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the numerator of which shall be the total number of Common Shares outstanding on such date immediately
after giving effect to such Common Share Reorganization (including, in the case where securities exercisable, exchangeable for
or convertible into Common Shares are distributed, the number of Common Shares that would have been outstanding had such securities
been exercised, or exchanged for or converted into Common Shares on such record date, assuming in any case where such securities
are not then convertible, exercisable or exchangeable but subsequently become so, that they were convertible, exercisable or exchangeable
on the record date on the basis upon which they first become convertible, exercisable or exchangeable), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the denominator of which shall be the total number of Common Shares outstanding on such date before
giving effect to such Common Share Reorganization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The resulting
product, adjusted to the nearest 1/100th, shall thereafter be the Exchange Basis until further adjusted as provided in this Article&nbsp;2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any Common Shares owned by or
held for the account of the Company or any of its Subsidiaries or a partnership in which the Company is directly or indirectly
a party to will be deemed not to be outstanding for the purpose of any computation. To the extent that any adjustment in the Exchange
Basis occurs pursuant to this subsection&nbsp;2.13(1) as a result of the fixing by the Company of a record date for the distribution
of securities exchangeable or exercisable for or convertible into Common Shares and the Common Share Reorganization does not occur
or any conversion, exercise or exchange rights are not fully converted, exercised or exchanged, the Exchange Basis shall be readjusted
immediately after the expiry of any relevant exchange or conversion right or the termination of the Common Share Reorganization,
as the case may be, to the Exchange Basis that would then be in effect, based upon the number of Common Shares actually issued
and remaining issuable after such expiry and shall be further readjusted in such manner upon the expiry of any further such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, the Company shall fix a record date for the distribution
to all or substantially all of the holders of its outstanding Common Shares of rights, options or warrants entitling them, for
a period expiring not more than 45&nbsp;days after such record date, to subscribe for or purchase Common Shares, or securities
exchangeable or exercisable for or convertible into Common Shares, at a price per share to the holder (or at an exchange, exercise
or conversion price per share) of less than 95% of the Current Market Price on such record date (any of such events being called
a &ldquo;<B>Rights Offering</B>&rdquo;), then the Exchange Basis shall be adjusted effective immediately after such record date
for the Rights Offering by multiplying the Exchange Basis in effect immediately prior to such record date by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the numerator of which shall be the number of Common Shares which would be outstanding after giving
effect to the Rights Offering (assuming the exercise of all of the rights, options or warrants under the Rights Offering and assuming
the exchange, exercise or conversion into Common Shares of all exchangeable, exercisable or convertible securities issued upon
exercise of such rights, options or warrants, if any), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the denominator of which shall be the aggregate of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the total number of Common Shares outstanding as of the record date for the Rights Offering, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a number of Common Shares determined by dividing</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the amount equal to the aggregate consideration payable on the exercise of all of the rights, options
and warrants under the Rights Offering plus the aggregate consideration, if any, payable on the exchange, exercise or conversion
of the exchangeable or convertible securities issued upon exercise of such rights, options or warrants (assuming the exercise of
all rights, options and warrants under the Rights Offering and assuming the exchange or conversion of all exchangeable or convertible
securities issued upon exercise of such rights, options and warrants);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Current Market Price as of the record date for the Rights Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resulting product, adjusted to the
nearest 1/100th, shall thereafter be the Exchange Basis until further adjusted as provided in this Article&nbsp;2. Any Common Shares
owned by or held for the account of the Company or any of its Subsidiaries or a partnership in which the Company is directly or
indirectly a party to will be deemed not to be outstanding for the purpose of any computation. If, at the date of expiry of the
rights, options or warrants subject to the Rights Offering, less than all the rights, options or warrants have been exercised,
then the Exchange Basis shall be readjusted effective immediately after the date of expiry to the Exchange Basis which would have
been in effect on the date of expiry if only the rights, options or warrants issued had been those exercised. If at the date of
expiry of the rights of exchange, exercise or conversion of any securities issued pursuant to the Rights Offering less than all
of such securities have been exchanged or exercised for, or converted into, Common Shares, then the Exchange Basis shall be readjusted
effective immediately after the date of expiry to the Exchange Basis which would have been in effect on the date of expiry if only
the exchangeable, exercisable or convertible securities issued had been those securities actually exchanged or exercised for or
converted into Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, the Company shall fix a record date for the issuance
or distribution to all or substantially all the holders of its outstanding Common Shares of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">shares of the Company of any class other than Common Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">rights, options or warrants to acquire Common Shares or securities exchangeable or exercisable
for or convertible into Common Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">evidences of indebtedness; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">cash, securities or any property or other assets,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and if such issuance or distribution does
not constitute a Common Share Reorganization or a Rights Offering (any of such non-excluded events being herein called a &ldquo;<B>Special
Distribution</B>&rdquo;), the Exchange Basis shall be adjusted effective immediately after the record date for the Special Distribution
by multiplying the Exchange Basis in effect on such record date by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the numerator of which shall be the number of Common Shares outstanding on such record date multiplied
by the Current Market Price on such record date, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the denominator of which shall be:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the product of the number of Common Shares outstanding on such record date and the Current Market
Price on such record date,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">less</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the fair market value, as determined by action by the board of directors acting reasonably and
in good faith (whose determination shall, absent manifest error, be conclusive), to the holders of the Common Shares of the shares,
rights, options, warrants, evidences of indebtedness or property or other assets issued or distributed in the Special Distribution,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that no such adjustment shall
be made if the result of such adjustment would be to decrease the Exchange Basis in effect immediately before such record date.
The resulting product, adjusted to the nearest 1/100th, shall thereafter be the Exchange Basis until further adjusted as provided
in this Article&nbsp;2. Any shares owned by or held for the account of the Company or its Subsidiaries or a partnership of which
the Company is directly or indirectly a party to shall be deemed not to be outstanding for the purpose of any such computation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, there shall be a reclassification of the Common
Shares at any time outstanding or change or exchange of the Common Shares into other shares or into other securities (other than
a Common Share Reorganization), or a consolidation, amalgamation, plan of arrangement or merger of the Company with or into any
other corporation or other entity (other than a consolidation, amalgamation, plan of arrangement or merger which does not result
in any reclassification of the outstanding Common Shares or a change of the Common Shares into other shares), or a transfer (other
than to a Subsidiary) of the undertaking or assets of the Company as an entirety or substantially as an entirety to another corporation
or other entity (any of such events being herein called a &ldquo;<B>Capital Reorganization</B>&rdquo;), any Warrantholder who thereafter
shall exercise his right to receive Warrant Shares pursuant to Warrant(s) shall be entitled to receive, and shall accept in lieu
of the number of Warrant Shares to which such holder was theretofore entitled upon such exercise, the aggregate number of shares,
other securities or other property resulting from the Capital Reorganization which such holder would have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof, as the case may be, the Warrantholder
had been the registered holder of the number of Warrant Shares to which such holder was theretofore entitled upon exercise. If
appropriate, adjustments shall be made as a result of any such Capital Reorganization in the application of the provisions set
forth in this Article&nbsp;2 with respect to the rights and interests thereafter of Warrantholders to the end that the provisions
set forth in this Article&nbsp;2 shall thereafter correspondingly be made applicable as nearly as may reasonably be in relation
to any shares, other securities or other property thereafter deliverable upon the exercise of any Warrant. Any such adjustment
shall be made by and set forth in an indenture supplemental hereto approved by the directors and by the Warrant Agent and entered
into pursuant to the provisions of this Indenture and shall for all purposes be conclusively deemed to be an appropriate adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
adjustment to the Exchange Basis as set forth herein (except resulting from a Capital Reorganization) shall also include a corresponding
adjustment to the Exercise Price which shall be calculated by multiplying the Exercise Price by a fraction: (a) the numerator of
which shall be the Exchange Basis prior to the adjustment, and (b) the denominator of which shall be the Exchange Basis after the
adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.14</TD><TD STYLE="text-align: justify"><U>Rules Regarding Calculation of Adjustment of Exchange Basis</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">For the purposes of section&nbsp;2.13:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
adjustments provided for in section&nbsp;2.13 shall be cumulative and such adjustments shall be made successively whenever an event
referred to in section&nbsp;2.13 shall occur, subject to the following subsections of this section&nbsp;2.14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
adjustment in the: (a)&nbsp;Exchange Basis shall be required unless such adjustment would result in a change of at least 0.01 of
a Warrant Share based on the prevailing Exchange Basis; or (b)&nbsp;Exercise Price shall be required unless such adjustment would
result in a change of at least 1%, provided that any adjustments which, except for the provisions of this subsection, would otherwise
have been required to be made, shall be carried forward and taken into account in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
adjustment in the Exchange Basis shall be made in respect of any event described in section&nbsp;2.13, other than the events referred
to in paragraphs&nbsp;(ii) and&nbsp;(iii) of subsection&nbsp;(1) thereof, if Warrantholders are entitled to participate in such
event on the same terms, mutatis mutandis, as if Warrantholders had exercised their Warrants prior to or on the effective date
or record date of such event, any such participation being subject to regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
adjustment in the Exchange Basis shall be made pursuant to section&nbsp;2.13 in respect of the issue from time to time of Warrant
Shares purchasable on exercise of the Warrants or pursuant to the exercise, conversion or exchange of securities of the Company
outstanding as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a dispute shall at any time arise with respect to adjustments provided for in section&nbsp;2.13, such dispute shall, absent manifest
error, be conclusively determined by the Company&rsquo;s Auditors, or if they are unable or unwilling to act, by such other firm
of independent chartered accountants as may be selected by the directors and any further determination, absent manifest error,
shall be binding upon the Company, the Warrant Agent and the Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Company shall set a record date to determine the holders of the Common Shares for the purpose of entitling them to receive
any dividend or distribution or any subscription or purchase rights and shall, thereafter and before the distribution to such shareholders
of any such dividend, distribution, or subscription or purchase rights, legally abandon its plan to pay or deliver such dividend,
distribution, or subscription or purchase rights, then no adjustment in the Exchange Basis shall be required by reason of the setting
of such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the absence of a resolution of the directors fixing a record date for a Rights Offering or Special Distribution, the Company shall
be deemed to have fixed as the record date therefor the date on which the Rights Offering or Special Distribution is effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the purchase price provided for in any Rights Offering (the &ldquo;<B>Rights Offering Price</B>&rdquo;) is decreased, the Exchange
Basis shall forthwith be changed so as to increase the Exchange Basis to such Exchange Basis as would have been obtained had the
adjustment to the Exchange Basis made pursuant to subsection&nbsp;2.13(2) upon the issuance of such Rights Offering been made upon
the basis of the Rights Offering Price as so decreased, provided that the provisions of this subsection shall not apply to any
decrease in the Rights Offering Price resulting from provisions in any such Rights Offering designed to prevent dilution if the
event giving rise to such decrease in the Rights Offering Price itself requires an adjustment to the Exchange Basis pursuant to
the provisions of section&nbsp;2.13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a condition precedent to the taking of any action that would require any adjustment in any of the subscription rights pursuant
to any of the Warrants, including the Exchange Basis, the Company shall take any corporate action which may, in the opinion of
counsel, be necessary in order that the Company have unissued and reserved in its authorized capital and may validly and legally
issue as fully paid and non-assessable all the shares or other securities that all the holders of such Warrants are entitled to
receive on the exercise of all the subscription rights attaching thereto in accordance with the provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall be entitled to act and rely on any adjustment calculations by the Company or the Company&rsquo;s Auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.15</TD><TD STYLE="text-align: justify"><U>Postponement of Subscription</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In any case where the
application of section&nbsp;2.13 results in an increase in the number of Common Shares that are issuable upon exercise of the Warrants
taking effect immediately after the record date for a specific event, if any Warrant is exercised after that record date and prior
to completion of such specific event, the Company may postpone the issuance to the Warrantholder of the Warrant Shares to which
he is entitled by reason of such adjustment, but such Warrant Shares shall be so issued and delivered to that holder upon completion
of that event, with the number of such Warrant Shares calculated on the basis of the number of Warrant Shares on the date that
the Warrant was exercised, adjusted for completion of that event and the Company shall deliver to the person or persons in whose
name or names the Warrant Shares are to be issued an appropriate instrument evidencing the right of such person or persons to receive
such Warrant Shares and the right to receive any dividends or other distributions which, but for the provisions of this section&nbsp;2.15,
such person or persons would have been entitled to receive in respect of such Warrant Shares from and after the date that the Warrant
was exercised in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.16</TD><TD STYLE="text-align: justify"><U>Notice of Adjustment</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
least 14&nbsp;days prior to the effective date or record date, as the case may be, of any event which requires or might require
adjustment pursuant to section&nbsp;2.13, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">file with the Warrant Agent a certificate of the Company specifying the particulars of such event
(including the record date or the effective date for such event) and, if determinable, the required adjustment and the computation
of such adjustment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">give notice to the Warrantholders of the particulars of such event (including the record date or
the effective date for such event) and, if determinable, the required adjustment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
case any adjustment for which a notice in subsection&nbsp;2.16(1) has been given is not then determinable, the Company shall promptly
after such adjustment is determinable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">file with the Warrant Agent a computation of such adjustment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">give notice to the Warrantholders of the adjustment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may, absent manifest error, act and rely upon certificates and other documents filed by the Company pursuant to this
section&nbsp;2.16 for all purposes of the adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.17</TD><TD STYLE="text-align: justify"><U>No Action after Notice</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company covenants
with the Warrant Agent that it will not take any other corporate action which might deprive a Warrantholder of the opportunity
of exercising the rights of acquisition pursuant thereto during the period of 10&nbsp;days after the giving of the notice set forth
in subsection&nbsp;2.16(1) and paragraph&nbsp;(b) of subsection&nbsp;2.16(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.18</TD><TD STYLE="text-align: justify"><U>Optional Purchases by the Company</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to applicable
law and prior approval of the TSXV, if required, the Company may from time to time purchase on any stock exchange (if then listed),
in the open market, by private agreement or otherwise any of the Warrants. Any such purchase shall be made at the lowest price
or prices at which, in the opinion of the board of directors of the Company, such Warrants are then obtainable, plus reasonable
costs of purchase, and may be made in such manner, from such persons, and on such other terms as the Company in its sole discretion
may determine. The Warrant Certificates representing the Warrants purchased pursuant to this section&nbsp;2.18 shall forthwith
be delivered to and cancelled by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.19</TD><TD STYLE="text-align: justify"><U>Protection of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to Article&nbsp;8,
the Warrant Agent shall not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">at any time be under any duty or responsibility to any registered holder of Warrants to determine
whether any facts exist that may require any adjustment contemplated by this Article&nbsp;2, nor to verify the nature and extent
of any such adjustment when made or the method employed in making the same;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">be accountable with respect to the validity or value or the kind or amount of any Warrant Shares
that may at any time be issued or delivered upon the exercise of the Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">be responsible for any failure of the Company to make any cash payment upon the surrender of any
Warrants for the purpose of the exercise of such rights or to comply with any of the covenants contained in this Article&nbsp;2;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">incur any liability or responsibility whatsoever or be in any way responsible for the consequence
of any breach on the part of the Company of any of the representations, warranties or covenants of the Company or any acts or deeds
of the agents or servants of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.20</TD><TD STYLE="text-align: justify"><U>U.S. Legend on Warrant Certificates and Warrant Share certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent understands and acknowledges that the Warrants and the Warrant Shares issuable upon exercise of the Warrants have
not been, and will not be, registered under the U.S.&nbsp;Securities&nbsp;Act or the securities laws of any state of the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Warrant, in certificated form, originally issued in the United States or, to, or for the account or benefit of, a person in the
United States or U.S. Persons that are Accredited Investors, and all Warrant Shares issued upon exercise of such Warrants, and
all certificates issued in exchange or in substitution thereof or upon transfer thereof, shall bear legends in substantially the
following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;THE SECURITIES REPRESENTED
HEREBY [FOR WARRANTS: AND THE SECURITIES DELIVERABLE UPON EXERCISE HEREOF] HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF&nbsp;1933, AS AMENDED (THE &ldquo;U.S.&nbsp;SECURITIES&nbsp;ACT&rdquo;) OR U.S. STATE SECURITIES LAWS.
THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY, ONLY (A) TO PROFOUND MEDICAL CORP.
(THE &ldquo;CORPORATION&rdquo;), (B)&nbsp;OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE&nbsp;904 OF REGULATION&nbsp;S UNDER
THE U.S.&nbsp;SECURITIES&nbsp;ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS, (C)&nbsp;IN COMPLIANCE WITH THE
EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT PROVIDED BY (I)&nbsp;RULE&nbsp;144 UNDER THE U.S.&nbsp;SECURITIES&nbsp;ACT,
IF AVAILABLE, OR (II)&nbsp;RULE&nbsp;144A UNDER THE U.S.&nbsp;SECURITIES&nbsp;ACT, IF AVAILABLE, (D)&nbsp;IN ANOTHER TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S.&nbsp;SECURITIES&nbsp;ACT, OR (E) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE U.S. SECURITIES ACT, AND, IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE STATE SECURITIES LAWS IN THE UNITED STATES,
PROVIDED THAT, IN THE CASE OF TRANSFERS PURSUANT TO (C)(I) OR (D)&nbsp;ABOVE, THE HOLDER HAS, PRIOR TO SUCH TRANSFER, FURNISHED
TO THE CORPORATION AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE, REASONABLY SATISFACTORY TO THE CORPORATION.
DELIVERY OF THIS CERTIFICATE MAY NOT CONSTITUTE &ldquo;GOOD DELIVERY&rdquo; IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN
CANADA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">and, for Warrants only:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">[&ldquo;THIS WARRANT MAY NOT
BE EXERCISED UNLESS REGISTERED UNDER THE U.S.&nbsp;SECURITIES&nbsp;ACT OR PURSUANT TO AN AVAILABLE EXEMPTION THEREFROM, AND IN
EACH CASE IN COMPLIANCE WITH APPLICABLE U.S. STATE SECURITIES LAWS.&rdquo;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>provided</I> that, the Company
shall use commercially reasonable efforts to cause the legend to be removed within 5 Business Days upon receipt by the Company
and the Warrant Agent or the Transfer Agent, as applicable, of (i)&nbsp;a declaration in the form attached hereto as Schedule B
(or as the Company may prescribe from time to time in order to address changes in applicable laws) and (ii)&nbsp;any other evidence
reasonably requested by the Company, which may include an opinion of counsel, of recognized standing reasonably satisfactory to
the Company, that the legend is no longer required under the U.S.&nbsp;Securities&nbsp;Act and any applicable state securities
laws (upon receipt of a duly executed certificate attesting to the facts necessary to support the removal of such legend);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>and provided, further</I>,
that, if any Warrants or Warrant Shares issuable upon exercise of the Warrants are being sold under Rule&nbsp;144, the legend may
be removed by delivering to the Company and the Warrant Agent or the Transfer Agent, as applicable, an opinion of counsel of recognized
standing reasonably satisfactory to the Company, that the legend is no longer required under applicable requirements of the U.S.&nbsp;Securities&nbsp;Act
or any applicable state securities laws (upon receipt of a duly executed certificate attesting to the facts necessary to support
the removal of such legend).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Warrant or Warrant Share issued with respect to an exercise of Warrants is tendered for transfer and bears the legend set forth
in subsection&nbsp;2.20(2) herein and the holder thereof has not obtained the prior written consent of the Company, the Warrant
Agent or the Transfer Agent, as the case may be, shall not register such transfer unless the holder complies with the requirements
of the said subsection&nbsp;2.20(2) hereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;3<BR>
EXERCISE OF WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.1</TD><TD STYLE="text-align: justify"><U>Method of Exercise of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of any Warrant may exercise the rights thereby conferred on him to acquire all or any part of the Warrant Shares
to which such Warrant entitles the holder, by surrendering the Warrant Certificate representing such Warrants to the Warrant Agent
at any time prior to the Time of Expiry at its principal stock transfer offices in the City of Toronto, Ontario (or at such additional
place or places as may be decided by the Company from time to time with the approval of the Warrant Agent), with a duly completed
and executed exercise form of the registered holder or his executors, administrators or other legal representative or his attorney
duly appointed by an instrument in writing in the form and manner satisfactory to the Warrant Agent, substantially in the form
endorsed on the Warrant Certificate specifying the number of Warrant Shares subscribed for together with a certified cheque, bank
draft or money order in lawful money of Canada, payable to or to the order of the Company in an amount equal to the Exercise Price
multiplied by the number of Warrant Shares subscribed for. A Warrant Certificate with the duly completed and executed exercise
form and payment of the Exercise Price shall be deemed to be surrendered only upon personal delivery thereof to or, if sent by
mail or other means of transmission, upon actual receipt thereof by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
exercise form referred to in subsection&nbsp;3.1(1) shall be signed by the Warrantholder, or his executors, or administrators or
other legal representative or his attorney duly appointed by an instrument in writing in the form and manner satisfactory to the
Warrant Agent, shall specify the person(s) in whose name such Warrant Shares are to be issued, the address(es) of such person(s)
and the number of Warrant Shares to be issued to each person, if more than one is so specified. If any of the Warrant Shares subscribed
for are to be issued to (a)&nbsp;person(s) other than the Warrantholder, the signatures set out in the exercise form referred to
in subsection&nbsp;3.1(1) shall be guaranteed by a Canadian Schedule&nbsp;I chartered bank or a medallion signature guarantee from
a member of a recognized Signature Medallion Guarantee Program and (b)&nbsp;the Warrantholder shall pay to the Company or the Warrant
Agent all applicable transfer or similar taxes and the Company shall not be required to issue or deliver certificates evidencing
Warrant Shares unless or until such Warrantholder shall have paid to the Company or the Warrant Agent on behalf of the Company
the amount of such tax or shall have established to the reasonable satisfaction of the Company that such tax has been paid or that
no tax is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at the time of exercise of the Warrants, in accordance with the provisions of subsection&nbsp;3.1(1), there are any trading restrictions
on the Warrant Shares pursuant to Securities Laws or stock exchange requirements, the Company shall, on the advice of counsel,
endorse any certificates representing the Warrant Shares to such effect. The Warrant Agent is entitled to assume compliance with
all Securities Laws unless otherwise notified in writing by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
Beneficial Owner who desires to exercise his Uncertificated Warrants, must do so by causing a CDS Participant to deliver to CDS
(at its office in the City of Toronto), on behalf of the Beneficial Owner at any time prior to the Time of Expiry, a written notice
of the Beneficial Owner&rsquo;s intention to exercise Warrants (the &ldquo;<B>Exercise Notice</B>&rdquo;). Forthwith upon receipt
by CDS of such notice, as well as payment for the Exercise Price, CDS shall deliver to the Warrant Agent confirmation of its intention
to exercise Warrants (the &ldquo;<B>Confirmation</B>&rdquo;) in a manner acceptable to the Warrant Agent, including by electronic
means through the Book-Based System. CDS will initiate the exercise by way of the Confirmation and forward the aggregate Exercise
Price electronically to the Warrant Agent and the Warrant Agent will execute the exercise by issuing to CDS through the Book-Based
System the Warrant Shares to which the exercising Beneficial Owner is entitled pursuant to the exercise. Any expense associated
with the preparation and delivery of Exercise Notices will be for the account of the Beneficial Owner exercising the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">By causing a CDS Participant
to deliver notice to CDS, a Beneficial Owner shall be deemed to have irrevocably surrendered his Warrants so exercised and appointed
such CDS Participant to act as his or her exclusive settlement agent with respect to the exercise and the receipt of Warrant Shares
in connection with the obligations arising from such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any notice which CDS
determines to be incomplete, not in proper form or not duly executed shall for all purposes be void and of no effect and the exercise
to which it relates shall be considered for all purposes not to have been exercised thereby. A failure by a CDS Participant to
exercise or to give effect to the settlement thereof in accordance with the Beneficial Owner&rsquo;s instructions will not give
rise to any obligations or liability on the part of the Company or Warrant Agent to the CDS Participant or the Beneficial Owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.2</TD><TD STYLE="text-align: justify"><U>No Fractional Warrant Shares</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Under no circumstances
shall the Company be obliged to issue any fractional Warrant Shares or any cash or other consideration in lieu thereof upon the
exercise of one or more Warrants. To the extent that the holder of one or more Warrants would otherwise have been entitled to receive
on the exercise or partial exercise thereof a fraction of a Warrant Share, that holder may exercise that right in respect of the
fraction only in combination with another Warrant or Warrants that in the aggregate entitle the holder to purchase a whole number
of Warrant Shares; otherwise fractional Warrant Shares shall be rounded down to the nearest whole number of Warrant Shares without
compensation therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.3</TD><TD STYLE="text-align: justify"><U>Effect of Exercise of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
compliance by the Warrantholder with the provisions of section&nbsp;3.1, the Warrant Shares subscribed for shall be deemed to have
been issued and the person to whom such Warrant Shares are to be issued shall be deemed to have become the holder of record of
such Warrant Shares on the Exercise Date unless the transfer registers of the Company for the Common Shares shall be closed on
such date, in which case the Warrant Shares subscribed for shall be deemed to have been issued and such person shall be deemed
to have become the holder of record of such Warrant Shares on the date on which such transfer registers are reopened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
three Business Days following the due exercise of a Warrant pursuant to section&nbsp;3.1 and forthwith after the Time of Expiry,
the Warrant Agent shall deliver to the Company a notice setting forth the particulars of all Warrants exercised, if any, and the
persons in whose names the Warrant Shares are to be issued (as applicable) and the addresses of such holders of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
three Business Days of the due exercise of a Warrant pursuant to section&nbsp;3.1, the Company shall cause the Transfer Agent to
issue, within such three Business Day period, to CDS through the Book-Based System the Warrant Shares (which shall include Warrant
Shares issued to a Purchaser that is a Qualified Institutional Buyer) to which the exercising Warrantholder is entitled pursuant
to the exercise or mail to the person in whose name the Warrant Shares so subscribed for are to be issued, as specified in the
exercise form completed on the Warrant Certificate, at the address specified in such exercise form, a certificate or certificates
for the Warrant Shares to which the Warrantholder is entitled and, if applicable, shall cause the Warrant Agent to mail a Warrant
Certificate representing any Warrants not then exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.4</TD><TD STYLE="text-align: justify"><U>Cancellation of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All Warrants surrendered
to the Warrant Agent pursuant to sections&nbsp;2.6, 2.8(2), 2.10, 2.18 or&nbsp;3.1 shall be cancelled by the Warrant Agent and
the Warrant Agent shall record the cancellation of such Warrants on the register of holders maintained by the Warrant Agent pursuant
to subsection&nbsp;2.8(1). The Warrant Agent shall, if required by the Company, furnish the Company with a certificate identifying
the Warrants so cancelled. All Warrants that have been duly cancelled shall be without further force or effect whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.5</TD><TD STYLE="text-align: justify"><U>Subscription for less than Entitlement</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The holder of any Warrant
may subscribe for and purchase a whole number of Warrant Shares that is less than the number that the holder is entitled to purchase
pursuant to a surrendered Warrant. In such event, the holder thereof shall be entitled to receive a new Warrant Certificate, if
applicable, in respect of the balance of Warrants that were not then exercised, such new Warrant Certificate to contain the same
legend as provided for in subsection 2.20(2) if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.6</TD><TD STYLE="text-align: justify"><U>Expiration of Warrant</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">After the Time of Expiry,
all rights under any Warrant in respect of which the right of subscription and purchase herein and therein provided for shall not
theretofore have been exercised shall wholly cease and terminate and such Warrant shall be void and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.7</TD><TD STYLE="text-align: justify"><U>Prohibition on Exercise by U.S.&nbsp;Persons; Exception</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants
may not be exercised within the United States or by or on behalf of, or for the account or benefit of, any U.S.&nbsp;Person or
any person in the United States except in compliance with this section 3.7. The Warrant Agent shall be entitled to rely upon the
registered address of the Warrantholder as set forth in such Warrantholder&rsquo;s register for the purchase of Units in determining
whether the address is in the United States or the Warrantholder is a U.S.&nbsp;Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
holder which exercises any Warrants represented by a Warrant Certificate shall provide to the Company either:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a written certification that such holder (i)&nbsp;at the time of exercise of the Warrants is not
in the United States; (ii)&nbsp;is not a U.S.&nbsp;Person and is not exercising the Warrants on behalf of a U.S.&nbsp;Person or
person in the United States; (iii)&nbsp;did not execute or deliver the exercise form for the Warrants in the United States; and
(iv)&nbsp;has in all other aspects complied with the terms of Regulation&nbsp;S (which written certification shall be deemed delivered
by checking Box 1 in the Exercise Form attached to the Warrant, as provided for in Schedule A hereof);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a written certification that the holder (i)&nbsp;purchased the Warrants as a part of the Units
in the Offering; (ii)&nbsp;is exercising the Warrants solely for its own account or for the benefit of a U.S.&nbsp;Person or a
person in the United States for whose account such holder acquired the Warrants as a part of the Units in the Offering and for
whose account such holders exercises sole investment discretion; (iii)&nbsp;was and is, and any beneficial purchaser for whose
account such holder acquired the Warrant and is exercising the Warrants was and is an Accredited Investor and/or Qualified Institutional
Buyer both on the date the Units were purchased in the Offering and on the Exercise Date; and (iv)&nbsp;the representations and
warranties made by the holder or any beneficial purchaser, as the case may be, to the Company in such holder&rsquo;s U.S. Subscription
Agreement remain true and correct on the Exercise Date (which written certification shall be deemed delivered by checking Box 2
in the Exercise Form attached to the Warrant, as provided for in Schedule A hereof); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">a written opinion of counsel of recognized standing in form and substance satisfactory to the Company
to the effect that an exemption from the registration requirements of the U.S.&nbsp;Securities&nbsp;Act and applicable state securities
laws is available for the issuance of the Warrant Shares issuable on exercise of the Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Warrant Shares will be registered or delivered to an address in the United States unless the holder of Warrants complies with the
requirements of paragraphs&nbsp;(b) or (c) of this subsection&nbsp;3.7(2).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;4<BR>
COVENANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.1</TD><TD STYLE="text-align: justify"><U>General Covenants of the Company</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company represents,
warrants and covenants with the Warrant Agent for the benefit of the Warrant Agent and the Warrantholders that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will at all times, so long as any Warrants remain outstanding, maintain its existence, unless otherwise inconsistent with
the fiduciary duties of the board of directors of the Company, and will carry on and conduct its business in a prudent manner in
accordance with industry standards and good business practice, and will keep or cause to be kept proper books of account in accordance
with applicable law until the Time of Expiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is duly authorized to create and issue the Warrants to be issued hereunder and the Warrants, when issued, Authenticated
and certified, as applicable, will be legal, valid, binding and enforceable obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use its commercially reasonable efforts to maintain the listing of the Common Shares on the TSXV or such other recognized
stock exchange or quotation system, so long as any Warrants remain outstanding, and to have the Warrant Shares issued pursuant
to the exercise of the Warrants listed and posted for trading on the TSXV, or such other recognized stock exchange or quotation
system, as expeditiously as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use commercially reasonable efforts to maintain its status as a &ldquo;reporting issuer&rdquo; (or the equivalent
thereof) in each of the provinces of Canada in which it is currently a reporting issuer, not in default of the requirements of
the applicable Securities Laws of such province until the Time of Expiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will allot and reserve and keep available a sufficient number of Warrant Shares for issuance upon the exercise of Warrants
issued by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will cause the Warrant Shares from time to time subscribed for pursuant to the Warrants issued by the Company hereunder,
in the manner herein provided, to be duly issued in accordance with the Warrants and the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will cause the certificates representing the Warrant Shares from time to time to be acquired, pursuant to the Warrants
in the manner herein provided, to be duly issued and delivered in accordance with the Warrants and the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Warrant Shares that shall be issued by the Company upon exercise of the rights provided for herein shall be issued as fully paid
and non-assessable Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will perform and carry out all of the acts or things to be done by it as provided in this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will promptly advise the Warrant Agent and the Warrantholders in writing of any breach or default under the terms of this
Indenture no later than 5&nbsp;Business Days following the occurrence of such breach or default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(11)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use its commercially reasonable efforts to cause the Warrant Agent to keep open the register of Warrantholders during
the Warrant Agent&rsquo;s regular business hours and will not take any action or omit to take any action which would have the effect
of preventing the Warrantholders from receiving any of the Warrant Shares issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.2</TD><TD STYLE="text-align: justify"><U>Securities Qualification Requirements</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
in the opinion of counsel, any instrument is required to be filed with, or any permission, order or ruling is required to be obtained
from, any securities regulatory authority or any other step is required under any federal or provincial law of Canada before the
Warrant Shares may be issued or delivered to a Warrantholder, the Company covenants that it will use its best efforts to file such
instrument, obtain such permission, order or ruling or take all such other actions, at its expense, as is required or appropriate
in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will give written notice of the issue of Warrant Shares pursuant to the exercise of Warrants, in such detail as may be
required, to each securities regulatory authority in each jurisdiction in which there is legislation requiring the giving of any
such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.3</TD><TD STYLE="text-align: justify"><U>Warrant Agent&rsquo;s Remuneration and Expenses</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company covenants
that it will pay to the Warrant Agent from time to time reasonable remuneration for its services hereunder and will pay or reimburse
the Warrant Agent upon its request for all reasonable expenses and disbursements of the Warrant Agent in the administration or
execution of the duties and obligations hereby created (including the reasonable compensation and the disbursements of its counsel
and all other advisers, experts, accountants and assistants not regularly in its employ) both before any default hereunder and
thereafter until all duties of the Warrant Agent hereunder shall be finally and fully performed, except any such expense or disbursement
in connection with or related to or required to be made as a result of the gross negligence, wilful misconduct, bad faith or fraud
of the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.4</TD><TD STYLE="text-align: justify"><U>Performance of Covenants by Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to section&nbsp;8.7, if the Company
shall fail to perform any of its covenants contained in this Indenture and the Company has not rectified such failure within 10&nbsp;Business
Days after either giving notice of such default pursuant to subsection&nbsp;4.1(10) or receiving written notice from the Warrant
Agent of such failure, the Warrant Agent may notify the Warrantholders of such failure on the part of the Company or may itself
perform any of the said covenants capable of being performed by it, but shall be under no obligation to perform said covenants.
All reasonable sums expended or disbursed by the Warrant Agent in so doing shall be repayable as provided in section&nbsp;4.3.
No such performance, expenditure or advance by the Warrant Agent shall be deemed to relieve the Company of any default hereunder
or of its continuing obligations under the covenants herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;5<BR>
ENFORCEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">5.1</TD><TD STYLE="text-align: justify"><U>Suits by Warrantholders</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to section&nbsp;6.10,
all or any of the rights conferred upon a Warrantholder by the terms of the Warrants held by him and/or this Indenture may be enforced
by such Warrantholder by appropriate legal proceedings but without prejudice to the right that is hereby conferred upon the Warrant
Agent to proceed in its own name to enforce each and all of the provisions herein contained for the benefit of the holders of the
Warrants from time to time outstanding. The Warrant Agent shall also have the power at any time and from time to time to institute
and to maintain such suits and proceedings as it may reasonably be advised shall be necessary or advisable to preserve and protect
its interests and the interests of the Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">5.2</TD><TD STYLE="text-align: justify"><U>Limitation of Liability</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The obligations hereunder
(including without limitation under subsection&nbsp;8.7(5)) are not personally binding upon, nor shall resort hereunder be had
to, the private property of any of the past, present or future directors or shareholders of the Company or any of the past, present
or future officers, employees or agents of the Company, but only the property of the Company (or any successor person) shall be
bound in respect hereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;6<BR>
MEETINGS OF WARRANTHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.1</TD><TD STYLE="text-align: justify"><U>Right to Convene Meetings</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent may
at any time and from time to time, and shall on receipt of a written request of the Company or of a Warrantholders&rsquo; Request,
convene a meeting of the Warrantholders provided that the Warrant Agent has been provided with sufficient funds and is indemnified
to its reasonable satisfaction by the Company or by the Warrantholders signing such Warrantholders&rsquo; Request against the costs,
charges, expenses and liabilities that may be incurred in connection with the calling and holding of such meeting. If within 15&nbsp;Business
Days after the receipt of a written request of the Company or a Warrantholders&rsquo; Request, funding and indemnity given as aforesaid
the Warrant Agent fails to give the requisite notice specified in section&nbsp;6.2 to convene a meeting, the Company or such Warrantholders,
as the case may be, may convene such meeting. Every such meeting shall be held in the City of Toronto, Ontario or at such other
place as may be approved or determined by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.2</TD><TD STYLE="text-align: justify"><U>Notice</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">At least 14&nbsp;days&rsquo;
prior notice of any meeting of Warrantholders shall be given to the Warrantholders at the expense of the Company in the manner
provided for in section&nbsp;9.2 and a copy of such notice shall be delivered to the Warrant Agent unless the meeting has been
called by it, and to the Company unless the meeting has been called by it. Such notice shall state the date, time and place of
the meeting, the general nature of the business to be transacted and shall contain such information as is reasonably necessary
to enable the Warrantholders to make a reasoned decision on the matter, but it shall not be necessary for any such notice to set
out the terms of any resolution to be proposed or any of the provisions of this Article&nbsp;6. The notice convening any such meeting
may be signed by an appropriate officer of the Warrant Agent or of the Company or the person designated by such Warrantholders,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.3</TD><TD STYLE="text-align: justify"><U>Chairman</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent may
nominate in writing an individual (who need not be a Warrantholder) to be chairman of the meeting and if no individual is so nominated,
or if the individual so nominated is not present within 15&nbsp;minutes after the time fixed for the holding of the meeting, the
Warrantholders present in person or by proxy shall appoint an individual present to be chairman of the meeting. The chairman of
the meeting need not be a Warrantholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.4</TD><TD STYLE="text-align: justify"><U>Quorum</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions
of section&nbsp;6.11, at any meeting of the Warrantholders a quorum shall consist of two Warrantholders present in person or represented
by proxy and representing at least 20% of the aggregate number of Warrants then outstanding. If a quorum of the Warrantholders
shall not be present within one-half hour from the time fixed for holding any meeting, the meeting, if summoned by the Warrantholders
or on a Warrantholders&rsquo; Request, shall be dissolved; but in any other case the meeting shall be adjourned to the same day
in the next week (unless such day is not a Business Day in which case it shall be adjourned to the next following Business Day)
at the same time and place to the extent possible and, subject to the provisions of section&nbsp;6.11, no notice of the adjournment
need be given. Any business may be brought before or dealt with at an adjourned meeting that might have been dealt with at the
original meeting in accordance with the notice calling the same. At the adjourned meeting the Warrantholders present in person
or represented by proxy shall form a quorum and may transact the business for which the meeting was originally convened, notwithstanding
that they may not represent at least 20% of the aggregate number of Warrants then unexercised and outstanding. No business shall
be transacted at any meeting, except an adjourned meeting as described above, unless a quorum is present at the commencement of
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.5</TD><TD STYLE="text-align: justify"><U>Power to Adjourn</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The chairman of any meeting
at which a quorum of the Warrantholders is present may, with the consent of the meeting, adjourn any such meeting, and no notice
of such adjournment need be given except such notice, if any, as the meeting may prescribe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.6</TD><TD STYLE="text-align: justify"><U>Show of Hands</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Every question submitted
to a meeting shall be decided in the first place by a majority of the votes given on a show of hands except that votes on an extraordinary
resolution shall be given in the manner hereinafter provided. At any such meeting, unless a poll is duly demanded as herein provided,
a declaration by the chairman that a resolution has been carried or carried unanimously or by a particular majority or lost or
not carried by a particular majority shall be conclusive evidence of the fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.7</TD><TD STYLE="text-align: justify"><U>Poll and Voting</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">On every extraordinary
resolution, and when demanded by the chairman or by one or more of the Warrantholders acting in person or by proxy on any other
question submitted to a meeting and after a vote by show of hands, a poll shall be taken in such manner as the chairman shall direct.
Questions other than those required to be determined by extraordinary resolution shall be decided by a majority of the votes cast
on the poll. On a show of hands, every person who is present and entitled to vote, whether as a Warrantholder or as proxy for one
or more absent Warrantholders, or both, shall have one vote. On a poll, each Warrantholder present in person or represented by
a proxy duly appointed by instrument in writing shall be entitled to one vote in respect of each whole Warrant then held by him.
A proxy need not be a Warrantholder. The chairman of any meeting shall be entitled, both on a show of hands and on a poll, to vote
in respect of the Warrants, if any, held or represented by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.8</TD><TD STYLE="text-align: justify"><U>Regulations</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions
of this Indenture, the Warrant Agent or the Company with the approval of the Warrant Agent may from time to time make and from
time to time vary such regulations as it shall consider necessary or appropriate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">for the deposit of instruments appointing proxies at such place and time as the Warrant Agent,
the Company or the Warrantholders convening the meeting, as the case may be, may in the notice convening the meeting direct;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for the deposit of instruments appointing proxies at some approved place other than the place at
which the meeting is to be held and enabling particulars of such instruments appointing proxies to be mailed or forwarded via facsimile
before the meeting to the Company or to the Warrant Agent at the place where the same is to be held and for the voting of proxies
so deposited as though the instruments themselves were produced at the meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">for the form of instrument appointing a proxy and the manner in which the form of proxy may be
executed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">generally for the calling of meetings of Warrantholders and the conduct of business thereat including
setting a record date for Warrantholders entitled to receive notice of or to vote at such meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any regulations so made
shall be binding and effective and the votes given in accordance therewith shall be valid and shall be counted. Save as such regulations
may provide, the only persons who shall be recognized at any meeting as a Warrantholder, or be entitled to vote or be present at
the meeting in respect thereof (subject to section&nbsp;6.9), shall be Warrantholders or persons holding proxies of Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.9</TD><TD STYLE="text-align: justify"><U>Company, Warrant Agent and Counsel may be Represented</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company, the Warrantholders
and the Warrant Agent, by their respective directors, officers and employees and the counsel for each of the Company, the Warrantholders
and the Warrant Agent may attend any meeting of the Warrantholders and speak thereat but shall not be entitled to vote unless in
their capacities as Warrantholders or proxies therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.10</TD><TD STYLE="text-align: justify"><U>Powers Exercisable by Extraordinary Resolution</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition to all other
powers conferred upon them by any other provisions of this Indenture or by law, the Warrantholders at a meeting shall have the
power, exercisable from time to time by extraordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to agree to any modification, alteration, compromise or arrangement of the rights of Warrantholders
and/or the Warrant Agent in its capacity as warrant agent hereunder (subject to the Warrant Agent&rsquo;s approval) or on behalf
of the Warrantholders against the Company, whether such rights arise under this Indenture or the Warrants or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">to amend, modify or repeal any extraordinary resolution previously passed or sanctioned by the
Warrantholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">to direct or authorize the Warrant Agent (subject to the Warrant Agent receiving funding and indemnity
to its satisfaction) to enforce any of the covenants on the part of the Company contained in this Indenture or the Warrants or
to enforce any of the rights of the Warrantholders in any manner specified in such extraordinary resolution or to refrain from
enforcing any such covenant or right;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">to waive, authorize and direct the Warrant Agent to waive any default on the part of the Company
in complying with any provisions of this Indenture or the Warrants either unconditionally or upon any conditions specified in such
extraordinary resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">to restrain any Warrantholder from taking or instituting any suit, action or proceeding against
the Company for the enforcement of any of the covenants on the part of the Company contained in this Indenture or the Warrants
or to enforce any of the rights of the Warrantholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">to direct any Warrantholder who, as such, has brought any suit, action or proceeding to stay or
discontinue or otherwise deal with any such suit, action or proceeding, upon payment of the costs, charges and expenses reasonably
and properly incurred by such Warrantholder in connection therewith;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">to assent to any change in or omission from the provisions contained in this Indenture or any ancillary
or supplemental instrument which may be agreed to by the Company, and to authorize the Warrant Agent to concur in and execute any
ancillary or supplemental indenture embodying the change or omission;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">with the consent of the Company, such consent not to be unreasonably withheld, to remove the Warrant
Agent or its successor in office and to appoint a new warrant agent or warrant agents to take the place of the Warrant Agent so
removed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">to assent to any compromise or arrangement with any creditor or creditors or any class or classes
of creditors, whether secured or otherwise, and with holders of any shares or other securities of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.11</TD><TD STYLE="text-align: justify"><U>Meaning of &ldquo;Extraordinary Resolution&rdquo;</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
expression &ldquo;<B>extraordinary resolution</B>&rdquo; when used in this Indenture means, subject as hereinafter in this section&nbsp;6.11
and in section&nbsp;6.14 provided, a resolution proposed at a meeting of Warrantholders duly convened for that purpose and held
in accordance with the provisions of this Article&nbsp;6 at which there are present in person or by proxy at least two Warrantholders
representing at least 20% of the aggregate number of all the then outstanding Warrants and passed by the affirmative votes of Warrantholders
representing not less than 66&#8532;% of the aggregate number of all the then outstanding Warrants represented at the meeting and
voted on the poll for such resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any meeting called for the purpose of passing an extraordinary resolution, Warrantholders representing at least 20% of the aggregate
number of all the then outstanding Warrants are not present in person or by proxy within one-half hour after the time appointed
for the meeting, then the meeting, if convened by Warrantholders or on a Warrantholders&rsquo; Request, shall be dissolved; but
in any other case it shall stand adjourned to such day, being not less than 10 Business Days later, and to such place and time
as may be appointed by the chairman. Not less than three Business Days prior notice shall be given of the time and place of such
adjourned meeting in the manner provided in sections&nbsp;9.1 and&nbsp;9.2. Such notice shall state that at the adjourned meeting
the Warrantholders present in person or represented by proxy shall form a quorum but it shall not be necessary to set forth the
purposes for which the meeting was originally called or any other particulars. At the adjourned meeting the Warrantholders present
in person or represented by proxy shall form a quorum and may transact the business for which the meeting was originally convened
and a resolution proposed at such adjourned meeting and passed by the requisite vote as provided in subsection&nbsp;6.11(1) shall
be an extraordinary resolution within the meaning of this Indenture notwithstanding that Warrantholders representing at least 20%
of all the then outstanding Warrants are not present in person or represented by proxy at such adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes
on an extraordinary resolution shall always be given on a poll and no demand for a poll on an extraordinary resolution shall be
necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.12</TD><TD STYLE="text-align: justify"><U>Powers Cumulative</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It is hereby declared
and agreed that any one or more of the powers or any combination of the powers in this Indenture stated to be exercisable by the
Warrantholders by extraordinary resolution or otherwise may be exercised from time to time and the exercise of any one or more
of such powers or any combination of powers from time to time shall not be deemed to exhaust the right of the Warrantholders to
exercise such powers or combination of powers then or thereafter from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.13</TD><TD STYLE="text-align: justify"><U>Minutes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Minutes of all resolutions
and proceedings at every meeting of Warrantholders as aforesaid shall be made and duly entered in books to be provided for that
purpose by the Warrant Agent at the expense of the Company and any minutes as aforesaid, if signed by the chairman of the meeting
at which resolutions were passed or proceedings had, or by the chairman of the next succeeding meeting of the Warrantholders, shall
be prima facie evidence of the matters therein stated and, until the contrary is proved, every meeting, in respect of the proceedings
of which minutes shall have been made, shall be deemed to have been duly convened and held, and all resolutions passed thereat
or proceedings taken, to have been duly passed and taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.14</TD><TD STYLE="text-align: justify"><U>Instruments in Writing</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All actions that may
be taken and all powers that may be exercised by the Warrantholders at a meeting held as provided in this Article&nbsp;6 also may
be taken and exercised by Warrantholders representing a majority, or in the case of an extraordinary resolution at least 66&#8532;%,
of the aggregate number of all the then outstanding Warrants by an instrument in writing signed in one or more counterparts by
such Warrantholders in person or by attorney duly appointed in writing, and the expression &ldquo;extraordinary resolution&rdquo;
when used in this Indenture shall include an instrument so signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.15</TD><TD STYLE="text-align: justify"><U>Binding Effect of Resolutions</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Every resolution and
every extraordinary resolution passed in accordance with the provisions of this Article&nbsp;6 at a meeting of Warrantholders shall
be binding upon all Warrantholders, whether present at or absent from such meeting, and every instrument in writing signed by Warrantholders
in accordance with section&nbsp;6.14 shall be binding upon all the Warrantholders, whether signatories thereto or not, and each
and every Warrantholder and the Warrant Agent (subject to the provisions for indemnity herein contained) shall be bound to give
effect accordingly to every such resolution and instrument in writing. In the case of an instrument in writing, the Warrant Agent
shall give notice in the manner contemplated in sections&nbsp;9.1 and&nbsp;9.2 of the effect of the instrument in writing to all
Warrantholders and the Company as soon as is reasonably practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.16</TD><TD STYLE="text-align: justify"><U>Holdings by the Company or Subsidiaries of the Company Disregarded</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In determining whether
Warrantholders are present at a meeting of Warrantholders for the purpose of determining a quorum or have concurred in any consent,
waiver, extraordinary resolution, Warrantholders&rsquo; Request or other action under this Indenture, Warrants owned legally or
beneficially by the Company or its Subsidiaries or in partnership of which the Company is directly or indirectly a party to shall
be disregarded. The Company shall provide, upon the written request of the Warrant Agent, a certificate as to the registration
particulars of any Warrants held by the Company or its Subsidiaries or in partnership of which the Company is directly or indirectly
a party.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;7<BR>
SUPPLEMENTAL INDENTURES AND SUCCESSOR COMPANIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">7.1</TD><TD STYLE="text-align: justify"><U>Provision for Supplemental Indentures for Certain Purposes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">From time to time the
Company (if properly authorized by its board of directors) and the Warrant Agent may, subject to the provisions hereof, and they
shall, when so required hereby, execute and deliver by their proper officers, indentures or instruments supplemental hereto, which
thereafter shall form part hereof, for any one or more or all of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">providing for the issuance of additional Warrants hereunder and any consequential amendments hereto
as may be required by the Warrant Agent, relying on the advice (but for certainty, not an opinion) of counsel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">setting forth adjustments in the application of Article&nbsp;2;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">adding to the provisions hereof such additional covenants and enforcement provisions as, in the
opinion of counsel are necessary or advisable, provided that the same are not in the opinion of the Warrant Agent, relying on the
advice of counsel, prejudicial to the interests of the Warrantholders as a group;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">giving effect to any extraordinary resolution passed as provided in Article&nbsp;6;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">making such provisions not inconsistent with this Indenture as may be necessary or desirable with
respect to matters or questions arising hereunder provided that such provisions are not, in the opinion of the Warrant Agent, relying
on the advice of counsel, prejudicial to the interests of the Warrantholders as a group;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">adding to or amending the provisions hereof in respect of the transfer of Warrants, making provision
for the exchange of Warrants and making any modification in the form of the Warrant Certificate that does not affect the substance
thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">amending any of the provisions of this Indenture or relieving the Company from any of the obligations,
conditions or restrictions herein contained, provided that no such amendment or relief shall be or become operative or effective
if, in the opinion of the Warrant Agent, relying on the advice of counsel, such amendment or relief impairs any of the rights of
the Warrantholders as a group or of the Warrant Agent, and provided further that the Warrant Agent may in its sole discretion decline
to enter into any supplemental indenture that in its opinion may not afford adequate protection to the Warrant Agent when the same
shall become operative; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">for any other purpose not inconsistent with the terms of this Indenture, including the correction
or rectification of any ambiguities, defective or inconsistent provisions, errors, mistakes or clerical omissions herein, provided
that, in the opinion of the Warrant Agent, relying on the advice of counsel, the rights of the Warrant Agent and the Warrantholders
as a group are in no way prejudiced thereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">7.2</TD><TD STYLE="text-align: justify"><U>Successor Companies</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In the case of the amalgamation,
consolidation, arrangement, merger or transfer of the undertaking or assets of the Company as an entirety or substantially as an
entirety to another person (a &ldquo;<B>successor company</B>&rdquo;), the successor company resulting from the amalgamation, consolidation,
arrangement, merger or transfer (if not the Company) shall be bound by the provisions hereof and all obligations for the due and
punctual performance and observance of each and every covenant and obligation contained in this Indenture to be performed by the
Company and the successor company shall by supplemental indenture satisfactory in form and substance to the Warrant Agent and executed
and delivered by the successor company to the Warrant Agent, expressly assume those obligations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;8<BR>
CONCERNING THE WARRANT AGENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.1</TD><TD STYLE="text-align: justify"><U>Indenture Legislation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and to the extent that any provision of this Indenture limits, qualifies or conflicts with a mandatory requirement of Applicable
Legislation, such mandatory requirement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and the Warrant Agent agree that each will at all times in relation to this Indenture and any action to be taken hereunder
observe and comply with and be entitled to the benefit of Applicable Legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.2</TD><TD STYLE="text-align: justify"><U>Rights and Duties of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent accepts the duties and responsibilities under this Indenture, solely as custodian, bailee and agent. No trust is
intended to be, or is or will be, created hereby and the Warrant Agent shall owe no duties hereunder as a trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the exercise of the rights and duties prescribed or conferred by the terms of this Indenture, the Warrant Agent shall act honestly
and in good faith and shall exercise the degree of care, diligence and skill that a reasonably prudent warrant agent would exercise
in comparable circumstances. No provision of this Indenture shall be construed to relieve the Warrant Agent from, or require any
other person to indemnify the Warrant Agent against liability for its own gross negligence, wilful misconduct, bad faith or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be bound to do or take any act, action or proceeding for the enforcement of any of the obligations of the
Company under this Indenture unless and until it shall have received a Warrantholders&rsquo; Request specifying the act, action
or proceeding that the Warrant Agent is requested to take. The obligation of the Warrant Agent to commence or continue any act,
action or proceeding for the purpose of enforcing any rights of the Warrant Agent or the Warrantholders hereunder shall be conditional
upon the Warrantholders furnishing, when required by notice in writing by the Warrant Agent, sufficient funds to commence or continue
such act, action or proceeding and an indemnity reasonably satisfactory to the Warrant Agent and its counsel to protect and hold
harmless the Warrant Agent, its officers, directors, employees, agents, successors and assigns against the costs, charges and expenses
and liabilities to be incurred thereby and any loss and damage it may suffer by reason thereof. None of the provisions contained
in this Indenture shall require the Warrant Agent to expend or risk its own funds or otherwise incur financial liability in the
performance of any of its duties or in the exercise of any of its rights or powers unless indemnified and funded as aforesaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may, before commencing any act, action or proceeding, or at any time during the continuance thereof require the Warrantholders
at whose instance it is acting to deposit with the Warrant Agent the Warrants held by them, for which Warrants the Warrant Agent
shall issue receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every
provision of this Indenture that, by its terms, relieves the Warrant Agent of liability or entitles it to rely upon any evidence
submitted to it is subject to the provisions of Applicable Legislation, this section&nbsp;8.2 and section&nbsp;8.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be bound to give any notice or do or take any act, action or proceeding by virtue of the powers conferred
on it hereunder unless and until it shall have been required to do so under the terms hereof; nor shall the Warrant Agent be required
to take notice of any default hereunder, unless and until notified in writing of such default, which notice shall specifically
set out the default desired to be brought to the attention of the Warrant Agent and in the absence of such notice the Warrant Agent
may for all purposes of this Indenture conclusively assume that no default has occurred or been made in the performance or observance
of the representations, warranties and covenants, agreements or conditions herein contained. Any such notice shall in no way limit
any discretion herein given to the Warrant Agent to determine whether or not the Warrant Agent shall take action with respect to
any default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this Indenture, whenever confirmations or instructions are required to be given to the Warrant Agent, in order to be valid, such
confirmations and instructions shall be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.3</TD><TD STYLE="text-align: justify"><U>Evidence, Experts and Advisers</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the reports, certificates, opinions and other evidence required by this Indenture, the Company shall furnish to the
Warrant Agent such additional evidence of compliance with any provision hereof and in such form as may be prescribed by Applicable
Legislation or as the Warrant Agent may reasonably require by written notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the exercise of its rights and duties hereunder, the Warrant Agent may, if it is acting in good faith, act and rely absolutely
as to the truth of the statements and the accuracy of the opinions expressed therein, upon statutory declarations, opinions, reports,
written requests, consents, or orders of the Company, certificates of the Company or other evidence furnished to the Warrant Agent
pursuant to any provision hereof or of Applicable Legislation or pursuant to a request of the Warrant Agent. The Warrant Agent
shall be under no responsibility in respect of the validity of this Indenture or the execution and delivery hereof by or on behalf
of the Company or in respect of the validity or the execution of any Warrant Certificate by the Company and issued hereunder, nor
shall it be responsible for any breach by the Company of any covenant or condition contained in this Indenture or in any such Warrant
Certificate; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation
of any securities to be issued upon the right to acquire provided for in this Indenture and/or in any Warrant or as to whether
any securities will when issued be duly authorized or be validly issued and fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever
Applicable Legislation requires that evidence referred to in subsection&nbsp;8.3(1) be in the form of a statutory declaration,
the Warrant Agent may accept the statutory declaration in lieu of a certificate of the Company required by any provision hereof.
Any such statutory declaration may be made by one or more of the directors or officers of the Company and may be relied upon by
the Warrant Agent in good faith without further inquiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proof
of the execution of an instrument in writing, including a Warrantholders&rsquo; Request, by any Warrantholder may be made by a
certificate of a notary public or other person with similar powers that the person signing such instrument acknowledged to him
the execution thereof, or by an affidavit of a witness to such execution or in any other manner which the Warrant Agent may consider
adequate and in respect of a corporate Warrantholder, shall include a certificate of incumbency of such Warrantholder together
with a certified resolution authorizing the person who signs such instrument to sign such instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may act and rely and shall be protected in acting and relying upon any resolution, certificate, statement, instrument,
opinion, report, notice, request, consent, order, letter, or other paper document believed by it to be genuine and to have been
signed, sent or presented by or on behalf of the proper party or parties. The Warrant Agent has sole discretion and shall be protected
in acting and relying upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order,
letter or other paper document received in facsimile or e-mail form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may employ or retain such counsel, accountants, engineers, appraisers or other experts or advisers as it may reasonably
require for the purpose of determining and discharging its duties hereunder and may pay reasonable remuneration for all services
so performed by any of them, without taxation of costs of any counsel and shall not be responsible for any misconduct on the part
of any of them who has been selected with due care by the Warrant Agent. Any reasonable remuneration paid by the Warrant Agent
shall be paid by the Company in accordance with section&nbsp;4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may act and rely and shall be protected in acting and relying in good faith on the opinion or advice of or information
obtained from any counsel, accountant, appraiser, engineer or other expert or advisor, whether retained or employed by the Company
or the Warrant Agent, in relation to any matter arising in fulfilling its duties and obligations hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may, as a condition precedent to any action to be taken by it under this Indenture, require such opinions, statutory
declarations, reports, certificates or other evidence as it, acting reasonably, considers necessary or advisable in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent is not required to expend or place its own funds at risk in executing its duties and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.4</TD><TD STYLE="text-align: justify"><U>Securities, Documents and Monies Held by Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any securities, documents
of title, monies or other instruments that may at any time be held by the Warrant Agent subject to the duties and obligations hereof,
for the benefit of the Company, may be placed in the deposit vaults of the Warrant Agent or of any Schedule&nbsp;I Canadian chartered
bank for safekeeping with any such bank. All interest or other income received by the Warrant Agent in respect of such deposits
and investments shall, subject to section&nbsp;4.4, belong to the Company and shall be paid to the Company upon discharge of this
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.5</TD><TD STYLE="text-align: justify"><U>Actions by Warrant Agent to Protect Interests</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions
of this Indenture and Applicable Legislation, the Warrant Agent shall have the power to institute and to maintain such actions
and proceedings as it may consider necessary or expedient to preserve, protect or enforce its interests and the interests of the
Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.6</TD><TD STYLE="text-align: justify"><U>Warrant Agent not Required to Give Security</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent shall
not be required to give any bond or security in respect of the execution of the duties and obligations of this Indenture or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.7</TD><TD STYLE="text-align: justify"><U>Protection of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">By way of supplement
to the provisions of any law for the time being relating to warrant agents, it is expressly declared and agreed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be liable for or by reason of any representations, statements of fact or recitals in this Indenture or
in the Warrants (except the representation contained in section&nbsp;8.9 or in the certificate of the Warrant Agent on the Warrants)
or be required to verify the same and all such statements of fact or recitals are and shall be deemed to be made by the Company
(except the representation contained in section&nbsp;8.9 or in the certificate of the Warrant Agent on the Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
herein contained shall impose any obligation on the Warrant Agent to see to or to require evidence of the registration or filing
(or renewal thereof) of this Indenture or any instrument ancillary or supplemental hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be bound to give notice to any person or persons of the execution hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not incur any liability or responsibility whatsoever or be in any way responsible for the consequence of any
breach on the part of the Company of any of the covenants or warranties herein contained or of any acts of any directors, officers,
employees, agents or servants of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting any protection or indemnity of the Warrant Agent under any other provision hereof, or otherwise at law, the Company hereby
agrees to indemnify and hold harmless the Warrant Agent and its directors, officers, agents and employees from and against any
and all liabilities, losses, damages, penalties, claims, actions, suits, costs, expenses and disbursements, including reasonable
legal or advisor fees and disbursements, of whatever kind and nature which may at any time be imposed on, incurred by or asserted
against the Warrant Agent in connection with the performance of its duties and obligations hereunder, other than such liabilities,
losses, damages, penalties, claims, actions, suits, costs, expenses and disbursements arising by reason of the gross negligence,
wilful misconduct, bad faith or fraud of the Warrant Agent. This provision shall survive the resignation or removal of the Warrant
Agent, or the termination of this Indenture. The Warrant Agent shall not be under any obligation to prosecute or defend any action
or suit in respect of this Indenture which, in the opinion of its counsel, may involve it in expense or liability, unless the Company
shall, so often as required, furnish the Warrant Agent with satisfactory indemnity and funding against such expense or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of the funds provided to the Warrant Agent hereunder are received by it in the form of an uncertified cheque or bank draft,
the Warrant Agent shall delay the release of such funds and the related Warrant Shares until such uncertified cheque has cleared
the financial institution upon which the same is drawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
forwarding of a cheque or the sending of funds by wire transfer by the Warrant Agent will satisfy and discharge the liability of
any amounts due to the extent of the sum represented thereby unless such cheque is not honoured on presentation, provided that
in the event of the non-receipt of such cheque by the payee, or the loss or destruction thereof, the Warrant Agent, upon being
furnished with reasonable evidence of such non-receipt, loss or destruction and indemnity reasonably satisfactory to it, will issue
to such payee a replacement cheque for the amount of such cheque.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or
for any other reason whatsoever, the Warrant Agent, in its sole judgement, determines that such act might cause it to be in non-compliance
with any applicable anti-money laundering or anti-terrorist legislation, regulation or guideline. Further, should the Warrant Agent,
in its sole judgement, determine at any time that its acting under this Warrant Indenture has resulted in its being in non-compliance
with any applicable anti-money laundering or anti-terrorist legislation, regulation or guideline, then it shall have the right
to resign on 10&nbsp;days&rsquo; written notice to the Company provided: (i) that the Warrant Agent&rsquo;s written notice shall
describe the circumstances of such non-compliance; and (ii) that if such circumstances are rectified to the Warrant Agent&rsquo;s
satisfaction within such 10-day period, then such resignation shall not be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be liable for any error in judgment or for any act done or step taken or omitted by it in good faith or
for any mistake, in fact or law, or for anything which it may do or refrain from doing in connection herewith except arising out
of its own gross negligence, bad faith or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.8</TD><TD STYLE="text-align: justify"><U>Replacement of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may resign its appointment and be discharged from all further duties and liabilities hereunder by giving to the Company
not less than 60&nbsp;days prior notice in writing or such shorter prior notice as the Company may accept as sufficient. The Warrantholders
by extraordinary resolution shall have the power at any time to remove the existing Warrant Agent and to appoint a new Warrant
Agent. In the event of the Warrant Agent resigning or being removed as aforesaid or being dissolved, becoming bankrupt, going into
liquidation or otherwise becoming incapable of acting hereunder, the Company shall forthwith appoint a new Warrant Agent unless
a new Warrant Agent has already been appointed by the Warrantholders; failing such appointment by the Company, the retiring Warrant
Agent or any Warrantholder may apply to a judge of the Province of Ontario at the Company&rsquo;s expense, on such notice as such
judge may direct, for the appointment of a new Warrant Agent; but any new Warrant Agent so appointed by the Company or by the Court
shall be subject to removal as aforesaid by the Warrantholders. Any new Warrant Agent appointed under any provision of this section&nbsp;8.8
shall be a corporation authorized to carry on the business of a transfer agent or a trust company in the Province of Ontario and,
if required by Applicable Legislation of any other province, in such other province. On any such appointment the new Warrant Agent
shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as Warrant
Agent without any further assurance, conveyance, act or deed; but there shall be immediately executed, at the expense of the Company,
all such conveyances or other instruments as may, in the opinion of counsel, be necessary or advisable for the purpose of assuring
the same to the new Warrant Agent, provided that any resignation or removal of the Warrant Agent and appointment of a successor
Warrant Agent shall not become effective until the successor Warrant Agent shall have executed an appropriate instrument accepting
such appointment and, at the request of the Company, the predecessor Warrant Agent, upon payment of its outstanding remuneration
and expenses, shall execute and deliver to the successor Warrant Agent an appropriate instrument transferring to such successor
Warrant Agent all rights and powers of the Warrant Agent hereunder and all securities, documents of title and other instruments
and all monies and properties held by the Warrant Agent hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the appointment of a successor Warrant Agent, the Company shall promptly notify the Warrantholders thereof in the manner provided
for in section&nbsp;9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
corporation into or with which the Warrant Agent may be merged or consolidated or amalgamated, or to which all or substantially
all of the corporate trust business is sold or any corporation succeeding to the stock transfer business of the Warrant Agent,
shall be the successor to the Warrant Agent hereunder without any further act on its part or of any of the parties hereto, provided
that such corporation would be eligible for appointment as a new Warrant Agent under subsection&nbsp;8.8(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Warrants Authenticated or certified but not delivered by a predecessor Warrant Agent may be Authenticated or certified by the new
or successor Warrant Agent in the name of the predecessor or the new or successor Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.9</TD><TD STYLE="text-align: justify"><U>Conflict of Interest</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent represents to the Company that at the time of execution and delivery hereof no material conflict of interest exists
which it is aware of in the Warrant Agent&rsquo;s role hereunder and agrees that in the event of a material conflict of interest
arising which it becomes aware of hereafter it will, within 90&nbsp;days after ascertaining that it has such a material conflict
of interest, either eliminate the same or resign its appointment hereunder. If any such material conflict of interest exists or
hereafter shall exist, the validity and enforceability of this Indenture and the Warrants shall not be affected in any manner whatsoever
by reason thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to subsection&nbsp;8.9(1), the Warrant Agent, in its personal or any other capacity, may buy, lend upon and deal in securities
of the Company and generally may contract and enter into financial transactions with the Company or any Subsidiary without being
liable to account for any profit made thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.10</TD><TD STYLE="text-align: justify"><U>Acceptance of Duties and Obligations</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent hereby
accepts the duties and obligations in this Indenture declared and provided for and agrees to perform the same upon the terms and
conditions herein set forth and agrees to hold all rights, interests and benefits contained herein on behalf of those persons who
become holders of Warrants from time to time issued under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.11</TD><TD STYLE="text-align: justify"><U>Warrant Agent not to be Appointed Receiver</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent and
any person related to the Warrant Agent shall not be appointed a receiver or receiver and manager or liquidator of all or any part
of the assets or undertaking of the Company or any Subsidiary or any partnership of which the Company is directly or indirectly
involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.12</TD><TD STYLE="text-align: justify"><U>Authorization to Carry on Business</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent represents
to the Company that it is registered to carry on the business of a transfer agent and warrant agent under Applicable Legislation
in the Province of Ontario.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;9<BR>
GENERAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.1</TD><TD STYLE="text-align: justify"><U>Notice to the Company and the Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
herein otherwise expressly provided, any notice to be given hereunder to the Company or the Warrant Agent shall be deemed to be
validly given if delivered, if sent by registered letter, postage prepaid or if transmitted by facsimile or email to the following
addresses or facsimile numbers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If to the Company, to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">PROFOUND MEDICAL CORP.<BR>
2400 Skymark Avenue, Unit 6<BR>
Mississauga, Ontario L4W 5K5<BR>
<BR>
Attention:&#9;Rashed Dewan<BR>
Facsimile:&#9;(647) 847-3739<BR>
Email: &#9;<U>rdewan@profoundmedical.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If to the Warrant Agent, to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1<BR>
<BR>
Attention: &#9;Vice President, Trust Services<BR>
Facsimile: &#9;(416) 361-0470<BR>
Email: &#9;<U>tmxestaff-corporatetrust@tmx.com</U><BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and any notice given in accordance with
the foregoing shall be deemed to have been received on the date of delivery if that date is a Business Day or, if mailed, on the
fifth Business Day following the date of the postmark on such notice or, if transmitted by facsimile or email, on the next Business
Day following the date of transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company or the Warrant Agent, as the case may be, may from time to time notify the other in the manner provided in subsection&nbsp;9.1(1)
of a change of address which, from the effective date of such notice and until changed by like notice, shall be the address of
the Company or the Warrant Agent, as the case may be, for all purposes of this Indenture. A copy of any notice of change of address
given pursuant to this subsection&nbsp;9.1(2) shall be available for inspection at the principal stock transfer offices of the
Warrant Agent in the City of Toronto, Ontario by Warrantholders during normal business hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given
to the Warrant Agent or to the Company hereunder could reasonably be considered unlikely to reach its destination, the notice shall
be valid and effective only if it is delivered to an officer of the party to which it is addressed or if it is delivered to that
party at the appropriate address provided in subsection&nbsp;9.1(1) by facsimile, email or other means of prepaid, transmitted
or recorded communication and any notice delivered in accordance with the foregoing shall be deemed to have been received on the
date of delivery to the officer or if delivered by facsimile, email or other means of prepaid, transmitted, recorded communication
on the first Business Day following the date of the sending of the notice by the person giving the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.2</TD><TD STYLE="text-align: justify"><U>Notice to the Warrantholders</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
notice to the Warrantholders under the provisions of this Indenture shall be deemed to be validly given if the notice is sent by
prepaid mail or, if delivered by hand, to the holders at their addresses appearing in the register of holders. Any notice so delivered
shall be deemed to have been received on the date of delivery if that date is a Business Day or the Business Day following the
date of delivery if such date is not a Business Day or on the third Business Day if delivered by mail. All notices may be given
to whichever one of the Warrantholders (if more than one) is named first in the appropriate register hereinbefore mentioned, and
any notice so given shall be sufficient notice to all Warrantholders and any other persons (if any) interested in such Warrants.
Accidental error or omission in giving notice or accidental failure to mail notice to any Warrantholder will not invalidate any
action or proceeding founded thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
by reason of strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to
the Warrantholders could reasonably be considered unlikely to reach its destination, the notice may be given in a news release
disseminated through a newswire service, filed on SEDAR and posted on the Company&rsquo;s website; provided that in the case of
a notice convening a meeting of the holders of Warrants, the Warrant Agent may require such additional publications of that notice,
in Toronto, Ontario or in other cities or both, as it may deem necessary for the reasonable notification of the holders of Warrants
or to comply with any applicable requirement of law or any stock exchange. Any notice so given shall be deemed to have been given
on the day on which it has been published in all of the cities in which publication was required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.3</TD><TD STYLE="text-align: justify"><U>Privacy</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Despite any other provision
of this Indenture, no party hereto shall take or direct any action that would contravene, or cause the other to contravene, applicable
federal and/or provincial legislation that addresses the protection of individuals&rsquo; personal information (collectively, &ldquo;<B>Privacy
Laws</B>&rdquo;). The Company shall, prior to transferring or causing to be transferred personal information to the Warrant Agent,
obtain and retain required consents of the relevant individuals to the collection, use and disclosure of their personal information,
or shall have determined that such consents either have previously been given upon which the parties can rely or are not required
under the Privacy Laws. The Warrant Agent shall use commercially reasonable efforts to ensure that its services hereunder comply
with Privacy Laws. Specifically, the Warrant Agent agrees: (a)&nbsp;to have a designated chief privacy officer; (b)&nbsp;to maintain
policies and procedures to protect personal information and to receive and respond to any privacy complaint or inquiry; (c)&nbsp;to
use personal information solely for the purposes of providing its services under or ancillary to this Indenture and not to use
it for any other purpose except with the consent of or direction from the Company or the individual involved; (d)&nbsp;not to sell
or otherwise improperly disclose personal information to any third party; and (e)&nbsp;to employ administrative, physical and technological
safeguards to reasonably secure and protect personal information against loss, theft, or unauthorized access, use or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.4</TD><TD STYLE="text-align: justify"><U>Third Party Interests</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company represents
to the Warrant Agent that any account to be opened by, or interest to held by the Warrant Agent in connection with this Indenture,
for or to the credit of such party, either (i)&nbsp;is not intended to be used by or on behalf of any third party; or (ii)&nbsp;is
intended to be used by or on behalf of a third party, in which case such party hereto agrees to complete and execute forthwith
a declaration in the Warrant Agent prescribed form as to the particulars of such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.5</TD><TD STYLE="text-align: justify"><U>Discretion of Directors</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any matter provided herein
to be determined by the directors in their sole discretion and determination so made will be conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.6</TD><TD STYLE="text-align: justify"><U>Satisfaction and Discharge of Indenture</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Upon the earlier of the
Time of Expiry or the date by which there shall have been delivered to the Warrant Agent for exercise or cancellation in accordance
with the provisions hereof all Warrants theretofore Authenticated or certified hereunder, this Indenture, except to the extent
that Warrant Shares and any certificates therefor have not been issued and delivered hereunder or the Company has not performed
any of its obligations hereunder, shall cease to be of further effect in respect of the Company, and the Warrant Agent, on written
demand of and at the cost and expense of the Company, and upon delivery to the Warrant Agent of a certificate of the Company stating
that all conditions precedent to the satisfaction and discharge of this Indenture have been complied with and upon payment to the
Warrant Agent of the expenses, fees and other remuneration payable to the Warrant Agent, shall execute proper instruments acknowledging
satisfaction of and discharging this Indenture; provided that if the Warrant Agent has not then performed any of its obligations
hereunder any such satisfaction and discharge of the Company&rsquo;s obligations hereunder shall not affect or diminish the rights
of any Warrantholder or the Company against the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.7</TD><TD STYLE="text-align: justify"><U>Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Nothing in this Indenture
or the Warrant Certificates, expressed or implied, shall give or be construed to give to any person other than the parties hereto
and the holders from time to time of the Warrants any legal or equitable right, remedy or claim under this Indenture, or under
any covenant or provision therein contained, all such covenants and provisions being for the sole benefit of the parties hereto
and the Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.8</TD><TD STYLE="text-align: justify"><U>Indenture to Prevail</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">To the extent of any
discrepancy or inconsistency between the terms and conditions of this Indenture and the Warrant Certificate, the terms of this
Indenture will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.9</TD><TD STYLE="text-align: justify"><U>Assignment</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except as provided in
subsection&nbsp;8.8(3), this Indenture nor any benefits or burdens under this Indenture shall be assignable by the Company or the
Warrant Agent without the prior written consent of the other party, such consent not to be unreasonably withheld. Subject to the
foregoing, this Indenture shall enure to the benefit of and be binding upon the Company and the Warrant Agent and their respective
successors (including any successor by reason of amalgamation) and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.10</TD><TD STYLE="text-align: justify"><U>Counterparts and Formal Date</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Indenture may be
simultaneously executed in several counterparts and by electronic means, each of which when so executed shall be deemed to be an
original and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution
shall be deemed to bear the date set out at the top of the first page of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<B><I>Signature page follows</I></B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">I<B>N WITNESS WHEREOF</B>
the parties hereto have executed this Indenture under the hands of their proper officers in that behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Per:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">/s/
    Rashed Dewan<I></I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">TSX TRUST COMPANY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Per:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">/s/
    Donald Crawford</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">/s/ Michael Rosenberg</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page &ndash;Warrant Indenture
between Profound Medical Corp.</I><BR>
<I>and TSX Trust Company]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>Schedule&nbsp;A</U><BR>
FORM OF WARRANT CERTIFICATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Include on Warrant Certificates issued
to U.S. Purchasers: &ldquo;THE SECURITIES REPRESENTED HEREBY AND THE SECURITIES DELIVERABLE UPON EXERCISE HEREOF HAVE NOT BEEN
AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF&nbsp;1933, AS AMENDED (THE &ldquo;U.S.&nbsp;SECURITIES&nbsp;ACT&rdquo;),
OR U.S. STATE SECURITIES LAWS. THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED, DIRECTLY OR INDIRECTLY,
ONLY (A)&nbsp;TO PROFOUND MEDICAL CORP. (THE &ldquo;CORPORATION&rdquo;), (B)&nbsp;OUTSIDE THE UNITED STATES IN COMPLIANCE WITH
RULE&nbsp;904 OF REGULATION&nbsp;S UNDER THE U.S.&nbsp;SECURITIES&nbsp;ACT AND IN COMPLIANCE WITH APPLICABLE LOCAL LAWS AND REGULATIONS,
(C) IN COMPLIANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE U.S. SECURITIES ACT PROVIDED BY (I) RULE 144
UNDER THE U.S. SECURITIES ACT, IF AVAILABLE, OR (II) RULE 144A UNDER THE U.S. SECURITIES ACT, IF AVAILABLE, (D) IN ANOTHER TRANSACTION
THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT, OR (E) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE U.S. SECURITIES ACT, AND, IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE STATE SECURITIES LAWS IN THE UNITED STATES, PROVIDED
THAT, IN THE CASE OF TRANSFERS PURSUANT TO (C)(I) OR (D) ABOVE, THE HOLDER HAS, PRIOR TO SUCH TRANSFER, FURNISHED TO THE CORPORATION
AN OPINION OF COUNSEL OR OTHER EVIDENCE OF EXEMPTION, IN EITHER CASE, REASONABLY SATISFACTORY TO THE CORPORATION. DELIVERY OF THIS
CERTIFICATE MAY NOT CONSTITUTE &ldquo;GOOD DELIVERY&rdquo; IN SETTLEMENT OF TRANSACTIONS ON STOCK EXCHANGES IN CANADA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;THIS WARRANT MAY NOT BE EXERCISED
UNLESS REGISTERED UNDER THE U.S.&nbsp;SECURITIES&nbsp;ACT OR PURSUANT TO AN AVAILABLE EXEMPTION THEREFROM, AND IN EACH CASE, IN
COMPLIANCE WITH APPLICABLE U.S. STATE SECURITIES LAWS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANTS TO PURCHASE COMMON SHARES</B><BR>
<B>OF PROFOUND MEDICAL CORP.</B><BR>
(a corporation incorporated pursuant to the laws of Ontario)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">CUSIP No. 74319B304<BR>
ISIN No. CA 74319B3048</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">Warrant Certificate Number: &bull;</TD>
    <TD STYLE="width: 50%; text-align: right">Representing &bull; Warrants to</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">purchase Common Shares</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS CERTIFIES</B>
that, for value received, the registered holder hereof, &bull; (the &ldquo;<B>holder</B>&rdquo;) is entitled, subject to Profound
Medical Corp.&rsquo;s (the &ldquo;<B>Company</B>&rdquo;) right to accelerate the expiry time in certain circumstances, at any time
at or before 5:00&nbsp;p.m. (Toronto time) on September 20, 2020 (the &ldquo;<B>Expiry Time</B>&rdquo;) to acquire, subject to
adjustment in certain events, the number of common shares (&ldquo;<B>Common Shares</B>&rdquo;) of the Company specified above,
as presently constituted, by surrendering to TSX Trust Company (the &ldquo;<B>Warrant Agent</B>&rdquo;) at its principal office
in Toronto, Ontario, this Warrant Certificate with the duly completed and executed Exercise Form endorsed on the back of this Warrant
Certificate, and accompanied by payment of $1.40 per Common Share (subject to adjustment in certain events) (the &ldquo;<B>Warrant
Exercise Price</B>&rdquo;) by certified cheque, bank draft or money order in lawful money of Canada payable to, or to the order
of, the Company at par at the above-mentioned office of the Warrant Agent. The holder of this Warrant Certificate may purchase
less than the number of Common Shares which he is entitled to purchase on the exercise of the Warrants represented by this Warrant
Certificate, in which event a new Warrant Certificate representing the Warrants not then exercised will be issued to the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time on or
after the date that is 18 months from September 20, 2017, the closing trading price of the Common Shares on the TSX Venture Exchange
(&ldquo;<B>TSXV</B>&rdquo;) (or if the Common Shares are not listed on the TSXV, then on such other recognized Canadian stock exchange
on which the Common Shares are then listed) equals or exceeds $2.50 for a period of at least 10 consecutive trading days, the Company
shall be entitled, within 15 days of the occurrence of such event, to accelerate the Expiry Time of the Warrants to a period ending
on the date that is 20 days from the date that notice of such acceleration (the &ldquo;<B>Acceleration Notice</B>&rdquo;) is provided
to the Warrant Agent and to the Warrantholders pursuant to a press release issued by the Company, with the new Expiry Time specified
in such Acceleration Notice. From and after the new Expiry Time specified in such Acceleration Notice, no Warrants may be issued
or exercised, and all unexercised Warrants shall be void and of no effect following the new Expiry Time. For greater certainty,
the new Expiry Time specified in an Acceleration Notice shall not be later than 5:00 p.m. (Toronto Time) on September 20, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants evidenced
hereby are exercisable on or before the Expiry Time, after which time the Warrants evidenced hereby shall be deemed to be void
and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant Certificate
represents Warrants of the Company issued or issuable under the provisions of a warrant indenture (which indenture together with
all other instruments supplemental or ancillary thereto is herein referred to as the &ldquo;<B>Warrant Indenture</B>&rdquo;) dated
as of September 20, 2017, between the Company and the Warrant Agent, as may be amended from time to time, which contains particulars
of the rights of the holders of the Warrants and the Company and of the Warrant Agent in respect thereof and the terms and conditions
upon which the Warrants are issued and held, all to the same effect as if the provisions of the Warrant Indenture were herein set
forth, to all of which the holder of this Warrant Certificate by acceptance hereof assents. Unless otherwise defined herein, all
capitalized terms shall have the meanings ascribed to them in the Warrant Indenture. A copy of the Warrant Indenture will be available
for inspection at the principal office of the Company in the City of Mississauga, Ontario. <B>In the event of any conflict between
the provisions contained in this Warrant Certificate and the provisions of the Warrant Indenture, the provisions of the Warrant
Indenture shall prevail.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon acceptance hereof,
the holder hereof hereby expressly waives the right to receive any fractional Common Shares upon the exercise hereof in full or
in part and further waives the right to receive any cash or other consideration in lieu thereof. The Warrants represented by this
Warrant Certificate shall be deemed to have been surrendered, and payment by certified cheque, bank draft or money order shall
be deemed to have been made only upon personal delivery thereof or, if sent by post or other means of transmission, upon actual
receipt thereof by the Warrant Agent at its office in the City of Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon due exercise of
the Warrants represented by this Warrant Certificate and payment of the Warrant Exercise Price, the Company shall cause to be issued
to the person(s) in whose name(s) the Common Shares so subscribed for (provided that if the Common Shares are to be issued to a
person other than the registered holder of this Warrant Certificate, the holder&rsquo;s signature on the Exercise Form herein shall
be guaranteed by a Schedule&nbsp;I Canadian chartered bank, or by a medallion signature guarantee from a member of a recognized
Signature Medallion Guarantee Program and the holder shall pay to the Company or the Warrant Agent all applicable transfer or similar
taxes and the Company shall not be required to issue or deliver certificates evidencing the Common Shares unless or until the holder
shall have paid the Company or the Warrant Agent the amount of such tax (or shall have satisfied the Company that such tax has
been paid or that no tax is due)) are to be issued, the number of Common Shares to be issued to such person(s) and such person(s)
shall become a holder in respect of such Common Shares with effect from the date of such exercise, and upon due surrender of this
Warrant Certificate and all other documentation required, the Warrant Agent shall cause the issuance of a certificate(s) representing
such Common Shares to be issued within three Business Days after the exercise of the Warrants (or portion thereof) represented
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the Warrants
represented by this Warrant Certificate nor the Common Shares issuable upon exercise hereof have been or will be registered under
the U.S.&nbsp;Securities&nbsp;Act or any state securities laws. The Warrants represented by this Warrant Certificate may not be
exercised within the United States or by, or for the account or benefit of, a U.S.&nbsp;Person (as defined by Regulation&nbsp;S
under the U.S.&nbsp;Securities&nbsp;Act) or a person within the United States unless registered under the U.S.&nbsp;Securities&nbsp;Act
and any applicable state securities laws or unless an exemption from such registration is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holder acknowledges
that the Warrants represented by this Warrant Certificate and the Common Shares issuable upon exercise hereof may be offered, sold
or otherwise transferred only in compliance with all applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No transfer of any
Warrant will be valid unless entered on the register of transfers, upon surrender to the Warrant Agent of the Warrant Certificate
evidencing such Warrant, duly endorsed by, or accompanied by a transfer form or other written instrument of transfer in form satisfactory
to the Warrant Agent executed by the registered holder or his executors, administrators or other legal representatives or his or
their attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent. Subject to the
provisions of the Warrant Indenture and upon compliance with the reasonable requirements of the Warrant Agent, Warrant Certificates
may be exchanged for Warrant Certificates representing in the aggregate an equal number of Warrants. The Company and the Warrant
Agent may treat the registered holder of this Warrant Certificate for all purposes as the absolute owner hereof. The holding of
the Warrants represented by this Warrant Certificate shall not constitute the holder hereof a holder of Common Shares nor entitle
him to any right or interest in respect thereof except as herein and in the Warrant Indenture expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Indenture
provides for adjustment in the number of Common Shares to be delivered upon exercise of the right of purchase hereby granted and
to the Warrant Exercise Price in certain events therein set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Indenture
contains provisions making binding upon all holders of Warrants outstanding thereunder resolutions passed at meetings of such holders
held in accordance with such provisions and instruments in writing signed by the Warrantholders holding a specified percentage
of the then outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants and the
Warrant Indenture shall be governed by and performed, construed and enforced in accordance with the laws of the Province of Ontario
and the federal laws of Canada applicable therein and shall be treated in all respects as Ontario contracts. Time shall be of the
essence hereof and of the Warrant Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may from
time to time at any time prior to the Expiry Time purchase any of the Warrants by private agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant Certificate
shall not be valid for any purpose until it has been certified by or on behalf of the Warrant Agent for the time being under the
Warrant Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All dollar amounts
herein are expressed in the lawful money of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>
the Company has caused this Warrant Certificate to be signed by its duly authorized officer as of this &bull; day of &bull;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><FONT STYLE="font-weight: normal">Certified this &bull; day of &bull;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">TSX TRUST COMPANY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EXERCISE
FORM</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">TO:</TD>
    <TD STYLE="width: 90%; text-align: justify">PROFOUND MEDICAL CORP.<BR>
c/o TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned holder of the within Warrants
hereby irrevocably exercises the right of such holder to be issued and hereby subscribes for ____________ Common Shares of Profound
Medical Corp. (the &ldquo;<B>Company</B>&rdquo;) at the Warrant Exercise Price referred to in the attached Warrant Certificate
on the terms and conditions set forth in such certificate and the Warrant Indenture and encloses herewith a certified cheque, bank
draft or money order in lawful money of Canada payable to, or to the order of, the Company at par in payment in full of the subscription
price of the Common Shares hereby subscribed for.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise defined herein, all capitalized
terms shall have the meanings ascribed to them in the warrant indenture between the Company and TSX Trust Company dated September
20, 2017 (the &ldquo;<B>Warrant Indenture</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please check the ONE box applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">&bull;<FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 10%; text-align: justify">1.</TD>
    <TD STYLE="width: 80%; text-align: justify">The undersigned certifies that it (i)&nbsp;is not in the United States and is not a &ldquo;U.S.&nbsp;Person&rdquo;, within the meaning of Regulation&nbsp;S under the United States Securities Act of&nbsp;1933, as amended (the &ldquo;<B>U.S.&nbsp;Securities&nbsp;Act</B>&rdquo;), (ii)&nbsp;is not exercising this Warrant for the account or benefit of any U.S.&nbsp;Person, (iii)&nbsp;did not execute or deliver this Exercise Form within the United States and (iv)&nbsp;has in all other aspects complied with the terms of Regulation&nbsp;S under the U.S.&nbsp;Securities&nbsp;Act.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&bull;<FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify">2.</TD>
    <TD STYLE="text-align: justify">The undersigned holder (a)&nbsp;purchased the Warrants as a part of the Units in the Offering; (b)&nbsp;is exercising the Warrants solely for its own account or for the benefit of a U.S.&nbsp;Person or a person in the United States for whose account such holder acquired the Warrants as a part of the Units in the Offering and for whose account such holders exercises sole investment discretion; (c)&nbsp;was and is, and any beneficial purchaser for whose account such holder acquired the Warrant and is exercising the Warrants was and is an Accredited Investor and/or Qualified Instructional Buyer both on the date the Units were purchased in the Offering and on the Exercise Date; and (d)&nbsp;the representations and warranties made by the holder or any beneficial purchaser, as the case may be, to the Company in such holder&rsquo;s U.S. Subscription Agreement remain true and correct on the Exercise Date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;<FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">3<FONT STYLE="font-size: 10pt">.</FONT></TD>
    <TD STYLE="text-align: justify">The undersigned is delivering a written opinion of United States legal counsel or evidence satisfactory to the Company to the effect the Common Shares to be delivered upon exercise hereof have been registered under the U.S.&nbsp;Securities&nbsp;Act or are exempt from the registration requirements of the U.S.&nbsp;Securities&nbsp;Act and applicable state securities laws.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby directs that the
said Common Shares be issued as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; border: Black 1pt solid; text-align: center; font-weight: bold">NAME(S) IN FULL</TD>
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">ADDRESS(ES)</TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">NUMBER OF<BR>
COMMON SHARES</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please print. If securities are issued
to a person other than the registered Warrantholder, the holder must pay to the Warrant Agent all applicable taxes and the signature
of the holder must be guaranteed by a Schedule&nbsp;I Canadian chartered bank, or by a medallion signature guarantee from a member
of a recognized Signature Medallion Guarantee Program).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this ________ day of ______________,
____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Signature of Warrantholder</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Signature Guarantee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Print name</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Address</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">Please check this box if the securities are to be delivered at the office where these Warrants are surrendered, failing which the securities will be mailed.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>NOTES</U>:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certificates will not be registered or delivered to an address in the United States unless Box&nbsp;2 or 3 above is checked.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Box&nbsp;3 is checked, holders are encouraged to contact the Company in advance to determine that the legal opinion tendered in connection with exercise will be satisfactory in form and substance to the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TRANSFER FORM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">TO:</TD>
    <TD STYLE="width: 90%; text-align: justify">PROFOUND MEDICAL CORP.<BR>
c/o TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FOR VALUE RECEIVED</B>, the undersigned
transferor hereby sells, assigns and transfers unto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in">(Transferee)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in">(Address)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in">(Social Insurance Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">___________________ of the Warrants registered
in the name of the undersigned transferor represented by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE UNDERSIGNED TRANSFEROR HEREBY CERTIFIES
AND DECLARES</B> that the Warrants are not being offered, sold or transferred to, or for the account or benefit of, a U.S.&nbsp;Person
(as defined in Regulation&nbsp;S under the U.S.&nbsp;Securities&nbsp;Act of&nbsp;1933 as amended) or a person within the United
States unless registered under the U.S.&nbsp;Securities&nbsp;Act and any applicable state securities laws or unless an exemption
from such registration is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this ________ day of ______________,
____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">Signature of Warrantholder</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">(Transferor)</P></TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Signature Guarantee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Print name</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Address</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>NOTES</U>:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">The signature to this transfer must correspond with the name as recorded on the Warrants in every particular without alteration or enlargement or any change whatever. The signature of the person executing this transfer must be guaranteed by a Schedule&nbsp;I Canadian chartered bank, or by a medallion signature guarantee from a member of a recognized Signature Medallion Guarantee Program.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Warrants shall only be transferable in accordance with the Warrant Indenture between Profound Medical Corp. (the &ldquo;<B>Company</B>&rdquo;) and TSX Trust Company (the &ldquo;<B>Warrant Agent</B>&rdquo;) dated as of September 20, 2017, applicable laws and the rules and policies of any applicable stock exchange. Without limiting the foregoing, if the Warrant Certificate bears a legend restricting the transfer of the Warrants except pursuant to an exemption from registration under the United States Securities Act of&nbsp;1933, as amended (the &ldquo;<B>U.S.&nbsp;Securities&nbsp;Act</B>&rdquo;), and applicable state securities laws, this Transfer Form must be accompanied by a properly completed and executed declaration for removal of legend in the form attached as Schedule B to the Warrant Indenture or if Warrants are transferred in compliance pursuant to an exemption from the registration requirements of the U.S.&nbsp;Securities&nbsp;Act, an opinion of counsel of recognized standing, reasonably satisfactory to the Company, to the effect that such legend is no longer required under applicable requirements of the U.S.&nbsp;Securities&nbsp;Act or state securities laws, together with such other documents or instruments as the Company or the Warrant Agent may require.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>Schedule&nbsp;B</U><BR>
FORM OF DECLARATION FOR REMOVAL OF LEGEND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">TO:</TD>
    <TD STYLE="width: 90%; text-align: justify">PROFOUND MEDICAL CORP.<BR>
c/o TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned (a)&nbsp;acknowledges that
the sale of _____________ Profound Medical Corp. (the &ldquo;<B>Company</B>&rdquo;) represented by certificate number _______________
to which this declaration relates is being made in reliance on Rule&nbsp;904 of Regulation&nbsp;S (&ldquo;<B>Regulation&nbsp;S</B>&rdquo;)
under the United States Securities Act of&nbsp;1933, as amended (the &ldquo;<B>U.S.&nbsp;Securities&nbsp;Act</B>&rdquo;) and (b)&nbsp;certifies
that (1)&nbsp;it is not an affiliate (as defined in Rule&nbsp;405 under the U.S.&nbsp;Securities&nbsp;Act) of the Company, other
than a director or officer who is an affiliate solely by virtue of holding such position, (2)&nbsp;the offer of such securities
was not made to a person in the United States and either (A)&nbsp;at the time the buy order was originated, the buyer was outside
the United States, or the seller and any person acting on its behalf reasonably believe that the buyer was outside the United States,
or (B)&nbsp;the transaction was executed on or through the facilities of the TSX&nbsp;Venture Exchange or another &ldquo;designated
offshore securities market&rdquo; and neither the seller nor any person acting on its behalf knows that the transaction has been
prearranged with a buyer in the United States, (3)&nbsp;neither the seller nor any affiliate of the seller nor any person acting
on any of their behalf has engaged or will engage in any directed selling efforts in the United States in connection with the offer
and sale of such securities, (4)&nbsp;the sale is <I>bona fide</I> and not for the purpose of &ldquo;washing off&rdquo; the resale
restrictions imposed because the securities are &ldquo;restricted securities&rdquo; (as such term is defined in Rule&nbsp;144(a)(3)
under the U.S.&nbsp;Securities&nbsp;Act), (5)&nbsp;the seller does not intend to replace the securities sold in reliance on Rule&nbsp;904
of the U.S.&nbsp;Securities&nbsp;Act with fungible unrestricted securities, and (6)&nbsp;the sale was not a transaction, or part
of a series of transactions which, although in technical compliance with Regulation&nbsp;S, is part of a plan or scheme to evade
the registration provisions of the U.S.&nbsp;Securities&nbsp;Act. Terms used herein have the meanings given to them by Regulation&nbsp;S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">Dated:</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="width: 43%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>15
<FILENAME>tv526458_ex4-9.htm
<DESCRIPTION>EXHIBIT 4.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 4.9</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">PROFOUND
MEDICAL CORP.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- and -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">TSX TRUST
COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">COMMON SHARE
PURCHASE WARRANT INDENTURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Providing for the Issue of<BR>
up to 17,250,000 Common Share Purchase Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March 20, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;1 INTERPRETATION</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%; padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.1</TD>
    <TD STYLE="text-indent: 0in">Definitions</TD>
    <TD STYLE="text-indent: 0in; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.2</TD>
    <TD STYLE="text-indent: 0in">Words Importing the Singular</TD>
    <TD STYLE="text-indent: 0in; text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.3</TD>
    <TD STYLE="text-indent: 0in">Interpretation not Affected by Headings</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.4</TD>
    <TD STYLE="text-indent: 0in">Day not a Business Day</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.5</TD>
    <TD STYLE="text-indent: 0in">Time of the Essence</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.6</TD>
    <TD STYLE="text-indent: 0in">Governing Law</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.7</TD>
    <TD STYLE="text-indent: 0in">Meaning of &ldquo;outstanding&rdquo; for Certain Purposes</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.8</TD>
    <TD STYLE="text-indent: 0in">Currency</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">1.9</TD>
    <TD STYLE="text-indent: 0in">Termination</TD>
    <TD STYLE="text-indent: 0in; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;2 ISSUE OF WARRANTS</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.1</TD>
    <TD STYLE="text-indent: 0in">Issue of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.2</TD>
    <TD STYLE="text-indent: 0in">Form and Terms of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.3</TD>
    <TD STYLE="text-indent: 0in">Signing of Warrant Certificates</TD>
    <TD STYLE="text-indent: 0in; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.4</TD>
    <TD STYLE="text-indent: 0in">Authentication or Certification by the Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.5</TD>
    <TD STYLE="text-indent: 0in">Warrantholder not a Shareholder,&nbsp;etc.</TD>
    <TD STYLE="text-indent: 0in; text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.6</TD>
    <TD STYLE="text-indent: 0in">Issue in Substitution for Lost Warrant Certificates</TD>
    <TD STYLE="text-indent: 0in; text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.7</TD>
    <TD STYLE="text-indent: 0in">Warrants to Rank <I>Pari Passu</I></TD>
    <TD STYLE="text-indent: 0in; text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.8</TD>
    <TD STYLE="text-indent: 0in">Registration and Transfer of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.9</TD>
    <TD STYLE="text-indent: 0in">Registers Open for Inspection</TD>
    <TD STYLE="text-indent: 0in; text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.10</TD>
    <TD STYLE="text-indent: 0in">Exchange of Warrant Certificates</TD>
    <TD STYLE="text-indent: 0in; text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.11</TD>
    <TD STYLE="text-indent: 0in">Ownership of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">12</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.12</TD>
    <TD STYLE="text-indent: 0in">Book-Based System Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.13</TD>
    <TD STYLE="text-indent: 0in">Adjustment of Exchange Basis</TD>
    <TD STYLE="text-indent: 0in; text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.14</TD>
    <TD STYLE="text-indent: 0in">Rules Regarding Calculation of Adjustment of Exchange Basis</TD>
    <TD STYLE="text-indent: 0in; text-align: right">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.15</TD>
    <TD STYLE="text-indent: 0in">Postponement of Subscription</TD>
    <TD STYLE="text-indent: 0in; text-align: right">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.16</TD>
    <TD STYLE="text-indent: 0in">Notice of Adjustment</TD>
    <TD STYLE="text-indent: 0in; text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.17</TD>
    <TD STYLE="text-indent: 0in">No Action after Notice</TD>
    <TD STYLE="text-indent: 0in; text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.18</TD>
    <TD STYLE="text-indent: 0in">Optional Purchases by the Company</TD>
    <TD STYLE="text-indent: 0in; text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.19</TD>
    <TD STYLE="text-indent: 0in">Protection of Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">2.20</TD>
    <TD STYLE="text-indent: 0in">U.S. Securities Law Matters</TD>
    <TD STYLE="text-indent: 0in; text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;3 EXERCISE OF WARRANTS</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.1</TD>
    <TD STYLE="text-indent: 0in">Method of Exercise of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.2</TD>
    <TD STYLE="text-indent: 0in">No Fractional Warrant Shares</TD>
    <TD STYLE="text-indent: 0in; text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.3</TD>
    <TD STYLE="text-indent: 0in">Effect of Exercise of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.4</TD>
    <TD STYLE="text-indent: 0in">Cancellation of Warrants</TD>
    <TD STYLE="text-indent: 0in; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.5</TD>
    <TD STYLE="text-indent: 0in">Subscription for less than Entitlement</TD>
    <TD STYLE="text-indent: 0in; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.6</TD>
    <TD STYLE="text-indent: 0in">Expiration of Warrant</TD>
    <TD STYLE="text-indent: 0in; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.7</TD>
    <TD STYLE="text-indent: 0in">Exercise by U.S.&nbsp;Persons</TD>
    <TD STYLE="text-indent: 0in; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">3.8</TD>
    <TD STYLE="text-indent: 0in">Limitation on Exercise</TD>
    <TD STYLE="text-indent: 0in; text-align: right">25</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">(continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;4 COVENANTS</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%; padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.1</TD>
    <TD STYLE="text-indent: 0in">General Covenants of the Company</TD>
    <TD STYLE="text-indent: 0in; text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.2</TD>
    <TD STYLE="text-indent: 0in">Securities Qualification Requirements</TD>
    <TD STYLE="text-indent: 0in; text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.3</TD>
    <TD STYLE="text-indent: 0in">Warrant Agent&rsquo;s Remuneration and Expenses</TD>
    <TD STYLE="text-indent: 0in; text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">4.4</TD>
    <TD STYLE="text-indent: 0in">Performance of Covenants by Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;5 ENFORCEMENT</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">5.1</TD>
    <TD STYLE="text-indent: 0in">Suits by Warrantholders</TD>
    <TD STYLE="text-indent: 0in; text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">5.2</TD>
    <TD STYLE="text-indent: 0in">Limitation of Liability</TD>
    <TD STYLE="text-indent: 0in; text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;6 MEETINGS OF WARRANTHOLDERS</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.1</TD>
    <TD STYLE="text-indent: 0in">Right to Convene Meetings</TD>
    <TD STYLE="text-indent: 0in; text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.2</TD>
    <TD STYLE="text-indent: 0in">Notice</TD>
    <TD STYLE="text-indent: 0in; text-align: right">28</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.3</TD>
    <TD STYLE="text-indent: 0in">Chairman</TD>
    <TD STYLE="text-indent: 0in; text-align: right">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.4</TD>
    <TD STYLE="text-indent: 0in">Quorum</TD>
    <TD STYLE="text-indent: 0in; text-align: right">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.5</TD>
    <TD STYLE="text-indent: 0in">Power to Adjourn</TD>
    <TD STYLE="text-indent: 0in; text-align: right">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.6</TD>
    <TD STYLE="text-indent: 0in">Show of Hands</TD>
    <TD STYLE="text-indent: 0in; text-align: right">29</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.7</TD>
    <TD STYLE="text-indent: 0in">Poll and Voting</TD>
    <TD STYLE="text-indent: 0in; text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.8</TD>
    <TD STYLE="text-indent: 0in">Regulations</TD>
    <TD STYLE="text-indent: 0in; text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.9</TD>
    <TD STYLE="text-indent: 0in">Company, Warrant Agent and Counsel may be Represented</TD>
    <TD STYLE="text-indent: 0in; text-align: right">30</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.10</TD>
    <TD STYLE="text-indent: 0in">Powers Exercisable by Extraordinary Resolution</TD>
    <TD STYLE="text-indent: 0in; text-align: right">31</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.11</TD>
    <TD STYLE="text-indent: 0in">Meaning of &ldquo;Extraordinary Resolution&rdquo;</TD>
    <TD STYLE="text-indent: 0in; text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.12</TD>
    <TD STYLE="text-indent: 0in">Powers Cumulative</TD>
    <TD STYLE="text-indent: 0in; text-align: right">32</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.13</TD>
    <TD STYLE="text-indent: 0in">Minutes</TD>
    <TD STYLE="text-indent: 0in; text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.14</TD>
    <TD STYLE="text-indent: 0in">Instruments in Writing</TD>
    <TD STYLE="text-indent: 0in; text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.15</TD>
    <TD STYLE="text-indent: 0in">Binding Effect of Resolutions</TD>
    <TD STYLE="text-indent: 0in; text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">6.16</TD>
    <TD STYLE="text-indent: 0in">Holdings by the Company or Subsidiaries of the Company Disregarded</TD>
    <TD STYLE="text-indent: 0in; text-align: right">33</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;7 SUPPLEMENTAL INDENTURES AND SUCCESSOR COMPANIES</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">7.1</TD>
    <TD STYLE="text-indent: 0in">Provision for Supplemental Indentures for Certain Purposes</TD>
    <TD STYLE="text-indent: 0in; text-align: right">34</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">7.2</TD>
    <TD STYLE="text-indent: 0in">Successor Companies</TD>
    <TD STYLE="text-indent: 0in; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;8 CONCERNING THE WARRANT AGENT</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.1</TD>
    <TD STYLE="text-indent: 0in">Indenture Legislation</TD>
    <TD STYLE="text-indent: 0in; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.2</TD>
    <TD STYLE="text-indent: 0in">Rights and Duties of Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.3</TD>
    <TD STYLE="text-indent: 0in">Evidence, Experts and Advisers</TD>
    <TD STYLE="text-indent: 0in; text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.4</TD>
    <TD STYLE="text-indent: 0in">Securities, Documents and Monies Held by Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.5</TD>
    <TD STYLE="text-indent: 0in">Actions by Warrant Agent to Protect Interests</TD>
    <TD STYLE="text-indent: 0in; text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.6</TD>
    <TD STYLE="text-indent: 0in">Warrant Agent not Required to Give Security</TD>
    <TD STYLE="text-indent: 0in; text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.7</TD>
    <TD STYLE="text-indent: 0in">Protection of Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">38</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.8</TD>
    <TD STYLE="text-indent: 0in">Replacement of Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">40</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.9</TD>
    <TD STYLE="text-indent: 0in">Conflict of Interest</TD>
    <TD STYLE="text-indent: 0in; text-align: right">41</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">(continued)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%; text-indent: 0in; padding-left: 0.125in">8.10</TD>
    <TD STYLE="text-indent: 0in">Acceptance of Duties and Obligations</TD>
    <TD STYLE="width: 10%; text-indent: 0in; text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.11</TD>
    <TD STYLE="text-indent: 0in">Warrant Agent not to be Appointed Receiver</TD>
    <TD STYLE="text-indent: 0in; text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">8.12</TD>
    <TD STYLE="text-indent: 0in">Authorization to Carry on Business</TD>
    <TD STYLE="text-indent: 0in; text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Article&nbsp;9 GENERAL</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="padding-right: 0.5in; text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.1</TD>
    <TD STYLE="text-indent: 0in">Notice to the Company and the Warrant Agent</TD>
    <TD STYLE="text-indent: 0in; text-align: right">41</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.2</TD>
    <TD STYLE="text-indent: 0in">Notice to the Warrantholders</TD>
    <TD STYLE="text-indent: 0in; text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.3</TD>
    <TD STYLE="text-indent: 0in">Privacy</TD>
    <TD STYLE="text-indent: 0in; text-align: right">43</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.4</TD>
    <TD STYLE="text-indent: 0in">Third Party Interests</TD>
    <TD STYLE="text-indent: 0in; text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.5</TD>
    <TD STYLE="text-indent: 0in">Discretion of Directors</TD>
    <TD STYLE="text-indent: 0in; text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.6</TD>
    <TD STYLE="text-indent: 0in">Satisfaction and Discharge of Indenture</TD>
    <TD STYLE="text-indent: 0in; text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.7</TD>
    <TD STYLE="text-indent: 0in">Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders</TD>
    <TD STYLE="text-indent: 0in; text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.8</TD>
    <TD STYLE="text-indent: 0in">Indenture to Prevail</TD>
    <TD STYLE="text-indent: 0in; text-align: right">44</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.9</TD>
    <TD STYLE="text-indent: 0in">Assignment</TD>
    <TD STYLE="text-indent: 0in; text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-indent: 0in; padding-left: 0.125in">9.10</TD>
    <TD STYLE="text-indent: 0in">Counterparts and Formal Date</TD>
    <TD STYLE="text-indent: 0in; text-align: right">45</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0in; text-transform: uppercase; padding-left: 0.125in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-indent: 0in; text-transform: uppercase">Schedule&nbsp;A FORM OF WARRANT CERTIFICATE</TD>
    <TD STYLE="text-indent: 0in; text-transform: uppercase; text-align: right">A-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>THIS WARRANT INDENTURE</B>
dated as of March 20, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BETWEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>PROFOUND MEDICAL CORP.</B><BR>
a corporation incorporated under the laws of Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(hereinafter called the &ldquo;<B>Company</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>TSX TRUST COMPANY</B><BR>
a trust company continued under the laws of Canada and registered to carry on business in the Province of Ontario</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(hereinafter called the &ldquo;<B>Warrant
Agent</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>RECITALS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">WHEREAS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">In connection with a public offering in Canada (and concurrent private offering in the United States)
by the Company of up to an aggregate of 34,500,000 Units (the &ldquo;<B>Offering</B>&rdquo;), the Company proposes to issue up
to 17,250,000 Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">Each whole Warrant entitles the holder thereof to purchase, subject to adjustment in certain events,
one Warrant Share at a price of $1.40 at any time prior to 5:00&nbsp;p.m. (Toronto time) on March 20, 2023, subject to earlier
expiry in accordance with this Indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">For such purpose the Company deems it necessary to create and issue Warrants and Warrant Certificates
to be constituted and issued in the manner hereinafter set forth;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">The Company is duly authorized to create and issue the Warrants to be issued as herein provided;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify">All things necessary have been done and performed to make the Warrants, when Authenticated or certified
by the Warrant Agent and issued as provided in this Indenture, legal, valid and binding upon and obligations of the Company that
are entitled to the benefits of and subject to the terms of this Indenture;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: justify">The foregoing recitals are made as statements of fact by the Company and not by the Warrant Agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: justify">The Warrant Agent has agreed to enter into this Indenture and to hold all rights, interests and
benefits contained herein for and on behalf of those persons who become holders of Warrants issued pursuant to this Indenture from
time to time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>NOW THEREFORE THIS
INDENTURE WITNESSES</B> that for good and valuable consideration mutually given and received, the receipt and sufficiency of which
are hereby acknowledged, it is hereby agreed and declared as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;1<BR>
INTERPRETATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.1</TD><TD STYLE="text-align: justify"><U>Definitions</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In this Indenture, unless
there is something in the subject matter or context inconsistent therewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Accredited Investor</B>&rdquo;
means an &ldquo;accredited investor&rdquo; as defined in Rule 501(a) of Regulation D;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Acceleration Notice</B>&rdquo;
has the meaning ascribed to that term in subsection 2.2(3);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Applicable Legislation</B>&rdquo;
means the provisions of the statutes of Canada and its provinces and the regulations under those statutes relating to warrant indentures
and/or the rights, duties or obligations of issuers and warrant agents under warrant indentures as are from time to time in force
and applicable to this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Attribution Parties</B>&rdquo;
has the meaning ascribed to that term in section 3.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Authenticated</B>&rdquo; means
with respect to the issuance of an Uncertificated Warrant, one in respect of which the Warrant Agent has completed all Internal
Procedures such that the particulars of such Uncertificated Warrant are entered in the register of Warrantholders, and &ldquo;<B>Authenticate</B>&rdquo;,
 &ldquo;<B>Authenticating</B>&rdquo; and &ldquo;<B>Authentication</B>&rdquo; have the appropriate correlative meanings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Beneficial Owner</B>&rdquo; means
a person that has a beneficial interest in a Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Beneficial Ownership Limitation</B>&rdquo;
has the meaning ascribed to that term in section 3.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Book-Based System</B>&rdquo;
means the book-based securities system administered by CDS in accordance with its operating rules and procedures in force from
time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Business Day</B>&rdquo; means
a day that is not a Saturday, Sunday, or a day on which banks are closed or which is a civic or statutory holiday in the City of
Toronto, Ontario;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Capital Reorganization</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.13(4);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>CDS</B>&rdquo; means CDS Clearing
and Depository Services Inc. and its successors in interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>CDS Participant</B>&rdquo; means
a person recognized by CDS as a participant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Closing Date</B>&rdquo; means
March 20, 2018;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Common Shares</B>&rdquo; means
the common shares in the capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Common Share Equivalents</B>&rdquo;
means any other securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common
Shares, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Common Share Reorganization</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.13(1);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Company</B>&rdquo; means Profound
Medical Corp., a corporation incorporated under the laws of Ontario, and its lawful successors from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Company&rsquo;s Auditors</B>&rdquo;
means the chartered (professional) accountant or firm of chartered (professional) accountants duly appointed as auditor or auditors
of the Company from time to time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Confirmation</B>&rdquo; means
that CDS shall deliver to the Warrant Agent confirmation of its intention to exercise Warrants in a manner acceptable to the Warrant
Agent, including by electronic means through the Book-Based System;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>counsel</B>&rdquo; means a barrister
and solicitor or lawyer or a firm of barristers and solicitors or lawyers (who may be counsel to the Company), in both cases acceptable
to the Warrant Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Current Market Price</B>&rdquo;
means, at any date, the volume weighted average price per share at which the Common Shares have traded:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">on the TSXV;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">if the Common Shares are not listed on the TSXV, on any stock exchange upon which the Common Shares
are listed as may be selected for this purpose by the board of directors of the Company, acting reasonably; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">if the Common Shares are not listed on any stock exchange, on any over-the-counter market on which
the Common Shares are trading, as may be selected for this purpose by the board of directors of the Company, acting reasonably;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">during the 10&nbsp;consecutive trading
days (on each of which at least 100&nbsp;Common Shares are traded in board lots) ending the third trading day before such date
and the weighted average price shall be determined by dividing the aggregate sale price of all Common Shares sold in board lots
on the exchange or market, as the case may be, during the 10&nbsp;consecutive trading days by the number of Common Shares sold
or, if not traded on any recognized exchange or market, as determined by the directors of the Company, acting reasonably;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>director</B>&rdquo; means a member
of the board of directors of the Company for the time being, and unless otherwise specified herein, reference to &ldquo;<B>action
by the board of directors</B>&rdquo; means action by the board of directors of the Company as a board or, whenever duly empowered,
action by a committee of the board;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exchange Basis</B>&rdquo; means,
at any time, the number of Warrant Shares or other classes of shares or securities which a Warrantholder is entitled to receive
upon the exercise of the rights attached to the Warrants pursuant to the terms of this Indenture, as the number may be adjusted
pursuant to Section 2.13 hereof, such number being equal to one Warrant Share per Warrant as of the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exercise Date</B>&rdquo; with
respect to any Warrant means the date on which such Warrant is duly surrendered for exercise in accordance with the provisions
of Article&nbsp;3 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Exercise Price</B>&rdquo; means
$1.40 for each Warrant Share, subject to adjustment in accordance with the provisions of this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>extraordinary resolution</B>&rdquo;
has the meaning ascribed to that term in sections&nbsp;6.11 and&nbsp;6.14;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Internal Procedures</B>&rdquo;
means in respect of the making of any one or more entries to, changes in or deletions of any one or more entries in the register
at any time (including without limitation, original issuance or registration of transfer of ownership) the minimum number of the
Warrant Agent&rsquo;s internal procedures customary at such time for the entry, change or deletion made to be complete under the
operating procedures followed at the time by the Warrant Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>NCI</B>&rdquo; has the meaning
ascribed to that term in subsection 2.12(1);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Offering</B>&rdquo; the public
offering in Canada (and concurrent private offering in the United States) by the Company of up to an aggregate of 34,500,000 Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>person</B>&rdquo; means an individual,
a corporation, a partnership, a syndicate, a trustee or any unincorporated organization and words importing persons that are intended
to have a similarly extended meaning;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Purchaser</B>&rdquo; means a
purchaser of Units;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Qualified Institutional Buyer</B>&rdquo;
means a &ldquo;qualified institutional buyer&rdquo; within the meaning of Rule&nbsp;144A;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>QIB Letter</B>&rdquo; means a
representation letter signed by Qualified Institutional Buyer(s) in connection with the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Regulation&nbsp;D</B>&rdquo;
means Regulation&nbsp;D as promulgated under the U.S.&nbsp;Securities&nbsp;Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Regulation&nbsp;S</B>&rdquo;
means Regulation&nbsp;S as promulgated under the U.S.&nbsp;Securities&nbsp;Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Rights Offering</B>&rdquo; has
the meaning ascribed to that term in subsection&nbsp;2.13(2);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Rights Offering Price</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.14(8);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Rule&nbsp;144A</B>&rdquo; means
Rule&nbsp;144A as promulgated under the U.S.&nbsp;Securities&nbsp;Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Securities Laws</B>&rdquo; means,
collectively, the applicable securities laws of each of the provinces of Canada, the United States and each of the states of the
United States, as applicable, and the respective regulations made and forms prescribed thereunder together with all applicable
published rules, policy statements, notices and blanket orders and rulings of the securities commissions or similar regulatory
authorities in each of the provinces of Canada;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>shareholder</B>&rdquo; means
an owner of record of one or more Common Shares or shares of any other class or series of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Special Distribution</B>&rdquo;
has the meaning ascribed to that term in subsection&nbsp;2.13(3);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Subsidiary</B>&rdquo; means a
corporation, a majority of the outstanding voting shares of which are owned, directly or indirectly, by the Company or by one or
more subsidiaries of the Company and, as used in this definition, &ldquo;<B>voting shares</B>&rdquo; means shares of a class or
classes ordinarily entitled to vote for the election of the majority of the directors of a corporation irrespective of whether
or not shares of any other class or classes shall have or might have the right to vote for directors by reason of the happening
of any contingency;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>successor company</B>&rdquo;
has the meaning ascribed to that term in section&nbsp;7.2;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>this Indenture</B>&rdquo;, &ldquo;<B>herein</B>&rdquo;,
 &ldquo;<B>hereby</B>&rdquo; and similar expressions mean or refer to this common share purchase warrant indenture and any indenture,
deed or instrument supplemental or ancillary hereto; and the expressions &ldquo;<B>Article</B>&rdquo;, &ldquo;<B>section</B>&rdquo;,
 &ldquo;<B>subsection</B>&rdquo; or &ldquo;<B>paragraph</B>&rdquo; followed by a number or letter mean and refer to the specified
Article, section, subsection or paragraph of this Indenture;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Time of Expiry</B>&rdquo; means
5:00&nbsp;p.m. (Toronto time) on March 20, 2023, unless the term of the Warrants shall be accelerated as provided for in subsection
2.2(3), in which case the Time of Expiry shall be the earlier of (i) 5:00 p.m. (Toronto time) on the date that is 20 days following
delivery of the Acceleration Notice and (ii) 5:00&nbsp;p.m. (Toronto time) on March 20, 2023;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>trading day</B>&rdquo; means
a day on which the TSXV (or such other exchange on which the Common Shares are listed and which forms the primary trading market
for such shares) is open for trading, and if the Common Shares are not listed on a stock exchange, a day on which an over-the-counter
market where such shares are traded is open for business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>transaction instruction</B>&rdquo;
means a written order signed by the holder or CDS, entitled to request that one or more actions be taken, or such other form as
may be reasonably acceptable to the Warrant Agent, requesting one or more such actions to be taken in respect of an Uncertificated
Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Transfer Agent</B>&rdquo; means
the transfer agent or agents for the time being for the Common Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>TSXV</B>&rdquo; means the TSX
Venture Exchange;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S.&nbsp;Person</B>&rdquo; means
a U.S. person as that term is defined in Regulation&nbsp;S;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S.&nbsp;Exchange&nbsp;Act</B>&rdquo;
means the United States Securities Exchange Act of 1934, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>U.S.&nbsp;Securities&nbsp;Act</B>&rdquo;
means the United States Securities Act of 1933, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Uncertificated Warrant</B>&rdquo;
means any Warrant which is issued under the Book-Based System;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Unit Share</B>&rdquo; means a
Common Share comprising part of each Unit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>United States</B>&rdquo; means
the United States as that term is defined in Regulation&nbsp;S;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Units</B>&rdquo; means the units
of the Company, each Unit being comprised of one Unit Share and one-half of one Warrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant Agent</B>&rdquo; means
TSX Trust Company, a trust company existing under the laws of Canada, or any lawful successor thereto including through the operation
of section&nbsp;8.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant Certificates</B>&rdquo;
means the certificates representing Warrants substantially in the form attached as Schedule A hereto or such other form as may
be approved by the Company and the Warrant Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrant Shares</B>&rdquo; means
the Common Shares or other securities or property issuable upon the exercise of the Warrants as a result of any adjustment to the
subscription rights pursuant to Section 2.13 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrantholders</B>&rdquo; or
 &ldquo;<B>holders</B>&rdquo; means the persons whose names are entered for the time being in the register maintained pursuant to
section&nbsp;2.8;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrantholders&rsquo; Request</B>&rdquo;
means an instrument, signed in one or more counterparts by Warrantholders representing, in the aggregate, at least 25% of the aggregate
number of Warrants then outstanding, which requests the Warrant Agent to take some action or proceeding specified therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Warrants</B>&rdquo; means the
common share purchase warrants of the Company issued and Authenticated hereunder as Uncertificated Warrants or to be issued and
countersigned in the form of Warrant Certificates, in either case, entitling the holders thereof to purchase Warrant Shares on
the basis of one Warrant Share for each whole Warrant upon payment of the Exercise Price at any time prior to the Time of Expiry;
provided that in each case the number and/or class of shares or securities receivable on the exercise of the Warrants may be subject
to increase or decrease or change in accordance with the terms and provisions hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>written direction of the Company</B>&rdquo;,
 &ldquo;<B>written request of the Company</B>&rdquo;, &ldquo;<B>written consent of the Company</B>&rdquo; and &ldquo;<B>certificate
of the Company</B>&rdquo; and any other document required to be signed by the Company, means, respectively, a written direction,
request, consent, certificate or other document signed in the name of the Company by any executive officer or director and may
consist of one or more instruments so executed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.2</TD><TD STYLE="text-align: justify"><U>Words Importing the Singular</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless elsewhere otherwise
expressly provided, or unless the context otherwise requires, words importing the singular include the plural and <I>vice versa</I>
and words importing the masculine gender include the feminine and neuter genders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.3</TD><TD STYLE="text-align: justify"><U>Interpretation not Affected by Headings</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The division of this
Indenture into Articles, sections, subsections and paragraphs, the provision of a table of contents and the insertion of headings
are for convenience of reference only and shall not affect the construction or interpretation of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.4</TD><TD STYLE="text-align: justify"><U>Day not a Business Day</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If any day on or before
which any action is required or permitted to be taken hereunder is not a Business Day, then such action shall be required or permitted
to be taken on or before the requisite time on the next succeeding day that is a Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.5</TD><TD STYLE="text-align: justify"><U>Time of the Essence</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Time shall be of the
essence in all respects of this Indenture and the Warrants issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.6</TD><TD STYLE="text-align: justify"><U>Governing Law</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Indenture and the
Warrants issued hereunder shall be construed and enforced in accordance with the laws of the Province of Ontario and the federal
laws of Canada applicable therein and shall be treated in all respects as Ontario contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.7</TD><TD STYLE="text-align: justify"><U>Meaning of &ldquo;outstanding&rdquo; for Certain Purposes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Every Warrant Authenticated
or certified by the Warrant Agent hereunder shall be deemed to be outstanding until it shall be cancelled or delivered to the Warrant
Agent for cancellation, exercised pursuant to section&nbsp;3.1 or until the Time of Expiry; provided that where a new Warrant Certificate
has been issued pursuant to section&nbsp;2.6 hereof to replace one which is lost, mutilated, stolen or destroyed, the Warrants
represented by only one of such Warrant Certificates shall be counted for the purpose of determining the aggregate number of Warrants
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.8</TD><TD STYLE="text-align: justify"><U>Currency</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Unless otherwise stated,
all dollar amounts referred to in this Indenture are in Canadian dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">1.9</TD><TD STYLE="text-align: justify"><U>Termination</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Indenture shall
continue in full force and effect until the earlier of: (a) the Time of Expiry; and (b) the date that no Warrants are outstanding
hereunder; provided that this Indenture shall continue in effect thereafter, if applicable, until the Company and the Warrant Agent
have fulfilled all of their respective obligations under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;2<BR>
ISSUE OF WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.1</TD><TD STYLE="text-align: justify"><U>Issue of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A maximum of 17,250,000
Warrants are hereby created and authorized to be issued hereunder entitling the registered holders thereof to acquire an aggregate
of 17,250,000 Warrant Shares (subject to adjustment in accordance with Section 2.13) at the Exercise Price upon the terms and conditions
herein set forth. Uncertificated Warrants shall be Authenticated by the Warrant Agent and deposited in CDS and Warrant Certificates
evidencing the Warrants, if any, shall be executed by the Company, certified by or on behalf of the Warrant Agent and delivered
by the Warrant Agent to the Company, as applicable, in accordance with a written direction of the Company, all in accordance with
sections&nbsp;2.3 and&nbsp;2.4. Subject to adjustment in accordance with the provisions of this Indenture, each of the Warrants
issued hereunder shall entitle the holder thereof to receive from the Company, at the Exercise Price, the number of Warrant Shares
equal to the Exchange Basis in effect on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.2</TD><TD STYLE="text-align: justify"><U>Form and Terms of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrants may be issued in either certificated or uncertificated form. The Warrant Certificates shall be substantially in the form
attached as Schedule A hereto and dated as of the date of issue, subject to the provisions of this Indenture, with such additions,
variations and changes as may be required or permitted by the terms of this Indenture, and to give effect to any Warrants not being
issued as Uncertificated Warrants, and which may from time to time be agreed upon by the Warrant Agent and the Company, and shall
have such distinguishing letters and numbers as the Company may, with the approval of the Warrant Agent, prescribe. Except as hereinafter
provided in this Article&nbsp;2, all Warrants shall, save as to denominations, be of like tenor and effect. The Warrant Certificates
may be engraved, printed, lithographed, photocopied or be partially in one form or another, as the Company may determine. No change
in the form of the Warrant Certificate shall be required by reason of any adjustment made pursuant to this Article&nbsp;2 in the
number and/or class of securities or type of securities that may be acquired pursuant to the exercise of Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Warrant authorized to be issued hereunder shall entitle the registered holder thereof to acquire (subject to sections&nbsp;2.13,
2.14 and&nbsp;2.15) upon due exercise and upon the transaction instruction or due execution of the exercise form endorsed on the
Warrant Certificate, as applicable, or other instrument of exercise in such form as the Warrant Agent and/or the Company may from
time to time prescribe and upon payment of the Exercise Price, one Warrant Share or such other kind and amount of shares or securities
or property, calculated pursuant to the provisions of sections&nbsp;2.13 and&nbsp;2.14, as the case may be, at any time after the
date of issuance of such Warrants and prior to the Time of Expiry, in accordance with the provisions of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fractional
Warrants shall not be issued or otherwise provided for and shall be disregarded for all purposes and no cash amount will be payable
in lieu thereof. If the exercise of any Warrant would result in a fraction of a Common Share being issued to any person, any such
fraction shall be rounded down to the next whole number of Common Shares and no cash amount will be payable in lieu thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any other provision herein, if at any time on or after the date that is 18 months after March 20, 2018, the closing trading price
of the Common Shares on the TSXV (or if the Common Shares are not listed on the TSXV, then on such other recognized Canadian stock
exchange on which the Common Shares are then listed and primarily traded) exceeds $2.80 for a period of 90 consecutive calendar
days, the Company shall be entitled, within 30 days of the occurrence of such event, to accelerate the Time of Expiry of the Warrants
to a period ending on the date that is 20 days from the date that notice of such acceleration (the &ldquo;<B>Acceleration Notice</B>&rdquo;)
is given to the Warrantholders pursuant to a press release issued by the Company, with the new Time of Expiry specified in such
Acceleration Notice. For purposes of this section, the closing trading price of the Common Shares for a day that is not a Business
Day shall be deemed to be last published closing trading price of the Common Shares. From and after the new Time of Expiry specified
in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants shall be void and of no effect
following the new Time of Expiry. The Company shall give prompt written notice of such acceleration to the Warrant Agent pursuant
to section 9.1. For greater certainty, the new Time of Expiry specified in an Acceleration Notice shall not be later than 5:00
p.m. (Toronto Time) on March 20, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.3</TD><TD STYLE="text-align: justify"><U>Signing of Warrant Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Warrant Certificates
shall be signed by any one of the directors or executive officers of the Company and may, but need not be under the corporate seal
of the Company or a reproduction thereof. The signature of any such director or officer may be mechanically reproduced in facsimile
or other electronic format and Warrant Certificates bearing such facsimile or other electronic format signatures shall be binding
upon the Company as if they had been manually signed by such director or officer. Notwithstanding that the person whose manual
or electronic signature appears on any Warrant Certificate as a director or executive officer may no longer hold office at the
date of issue of the Warrant Certificate or at the date of certification or delivery thereof, any Warrant Certificate signed as
aforesaid shall, subject to section&nbsp;2.4, be valid and binding upon the Company and the registered holder thereof will be entitled
to the benefits of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.4</TD><TD STYLE="text-align: justify"><U>Authentication or Certification by the Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Warrant Certificate shall be issued or, if issued, shall be valid for any purpose or entitle the registered holder to the benefit
hereof or thereof until it has been certified by manual signature by or on behalf of the Warrant Agent and such certification by
the Warrant Agent shall be conclusive evidence as against the Company that the Warrant so certified has been duly issued hereunder
and the holder is entitled to the benefits hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Uncertificated Warrant shall be issued or, if issued, shall be valid for any purposes or entitle the holder to the benefits hereof
and thereof until it has been Authenticated by the Warrant Agent and such Authentication shall be conclusive evidence as against
the Company that the Uncertificated Warrant has been duly issued hereunder and that the holder is entitled to the benefits hereof
and thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
certification of the Warrant Agent on the Warrant Certificates issued hereunder, or the Authentication of the Warrant Agent of
the Uncertificated Warrants made hereunder, as applicable, shall not be construed as a representation or warranty by the Warrant
Agent as to the validity of this Indenture or the Warrant Certificates (except the due certification thereof) or the Uncertificated
Warrants (except the due Authentication thereof) as applicable, and the Warrant Agent shall in no respect be liable or answerable
for the use made of the Warrant Certificates or Uncertificated Warrants, as applicable, or any of them or of the consideration
therefor except as otherwise specified herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.5</TD><TD STYLE="text-align: justify"><U>Warrantholder not a Shareholder,&nbsp;etc.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Nothing in this Indenture
or the holding of a Warrant evidenced by a Warrant Certificate shall be construed as conferring upon a Warrantholder any right
or interest whatsoever as a shareholder, including but not limited to the right to vote at, to receive notice of, or to attend
meetings of shareholders or any other proceedings of the Company, nor entitle the holder to any right or interest in respect thereof
except as herein and in the Warrants expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.6</TD><TD STYLE="text-align: justify"><U>Issue in Substitution for Lost Warrant Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any Warrant Certificates issued and certified under this Indenture shall become mutilated or be lost, destroyed or stolen, the
Company, subject to applicable law, and subsection&nbsp;2.6(2), shall issue and thereupon the Warrant Agent shall certify and deliver
a new Warrant Certificate of like denomination, date and tenor as the one mutilated, lost, destroyed or stolen in exchange for,
in place of and upon cancellation of such mutilated Warrant Certificate, or in lieu of and in substitution for such lost, destroyed
or stolen Warrant Certificate, and the substituted Warrant Certificate shall be substantially in the form set out in Schedule A
hereto and Warrants evidenced by it will entitle the holder thereof to the benefits hereof and shall rank equally in accordance
with its terms with all other Warrant Certificates issued or to be issued hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicant for the issue of a new Warrant Certificate pursuant to this section&nbsp;2.6 shall bear the reasonable cost of the issue
thereof and in the case of mutilation shall, as a condition precedent to the issue thereof, deliver to the Warrant Agent the mutilated
Warrant Certificate, and in the case of loss, destruction or theft shall, as a condition precedent to the issue thereof, furnish
to the Company and to the Warrant Agent such evidence of ownership and of the loss, destruction or theft of the Warrant Certificate
so lost, destroyed or stolen as shall be satisfactory to the Company and to the Warrant Agent in their sole discretion and such
applicant may be required to furnish an indemnity and surety bond in amount and form satisfactory to the Company and the Warrant
Agent in their sole discretion and shall pay the reasonable charges of the Company and the Warrant Agent in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.7</TD><TD STYLE="text-align: justify"><U>Warrants to Rank <I>Pari Passu</I></U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All Warrants shall rank
<I>pari passu</I> with all other Warrants, whatever may be the actual date of issue of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.8</TD><TD STYLE="text-align: justify"><U>Registration and Transfer of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent will create and keep at the principal stock transfer offices of the Warrant Agent in the City of Toronto, Ontario:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">a register of holders in which shall be entered in alphabetical order the names and addresses of
the holders of Warrants and particulars of the Warrants held by them and the Warrant Agent shall be entitled to rely on such register
in connection with the exchange, transfer or exercise of any Warrant(s) pursuant to the terms of this Indenture or the terms thereof;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">a register of transfers in which all transfers of Warrants and the date and other particulars of
each such transfer shall be entered.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
transfer of any Warrant will be valid unless entered on the register of transfers referred to in subsection&nbsp;2.8(1), and, in
the case of a Warrant Certificate, upon surrender to the Warrant Agent of the Warrant Certificate evidencing such Warrant, and
a duly completed and executed transfer form endorsed on the Warrant Certificate executed by the registered holder or his executors,
administrators or other legal representatives or his attorney duly appointed by an instrument in writing in form and execution
satisfactory to the Warrant Agent, if applicable, and, upon compliance with such requirements and such other reasonable requirements
as the Warrant Agent may prescribe, such transfer will be recorded on the register of transfers by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of a Warrant Certificate, the transferee of any Warrant will, after surrender to the Warrant Agent of the Warrant Certificate
evidencing such Warrant as required by subsection&nbsp;2.8(2) and upon compliance with all other conditions in respect thereof
required by this Indenture or by law, be entitled to be entered on the register of holders referred to in subsection&nbsp;2.8(1)
as the owner of such Warrant free from all equities or rights of set-off or counterclaim between the Company and the transferor
or any previous holder of such Warrant, except in respect of equities or rights of which the Company is required to take notice
by statute or by order of a court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will be entitled, and may direct the Warrant Agent, to refuse to recognize any transfer, or enter the name of any transferee,
of any Warrant on the registers referred to in subsection&nbsp;2.8(1), if such transfer would constitute a violation of (a) the
Securities Laws of any applicable jurisdiction or the rules, regulations or policies of any regulatory authority having jurisdiction,
(b) any restrictive legend on such Warrant or (c) any applicable representations and warranties made by the Warrantholder in a
QIB Letter executed by such Warrantholder in connection with the Offering. The Warrant Agent is entitled to assume compliance with
all applicable Securities Laws unless otherwise notified in writing by the Company. No duty shall rest with the Warrant Agent to
determine compliance of the transferee or transferor of any Warrant with applicable Securities Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants
held by a Warrantholder in the United States or a U.S.&nbsp;Person that is a Qualified Institutional Buyer shall not be offered,
sold or otherwise transferred except (A)&nbsp;to the Company or (B)&nbsp;outside the United States in accordance with Rule&nbsp;904
of Regulation&nbsp;S and in compliance with applicable local securities laws and regulations, as provided for in the QIB Letter
for such Warrantholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.9</TD><TD STYLE="text-align: justify"><U>Registers Open for Inspection</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The registers referred
to in subsection&nbsp;2.8(1) shall be open at all reasonable times during business hours on a Business Day for inspection by the
Company or any Warrantholder. The Warrant Agent shall, from time to time when requested to do so in writing by the Company and
upon payment of its reasonable fees, furnish the Company with a list of the names and addresses of holders of Warrants entered
in the register of holders kept by the Warrant Agent and showing the number of Warrants held by each such holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.10</TD><TD STYLE="text-align: justify"><U>Exchange of Warrant Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant
Certificates may, upon compliance with the reasonable requirements of the Warrant Agent, be exchanged for Warrant Certificates
in any other authorized denomination representing in the aggregate an equal number of Warrants as the number of Warrants represented
by the Warrant Certificates being exchanged. The Company shall sign and the Warrant Agent shall certify, in accordance with sections&nbsp;2.3
and&nbsp;2.4, all Warrant Certificates necessary to carry out the exchanges contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrant
Certificates may be exchanged only at the principal stock transfer offices of the Warrant Agent in the City of Toronto, Ontario
or at any other place that is designated by the Company with the approval of the Warrant Agent. Any Warrant Certificates tendered
for exchange shall be surrendered to the Warrant Agent and cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise herein provided, the Warrant Agent may charge Warrantholders requesting an exchange a reasonable sum for each Warrant
Certificate issued; and payment of such charges and reimbursement of the Warrant Agent or the Company for any and all taxes or
governmental or other charges required to be paid shall be made by the party requesting such exchange as a condition precedent
to such exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.11</TD><TD STYLE="text-align: justify"><U>Ownership of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company and the Warrant
Agent and their respective agents may deem and treat the registered holder of any Warrant as the absolute owner of the Warrant
represented thereby for all purposes and the Company and the Warrant Agent and their respective agents shall not be affected by
any notice or knowledge to the contrary except as required by statute or order of a court of competent jurisdiction. The holder
of any Warrant shall be entitled to the rights evidenced by that Warrant free from all equities or rights of set-off or counterclaim
between the Company and the original or any intermediate holder thereof and all persons may act accordingly and the receipt by
any holder of the Warrant Shares or monies obtainable pursuant to the exercise of the Warrant shall be a good discharge to the
Company and the Warrant Agent for the same and neither the Company nor the Warrant Agent shall be bound to inquire into the title
of any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.12</TD><TD STYLE="text-align: justify"><U>Book-Based System Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as described above, and except as may be directed by the Company, registration of interests in and transfers of Warrants shall
be made only through the Book-Based System. Other than as may be directed by the Company, the Warrants will be evidenced by a non-certificated
inventory (&ldquo;<B>NCI</B>&rdquo;) deposit though the Book-Based System for an amount representing the aggregate number of such
Warrants outstanding from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfers
of beneficial ownership in any Warrant represented by an NCI deposit will be effected only (i) with respect to the interest of
a CDS Participant, through records maintained by CDS or its nominee for such Warrants, and (ii) with respect to the interest of
any person other than a CDS Participant, through records maintained by CDS Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
rights of Beneficial Owners who hold security entitlements in respect of Warrants through the Book-Based System shall be limited
to those established by applicable law and agreements between CDS and CDS Participants and between such CDS Participants and Beneficial
Owners who hold security entitlements in respect of Warrants through the Book-Based System and must be exercised through a CDS
Participant in accordance with the rules and procedures of CDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of the following events occurs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">CDS or the Company has notified the Warrant Agent that (A) CDS is unwilling or unable to continue
as depository or (B) CDS ceases to be a clearing agency in good standing under applicable laws and, in either case, the Company
is unable to locate a qualified successor depository within 90&nbsp;days of delivery of such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Company has determined, in its sole discretion, to terminate the Book-Based System in respect
of such Uncertificated Warrants and has communicated such determination to the Warrant Agent in writing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Company or CDS is required by applicable law to take the action contemplated in this subsection;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the Book-Based System administered by CDS ceases to exist,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">then one or more definitive fully registered
Warrant Certificates shall be executed by the Company and certified and delivered by the Warrant Agent to CDS in exchange for the
Uncertificated Warrants form held by CDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fully registered Warrant
Certificates issued and exchanged pursuant to this subsection shall be registered in such names and in such denominations as CDS
shall instruct the Warrant Agent, provided that the aggregate number of Warrants represented by such Warrant Certificates shall
be equal to the aggregate number of Uncertificated Warrants so exchanged. Upon exchange of Uncertificated Warrants for one or more
Warrant Certificates in definitive form, such Uncertificated Warrants shall be cancelled by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything in this Indenture in terms of an NCI deposit, neither the Company nor the Warrant Agent nor any agent thereof shall have
any responsibility or liability for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the records maintained by CDS relating to any ownership interests or any other interests in the
Warrants or the depository system maintained by CDS, or payments made on account of any ownership interest or any other interest
of any person in any Warrant represented by any NCI deposit (other than CDS or its nominee);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">maintaining, supervising or reviewing any records of CDS or any CDS Participant relating to any
such interest; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">any advice or representation made or given by CDS or those contained in this Indenture that relate
to the rules and regulations of CDS or any action to be taken by CDS on its own direction or at the direction of any CDS Participant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.13</TD><TD STYLE="text-align: justify"><U>Adjustment of Exchange Basis</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to section&nbsp;2.14,
the Exchange Basis shall be subject to adjustment from time to time in the events and in the manner provided as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">issue Common Shares or securities exchangeable for or convertible into Common Shares to all or
substantially all the holders of the Common Shares as a stock dividend or other distribution (other than a distribution of Warrant
Shares upon exercise of the Warrants or pursuant to the exercise, conversion or exchange of securities of the Company outstanding
as of the date hereof), or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">subdivide, redivide or change its then outstanding Common Shares into a greater number of Common
Shares, or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">reduce, combine or consolidate its then outstanding Common Shares into a lesser number of Common
Shares,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(any of such events in these paragraphs&nbsp;(i),
(ii) or&nbsp;(iii) being called a &ldquo;<B>Common Share Reorganization</B>&rdquo;), then the Exchange Basis in effect on the effective
date of such subdivision, redivision or change, or reduction, combination or consolidation, or on the record date of such stock
dividend or other distribution, as the case may be, shall be adjusted by multiplying the Exchange Basis in effect immediately prior
to such effective or record date by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the numerator of which shall be the total number of Common Shares outstanding on such date immediately
after giving effect to such Common Share Reorganization (including, in the case where securities exercisable, exchangeable for
or convertible into Common Shares are distributed, the number of Common Shares that would have been outstanding had such securities
been exercised, or exchanged for or converted into Common Shares on such record date, assuming in any case where such securities
are not then convertible, exercisable or exchangeable but subsequently become so, that they were convertible, exercisable or exchangeable
on the record date on the basis upon which they first become convertible, exercisable or exchangeable), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the denominator of which shall be the total number of Common Shares outstanding on such date before
giving effect to such Common Share Reorganization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The resulting
product, adjusted to the nearest 1/100th, shall thereafter be the Exchange Basis until further adjusted as provided in this Article&nbsp;2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any Common Shares owned by or
held for the account of the Company or any of its Subsidiaries or a partnership in which the Company is directly or indirectly
a party to will be deemed not to be outstanding for the purpose of any computation. To the extent that any adjustment in the Exchange
Basis occurs pursuant to this subsection&nbsp;2.13(1) as a result of the fixing by the Company of a record date for the distribution
of securities exchangeable or exercisable for or convertible into Common Shares and the Common Share Reorganization does not occur
or any conversion, exercise or exchange rights are not fully converted, exercised or exchanged, the Exchange Basis shall be readjusted
immediately after the expiry of any relevant exchange or conversion right or the termination of the Common Share Reorganization,
as the case may be, to the Exchange Basis that would then be in effect, based upon the number of Common Shares actually issued
and remaining issuable after such expiry and shall be further readjusted in such manner upon the expiry of any further such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, the Company shall fix a record date for the distribution
to all or substantially all of the holders of its outstanding Common Shares of rights, options or warrants entitling them, for
a period expiring not less than 21 days and not more than 90&nbsp;days after such record date, to subscribe for or purchase Common
Shares, or securities exchangeable or exercisable for or convertible into Common Shares, at a price per share to the holder (or
at an exchange, exercise or conversion price per share) of less than 95% of the Current Market Price on such record date (any of
such events being called a &ldquo;<B>Rights Offering</B>&rdquo;), then the Exchange Basis shall be adjusted effective immediately
after such record date for the Rights Offering by multiplying the Exchange Basis in effect immediately prior to such record date
by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the numerator of which shall be the number of Common Shares which would be outstanding after giving
effect to the Rights Offering (assuming the exercise of all of the rights, options or warrants under the Rights Offering and assuming
the exchange, exercise or conversion into Common Shares of all exchangeable, exercisable or convertible securities issued upon
exercise of such rights, options or warrants, if any), and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the denominator of which shall be the aggregate of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the total number of Common Shares outstanding as of the record date for the Rights Offering, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">a number of Common Shares determined by dividing</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the amount equal to the aggregate consideration payable on the exercise of all of the rights, options
and warrants under the Rights Offering plus the aggregate consideration, if any, payable on the exchange, exercise or conversion
of the exchangeable or convertible securities issued upon exercise of such rights, options or warrants (assuming the exercise of
all rights, options and warrants under the Rights Offering and assuming the exchange or conversion of all exchangeable or convertible
securities issued upon exercise of such rights, options and warrants);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">by</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the Current Market Price as of the record date for the Rights Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The resulting product, adjusted to the
nearest 1/100th, shall thereafter be the Exchange Basis until further adjusted as provided in this Article&nbsp;2. Any Common Shares
owned by or held for the account of the Company or any of its Subsidiaries or a partnership in which the Company is directly or
indirectly a party to will be deemed not to be outstanding for the purpose of any computation. If, at the date of expiry of the
rights, options or warrants subject to the Rights Offering, less than all the rights, options or warrants have been exercised,
then the Exchange Basis shall be readjusted effective immediately after the date of expiry to the Exchange Basis which would have
been in effect on the date of expiry if only the rights, options or warrants issued had been those exercised. If at the date of
expiry of the rights of exchange, exercise or conversion of any securities issued pursuant to the Rights Offering less than all
of such securities have been exchanged or exercised for, or converted into, Common Shares, then the Exchange Basis shall be readjusted
effective immediately after the date of expiry to the Exchange Basis which would have been in effect on the date of expiry if only
the exchangeable, exercisable or convertible securities issued had been those securities actually exchanged or exercised for or
converted into Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, the Company shall fix a record date for the issuance
or distribution to all or substantially all the holders of its outstanding Common Shares of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">shares of the Company of any class other than Common Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">rights, options or warrants to acquire Common Shares or securities exchangeable or exercisable
for or convertible into Common Shares; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">evidences of indebtedness; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">cash, securities or any property or other assets,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and if such issuance or distribution does
not constitute a Common Share Reorganization or a Rights Offering (any of such non-excluded events being herein called a &ldquo;<B>Special
Distribution</B>&rdquo;), the Exchange Basis shall be adjusted effective immediately after the record date for the Special Distribution
by multiplying the Exchange Basis in effect on such record date by a fraction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the numerator of which shall be the number of Common Shares outstanding on such record date multiplied
by the Current Market Price on such record date, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the denominator of which shall be:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">the product of the number of Common Shares outstanding on such record date and the Current Market
Price on such record date,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">less</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">the fair market value, as determined by action by the board of directors acting reasonably and
in good faith (whose determination shall, absent manifest error, be conclusive), to the holders of the Common Shares of the shares,
rights, options, warrants, evidences of indebtedness or property or other assets issued or distributed in the Special Distribution,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that no such adjustment shall
be made if the result of such adjustment would be to decrease the Exchange Basis in effect immediately before such record date.
The resulting product, adjusted to the nearest 1/100th, shall thereafter be the Exchange Basis until further adjusted as provided
in this Article&nbsp;2. Any shares owned by or held for the account of the Company or its Subsidiaries or a partnership of which
the Company is directly or indirectly a party to shall be deemed not to be outstanding for the purpose of any such computation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and whenever, at any time after the date hereof and prior to the Time of Expiry, there shall be a reclassification of the Common
Shares at any time outstanding or change or exchange of the Common Shares into other shares or into other securities (other than
a Common Share Reorganization), or a consolidation, amalgamation, plan of arrangement or merger of the Company with or into any
other corporation or other entity (other than a consolidation, amalgamation, plan of arrangement or merger which does not result
in any reclassification of the outstanding Common Shares or a change of the Common Shares into other shares), or a transfer (other
than to a Subsidiary) of the undertaking or assets of the Company as an entirety or substantially as an entirety to another corporation
or other entity (any of such events being herein called a &ldquo;<B>Capital Reorganization</B>&rdquo;), any Warrantholder who thereafter
shall exercise his right to receive Warrant Shares pursuant to Warrant(s) shall be entitled to receive, and shall accept in lieu
of the number of Warrant Shares to which such holder was theretofore entitled upon such exercise, the aggregate number of shares,
other securities or other property resulting from the Capital Reorganization which such holder would have been entitled to receive
as a result of such Capital Reorganization if, on the effective date or record date thereof, as the case may be, the Warrantholder
had been the registered holder of the number of Warrant Shares to which such holder was theretofore entitled upon exercise. If
appropriate, adjustments shall be made as a result of any such Capital Reorganization in the application of the provisions set
forth in this Article&nbsp;2 with respect to the rights and interests thereafter of Warrantholders to the end that the provisions
set forth in this Article&nbsp;2 shall thereafter correspondingly be made applicable as nearly as may reasonably be in relation
to any shares, other securities or other property thereafter deliverable upon the exercise of any Warrant. Any such adjustment
shall be made by and set forth in an indenture supplemental hereto approved by the directors and by the Warrant Agent and entered
into pursuant to the provisions of this Indenture and shall for all purposes be conclusively deemed to be an appropriate adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
adjustment to the Exchange Basis as set forth herein (except resulting from a Capital Reorganization) shall also include a corresponding
adjustment to the Exercise Price which shall be calculated by multiplying the Exercise Price by a fraction: (a) the numerator of
which shall be the Exchange Basis prior to the adjustment, and (b) the denominator of which shall be the Exchange Basis after the
adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.14</TD><TD STYLE="text-align: justify"><U>Rules Regarding Calculation of Adjustment of Exchange Basis</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">For the purposes of section&nbsp;2.13:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
adjustments provided for in section&nbsp;2.13 shall be cumulative and such adjustments shall be made successively whenever an event
referred to in section&nbsp;2.13 shall occur, subject to the following subsections of this section&nbsp;2.14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
adjustment in the: (a)&nbsp;Exchange Basis shall be required unless such adjustment would result in a change of at least 0.01 of
a Warrant Share based on the prevailing Exchange Basis; or (b)&nbsp;Exercise Price shall be required unless such adjustment would
result in a change of at least 1%, provided that any adjustments which, except for the provisions of this subsection, would otherwise
have been required to be made, shall be carried forward and taken into account in any subsequent adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
adjustment in the Exchange Basis shall be made in respect of any event described in section&nbsp;2.13, other than the events referred
to in paragraphs&nbsp;(ii) and&nbsp;(iii) of subsection&nbsp;(1) thereof, if Warrantholders are entitled to participate in such
event on the same terms, mutatis mutandis, as if Warrantholders had exercised their Warrants prior to or on the effective date
or record date of such event, any such participation being subject to regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
adjustment in the Exchange Basis shall be made pursuant to section&nbsp;2.13 in respect of the issue from time to time of Warrant
Shares purchasable on exercise of the Warrants or pursuant to the exercise, conversion or exchange of securities of the Company
outstanding as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a dispute shall at any time arise with respect to adjustments provided for in section&nbsp;2.13, such dispute shall, absent manifest
error, be conclusively determined by the Company&rsquo;s Auditors, or if they are unable or unwilling to act, by such other firm
of independent chartered accountants as may be selected by the directors and any further determination, absent manifest error,
shall be binding upon the Company, the Warrant Agent and the Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Company shall set a record date to determine the holders of the Common Shares for the purpose of entitling them to receive
any dividend or distribution or any subscription or purchase rights and shall, thereafter and before the distribution to such shareholders
of any such dividend, distribution, or subscription or purchase rights, legally abandon its plan to pay or deliver such dividend,
distribution, or subscription or purchase rights, then no adjustment in the Exchange Basis shall be required by reason of the setting
of such record date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the absence of a resolution of the directors fixing a record date for a Rights Offering or Special Distribution, the Company shall
be deemed to have fixed as the record date therefor the date on which the Rights Offering or Special Distribution is effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the purchase price provided for in any Rights Offering (the &ldquo;<B>Rights Offering Price</B>&rdquo;) is decreased, the Exchange
Basis shall forthwith be changed so as to increase the Exchange Basis to such Exchange Basis as would have been obtained had the
adjustment to the Exchange Basis made pursuant to subsection&nbsp;2.13(2) upon the issuance of such Rights Offering been made upon
the basis of the Rights Offering Price as so decreased, provided that the provisions of this subsection shall not apply to any
decrease in the Rights Offering Price resulting from provisions in any such Rights Offering designed to prevent dilution if the
event giving rise to such decrease in the Rights Offering Price itself requires an adjustment to the Exchange Basis pursuant to
the provisions of section&nbsp;2.13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a condition precedent to the taking of any action that would require any adjustment in any of the subscription rights pursuant
to any of the Warrants, including the Exchange Basis, the Company shall take any corporate action which may, in the opinion of
counsel, be necessary in order that the Company have unissued and reserved in its authorized capital and may validly and legally
issue as fully paid and non-assessable all the shares or other securities that all the holders of such Warrants are entitled to
receive on the exercise of all the subscription rights attaching thereto in accordance with the provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall be entitled to act and rely on any adjustment calculations by the Company or the Company&rsquo;s Auditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.15</TD><TD STYLE="text-align: justify"><U>Postponement of Subscription</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In any case where the
application of section&nbsp;2.13 results in an increase in the number of Common Shares that are issuable upon exercise of the Warrants
taking effect immediately after the record date for a specific event, if any Warrant is exercised after that record date and prior
to completion of such specific event, the Company may postpone the issuance to the Warrantholder of the Warrant Shares to which
he is entitled by reason of such adjustment, but such Warrant Shares shall be so issued and delivered to that holder upon completion
of that event, with the number of such Warrant Shares calculated on the basis of the number of Warrant Shares on the date that
the Warrant was exercised, adjusted for completion of that event and the Company shall deliver to the person or persons in whose
name or names the Warrant Shares are to be issued an appropriate instrument evidencing the right of such person or persons to receive
such Warrant Shares and the right to receive any dividends or other distributions which, but for the provisions of this section&nbsp;2.15,
such person or persons would have been entitled to receive in respect of such Warrant Shares from and after the date that the Warrant
was exercised in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.16</TD><TD STYLE="text-align: justify"><U>Notice of Adjustment</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
least 14&nbsp;days prior to the effective date or record date, as the case may be, of any event which requires or might require
adjustment pursuant to section&nbsp;2.13, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">file with the Warrant Agent a certificate of the Company specifying the particulars of such event
(including the record date or the effective date for such event) and, if determinable, the required adjustment and the computation
of such adjustment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">give notice to the Warrant Agent and the Warrantholders of the particulars of such event (including
the record date or the effective date for such event) and, if determinable, the required adjustment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
case any adjustment for which a notice in subsection&nbsp;2.16(1) has been given is not then determinable, the Company shall promptly
after such adjustment is determinable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">file with the Warrant Agent a computation of such adjustment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">give notice to the Warrantholders of the adjustment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may, absent manifest error, act and rely upon certificates and other documents filed by the Company pursuant to this
section&nbsp;2.16 for all purposes of the adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.17</TD><TD STYLE="text-align: justify"><U>No Action after Notice</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company covenants
with the Warrant Agent that it will not take any other corporate action which might deprive a Warrantholder of the opportunity
of exercising the rights of acquisition pursuant thereto during the period of 10&nbsp;days after the giving of the notice set forth
in subsection&nbsp;2.16(1) and paragraph&nbsp;(b) of subsection&nbsp;2.16(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.18</TD><TD STYLE="text-align: justify"><U>Optional Purchases by the Company</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to applicable
law and prior approval of the TSXV, if required, the Company may from time to time purchase on any stock exchange (if then listed),
in the open market, by private agreement or otherwise any of the Warrants. Any such purchase shall be made at the lowest price
or prices at which, in the opinion of the board of directors of the Company, such Warrants are then obtainable, plus reasonable
costs of purchase, and may be made in such manner, from such persons, and on such other terms as the Company in its sole discretion
may determine. The Warrant Certificates representing the Warrants purchased pursuant to this section&nbsp;2.18 shall forthwith
be delivered to and cancelled by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.19</TD><TD STYLE="text-align: justify"><U>Protection of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to Article&nbsp;8,
the Warrant Agent shall not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">at any time be under any duty or responsibility to any registered holder of Warrants to determine
whether any facts exist that may require any adjustment contemplated by this Article&nbsp;2, nor to verify the nature and extent
of any such adjustment when made or the method employed in making the same;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">be accountable with respect to the validity or value or the kind or amount of any Warrant Shares
that may at any time be issued or delivered upon the exercise of the Warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">be responsible for any failure of the Company to make any cash payment upon the surrender of any
Warrants for the purpose of the exercise of such rights or to comply with any of the covenants contained in this Article&nbsp;2;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">incur any liability or responsibility whatsoever or be in any way responsible for the consequence
of any breach on the part of the Company of any of the representations, warranties or covenants of the Company or any acts or deeds
of the agents or servants of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">2.20</TD><TD STYLE="text-align: justify"><U>U.S. Securities Law Matters</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Agent understands
and acknowledges that the Warrants and the Warrant Shares issuable upon exercise of the Warrants have not been, and will not be,
registered under the U.S.&nbsp;Securities&nbsp;Act or the securities laws of any state of the United States. The Warrant Agent
further understands and acknowledges that Warrants originally issued in the United States or, to, or for the account or benefit
of, a person in the United States or U.S. Persons, will be issued only to Qualified Institutional Buyers, each of whom will be
required to sign a QIB Letter prior to such issuance. In accordance with the terms of each such QIB Letter, such Warrants issued
to Qualified Institutional Buyers shall be issued in uncertificated form and deposited in CDS in accordance with this Section 2,
and shall not bear a legend relating to transfer restrictions under the U.S. Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;3<BR>
EXERCISE OF WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.1</TD><TD STYLE="text-align: justify"><U>Method of Exercise of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered holder of any Warrant may exercise the rights thereby conferred on him to acquire all or any part of the Warrant Shares
to which such Warrant entitles the holder, by surrendering the Warrant Certificate representing such Warrants to the Warrant Agent
at any time prior to the Time of Expiry at its principal stock transfer offices in the City of Toronto, Ontario (or at such additional
place or places as may be decided by the Company from time to time with the approval of the Warrant Agent), with a duly completed
and executed exercise form of the registered holder or his executors, administrators or other legal representative or his attorney
duly appointed by an instrument in writing in the form and manner satisfactory to the Warrant Agent, substantially in the form
endorsed on the Warrant Certificate specifying the number of Warrant Shares subscribed for together with a certified cheque, bank
draft or money order in lawful money of Canada, payable to or to the order of the Company in an amount equal to the Exercise Price
multiplied by the number of Warrant Shares subscribed for. A Warrant Certificate with the duly completed and executed exercise
form and payment of the Exercise Price shall be deemed to be surrendered only upon personal delivery thereof to or, if sent by
mail or other means of transmission, upon actual receipt thereof by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
exercise form referred to in subsection&nbsp;3.1(1) shall be signed by the Warrantholder, or his executors, or administrators or
other legal representative or his attorney duly appointed by an instrument in writing in the form and manner satisfactory to the
Warrant Agent, shall specify the person(s) in whose name such Warrant Shares are to be issued, the address(es) of such person(s)
and the number of Warrant Shares to be issued to each person, if more than one is so specified. If any of the Warrant Shares subscribed
for are to be issued to (a)&nbsp;person(s) other than the Warrantholder, the signatures set out in the exercise form referred to
in subsection&nbsp;3.1(1) shall be guaranteed by a Canadian Schedule&nbsp;I chartered bank or a medallion signature guarantee from
a member of a recognized Signature Medallion Guarantee Program and (b)&nbsp;the Warrantholder shall pay to the Company or the Warrant
Agent all applicable transfer or similar taxes and the Company shall not be required to issue or deliver certificates evidencing
Warrant Shares unless or until such Warrantholder shall have paid to the Company or the Warrant Agent on behalf of the Company
the amount of such tax or shall have established to the reasonable satisfaction of the Company that such tax has been paid or that
no tax is due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at the time of exercise of the Warrants, in accordance with the provisions of subsection&nbsp;3.1(1), there are any trading restrictions
on the Warrant Shares pursuant to Securities Laws or stock exchange requirements, the Company shall, on the advice of counsel,
endorse any certificates representing the Warrant Shares to such effect. The Warrant Agent is entitled to assume compliance with
all Securities Laws unless otherwise notified in writing by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
Beneficial Owner who desires to exercise his Uncertificated Warrants, must do so by causing a CDS Participant to deliver to CDS
(at its office in the City of Toronto), on behalf of the Beneficial Owner at any time prior to the Time of Expiry, a written notice
of the Beneficial Owner&rsquo;s intention to exercise Warrants (the &ldquo;<B>Exercise Notice</B>&rdquo;). Forthwith upon receipt
by CDS of such notice, as well as payment for the Exercise Price, CDS shall deliver to the Warrant Agent confirmation of its intention
to exercise Warrants (the &ldquo;<B>Confirmation</B>&rdquo;) in a manner acceptable to the Warrant Agent, including by electronic
means through the Book-Based System. CDS will initiate the exercise by way of the Confirmation and forward the aggregate Exercise
Price electronically to the Warrant Agent and the Warrant Agent will execute the exercise by causing the issuance to CDS through
the Book-Based System of the Warrant Shares to which the exercising Beneficial Owner is entitled pursuant to the exercise. Any
expense associated with the preparation and delivery of Exercise Notices will be for the account of the Beneficial Owner exercising
the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">By causing a CDS Participant
to deliver notice to CDS, a Beneficial Owner shall be deemed to have irrevocably surrendered his Warrants so exercised and appointed
such CDS Participant to act as his or her exclusive settlement agent with respect to the exercise and the receipt of Warrant Shares
in connection with the obligations arising from such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any notice which CDS
determines to be incomplete, not in proper form or not duly executed shall for all purposes be void and of no effect and the exercise
to which it relates shall be considered for all purposes not to have been exercised thereby. A failure by a CDS Participant to
exercise or to give effect to the settlement thereof in accordance with the Beneficial Owner&rsquo;s instructions will not give
rise to any obligations or liability on the part of the Company or Warrant Agent to the CDS Participant or the Beneficial Owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.2</TD><TD STYLE="text-align: justify"><U>No Fractional Warrant Shares</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Under no circumstances
shall the Company be obliged to issue any fractional Warrant Shares or any cash or other consideration in lieu thereof upon the
exercise of one or more Warrants. To the extent that the holder of one or more Warrants would otherwise have been entitled to receive
on the exercise or partial exercise thereof a fraction of a Warrant Share, that holder may exercise that right in respect of the
fraction only in combination with another Warrant or Warrants that in the aggregate entitle the holder to purchase a whole number
of Warrant Shares; otherwise fractional Warrant Shares shall be rounded down to the nearest whole number of Warrant Shares without
compensation therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.3</TD><TD STYLE="text-align: justify"><U>Effect of Exercise of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
compliance by the Warrantholder with the provisions of section&nbsp;3.1, the Warrant Shares subscribed for shall be deemed to have
been issued and the person to whom such Warrant Shares are to be issued shall be deemed to have become the holder of record of
such Warrant Shares on the Exercise Date unless the transfer registers of the Company for the Common Shares shall be closed on
such date, in which case the Warrant Shares subscribed for shall be deemed to have been issued and such person shall be deemed
to have become the holder of record of such Warrant Shares on the date on which such transfer registers are reopened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
three Business Days following the due exercise of a Warrant pursuant to section&nbsp;3.1, and if requested by the Company forthwith
after the Time of Expiry, the Warrant Agent shall deliver to the Company a notice setting forth the particulars of all Warrants
exercised, if any, and the persons in whose names the Warrant Shares are to be issued (as applicable) and the addresses of such
holders of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within
three Business Days of the due exercise of a Warrant pursuant to section&nbsp;3.1, the Company shall cause the Transfer Agent to
issue, within such three Business Day period, to CDS through the Book-Based System the Warrant Shares (which shall include Warrant
Shares issued to a Purchaser that is a Qualified Institutional Buyer) to which the exercising Warrantholder is entitled pursuant
to the exercise or mail to the person in whose name the Warrant Shares so subscribed for are to be issued, as specified in the
exercise form completed on the Warrant Certificate, at the address specified in such exercise form, a certificate or certificates
for the Warrant Shares to which the Warrantholder is entitled and, if applicable, shall cause the Warrant Agent to mail a Warrant
Certificate representing any Warrants not then exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.4</TD><TD STYLE="text-align: justify"><U>Cancellation of Warrants</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All Warrants surrendered
to the Warrant Agent pursuant to sections&nbsp;2.6, 2.8(2), 2.10, 2.18 or&nbsp;3.1 shall be cancelled by the Warrant Agent and
the Warrant Agent shall record the cancellation of such Warrants on the register of holders maintained by the Warrant Agent pursuant
to subsection&nbsp;2.8(1). The Warrant Agent shall, if required by the Company, furnish the Company with a certificate identifying
the Warrants so cancelled. All Warrants that have been duly cancelled shall be without further force or effect whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.5</TD><TD STYLE="text-align: justify"><U>Subscription for less than Entitlement</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The holder of any Warrant
may subscribe for and purchase a whole number of Warrant Shares that is less than the number that the holder is entitled to purchase
pursuant to a surrendered Warrant. In such event, the holder thereof shall be entitled to receive a new Warrant Certificate, if
applicable, in respect of the balance of Warrants that were not then exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.6</TD><TD STYLE="text-align: justify"><U>Expiration of Warrant</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">After the Time of Expiry,
all rights under any Warrant in respect of which the right of subscription and purchase herein and therein provided for shall not
theretofore have been exercised shall wholly cease and terminate and such Warrant shall be void and of no effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.7</TD><TD STYLE="text-align: justify"><U>Exercise by U.S.&nbsp;Persons</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent understands
and acknowledges that the Warrants may not be exercised within the United States or by or on behalf of, or for the account or benefit
of, any U.S.&nbsp;Person or any person in the United States except pursuant to an available exemption under the Securities Act
and applicable U.S. state securities laws. The Warrant Agent further understands and acknowledges that Warrantholders that have
executed and delivered a QIB Letter are required to be a Qualified Institutional Buyer and/or an Accredited Investor in connection
with the exercise of Warrants by such Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">3.8</TD><TD STYLE="text-align: justify"><U>Limitation on Exercise</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Neither the Company nor
the Warrant Agent shall effect any exercise of a Warrant, and a Warrantholder shall not have the right to exercise any portion
of a Warrant, pursuant to this Article 3 or otherwise, to the extent that, after giving effect to such issuance after exercise
as set forth on the applicable exercise form, the Warrantholder (together with the Warrantholder&rsquo;s affiliates, and any other
persons acting as a group together with the Warrantholder or any of the Warrantholder&rsquo;s affiliates (such persons, &ldquo;<B>Attribution
Parties</B>&rdquo;)), would beneficially own, or exercise control or direction over, in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of Common Shares beneficially owned by the Warrantholder
and its affiliates and Attribution Parties shall include the number of Common Shares issuable upon exercise of a Warrant with respect
to which such determination is being made, but shall exclude the number of Common Shares that would be issuable upon (i) exercise
of the remaining, non-exercised portion of a Warrant beneficially owned by the Warrantholder or any of its affiliates or Attribution
Parties, and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including,
without limitation, any other Common Share Equivalents), subject to a limitation on conversion or exercise analogous to the limitation
contained herein, beneficially owned by the Warrantholder or any of its affiliates or Attribution Parties. Except as set forth
in the preceding sentence, for purposes of this section 3.8, beneficial ownership shall be calculated in accordance with Section
13(d) of the U.S. Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Warrantholder
that neither the Warrant Agent nor the Company is representing to the Warrantholder that such calculation is in compliance with
Section 13(d) of the U.S. Exchange Act and the Warrantholder further acknowledges that it is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this Section 3.8 applies, the determination
of whether a Warrant is exercisable (in relation to other securities owned by the Warrantholder together with any affiliates and
Attribution Parties) and of which portion of a Warrant is exercisable shall be in the sole discretion and at the sole responsibility
of the Warrantholder, and the submission of an exercise form shall be deemed to be the Warrantholder&rsquo;s determination of whether
a Warrant is exercisable (in relation to other securities owned by the Warrantholder together with any affiliates and Attribution
Parties) and of which portion of a Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and neither
the Warrant Agent nor the Company shall have any obligation to verify or confirm the accuracy of such determination. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the U. S.
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 3.8 in determining the number of
outstanding Common Shares, a Warrantholder may rely on the number of outstanding Common Shares as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed on SEDAR, (B) a more recent public announcement by the Company, or (C) a more recent
written notice by the Company or the Company&rsquo;s transfer agent setting forth the number of Common Shares outstanding. Upon
the written or oral request of a Warrantholder, the Company shall, within two trading days, confirm orally and in writing to the
Warrantholder the number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined
after giving effect to the conversion or exercise of securities of the Company, including the Warrant being exercised, by the Warrantholder
or its affiliates or Attribution Parties since the date as of which such number of outstanding Common Shares was reported. The
 &ldquo;<B>Beneficial Ownership Limitation</B>&rdquo; shall be 9.99% of the number of Common Shares outstanding immediately after
giving effect to the issuance of Warrant Shares issuable upon exercise of the Warrant in question. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3.8 to correct
this paragraph (or any portion hereof) that may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this Section 3.8 shall apply to a successor holder of a Warrant. For greater certainty, the Warrant Agent will have
no responsibility for monitoring the beneficial ownership level of the Common Shares held by Warrantholders or their Attribution
Parties and will have no liability in regards to the determinations made of whether or not a Warrantholder or their Attribution
Parties would become a beneficial holder in excess of the Beneficial Ownership Limitation of the issued and outstanding Common
Shares upon exercise of their Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;4<BR>
COVENANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.1</TD><TD STYLE="text-align: justify"><U>General Covenants of the Company</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company represents,
warrants and covenants with the Warrant Agent for the benefit of the Warrant Agent and the Warrantholders that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will at all times, so long as any Warrants remain outstanding, maintain its existence, unless otherwise inconsistent with
the fiduciary duties of the board of directors of the Company, and will carry on and conduct its business in a prudent manner in
accordance with industry standards and good business practice, and will keep or cause to be kept proper books of account in accordance
with applicable law until the Time of Expiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is duly authorized to create and issue the Warrants to be issued hereunder and the Warrants, when issued, Authenticated
and certified, as applicable, will be legal, valid, binding and enforceable obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use its commercially reasonable efforts to maintain the listing of the Common Shares on the TSXV or such other recognized
stock exchange or quotation system, so long as any Warrants remain outstanding, and to have the Warrant Shares issued pursuant
to the exercise of the Warrants listed and posted for trading on the TSXV, or such other recognized stock exchange or quotation
system, as expeditiously as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use commercially reasonable efforts to maintain its status as a &ldquo;reporting issuer&rdquo; (or the equivalent
thereof) in each of the provinces of Canada in which it is currently a reporting issuer, not in default of the requirements of
the applicable Securities Laws of such province until the Time of Expiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will allot and reserve and keep available a sufficient number of Warrant Shares for issuance upon the exercise of Warrants
issued by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will cause the Warrant Shares from time to time subscribed for pursuant to the Warrants issued by the Company hereunder,
in the manner herein provided, to be duly issued in accordance with the Warrants and the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will cause the certificates representing the Warrant Shares from time to time to be acquired, pursuant to the Warrants
in the manner herein provided, to be duly issued and delivered in accordance with the Warrants and the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
Warrant Shares that shall be issued by the Company upon exercise of the rights provided for herein shall be issued as fully paid
and non-assessable Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will perform and carry out all of the acts or things to be done by it as provided in this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(10)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will promptly advise the Warrant Agent and the Warrantholders in writing of any breach or default under the terms of this
Indenture no later than 5&nbsp;Business Days following the occurrence of such breach or default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(11)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will use its commercially reasonable efforts to cause the Warrant Agent to keep open the register of Warrantholders during
the Warrant Agent&rsquo;s regular business hours and will not take any action or omit to take any action which would have the effect
of preventing the Warrantholders from receiving any of the Warrant Shares issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.2</TD><TD STYLE="text-align: justify"><U>Securities Qualification Requirements</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
in the opinion of counsel, any instrument is required to be filed with, or any permission, order or ruling is required to be obtained
from, any securities regulatory authority or any other step is required under any federal or provincial law of Canada before the
Warrant Shares may be issued or delivered to a Warrantholder, the Company covenants that it will use its best efforts to file such
instrument, obtain such permission, order or ruling or take all such other actions, at its expense, as is required or appropriate
in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will give written notice of the issue of Warrant Shares pursuant to the exercise of Warrants, in such detail as may be
required, to each securities regulatory authority in each jurisdiction in which there is legislation requiring the giving of any
such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.3</TD><TD STYLE="text-align: justify"><U>Warrant Agent&rsquo;s Remuneration and Expenses</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company covenants
that it will pay to the Warrant Agent from time to time reasonable remuneration for its services hereunder and will pay or reimburse
the Warrant Agent upon its request for all reasonable expenses and disbursements of the Warrant Agent in the administration or
execution of the duties and obligations hereby created (including the reasonable compensation and the disbursements of its counsel
and all other advisers, experts, accountants and assistants not regularly in its employ) both before any default hereunder and
thereafter until all duties of the Warrant Agent hereunder shall be finally and fully performed, except any such expense or disbursement
in connection with or related to or required to be made as a result of the gross negligence, wilful misconduct, bad faith or fraud
of the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">4.4</TD><TD STYLE="text-align: justify"><U>Performance of Covenants by Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to section&nbsp;8.7,
if the Company shall fail to perform any of its covenants contained in this Indenture and the Company has not rectified such failure
within 10&nbsp;Business Days after either giving notice of such default pursuant to subsection&nbsp;4.1(10) or receiving written
notice from the Warrant Agent of such failure, the Warrant Agent may notify the Warrantholders of such failure on the part of the
Company or may itself perform any of the said covenants capable of being performed by it, but shall be under no obligation to provide
such notice or perform said covenants. All reasonable sums expended or disbursed by the Warrant Agent in so doing shall be repayable
as provided in section&nbsp;4.3. No such performance, expenditure or advance by the Warrant Agent shall be deemed to relieve the
Company of any default hereunder or of its continuing obligations under the covenants herein contained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;5<BR>
ENFORCEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">5.1</TD><TD STYLE="text-align: justify"><U>Suits by Warrantholders</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to section&nbsp;6.10,
all or any of the rights conferred upon a Warrantholder by the terms of the Warrants held by him and/or this Indenture may be enforced
by such Warrantholder by appropriate legal proceedings but without prejudice to the right that is hereby conferred upon the Warrant
Agent to proceed in its own name to enforce each and all of the provisions herein contained for the benefit of the holders of the
Warrants from time to time outstanding. The Warrant Agent shall also have the power at any time and from time to time to institute
and to maintain such suits and proceedings as it may reasonably be advised shall be necessary or advisable to preserve and protect
its interests and the interests of the Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">5.2</TD><TD STYLE="text-align: justify"><U>Limitation of Liability</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The obligations hereunder
(including without limitation under subsection&nbsp;8.7(5)) are not personally binding upon, nor shall resort hereunder be had
to, the private property of any of the past, present or future directors or shareholders of the Company or any of the past, present
or future officers, employees or agents of the Company, but only the property of the Company (or any successor person) shall be
bound in respect hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;6<BR>
MEETINGS OF WARRANTHOLDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.1</TD><TD STYLE="text-align: justify"><U>Right to Convene Meetings</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent may
at any time and from time to time, and shall on receipt of a written request of the Company or of a Warrantholders&rsquo; Request,
convene a meeting of the Warrantholders provided that the Warrant Agent has been provided with sufficient funds and is indemnified
to its reasonable satisfaction by the Company or by the Warrantholders signing such Warrantholders&rsquo; Request against the costs,
charges, expenses and liabilities that may be incurred in connection with the calling and holding of such meeting. If within 15&nbsp;Business
Days after the receipt of a written request of the Company or a Warrantholders&rsquo; Request, funding and indemnity given as aforesaid
the Warrant Agent fails to give the requisite notice specified in section&nbsp;6.2 to convene a meeting, the Company or such Warrantholders,
as the case may be, may convene such meeting. Every such meeting shall be held in the City of Toronto, Ontario or at such other
place as may be approved or determined by the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.2</TD><TD STYLE="text-align: justify"><U>Notice</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">At least 14&nbsp;days&rsquo;
prior notice of any meeting of Warrantholders shall be given to the Warrantholders at the expense of the Company in the manner
provided for in section&nbsp;9.2 and a copy of such notice shall be delivered to the Warrant Agent unless the meeting has been
called by it, and to the Company unless the meeting has been called by it. Such notice shall state the date, time and place of
the meeting, the general nature of the business to be transacted and shall contain such information as is reasonably necessary
to enable the Warrantholders to make a reasoned decision on the matter, but it shall not be necessary for any such notice to set
out the terms of any resolution to be proposed or any of the provisions of this Article&nbsp;6. The notice convening any such meeting
may be signed by an appropriate officer of the Warrant Agent or of the Company or the person designated by such Warrantholders,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.3</TD><TD STYLE="text-align: justify"><U>Chairman</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent may
nominate in writing an individual (who need not be a Warrantholder) to be chairman of the meeting and if no individual is so nominated,
or if the individual so nominated is not present within 15&nbsp;minutes after the time fixed for the holding of the meeting, the
Warrantholders present in person or by proxy shall appoint an individual present to be chairman of the meeting. The chairman of
the meeting need not be a Warrantholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.4</TD><TD STYLE="text-align: justify"><U>Quorum</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions
of section&nbsp;6.11, at any meeting of the Warrantholders a quorum shall consist of two Warrantholders present in person or represented
by proxy and representing at least 20% of the aggregate number of Warrants then outstanding. If a quorum of the Warrantholders
shall not be present within one-half hour from the time fixed for holding any meeting, the meeting, if summoned by the Warrantholders
or on a Warrantholders&rsquo; Request, shall be dissolved; but in any other case the meeting shall be adjourned to the same day
in the next week (unless such day is not a Business Day in which case it shall be adjourned to the next following Business Day)
at the same time and place to the extent possible and, subject to the provisions of section&nbsp;6.11, no notice of the adjournment
need be given. Any business may be brought before or dealt with at an adjourned meeting that might have been dealt with at the
original meeting in accordance with the notice calling the same. At the adjourned meeting the Warrantholders present in person
or represented by proxy shall form a quorum and may transact the business for which the meeting was originally convened, notwithstanding
that they may not represent at least 20% of the aggregate number of Warrants then unexercised and outstanding. No business shall
be transacted at any meeting, except an adjourned meeting as described above, unless a quorum is present at the commencement of
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.5</TD><TD STYLE="text-align: justify"><U>Power to Adjourn</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The chairman of any meeting
at which a quorum of the Warrantholders is present may, with the consent of the meeting, adjourn any such meeting, and no notice
of such adjournment need be given except such notice, if any, as the meeting may prescribe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.6</TD><TD STYLE="text-align: justify"><U>Show of Hands</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Every question submitted
to a meeting shall be decided in the first place by a majority of the votes given on a show of hands except that votes on an extraordinary
resolution shall be given in the manner hereinafter provided. At any such meeting, unless a poll is duly demanded as herein provided,
a declaration by the chairman that a resolution has been carried or carried unanimously or by a particular majority or lost or
not carried by a particular majority shall be conclusive evidence of the fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.7</TD><TD STYLE="text-align: justify"><U>Poll and Voting</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">On every extraordinary
resolution, and when demanded by the chairman or by one or more of the Warrantholders acting in person or by proxy on any other
question submitted to a meeting and after a vote by show of hands, a poll shall be taken in such manner as the chairman shall direct.
Questions other than those required to be determined by extraordinary resolution shall be decided by a majority of the votes cast
on the poll. On a show of hands, every person who is present and entitled to vote, whether as a Warrantholder or as proxy for one
or more absent Warrantholders, or both, shall have one vote. On a poll, each Warrantholder present in person or represented by
a proxy duly appointed by instrument in writing shall be entitled to one vote in respect of each whole Warrant then held by him.
A proxy need not be a Warrantholder. The chairman of any meeting shall be entitled, both on a show of hands and on a poll, to vote
in respect of the Warrants, if any, held or represented by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.8</TD><TD STYLE="text-align: justify"><U>Regulations</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions
of this Indenture, the Warrant Agent or the Company with the approval of the Warrant Agent may from time to time make and from
time to time vary such regulations as it shall consider necessary or appropriate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">for the deposit of instruments appointing proxies at such place and time as the Warrant Agent,
the Company or the Warrantholders convening the meeting, as the case may be, may in the notice convening the meeting direct;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for the deposit of instruments appointing proxies at some approved place other than the place at
which the meeting is to be held and enabling particulars of such instruments appointing proxies to be mailed or forwarded via facsimile
before the meeting to the Company or to the Warrant Agent at the place where the same is to be held and for the voting of proxies
so deposited as though the instruments themselves were produced at the meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">for the form of instrument appointing a proxy and the manner in which the form of proxy may be
executed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">generally for the calling of meetings of Warrantholders and the conduct of business thereat including
setting a record date for Warrantholders entitled to receive notice of or to vote at such meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any regulations so made
shall be binding and effective and the votes given in accordance therewith shall be valid and shall be counted. Save as such regulations
may provide, the only persons who shall be recognized at any meeting as a Warrantholder, or be entitled to vote or be present at
the meeting in respect thereof (subject to section&nbsp;6.9), shall be Warrantholders or persons holding proxies of Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.9</TD><TD STYLE="text-align: justify"><U>Company, Warrant Agent and Counsel may be Represented</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company, the Warrantholders
and the Warrant Agent, by their respective directors, officers and employees and the counsel for each of the Company, the Warrantholders
and the Warrant Agent may attend any meeting of the Warrantholders and speak thereat but shall not be entitled to vote unless in
their capacities as Warrantholders or proxies therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.10</TD><TD STYLE="text-align: justify"><U>Powers Exercisable by Extraordinary Resolution</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition to all other
powers conferred upon them by any other provisions of this Indenture or by law, the Warrantholders at a meeting shall have the
power, exercisable from time to time by extraordinary resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">to agree to any modification, alteration, compromise or arrangement of the rights of Warrantholders
and/or the Warrant Agent in its capacity as warrant agent hereunder (subject to the Warrant Agent&rsquo;s approval) or on behalf
of the Warrantholders against the Company, whether such rights arise under this Indenture or the Warrants or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">to amend, modify or repeal any extraordinary resolution previously passed or sanctioned by the
Warrantholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">to direct or authorize the Warrant Agent (subject to the Warrant Agent receiving funding and indemnity
to its satisfaction) to enforce any of the covenants on the part of the Company contained in this Indenture or the Warrants or
to enforce any of the rights of the Warrantholders in any manner specified in such extraordinary resolution or to refrain from
enforcing any such covenant or right;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">to waive, authorize and direct the Warrant Agent to waive any default on the part of the Company
in complying with any provisions of this Indenture or the Warrants either unconditionally or upon any conditions specified in such
extraordinary resolution;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">to restrain any Warrantholder from taking or instituting any suit, action or proceeding against
the Company for the enforcement of any of the covenants on the part of the Company contained in this Indenture or the Warrants
or to enforce any of the rights of the Warrantholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">to direct any Warrantholder who, as such, has brought any suit, action or proceeding to stay or
discontinue or otherwise deal with any such suit, action or proceeding, upon payment of the costs, charges and expenses reasonably
and properly incurred by such Warrantholder in connection therewith;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">to assent to any change in or omission from the provisions contained in this Indenture or any ancillary
or supplemental instrument which may be agreed to by the Company, and to authorize the Warrant Agent to concur in and execute any
ancillary or supplemental indenture embodying the change or omission;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">with the consent of the Company, such consent not to be unreasonably withheld, to remove the Warrant
Agent or its successor in office and to appoint a new warrant agent or warrant agents to take the place of the Warrant Agent so
removed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">to assent to any compromise or arrangement with any creditor or creditors or any class or classes
of creditors, whether secured or otherwise, and with holders of any shares or other securities of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.11</TD><TD STYLE="text-align: justify"><U>Meaning of &ldquo;Extraordinary Resolution&rdquo;</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
expression &ldquo;<B>extraordinary resolution</B>&rdquo; when used in this Indenture means, subject as hereinafter in this section&nbsp;6.11
and in section&nbsp;6.14 provided, a resolution proposed at a meeting of Warrantholders duly convened for that purpose and held
in accordance with the provisions of this Article&nbsp;6 at which there are present in person or by proxy at least two Warrantholders
representing at least 20% of the aggregate number of all the then outstanding Warrants and passed by the affirmative votes of Warrantholders
representing not less than 66&#8532;% of the aggregate number of all the then outstanding Warrants represented at the meeting and
voted on the poll for such resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any meeting called for the purpose of passing an extraordinary resolution, Warrantholders representing at least 20% of the aggregate
number of all the then outstanding Warrants are not present in person or by proxy within one-half hour after the time appointed
for the meeting, then the meeting, if convened by Warrantholders or on a Warrantholders&rsquo; Request, shall be dissolved; but
in any other case it shall stand adjourned to such day, being not less than 10 Business Days later, and to such place and time
as may be appointed by the chairman. Not less than three Business Days prior notice shall be given of the time and place of such
adjourned meeting in the manner provided in sections&nbsp;9.1 and&nbsp;9.2. Such notice shall state that at the adjourned meeting
the Warrantholders present in person or represented by proxy shall form a quorum but it shall not be necessary to set forth the
purposes for which the meeting was originally called or any other particulars. At the adjourned meeting the Warrantholders present
in person or represented by proxy shall form a quorum and may transact the business for which the meeting was originally convened
and a resolution proposed at such adjourned meeting and passed by the requisite vote as provided in subsection&nbsp;6.11(1) shall
be an extraordinary resolution within the meaning of this Indenture notwithstanding that Warrantholders representing at least 20%
of all the then outstanding Warrants are not present in person or represented by proxy at such adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes
on an extraordinary resolution shall always be given on a poll and no demand for a poll on an extraordinary resolution shall be
necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.12</TD><TD STYLE="text-align: justify"><U>Powers Cumulative</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It is hereby declared
and agreed that any one or more of the powers or any combination of the powers in this Indenture stated to be exercisable by the
Warrantholders by extraordinary resolution or otherwise may be exercised from time to time and the exercise of any one or more
of such powers or any combination of powers from time to time shall not be deemed to exhaust the right of the Warrantholders to
exercise such powers or combination of powers then or thereafter from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.13</TD><TD STYLE="text-align: justify"><U>Minutes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Minutes of all resolutions
and proceedings at every meeting of Warrantholders as aforesaid shall be made and duly entered in books to be provided for that
purpose by the Warrant Agent at the expense of the Company and any minutes as aforesaid, if signed by the chairman of the meeting
at which resolutions were passed or proceedings had, or by the chairman of the next succeeding meeting of the Warrantholders, shall
be prima facie evidence of the matters therein stated and, until the contrary is proved, every meeting, in respect of the proceedings
of which minutes shall have been made, shall be deemed to have been duly convened and held, and all resolutions passed thereat
or proceedings taken, to have been duly passed and taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.14</TD><TD STYLE="text-align: justify"><U>Instruments in Writing</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All actions that may
be taken and all powers that may be exercised by the Warrantholders at a meeting held as provided in this Article&nbsp;6 also may
be taken and exercised by Warrantholders representing a majority, or in the case of an extraordinary resolution at least 66&#8532;%,
of the aggregate number of all the then outstanding Warrants by an instrument in writing signed in one or more counterparts by
such Warrantholders in person or by attorney duly appointed in writing, and the expression &ldquo;extraordinary resolution&rdquo;
when used in this Indenture shall include an instrument so signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.15</TD><TD STYLE="text-align: justify"><U>Binding Effect of Resolutions</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Every resolution and
every extraordinary resolution passed in accordance with the provisions of this Article&nbsp;6 at a meeting of Warrantholders shall
be binding upon all Warrantholders, whether present at or absent from such meeting, and every instrument in writing signed by Warrantholders
in accordance with section&nbsp;6.14 shall be binding upon all the Warrantholders, whether signatories thereto or not, and each
and every Warrantholder and the Warrant Agent (subject to the provisions for indemnity herein contained) shall be bound to give
effect accordingly to every such resolution and instrument in writing. In the case of an instrument in writing, the Warrant Agent
shall give notice in the manner contemplated in sections&nbsp;9.1 and&nbsp;9.2 of the effect of the instrument in writing to all
Warrantholders and the Company as soon as is reasonably practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">6.16</TD><TD STYLE="text-align: justify"><U>Holdings by the Company or Subsidiaries of the Company Disregarded</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In determining whether
Warrantholders are present at a meeting of Warrantholders for the purpose of determining a quorum or have concurred in any consent,
waiver, extraordinary resolution, Warrantholders&rsquo; Request or other action under this Indenture, Warrants owned legally or
beneficially by the Company or its Subsidiaries or in partnership of which the Company is directly or indirectly a party to shall
be disregarded. The Company shall provide, upon the written request of the Warrant Agent, a certificate as to the registration
particulars of any Warrants held by the Company or its Subsidiaries or in partnership of which the Company is directly or indirectly
a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;7<BR>
SUPPLEMENTAL INDENTURES AND SUCCESSOR COMPANIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">7.1</TD><TD STYLE="text-align: justify"><U>Provision for Supplemental Indentures for Certain Purposes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">From time to time the
Company (if properly authorized by its board of directors) and the Warrant Agent may, subject to the provisions hereof, and they
shall, when so required hereby, execute and deliver by their proper officers, indentures or instruments supplemental hereto, which
thereafter shall form part hereof, for any one or more or all of the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">providing for the issuance of additional Warrants hereunder and any consequential amendments hereto
as may be required by the Warrant Agent, relying on the advice (but for certainty, not an opinion) of counsel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">setting forth adjustments in the application of Article&nbsp;2;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">adding to the provisions hereof such additional covenants and enforcement provisions as, in the
opinion of counsel are necessary or advisable, provided that the same are not in the opinion of the Warrant Agent, relying on the
advice of counsel, prejudicial to the interests of the Warrantholders as a group;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">giving effect to any extraordinary resolution passed as provided in Article&nbsp;6;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">making such provisions not inconsistent with this Indenture as may be necessary or desirable with
respect to matters or questions arising hereunder provided that such provisions are not, in the opinion of the Warrant Agent, relying
on the advice of counsel, prejudicial to the interests of the Warrantholders as a group;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">adding to or amending the provisions hereof in respect of the transfer of Warrants, making provision
for the exchange of Warrants and making any modification in the form of the Warrant Certificate that does not affect the substance
thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">amending any of the provisions of this Indenture or relieving the Company from any of the obligations,
conditions or restrictions herein contained, provided that no such amendment or relief shall be or become operative or effective
if, in the opinion of the Warrant Agent, relying on the advice of counsel, such amendment or relief impairs any of the rights of
the Warrantholders as a group or of the Warrant Agent, and provided further that the Warrant Agent may in its sole discretion decline
to enter into any supplemental indenture that in its opinion may not afford adequate protection to the Warrant Agent when the same
shall become operative; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">for any other purpose not inconsistent with the terms of this Indenture, including the correction
or rectification of any ambiguities, defective or inconsistent provisions, errors, mistakes or clerical omissions herein, provided
that, in the opinion of the Warrant Agent, relying on the advice of counsel, the rights of the Warrant Agent and the Warrantholders
as a group are in no way prejudiced thereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">7.2</TD><TD STYLE="text-align: justify"><U>Successor Companies</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In the case of the amalgamation,
consolidation, arrangement, merger or transfer of the undertaking or assets of the Company as an entirety or substantially as an
entirety to another person (a &ldquo;<B>successor company</B>&rdquo;), the successor company resulting from the amalgamation, consolidation,
arrangement, merger or transfer (if not the Company) shall be bound by the provisions hereof and all obligations for the due and
punctual performance and observance of each and every covenant and obligation contained in this Indenture to be performed by the
Company and the successor company shall by supplemental indenture satisfactory in form and substance to the Warrant Agent and executed
and delivered by the successor company to the Warrant Agent, expressly assume those obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;8<BR>
CONCERNING THE WARRANT AGENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.1</TD><TD STYLE="text-align: justify"><U>Indenture Legislation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
and to the extent that any provision of this Indenture limits, qualifies or conflicts with a mandatory requirement of Applicable
Legislation, such mandatory requirement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company and the Warrant Agent agree that each will at all times in relation to this Indenture and any action to be taken hereunder
observe and comply with and be entitled to the benefit of Applicable Legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.2</TD><TD STYLE="text-align: justify"><U>Rights and Duties of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent accepts the duties and responsibilities under this Indenture, solely as custodian, bailee and agent. No trust is
intended to be, or is or will be, created hereby and the Warrant Agent shall owe no duties hereunder as a trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the exercise of the rights and duties prescribed or conferred by the terms of this Indenture, the Warrant Agent shall act honestly
and in good faith and shall exercise the degree of care, diligence and skill that a reasonably prudent warrant agent would exercise
in comparable circumstances. No provision of this Indenture shall be construed to relieve the Warrant Agent from, or require any
other person to indemnify the Warrant Agent against liability for its own gross negligence, wilful misconduct, bad faith or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be bound to do or take any act, action or proceeding for the enforcement of any of the obligations of the
Company under this Indenture unless and until it shall have received a Warrantholders&rsquo; Request specifying the act, action
or proceeding that the Warrant Agent is requested to take. The obligation of the Warrant Agent to commence or continue any act,
action or proceeding for the purpose of enforcing any rights of the Warrant Agent or the Warrantholders hereunder shall be conditional
upon the Warrantholders furnishing, when required by notice in writing by the Warrant Agent, sufficient funds to commence or continue
such act, action or proceeding and an indemnity reasonably satisfactory to the Warrant Agent and its counsel to protect and hold
harmless the Warrant Agent, its officers, directors, employees, agents, successors and assigns against the costs, charges and expenses
and liabilities to be incurred thereby and any loss and damage it may suffer by reason thereof. None of the provisions contained
in this Indenture shall require the Warrant Agent to expend or risk its own funds or otherwise incur financial liability in the
performance of any of its duties or in the exercise of any of its rights or powers unless indemnified and funded as aforesaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may, before commencing any act, action or proceeding, or at any time during the continuance thereof require the Warrantholders
at whose instance it is acting to deposit with the Warrant Agent the Warrants held by them, for which Warrants the Warrant Agent
shall issue receipts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Every
provision of this Indenture that, by its terms, relieves the Warrant Agent of liability or entitles it to rely upon any evidence
submitted to it is subject to the provisions of Applicable Legislation, this section&nbsp;8.2 and section&nbsp;8.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be bound to give any notice or do or take any act, action or proceeding by virtue of the powers conferred
on it hereunder unless and until it shall have been required to do so under the terms hereof; nor shall the Warrant Agent be required
to take notice of any default hereunder, unless and until notified in writing of such default, which notice shall specifically
set out the default desired to be brought to the attention of the Warrant Agent and in the absence of such notice the Warrant Agent
may for all purposes of this Indenture conclusively assume that no default has occurred or been made in the performance or observance
of the representations, warranties and covenants, agreements or conditions herein contained. Any such notice shall in no way limit
any discretion herein given to the Warrant Agent to determine whether or not the Warrant Agent shall take action with respect to
any default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this Indenture, whenever confirmations or instructions are required to be given to the Warrant Agent, in order to be valid, such
confirmations and instructions shall be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.3</TD><TD STYLE="text-align: justify"><U>Evidence, Experts and Advisers</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the reports, certificates, opinions and other evidence required by this Indenture, the Company shall furnish to the
Warrant Agent such additional evidence of compliance with any provision hereof and in such form as may be prescribed by Applicable
Legislation or as the Warrant Agent may reasonably require by written notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the exercise of its rights and duties hereunder, the Warrant Agent may, if it is acting in good faith, act and rely absolutely
as to the truth of the statements and the accuracy of the opinions expressed therein, upon statutory declarations, opinions, reports,
written requests, consents, or orders of the Company, certificates of the Company or other evidence furnished to the Warrant Agent
pursuant to any provision hereof or of Applicable Legislation or pursuant to a request of the Warrant Agent. The Warrant Agent
shall be under no responsibility in respect of the validity of this Indenture or the execution and delivery hereof by or on behalf
of the Company or in respect of the validity or the execution of any Warrant Certificate by the Company and issued hereunder, nor
shall it be responsible for any breach by the Company of any covenant or condition contained in this Indenture or in any such Warrant
Certificate; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation
of any securities to be issued upon the right to acquire provided for in this Indenture and/or in any Warrant or as to whether
any securities will when issued be duly authorized or be validly issued and fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever
Applicable Legislation requires that evidence referred to in subsection&nbsp;8.3(1) be in the form of a statutory declaration,
the Warrant Agent may accept the statutory declaration in lieu of a certificate of the Company required by any provision hereof.
Any such statutory declaration may be made by one or more of the directors or officers of the Company and may be relied upon by
the Warrant Agent in good faith without further inquiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proof
of the execution of an instrument in writing, including a Warrantholders&rsquo; Request, by any Warrantholder may be made by a
certificate of a notary public or other person with similar powers that the person signing such instrument acknowledged to him
the execution thereof, or by an affidavit of a witness to such execution or in any other manner which the Warrant Agent may consider
adequate and in respect of a corporate Warrantholder, shall include a certificate of incumbency of such Warrantholder together
with a certified resolution authorizing the person who signs such instrument to sign such instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may act and rely and shall be protected in acting and relying upon any resolution, certificate, statement, instrument,
opinion, report, notice, request, consent, order, letter, or other paper document believed by it to be genuine and to have been
signed, sent or presented by or on behalf of the proper party or parties. The Warrant Agent shall be protected in acting and relying
upon any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, letter or other paper
document received in facsimile or e-mail form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may employ or retain such counsel, accountants, engineers, appraisers or other experts or advisers as it may reasonably
require for the purpose of determining and discharging its duties hereunder and may pay reasonable remuneration for all services
so performed by any of them, without taxation of costs of any counsel and shall not be responsible for any misconduct on the part
of any of them who has been selected with due care by the Warrant Agent. Any reasonable remuneration paid by the Warrant Agent
shall be paid by the Company in accordance with section&nbsp;4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may act and rely and shall be protected in acting and relying in good faith on the opinion or advice of or information
obtained from any counsel, accountant, appraiser, engineer or other expert or advisor, whether retained or employed by the Company
or the Warrant Agent, in relation to any matter arising in fulfilling its duties and obligations hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may, as a condition precedent to any action to be taken by it under this Indenture, require such opinions, statutory
declarations, reports, certificates or other evidence as it, acting reasonably, considers necessary or advisable in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent is not required to expend or place its own funds at risk in executing its duties and obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.4</TD><TD STYLE="text-align: justify"><U>Securities, Documents and Monies Held by Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any securities, documents
of title, monies or other instruments that may at any time be held by the Warrant Agent subject to the duties and obligations hereof,
for the benefit of the Company, may be placed in the deposit vaults of the Warrant Agent or of any Schedule&nbsp;I Canadian chartered
bank for safekeeping with any such bank. All interest or other income received by the Warrant Agent in respect of such deposits
and investments shall, subject to section&nbsp;4.4, belong to the Company and shall be paid to the Company upon discharge of this
Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.5</TD><TD STYLE="text-align: justify"><U>Actions by Warrant Agent to Protect Interests</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the provisions
of this Indenture and Applicable Legislation, the Warrant Agent shall have the power to institute and to maintain such actions
and proceedings as it may consider necessary or expedient to preserve, protect or enforce its interests and the interests of the
Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.6</TD><TD STYLE="text-align: justify"><U>Warrant Agent not Required to Give Security</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent shall
not be required to give any bond or security in respect of the execution of the duties and obligations of this Indenture or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.7</TD><TD STYLE="text-align: justify"><U>Protection of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">By way of supplement
to the provisions of any law for the time being relating to warrant agents, it is expressly declared and agreed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be liable for or by reason of any representations, statements of fact or recitals in this Indenture or
in the Warrants (except the representation contained in section&nbsp;8.9 or in the certificate of the Warrant Agent on the Warrants)
or be required to verify the same and all such statements of fact or recitals are and shall be deemed to be made by the Company
(except the representation contained in section&nbsp;8.9 or in the certificate of the Warrant Agent on the Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
herein contained shall impose any obligation on the Warrant Agent to see to or to require evidence of the registration or filing
(or renewal thereof) of this Indenture or any instrument ancillary or supplemental hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be bound to give notice to any person or persons of the execution hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not incur any liability or responsibility whatsoever or be in any way responsible for the consequence of any
breach on the part of the Company of any of the covenants or warranties herein contained or of any acts of any directors, officers,
employees, agents or servants of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
limiting any protection or indemnity of the Warrant Agent under any other provision hereof, or otherwise at law, the Company hereby
agrees to indemnify and hold harmless the Warrant Agent and its directors, officers, agents and employees from and against any
and all liabilities, losses, damages, penalties, claims, actions, suits, costs, expenses and disbursements, including reasonable
legal or advisor fees and disbursements, of whatever kind and nature which may at any time be imposed on, incurred by or asserted
against the Warrant Agent in connection with the performance of its duties and obligations hereunder, other than such liabilities,
losses, damages, penalties, claims, actions, suits, costs, expenses and disbursements arising by reason of the gross negligence,
wilful misconduct, bad faith or fraud of the Warrant Agent. This provision shall survive the resignation or removal of the Warrant
Agent, or the termination of this Indenture. The Warrant Agent shall not be under any obligation to prosecute or defend any action
or suit in respect of this Indenture which, in the opinion of its counsel, may involve it in expense or liability, unless the Company
shall, so often as required, furnish the Warrant Agent with satisfactory indemnity and funding against such expense or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of the funds provided to the Warrant Agent hereunder are received by it in the form of an uncertified cheque or bank draft,
the Warrant Agent shall delay the release of such funds and the related Warrant Shares until such uncertified cheque has cleared
the financial institution upon which the same is drawn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
forwarding of a cheque or the sending of funds by wire transfer by the Warrant Agent will satisfy and discharge the liability of
any amounts due to the extent of the sum represented thereby unless such cheque is not honoured on presentation, provided that
in the event of the non-receipt of such cheque by the payee, or the loss or destruction thereof, the Warrant Agent, upon being
furnished with reasonable evidence of such non-receipt, loss or destruction and indemnity reasonably satisfactory to it, will issue
to such payee a replacement cheque for the amount of such cheque.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall retain the right not to act and shall not be liable for refusing to act if, due to a lack of information or
for any other reason whatsoever, the Warrant Agent, in its sole judgement, determines that such act might cause it to be in non-compliance
with any applicable anti-money laundering or anti-terrorist legislation, regulation or guideline. Further, should the Warrant Agent,
in its sole judgement, determine at any time that its acting under this Warrant Indenture has resulted in its being in non-compliance
with any applicable anti-money laundering or anti-terrorist legislation, regulation or guideline, then it shall have the right
to resign on 10&nbsp;days&rsquo; written notice to the Company provided: (i) that the Warrant Agent&rsquo;s written notice shall
describe the circumstances of such non-compliance; and (ii) that if such circumstances are rectified to the Warrant Agent&rsquo;s
satisfaction within such 10-day period, then such resignation shall not be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent shall not be liable for any error in judgment or for any act done or step taken or omitted by it in good faith or
for any mistake, in fact or law, or for anything which it may do or refrain from doing in connection herewith except arising out
of its own gross negligence, bad faith or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.8</TD><TD STYLE="text-align: justify"><U>Replacement of Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent may resign its appointment and be discharged from all further duties and liabilities hereunder by giving to the Company
not less than 60&nbsp;days prior notice in writing or such shorter prior notice as the Company may accept as sufficient. The Warrantholders
by extraordinary resolution shall have the power at any time to remove the existing Warrant Agent and to appoint a new Warrant
Agent. In the event of the Warrant Agent resigning or being removed as aforesaid or being dissolved, becoming bankrupt, going into
liquidation or otherwise becoming incapable of acting hereunder, the Company shall forthwith appoint a new Warrant Agent unless
a new Warrant Agent has already been appointed by the Warrantholders; failing such appointment by the Company, the retiring Warrant
Agent or any Warrantholder may apply to a judge of the Province of Ontario at the Company&rsquo;s expense, on such notice as such
judge may direct, for the appointment of a new Warrant Agent; but any new Warrant Agent so appointed by the Company or by the Court
shall be subject to removal as aforesaid by the Warrantholders. Any new Warrant Agent appointed under any provision of this section&nbsp;8.8
shall be a corporation authorized to carry on the business of a transfer agent or a trust company in the Province of Ontario and,
if required by Applicable Legislation of any other province, in such other province. On any such appointment the new Warrant Agent
shall be vested with the same powers, rights, duties and responsibilities as if it had been originally named herein as Warrant
Agent without any further assurance, conveyance, act or deed; but there shall be immediately executed, at the expense of the Company,
all such conveyances or other instruments as may, in the opinion of counsel, be necessary or advisable for the purpose of assuring
the same to the new Warrant Agent, provided that any resignation or removal of the Warrant Agent and appointment of a successor
Warrant Agent shall not become effective until the successor Warrant Agent shall have executed an appropriate instrument accepting
such appointment and, at the request of the Company, the predecessor Warrant Agent, upon payment of its outstanding remuneration
and expenses, shall execute and deliver to the successor Warrant Agent an appropriate instrument transferring to such successor
Warrant Agent all rights and powers of the Warrant Agent hereunder and all securities, documents of title and other instruments
and all monies and properties held by the Warrant Agent hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the appointment of a successor Warrant Agent, the Company shall promptly notify the Warrantholders thereof in the manner provided
for in section&nbsp;9.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
corporation into or with which the Warrant Agent may be merged or consolidated or amalgamated, or to which all or substantially
all of the corporate trust business is sold or any corporation succeeding to the stock transfer business of the Warrant Agent,
shall be the successor to the Warrant Agent hereunder without any further act on its part or of any of the parties hereto, provided
that such corporation would be eligible for appointment as a new Warrant Agent under subsection&nbsp;8.8(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Warrants Authenticated or certified but not delivered by a predecessor Warrant Agent may be Authenticated or certified by the new
or successor Warrant Agent in the name of the predecessor or the new or successor Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.9</TD><TD STYLE="text-align: justify"><U>Conflict of Interest</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Warrant Agent represents to the Company that at the time of execution and delivery hereof no material conflict of interest exists
which it is aware of in the Warrant Agent&rsquo;s role hereunder and agrees that in the event of a material conflict of interest
arising which it becomes aware of hereafter it will, within 90&nbsp;days after ascertaining that it has such a material conflict
of interest, either eliminate the same or resign its appointment hereunder. If any such material conflict of interest exists or
hereafter shall exist, the validity and enforceability of this Indenture and the Warrants shall not be affected in any manner whatsoever
by reason thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to subsection&nbsp;8.9(1), the Warrant Agent, in its personal or any other capacity, may buy, lend upon and deal in securities
of the Company and generally may contract and enter into financial transactions with the Company or any Subsidiary without being
liable to account for any profit made thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.10</TD><TD STYLE="text-align: justify"><U>Acceptance of Duties and Obligations</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent hereby
accepts the duties and obligations in this Indenture declared and provided for and agrees to perform the same upon the terms and
conditions herein set forth and agrees to hold all rights, interests and benefits contained herein on behalf of those persons who
become holders of Warrants from time to time issued under this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.11</TD><TD STYLE="text-align: justify"><U>Warrant Agent not to be Appointed Receiver</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent and
any person related to the Warrant Agent shall not be appointed a receiver or receiver and manager or liquidator of all or any part
of the assets or undertaking of the Company or any Subsidiary or any partnership of which the Company is directly or indirectly
involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">8.12</TD><TD STYLE="text-align: justify"><U>Authorization to Carry on Business</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Warrant Agent represents
to the Company that it is registered to carry on the business of a transfer agent and warrant agent under Applicable Legislation
in the Province of Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;9<BR>
GENERAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.1</TD><TD STYLE="text-align: justify"><U>Notice to the Company and the Warrant Agent</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
herein otherwise expressly provided, any notice to be given hereunder to the Company or the Warrant Agent shall be deemed to be
validly given if delivered, if sent by registered letter, postage prepaid or if transmitted by facsimile or email to the following
addresses or facsimile numbers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If to the Company, to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">PROFOUND MEDICAL CORP.<BR>
2400 Skymark Avenue, Unit 6<BR>
Mississauga, Ontario L4W 5K5<BR>
<BR>
Attention:&#9;Rashed Dewan<BR>
Facsimile:&#9;(647) 847-3739<BR>
Email: &#9;<U>rdewan@profoundmedical.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If to the Warrant Agent, to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1<BR>
<BR>
Attention: &#9;Vice President, Trust Services<BR>
Facsimile: &#9;(416) 361-0470<BR>
Email: &#9;<U>tmxestaff-corporatetrust@tmx.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and any notice given in accordance with
the foregoing shall be deemed to have been received on the date of delivery if that date is a Business Day or, if mailed, on the
fifth Business Day following the date of the postmark on such notice or, if transmitted by facsimile or email, on the next Business
Day following the date of transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company or the Warrant Agent, as the case may be, may from time to time notify the other in the manner provided in subsection&nbsp;9.1(1)
of a change of address which, from the effective date of such notice and until changed by like notice, shall be the address of
the Company or the Warrant Agent, as the case may be, for all purposes of this Indenture. A copy of any notice of change of address
given pursuant to this subsection&nbsp;9.1(2) shall be available for inspection at the principal stock transfer offices of the
Warrant Agent in the City of Toronto, Ontario by Warrantholders during normal business hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
by reason of a strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given
to the Warrant Agent or to the Company hereunder could reasonably be considered unlikely to reach its destination, the notice shall
be valid and effective only if it is delivered to an officer of the party to which it is addressed or if it is delivered to that
party at the appropriate address provided in subsection&nbsp;9.1(1) by facsimile, email or other means of prepaid, transmitted
or recorded communication and any notice delivered in accordance with the foregoing shall be deemed to have been received on the
date of delivery to the officer or if delivered by facsimile, email or other means of prepaid, transmitted, recorded communication
on the first Business Day following the date of the sending of the notice by the person giving the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.2</TD><TD STYLE="text-align: justify"><U>Notice to the Warrantholders</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
notice to the Warrantholders under the provisions of this Indenture shall be deemed to be validly given if the notice is sent by
prepaid mail or, if delivered by hand, to the holders at their addresses appearing in the register of holders. Any notice so delivered
shall be deemed to have been received on the date of delivery if that date is a Business Day or the Business Day following the
date of delivery if such date is not a Business Day or on the third Business Day if delivered by mail. All notices may be given
to whichever one of the Warrantholders (if more than one) is named first in the appropriate register hereinbefore mentioned, and
any notice so given shall be sufficient notice to all Warrantholders and any other persons (if any) interested in such Warrants.
Accidental error or omission in giving notice or accidental failure to mail notice to any Warrantholder will not invalidate any
action or proceeding founded thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
by reason of strike, lockout or other work stoppage, actual or threatened, involving postal employees, any notice to be given to
the Warrantholders could reasonably be considered unlikely to reach its destination, the notice may be given in a news release
disseminated through a newswire service, filed on SEDAR and posted on the Company&rsquo;s website; provided that in the case of
a notice convening a meeting of the holders of Warrants, the Warrant Agent may require such additional publications of that notice,
in Toronto, Ontario or in other cities or both, as it may deem necessary for the reasonable notification of the holders of Warrants
or to comply with any applicable requirement of law or any stock exchange. Any notice so given shall be deemed to have been given
on the day on which it has been published in all of the cities in which publication was required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.3</TD><TD STYLE="text-align: justify"><U>Privacy</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Despite any other provision
of this Indenture, no party hereto shall take or direct any action that would contravene, or cause the other to contravene, applicable
federal and/or provincial legislation that addresses the protection of individuals&rsquo; personal information (collectively, &ldquo;<B>Privacy
Laws</B>&rdquo;). The Company shall, prior to transferring or causing to be transferred personal information to the Warrant Agent,
obtain and retain required consents of the relevant individuals to the collection, use and disclosure of their personal information,
or shall have determined that such consents either have previously been given upon which the parties can rely or are not required
under the Privacy Laws. The Warrant Agent shall use commercially reasonable efforts to ensure that its services hereunder comply
with Privacy Laws. Specifically, the Warrant Agent agrees: (a)&nbsp;to have a designated chief privacy officer; (b)&nbsp;to maintain
policies and procedures to protect personal information and to receive and respond to any privacy complaint or inquiry; (c)&nbsp;to
use personal information solely for the purposes of providing its services under or ancillary to this Indenture and not to use
it for any other purpose except with the consent of or direction from the Company or the individual involved; (d)&nbsp;not to sell
or otherwise improperly disclose personal information to any third party; and (e)&nbsp;to employ administrative, physical and technological
safeguards to reasonably secure and protect personal information against loss, theft, or unauthorized access, use or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.4</TD><TD STYLE="text-align: justify"><U>Third Party Interests</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Company represents
to the Warrant Agent that any account to be opened by, or interest to held by the Warrant Agent in connection with this Indenture,
for or to the credit of such party, either (i)&nbsp;is not intended to be used by or on behalf of any third party; or (ii)&nbsp;is
intended to be used by or on behalf of a third party, in which case such party hereto agrees to complete and execute forthwith
a declaration in the Warrant Agent prescribed form as to the particulars of such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.5</TD><TD STYLE="text-align: justify"><U>Discretion of Directors</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Any matter provided herein
to be determined by the directors in their sole discretion and determination so made will be conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.6</TD><TD STYLE="text-align: justify"><U>Satisfaction and Discharge of Indenture</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Upon the earlier of the
Time of Expiry or the date by which there shall have been delivered to the Warrant Agent for exercise or cancellation in accordance
with the provisions hereof all Warrants theretofore Authenticated or certified hereunder, this Indenture, except to the extent
that Warrant Shares and any certificates therefor have not been issued and delivered hereunder or the Company has not performed
any of its obligations hereunder, shall cease to be of further effect in respect of the Company, and the Warrant Agent, on written
demand of and at the cost and expense of the Company, and upon delivery to the Warrant Agent of a certificate of the Company stating
that all conditions precedent to the satisfaction and discharge of this Indenture have been complied with and upon payment to the
Warrant Agent of the expenses, fees and other remuneration payable to the Warrant Agent, shall execute proper instruments acknowledging
satisfaction of and discharging this Indenture; provided that if the Warrant Agent has not then performed any of its obligations
hereunder any such satisfaction and discharge of the Company&rsquo;s obligations hereunder shall not affect or diminish the rights
of any Warrantholder or the Company against the Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.7</TD><TD STYLE="text-align: justify"><U>Provisions of Indenture and Warrants for the Sole Benefit of Parties and Warrantholders</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Nothing in this Indenture
or the Warrant Certificates, expressed or implied, shall give or be construed to give to any person other than the parties hereto
and the holders from time to time of the Warrants any legal or equitable right, remedy or claim under this Indenture, or under
any covenant or provision therein contained, all such covenants and provisions being for the sole benefit of the parties hereto
and the Warrantholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.8</TD><TD STYLE="text-align: justify"><U>Indenture to Prevail</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">To the extent of any
discrepancy or inconsistency between the terms and conditions of this Indenture and the Warrant Certificate, the terms of this
Indenture will prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.9</TD><TD STYLE="text-align: justify"><U>Assignment</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Except as provided in
subsection&nbsp;8.8(3), this Indenture nor any benefits or burdens under this Indenture shall be assignable by the Company or the
Warrant Agent without the prior written consent of the other party, such consent not to be unreasonably withheld. Subject to the
foregoing, this Indenture shall enure to the benefit of and be binding upon the Company and the Warrant Agent and their respective
successors (including any successor by reason of amalgamation) and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in">9.10</TD><TD STYLE="text-align: justify"><U>Counterparts and Formal Date</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Indenture may be
simultaneously executed in several counterparts and by electronic means, each of which when so executed shall be deemed to be an
original and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution
shall be deemed to bear the date set out at the top of the first page of this Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<B><I>Signature page follows</I></B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>IN WITNESS WHEREOF</B>
the parties hereto have executed this Indenture under the hands of their proper officers in that behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">Per:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">/s/ Matthew Sobczyk</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">TSX TRUST COMPANY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">Per:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">/s/ Donald Crawford</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Per:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Michael Rosenberg</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page &ndash;Warrant Indenture
between Profound Medical Corp.</I><BR>
<I>and TSX Trust Company]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>Schedule&nbsp;A</U><BR>
FORM OF WARRANT CERTIFICATE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANTS TO PURCHASE COMMON SHARES</B><BR>
<B>OF PROFOUND MEDICAL CORP.</B><BR>
(a corporation incorporated pursuant to the laws of Ontario)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">CUSIP No. <FONT STYLE="font-family: Wingdings"><B>n</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">ISIN No. <FONT STYLE="font-family: Wingdings"><B>n</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">Warrant Certificate Number: &bull;</TD>
    <TD STYLE="width: 50%; text-align: right">Representing &bull; Warrants to</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">purchase Common Shares</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS CERTIFIES</B>
that, for value received, the registered holder hereof, &bull; (the &ldquo;<B>holder</B>&rdquo;) is entitled, subject to Profound
Medical Corp.&rsquo;s (the &ldquo;<B>Company</B>&rdquo;) right to accelerate the expiry time in certain circumstances, at any time
at or before 5:00&nbsp;p.m. (Toronto time) on March 20, 2023 (the &ldquo;<B>Expiry Time</B>&rdquo;) to acquire, subject to adjustment
in certain events, the number of common shares (&ldquo;<B>Common Shares</B>&rdquo;) of the Company specified above, as presently
constituted, by surrendering to TSX Trust Company (the &ldquo;<B>Warrant Agent</B>&rdquo;) at its principal office in Toronto,
Ontario, this Warrant Certificate with the duly completed and executed Exercise Form endorsed on the back of this Warrant Certificate,
and accompanied by payment of $1.40 per Common Share (subject to adjustment in certain events) (the &ldquo;<B>Warrant Exercise
Price</B>&rdquo;) by certified cheque, bank draft or money order in lawful money of Canada payable to, or to the order of, the
Company at par at the above-mentioned office of the Warrant Agent. The holder of this Warrant Certificate may purchase less than
the number of Common Shares which he is entitled to purchase on the exercise of the Warrants represented by this Warrant Certificate,
in which event a new Warrant Certificate representing the Warrants not then exercised will be issued to the holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time on or
after the date that is 18 months from March 20, 2018, the closing trading price of the Common Shares on the TSX Venture Exchange
(&ldquo;<B>TSXV</B>&rdquo;) (or if the Common Shares are not listed on the TSXV, then on such other recognized Canadian stock exchange
on which the Common Shares are then listed) exceeds $2.80 for a period of 90 consecutive calendar days, the Company shall be entitled,
within 30 days of the occurrence of such event, to accelerate the Expiry Time of the Warrants to a period ending on the date that
is 20 days from the date that notice of such acceleration (the &ldquo;<B>Acceleration Notice</B>&rdquo;) is given to the Warrantholders
pursuant to a press release issued by the Company, with the new Expiry Time specified in such Acceleration Notice. From and after
the new Expiry Time specified in such Acceleration Notice, no Warrants may be issued or exercised, and all unexercised Warrants
shall be void and of no effect following the new Expiry Time. The Company shall give prompt written notice of such acceleration
to the Warrant Agent pursuant to section 9.1. For greater certainty, the new Expiry Time specified in an Acceleration Notice shall
not be later than 5:00 p.m. (Toronto Time) on March 20, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants evidenced
hereby are exercisable on or before the Expiry Time, after which time the Warrants evidenced hereby shall be deemed to be void
and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant Certificate
represents Warrants of the Company issued or issuable under the provisions of a warrant indenture (which indenture together with
all other instruments supplemental or ancillary thereto is herein referred to as the &ldquo;<B>Warrant Indenture</B>&rdquo;) dated
as of March 20, 2018, between the Company and the Warrant Agent, as may be amended from time to time, which contains particulars
of the rights of the holders of the Warrants and the Company and of the Warrant Agent in respect thereof and the terms and conditions
upon which the Warrants are issued and held, all to the same effect as if the provisions of the Warrant Indenture were herein set
forth, to all of which the holder of this Warrant Certificate by acceptance hereof assents. Unless otherwise defined herein, all
capitalized terms shall have the meanings ascribed to them in the Warrant Indenture. A copy of the Warrant Indenture will be available
for inspection at the principal office of the Company in the City of Mississauga, Ontario. <B>In the event of any conflict between
the provisions contained in this Warrant Certificate and the provisions of the Warrant Indenture, the provisions of the Warrant
Indenture shall prevail.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon acceptance hereof,
the holder hereof hereby expressly waives the right to receive any fractional Common Shares upon the exercise hereof in full or
in part and further waives the right to receive any cash or other consideration in lieu thereof. The Warrants represented by this
Warrant Certificate shall be deemed to have been surrendered, and payment by certified cheque, bank draft or money order shall
be deemed to have been made only upon personal delivery thereof or, if sent by post or other means of transmission, upon actual
receipt thereof by the Warrant Agent at its office in the City of Toronto, Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon due exercise of
the Warrants represented by this Warrant Certificate and payment of the Warrant Exercise Price, the Company shall cause to be issued
to the person(s) in whose name(s) the Common Shares so subscribed for (provided that if the Common Shares are to be issued to a
person other than the registered holder of this Warrant Certificate, the holder&rsquo;s signature on the Exercise Form herein shall
be guaranteed by a Schedule&nbsp;I Canadian chartered bank, or by a medallion signature guarantee from a member of a recognized
Signature Medallion Guarantee Program and the holder shall pay to the Company or the Warrant Agent all applicable transfer or similar
taxes and the Company shall not be required to issue or deliver certificates evidencing the Common Shares unless or until the holder
shall have paid the Company or the Warrant Agent the amount of such tax (or shall have satisfied the Company that such tax has
been paid or that no tax is due)) are to be issued, the number of Common Shares to be issued to such person(s) and such person(s)
shall become a holder in respect of such Common Shares with effect from the date of such exercise, and upon due surrender of this
Warrant Certificate and all other documentation required, the Warrant Agent shall cause the issuance of a certificate(s) representing
such Common Shares to be issued within three Business Days after the exercise of the Warrants (or portion thereof) represented
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither the Warrants
represented by this Warrant Certificate nor the Common Shares issuable upon exercise hereof have been or will be registered under
the U.S.&nbsp;Securities&nbsp;Act or any state securities laws. The Warrants represented by this Warrant Certificate may not be
exercised within the United States or by, or for the account or benefit of, a U.S.&nbsp;Person (as defined by Regulation&nbsp;S
under the U.S.&nbsp;Securities&nbsp;Act) or a person within the United States unless registered under the U.S.&nbsp;Securities&nbsp;Act
and any applicable state securities laws or unless an exemption from such registration is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holder acknowledges
that the Warrants represented by this Warrant Certificate and the Common Shares issuable upon exercise hereof may be offered, sold
or otherwise transferred only in compliance with all applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No transfer of any
Warrant will be valid unless entered on the register of transfers, upon surrender to the Warrant Agent of the Warrant Certificate
evidencing such Warrant, duly endorsed by, or accompanied by a transfer form or other written instrument of transfer in form satisfactory
to the Warrant Agent executed by the registered holder or his executors, administrators or other legal representatives or his or
their attorney duly appointed by an instrument in writing in form and execution satisfactory to the Warrant Agent. Subject to the
provisions of the Warrant Indenture and upon compliance with the reasonable requirements of the Warrant Agent, Warrant Certificates
may be exchanged for Warrant Certificates representing in the aggregate an equal number of Warrants. The Company and the Warrant
Agent may treat the registered holder of this Warrant Certificate for all purposes as the absolute owner hereof. The holding of
the Warrants represented by this Warrant Certificate shall not constitute the holder hereof a holder of Common Shares nor entitle
him to any right or interest in respect thereof except as herein and in the Warrant Indenture expressly provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Indenture
provides for adjustment in the number of Common Shares to be delivered upon exercise of the right of purchase hereby granted and
to the Warrant Exercise Price in certain events therein set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrant Indenture
contains provisions making binding upon all holders of Warrants outstanding thereunder resolutions passed at meetings of such holders
held in accordance with such provisions and instruments in writing signed by the Warrantholders holding a specified percentage
of the then outstanding Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants and the
Warrant Indenture shall be governed by and performed, construed and enforced in accordance with the laws of the Province of Ontario
and the federal laws of Canada applicable therein and shall be treated in all respects as Ontario contracts. Time shall be of the
essence hereof and of the Warrant Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company may from
time to time at any time prior to the Expiry Time purchase any of the Warrants by private agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Warrant Certificate
shall not be valid for any purpose until it has been certified by or on behalf of the Warrant Agent for the time being under the
Warrant Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All dollar amounts
herein are expressed in the lawful money of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>
the Company has caused this Warrant Certificate to be signed by its duly authorized officer as of this &bull; day of &bull;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><FONT STYLE="font-weight: normal; font-style: normal">Certified this &bull; day
    of &bull;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">TSX TRUST COMPANY</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in">Authorized Signing Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>EXERCISE
FORM</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">TO:</TD>
    <TD STYLE="width: 90%; text-align: justify">PROFOUND MEDICAL CORP.<BR>
c/o TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned holder of the within Warrants
hereby irrevocably exercises the right of such holder to be issued and hereby subscribes for ____________ Common Shares of Profound
Medical Corp. (the &ldquo;<B>Company</B>&rdquo;) at the Warrant Exercise Price referred to in the attached Warrant Certificate
on the terms and conditions set forth in such certificate and the Warrant Indenture and encloses herewith a certified cheque, bank
draft or money order in lawful money of Canada payable to, or to the order of, the Company at par in payment in full of the subscription
price of the Common Shares hereby subscribed for.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise defined herein, all capitalized
terms shall have the meanings ascribed to them in the warrant indenture between the Company and TSX Trust Company dated March 20,
2018 (the &ldquo;<B>Warrant Indenture</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please check the ONE box applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">&bull;<FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 10%; text-align: justify">1.</TD>
    <TD STYLE="width: 80%; text-align: justify">The undersigned certifies that it (i)&nbsp;is not in the United States and is not a &ldquo;U.S.&nbsp;Person&rdquo;, within the meaning of Regulation&nbsp;S under the United States Securities Act of&nbsp;1933, as amended (the &ldquo;<B>U.S.&nbsp;Securities&nbsp;Act</B>&rdquo;), (ii)&nbsp;is not exercising this Warrant for the account or benefit of any U.S.&nbsp;Person, (iii)&nbsp;did not execute or deliver this Exercise Form within the United States and (iv)&nbsp;has in all other aspects complied with the terms of Regulation&nbsp;S under the U.S.&nbsp;Securities&nbsp;Act.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&bull;<FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="text-align: justify">2.</TD>
    <TD STYLE="text-align: justify">The undersigned holder (a)&nbsp;purchased the Warrants as a part of the Units in the Offering; (b)&nbsp;is exercising the Warrants solely for its own account or for the benefit of a U.S.&nbsp;Person or a person in the United States for whose account such holder acquired the Warrants as a part of the Units in the Offering and for whose account such holders exercises sole investment discretion; and (c)&nbsp;is, and any beneficial purchaser for whose account such holder is exercising the Warrants is, an Accredited Investor and/or Qualified Institutional Buyer on the Exercise Date.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;<FONT STYLE="font-family: Wingdings">o</FONT></FONT></TD>
    <TD STYLE="text-align: justify">3<FONT STYLE="font-size: 10pt">.</FONT></TD>
    <TD STYLE="text-align: justify">The undersigned is delivering a written opinion of United States legal counsel or evidence satisfactory to the Company to the effect the Common Shares to be delivered upon exercise hereof have been registered under the U.S.&nbsp;Securities&nbsp;Act or are exempt from the registration requirements of the U.S.&nbsp;Securities&nbsp;Act and applicable state securities laws.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby directs that the
said Common Shares be issued as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 33%; border: Black 1pt solid; text-align: center; font-weight: bold">NAME(S) IN FULL</TD>
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">ADDRESS(ES)</TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-weight: bold">NUMBER OF<BR>
COMMON SHARES</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please print. If securities are issued
to a person other than the registered Warrantholder, the holder must pay to the Warrant Agent all applicable taxes and the signature
of the holder must be guaranteed by a Schedule&nbsp;I Canadian chartered bank, or by a medallion signature guarantee from a member
of a recognized Signature Medallion Guarantee Program).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this ________ day of ______________,
____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Signature of Warrantholder</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Signature Guarantee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Print name</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Address</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">Please check this box if the securities are to be delivered at the office where these Warrants are surrendered, failing which the securities will be mailed.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>NOTES</U>:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certificates will not be registered or delivered to an address in the United States unless Box&nbsp;2 or 3 above is checked.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If Box&nbsp;3 is checked, holders are encouraged to contact the Company in advance to determine that the legal opinion tendered in connection with exercise will be satisfactory in form and substance to the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TRANSFER FORM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify">TO:</TD>
    <TD STYLE="width: 90%; text-align: justify">PROFOUND MEDICAL CORP.<BR>
c/o TSX TRUST COMPANY<BR>
301 &ndash; 100 Adelaide Street West<BR>
Toronto, Ontario M5H 4H1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>FOR VALUE RECEIVED</B>, the undersigned
transferor hereby sells, assigns and transfers unto</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in">(Transferee)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in">(Address)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-align: center; text-indent: -0.5in">(Social Insurance Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">___________________ of the Warrants registered
in the name of the undersigned transferor represented by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THE UNDERSIGNED TRANSFEROR HEREBY CERTIFIES
AND DECLARES</B> that the Warrants are not being offered, sold or transferred to, or for the account or benefit of, a U.S.&nbsp;Person
(as defined in Regulation&nbsp;S under the U.S.&nbsp;Securities&nbsp;Act of&nbsp;1933 as amended) or a person within the United
States unless registered under the U.S.&nbsp;Securities&nbsp;Act and any applicable state securities laws or unless an exemption
from such registration is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DATED this ________ day of ______________,
____.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.75pt; padding-left: 5.75pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">Signature of Warrantholder</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">(Transferor)</P></TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.75pt; padding-left: 0.5in; text-indent: -0.5in">Signature Guarantee</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Print name</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">Address</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>NOTES</U>:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">The signature to this transfer must correspond with the name as recorded on the Warrants in every particular without alteration or enlargement or any change whatever. The signature of the person executing this transfer must be guaranteed by a Schedule&nbsp;I Canadian chartered bank, or by a medallion signature guarantee from a member of a recognized Signature Medallion Guarantee Program.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Warrants shall only be transferable in accordance with the Warrant Indenture between Profound Medical Corp. (the &ldquo;<B>Company</B>&rdquo;) and TSX Trust Company (the &ldquo;<B>Warrant Agent</B>&rdquo;) dated as of March 20, 2018, applicable laws and the rules and policies of any applicable stock exchange.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.10
<SEQUENCE>16
<FILENAME>tv526458_ex4-10.htm
<DESCRIPTION>EXHIBIT 4.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2.0pt solid; width: 65%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AMENDED AND RESTATED SHARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OPTION PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">July 13, 2018&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2.0pt solid; width: 65%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Share Option Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PREAMBLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">A.</TD><TD STYLE="text-align: justify">The Company adopted a Share Option Plan on June 4, 2015
(the &ldquo;<B>Original Plan</B>&rdquo;), which was amended and restated on December 8, 2016.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">B.</TD><TD STYLE="text-align: justify">The Company wishes to further amend and restate the Plan
in the manner contemplated herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INTRODUCTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>1.1</B></TD><TD STYLE="text-align: justify"><B>Purpose</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The purpose of this Plan is to
assist the Company in attracting, retaining and motivating key employees, officers, directors and consultants of the Company or
of a Designated Affiliate by granting to them options to purchase Common Shares in the capital of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.2</TD><TD STYLE="text-align: justify">No Changes to Outstanding Options</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">This Plan shall have no effect
on any outstanding Options granted under the Plan prior to the date hereof, which shall continue in effect in accordance with their
terms and conditions and the terms and conditions of the Plan in effect prior to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.3</TD><TD STYLE="text-align: justify">Definitions</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">When used herein, unless the context
otherwise requires, the following terms have the following meanings, respectively:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Affiliate</B>&rdquo;
has the meaning ascribed thereto in National Instrument 45-106 &ndash; <I>Prospectus Exemptions</I>, as amended from time to time,
and any successor to such instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in">&ldquo;<B>Associate</B>&rdquo; has the meaning ascribed
thereto in the <I>Securities Act </I>(Ontario).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Board</B>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Business Day</B>&rdquo;
means a day, other than a Saturday or Sunday, on which the principal commercial banks located in Toronto, Ontario, Canada are open
for business during normal banking hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;<B>Change of Control</B>&rdquo;
means the happening of any of the following events:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">any transaction at any time and by whatever means
pursuant to which any Person or any group of two or more Persons acting jointly or in concert (other than the Company or a wholly-owned
subsidiary of the Company) hereafter acquires the direct or indirect &ldquo;beneficial ownership&rdquo; (as defined in the <I>Business
Corporations Act</I> (Ontario) of, or acquires the right to exercise control or direction over, securities of the Company representing
50% or more of the then issued and outstanding voting securities of the Company, including, without limitation, as a result of
a take-over bid, an exchange of securities, an amalgamation of the Company with any other entity, an arrangement, a capital reorganization
or any other business combination or reorganization;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the sale, assignment or other transfer of all or substantially all of the assets of the Company
to a Person other than a wholly-owned subsidiary of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the dissolution or liquidation of the Company, other than in connection with the distribution of
assets of the Company to one or more Persons which were wholly-owned subsidiaries of the Company prior to such event;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">the occurrence of a transaction requiring approval of the Company&rsquo;s shareholders whereby
the Company is acquired through consolidation, merger, exchange of securities, purchase of assets, amalgamation, statutory arrangement
or otherwise by any other Person (other than a short form amalgamation or exchange of securities with a wholly-owned subsidiary
of the Company);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">the Board determines that a Change of Control shall be deemed to have occurred in such circumstances
as the Board shall determine; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">individuals who comprise the Board as of the last annual meeting of shareholders of the Company
for any reason cease to constitute at least a majority of the members of the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">provided that, notwithstanding
clauses (a), (b), (c) and (d) above, a Change of Control shall be deemed not to have occurred if immediately following the transaction
set forth in clause (a), (b), (c) or (d) above: (i) the holders of securities of the Company that immediately prior to the consummation
of such transaction represented more than 50% of the combined voting power of the then outstanding securities eligible to vote
for the election of directors of the Company hold (A) securities of the entity resulting from such transaction (the <B>&ldquo;Surviving
Entity&rdquo;</B>) that represent more than 50% of the combined voting power of the then outstanding securities eligible to vote
for the election of directors (<B>&ldquo;voting power&rdquo;</B>) of the Surviving Entity, or (B) if applicable, securities of
the entity that directly or indirectly has beneficial ownership of 100% of the securities eligible to elect directors of the Surviving
Entity (the <B>&ldquo;Parent Entity&rdquo;</B>) that represent more than 50% of the combined voting power of the then outstanding
securities eligible to vote for the election of directors of the Parent Entity, and (ii) no Person, or group of two or more Persons
acting jointly or in concert, is the beneficial owner, directly or indirectly, of 50% or more of the voting power of the Parent
Entity (or, if there is no Parent Entity, the Surviving Entity) (any such transaction which satisfies all of the criteria specified
in clauses (i) and (ii) above being referred to as a <B>&ldquo;Non-Qualifying Transaction&rdquo;</B> and, following the Non-Qualifying
Transaction, references in this definition of &ldquo;Change in Control&rdquo; to the &ldquo;Company&rdquo; shall mean and refer
to the Parent Entity (or, if there is no Parent Entity, the Surviving Entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Committee</B>&rdquo;
has the meaning set forth in Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Common Share</B>&rdquo;
means a common share in the capital of the Company. &ldquo;<B>Company</B>&rdquo; means Profound Medical Corp. and its successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Consultant Participant</B>&rdquo;
means an individual consultant or a consultant entity, other than an Employee Participant or Director Participant that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">is engaged to provide services on a <I>bona fide</I>
basis to the Company or a Designated Affiliate, other than services provided in relation to a distribution of securities of the
Company or a Designated Affiliate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">provides the services under a written contract with
the Company or a Designated Affiliate; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">spends or will spend a significant amount of time and
attention on the affairs and business of the Company or a Designated Affiliate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">and includes, (i) for an individual
consultant, (A) a company of which the individual consultant is an employee or shareholder; or (B) a partnership of which the individual
consultant is an employee or partner, and (ii) for a consultant that is not an individual, an employee or director of the consultant,
provided that the individual employee or director spends or will spend a significant amount of time and attention on the affairs
and business of the Company or a Designated Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Date of Grant</B>&rdquo;
means, for any Option, the date specified by the Plan Administrator at the time it grants the Option (provided, however, that such
date shall not be prior to the date the Plan Administrator acts to grant the Option) or, if no such date is specified, the date
upon which the Option was granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Designated Affiliate</B>&rdquo;
means each Subsidiary of the Company and any other Affiliate of the Company as designated by the Plan Administrator for purposes
of the Plan from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Director</B>&rdquo;
means a member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Director Participant</B>&rdquo;
means a Director (i) who is not an officer or employee of the Company or of a Designated Affiliate and (ii) who is not an Associate
of a Significant Shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Disabled</B>&rdquo;
or &ldquo;<B>Disability</B>&rdquo; means eligible for long-term disability under the terms of a long-term disability plan sponsored
by the Participant&rsquo;s employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Employee Participant</B>&rdquo;
means a <I>bona fide</I> current employee (other than a Consultant Participant) of the Company or of a Designated Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Exercise Notice</B>&rdquo;
means a notice in writing, in the form set out in Schedule B, signed by an Optionee and stating the Optionee&rsquo;s intention
to exercise a particular Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Exercise Price</B>&rdquo;
means the price at which an Option Share may be purchased pursuant to the exercise of an Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Expiry Date</B>&rdquo;
means the expiry date specified in the Option Agreement, provided that such date shall not be later than the tenth (10<FONT STYLE="font-size: 10pt">th</FONT>)
anniversary of the Date of Grant, or, if not so specified, means the tenth (10<FONT STYLE="font-size: 10pt">th</FONT>) anniversary
of the Date of Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Fiscal Year</B>&rdquo;
means the twelve month period ending December 31 in each calendar year or as otherwise determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Individual Optionee</B>&rdquo;
means an Optionee who is an individual.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Market Price</B>&rdquo;
means the volume-weighted average price of the Common Shares on the stock exchange where the majority of trading volume and value
of the Common Shares occurs, for the five trading days immediately preceding the relevant date on which the Market Price is to
be determined. If the Common Shares are not listed for trading on a stock exchange, the Market Price shall be the fair market value
of the Common Shares as determined by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Option</B>&rdquo; means
a right to purchase Common Shares under this Plan that is non-assignable and non-transferable unless otherwise approved by the
Plan Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Optionee</B>&rdquo;
means a Participant who has been granted one or more Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Option Agreement</B>&rdquo;
means a signed, written agreement between an Optionee and the Company, in the form attached as Schedule A, subject to any amendments
or additions thereto as may, in the discretion of the Plan Administrator, be necessary or advisable, evidencing the terms and conditions
on which an Option has been granted under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Option Shares</B>&rdquo;
means Common Shares issuable by the Company upon the exercise of outstanding Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Participant</B>&rdquo;
means an Employee Participant, a Director Participant or a Consultant Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Person</B>&rdquo; includes
an individual, sole proprietorship, corporation, company, partnership, limited partnership, joint venture, association, trust,
trustee, unincorporated organization or government or any agency or political subdivision thereof, and a natural person in his
or her capacity as trustee, executor, administrator or other legal representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Plan</B>&rdquo; means
this Share Option Plan as set out herein and as amended from time to time in accordance with the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Plan Administrator</B>&rdquo;
means the Board or, if the administration of this Plan has been delegated by the Board to the Committee pursuant to Section 2.2,
the Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Retirement</B>&rdquo;
means retirement from active employment under the retirement policies of the Company, its Designated Affiliates or a Consultant,
as applicable, at or after the age of 65, or, with the consent for the purposes of the Plan of such officer of the Company as may
be designated by the Plan Administrator, at or after such earlier age and upon the completion of such years of service as the Plan
Administrator may specify.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Security</B>&rdquo;
has the meaning assigned to the term &ldquo;security&rdquo; in the <I>Securities Act</I> (Ontario), and &ldquo;<B>Securities</B>&rdquo;
has a corresponding meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Significant Shareholder</B>&rdquo;
has the meaning ascribed thereto in National Instrument 55-104 &ndash; <I>Insider Reporting Requirements and Exemptions</I>, as
amended from time to time, and any successor to such instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Subsidiary</B>&rdquo;
has the meaning assigned to the term &ldquo;subsidiary&rdquo; in the <I>Securities Act </I></FONT>(Ontario).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-align: justify">&ldquo;<B>Termination Date</B>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">in the case of an Employee Participant whose employment
with the Company or a Designated Affiliate terminates in the circumstances set out in Subsection 3.9(a) or Subsection 3.9(b),
the date designated by the Company or a Designated Affiliate, as the case may be, on which an Employee Participant ceases to be
an employee of the Company or the Designated Affiliate, as the case may be, provided that in the case of termination of employment
by voluntary resignation by the Optionee, such date shall not be earlier than the date notice of resignation was given, and &ldquo;<B>Termination
Date</B>&rdquo; specifically does not mean the date of termination of any period of reasonable notice that the Company or the
Designated Affiliate (as the case may be) may be required by law to provide to the Optionee;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in the case of a Consultant Participant whose consulting
agreement or arrangement with the Company or a Designated Affiliate, as the case may be, terminates in the circumstances set out
in Subsection 3.9(c) or Subsection 3.9(d), the date that is designated by the Company or the Designated Affiliate, as the case
may be, as the date on which the Optionee&rsquo;s consulting agreement or arrangement is terminated, provided that in the case
of voluntary termination by the Optionee of the Optionee&rsquo;s consulting agreement or arrangement, such date shall not be earlier
than the date notice of voluntary termination was given, and &ldquo;<B>Termination Date</B>&rdquo; specifically does not mean
the date on which any period of notice of termination that the Company or the Designated Affiliate (as the case may be) may be
required to provide to the Optionee under the terms of the consulting agreement or arrangement expires; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">in the case of a Director Participant who ceases to hold office in the circumstances set out in
Section 3.9(e), the date upon which the Optionee ceases to hold office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.4</TD><TD STYLE="text-align: justify">Interpretation</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Whenever the Plan Administrator is to exercise discretion in the administration of the terms and
conditions of this Plan, the term &ldquo;discretion&rdquo; means the sole and absolute discretion of the Plan Administrator.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">As used in this Plan, the terms &ldquo;Article&rdquo;, &ldquo;Section&rdquo;, &ldquo;Subsection&rdquo;,
 &ldquo;clause&rdquo;, and &ldquo;Schedule&rdquo; mean and refer to the specified Article, Section, Subsection, clause and Schedule
of this Plan, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Where the word &ldquo;including&rdquo; or &ldquo;includes&rdquo; is used in this Plan, it means
 &ldquo;including (or includes) without limitation&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Unless otherwise specified, time periods within or following which any payment is to be made or
act is to be done shall be calculated by excluding the day on which the period begins, including the day on which the period ends,
and abridging the period to the immediately preceding Business Day in the event that the last day of the period is not a Business
Day. In the event an action is required to be taken or a payment is required to be made on a day which is not a Business Day such
action shall be taken or such payment shall be made on the immediately preceding Business Day.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Words importing the singular meaning include the plural and vice versa and words importing any
gender include any other gender.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Unless otherwise specified, all references to money amounts are to Canadian currency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE
2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PLAN ADMINISTRATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><B>2.1</B></TD><TD STYLE="text-align: justify"><B>Plan Administration</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">This Plan will be administered by the Plan Administrator
and the Plan Administrator has sole and complete authority, in its discretion, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">determine the individuals and entities (from among the Participants) to whom Options may be granted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">grant Options in such amounts and, subject to the provisions of this Plan, on such terms and conditions as it determines including:</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the time or times at which Options may be granted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the Exercise Price at which Option Shares subject to each Option may be purchased;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the time or times when each Option becomes exercisable and the Expiry Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">whether restrictions or limitations are to be imposed on the Option Shares and the nature of such
restrictions or limitations, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">authorize any acceleration of exercisability or waiver of termination regarding any Option, based
on such factors as the Plan Administrator may determine;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">cancel, amend, adjust or otherwise change any Option under such circumstances as the Plan Administrator
may consider appropriate in accordance with the provisions of this Plan;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">construe and interpret this Plan and all Option Agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">adopt, amend, prescribe and rescind administrative guidelines and other rules and regulations relating
to this Plan; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">make all other determinations and take all other actions necessary or advisable for the implementation
and administration of this Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.2</TD><TD STYLE="text-align: justify">Delegation of Plan Administration</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The initial Plan Administrator shall be the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">To the extent permitted by applicable law, the Board may, from time to time, delegate to a committee
of the Board (the &ldquo;<B>Committee</B>&rdquo;) all or any of the powers conferred on the Plan Administrator pursuant to this
Plan. In such event, the Committee will exercise the powers delegated to it by the Board in the manner and on the terms authorized
by the Board. Any decision made or action taken by the Committee arising out of or in connection with the administration or interpretation
of this Plan in this context is final and conclusive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The day-to-day administration of this Plan may be delegated to such officers and employees of the
Company or a Designated Affiliate as the Plan Administrator determines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.3</TD><TD STYLE="text-align: justify">Determinations Binding</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Any decision made or action taken
by the Plan Administrator, the Committee or any officers or employees to whom authority has been delegated pursuant to Subsection
2.2(c) arising out of or in connection with the administration or interpretation of this Plan is final, conclusive and binding
on the Company, the affected Participant(s), their legal and personal representatives and all other Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.4</TD><TD STYLE="text-align: justify">Eligibility</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">All Employee Participants, Director
Participants and Consultant Participants are eligible to participate in this Plan, subject to Subsections 3.8(b) and 3.9(f). Eligibility
to participate does not confer upon any Participant any right to be granted Options pursuant to this Plan. The extent to which
any Participant is entitled to be granted Options pursuant to this Plan will be determined in the discretion of the Plan Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">2.5</TD><TD>Compliance with Regulatory Requirements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Company&rsquo;s obligation
to issue Common Shares in accordance with the terms of this Plan and any Options granted hereunder are subject to compliance with
any applicable legislation and the rules, regulations and published policies of any stock exchange, regulatory authority or agency
having jurisdiction over the issuance and distribution of such Common Shares in such jurisdictions as the Company may elect to
grant Options to Participants. Participants shall, to the extent applicable, cooperate with the Company in complying with such
legislation, rules, regulations and policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify">Total Common Shares Subject to Options</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The maximum number of Common Shares reserved for issuance under this Plan shall be equal to a number
that is 13% of the issued and outstanding shares in the capital of the Company at the time of any Option grant. Subject to the
provisions and restrictions of this Plan, if any Option is exercised, cancelled, expired, surrendered or otherwise terminated for
any reason whatsoever, the number of Common Shares in respect of which the Option is exercised, cancelled, expired, surrendered
or otherwise terminated for any reason whatsoever, as the case may be, will <I>ipso facto</I> be immediately available for purchase
pursuant to Options granted under the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The maximum number of Common Shares reserved for issuance under this Plan shall be automatically
adjusted to take into account any conversion, changing, reclassification, redivision, redesignation, subdivision or consolidation
of the Common Shares and shall also apply to securities of the Company or of any successor or continuing entity which may result
from a reorganization, amalgamation, consolidation or merger, statutory or otherwise, take-over bid or any transaction similar
to any of the foregoing. To the extent any Options terminate, lapse or are cancelled for any reason prior to exercise in full,
or are surrendered to the Company by the Participant, the Common Shares subject to such Options shall be added back to the number
of Common Shares reserved for issuance under this Plan and will again become available for issuance pursuant to the exercise of
Options granted under this Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Plan, the aggregate number of Common Shares that may be (i) issued
to insiders of the Company within any one-year period, or (ii) issuable to insiders of the Company at any time, in each case, under
this Plan alone or when combined with all other security-based compensation arrangements of the Company cannot exceed 10% of the
outstanding Common Shares. For purposes of this Subsection 2.6(c) and Subsection 5.1(b), &ldquo;insider&rdquo; and &ldquo;security-
based compensation arrangement&rdquo; have the meanings given to them in the Toronto Stock Exchange Company Manual in respect of
the rules governing security-based compensation arrangements, as amended from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">2.7</TD><TD>Option Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">All grants of Options under this
Plan will be evidenced by Option Agreements. Such Option Agreements will be subject to the applicable provisions of this Plan and
will contain such provisions as are required by this Plan and any other provisions that the Plan Administrator may direct which
are not inconsistent with this Plan. The Board shall authorize and empower any director or officer of the Company to execute and
deliver, for and on behalf of the Company, an Option Agreement to each Optionee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">ARTICLE 3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">GRANT OF OPTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"><B>3.1</B></TD><TD><B>Grant of Options</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Plan Administrator may, from
time to time, subject to the provisions of this Plan and such other terms and conditions as the Plan Administrator may prescribe,
grant Options to any Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.2</TD><TD>Exercise Price</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Board will establish the Exercise
Price at the time each Option is granted, which Exercise Price must in all cases be not less than the Market Price of the Common
Shares on the date the Option is granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.3</TD><TD>Term of Options</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Subject to any accelerated termination
as set forth in this Plan, each Option expires on its Expiry Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.4</TD><TD>Blackout Periods</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">If an Option is due to expire on
a date that falls within a corporate blackout period applicable to the holder of such Option, or within 5 business days following
the expiry of such a blackout period, the Expiry Date of such Option shall be extended to the 10<FONT STYLE="font-size: 10pt">th</FONT>
business day following the expiry of the blackout period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.5</TD><TD>Vesting and Exercisability</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Unless otherwise specified by the Plan Administrator at the time of granting an Option and except as otherwise provided in
this Plan, each Option will vest and be exercisable as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR>
    <TD STYLE="vertical-align: top; width: 37%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Number of Option Shares</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>that may be Purchased</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 60%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vesting Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From the first anniversary of the Date of Grant.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/36</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the first day of each calendar month following the first anniversary of the Date of Grant.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Once an instalment becomes vested, it shall remain vested and shall be exercisable until expiration or termination of the Option,
unless otherwise specified by the Plan Administrator. Each Option or instalment may be exercised at any time or from time to time,
in whole or in part, for up to the total number of Option Shares with respect to which it is then exercisable. The Plan Administrator
has the right to accelerate the date upon which any instalment of any Option becomes exercisable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to the provisions of this Plan and any Option Agreement, Options shall be exercised by means of a fully completed Exercise
Notice delivered to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Plan Administrator may provide at the time of granting an Option that the exercise of that Option is subject to additional
restrictions, such as performance- based vesting conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.6</TD><TD>Payment of Exercise Price</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Unless otherwise specified by
the Plan Administrator at the time of granting an Option, the Exercise Notice must be accompanied by payment in full of the purchase
price for the Option Shares to be purchased. The Exercise Price must be fully paid by certified cheque, bank draft or money order
payable to the Company or by such other means as might be specified from time to time by the Plan Administrator<B>,</B> <I>provided
that</I> under no circumstances shall satisfaction of the Exercise Price by way of surrender of a portion of the Option or Option
Shares, be permitted. No Common Shares will be issued or transferred until full payment therefor has been received by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.7</TD><TD>Retirement of Optionee</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Subject to Section 3.10 or unless otherwise specified
by the Plan Administrator at the time of granting an Option, if the employment of a Participant terminates due to Retirement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">such Participant shall continue to be a Participant notwithstanding the Participant&rsquo;s Retirement
and each Option held by the Individual Optionee that has vested as of the date of the Individual Optionee&rsquo;s Retirement or
that vests within 12 months of the date of the Individual Optionee&rsquo;s Retirement (the &ldquo;<B>Post-Retirement Date</B>&rdquo;)
continues to be exercisable by the Individual Optionee until the earlier of: (i) its Expiry Date; and (ii) the Post-Retirement
Date. Any Options held by the Individual Optionee that have not been exercised as at the Post-Retirement Date immediately expire
and shall be cancelled as of the Post-Retirement Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Individual Optionee&rsquo;s eligibility to receive further grants of Options under this Plan ceases as of the date of the
Individual Optionee&rsquo;s Retirement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.8</TD><TD>Death or Disability of Optionee</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Subject to Section 3.10 or unless
otherwise specified by the Plan Administrator at the time of granting an Option, if an Individual Optionee dies or becomes Disabled
while an employee or officer of the Company or a Designated Affiliate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the executor or administrator of the Individual Optionee&rsquo;s estate or the Individual Optionee,
as the case may be, may exercise any Options of the Individual Optionee to the extent that the Options have vested as at the date
of such death or Disability and the right to exercise each such Option terminates on the earlier of: (i) its Expiry Date; and (ii)
the date that is 180 days after the Individual Optionee&rsquo;s death or Disability. Any Options held by the Individual Optionee
that have not vested as at the date of death or Disability immediately expire and shall be cancelled as of such date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Individual Optionee&rsquo;s eligibility to receive further grants of Options under this Plan
ceases as of the date of the Individual Optionee&rsquo;s death or Disability, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.9</TD><TD STYLE="text-align: justify">Termination of Employment or Services</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Subject to Section 3.10 or unless
otherwise specified by the Plan Administrator at the time of granting an Option:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">where, in the case of an Employee Participant, an Individual Optionee&rsquo;s employment is terminated
by the Company or a Designated Affiliate without cause (whether such termination occurs with or without any or adequate reasonable
notice, or with or without any or adequate compensation in lieu of such reasonable notice), then each Option held by the Individual
Optionee that has vested as at the Termination Date continues to be exercisable by the Individual Optionee until the earlier of:
(i) its Expiry Date; and (ii) the date that is 90 days after the Termination Date. Any Options held by the Individual Optionee
that have not vested as at the Termination Date immediately expire and shall be cancelled as of the Termination Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">where, in the case of an Employee Participant, an Individual Optionee&rsquo;s employment terminates
by reason of: (i) termination by the Company or a Designated Affiliate for cause; or (ii) voluntary resignation by the Individual
Optionee, then any Options held by the Individual Optionee, whether or not they have vested as at the Termination Date, immediately
expire and are cancelled on the Termination Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">where, in the case of a Consultant Participant, an Optionee&rsquo;s consulting agreement or arrangement
terminates by reason of: (i) termination by the Company or a Designated Affiliate for any reason whatsoever other than for breach
of the consulting agreement or arrangement (whether or not such termination is effected in compliance with any termination provisions
contained in the Optionee&rsquo;s consulting agreement or arrangement); or (ii) the death or Disability of the Individual Optionee,
then each Option held by the Optionee that has vested as at the Termination Date, or at the date of the death or Disability of
the Individual Optionee, as the case may be, continues to be exercisable by the Optionee until the earlier of: (i) its Expiry Date;
and (ii) the date that is 90 days after the Termination Date. Any Options held by the Optionee that have not vested as at the Termination
Date, or at the date of the death or Disability of the Individual Optionee, as the case may be, immediately expire and shall be
cancelled as of the Termination Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">where, in the case of a Consultant Participant, an Optionee&rsquo;s consulting agreement or arrangement
terminates by reason of: (i) termination by the Company or a Designated Affiliate for breach of the consulting agreement or arrangement
(whether or not such termination is effected in compliance with any termination provisions contained in Optionee&rsquo;s consulting
agreement or arrangement); or (ii) voluntary termination by the Optionee (whether or not such termination is effected in compliance
with any termination provisions contained in the Optionee&rsquo;s consulting agreement or arrangement), then any Options held by
the Optionee, whether or not such Options have vested as at the Termination Date, immediately expire and shall be cancelled as
of the Termination Date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">where, in the case of a Director Participant, an Individual Optionee ceases to hold office, then
any Options held by the Individual Optionee that have vested as at the Termination Date continue to be exercisable by the Optionee
until the earlier of: (i) its Expiry Date; and (ii) the date that is 60 days after the Termination Date; except that this Section
3.9(e) will not apply if such Director Participant is also an Employee Participant or a Consultant Participant and such Participant&rsquo;s
employment or consulting agreement is not terminated. Any Options held by the Individual Optionee that have not vested as at the
Termination Date immediately expire and shall be cancelled as of the Termination Date; except for such Director Participant who
is also an Employee Participant or a Consultant Participant and such Participant&rsquo;s employment or consulting agreement is
not terminated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">an Optionee&rsquo;s eligibility to receive further grants of Options under this Plan ceases as
of the date that the Company or a Designated Affiliate, as the case may be, provides the Optionee with written notification that
the Optionee&rsquo;s employment or consulting agreement or arrangement, as the case may be, is terminated in the circumstances
contemplated by this Section 3.9, notwithstanding that such date may be prior to the Termination Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">notwithstanding Subsections 3.9(a) and 3.9(c), unless the Plan Administrator, in its discretion,
otherwise determines, at any time and from time to time, Options are not affected by a change of employment or consulting arrangement
within or among the Company or a Designated Affiliate for so long as the Employee Participant continues to be an employee of the
Company or a Designated Affiliate or for so long as the Consultant Participant continues to be engaged as a consultant to the Company
or a Designated Affiliate, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.10</TD><TD>Discretion to Permit Exercise</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Notwithstanding the provisions
of Sections 3.7, 3.8 and 3.9, the Plan Administrator may, in its discretion, at any time prior to or following the events contemplated
in such sections, permit the exercise of any or all Options held by the Optionee in the manner and on the terms authorized by the
Plan Administrator, provided that the Plan Administrator will not, in any case, authorize the exercise of an Option pursuant to
this Section 3.10 at any time after the earlier of (i) its Expiry Date or (ii) after the Post-Retirement Date or the date that
is 12 months from the Termination Date, as the case may be, and any Options held by an Individual Optionee as of such date, whether
or not they have vested, shall immediately expire and be cancelled as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.11</TD><TD>Change of Control</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Upon the Company entering into
an agreement relating to, or otherwise becoming aware of, a transaction which, if completed, would result in a Change of Control,
the Company shall give written notice of the proposed Change of Control to the Participants, together with a description of the
effect of such Change of Control on Options, not less than ten (10) Business Days prior to the closing of the transaction resulting
in the Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.12</TD><TD>Conditions of Exercise</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Each Optionee will, when requested
by the Company, sign and deliver all such documents relating to the granting or exercise of Options which the Company deems necessary
or desirable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE
4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SHARE CAPITAL ADJUSTMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"><B>4.1</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The existence of any Options does
not affect in any way the right or power of the Company or its shareholders to make, authorize or determine any adjustment, recapitalization,
reorganization or any other change in the Company&rsquo;s capital structure or its business, or any amalgamation, combination,
merger or consolidation involving the Company, to create or issue any bonds, debentures, Common Shares or other securities of the
Company or to determine the rights and conditions attaching thereto, to effect the dissolution or liquidation of the Company or
any sale or transfer of all or any part of its assets or business, or to effect any other corporate act or proceeding, whether
of a similar character or otherwise, whether or not any such action referred to in this section would have an adverse effect on
this Plan or any Option granted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.2</TD><TD>Reorganization of Company&rsquo;s Capital</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Should the Company effect a subdivision
or consolidation of Common Shares or any similar capital reorganization or a payment of a stock dividend (other than a stock dividend
that is in lieu of a cash dividend), or should any other change be made in the capitalization of the Company that, in the opinion
of the Plan Administrator, would warrant the replacement or amendment of any existing Options in order to adjust: (a) the number
of Common Shares that may be acquired on the exercise of any outstanding Options; and/or (b) the Exercise Price of any outstanding
Options in order to preserve proportionately the rights and obligations of the Optionees, the Plan Administrator, will authorize
such steps to be taken as may be equitable and appropriate to that end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.3</TD><TD>Other Events Affecting the Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In the event of an amalgamation,
combination, merger or other reorganization involving the Company by exchange of Common Shares, by sale or lease of assets or otherwise,
that, in the opinion of the Plan Administrator, warrants the replacement or amendment of any existing Options in order to adjust:
(a) the number of Common Shares or the securities or other property that may be acquired on the exercise of any outstanding Options;
or (b) the Exercise Price of any outstanding Options in order to preserve proportionately the rights and obligations of the Optionees,
the Plan Administrator will authorize such steps to be taken as may be equitable and appropriate to that end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.4</TD><TD>Immediate Exercise of Awards</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Where the Plan Administrator determines
that the steps provided in Sections 4.2 and 4.3 would not preserve proportionately the rights and obligations of the Optionees
in the circumstances or otherwise determines that it is appropriate, the Plan Administrator may permit the immediate exercise of
any outstanding Options that are not otherwise exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.5</TD><TD>Issue by Company of Additional Shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Except as expressly provided in
this Article 4, neither the issue by the Company of shares of any class or securities convertible into or exchangeable for shares
of any class, nor the conversion or exchange of such shares or securities, affects, and no adjustment by reason thereof is to be
made with respect to: (a) the number of Common Shares that may be acquired on the exercise of any outstanding Options; or (b) the
Exercise Price of any outstanding Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.6</TD><TD>Fractions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">No fractional Common Shares will
be issued on the exercise of an Option. Accordingly, if, as a result of any adjustment under Sections 4.2 to 4.4 inclusive, an
Optionee would become entitled to a fractional Common Share, the Optionee has the right to acquire only the adjusted number of
full Common Shares and no payment or other adjustment will be made with respect to the fractional Common Shares so disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.7</TD><TD>Conditions of Exercise</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Plan and each Option are subject
to the requirement that if at any time the Plan Administrator determines that the listing, registration or qualification of the
Common Shares subject to such Option upon any securities exchange or under any provincial, state or federal law, or the consent
or approval of any governmental body, securities exchange or of the holders of voting shares in the capital of the Company or of
the Common Shares generally, is necessary or desirable, as a condition of, or in connection with, the granting of such Option or
the issue or purchase of Common Shares thereunder, no such Option may be granted or exercised in whole or in part unless such listing,
registration, qualification, consent or approval has been effected or obtained free of any conditions not acceptable to the Plan
Administrator. The Optionees shall, to the extent applicable, cooperate with the Company in relation to such listing, registration,
qualification, consent or other approval and shall have no claim or cause of action against the Company or any of its officers
or directors as a result of any failure by the Company to obtain or to take any steps to obtain any such registration, qualification
or approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">ARTICLE 5</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">GENERAL PROVISIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"><B>5.1</B></TD><TD><B>Amendment, Suspension, or Termination of the Plan</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Plan Administrator may from
time to time, without notice and without approval of the holders of voting shares in the capital of the Company, amend, modify,
change, suspend or terminate the Plan or any Options granted pursuant to the Plan as it, in its discretion determines appropriate,
provided, however, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">no such amendment, modification, change, suspension or termination of the Plan or any Option granted
hereunder may materially impair any rights of a Participant or materially increase any obligations of a Participant under the Plan
without the consent of the Participant, unless the Plan Administrator determines such adjustment is required or desirable in order
to comply with any applicable securities laws or stock exchange requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">shareholder approval (in accordance with the rules of the exchange upon which the Common Shares
may be listed) shall be required for any amendment, modification or change that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">increases the number of Common Shares reserved for issuance under the Plan, except pursuant to
the provisions in the Plan which permit the Plan Administrator to make equitable adjustments in the event of transactions affecting
the Company or its capital;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">reduces the exercise price of an Option (for this purpose, a cancellation or termination of an
Option of a Participant prior to its Expiry Date for the purpose of reissuing an Option to the same Participant with a lower exercise
price shall be treated as an amendment to reduce the exercise price of an Option) except pursuant to the provisions in the Plan
which permit the Plan Administrator to make equitable adjustments in the event of transactions affecting the Company or its capital;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">extends the term of an Option beyond the original Expiry Date (except where an Expiry Date would
have fallen within a blackout period applicable to the Participant or within 5 business days following the expiry of such a blackout
period);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">permits an Option to be exercisable beyond 10 years from its Date of Grant (except where an Expiry
Date would have fallen within a blackout period of the Company);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">permits Options to be transferred other than for normal estate settlement purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify">removes or exceeds the insider participation limits set out in Section 2.6(c);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vii)</TD><TD STYLE="text-align: justify">permits awards, other than the Options to be granted under the Plan; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(viii)</TD><TD STYLE="text-align: justify">deletes or reduces the range of amendments which require approval of the holders of voting shares
in the capital of the Company under this Section 5.1.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">if required by the rules of the exchange upon which the Common Shares may be listed, the Company
will seek the approval of shareholders excluding the votes of securities held directly or indirectly by insiders entitled to receive
a benefit directly or indirectly under the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.2</TD><TD>Legal Requirement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Company is not obligated to
grant any Options, issue any Common Shares or other securities, make any payments or take any other action if, in the opinion of
the Plan Administrator, in its sole discretion, such action would constitute a violation by an Optionee or the Company of any provision
of any applicable statutory or regulatory enactment of any government or government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.3</TD><TD>Non-Transferability</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Except as otherwise may be expressly
provided for in this Plan, no Options granted under this Plan shall be transferrable or assignable by the Participant (except to
an Optionee&rsquo;s estate) and no Options may be exercised by anyone other than the Participant or his or her legal representative
during the lifetime of the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.4</TD><TD>No Other Benefit</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">No amount will be paid to, or in
respect of, a Participant under the Plan to compensate for a downward fluctuation in the price of a Common Share, nor will any
other form of benefit be conferred upon, or in respect of, a Participant for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.5</TD><TD>Governing Law</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Plan shall be governed by,
and interpreted in accordance with, the laws of the Province of Ontario and the federal laws of Canada applicable in the Province
of Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.6</TD><TD>Submission To Jurisdiction</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Company and each Participant
irrevocably submits to the exclusive jurisdiction of the courts of competent jurisdiction in the Province of Ontario in respect
of any action or proceeding relating in any way to the Plan, including with respect to the grant of Options and any issuance of
Common Shares made in accordance with the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.7</TD><TD>Optionee&rsquo;s Entitlement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Except as otherwise provided in
this Plan, Options previously granted under this Plan, whether or not then exercisable, are not affected by any change in the relationship
between, or ownership of, the Company and a Designated Affiliate and do not interfere in any way with any right of the Company
to discharge any Participant at any time for any reason whatsoever, with or without cause. For greater certainty, all Options remain
valid and exercisable in accordance with the terms and conditions of this Plan and are not affected by reason only that, at any
time, a Designated Affiliate ceases to be a Designated Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.8</TD><TD>Withholding Taxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In addition to the other conditions
on exercise set forth in this Plan, the exercise of each Option granted under this Plan is subject to the satisfaction of all applicable
withholding taxes or other withholding liabilities as the Company may determine to be necessary or desirable in respect of such
exercise. The Company may (a) require that a Participant pay to the Company, in addition to, and in the same manner as, the Exercise
Price, such amount as the Company is obliged to remit to the relevant taxing authority in respect of the exercise of the Option;
(b) withhold such amount from any remuneration or other amount payable by the Company or any Affiliate of the Company to the Participant;
(c) permit the Participant to sell a number of Option Shares issued upon the exercise of the Option and remit to the Company a
portion of the net proceeds from such sale sufficient to satisfy such amount; or (d) enter into any other suitable arrangements
for the receipt of such amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.9</TD><TD>Participation in this Plan</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The participation of any Participant
in this Plan is entirely voluntary and not obligatory and shall not be interpreted as conferring upon such Participant any rights
or privileges other than those rights and privileges expressly provided in this Plan. In particular, participation in this Plan
does not constitute a condition of employment or service nor a commitment on the part of the Company to ensure the continued employment
or service of such Participant. This Plan does not provide any guarantee against any loss which may result from fluctuations in
the market value of the Common Shares. The Company does not assume responsibility for the personal income or other tax consequences
of the Participants and Participants are advised to consult with their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.10</TD><TD>Corporate Action</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Nothing contained in this Plan
or in an Option shall be construed so as to prevent the Company from taking corporate action which is deemed by the Company to
be appropriate or in its best interest, whether or not such action would have an adverse effect on this Plan or any Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.11</TD><TD>Rights of Participant/Optionee</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">No Participant has any claim or
right to be granted an Option (including an Option granted in substitution for any Option that has expired pursuant to the terms
of this Plan), and the granting of any Option is not to be construed as giving an Optionee a right to remain in the employ of the
Company or a Designated Affiliate. No Optionee has any rights as a shareholder of the Company in respect of Common Shares issuable
on the exercise of rights to acquire Common Shares under any Option until the allotment and issuance to the Optionee of certificates
representing such Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.12</TD><TD>Conflict</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In the event of any conflict between
the provisions of this Plan and an Option Agreement, the provisions of this Plan shall govern. In the event of any conflict between
or among the provisions of this Plan, an Option Agreement and an employment agreement between the Company or a Designated Affiliate
and a Participant, the provisions of such employment agreement shall govern. In the event of any conflict between the provisions
of this Plan, an Option Agreement or an employment agreement between the Company or a Designated Affiliate and a Participant and
any applicable law, regulation of any governmental agency having jurisdiction or the rule, policy or decision of any stock exchange
upon which the Common Shares are or may become listed for trading, the applicable law, regulation, rule, policy or decision, as
the case may be, shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.13</TD><TD>Participant Information</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Each Participant shall provide
the Company with all information (including personal information) required by the Company in order to administer to the Plan. Each
Participant acknowledges that information required by the Company in order to administer the Plan may be disclosed to any custodian
appointed in respect of the Plan and other third parties, and may be disclosed to such persons (including persons located in jurisdictions
other than the Participant&rsquo;s jurisdiction of residence), in connection with the administration of the Plan. Each Participant
consents to such disclosure and authorizes the Company to make such disclosure on the Participant&rsquo;s behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.14</TD><TD>International Participants</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">With respect to Participants who
reside or work outside Canada, the Plan Administrator may, in its sole discretion, amend, or otherwise modify, without shareholder
approval, the terms of the Plan or Options with respect to such Participants in order to conform such terms with the provisions
of local law, and the Plan Administrator may, where appropriate, establish one or more sub-plans to reflect such amended or otherwise
modified provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.15</TD><TD>Successors and Assigns</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Plan shall be binding on all
successors and assigns of the Company and its Designated Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.16</TD><TD>General Restrictions and Assignment</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Except as required by law, the
rights of a Participant under the Plan are not capable of being assigned, transferred, alienated, sold, encumbered, pledged, mortgaged
or charged and are not capable of being subject to attachment or legal process for the payment of any debts or obligations of the
Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.17</TD><TD>Severability</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The invalidity or unenforceability
of any provision of the Plan shall not affect the validity or enforceability of any other provision and any invalid or unenforceable
provision shall be severed from the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.18</TD><TD>Notices</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">All written notices to be given
by the Optionee to the Company shall be delivered personally or by registered mail, postage prepaid, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Profound Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">2400 Skymark Avenue, Unit 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Mississauga, Ontario L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%; border-collapse: collapse; margin-left: 1.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%">Attention:</TD>
    <TD STYLE="width: 87%">Vice President, Finance</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">All notices to the Optionee will
be addressed to the principal address of the Optionee on file with the Company. Either the Company or the Optionee may designate
a different address by written notice to the other. Such notices are deemed to be received, if delivered personally, on the date
of delivery, and if sent by prepaid, registered mail, on the fifth business day following the date of mailing. Any notice given
by either the Optionee or the Company is not binding on the recipient thereof until received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>THIS AMENDED AND RESTATED SHARE OPTION PLAN</B> was
adopted by the board of directors of Profound Medical Corp. on July 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">PROFOUND MEDICAL CORP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.4pt; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 0">/s/ Aaron Davidson</TD>
    <TD STYLE="width: 50%; padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0">Name: Aaron Davidson</TD>
    <TD STYLE="padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0">Title: &nbsp;&nbsp;Chief Financial Officer</TD>
    <TD STYLE="padding-right: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.4pt; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><I>Profound Medical
Corp. &ndash; Signature Page to Share Option Plan</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SCHEDULE A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Share Option Plan Option Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Profound Medical Corp. (the &ldquo;<B>Company</B>&rdquo;)
hereby grants to the Optionee named below (the &ldquo;<B>Optionee</B>&rdquo;), an option (the &ldquo;<B>Option</B>&rdquo;) to purchase,
in accordance with and subject to the terms, conditions and restrictions of this Share Option Agreement, together with the provisions
of the Amended and Restated Share Option Plan of the Company dated <FONT STYLE="font-family: Wingdings">n</FONT>, 2018 (the &ldquo;<B>Plan</B>&rdquo;),
the number of common shares in the capital of the Company (&ldquo;<B>Common Shares</B>&rdquo;) at the price per share set forth
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Optionee:</FONT></TD>
    <TD STYLE="width: 85%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type of Participant:</FONT></TD>
    <TD STYLE="width: 85%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Employee Participant, Director Participant or Consultant Participant]</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of Grant:</FONT></TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total No. of Common Shares Subject to Option:</FONT></TD>
    <TD STYLE="width: 60%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise Price:</FONT></TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The terms and conditions of the Plan are hereby incorporated by reference as terms and conditions of this Option Agreement
and all capitalized terms used herein, unless expressly defined in a different manner, have the meanings ascribed thereto in the
Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Subject to Sections 3.10 and 4.4 of the Plan and unless otherwise determined by the Plan Administrator at the time of granting
an Option, each Option is exercisable in the instalments set forth in Section 3.5 of the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Subject to Section 3.4 of the Plan, in no event is the Option granted hereunder exercisable after the Expiry Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">No fractional Common Shares will be issued on the exercise of the Option granted hereunder. If, as a result of any adjustment
to the number of Common Shares issuable on the exercise of the Option granted hereunder pursuant to the Plan, the Optionee would
be entitled to receive a fractional Common Share, the Optionee has the right to acquire only the adjusted number of full Common
Shares and no payment or other adjustment will be made with respect to the fractional Common Shares so disregarded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">Nothing in the Plan or in this Option Agreement will affect the Company&rsquo;s right, or that of a Designated Affiliate, to
terminate the employment of, or consulting agreement or arrangement with, the Optionee at any time for any reason whatsoever. Upon
such termination, the Optionee&rsquo;s rights to exercise Options will be subject to restrictions and time limits for the exercise
of Options. Complete details of such restrictions are set out in the Plan, and in particular in Sections 3.7, 3.8 and 3.9 of the
Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">Each notice relating to the Option, including the exercise thereof, must be in writing. All notices
to the Company must be delivered personally or by prepaid registered mail and must be addressed to the Secretary. All notices to
the Optionee will be addressed to the principal address of the Optionee on file with the Company. Either the Company or the Optionee
may designate a different address by written notice to the other. Such notices are deemed to be received, if delivered personally,
on the date of delivery, and if sent by prepaid, registered mail, on the fifth business day following the date of mailing. Any
notice given by either the Optionee or the Company is not binding on the recipient thereof until received.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify">When the issuance of Common Shares on the exercise of the Option may, in the opinion of the Company, conflict or be inconsistent
with any applicable law, regulation of any governmental agency having jurisdiction or the rule, policy or decision of any stock
exchange upon which the Common Shares are or may become listed for trading, the Company reserves the right to refuse to issue such
Common Shares for so long as such conflict or inconsistency remains outstanding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify">Subject to Section 3.8 of the Plan, the Option granted pursuant to this Option Agreement may only be exercised during the lifetime
of the Optionee by the Optionee personally and, subject to Section 5.3 of the Plan, no assignment or transfer of the Option, whether
voluntary, involuntary, by operation of law or otherwise, vests any interest or right in such Option whatsoever in any assignee
or transferee, and immediately upon any assignment or transfer or any attempt to make such assignment or transfer, the Option granted
hereunder terminates and is of no further force or effect. Complete details of this restriction are set out in the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">9.</TD><TD>The Optionee hereby agrees that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any rule, regulation or determination, including the interpretation by the Plan Administrator of the Plan, the Option granted
hereunder and the exercise thereof, is final and conclusive for all purposes and binding on all persons including the Company and
the Optionee; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the grant of the Option does not affect in any way the right of the Company or any Designated Affiliate to terminate the employment
or service of the Optionee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify">This Option Agreement has been made in and is to be construed under and in accordance with the laws of the Province of Ontario
and the laws of Canada applicable therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt .5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-indent: 0in">PROFOUND MEDICAL CORP.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 45%; font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">I have read the foregoing Option
Agreement and hereby accept the Option to purchase Common Shares in accordance with and subject to the terms and conditions of
such agreement and the Plan. I understand that I may review the complete text of the Plan by contacting the Secretary of the Company.
I agree to be bound by the terms and conditions of the Plan governing the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date Accepted</TD>
    <TD>&nbsp;</TD>
    <TD>Optionee&rsquo;s Signature</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-left: 0">Optionee&rsquo;s Name</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please Print)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SCHEDULE B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Share Option Plan Exercise Notice Form
 &ndash; Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">I, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
hereby exercise the option</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113pt">(print name)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;common
shares (each, a &ldquo;<B>Common Share</B>&rdquo;) in the capital of Profound Medical Corp. (the &ldquo;<B>Company</B>&rdquo;)
at a purchase price of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> per Common Share. This
Exercise Notice is delivered in respect of the option to purchase <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
Common Shares in the capital of the Company that was granted to me on <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
pursuant to the Option Agreement entered into between the Company and me. In connection with the foregoing, I enclose a certified
cheque, bank draft or money order payable to the Company in the amount of $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
as full payment for the Common Shares to be received upon exercise of the Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">I understand that my exercise of
the option to purchase the number of Common Shares indicated above is subject to the satisfaction of all applicable withholding
taxes or other withholding liabilities as the Company may determine to be necessary or desirable in respect of such exercise. I
further understand that I may be required to make such payment in connection with the exercise of my options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date</TD>
    <TD>&nbsp;</TD>
    <TD>Optionee&rsquo;s Signature</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>17
<FILENAME>tv526458_ex4-11.htm
<DESCRIPTION>EXHIBIT 4.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Execution Copy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tv526458_ex4-11img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>AMENDED AND RESTATED EMPLOYMENT
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the &ldquo;<B>Agreement</B>&rdquo;)
dated as of the 1st day of January, 2018 (the &ldquo;<B>Effective Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BETWEEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AND:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ARUN MENAWAT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>(the &ldquo;Employee&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS the Company and the Employee entered into a letter agreement
as to employment on August&nbsp;12, 2016 (the &ldquo;<B>Original Agreement</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHEREAS the Company and the Employee wish to amend and restate
the Original Agreement on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOW THEREFORE</B> in consideration of the covenants and agreements
herein, the sufficiency of which is acknowledged by each of the parties, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD STYLE="text-align: justify"><U>EMPLOYMENT</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.1</TD><TD STYLE="text-align: justify"><B>Effectiveness of the Agreement:</B> The terms and conditions
of employment of the Employee by the Company prior to the Effective Date shall be governed by the Original Agreement and the attachments
and exhibits thereto, and as of the Effective Date will be governed by the Agreement. The Employee&rsquo;s employment with the
Company commenced on August 15, 2016 and will continue until this Agreement is terminated in accordance with section 4 herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.2</TD><TD STYLE="text-align: justify"><B>Title:</B> The Company agrees to continue to employ
the Employee as Chief Executive Officer upon the terms and conditions set out in this Agreement. The Employee will report to the
board of directors of the Company (the &ldquo;<B>Board</B>&rdquo;). The Employee acknowledges that he shall undertake such duties
and responsibilities for the Company and its affiliates in connection with and commensurate with the Employee&rsquo;s position
as are determined by the Board. The Employee further acknowledges the Company may re-assign, re-allocate, or re-organize the Employee&rsquo;s
duties and responsibilities if reasonable based on changing circumstances, provided such duties and responsibilities are consistent
with the role of a Chief Executive Officer and do not reflect a material change in the Employee&rsquo;s status, duties or reporting
relationship.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.3</TD><TD STYLE="text-align: justify"><B>Service:</B> During the term of this Agreement, in addition
to the Employee&rsquo;s common law duties to the Company, the Employee covenants and agrees as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Loyalty
to the Company</B></FONT><B>:</B> Throughout the Employee&rsquo;s employment, the Employee will faithfully serve the Company and
use the Employee&rsquo;s best efforts to promote the business of the Company. The Employee will act honestly and in good faith,
in the best interests of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><B>Service:</B> The Employee shall devote his full working
time and attention to the affairs of the Company. The Employee shall not engage in any other business, profession or occupation,
or become an officer, employee, contractor for service, agent, or representative of any other company, partnership, firm, person,
organization, or enterprise during the term of this Agreement, provided that the Employee may participate on boards of directors
of other organizations (to a maximum of two (2) at any one time) and in business associations, charitable organizations or other
similar organizations, as may be approved by the Board in its discretion, acting reasonably, and provided that such participation
does not interfere with the proper discharge of his duties to the Company. The Employee is currently a director of the boards
set forth on <B>Exhibit A</B> hereto and also involved in business associations, charitable organizations or other similar organizations
as set forth on <B>Exhibit&nbsp;A</B> hereto. The Parties acknowledge that, without limitation to further activities that the
Employee may perform, the Board has approved of the Employee&rsquo;s involvement in the entities and activities set forth on <B>Exhibit
A</B> hereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>No
Personal Benefit</B></FONT><B>:</B> The Employee will not receive or accept for the Employee&rsquo;s own benefit or for any other
person or entity&rsquo;s benefit, either directly or indirectly, any commission, rebate, discount, gratuity or profit from any
person or entity having or proposing to have one or more business transactions with the Company, without the prior approval of
the Company, except as permitted by the Company policy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Business
Opportunities</B></FONT><B>:</B> During the Employee&rsquo;s employment with the Company, the Employee will, to the extent reasonably
practicable, communicate and channel to the Company all knowledge, business and customer contacts and any other information that
could concern or be in any way beneficial to the business of the Company. Any such information communicated to the Company as
aforesaid will be and remain the property of the Company notwithstanding any subsequent termination of the Employee&rsquo;s employment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Place
of Work</B></FONT><B>:</B> The Employee will work from the Company&rsquo;s premises located in 2400&nbsp;Skymark Avenue, Unit
#6, Mississauga, Ontario L4W 5K5 and it is anticipated that the Employee will be required to travel (both domestically and internationally)
in the course of performing the Employee&rsquo;s duties. In addition, it is anticipated that the Company will increase its focus
on sales in the U.S., and the Employee may relocate to the Company&rsquo;s U.S. headquarters, if and when appropriate, as determined
by the Employee and the Board, acting reasonably. In the event of such relocation, the Company and the Employee will discuss any
amendments to this Agreement as appropriate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(f)</TD><TD STYLE="text-align: justify"><B>Pre-existing Obligations:</B> The Employee is hereby
requested and directed by the Company to comply with any existing common law, contractual or statutory obligations to the Employee&rsquo;s
former employer and to any other person or entity. The Company is not employing the Employee to obtain the confidential information
or business opportunities of the Employee&rsquo;s former employer or any other person or entity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.4</TD><TD STYLE="text-align: justify"><B>Directorship and Offices:</B> Upon the termination of
employment with the Company for any reason, the Employee will immediately resign any directorship or office the Employee may hold
in the Company or any parent, subsidiary or affiliated companies of the Company and, except as provided expressly in this Agreement,
the Employee will not be entitled to receive any written notice of termination or payment in lieu of notice, or to receive any
severance pay, damages or compensation for loss of any directorship, office or otherwise. The Employee agrees that failure to
tender such resignation(s) will amount to cause for termination, for which the Company may treat the employment as being terminated
for after-acquired cause. Notwithstanding the foregoing, the termination of employment will not automatically disqualify the Employee
from serving as a director.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.5</TD><TD STYLE="text-align: justify"><B>Exclusion/Debarment:</B> The Employee represents and
warrants that the Employee has never been, and as a condition of continued employment shall never be, during the term of this
Agreement, excluded from any contracting by any Canadian or United States government agency or authority. The Employee further
represents and warrants that the Employee is not subject to any final adverse action, as that term is defined in 42 U.S.C. &sect;
1320a-7e(g), and that no final adverse action has previously occurred or is pending or threatened against the Employee. The Employee
represents and warrants that the Employee is not under investigation by the FDA or any other Canadian, United States or foreign
regulatory agency nor has the Employee been debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded
by any Canadian, United States or foreign government department or agency.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.6</TD><TD STYLE="text-align: justify"><B>Company Policy:</B> The Employee acknowledges and agrees
that the employment relationship will be governed by the standards and terms established by the Company&rsquo;s policies as they
are established from time to time and the Employee agrees to comply with the terms of such policies which may be introduced, amended,
deleted or modified in the sole discretion of the Company, provided that doing so does not constitute a material change in the
Employee&rsquo;s terms of employment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.7</TD><TD STYLE="text-align: justify"><B>Professional Conduct:</B> The Employee acknowledges
and agrees that effective performance of the Employee&rsquo;s duties requires integrity and the Company&rsquo;s confidence in
the Employee&rsquo;s working relationships with other employees of the Company and with all other persons with whom the Employee
deals in the course of employment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD STYLE="text-align: justify"><U>COMPENSATION</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.1</TD><TD STYLE="text-align: justify"><B>Base Salary:</B> The Employee will earn an annual salary
equivalent to US$500,000.00 (the &ldquo;<B>Base Salary</B>&rdquo;), less applicable deductions, payable in arrears for all services
and work the Employee performs for the Company. Any increases will be in the discretion of the Board. The Base Salary will be
payable in accordance with the Company&rsquo;s normal payroll practices and will be payable in Canadian dollars at the U.S./Canadian
dollar Bank of Canada noon exchange rate on the applicable payroll date. The Employee&rsquo;s hours and schedule may change from
time to time depending on the Company&rsquo;s business needs.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.2</TD><TD STYLE="text-align: justify"><B>Annual Discretionary Bonus:</B> Provided the Employee
remains an employee of the Company in good standing and the Employee has not received or given notice of termination, for each
calendar year, the Employee will be eligible to receive an annual bonus of up to 65% of the Employee&rsquo;s Base Salary based
on the assessment of the Board of the Employee&rsquo;s and the Company&rsquo;s achievement of certain milestones and objectives
determined by the Board. Such milestones and objectives (including the evaluation of achievement thereof), and the bonus amount,
will be at the sole discretion of the Board and will be payable in accordance with the Company&rsquo;s standard payroll policies,
subject to applicable payroll deductions and withholdings. Such bonus shall be paid within ninety (90)<B>&nbsp;</B>days after
the end of the applicable calendar year.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.3</TD><TD STYLE="text-align: justify"><B>Stock Options:</B> The options to purchase common shares
of the Company previously received by the Employee (&ldquo;<B>Stock Options</B>&rdquo;) shall continue to vest during the term
of this Agreement in accordance with their terms. The Company shall consider compensation as a whole annually, including stock
incentives and the number of options, of chief executive officers of comparable companies when considering compensation or the
grant of stock options for the Employee by reference to comparable companies and information and/or reports from independent compensation
consultants (which information and reports will be shared with the Employee).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.4</TD><TD STYLE="text-align: justify"><B>Benefits:</B> The Employee will be entitled to participate
in the standard insurance plans and other benefit programs (the &ldquo;<B>Employee Benefits</B>&rdquo;) which the Company may
offer to executive level employees from time-to-time. The Company reserves the right to unilaterally revise the terms of the Employee
Benefits, to change carriers, or to eliminate any Employee Benefits altogether. The Employee Benefits will be provided in accordance
with the formal plan documents or policies and any issues with respect to entitlement or payment of benefits under any of the
Employee Benefits will be governed by the terms of such documents or policies establishing the benefits in issue and will be a
matter between the Employee and the insurer. The Company&rsquo;s liability with respect to the Employee Benefits will be limited
to the payment of its share of applicable premiums.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.5</TD><TD STYLE="text-align: justify"><B>Car Allowance:</B> The Company shall provide the Employee
with a monthly car allowance of CDN$1,000 in accordance with the Company&rsquo;s payroll policy, as amended from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.6</TD><TD STYLE="text-align: justify"><B>Expenses:</B> The Company will reimburse the Employee
for all reasonable business expenses actually and exclusively incurred in connection with the performance of duties under this
Agreement, provided such expenses are incurred and accounted for in accordance with the general policies and procedures of the
Company, as established from time to time.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.7</TD><TD STYLE="text-align: justify"><B>Statutory Holidays:</B> The Company recognizes the statutory
holidays observed in Ontario.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">2.8</TD><TD STYLE="text-align: justify"><B>Vacation:</B> The Employee shall be entitled to 4 weeks
of paid vacation per annum, to be taken at such reasonable times as the Company shall in its discretion permit and in accordance
with the Company&rsquo;s vacation policy in effect from time to time. Vacation entitlement for any partial year of employment
shall be pro-rated based on the portion of the year worked by the Employee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD STYLE="text-align: justify"><U>TERMINATION OF AGREEMENT AND EMPLOYMENT</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.1</TD><TD STYLE="text-align: justify"><B>Obligations Upon Termination:</B> Upon termination of
the Employee&rsquo;s employment, for any reason:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">the Company shall pay the Employee all unpaid Base Salary
and vacation pay earned up to and including the Employee&rsquo;s last day of employment (the &ldquo;<B>Termination Date</B>&rdquo;),
inclusive of any vacation pay required by <I>Ontario Employment Standards Act 2000</I>, as amended;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">all benefits coverage and other perquisites of the Employee&rsquo;s
employment shall cease on the later of the Termination Date or as specified in 3.3(a);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">all files, computer disks, information and documents pertaining
to the Company&rsquo;s business shall remain the property of the Company, and shall promptly be delivered by the Employee to the
Company&rsquo;s office, and no copy, duplication or reproduction of any kind whatsoever shall be made of such files, computer
disks, information or documents, or retained by the Employee, without the express written consent of the Company. The Employee
agrees to deliver all electronic information to the Company and to destroy any copies held by the Employee belonging to the Company.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.2</TD><TD STYLE="text-align: justify"><B>Termination by the Employee:</B> The Employee may terminate
this Agreement at any time by providing the Company with ninety (90) days&rsquo; prior written notice. Upon receipt of such notice,
the Company may at any time terminate the employment of the Employee and pay the Employee the amount of Base Salary and continue
all Employee Benefits the Employee would have otherwise received during the balance of the aforementioned notice period.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.3</TD><TD STYLE="text-align: justify"><B>Termination by the Company:</B> The Company may terminate
the Employee&rsquo;s employment at any time:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">without Cause by providing the Employee with the greater
of: (i) pay in lieu of notice, benefit continuation (and severance pay, if applicable) that is required by the Ontario <I>Employment
Standards Act, 2000 </I>as amended or (ii) (A) twelve (12) months of pay of Base Salary in lieu of notice (the &ldquo;<B>Severance
Period</B>&rdquo;) and (B) an amount equal to the then current target annual bonus prorated based on the number of days elapsed
in the calendar year until the date of termination as a percentage of the total number of days in such calendar year. The Employee
will continue to provide reasonable services to the Company on an as-needed and part-time basis for a period of up to three (3)
months following the termination of his employment (the &ldquo;<B>Transition Period</B>&rdquo;), including assistance with transition
of duties, unless the requirement for active service is expressly waived in whole or in part by the Company, in its sole discretion.
The Employee agrees that the Company may, in its sole discretion, limit or discontinue the Executive&rsquo;s access to business
records and Confidential Information during the Transition Period. The Employee agrees that any services provided to the Company
during the Transition Period shall be for no additional compensation in excess of the severance payments and benefits contemplated
under this Agreement. Regardless of whether or not the Employee provides active service during the Transition Period, the Employee
shall continue to abide by all obligations owing under this Agreement. The payments due the Employee hereunder are not subject
to mitigation if the Employee receives compensation during the Severance Period from third parties as long as the Employee provides
the services during the Transition Period as set forth herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">for frustration of contract upon the death of the Employee
or any incapacitation of the Employee that constitutes an undue hardship for the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">at any time for just Cause, without notice or pay in lieu
of notice or any other form of compensation, severance pay or damages. For the purposes of this Agreement, &ldquo;<B>Cause</B>&rdquo;
includes:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">i.</TD><TD STYLE="text-align: justify">any material breach of the provisions of this Agreement
or the Company&rsquo;s policies by the Employee if the Company has provided the Employee, with written notice of such breach and
such breach has not been remedied within thirty (30) days thereafter;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">ii.</TD><TD STYLE="text-align: justify">any intentional or grossly negligent disclosure of any
confidential information by the Employee;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">iii.</TD><TD STYLE="text-align: justify">any fraud, misappropriation of the property or funds of
the Company or its subsidiaries, embezzlement, or other similar acts of dishonesty;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">iv.</TD><TD STYLE="text-align: justify">the willful allowance by the Employee of the Employee&rsquo;s
duty to the Company and the Employee&rsquo;s personal interests to come into conflict in a material way in relation to any transaction
or matter that is of a substantial nature, other than conflicts which are fully disclosed and approved by the Board;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">v.</TD><TD STYLE="text-align: justify">the Employee&rsquo;s criminal, or other conviction of any
criminal summary conviction offence or indictable offence that is detrimental to the business or reputation of the Company;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">vi.</TD><TD STYLE="text-align: justify">if the Employee&rsquo;s misconduct causes the Employee
to be subject to a final and non-appealable enforcement order (or regulatory settlement in respect thereof) concerning a securities,
financial services, health or other regulatory offence that is detrimental to the business or reputation of the Company; and/or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">vii.</TD><TD STYLE="text-align: justify">any and all commissions, omissions or other conduct which
would constitute just cause at law, in addition to the specified causes noted above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.4</TD><TD STYLE="text-align: justify"><B>Termination in Connection with Change In Control:</B>
This Agreement terminates if it is not assumed by the successor corporation (or affiliate thereto) upon a Change in Control (as
defined below).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">&ldquo;Change in Control&rdquo; means a reorganization
or merger of the Company with or into any other corporation or corporations or on an acquisition of securities of the Company
(excluding an equity financing of the Company with the principal purpose of raising capital or a merger with any subsidiary or
other affiliate) in which transaction the Company&rsquo;s shareholders immediately prior to such transaction own immediately after
such transaction, less than 50% of the voting power of the surviving corporation or its parent, and/or (ii) the sale or disposition
by the Company to an unrelated third party of substantially all of its business and assets. Without limiting the foregoing, a
transaction will not constitute a Change in Control if (x) its sole purpose is to change the jurisdiction of the Company&rsquo;s
incorporation, or (y) its sole purpose is to create a holding company or other entity that will be owned in substantially the
same proportions by the persons who held the Company&rsquo;s securities immediately prior to such transaction.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If the Company terminates this Agreement other than for
Cause in advance of the closing relating to a Change of Control, or the Company&rsquo;s successor terminates this Agreement other
than for Cause within 12 months following the occurrence of a Change in Control, and the Employee signs and returns to the Company
without revocation a release prepared by the Company of all legally waivable claims related to or arising from the Employee&rsquo;s
employment with the Company, then (i)&nbsp;the Company shall pay the Employee a sum equal to (A) twenty-four (24) months of the
Employee&rsquo;s then-current annual Base Salary and (B) the then current annual target bonus and (ii)&nbsp;the Stock Options
shall vest as set forth in Section 3.4(d) (collectively, the &ldquo;Change in Control Benefits&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If, within twelve (12) months following a Change in Control,
there is a material diminution of the Employee&rsquo;s role in the company, change in work location of more than 50 kilometers
(except as contemplated pursuant to Section 1.3(e) hereto), diminution of status, any materially detrimental change in compensation
(including options and bonus) or benefits (considered as a whole), or diminution of reporting structure, the Employee shall have
the right to resign and receive the Change in Control Benefits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">If the Employee is entitled to Change in Control Benefits,
then any unvested Stock Options shall immediately vest. If any provision of this Agreement conflicts with a provisions of the
Stock Options or applicable stock option plan, the provision more favorable to the Employee shall govern.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.5</TD><TD STYLE="text-align: justify"><B>Timing of Payments:</B> All amounts payable hereunder
in respect of Base Salary or with respect to payments made under the Ontario <I>Employment Standards Act, 2000</I>, as amended,
shall be paid in installments in accordance with the Company&rsquo;s normal payroll practices. Payments in respect of annual or
prorated bonuses shall be paid at the time the annual bonus would otherwise be paid.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>No
Implied Entitlement</B></FONT><B>:</B> Other than as expressly provided herein, the Employee will not be entitled to receive any
further pay or compensation, severance pay, notice, payment in lieu of notice, incentives, bonuses, benefits or damages of any
kind from the Company or from any affiliate of the Company. Any payment in lieu of the Severance Period payment provided to the
Employee will be inclusive of any entitlements upon termination or severance pay pursuant to the Ontario <I>Employment Standards
Act, 2000</I> as amended, contract, tort, common law or otherwise, and will be subject to statutory withholdings. The Employee
will not be entitled to receive any further pay or compensation (except for pay, if any, accrued and owing under this Agreement
up to the date of termination of employment) from the Company, and for clarity, without limiting the foregoing, the Employee will
not be entitled to any bonus or pro rata bonus payment that has not already been awarded to the Employee by the Company, except
as set out in paragraph 3.3(a) or except for that which was specified as part of the Change in Control Benefits.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Continued
Effect</B></FONT><B>:</B> Notwithstanding any changes in the terms and conditions of the Employee&rsquo;s employment which may
occur in the future, including any changes in position, duties or compensation, the termination provisions in this Agreement will
continue to be in effect for the duration of the Employee&rsquo;s employment&nbsp;with the Company unless otherwise amended in
writing and signed by the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.8</TD><TD STYLE="text-align: justify"><B>Obligations Upon Termination:</B> The Employee agrees that he shall not be entitled to
                                                                             receive any severance fee or other benefits under Section 3 of this Agreement if the Employee breaches any of his obligations
                                                                             arising under Sections 4, 5, 6,  7, 8, 9 and 11 hereof. The Employee acknowledges that until a release in the form of <B>Exhibit
                                                                             B</B> hereto (a &ldquo;<B>Release</B>&rdquo;) is timely executed and delivered to the Company, the Company will not be
                                                                             obligated to make any severance payments or provide any other benefits due under this Agreement following termination of the
                                                                             Employee. The Employee further acknowledges that if the Release is not timely executed and delivered to the Company, the
                                                                             severance payments and other benefits described in this Section 3 shall be forfeited, except as required by statutory minimum
                                                                             standards.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">4.</FONT></TD><TD STYLE="text-align: justify"><U>CONFIDENTIAL INFORMATION PROTECTIONS</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.1</TD><TD STYLE="text-align: justify">At all times during and after the Employee&rsquo;s employment,
the Employee will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&rsquo;s Confidential
Information (defined below), except as may be required in connection with the Employee&rsquo;s work for Company, or as expressly
authorized by the Board. Unless forming part of the Employee&rsquo;s customary duties for the Company, the Employee will obtain
the written approval of the Board before publishing or submitting for publication any material (written, oral, or otherwise) that
relates to the Employee&rsquo;s work at Company and/or incorporates any Confidential Information. The Employee hereby assigns
to Company any rights the Employee may have or acquire in any and all Confidential Information and recognize that all Confidential
Information shall be the sole and exclusive property of Company and its assigns.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.2</TD><TD STYLE="text-align: justify">The term &ldquo;Confidential Information&rdquo; shall mean
any and all confidential knowledge, data or information related to Company&rsquo;s or its affiliates business or its actual or
demonstrably anticipated research or development, including without limitation (a) trade secrets, inventions, ideas, processes,
computer source and object code, data, formulae, programs, other works of authorship, know-how, improvements, discoveries, developments,
designs, and techniques; (b) information regarding products, services, plans for research and development, marketing and business
plans, budgets, financial statements, contracts, prices, suppliers, employees and customers; (c) information regarding the skills
and compensation of Company&rsquo;s employees, contractors, and any other service providers of Company; and (d) the existence
of any business discussions, negotiations, or agreements between Company and any third party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.3</TD><TD STYLE="text-align: justify">The Employee understands that Company has received and
in the future will receive from third parties confidential or proprietary information <B>(</B>&ldquo;<B>Third Party Information</B>&rdquo;)
subject to a duty on Company&rsquo;s part to maintain the confidentiality of such information and to use it only for certain limited
purposes. During and after the term of the Employee&rsquo;s employment, the Employee will hold Third Party Information in strict
confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with
their work for Company) or use, Third Party Information, except in connection with the Employee&rsquo;s work for Company or unless
expressly authorized by an officer of Company in writing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">4.4</TD><TD STYLE="text-align: justify">The Employee represents that employment by Company does
not and will not breach any agreement with any former employer, including any non-compete agreement or any agreement to keep in
confidence or refrain from using information acquired by the Employee prior to employment by Company. The Employee further represents
that the Employee has not entered into, and will not enter into, any agreement, either written or oral, in conflict with the Employee&rsquo;s
obligations under this Agreement. During employment by Company, the Employee will not improperly make use of, or disclose, any
information or trade secrets of any former employer or other third party, nor will the Employee bring onto the premises of Company
or use any unpublished documents or any property belonging to any former employer or other third party, in violation of any lawful
agreements with that former employer or third party. The Employee will use in the performance of the Employee&rsquo;s duties only
information that is generally known and used by persons with training and experience comparable to the Employee&rsquo;s own, is
common knowledge in the industry or otherwise legally in the public domain, or is otherwise provided or developed by Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD STYLE="text-align: justify"><U>INVENTIONS</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.1</TD><TD STYLE="text-align: justify">As used in this Agreement, the term &ldquo;<B>Invention</B>&rdquo;
means any ideas, concepts, information, materials, processes, data, programs, know-how, improvements, discoveries, developments,
designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights in any of the items
listed above. The term &ldquo;<B>Intellectual Property Rights</B>&rdquo; means all trade secrets, copyrights, trademarks, mask
work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country. The term &ldquo;<B>Moral
Rights</B>&rdquo; means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the
laws of any jurisdiction or country.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.2</TD><TD STYLE="text-align: justify">The Employee has disclosed in <B>Exhibit C</B> a complete
list of all Inventions that (a) the Employee has, or has caused to be, alone or jointly with others, conceived, developed, or
reduced to practice prior to the commencement of the Employee&rsquo;s employment by Company; (b) in which the Employee has an
ownership interest or which the Employee has a license to use; (c) and that the Employee wishes to have excluded from the scope
of this Agreement (collectively referred to as &ldquo;<B>Prior Inventions</B>&rdquo;). If no Prior Inventions are listed in <B>Exhibit
C</B>, the Employee warrants that there are no Prior Inventions. The Employee agrees that the Employee will not incorporate, or
permit to be incorporated, Prior Inventions in any Company Inventions (defined below) without Company&rsquo;s prior written consent.
If, in the course of the Employee&rsquo;s employment with Company, the Employee incorporates a Prior Invention into a Company
process, machine or other work, the Employee hereby grants Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable
and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works
of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have
made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Prior Invention.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.3</TD><TD STYLE="text-align: justify">Inventions assigned to the Company or to a third party
as directed by the Company pursuant to the subsection 5.5 are referred to in this Agreement as &ldquo;<B>Company Inventions</B>&rdquo;.
Subject to the subsection 5.5 (including the proviso set forth therein) and the Prior Inventions Employee has set forth in <B>Exhibit
C</B>, the Employee hereby assigns and agrees to assign in the future (when any such Inventions or Intellectual Property Rights
are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all rights, title, and interest
in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice,
or learned by the Employee, either alone or with others, during the period of the Employee&rsquo;s employment by the Company.
Any assignment of Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all
Moral Rights. To the extent such Moral Rights cannot be assigned to the Company and to the extent the following is allowed by
the laws in any country where Moral Rights exist, the Employee hereby unconditionally and irrevocably waives the enforcement of
such Moral Rights, and all claims and causes of action of any kind against the Company or related to the Company&rsquo;s customers,
with respect to such rights. The Employee further acknowledges and agrees that neither the Employee&rsquo;s successors-in-interest
nor legal heirs retain any Moral Rights in any Inventions (and any Intellectual Property Rights with respect thereto).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.4</TD><TD STYLE="text-align: justify">During the period of employment, the Employee will promptly
and fully disclose to the Company in writing (a) all Inventions authored, conceived, or reduced to practice by the Employee, either
alone or with others, and (b) all patent applications filed by the Employee or in which the Employee is named as an inventor or
co-inventor; provided, however, that such disclosure obligation does not apply to Inventions (or Intellectual Property Rights
with respect thereto) which are not directly or indirectly related to the Company&rsquo;s then current or future business or are
not invented with Company resources or during Employee&rsquo;s working hours. The Employee agrees to keep and maintain adequate
and current records (in the form of notes, sketches, drawings and in any other form that is required by the Company) of all Inventions
made by the Employee during the period of the Employee&rsquo;s employment by the Company, which records shall be available to,
and remain the sole property of, the Company at all times.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.5</TD><TD STYLE="text-align: justify">The Employee agrees that, as directed by the Company, the
Employee will assign to the Company or a third party, including without limitation, all rights, title, and interest in and to
any particular Company Invention; provided, however, it is understood that the Company will not elect to direct such assignment
of a Company Invention if it is not directly or indirectly related to the Company&rsquo;s then current or future business or was
not invented with Company resources or during Employee&rsquo;s working hours.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.6</TD><TD STYLE="text-align: justify">During and after the period of employment and at the Company&rsquo;s
request and expense, the Employee will provide reasonable assistance to the Company, including consenting to and joining in any
action, to obtain and enforce Canadian, United States and foreign Intellectual Property Rights and Moral Rights relating to Company
Inventions in all countries. If the Company is unable to secure the Employee&rsquo;s signature on any document needed in connection
with such purposes, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents
as the Employee&rsquo;s agent and attorney in fact, which appointment is coupled with an interest, to act on the Employee&rsquo;s
behalf to execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the same
legal force and effect as if executed by the Employee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">5.7</TD><TD STYLE="text-align: justify">The Employee agrees that the Employee will not incorporate
into any Company software or otherwise deliver to the Company any software code licensed under the GNU General Public License
or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such
code on the disclosure, licensing, or distribution of any source code owned or licensed by the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">6.</FONT></TD><TD STYLE="text-align: justify"><B><U>RETURN
                                         OF COMPANY PROPERTY</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">6.1</TD><TD STYLE="text-align: justify">Without limiting the <FONT STYLE="font-family: Times New Roman, Times, Serif">provisions
</FONT>of Section&nbsp;3.1(c), upon termination of the Employee&rsquo;s employment or upon the Company&rsquo;s request at any
other time, the Employee will deliver to the Company all of the Company&rsquo;s property, equipment, and documents, together with
all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential Information
and certify in writing that the Employee has fully complied with the foregoing obligation. The Employee agrees that the Employee
will not copy, delete, or alter any information contained upon any Company computer or Company equipment before the Employee returns
it to the Company. In addition, if the Employee has used any personal computer, server, or e-mail system to receive, store, review,
prepare or transmit any Company information, including but not limited to, Confidential Information, the Employee agrees to provide
the Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential
Information from those systems; and the Employee agrees to provide the Company access to the Employee&rsquo;s system as reasonably
requested to verify that the necessary copying and/or deletion is completed.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">7.</FONT></TD><TD STYLE="text-align: justify"><U>NON-COMPETITION/NON-SOLICITATION</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.1</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of
the Employee&rsquo;s employment by the Company and for one (1) year after termination of such employment for any reason, the Employee
will not, without the Company&rsquo;s express written consent, anywhere in the world, be employed by or contribute to any business
activity that is competitive with the business of the Company or involves the use of real-time magnetic resonance imaging or ultrasound
or similar technologies in the delivery of ablative tools.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">7.2</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of
the Employee&rsquo;s employment by the Company and for one (1) year after termination of such employment for any reason, the Employee
will not, either directly or indirectly, solicit or attempt to solicit any employee, independent contractor, or consultant of
the Company to terminate his, her or its relationship with Company in order to become an employee, consultant, or independent
contractor to or for any other person or entity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">8.</FONT></TD><TD STYLE="text-align: justify"><U>NOTIFICATION OF NEW EMPLOYER</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">8.1</TD><TD STYLE="text-align: justify">After the termination of this Agreement, the Employee consents
to the notification of any new employer of the Employee&rsquo;s rights and obligations under this Agreement, by the Company providing
a copy of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">9.</FONT></TD><TD STYLE="text-align: justify"><U>INJUNCTIVE RELIEF</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">9.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that, because the Employee&rsquo;s
services are personal and unique and because the Employee will have access to the Confidential Information of the Company, any
breach of this Agreement would cause irreparable injury to the Company for which monetary damages would not be an adequate remedy
and, therefore, will entitle the Company to injunctive relief (including specific performance). The rights and remedies provided
to each party in this Agreement are cumulative and in addition to any other rights and remedies available to such party at law
or in equity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">10.</FONT></TD><TD STYLE="text-align: justify"><U>PUBLICITY</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">10.1</TD><TD STYLE="text-align: justify">Except to the extent required by the Employee&rsquo;s duties
or customarily performed by the Employee, the Employee shall not, without the prior written consent of the Company, make or give
any public announcements, press releases or statements to the public or the press regarding the Employee&rsquo;s work or the Company&rsquo;s
business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">11.</FONT></TD><TD STYLE="text-align: justify"><U>NOTICES</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">11.1</TD><TD STYLE="text-align: justify">All notices, requests, demands and other communications
to be given pursuant to the terms of this Agreement shall be in writing and shall be deemed to have been duly given (i) on the
date of delivery if personally delivered or sent by a recognized overnight courier or (ii) on the date of transmission if sent
by email (provided notice is then also promptly delivered personally or by a recognized overnight courier), in each case to the
parties at the addresses listed below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If to the Employee, at the Employee&rsquo;s then current
address in the Company&rsquo;s payroll records;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If to the Company:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Profound Medical Corp.<BR>
2400 Skymark Avenue, Unit 6<BR>
Mississauga, ON L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention</FONT>:&nbsp;&nbsp;&nbsp;&nbsp;Chair
of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;damian@genesyscapital.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Each party may change its address for receipt of notice
by giving notice of the change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">12.</FONT></TD><TD STYLE="text-align: justify"><U>SURVIVAL</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.1</TD><TD STYLE="text-align: justify">The Employee&rsquo;s obligations under this Agreement shall
survive the termination of the Employee&rsquo;s employment, regardless of the manner or reason for termination, including, without
limitation, those set forth in Sections&nbsp;4 through 7 hereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">12.2</TD><TD STYLE="text-align: justify">The assignment of this Agreement by the Company to any
successor or other assignee and shall be binding upon the Employee&rsquo;s heirs and legal representatives.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">13.</FONT></TD><TD STYLE="text-align: justify"><U>SEVERABILITY</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">13.1</TD><TD STYLE="text-align: justify">If any provision of this Agreement is, for any reason,
held to be invalid or unenforceable, the other provisions of this Agreement will remain enforceable and the invalid or unenforceable
provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">14.</FONT></TD><TD STYLE="text-align: justify"><U>WAIVER</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">14.1</TD><TD STYLE="text-align: justify">Any waiver or failure to enforce any provision of this
Agreement on one occasion will not be deemed a waiver of that provision or any other provision on any other occasion.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">15.</FONT></TD><TD STYLE="text-align: justify"><U>ASSIGNMENT</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">15.1</TD><TD STYLE="text-align: justify">The Company may assign this Agreement to (i) an affiliate,
subsidiary, related company or partnership without prior notice or consent of the Employee, or (ii) a new employer in connection
with any transaction or reorganization; provided that any such successor or assignee expressly assumes in writing the Company&rsquo;s
obligations under this Agreement and has responsibility for managing the underlying business of the Company. The Employee may
not assign any of his rights nor delegate any of the duties hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">16.</FONT></TD><TD STYLE="text-align: justify"><U>ENTIRE AGREEMENT</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16.1</TD><TD STYLE="text-align: justify">This Agreement is the final, complete and exclusive agreement
of the parties with respect to the subject matter hereof and supersedes and merges all prior communications between us with respect
to such matters. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be
effective unless in writing and signed by the Employee and the Company. Any subsequent change or changes in duties, salary or
compensation will not affect the validity or scope of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">17.</FONT></TD><TD STYLE="text-align: justify"><U>HEADINGS</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">17.1</TD><TD STYLE="text-align: justify">The headings utilized in this Agreement are for convenience
only and are not to be construed in any way as additions or limitations of the covenants and agreements contained in this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">18.</FONT></TD><TD STYLE="text-align: justify"><U>INDEPENDENT LEGAL ADVICE</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">18.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that the Employee has read and
understands this Agreement, and acknowledges that an opportunity was provided to obtain legal advice about it. The Company shall
reimburse the Employee for the reasonable costs of obtaining legal advice regarding this Agreement, but in no event more than
CDN$3,500 plus HST or such reasonable amount over and above CDN$3,500 plus HST.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">19.</FONT></TD><TD STYLE="text-align: justify"><U>COUNTERPARTS</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">19.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This Agreement may be
executed in two or more counterparts, each of which will be deemed to be an original and all of which will constitute one Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">20.</FONT></TD><TD STYLE="text-align: justify"><U>LAWS</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">20.1</TD><TD STYLE="text-align: justify">This Agreement shall be governed by and interpreted in
accordance with the laws of Ontario and the laws of Canada applicable therein. The Employee and the Company hereby attorn to the
exclusive jurisdiction of the superior courts of Ontario to resolve any dispute arising from this Agreement except to the extent
the Company seeks injunctive relief outside Ontario where applicable to enforce the Employee&rsquo;s covenants hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to Follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the parties have duly
executed this Agreement as of the __<U>1st</U>___ day of ________<U>January</U>_______, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><B>Signed, Sealed and Delivered</B> in the presence of:</TD>
    <TD STYLE="width: 4%; text-align: center">)</TD>
    <TD STYLE="width: 48%; padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Maureen Belza</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name (witness)</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">Maureen Belza</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Address</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">2460 Willowburne Drive</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">Director, Human Resources</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in; border-bottom: Black 1pt solid">/s/ Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Occupation</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in"><B>ARUN MENAWAT</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">)</TD>
    <TD STYLE="padding-left: 0.05in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Per:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Damian Lamb</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 38%">Damian Lamb</TD>
    <TD STYLE="width: 52%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chair of the Board</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>CURRENT
BOARD POSITIONS and Other Business Activities<BR>
Approved by the Company</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elminda Ltd, Chairman of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stereotexis Inc., Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Baylis Medical, Advisor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sudev Foundation, Advisor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>R E L
E A S E</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Arun Menawat of the City of ________, in the Province of
Ontario, for and in consideration of the sum of <FONT STYLE="background-color: lightgrey">*</FONT> ($<FONT STYLE="background-color: lightgrey">*</FONT>)
and other good and valuable consideration which is being delivered to me concurrently with the execution and delivery hereof (the
receipt and sufficiency of which is hereby acknowledged) do hereby remise, release and forever discharge <B>PROFOUND MEDICAL CORP.</B>
(hereinafter called the &ldquo;<B>Company</B>&rdquo;), its officers, directors, servants, employees and agents, including any related
or associated companies, and their heirs, executors, administrators, successors and assigns, as the case may be, of and from any
and all manner of actions, causes of action, suits, contracts, claims, damages, costs and expenses of any nature or kind whatsoever,
whether in law or in equity, which, as against the Company or such persons as aforesaid or any of them I have ever had, now have,
or at any time hereafter I or my personal representatives can, shall or may have, by reason of or arising out of the termination
of my employment with the Company or in any other way connected with my employment with the Company (except as otherwise set forth
below), and more specifically, without limiting the generality of the foregoing, any and all claims for damages for termination
of my employment, constructive termination of my employment, loss of position, loss of status, loss of future job opportunity,
loss of opportunity to enhance my reputation, the timing of the termination and the manner in which it was effected, loss of bonuses,
loss of benefits, including life insurance and short and long-term disability benefit coverage, and any other type of damages;
<U>provided, however</U>, that notwithstanding anything contained herein, this Release does not apply to any claims related to
(i)&nbsp;equity in the Company or its affiliates that I hold, directly or indirectly, including without limitation, the options
granted to me in connection with my employment with the Company, or (ii)&nbsp;any unpaid reimbursement of expenses and accrued
but unpaid salary or termination payments provided for in the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I FURTHER AGREE that this Release includes any and all claims
I may have arising under contract, the Ontario <I>Employment Standards Act</I>, <I>2000</I>, as amended, common law or other applicable
law related to my employment with the Company and that the consideration provided includes any amount that I may be entitled to
under such legislation and I agree to immediately withdraw any complaint as settled and not to file any complaint pursuant to such
legislation with respect to my employment or the termination of my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IT IS UNDERSTOOD that the Company has withheld income tax and
other statutory deductions from the aforesaid consideration and I agree to indemnify and hold harmless the Company from any further
assessment for income tax or other statutory deductions which may be made under statutory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IT IS FURTHER UNDERSTOOD that as a former officer of the Company
I owe a fiduciary duty to the Company and I agree that the Company will suffer irreparable harm if confidential information or
information unique to the Company is disclosed in any way by me without authorization of the Company and that I have returned to
the Company originals or copies of the Company&rsquo;s corporate records, files, financial documents, client lists, or any other
material that is related to the Company&rsquo;s business, clients, personnel or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IT IS FURTHER UNDERSTOOD AND AGREED that this is not to be construed
or considered as an admission of liability on the part of the Company. The terms of this Release set out the entire agreement between
myself and the Company and are intended to be contractual and not a mere recital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IT IS EXPRESSLY ACKNOWLEDGED that the contents, terms and effect
of this Release have been explained to me by my lawyer and are fully understood.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF I, Arun Menawat, have hereunto set my hand
and seal this ____ day of __________________, 20___ in the City of __________________, Province of Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Arun Menawat</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Exhibit</B></FONT><B>
C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>INVENTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prior
Inventions Disclosure. </B>The following is a complete list of all Prior Inventions (as provided in Subsection 5.2 of the attached
Employment Agreement):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify">None</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify">See immediately below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>18
<FILENAME>tv526458_ex4-12.htm
<DESCRIPTION>EXHIBIT 4.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.12</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="tv526458_ex4-12img01.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>EMPLOYMENT
AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent; text-align: justify">THIS
AGREEMENT dated as of the 10<SUP>th</SUP> day of April, 2018 (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Effective
Date&rdquo;), </B></FONT>with an expected start date between April 23, 2018 and May 7, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1pt"></TD><TD STYLE="width: 35pt">BETWEEN:</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt"><B>(the &ldquo;Employer&rdquo; or &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1pt"></TD><TD STYLE="width: 35pt">AND:</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>AARON DAVIDSON</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt"><B>(the &ldquo;Employee&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1pt"></TD><TD STYLE="width: 35pt">WHEREAS:</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">The Employer has offered to employ the Employee on the terms and conditions described in
                                                                 this Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">The Employee wishes to provide services to the Employer on such terms and conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>NOW
THEREFORE </B></FONT>in consideration of the covenants and agreements herein, the sufficiency of which is acknowledged by each
of the parties, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>EMPLOYMENT</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Start Date:
</B></FONT>The Employee&rsquo;s employment with the Company will commence on the Effective Date and will continue until this Agreement
is terminated in accordance with section 4 herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Title: </B></FONT>The
Employer agrees to employ the Employee as Chief Financial Officer and Senior Vice President of Corporate Development, upon the
terms and conditions set out in this Agreement. The Employee will report to the Chief Executive Officer (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;CEO&rdquo;).
</B></FONT>The Employee acknowledges that he shall undertake such duties and responsibilities for the Company and its affiliates
in connection with the Employee&rsquo;s position as are determined by the CEO from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Service: </B></FONT>During
the term of this Agreement, in addition to the Employee&rsquo;s common law duties to the Company, the Employee covenants and agrees
as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Loyalty to
the Company: </B></FONT>Throughout the Employee&rsquo;s employment, the Employee will well and faithfully serve the Company and
use the Employee&rsquo;s best efforts to promote the business of the Company. The Employee will act honestly and in good faith,
in the best <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-variant: normal">interests of the
Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Service: </B></FONT>The
Employee shall devote his full working time and attention to the affairs of the Company. The Employee shall not engage in any other
business, profession or occupation, or become an officer, employee, contractor for service, agent, or representative of any other
company, partnership, firm, person, organization, or enterprise during the term of this Agreement, provided that the Employee may,
with the consent of the CEO, which shall not be unreasonably withheld, (I) during a transition period expiring on the two (2) year
anniversary of the Effective Date (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Transition
Period&rdquo;) </B></FONT>(A) serve as a consultant to the Employee&rsquo;s prior employer on a limited time basis to aid in a
transition, and (B) serve as director to up to three (3) companies and (II) after the Transition Period, serve as a director of
up to two (2) companies. Notwithstanding the foregoing, the Employee will not, during the Employee&rsquo;s employment with the
Company, engage in any business, enterprise or activity that is contrary to or detracts from the due performance of the Employee&rsquo;s
duties or the business of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>No Personal
Benefit: </B></FONT>The Employee will not receive or accept for the Employee&rsquo;s own benefit or for any other person or entity&rsquo;s
benefit, either directly or indirectly, any commission, rebate, discount, gratuity or profit from any person or entity having or
proposing to have one or more business transactions with the Company, without the prior approval of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Business
                                         Opportunities: </B></FONT>During the Employee&rsquo;s employment with the Company, the
                                         Employee will communicate and channel to the Company all knowledge, business and customer
                                         contacts and any other information that could concern or be in any way beneficial to
                                         the business of the Company. Any such information communicated to the Company <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">as
                                         </FONT>aforesaid will be and remain the property of the Company notwithstanding any subsequent
                                         termination of the Employee&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Place of Work:
</B></FONT>The Employee will work from the Company&rsquo;s premises located in 2400 Skymark Avenue, Unit #6, Mississauga, Ontario
L4W 5K5 and it is anticipated that the Employee will be required to travel (both domestically and internationally) in the course
of performing the Employee&rsquo;s duties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Pre-existing
Obligations</B></FONT>. The Employee is hereby requested and directed by the Company to comply with any existing common law, contractual
or statutory obligations to the Employee&rsquo;s former employer and to any other person or entity. The Company is not employing
the Employee to obtain the confidential information or business opportunities of the Employee&rsquo;s former employer or any other
person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Qualifications,
Licences and Permits: </B></FONT>The Employee must hold and maintain the appropriate class of licence, certificate, degree, accreditation,
qualification, visa and/or permit <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>(&ldquo;Authorizations&rdquo;)
</B></FONT>for the proper performance of the Employee&rsquo;s duties, and to work in the jurisdictions in which the Employee is
performing the Employee&rsquo;s duties. The Company may require the Employee to provide copies of Authorizations which are necessary
for the Employee to perform the Employee&rsquo;s duties. Should the Employee fail to make reasonable efforts to maintain such Authorizations
or if the Employee misrepresents such Authorizations, the Employee&rsquo;s employment will be deemed frustrated and will terminate
without compensation or notice of any kind. All expenses related to the acquisition and maintenance of Authorizations will be borne
by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Directorship
                                         and Offices: </B></FONT>Upon the termination of employment with the Company for any reason,
                                         the Employee will immediately resign any directorship or office the Employee may hold
                                         in the Company or any parent, subsidiary or affiliated companies of the Company and,
                                         except <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">as
                                         </FONT>provided expressly in this Agreement, the Employee will not be entitled to receive
                                         any written notice of termination or payment in lieu of notice, or to receive any severance
                                         pay, damages or compensation for loss of any directorship, office or otherwise. The Employee
                                         agrees that failure to tender such resignation(s) will amount to cause for termination,
                                         for which the Company may treat the employment as being terminated for after-acquired
                                         cause. Notwithstanding the foregoing, the termination of employment will not automatically
                                         disqualify the Employee from serving <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">as
                                         </FONT>a director.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exclusion/Debarment:
                                         </B></FONT>The Employee represents and warrants that the Employee has never been, and
                                         as a condition of continued employment shall never be, during the term of this Agreement,
                                         excluded from any contracting by any Canadian or United States government agency or authority.
                                         The Employee further represents and warrants that the Employee is not subject to any
                                         final adverse action, as that term is defined in 42 U.S.C. &sect; 1320a-7e(g), and that
                                         no final adverse action has previously occurred or is pending or threatened against the
                                         Employee. The Employee represents and warrants that <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">the
                                         </FONT>Employee is not under investigation by <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">the
                                         </FONT>FDA or any other Canadian, United States or foreign regulatory agency nor has
                                         the Employee been debarred, suspended, proposed for debarment, declared ineligible, or
                                         voluntarily excluded by any Canadian, United States or foreign government department
                                         or agency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">1.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Company Policy:
</B></FONT>The Employee acknowledges and agrees that the employment relationship will be governed by the standards and terms established
by the Employer&rsquo;s policies as they are established from time to time and the Employee agrees to comply with the terms of
such policies which may be introduced, amended, deleted or modified in the sole discretion of the Employer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.05pt"></TD><TD STYLE="width: 32.85pt">1.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Professional
Conduct: </B></FONT>The Employee acknowledges and agrees that effective performance of the Employee&rsquo;s duties requires the
highest level of integrity and the Employer&rsquo;s complete confidence in the Employee&rsquo;s relationship with other employees
of the Employer and with all other persons with whom the Employee deals in the course of employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.05pt"></TD><TD STYLE="width: 32.85pt">2</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>COMPENSATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Base
                                                             Salary: </B></FONT>The Employee will earn an annual salary of CAD$317,000.00 (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Base
                                                             Salary&rdquo;</B></FONT>), less applicable deductions, payable in arrears for all services and work the Employee performs
                                                             for the Company. Any increases will be in the discretion of the CEO. The Employee&rsquo;s hours and schedule may change from
                                                             time to time depending on the Company&rsquo;s business needs. In the event of a substantial decrease in hours, the
                                                             employee&rsquo;s annual salary will be adjusted accordingly; in the Company&rsquo;s sole discretion up to a 50% reduction,
                                                             beyond a 50% reduction requires mutual written consent of both parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Annual Discretionary
Bonus: </B></FONT>Provided the Employee remains an employee of the Company in good standing and the Employee has not received or
given notice of termination, the Employee will be eligible to receive an annual bonus of up to 45% of the Employee&rsquo;s Base
Salary (pro-rated in the first year of employment), based on the assessment of the CEO of the Employee&rsquo;s and the Company&rsquo;s
achievement of certain milestones and objectives mutually agreed to by Employee and the CEO prior to the start of the bonus period.
Such milestones and objectives (including the evaluation of achievement thereof), and the bonus amount, will be at the sole discretion
of the CEO and will be payable in accordance with the Company&rsquo;s standard payroll policies, subject to applicable payroll
deductions and withholdings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify"><B>Stock Options:</B> The Employee
                                         will be eligible to participate in the Company&rsquo;s stock option plan, subject to
                                         the terms of such plan as may be in place and amended from time to time. Subject to the
                                         approval of the Board of Directors of the Company (the &ldquo;<B>Board</B>&rdquo;), the
                                         Company will grant the Employee (i) on the Effective Date, stock options to purchase
                                         500,000 common shares of the Company (&ldquo;<B>Common Shares</B>&rdquo;) and (ii) on
                                         the later of (A) the date on which the Company completes a listing on the Toronto Stock
                                         Exchange and (B) the date on which the number of Common Shares subject to the option
                                         pool is 10% or more of the number of outstanding Common Shares as determined on a fully
                                         diluted basis, stock options to purchase another 500,000 Common Shares. Such stock options
                                         shall vest as set forth in <B>Exhibit A</B> attached hereto. The stock options will be
                                         subject to other standard terms and conditions as set out in the Company&rsquo;s stock
                                         option plan and a grant agreement which will be provided in due course.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify"><B>Benefits:</B> The Employee will
                                         be entitled to participate in the standard insurance plans and other benefit programs
                                         (the &ldquo;<B>Employee Benefits</B>&rdquo;) which the Company may offer to similarly
                                         situated employees from time-to-time. The Employer reserves the right to unilaterally
                                         revise the terms of the Employee Benefits, to change carriers, or to eliminate any Employee
                                         Benefits altogether. Eligibility for benefits, unless otherwise noted, will commence
                                         90 days after enrolment. The Employee Benefits will be provided in accordance with the
                                         formal plan documents or policies and any issues with respect to entitlement or payment
                                         of benefits under any of the Employee Benefits will be governed by the terms of such
                                         documents or policies establishing the benefits in issue and will be a matter between
                                         the Employee and the insurer. The Employer&rsquo;s liability with respect to the Employee
                                         Benefits will be limited to the payment of its share of applicable premiums.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify"><B>Expenses:</B> The Company will
                                         reimburse the Employee for all reasonable business expenses actually and exclusively
                                         incurred in connection with the performance of duties under this Agreement, provided
                                         such expenses are incurred in accordance with the general policies and procedures of
                                         the Employer, as established from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify"><B>Statutory Holidays:</B> The Employer
                                         recognizes the statutory holidays observed in Ontario.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.7</TD><TD STYLE="text-align: justify"><B>Vacation:</B> The Employee shall
                                         be entitled to 4 weeks of paid vacation per annum, to be taken at such reasonable times
                                         as the Employer shall in its discretion permit and in accordance with the Company&rsquo;s
                                         vacation policy in effect from time to time. Vacation entitlement for any partial year
                                         of employment shall be pro-rated based on the portion of the year worked by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>TERMINATION
OF AGREEMENT AND EMPLOYMENT</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify">Upon termination of the Employee&rsquo;s employment, for any reason:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Employer shall pay the Employee
                                         all unpaid Base Salary and vacation pay earned up to and including the Employee&rsquo;s
                                         last day of employment (the &ldquo;<B>Termination Date</B>&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">all benefits coverage and other perquisites of the Employee&rsquo;s employment shall cease on the
later of the Termination Date or as specified in 3.3(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">all files, computer disks, information and documents pertaining to the Employer&rsquo;s business
shall remain the property of the Employer, and shall promptly be delivered by the Employee to the Employer&rsquo;s office, and
no copy, duplication or reproduction of any kind whatsoever shall be made of such files, computer disks, information or documents,
or retained by the Employee, without the express written consent of the Employer. The Employee agrees to destroy all electronic
information belonging to the Employer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Termination
by Employee: </B></FONT>The Employee may terminate this Agreement at any time by providing the Employer with thirty (30) days&rsquo;
prior written notice. Upon receipt of such notice, the Employer may at any time terminate the employment of the Employee and pay
the Employee the amount of Base Salary the Employee would have otherwise received during the balance of the aforementioned notice
period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Termination
by Employer: </B></FONT>The Employer may terminate the Employee&rsquo;s employment at any time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">without Cause by providing the
                                         Employee with the greater of: (i) working notice or pay in lieu of notice, benefit continuation
                                         (and severance pay, if applicable) that is required by the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
                                         Standards Act, 2000</I></FONT> as amended or (ii) six (6) months of working notice or
                                         pay in lieu of notice if terminated on or before twelve (12) months after the Effective
                                         Date, which shall be increased to twelve (12) months of working notice or pay of Base
                                         Salary in lieu of notice if terminated after twelve (12) months after the Effective Date
                                         (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Severance
                                         Benefit and Severance Period&rdquo;</B>);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">for frustration of contract upon the death of the Employee
or any incapacitation of the Employee that constitutes an undue hardship for the Employer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(c)</TD><TD STYLE="text-align: justify">at any time for just Cause, without notice or pay in lieu
of notice or any other form of compensation, severance pay or damages. For the purposes of this Agreement, <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Cause&rdquo;
</B></FONT>includes:</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i</TD><TD STYLE="text-align: justify">any material breach of the provisions of this Agreement by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">any intentional or grossly negligent disclosure of any confidential information by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">conduct on the Employee&rsquo;s part that is materially detrimental to the business or the financial
position of the Employer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">personal conduct on the Employee&rsquo;s part which is of such a serious and substantial nature
that it will injure the reputation of the Employer if the Employee was retained as an employee; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">any and all commissions, omissions or other conduct which would constitute just cause at law, in
addition to the specified causes noted above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.4</TD><TD><B>Termination in Connection with Change in Control:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">This
Agreement terminates if it is not assumed by the successor corporation (or affiliate thereto) upon a Change in Control (as defined
below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;Change in Control&rdquo; means a reorganization or merger of the Company with or into any other corporation or corporations
or on an acquisition of securities of the Company (excluding an equity financing of the Company with the principal purpose of raising
capital or a merger with any subsidiary or other affiliate) in which transaction the Company&rsquo;s shareholders immediately prior
to such transaction own immediately after such transaction, less than 50% of the voting power of the surviving corporation or its
parent, and/or (ii) the sale or disposition by the Company to an unrelated third party of substantially all of its business and
assets. Without limiting the foregoing, a transaction will not constitute a Change in Control if (a) its sole purpose is to change
the jurisdiction of the Company&rsquo;s incorporation, or (b) its sole purpose is to create a holding company that will be owned
in substantially the same proportions by the persons who held the Company&rsquo;s securities immediately prior to such transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-indent: -37pt; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 37pt">(b)</TD><TD STYLE="text-align: justify">If the Company terminates this Agreement other than for Cause in advance of the closing, or the Company&rsquo;s successor terminates
this Agreement other than for Cause within 12 months following the occurrence of a Change in Control of the Company, and the Employee
signs and returns to the Company without revocation a release prepared by the Company of all legally waivable claims related to
or arising from the Employee&rsquo;s employment with the Company, then (i) the Company shall pay the Employee a sum equal to (A)
twelve (12) months of Employee&rsquo;s then-current annual Base Salary and (B) the then current annual target bonus and (ii) Employee&rsquo;s
Equity Incentive Awards shall vest as set forth in Section 3.4 (d) (collectively, the &ldquo;Change in Control Benefits&rdquo;);
provided that in the event of a Change of Control that results in the holders of Common Shares receiving consideration for each
Common Share of at least three (3) times the thirty (30) day average VWAP for a Common Share for the period ending on the day prior
to the Effective Date, the amounts set forth in clauses (i)(A) and (B) above shall be increased from twelve (12) months to eighteen
(18) months of the Employee&rsquo;s then current annual Base Salary and from 100% to 150% of the Employee&rsquo;s then current
annual target bonus, respectively. Amounts payable hereunder in respect of Base Salary shall be paid in installments in accordance
with the Company&rsquo;s normal payroll practices. Payments in respect of annual bonuses shall be paid at the time the annual bonus
would otherwise be paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 73pt; text-indent: -37pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">If, within 12 months following a Change in Control, there is a material diminution of Employee&rsquo;s role in the company,
material diminution of status, or diminution of reporting structure, Employee shall have the right to resign and receive the Change
in Control Benefits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Effect Of Termination On Equity Incentive Award.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">If Employee is entitled to Change in Control Benefits, then any unvested Equity Incentive Awards shall immediately vest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">If any provision of this Agreement conflicts with a provision of the Award Agreement and/or the Plan, the provision more favorable
to the Employee shall govern.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>No Implied
Entitlement: </B></FONT>Other than as expressly provided herein, the Employee will not be entitled to receive any further pay or
compensation, severance pay, notice, payment in lieu of notice, incentives, bonuses, benefits or damages of any kind from the Company
or from any affiliate of the Company. Any payment in lieu of the Severance Period provided to the Employee will be inclusive of
any entitlements upon termination or severance pay pursuant to the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
Standards Act, 2000</I></FONT> as amended, contract, tort, common law or otherwise, and will be subject to statutory withholdings.
The Employee will not be entitled to receive any further pay or compensation (except for pay, if any, accrued and owing under this
Agreement up to the date of termination of employment) from the Company, and for clarity, without limiting the foregoing, the Employee
will not be entitled to any bonus or pro rata bonus payment that has not already been awarded to the Employee by the Company, except
for that which was specified as part of the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; font-variant: normal">Change
in Control Benefits.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify"><B>Continued Effect:</B> Notwithstanding any changes in the terms and conditions of the Employee&rsquo;s
employment which may occur in the future, including any changes in position, duties or compensation, the termination provisions
in this Agreement will continue to be in effect for the duration of the Employee&rsquo;s employment with the Company unless otherwise
amended in writing and signed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify"><B>Obligations Upon Termination:
                                         </B>Employee agrees that he shall not be entitled to receive any severance fee or other
                                         benefits under Section 3 of this Agreement if Employee breaches any of his obligations
                                         arising under Sections 4, 5, 6, 7, 8, 9 and 11 hereof. Employee acknowledges that until
                                         a release in the form of <B>Exhibit B</B> hereto (a &ldquo;<B>Release</B>&rdquo;) is
                                         timely executed and delivered to the Company, the Company will not be obligated to make
                                         any severance payments or provide any other benefits due under this Agreement following
                                         termination of Employee. Employee further acknowledges that if the Release is not timely
                                         executed and delivered to the Company, the severance payments and other benefits described
                                         in this Section 3 shall be forfeited, except as required by statutory minimum standards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>CONFIDENTIAL
INFORMATION PROTECTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">At all times during and after the Employee&rsquo;s employment, the Employee will hold in confidence
and will not disclose, use, lecture upon, or publish any of Company&rsquo;s Confidential Information (defined below), except as
may be required in connection with the Employee&rsquo;s work for Company, or as expressly authorized by the Board. The Employee
will obtain the written approval of the Board before publishing or submitting for publication any material (written, oral, or otherwise)
that relates to the Employee&rsquo;s work at Company and/or incorporates any Confidential Information. The Employee hereby assigns
to Company any rights Employee may have or acquire in any and all Confidential Information and recognize that all Confidential
Information shall be the sole and exclusive property of Company and its assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The term &ldquo;Confidential Information&rdquo; shall mean any and all confidential knowledge,
data or information related to Company&rsquo;s or its affiliates business or its actual or demonstrably anticipated research or
development, including without limitation (a) trade secrets, inventions, ideas, processes, computer source and object code, data,
formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques; (b)
information regarding products, services, plans for research and development, marketing and business plans, budgets, financial
statements, contracts, prices, suppliers, employees and customers; (c) information regarding the skills and compensation of Company&rsquo;s
employees, contractors, and any other service providers of Company; and (d) the existence of any business discussions, negotiations,
or agreements between Company and any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify">The Employee understands that Company
                                         has received and in the future will receive from third parties confidential or proprietary
                                         information (&ldquo;<B>Third Party Information</B>&rdquo;) subject to a duty on Company&rsquo;s
                                         part to maintain the confidentiality of such information and to use it only for certain
                                         limited purposes. During and after the term of the Employee&rsquo;s employment, the Employee
                                         will hold Third Party Information in strict confidence and will not disclose to anyone
                                         (other than Company personnel who need to know such information in connection with their
                                         work for Company) or use, Third Party Information, except in connection with the Employee&rsquo;s
                                         work for Company or unless expressly authorized by an officer of Company in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">The Employee represents that employment by Company does not and will not breach any agreement with
any former employer, including any non-compete agreement or any agreement to keep in confidence or refrain from using information
acquired by Employee prior to employment by Company. Employee further represents that Employee has not entered into, and will not
enter into, any agreement, either written or oral, in conflict with Employee&rsquo;s obligations under this Agreement. During employment
by Company, Employee will not improperly make use of, or disclose, any information or trade secrets of any former employer or other
third party, nor will Employee bring onto the premises of Company or use any unpublished documents or any property belonging to
any former employer or other third party, in violation of any lawful agreements with that former employer or third party. Employee
will use in the performance of Employee&rsquo;s duties only information that is generally known and used by persons with training
and experience comparable to the Employee&rsquo;s own, is common knowledge in the industry or otherwise legally in the public domain,
or is otherwise provided or developed by Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.5</TD><TD STYLE="text-align: justify">The obligations and rights granted in this section shall survive the termination of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>5</B>.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B><U>INVENTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">As used in this Agreement, the term
                                         &ldquo;<B>Invention</B>&rdquo; means any ideas, concepts, information, materials, processes,
                                         data, programs, know-how, improvements, discoveries, developments, designs, artwork,
                                         formulae, other copyrightable works, and techniques and all Intellectual Property Rights
                                         in any of the items listed above. The term &ldquo;<B>Intellectual Property Rights</B>&rdquo;
                                         means all trade secrets, copyrights, trademarks, mask work rights, patents and other
                                         intellectual property rights recognized by the laws of any jurisdiction or country. The
                                         term &ldquo;<B>Moral Rights</B>&rdquo; means all paternity, integrity, disclosure, withdrawal,
                                         special and any other similar rights recognized by the laws of any jurisdiction or country.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">The Employee has disclosed in <B>Exhibit
                                         C</B> a complete list of all Inventions that (a) the Employee has, or has caused to be,
                                         alone or jointly with others, conceived, developed, or reduced to practice prior to the
                                         commencement of the Employee&rsquo;s employment by Company; (b) in which the Employee
                                         has an ownership interest or which the Employee has a license to use; (c) and that the
                                         Employee wishes to have excluded from the scope of this Agreement (collectively referred
                                         to as &ldquo;<B>Prior Inventions</B>&rdquo;). If no Prior Inventions are listed in <B>Exhibit
                                         C</B>, the Employee warrants that there are no Prior Inventions. The Employee agrees
                                         that the Employee will not incorporate, or permit to be incorporated, Prior Inventions
                                         in any Company Inventions (defined below) without Company&rsquo;s prior written consent.
                                         If, in the course of the Employee&rsquo;s employment with Company, the Employee incorporates
                                         a Prior Invention into a Company process, machine or other work, the Employee hereby
                                         grants Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and
                                         worldwide license, with rights to sublicense through multiple levels of sublicensees,
                                         to reproduce, make derivative works of, distribute, publicly perform, and publicly display
                                         in any form or medium, whether now known or later developed, make, have made, use, sell,
                                         import, offer for sale, and exercise any and all present or future rights in, such Prior
                                         Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">Inventions assigned to the Company
                                         or to a third party as directed by the Company pursuant to the subsection 5.5 are referred
                                         to in this Agreement as &ldquo;<B>Company Inventions</B>&rdquo;. Subject to the subsection
                                         5.5 and the Prior Inventions Employee has set forth in <B>Exhibit C</B>, Employee hereby
                                         assigns and agrees to assign in the future (when any such Inventions or Intellectual
                                         Property Rights are first reduced to practice or first fixed in a tangible medium, as
                                         applicable) to the Company all rights, title, and interest in and to any and all Inventions
                                         (and all Intellectual Property Rights with respect thereto) made, conceived, reduced
                                         to practice, or learned by Employee, either alone or with others, during the period of
                                         the Employee&rsquo;s employment by the Company. Any assignment of Inventions (and all
                                         Intellectual Property Rights with respect thereto) hereunder includes an assignment of
                                         all Moral Rights. To the extent such Moral Rights cannot be assigned to the Company and
                                         to the extent the following is allowed by the laws in any country where Moral Rights
                                         exist, the Employee hereby unconditionally and irrevocably waives the enforcement of
                                         such Moral Rights, and all claims and causes of action of any kind against the Company
                                         or related to the Company&rsquo;s customers, with respect to such rights. The Employee
                                         further acknowledges and agrees that neither the Employee&rsquo;s successors-in-interest
                                         nor legal heirs retain any Moral Rights in any Inventions (and any Intellectual Property
                                         Rights with respect thereto).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">During the period of employment, the Employee will promptly and fully disclose to the Company in
writing (a) all Inventions authored, conceived, or reduced to practice by the Employee, either alone or with others, and (b) all
patent applications filed by the Employee or in which the Employee is named as an inventor or co-inventor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.5</TD><TD STYLE="text-align: justify">The Employee agrees that, as&#9;directed by the Company,
the Employee will assign to a third party, including without limitation, all rights, title, and interest in and to any particular
Company Invention.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">5.6</TD><TD STYLE="text-align: justify">During and after the period of employment and at the Company&rsquo;s
request and expense, the Employee will assist the Company in every proper way, including consenting to and joining in any action,
to obtain and enforce Canadian, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions
in all countries. If the Company is unable to secure the Employee&rsquo;s signature on any document needed in connection with
such purposes, the Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents
as the Employee&rsquo;s agent and attorney in fact, which appointment is coupled with an interest, to act on the Employee&rsquo;s
behalf to&#9;execute and file any such documents and to do all other lawfully permitted acts to further such purposes with the
same legal force and effect as if executed by the Employee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.7</TD><TD STYLE="text-align: justify">The Employee agrees that the Employee will not incorporate into any Company software or otherwise
deliver to the Company any software code licensed under the GNU General Public License or Lesser General Public License or any
other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or
distribution of any source code owned or licensed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.8</TD><TD STYLE="text-align: justify">The obligations and rights granted in this section shall survive the termination of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>RETURN
                                         OF COMPANY PROPERTY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">Upon termination of the Employee&rsquo;s employment or upon the Company&rsquo;s request at any
other time, the Employee will deliver to the Company all of the Company&rsquo;s property, equipment, and documents, together with
all copies thereof, and any other material containing or disclosing any Inventions, Third Party Information or Confidential Information
and certify in writing that the Employee has fully complied with the foregoing obligation. The Employee agrees that the Employee
will not copy, delete, or alter any information contained upon any Company computer or Company equipment before the Employee returns
it to the Company. In addition, if the Employee has used any personal computer, server, or e-mail system to receive, store, review,
prepare or transmit any Company information, including but not limited to, Confidential Information, the Employee agrees to provide
the Company with a computer-useable copy of all such Confidential Information and then permanently delete and expunge such Confidential
Information from those systems; and the Employee agrees to provide the Company access to the Employee&rsquo;s system as reasonably
requested to verify that the necessary copying and/or deletion is completed. The Employee further agrees that any property situated
on the Company&rsquo;s premises and owned by the Company is subject to inspection by the Company&rsquo;s personnel at any time
with or without notice. Prior to the termination of employment or promptly after termination of employment, the Employee will cooperate
with the Company in attending an exit interview and certify in writing that the Employee has complied with the requirements of
this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">6.2</TD><TD STYLE="text-align: justify">The obligations and rights granted in this section shall survive the termination of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>RECORDS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Employee agrees to keep and maintain adequate and current records (in the form of notes, sketches,
drawings and in any other form that is required by the Company) of all Inventions made by the Employee during the period of the
Employee&rsquo;s employment by the Company, which records shall be available to, and remain the sole property of, the Company at
all times.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>NON-COMPETlTION/NON-SOLICITATlON</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.1</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of
the Employee&rsquo;s employment by the Company and for one (1) year after termination of such employment for any reason (except
in the event of a Change of Control pursuant to the proviso at the end of Section 3.4(b), in which event such period shall extend
to eighteen (18) months after termination of such employment), the Employee will not, without the Company&rsquo;s express written
consent, anywhere in the world, be employed by or contribute to any business activity that is competitive with the business of
the Company and involves the use of real-time magnetic resonance imaging or ultrasound or similar technologies in the delivery
of ablative tools.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">8.2</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of the
                                                                               Employee&rsquo;s employment by the Company and for one (1) year after termination of such employment for any
                                                                               reason (except in the event of a Change of Control pursuant to the proviso at the end of Section 3.4(b), in which event such
                                                                               period shall extend to eighteen (18) months after termination of such employment), the Employee will not, either directly or
                                                                               indirectly, solicit or attempt to solicit any employee, independent contractor, or consultant of the Company to terminate
                                                                               his, her or its relationship with Company in order to become an employee, consultant, or independent contractor to or for
                                                                               any                                                                                other person or entity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">8.3</TD><TD STYLE="text-align: justify">The obligations and rights granted in this section shall survive the termination of this&#9;agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">9.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>NOTIFICATION
OF NEW EMPLOYER</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">9.1</TD><TD STYLE="text-align: justify">After the termination of this Agreement, the&#9;Employee&#9;consents
to the&#9;notification of any new employer of the Employee&rsquo;s rights and obligations under this Agreement, by the Company
providing a copy of this Agreement or otherwise as the Company deems fit.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>INJUNCTIVE
RELIEF</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that, because the Employee&rsquo;s services are personal and unique and
because Employee will have access to the Confidential Information of the Company, any breach of this Agreement would cause irreparable
injury to the Company for which monetary damages would not be an adequate remedy and, therefore, will entitle the Company to injunctive
relief (including specific performance). The rights and remedies provided to each party in this Agreement are cumulative and in
addition to any other rights and remedies available to such party at law or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">11.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>PUBLICITY</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">11.1</TD><TD STYLE="text-align: justify">The Employee shall not, without the prior written consent
of the Employer,&#9;make or give any public announcements, press releases or statements to the public or the press regarding the
Employee&rsquo;s work or the Employer&rsquo;s business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">12.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>NOTICES</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">12.1</TD><TD STYLE="text-align: justify">All notices, requests,&#9;demands and&#9;other communications
to be given pursuant to the terms of this Agreement shall be in writing and shall be deemed to have been duly given on the date
of delivery if personally delivered, on the date of transmission if sent by facsimile, one day after being deposited with a recognized
overnight courier with postage prepaid, or three days after being mailed first class, postage prepaid, in each case to the parties
at the addresses listed below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">If to Employee, at the Employee&rsquo;s then current address
in the Company&rsquo;s payroll records;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If to the Company:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Profound Medical Corp.</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">2400 Skymark Avenue, Unit 6</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Mississauga, ON L4W 5K5</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 15%; text-align: justify; text-indent: 0in; font-size: 10pt">Attention:</TD>
    <TD STYLE="width: 85%; text-align: justify; text-indent: 0in; font-size: 10pt">Arun Menawat</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">E-mail:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">amenawat@profoundmedical.com</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">Each
party may change its address for receipt of notice by giving notice of the change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">13</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>SURVIVAL</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">This Employee&rsquo;s obligations under this Agreement shall survive the termination of the Employee&rsquo;s employment, regardless
of the manner or reason for termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">13.2</TD><TD STYLE="text-align: justify">The assignment of this Agreement by the Company to any successor or other assignee and shall be binding upon the Employee&rsquo;s
heirs and legal representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">14.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>SEVERABILITY</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">14.1</TD><TD STYLE="text-align: justify">If any provision of this Agreement is, for any reason,
held to be invalid or unenforceable, the other provisions of this Agreement will remain enforceable and the invalid or unenforceable
provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted by law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">15.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>WAIVER</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">15.1</TD><TD STYLE="text-align: justify">Any waiver or failure to enforce any provision of this
Agreement on one occasion will not be deemed a waiver of that provision or any other provision on any other occasion.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35pt; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">16.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>ASSIGNMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">16.1</TD><TD STYLE="text-align: justify">The Company may assign this Agreement to (i) an affiliate, subsidiary, related company or partnership
without prior notice or consent of the Employee, or (ii) a new employer in connection with any transaction or reorganization; provided
that any such successor or assignee expressly assumes in writing the Company&rsquo;s obligations under this Agreement and has responsibility
for managing the underlying business of the Company. The Employee may not assign any of his rights nor delegate any of the duties
hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">17<B>.</B></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>ENTIRE
                                         AGREEMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">17.1</TD><TD STYLE="text-align: justify">This Agreement is the final, complete and exclusive agreement of the parties with respect to the
subject matter hereof and supersedes and merges all prior communications between us with respect to such matters. No modification
of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed
by the Employee and the Company. Any subsequent change or changes in duties, salary or compensation will not affect the validity
or scope of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">18.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>HEADINGS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">18.1</TD><TD STYLE="text-align: justify">The headings utilized in this Agreement are for convenience only and are not to be construed in
any way as additions or limitations of the covenants and agreements contained in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">19.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>INDEPENDENT
                                         LEGAL ADVICE</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">19.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that the Employee has read and understands this Agreement, and acknowledges
that an opportunity was provided to obtain legal advice about it. The Company shall reimburse the Employee for the reasonable costs
of obtaining legal advice regarding this Agreement, but in no event more than $1,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">20.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>COUNTERPARTS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">20.1</TD><TD STYLE="text-align: justify">This Agreement may be executed in two or more counterparts,
each of which will be deemed to be an original and all of which will constitute one Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">21.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>LAWS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -35pt; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">21.1</TD><TD STYLE="text-align: justify">This Agreement shall be governed by and interpreted in accordance with the laws of Ontario and
the laws of Canada applicable therein. The Employee and the Company hereby attorn to the exclusive jurisdiction of the superior
courts of Ontario to resolve any dispute arising from this Agreement except to the extent the Company seeks injunctive relief outside
Ontario where applicable to enforce the Employee&rsquo;s covenants hereunder.</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: transparent">[Signature
Page to Follow]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -35pt; background-color: transparent"></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IN WITNESS WHEREOF the parties have duly executed this Agreement
as of the 10th day of April, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signed, Sealed</B> and
    Delivered in the presence of:</FONT></TD>
    <TD STYLE="width: 4%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ IAN HEYNEN</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name(witness)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">IAN HEYNEN</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">148 BRENTWOOD RD N.</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt">TORONTO</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I STYLE="font-style: normal; font-weight: normal">)</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    AARON     DAVIDSON</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">SVP Sales and Marketing</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AARON DAVIDSON</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupation </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROFOUND MEDICAL CORP.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid">/s/ Arun Menawat</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arun Menawat, CEO</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profound Medical</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent; text-align: justify">Pursuant to
Section 3.5(a) of the an amended and restated share option plan of the Company dated December 8, 2016 (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Share
Option Plan&rdquo;):</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in; background-color: transparent; text-align: justify">Unless
otherwise specified by the Plan Administrator at the time of granting an Option and except as otherwise provided in this Plan,
each Option will vest and be exercisable as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><B><U>Total
    Number of Option Shares</U></B></FONT></TD>
    <TD STYLE="width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><B><U>Vesting
    Date</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><B><U>that
    may be Purchased</U></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">1/4</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">On the first anniversary of the Date of Grant.</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">1/36</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">On the first day of each calendar month following the</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">first anniversary of the Date of Grant.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent; text-align: justify">Capitalized
terms used in this Exhibit A shall have the meaning given in the Share Option Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>Exhibit
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>RELEASE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">I,
Aaron Davidson of the City of______&#9;, in the Province of Ontario, for and in consideration of the sum of <B>*</B> ($<B>*</B>)
and other good and valuable consideration which is being delivered to me concurrently with the execution and delivery hereof (the
receipt and sufficiency of which is hereby acknowledged) do hereby remise, release and forever discharge <B>PROFOUND MEDICAL CORP.
</B>(hereinafter called the &ldquo;<B>Company</B>&rdquo;), its officers, directors, servants, employees and agents, including
any related or associated companies, and their heirs, executors, administrators, successors and assigns, as the case may be, of
and from any and all manner of actions, causes of action, suits, contracts, claims, damages, costs and expenses of any nature
or kind whatsoever, whether in law or in equity, which, as against the Company or such persons as aforesaid or any of them I have
ever had, now have, or at any time hereafter I or my personal representatives can, shall or may have, by reason of or arising
out of the termination of my employment with the Company or in any other way connected with my employment with the Company (except
as otherwise set forth below), and more specifically, without limiting the generality of the foregoing, any and all claims for
damages for termination of my employment, constructive termination of my employment, loss of position, loss of status, loss of
future job opportunity, loss of opportunity to enhance my reputation, the timing of the termination and the manner in which it
was effected, loss of bonuses, loss of benefits, including life insurance and short and long-term disability benefit coverage,
and any other type of damages; <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><U>provided,
however</U></FONT>, that notwithstanding anything contained herein, this Release does not apply to any claims related to (i) equity
in the Company or its affiliates that I hold, directly or indirectly, including without limitation, the options granted to me
in connection with my employment with the Company, or (ii) any unpaid reimbursement of expenses and accrued but unpaid salary
or termination payments provided for in the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent; text-align: justify">I FURTHER
AGREE that this Release includes any and all claims I may have arising under contract, the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
Standards Act, 2000,</I></FONT> as amended, common law or other applicable law related to my employment with the Company and that
the consideration provided includes any amount that I may be entitled to under such legislation and I agree to immediately withdraw
any complaint as settled and not to file any complaint pursuant to such legislation with respect to my employment or the termination
of my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent; text-align: justify">IT
IS UNDERSTOOD that the Company has withheld income tax and other statutory deductions from the aforesaid consideration and I agree
to indemnify and hold harmless the Company from any further assessment for income tax or other statutory deductions which may be
made under statutory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent; text-align: justify">IT
IS FURTHER UNDERSTOOD that as a former officer of the Company I owe a fiduciary duty to the Company and I agree that the Company
will suffer irreparable harm if confidential information or information unique to the Company is disclosed in any way by me without
authorization of the Company and that I have returned to the Company originals or copies of the Company&rsquo;s corporate records,
files, financial documents, client lists, or any other material that is related to the Company&rsquo;s business, clients, personnel
or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS FURTHER UNDERSTOOD AND AGREED that this is not to be construed or considered as an admission of liability on the part of the
Company. The terms of this Release set out the entire agreement between myself and the Company and are intended to be contractual
and not a mere recital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent; text-align: justify">IT
IS EXPRESSLY ACKNOWLEDGED that the contents, terms and effect of this Release have been explained to me by my lawyer and are fully
understood.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">IN
WITNESS WHEREOF I, Aaron Davidson, have hereunto set my hand and seal this___day of ________________, 20___in the City
of________________, Province of Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">Aaron Davidson</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 202pt; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-indent: 0in; background-color: transparent"></P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; background-color: transparent"><B>EXHIBIT
C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; background-color: transparent"><B>INVENTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prior
Inventions Disclosure</B>. The following is a complete list of all Prior Inventions (as provided in Subsection 5.2 of the attached
Employment Agreement):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See immediately below:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>19
<FILENAME>tv526458_ex4-13.htm
<DESCRIPTION>EXHIBIT 4.13
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-style: normal; font-variant: normal"><B>Exhibit
4.13</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal"><IMG SRC="tv526458_ex4-13img1.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>AMENDED
AND RESTATED EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">THIS
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Agreement&rdquo;</B>)
</FONT>dated as of the August 23, 2019 (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Effective
Date&rdquo;</B>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">BETWEEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">AND:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RASHED DEWAN (the &ldquo;Employee&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">WHEREAS
the Company and the Employee entered into a letter agreement as to employment on May 27, 2015 (the <B>&ldquo;Original
Agreement&rdquo;</B>); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">WHEREAS
the Company and the Employee wish to amend and restate the Original Agreement on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>NOW
THEREFORE </B></FONT>in consideration of the covenants and agreements herein, the sufficiency of which is acknowledged by each
of the parties, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>EMPLOYMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Effectiveness
                                         of the Agreement</B>: The terms and conditions of employment of the Employee by the Company
                                         prior to the Effective Date shall be governed by the Original Agreement and the attachments
                                         and exhibits thereto, and as of the Effective Date will be governed by the Agreement.
                                         The Employee&rsquo;s employment with the Company commenced on July 6, 2015 and will continue
                                         until this Agreement is terminated in accordance with section 4 herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Title: </B></FONT>The
Company agrees to continue to employ the Employee as <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>VP
Finance, Manufacturing, and Service </B></FONT>upon the terms and conditions set out in this Agreement. The Employee will report
to the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Chief Financial Officer (CFO) &amp;
SVP Corporate Development </B></FONT>of the Company or such person the Company advises from time to time. The Employee acknowledges
that he shall undertake such duties and responsibilities for the Company and its affiliates in connection with and commensurate
with the Employee&rsquo;s position as are determined by the CEO or to anyone else the CEO designates from time to time. The Employee
further acknowledges the Company may re-assign, re-allocate, or re-organize the Employee&rsquo;s duties and responsibilities as
circumstances change, provided such duties and responsibilities are consistent with the role of a VP Finance, Manufacturing, &amp;
Service.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Service: </B></FONT>During
the term of this Agreement, in addition to the Employee&rsquo;s common law duties to the Company, the Employee covenants and agrees
as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Loyalty to
the Company: </B></FONT>Throughout the Employee&rsquo;s employment, the Employee will faithfully serve the Company and use the
Employee&rsquo;s best efforts to promote the business of the Company. The Employee will act honestly and in good faith, in the
best interests of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Service: </B></FONT>The
Employee shall devote his full working time and attention to the affairs of the Company. The Employee shall not engage in any other
business, profession or occupation, or become an officer, employee, contractor for service, agent, or representative of any other
company, partnership, firm, person, organization, or enterprise during the term of this Agreement, provided that the Employee may
participate on boards of directors of other organizations (to a maximum of one (1) at any one time) and in business associations,
charitable organizations or other similar organizations, as may be approved by the CEO in its discretion, acting reasonably, and
provided that such participation does not interfere with the proper discharge of his duties to the Company. The Employee currently
has disclosed that he is not currently a director of a board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>No Personal
Benefit: </B></FONT>The Employee will not receive or accept for the Employee&rsquo;s own benefit or for any other person or entity&rsquo;s
benefit, either directly or indirectly, any commission, rebate, discount, gratuity or profit from any person or entity having or
proposing to have one or more business transactions with the Company, without the prior approval of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Business Opportunities:
</B></FONT>During the Employee&rsquo;s employment with the Company, the Employee will communicate and channel to the Company all
knowledge, business and customer contacts and any other information that could concern or be in any way beneficial to the business
of the Company. Any such information communicated to the Company as aforesaid will be and remain the property of the Company notwithstanding
any subsequent termination of the Employee&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Place of Work:
</B></FONT>The Employee will work from the Company&rsquo;s premises located in 2400 Skymark Avenue, Unit #6, Mississauga, Ontario
L4W 5K5 and it is anticipated that the Employee will be required to travel extensively (both domestically and internationally)
in the course of performing the Employee&rsquo;s duties. In addition, it is anticipated that the Company will increase its focus
on sales in the U.S.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Pre-existing
Obligations. </B></FONT>The Employee is hereby requested and directed by the Company to comply with any existing common law, contractual
or statutory obligations to the Employee&rsquo;s former employer and to any other person or entity. The Company is not employing
the Employee to obtain the confidential information or business opportunities of the Employee&rsquo;s former employer or any other
person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Qualifications,
                                         Licences and Permits: </B></FONT>The Employee must hold and maintain the appropriate
                                         class of licence, certificate, degree, accreditation, qualification, visa and/or permit
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(<B>&ldquo;Authorizations&rdquo;</B>)
                                         </FONT>for the proper performance of the Employee&rsquo;s duties, and to work in the
                                         jurisdictions in which the Employee is performing the Employee&rsquo;s duties. The Company
                                         may require the Employee to provide copies of Authorizations which are necessary for
                                         the Employee to perform the Employee&rsquo;s duties. Should the Employee fail to make
                                         reasonable efforts to maintain such Authorizations or if the Employee misrepresents such
                                         Authorizations, the Employee&rsquo;s employment will be deemed frustrated and will terminate
                                         without compensation or notice of any kind. All expenses related to the acquisition and
                                         maintenance of Authorizations will be borne by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Exclusion/Debarment:
                                         </B></FONT><FONT STYLE="font-size: 10pt">The Employee represents and warrants that the
                                         Employee has never been, and as a condition of continued employment shall never be, during
                                         the term of this Agreement, excluded from any contracting by any Canadian or United States
                                         government agency or authority. The Employee further represents and warrants that the
                                         Employee is not subject to any final adverse action, as that term is defined in 42 U.S.C.
                                         &sect; 1320a-7e(g), and that no final adverse action has previously occurred or is pending
                                         or threatened against the Employee. The Employee represents and warrants that the Employee
                                         is not under investigation <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">by
                                         </FONT>the FDA or any other Canadian, United States or foreign regulatory agency nor
                                         has the Employee been debarred, suspended, proposed for debarment, declared ineligible,
                                         or voluntarily excluded by any Canadian, United States or foreign government department
                                         or agency.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">1.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Company
Policy: </B></FONT><FONT STYLE="font-size: 10pt">The Employee acknowledges and agrees that the employment relationship will be
governed by the standards and terms established by the Company&rsquo;s policies as they are established from time to time and the
Employee agrees to comply with the terms of such policies which may be introduced, amended, deleted or modified in the sole discretion
of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">1.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Professional
Conduct: </B></FONT><FONT STYLE="font-size: 10pt">The Employee acknowledges and agrees that effective performance of the Employee&rsquo;s
duties requires the highest level of integrity and the Company&rsquo;s complete confidence in the Employee&rsquo;s relationship
with other employees of the Company and with all other persons with whom the Employee deals in the course of employment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="background-color: white">2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>COMPENSATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">2.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Base
Salary: </B></FONT><FONT STYLE="font-size: 10pt">The Employee will earn an annual salary equivalent to <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>CDN$
190,102.00 </B></FONT>(the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Base Salary&rdquo;</B>),
</FONT>less applicable deductions, payable in arrears for all services and work the Employee performs for the Company. Any
increases will be in the discretion of the CEO. The Base Salary will be payable in accordance with the Company&rsquo;s normal payroll
practices and will be payable in Canadian dollars on the applicable payroll date. The Employee&rsquo;s hours and schedule may change
from time to time depending on the Company&rsquo;s business needs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">2.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Annual
                                         Discretionary Bonus: </B></FONT><FONT STYLE="font-size: 10pt">Provided the Employee remains
                                         an employee of the Company in good standing and the Employee has not received or given
                                         notice of termination, for each calendar year, the Employee will be eligible to receive
                                         an <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>annual
                                         bonus of up to 20% of the Employee&rsquo;s Base Salary </B></FONT>based on the assessment
                                         of the Board of the Employee&rsquo;s and the Company&rsquo;s achievement of certain milestones
                                         and objectives determined <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">by
                                         </FONT>the Board. Such milestones and objectives (including the evaluation of achievement
                                         thereof), and the bonus amount, will be at the sole discretion of the Board and will
                                         be payable in accordance with the Company&rsquo;s standard payroll policies, subject
                                         to applicable payroll deductions and withholdings. Such bonus shall be paid within ninety
                                         (90) days after the end of the applicable calendar year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">2.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Stock
                                         Options: </B></FONT><FONT STYLE="font-size: 10pt">The options to purchase common shares
                                         of the Company previously received by the Employee <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(<B>&ldquo;Stock
                                         Options&rdquo;</B>) </FONT>shall continue to vest during the term of this Agreement in
                                         accordance with their terms. The Company shall consider compensation as a whole, including
                                         stock incentives, of Vice President Finance, Manufacturing and Service or similar roles
                                         of comparable companies when considering compensation or the grant of stock options for
                                         the Employee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal; background-color: white">2.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Benefits:
</B></FONT><FONT STYLE="font-size: 10pt">The Employee will be entitled to participate in the standard insurance plans and other
benefit programs (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Employee Benefits&rdquo;</B>)
</FONT>which the Company may offer to management level employees from time-to-time. The Company reserves the right to unilaterally
revise the terms of the Employee Benefits, to change carriers, or to eliminate any Employee Benefits altogether. The Employee Benefits
will be provided in accordance with the formal plan documents or policies and any issues with respect to entitlement or payment
of benefits under any of the Employee Benefits will be governed by the terms of such documents or policies establishing the benefits
in issue and will be a matter between the Employee and the insurer. The Company&rsquo;s liability with respect to the Employee
Benefits will be limited to the payment of its share of applicable premiums.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Expenses:
</B></FONT>The Company will reimburse the Employee for all reasonable business expenses actually and exclusively incurred in connection
with the performance of duties under this Agreement, provided such expenses are incurred and accounted for in accordance with the
general policies and procedures of the Company, as established from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Statutory
Holidays: </B></FONT>The Company recognizes the statutory holidays observed in Ontario.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Vacation:
</B></FONT>The Employee shall be entitled to 4 weeks of paid vacation per annum, to be taken at such reasonable times as the Company
shall in its discretion permit and in accordance with the Company&rsquo;s vacation policy in effect from time to time. Vacation
entitlement for any partial year of employment shall be pro-rated based on the portion of the year worked by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>TERMINATION
                                         OF AGREEMENT AND EMPLOYMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Obligations
Upon Termination: </B></FONT>Upon termination of the Employee&rsquo;s employment, for any reason:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Company shall pay the Employee all unpaid Base Salary and vacation pay earned up to and including
the Employee&rsquo;s last day of employment (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Termination
Date&rdquo;</B>);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">all benefits coverage and other perquisites of the Employee&rsquo;s employment shall cease on the
later of the Termination Date or as specified in 3.3(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">all files, computer disks, information and documents pertaining to the Company&rsquo;s business
shall remain the property of the Company, and shall promptly be delivered by the Employee to the Company&rsquo;s office, and no
copy, duplication or reproduction of any kind whatsoever shall be made of such files, computer disks, information or documents,
or retained by the Employee, without the express written consent of the Company. The Employee agrees to deliver all electronic
information to the Company and to destroy any copies held by the Employee belonging to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Termination&#9;by
the Employee: </B></FONT>The Employee may terminate this Agreement at any time by providing the Company with ninety (90) days&rsquo;
prior written notice. Upon receipt of such notice, the Company may at any time terminate the employment of the Employee and pay
the Employee the amount of Base Salary the Employee would have otherwise received during the balance of the aforementioned notice
period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Termination
by the Company: </B></FONT>The Company may terminate the Employee&rsquo;s employment at any time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">without Cause by providing the
                                         Employee with the greater of: (i) pay in lieu of notice, benefit continuation (and severance
                                         pay, if applicable) that is required by the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
                                         Standards Act, 2000</I></FONT> as amended or (ii) (A) a minimum of six (6) months of
                                         pay of Base Salary in lieu of notice (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Severance
                                         Period&rdquo;</B>) </FONT>and (B) an amount equal to the then current target annual bonus
                                         prorated based on the number of days elapsed in the calendar year until the date of termination
                                         as a percentage of the total number of days in such calendar year. The Employee will
                                         continue to provide services to the Company on an as-needed basis for a period of up
                                         to 1 month following the termination of his employment (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Transition
                                         Period&rdquo;</B>), </FONT>including assistance with transition of duties, unless the
                                         requirement for active service is expressly waived in whole or in part by the Company,
                                         in its sole discretion. The Employee agrees that the Company may, in its sole discretion,
                                         limit or discontinue the Executive&rsquo;s access to business records and Confidential
                                         Information during the Transition Period. The Employee agrees that any services provided
                                         to the Company during the Transition Period shall be for no additional compensation in
                                         excess of the severance payments and benefits contemplated under this Agreement. Regardless
                                         of whether or not the Employee provides active service during the Transition Period,
                                         the Employee shall continue to abide by all obligations owing under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for frustration of contract upon the death of the Employee or any incapacitation of the Employee
that constitutes an undue hardship for the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">at any time for just Cause, without
                                         notice or pay in lieu of notice or any other form of compensation, severance pay or damages.
                                         For the purposes of this Agreement, <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&ldquo;<B>Cause</B>&rdquo;
                                         </FONT>includes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">any material breach of the provisions of this Agreement by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">any intentional or grossly negligent disclosure of any confidential information by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">conduct on the Employee&rsquo;s part that is materially detrimental to the business or the financial
position of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">personal conduct on the Employee&rsquo;s part which is of such a serious and substantial nature
that it will injure the reputation of the Company if the Employee was retained as an employee; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">any and all commissions, omissions or other conduct which would constitute just cause at law, in
addition to the specified causes noted above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Timing of
Payments: </B></FONT>All amounts payable hereunder in respect of Base Salary or with respect to payments made under the Ontario
<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment Standards Act, 2000,</I></FONT>
as amended, shall be paid in installments in accordance with the Company&rsquo;s normal payroll practices. Payments in respect
of annual or prorated bonuses shall be paid at the time the annual bonus would otherwise be paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify"><B>No</B> <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Implied
                                         Entitlement: </B></FONT>Other than as expressly provided herein, the Employee will not
                                         be entitled to receive any further pay or compensation, severance pay, notice, payment
                                         in lieu of notice, incentives, bonuses, benefits or damages of any kind from the Company
                                         or from any affiliate of the Company. Any payment in lieu of the Severance Period payment
                                         provided to the Employee will be inclusive of any entitlements upon termination or severance
                                         pay pursuant to the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
                                         Standards Act, 2000</I></FONT> as amended, contract, tort, common law or otherwise, and
                                         will be subject to statutory withholdings. The Employee will not be entitled to receive
                                         any further pay or compensation (except for pay, if any, accrued and owing under this
                                         Agreement up to the date of termination of employment) from the Company, and for clarity,
                                         without limiting the foregoing, the Employee will not be entitled to any bonus or pro
                                         rata bonus payment that has not already been awarded to the Employee by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Continued
Effect: </B></FONT>Notwithstanding any changes in the terms and conditions of the Employee&rsquo;s employment which may occur in
the future, including any changes in position, duties or compensation, the termination provisions in this Agreement will continue
to be in effect for the duration of the Employee&rsquo;s employment with the Company unless otherwise amended in writing and signed
by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Obligations
                                         Upon Termination. </B></FONT>The Employee agrees that he shall not be entitled to receive
                                         any severance fee or other benefits under Section 3 of this Agreement if the Employee
                                         breaches any of his obligations arising under Sections 4, 5, 6, 7, 8, 9, and 10 hereof.
                                         The Employee acknowledges that until a release in the form of <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
                                         B </B></FONT>hereto (a <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Release&rdquo;</B>)
                                         </FONT>is timely executed and delivered to the Company, the Company will not be obligated
                                         to make any severance payments or provide any other benefits due under this Agreement
                                         following termination of the Employee. The Employee further acknowledges that if the
                                         Release is not timely executed and delivered to the Company, the severance payments and
                                         other benefits described in this Section 3 shall be forfeited, except as required by
                                         statutory minimum standards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>CONFIDENTIAL INFORMATION PROTECTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">At all times during and after the Employee&rsquo;s employment, the Employee will hold in confidence
and will not disclose, use, lecture upon, or publish any of Company&rsquo;s Confidential Information (defined below), except as
may be required in connection with the Employee&rsquo;s work for Company, or as expressly authorized by the Board. The Employee
will obtain the written approval of the Board before publishing or submitting for publication any material (written, oral, or otherwise)
that relates to the Employee&rsquo;s work at Company and/or incorporates any Confidential Information. The Employee hereby assigns
to Company any rights the Employee may have or acquire in any and all Confidential Information and recognize that all Confidential
Information shall be the sole and exclusive property of Company and its assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The term &ldquo;Confidential Information&rdquo; shall mean any and all confidential knowledge,
data or information related to Company&rsquo;s or its affiliates business or its actual or demonstrably anticipated research or
development, including without limitation (a) trade secrets, inventions, ideas, processes, computer source and object code, data,
formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques; (b)
information regarding products, services, plans for research and development, marketing and business plans, budgets, financial
statements, contracts, prices, suppliers, employees and customers; (c) information regarding the skills and compensation of Company&rsquo;s
employees, contractors, and any other service providers of Company; and (d) the existence of any business discussions, negotiations,
or agreements between Company and any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify">The Employee understands that Company
                                         has received and in the future will receive from third parties confidential or proprietary
                                         information <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(<B>&ldquo;Third
                                         Party Information&rdquo;</B>) </FONT>subject to a duty on Company&rsquo;s part to maintain
                                         the confidentiality of such information and to use it only for certain limited purposes.
                                         During and after the term of the Employee&rsquo;s employment, the Employee will hold
                                         Third Party Information in strict confidence and will not disclose to anyone (other than
                                         Company personnel who need to know such information in connection with their work for
                                         Company) or use, Third Party Information, except in connection with the Employee&rsquo;s
                                         work for Company or unless expressly authorized by an officer of Company in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">The Employee represents that employment by Company does not and will not breach any agreement with
any former employer, including any non-compete agreement or any agreement to keep in confidence or refrain from using information
acquired by the Employee prior to employment by Company. The Employee further represents that the Employee has not entered into,
and will not enter into, any agreement, either written or oral, in conflict with the Employee&rsquo;s obligations under this Agreement.
During employment by Company, the Employee will not improperly make use of, or disclose, any information or trade secrets of any
former employer or other third party, nor will the Employee bring onto the premises of Company or use any unpublished documents
or any property belonging to any former employer or other third party, in violation of any lawful agreements with that former employer
or third party. The Employee will use in the performance of the Employee&rsquo;s duties only information that is generally known
and used by persons with training and experience comparable to the Employee&rsquo;s own, is common knowledge in the industry or
otherwise legally in the public domain, or is otherwise provided or developed by Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>INVENTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">As used in this Agreement, the term
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Invention&rdquo;
                                         </B></FONT>means any ideas, concepts, information, materials, processes, data, programs,
                                         know-how, improvements, discoveries, developments, designs, artwork, formulae, other
                                         copyrightable works, and techniques and all Intellectual Property Rights in any of the
                                         items listed above. The term <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Intellectual
                                         Property Rights&rdquo;</B></FONT> means all trade secrets, copyrights, trademarks, mask
                                         work rights, patents and other intellectual property rights recognized by the laws of
                                         any jurisdiction or country. The term <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Moral
                                         Rights&rdquo;</B> </FONT>means all paternity, integrity, disclosure, withdrawal, special
                                         and any other similar rights recognized by the laws of any jurisdiction or country.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">The Employee has disclosed in <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
                                         C</B></FONT> a complete list of all Inventions that (a) the Employee has, or has caused
                                         to be, alone or jointly with others, conceived, developed, or reduced to practice prior
                                         to the commencement of the Employee&rsquo;s employment by Company; (b) in which the Employee
                                         has an ownership interest or which the Employee has a license to use; (c) and that the
                                         Employee wishes to have excluded from the scope of this Agreement (collectively referred
                                         to as <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Prior
                                         Inventions&rdquo;</B>). </FONT>If no Prior Inventions are listed in <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
                                         </B></FONT><B>C</B>, the Employee warrants that there are no Prior Inventions. The Employee
                                         agrees that the Employee will not incorporate, or permit to be incorporated, Prior Inventions
                                         in any Company Inventions (defined below) without Company&rsquo;s prior written consent.
                                         If, in the course of the Employee&rsquo;s employment with Company, the Employee incorporates
                                         a Prior Invention into a Company process, machine or other work, the Employee hereby
                                         grants Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and
                                         worldwide license, with rights to sublicense through multiple levels of sublicensees,
                                         to reproduce, make derivative works of, distribute, publicly perform, and publicly display
                                         in any form or medium, whether now known or later developed, make, have made, use, sell,
                                         import, offer for sale, and exercise any and all present or future rights in, such Prior
                                         Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">Inventions assigned to the Company
                                         or to a third party as directed by the Company pursuant to the subsection 5.5 are referred
                                         to in this Agreement as <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Company
                                         Inventions&rdquo;</B>. </FONT>Subject to the subsection 5.5 and the Prior Inventions
                                         Employee has set forth in <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
                                         C</B>, </FONT>the Employee hereby assigns and agrees to assign in the future (when any
                                         such Inventions or Intellectual Property Rights are first reduced to practice or first
                                         fixed in a tangible medium, as applicable) to the Company all rights, title, and interest
                                         in and to any and all Inventions (and all Intellectual Property Rights with respect thereto)
                                         made, conceived, reduced to practice, or learned by the Employee, either alone or with
                                         others, during the period of the Employee&rsquo;s employment by the Company. Any assignment
                                         of Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes
                                         an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned
                                         to the Company and to the extent the following is allowed by the laws in any country
                                         where Moral Rights exist, the Employee hereby unconditionally and irrevocably waives
                                         the enforcement of such Moral Rights, and all claims and causes of action of any kind
                                         against the Company or related to the Company&rsquo;s customers, with respect to such
                                         rights. The Employee further acknowledges and agrees that neither the Employee&rsquo;s
                                         successors-in-interest nor legal heirs retain any Moral Rights in any Inventions (and
                                         any Intellectual Property Rights with respect thereto).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">During the period of employment, the Employee will promptly and fully disclose to the Company in
writing (a) all Inventions authored, conceived, or reduced to practice by the Employee, either alone or with others, and (b) all
patent applications filed by the Employee or in which the Employee is named as an inventor or co-inventor. The Employee agrees
to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required
by the Company) of all Inventions made by the Employee during the period of the Employee&rsquo;s employment by the Company, which
records shall be available to, and remain the sole property of, the Company at all times.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.5</TD><TD STYLE="text-align: justify">The Employee agrees that, as directed by the Company, the Employee will assign to the Company or
a third party, including without limitation, all rights, title, and interest in and to any particular Company Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.6</TD><TD STYLE="text-align: justify">During and after the period of employment and at the Company&rsquo;s request and expense, the Employee
will assist the Company in every proper way, including consenting to and joining in any action, to obtain and enforce Canadian,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in all countries. If the
Company is unable to secure the Employee&rsquo;s signature on any document needed in connection with such purposes, the Employee
hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee&rsquo;s agent
and attorney in fact, which appointment is coupled with an interest, to act on the Employee&rsquo;s behalf to execute and file
any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as
if executed by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.7</TD><TD STYLE="text-align: justify">The Employee agrees that the Employee will not incorporate into any Company software or otherwise
deliver to the Company any software code licensed under the GNU General Public License or Lesser General Public License or any
other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or
distribution of any source code owned or licensed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>RETURN OF COMPANY PROPERTY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">Without limiting the provisions of Section 3.1(c), upon termination of the Employee&rsquo;s employment
or upon the Company&rsquo;s request at any other time, the Employee will deliver to the Company all of the Company&rsquo;s property,
equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third
Party Information or Confidential Information and certify in writing that the Employee has fully complied with the foregoing obligation.
The Employee agrees that the Employee will not copy, delete, or alter any information contained upon any Company computer or Company
equipment before the Employee returns it to the Company. In addition, if the Employee has used any personal computer, server, or
e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential
Information, the Employee agrees to provide the Company with a computer-useable copy of all such Confidential Information and then
permanently delete and expunge such Confidential Information from those systems; and the Employee agrees to provide the Company
access to the Employee&rsquo;s system as reasonably requested to verify that the necessary copying and/or deletion is completed.
The Employee further agrees that any property situated on the Company&rsquo;s premises and owned by the Company is subject to inspection
by the Company&rsquo;s personnel at any time with or without notice. Prior to the termination of employment or promptly after termination
of employment, the Employee will cooperate with the Company in attending an exit interview and certify in writing that the Employee
has complied with the requirements of this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>NON-COMPETITION/NON-SOLICITATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of the Employee&rsquo;s employment by the
Company and for one (1) year after termination of such employment for any reason (except in the event of a Change of Control pursuant
to the proviso at the end of Section 3.4(b), in which event such period shall extend to eighteen (18) months after termination
of such employment), the Employee will not, without the Company&rsquo;s express written consent, anywhere in the world, be employed
by or contribute to any business activity that is competitive with the business of the Company or involves the use of real-time
magnetic resonance imaging or ultrasound or similar technologies in the delivery of ablative tools.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that
for the period of the Employee&rsquo;s employment by the Company and for one (1) year after termination of such employment for
any reason (except in the event of a Change of Control pursuant to the proviso at the end of Section 3.4(b), in which event such
period shall extend to eighteen <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(18) </FONT>months
after termination of such employment), the Employee will not, either directly or indirectly, solicit or attempt to solicit any
employee, independent contractor, or consultant of the Company to terminate his, her or its relationship with Company in order
to become an employee, consultant, or independent contractor to or for any other person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>NOTIFICATION
                                         OF NEW EMPLOYER</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">After the termination of this Agreement, the Employee consents to the notification of any new employer
of the Employee&rsquo;s rights and obligations under this Agreement, by the Company providing a copy of this Agreement or otherwise
as the Company deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>INJUNCTIVE
                                         RELIEF</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that, because the Employee&rsquo;s services are personal and unique and
because the Employee will have access to the Confidential Information of the Company, any breach of this Agreement would cause
irreparable injury to the Company for which monetary damages would not be an adequate remedy and, therefore, will entitle the Company
to injunctive relief (including specific performance). The rights and remedies provided to each party in this Agreement are cumulative
and in addition to any other rights and remedies available to such party at law or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>PUBLICITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">The Employee shall not, without the prior written consent of the Company, make or give any public
announcements, press releases or statements to the public or the press regarding the Employee&rsquo;s work or the Company&rsquo;s
business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT>1<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal"><B><U>NOTICES</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">All notices, requests, demands and other communications to be given pursuant to the terms of this
Agreement shall be in writing and shall be deemed to have been duly given (i) on the date of delivery if personally delivered or
sent by a recognized overnight courier or (ii) on the date of transmission if sent by email (provided notice is then also promptly
delivered personally or by a recognized overnight courier), in each case to the parties at the addresses listed below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If to the Employee, at the Employee&rsquo;s then current address in the Company&rsquo;s payroll
records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If to the Company:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent">Profound
Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent">2400
Skymark Avenue, Unit 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent">Mississauga,
ON L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent">Attention:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chair
of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent">E-mail:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[_______________________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">Each
party may change its address for receipt of notice by giving notice of the change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>SURVIVAL</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify">The Employee&rsquo;s obligations under this Agreement shall survive the termination of the Employee&rsquo;s
employment, regardless of the manner or reason for termination, including, without limitation, those set forth in Sections 4 through
7 hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify">The assignment of this Agreement by the Company to any successor or other assignee and shall be
binding upon the Employee&rsquo;s heirs and legal representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>SEVERABILITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">If any provision of this Agreement is, for any reason, held to be invalid or unenforceable, the
other provisions of this Agreement will remain enforceable and the invalid or unenforceable provision will be deemed modified so
that it is valid and enforceable to the maximum extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>WAIVER</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.1</TD><TD STYLE="text-align: justify">Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed
a waiver of that provision or any other provision on any other occasion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>ASSIGNMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.1</TD><TD STYLE="text-align: justify">The Company may assign this Agreement to (i) an affiliate, subsidiary, related company or partnership
without prior notice or consent of the Employee, or (ii) a new employer in connection with any transaction or reorganization; provided
that any such successor or assignee expressly assumes in writing the Company&rsquo;s obligations under this Agreement and has responsibility
for managing the underlying business of the Company. The Employee may not assign any of his rights nor delegate any of the duties
hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>ENTIRE
                                         AGREEMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">16.1</TD><TD STYLE="text-align: justify">This Agreement is the final, complete and&#9;exclusive
agreement&#9;of the parties with&#9;respect to the subject matter hereof and supersedes and merges all prior communications between
us with respect to such matters. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement,
will be effective unless in writing and signed by the Employee and the Company. Any subsequent change or changes in duties, salary
or compensation will not affect the validity or scope of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>HEADINGS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.1</TD><TD STYLE="text-align: justify">The headings utilized in this Agreement are for convenience only and are not to be construed in
any way as additions or limitations of the covenants and agreements contained in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>COUNTERPARTS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.1</TD><TD STYLE="text-align: justify">This Agreement may be executed in two or more counterparts, each of which will be deemed to be
an original and all of which will constitute one Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>LAWS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.1</TD><TD STYLE="text-align: justify">This Agreement shall be governed by and interpreted in accordance with the laws of Ontario and
the laws of Canada applicable therein. The Employee and the Company hereby attorn to the exclusive jurisdiction of the superior
courts of Ontario to resolve any dispute arising from this Agreement except to the extent the Company seeks injunctive relief outside
Ontario where applicable to enforce the Employee&rsquo;s covenants hereunder.</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">[Signature
Page to Follow]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"><FONT STYLE="font-style: normal">IN
WITNESS WHEREOF the parties have duly executed this Agreement as of the 26<SUP>th</SUP> day of August<FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal">,
2019.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signed,
    Sealed and Delivered</B> <FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">in the presence of:</FONT></FONT></TD>
    <TD STYLE="width: 6%; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-weight: normal; font-style: normal"></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-weight: normal; font-style: normal; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal">Arun
    Menawat</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Name
    (witness)</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-size: 12pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; background-color: white">2400
    Skymark Unit 6</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-size: 12pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Address</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Miss.
    &nbsp;&nbsp;&nbsp;ON</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-size: 18pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; background-color: white; font-size: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Rashed Dewan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-size: 18pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-size: 18pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RASHED
    DEWAN</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Occupation</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Arun Menawat</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Arun Menawat</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in; background-color: transparent"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>Exhibit
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>RELEASE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">I,
Rashed Dewan of the City of ________, in the Province of Ontario, for and in consideration of the sum of * ($*) and other good
and valuable consideration which is being delivered to me concurrently with the execution and delivery hereof (the receipt and
sufficiency of which is hereby acknowledged) do hereby remise, release and forever discharge <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>PROFOUND
MEDICAL CORP. </B></FONT>(hereinafter called the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Company&rdquo;</B>),
</FONT>its officers, directors, servants, employees and agents, including any related or associated companies, and their heirs,
executors, administrators, successors and assigns, as the case may be, of and from any and all manner of actions, causes of action,
suits, contracts, claims, damages, costs and expenses of any nature or kind whatsoever, whether in law or in equity, which, as
against the Company or such persons as aforesaid or any of them I have ever had, now have, or at any time hereafter I or my personal
representatives can, shall or may have, by reason of or arising out of the termination of my employment with the Company or in
any other way connected with my employment with the Company (except as otherwise set forth below), and more specifically, without
limiting the generality of the foregoing, any and all claims for damages for termination of my employment, constructive termination
of my employment, loss of position, loss of status, loss of future job opportunity, loss of opportunity to enhance my reputation,
the timing of the termination and the manner in which it was effected, loss of bonuses, loss of benefits, including life insurance
and short and long-term disability benefit coverage, and any other type of damages; <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><U>provided,
however,</U></FONT> that notwithstanding anything contained herein, this Release does not apply to any claims related to (i) equity
in the Company or its affiliates that I hold, directly or indirectly, including without limitation, the options granted to me
in connection with my employment with the Company, or (ii) any unpaid reimbursement of expenses and accrued but unpaid salary
or termination payments provided for in the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">I
FURTHER AGREE that this Release includes any and all claims I may have arising under contract, the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
Standards Act, 2000,</I></FONT> as amended, common law or other applicable law related to my employment with the Company and that
the consideration provided includes any amount that I may be entitled to under such legislation and I agree to immediately withdraw
any complaint as settled and not to file any complaint pursuant to such legislation with respect to my employment or the termination
of my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS UNDERSTOOD that the Company has withheld income tax and other statutory deductions from the aforesaid consideration and I agree
to indemnify and hold harmless the Company from any further assessment for income tax or other statutory deductions which may be
made under statutory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS FURTHER UNDERSTOOD that as a former officer of the Company I owe a fiduciary duty to the Company and I agree that the Company
will suffer irreparable harm if confidential information or information unique to the Company is disclosed in any way by me without
authorization of the Company and that I have returned to the Company originals or copies of the Company&rsquo;s corporate records,
files, financial documents, client lists, or any other material that is related to the Company&rsquo;s business, clients, personnel
or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS FURTHER UNDERSTOOD AND AGREED that this is not to be construed or considered as an admission of liability on the part of the
Company. The terms of this Release set out the entire agreement between myself and the Company and are intended to be contractual
and not a mere recital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">IT
IS EXPRESSLY ACKNOWLEDGED that the contents, terms and effect of this Release have been explained to me by my lawyer and are fully
understood.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">IN
WITNESS WHEREOF I, Rashed Dewan, have hereunto set my hand and seal this _____ day of ________________________, 20__ in the City
of _______________, Province of Ontario.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal">Rashed Dewan</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT <FONT STYLE="font-variant: normal">C</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INVENTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>1.
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Prior
Inventions Disclosure. </FONT></FONT></B><FONT STYLE="font-size: 10pt">The following is a complete list of all Prior Inventions
(as provided in Subsection 5.2 of the attached Employment Agreement):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings; font-size: 10pt; background-color: white">&uml;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">None</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">See immediately below:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.14
<SEQUENCE>20
<FILENAME>tv526458_ex4-14.htm
<DESCRIPTION>EXHIBIT 4.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-style: normal; font-variant: normal"><B>Exhibit
4.14</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="tv526458_ex4-14img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>AMENDED
AND RESTATED EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">THIS AMENDED
AND RESTATED EMPLOYMENT AGREEMENT (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Agreement&rdquo;) </B></FONT>dated
as of the August 20, 2019 (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Effective Date&rdquo;</B>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">BETWEEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">AND:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>GOLDY SINGH (the &ldquo;Employee&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">WHEREAS the
Company and the Employee entered into a letter agreement as to employment on November 2, 2011 (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Original
Agreement&rdquo;); </B></FONT>and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">WHEREAS the
Company and the Employee wish to amend and restate the Original Agreement on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW
THEREFORE </B></FONT>in consideration of the covenants and agreements herein, the sufficiency of which is acknowledged by each
of the parties, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>EMPLOYMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Effectiveness
                                         of the Agreement: </B></FONT>The terms and conditions of employment of the Employee by
                                         the Company prior to the Effective Date shall be governed by the Original Agreement and
                                         the attachments and exhibits thereto, and as of the Effective Date will be governed by
                                         the Agreement. The Employee&rsquo;s employment with the Company commenced on December
                                         1, 2011 and will continue until this Agreement is terminated in accordance with section
                                         4 herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Title</B>:
                                         </FONT>The Company agrees to continue to employ the Employee as <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>VP
                                         Regulatory Affairs and Product Management </B></FONT>upon the terms and conditions set
                                         out in this Agreement. The Employee will report to the Chief Executive Officer of the
                                         Company (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;CEO&rdquo;</B>)
                                         </FONT>or such person the Company advises from time to time. The Employee acknowledges
                                         that she shall undertake such duties and responsibilities for the Company and its affiliates
                                         in connection with and commensurate with the Employee&rsquo;s position as are determined
                                         by the CEO or to anyone else the CEO designates from time to time. The Employee further
                                         acknowledges the Company may re-assign, re-allocate, or re-organize the Employee&rsquo;s
                                         duties and responsibilities as circumstances change, provided such duties and responsibilities
                                         are consistent with the role of a VP Clinical Affairs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Service</B>:
                                         </FONT>During the term of this Agreement, in addition to the Employee&rsquo;s common
                                         law duties to the Company, the Employee covenants and agrees as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Loyalty
                                         to the Company</B>: Throughout the Employee&rsquo;s employment, the Employee will faithfully
                                         serve the Company and use the Employee&rsquo;s best efforts to promote the business of
                                         the Company. The Employee will act honestly and in good faith, in the best interests
                                         of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Service</B>:
                                         </FONT>The Employee shall devote her full working time and attention to the affairs of
                                         the Company. The Employee shall not engage in any other business, profession or occupation,
                                         or become an officer, employee, contractor for service, agent, or representative of any
                                         other company, partnership, firm, person, organization, or enterprise during the term
                                         of this Agreement, provided that the Employee may participate on boards of directors
                                         of other organizations (to a maximum of one (1) at any one time) and in business associations,
                                         charitable organizations or other similar organizations, as may be approved by the CEO
                                         in its discretion, acting reasonably, and provided that such participation does not interfere
                                         with the proper discharge of her duties to the Company. The Employee currently has disclosed
                                         that she is not currently a director of a board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>No
                                         Personal Benefit</B>: The Employee will not receive or accept for the Employee&rsquo;s
                                         own benefit or for any other person or entity&rsquo;s benefit, either directly or indirectly,
                                         any commission, rebate, discount, gratuity or profit from any person or entity having
                                         or proposing to have one or more business transactions with the Company, without the
                                         prior approval of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Business
                                         Opportunities</B>: During the Employee&rsquo;s employment with the Company, the Employee
                                         will communicate and channel to the Company all knowledge, business and customer contacts
                                         and any other information that could concern or be in any way beneficial to the business
                                         of the Company. Any such information communicated to the Company as aforesaid will be
                                         and remain the property of the Company notwithstanding any subsequent termination of
                                         the Employee&rsquo;s employment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Place
                                         of Work</B>: The Employee will work from the Company&rsquo;s premises located in 2400
                                         Skymark Avenue, Unit #6, Mississauga, Ontario L4W 5K5 and it is anticipated that the
                                         Employee will be required to travel extensively (both domestically and internationally)
                                         in the course of performing the Employee&rsquo;s duties. In addition, it is anticipated
                                         that the Company will increase its focus on sales in the U.S.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-existing
                                         Obligations</B>.</FONT> The Employee is hereby requested and directed by the Company
                                         to comply with any existing common law, contractual or statutory obligations to the Employee&rsquo;s
                                         former employer and to any other person or entity. The Company is not employing the Employee
                                         to obtain the confidential information or business opportunities <FONT STYLE="font-family: Times New Roman, Times, Serif">of
                                         </FONT>the Employee&rsquo;s former employer <FONT STYLE="font-family: Times New Roman, Times, Serif">or
                                         </FONT>any other person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Qualifications,
                                         Licences and Permits</B>: </FONT>The Employee must hold and maintain the appropriate
                                         class of licence, certificate, degree, accreditation, qualification, visa and/or permit
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(&ldquo;Authorizations&rdquo;)
                                         </B></FONT>for the proper performance of the Employee&rsquo;s duties, and to work in
                                         the jurisdictions in which the Employee is performing the Employee&rsquo;s duties. The
                                         Company may require the Employee to provide copies of Authorizations which are necessary
                                         for the Employee to perform the Employee&rsquo;s duties. Should the Employee fail to
                                         make reasonable efforts to maintain such Authorizations or if the Employee misrepresents
                                         such Authorizations, the Employee&rsquo;s employment will be deemed frustrated and will
                                         terminate without compensation or notice of any kind. All expenses related to the acquisition
                                         and maintenance of Authorizations will be borne by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exclusion/Debarment</B>:
</FONT>The Employee represents and warrants that the Employee has never been, and as a condition of continued employment shall
never be, during the term of this Agreement, excluded from any contracting by any Canadian or United States government agency
or authority. The Employee further represents and warrants that the Employee is not subject to any final adverse action, as that
term is defined in 42 U.S.C. &sect; 1320a-7e(g), and that no final adverse action has previously occurred or is pending or threatened
against the Employee. The Employee represents and warrants that the Employee is not under investigation by the FDA or any other
Canadian, United States or foreign regulatory agency nor has the Employee been debarred, suspended, proposed for debarment, declared
ineligible, or voluntarily excluded by any Canadian, United States or foreign government department or agency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Company
                                         Policy</B>: </FONT>The Employee acknowledges and agrees that the employment relationship
                                         will be governed by the standards and terms established <FONT STYLE="font-family: Times New Roman, Times, Serif">by
                                         </FONT>the Company&rsquo;s policies as they are established from time to time and the
                                         Employee agrees to comply with the terms of such policies which may be introduced, amended,
                                         deleted or modified in the sole discretion of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Professional
                                         Conduct</B>: </FONT>The Employee acknowledges and agrees that effective performance of
                                         the Employee&rsquo;s duties requires the highest level of integrity and the Company&rsquo;s
                                         complete confidence in the Employee&rsquo;s relationship with other employees of the
                                         Company and with all other persons with whom the Employee deals in the course of employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-style: normal; font-variant: normal">2.</FONT></TD><TD><FONT STYLE="font-style: normal; font-variant: normal"><B><U>COMPENSATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Base
                                         Salary: </B></FONT>The Employee will earn an annual salary equivalent to <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CDN$
                                         212,221.20 </B></FONT>(the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Base
                                         Salary&rdquo;), </B></FONT>less applicable deductions, payable in arrears for all services
                                         and work the Employee performs for the Company. Any increases will be in the discretion
                                         of the CEO. The Base Salary will be payable in accordance with the Company&rsquo;s normal
                                         payroll practices and will be payable in Canadian dollars on the applicable payroll date.
                                         The Employee&rsquo;s hours and schedule may change from time to time depending on the
                                         Company&rsquo;s business needs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Annual
                                         Discretionary Bonus: </B></FONT>Provided the Employee remains an employee of the Company
                                         in good standing and the Employee has not received or given notice of termination, for
                                         each calendar year, the Employee will be eligible to receive an <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>annual
                                         bonus of up to 20% of the Employee&rsquo;s Base Salary </B></FONT>based on the assessment
                                         of the Board of the Employee&rsquo;s and the Company&rsquo;s achievement of certain milestones
                                         and objectives determined by the Board. Such milestones and objectives (including the
                                         evaluation of achievement thereof), and the bonus amount, will be at the sole discretion
                                         of the Board and will be payable in accordance with the Company&rsquo;s standard payroll
                                         policies, subject to applicable payroll deductions and withholdings. Such bonus shall
                                         be paid within ninety (90) days after the end of the applicable calendar year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Stock
                                         Options</B>: </FONT>The options to purchase common shares of the Company previously received
                                         by the Employee <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(&ldquo;Stock
                                         Options&rdquo;) </B></FONT>shall continue to vest during the term of this Agreement in
                                         accordance with their terms. The Company shall consider compensation as a whole, including
                                         stock incentives, of Vice President Regulatory Affairs and Product Management or similar
                                         roles of comparable companies when considering compensation or the grant of stock options
                                         for the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Benefits</B>:
                                         </FONT>The Employee will be entitled to participate in the standard insurance plans
                                         and other benefit programs (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Employee
                                         Benefits&rdquo;) </B></FONT>which the Company may offer to management level employees
                                         from time-to-time. The Company reserves the right to unilaterally revise the terms of
                                         the Employee Benefits, to change carriers, or to eliminate any Employee Benefits altogether.
                                         The Employee Benefits will be provided in accordance with the formal plan documents or
                                         policies and any issues with respect to entitlement or payment of benefits under any
                                         of the Employee Benefits will be governed by the terms of such documents or policies
                                         establishing the benefits in issue and will be a matter between the Employee and the
                                         insurer. The Company&rsquo;s liability with respect to the Employee Benefits will be
                                         limited to the payment of its share of applicable premiums.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Expenses</B>:
                                         </FONT>The Company will reimburse the Employee for all reasonable business expenses actually
                                         and exclusively incurred in connection with the performance of duties under this Agreement,
                                         provided such expenses are incurred and accounted for in accordance with the general
                                         policies and procedures of the Company, as established from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Statutory
                                         Holidays</B>: </FONT>The Company recognizes the statutory holidays observed in Ontario.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Vacation</B>:
                                         </FONT>The Employee shall be entitled to 4 weeks of paid vacation per annum, to be
                                         taken at such reasonable times as the Company shall in its discretion permit and in accordance
                                         with the Company&rsquo;s vacation policy in effect from time to time. Vacation entitlement
                                         for any partial year of employment shall be pro-rated based on the portion of the year
                                         worked by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>TERMINATION
                                         OF AGREEMENT AND EMPLOYMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Obligations
                                         Upon Termination</B>: </FONT>Upon termination of the Employee&rsquo;s employment, for
                                         any reason:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Company shall pay the Employee
                                         all unpaid Base Salary and vacation pay earned up to and including the Employee&rsquo;s
                                         last day of employment (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Termination
                                         Date&rdquo;);</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">all benefits coverage and other
                                         perquisites of the Employee&rsquo;s employment shall cease on the later of the Termination
                                         Date or as specified in 3.3(a);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">all files, computer disks, information
                                         and documents pertaining to the Company&rsquo;s business shall remain the property of
                                         the Company, and shall promptly be delivered by the Employee to the Company&rsquo;s office,
                                         and no copy, duplication or reproduction of any kind whatsoever shall be made of such
                                         files, computer disks, information or documents, or retained by the Employee, without
                                         the express written consent of the Company. The Employee agrees to deliver all electronic
                                         information to the Company and to destroy any copies held by the Employee belonging to
                                         the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Termination
                                         by the Employee</B>: </FONT>The Employee may terminate this Agreement at any time by
                                         providing the Company with ninety (90) days&rsquo; prior written notice. Upon receipt
                                         of such notice, the Company may at any time terminate the employment of the Employee
                                         and pay the Employee the amount of Base Salary the Employee would have otherwise received
                                         during the balance of the aforementioned notice period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Termination
                                         by the Company</B>: </FONT>The Company may terminate the Employee&rsquo;s employment
                                         at any time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">without Cause by providing the
                                         Employee with the greater of: (i) pay in lieu of notice, benefit continuation (and severance
                                         pay, if applicable) that is required by the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Employment
                                         Standards Act, 2000</I></FONT> as amended or (ii) (A) a minimum of six (6) months of
                                         pay of Base Salary in lieu of notice (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Severance
                                         Period&rdquo;) </B></FONT>and (B) an amount equal to the then current target annual bonus
                                         prorated based on the number of days elapsed in the calendar year until the date of termination
                                         as a percentage of the total number of days in such calendar year. The Employee will
                                         continue to provide services to the Company on an as-needed basis for a period of up
                                         to I month following the termination of her employment (the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Transition
                                         Period&rdquo;), </B></FONT>including assistance with transition of duties, unless the
                                         requirement for active service is expressly waived in whole or in part by the Company,
                                         in its sole discretion. The Employee agrees that the Company may, in its sole discretion,
                                         limit or discontinue the Executive&rsquo;s access to business records and Confidential
                                         Information during the Transition Period. The Employee agrees that any services provided
                                         to the Company during the Transition Period shall be for no additional compensation in
                                         excess of the severance payments and benefits contemplated under this Agreement. Regardless
                                         of whether or not the Employee provides active service during the Transition Period,
                                         the Employee shall continue to abide by all obligations owing under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for frustration of contract upon
                                         the death of the Employee or any incapacitation of the Employee that constitutes an undue
                                         hardship for the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">at any time for just Cause, without
                                         notice or pay in lieu of notice or any other form of compensation, severance pay or damages.
                                         For the purposes of this Agreement, <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Cause&rdquo;
                                         </B></FONT>includes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">any material breach of the provisions
                                         of this Agreement by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">any intentional or grossly negligent
                                         disclosure of any confidential information by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">conduct on the Employee&rsquo;s
                                         part that is materially detrimental to the business or the financial position of the
                                         Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">personal conduct on the Employee&rsquo;s
                                         part which is of such a serious and substantial nature that it will injure the reputation
                                         of the Company if the Employee was retained as an employee; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">any and all commissions, omissions
                                         or other conduct which would constitute just cause at law, in addition to the specified
                                         causes noted above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Timing
                                         of Payments: </B></FONT>All amounts payable hereunder in respect of Base Salary or with
                                         respect to payments made under the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Employment
                                         Standards Act, 2000,</I></FONT> as amended, shall be paid in installments in accordance
                                         with the Company&rsquo;s normal payroll practices. Payments in respect of annual or prorated
                                         bonuses shall be paid at the time the annual bonus would otherwise be paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>No
                                         Implied Entitlement</B>: </FONT>Other than as expressly provided herein, the Employee
                                         will not be entitled to receive any further pay or compensation, severance pay, notice,
                                         payment in lieu of notice, incentives, bonuses, benefits or damages of any kind from
                                         the Company or from any affiliate of the Company. Any payment in lieu of the Severance
                                         Period payment provided to the Employee will be inclusive of any entitlements upon termination
                                         or severance pay pursuant to the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Employment
                                         Standards Act, 2000</I></FONT> as amended, contract, tort, common law or otherwise, and
                                         will be subject to statutory withholdings. The Employee will not be entitled to receive
                                         any further pay or compensation (except for pay, if any, accrued and owing under this
                                         Agreement up to the date of termination of employment) from the Company, and for clarity,
                                         without limiting the foregoing, the Employee will not be entitled to any bonus or pro
                                         rata bonus payment that has not already been awarded to the Employee by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Continued
                                         Effect: </B></FONT>Notwithstanding any changes in the terms and conditions of the Employee&rsquo;s
                                         employment which may occur in the future, including any changes in position, duties or
                                         compensation, the termination provisions in this Agreement will continue to be in effect
                                         for the duration of the Employee&rsquo;s employment with the Company unless otherwise
                                         amended in writing and signed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Obligations
                                         Upon Termination. </B></FONT>The Employee agrees that she shall not be entitled to receive
                                         any severance fee or other benefits under Section 3 of this Agreement if the Employee
                                         breaches any of her obligations arising under Sections 4, 5, 6, 7, 8, 9 and 10 hereof.
                                         The Employee acknowledges that until a release in the form of <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
                                         B </B></FONT>hereto (a <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Release&rdquo;)
                                         </B></FONT>is timely executed and delivered to the Company, the Company will not be obligated
                                         to make any severance payments or provide any other benefits due under this Agreement
                                         following termination of the Employee. The Employee further acknowledges that if the
                                         Release is not timely executed and delivered to the Company, the severance payments and
                                         other benefits described in this Section 3 shall be forfeited, except as required by
                                         statutory minimum standards.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>CONFIDENTIAL
                                         INFORMATION PROTECTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">At all times during and after the Employee&rsquo;s
                                         employment, the Employee will hold in confidence and will not disclose, use, lecture
                                         upon, or publish any of Company&rsquo;s Confidential Information (defined below), except
                                         as may be required in connection with the Employee&rsquo;s work for Company, or as expressly
                                         authorized by the Board. The Employee will obtain the written approval of the Board before
                                         publishing or submitting for publication any material (written, oral, or otherwise) that
                                         relates to the Employee&rsquo;s work at Company and/or incorporates any Confidential
                                         Information. The Employee hereby assigns to Company any rights the Employee may have
                                         or acquire in any and all Confidential Information and recognize that all Confidential
                                         Information shall be the sole and exclusive property of Company and its assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The term &ldquo;Confidential Information&rdquo;
                                         shall mean any and all confidential knowledge, data or information related to Company&rsquo;s
                                         or its affiliates business or its actual or demonstrably anticipated research or development,
                                         including without limitation (a) trade secrets, inventions, ideas, processes, computer
                                         source and object code, data, formulae, programs, other works of authorship, know-how,
                                         improvements, discoveries, developments, designs, and techniques; (b) information regarding
                                         products, services, plans for research and development, marketing and business plans,
                                         budgets, financial statements, contracts, prices, suppliers, employees and customers;
                                         (c) information regarding the skills and compensation of Company&rsquo;s employees, contractors,
                                         and any other service providers of Company; and (d) the existence of any business discussions,
                                         negotiations, or agreements between Company and any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify">The Employee understands that Company
                                         has received and in the future will receive from third parties confidential or proprietary
                                         information <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(&ldquo;Third
                                         Party Information&rdquo;) </B></FONT>subject to a duty on Company&rsquo;s part to maintain
                                         the confidentiality of such information and to use it only for certain limited purposes.
                                         During and after the term of the Employee&rsquo;s employment, the Employee will hold
                                         Third Party Information in strict confidence and will not disclose to anyone (other than
                                         Company personnel who need to know such information in connection with their work for
                                         Company) or use, Third Party Information, except in connection with the Employee&rsquo;s
                                         work for Company or unless expressly authorized by an officer of Company in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">The Employee represents that employment
                                         by Company does not and will not breach any agreement with any former employer, including
                                         any non-compete agreement or any agreement to keep in confidence or refrain from using
                                         information acquired by the Employee prior to employment by Company. The Employee further
                                         represents that the Employee has not entered into, and will not enter into, any agreement,
                                         either written or oral, in conflict with the Employee&rsquo;s obligations under this
                                         Agreement. During employment by Company, the Employee will not improperly make use of,
                                         or disclose, any information or trade secrets of any former employer or other third party,
                                         nor will the Employee bring onto the premises of Company or use any unpublished documents
                                         or any property belonging to any former employer or other third party, in violation of
                                         any lawful agreements with that former employer or third party. The Employee will use
                                         in the performance of the Employee&rsquo;s duties only information that is generally
                                         known and used by persons with training and experience comparable to the Employee&rsquo;s
                                         own, is common knowledge in the industry or otherwise legally in the public domain, or
                                         is otherwise provided or developed by Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>INVENTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">As used in this Agreement, the term
                                         <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Invention&rdquo; </B></FONT>means
                                         any ideas, concepts, information, materials, processes, data, programs, know-how, improvements,
                                         discoveries, developments, designs, artwork, formulae, other copyrightable works, and
                                         techniques and all Intellectual Property Rights in any of the items listed above. The
                                         term <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Intellectual
                                         Property Rights&rdquo; </B></FONT>means all trade secrets, copyrights, trademarks, mask
                                         work rights, patents and other intellectual property rights recognized by the laws of
                                         any jurisdiction or country. The term <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Moral
                                         Rights&rdquo; </B></FONT>means all paternity, integrity, disclosure, withdrawal, special
                                         and any other similar rights recognized by the laws of any jurisdiction or country.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">The Employee has disclosed in <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
                                         </B></FONT><B>C</B> a complete list of all Inventions that (a) the Employee has, or has
                                         caused to be, alone or jointly with others, conceived, developed, or reduced to practice
                                         prior to the commencement of the Employee&rsquo;s employment by Company; (b) in which
                                         the Employee has an ownership interest or which the Employee has a license to use; (c)
                                         and that the Employee wishes to have excluded from the scope of this Agreement (collectively
                                         referred to as <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Prior
                                         Inventions&rdquo;). </B></FONT>If no Prior Inventions are listed in <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
                                         </B></FONT><B>C</B>, the Employee warrants that there are no Prior Inventions. The Employee
                                         agrees that the Employee will not incorporate, or permit to be incorporated, Prior Inventions
                                         in any Company Inventions (defined below) without Company&rsquo;s prior written consent.
                                         If, in the course of the Employee&rsquo;s employment with Company, the Employee incorporates
                                         a Prior Invention into a Company process, machine or other work, the Employee hereby
                                         grants Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and
                                         worldwide license, with rights to sublicense through multiple levels of sublicensees,
                                         to reproduce, make derivative works of, distribute, publicly perform, and publicly display
                                         in any form or medium, whether now known or later developed, make, have made, use, sell,
                                         import, offer for sale, and exercise any and all present or future rights in, such Prior
                                         Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">Inventions assigned to the Company
                                         or to a third party as directed by the Company pursuant to the subsection 5.5 are referred
                                         to in this Agreement as <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Company
                                         Inventions&rdquo;. </B></FONT>Subject to the subsection 5.5 and the Prior Inventions
                                         Employee has set forth in <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
                                         C, </B></FONT>the Employee hereby assigns and agrees to assign in the future (when any
                                         such Inventions or Intellectual Property Rights are first reduced to practice or first
                                         fixed in a tangible medium, as applicable) to the Company all rights, title, and interest
                                         in and to any and all Inventions (and all Intellectual Property Rights with respect thereto)
                                         made, conceived, reduced to practice, or learned by the Employee, either alone or with
                                         others, during the period of the Employee&rsquo;s employment by the Company. Any assignment
                                         of Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes
                                         an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned
                                         to the Company and to the extent the following is allowed by the laws in any country
                                         where Moral Rights exist, the Employee hereby unconditionally and irrevocably waives
                                         the enforcement of such Moral Rights, and all claims and causes of action of any kind
                                         against the Company or related to the Company&rsquo;s customers, with respect to such
                                         rights. The Employee further acknowledges and agrees that neither the Employee&rsquo;s
                                         successors-in-interest nor legal heirs retain any Moral Rights in any Inventions (and
                                         any Intellectual Property Rights with respect thereto).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">During the period of employment, the
                                         Employee will promptly and fully disclose to the Company in writing (a) all Inventions
                                         authored, conceived, or reduced to practice by the Employee, either alone or with others,
                                         and (b) all patent applications filed by the Employee or in which the Employee is named
                                         as an inventor or co-inventor. The Employee agrees to keep and maintain adequate and
                                         current records (in the form of notes, sketches, drawings and in any other form that
                                         is required by the Company) of all Inventions made by the Employee during the period
                                         of the Employee&rsquo;s employment by the Company, which records shall be available to,
                                         and remain the sole property of, the Company at all times.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.5</TD><TD STYLE="text-align: justify">The Employee agrees that, as directed
                                         by the Company, the Employee will assign to the Company or a third party, including without
                                         limitation, all rights, title, and interest in and to any particular Company Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.6</TD><TD STYLE="text-align: justify">During and after the period of employment
                                         and at the Company&rsquo;s request and expense, the Employee will assist the Company
                                         in every proper way, including consenting to and joining in any action, to obtain and
                                         enforce Canadian, United States and foreign Intellectual Property Rights and Moral Rights
                                         relating to Company Inventions in all countries. If the Company is unable to secure the
                                         Employee&rsquo;s signature on any document needed in connection with such purposes, the
                                         Employee hereby irrevocably designates and appoints the Company and its duly authorized
                                         officers and agents as the Employee&rsquo;s agent and attorney in fact, which appointment
                                         is coupled with an interest, to act on the Employee&rsquo;s behalf to execute and file
                                         any such documents and to do all other lawfully permitted acts to further such purposes
                                         with the same legal force and effect as if executed by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.7</TD><TD STYLE="text-align: justify">The Employee agrees that the Employee
                                         will not incorporate into any Company software or otherwise deliver to the Company any
                                         software code licensed under the GNU General Public License or Lesser General Public
                                         License or any other license that, by its terms, requires or conditions the use or distribution
                                         of such code on the disclosure, licensing, or distribution of any source code owned or
                                         licensed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>RETURN
                                         OF COMPANY PROPERTY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">Without limiting the provisions of
                                         Section 3.1(c), upon termination of the Employee&rsquo;s employment or upon the Company&rsquo;s
                                         request at any other time, the Employee will deliver to the Company all of the Company&rsquo;s
                                         property, equipment, and documents, together with all copies thereof, and any other material
                                         containing or disclosing any Inventions, Third Party Information or Confidential Information
                                         and certify in writing that the Employee has fully complied with the foregoing obligation.
                                         The Employee agrees that the Employee will not copy, delete, or alter any information
                                         contained upon any Company computer or Company equipment before the Employee returns
                                         it to the Company. In addition, if the Employee has used any personal computer, server,
                                         or e-mail system to receive, store, review, prepare or transmit any Company information,
                                         including but not limited to, Confidential Information, the Employee agrees to provide
                                         the Company with a computer-useable copy of all such Confidential Information and then
                                         permanently delete and expunge such Confidential Information from those systems; and
                                         the Employee agrees to provide the Company access to the Employee&rsquo;s system as reasonably
                                         requested to verify that the necessary copying and/or deletion is completed. The Employee
                                         further agrees that any property situated on the Company&rsquo;s premises and owned by
                                         the Company is&#9;subject to inspection by the Company&rsquo;s personnel at any time
                                         with or without notice. Prior to the&#9;termination of employment or promptly after termination
                                         of employment, the Employee will cooperate with the Company in attending an exit interview
                                         and certify in writing that the Employee has complied with the requirements of this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>NON-COMPETITION/NON-SOLICITATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that
                                         for the period&#9;of the Employee&rsquo;s employment by the Company and for one (1) year
                                         after termination of such employment for any reason (except in the event of a Change
                                         of Control pursuant to the proviso at the end of Section 3.4(b), in which event such
                                         period shall extend to eighteen (18) months after termination of such employment), the
                                         Employee will not, without the Company&rsquo;s express written consent, anywhere in the
                                         world, be employed by or contribute to any business activity that is competitive with
                                         the business of the Company or involves the use of real-time magnetic resonance imaging
                                         or ultrasound or similar technologies in the delivery of ablative tools.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that
                                         for the period of the Employee&rsquo;s employment by the Company and for one (1) year
                                         after termination of such employment for any reason (except in the event of a Change
                                         of Control pursuant to the proviso at the end of Section 3.4(b), in which event such
                                         period shall extend to eighteen (18) months after termination of such employment), the
                                         Employee will not, either directly or indirectly, solicit or attempt to solicit any employee,
                                         independent contractor, or consultant of the Company to terminate , her or its relationship
                                         with Company in order to become an employee, consultant, or independent contractor to
                                         or for any other person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>NOTIFICATION
                                         OF NEW EMPLOYER</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">After the termination of this Agreement,
                                         the Employee consents to the notification of any new employer of the Employee&rsquo;s
                                         rights and obligations under this Agreement, by the Company providing a copy of this
                                         Agreement or otherwise as the Company deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>INJUNCTIVE
                                         RELIEF</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that, because
                                         the Employee&rsquo;s services are personal and unique and because the Employee will have
                                         access to the Confidential Information of the Company, any breach of this Agreement would
                                         cause irreparable injury to the Company for which monetary damages would not be an adequate
                                         remedy and, therefore, will entitle the Company to injunctive relief (including specific
                                         performance). The rights and remedies provided to each party in this Agreement are cumulative
                                         and in addition to any other rights and remedies available to such party at law or in
                                         equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>PUBLICITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">The Employee shall not, without the
                                         prior written consent of the Company, make or give any public announcements, press releases
                                         or statements to the public or the press regarding the Employee&rsquo;s work or the Company&rsquo;s
                                         business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>NOTICES</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">All notices, requests, demands and
                                         other communications to be given pursuant to the terms of this Agreement shall be in
                                         writing and shall be deemed to have been duly given (i) on the date of delivery if personally
                                         delivered or sent by a recognized overnight courier or (ii) on the date of transmission
                                         if sent by email (provided notice is then also promptly delivered personally or by a
                                         recognized overnight courier), in each case to the parties at the addresses listed below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>If to the Employee, at the Employee&rsquo;s then current address
                                         in the Company&rsquo;s payroll records;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If to the Company:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; background-color: transparent">Profound
Medical Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; background-color: transparent">2400
Skymark Avenue, Unit 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; background-color: transparent">Mississauga,
ON L4W 5K5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in; background-color: transparent">Attention:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chair
of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[___________________]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent">Each
party may change its address for receipt of notice by giving notice of the change to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>SURVIVAL</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify">The Employee&rsquo;s obligations under
                                         this Agreement shall survive the termination of the Employee&rsquo;s employment, regardless
                                         of the manner or reason for termination, including, without limitation, those set forth
                                         in Sections 4 through 7 hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify">The assignment of this Agreement by
                                         the Company to any successor or other assignee and shall be binding upon the Employee&rsquo;s
                                         heirs and legal representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>SEVERABILITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify">If any provision of this Agreement
                                         is, for any reason, held to be invalid or unenforceable, the other provisions of this
                                         Agreement will remain enforceable and the invalid or unenforceable provision will be
                                         deemed modified so that it is valid and enforceable to the maximum extent permitted by
                                         law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>WAIVER</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.1</TD><TD STYLE="text-align: justify">Any waiver or failure to enforce any
                                         provision of this Agreement on one occasion will not be deemed a waiver of that provision
                                         or any other provision on any other occasion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>ASSIGNMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.1</TD><TD STYLE="text-align: justify">The Company may assign this Agreement
                                         to (i) an affiliate, subsidiary, related company or partnership without prior notice
                                         or consent of the Employee, or (ii) a new employer in connection with any transaction
                                         or reorganization; provided that any such successor or assignee expressly assumes in
                                         writing the Company&rsquo;s obligations under this Agreement and has responsibility for
                                         managing the underlying business of the Company. The Employee may not assign any of her
                                         rights nor delegate any of the duties hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>ENTIRE
                                         AGREEMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.1</TD><TD STYLE="text-align: justify">This Agreement is the final, complete
                                         and exclusive agreement of the parties with respect to the subject matter hereof and
                                         supersedes and merges all prior communications between us with respect to such matters.
                                         No modification of or amendment to this Agreement, or any waiver of any rights under
                                         this Agreement, will be effective unless in writing and signed by the Employee and the
                                         Company. Any subsequent change or changes in duties, salary or compensation will not
                                         affect the validity or scope of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>HEADINGS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.1</TD><TD STYLE="text-align: justify">The headings utilized in this Agreement
                                         are for convenience only and are not to be construed in any way as additions or limitations
                                         of the covenants and agreements contained in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>COUNTERPARTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.2</TD><TD STYLE="text-align: justify">This Agreement may be executed in
                                         two or more counterparts, each of which will be deemed to be an original and all of which
                                         will constitute one Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; color: black"><B><U>LAWS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.1</TD><TD STYLE="text-align: justify">This Agreement shall be governed by
                                         and interpreted in accordance with the laws of Ontario and the laws of Canada applicable
                                         therein. The Employee and the Company hereby attorn to the exclusive jurisdiction of
                                         the superior courts of Ontario to resolve any dispute arising from this Agreement except
                                         to the extent the Company seeks injunctive relief outside Ontario where applicable to
                                         enforce the Employee&rsquo;s covenants hereunder.</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">[Signature
Page to Follow]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">IN WITNESS
WHEREOF the parties have duly executed this Agreement as of the 26 day of august, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signed, Sealed and Delivered
    </B>in the presence</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARUN
    MENAWAT</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (witness)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">2400 SKYMARK
                                         UNIT 6 </TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">)</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0in">MISS., ON.</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">)</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address </FONT></TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt"></TD>
    <TD>&nbsp;</TD>
    <TD>)</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Goldy
    Singh</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Goldy Singh</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Occupation</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal"><B>PROFOUND
    MEDICAL CORP.</B></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Per:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/
    <FONT STYLE="font-size: 10pt">Arun Menawat</FONT></FONT></TD>
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Arun
    Menawat</FONT></TD>
    <TD STYLE="text-indent: 0in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>Exhibit
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>RELEASE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">I, Goldy Singh
of the City of ______, in the Province of Ontario, for and in consideration of the sum of * ($*) and other good and valuable consideration
which is being delivered to me concurrently with the execution and delivery hereof (the receipt and sufficiency of which is hereby
acknowledged) do hereby remise, release and forever discharge <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROFOUND
MEDICAL CORP. </B></FONT>(hereinafter called the <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&ldquo;Company&rdquo;</B>),
</FONT>its officers, directors, servants, employees and agents, including any related or associated companies, and their heirs,
executors, administrators, successors and assigns, as the case may be, of and from any and all manner of actions, causes of action,
suits, contracts, claims, damages, costs and expenses of any nature or kind whatsoever, whether in law or in equity, which, as
against the Company or such persons as aforesaid or any of them I have ever had, now have, or at any time hereafter I or my personal
representatives can, shall or may have, by reason of or arising out of the termination of my employment with the Company or in
any other way connected with my employment with the Company (except as otherwise set forth below), and more specifically, without
limiting the generality of the foregoing, any and all claims for damages for termination of my employment, constructive termination
of my employment, loss of position, loss of status, loss of future job opportunity, loss of opportunity to enhance my reputation,
the timing of the termination and the manner in which it was effected, loss of bonuses, loss of benefits, including life insurance
and short and long-term disability benefit coverage, and any other type of damages; <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>provided,
however,</U></FONT> that notwithstanding anything contained herein, this Release does not apply to any claims related to (i) equity
in the Company or its affiliates that I hold, directly or indirectly, including without limitation, the options granted to me
in connection with my employment with the Company, or (ii) any unpaid reimbursement of expenses and accrued but unpaid salary
or termination payments provided for in the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">I FURTHER
AGREE that this Release includes any and all claims I may have arising under contract, the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Employment
Standards Act, 2000,</I></FONT> as amended, common law or other applicable law related to my employment with the Company and that
the consideration provided includes any amount that I may be entitled to under such legislation and I agree to immediately withdraw
any complaint as settled and not to file any complaint pursuant to such legislation with respect to my employment or the termination
of my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">IT IS UNDERSTOOD
that the Company has withheld income tax and other statutory deductions from the aforesaid consideration and I agree to indemnify
and hold harmless the Company from any further assessment for income tax or other statutory deductions which may be made under
statutory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">IT IS FURTHER
UNDERSTOOD that as a former officer of the Company I owe a fiduciary duty to the Company and I agree that the Company will suffer
irreparable harm if confidential information or information unique to the Company is disclosed in any way by me without authorization
of the Company and that I have returned to the Company originals or copies of the Company&rsquo;s corporate records, files, financial
documents, client lists, or any other material that is related to the Company&rsquo;s business, clients, personnel or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">IT IS FURTHER
UNDERSTOOD AND AGREED that this is not to be construed or considered as an admission of liability on the part of the Company.
The terms of this Release set out the entire agreement between myself and the Company and are intended to be contractual and not
a mere recital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS EXPRESSLY ACKNOWLEDGED that the contents, terms and effect of this Release have been explained to me by my lawyer and are fully
understood.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IN
WITNESS WHEREOF I, Goldy Singh, have hereunto set my hand and seal this ___ day of _______________, 20___ in the City of __________________,
Province of Ontario.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">Goldy Singh</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INVENTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
Inventions Disclosure. </B></FONT>The following is a complete list of all Prior Inventions (as provided in Subsection 5.2 of the
attached Employment Agreement):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD>None</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD>See
                                         immediately below:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; background-color: transparent">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.15
<SEQUENCE>21
<FILENAME>tv526458_ex4-15.htm
<DESCRIPTION>EXHIBIT 4.15
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-style: normal; font-variant: normal"><B>Exhibit
4.15</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="tv526458_ex4-15img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>AMENDED
AND RESTATED EMPLOYMENT AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">THIS
AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the <B>&ldquo;Agreement&rdquo;</B>) dated as of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal">August
</FONT>20, 2019 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal">(the </FONT><B>&ldquo;Effective
Date&rdquo;</B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">BETWEEN;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>(the &ldquo;Company&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">AND:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MATHIEU BURTNYK (the &ldquo;Employee&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">WHEREAS
the Company and the Employee entered into a letter agreement as to employment on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal">June
</FONT>3, 2011 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal">(the </FONT><B>&ldquo;Original Agreement&rdquo;</B>);
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: normal">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">WHEREAS
the Company and the Employee wish to amend and restate the Original Agreement on the terms and conditions set forth herein.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white"><B>NOW
THEREFORE </B>in consideration of the covenants and agreements herein, the sufficiency of which is acknowledged by each of the
parties, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>EMPLOYMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Effectiveness
of the Agreement: </B>The terms and conditions of employment of the Employee by the Company prior to the Effective Date shall be
governed by the Original Agreement and the attachments and exhibits thereto, and as of the Effective Date will be governed by the
Agreement. The Employee&rsquo;s employment with the Company commenced on July 7, 2011 and will continue until this Agreement is
terminated in accordance with section 4 herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Title: </B>The
Company agrees to continue to employ the Employee as <B>VP Clinical Affairs </B>upon the terms and conditions set out in this Agreement.
The Employee will report to the Chief Executive Officer of the Company (the <B>&ldquo;CEO&rdquo;) </B>or such person the Company
advises from time to time. The Employee acknowledges that he shall undertake such duties and responsibilities for the Company and
its affiliates in connection with and commensurate with the Employee&rsquo;s position as are determined by the CEO or to anyone
else the CEO designates from time to time. The Employee further acknowledges the Company may re-assign, re-allocate, or re-organize
the Employee&rsquo;s duties and responsibilities as circumstances change, provided such duties and responsibilities are consistent
with the role of a VP Clinical Affairs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Service: </B>During
the term of this Agreement, in addition to the Employee&rsquo;s common law duties to the Company, the Employee covenants and agrees
as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Loyalty to
the Company: </B>Throughout the Employee&rsquo;s employment, the Employee will </FONT>faithfully serve the Company and use the
Employee&rsquo;s best efforts to promote the business of the Company. The Employee will act honestly and in good faith, in the
best interests of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Service: </B></FONT>The
Employee shall devote his full working time and attention to the affairs of the Company. The Employee shall not engage in any other
business, profession or occupation, or become an officer, employee, contractor for service, agent, or representative of any other
company, partnership, firm, person, organization, or enterprise during the term of this Agreement, provided that the Employee may
participate on boards of directors of other organizations (to a maximum of one (1) at any one time) and in business associations,
charitable organizations or other similar organizations, as may be approved by the CEO in its discretion, acting reasonably, and
provided that such participation does not interfere with the proper discharge of his duties to the Company. The Employee currently
has disclosed that he is not currently a director of a board.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>No Personal
Benefit: </B></FONT>The Employee will not receive or accept for the Employee&rsquo;s own benefit or for any other person or entity&rsquo;s
benefit, either directly or indirectly, any commission, rebate, discount, gratuity or profit from any person or entity having or
proposing to have one or more business transactions with the Company, without the prior approval of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Business Opportunities:
</B></FONT>During the Employee&rsquo;s employment with the Company, the Employee will communicate and channel to the Company all
knowledge, business and customer contacts and any other information that could concern or be in any way beneficial to the business
of the Company. Any such information communicated to the Company as aforesaid will be and remain the property of the Company notwithstanding
any subsequent termination of the Employee&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Place of Work:
</B></FONT>The Employee will work from the Company&rsquo;s premises located in 2400 Skymark Avenue, Unit #6, Mississauga, Ontario
L4W 5K5 and it is anticipated that the Employee will be required to travel extensively (both domestically and internationally)
in the course of performing the Employee&rsquo;s duties. In addition, it is anticipated that the Company will increase its focus
on sales in the U.S.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Pre-existing
Obligations. </B></FONT>The Employee is hereby requested and directed by the Company to comply with any existing common law, contractual
or statutory obligations to the Employee&rsquo;s former employer and to any other person or entity. The Company is not employing
the Employee to obtain the confidential information or business opportunities of the Employee&rsquo;s former employer or any other
person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Qualifications,
Licences and Permits: </B></FONT>The Employee must hold and maintain the appropriate class of licence, certificate, degree, accreditation,
qualification, visa and/or permit <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(<B>&ldquo;Authorizations&rdquo;</B>)
</FONT>for the proper performance of the Employee&rsquo;s duties, and to work in the jurisdictions in which the Employee is
performing the Employee&rsquo;s duties. The Company may require the Employee to provide copies of Authorizations which are necessary
for the Employee to perform the Employee&rsquo;s duties. Should the Employee fail to make reasonable efforts to maintain such Authorizations
or if the Employee misrepresents such Authorizations, the Employee&rsquo;s employment will be deemed frustrated and will terminate
without compensation or notice of any kind. All expenses related to the acquisition and maintenance of Authorizations will be borne
by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="background-color: white">1.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white"><B>Exclusion/Debarment: </B>The Employee represents and warrants
that the Employee has never been, and as a condition of continued employment shall never be, during the term of this Agreement,
excluded from any contracting by any Canadian or United States government agency or authority. The Employee further represents
and warrants that the Employee is not subject to any final adverse action, as that term is defined in 42 U.S.C. &sect; 1320a-7e(g),
and that no final adverse action has previously occurred or is pending or threatened against the Employee. The Employee represents
and warrants that the Employee is not under investigation by the FDA or any other Canadian, United States or foreign regulatory
agency nor has the Employee been debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded by any
Canadian, United States or foreign government department or agency.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Company Policy:
</B>The Employee acknowledges and agrees that the employment relationship will be governed by the standards and terms established
by the Company&rsquo;s policies as they are established from time to time and the Employee agrees to comply with the terms of such
policies which may be introduced, amended, deleted or modified in the sole discretion of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Professional
Conduct: </B>The Employee acknowledges and agrees that effective performance of the Employee&rsquo;s duties requires the highest
level of integrity and the Company&rsquo;s complete confidence in the Employee&rsquo;s relationship with other employees of the
Company and with all other persons with whom the Employee deals in the course of employment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-style: normal; font-variant: normal">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>COMPENSATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Base Salary:
</B>The Employee will earn an annual salary equivalent to CDN$160,500.00 (the <B>&ldquo;Base Salary&rdquo;</B>), less applicable
deductions, payable in arrears for all services and work the Employee performs for the Company. Any increases will be in the discretion
of the CEO. The Base Salary will be payable in accordance with the Company&rsquo;s normal payroll practices and will be payable
in Canadian dollars on the applicable payroll date. The Employee&rsquo;s hours and schedule may change from time to time depending
on the Company&rsquo;s business needs.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Annual Discretionary
Bonus: </B>Provided the Employee remains an employee of the Company in good standing and the Employee has not received or given
notice of termination, for each calendar year, the Employee will be eligible to <B>receive an annual bonus of up to 20% of the
Employee&rsquo;s Base Salary </B>based on the assessment of the Board of the Employee&rsquo;s and the Company&rsquo;s achievement
of certain milestones and objectives determined by the Board. Such milestones and objectives (including the evaluation of achievement
thereof), and the bonus amount, will be at the sole discretion of the Board and will be payable in accordance with the Company&rsquo;s
standard payroll policies, subject to applicable payroll deductions and withholdings. Such bonus shall be paid within ninety (90)
days after the end of the applicable calendar year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Stock Options:
</B>The options to purchase common shares of the Company previously received by the Employee (<B>&ldquo;Stock Options&rdquo;</B>) shall
continue to vest during the term of this Agreement in accordance with their terms. The Company shall consider compensation as a
whole, including stock incentives, of Vice President Clinical Affairs or similar roles of comparable companies when considering
compensation or the grant of stock options for the Employee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Benefits:
</B>The Employee will be entitled to participate in the standard insurance plans and other benefit programs (the <B>&ldquo;Employee
Benefits&rdquo;</B>) which the Company may offer to management level employees from time-to-time. The Company reserves the right
to unilaterally revise the terms of the Employee Benefits, to change carriers, or to eliminate any Employee Benefits altogether.
The Employee Benefits will be provided in accordance with the formal plan documents or policies and </FONT>any issues with respect
to entitlement or payment of benefits under any of the Employee Benefits will be governed by the terms of such documents or policies
establishing the benefits in issue and will be a matter between the Employee and the insurer. The Company&rsquo;s liability with
respect to the Employee Benefits will be limited to the payment of its share of applicable premiums.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Expenses:
</B></FONT>The Company will reimburse the Employee for all reasonable business expenses actually and exclusively incurred in connection
with the performance of duties under this Agreement, provided such expenses are incurred and accounted for in accordance with the
general policies and procedures of the Company, as established from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Statutory
Holidays: </B></FONT>The Company recognizes the statutory holidays observed in Ontario.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Vacation:
</B></FONT>The Employee shall be entitled to 4 weeks of paid vacation per annum, to be taken at such reasonable times as the Company
shall in its discretion permit and in accordance with the Company&rsquo;s vacation policy in effect from time to time. Vacation
entitlement for any partial year of employment shall be pro-rated based on the portion of the year worked by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>TERMINATION
                                         OF AGREEMENT AND EMPLOYMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Obligations
Upon Termination: </B></FONT>Upon termination of the Employee&rsquo;s employment, for any reason:</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Company shall pay the Employee
                                         all unpaid Base Salary and vacation pay earned up to and including the Employee&rsquo;s
                                         last day of employment (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Termination
                                         Date&rdquo;</B>);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">all benefits coverage and other perquisites of the Employee&rsquo;s employment shall cease on the
later of the Termination Date or as specified in 3.3(a);</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">all files, computer disks, information and documents pertaining to the Company&rsquo;s business
shall remain the property of the Company, and shall promptly be delivered by the Employee to the Company&rsquo;s office, and no
copy, duplication or reproduction of any kind whatsoever shall be made of such files, computer disks, information or documents,
or retained by the Employee, without the express written consent of the Company. The Employee agrees to deliver all electronic
information to the Company and to destroy any copies held by the Employee belonging to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Termination
by the Employee: </B></FONT>The Employee may terminate this Agreement at any time by providing the Company with ninety (90) days&rsquo;
prior written notice. Upon receipt of such notice, the Company may at any time terminate the employment of the Employee and pay
the Employee the amount of Base Salary the Employee would have otherwise received during the balance of the aforementioned notice
period.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Termination
by the Company: </B></FONT>The Company may terminate the Employee&rsquo;s employment at any time:</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">without Cause by providing the Employee with the greater of: (i) pay in lieu of notice, benefit
continuation (and severance pay, if applicable) that is required by the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
Standards Act, 2000</I></FONT> as amended or (ii) (A) a minimum of six (6) months of pay of Base Salary in lieu of notice (the
<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Severance Period&rdquo;</B>) </FONT>and
(B) an amount equal to the then current target annual bonus prorated based on the number of days elapsed in the calendar year until
the date of termination as a percentage of the total number of days in such calendar year. The Employee will continue to provide
services to the Company on an as-needed basis for a period of up to 1 month following the termination of his employment (the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Transition
Period&rdquo;</B>), </FONT>including assistance with transition of duties, unless the requirement for active service is expressly
waived in whole or in part by the Company, in its sole discretion. The Employee agrees that the Company may, in its sole discretion,
limit or discontinue the Executive&rsquo;s access to business records and Confidential Information during the Transition Period.
The Employee agrees that any services provided to the Company during the Transition Period shall be for no additional compensation
in excess of the severance payments and benefits contemplated under this Agreement. Regardless of whether or not the Employee provides
active service during the Transition Period, the Employee shall continue to abide by all obligations owing under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for frustration of contract upon the death of the Employee or any incapacitation of the Employee
that constitutes an undue hardship for the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">at any time for just Cause, without notice or pay in lieu of notice or any other form of compensation,
severance pay or damages. For the purposes of this Agreement, <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Cause&rdquo;
</B></FONT>includes:</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">any material breach of the provisions of this Agreement by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">any intentional or grossly negligent disclosure of any confidential information by the Employee;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">conduct on the Employee&rsquo;s part that is materially detrimental to the business or the financial
position of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">iv.</TD><TD STYLE="text-align: justify">personal conduct on the Employee&rsquo;s part which is of such a serious and substantial nature
that it will injure the reputation of the Company if the Employee was retained as an employee; or</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">v.</TD><TD STYLE="text-align: justify">any and all commissions, omissions or other conduct which would constitute just cause at law, in
addition to the specified causes noted above.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Timing of
Payments: </B></FONT>All amounts payable hereunder in respect of Base Salary or with respect to payments made under the Ontario
<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment Standards Act, 2000,</I></FONT>
as amended, shall be paid in installments in accordance with the Company&rsquo;s normal payroll practices. Payments in respect
of annual or prorated bonuses shall be paid at the time the annual bonus would otherwise be paid.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>No Implied
Entitlement: </B></FONT>Other than as expressly provided herein, the Employee will not be entitled to receive any further pay or
compensation, severance pay, notice, payment in lieu of notice, incentives, bonuses, benefits or damages of any kind from the Company
or from any affiliate of the Company. Any payment in lieu of the Severance Period payment provided to the Employee will be inclusive
of any entitlements upon termination or severance pay pursuant to the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
Standards Act, 2000</I></FONT> as amended, contract, tort, common law or otherwise, and will be subject to statutory withholdings.
The Employee will not be entitled to receive any further pay or compensation (except for pay, if any, accrued and owing under this
Agreement up to the date of termination of employment) from the Company, and for clarity, without limiting the foregoing, the Employee
will not be entitled to any bonus or pro rata bonus payment that has not already been awarded to the Employee by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Continued
Effect: </B></FONT>Notwithstanding any changes in the terms and conditions of the Employee&rsquo;s employment which may occur in
the future, including any changes in position, duties or compensation, the termination provisions in this Agreement will continue
to be in effect for the duration of the Employee&rsquo;s employment with the Company unless otherwise amended in writing and signed
by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Obligations
Upon Termination. </B></FONT>The Employee agrees that he shall not be entitled to receive any severance fee or other benefits under
Section 3 of this Agreement if the Employee breaches any of his obligations arising under Sections 4, 5, 6, 7, 8, 9 and 10 hereof.
The Employee acknowledges that until a release in the form of <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
B </B></FONT>hereto (a <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Release&rdquo;</B>)
</FONT>is timely executed and delivered to the Company, the Company will not be obligated to make any severance payments or
provide any other benefits due under this Agreement following termination of the Employee. The Employee further acknowledges that
if the Release is not timely executed and delivered to the Company, the severance payments and other benefits described in this
Section 3 shall be forfeited, except as required by statutory minimum standards.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD><FONT STYLE="font-variant: normal"><B><U>CONFIDENTIAL INFORMATION PROTECTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD STYLE="text-align: justify">At all times during and after the Employee&rsquo;s employment, the Employee will hold in confidence
and will not disclose, use, lecture upon, or publish any of Company&rsquo;s Confidential Information (defined below), except as
may be required in connection with the Employee&rsquo;s work for Company, or as expressly authorized by the Board. The Employee
will obtain the written approval of the Board before publishing or submitting for publication any material (written, oral, or otherwise)
that relates to the Employee&rsquo;s work at Company and/or incorporates any Confidential Information. The Employee hereby assigns
to Company any rights the Employee may have or acquire in any and all Confidential Information and recognize that all Confidential
Information shall be the sole and exclusive property of Company and its assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.2</TD><TD STYLE="text-align: justify">The term &ldquo;Confidential Information&rdquo; shall mean any and all confidential knowledge,
data or information related to Company&rsquo;s or its affiliates business or its actual or demonstrably anticipated research or
development, including without limitation (a) trade secrets, inventions, ideas, processes, computer source and object code, data,
formulae, programs, other works of authorship, know-how, improvements, discoveries, developments, designs, and techniques; (b)
information regarding products, services, plans for research and development, marketing and business plans, budgets, financial
statements, contracts, prices, suppliers, employees and customers; (c) information regarding the skills and compensation of Company&rsquo;s
employees, contractors, and any other service providers of Company; and (d) the existence of any business discussions, negotiations,
or agreements between Company and any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.3</TD><TD STYLE="text-align: justify">The Employee understands that Company has received and in the future will receive from third parties
confidential or proprietary information <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">(<B>&ldquo;Third
Party Information&rdquo;</B>) </FONT>subject to a duty on Company&rsquo;s part to maintain the confidentiality of such information
and to use it only for certain limited purposes. During and after the term of the Employee&rsquo;s employment, the Employee will
hold Third Party Information in strict confidence and will not disclose to anyone (other than Company personnel who need to know
such information in connection with their work for Company) or use, Third Party Information, except in connection with the Employee&rsquo;s
work for Company or unless expressly authorized by an officer of Company in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.4</TD><TD STYLE="text-align: justify">The Employee represents that employment by Company does not and will not breach any agreement with
any former employer, including any non-compete agreement or any agreement to keep in confidence or refrain from using information
acquired by the Employee prior to employment by Company. The Employee further represents that the Employee has not entered into,
and will not enter into, any agreement, either written or oral, in conflict with the Employee&rsquo;s obligations under this Agreement.
During employment by Company, the Employee will not improperly make use of, or disclose, any information or trade secrets of any
former employer or other third party, nor will the Employee bring onto the premises of Company or use any unpublished documents
or any property belonging to any former employer or other third party, in violation of any lawful agreements with that former employer
or third party. The Employee will use in the performance of the Employee&rsquo;s duties only information that is generally known
and used by persons with training and experience comparable to the Employee&rsquo;s own, is common knowledge in the industry or
otherwise legally in the public domain, or is otherwise provided or developed by Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>INVENTIONS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.1</TD><TD STYLE="text-align: justify">As used in this Agreement, the term <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Invention&rdquo;
</B></FONT>means any ideas, concepts, information, materials, processes, data, programs, know-how, improvements, discoveries, developments,
designs, artwork, formulae, other copyrightable works, and techniques and all Intellectual Property Rights in any of the items
listed above. The term <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Intellectual
Property Rights&rdquo; </B></FONT>means all trade secrets, copyrights, trademarks, mask work rights, patents and other intellectual
property rights recognized by the laws of any jurisdiction or country. The term <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Moral
Rights&rdquo; </B></FONT>means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized
by the laws of any jurisdiction or country.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.2</TD><TD STYLE="text-align: justify">The Employee has disclosed in <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
                                         </B></FONT><B>C</B> a complete list of all Inventions that (a) the Employee has, or has
                                         caused to be, alone or jointly with others, conceived, developed, or reduced to practice
                                         prior to the commencement of the Employee&rsquo;s employment by Company; (b) in which
                                         the Employee has an ownership interest or which the Employee has a license to use; (c)
                                         and that the Employee wishes to have excluded from the scope of this Agreement (collectively
                                         referred to as <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Prior
                                         Inventions&rdquo;). </B></FONT>If no Prior Inventions are listed in <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
                                         C</B></FONT>, the Employee warrants that there are no Prior Inventions. The Employee
                                         agrees that the Employee will not incorporate, or permit to be incorporated, Prior Inventions
                                         in any Company Inventions (defined below) without Company&rsquo;s prior written consent.
                                         If, in the course of the Employee&rsquo;s employment with Company, the Employee incorporates
                                         a Prior Invention into a Company process, machine or other work, the Employee hereby
                                         grants Company a non-exclusive, perpetual, fully-paid and royalty-free, irrevocable and
                                         worldwide license, with rights to sublicense through multiple levels of sublicensees,
                                         to reproduce, make derivative works of, distribute, publicly perform, and publicly display
                                         in any form or medium, whether now known or later developed, make, have made, use, sell,
                                         import, offer for sale, and exercise any and all present or future rights in, such Prior
                                         Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">Inventions assigned to the Company or to a third party as directed by the Company pursuant to the
subsection 5.5 are referred to in this Agreement as <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Company
Inventions&rdquo;</B>. </FONT>Subject to the subsection 5.5 and the Prior Inventions Employee has set forth in <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Exhibit
C, </B></FONT>the Employee hereby assigns and agrees to assign in the future (when any such Inventions or Intellectual Property
Rights are first reduced to practice or first fixed in a tangible medium, as applicable) to the Company all rights, title, and
interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced
to practice, or learned by the Employee, either alone or with others, during the period of the Employee&rsquo;s employment by the
Company. Any assignment of Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment
of all Moral Rights. To the extent such Moral Rights cannot be assigned to the Company and to the extent the following is allowed
by the laws in any country where Moral Rights exist, the Employee hereby unconditionally and irrevocably waives the enforcement
of such Moral Rights, and all claims and causes of action of any kind against the Company or related to the Company&rsquo;s customers,
with respect to such rights. The Employee further acknowledges and agrees that neither the Employee&rsquo;s successors-in-interest
nor legal heirs retain any Moral Rights in any Inventions (and any Intellectual Property Rights with respect thereto).</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.4</TD><TD STYLE="text-align: justify">During the period of employment, the Employee will promptly and fully disclose to the Company in
writing (a) all Inventions authored, conceived, or reduced to practice by the Employee, either alone or with others, and (b) all
patent applications filed by the Employee or in which the Employee is named as an inventor or co-inventor. The Employee agrees
to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required
by the Company) of all Inventions made by the Employee during the period of the Employee&rsquo;s employment by the Company, which
records shall be available to, and remain the sole property of, the Company at all times.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.5</TD><TD STYLE="text-align: justify">The Employee agrees that, as directed by the Company, the Employee will assign to the Company or
a third party, including without limitation, all rights, title, and interest in and to any particular Company Invention.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.6</TD><TD STYLE="text-align: justify">During and after the period of employment and at the Company&rsquo;s request and expense, the Employee
will assist the Company in every proper way, including consenting to and joining in any action, to obtain and enforce Canadian,
United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in all countries. If the
Company is unable to secure the Employee&rsquo;s signature on any document needed in connection with such purposes, the Employee
hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee&rsquo;s agent
and attorney in fact, which appointment is coupled with an interest, to act on the Employee&rsquo;s behalf to execute and file
any such documents and to do all other lawfully permitted acts to further such purposes with the same legal force and effect as
if executed by the Employee.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.7</TD><TD STYLE="text-align: justify">The Employee agrees that the Employee will not incorporate into any Company software or otherwise
deliver to the Company any software code licensed under the GNU General Public License or Lesser General Public License or any
other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or
distribution of any source code owned or licensed by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD><FONT STYLE="font-variant: normal"><B><U>RETURN OF COMPANY PROPERTY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.1</TD><TD STYLE="text-align: justify">Without limiting the provisions of Section 3.1(c), upon termination of the Employee&rsquo;s employment
or upon the Company&rsquo;s request at any other time, the Employee will deliver to the Company all of the Company&rsquo;s property,
equipment, and documents, together with all copies thereof, and any other material containing or disclosing any Inventions, Third
Party Information or Confidential Information and certify in writing that the Employee has fully complied with the foregoing obligation.
The Employee agrees that the Employee will not copy, delete, or alter any information contained upon any Company computer or Company
equipment before the Employee returns it to the Company. In addition, if the Employee has used any personal computer, server, or
e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to. Confidential
Information, the Employee agrees to provide the Company with a computer-useable copy of all such Confidential Information and then
permanently delete and expunge such Confidential Information from those systems; and the Employee agrees to provide the Company
access to the Employee&rsquo;s system as reasonably requested to verify that the necessary copying and/or deletion is completed.
The Employee further agrees that any property situated on the Company&rsquo;s premises and owned by the Company is subject to inspection
by the Company&rsquo;s personnel at any time with or without notice. Prior to the termination of employment or promptly after termination
of employment, the Employee will cooperate with the Company in attending an exit interview and certify in writing that the Employee
has complied with the requirements of this section.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD><FONT STYLE="font-variant: normal"><B><U>NON-COMPETITION/NON-SOLICITATION</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.1</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of the Employee&rsquo;s employment by the
Company and for one (1) year after termination of such employment for any reason (except in the event of a Change of Control pursuant
to the proviso at the end of Section 3.4(b), in which event such period shall extend to eighteen (18) months after termination
of such employment), the Employee will not, without the Company&rsquo;s express written consent, anywhere in the world, be employed
by or contribute to any business activity that is competitive with the business of the Company or involves the use of real-time
magnetic resonance imaging or ultrasound or similar technologies in the delivery of ablative tools.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.2</TD><TD STYLE="text-align: justify">The Employee covenants and agrees that for the period of the Employee&rsquo;s employment by the
Company and for one (1) year after termination of such employment for any reason (except in the event of a Change of Control pursuant
to the proviso at the end of Section 3.4(b), in which event such period shall extend to eighteen (18) months after termination
of such employment), the Employee will not, either directly or indirectly, solicit or attempt to solicit any employee, independent
contractor, or consultant of the Company to terminate his, her or its relationship with Company in order to become an employee,
consultant, or independent contractor to or for any other person or entity.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD><FONT STYLE="font-variant: normal"><B><U>NOTIFICATION OF NEW EMPLOYER</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.1</TD><TD STYLE="text-align: justify">After the termination of this Agreement, the Employee consents to the notification of any new employer
of the Employee&rsquo;s rights and obligations under this Agreement, by the Company providing a copy of this Agreement or otherwise
as the Company deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD><FONT STYLE="font-variant: normal"><B><U>INJUNCTIVE RELIEF</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.1</TD><TD STYLE="text-align: justify">The Employee acknowledges that, because the Employee&rsquo;s services are personal and unique and
because the Employee will have access to the Confidential Information of the Company, any breach of this Agreement would cause
irreparable injury to the Company for which monetary damages would not be an adequate remedy and, therefore, will entitle the Company
to injunctive relief (including specific performance). The rights and remedies provided to each party in this Agreement are cumulative
and in addition to any other rights and remedies available to such party at law or in equity.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD><FONT STYLE="font-variant: normal"><B><U>PUBLICITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">The Employee shall not, without the prior written consent of the Company, make or give any public
announcements, press releases or statements to the public or the press regarding the Employee&rsquo;s work or the Company&rsquo;s
business.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT>1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal"><B><U>NOTICES</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">All notices,
requests, demands and other communications to be given pursuant to the terms of this Agreement shall be in writing and shall be
deemed to have been duly given (i) on the date of delivery if personally delivered or sent by a recognized overnight courier or
(ii) on the date of transmission if sent by email (provided notice is then also promptly delivered personally or by a recognized
overnight courier), in each case to the parties at the addresses listed below:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">If to the Employee,
at the Employee&rsquo;s then current address in the Company&rsquo;s payroll records;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">If to the Company:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">Profound
Medical Corp.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">2400
Skymark Avenue, Unit 6</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">Mississauga,
ON L4W 5K5</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">Attention:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chair
of the Board of Directors</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">E-mail:&#9;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[_______________________]</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="background-color: white">Each
party may change its address for receipt of notice by giving notice of the change to the other party.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>SURVIVAL</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The Employee&rsquo;s
obligations under this Agreement shall survive the termination of the Employee&rsquo;s employment, regardless of the manner or
reason for termination, including, without limitation, those set forth in Sections 4 through 7 hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">12.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The assignment
of this Agreement by the Company to any successor or other assignee and shall be binding upon the Employee&rsquo;s heirs and legal
representatives.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>SEVERABILITY</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">If any provision
of this Agreement is, for any reason, held to be invalid or unenforceable, the other provisions of this Agreement will remain enforceable
and the invalid or unenforceable provision will be deemed modified so that it is valid and enforceable to the maximum extent permitted
by law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>WAIVER</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Any waiver or
failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of that provision or any other provision
on any other occasion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>ASSIGNMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The Company may
assign this Agreement to (i) an affiliate, subsidiary, related company or partnership without prior notice or consent of the Employee,
or (ii) a new employer in connection with any transaction or reorganization; provided that any such successor or assignee expressly
assumes in writing the Company&rsquo;s obligations under this Agreement and has responsibility for managing the underlying business
of the Company. The Employee may not assign any of his rights nor delegate any of the duties hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>ENTIRE AGREEMENT</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">16.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">This Agreement
is the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes and merges
all prior communications between us with respect to such matters. No modification of or amendment to this Agreement, or any waiver
of any rights under this Agreement, will be effective unless in writing and signed by the Employee and the Company. Any subsequent
change or changes in duties, salary or compensation will not affect the validity or scope of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>HEADINGS</U></B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: transparent"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The headings
utilized in this Agreement are for convenience only and are not to be construed in any way as additions or limitations of the covenants
and agreements contained in this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">18.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>COUNTERPARTS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">18.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">This
Agreement may be executed in two or more counterparts, each of which will be deemed to be an original and all of which will constitute
one Agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">19.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: normal"><B><U>LAWS</U></B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">19.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">This
Agreement shall be governed by and interpreted in accordance with the laws of Ontario and the laws of Canada applicable therein.
The Employee and the Company hereby attorn to the exclusive jurisdiction of the superior courts of Ontario to resolve any dispute
arising from this Agreement except to the extent the Company seeks injunctive relief outside Ontario where applicable to enforce
the Employee&rsquo;s covenants hereunder.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal; font-variant: normal"><I>[Signature
Page to Follow]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the parties have duly
executed this Agreement as of the 26 day of August, 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signed,
    Sealed and Delivered</B> <FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">in the presence of:</FONT></FONT></TD>
    <TD STYLE="width: 6%; text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-weight: normal; font-style: normal"></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-weight: normal; font-style: normal; border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal">Arun
    Menawat</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Name
    (witness)</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-size: 12pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; background-color: white">2400
    Skymark Unit #6</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-size: 12pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Address</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Miss.
    &nbsp;&nbsp;&nbsp;ON</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-size: 18pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; background-color: white; font-size: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mathieu Burtynk</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; background-color: white; font-size: 18pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; background-color: white; font-size: 18pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MATHIEU
BURTNYK</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">Occupation</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PROFOUND MEDICAL CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">Per:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Arun Menawat</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Arun Menawat</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>Exhibit
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-variant: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-style: normal; font-variant: normal"><B><U>RELEASE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">I,
Mathieu Burtnyk of the City of_________, in the Province of Ontario, for and in consideration of the sum of * ($*) and other good
and valuable consideration which is being delivered to me concurrently with the execution and delivery hereof (the receipt and
sufficiency of which is hereby acknowledged) do hereby remise, release and forever discharge <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>PROFOUND
MEDICAL CORP. </B></FONT>(hereinafter called the <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>&ldquo;Company&rdquo;</B>),
</FONT>its officers, directors, servants, employees and agents, including any related or associated companies, and their heirs,
executors, administrators, successors and assigns, as the case may be, of and from any and all manner of actions, causes of action,
suits, contracts, claims, damages, costs and expenses of any nature or kind whatsoever, whether in law or in equity, which, as
against the Company or such persons as aforesaid or any of them I have ever had, now have, or at any time hereafter I or my personal
representatives can, shall or may have, by reason of or arising out of the termination of my employment with the Company or in
any other way connected with my employment with the Company (except as otherwise set forth below), and more specifically, without
limiting the generality of the foregoing, any and all claims for damages for termination of my employment, constructive termination
of my employment, loss of position, loss of status, loss of future job opportunity, loss of opportunity to enhance my reputation,
the timing of the termination and the manner in which it was effected, loss of bonuses, loss of benefits, including life insurance
and short and long-term disability benefit coverage, and any other type of damages; <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><U>provided,
however</U></FONT>&rsquo; that notwithstanding anything contained herein, this Release does not apply to any claims related to (i) equity
in the Company or its affiliates that I hold, directly or indirectly, including without limitation, the options granted to me in
connection with my employment with the Company, or (ii) any unpaid reimbursement of expenses and accrued but unpaid salary or termination
payments provided for in the Employment Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">I
FURTHER AGREE that this Release includes any and all claims I may have arising under contract, the Ontario <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Employment
Standards Act, 2000,</I></FONT> as amended, common law or other applicable law related to my employment with the Company and that
the consideration provided includes any amount that I may be entitled to under such legislation and I agree to immediately withdraw
any complaint as settled and not to file any complaint pursuant to such legislation with respect to my employment or the termination
of my employment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS UNDERSTOOD that the Company has withheld income tax and other statutory deductions from the aforesaid consideration and I agree
to indemnify and hold harmless the Company from any further assessment for income tax or other statutory deductions which may be
made under statutory authority.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS FURTHER UNDERSTOOD that as a former officer of the Company I owe a fiduciary duty to the Company and I agree that the Company
will suffer irreparable harm if confidential information or information unique to the Company is disclosed in any way by me without
authorization of the Company and that I have returned to the Company originals or copies of the Company&rsquo;s corporate records,
files, financial documents, client lists, or any other material that is related to the Company&rsquo;s business, clients, personnel
or operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS FURTHER UNDERSTOOD AND AGREED that this is not to be construed or considered as an admission of liability on the part of the
Company. The terms of this Release set out the entire agreement between myself and the Company and are intended to be contractual
and not a mere recital.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IT
IS EXPRESSLY ACKNOWLEDGED that the contents, terms and effect of this Release have been explained to me by my lawyer and are fully
understood.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">IN
WITNESS WHEREOF I, Mathieu Burtnyk, have hereunto set my hand and seal this ______ day of _____________________, 20__ in the City
of ______________, Province of Ontario.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 60%; text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">Mathieu Burtnyk</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">EXHIBIT
C</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">&nbsp;</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: transparent">INVENTIONS</P>

<P STYLE="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>1.
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Prior
Inventions Disclosure. </FONT></B>The following is a complete list of all Prior Inventions (as provided Subsection 5.2 of the attached
Employment Agreement):</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">None</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">See immediately below:</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 0.5in; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">Patent #: 8989838 - System for treatment of diseased tissue using controlled ultrasonic heating.</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in"><P STYLE="margin: 0pt 0">Filed July 6, 2010 - Granted March 24, 2015</P>


</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in"><P STYLE="margin: 0pt 0">Patent #: 7771418 - Treatment of diseased tissue using controlled ultrasonic heating.</P>


</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in"><P STYLE="margin: 0pt 0">Filed March 9, 2005 - Granted August 10, 2010</P>


</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: transparent">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal"><I>&nbsp;</I></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>22
<FILENAME>tv526458_ex8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>List of Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Company Name</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Jurisdiction of Incorporation&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Profound Medical Inc.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Ontario</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Profound Medical Oy</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Finland</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Profound Medical GmbH</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Germany</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Profound Medical (U.S.) Inc.</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>23
<FILENAME>tv526458_ex15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 28, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
We hereby consent to the use in this registration statement on Form 20-F of Profound Medical Corp. of our report dated August 14,
2019 relating to the financial statements of Profound Medical Corp., which appears in such registration statement. We also consent
to the reference to us under the heading &ldquo;G. Statement by Experts&rdquo; in such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Chartered Professional Accountants, Licensed Public Accountants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oakville, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%; border-top: rgb(163,32,32) 1pt dotted; border-left: rgb(163,32,32) 1pt dotted"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 8pt">PricewaterhouseCoopers LLP</FONT></TD>
</TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">PwC Centre, 354 Davis Road,
Suite 600, Oakville, Ontario, Canada L6J 0C5</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">T: +1 905 815 6300, F:
+1 905 815 6499</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&ldquo;PwC&rdquo; refers to PricewaterhouseCoopers
LLP, an Ontario limited liability partnership.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>chart.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X >H# 2(  A$! Q$!_\0
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MV7_R/7044 <__P (]JG_ $.>N?\ ?FR_^1Z/^$>U3_H<]<_[\V7_ ,CUT%%
M'/\ _"/:I_T.>N?]^;+_ .1ZJ3P:IHVNZ"K>(]1OX+V]>VFANHK8*5%M-("#
M'$C [HU[^M=77/\ B'_D.>$_^PK)_P"D5U0!T%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7/^!/^2>>&O\ L%6O_HI:Z"N?\"?\D\\-?]@JU_\
M12T =!1110!POCP2C7O"ZQ+J\RW%S-%-::;J#VS3*()' XEC7AE#9)!P,<]#
M3TF_\9Z-]ETN]GL+D6=A'>W;7.][CR_,<-'Y@;:[A%'SD $KSG=N'9:CX?T[
M5=1L=0NTN#<V#[[9H[J6,(QX)VHP!R"0<@Y!(Z'%/_L.P_MQ]9V3_;7A$#,;
MF384'0>7NV=R>G<T <9=>)]?ET2Y1Y[&&YOM!EU:TD@MW_T8*$W1MF3YVQ*N
M'&WD$E>U5[75[WPQH=Z+&WTB*VT:RAOK]8;%HS>&0,S;,281@B#YFW[F/0 <
M]=%X-T.&SNK2.UF6"YB\AU^US?)%_P \XSNS&G^RFT>U.;PAHCM;,]M,QMXU
MB&Z[F/F(IRJR_-^] ). ^[&3ZF@#&N/$VLP:W>6NZP,%MK%K9_\ 'N^YHID1
MNOF8#+OZXP<=!56#Q?KMMJ4/]HKITEB]_>V16WA=)#Y$<D@DRSD#/E[=N#_>
MW<[1T-]X.T34=3;4;BWN/M+O'*S17DT2EX\;'*HX7<  ,XSCCI60^E^#-/N+
MF[DGNE;1KAKV:1KZZ=(II!\V?G*LS \Q\G#_ '?GY ,[PL;V\\?P:Q?1:='+
MJ>@BYQ:0%'4&1,+(Y8^857:-V%Z=!3M.N;O2=>U;1CJ%Y+%J>\Z:;BX>5X9%
M?RY K.2< /&^,\;7-:7AG3_"0ULR:1'J%OJ%K!A;>[:\AV0,3PD,Q \O(X"K
MM!'&#5R?P]X=T2UDNI_M<://_KGO;B1UDFQ%E6WED+;P,KCUXQD '$:3XNU?
M2?".B06*W6H7]QI\NH2M<0W5^\[*P58AL),>X_QM\JX'!SQ>UN^O/$.K:9?-
M:V4-GIVOVUI&L]N6N@Q",["3=A!E@I7:2=N2>U=;#X'T"WL;2SAM[J.*TW"
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M/^(?^0YX3_["LG_I%=5T%<_XA_Y#GA/_ +"LG_I%=4 =!1110 4444 %%%%
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MH** .?\ ^$RTO_GUUS_P17O_ ,9H_P"$RTO_ )]=<_\ !%>__&:Z"B@#G_\
MA,M+_P"?77/_  17O_QFC_A,M+_Y]=<_\$5[_P#&:Z"B@#G_ /A,M+_Y]=<_
M\$5[_P#&:/\ A,M+_P"?77/_  17O_QFN@HH Y__ (3+2_\ GUUS_P $5[_\
M9H_X3+2_^?77/_!%>_\ QFN@HH YU?&NDNSJMOK9*':P&A7IVG .#^Z]"#^-
M._X3+2_^?77/_!%>_P#QFG:$6&N^*%/3^T(V'_@+ /Z5O4 <_P#\)EI?_/KK
MG_@BO?\ XS1_PF6E_P#/KKG_ ((KW_XS7044 <__ ,)EI?\ SZZY_P""*]_^
M,T?\)EI?_/KKG_@BO?\ XS7044 <_P#\)EI?_/KKG_@BO?\ XS1_PF6E_P#/
MKKG_ ((KW_XS7044 <__ ,)EI?\ SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\
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M<9[BMNN?\/?\ASQ9_P!A6/\ ](K6@ _X3+2_^?77/_!%>_\ QFC_ (3+2_\
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M6=T;:P2579,(P(*D$D<$<@ Z#3_%6@:H(/L>L6,LDZ>8D0G428VASE,[@0K
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY#*02K1L.C*PY5AV((-8JZG?>&6$.N2&ZTOI'JNT Q>@N .!_P!=!\OJ%ZD
MQ$T#6I(+713930FVUF74#JXEC*.C2R2#:-WF;R) A!4#[W.,998>'=2NK+0=
M-U#0S%#HVGRVMP9)XS'?$Q"/;&58L%8C>2X4C"\$]/1%974,K!E(R"#D$4M
M'FH\&ZOH^MVD^FB[E>1HGDN$OF\N%O/#S"4/)NE1H\JN0YW9/RY!'I5%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%8EUXLTNTO[BR9=1FG
MMF"3?9=,N;A48JK@%HXV7.UE.,]Q47_"9:7_ ,^NN?\ @BO?_C- '045S_\
MPF6E_P#/KKG_ ((KW_XS1_PF6E_\^NN?^"*]_P#C- '045S_ /PF6E_\^NN?
M^"*]_P#C-'_"9:7_ ,^NN?\ @BO?_C- '045S_\ PF6E_P#/KKG_ ((KW_XS
M1_PF6E_\^NN?^"*]_P#C- '045S_ /PF6E_\^NN?^"*]_P#C-'_"9:7_ ,^N
MN?\ @BO?_C- '045S_\ PF6E_P#/KKG_ ((KW_XS1_PF6E_\^NN?^"*]_P#C
M- '045S_ /PF6E_\^NN?^"*]_P#C-'_"9:7_ ,^NN?\ @BO?_C- '045S_\
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M9N--SF722P'E^IMR>%_ZYGY3V*]ZMK\2_#U[XNLO#EO<.UY=0O)\RE/*=?\
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M #ZZY_X(KW_XS1_PF6E_\^NN?^"*]_\ C- '045S_P#PF6E_\^NN?^"*]_\
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M>[T+^S;V.6U@2X>X<Q>45<D+C#ELDJX^[_"?49V* .?\"?\ )//#7_8*M?\
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M_P /?\ASQ9_V%8__ $BM: .@KG_ G_)//#7_ &"K7_T4M=!7/^!/^2>>&O\
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MV@L[>.WC,A!8JBA1DC'.!5RBB@#F+'PA=Z;I]M86?B[7(K6VB6&&/R[-MB*
M%&3;DG  ZG-3_P#"/:I_T.>N?]^;+_Y'HHH /^$>U3_H<]<_[\V7_P CT?\
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M1[5/^ASUS_OS9?\ R/1_PCVJ?]#GKG_?FR_^1Z** #_A'M4_Z'/7/^_-E_\
A(]:FE:=#H^CV.F6S.T%G;QV\9D(+%44*,D8YP*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) %\# 2(  A$! Q$!_\0
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K_>62!2Y^IZFMRB@#/TO0=(T.,QZ5IEI9*>HMX53/UP.:T*** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tv526458_ex1-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ ,@") P$1  (1 0,1 ?_$ ((   (" 04! 0
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ME7@)*VPR%=L[^&BWD_7FSTDFW@9ES'MEY6%1E$RII2B47(**H%<E*4JQ2 <
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MDBOW4%!FT<H]BJ._ &U42E0(5(J9$DRE "%3[ DF4.Q2)$+V*!2E .Q0 .P
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MWK;.3;E?1-CD56DRVCIFSQ1%2LH&'%612[E7=.T@#S%!SKV[S_18_P# ??\
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M*0"B_7@C"T4<^3UC(G, F[B(]!EWT$Z"=!.@G03H)T$Z"=!.@X2GYE/]I/\
M)^?ZF^O[?N_9WZ"MJ9_?#)7^%W_/Q/\ <[^^W_K0_P 3/_I?]+_V_06D7\W^
?;^4?I]?S!]?];[_V]!N=!.@G03H)T$Z"=!.@G0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tv526458_ex1-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ +P  0 !! ,! 0$
M       ( @,'"0$%!@0*"P$!                     !    8" @$" @8&
M!08$"P S 0(#! 4&  <1"!(A"3$305&!(A0587&QP3(6D4*"(Q?PH5(D&!G1
M,Y@*8G*R4R4FUB?76%F20S0UM=4W5Y>W*'@Y>>'QHM)CDT14E%655K9G.+@:
M@]-T-G9W2834176EAI;&1X=(B&D1 0                    #_V@ , P$
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M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"\3^$/M_:.!9P& P& P& P&
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#D/B'ZP_;@7#_  ^W]PX%K 8# 8#
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MK4NNJ?JZ<FV+C7[<&'5RE*33S5E7ATR1BLU:=P2\T@Z?IKJ%<."_(3$B29
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MW_J_5-QLVL;O2J#UA#L5:=-4QDEL4T+$7NBRHMZ]+R!I5P<J,FW6%JB]*LV
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MJ:192#P%4)6%$J[3YBH&;8&&:I[[^DKA#4:\1.@MX/->/9G6M1W1>(E_KQY
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MP& P& P& P& P& P& P& P& P& P& P& P&!R'Q#]8?MP+A_A]O[AP+6 P&
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MHYDYZ(WYM>.DJ>TF=C.-LRT'K(S:SE:4"MRNP'SF2<,(])-LLJZ5(H0R9O$
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M]5BJ_>=GVJ[UV@T>J.7[RN4C7D+..UV59K48ZEG!R$*"CG@2)BL*1")D"9F
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MZ<,F#)&.8H]5^OQ6K%NF**35,VJ:J?Y9$1 !1]3\F+_IB(_3@2WP& P& P&
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M,^H_'ISUCT)Z?5QJJJ?#ZOC]HX$FL!@,!@,!@,!@,"]_4_L_NP+. P&!R/B
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MJ<S1(-U7:Q&4J7M,BYH%78QSU15T9Q7*B9JV<K'$16<E4.'H8,"0^ P& P&
MP& P& P& P& P& P& P& P+B?T_9^_ I/_$/V?L# IP& P& P& P& P& P&
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M14P+P)_OB/B <\_3@2OP& P& P& P& P+W]3^S^[ LX# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8%Q/Z?L_?@4G_B'[/V!@4X# 8# 8# 8# 8# 8# 8#
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MP*G3((E()N $>.<#+. P& P& P& P&!>_J?V?W8%G 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# N)_3]G[\"D_P#$/V?L# IP& P& P& P& P& P& P&
MP& P& P& P& P&!R'Q#]8?MP+A_A]O[AP+6 P& P& P& P& P& P& P& P&
MP& P& P& P&!>)_"'V_M' LX# 8# 8# ?Y?']WQP& P& P& P& P& P& P&
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MFTZ3KF,:R=@9-C)-81Q:$8LZ0N6S@2A^A;_(/U?1@,!@,!@7OZG]G]V!9P&
MP& P& P& P& P& P& P& P& P& P& P& P+B?T_9^_ I/_$/V?L# IP& P&
MP& P& P& P& P& P& P& P& P& P&!R'Q#]8?MP+A_A]O[AP+6 P& P& P&
MP& P& P& P'^7^7QP/S4^[WJ=7W'>V75KH%H66M6O=]Z56>]C]T=M-?W"6@)
MSJ!H2Y-G=,?P<*C!2,>K-[5[ -D181+!<W#5@BH]/XI<\AD_O_!T[VEO:MM>
MM>F$7':UN6X+Q0>O%3V3/3BJUH/L;L-:F=+LV]]D;&L;@SV;NT)!/GTN:6DW
M12).42E**21"EP,7=9.MU?[FU30=+BH=:B>SSTB_*":CB9]9=H^]P?:6K#K*
MFWWL9)RLW40ZX5N\,W5@8"^Y6M\X7\R7X:%*0X0]L'NJ]Y>V>PMU+=7I-EJ+
MK1V/W[2_;-Z"7US747IK)LU[-6"5WIW$B9U\W:/31U$UA5Y).#:(&68 ^6:$
M**BB"X@&Z63UMU.]KCKW=:_!;)VW6+EO=I7Z-!2L==+5N#L7N/=C.I.:Y 6'
M6=4NTI:BS>T)IP!WCI1)N2+,8I5'YDVS?R(&J;V:*N_K77CN?[[W;Y^.Q-];
ML@MKSD%9[ PC&,S6.O'6^.F:?"5E*!8&)7("S; >T/S?IQRA4G'DBFD8I3&*
M(>!]E+76V_<+J>L]]W.?V13^J=<O]B[-;&DXZ6L>NK3W:]P#8MA"R6N>L[N)
M<1\_,==NKD8DRJD&U4<E:S;V*$RJ:K=$I"AN6]RG>^YS2.J^DW4[:L!I_LQV
M$BKW<K7M67J_\[(]?>K>M8"05V9N(L0JX9L&]A>3#AC!5Y5PL!32;PRA0$4!
M,4,O>TGO'8G9'VY^J6Z=K-FJ5XNFM$!DI!FB^02M4;7I>5JE9OBC>36<OF[V
M_P!8@FDRX3455%-=\8OF8  PAK_]R;L33*E[C729AL^^OJ3H+I?J_<O>/?)X
MB7=*/+!;;$+?0O6G7"56A%#2=NM5TM$W+?DD$0JJTLJ!OEI'^680#JNO6^?<
MA[-^YSIE>_KK=8>L\'H?8F\K5T]0:P,O>8FEVER&O=$G[+7!NV?_ "-L[.G$
MY*PM:XQ5;)5Z-A@(<[AR=4P!-RE2\#[ANX.SVM=LZKI]AZZ]*^TFFX[2MJ.Z
MD'TA=>Q>HJZUO6P9J4:"H$*O T&RV=I%%9^*R:ZI'22XFX$A0M>X/NC;LI=M
M(>WIU<F'%"WKVX@-@R=CW:V8HNVO6KK?KQK%L-H[/B67ST0'8$FK8V<%44Q\
M44I5U^(,8 ;<"$4MF[4ZH^T);J7IWJCT,<;.V*?4#39?8Z^:S;4BH677?6VL
M31H9_N/>^VIY LG?+C;+2B\5CHIRZ4?SK]%R*9R^ C@3@U7[BFM]Z]X;STZT
M17W.U(S1FL$;GV)WI 3D:K0=57F??LV=#TP91O\ CBV+84ZU*\<R#=LN0(@C
M/P5 R@JE3"'GOZ=H['JCKWIOJYKMC<)39G?C;A-!M8G7<:_E=AR&LF<&YLVU
MH:DMX\GS65FNT4DUK"+Y4R2$82;4>JJ$(V,<H1*[:TRS>V;[2- ZXZ^CIIUV
M<[P[JUCHNR,=-E;-MEK2>X%&[.]4G2Y5'!?Q(ZNT]!_R36#"L@E&LTD'8B7P
M5 X69K==N]M9[HCKUIZA5#</N8=VMIZ6K=NU#1(@937G6/K)0()2.I>G#R:<
MVW94JL4+7<2Z:QDA(+I_FLPXE["=!=-,R9PWK]>>Z6E=\[5VGUVK]\JL_P!C
M.NM7U[(=C:7174I8ZEKNR7UM(_)K$=>G,9'Q]B7C)&%=H+%3 CE$R8?B$TU!
M%,H3*P'&!$'OWV#0ZM=*>U78%1L1ROJ716P[;%H++"W:NI]"ONVM9:N7(*)F
M;MG4^Z;E4. E$J8F$! 0P,<>V#UXANLWM\=2M(0$L>7)6-+5.6G+ B_;O0L-
MNOK(U[NTP$BV.[0D"2-HM#M5-8BBGW0)XG$.!P,UTC3]IU].:^;5C;UOL&NZ
MC'[ 8W:!V*X1V!<+M*V&3/+5UXZV"Y7;RD<XH[I5PV;M0343,R7(D< %(IL#
M0;[P?=E/9^P+OT_J:(V+0O7?_#B?[71,2DLXG^S/9.VSD9,]6O;8UPK\HJ;N
MP[4G&C"<NIFQ7*C.I)*%4!(IE#8&Y#VZNK%BZC]9ZW4MA2<=:][;!L5FW9V/
MM44V38M+/O#9SI.9M@QC9$XI-Z_54!:P,4@'*:,7&-RD I0\<#&^U.UFR-V[
MIOG6+IK*5Z 3UG5)@W9#NK--XNVZWZS6T(W\UK.OJ[5Y [>O;5VPLV 74S'*
M/FS.O1JA%7AQ5.1  _.? ;K[C>[=L#6^O;+.0-S9T"V3;CK9%U"JJUK5FSHJ
MD;$FZHG[K79JGNW#QI%4& CF90U;0SKKL;#=D%'9"+,VYC$#]>_6+KKK/JEI
M*E:+U-'N6M3IK5V"LG*.3R-DN%FEGKB7MM\N4RL'XJ=N5UL+UQ(R;Q7DZSIP
M;C@H%* 9]P& P& P+W]3^S^[ LX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8%Q/Z?L_?@4G_B'[/V!@4X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# Y
M#XA^L/VX%P_P^W]PX%K 8# 8# 8# 8# 8# 8# 8'(  B #\.?\@^W _,;[:W
M<'J9UOK/N+;V[;[\HNN>W%[[Y[Y+V*H]VGDEMK5YA1+.^HW7G6E.UTR!2YVZ
M$_PGC6"L"E$,7!'IWJOR_(Y3@ 9#WUU8WI[YD&:)WVTV5U ]O",_+[9I_6[J
MN5MOV=WKLIBS7<TW=^SHBQ,Y]IJW6]57D1/'4UXV-*2Q_P"^D"MTP*D 2"/[
M8?:+:T3%:M[9^X]LG9?6R)AHNMNM&]?-'T'J:TOM?BT$V9*]LB[T.5FK:ZJ[
MU@A\AW'P:T&BLD;Q^ZF(D )%[B]LW0%_Z^:0Z\:L5M'5V!ZNW^L[+ZU6S1JD
M>SL^F+E64K W:R5="X,;3%RC>296=^@_1D$':3LC@04 WQP+VEO;>U-J*Y7+
M=%CNVUM_=J+K2GM.<]HM\SS&X7^J1KQHY:F9ZO@HR,@Z'JB,!=R"YVE>CH\C
M@Q *J8Q0] Z&P^V+J:?]MB$]LD;]L^#U"TUU6-93MSI\A&P=_LE>A+ UL-G;
MO7:C!XR31OSQ%5&43*3^]:.U"D/Y?>P)Z:EU;0-+:VI>I=7U*'HVNM>5V*J=
M.J$"T!C#P4'$-2-6C-FW(5,1$A4_)10W)UE3&4.8QSF,(:I^W?M26WLYVML^
M^ZQVQOFBZ)N?0E-ZT]F=?TJJQCBY;$U%2+G.74M8H&V%WZ4UJ=.[N9]6/L"S
M)LLY=L X343/P8 VRZRUY2=2:]I6KM<5B.IFOM>UB#IM+J<.B9O&5^L5V.0C
M(B)9H#]XB+%FW*F'/)C<>1A$PB.!HYZP^TGL-+W%NU'N&=V[E6]LV&[;E2G.
MKNG(-60F=>ZGJ-(9KUC5VPYU*6:,$G&T*]3W;AK'H_)<-H19Z]=)**.5RJ%"
M:W1SKUO;7&N>SNR=Y158@NX/8[=&V;Q8K5%V0+A A7XIS)5?K7#1SL6:9HVI
M4#6S2,0+%F2,"3P7JQ@.=R81#(/MO]<[GU3Z;:1TGLY*MJ;=K\!+3&Z)ZJOG
M<M#73;UNL4I:M@7I*:?1L4]E5[;8)=9VHHL@DHF*GR@#Q3+@88[0Z([ U7NY
MIWOQUVHD+NU_3NOUZZR[9T5)W"/H%FLM%M=UA[_5[EJVWV)(]/966J6>.7)(
MLI-1J228."%37(HD7D,*7[V_+WWVW!*[<[5P=XZP:NMVLZQIS9W6K7.Z(JW/
M^QU!IUS?WRGP^^;#6X/\CI\36K),OS)MZE)?CI!H_5;NW_R@ @A$?VY>TG2?
MI!7>_$;LQQ1=)=AGG>_>#&4ZK:^KK9WNR4J%-7AJ5UYA-9:8J312YV^)L6MX
MV/=QCU!LNV=.Y%959UY&65P/?V_JC[D_:7LMUU]S6&<Z;TKLC4K':-+TAT^[
M$1]DFX#5^E]L55S!*;&V9,T GYHOV3E'1FTD\BF:Q6$8S(E&?B#JD76,$II/
MVB:-O./DKSW7W1LW?W:!U)5R<I&_*B_>Z:4ZSR-5ET;# (]3ZC7Y*3C]3I,)
M1L073U8[^4F?'A\LHF((@$=N\73'IYUZIW7"(JD-O>>[$7_L+*US5U?UUO2S
M4[<O:[:6XH)M"[8?[]W$9.0N,I2HK6D2X>S\H19H,/"M3MF9VY%4TA#T_LA4
MFLVJ=[[=P*9 5BL:QW7V7DM(]>*_5(I"/AXGK_U%2?ZGA7L<NBDB,BTN.P1G
MY4SE8IG#I9<RRBAS*".!ONP.BLUAAZE7YNT6.5:0-;KD1)V"Q3K]8C=A"0<*
MQ7DI66?N%!*FW91[%LHJJ<WH4A!' _$-[C4IW,]Z"2ZTZFHUYG='Z2[C[5V(
MAU6Z^J0LB1E=>K&H:HX?7?N_VF.P=Q$R\J5HLTC")TRM_-(B@B[1?&(Y4/X&
M#;QM+MMV%]J7VF*3'["U1KF1[34'7^F]!:9U7K.V2-TJ<?*R@5K3E.V+LFSR
M,-6&C2KHWAP5R]29M_PZ)E4&1553*&5*$Q.N]"B?:A]NB;E^P&ZAN5SI<%>]
MW[WVOL2PF*UM^^MA*+V6RQ\*N\55.WAY6[.T(>#CD 45.0$DDR&4.!<#\V/M
M";%ZXZZU!5?<1[][ZU[M?L5<]D;QW;UPZCZ<5_Q9W2.RMR6ETUMNRIG4$(M,
MW*<['3)6J55A3O$&[*J5MFFDF= R[A0H;$+;MKW50M%O?[ 1-HO;WNIS^K]
M],=2-KDC.MNBVH*-#[0M^\]J;+CB@>*4W/!:G3+.NWC(RZ*DV]91_F!6)"B'
M3]H-@ZT/UWJ'L?>U5%W"Q3VXK0CULV[V>JL3)SVJ-+P4I&IWOL/=K]N-HL2*
MO>]+#2_Q[EZV:.ECE>2(I.%D%!21$-['1KH/U\Z :>AM1:.@7RAT(:MQEMV+
M:'RTWL+8;BK0K:"AW=JL#HPN%647&-BH1T:C\N/C&X D@D4/(3!-<I0*' !P
M'ZQ']N!S@,!@,!@7OZG]G]V!9P& P& P& P& P& P& P& P& P& P& P& P&
M P+B?T_9^_ I/_$/V?L# IP& P& P& P& P& P& P& P& P& P& P& P&!R'
MQ#]8?MP+A_A]O[AP+6 P& P& P& P& P& P& P X&&E>O6CE=AJ;='3NJ3;6
M7;M6KG9:FO*HM?7*#'U:I*VU2,-.""/(^(_.$Q0_A$,#,291*4 ,(&./J<P%
M @&,/Q'CD?\ .(C@5X# 8# 8# 8# O$_A#[?VC@6<!@./I^C \B-%I_\T+78
ME3JA+DLW(S/;0KD3_-"K0B1$2-5K 5J27.W(F3Q @K>(%]../3 ]0DB"7EP(
MB!A ?7_H2@4OI\"\ '' ?MP*U!,5,XE]#^(@0?$3<'-]TOH'J(@(\X'Y$^ZW
M8^[WG?WN&[^J*OE>]2*5/V:O;8@U2E6,OVL[-HP[SL1M:N'9JK%"9K4?,,DW
M+LI#J,XN$5(H*8"H4P?I;Z>=;*IT_P"KVA.LU+^]7])ZNJM"2=>)04F)2*CD
MQL-B="  )GMCL*SE\L(_Q*N##\?7 DI@:B?><M3%_P!9*/UB=6\:$EW:WIK_
M *XV:X*"HU95O3J_YGLGL-,R<J<R+*)CD-':^GD5%EE4BB1<0 P#Z@&&O:SK
M"?9C>^]?<S&ON*YIZV52I=3O;RK,@P<Q@0_3C3C@P/-E1<(Z*0L(VWO?43/F
MP$32,>&C6@>J9BX&W?>/7_3O9/7LYJK>6OJULO7ME")"<K%E8BNRD @IEG88
M<QUFJC5\B>.FX]!TD*2R8E63 ?K 0^^_Z6UKM.#K%9V)3H&X5ZFVVJWNMPDV
MU4>1,;;Z*]3DZ7._EYE2MW;NLR*"2[8JX*)E62(<2B8I1 .JI'7#0.M;;.W[
M7VE-2T>\V=99Q8KC4=<U"NV>;<.516<K24[$Q#63=G<*#Y'\U1\C>H\CR(AC
MCM-TDZX=SXNDPW8>CO+DRU[-RD]5%8VW6^FRD<ZGXH\#9&1IBFS<#)NX.S0:
M@M)%BJJ9L\0'P4*(>F!FW7>J==ZAI\+K[55)J>NJ/6VQ&E?J=.@(ZOP,.@5,
MJ1OP<=&H-VY55R$**B@E^8J</(YC"(C@9$^K]0?T\>O^? 8# 8# 8# O?U/[
M/[L"S@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@7$_I^S]^!2?^(?L_8&
M!3@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#D/B'ZP_;@7#_#[?W#@6L!@
M,!@,!@,!@,!@,!@,!@,!@,!@,#@1 ..1 !'X (@ C^H/IXYP.<!@,!@4F,!0
M 3>@<@7GCX"/H&!K#]QKW&%>DL55JKJO3LKV:['WNOWN_P!<T;!6R,I98S3^
MI:^^M6UMPWJVRC&295"D5>.8@S0672\I*6=(M&X&4$> G7I+9T%NK4>L=Q59
M1=2L[7U[2]CU[\4<IETX>ZUUA8V"2GAR0RJ:$B!3B41*)BCQZ &!E/D ]1]
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M!@=Y@,!@,!@,!@,!@,!@,"]_4_L_NP+. P& P& P& P& P& P& P& P& P&
MP& P& P&!<3^G[/WX%)_XA^S]@8%. P& P& P& P& P& P& P& P& P& P&
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M5BG*M&?A]:UU,62Q#B=0#MA^[P8>2B X$OC\@0P\@7@HCY']"A]T1$3"/H
M'QY^'TX'Y1[9>&?O:]][#I*@S)IGIQU*OB]=NUBKSE%:$ED*K/-&NVBR:H)"
MLXM6\K/&_P F0)$5$RMJ4RL#]0#ED&_D'Z=*#LS6U^_F:-US<:M;B:[M3[7-
MN1J<G'R:50N$$W:JR%/ETXTYTHR9B&KM %6I@*9$#  @ ^F!D7_+X\_LP.!
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MI.4#>"[=02&'Y:Z)PX.0W!B#Z" #@?1@,!@,!@7OZG]G]V!9P& P& P& P&
MP& P& P& P& P& P& P& P& P+B?T_9^_ I/_$/V?L# IP& P& P& P& P&
MP& P& P& P& P& P& P&!R'Q#]8?MP+A_A]O[AP+6 P& P& P& P& P& P&
MP& P& P*3B($,(!Y"!1$"\\<B ?#G].!^?78+C:_2_NGWTMFP.F&ZNY77OW"
M873,C3%M$4>"V:LQNVO]8O-6V71>XJU/S46A6ZA9&Q2NX^8<"M%IIN5BK<"
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MC@    8! #>@@/T% .!X^K MBW)Q]T1#TX'T(8# /Q ?(HCP/T?5]&!> .
M/4>/3U'D?Z<#G I.)@+]SCR$Y"ASZA]X?I#D,#\9'N%6*1]QCL>XL$D_7?Z
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M,!@,!@,#D/B'ZP_;@7#_  ^W]PX%K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# O$_A#[?VC@6<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"]_4_L_NP
M+. P& P& P& P& P& P& P& P& P& P& P& P&!<3^G[/WX%)_XA^S]@8%.
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M )50/X\AR//\(&'TP."^\/L0ZS!'_=(^ZF"\DU1>MTQT-2P $3IE,L59<=E
MV;'0-Y 8BYT5/N^A1Y#D.X4]WVV)J*H%]J/W7'*Q%!( I==:4*)B#P=(Y' [
M7!(Q3IG#D0$0 0XYY > M#[NVR#ARV]HOW5%_3[WEH_73<>?T@MMHHB(_H],
M#G_>T;G5*(M/9X]T54?02@OK#4[,Q@'Z>%]NAQ_1@?&Z]V??[=(RI?9G]SLZ
M8"! ,6E:8\_,_/A_<EVXHN!>0]3> E+\1P+)/=SW;Y-4E_9U]S]NLH<@.BAK
M?5:X-R+?B"MC$52VB+=V+@R( 8I3%%(#@)N/3D+37WAMFJJ/R+^T1[J#4&/'
MS/+2E"5\C&.<O@3QV<0#^)2<AX"<H\_Q8'8+>\#=&AR"\]ISW6$TO!,Z@MNO
MM,?B!#E 5#%3:[1.90R!P$!+R B'K^C ^E3WBY!/QY]K+W:3<@ \AU8@C>@^
MH?P;/-S^X<"U_OD'_P#Y+#W:_P#DJ0W_ (2\!_OD'_\ Y+#W:_\ DJ0W_A+P
M.0]X]^(_^PL?=J^WJK"A^W9@8')?>%L2IRD2]J;W913'U,HIUIJJ'@'')1\%
M-I (^0^@_5S@?(E[S"H"!Y/VP_=<AF@."MG#U;JRR?D;'(JBFX'\+$WM^^7*
MB"X#_=)G\PY\<"LOO&RZWFFW]K[W55UVZ@@X1_V7HUN!"F^4*0E5=7]) WS"
M'\^"F$Q0]# !@$,#N'?O#%:^/'MF^ZXN<3J$\&O5%FHH'RRE.8W [# /$2F^
M//&!UP>\@\/]XOM;>[:<@"( /^RE#E ?7CU*?913A_1@<?[Y!_\ ^2P]VO\
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M_17@/]]_I#_Q-/='_P"0%N[_ -%>!R'O>Z0$!_\ 6-/='Y .0_\ 6 =V^O\
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M$#<=<.QHD 2CP(";_"[CGT],#C_ZH!]K'_T^UX_Y./8S_P %N _^J ?:Q_\
M3[7C_DX]C/\ P6X#_P"J ?:Q_P#3[7C_ )./8S_P6X%L/^<"^U<8QTR;YNPK
M)D!0Z0=<NQ@JIICSPH=/_"X#%(/'H8> P'_U0-[5_P DS@V^+H1N0J1A<*=>
M.PB2 E6."9#$44UF4IR_,'@>!'U],"J-_P"< >U7)(K.B=DI1HDBJD@9&0T9
MOIHY4.X\P14;-SZY,HJ@ D$#"'(@(<8'9_[_ #]J@1)X=F9 Q%C+I)+HZ1WV
MH@HLB;Q^60Y=9G ZA_Z@!_%@?(I[_P#[4Y/4O8R=7]1#Q:Z%[!*FY#_H2ZQ$
M0#[,"R/_ #@'VL/ZN^+L</H$G7/L6<OK_P!$75O \8$Q^I7N#]5.\#JYL>MU
M^F[HZU\VAW5J3F-:[*U_^!0G57J,:HW-?ZI6TY('"D>J @V,J*7 >8!R'(35
MP&!>_J?V?W8%G 8# YY$/@(A@<<X'/(_6.!Q@,!@<\C]8_7@.1^L?Z<!R/UC
MZ_' <C]8_P!(X#D?K'^D<!R/UC_2. Y'ZQ_I' IY,*A0 ?J^(C\ $1'_ #8&
ME_V;U5"./=':F$3E9^[AV^!(H_\ FLCM>EO!(''U*N!'[<#=%R/UC_2. Y'Z
MQ_I' C[VJ[-ZMZ<=>]J]FMU2,C&ZRT_5G-JM*T0S_,IE=LDL@S:1T-'?-0!_
M+2D@[2;MTA.0#**!R(  B =#U7[@:4[A=;]9=J-03ZY]3[6A$IFO/[.5M 2#
M%491Q NX.=:N'AT(Z=CYUJHT40%4_*H%\!,!RB(=9=>[W72C;I@^NTA>0EMT
M6G4.P=WU2AUEDXL4I9Z+K1R1C930:\:"L:\L1GYQ09QGSP>.U2' I."F$ ]5
MHGLY0-\Z1U_OI@PMNKZKLAFJ\@H#=L.36=W: G*O8E-O,UR:>"JP<NUF)E$"
M?,.*K<Y% ]#A@>=BNX^HI?M]<.D33^:1W;2-'5[L-,@I"BG3#ZVLUC<U6/=L
M[2+K\,K*EF&IB*-C$(($^^!A* X$CX^UUR3C'$U'3\)(0S45_P 1+L9B->13
M;\*(E<@XD6[I5H@9N8! X&.'AP//&!>C+#"SC1&2@Y>-FHQP)OD2$0_:R3!;
MP$2*?*=L5EVZGRSAP8 -R _1@6G%DAV<@QB'<K&M):3,H6,BG,FR0E),$DCK
MJ&CXY5P5V]$B*1SB"1#"!2&'X!@0LUS[B>A]M]PML=*M=Q.U+1L?1C4@[6O<
M=1'A]+4^?4A(NQ)4J1V*+P6G\WJQ4N@<K0J E,(F*503$, !WVG.^N@MW]@.
MT_6RI25A8;%Z?6FA4S;:UIC&T!65)W9$2:8K+>IS3J2$)X5D$S$.'RTC?- "
MD*<1# EHA989TW?.V\I'.6T6H[0DG#:29.&T<X8<?CT'KA%R=)HJP W]\54Q
M#)_UP*&!;86RNRD$6SQL_"/JZ*"SK\^9S,:[A/PK<1!PX_-VKM:.%! 2B!S@
MKXE$!Y'T' OL;)!2<<TF(V:BI&(?_P#G%*L9-D\C'?(F* -9!NX4:.1$Y1#^
M[.;U 0P+9;37Q227&=A@1<+)(ME!F(X$G!G"IT6P(*"[ BPKJIF*0"B83&*(
M  B A@7G\['1?X7\Q?,F)GKC\,S3>R#1D=VH!3G,1H#M9(7*I4R"<2%Y-XE$
M>/3 N*S4>WX!V^9LS_ZN4R3A\V24*=TJ"#9,2**E,8[AP8$TP /OG]"\B/&!
M\LA:(*+:R;Z0EX]FSA6#J5F'"[]LFE%QK)([AV]D.53*-$$$$Q,8QRE  #Z_
M3 B)6?<&ZU7T.L,AK.P6O:-0[=V2]5;3NQM?T>RV+7RLCKUI*.9IQ<;&@S22
MI44]/#+HQ[M^1)!\J4H)&$IRF$)C$F8Y5==L@^;+N6@$,]:(N45'C,JH&%,7
M35-0Z[?YGC]WS*4!Y],"M*3:+F3*DY;J&60_%(D1>-ECJM/("?BR%(L83MO(
MP??#DO)@#G ^TIQ,'Q$! >! 1'D/I#R#Z!$/HP*N1^L?Z1P'(_6/](X#D?K'
M^D<!R/UC_2. Y'ZQ_I' <C]8_P!(X#D?K'^D<!R/UC_2. Y'ZQ_I' <C]8_T
MC@<@(\AZC\0^G K./ >GU_\ #@6^1^L?Z1P'(_6/](X#D?K'^D<!R/UC_2.
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M"UC6@DBF*K-!5HBV<.BBH!S*F$1#]XY2D /N#R'QYYYYYX#GGZ?+CGG JP&
MP& P& P& P&!R'Q#]8?MP+A_A]O[AP+6 P& P& P& P& P& P& P& P& P&
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M P& P& P& P& P& P& P+Q/X0^W]HX%G 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# O?U/[/[L"S@,!@,!@,!@,!@,!@,!@,!@,"HO'/J'/ AQ^@1, <_P"?
M TR>TBV>M]E>[L=R50&KGW7]XJQGS#<D,@&J]+?/^041'Q(5\54!] Y.!L#<
MS@,#2;[\DA1G73.-UWNGK-NGL5UUVKM>E5'>LQU^=RQMI=?:JBZ4G(?>M>KD
M##SDM;5JG8XM /P14!04%3A4?$<#\NNRXKM7.^VQ[J)W2?;3M!U#3KO6?2?3
M;=7:714O ]OTD9+9U(<[)1A4"1;#:4SIBB1)"CP\Y9NW*)5 2+YJ  8H]R[7
MC>V.6'5KIMTOVC7*MHSKKU*I.AK?*:N[7V::L<3O&:B;Q<]OT6/82<=KC04O
M5INPF)+3,DC(3#E<RC+Y**1501"5.]M'I53M'[[FXH716Z[!VCZ]=+-*ZPZI
M6Y"K;BFWL^#[2L/I_<6[*W9D'BT'-3"R,OY@B95RX*BB=XBF"Y%U0#SM]<2F
M\=>;=F=*ZN[#7#0O1#_F_P"RZ_T9SL'7&Y]:ALSL1N&4A8FQR]<B9^.@)VW/
M6,=&KNG"[9(3/%6"A?-1N<JA@AMV-T55:'K#I53]%:SWE,P]0Z*46Q,NJVVN
MO_;,=8]FMX[>;QSG:MNT[<]23:4S0=ZM;*11@NO8$(EFR29(F;B9 X (?LK[
M/Z/[!N?8?V+H70]1N,+V"<=$HRE0&NG]LF;I?&$PM3(@EOUX2VS+DTY8K46"
M4D(ELLX5%55SX%,(CS@0YZJ=X8?L3KWIYU!ZP>W%L78]%T7HF+=;6N?8W3LG
MK#7'6?;VFM6(EUU UAIL&J*-+SM%QL-B5$JD:*0H@X!P1SY"IXAITZ>Q5][%
M;!Z';(KM4[=J^YS1^V5U[.>Z9OB]QVUJ%5M7Z2H4S;S3G7]VREOP%&G*[?(.
M(C8ZL5^$06+X 85@'S'Q#GKWUKNEF+[4'82>H>]U.S_<7W3^S/<"[3YG>RRV
M3776G5ZUQN8ZM9P<B_;5VK,+FFUC%$D7K9(CI\Y,B8YB^ @'T^V?1K19/<DH
M6PD-6[=[&.W6P>S6^MG[IV!3NTW7CL[UE=!"S1V>G^Q03%A?Z4VW79^1=MV$
M#7H9=R51)0%@*01 I0\'[;&EH=6H^VA3JQJK=]0V5OSW.>Q/8GNR\"J;B@#!
M5^ID=>[_ *OUK:AG@:L4$7!K9'((JH$ TB\,=-5P=5,2$#%W7?7]8HW63K!L
M5IISLIKY7L9[UKV[]T+2TU?ORUW'7^JM-W6:N^F-1RU?:L9*>MS:R&F4$%I%
MFV<&=N/G).%CJH@0 ]IV+UF3MCKVR[Y[$ZR[!QNM^[?O_1[23<2-.VLM9-;=
M0-*5>4JC16/I\&R5N%8<6C\6O'\K,0*DJCYH_ASI?- ,C=F^NSKLC']KM:1-
M'VX-&['^\YTVZ3Z5@"$VJA%UCJ_U.U^E4;98E6TB['Y]6:0K]X@,@_,J@NXX
M7,M^((10 QGL36\O:/<P@M1T?5^]-O5N)[>Z@TIKGK3>5.UVEM\],])Z>+%U
MYE?=6;+J]@L6B'W7E["Q97IYB264?2!/ BI0.(JX']$E!,4_,HB8W E*!S&\
MCG*F7P*<QO3R.< \C#P'WA'ZL"_@,!@,!@,!@,!@,!@,!@,#D/B'ZP_;@7#_
M  ^W]PX%K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# O$_A#[?VC@6<!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"]_4_L_NP+. P& P/D<O6S0.7#ALW
M#Q,;R<.$6Y>"E,8P@*IBE'P*41-Z^A0YP*F[I-R!%$5$UD%$R*IK)&!1(Y#E
M\BF35()B*E.' @(#_"(#].!].!P(^(E]/CS_ $ 'J/KZ<?IP #R #]?J'ZOH
MP.<!@,!@,!@,#D/WE_ZLN!J']JB.,UNONHO1>&=%E/=-WVY3;<%XCOP]!U''
MF0*/ "/SA;"L/QX%00#TP-N^ P,0;LW=JGKW2U-E[FO=:US1V<E$PCBRVB50
MBV*<K8I)K#PD:B"A3N'[R7E'B2":#<BBPB;R OB4P@&53MDUP*=01. @42^I
M3 (" "!@'DQ3#\.#>O&!RFW^5Y^*BH_-'DP"<W'/'  0!,()AZ_1@:X1]V;H
M$7=9>NH;X5#=/\P*U<]!-J_=!I!*2;SBE;5<JNPUX,*E!(SJ1VYY;Y_Y:4Y!
M,9?Q#G G+K^]U':M*K>Q:-.,K/2;;#MYVKV)@HH+2;A'J?S6THR%VBV7*R<I
MEY+\Q,@B'(_PCZA[0@"?P,0XD 2_-(FF8.3$4*($,(\B3R,'/'B/'U_H"LBI
MA2$3 ! \S%$1,45/0W@!A,7R+Y_,^Z("(#Y>G'.!3]X !(0\A.8!Y$QS\&+R
M8 X-Y"80#CR HB/T_P /K@6BJ(@(F Y#**'*)S% G*BI@4(0!%, !0/!,Y2<
M<^I1Y]<"P9!,I0/\M @(% OEX%*"90'^Z #@3D !0"CR3Q#[H '&!AY/?&KU
M]ZK=;D+"=]N=O0B;0F*BRAIYT6%I:TE^2Q\U/SR<6-9B3S3U(Z4>V6>$=NBM
MUC)D.1(Q@#BG]B-)7^WM:%2-@UVUW!Q3978#.+A%W+Y1>G1-^D];2LVVD$T!
M9*MFM_A74:J +"J+ANH'B8I1-@9I2)\PX !E$P\0./BL8H\G-Y (%\BG("IB
M^0^@<CR _2&!48!34*0 5$"@8X*"(G4.8!*8W \@H?Q*;CR^  / C@6")&%0
M3&\@4$XD^")OED*"AA(4P 8/05#&$!'DOD;X>F!]'RD1^6N')3B!!.L!$BJ_
M**8O]R8W'S3("(!\!\?7Z<#Z3J' /0@B/WN>.1$I0$0 X@)0Y 1#U^K Z.U6
MN I5?E;5:IF*KM;@69Y&:G)IZA'Q<8Q((%,Z>OG1TD&Z(&,  )AX$1  P.GI
M^QZE>G=QCZQ+MY1[KVVN*'=4$D'R0P%R:1,3-.H%<[UFT3<JH1TZT5^<@*J!
MRK% IQ-R ![851\DB>)>51,'B ^H^/Q4+R #X%'CR]/3D/KP/#I[&JKN_3NL
M&$LDXO59K%?N4[ ':2*)V5:M$A-1<%)EDUFJ<,X_'R%>=I@DFN=9,41^80@'
M()@]HFJ)S>/(%$.>2\AY?='Q'[OJ( !@$/7Z>0^C QO?MRZUUA)U^(OUVK52
M>VEI;9&!1GY)*,_'Q= KCFW7J4*NL'X9&-J=;;&>O7"IDT6Z/CYG QR 8,,=
M;^]75#MS*6B!ZZ[JJ^RYREL&$M8XB/:6*$E6T'*.5VD79XZ,M4) O9ZG2SEL
MHFUF&!',:N<  BP\EY"1;^[U>-M,#2)"P0C"X6EG,2-:J[R0;-IZP1M>39*6
M!_#1BIBNY)I"%DFWXE5(IDT16(!A#R# ]1YF\?+Q#CGQ_B$0Y'X!Y 3CCGZ?
MA@>?L5MKM0CB2MIFHRO1JLI$0J<A./&\8R4EY^2:P\)&)NG)DTC/I:5?(MFR
M0#Y++JE(7DQ@# ZYQ>H)M<HW7ZKQ/^;Y:NR=L8P_R70JKU^&D(V)E)$JJ:)F
M8 TD9=ND=,5?F@*Q3 02@82A5?M@T_5E'M6Q]B6".J-&H\#)6BVV>8.9O%5^
MO0[15_*RTDN4AS)LV#1$ZBA@*/B4HX$7];>XKT>V]7;3;=<]H-0V:O48:L%T
M?I69*.-50O$^VJU-<SC.738R#!C:;(]28L7"B((.7)P(0XF],#,&_.R^BNKM
M+)L'L!M"I:KJ2\BC#L).T/3I+R\PN!S)P\#$,D7DU8991-,3@V9-UU_ !-X\
M (X&,)[O]TWK&C:WV6F>Q.MDM'W*3"%I]^CY1Q-M+1. +KY\!!0T*SD+')6-
MD+%P#F.29F>-OD'^:D3Q-P'KZ3W$ZS;,9:[D*!N[6UM8[7@[U9=>O8BSQZS6
MSP6K_P O#94@S,HH06Q-?#+-2S1'((JQQURE6*4P\8'?5;LUH6Z:6=]C*QMF
MA2VAV$=8YEYMQ"?:$H24/4G;YA8)<+&Y^3'J1D<\CEDQ7(<R*OAY)F. @(AX
MC3G=SJQV"@[W9=-;PU_?(75T>67V2ZCI-PR<4:%5BG4VTG+-&3#>,DXF"?Q;
M)9PW>JH@U<(I',100(;Q#HK+[@W3"F:3UUV/LW9+549HS;KU"+UAL\TZ=U5+
MU)KIR2GX&LNF3=VO)NRA#N_)(J?FG\@WEQQ@?(W]Q;I [U]![58]G]/R.O+(
MWOKB#M<99TY.-D U<VC7FQ$4BLD'#HCNF-)AHI(('3(X1*X3$4^# .!\NFO<
M=Z0]BE[@VT7V<U+LH^OJO*W6\K5^=4.RJE3@3@G.3DY(.VK5C&LXD_(.!54
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M80F#@,!@,#D/WE_ZLN!JP]K[_P ^_N1?^S-NRW_H-H&!M.P.! #!P/\ "/\
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M@C*MB:5VJ\(W?E(W+\],'2)#\?2)?7GUP)+_ )-"$$"DB8HH? H%CV8?#@.
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M3:=V!9V3QN37M4.@Y:(:XLS_ .6LK^3_ .K?+=MR&*8.!.)?$1P,Z)Z@U(!
M5#5NN$S*@!UA)2*P7Y@BDF3^\_[%_>#Q(4/7Z"A]08'RN]*:7DBH)/-4:Q>)
MMU2?)2<46JN"(F#S]$TU(LQ4A$BA@Y  'Q$<",W4C3NG+#H2GRLQJ#53]\I,
M;$3(\<TRGRRJS)GLJW-8U7\;^5'%1,&""8$*/JF0 ((<A@25+HK1OP+IO4P"
M(_U=>4_U'ZONQ''(_P!.!'-?4^J2]OX6NEU9K8L&;K1:ID\:6AU4K-23+M*G
MLB.U&Y8H$3KIM.4RF$OD!3"'/K@22+I'2A/O%U%JQ,?K+KZIE'T_2$/@82[)
MZCU+%:#VQ)Q^K==M7C&F2KUNX94FKMEP50(10IDUDXU$2&,!/'S Q3 41X'
MS4TTYJ%=H@JOJG6AA60:*'!6BU503&*W2.F)C?E0@<Z9A'@>1 /3C ZY?KUH
M-P"PJZ2U*L#HJ"3D3:[J)Q<)-1%1!-3RB1 Q4U.! ,#!.K]):3GKMO\ CIK3
MFJY%E6=IQ<3 LWVKZ@"$5'*:TH[X6\<LI#F*Y2<.G*AS"7CQ,(E'X!@9L#K-
MUQ#U#0.EP$?_ )V-+#]D-ZX$<>QVB=(U\-!*06GM7PQI#LUJ2)D#1E!JK,7L
M4_7F2/8UW\F*)\]@[ I042-R0X  " A@2:_V>- A\-'ZA#D#%$ UO3N!*8HE
M,4?^PW\(E' OI: T4FH0Z>F-5$$I2IE\=?5,OB0$_D 4.(D!X^1]SC_0^[_#
MZ8$<.I&GM2R^E&SV6UCKZ5>GV/O)JH[D:?7WSDR+'=E^9,T16<QZAP2:,VZ:
M*9>>"))E*  !0  D&\ZY=?GYP4>Z2U4Y.4K@H"K0ZT8/%V=NHY#Q_+O$?FG:
MIB/I\2!@8>D-':*/O=I6%M-Z>5C9C5%@L\BR5UW6C2,C*-;M5XX'ZKP8\"&;
M)-GIBG3$O)SG*/P#C RP'63KD!O,-#ZA$P_$QM>54QAX  #D1B_40 ,#$/8'
M06B*YHS<MA@](:D9S,-K"Z2,8Z1UW4RJI/64 ]=-3D'\K]#E<)%X'T]<#*L7
MUVZ_.XR)5<Z(T]\T\:Q7.4VN*B<4U5&B(G*!AB1'[HF$/K' ^P.M/70IA4+H
M;3A3\&^^76U0*;UYY$1+$ (\B/K].!B77>A-(/M@;O1>:BT^_9Q%RKC&';IT
MFI.OREJMKVK.WC,[<L2'Y<HJ^6.J*0\F$#@81X,&!F4_7G0:A3D/I350E4(9
M,X?R%60\B'+XF+Z1H" "4>/3 P9MK2VIM=GTE8=?:TUM4)^%WEJ^'C9AA7X"
M%?1T+/3PL)QC&OP:%6(O*,E3(E3*;R6,(%#U$,":29?$A2@ @    !N>0#Z
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M=([%B6DS2=N4"U:^M$8\1!TV<Q%IAG42Z-\DPE RK?\ $@JF8!*8JB93%$!
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MCJB[6+34CUFM&^]B[>ZOTW7"=S1G]25O9=G=6"7UO*HSZ24&C68MRY!=B@R
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M-,""!S"4-C^Q@1-KN\E?$5615HUL([(50$%3H&@)$SA,BH>)43&* @!_3QY
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M0%1D!OE'.<0YP/.^Z7HC=O:3V_.PO7/K[7J78]E;TURIK:-_Q"MCBF56$C[
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M+Q&HZ0[5;M':SA(T>C6XQ/\ '-EB-2)+,A#Q,0Y> ,0Y1 ,#WX=G=!"J*/\
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MQ$1$"CS\.!$.Q4N-7^494MDK@H 4_DL,[$_+ R8??*!A=^ F(?@!Y] Y]<#
MVJYF,C-E=C'SZ3C&K.6O=,<Q;M[9(H6\B@EJVH-EG#--1P11! BR0E#RY\Q
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M](ZCE)(#.9-_KBG.'SQRD4';AR>"9F77=& I1!5<P^0AP4 $>  /A@9=!LV
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MFV*54H?8W6&.B*?3HZ#>[7M+%_%M:U"-VRZ*^H[TH5$K-./!$" NB8Y^ */
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M1K3^1:^=5DW3U33E"I.A5CQ\U"BI_=F#C^ZX#Z,#.O\ @/I+\.1H&HM;E:I
MD";<M,@"))@@H99("$*Q I035.)@X^D<##^X]4ZWK9=3S%8H%1@)EGO74P-9
M6$KT/'2+5$]@!NN1)VFT*JFBLU.9,Y2B'D4WU\<!+?[/$ ] #Z@#T /Z P&
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M]7'.!GS P'V",<L3JX2'*F([XU&43&#R#Q&S)\AQP/Q# SZ;XC^O XP& P&
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M(F,DD8?4. XP(X=J=[Z;M>D;G!0FPJG)RQ#ZULOY=^9+('_)DMD4IZ63^?\
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M8#>0% H@.!\<AV#TH^B714MHTGSD8V40:B>6("2YTV:Y50\?#DZ3<_E\S_1
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MZ%,N],[1!=N#1+\8!E_G-S H7CGD@@/P'G PWU^VGK*NZMB8R>VCKM"1_/\
M9DFH*EJ@&WS&;[;-U%!?Y022J9/%5;Y)_$YP*J0Q1'D!  S,KO/3")?F*[;U
MD5'ES_?&O%;!, 9@7\9_>?F0)_ZK\PHJ<CP4!#G@1#D, V_9FO)3LCH:>B]@
M4-]&0E"W]&RS].XU@R+!Z]4U.5JU<^,H9=)=1PD!3 0H^'D &^(8$@5-VZ>1
M<I-%=KZT1<JG731;'N]<*X649F.1ZBDB>0*911JJD<IP+R)1((#P("&!Y^\;
M9U:ZI=J;EV9KT7+FH691J@6Y5X#.4AC)-@*J0&?ARD#U,Z0F#DOS""7GD!#
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MU*8!#XX&"M"W.@5TNX&SVW4N+5D^PNWYU%-Q<*X"C]!S),ES29"EDS"FF)5
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MYGKE,Q3-TU %%;9U.07\2>/\94E.0,/(%$.<"4!D4!$_**(^?W3\I)CY@'(
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M4O!0%,?(/+U ,#/J59K:)?%&O0211\>2IQ$<F ^!0(3D"-@#[A   ^H XP/
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M#F4,]4BXP#.#%4;G%-0$6J)#  \\(@'(@ 8'TN.M/7]T0Y7>F-9N0.W20/\
MB:?"KA\EJHNHV2,4[0?,J8N5..>>"F\?@ 8&(-;ZIU;9-A=B(.5U=KE9A6]B
MT5")3_E&)(;Y)=-TL4'#GEH4'B[9!\JV14X 2-P!,/NEP,NJ=:- N!3%QIG6
MBORS_-*8]1AQ4*MYH*?,*H#;S QCH%Y'GU\0YP,6;FUWKC7YM7V&MZRHC.<D
M]]ZCC%)1& 9HO4 D;$H@K(H+(_AA)(-"',*9^3<"(CXB/&!,8@"4I0,/D8 #
MD?K'Z>.?HYP*L!@,!@,!@,!@7OZG]G]V!9P& P&!@;=O5[KOV1_E?_'K3E"V
MT%*6EEJL6[P+6:+#A/MVS2>:H%<%$JL9.-F:)'K13S:NBHI_-3-X%X#'[GH1
MTQ>7"[7YSUKU,K;]C4YOK^ZS8U1@5Q.TYM%L8-.#51*0&C- \)$LV2JC9-%P
MNT9-D5%#IH)%*'WS/1WJ+8;?0+].=>]82EPU;)2\Q09UW6F:CJN2L]/.;5*R
M") *5N^=N+0[5DR'=D<&;R*AG2/RUQ$^!Q?NCG4;:%,2U]>] :ZGZBU@8NKL
M(Q2'_ +15>A+2K=X>)AY>*583,2UC+<N>10!NX3,F[.90! QC"(9_HE$INL*
M;6=>:]K4/3J/3(9C7JK5H!DC'0T%"QJ)4&4='LT"E31002+^DQAY,81,(B(>
MLP& P& P& P.0_>7_JRX&K'VOP$);W(1'X&]S7LL(?I_[&Z_YX_5@;3<!@1/
MJQA_VU]P%^@O731YP^OG^>]P?YONX$L,"*_=9<&W6K8"QO+C\SUND7P,!#B9
M?:5*1*'D8!* >1P^S E2/Q']8_YA$,#@1$/4/B'K]?\ F]1'C]'K]6!'7K4=
M=6)VX==5%42]C=\)I?(=?BA(W3OK]-))P'S%0;.$BEX%(/'Q+QR "(X$C#_Q
M#]G[ P(H]@C&+MOIKXC_ ![XLI#?]*.B-LF'_J,"5@>@ 'U  ?T  ?NP.GL
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M=-%^T-PP)A_S#@2LP(U=P4_F];MHI?,%$58R&3*J"::W@=2U0)2&^6JDNF(
M80Y$Q!*4/4?KP)* /(%]>?N@'/(#SP !SR4 +Z\?1Z8'.!''21Q'9/:(PBF(
M?XQ0R902 2G#Y>J:#S\TQA$#&Y^KC D=@1=[-)JG==<12*F;Y?:/5YU .H=/
MA(8RUE.8@D ?-0OD @4?NFP)0EY\?7G^(>.0$!^CGR ?4!_1@4*? O(<@)P
M?K\1_B'GZ *'J.!&'J2FB37]^,DL@J9;L7V27< @3P%!<^Z+CY(+_?/Y.$R
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M(" @ >N!(=+_ (H@\< )0$ ^G^$OQ_3@<F_J"(B  <IAXY_JCY<<  B;X?#
MC1TZ<&=]<M?.C"0P.'%X71.1NLU!1HKL2VG9*'0<$36(LHT$AC^10Y.(C\!P
M),X$4EBF#O+#J#QP?J78R\!\>2;@JYA_I!4,"5N!@#M0F17KKN!)0A5"*TN1
M1,0Q3G*8%3H$X,5,!.)>1]>,#.S,/%HW*/\ 500 . $  /E%'@ 'U  YX#]
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M2$(0QA.8I2E,<WQ.8 X$PAZ@'.!5@,!@,!@,!@,"]_4_L_NP+. P& P& P&
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M8$>>PITTT]*?,453%3L3JI-+Y:9E 55%Y)F^4IXB'RTA( B)A] $ # D,'J
M<_4'[ P& P& P& P& P+W]3^S^[ LX# 8# 8# 8# 8# 8# 8# 8# H4#D"#S
MP(*D'GX\>OAS\0_T\#51[89C%NWN@H"0/[GW.MX'XYY_\Z=>:@<^GH  ']X&
M!M:P.!^ _J']F!&:*. =Q[L'*7D;K;K8>.>%RE_Q)V04# 'P%(!4'X_U@],"
M37Q_RY_RYP(T=P&:TCUUV*Q;H@NLY)4R))"N#8#F_GNKC]Y<>03 O'/P]?A@
M28-\1_6.!QP(_#T'Z!_3]''Z><"/W6\0_E_97@4P%_Q\W?R<R*B JF_GZ4\E
M (H8W)3"(_> ?$W'.!(,_P#$/V?L# C!V#+S>NIZG_6^PX>GU_,U#M5/_-Y<
MX$GA'GU^'(?#X\?1Q_FP.KG  829-_HP\D'I\1Y:+#\/IP,7]=_O:"TJ8?B&
MK:('P]1XK4>7G]'/'.!F/X>OU?7\/MP(\D??-[5(L/D.2BWZ\NGGSO,OX-0'
MVR6B8)%2\O/\2B5IY&-QX^)P#GGG D-@1Y[6(?BNO^Q6W!A!=G!(\%2^>;^]
MM<"3T1\T_F"'/P\@P)#B' \?OY_]M@<8$<-(K)#L#LZ@0#_,1W<R,L(@L!?-
M;5>NU">)E2%3. )\<@GY% ?B(#@2/P(^[Z IW6C3"0!%'L%0! 0\@$IE(ZRI
MB?DH@'\)_'@0$,"0)?0H?Y?'UP*@_B*/^7J(?\&!&'J('CIUT0/@3;_8(H#_
M *0!O+8 \\?1\<"3N!&FPKJ%[>:L;?/2*0^AMN+"V$!^<8Z=TU>4JY1Y\0(0
MJ@E'Z_+]&!); Q?O OGI7<*8^GS-6;")S]7E4I<.?LP+FE#>6E]0FXXYU?0!
MXYY_BJD2/^; R6;X?1]0<C]/ _#].!'C5AQ';O:$@J%4$EYUY\"B44_+3U*_
MNS /Q$HE^(>GK@2(^D?^F-_U0X$7.UI0-5=5\E 1#LCU],'D'D4!'8T43D"\
M@')0' E0?X?;^X<"@O\ $'^7T8& >L92ETO60*4I0"8V"    '\6R+:8WP /
MXC>H_IP,^8$9;:*8=N=(@/B"A]*;V*01( FX"RZ?,804YY  ]/3Z<"36!X+:
MWKJS9 ?70KGZ_P#[M2>!Y?KO_P"D#T:;_2TUK3T^K_M0@PP,RX$7:=]WMYN\
MOUZ3T2;GZ1XL6VR_T8$HL# /94J9]:,4E2F,5;:>D4P J9E \_\ %^E'()P*
M B4A3E 1']&!GX?B/KSZCSZ<>OT\?;@<A\0_7@8"Z^JD5B]K"4?0G8#<R8\'
M4.(G);W(#Y?-$1+P/]4."A]&!GL?@/ZAP(S;I!,VYNI9U'";8Q-E7P4B'*8Y
MG2@Z>NA/PJ7CZ%5.03& 1]  @X$EDN/#D/@)CF#@>?0QA,'KZ>OWL"Z7XA^L
M,"+_ $Q#CK-JXO'\+2S$Y_Z2ZV0OV?# D_@1]77;E[50;=04"O%^OEK5;E'S
M%P9LVV142N3<\ F*0'<IB ?Q (_5@2"P(W=OR'/UGW$5,&QCC4S^(/#&(U$0
MD6 _WYBB4P$]/7@<"1+0/%L@3T]$$.1 1\>?DE#@@#ZE*'T /(X'T"82ASZ"
M <B(#\1\0$WI\?7@!P,#:6 1LO8H@\!SO-X8! XG]/\ #76P^H?U1^Y\/HP,
M\X$9NQCM9G*==2(@@)9'LI0&*_S405422&O75V)VAQ, -EE#L@*8P (F3.8O
MTX$F<#D.>?0>! 0^CGZ0 0^T!P(U]2D4D-(Q1$73]Z!KKMI4[J2D_P X>*G5
MVM=%#%5D/@L1 3>"8? B92E^C DG@1P533_VO6:G@X%;_9LD" H)P_"E2#:,
M4=1,I/\ X8.80Y'_ $2@&!(_ CUVO$I>MN]#*+%;E#5UK 5CF(F5(HQJYO(R
MB@>! 'X>OQP,[QIN8Z.#T^]'M#>@\_\ P,CQ]'J'WOC@?:/P']6!'S3/D&P>
MS!!.8WCN"*, F$QN"J:KU^<"!Y? I1-Z<>F!(3 CEV,*?Y.C#$)Y^/9+5!C\
M\_<3,ZDTA.' #QXB<,"1O'' <<<  <?J#C 8# 8# 8# 8# O?U/[/[L"S@,!
M@,!@,!@,!@,!@,!@,!@,#@>/0!YY$Q0#U]/X@'X? 1P-4?MEAX[,]U-$3#_=
M^YIM,W'(^GXC36C'GB''P 06YP-KN!2;GC@/B(\8$1K%L6HZ[[.S[R\62N5*
M%F=%T)K&24XY%BM(2S6_7D563555($%T4D'!!,'S/(AS@/CP/.!E(>QN@R*%
M0-N'7I5Q63;?+/9XP#_B%% 1(B/*_HH94P%X^OTP,%]D-^:3G-/W>%C-G4R7
M?_F5<C5(R+GF#F0!\PN5:<OFX))KB<5&C;^\5*'(E('( .!G)QV2Z_MF2,FX
MW+KA%@Y 5&SQ2V1 -W!/Q3AEYHJ_B?%0HNFJB8"'/)B#Q@6S]E^O1! H[JUL
M4YE/DE_[;(@?[X2 <"!PZ]3"4P" ?2&!AO1^Z],5*,V(TG-HZ[AE'^]=M/6R
M#BUQJ?X@LW;'LHP53%RY)PH\8J@L*9?X -@9U3[!Z+<-UGJ.WM<J-$2%45<E
MMT+\DA#?PF,I^+ @<\?7@1\WQM[5<E8.KTU&[$ISZ*8]@B/7DDTL$8NS:LV>
MK=DHO7+ARFY,DB@V.\2*H81 "BJ4!^(8&?2=BM"K&5*EN+7!Q1!R98I+;"F,
M@1D7R=J+%!WRFD@ #Y''@H#Z<X'Q2^_=(+(2,,EMS7:DJX92;5".+;8;\6NY
M!JLF+=)/\7Y'5\S!Z  C@8[TGN_3-7TWJ."G]L:ZBI1IK6CIJLGMP@VZI2KP
MR#9J<A57A!.FNHV.!#  @(E']>!E5QV#T4U(FHYW#K=%-59=NF8]P@P!19LB
M9PX2(/XP?(Z+<HG-QSP4.?A@1XDM^Z&@-_-+],;)HD/4%^O:B2.PI&V1+6LO
MDG6TDV[*,0DEW)&8KIOFSCQ #>1Q$?0>.<"02/8G0CANT=(;EUDLVD"NSL7"
M=T@#(NR,$%G+XR"@/O%0K-NW.=00]"%((C\!P,!;Q[$=?-AZ(OP4W=NIK0B8
ML2B*L3L*IN6P*LK/7UW!#NOS,6J?R2'*)A,8 #R#U]0P)$I[YTBHY4:!N#68
MO"%,JJT&\UL'")/B/FF,EY% @#Z_5@<_X]:.\"J!N+6/RC&^6"@WBM@F*GJ/
MAY_F7CY<!@87U/M#5L)=^P*\GLO7+,+%MN.D8@/YS@#*OFJ^M:$U;+%3!^)C
M&<G0'Y8%Y\B<&#T$!$,U);WTBN"PH;?UHM^''A?Y5VKJ@HC\PR7"H$D!$G]Z
M02^O]8!#Z,#"VZMHZLDG>GFS'9M"4>1^^*%(NFI+C E7%N@G,IKF%'\:)U2I
ME5\N ^@>?AS@9I-O;2::)%E-MZX22&-3E@44N=?(3\K5<_A$Y#S%_P"/X0[H
MP)@ISX^8@'/.!6AO'2[E=HBVVWK9PLZ^:9NBC=:\HHL5%(ZRIB$)("82IIIB
M8P_  #G C?U9V]JJ#U-))S>RJ-$G/N/>BJ24G:85DH9O*[IO+B,6(DX>$.+=
M^@J51$_'@<I@$!$!P))AN_2X_+_[[>MBBJJH@F"EUKJ8J+HD(HJBF!Y$HG43
M(J43 'J & 1^.!'B>V_JAUV>UK-I;/U>>!B-+;82?S(7NJA^%>/[;K=-LW6/
M^9 H1L8C)83'$?ED.4 '@3!R$@#[YT:F;P4W+JLA_GD:^!M@54#?B5/X$ +^
M:\BL;Z"_'CU^&!CS<&Z]-/\ 4FUF3';.M7CM?7M^CD6K>\5E9PM(#4Y8?P*2
M*<F8ZKKQ'GY8 )N!^&!3IG<^H8[3VH8Z1VGKIE(M]::]:.FCNZUM!P@Y&K1B
M((N$U)(IDC_.1,3@?ZP"'QP,GI;HT\Y55;(;4URLZ05,W5:DNE<,Y1<E(!A0
M52"1$Z2X%. B40 0 0^O PCK?8^NHO9W8R8D=@ZU:P\U>:":)?(W"N#^/,75
ME59G2=F+(B(/A<(B5,IO4Z8%,7DH\X&;U]T:?:'43=[4UVU42.4BI'%SKJ1R
M'4%0" <#R("4QS)& .?B)1P(W=F=IZQG*CK4838U$EA:]@] 2;@8ZVP+SY$>
MGLF(.9\K^'?J"1H()F#Y@_=^/K@2?';FJU&;E^GLFAJ,69EBNWB=N@#M6PMD
M_FN 7<%D!22^0C]\_(AXD^\/ >N!\)=U:=^=\H-LZU%0HH>:87FL^9/Q)B%;
M^8?FG)?GBH4"<A][R#CXX&&^ONT-8P>G*P26V10(\%9O89FYW5QKZ)'!1V/:
M3!^'.=^4JW@58@#X\^(CQ\<#-RNV]4H&,5?9NOD1(')_G7*O)>/'QY\Y O'&
M!'*W;*UNMV9TW9DM@T ]?B=2[T82DV-WK)&<>Z<SNI#(H.#'DRF)Y?AC^1AX
M*F8  P@)@ 0DB&U]6"9(A=EZ_.==44$$R7*NF.LL'\221 D1,HH0 Y$H!R 8
M'C=E;,UNZUO?6K>_TI=P\H=N.U03M,&HJX34KS\B:B*97QC*$5%0H%$ X-Y!
MQ@>7Z\;"H+;0NCFCN\T]N\3U%KA%5LXLT*DY26)3H8YD54%'I54E0*(&$I@
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MU#Z#@1KZ<V:M-.M^MFSJPP39PF2VF417F(Y)5,JE[LYDA.FJY(<"F*8./3U
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MH3%$0.0)!H)R&#GDIR"L!B" @//(!@5$G(0QRE"9BC"*GR@ LDR$15 1_NN
M7Y$_W1]/CZ8$9^G\RQ-H.LJ/)./*X<6?:RY_)VV((E_Q8NJ0'\14 P@()_'C
MU]<"303$28>"RD<8.1#R*^:"7D/B4!^=ZF /7CZL".Z[MI_M:1[\';86(=<9
MEL=V5ZV,W*Y3V? K$;F JP\+&3,80'Z@'ZL"0WYW#&#R"7C#AX^7D60:&#Q
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MNC)NP[ED8?JJX["[KBX^IM]/Z6L'9/L"TH=?K,I0I"T-;18EE:.V<#(NXO\
M$I1"RZ"AOF 8P%"0VV??%K.J%$3S'66ZH?S7L7>M3T^A/;<U#3U-HT3K+-RU
M9W5M.//,S::->C8RRQA8J$C'PDD)Y\LF1,$P^]@>YJ7O7Z;NVX([752U#L67
MJ;_KK#]@?YOD+#1JW='[&=TW)[JB:Y6-)V6<C+]>G"L+&K0RKJ(*\*A9""S,
MGX$.X*$C.B/N.47N_IW8&W6=(D=4Q.N4XZ6FHZ6O%'OKH:K,T\EUC9U4VOY6
M5=1,JTB"K-Y*)?(-I!C)M5VXE.!/F&#71V,]Z;83GK3;+1U]Z[[ USN*_P"O
M-);?ZT2VRGNM9^(V1UTW/O:A:2+O&'B&=M/%1$U#/M@Q2J-=L"C)<%9=FHN!
MD2N2D"3W=?N]V%ZUW>+T]4::UEOQ?MQ]ONSTSM^;3AA>QNVNML'1SQ,:6K,Y
MA&-=H/):?.$BR;%5;J*OV@-U/E$6P,,3?OLTG55'@8K=/7+8^N^Q\I;->4Z(
MT5:[]J:ONK+'7G4#7=!-A%V*YM ZUK<4E55_):-=R 2+9^N@S,F!E $H3GL'
MN,ZX#HUKKO7JW7NR]MU+;R^JH;66L8-K$P&Q+':=MWV)UG7*XX1M+]C"QKAM
M;I<J3E==R+5)!(ZY#F3X$0A^A[^W5QILW8-"MM)N-:CM<QFWHN7L[&TT"XG7
MVOH*E2%RVIK!&D5FP/+J@BP-#O8R)L:S(D)-R+4Z:"P$\3F#)M6]SV2NLF:N
M7#06\^M%[H-^U<>^4*[UVF;1D[7KO:>LMC[*K3FDOJ!<WC=TI+Q%#72,+8J[
M]E)D_"&;"<#^ 8^CO=]?; JG6G8NL>NDXO4=N=GF.H-ALI/8>N9>?H>K'.H+
MOM9_L-_'U*T/G57M%=CJDHI)5^80:R"'X5R@!#K&3$P>=UY[_P!UNV12;_;X
M?2N\596MT/7NR]>4F+=:LMMBW'5=F;2J6H*@->&JWZ5BZ=//+=?HGYT59EHF
M1;LG!G!T?%!;P#U+GWU^MU6VU;M7[/UWL77P:Z7V%5-ASSF>US9W=3VSJS5[
MG:EVUF]I%5MDK>G9&$9&/HYO8D&)J\_F&1T4')BG(H(9TZ6]Y]N=J.PF]:K>
MM#7+KIKG7FA>ONSJI5MGIUQU?)5SMA]LJ36M"<S2K)9(*2J,A5:W'@DV\DGK
M&03=(+D Y?$ B!N7WH[=+]?MGS^D>L6XZ1LJT:??;>Z;6/9C"AR54WU08[;=
M(U3/WN/@F]S;R%?4JZEZ8R:T%/"P=BQ=MU%/!,_(!X+4_NL]@*19]^7_ +=,
MK/ :FTK9]YZO@M81FI->)7F^6S0T/I2,?N$[K5-L6",97&Y;"V@BT9PY6Q8[
ME\BB5V()F5$,\[S]\_7?6EO3Z]OSJSOS4VZ+"UN]KDM+7NPZ?@)N,U904X=:
M9V-"6QW>RT[83=[^<@VCHJ#=O)-](M'34B?FB(F":G9;O/1- 4?06WGJ=Q?Z
M_P!KQEVO 1D!1U)ZU3--J>@+=O,S%.*>2D7(5Z95A:\ D1(BX6,Y_N#$( F.
M 4=3.]A>W^NM>;(HNDKS&PMNOD]2K.LG>]27.#U]'Q52+;8RZS=BIEWF6,W7
M+&9PWBTTX\%9-K**G1<-DDTE%0#8.F(B0HCQSQ] B/[0+P.!7@,!@,#D/B'Z
MP_;@7#_#[?W#@6L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"\3^$/M_:
M.!9P& P& P& P& P& P& P& P& P& P& P& P+W]3^S^[ LX# 8# 8# 8# 8
M# 8# 8# 8# M*E X 42E.'D7DIPY*(<A\?0>!X]0]/7C T]>U(9<VX/>!_$-
MTVJI/=*V4E\M(YSIF22T!U[307**ASF*+E I5#%YX*8P@'   8&XK 8$(^X'
M072_=F5TO8-JV;<E4G^OMDL-PU=.:@V=+ZWDJ_:[+#I0+JQF6C$5R/)AA$E4
M28KG*)V7XA4R7B<_D 2#UGJ=IK$JR+6^[1NZ:\#481(-EW5[<U&:=/B5HC\V
M:.7R1''Y_9OFBYF'9S'5?NP*H<0X ,#+/'/I]?I_3@1TG=0:5E.QT7N"2<MU
M=\I:*L6H8F./;2,W@ZBF[='6*Q.VE1!V19<!L;! AY,$A^5P"0&+SZA%FX^V
M;T^LVMJIHF2:7*(:U/4]?U]KA>$V;(LKW5(77.R&^TJQ=ZFY%51R:Y4:^F0=
MHRQD%A**@(*%,FH)#!DV'Z*:/'J7L;J%9;!N#9.LMRQEU;;%L>SMEV"?V=/?
MSN)?SF0_FM86;F&5;+$2,S09MVS-L"12E1\!,!@C%5/99ZL4PTK-UW8O9>*V
MG,7"FW$V[8W;I8C:\:O3->S&IBP59G8>MQ<?7ZG9=<SB\7*L&C,B3I--%41!
M9!-0 0OLK]1:T&MHJGW+L33:9KJ$TA"2FNJUNJ7:4W:Y.NE^D-BZBE-PL58]
M9W<YBM6.2$%%S+-SO6Q$TE_F%(7@,E;D]M;K5/T6CJJ["VYH]?13_?MKB-OZ
MZV2UIMOAJ_O^Q35[W5!3]JEH>3C%:5-3<D9Z5NNB!8\[9%1$Z9T0,(=:Z]J[
MK-=+YK?8\S=MYVRNZY@:TIK"AR^W9*9H=;LT!K)?6E=VW5WB[5:V1FP$JT]%
MX20;2Q4%Y8Q9$4C.!!3 R]UAZ":0ZKGW5*5V:V;M.W]AFU4C-P7W=%S/=[;;
MH"EP<Q7*C!RCU"/B&9(R)@YIXW^;\@7;D%A,NLJ?@0",>OO:?Z.P\&K21V'M
M';,58*?0*YJZ)O6ZD+BKK/1NE]N4[;=?UCI(6S9NXA=51FQ*9""^33_%&528
MMVZJX%(4,"6W9?HSI+MA9:];=I.;XU?5_5.[])G;4ZXNJO&V#7/8!K7&E_@;
M"V;HG_'"+FI1[EFKR0[=TW X"8!,40P_M;VK^M>S[S);4+/;>USMQY-:[EX[
M9NN;XE$6VL):XU2MI=A!UTTC#3$2P@;)17!DI=$[=07S@B:HF*9)+Q"03_IU
MI1WI73.@3-K0GKS1%MU)=J.R_F9^[G!G=-V%M:*BZL,^_,ZDIH7<\U*X?"J<
M1<F$0Y* X$1=F>UEIR45[$S],M-OC&VXJYO)TWTA8+(\'K9#[%WM4)&!V+<)
MJIUAM$W:1BK6_>+R#MB68*Q:O7"Z[-!%=43 $:?;S]KZ^:Z;W38O:7:KO9=O
MMEAT](T!"F[SV%L^/KE=TGK6YZS@71-LW"+@Y]^U>1-[>_A8U)L0D65%$P.G
M3D5%Q"0M2]I#KI&R[V^QFTMV6F\36S]=[$?;-EKY S$Y,0FL:Y=Z%&ZQD%V,
M"A$62HRE*V#-PTJL[25EG:+P3*/!623.0/OU![0>A]45&2H".W^RUOI"1M<1
M]!J]JV/'&AM85+4VS:SMB@U6I-H>LQ@/V\39JFT;C(2IG\JI#A^"%P"0!P'L
M+%[5F@[5M[9^RK!<-SO*-MQ[L:P77KV%V:M-,/;SMJI2E+V#=BL64(C<!?3D
M-..U@8GE3Q:$BX.[20*J.!E#J#T&U[U%=WZ>BMH[TW3;MC5B@46P6_?%\3NL
MNC0M6L)B*U_4(=-K%P\?&0\!&SCE,QBI"Y=G4%5=5141,(1]U[[.?6"@1EBA
ME+KOZ]P+FB.M3:WA-@[+/8XG0VII+8-:V5*:]TRBM#(#6HF9L5.CDWCE8[I\
MX9-$T#+>!"@ 9&O_ +6O6#:,=LN+MJ%]=1>U;GOJ_6AJSMZ[(Z%N[!DUT:TS
ME?=I,P=0[JKRVJX62@3IF$6+]M\P?/GC PS+>S#I66ES7M[V.[DO]X2S>?KM
MV[!/]S-93;MRUK8F<&U6U:XE9.K/(*NU2(4KS9S%C#L(]Y'/5'#A)<%5SF$)
MG[CZ8:FWA6-.UJUR&Q8Y+0[.<9:XGJK?):!MC$)_5\SJ)](/K(B"LF]E$ZK,
MJ*I.C'^;^/*58?+@2F#&'5WV]Z)U(<R\GKK:6V96U; VJZVONNQV5Q2A=[ME
M4Z0O0ZY$W6*KM2@:[&P]7C ;+HC"M(YVZ?M2N':JYC* (;"R?P%Y#Q'Q#D/C
MP/'J CZ^0E^ CR/(A@58# 8# Y#XA^L/VX%P_P /M_<.!:P& P& P& P& P&
M P& P& P& P& P& P& P& P+Q/X0^W]HX%G 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# O?U/[/[L"S@,!@,!@,!@,!@,!@,!@,!@,"DP@'CSSR)R 'IZ?Q
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M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@7B?PA]O[1P+. P& P& P& P& P& P&
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MA.1(/(3@'A].>Y=6JGJO6$7LO9L9VSMMVZV]L^U]4WYH&$KD=K7:&H>M]P1
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M]?(/K# [0OB(<^90]1 0Y*(@(>@@/ ^@@.!SP3_KA?Z0_P"' X'Q /0Y1_M
M'^?G MG4(0 'S2$OTF%4A0 ?M'@<"T9VU+Z&<MP_6X0#]J@8%@)-D*@))O6)
MU3%,*:0/&PJJ&*7S$$R%4,8>"@(CZ?#UP*TI1FY/\I%VQ64!04O%%XW6'YP
M)ODB4IQ$%?E@(^/QX 1P/K*8AB^0*)C\?X3%$.2CP;U W'W1 0'ZN,"O@G_7
M"_TA_P . X)_UPO](?\ #@."_P"F7^D/^' <$_ZX7^D/^' <$_TRC^CD/7_/
M@?&9P8HF\@1_AY ?GI$ /B(?, 1Y('RRF-R'/H4<"OYIR^(>)!,8!Y*4Q3B4
M2F* AP \B %-R(_1@?1Z>0E^\ _'C@/4/K#U]0#GU_3@<#R \>)AY^G@/^'
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MB:8E'M:\]HJ"UV%ORE,MD4W2L-/O-J15;E-I)4EX:56(1=*/;1J)E3NB< 3
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MW&;LVE+9N#9=:M$-%W4QJ!8M:%I<E&/6CPR3DSUNHF)2G'Q$.HM>A_8&8KQ
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MFUCJ2F+=J;7V!U'6ZC#;#+*N(_9]ZCZM:[3;D:X[C8XJS0K9 7#A-VDJ8"E
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M>LW215VKMFZ0.H@Y:N$%"F34(8Q3E$! 1YP/MP& P& P&!>)_"'V_M' LX#
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M)N1X$>1]1Y'XX $$P^OGZ1Y]1^\!O40]?X@_R# X%NF/^ER(G$1 >!$#F\S
M(AP(!Y\"'' @(8%?RB?=$0$WAR!?(1X !^(" " #Z!]/K@<BF7](&$0-Y /!
MO(/ZWU<\!Q^K I^23CQX'CGG@1$0#UY].>>.,#D$B ;R]1-Z>O/ ^G_2\<\B
M/K] X#Y1/$"\< 'T?T^7_F7(\_KP.KEH"&G6Y6DU&L95H5=!U^%DF31^U,Y;
M&%1LX,W>(+HBNV4'R34\?-,P )1# [(J"9 *! \0*  4 ]   ] #CCCQ#Z ^
M&!29LD8_S! WD(<#]X>.../X1] Y#X\<<X%9D2&\O3CS,)C"7@HB(@(#]X \
MO4H\?'X8''X=,2?*'GP,/J " >@^G <    %]/U!@7#-TR^I?(.?NB &]! 1
M$1Y+\#"/Z<"U^'2YYX'X'#CGT_O! 5/TAY>(?T8%144R")BAP(_2 \?0'IZ?
M$.0Y]>?7 J^67]/Q\OC\!X /3^C Y A0*!0#T 1$/IX'Z!]?I+SZ8%D&J0#S
MP(^O( (\@'J81]/I ?+Z>?0,"HR"9_+D!^^'B(@(@/'(#P4P<&+R(?0(8 6Z
M8@ " \%X\?7X   7C](>(<#S\>?KP ($X\1,H)?7T,H8>?(3&'R$.!-ZF^GG
MX!@!;I"(B)?4?I^H>0'D/T^GQ^(8%(M41#CQ'C@ X\C>/H   B7GQ$Q> X'X
MA]HX 6R8F\A,J(^7F']X;[H^)2\$XX\"CX\B ?2(_7@<"U3'T,90P?='@3B
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M2LON9N"&7%5U[GW8E5<%$P!$ITZWK5N'X8XD*)RG11)Y<"/!@^/T8&V+ 8#
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M/A@63>Z)[;9?CWUZ@^@\#_ZT-JT>!^KTLPX'QJ>ZE[:2(\*=^.HG(\ 'AO\
MUJK_ !?P_P#%V$WH(^GZ_3 Z];W9_;%;F$JO?KJ842D%00#>-".(%*8"F-]R
M9-R "(8'6K>[[[6S<>%>_P#U2)__ 'FIQOT?U9(WT_Y\#KE/>3]J=+GYGN"=
M5B\!Z\;<K!@_1ZE>#]6!UBWO5>TNW_X[W"^JQ.!$!_[ZU?'Q$..0,)5Q HAS
M].!ZR$]W+VO[$W2=PW?KJB\07?(1J1O\::4V,+UR=1-%$Z3N4062\CHGY,8H
M$*!>1$ ]<#O6WNG^VJ[ QT.^G4<Q"/GL<90V_-;I)E>1PJ [2$ZM@(0 3^4;
M@_/@IQ]P38'UC[H7MN!QSWTZA!Y%\B\]A=6AY% 1*)B_]L_WB^0"'(8''^]#
M]MO_ ,?7J#_RAM6?]T^ _P!Z'[;?_CZ]0?\ E#:L_P"Z? J_WH/MNB/ =\^H
M0CP ^G875HAP//CR(680 1\1],"P?W2/;93 14[Z=1B^)BD, ;_UF80,;RX
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M87_D_P#J+_Z@;7/_ '/X#_=->V%_Y/\ ZB_^H&US_P!S^!P/M->V$(<?[O\
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MAE!4*+2S[0;F6\DU$Q3<&+>A%=+^\$W!O@8 'XA@4/?^;G^RR^:BT'H;K5J
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M@,!@,!@,!@,!@,!@,!@<A^\O_5EP-6'M??\ GW]R+_V9MV6_]!M P-IV P&
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M9Z_J+7>R=7-@N_XLO83;E5K2;)A9HIS..Y_^>-L2D::5?N%G*YER"HY5X2$
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MI)-TB(E A0W'^GT?#Z/7GT_7]. P&!R'Q#]8?MP+A_A]O[AP+6 P& P& P&
MP& P& P& P& P& P& P& P& P&!=+QX>O''KSS\..1YY^S _*XG7&5JW,.U^
MQFJ=D]F]/T3N=[BM4[)ZPB=9N]U.:1N&37J4+U6MDWIZM$D9*<I;'KQ"MHR
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M>1+1515)5LFF9J0OD'ZO*2I85:945;:@1M:U:O7U+.W3."A$+"I$M#S2)%
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MGGQ+R < / <@'QX >.0#G  4H? I0X^'  '']'Z<#G_/]'KZ^GTA^H><#@
M..  . \0X  X+Z?=#CX%]/A@/$H<CXEY'CD?$/7CX"/IZB'T8#Q+SSXE$>>>
M1*'/(<\#SQSR CZ?5@. ^H/Z/T<?LP @ \\@ \AP/(?$/J'ZPP' >GH  'H
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MQG+9=T (HF4/Y 4,TQON&=&YA+;CB-[6Z-<MM"MQ=[B=_P"($$DTUZT"9&N
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MO(*'TUMHB0CY>/B50]-*!AY^KG K#LGK$3+D*GL4QFX\'XT_M/Q./I_Q1QJ
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M5?FG  F;T6]M*^=9=I:7VS:YC3L2C1-']A:':]=ZQ0V9-0J.P]\;VAMLN[+
M7+:LY/VV7!HSC#(2#Z07*[?.U1,0B:7! #J=J>VQORZ]J[Q:X#8NDXCK5LSM
MQU_[L6U[+U2VO^Q<5LC0=2J=;:ZYJ\PF\;U!&@6-6ALESO%SE=M6SMXV33\5
M/(P93V)T)NUFZ#ZAZQ4J_P!*6VOHC8VJ=QT^=L\')I:GN-SU'MC_ !(CJQ>8
M"--^:A4Y[[[58$O)9!P1-<I3?)\3!!J6]E_L+>H&[R=VW+H9+9FV;7VYN5\)
M3:-;(C7=?D.TE]Z\6M["U6,?N'[^8AZ]":<>LG"K\?FR*[XBQ@ 14X#U^Q_9
MDN5M[K[(W0RL^LUM.;?WC%=BY>>EYS=[;;VL;=!:P0UQ&52A:]@KO&Z)G44%
M6Q7,=/2+('\<W55;_(<$ HX%%?\ ;1[V-*9ULI-DNO1YVRZA6C0;/5PUG5]V
MKT_LFDZH;W"LSUBV/>7;:0L$';7U0N8FC(N.^?#I3"*SA0QA7^Z'F(WV:>P=
MMAJ[1=G[)Z]P%7T+IRE=<M&2>N*390E]BZZ@.Q^J=[3-MWU'2QFT<%S6C=3H
M,4&D9\UH,M).GZBG!_E $LJ?T"["T[W)IWM/7MB:QH.B+%<+/?+G5Z -^;VC
M;KB8I"=4AJQL#7,\ZG-50<Y +H(KNKA J,)>808H(.$.!'D(V]V/::[$[QOF
M\-@ZDM>CF=FVUV)':5'LUDLFVJ%L#4\'+==-?Z2F)&#LVO\ YC2:DD'E,4=O
MZ[(LI&%G& ()K&2.01P/2[%]K_N(XT,G7:=V$US8]]7/L0;;>^[?*(V_5<;L
M6GM=+L-'U.L0ESI[*8O%%/5X"";/7)(PC;\P(LY9_-304 1##Z?LA[J2ZM;
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M6E;F+<Z;HM&0JK,T/Y>@G3@KAP"2!BH\%,)C  A[F1O5(B%'2,M<JG%K,?D
M^1D;'#LE68NE$DFP.DW3Q([?\0JL0J?F!?,QP .1$,"\XMU32>2D2>UUM&5A
MDFZLQ''G8M.0B$G@I%:*R3,[H%V)'1ER D*I2@H)R@'/(8'FEMJ4UI9YBFO9
MQ)C+P-996V6=OBJ,:\RAI&4DH9OY6=VFE C)IR$4L55I^(_$(E ISD*0Y1$/
M6L++79(7"<?/PD@JR719O4V,O'O#M'CAJ5\W:.BH.5#(.G#(P+$(?@QDA\P
M2^N!UCW8-!C" I)7FG1R9F*LF4[ZSPC0@QB!B$6D0,N^( L43*E RW_%E$P<
MCZA@=X\<-W4,\6;K).&SF,<JHKH'*LBNBJT4,DJBJD8Q%4E$S )3%$0$!],#
M!?45,H=9M)!\M1'C7\'PF8I4CD_NU!\3$3,)"\"// #Q@2( 1#Z1^T1']O.!
M3\!\Q,;TY$?O&XXX^D.>/$OQ^K Y\_(?0W(\ /H(\<#Z<\!Z>N Y$?I'GZ^1
MY#]0X%0F$?I_H],#@PF$H\"(<>OIZ#Z#]''K@1?U2!_]H/M@ F5\236EC)D\
MS^ "KJR/!4P$Y\?OCZ#^D,"3Q1-Z")C<\<<"(_1]/'UCQ@<B(AR(F'X>OJ/
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MI6T,+K>']R9["7U>TAH.(BK3H9B2.BD6+GYSY9M(K*H"Y7X$^!NI*8#!R
M?#T'D/3_ -K@<X%)Q$I#&#X@4PA]@#@1;TH$@[WOW ?.UB*-_P#$'6<+'IE
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MB7&XR68ER+LDZ  40MP6=,'OXP!!7YP<\\"(8&.6'MX=)8W96U]N->MVM2[
MWA'RT9L^=5B%G)+.SL3MJ_M*9XM=TI#11[:\8HJRZC-NW4E#IA^),J'("&09
MCJ)UNL-EFKA,Z>I\C9K!M*H;NF)=9JY%W(;:H5&/K.FWQ=1-TF 3E=H*IHEN
M;@"@S^[XB( .!C76'MS](]+Q#RO:SZW:[JD,\NNO=AGCVK%^\1;6W4TFC-:P
M?19Y)^]5B6-"F4 =Q;!L9-BT<&,<B(&,;D.WKW0KJ+4^Q$KVLK>BZE#[ZF7L
MY+/[\V&6^>,_:&'Y5:+.R@_S4]:C+598L ;OI)NT2>.4N04.;R,(A\5F]OOI
MS<^QD9VRM77^D378*&E("<C=C/"29GS6PU9D2.KUH+&$D"0*EHBXQ,K1.1,U
M%Y^$*5$5!(0H ',S[?W3NP[\5[.SF@*;,;O<6BM78;I)!*NCM[Q3XXL/7KTT
MACR@UUI;F4,F1F:13:@[79ID1.8Q \<#QVO?:[Z#:QD[++T_K!KR.?6V=JU@
MEE':4Q-HHO:'>6NSJ,T@VLS*/VU9@ZEL%H26CF# C=FT>@)B)@!N,#,-GZ:=
M6KK$R\!;-%4":@Y^X[(V!-P[R*%2.E[ON"$>5K9MJDVY%4R/9FZ0$@NS>JG\
MA.@J8OIS@?63IYU=2:KL$M%:Z29.+7L"\K-$X)$B![=M:CKZUV-/_*(8I D+
MC0G)XE\8  %61A3X ,#&1O;AZ.?XAV#:/^S3KH;K:*9)T&<E#L7ZK)Y69NI-
MZ%,HD@#2!Z^TE9.D-$HE:11:I2)V! 1%82<@(?;*>WMTXFM;36I9+0]6<46Q
MO==2<Q'%>6!M+/9;4-<94[6<XI:VLRA:T9VFU.-0C63Q)\FY29(E2\Q)R AT
MH^VAT2&IUBD%ZQZY3J5,IFS->0%=20EDHQ"G;?D&<SLB%=MRR?$RE;)Z/;R+
MA5Y\]P21;INDSE7(50 \4;VG>@B^FJ]H)YUUA'6LZ[L$VTV$>]M%\>V);8*L
M2->=6.8O*EJ4N<PI)UOF,=HNGZK9>.'\.<@I\%P,IR/M^=.I'6EMU,&@*7&T
M6YU+5U)F8B "4KCE.OZ01>(:<;04Q$R#29K3W6!9!885ZP7;NV1E#&34 1P/
M15WIMUYIVB!ZS4[7"%5TLLLI)OJQ 3=EC9"5GG-E;W.3LDO;$)C^;):TSEI:
ME?/Y)R\.\?.1.9PHJ"@A@2J('B0A?AXD(7CX<>)0#CXC\.,"K 8# 8%"G($-
MP'(\>@< /(_I 1+Z?;@0;NON$=3J!;^R=$M6U$XBW]38W5<WO6M&A)M:6K$+
MNL\2WUW.QS-NQ47LD1,NYIJ@JZ8%62;+*E*L8AO3 DXWVIJ)XK:VA-D:Y6>Z
M^,S&_-"W"MBZHRT@B5=D%O;?F/SZPH\0,!DP>E0,<OJ'.!C'8';/K?K^!C+-
M,[?HKF"D;7KFF&E:U9H6QMXN1VM,-8>B/K M#/7B<+6YMRZ*<)%V9)B5$/F&
M4\ YP,J*[3U0A'M9-WLG7S>.>UMU<VL@M<J\A'NJBP1^>_MC5ZI)$;.:TQ0
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MSP AZMY;*;&.CL)6TUF/?HI(.%F;V<C&KM%!RZ39-5E4%W*:R:"[U4B"9S@
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M-5)9,QTETU2& P&*(E, \\C@=?8B%&O3_!>1&%E> ^(>L<X)QP/H(" \<?#
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M[4MYVCN'<^UJ77J<C']@)%3K"'CWMJV'6G;:$.\D6+)LM+.V=?.M\D.544B
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M P& P& P& P& P& P& P&!>)_"'V_M' LX# 8# 8# 8# 8# 8# 8# 8# 8#
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M150"YA4[S:]6VK677N4UY2(ZEUJL2[*T;B-N!12*NMZN^Q8'7D5%I*ZC=1H
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M P& P& P& P& P& P& P& P+Q/X0^W]HX%G 8# 8# 8# 8# 8# 8# 8# 8#
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MUFM<<[MA80J]4AYYV5RPH<",'%1)1JM53**+#\2#AY\H?[Y=4WK@>_P& P&
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M+9NF)@.LNJ1,@"<Q0$._(H3U]1'D>/0HCP)>>0, !Y%$/IY /J^.!2*A#?>
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M6)Q_(1D5,G.9 &BC1Y(13A(O@H8P&2'R OIR'K_(.#"/H!?XA, E . Y'GR
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M^MO:5Z1Z<TI=5NM5!H5\VL\[!6JYU@NS[-LR*L$_3=.Z@?5:.<L8&P&@*_\
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M0 )@\@ 3%#T_1@5F*4P\F* CZ>HAZ^G/']'/I@! #%$I@Y*;GR*/J4>1Y$!
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M5RUO.PMAK&X[]KV_;IWYI[LK4+A#1U??CIG;&D*Q"56GO8.OO$#15IK3N-A
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M^@0$?U_7@5\?Y<AZ?K^K <"/^7^;]> X'ZO\A]?7ZL#C]'U?IYP'K]0_'CT
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M6BFT5>4D?QU?=T>&K#"/<NJ<59F>;=_F #^7B5+ ];!]O/<NOX4FT5SMQJV
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MTLZ[UK=K=E+U/2]!@-M1Z)=6VOK$9=37!J#<0;)T]B^7.1@@ZF2*._E"FF;
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MRY6#;5 T_J:L; O:RLM8=D4^C56*M-M-)I)F6?R=KBHY.3E0E$2IG5.9<Q7
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M/TF*'])@P-47LSG^9T\L"G//GVS[K&$>!+ZCV=V;S]T0 2^N!M<P& P& P&
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M4H\E!3P4  ]2AZ8'R?[\_K+_ .+1[DW_ " ^P/\ W-8#_?G]9?\ Q:/<F_Y
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M^TRZ10X^\MH[L0F7D?0 Y-J@/41P!O?V]J /0G9Y^L/P#Y.B.Q2GK]'PU/\
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MR:2YLL SME2<6"H31"/6<9;*M(HOXY?DR;A P^I5"J$($J##Y )1X,4WQ P
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M>UX]P3?OXZ/@'#FIQK2":&>+NI4C1NU(7^\.40XP)BFJ52<G(Y<5BMKKB<%
M<*P<4H<R@<^"B:QVIC'-P/H("(^OQP+2U*I+HY1<5"JKJ)B*I0<5Z(44(*B9
MT!4X49B8AE$A,01^DO(?# ^8^N=>*)D1/0J4=),  B1JK!&3( !P %(9@)2@
M ?4&!6&OJ"4"@6C4XH$#Q( 5B$ "%_T2@#'@H?H# OEI%*)Z$I]5( ? "UZ(
M+Q_0S# O!4*D42B6K5L!*/)1""BP$HCZ<E$&O(#@?0UK==8O"R#* A&<@1)5
M CYK$L&[PB"XD,NB5TBW(N5%8R91.4#<&$H<_# [K 8# 8%[^I_9_=@6<!@,
M!@,!@,!@,!@,!@,!@,!@..1)_P!"?G^D/'[,#3'[#\<[B>@#,CI=)P60[0=S
MY)D"#@ZX-V+CM!L\$6S@% #\,N4Z1^4B^12\_'U' W.8# \Y;EEV]8LBK:/<
MRKHE?F3M8IC\@7\LY",>?)C6)7*S=N+MXJ4J:?S%")B8X<F /7 _*;T#Z*=N
M^D+;H#OB0T5?ME34GJ"]]9]^Z7LML@+I?^F<M:MBVN8J_8C0B<]<C5>NUN:A
M7[5"\PT0N*JS$&YT2F.11,0QRW]OGM5+ZH@J:?J;;:CMWKUU<]QC5W8K9:9]
M=2#/W K#OII(M=-1U:G3V523V$K9+2+>RN75E(Q/!*$!!(X&'Q .Y<='^QVJ
MIO89=>="IZ8UM9(?VC9B=J$*QUO)B[L>HZ->87L9=JEK^UWV)UW;-MT:8FXM
MLY)9$W<0Z(!WJJ3M1JF.!\&GNC'?A#2W6#5K;2&U=2W[6^HO>*U[!W*SVB@2
M4?K:W]C/O:$LDC+4^Q)L(1A:(MP=BS!@U7;QRH>0)(I 0Q0GK[7FC]D5#N&^
MV:\Z%7;I7KL/;RT;H68_F8-5MV5HW)K#8DLK8CMAU[;)Z1FQ<1;WYS:7DDDW
MDB@7YRWB8XEP,:[OZ[;XL'="S;[ZY]8>Q/5_MNAVJHE3?;UU9.U5MU3[5=2V
M%GK9Y^Y]F(1_9Y%E+S;*A-W[8HEB$YP'J;8&XK$$QD@C!L3IKNR1ZY>X?IN8
M]N>]6'M=%T#OA%Z[[JQ=JJS\G8FM=DK^6X42M5='^8DKAL.T2U>_!Q[II--R
MI5A"'#\,N(JE3 +EM]MW<SDNT]=TCI_,QFE++VG]E_:ZVNF3*GP%.L\'J>ID
M3[<V%1BI8S'<R\2X6^18?F$(=\=$@D,X,(B(>GT+[>VU],;?T;=Z#U(LNL[E
M$>Z=W_FD-DU^.JL(CK#I[?\ 6&SJQJ 7JL?8'#XFG92U6.+?QT4@D";99%54
M6A#E QPQ!K[V^>RR/2?N+3K)TN[#QW:60ZU:MT9:K3:MTZUN=0[&[!I^]:G?
M/YITY5J^6)2D6::"+V9<6FR+)RQ .#,#*B4P@$Z(CK]NR'[<]G9C97MXVC<M
MHE-N;2[#:#[NL]I4^.)6]<6/K>77]1TBP9J3J%X?66%E2NH1&J+(?RV=9_\
MF!S$,7S$->E>]N'N9&:?>5K6O5N\ZTG;E[4/5&F[B@V%BJE)<[;WEJ?M POV
MU-,R]F92LJR;[)LFETG<0SDWC=5@";DJ)E12$Y,"?FM>L&UHR1Z63FN^GO87
M3U,;^Z,'9*^5G;6R*!>;31*@MUXO^O[7?[/5*9(HTO4]=F;E9&Z3"#KIW@*D
M2,_611.L8@!^F# 8# 8# 8# 8# 8# 8&E_WHE"I5[VVG(^@-_=MZ8&Y .0#Y
MKR\H<B(!Z!_??:/I@>[]U>@:4W31ZMIS;O2O<_:>:M=?V@OINZ:@J;20D-*[
M48P#48"52V2E:*Y-Z6GYMV5 S.=(<C0@-#E74X_NSAY?LYJ[LBQ]DO9NC[Y$
MVO?W:)_TA7T_88W7[52VVJ];6G:.WJ:ZK0SM=@>;63DW7+Q^HH05_E*N/43
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MF931D;I&U];4:7=7[:Z-Y_\ "*1+#80N22L65 Z# J7S%2ARGY!AS5'5WL/
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M(@ 8&VK 8' E*(@(@ B40$HB'J @/(<#\0]<"@$4@$!!-,! 1$!\"\@)OXA
M>.>1^G J$A!+X"4HD]/NB >/I\/3X>G&!SXE$!#Q+P/'(<!]'P_HP*?EI\\^
M!.>0'^$/B!O(!'T]1 P<X%::20<\)D#@ *'!0#[OU?#X>F!P=,@F-R4H^0<&
M]/B ^H@(_2 _5@4 BD!@."28&* @4W@7D '@1 !XYX$0^& %),P^0ID$W^D)
M0\@^CT'CD/0, *21N/),@\" AR4!X$#>11#]1AY#]. ^4D(<"DF(?5X%X^KX
M<<8'/RR?Z!?B \^(<\EX\?7CZ. _HP )I@' $* >GIXAQZ"(A_0(X' (HE_A
M23+P @'!"AP!A$1 . ] $1^C N8# 8# 8# 8# 8# 8# TS^\^W<N*C[=X,P*
M"R/NN=+U^12*L!2$G+6"QOEF*8!_N#F#D/4O/(?# S?[A7=+='2JCWG<%2ZO
M-]RZ=U-HO8FZ-HWN1VTQUZC#NZA(QC&'U[!19ZK:GDY9+,A(K/ 4,5NU;-6J
M@&.*AB%$+NM.],S6JE(W?O71-9].:W)K4974=H6WC';$JNVF=UI@6MTVA'9Z
MO4)IG8:F@BHF_9'8J 5),7)5!0Y, 9_>]VNG,=;J-0GO9O1B%SV=$5R?UY7#
M;(JII6ZP5O3?*5>:K:!)$PR\5.I1;@S9RB)TE"HF$#< .!UB'>[I0[K%VO*/
M9_1@U'6SF#97RT*7ZNHPU5-;I4D/6%IB06>)(-XZTS'"#!WR+5\J0P(J'$H\
M!CJQ>Y?TBA0T?)1O8&A72*[$[V<]:M92M"FVEHBY+:L5'O92P1#][%*JMV#:
MOHM44W2IS"5-9\V+Q_?$$0SI2>UW5S96UK1HZ@;PU7;]P4U*24L^OJ_:(B1M
M$8E$.$VLW\Q@@L8[K\F>+D3>E1%06BI@*L!##Q@>:[B]J:!TST=-[FOD=+SK
M49ZIT6B4BK)H&M.R-J;#G6=8U]KZND<JH,TY:U6>021!9<Y&[5$%%U1\$QX"
M+\#W_O\ J_>&J]'=Y]$U7K$XWW4+K8]0; KNZH[:6M'4_K*"+;+[K&YV)6JT
M5:M7J$JQCR"2A$7,8];-5Q1<B9(0$,@[%]U/V_*!IW:^[R]H=37.C:;"EIWI
M?6MM@KO)Q3[9#]*+HC(C&%?KBNXM#U02MA W@8J:HB8/EGX#/$?VVZO'O(ZT
M_P!H/4IMBJPB5D+337B")84X0U5"Z?CACE7:;E-$:B0942F#YA8\!7$/E )L
M# $OWYU-;;IH2O\ 6W9_6S>D=L[=,3K?83]IV&J,7(4Z GZ?/VZ,D:3"-0E3
M["NTDA"D,C IG1<*-147\P(D/(28UUV7Z[;6NEFUMKG=NJ]@;"J NE[-3:G<
MX.?LD,W82)HEV\>Q#)XN\*U8RJ8MEURE,BDX*)#&*<!+@9Y A.0-X$\@$3 /
MB'("(B(CZASSR8?Z<#5Y[A/?35GM\7SJO;]@:?=6N/[!;+4T/:-LP*44E(Z4
MI:ZL;,N[C:%UV"S]UKQE+/D%9(@+MT$! JIS";Q 0]'NOW#:1J?O5U/Z'PE)
MF[Y>>RS6XR\_9X22:L*KJ*M5^JV.U0;VSN56BZ<A,WA.K2!HZ-362<K-6JK@
MH&2 /(,-ZB]SV:W](]PIK1^@F5XU!U:@-OEB-EI=@=:EDMC[$T\=^R=4*1U<
MU!Y?=4IVR3A9 (^1FD")*LVQ' I"54O 6>F/NS,.TFS^OVI+SUXM&C['VGZI
M)=M]%/C7RL[(A[%K=JZCVEDCK0G ,XN2H<]%'DVYFH/6ZC6024$$5A4(<@![
MSNW[A^PNH+V[V6-Z:;8W+H;251JUY[!;RA[54J=#TVKV>4(S5-KF LW,GM^8
MJT-YR<TWCC-P9M_%(#G7,! #S%L]R';;_LAO/KQHKJ*YW:OHS36H-[O[0_WK
M5]6)V:I[H@)V7J496H2P5.1=*6;\37W#,S5RNB0%13,*@>8  2/_ -L1Q'[_
M .F^A;3HZ\U:P]N-.;*VDC*3\S703U/-:SK50L]JU?;(I!PXD'EK:#:4T#*M
M _!%4;J<*#Z!@3HX#D3<!R(<"/ <B _$!'].!S@,!@,!@,!@,!@,"\3^$/M_
M:.!9P& P&!J9]]1B:3]I/N_'D!/YSS5L4W;F5.":0.%-@4XK85#CZ%(5P)1'
MGTXP-G5!04;42DMU1**J%0K2*@D$!(*B4*R3.)1#XE$Q1X_1@>LP& P& P.!
M*40 HE*)0] *( (<#P/''PXY# Y^K_H0X#CTX#ZL#@"E*)A*4 $XB8P@ !Y&
M'XB/'Q$<#G 8# 8# 8# 8# O?U/[/[L"S@,#H9EO-++Q!XE^V9-D9%-2826C
MCOUG\<5-3R;-#E<(ECUP4$#?.$#^@<<8'>(\BB43>7D!2@/E\1X  $3?I$><
M"K 8# 8# 8# 8# 8# 8#G@Q?7U\@#CZ!Y$ '^C U->ROS_L0%3'X,^S7<AL
M>O\  3L_M,0#ZA#U_5@;9<!@,!@,!@,"XG]/V?OP*3_Q#]G[ P*<!@,!@,!@
M,!@,!@,!@,!@,!@,!@,#49[O$228K'0)FHX5;@/ND=.U@52_C 6\Q:W()_P'
M^XL9 "&]/X3#@9Y]S_1.SNS70'MCUUTU$0TWLS=6G[-KRGM+%8$JM"DE+&9!
MF5U(SB[1Z5JUCT5#K&#Y8BI\H"!ZFY (N;XZO]ET;W[=W9G76N:AM^S=6M);
M'T[MCK-8]@1E?A; EM_5]0J\E9J1=YJ+=58UBIEBJ0-%5'+=,'\&\<E3$IA
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M-DN*C%K2#^)K-1@D6!91\JN *O' $13.<WRP"5]%]T;JML[=>O\ 0VLK%?\
M9UOV75=;[ K,[0]2WR>UPAK_ &S7;79*-=;!L%I%*5B!K<FWISYF=PY<)?(E
M$#M%"E7*=,H;&P$1 !'U'@.?U\8'. P& P& P& P& P& P& P&!I?]Y,.5O:
MP ?_ "N_4[_YF=O8$EN^VX>Z^FZ?8+SU:I76I>G:QU3?-N[-O'96U7",A7I:
M8V/)IZVJD;15FTA%3DU%,W"YIR2.:*9\)D,FH8P^(14WG[LUDH^F>E]PUYI8
M9/:79&1Z<V?;U!LS]=!GUPT]V<V31-;J6*X/VHM%G%CD[#<3,:RR*0BT@HV7
M='2_#-5\#V#3W';U8/<WM?21F32FL*-KADI*3)-V-=MU;=&XZ]%:_9V^TW7K
MPZ"%0U%<JM6).<;-78C(K/4$V+]11 I2$, ?+T%]SI#OYO&^_P B7;0]=TS%
M0=G>ZRT^Y?STCVJOE7@;,WJJ&^K(@9Y'U&JZRG)=HY)'1[5"2?BW505=KMSF
M!' K7]S2T:F]R^V]'.RE/JU8U3=VVL$>L_8FJMK"E77.QMEMK0_@]#[G>3;M
M:)A=DVF-J+UQ +M/DLY,R!FP%!<2@(1F<>Z)V]DH#HRH@]Z5ZQ<=J=L=TM:7
M"\;;9[5BZ14AZT3]I1I;R"8*76$D%7UQ@ZRH1XB]=D CP?)$0)PF(;,] ;V[
M';-ZB2>X#06@-S;:>*78VIU=#WJ0;Z+W+"M9Q>,U]:XNSV529E:M&2: ",LB
ML9XNT4:K E\P3) 8(D:M[=>Y1<KCW&ZOR&G.IDWVFZZ_[/,W3M@5BU;/B.M$
MS6][?F4J_CKDE-H/]@1MWU_6X59V=@W,)I))PV43^450<#S6B_=AV$A;*;JK
MMAKNCQNR=X=YMJ=,-#O.M++8U]UW).--5%G([ V!:K%9XU@;\KB+:=PR!- $
M#'0;KJ< 1JNJ 9:]M3W0:#W&HVOJ1?KE5&W;6>@MQ6>PZYJM3NL!630>L-SV
M?6SUQ6)JP-G<--J0;1G&FD46DBZ7;G>%,<I0,  'N/<Q]QAA[>.MM>WC_#^1
MVI*6W8$0A9*]!E646HNC*Y(Q:^]-VS(M"JN@@]85J31/Z@":SYVW2,(%/R 2
MSM?:C1],VCI'2]COC..V)V0BK3-Z0BU6$LNPOT=38=K8;#^66!JQ4KZ+UE!/
M$W94%G22RS<1.F0P%-P$?DO=(Z/J&U* [XA$2[M>U..H"SJNW!K'K/;[8)^J
MT$EEDUH C"E);"LE8>,8%255:$EUT1!I\XH@80^;7_NK]%-G6F?I-*WQ&S=E
MK==V_9))D%-O\6W.TT&_>Q^WV,>]EJXT9S%@H9H]1P^C&:J[])GXK_*%(P&P
M,@I>X'U+78I2A=U5LC%SI+6'8UF9:.GFZDCIS=4O_+VJK3$%7C 5EW=WGP*S
M91S<JDBJZ532^04YR\AE_0O8W4'9JEK[!TE=6%XJ\?:;#19UTV8RL1(5R[5)
MU^!L]0L<%.LHZ;@+' /!!)VT>-T54Q.4>.!YP,YX# 8# 8# 8# 8# 8# 8#
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M$_U4#  G,/(F#<$ <  <B/!0 1'XB(  "(_I' YP& P& P& P& P& P& P&
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M00Y W(<B ^G''!O$?(#<"40-Z#S].!7@,!@,!@,!@,!@,"\3^$/M_:.!9P&
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M:VV1/T9"T6-Y+3DG'5^WSKQPW2=NG"K)-^"(& A4PP-O7^? 8# 8# 8# 8#
M8%XG\(?;^T<"S@,!@,#59[R1Q3Z8M#@'(AV?Z<?_ $SNKN?\V!M4'XC^L?VX
M'& P& P(V]MM'6OL3UWVSJ&@[>O6A;]<ZF]8T3;^MYF0K]OH%Q0\'U=GF4G%
M+MWQF*$LV2*\;D,'XEF=5/D!$IBAI5Z@]F=^;L@_]H+M&.TM'4+VHM5[7U3V
MAKU;NCY1CV/[;ZRC&K._6=VRC9)4U_U?5Z'7$Y:-3DR\O+!9N. ,P,*@>S#W
MDM_1>A[CNRX=%[91:6J.A[+K?:EAD+O_ (,-M7;V_,5U+SM.89:]=7.+B=/-
M$&9[._AHB3BQ))I*M%U$4U%,#<[UOVVYWOHC56WWK&K1CW8-,B+*\CZ1=XG9
M-/:NGZ(BNG6KY!D2B[3#"H03(.TB)B<@@!R$.!B%#-F P& P& P& P&!>_J?
MV?W8%G 8# 8# 8# 8# 8# 8# 8# 8'36( & G $/4866*'I];!?D/M ,#6O[
M+:HK>UWT^.;GD*#/I#S\?[C8=Q0X^SY>!M!P&!XG8NNJ-MND6C6FS:A 7V@7
M:(<0-LI]ICV\M7Y^'=^/XB.E(UT4R#MJH)"B)3!\0 0X$.<#"L[TLZHVC5=!
MT?8.O6J)+4>JG2;S6U$7J<:2!I+SY+]NLZK+9N1%2&<.D91R1R=(P&>%<* M
MY^9N0]37>M.A*C<9O8%6TYKRO7"SZ^K^I;#.158C&+B6U?4VJK.M4)\U11_+
MUZG",U#(M6(I @BD<2E  $0$,$QOMD^W_#0UGKT1TYZ^QL+<VT+'6F.:Z\A$
M6\W'5JQDN%<:N@*B"A$*]9RE>L")G(#1<H"EX@'&!Z:O] .E]0=HNZIU?TQ6
MED&NT6B!Z]3F$05NANV+:0>VFR"; &J2#:_0[!%M) 4@ X13*00* 8'NK5U+
MZXW;KR'4VSZ6HTQUN2KL14T],K1GR**E6J\[:/X.%;13-9O^$81KQFDH@0A@
M^69(O'P] ZZ5Z=]:)C<&KM]2NC*"_P!QZ6IP:]U9LI:-'^;:;2"M7+4M4CI
MKD@_D";=\N4C=?YY"_.4$  3F$0@CV6]FWJ]L'J_NS1'6W3ND.N-SW!4$*0X
MV9'4->6<)5)UM*"VC:*G+"RF8VP/H"?E(M4"MTWA4&QU@,F4"$!+ E[ ]!.H
MD#0&NMVW7C77\KDVI3]ZN8O\$]<)N-S4=2/6JFPSOWTB[F3SM6-%H%C_ #<F
M2:()@@F4$@\<#YT?;TZ7M6,!&(=:=:_EE4G]UV:NLAC7*K>,GNQ\>XB-YR:#
M=>1.F9ULJ+<J(RAS@<JJ2@E(4G(X'8TGH-T\URE4$*;URUK"$H%CD[94UDHQ
M=X[B;%,4C_#>2DT7TD]>R#Y5>@_]AB%<J*I)1O\ JZ92D],#"O\ N]6<+M;K
MS$Z\LM-UET>ZTOF>RZ%T_I&L(>,:*]A(U_<'L+L!Y?G+]R^95*#/:A=-H)FV
M1(620*M\WQX( ;+@* <&\0 _CP)@* "(CP)N>/3U-@58# 8# 8# 8# 8# 8#
M 8&I7W%&R*W:GVAS.  Y6_>&S*)@0YTCD<?[->WS-Q$2< H4I@Y,4?NF#]6!
ME3N!IGVYMB[/UY<NXDEI-#85%K#UO4F&UMPH4!I(TN3G6;]PSL-.>7:O0MXJ
M:ECCDCD3DV;UF5V7C@1$Q!#-=]IW4GO;HNRZFG76LNPVB9U[%P]G@J;<F<Y5
M#O:G*1D]'1#F6H,R!&#F&D8]HL#8%TO$I2 8O@8 $/BVETOZM;@N,)L#:>IZ
M]=K;7M-7SKRP>33J9=- TMLQFC'7B@O8@LLG&2<+/-$"%4,X1.X Q .54IN!
MP(UL/9P]MEHQ_+V76*"00"7UG/*."739I7[NPZ9:OV.L9J2E NP/Y&8IS.56
M(R<K*'6('@/ERBGXAZU][47MYS;JD.+!UMJ=HD]<6>SV^MRUMG+G99H\S=IU
MK:[0E99Z>LLA)7>$F)YDB[4C)A9_'E6*)BHEY' ]M:/;HZ7W9Q9U[+HBOR+R
MV=@8+M5-KGE+4DX5W[7HIK 1NQX]9O/(C%2/Y&U28N6[3Y#)TS+\E9%4G)0#
MS"WMT] J!+;JV3):5HE7;[.K>R&VTY&9L,Y$T2*@MKL?PVXGT)&OK WJ>K2[
M&9!S87D.C'*/RE 5E..>0]'UGUQT8C+)+[2ZFK:CFK)7M;Z^Z[66W:QV$6^N
MHO7&K$5TM<:[FOPMDGFS9C66YU3,06(1P<ISG\U ,83![9CTOZS,M2;XT6AK
M)N;579RQ["M^\*B]G[1*M;S9-JII)7R3>.Y*:=24<M8R(E\RMED")E( D O
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M@,!@,!@,!@,!@,!@,!@,!@,!@,#2A[H0"3NQ[(3CX 3O1L%N/'T_BNM>S"
M_K$G]&!N O%"IFR:^YJ>P*C6+S5WRC99[7+? Q=C@W2K)8'+51Q%S#5XS56;
MN"@=(XD\TCAY%$!P.HNVI=8[,C(>$V/K>A7^&K[]K*P<7=*E7[-'P\HS2%!J
M_BV$S&O6D>\;H#\LBB()F*GP < '&!V;77E&8V"?MK&FU1G:K7%QT%:;$VK\
M2C-V2#B4ED(J'L$LFS*_EHN+07.1NW64.BD0PE*4 ],#QL!UZT15JXWJE9TE
MJ.NUIK:6EX;5J%UU48V ;76.4^;&W!*+9Q"31.SL%.#(OBE!TB(?<.&!]_\
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M#4U[SG =1:6H/_P-W(Z0./3XAX]G];@ A]0A\<#;,/Q']8_M'C_-@<8# 8#
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MS.7T9UABY!$'#%_[D_MXMG:!A, *H*]GZ(!R#XB'Q_3Z8&V4WQ']8X'& P&
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M=[=W_P!-#0\#:N/Q']8_MP.,!@,!@,!@,!@,!@,!@,!@,!@,"]_4_L_NP+.
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MA^(_K']N!Q@,!@,!@,!@,!@,!@,!@,!@,!@7OZG]G]V!9P& P& P& P& P&
MP& P& P&!CS;SI-EJ;:+M<P$;MM=7=PNH/P(DA69-90W'T^)"".!"GV@O_85
M_MY?^N>:!_\ 5<P.!L9P& P& P& P+B?T_9^_ I/_$/V?L# IP& P& P& P&
M P& P& P& P& P& P-,'<[_V,/[+W_ZN]P/_ .EV98&Y_ 8# 8'(?$/UA^W
MN'^'V_N' M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%XG\(?;^T<"S@
M,!@,#49[NE=4M<%[>T,FX1:&_P!ZATSE_GK (E *U8[#9!1+Q\#N@B12+S])
MPP-N@\\CSQ\1^'P^/I]O&!Q@,!@,!@,!@,!@,!@,!@,!@,!@7OZG]G]V!9P&
M P& P& P& P& P& P& P&!@'M@4QNK'97Y9C%4#0&YO Q3&*8IQUQ8RD,42B
M @8!'D!#U# BW[.QQ4]J;V[##\?]CG0)!]!#U3US!)_ >!_JX&R+ 8# 8# 8
M# N)_3]G[\"D_P#$/V?L# IP& P& P& P& P& P& P& P& P& P--_<B->NO
M=T]G!^T2!9**C^_#B0$#IE,@Q=:$B8\JH%.8IE !T\2*(%Y$ $1XX <#<A@,
M!@,#D/B'ZP_;@7#_  ^W]PX%K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# O$_A#[?VC@6<!@,!@:JO=//\IO[?"O'W2^Y]U.(;_ZZYMZ9?3U_KF#[,#:
ML/Q']8_MP.,!@,!@,!@,!@,!@,!@,!@,!@,"]_4_L_NP+. P& P& P& P& P
M& P& P& P,#]J ,;K!V1 H\";06X@#T^!AU[8 */Z?B.!@'VL&3..]M7H4RC
M_,63?J/H--L*ABG.*?\ AM7A 1.4I2FYY^/ 8$]L!@,!@,!@,"XG]/V?OP*3
M_P 0_9^P,"G 8# 8# 8# 8# 8# 8# 8# 8# 8# U1=I52$]U;VI4Q^9YK57O
M80IO$P)B :@JBHE%0H@43\I?PB ^F!M=P& P&!R'Q#]8?MP+A_A]O[AP+6 P
M& P& P& P& P& P& P& P& P& P& P& P&!>)_"'V_M' LX# 8# U!^[?+NF
M*_MHQC1)18\_[J75=HH1)JJZ5!O'L=@S2ZA"HCY)BDE&B8QQ 0*0H\X&WT?K
M ?(!^ _'D/U_3@<8# 8# 8# 8# 8# 8# 8# 8# 8%[^I_9_=@6<!@,"U\X@&
M$.?0 Y$P^A?3X^H\ (?IYXY],"I,Y5"@<G(E$ $.0$!X$ $.0'@0^/TX%?T"
M/U?0'Q'CXX%L5 #@?$1#D?I(4> 'CG[PA]WGZ?HP*^0Y^K]?T!\>1$/@ A].
M!3YAR <#ZCP _7^KZ^ ]?U8'!EB%,)?$XB7X\" _I^'Q$?#[W'Q\?7 Y%0@
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;@,!@,!@,!@,!@,!@,!@,!@,"]_4_L_NP/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tv526458_ex1-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ )T  0 !! ,! 0
M       # 0('" 4&"00* 0$                     $   !@(! 04%!P("
M P@,"PD  0(#!08$!P@1(3&!$@E!L<$R$U%Q(D*"%!5A%A<8D:$C4F(D-K<H
M.'CPT7(EM29V)W<9.0KADJ)#4X:V1Z=H*?'"@[,T9I:76!$!
M         /_:  P# 0 "$0,1 #\ _?@
M    D;]OA\0%J_F/P]Q +0                               5+O+[R]
MX"1?=X_ P$0                                "9'REX^\P$(
M                        F_)^GX (0
M     $C?M\/B M7\Q^'N(!:                               "I=Y?>
M7O 2+[O'X& B                                 3(^4O'WF A
M                         $WY/T_ !"
M       D;]OA\0%J_F/P]Q +0                               5+O+
M[R]X"1?=X_ P$0                                "9'REX^\P$(
M                           F_)^GX (0                   =:MEP
MK-%@9.TW"=AZQ681A.5,V"PRL?"0L5BK6AE.3(RDGD8N%A8YON(;\[BTI\ZB
M+O,@'/8^0C(0EUM2%MNMH=:6VM+B%-N$2FUDM!FDT.-F2DF74E$?4NP!.
M  KT,^XC, Z']A]G> H J?E2GSJ424^TS[B[>G?U]H"1'3IU(^I'T,CZ=/\
ML[P%BB_$?_9[ %O3IW@*]#^PP%   Z?Z^X!7H9=Y&0!T/[#[>X!3I_V@#_\
M:     KT,N\C 4     5Z']A_P"@!3IU[@#IT .G7N .G_;   !4N\OO+W@)
M%]WC\# 1 'LZ^S[?8  '3KW '0  5Z']A_Z #H9=Y& =#^PP%    .@   '0
M   #I_J[P !7H?V& =#^PP%.@   )D?*7C[S 0@ !T]OL
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M;3[D)QWBMO16A(S<R]:W&R,VF3LE45DXL@P6=DX^!(QL6_F)QEYWU$I,P[/
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MKNIH>AP<[M+8/^.3U@Q=.66H0E<N<S&/5F\9M7S<=*LS-P\N.R&B3GL8AF1
M*V7U>M=62M;$>U+1MW5G'JTFQ&5K?.V./5UD>-ERE:[NNH:CV75JW9*G.,2L
MQ8H&4G7\''-7[/%=SDFZRO*8QWDF':\#UF>)TEK#:VWV(7>3%$UI<XF@1LSG
M:[Q&4;9N-AV!(:O@:WK%P[%^W>GY"[1CN,O FUP>7BL)_<OMM8QDZ W#X=<O
M=4<T]59^U]2O6!F+A;S:M;6JOVV.PHNRU*]TO,3B6&NR[47(S4-E.L?5:>;R
M,'.S,-YEY!M/*[>@;7]2/M+M+_0                       ";\GZ?@ A
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M1)L.)4 ];@   4Z%W]"ZEU[>A=>WO[>_M 3H+HDNG]?> A
M                $WY/T_ !"   #C),\CZF-](W>GU4*>)G\/E929J-Q3AG
MY"22DD1]YGYB 89TY7MW0&);7-R;)@-CYDIL.SR=1?KE%*C,UC6F>]C'3:5)
MX29F<8G9NN-(=+*ER6VK.^HD_IH\O0!GD            !YC^L[(,1WI3>H#
MDY>4QAXZ>+NT&&G7U$@CS\V$7AQK"5=A>?,S\AME!=YN+(B >A5#6I5+J!J[
M5'4JT9F?S=3AL$S\3,!VX    !&ZTAY!MK(C2KIUZI2KN/J78M*D]BB(^[V
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MI*2)_8%/8<5U3VG],G"/IW=0'J_0R/\ LRI+Z?A75JV:>TN[^#CB]Y& [<
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MDL%])>1_%D,'(0\THNQ2%$?9V@.73F,&XEHS42E=Q]GE+[/,KKT(S,NPO;[
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M7E/&5:K1NL,.GV_96S=PY5.V%(W/$.EJ?RZS>XE].)FQN*[AXA/^5;9(\A)
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M'3<FP>-*36%DIPB>QIJ28/R9&4VI#[[9^5:S(!W(            !-^3]/P
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MJM623KK^9EUN2,\S%C9-Z,/(P'5'_P *P7&GB+HL!EX
M       !4N\OO+W@)%]WC\# 1                                 )D
M?*7C[S 0@                             ";\GZ?@ A   !:I:4%YEGY
M4]2+K_4^XO$!<7:1'[#[2_J7V@             #RD]<M/F](OG^23ZJ_P O
M%G_#[2(LN.,_]1 /3.B?\1*9_P"2M<_\"X0#M     "AEU+IU,ON[_N[2/O
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M57F,_-T(S(S274B/O-1_A4GM4?M 7$7>9F9F?>9^WIW=A="[" 5
M                5+O+[R]X"1?=X_ P$0
M      "9'REX^\P$(                              F_)^GX (0   =
M4OL599>FV>.I4]AUJXYE>F<6J6"0C"FXZ#LN3'Y#$'-2$,;^.4MAQ,DXV^YC
M?4;^NALT>8O-U(.E:!KVXZGIS7];Y!;#KNV-SPT$C#V'L>IU(Z'7;A/)R,A2
MIB*J'[R01 8[N(MI)L)><22T*,CZ'T(,P             /*SUOTH/TD.?\
MYU>0CXZ7'JK^J7,$T%T_[HN@#TFU^HU4.DGUZD=0K*O X3![?M[3 =M
M     $C?M\/B M7\Q^'N(!:                               "I=Y?>
M7O 2+[O'X& B                                 3(^4O'WF A
M                         $WY/T_ !"                   #RT];=L
MG?26Y_-J+\/^7"[*+V]5)1B++L_[I) /1'63BG-=T!T__GJ)3W.GLZG 8*C[
M?;VJ_P!0#O0          D;]OA\0%J_F/P]Q +0
M          5+O+[R]X"1?=X_ P$0
M"9'REX^\P$(                              F_)^GX (0
M         >7WK5-F[Z3_ #\01>8SXV7TR(^G::<5I7M[.O8 ] -2GY]5ZR<Z
MFHE:[I/XC[S,ZW'*,S^TS(R 9!          $C?M\/B M7\Q^'N(!:
M                         "I=Y?>7O 2+[O'X& B
M                3(^4O'WF A                              $WY/
MT_ !"                   #S*]9Y!*]*7GN1F9=>->PU=G^\P$*(ON,R[0
M&].E'C?TQJ-Y1$E;^LZ"ZHD]>GF<J,0XHBZ]3Z$:@&3          !(W[?#X
M@+5_,?A[B 6@                               J7>7WE[P$B^[Q^!@(
M@                                $R/E+Q]Y@(0
M             !-^3]/P 0@                   \RO6<,R]*?GQT(UG_E
MHV/T2GM/JN-22.S^A_Z &\.B3\VC]-J,_P 1ZIUT?0^G4NM/AS,S+[>I@,J
M         "1OV^'Q 6K^8_#W$ M                               !4
MN\OO+W@)%]WC\# 1                                 )D?*7C[S 0@
M                             ";\GZ?@ A                   !YI
M^L@VEWTL.>R%]?*?&?9)F23Z&?DB%K(B/H?0S,@&YG'IXLC0>CWRZ'^XT]K'
M((_]Z[2811%UZ]OV^(#,           D;]OA\0%J_F/P]Q +0
M                    5+O+[R]X"1?=X_ P$0
M          "9'REX^\P$(                              F_)^GX (0
M                   >;7K"EYO2XYY]/9QIV3W_ &IAG5>SK]@#;GC.X3G&
M_C\XDC(G-(ZG<(C[R)5!@#[?Z]#(!FP^TC+NZD9=?:7]2_J C;0;9&1J-?7I
M\WL^[[P$@       )&_;X?$!:OYC\/<0"T
M     %2[R^\O> D7W>/P,!$                                 F1\I
M>/O,!"                              )OR?I^ "$
M    'F]ZOR//Z7O/-)]2)7&?9A%]_P#!O]O^D!MCQA+_ )L_'@_;_@;J,O\
M\/Z^ S@          )&_;X?$!:OYC\/<0"T
M      %2[R^\O> D7W>/P,!$                                 F1\
MI>/O,!"                              )OR?I^ "$
M     'G)ZO1>?TP.=R4]#5_EIV:?3K]D&\9^X!M7QA_Z,_'C_P!!NH_^3ZO@
M,X          "1OV^'Q 6K^8_#W$ M
M !4N\OO+W@)%]WC\# 1                                 )D?*7C[S
M 0@                             ";\GZ?@ A
M!YU^K>1'Z8_.TBZ'_P V;:)F77[*]E&9G]G0@&T?& R/C/QXZ'_]QNHS\#U]
M7C(P&<0         !(W[?#X@+5_,?A[B 6@
M      J7>7WE[P$B^[Q^!@(@                                $R/E
M+Q]Y@(0                             !-^3]/P 0@
M     \[_ %:4H_\ 5G\ZDNJ4EM7&7:7G6E)K-"5US*\R_*7:9-EVG_0@&S?&
M TEQOX^(;,G&DZ+U#])Y/7RNM_X?P!)61'VI(R(C[>WM 9U          $C?
MM\/B M7\Q^'N(!:                               "I=Y?>7O 2+[O'
MX& B                                 3(^4O'WF A
M                 $WY/T_ !"                   #SW]6!"7/32YUI-
M1I_YKVW%&9=?,1-5.0<+IV^WH V/XM'YN,_'19=?*O0VGS+K_77M=/KT^WM
M9Y          $C?M\/B M7\Q^'N(!:
M "I=Y?>7O 2+[O'X& B                                 3(^4O'WF
M A                              $WY/T_ !"
M#0'U56TK]-?G::NO3_*ON4^GLZHI,PX1_P"E(#8+BDOS\7.-:_\ =Z TVL_O
M5KJNF??_ $ 9\          $C?M\/B M7\Q^'N(!:
M            "I=Y?>7O 2+[O'X& B
M   3(^4O'WF A                              $WY/T_ !"
M           #0_U2&D/>FYSJ97U\BN*6\UJ__AZ_G%%T_P#B@,S\0%?4XE\7
M'"[27QST@X7?U\J]9UCIUZ^WJ V)          $C?M\/B M7\Q^'N(!:
M                           "I=Y?>7O 2+[O'X& B
M                  3(^4O'WF A                              $W
MY/T_ !"                   #17U/D*>].7G.VDC4I7%#>Z$I3TZJ5_AY/
M>4NWLZF8#+G#L^G$CBRTKL<:XW:,)PB,C)*CUE62\O9U+\I]O7H V.
M    $C?M\/B M7\Q^'N(!:                               "I=Y?>7
MO 2+[O'X& B                                 3(^4O'WF A
M                        $WY/T_ !"                   #1WU->JO
M3IYSDD_IJ3Q0WUY5D7:2BUI8%DK^O0S 9#X3&ESAMQ)RC/J]E<8= +=47YC_
M ,**JHC,S_[HP&SX          D;]OA\0%J_F/P]Q +0
M               5+O+[R]X"1?=X_ P$0
M     "9'REX^\P$(                              F_)^GX (0
M              :/^IB1GZ=G.,DF1*<XJ;Y;(S[B->MY]HC/KV=G4!ESB7$_
MP/%CC+!F9*.&X\Z7BC4D_,E1QVN*WA=4JZ%YB/Z'> V$          $C?M\/
MB M7\Q^'N(!:                               "I=Y?>7O 2+[O'X&
MB                                 3(^4O'WF A
M              $WY/T_ !"                   #2'U+>WT\>;J>W_HL[
MS/P_P]G0&=N./_1ZT'_Z$]6?_8B# 9H          $C?M\/B M7\Q^'N(!:
M                              "I=Y?>7O 2+[O'X& B
M                     3(^4O'WF A
M $WY/T_ !"                   #2OU'DDOT_^;B32E73BKO4TI7U\GG+6
MUC4DU=",^A+21^ #*7$UV1R.+O&S(DU,N9KO'S2SN:[CF9L.9SNN:ZYF+8,^
MTV5/J,T_[WH V"          $C?M\/B M7\Q^'N(!:
M             "I=Y?>7O 2+[O'X& B
M    3(^4O'WF A                              $WY/T_ !"
M            #2WU'34WZ?O-EU)=5?Y6=Z)(C/H1'_AQ8DD?7QZ@,K<5FUM<
M8>-[3B_.IO0>GD&HNY1HUY7$FOL[/Q*(P&?          !(W[?#X@+5_,?A[
MB 6@                               J7>7WE[P$B^[Q^!@(@
M                         $R/E+Q]Y@(0
M     !-^3]/P 0@                   TO]1A)KX#<UT?-YN*N]"))]#(S
M+7%DZ]A]GYB 94XK?BXQ<;UEVI5H'3O0S_KKRNGW?<8#/@          D;]O
MA\0%J_F/P]Q +0                               5+O+[R]X"1?=X_
MP$0                                "9'REX^\P$(
M                F_)^GX (0                   ::>HDG_F&\T2+KV\
M5M[GX_X;SY_Z.P!D[BGU_P KG&H_MT#IO_DYKA@,^@         "1OV^'Q 6
MK^8_#W$ M                               !4N\OO+W@)%]WC\# 1
M                               )D?*7C[S 0@
M           ";\GZ?@ A                   !ISZA7;P0YH&?4R+BQOA/
M_P"&MA[.W^I ,B<2U$KBMQE/KUZ\>=+*[>O<K7-=Z'X] &P0          D;
M]OA\0%J_F/P]Q +0                               5+O+[R]X"1?=X
M_ P$0                                "9'REX^\P$(
M                  F_)^GX (0                   :A\_FDN\%^93:N
MOE=XN[W2KIW]#UI9.[L[^T!W;B-V\4N,2NX_\N^DRZ?81:UK2B[/O68#88
M        2-^WP^("U?S'X>X@%H                               *EW
ME]Y>\!(ON\?@8"(                                !,CY2\?>8"$
M                            3?D_3\ $(                   -1N?
MI>;@QS'02OIF?&#>QDX7>DRUM8NOAU =HX=._5XD\5_*HG&_\MNCED[[5J5K
M2MI,^GV?A[?Z@-D0         !(W[?#X@+5_,?A[B 6@
M               J7>7WE[P$B^[Q^!@(@
M     $R/E+Q]Y@(0                             !-^3]/P 0@
M              U6YSL%D\+^7&.:/.3W&7=[9I[_ #>?6]BZEX@.6X:I\G$+
MBHV9>5:.-^D24D^G4D_X:ULB(^AG[2 ;)@         "1OV^'Q 6K^8_#W$
MM                               !4N\OO+W@)%]WC\# 1
M                       )D?*7C[S 0@
M   ";\GZ?@ A                   !K)S23Y^'O+!/7H:N-N[DD9=Y&K6U
MC(C+[3ZF Z]P <RWN#7#A[.>4_F+XN:)_=/+0I)O/%K6MFIP_/U/JHU=W7J
MV\          $C?M\/B M7\Q^'N(!:
M "I=Y?>7O 2+[O'X& B                                 3(^4O'WF
M A                              $WY/T_ !"
M#6;F@HT</^5BB;<<,N.>Z")#77ZJO/KJQ)_ 77J:DE]@#K? !UIS@YP^^FMY
M?_-ETCY3?,S7Y"UW7DI\W4SZF2>A=G<70!MZ          )&_;X?$!:OYC\/
M<0"T                               %2[R^\O> D7W>/P,!$
M                          F1\I>/O,!"
M      )OR?I^ "$                   &MO,0S+B5RD/S^0RX[[F22B;2X
MHO/KVP$DB;ZH^HI1]A$9EU/V@,3^F.G(1Z>7")K,/)/+:XLZ5;=/-1]',,T4
M:'1U?9-QXVW%$DC,O.KH WJ          $C?M\/B M7\Q^'N(!:
M                      "I=Y?>7O 2+[O'X& B
M             3(^4O'WF A                              $WY/T_
M!"                   #7+F 25<3N3W5)++_+]N E),S22C_L&>Z),R(S+
MJ?<?L 8A],W.=S^ /"U_*)S]V_Q;TR^Z9N?61^*GQK9)-\E']1Q!-].WN(!O
M6          )&_;X?$!:OYC\/<0"T
M%2[R^\O> D7W>/P,!$                                 F1\I>/O,!
M"                              )OR?I^ "$                   &
MMW,1?T.)?)YPD^;IH#;ZC29>8CZ4.=_#Y2Z&HE=>G0!C'TWXQZ*X(\.,-3;#
M+.)QGU+C?280M"4.%5HYQ/D\RU=$DV9=2/KVF W?          $C?M\/B M7
M\Q^'N(!:                               "I=Y?>7O 2+[O'X& B
M                              3(^4O'WF A
M          $WY/T_ !"                   #7GEOT/BMR4(B)1_X#[:(D
MGT[5'1IOI\W9W^ #H'I\.K?X.<1'EJ;4;O'#4"S-IQ+C9J_LV,-1I4@S29?B
M+N]H#<4          2-^WP^("U?S'X>X@%H
M      *EWE]Y>\!(ON\?@8"(                                !,CY
M2\?>8"$                              3?D_3\ $(
M     -?N5Z2/B[R3/H1_^83;G8HB-)D="GNI&1D?7Y0&-/3LQ6<3@?PZ:81Y
M&T<:=-I2DNG1)'2(EP^A$1=JE+/J W,          $C?M\/B M7\Q^'N(!:
M                              "I=Y?>7O 2+[O'X& B
M                     3(^4O'WF A
M $WY/T_ !"                   # ?*M!JXP<D3(R[=![>277V=*#/J,S
M8X]/;MX)\/#^WC7IH_\ 3188_B W#          $C?M\/B M7\Q^'N(!:
M                            "I=Y?>7O 2+[O'X& B
M                   3(^4O'WF A                              $
MWY/T_ !"                   #!?* O/QGY&H67F0>B=M$HN[JDZ!8",NO
M]4@,5>G>KZG OAHYUZ_4XRZ6,_MZG0(-1F?B?0!N2          )&_;X?$!:
MOYC\/<0"T                               %2[R^\O> D7W>/P,!$
M                               F1\I>/O,!"
M           )OR?I^ "$                   &$>339JXV<ATEVF[HW;"2
M+^O]A3Z?>8##OIQK-7 +A>HR,C5QBTJ9E_\ 4&#Z]I=G>0#=           2
M-^WP^("U?S'X>X@%H                               *EWE]Y>\!(ON
M\?@8"(                                !,CY2\?>8"$
M                   3?D_3\ $(                   ,(\F$D]QMY"LK
M<^@E>CMM-F_YR:^DE=#GTF[]19I0W],CZ^8S(BZ=0&%/3:-2?3^X6,K2X2V^
M+^E.IN&2E'Y:'"H_&HC-*E="(S,CZ'YOL ;L@         "1OV^'Q 6K^8_#
MW$ M                               !4N\OO+W@)%]WC\# 1
M                          )D?*7C[S 0@
M      ";\GZ?@ A                   !@?E2E+G%[DDE>*[G(5H+<2%X.
M/BX^:_F)5KRPDK%:PLDT8^8[D$?D2TX9(<4?E4?0S 84]-$R7Z?/"!1(-!%Q
M0T6DD+)I+C)%KV 23!HQR+';4WY#2I+9>1!I)*>PB ;Q@         "1OV^'
MQ 6K^8_#W$ M                               !4N\OO+W@)%]WC\#
M1                                 )D?*7C[S 0@
M              ";\GZ?@ A                   !B'D$770F\"\R4]=/[
M,+S*[$IZTN;[5'[$EWF UN]+[REZ<_!U*7$OE_E:TP:7F^UI:3H\-T-"CZ'T
MZ= &]X          D;]OA\0%J_F/P]Q +0
M     5+O+[R]X"1?=X_ P$0                                "9'RE
MX^\P$(                              F_)^GX (0
M    :\<O,W*C>)O*&1P738S8_CKNW-Q'T]#4QE8NM+,_CO))75)J;>01EU[.
MP!A+TN/)_P"K@X'&TI2VW>(?'_(4XH^IK??UM7WLDS/H7<^XKH7L(P&^@
M       D;]OA\0%J_F/P]Q +0                               5+O+
M[R]X"1?=X_ P$0                                "9'REX^\P$(
M                           F_)^GX (0                   :W<RO
M^A_RO_ZM6]?^2^T ,(>E0KKZ:/ -)'V?Y/\ 0"SZ]YF>MJX1=O@8#T
M     $C?M\/B M7\Q^'N(!:                               "I=Y?>
M7O 2+[O'X& B                                 3(^4O'WF A
M                         $WY/T_ !"                   #6[F3V\
M/^5Q?_EJWI_R86@!@STH>JO3-X!.'VF?#_0">I=WX=<0'=]W4!Z"
M  "1OV^'Q 6K^8_#W$ M                               !4N\OO+W@
M)%]WC\# 1                                 )D?*7C[S 0@
M                      ";\GZ?@ A                   !K?S)[.('*
MX_\ \M>]/^3"T ,$>DWU3Z8W !"B,E%Q#T(KH?3N/7,#T]OM(!Z#@
M  "1OV^'Q 6K^8_#W$ M                               !4N\OO+W@
M)%]WC\# 1                                 )D?*7C[S 0@
M                      ";\GZ?@ A                   !K?S)[.('*
MX^AGTXU[T["+J9_^;"T=A%[3 89]+;"<C?3AX&X+KK+SC7#OCPI2V%$IH_/K
M.O/?[-2?PGY2R"2?;V&7V@-]@         !(W[?#X@+5_,?A[B 6@
M                        J7>7WE[P$B^[Q^!@(@
M              $R/E+Q]Y@(0                             !-^3]/
MP 0@                   UWY>)-?$WE$V1=?/QUW:CH9=>OFUI9BZ=/Z@,
M&>E>39>FSP)-#JG_ /FAZ$23BR,E*(M<UWSDKKVEY5]A?]R W[
M$C?M\/B M7\Q^'N(!:                               "I=Y?>7O 2+
M[O'X& B                                 3(^4O'WF A
M                    $WY/T_ !"                   # '+%)+XK\F4
M&?0E\?=S)Z_9YM<V,C,O P&N?I-D]_ZL[@2;BE++_*1HI'G7\ZE(H<21=>PN
MY'0!Z%@         "1OV^'Q 6K^8_#W$ M
M     !4N\OO+W@)%]WC\# 1                                 )D?*
M7C[S 0@                             ";\GZ?@ A
M    !@7E2CZG%_DBWUZ?4T'N)'4NWIYM=V-/7IV=W4!AWTU<-K!]/3@SCXY>
M5AOB1Q_)*/8DUZPK+RB[.SYG#_T -W          !(W[?#X@+5_,?A[B 6@
M                              J7>7WE[P$B^[Q^!@(@
M                    $R/E+Q]Y@(0
M!-^3]/P 0@                   PAR;1]3C;R$;\OF^IH[;2/+V'YO-0;
MGR]#[.WJ PAZ:CBG/3VX/K^J3R/\I^AD_4(B(E*;UO7D="+J9_@)/EZ]Q] &
M[P          D;]OA\0%J_F/P]Q +0
M 5+O+[R]X"1?=X_ P$0                                "9'REX^\P
M$(                              F_)^GX (0
M8=Y$I0OC]O5#A]$*TWL]*S^Q"J1.$H_ C :O>E0Y(K]-W@P<F32<G_*QII"F
MV242$H;I\<WCJ+SFHR4>(AOK_ONO3H0#T#          $C?M\/B M7\Q^'N(
M!:                               "I=Y?>7O 2+[O'X& B
M                        3(^4O'WF A
M    $WY/T_ !"                   #$N_D&[HC=C9$1FYJ/9*"(^TC-=,
MFD]#+VEV@-9?2[/_ /3IX.$GS?3+BOI;R^<R4OJFD1*3\ZBZ=2[N@#?0
M      2-^WP^("U?S'X>X@%H                               *EWE]
MY>\!(ON\?@8"(                                !,CY2\?>8"$
M                          3?D_3\ $(                   ,7;P(C
MTKN E=QZLV$1_=_:,OU_U -4?2M?4[Z</!OS=IGQ=U"KS=OY:G&MD7;["(@&
M_P"          )&_;X?$!:OYC\/<0"T
M  %2[R^\O> D7W>/P,!$                                 F1\I>/O
M,!"                              )OR?I^ "$
M &+]WF2=+;@4?<6K=@F?W%4I<P&HOI0]#]-O@NKM[>+>IB+]%9CB5U\5 /0H
M          2-^WP^("U?S'X>X@%H                               *
MEWE]Y>\!(ON\?@8"(                                !,CY2\?>8"$
M                              3?D_3\ $(                   ,6
M[RZ?X)[B[2Z_X5["[.WK_P 49C^@#4?TH/\ V;/!;_JNZK_^S<6 ]"@
M    !(W[?#X@+5_,?A[B 6@                               J7>7WE
M[P$B^[Q^!@(@                                $R/E+Q]Y@(0
M                        !-^3]/P 0@                   P[OG-1B
M:6W4YDO-,X>/J78;SSSO1M##2*9-.NONNKZ))EOR]#/KV&8#5CTH2Z>FSP7[
M2/IQ=U1T4G\2%$NLQJDJ2LNJ5%T3U^XR >A(  =.G>       "1'M\/B M7\
MQ^'N(!:   !T         5Z']A_;X?: H           !T]OL     53WE]Y
M>\!(ON\?@8"(                                !,CY2\?>8"$
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ML.$=LN7/0V+7,?"_DG[!E2>%CP;$:39.G(/2SCQ8#6"31DKZRG";\I]>H"W
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MKU(!W8!,CY2\?>8"$                              3?D_3\ $(
M               ,/;_-O_ S=JG67,AIO3NS3=8;62/W#?\ 9TOYV$K/Y''"
M+HD^XNO4!J/Z0SA/^F!P/=Z&@E<8=5FAHU><VT_V]C)2@U_G4A)>4S]O0!Z,
M@    .HW^B5/:-&N&MKY"X=DI%^K,Y3K=7Y%OZN#-5RR1N3$3,;DH[#^GEX&
M6XCJ1DI)GU+H9$8#RSRO1?XW66DSU#VEMOE-NJ&7J.<T9K9_:NY<BQR6D=:S
MV=!9^9$ZVRF8:/Z23QUB/Q7\^63*967'8:,1]3C!K0L+*EZ+/%VJ85=Q57G>
M5D7%[8LFV[&=AM56_CKYGW[1RN/&S*?8Z[7Z7 5W&H&P-9J_;YD9'XN$EE\B
M>QUM*ZD8= V9Z2>)2]"RE4XX;&V5<MQ0$QI^1TU8=Y;ILU:Q]3Q.E9R5D*?$
MT"VZQJB,^IR47"S61@%*9L9.9,DUY6I+]TT9D ZGQY]$R!@M#:MJ^[]Z;BP=
MZ1T5O"#WC?-([&SX!O=.ON1&VY3<%_TWL*>G(7+F[S5F)F45B)F#9BIEQ!NK
M;6PEWR)#>7.],;B;FQ.?7':M8D5N1Y RW)%^ 9L^>U%MWF<T_EZ)DHC#901.
M8-)R-:9[V$4<TM!(6OZJ5DLB,!AZM>D1J:I:MG=80O)#F VVIZD,:XM.3M[
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MG'UFX URI_I#Z;HNF[)IRM;ZY1QV)).Z]PJI<,;8%9P[1KJDZO?6[4];UUC
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M >R4)=^F2F\=HC0@NI&?4S#M0"9'REX^\P$(
M      F_)^GX (0                   8IWBP6;IK<$>1J)6;JG8>/^!HW
MC(WZG+-$9,]4D\HO/V)ZEYC[.H#3#T?#-OTO^!^.LNAM<9-:MEYDFAP_V\0V
MP?F;,^K?X4EU3WI,^G4^@#TE          %[9%VGT+KT(NO]/L^[L 47\Q^'
MN(!:                   !]O\ 4NA_U+[#_H ?'O\ #N     .A%W$1>SL
M+IV>PNSV$     J7>7WE[P$B^[Q^!@(C+KW]OM[>T
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MPZ_BRDA!94Y2K+"VF*QIR(?/&EH?(D(/-S\1F2C<@O(\PI9.-J[%$ [P
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M!R+Y0]?4C)RH^0FIUEN7SW66%^0B(^@>FH
M     *EWE]Y>\!(ON\?@8"(                                !,CY2
M\?>8"$                              3?D_3\ $(
M    ,7[N4I.GML>7V:NOYD1?;_:4N??]X#53TM8UF*].K@[A83:&,+&XO:E\
MC#9$E"7<FJ160I:"[>SS*69_]T W\,^O:8"@   *&1'V&1']Y$?^CKW& L^D
MWYB5Y$FHCZD9D1F1^7R]2Z]WX>P!4VT*Z]4D9&9F9>SJ9$1]G<7< H3+1=.C
M:.PO*1="Z$GO\I)^4BZ@)&VF^W\">SIT[.A%V]>PN[O(!13;9.><DD2DI\I*
M[>I)/H9EW]#ZGX@*@                               J7>7WE[P$B^[
MQ^!@(@                                $R/E+Q]Y@(0
M                  !-^3]/P 0@                   Q;NYQE&G]M*>>
M:9;;U=L!;SCRTMM,M)J4N:WGG%FE#;2$D9J,^PB+M :S>F(X3WIW<)7$=/(?
M&+3Q)-/:@_+38M/5*NY1'Y>I&7>1]0&]8          D;]OA\0%J_F/P]Q +
M0                               5+O+[R]X"1?=X_ P$0
M                      "9'REX^\P$(
M   F_)^GX (0                   8KW/B8LCJK;&!F8K63A9VKKYAYV.\
MTA]G+QLFK2C+^.\RLC0\VZRLTJ2HC)1'T/L :Q>EYT3Z=7"1E!D2&>,FH&D(
M224I0TU48YEE!)2:DI2E#?0B(^A>7H WQ          $C?M\/B M7\Q^'N(!
M:                               "I=Y?>7O 2+[O'X& B
M                       3(^4O'WF A
M   $WY/T_ !"                   #7KE6\SB\9N2F3D.Y[&.QQ^W&^^]%
M.DS*,LM:ZL2W78UXR,F<]M"3-E7Y7"(P& ?2B,U^F?P+<-1K\_$W1BTFOI]8
MT+H,.II;YD9DI]39_P"T/VKZG[0'H&          )&_;X?$!:OYC\/<0"T
M                             %2[R^\O> D7W>/P,!$
M                    F1\I>/O,!"
M)OR?I^ "$                   &O/+=DWN+/)=LB(OK<>=U-=>X_QZVLJ"
M[>O9V@->_28(S],?@*I1)(_\I&B4=$ET+HW0(<BZ?>70!Z%          "1O
MV^'Q 6K^8_#W$ M                               !4N\OO+W@)%]WC
M\# 1                                 )D?*7C[S 0@
M                 ";\GZ?@ A                   !@;E2CZG&/D6W_N
M]";B1V?[[7MC3\0&MGI++4OTQN YJZ=G$_22>[H?X*/$MEX>5! /0P
M    2-^WP^("U?S'X>X@%H                               *EWE]Y>
M\!(ON\?@8"(                                !,CY2\?>8"$
M                        3?D_3\ $(                   ,'\FDDYQ
MPY H/N/1NVB5U[NBJ'/I_P#W@&M/I.H6WZ9G Y+I>5Q/%/2K9I/L/HW28HD]
MGL_ 8#T&          $C?M\/B M7\Q^'N(!:
M       "I=Y?>7O 2+[O'X& B                                 3(
M^4O'WF A                              $WY/T_ !"
M      #"O))'GX[[Z01=KND]K-GW]OFHT\7L_J0#!/IH&E7IY\'U(2E*?\J>
MBD^5"22DC3KN 2HR))$7:KK]Y@-X          !(W[?#X@+5_,?A[B 6@
M                            J7>7WE[P$B^[Q^!@(@
M                  $R/E+Q]Y@(0                             !-
M^3]/P 0@                   Q!R"1]70V[6O:K3NS4_?YZ9-(Z?\ R@&N
M/IA+^IZ=7!M1=Q<5]+)/NZF::)!H_P#D^0_](#>T          2-^WP^("U?
MS'X>X@%H                               *EWE]Y>\!(ON\?@8"(
M                             !,CY2\?>8"$
M          3?D_3\ $(                   ,5;U22M)[A3_\ 2:HV*A7W
M'49@!J_Z6RTN>G%P<6E1'_S7]/$7=[*;%)4?W>9(#?4          2-^WP^(
M"U?S'X>X@%H                               *EWE]Y>\!(ON\?@8"(
M                                !,CY2\?>8"$
M             3?D_3\ $(                   ,*<BI!N)T3O&6?\QXT3
MIK9>>\E!&:EMLTJ;=4E'3K_M#-)$7W@-8?2@=^IZ:O!!711F]Q=U(YYC+IT2
MNI1BT=?ZFDP'H49=#Z *         )&_;X?$!:OYC\/<0"T
M                  %2[R^\O> D7W>/P,!$
M         F1\I>/O,!"                              )OR?I^ "$
M                 & >5:B3QAY'GUZ&G1&V#Z^TO_$6>[@&N/I.'_\ II\"
M2Z]O^5?3YG__ (=%=/<8#T.7\Q^'N(!:         D;]OA\0%J_F/P]Q +0
M                              5+O+[R]X"1?=X_ P$0
M                    "9'REX^\P$(
M F_)^GX (0                   :_\JR(^,O(U!]R]$[6(_P"G6CSI -<O
M2;+KZ:/ M?\ ^5G3J>G]"IT>9?U >AZ_F/P]Q +0        $C?M\/B M7\Q
M^'N(!:                               "I=Y?>7O 2+[O'X& B
M                            3(^4O'WF A
M        $WY/T_ !"                   # O*4R+C/R*^TM$[75V$1GV4
M:=[NO0C/K]H# GI?0^77O3RX0PF;BY.'D1G&+3V._C9A-EEL.'3XY24/$TI;
M9&I"B4GH?RF0#?=?S'X>X@%H        "1OV^'Q 6K^8_#W$ M
M                     !4N\OO+W@)%]WC\# 1
M            )D?*7C[S 0@                             ";\GZ?@
MA                   !@SE TASC/R))70B5HS;"3,_E(BH<\KJ?4C+IU 8
M8].&2R)G@9PQE,C]]]3.XTZB==5(8B<#*4M5+B$]7\-)J)ESRMET+J?X.A^T
M!NXOYC\/<0"T        !(W[?#X@+5_,?A[B 6@
M          J7>7WE[P$B^[Q^!@(@
M$R/E+Q]Y@(0                             !-^3]/P 0@
M         P;R;/\ YMO(=!ET\^CML^51]W90)[J??VDGJ0#&7I_*)S@WP_<2
M?5+G&K3*D_U(Z'"*+_48#;\          2-^WP^("U?S'X>X@%H
M                      *EWE]Y>\!(ON\?@8"(
M            !,CY2\?>8"$                              3?D_3\
M$(                   -6.;DP] </>5]@QB,\^O\9M[RF"74R+ZN/K2Q.)
MZEU-*C-2$]",NPP'7O3Q[>!O"YSIT^MQ8T4\9$?7RJ>UO7'G$D?M)*G>A -R
M          !(W[?#X@+5_,?A[B 6@
MJ7>7WE[P$B^[Q^!@(@                                $R/E+Q]Y@(
M0                             !-^3]/P 0@                   U
M)YYL&]PCYD%YB2:N*N_R(^_IY=769?=^D!Q7IUJ)? 3A*LNPE<4-!JZ=_P ^
ML*N?3L^P!N6          )&_;X?$!:OYC\/<0"T
M          %2[R^\O> D7W>/P,!$
M F1\I>/O,!"                              )OR?I^ "$
M         &K/.1LG>%G,!D^PW>+/( D]>SJ1:JM77M^SJ9=0'5?3G2\WP$X2
M-O))#B.)N@36GJ1F7FUC63;[NSH:"Z_U ;H          "1OV^'Q 6K^8_#W
M$ M                               !4N\OO+W@)%]WC\# 1
M                         )D?*7C[S 0@
M     ";\GZ?@ A                   !J]S7;-?#SEL1_(?%[?R#Z=I]%Z
MLM!'T+P(!U/T[L8L+@5PAQTGD*3_ )2.//X\A)H<_%JNJ.D2TJ[>O1T^GVI(
M!N<9=#Z *         )&_;X?$!:OYC\/<0"T
M       %2[R^\O> D7W>/P,!$                                 F1
M\I>/O,!"                              )OR?I^ "$
M      &L_- E*X?<KTEWGQFWX1]W7H>KK.2.W[.H#@. ;?EX*<*C-1K_ .:3
MQOZ+4?F-1?X.4W\1G_4^H#;<          2-^WP^("U?S'X>X@%H
M                       *EWE]Y>\!(ON\?@8"(
M             !,CY2\?>8"$                              3?D_3\
M $(                   -9N:"C3Q"Y7I+V\8]\*Z]GLU=:#^S[0'7?3Y6;
MG ;A XKYE\0N-*U?>O2]+49%]A=3 ;=@         "1OV^'Q 6K^8_#W$ M
M                              !4N\OO+W@)%]WC\# 1
M                     )D?*7C[S 0@
M ";\GZ?@ A                   !K%S2ZGQ"Y6=.O_ $9=_%U_J>K;.?3K
M_3H Z_Z>W_0"X._]4#C/_P BM) ;>@         "1OV^'Q 6K^8_#W$ M
M                            !4N\OO+W@)%]WC\# 1
M                   )D?*7C[S 0@                             "
M;\GZ?@ A                   !J%Z@4J_#<$N:,IB*\F1@<4^0#S*S22_*
M\6K+0E"R(_L-0"[T^2\O 7@^1=>A<0N-!%U[3[-+4HNT_:8#;L
M2-^WP^("U?S'X>X@%H                               *EWE]Y>\!(O
MN\?@8"(                                !,CY2\?>8"$
M                    3?D_3\ $(                   -,O4629\ .;J
M?:KBAR!,O_\ 5MG <GZ?7_0&X0?]4/C3_P BU* ;=          "1OV^'Q 6
MK^8_#W$ M                               !4N\OO+W@)%]WC\# 1
M                               )D?*7C[S 0@
M           ";\GZ?@ A                   !IMZB"#>X%\UVB424JXF\
M@3/KW=4ZMLZC/M[NQ)D7]3 ??Z?7_0&X0?\ 5#XT_P#(O2_^T VZ
M  $C?M\/B M7\Q^'N(!:                               "I=Y?>7O
M2+[O'X& B                                 3(^4O'WF A
M                      $WY/T_ !"                   #3?U$.S@9S
M0[.I_P"5?>_4_8:%:VL/F0?]%$?;_0!D/B3BLX?%?C-C8K+6-B8W'O2V-BXK
M"?(QCX[.MJRVTRTV1$E#;2$^5)%V$D@&PH          D;]OA\0%J_F/P]Q
M+0                               5+O+[R]X"1?=X_ P$0
M                       "9'REX^\P$(
M    F_)^GX (0                   :=^H0E3O _F>V1&I2^+F]4I+_=%_
MAM8B\I%[0&1^*1DKBWQJ4D^J5: TV:3]AD>N:V9&7WD SZ          )&_;
MX?$!:OYC\/<0"T                               %2[R^\O> D7W>/P
M,!$                                 F1\I>/O,!"
M                )OR?I^ "$                   &I'/E'GX-\Q$=>U7
M&'>A$?3KWZWL7L]H#N7$A7FXI\8S/V\>=+*+^G76M8_[8#84          2-
M^WP^("U?S'X>X@%H                               *EWE]Y>\!(ON\
M?@8"(                                !,CY2\?>8"$
M                  3?D_3\ $(                   -2.?&4WB\(>8+K
MC.5D-L\8MX.N-8;/U\EU/^'-B+Z>.S_\ZX9^S[ ';.("R>XF<7'B5U2YQRTD
MHNO3S'YM;5HS\WE/IU+VGW=0&Q8          D;]OA\0%J_F/P]Q +0
M                          5+O+[R]X"1?=X_ P$0
M                "9'REX^\P$(                              F_)
M^GX (0                   :1^I+(YT-Z?O-J7C,MW S<'BQO+*Q\QHDJ<
MQW\?7LX:%(0LC2?4NI'U(^I ,F<.DM)XD<6B821-?Y<=)$@R_P!R>MZXKL]O
M:KK_ *0&R           D;]OA\0%J_F/P]Q +0
M         5+O+[R]X"1?=X_ P$0                                "
M9'REX^\P$(                              F_)^GX (0
M        :.^ID@G?3LYQ-'TZ+XJ;W3V]W56NY\BZ]A]A*/[.H#+?$:/=B>*G
M&>,>4VZ]@<?].X;SK1]6EK8UY7DFII1_.W["/V@-AP         !(W[?#X@+
M5_,?A[B 6@                               J7>7WE[P$B^[Q^!@(@
M                               $R/E+Q]Y@(0
M           !-^3]/P 0@                   T@]2W_V>7-[_ *J^]?:9
M?_=[/=>TNT@&:N+J$-\9^.K;2EFTC1&HFV_.LUJ-":!7O*I2C[5*Z>T!G4
M        2-^WP^("U?S'X>X@%H                               *EW
ME]Y>\!(ON\?@8"(                                !,CY2\?>8"$
M                            3?D_3\ $(                   -'_4
MN_\ 9X\X/^JKO?\ Y.Y\!F[B]_T9..O_ *"]1?\ )[7@&<@         !(W[
M?#X@+5_,?A[B 6@                               J7>7WE[P$B^[Q^
M!@(@                                $R/E+Q]Y@(0
M                !-^3]/P 0@                   T?]2[_V>/.#_JJ[
MW_Y.Y\!F[B]_T9..O_H+U%_R>UX!G(          2-^WP^("U?S'X>X@%H
M                             *EWE]Y>\!(ON\?@8"(
M                   !,CY2\?>8"$
M3?D_3\ $(                   -(/4O[/3PYP&9D1?Y5=[=IGT(NNNY_H1
MG[#,!FWB]_T9..O_ *"]1?\ )[7@&<@         !(W[?#X@+5_,?A[B 6@
M                              J7>7WE[P$B^[Q^!@(@
M                    $R/E+Q]Y@(0
M!-^3]/P 0@                   \Z_5Q>S,;TQ>>#V"Y]/)_RQ;6\BR5TZ
M(56<MIXC/V&K'6HOZ@-I.,!=.,W'<OLT;J,O_P /J\ S@          )&_;X
M?$!:OYC\/<0"T                               %2[R^\O> D7W>/P,
M!$                                 F1\I>/O,!"
M               )OR?I^ "$                   'GAZMB?/Z97.YKKT(
M^+VV%=?_ *KYRNG3P ;/\8?^C/QW_P#0;J/Q_P#-]7@&<          !(W[?
M#X@+5_,?A[B 6@                               J7>7WE[P$B^[Q^!
M@(@                                $R/E+Q]Y@(0
M               !-^3]/P 0@                   \^?5<;^MZ:W.Y*B_
M"7%;<BNWN/Z-,DW2,^A=?PFD!L;Q95YN,?''S&:EGH33RS5[#-6O:Z1G_4SZ
M ,\@         "1OV^'Q 6K^8_#W$ M
M  !4N\OO+W@)%]WC\# 1                                 )D?*7C[
MS 0@                             ";\GZ?@ A
M !H5ZI*EI]./FZ1$\LW>,>X,?RX_0WOI951D,9TD=Y$7TW3Z]?9U ;+<?<)J
M,T+I"+9-1M1VG]9X;7FZ>8V\6E0F,CS="(B5Y&BZ]/: R^          )&_;
MX?$!:OYC\/<0"T                               %2[R^\O> D7W>/P
M,!$                                 F1\I>/O,!"
M                )OR?I^ "$                   &B?J@*Z>G-S>5_\
M1\8MQ+,_L\E*E5G_ *"2 V5T09+TEIQPNWZFI]<+(_Z*I\.?9]X#*X
M    D;]OA\0%J_F/P]Q +0                               5+O+[R]
MX"1?=X_ P$0                                "9'REX^\P$(
M                        F_)^GX (0                   :&>J4ZIO
MTW><[B4^?R<6MT=$]2(S--&F"ZGU,B)!>W^@#9O0Q>71NF$D9]"U-KA/E]G1
M-.ANG>74!E@          2-^WP^("U?S'X>X@%H
M          *EWE]Y>\!(ON\?@8"(
M!,CY2\?>8"$                              3?D_3\ $(
M         /-+UD'W\/TJ_4&RV#:)UKBCN$T_52I3?3^U<TE$LDFD^AMF9=X#
M=W2*B5I?4"B3Y"5J[7QDC_<$=2B3)/@78 R@          )&_;X?$!:OYC\/
M<0"T                               %2[R^\O> D7W>/P,!$
M                          F1\I>/O,!"
M      )OR?I^ "$                   'F?ZS24K])_P!0M)]Q\3=S$KMZ
M'_Q2S^[M+M^S^H#>O3K18^HM68Q)4@\?7-%:^FOYT$W5HILDJ_JGR]#_ *@,
MB@         "1OV^'Q 6K^8_#W$ M
M!4N\OO+W@)%]WC\# 1                                 )D?*7C[S
M0@                             ";\GZ?@ A                   !
MYH^LHUYO2G]07M(B7Q2V^7;[/_%;,[P&_P#K]HD4.D$CH2$5"LMI3]B$P>"2
M2\.@#MX          D;]OA\0%J_F/P]Q +0
M      5+O+[R]X"1?=X_ P$0                                "9'R
MEX^\P$(                              F_)^GX (0
M     >:7K*+Z>E3Z@B>O7IQ1W"OIV=R:KEFK_1U >@="[*'2B_\ [3K?_@3"
M =J          $C?M\/B M7\Q^'N(!:
M  "I=Y?>7O 2+[O'X& B                 54GH1F2NI^PB(O_ (3 5/IT
M3T[^G;V_< M             3(^4O'WF A
M    $WY/T_ !"                   #S)]9=YICTK/4&=?<;9:+BCM]CS.
MK)"5/9=9>8QVB-79YWWEDA)=ZE*(B[P'H;0_^(=+_P#)2M_^!<(!VD
M    2-^WP^("U?S'X>X@%H                               *EWE]Y>
M\!(ON\?@8"(                                !,CY2\?>8"$
M                        3?D_3\ $(                   /*?UQVD.
M^D;S_2O_ /YWM3A=2(R);&3'/-?J^JDNA^PP'IA1/^(E,_\ )2M_^!<(!V@
M         2-^WP^("U?S'X>X@%H                               *E
MWE]Y>\!(ON\?@8"(                                !,CY2\?>8"$
M                             3?D_3\ $(                   /*K
MUQ/_ &1W/[_J[6W_ /G1X#TLH?\ Q#I?_DI6_P#P+A .T@         "1OV^
M'Q 6K^8_#W$ M                               !4N\OO+W@)%]WC\#
M 1                                 )D?*7C[S 0@
M               ";\GZ?@ A                   !Y:>MECM9OI0<\L-U
MQ;363Q_LS+SK;9O.-LJS(U#RVF4_B>>0VHS0@NU:NA%W@/1^B$TFETY#2G7$
M(J5;)I;K9M.*9*'PB0MQHRZMN*+YDGVI/L =L          $C?M\/B M7\Q^
M'N(!:                               "I=Y?>7O 2+[O'X& B
M                           3(^4O'WF A
M       $WY/T_ !"                   #S3]8K&+,],CF3BFI:2R=3.,&
MIM7D67U;' (ZH67:A7XNP_8 ]$:VE:(""2M7F,H*'29G\RC1@LDHU>SJ:@'-
M@         "1OV^'Q 6K^8_#W$ M                               !
M4N\OO+W@)%]WC\# 1                                 )D?*7C[S 0
M@                             ";\GZ?@ A   !']1/4^A*[#\I]"\QD
MLN])DCKT,B/V] %Z%)<2:B/IY3,E$KJ1I,OM+V #A_33YCZF7V))2C/LZ]A$
M1F9G]A=3/[ $:7VU=WF/_<F1?/V=3-'^Z21GTZ_;U^P!0WT)2HS)75/3S?[T
MNG4S/L[DEV]?@ L_=M'T+M\Q^8R27XNI)Z$HTGUZ*(NI=>AGW@+SR&NPRZJ_
MHGHH_P"O:7X>I>TNO9]X"TLE!H)?E6HS,B)*>AJ5YC,B-)'T_#V=I]Q=/M[
M$R%><NO0T]#\I^;L+K]I?T,^X!=_\/\ J[    >;?J_F9>FES",B,S1JDW"Z
M?[VR0"_]1)[0'H975D[7H!U)'^*$BCZ].SHO QUE_J4 Y@          2-^W
MP^("U?S'X>X@%H                               *EWE]Y>\!(ON\?@
M8"(                                !,CY2\?>8"$
M         'S?O&/K&QYE$Z2O*2#0LNO81]25T\IIZ'W]0'T]W?V'U/L]W^D
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M)_8,Y,1.9>(J N&SEPUGN&):(2OQ$')95V@:V[CQ4NF.PV<_'EV,@V6''>B
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M^'N(!:                               "I=Y?>7O 2+[O'X& B
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MP<1I#&)A8S.'BL-]20QBXK2&,9I'7M,FV6R3V^P@'U@         "1OV^'Q
M6K^8_#W$ M                               !4N\OO+W@)%]WC\# 1
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M@                                )&_;X?$!:OYC\/<0"T
M                      %2[R^\O> D7W>/P,!$
M             F1\I>/O,!"                      *]3[NI@+2(B[2[#
M/[ %>\    !-^3]/P 0@                                )&_;X?$!
M:OYC\/<0"T                               %2[R^\O> D7W>/P,!$
M                                F1\I>/O,!"
M            )OR?I^ "$                                !(W[?#X
M@+5_,?A[B 6@                               J7>7WE[P$B^[Q^!@(
M@                                $R/E+Q]Y@(0
2             !-^3]/P ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tv526458_ex1-1img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ )$  0$  @(# 0$
M       # @D!" 0&!P4* 0$                     $  ! P0! 08$! 0#
M!0,)!0D  0(#! 4&!P@1(3&!L1()0<$R$W%"@A1182(5D187H5)R(QCP8C/1
MDG,D-+4G&7FRPE,F-Z-T)96'6"DY:1$!                     /_:  P#
M 0 "$0,1 #\ _OP                             I'\?#Y@8O^I?#R0#
M$                           '*=Z?BGF!1_=X_)0)
M              69]*>/FH$0                          M^3]/R B
M                          !2/X^'S Q?]2^'D@&(
M           .4[T_%/,"C^[Q^2@2                             LSZ
M4\?-0(@                         !;\GZ?D!$               !*9Z
MQL5R=.O\T5?@J]R=%5>P#\NCOMKN3I8[9<J"XNI:N:W5RT593524ERI>G[NW
MU"TTLS::OI>J+)!(K96(J=4 _9          *1_'P^8&+_J7P\D Q
M                    !RG>GXIY@4?W>/R4"0
M      %F?2GCYJ!$                          +?D_3\@(@
M      'Q3LZ_U)V_[O;W_P  -*GLJO?)KKFVD$B5,4GN><RI)U;*^I6W)#D-
MDACH))97.]:O<J/8K.K6-=Z>B*!NK          *1_'P^8&+_J7P\D Q
M                       !RG>GXIY@4?W>/R4"0
M         %F?2GCYJ!$                          +?D_3\@(@
M         .41%Z?Q1S5[/Y+U_P .P#3%[*4;&:LYNM:G3T^Z!S5:JHB-<Y8L
MXMS&N>J?4Y8D1/P0#<X          4C^/A\P,7_4OAY(!B
M             #E.]/Q3S H_N\?DH$@                            +
M,^E/'S4"(                          6_)^GY 1                <
MM[T_% --OLO-_P#AKSE3JG]'NA<UE[/CZLXMJ?(#<B          4C^/A\P,
M7_4OAY(!B                           #E.]/Q3S H_N\?DH$@
M                      +,^E/'S4"(                          6_
M)^GY 1   .%5&HJN5$1.]55$3_: ]2?Q3XI_YO8O^"H!R          <IWI_
MQ)Y]J^ &G/V9VMCU[SIC8G1$]T3FLU4Z]53IG%M?T5%[E[?\ -Q8
M !2/X^'S Q?]2^'D@&(                           .4[T_%/,"C^[Q^
M2@2                             LSZ4\?-0(@
M       !;\GZ?D!$  7^7>!&IB^XQ(^KFJJL<BM1%Z.:Y%3KU:Y%:J]B]4[@
M/FF"T^T*6LS-VQK[@ERM]1F-6NO:;"<?OEJGM.!N@B2@MF73WJ\W2&Z90E2U
MZSU5&REI5:J(V%.U5#ZB          <M545.Q5151J]/AU^/^P#3U[0+H:/&
M.?5IC5Z5EN]TGF5'=6O@F9'!-6918KC2QQRO8D<ZS6^KA=ZHU<UJN5JJCDZ
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M<6X=IV#8>.<>M4<U[?K^Y8YK^.VX'NRZZ=WQA&J+7R4QNHH[Y%;*.;8-BO\
M!)3)#%445)+252T2+3U37-#K[S6]R7D3<\@]QKC?FV],7FP^ZZUY48YH>V:@
MIL&=781_HI8+7D5OO&5W['\VLF_M4[%MBT]:EQ7(K')CMV;]A+56-<KNH?7M
MQ>Y-S%XV8EF.H,AY+8SDN<XCOC5N&X3LVS:;TY;,DR'7&8<1K5O2+%LM39FS
M\'TOKZ_TN022Q+=+O6OJ*VBC2*""2KE0#UF3W>><62:(R_D;BV;X72V?7W#C
MA%L2]X5)JG&H;;)GW*'9N:ZOV3M3(\KNN1+1XSCFLO\ )LEUHJ-U8VS.B?\
M<K:E*9/4!^!GGN[\XL4TW1YS6[UT79\=P#<6]<9O>>V.HXS;"S_;.'Z]Q_7.
M66B[6[&+?M>T:8S.UXY2Y#<Z*\4.!9'4Y142?LG4M)]U:B)@;0O<XY_Y[H[0
MW%O(-(;?MFJ,TY)4=ZRC'+QD>N,&K*F_V3&M3_ZE2V>*IWGL376N=:U%4^JI
MDJ&WJIK;C)"]U-1P2575Z!T:QKW0.=>QX];[JQ[9^G;#KW%<=]L6KV#HZFU?
M17>Y[=O7-RLO.,YRVGV"F1W&HQ..W7B@CGL,-M9,GK<^.:1S&=5#][@5RGV_
MR2]R/B=E6U^3V%;-O^;<,.6N19GQWP6R6K#Y^,F64&YM96)=<YY9K-D-RN-U
MNEBBM,U+3U&0T\%W;/%4O8JPR-1H?%N07+[<VVMY6>NS'D?KVIDQ3//=8UW5
M<&+-CKL7O^#8WICC5MVV8#E6T+E3Y!39?E6/99;L?I+RY]TIZ.A?-=H'6V15
MB7H&6;>Y![@& X6W+,1V7@5CU5D')'2/$?!J:HQ?3^(6'3&-T/$G#=V97GV0
M;.W!D+,>6_9EE-X_LMN7(JB*VPTS/Z$DJ987 ?7M8>ZAR6V-:]42;<Y7\4^)
M]ZH./^*;)>ERQ6@V_C7*W-ZKD3E^J;Y:\'J[%>J7][1MQ7%J)9K?A-3<JZ"Z
MWML\3Y:*- .M^OO<7Y6Z2T/26:;F9I?$;QKG7G,GD+4T^ZL%I;SD>\-F81S
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MNFQ<:=2?V/,*Z;&:"2KOUN_M]SOE ^*MJD>CE95S-61KE]2JO1 [!@
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MC&.6>!M+9\?QVUT5DL=II&*]8Z.V6BVPTMNM]*Q9'*D<,;&HY55$[0/WP
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M:_K[K9\@RS.KEB%YO&+U<%146/\ N]?#:5?^WCD6.-B(&Q@
M    M^3]/R B   ?A9*EWEM%?#8ZBGM]WFMUPAM-SK*=]916^[2T<\=LJZJB
M;+"ZLIZ6M='(^+[C/NL8YO5%7J!\LX^XMNC$]2X-8N0NRL=W!N"BH)X\\V)B
M>&)KS'<@NKZZLJH*BT8<RXW-++0T]%+% D;IY'N6/UN7J[H!]P
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M'30O?Z^Q&H'R?$/=8U=D./9Q6Y%IS<VO,NUIK7EGL?/->93;L:?>[(WAU?\
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M6.&72RP4>0MBNC\@N\-/32LEJZ1LE:R=&*D",D Z:<>/>?S?/+MQCUCF^O\
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ME5=XK]:4]PT+=.0]6V@U+9<EQ5<QJ,HR^Z5DM4V2XRXK!=J:T6^>.HFD6&5
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MN^'\ ,EZ*O54[>G1.G9_'M7^*KU                  %OR?I^0$0
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MN7O >MB*U/4G5_3T=OU=>O3T_P"]UZ+W 9?#JBHJ?R5%[@
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M>/R4"0                            %F?2GCYJ!$
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MU@O>S<QRC&)<7M64W',G9)<[1D-TN3+KLJ[Y!=ZF:X9#4NDN=<V1632*WHU
M[2IW(G55Z(B(J]ZHG8G7^?0#D                    '*=Z?BGF!1_=X_)
M0)                             69]*>/FH$0
M       M^3]/R B                R;WHO\T3_ ! U0>U3;J*DP[FK5T;4
M@J[E[FW-6KN+FKU=7U<>P(Z&G=+ZNOH;#101M[.G7[: ;70         "C/C
MX?,#%WU+X>2 8@                           Y3O3\4\P*/[O'Y*!(
M                          "S/I3Q\U B
M  %OR?I^0$0               #HO5JI\'MZ_AU[P-1?M.3UJ_\ S%J"JG26
MBM?NB\L(K73?;1J4D5;6XS<:B*)47M^]653Y/AVO7^(&W0          I'\?
M#Y@8O^I?#R0#$                           '*=Z?BGF!1_=X_)0)
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MWI^*>8%']WC\E D                       ?]N_IY /\ MV]JK^*KVJ
M  +,^E/'S4"(                          6_)^GY 1
M  <HO1>O1%3X]O:GX)\0-7'MDM1E+SOIG=5E@]S3E8OQ5K4GK<3J47JG8C58
M[KT_BH&T8          I'\?#Y@8O^I?#R0#$
M   '*=Z?BGF!1_=X_)0)                             69]*>/FH$0
M                         M^3]/R B                Y3_ .\U/\5Z
M :M_;(=_ZS[@[._T>YIR>8WX]CJ/!IU3I\'(YR]O\ -HX         !2/X^'
MS Q?]2^'D@&(                           .4[T_%/,"C^[Q^2@2
M                         LSZ4\?-0(@
M!;\GZ?D!$               !S\$_P"-GF!JP]L;_P!O]P__ .IYR:7Q_LN
M@;3@         "D?Q\/F!B_ZE\/) ,0                           <I
MWI^*>8%']WC\E D                            !9GTIX^:@1
M                   "WY/T_("(               #GX)_QL\P-6'MC?\
MM_N'_P#U/.37_N7 0-IP         !2/X^'S Q?]2^'D@&(
M              .4[T_%/,"C^[Q^2@2
MLSZ4\?-0(@                         !;\GZ?D!$               !
MS\$_XV>8&K#VQO\ V_W#_P#ZGG)K_P!RX"!M.          *1_'P^8&+_J7P
M\D Q                           !RG>GXIY@4?W>/R4"0
M                 %F?2GCYJ!$                          +?D_3\@
M(@               .?@G_&SS U8>V-_[?[A_P#]3SDU_P"Y<! VG
M   %(_CX?,#%_P!2^'D@&(                           .4[T_%/,"C^
M[Q^2@2                             LSZ4\?-0(@
M          !;\GZ?D!$               !BJHBL551/^8Q.U>G7JO<G\P-6
M_ME(C;E[A[47KT]SODO_ +;#KY?'M4#:4          4C^/A\P,7_4OAY(!B
M                           #E.]/Q3S H_N\?DH$@
M             +,^E/'S4"(                          6_)^GY 1
M             2JH&R/IE<OI;'-&_NZHY[7)Z&K^/4#5_P"VC&D%U]Q>/KU<
MGN:\C7^E4^ETU@UK,UK>WIZ?1(BIT_B!M&7O7\?@!P         I'\?#Y@8O
M^I?#R0#$                           '*=Z?BGF!1_=X_)0)
M                     69]*>/FH$0                          M^3
M]/R B                \:I5_W*1R/:U$E1CXY$3^I/4U$<Q55.CT7N U@^
MVK*LF1>X\U&O;]OW-]^>I)6JU_I?B&JG]>B_EZKV+_ #:.G<@         !2
M/X^'S Q?]2^'D@&(                           .4[T_%/,"C^[Q^2@2
M                             LSZ4\?-0(@
M    !;\GZ?D!$               !XU:SURT?]".]-1&[ZO2K415ZN3^EWJZ
M?P[/Q U1>UU)]R_^Y6U7O>]/=!Y L>KX70>ES\1U<J-]+GO<Y&(O3KUZ+T[@
M-LW7KV]W7M_Q          *1_'P^8&+_ *E\/) ,0
M        <IWI^*>8%']WC\E D                            !9GTIX^
M:@1                          "WY/T_("(               "4T7WGP
M.7KUBF9(G;T3^E?X)TZ@:C_:TJG5.4>YLOK;(D?NF\@8$<QB,Z>C!]6N1'(B
MKU<QZIU7X@;=0         "D?Q\/F!B_ZE\/) ,0
M       <IWI^*>8%']WC\E D                            !9GTIX^:
M@1                          "WY/T_("(               #!\GVUC7
MLZ.D8Q>J.7ZE^'1%1%Z_Q U!^U.V.'+_ '2*=BJ]K/=1W[,O<OH?4X#J:145
M4543T^G_ &@;?P         "D?Q\/F!B_P"I?#R0#$
M         '*=Z?BGF!1_=X_)0)                             69]*>
M/FH$0                          M^3]/R B                G(CE1
MOI=Z?^8SU?S;U_J1/X*G?X :H/;%@=#=/<0_]:MU1#7^Y[R2DAIZ.E1E;1?M
M[5@B317R3L^]43/I'/@<[M^PYB=W0#;&O_;_ ++V@         %(_CX?,#%_
MU+X>2 8@                           Y3O3\4\P*/[O'Y*!(
M                    "S/I3Q\U B                          %OR?
MI^0$0               '"_!>_TKUZ?Q3LZI_@!J(]K6DIJ?(?<QJ**^?WFK
MN7NE<@ZB\6B-%@EP^:GQ?5\,%MFD5J_?_N-%2PU_]**BLJ_3V*!MX
M   *1_'P^8&+_J7P\D Q                           !RG>GXIY@4?W>
M/R4"0                            %F?2GCYJ!$
M         +?D_3\@(@               ,7=?Z.GQDCZ_AZDZH!IH]IY%9L[
MW;H^UJ?_ #7-R+T[D_JT_I5RJG\/4K>JKWJ!N9          *1_'P^8&+_J7
MP\D Q                           !RG>GXIY@4?W>/R4"0
M                  %F?2GCYJ!$                          +?D_3\
M@(@               .%[V?\;?,#3=[4K?\ XH^[E(O>GNL[@7I__1S1[>G\
MOKZ@;DE[.P          I'\?#Y@8O^I?#R0#$
M    '*=Z?BGF!1_=X_)0)                             69]*>/FH$0
M                          M^3]/R B                Q<Y&^ESEZ(
MCV]5\>@&GGVKH(X]D>[1+%515$E9[I^X5DIX&N6:WJS5NEF(VK1W1/5+&S[J
M.3K_ ,MZ)WH!N(7M[0         "D?Q\/F!B_P"I?#R0#$
M             '*=Z?BGF!1_=X_)0)                             6
M9]*>/FH$0                          M^3]/R B                \
M&X.G8R+[+5=ZIFMZ,8DBND[XF*JJC8V/=V*Y>QO>!JA]LRW5;-H>ZC43=/[?
M5>YWLFNM%530MHZ:L2'26BH+BU&H]TDCJ:Y1SPSN>O226)53^E40#;8
M     4C^/A\P,7_4OAY(!B                           #E.]/Q3S H_
MN\?DH$@                            +,^E/'S4"(
M           6_)^GY 1                8/=Z?0G7ZI&)TZ=_]2=>G\U U
M*^V4ZXTNP/=*BJTZVZ/W/=N?VEZL1&R4M3J[2\M6UDC%]4J-N+WL5%1$:]%3
MM VV@         %(_CX?,#%_U+X>2 8@                           Y
M3O3\4\P*/[O'Y*!(                            "S/I3Q\U B
M                    %OR?I^0$0               ''9ZF]>B+ZFJG5>G
MQ1?) -1?MASRR;8]V.EDK?NT])[GFQ4IZ)$>Y:)M3IS1U5+%U<S[;6555*Z;
M^E>Q7+U[5 VZ@         %(_CX?,#%_U+X>2 8@
M       Y3O3\4\P*/[O'Y*!(                            "S/I3Q\U
M B                          %OR?I^0$0               'CUK>KX%
M17)Z'>I/3T[>G9Z'(K7=6.Z]O3MZ :H_;B8VGWW[M5.E-#2.?[BE;5^B![9(
MY?W7''0,R5+GM^F>K2%9)&][)'*B@;9          "D?Q\/F!B_ZE\/) ,0
M                          <IWI^*>8%']WC\E D
M           !9GTIX^:@1                          "WY/T_("(
M           #Q+BUS_LM:K^U[>J1O=%(Y$7KT;(U45G=V]H&IWVX$C;R0]W.
M)LD4T;/<%94=8J9*9(YY^->D?NQO1(XUFEC<Q$=(J+ZW)ZNJ]>H&VT
M    I'\?#Y@8O^I?#R0#$                           '*=Z?BGF!1_=
MX_)0)                             69]*>/FH$0
M          M^3]/R B                \.ND<U(I&^EG25L:J])%3TO7X?
M::KD7L[.Y.H&J'VZ64K>2GNX1T<=2R1>>EOEJ_W-7%5M?*_CCICU.IUBFJ%I
MXW)'U1CU:YO8BM:J= -M:]JJO\5 X         4C^/A\P,7_ %+X>2 8@
M                        Y3O3\4\P*/[O'Y*!(
M         "S/I3Q\U B                          %OR?I^0$0
M         &+^U$3_ +R*G\E3KT7L U&>VS.[_J-]W*E2IB5*?GZ^5:5E'%#+
M E9HO54GJFJT3UU:U2HCFN<J_;:GH3IV@;=0         "D?Q\/F!B_ZE\/)
M ,0                           <IWI^*>8%']WC\E D
M               !9GTIX^:@1                          "WY/T_("(
M               "<KO0C7>ESOZFIT;\/4O>O\D TZ^VUT;RV]XRE<OK1O.W
M$JE'-5>B.JN/VLG^CHJ)T5GVNB]_7J!N.          *1_'P^8&+_J7P\D Q
M                           !RG>GXIY@4?W>/R4"0
M             %F?2GCYJ!$                          +?D_3\@(@
M             )2_2G]*NZO8G9\%5R=%_AW@:</;;F^[S#]Y+THG6/G%@K?2
MG7N9Q[UU&KE3N3K]M>J_R W*          %(_CX?,#%_U+X>2 8@
M                   Y3O3\4\P*/[O'Y*!(
M    "S/I3Q\U B                          %OR?I^0$0
M    $9TZQK_6YB-<QRJU.J^EKT5R>*(!IY]N*GD@YF^\C'+"R'U\S=<5;$8]
M'_=94<>,#?',Y4ZHUTC4153O1>\#<8O\NX          I'\?#Y@8O^I?#R0#
M$                           '*=Z?BGF!1_=X_)0)
M              69]*>/FH$0                          M^3]/R B
M              E,BJUJ>CU)]R-5Z+T5$1Z+UZ=4]2?Q0#3Q[<D<=/S-]Y#I
M*KTDYEZWD55]2^B2;CS@JK$B+W(Q5Z)\ -Q@         !2/X^'S Q?]2^'D
M@&(                           .4[T_%/,"C^[Q^2@2
M                LSZ4\?-0(@                         !;\GZ?D!$
M               !B]$5$Z_!S%\?4@&G;VZOZN97O'=>].96M/X=S>/6!>GN
MZ=R(!N,7O7\5 X         4C^/A\P,7_4OAY(!B
M       #E.]/Q3S H_N\?DH$@                            +,^E/'S
M4"(                          6_)^GY 1                82.]+>J
M]R.:J]._L<B]WX(!IT]NMJMYG>\@U?\ ^\G5[OY?\SCM@3_)W^(&X]>]?Q4#
M@        !2/X^'S Q?]2^'D@&(                           .4[T_%
M/,"C^[Q^2@2                             LSZ4\?-0(@
M               !;\GZ?D!$               !.942->J=>JIT_EW_ ,.H
M&G[V\6-3F=[QOQ5>8>K'JJ+W)_TXZ^7M_AT7J!N%_P!O\_X@         %(_
MCX?,#%_U+X>2 8@                           Y3O3\4\P*/[O'Y*!(
M                           "S/I3Q\U B
M   %OR?I^0$0               '"IZD]/=ZNB=?X?!?]B@:K.!-)3KR>]UB
M>*F6GJG\S<3_ '56K51M<R#0.L71,1WY_LP5#F?R50-J@         !2/X^'
MS Q?]2^'D@&(                           .4[T_%/,"C^[Q^2@2
M                         LSZ4\?-0(@
M!;\GZ?D!$               !B]51OJ3JG1R=J?S[@-9O!3I_P!0?N@(J)U3
MF?:E5%_@[C_J+HJ_R5% V:          %(_CX?,#%_U+X>2 8@
M                 Y3O3\4\P*/[O'Y*!(
M  "S/I3Q\U B                          %OR?I^0$0
M  &+^GI7KW?'I_#KV@:SN#+>G(WW16=55&\QL;D1?_2<=-.S>GI_W5?T_F@&
MS/KU[?X]O^(         !2/X^'S Q?\ 4OAY(!B
M      #E.]/Q3S H_N\?DH$@                            +,^E/'S4
M"(                          6_)^GY 1                8OZ>EW7N
MZ+_V[ -9W"!R)R7]TUB?4WESAJ^GIW+)QHTX[JG\W-[0-FB]Z_B!P
M  I'\?#Y@8O^I?#R0#$                           '*=Z?BGF!1_=X_
M)0)                             69]*>/FH$0
M        M^3]/R B                X<G5KN_IT[0-9/!Y5_ZI?=2C[.C.
M6FOI.OQ59.,NGT7L_EZ4 V;IV]H         !2/X^'S Q?\ 4OAY(!B
M                      #E.]/Q3S H_N\?DH$@
M        +,^E/'S4"(                          6_)^GY 1
M        8O153L7HO=^*KW(!K*X/M<G*KW5>O<[E;K9S43^'_3+J)/\ %?2!
MLV3N3\$ Y         4C^/A\P,7_ %+X>2 8@
M    Y3O3\4\P*/[O'Y*!(                            "S/I3Q\U B
M                         %OR?I^0$0               #KTZ?P]357P
M5.WP0#6;PB5K>5GNH)UZ+_U4ZT5>O=U=QDU'TZ+_ # V9          %(_CX
M?,#%_P!2^'D@&(                           .4[T_%/,"C^[Q^2@2
M                           LSZ4\?-0(@
M  !;\GZ?D!$               !X]4U70NZ*O5%:[HG>Y$7JY$[4^ &LWA%(
MLW+#W6&NCDB2+E+JUJ(]$3UHWC/J;I*Q45>K)%3JG^ &SI?Y]X         !
M2/X^'S Q?]2^'D@&(                           .4[T_%/,"C^[Q^2@
M2                             LSZ4\?-0(@
M     !;\GZ?D!$               !@]$5JIU1%5%1O7HG5>_HBKW+T0#6#P
M95?^K/W7T6?[ZIRIUAT15:KH6KQIU3Z8>C>YK.WIU[0-H2]Z_BH'
M "D?Q\/F!B_ZE\/) ,0                           <IWI^*>8%']WC\
ME D                            !9GTIX^:@1
M       "WY/T_("(               #Q:MOJ8Q.K&JLT;6N?UZ)ZG=%]*)W
MN<G8GP[0-87!BLIZWE[[L/[>%D"4O*75%#/]IWJ2:II^,NL/O3O_ *6^F67U
M)ZD[4[.\#:.G9V          %(_CX?,#%_U+X>2 8@
M         Y3O3\4\P*/[O'Y*!(                            "S/I3Q
M\U B                          %OR?I^0$0               'YMT:]
M\$;&?<57SQITC:U[E1J.>O1'*WM1&*O8J+V :K/;\K'U?,'W>?5(QZ4O,+6U
M(GVW->C&P\8]6=(WJU7>E[4<BJU>BHJ]P&V4          I'\?#Y@8O^I?#R
M0#$                           '*=Z?BGF!1_=X_)0)
M                69]*>/FH$0                          M^3]/R B
M                P<B*K%5$=T=V=?@JHJ=?QZ*!I]]ME7NYA^\RCG*]4YQ8
M.C5=^5G_ $O:A1K$_P"ZT#<(G8B)_(#D        !2/X^'S Q?\ 4OAY(!B
M                          #E.]/Q3S H_N\?DH$@
M            +,^E/'S4"(                          6_)^GY 1
M            82=S>U419(VJJ?S7IV_R U >W&S[7,GWEF(O3KS5US,J)W_\
M[C!J=RJO3L[43_8!N#7L54_F!P         I'\?#Y@8O^I?#R0#$
M                   '*=Z?BGF!1_=X_)0)
M     69]*>/FH$0                          M^3]/R B
M     G*G5K4[>R2-W9V]?2[KT_P U$>WIZ*?F=[QO5S42;F/J=4Z]>OW)>+^
MJNK5Z)V)_3V*!M\7M5?AV]W\ .         %(_CX?,#%_P!2^'D@&(
M                     .4[T_%/,"C^[Q^2@2
M       LSZ4\?-0(@                         !;\GZ?D!$
M      !@]%5$1._UL^*)T3KU5>WI\$ U;<"847E)[LJHUB/=S-PER]8V=51O
M&#2CFJLG3U=RJJ=>OI7KT[U VF          %(_CX?,#%_U+X>2 8@
M                     Y3O3\4\P*/[O'Y*!(
M      "S/I3Q\U B                          %OR?I^0$0
M      $9_P#PUZ+T7JB]?P[0-7?!1WHY7>[+$B]&IR]UM,B?'U3\7]-))U7X
MHJ1]?Y ;2E[.Q.[X          %(_CX?,#%_U+X>2 8@
M           Y3O3\4\P*/[O'Y*!(                            "S/I
M3Q\U B                          %OR?I^0$0               $YNG
MVW=45554:WIW>MW7T]?Y=0-6O!IK?^L#W:8$=U5O*?4=0O3JC4_<<7=6(B=_
M:Y'Q]O8G<@&TX          I'\?#Y@8O^I?#R0#$
M       '*=Z?BGF!1_=X_)0)                             69]*>/F
MH$0                          M^3]/R B                E,JHSKZ
M5=T<Q51%Z=.WZOT@:LN#$JR<SO=Q3THU(^3>E&=/][IQ@UI_7^KL VI
M     %(_CX?,#%_U+X>2 8@                           Y3O3\4\P*/
M[O'Y*!(                            "S/I3Q\U B
M           %OR?I^0$0               &+V^IOI[>U43L7IU[>G1?^ZOQ
M_D!J"]NF>2HYD>\>^1[W^CF-K:!GK<KE;'3<<]=0,:WJJ]&-2/HB?! -OX
M       !2/X^'S Q?]2^'D@&(                           .4[T_%/,
M"C^[Q^2@2                             LSZ4\?-0(@
M             !;\GZ?D!$               !PO=U3O3HO^"]?D!J"]O>%M
M)RS]WVK@@K5EK>9>$1ROG8R*EEDBT#@4;?[;(BN=.L3')]Q'=.C^J)V ;@%Z
M>EO;_4G3KT[.O9\>GQ Q         4C^/A\P,7_4OAY(!B
M             #E.]/Q3S H_N\?DH$@                            +
M,^E/'S4"(                          6_)^GY 1                <
M+WHW_>[/PZ]GS UC<$K="S?GN8UK9W.FJ^9L+GQN:GI@=1Z<P&&-6*G17+*R
M1>O7N V=KWK^('         "D?Q\/F!B_P"I?#R0#$
M         '*=Z?BGF!1_=X_)0)                             69]*>
M/FH$0                          M^3]/R B                Q<J(G
M;WKV)_%%_BGX?$#6=P05/]>?<S:JIU9S-B54=W)Z]-ZWD;_BUR*!LT7O7\0.
M         %(_CX?,#%_U+X>2 8@                           Y3O3\4
M\P*/[O'Y*!(                            "S/I3Q\U B
M               %OR?I^0$0               &+D16]J]/AT_CZD5O^SJ!
MK'X'2,GY >YXUB]C.9]%$Y?X/;I362/3P=U\ -G2KU[?X]O;_,
MI'\?#Y@8O^I?#R0#$                           '*=Z?BGF!1_=X_)0
M)                             69]*>/FH$0
M      M^3]/R B                A4_=^U_P F-)7H]B_;5RL]34=U7HY.
MY?Q[ -6GMXW"BNN^O=-EH*K]W'1\[ZVU53OM_;^S7VW2NKH:RD[_ .O]M*Y&
M^KXJ!M2          *1_'P^8&+_J7P\D Q
M !RG>GXIY@4?W>/R4"0                            %F?2GCYJ!$
M                       +?D_3\@(@               ,'N]"-=V_6U.S
M^*]51%_DO0#3_P"UX[_XV>[AZ5Z__P"2G.41%3M1':@U,_IV=.WUO7P W!K_
M #[P         "D?Q\/F!B_ZE\/) ,0                           <I
MWI^*>8%']WC\E D                            !9GTIX^:@1
M                   "WY/T_("(               #QZE7)$GIZ?\ B1=>
MO\/N-7L\4 U"^U]Z6[U]W=G3IT]R?+I%ZIV?\S2>G7=47IV@;@U[U^/;W@<
M        *1_'P^8&+_J7P\D Q                           !RG>GXIY
M@4?W>/R4"0                            %F?2GCYJ!$
M              +?D_3\@(@               )3*C8U5R=4ZM\%Z]47PZ :
MA_;*]#=\^[LQJN^ZWW'\A=,BIV(V;1&F)8NG9^9K^OB!M]          *1_'
MP^8&+_J7P\D Q                           !RG>GXIY@4?W>/R4"0
M                          %F?2GCYJ!$
M  +?D_3\@(@               (S]K$3^,D2?_M&@:E_;7HI*+??NX7!TE.Y
MEQ]Q:[I&QLK998UI>/.C(W?N(D7K3^O[B>CK]2)U[@-MZ]R*B+T7IWJG9U;U
M X         4C^/A\P,7_4OAY(!B                           #E.]/
MQ3S H_N\?DH$@                            +,^E/'S4"(
M                 6_)^GY 1                2F^CK_NN8J?BCV] -2_
MMT1TC-]>[<V*"X05,GN+5:S2S0HEMJW/XT\?G1-H94?ZWR1*Y[JE5[&=6=$[
M0-MW:K&JO3M:U7>GJK?5Z>WTJO3J@'         "D?Q\/F!B_P"I?#R0#$
M                         '*=Z?BGF!1_=X_)0)
M           69]*>/FH$0                          M^3]/R B
M           E-_X;OQ9_]MH&JCVY(HI=X>[0CV(Y$]Q^[I\?ZG,XQ<;'HY>W
M\OW.G@!M=^*]O1/@W^"_%>O\% X         4C^/A\P,7_4OAY(!B
M                    #E.]/Q3S H_N\?DH$@
M      +,^E/'S4"(                          6_)^GY 1
M      2F_P##7^;F)_C(U -5?MP?_KC[M*?_ /2&\_[>+W&A?F!M9
M   *1_'P^8&+_J7P\D Q                           !RG>GXIY@4?W>
M/R4"0                            %F?2GCYJ!$
M         +?D_3\@(@               )3IUC_!\;O_ #9&KY :K/;@7KO'
MW:?_ *D%X3_#B[QH3Y ;6          "D?Q\/F!B_P"I?#R0#$
M                 '*=Z?BGF!1_=X_)0)
M   69]*>/FH$0                          M^3]/R B
M   \>IE;$R/JCE66>&!OI:KOZI'=.U$[4;Z>O;\ -5OMO>G_ %P]VE6JJHON
M17OKU_WDXP<:FN1$7X(YJ@;6@         "D?Q\/F!B_ZE\/) ,0
M                   <IWI^*>8%']WC\E D
M    !9GTIX^:@1                          "WY/T_("(
M    #%S&O1/4G<YO3^+5=U:CD7X.3KV :D?;%EDFW+[N#I%5RM]SC.(6JO\
M^'#QZX\QL;U_@QJ= -N          !2/X^'S Q?]2^'D@&(
M              .4[T_%/,"C^[Q^2@2
MLSZ4\?-0(@                         !;\GZ?D!$
M5OK3I_WFJB_P5%ZI^(&H+VM5=_J[[NGJ[_\ YHNR^G_"FC-"-;V_@T#;Z
M       4C^/A\P,7_4OAY(!B                           #E.]/Q3S
MH_N\?DH$@                            +,^E/'S4"(
M             6_)^GY 1                /BG>J]4Z=%Z?%._^(&H/VN7
M_P#QD]W9G9_1[G>P7-3IV^J71>AT[?XHJM[/Q V^?AW          %(_CX?,
M#%_U+X>2 8@                           Y3O3\4\P*/[O'Y*!(
M                       "S/I3Q\U B                          %
MOR?I^0$0               &+G>GTK_WD3X]J]>QO9W=5 U"^V"YC-Y>[O$U
M6]4]RO+)5=U1$5TNBM'R^CLZJKV_:5%3^ &WQ>SL_@          4C^/A\P,
M7_4OAY(!B                           #E.]/Q3S H_N\?DH$@
M                      +,^E/'S4"(                          6_
M)^GY 1                8O15]/1?2J/8O7O3HCDZITZ+VJ!J\]MZ!O^??<
MQG9!11+4>X[MA\DL4'HJI_M:ZU)!]RLEZ]:B2-C/3$[\L;4;\ -HH
M  !2/X^'S Q?]2^'D@&(                           .4[T_%/,"C^[Q
M^2@2                             LSZ4\?-0(@
M        !;\GZ?D!$               !RG>GXI_AU3K_L UB>W5TCV%[DT;
M6HB+[AVTG=4_,LFN=82JJI_'J!LZ          *1_'P^8&+_ *E\/) ,0
M                        <IWI^*>8%']WC\E D
M         !9GTIX^:@1                          "WY/T_("(
M         #A5Z*U.O15<WI_B@&L3V\'M=LWW+(D[$B]P78+U1.S_ ,76.KNK
MOU.1>H&SSL^'=\/P^          !2/X^'S Q?]2^'D@&(
M            .4[T_%/,"C^[Q^2@2                             LS
MZ4\?-0(@                         !;\GZ?D!$               !PJ
M-56]>]'M5/X=X&I;VO:ZHN>Q/='J:AKHY8_<HW#0-:YR/Z06[!];TL'14ZIV
ML8G9\ -M0         !2/X^'S Q?]2^'D@&(
M   .4[T_%/,"C^[Q^2@2                             LSZ4\?-0(@
M                        !;\GZ?D!$                Z]K4_B]O7_$
M#4-[5#D7/?=,3O\ 3[G&\E=\?JQ+7J(G^P#;SW]H         !2/X^'S Q?]
M2^'D@&(                           .4[T_%/,"C^[Q^2@2
M                    LSZ4\?-0(@                         !;\GZ
M?D!$               !PO>S_P!(SS T_>U(]7[!]U+JB)T]S7=JKT^'7%<!
M3HO7K\$3_$#<$          4C^/A\P,7_4OAY(!B
M       #E.]/Q3S H_N\?DH$@                            +,^E/'S
M4"(                          6_)^GY 1                .G7TK_!
M[/,#3M[4DB)LCW7$[O3[FFZ.J=4^.)8$O7HU55.OI^/0#<2          4C^
M/A\P,7_4OAY(!B                           #E.]/Q3S H_N\?DH$@
M                           +,^E/'S4"(
M   6_)^GY 1                .OTI_%[/]B@:J?:]MU%%>/<EKHJ=D=57^
MYMR._>3-3H^I_:637<-/]U?S?:CD5$_D!M6          *1_'P^8&+_J7P\D
M Q                           !RG>GXIY@4?W>/R4"0
M               %F?2GCYJ!$                          +?D_3\@(@
M               .%[V?\;?,#5O[8/\ [=[C7_U-^2W_ +IUN!M)
M  *1_'P^8&+_ *E\/) ,0                           <IWI^*>8%']W
MC\E D                            !9GTIX^:@1
M         "WY/T_("(               #A>]O\ Q)T_'X?XJ!J\]L?[25_N
M,+&YJL7W-.2?:UR.17+9];*Y.O5>U%4#:(          4C^/A\P,7_4OAY(!
MB                           #E.]/Q3S H_N\?DH$@
M              +,^E/'S4"(                          6_)^GY 1
M              8JO;'_ #D;_'IT3M7N1>WHG9_,#53[6,K9)_<85L,4*)[G
M/)=BPP3MJ(FJVU:X17-F;U15?TZJGY5[ -K*]Z_B!P         I'\?#Y@8O
M^I?#R0#$                           '*=Z?BGF!1_=X_)0)
M                     69]*>/FH$0                          M^3
M]/R B                X56HK?5W>MB)U_WE<GI\>H&HGVD%8B>Y)$WHGV?
M='Y1M]"=S&NH]?/C:GPZ?;<B]/Y@;=P         "D?Q\/F!B_ZE\/) ,0
M                         <IWI^*>8%']WC\E D
M          !9GTIX^:@1                          "WY/T_("(
M          "<JHB,14>OJEB:GH;ZE:JO1$<O^ZC?][X :H/:HMLU%)[B]P<R
MGCHK_P"YWR@KK7^WG;,LE-14^!VB=\Z(BK#(M=;I?Z5[>G0#;&O\NX
M    I'\?#Y@8O^I?#R0#$                           '*=Z?BGF!1_=
MX_)0)                             69]*>/FH$0
M          M^3]/R B                )WI_Q-_P#M(!K"]L"-E/9><$3'
M(JM]R+EHUW8G8]<BLTBIU^*>EW5 -GH         !2/X^'S Q?\ 4OAY(!B
M                          #E.]/Q3S H_N\?DH$@
M            +,^E/'S4"(                          6_)^GY 1
M            <M3JJ)T^*+UZ]W144#5_[8CT?;N=*-Z*UON3\LD147KVI?+(
MCO\ !0-GX         !2/X^'S Q?]2^'D@&(
M   .4[T_%/,"C^[Q^2@2                             LSZ4\?-0(@
M                        !;\GZ?D!$               !POY>SJOW&=/
M\?\ R :G?:0K:FX83SCJ:U].ZJ7W.^;4,B4[_N,9%2;%AI:-KG*UJ_=;20,:
M[O\ ZD4#;&@         !2/X^'S Q?\ 4OAY(!B
M      #E.]/Q3S H_N\?DH$@                            +,^E/'S4
M"(                          6_)^GY 1                <>E'*WKU
M['-7L7XHY%3_ &H!J#]G)RNUMS?<O17?_--Y[,5W1/5Z&[?JT8CG=[O2U$1/
MX ;?4          *1_'P^8&+_J7P\D Q                           !
MRG>GXIY@4?W>/R4"0                            %F?2GCYJ!$
M                     +?D_3\@(@               .4[V_B@&G#V:IWK
M@//&)4=Z8/=5YXL;ZF*U%C=M=\CG-<Y$1S7/D=TZ*O:U4 W'          %(
M_CX?,#%_U+X>2 8@                           Y3O3\4\P*/[O'Y*!(
M                            "S/I3Q\U B
M    %OR?I^0$0               !/J;_P 2?,#59[1T;/\ 1[E5_0U/5[E?
MN#J[THC?4[_J4S5J.=TZ>IWI:B=5Z]B= -J:=G8          4C^/A\P,7_4
MOAY(!B                           #E.]/Q3S H_N\?DH$@
M                   +,^E/'S4"(                          6_)^G
MY 1                <IWM_% -5OM&__H]RH_E[E7N#I_AR4S9 -J(
M    !2/X^'S Q?\ 4OAY(!B                           #E.]/Q3S H
M_N\?DH$@                            +,^E/'S4"(
M            6_)^GY 1                <HG547^#F_A_!>H&J+V?JO\
M?Z0Y.UOVGP)5^Y'[@TZ0R*BO8UW);.$:CE:JHJN:B+V?Q VN          %(
M_CX?,#%_U+X>2 8@                           Y3O3\4\P*/[O'Y*!(
M                            "S/I3Q\U B
M    %OR?I^0$0               '+>].].U.[\>Y?Y*!J#]EF1[^-_(:5[E
M?(_W$^?\KE=WJLG)7-G*G7X^GU]$_DB ;>P         "D?Q\/F!B_ZE\/)
M,0                           <IWI^*>8%']WC\E D
M              !9GTIX^:@1                          "WY/T_("(
M              #A>O5G8JIZV]>G?W]B_@B]_P#(#4S[.=DGLW&S=[YI:>=E
M[Y[<ZK_2-I7*YM+2W/D?FCV4TJKVK/%)"[U=_>!MG[P         "D?Q\/F!
MB_ZE\/) ,0                           <IWI^*>8%']WC\E D
M                      !9GTIX^:@1                          "W
MY/T_("(               #E%[4[^US>[^/7LZ_R U5>SO>:#(>)N87^UP.@
MH;SR_P":-;$UR]5<DG)+8K5E551%ZR.BZ^(&U0          I'\?#Y@8O^I?
M#R0#$          >IK>U_=^*)VJO\55$ ^=8;M; L_O^>XQB.24=\ONKLH7#
M\_M=/'4PUF,9 ^W4MW@M]?#5PT[G_N+;712QRQ?<AD:O]+UZ ?10
M      .4[T_%/,"C^[Q^2@2                             LSZ4\?-0
M(@                         !;\GZ?D!$                [>K>B_F;
MV=.J*G5.O5?AT0#4%['S43@W6JURN1>5/,MSO5V+&YW)C9*K'T[?I7L^ &WT
M          I'\?#Y@8O^I?#R0#$          Q<U'M5KNO1>Q>G8O3\0/R:6
MQ6NBN%9=*2DIZ>NN*P.N=5#3TT51<7TL*4U*^NJ(X6U%4ZEIV^B/[CW(QO8@
M'[               '*=Z?BGF!1_=X_)0)
M   69]*>/FH$0                          M^3]/R B
M   Y:G54_%%_P7K\@-/_ +(+9(>$V0Q=B_;Y=<T&-:J=?2W_ *E-B+Z>_IU1
M7*H&X!>]>G=U[ .         %(_CX?,#%_U+X>2 8@
M         Y3ZD3X]B^'>!1_=X_)0)                             69
M]*>/FH$0                          M^3]/R B                (B
M]6JU43HY.O7XMZ]J)_-0-5?LUT$-!PNJ%@9"Q:SDWS#K)_L1K$UU2_DQLZ"5
M[D5SE61WV.U?B!M4          *1_'P^8&+_ *E\/) ,0
M            <M[']>U>J>G_ &IT\@*/[O'Y*!(
M       "S/I3Q\U B                          %OR?I^0$0
M       !$ZN:O\%3H!JP]G*ICJN&-1-"]DD#N3G,C[#XU16/A_ZH-INC<US?
MZ7-5J]Z ;3P         "D?Q\/F!B_ZE\/) ,0
M     <IWI^*>8%']WC\E D                            !9GTIX^:@1
M                          "WY/T_("(               "-0B+#*B^I
M$6*5%5J]'(BQ/ZJU?@Y.]/Y@:A?8Q_I]ORPQ]7.^SR$Y<PH][E?(]&<F-GIZ
MGO7M<Y?BH&X           I'\?#Y@8O^I?#R0#$
M      '*=Z?BGF!1_=X_)0)                             69]*>/FH
M$0                          M^3]/R B                G-V0S*G>
MD,O?_P"C<!J"]C"2.;V_K+)$YKV.Y#<N%1S.UKNO)39CO4B_'U=>H&X$
M      I'\?#Y@8O^I?#R0#$                           '*=Z?BGF!1
M_=X_)0)                             69]*>/FH$0
M            M^3]/R B                \2O;ZJ&M:O<ZDJF+U[NCJ>7O
M U@^S3;+;:N .M(;70T]!#49_OROGAIF>B.2LKMY[ J*JH<BJY5DGE?ZG+U[
M5 VD@         %(_CX?,#%_U+X>2 8@                           Y
M3O3\4\P*/[O'Y*!(                            "S/I3Q\U B
M                    %OR?I^0$0               'B5Z^FAK7(U7JVCJ
MW(U%Z=52GD7T_B[N UD>S8C'^WKIJKC21L=QR+<UQCCE=ZI86U6Y\]>D+U[_
M %1].G;V@;0@         "D?Q\/F!B_ZE\/) ,0
M      <IWI^*>8%']WC\E D                            !9GTIX^:@
M1                          "WY/T_("(               #\F_R+%8K
MV]J]'MM%S<Q4Z]4<RAJ'HJ?AZ0-4GL55%36>UOQFKJV1TM77-VG65$CE55=+
M4[BSV5W>JKT_J[.U>B ;<0         "D?Q\/F!B_P"I?#R0#$
M                 '*=Z?BGF!1_=X_)0)
M   69]*>/FH$0                          M^3]/R B
M   _+OB=;)>41$ZK:;DB=>[JM%.G\_X@:HO8I_\ ]67%_P#_ ';:"?P[MQ9\
MU>SX=%3H!MQ          *1_'P^8&+_J7P\D Q
M     !RG>GXIY@4?W>/R4"0                            %F?2GCYJ!
M$                          +?D_3\@(@               / NS4?:KH
MQ5Z>NW5S/Y_U4DR*J?@!JI]C:BFH/:WXNQS-E8LM'M"IC;,ST/\ LS[EV"^)
M>G1.K%;VM7XIV@;90         "D?Q\/F!B_ZE\/) ,0
M           <IWI^*>8%']WC\E D                            !9GT
MIX^:@1                          "WY/T_("(               #Q+@
MSUV^O:GYJ*K;_P"=33-_Q[0-:7LUN1?;.XJHG;Z,9S>+K_Z':^>Q?_< V<
M        %(_CX?,#%_U+X>2 8@                           Y3O3\4\
MP*/[O'Y*!(                            "S/I3Q\U B
M              %OR?I^0$0               'A7*18K?7R)U_Y=#6/_CVL
MI97)V?'N UD^RY4)5^V'Q0JNG3]QC6=RJG9WOVWG[E[OYKX ;0P
M"D?Q\/F!B_ZE\/) ,0                           <IWI^*>8%']WC\E
M D                            !9GTIX^:@1
M      "WY/T_("(               #\'*9GT^,Y%-$[TRQ6&\R1N5.OI?';
M*N1KN]/I<Q -7/L854M;[3_#>JG7U33X;FTDCO\ ><NV]@=5_EU VR
M    %(_CX?,#%_U+X>2 8@                           Y3O3\4\P*/[
MO'Y*!(                            "S/I3Q\U B
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M!B                Y1.O8@&#'LD1SHWMD:URL<K5ZHCVKT<U?YHH&0
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MJ_OU8JQ,1'(U.O:!V;7M55_F!P         I'\?#Y@8O^I?#R0#$
M                   '*=Z?BGF!1_=X_)0)
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M9O?;7C^/3Y-LG/)*"3([G;\6Q*AMN,8O9WI;8FT]#1P-9&U%<]TLCG2*':4
M!;\GZ?D!$                            "D?Q\/F!B_ZE\/) ,0
M                      <IWI^*>8%']WC\E D
M       !9GTIX^:@1                          "WY/T_("(
M                    %(_CX?,#%_U+X>2 8@
M     Y3O3\4\P*/[O'Y*!(                            "S/I3Q\U B
M                          %OR?I^0$0
M   *1_'P^8&+_J7P\D Q                           !RG>GXIY@4?W>
M/R4"0                            %F?2GCYJ!$
/         +?D_3\@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tv526458_ex1-1img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ )H  0 !! ,! 0
M       ) 0(#! 8'" 4* 0$                     $  ! @4"! ,& P0%
M!P8(#P   0(#! 4&!Q$((3$2"8'!$T%1<;$B%&&1H3(5%A="4G(C&.&"DK(S
M&3GP8C0E=;?1\:+"5B@X*5-SLW0F9C=WAZ=XF*BX"A$!
M     /_:  P# 0 "$0,1 #\ _?@
M
M                        %[.?AYH!E UP
M
M                                 O9S\/- ,H&N
MPS$=D!K.KBZ(]K&\]/J5$155$=QU7EH!\:C710;@@3,Q0JS1ZY+R=2F:1-S%
M%J<E5(,K5)%R0Y^FS,21F)EDM4)&(Y&Q8#U2+"7@Y$4#[_!>*<EY?#V
M
M                                  7LY^'F@&4#7
M 8')JZ%_\Y8OY:K^N@$-/9<EX$3%F\[Z$ANE>YCN_B(V$JLA>K_%M-Y0U^E$
M5D7C[%4"9Y>:_%0*
M                                                      O9S\/-
M ,H&N                /8B)"5$U7U6*O%?;P5?;IIJ!#QV<Z9,47'6]F1C
MN9]PSN6;N(D:&SJ5K$CW/1XC$1[D1(G5#5'=2<..GL F'7CQ
M
M                           O9S\/- ,H&N                JJ:*S5
M-4<Y/;RXHJ 1F=K^'#@V9NYZ&,AJ_N";JG1E:B)ZD5UTT[J=P3W_ " DS7FO
MQ7Y@4
M                                          !>SGX>: 90-<   IJG
M%?8WGSX>WB!7W\4X:>U/;\P          !<[BL-->2M5?TT_,",[MFHUMF;N
M/1>V)KW!]UNJM7JTZ;ND&]*\5T5K6@27ZZ\??Q_,
M
M                  "]G/P\T R@:X  !H5)TPR6ZY=KXKDB,58,)RL=$;K]
M37N:BNZ51/9HOX@=&8FQ=?\ 8%PY=K=TYSR-EFEY(O5MU6=:U[TNS9*E84H7
MV_I+85CS%L4&D52IT!(NL3UJM&G9S71/4TX >@D7J1%YZHG'P          ,
M<2&[^Y5K]-8['/\ IUZFZZHS75-$33\0(>NSY4)^HV5OHC1IF-%23[G^\*4A
MLC/ZVP9:#<M%1L*&FB=,-%B*NGO F)X+Q3E[/A[
M
M                  +V<_#S0#*!K@   "NJ^U55/<JKQ I\.          !
MBF.M/M^G73[F!KQ_HKKKX<0(BNS]3G4VRM]L*(U&+'[GV\6.B/X.<QUS4%&J
MK57J17=/)4U7GIHH$O:\U^(% /F5JIP:-2JA5IF++P):G2,[/S$Q-QVRLI @
M2,I'FXT:;FWZPY26APX*K$BN16PV:N7D!!%VK.XUN3WAYHO*T,V0;'HEJU[
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M[$NAEES^4&PIF\)B56KW!=$M.RU%MF4BS58GF2+HCVP/5AHX)#-R._ZVL"X
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MX+$KE3E[RA7M*QH\_(SLDR%#EY>5<V:APHL1K /<X
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MS*U,R$TZ/"?-+#B>I#C0XR)% \2W-VQ^WYBN<V[4J_LVY1M.R]N%%Q]<N/\
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MPK1L:=CV51)B3H.*IR>H-*I\[:TU)1$G)E\I,U%J5*/'8^*QS?3:'H
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M#J-*J<I"F):,B)$EX\-KX:M<B*!]Y(2)UJCWIZBHK^/4KN::*Y='::+HGL1
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M<D-R/Z--7-75O'7@CDX*J*BHON5- ,@ "G4W7IU^KGT_TM/?IS1NOMY*!4
M    %%;U)TZJFNFBHJHJ+KP5%3BBHH$3?:]J,U-7#W,:9&B5!TO;_<YS])R,
M*;BM?+08$Q:.,*O$;3H;6-6##CS$^^+%U5>N8B/?PZE EE
M
M                         O9S\/- ,H&N   :E1E&S].G9)SGM9.2LQ*1
MEAQXTM%]&8@O@Q5@S$N^%,2\;TWKTQ&.1[':*BHJ >5-E6T#'VQ["4/!>,[C
MR)==LP[VON^EK>4+KFKRNN-5+]N.;N&H2D>MSB,BS$C3GS+9>6U;U+"AHYZN
M>YRJ'K8 !JI)2S9QT^V'I-/@-EWQ$<NCH37=:(K>6J+[0-H      #VIQTXH
MFOQ5$]H$4/;$HTU(7!W*JM%2!]O<G<YW S4JD"'$9$5DA:V,Z%,K,=<1W4]8
MU.=HK4:@$KZ\%5/Q H  <_\ (!&5W-]U&XO9YAFQ,XX"L2V<RQ9+,N.;&O7"
M%0IE1;>V3[<ONNP*5,T_%-R2M:IU.H]_T^5]2))0IR5FY6>BIZ2HQW2C@ZQM
M/NFXTOK(%'R[0<FV)+[%8^P^M[H:]>55H%9E[XM^]Z+F25QK5;6JT6'/1(E/
MJ=O1GQ*7/4%:9$J3:TB0F.<KV, YK.=W[:%2J&L_=$WF6R+J@Y-QUB.>Q+=>
M!LC4W-%.N_,-&J5P8DC3>+&4N;N?^&\FR%+BLHU0A0HT"9F6^@KF1$<UH:=S
M]YG8Q9^%['SI6;YO9MLWW!R+.2]N)CBX(>0K5I>';L?9&8:K?EE34*2J=IR>
M,;E:LM54F%]=CF+Z$./HJ 2965>-M9#M*VK\LNMT^YK-O.@4>ZK3N.DQ?7I=
M?MVOT^!5*16*='T:L62J$A,PXL)RHFK'(O-5 Y0
M
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M4B_(][3%&BPK<K$S==TPOO9*%3Y.2E:;++Z#(?2B:!Z57FOQ H
M
M                 7LY^'F@&4#7                -->&FO%/SUU3\E A
M][6B1FY.[LT54?Z<;NB95=!>JJC8D-,082:Y8:\E8D1JIP]NH$P2KKQ]_$
M
M                                    "]G/P\T R@:X
M   !IKP]Z@0[=JW^\RWW<X2J[I@]T7)JM15^E&Q,+X/B:-3V?5$77W@3$JFG
M#W<
M                                          +V<_#S0#*!K@
M         *IQ5.:<4Y?$"'#M7N5N9.[ZB+P3NC9%1$_!V$,&.]WMU F.
M
M                                   O9S\/- ,H&N
M  ?^'C\/;^2 0X]K+1,S=W]$]G='R%^N"\$.TYK[5 F.
M
M                       O9S\/- ,H&N                JG--.>H$/W
M:_CQ'YA[M\J[T49)]SW("0DAP&0XJ)-X+P3/1/7C-573+O5F%1JNY-1$3@!,
M
M                                       !>SGX>: 90-<
M      !5.:?% (>NUXB_SJ[OO!?^)_>R_P#Y 8  F$
M
M                     O9S\/- ,H&N                *J(FJ\$0"('M
M>ITYN[ORJO!.YO>#N6J?5M^V_:(GO54<B^/Q E_7FOQ4"@
M
M                       +V<_#S0#*!K@               *.T5%UY: 1
M+]M":@S64^ZQ3)>62'-TGN69#AU"95C(?WBSV&\)566B^JW^\C.EY2=APOJY
M-AHU." 2TZ:<-==.&OO_ !\0
M
M  +V<_#S0#*!K@               *IS3XI\P(@NV"J_SQ[O:>[N:79^NWO;
M^OZ@2^KS7XK\P*
M                                                    O9S\/- ,
MH&N                )S3^TW_60"(CMB,5,X=WE4337N974NO#CIMXV^*O^
ML!+PO-?BOS H
M                                                 "]G/P\T R@:
MX                OFGMT]O/P B0[9R,3.O=U;#U33N3W ][=>3G[<MO:O=
M_GN34"7!>:_%?F!0
M                                                     %[.?AYH
M!E UP               #_)_E_0"([MGM]//W=YAIQ3_ 'CM6C*OXQ]N. 7*
MG^;HB 2Y+S7XK\P*
M                                                      O9S\/-
M ,H&N                H[73AIKJWGRXN1 (D>VZV/*[BN[U"CP^AR]PE)N
M$WFCI><VWX(6#%14X?WB,75/8!+@O%57WJ!0
M
M             %[.?AYH!E UP               %'*J(BISZF^[^LB+S_ "
M*CM[PH<#=!W<8<+]EV^2UYA45572+,[6\#Q8O!571'/55T3W@2LKS7XK\P*
M
M                                     O9S\/- ,H&N
M    1/H:UR(JJKF\.'M15^: 1-]NZ*Z+NE[O.NJ=.^:V&Z*J+P9MAPA!14TU
MT:J04X<T_0"65>:_%?F!0
M                                                          %[
M.?AYH!E UP               %.2+[4U151>/)=>'N4"(CMQQXB[H>[_ "CE
M:L.5WYT.)"T9TQ$=.;<<.Q8B/B:ZQ&HJ?2B_L@2\
M
M                   7LY^'F@&4#7                5335$7DJHGYJ!#
M[VY%TW8]XEFO+?1:433W=>VW$B*OP7T_T F!
M
M               O9S\/- ,H&N                >[XM_14 A\[<;7)NX[
MQ;WL>R$_>]9B0HKF/2%&>S;EBZ'$9"B.1&Q'0W)HY$UZ570"8,
M
M                            "]G/P\T R@:X               "J<T^
M*?,"(WMXUF+4MTG=RMJ+*P8<.V][MM3T"<;$BNC3:5_ &,IES(S'HC(:2CI7
M1G3P5J\0)<=-."\TX
M                                                        7LY^
M'F@&4#7                .6B_\YO\ K)^* 0_=N>6FY?>'WB:A'E9F#3ZA
MO/Q_!D9R+!B,EYR)([><=P)ULK$<U&Q5E8RHU^FJ(JH!,$O-?BH%
M
M                              7LY^'F@&4#7                473
M3CKHJHGTIJO%43@!#WV\*I5)_>/WAJ#,5"/%I%O[R,:S]*D'JKH$G%K6WNPX
MU32&BKHULW,R[(CM.;FH!,*B:(B:JNG#5>"K^*I[%
M
M                    O9S\/- ,H&N                 0Y=N>$C=[O>9
M557^]W<XAU_#_P!7>RE\P)CEYK\5^8%
M
M         7LY^'F@&4#7                %]_NX_EQ\@(>.WDCH>]KO'^S
MJW98?7A[4?MZL]VJ_BK53\@)AP
M
M    +V<_#S0#*!K@               *+R\43\U1% A_[>J(N]SO':Z\-U>&
MW</?_A[L]O\ JH!,$O!53\0*
M
M  O9S\/- ,H&N                HO+Q3YH!#YV]_\ VW.\9^&ZW#2?_P >
M;0=_YP$P@
M                                               %[.?AYH!E UP
M              #A[>6B_HFJ?J!$#V_6M;O=[Q*-]NZC"KE_M.VZV=K^H$OP
M
M                                      %[.?AYH!E UP
M     %KE:UKG/7I:B?4ON3E\U B6V&2L*%OA[OR0EZ?5W+8(CQ.KA_>1=M]F
M1'KI[E=$X+[0);%X*J>Y0*
M
MO9S\/- ,H&N                QS?0V75SN#5Z4>JKHG0[@[55X)P BQV3-
MZ=\_=P1L/H5<[[<7JNBIUN=MILY5?Q54553VH!*FO-?BH%
M
M                        7LY^'F@&4#7                6S"L]%.I4
MYMT1>3EY=/CK^8$5>R)'MWS]W%7O:Y[L_;=%16N5>F%_AHLU(3':HBHYJ)Q3
MD@$JZ\U^*_,"@
M                                                  +V<_#S0#*!
MK@               -2=AOBPV-8WKZ8D-Z-ZE:FK4<J_4GU-3JT C!V7>JW?
MCW;61'(YB9AVQQH2(WI5J1-M-L:ZKPZE56<P)25X\0
M
M                    +V<_#S0#*!K@               +7?LNXJW@O%.:
M?F!%WLW3IW\=VENJ_P#VH[5XJHJ\$]3;91&\.'MZ-0)1DX\0
M
M                          +V<_#S0#*!K@               +7?LN^"
M\^6OL_4",+9^C8?<![LO7P1V0=I#]/>U^VZEHCO\YS5_("3]=/9R]GP
M
M                                  O9S\/- ,H&N
M HO)?S_+B@$86TKAW".[%#1%T2\]G<7CSZHNW"3:[3WM^C5 )/UYK\5 H
M
M                                  "]G/P\T R@:X
M "CN*:>]4^: 1@[2^'<1[LC%]ER;,HGX?WFW9ZHNOM71OAH!)^
M
M                            !>SGX>: 90-<               !9$54
M8JIS333V^U (PMJ7T=QCNS-3A_UMLGC<?ZS]NTTBZ:^Q?30"4
M
M                            "]G/P\T R@:X               "UW+_
M #F_JY$ C!VL?\2#NQP]>*S&QIVNO#2)M_K#4\4Z )0%X<
M
M                         +V<_#S0#*!K@               +7\&Z^YS
M?]9 (O=JZ_\ O*.[*FNOU[$'HGL1'8#KR:HOM158H$HJ\U^*_,"@
M
M                             +V<_#S0#*!K@               +7_L
MK^''_15%T^*Z 1;[5N/<I[L&NB(LIL)?K_53^1-V*J>'1^H$I2?E^'N
M
M                                  O9S\/- ,H&N
M LB*J,<J)JNB\.>NO "+/:J[3N:=V>&JKTPZ9L#X?'!EZZKIRUT8!*>
M
M                                 !>SGX>: 90-<
M!1>2_!?D!%?M537N<]VM/?3=@7_<;>Z>8$J(
M
M              %[.?AYH!E UP               %K_ -EWP5?RX@15;4O^
M)OW95]JR';]U7_\  B]U^8$JR<D^"?("H
M
M          +V<_#S0#*!K@               *.XM<GO1?D!%=M4:U.YSW:4
MXZ-IVP!R*JZ:=.#+V:G_ )*@2HIR3X)\@*@
M
M            O9S\/- ,H&N                HO)?@OR BOVK?\3CNV_\
M96P3_N,O<"4]O[+?[*?("X
M                                                           %
M[.?AYH!E UP               %%Y+\%^0$5^U7_ (G/=L_[,V!Z_!<&WLFG
MY 2H-Y)IRT3Y 5
M                  ?KQTX<>/N^(
M  7LY^'F@&4#7                47DOP7Y 17[5?\ B<]VO_LS8%_W&WL!
M*@G)/@GR J
M             !\:!19>!5WUA&1_NW2+J<L1TY..@_:?<?<,;]DZ(Z4]=(B\
M8O2D14X:Z ?9                                %[.?AYH!E UP
M           %%Y+^/#Q7@GZ@18;5D5.YSW:E5-$=2]@:M7WHF#[W;\T E/3D
MGP3Y 5
M          KU.7@J\/AY@4                                %[.?AY
MH!E UP               %D1=&*O]71W^BJ+Y 1<;6DT[FW=A_Y]&V#.3\-,
M*WXB_P"J!*2W]E/@GR J
M                                                         "]G
M/P\T R@:X               "U^G0NO+V_ "+?;"O3W..ZTU.'5;FPQZ)_6;
M_)Z_H:.\%:J 2E
M                                                     7LY^'F@
M&4#7                61.,-Z?@!%MMG1&]SONH)K^U9NPMRK[E;BS)#=$]
M^J(@$IFNO'W\?S
M                                                     O9S\/-
M,H&N                M=IIQY:HB^*H@$7&VYR)W/\ NBMT_;L'8A$:FG-J
M8XR:S5/@X"4I>:_%?F!0
M                                                         %[.
M?AYH!E UP               %D3]AW@OY*B@1=;<V='=%[FW3K_>8QV*1%_!
M6V1E2&B)[TTA_F!*0
M                                                       !>SGX
M>: 90-<               !CC*B0HBJY&HC557+R1$XK^@$6FW688[NI=S*&
MU>IT+$^Q57Z<M?X0RI$3QZ(B+\% E/3@B)[@
M
M              +V<_#S0#*!K@               +(J,=!>CTU:J]+D]JM7
M@O/AQ0"*S;M#;#[K/<PZ-$28P]L6BO75%57-M3*DNC]/Z+?3AHG@!*L
M
M                                 !>SGX>: 90-<
M!:]-6/1>*=*KI[U1%5/U BFV],6'W7NY7P5$B8*V-O:O'BV';N78:\_Q33P
ME99^PW^RWY(!<
M                                                  "]G/P\T R@
M:X               #!-/="EHL1O[34;IKRU5R)Q\ (M<"N5>['W#X2:(C]O
M&R&(]NG!SU@9HA\_:G0F@$J"<D^"?("H
M
M         +V<_#S0#*!K@               ,<9C8D)['IJQR)UIKI]**BJN
MJ\M$34"*C D=C^[=W%(3'(JP=NFQY%TU^CKA9G>C5Y<5:Y%3X@2M)R3X)\@*
M@
M                                      O9S\/- ,H&N
M     PS/_1YC_P"(B_\ R;@(H< *Y>[OW$8:+P=MLV.1431-7(C<RM<]5TU5
M>EFGP0"65=-5TY:\/@!0
M                                                         %[.
M?AYH!E UP               &*.G5!BIKIK#?Q]WTJH$1^W>HMFN\-W*)=(2
ML_=>W+9#)JY7:^HCI/,$TCD3V:),:> $NB<D^ %0
M
M                 7LY^'F@&4#7                5375-$U77DOM3V\_
M;H!#UMNAP6=XKN<NAO<]\3;[LC=&1R.3HB)3LMHC&]7!6HQ$75.'$"8-.2?!
M/D!4
M                                         %[.?AYH!E UP
M        %6\_!?DH$.^VQ=>\AW.6<D7;[LAUUY*KI#++4X\^ $PR<DTY: 5
M
M                                    !>SGX>: 90-<
M   !1>2_!0(>MMW'O'=S5OM7;_L>=P1-51)7+2?A_5 F%3DGP3Y 5
M
M         !9ULZTA]2(]6]70JIU:)IJO3KKPU O                   "]
MG/P\T R@:X                O)=4UX+P\ (I-NEN.9W4^Y->#(C6?=XMV:
MVSIJKHG_ %=;^0:DYR0E_N]%_>+DZEX\4TY 2M-14:U%5%5$1%5."*NG%4_!
M0*@
M                   P)+2Z1_NO2;]ST+#6-_36&Y4<K-?=JB?D!G
M             "]G/P\T R@:X               "B\$\4^: 1H[=G?^\?[C
M;>?_ -%-GD7\%:ZQ+M3YL74"2].*(OO
M
M          O9S\/- ,H&N                <^"@1F[>5T[DW<8;IP_@O9Z
MO!=.5G7LWY)^0$F:\%5$Y(H%
M
M  7LY^'F@&4#7                %X(J^X",W;WP[E/<83_ .I&SMW^E:%[
M\/#0"3->:_%?F!0
M                                                    %[.?AYH!
ME UP               %%TT77EHNOP C/V^M7_>7=QGW)C_9HO\ IV??ZZ_^
M2OY 28JJ+Q3BB\4^"@
M                                                        7LY^
M'F@&4#7                6O5R,<K6J]R)P:G-R^Y."@14;6*A-3_<^[J,&
M9C0XC*31=E,C*,AQ4>Z%+NQ/<L\](K$1/2=ZTPY43VH!*RB=*(W^KP_+@
M
M                                   !>SGX>: 90-<
M  !9$U]-VCNE=.#O=^($06SESE[IW>!ZG]73,;)FM3^HW^1$XJ(B^[5573W@
M2_IR3X(!4
M                                            454:BJO).8!%U R,
MY^'F@&4#7                61?]E$Y_P"S?RY_LKR_$"(79\Q&=U#N_::_
MWG^"*(NOO=@RI-5/@G0!+XG)/@GR J
M
M     *.3J:K?ZR*GYIH 1$3E^'Z(C4_1 ,C.?AYH!E UP
M&.*ND*(O]5CG?Z*:^0$16T/AW5>[VWVI([&HFGX/PC7E3Q5& 2\HFB(GNX
M
M                                     7LY^'F@&4#7
M    89C_ &$9-=-841$7W*K51/U4")K:93IB#W2.[G5T;K*3$OL7I[6=2(]T
MU"P579AR\?J1JPXGPX@2U\?;S]OQ]O+\0
M
M           +V<_#S0#*!K@               ,4=O5">FNFJ<_@J+Y 1A;3
MDT[D?=F7FCZAL;B-_LOV\U%$^"ZM4"4(
M
M          "]G/P\T R@:X               "R*FL.(B<U8[Y*!&'M31$[D
M_=A8W@B/V*O5/CM_KK?#Z8:?D!)^
M
M      !>SGX>: 90-<               !9%7IA1'?U8;U_)JJ!&!M4<B]R[
MNQ-Y=4#8?$14YZ/P/=+$3XZP_P!0)04Y)\$ J
M
M              "]G/P\T R@:X               #'%36&]--=6JFGOUX>P
M"+G:@_J[G'=FAZ_[.3V#(K?ZJNP5=ZZ?CJ@$I:\U^*@4
M
M                     !>SGX>: 90-<               !CB\(;M>'#S0
M"+3:=_Q0.[=[G2FP)WYX(N]NGY- E07FOQ7Y@4
M
M               !>SGX>: 90-<               !CBHJPGHFJ_2JZ(BJO
M#BNB-155=$Y(!%EM+>Q_<^[MO0YKE;*; F/1'(KH;_Y$7>Y8<1$559$1KD54
M7CHJ>\"5)>:_%?F!0
M                                                      %[.?AY
MH!E UP               %'*K6N5.:-=II[^E=/U ATV)]7^]#[TZN>]ZK>^
MQ]$5[E=TL;MYJJ-AMU5>EC/8B<$U4"8U>:_%?F!0
M
M                 %[.?AYH!E UP               %43JX>\"';8LBIW0
M.]%K[;TV0JGCM]K*@3$KS7XK\P*
M
M     O9S\/- ,H&N                JBZ<4YHBK^G("'K8SHG= [S^G_IC
ML?54]W_J^5CY@3"KS7XK\P*
M
M O9S\/- ,H&N                *NB+\%3\T5 (?-CC5;W1.] BKKK=VQER
M?YVW:JNT^*(H$PB\U^*_,"@
M
M+V<_#S0#*!K@               '!-=?<OR4"('9"FG=%[SR(G!;HV*.^*KM
MVJ_4OY@2_KS7XK\P*
M                                                       O9S\/
M- ,H&N                H[31=?+SX:@1#;)H:L[HG>75532)<6Q1Z:?CMZ
MK:+KHJ\> $O:\U^*_,"@
M                                                         +V<
M_#S0#*!K@               ,4=$6#$1>/T+IQ5.*)JG%./,")_9=*3Z]ROO
M"5F-#:VF3=V[**3(16KJL2:HFWF==4FNUXHL-:E"X<>8$LR\U^*@4
M
M                              !>SGX>: 90-<               !AF
M?^CQ=7.;^S]3?VD=K]/N^G7]K\ (JMESW/[C'=ZU:U.F_-GC6QF5-\='].W=
MJ>F^D/:G[NB0=$58R*J3:.333TP)7%YKKQ74"@
M
M               +V<_#S0#*!K@               +7HJMT1$5=6\%35.#D
M5>"ZIR BXV:.5>X!W:NIC$<W)VU)J16M:D5\+_#C2U:QT1/J>R&[JZ45=&JJ
MZ<P)24UT37G[?C[0
M                                                      +V<_#S
M0#*!K@                $8FS^$Z'OV[K3E8C?6R/M7B(J<W(FWBGLU=X,
MD[
M                                         O9S\/- ,H&N
M        H[7I73GHNGQT C,VC:IOV[J;%YK?VU2(B<_I=M\DVIQ]^J<@)-%X
M<
M                                        +V<_#S0#*!K@
M       *IIQUY:*OY(J@1D[2EZ-_O=1T_P#3':>_3WJN H#57X?1^@$FNNO'
MW\?S
M                                           O9S\/- ,H&N
M          LB+I#>ON8Y?R:H$9.TY4_W@O=-AZ\4N3:9$Y<$1^"XB(GQ14 D
MX3DGP0"H
M                                             +V<_#S0#*!K@
M            +7MZF.;KIU-<W7W:HJ:^ $86TN)#B=PWNI(Q[56'<.T>&]B.
M170WLP9$5W4G-OJ(Y%37V<@)/P
M
M    +V<_#S0#*!K@               ,4='.@Q$9JCU35JHFJ\.*\-%UU0")
MC9#-QYON*]X#UXL)_P!GDW:I)06,:]'PH#-O5.C,;$<Z&QKEUC*J:*[@H$M@
M
M                                      %[.?AYH!E UP
M     %4TXZ\M%Y_!0(?]B\1W^\>[R+47Z4RMM0X>Q%7;G3-5^/ "7Y.2?! *
M@
M                                      O9S\/- ,H&N
M     M>K48Y7)JB(NJ<4_5 (A-C'2[N.=XM&PW,<F5MJZNBJJ>G%3_#I2>#>
M&O5#Y: 2^)R3X)\@*@
M                                                       O9S\/
M- ,H&N                Q1T>Z#%:SJZU8O1T*C7=6J*G2KE1J+K[_8!%/L
MDAS"[^.[I%UA+)_SHVUP8+$8[UTFV[;[:B1GQ(RJO5 1(B:,3@BJO! )70
M
M                                    +V<_#S0#*!K@
M    $5VR'_VZ>[C_ /?OMT__ *SV>!*B
M
M          !>SGX>: 90-<                7AQ BMV0.1=]/=R1.:9WVZ
M:_\ [:+03R E2
M                                                    O9S\/- ,
MH&N                M<YK6JYRZ-1./CP^8$5.QKU%WT=W98K$8O\_]O36:
M?TH3=M-G>FY?Q<BZ@2L
M                                                          7L
MY^'F@&4#7                45J.16JY6HO-R+HJ:<>"\TY 1-;"J@M0WQ=
MW]71&Q'2>Y#!-/U9KTL;*;<+.ALA\4_VC$X.TX:@2S
M
M                     7LY^'F@&4#7                %T]O+S3E^H$.
M_;F1$WN=Y=J+RW;8E73GHK]N]F/7BO'BKN7) )B
M
M                  +V<_#S0#*!K@               &FJIKRU15^"+JOZ
M(!#QVZ$TWP=YG_\ 5GA_C\=N5DNT_'1% F'
M
M              O9S\/- ,H&N                PS#_2@1HGU:,AN<O3^U
MR_H\^($1W;VD_M=[G>+?K_TK=3AN8T5S55.O;?8Z\4:JJWBO#7V(!+N
M
M                                 !>SGX>: 90-<
M!:YO4US=$7J:K=%Y+JFFB_@H$5VP6DR,'=GW9:] F8D:>K.[7'\G/PG(J0Y=
ME"V]8ZEI-L-5TUZX<R[J_% )4P
M
M    +V<_#S0#*!K@               ''V<]%T_("+S87";#W0=U9S7=21=W
M]HOX.5S6N_P\XM1[4XJUKD<B]2<%]X$H8
M
M           %[.?AYH!E UP               !55$54X*G%%]R@10]NB<@3
MFX_NT+!:B.E=]DO)15Z7IJ^7P#B-575ZKU?4]>7#W 2O
M
M                       7LY^'F@&4#7                47S3YH!$;V
MTIETSN-[O:Q-$= [@T:5:B:?[&#M[POZ:KII]2N<X"7,
M
M                      "]G/P\T R@:X               !PXZ^Q%7\D5
M4_5 (>NV,WIW+=XI-5T=W"GQ-%5>#G;?L/(NFO)%:Q )A0
M
M    %%71%7W)J!9#B)$U1$5-/>!D                 +V<_#S0#*!K@
M            '/5/>BI^:*@$3/;7IL.6S_W<:BUCFQ:AW#JC"B/7U-(B26W;
M!*P^GK1&Z-2<5/IU0"68
M                                                          "]
MG/P\T R@:X               "J<%U]W'\N/Z@1<=NKAF;NIMZE7I[B%PKTJ
MNO2K]NFWM_@BM<B@2C
M                                                         7LY
M^'F@&4#7                6O71CUY:-<NOP10(M^W2YKLW=US3FG<1K".^
M*;:-N:?) )2@
M                                                  +V<_#S0#*!
MK@               +7IU-<W15ZDTT3FNO ")/MAU1]6S)W:YB(FCY?N6WQ3
M=-471E+P+@60A)P]J0I=-0);@
M
M   +V<_#S0#*!K@               "KIHJ>]/F@$.7:D>YV8>\"Q?Z'=*R=
MHOOZL(X)4"8T
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MFMA[H<-&M]!.NCKJB\UX^T"6H
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M/DOY*@%0*IS3XI\P(O\ ME<)KN$)IQ_WDNY15=[7*L"R%U7X: 2?@
M
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M>G[WJ<6HMC7W>R4^'78]+AQ6M2F4R)#I4#HEF:LAN153]I0.\0
M
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M'I8"]G/P\T R@:X               "BHBIHJJB+[N?D!7A[&HU/<B:?Y
M
M                                     %[.?AYH!E UP
M
M                                              O9S\/- ,H&N
M
M                                                      %[.?AY
%H!E _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tv526458_ex1-1img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ )H  0 !! ,! 0
M       ) 0(#! 8'" 4* 0$                     $ $   8! @0# P8%
M#0X""P   0(#! 4&!Q$((3$2"4&!P5%Q$V&1H;$B%#(5%CAX0E)B<B.UMA<W
MMQBX.;)#<R1TM"5U)C9V)W<H,S7P@I+2@S1EI6=8&1$!
M     /_:  P# 0 "$0,1 #\ _?@
M
M       "^3S^7U@#*#7
M                                                           !
M?)Y_+ZP!E!K@             P7%>6WDEGFDFGA-4DI?L].D(U(](33QFFEA
M+)#XQ!H4LS:UJT]O)3N8UJ<\*=62%":/X<\8](0C&,8>'3QZ_"'GX^ /K
M
M                      OD\_E]8 R@UP             8JUO1N)9)+BG+
M4DA5I5)83P\/Q:<T)Z<T/+]J6:'6 (W/;PW#;N1+_OJCO>UY_:X:%[AG/^AZ
M3#.Y*K?2ZMIFN6&DSX+5L'"M&:%EA,34OZ\:%O+^Q3FJS=/.()*.G3PZQCT\
M.L?&,>GQC'[0
M                                    7R>?R^L 90:X
M *U?"6E'[*M+]?3Z@BM]L&I"%Y[BGAY^YUW-=/'[;+0O_N@E2CYQ^^/ZP4
M
M                     !?)Y_+ZP!E!K@             Q5(S=:,)HQZ1N
M).D(Q\Y8?D^, 18^V/TEN_<3A#I"/_\ I[W,2_9YVF@RPA\^L02J1\X_?$%
M
M                       7R>?R^L 90:X             ,%:?K&A&/2$)
M+BG+]_6,)?D"+'VQOV[OW%(_"'N?=R\T/R^FST":'YX^ )50
M
M            7R>?R^L 90:X  .);M:[#?:QF['5LC4PV>O\;?X_%9>G1IW,
MV*R%_:5+.QRLE"O"-&M4Q-Q7A<PI3]*=2-.$)IH=>L Z,[..*.=.$NWS1N->
MY#GB][E^7M>ES$NS<S9#!6VN7>U27N;R-[B:=;%6U2K"G/B,37HVT:DTT9ZO
MX?6,8@]0         5)9:D*<O26;I4IS1A&'];&$?T1@");VG+N%]C?<#N8W
M$UW/4]S7NBEJ7$]/\.:I&E#2:<.LG26$/1+)"7K\80!+5'SC]\04
M
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MG1H4JM:O5JQFA3I4J-&>K4J3^B6:;TR0D\>D/($06K^[+4SEAQQS1G.U_?\
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MUH_N-7/:WD+.%7^!&XLJTD(^J2, =DQ\(QA^4%
M                                           7R>?R^L 90:X
M        +JGE2\>G[4/I^B((A?:7R-?(:7WKV%:WI48:][D?=)AJ=:VO[FO^
M^R2Y;7;Z6ZJ^NYKVU&K&6]A)&G0]%&6$L.DOJ]402\1AT\/L\/&/7],?&( -
M2^H3W5K5MY)I)(UI)Z4T:E&G<4_PZM.>G/"I;UH34J].,)_VI)H=)I>L 07]
ME7M9<S]K'..X<^W&2[6L9M>+XVS'$'%."XJU[F'$Z;DM?WGES <B<B;QO>#V
MO;<W3TS.WV&P-&PQFNZO^%K]A7I_C21EEJ3TX!.A?6E._MJ]G7]4;>YM[JTK
MRRQA+-/0NJ-2C4A":,(^F?T5/"/PB"#'4_;1[L+'C#A_L>VWFC@;*]@O!W)G
M%^V:]DL9IV[4NZ#?..>(.0+7DO2^&MYA=9&IQ596,,SC;*PR>:LX5+K(8VA-
M&%M0JU9IH!\O!>U=SK1X:V[C3<.0N#IK^':/S5VM<=YG!83;;RTM9^0>X6KS
M#K&][)8YFSIUK2[L\-+1H9*VLJE:$;Z6,U":-.'J!Y_C[%/*%7=>>K>XWK@O
M/Z!R+#O-W7CGD?9\AW#97FC5>2>[CB[9=$FQ]QI=??*O"6'U[4;[9JGX^:L[
M&XS.4Q-+]UGI4HS^N0/:'?WVU<N0[(>S'@OAO5M;Y#Y X:[DNP"A)0S&K9?8
M^.J5CPSNNITLWMNZ8+#20S5#CJQEP\UQD*]*2-6RM9_QO1&:3I$.FL#[17(F
M3S?)FV<N\Q\;VNW]P7"?>]IG(-/BS5L_B]>T7D+N]VC2,S;S\066<N*^0J:1
MHN(U&$EU/>W%'(YBYKU:L:=&%Q-"0.&WWM3]Y'*_&'+.S;QRKVN\2=TUCJW:
MGJ_:ON_ FI[O)H6F97M&V'9LIJ7)W(M'8[:GG+S9]QL-IN["XQ]C3JV6.Q<\
M+2$U>6,\(A]CF?V>>3[CB7B_CKAW)\+9:/$&E\!:YJ5[MV9Y2XNVS';/QYJ?
M)N W[D33^3.+;BKG-,VG8MBY)N,K5C-9Y"US%G7N\?>T/17A5@'.<G[:G=AJ
MU3A#E?6>2>WKFCN%X*J\,Y:>]YJT_.ZSH/+>P:+V_;SPAM>8S]MI=CDZVEY3
MU[;1R&%K8^TGDH36LTE6G+-4_$E#@O%_LY<CZ#QWONIYGD[BG,YS=.">V_1+
M:YL=<V"TU;3=]XP[O^2.ZCD>XT[#WDF2N,!Q_<S[[1Q>O6]*/[Q3GQ\E2XED
MA&'I#O?LX]OCGSMR[UN7.:9=EXQTKMTW*TY>FFXDXVVGDC9;'>]LY+Y6M^3,
M1OL-8Y*M<E+P9E<%5JY#^.L=KN7N,1G<IDJEW+;6T)82Q#MW@'L)W3BCNVO>
MY#9=DXWS&.KS=Y%2CCL/A,K+MDE3N3YPXZY*U2C'.7\DM*2TU;6M'K6U]++"
M,T]_>S349HT81A$(^MS]I3O-Y$[T]]Y^VGESBBYX\QNR=WNQ\;8R7-;9:39N
MEW,=O>Y<-:GC,CQGBM5L--T[.<?5=BHRY?8(WF7RFPVM'U33R=(4XAP/OD[
M^:.(N)-YW7B*SR>8YTS?$?MW<3]JDW!VBYC9,UQMW1=LE_M^,J\C[%1M<;2P
MV XMN\/LEQ0N<E>QI4);2YFIW,LLL82Q"=3M1X-O^VCCSC/@3#X34J?&7$G"
MW'6D:YM-C>W<^[['N>.HY>?D*[V2RGQUOCY,7?Y2I+D:%:E<UZE>]O[J:>G3
MZ0C,'K8%LTT)8=8]?E_].D.H,<EQ3J1F]$8Q]'3K'TQA+'K"$?":/A'I+'K'
MIY0!F
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MM]@DN;JXJ4;C\2XLIJ%.6%66%7K&2 =CQ^D/U0!0
M                                       %\GG\OK &4&N
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M6]6YHU:MM"$_X4\GXD\(ASP
M                       %\GG\OK &4&N  "G6'6$O6'JCY0^/QCY>?]3'
M\P*]81C&$(PC&'A&$(]>D?LCT\H@         K+YP^^ (S/;&CUXP[B>GC_[
MXNZ3_#F ),X^<?OC^L%        5A'IXP C&,?,%
M                                                      7R>?R^
ML 90:X  .H.>>(:'//$/(7#]WO7(7&MGR'KEYK=QO7$^QU=/Y)U62[]$T,SI
M>U4:5S5P6>M9Z<L:-Q"G/Z.D?V8]0<DXTTB/'&C:GI'\H=IVR35-<Q&NT]EW
M?-5-CW#/2XFRI6,<SL^=JTZ4^5SF3_!_&N:\99?Q*T\T>D.O0'.P
M7?P(R1\_5&$/LZ=?#K\>O3J"+'VML]B<CQMW.VUE>4[FMA>_/NEQ64DHPGFC
M9Y+^65"ZGLZL)I9/[M3HW,D9NG6'[0)38^,8Q^V(*   ^%LNRX'3L'DMEV?,
M8K7]?P]K5OLMF\YDK+#X?%V5O3FJW%[DLIDJ]M86%G;TI(S5*M6I)3DEA&,T
M80A&(..S<I<=T]<P.XW&]:3;ZCM-?#6FM;74VW R:QL-[L=Q1M-?LL%L$;R7
M#Y>ZSEW7DI64EO6J1NZDT):/KF\ <_AXPA'X1\O'K^KP
M
M  !?)Y_+ZP!E!K@             K#QC+U\>D8=.OP^X$0/M%V%_8:+WH1R-
M"_I6N2]R3NLOL//<T984JF-ES."I?O%E-+/-&-G-?T*LL(QZ1]<)@2^QCU\8
M>4?'\X   .);[:XJ]TG;K7.6>.R&(KZSGJ>1LLM;6][C;FTFQ5W"XH7MG=R5
M+:ZMJM+K">G/+-)-)&,(PZ _&%Q!KO*O:5V=]@7#<M//\]]B/>IRMV%[WP=M
MUU6LM@N^T/N1ASQQGO>Z<>YC*7U66UM^#>0+?&7^3UFO#U3XC-4[BPDAZ*]"
M6(>W,7[C'=EE]TQ&_P!ISKA+?;L[W^]V7:#OO91<:MHU_'C'B?B#5.7,OH_)
MF,C9XFAR?C=MQ.(T7%;+D\CEK^MA<EC\E-3IT:<LUO&(=.:=[E'?5Q#PKEN4
M=E[A\=W'9O?/:7X2[S,!8Y[COCS6M>XWW[/=PN*X<Y#V_"T^/L!2RV:U#5M-
MS-3-9:6_C?T:%:R_$Z4K?UTP3*>VYW'[9N&B[5;\^=Y/:[W$7FU\Z9?4NW_9
M>(N2].VR_P IBY]&Q.]W'%^7V76M;T/5=\Y UJUN+N]]&&QE.O0P\:4MU)^-
M1J5)@E=
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MZ_;Z80AU^?0%0
M                           7R>?R^L 90:X             'V??#X=?
MC#RA]OV?E!%E[64D:/'O=;-TSD)J_?YW05_5DYH36E2:.TV,DU37X3Q],N$F
MFDC"$8=(_CPJ>'VA*;X_'S^/3[?T
M                                                     OD\_E]8
M R@UP             5AYP^^'ZP1F^V/"$>,^XN:'6,9N^+NCZPC-&,L/3O,
M>D)(31Z4Y?'KTAX=8@DRCYQ^^/ZP4
M                                                    !?)Y_+ZP
M!E!K@             LJ23>NE-#R]5/KX_9-+&/Z 1K^V'4ECQGW(>?[7?)W
M30AX?&&]1Z_<"2N/AX
M                                           OD\_E]8 R@UP
M        5J?[U_;R?K@",OVQO#C3N-A#RAWR]TWZ=Z!)I'SC]\?U@H
M
M                 "^3S^7U@#*#7        !;-'TPC'TQFZ>?3X0^,8_DA
M &A;96SNY*52A-5GIU:]6VEJ0HSQDA6HQC+4EGFA_ A+/+&'6/Q@#Z(  *S1
MZ_A_V,TO7\\( C*]L7_)CW&?TYNZ?_#H$FL?./WQ_6"@
M
M       +Y//Y?6 ,H-<        #IUZ>'7QZ^?3IT\>O7K ''M<U'6].LHXS
M5L198+&QO,GD(V&+I?NEE&^S-]5R64O)K>E&%*:YOK^M/5J3QA&:,\T8@Y"
M "Z,(=:?3^NA&;IX^72/C]GD",;VP9HS\7]Q4\8=(3]\G=-&$/A#_MUX](_'
MJ"3B/G'[X_K!0
M                                    %\GG\OK &4&N
M "Z/[,9(_P!=-"'W=>@(S/;'C+'C+N*],.D(=\?=)#IY](PWF$(_GB"3*/G'
M[X_K!0
M                             %\GG\OK &4&N             !YQE_)
M-+T_)^U $9_MB4YH\9=QGV?Z<G=--&/V0CO76'Q^(),8^<?OB"@
M
M              +Y//Y?6 ,H-<             %8>,8?VT/T1A$$:/MB5/3
MQCW&=8>$_?#W1PC^3IO$.GW@DNCX1C#[(@H
M                                                          "^
M3S^7U@#*#7             !6'G#[X?K!&9[8W^3'N*_)WQ]TL/G#>>D?TP!
M)G'SC]\?U@H
M                                  "^3S^7U@#*#7             !
M6'G#[X?HC"((S/;&_P F/<5^7OC[I8_GWGK'],029Q\X_?']8*
M
M              OD\_E]8 R@UP             5AYP^^'Z8P@",SVQO\F/<
M5^3OC[I8?.&\](_I@"3./G'[X_K!0
M                                                    %\GG\OK
M&4&N             !#IUA&/E",(QC'X=(]>OR!%[[765Q>1XZ[G[7'7E.ZN
M,)WZ=T^+R]*3KZK#)R[C0NJEI5ZPA^W"A<TY_NG@"4./G'[X_K!0
M
M               %\GG\OK &4&N             !TZQA_;2^?C#^%#K#X><
M 18^UEB[BQT3NQO:W[O&&8[_ #NAO[*-O)0DGEM)-HLK2$EU^#86<\:_XEO/
M_P#$GN9_3TC&K&$82RA*?'SCU\^H*
M                                                     OD\_E]8
M R@UP             5AYPZ_;#]<.GZ01B^U_"I#C?N4C4NJ=Q#_ $[.Z6$*
M=.626:RECN<D86U>$L\\85(>KU?M=(])OLZ DZCYQ^^/ZP4
M
M          !?)Y_+ZP!E!K@             >/AT\^L/GXP\/R=01/>U+>Z[
M?Z3WCTL!CZ]KD<=[A_=+8[15J3PIR9;8*>:PMS5R%I_=*T\*$^.N*$G2,M./
MKDFAZ?C$)8?S_/QC\X_:
M                                            "^3S^7U@#*#7
M         !6'G#[X?K!%)[65GL7\A.["?+7MM5L[KW!NZ2YUB:UM[>WKV. _
ME-84ZEM?U*%&E/=WD<E3N/[I4C//-1C)",?#I )6X^$8P^R(*
M
M             OD\_E]8 R@UP             5AYPZ?;#]?C^@$9GMB?M<7
M]P\TGE-WP]TOY/&7>YI9H=?_ *H),X^<?OC^L%
M
M  7R>?R^L 90:X             $/.']M+_NH C&]K62M2XK[C:5S-":I#OI
M[K(RPA"$?3)-OU6:6'6'6'C":'W DYC^7S
M                                                          !?
M)Y_+ZP!E!K@             K#SA]\/T1A$$9GMC?Y,NXN;XS=\?=)&/SWGK
MX?G!)G'SC]\?U@H
M                                      "^3S^7U@#*#7
M   !67SA]\ 1G^V/+_Y8=Q48>/3OC[HX1\?'QWF'3\\(@DPCYQ^^(*
M
M                  OD\_E]8 R@UP             5AYP^^'ZP1:>US<VM
M7CONIH4+VM=U+7O[[I+7)27$E663$WL-QMJLUG;?BT*$*]M"A/3FEFDC/+UG
MCX@E*CTAX0\H>7W
M                                        OD\_E]8 R@UP
M     5Z=(R=?ZJ,.G3Y1\?O!$-[2<+:EJ?>]-5K9'K5]R7N=EZ9&2:6A1K3W
M^M22VN+FC--"KCY?X4LT.D/5--#X EYCYQ^'CY?9^;P!0
M
M        %\GG\OK &4&N             !'Q]/7REFEC#P^R,.@(I/:UP5'$
MZ'W7W-/)5;Z?8_<&[HM@A;W<*52EBJ]/:;#&0Q%I);SSST[62EC85I9YX2QZ
MU>L?"()6_P _S\_G^4
M                                          %\GG\OK &4&N
M       !UC#QA\/'X?#S\XPAY?;X B*]I6K&GJ/?!&M1C4A:^Y#W4TJ$*-G;
M4*D+>IE=>C+-&I1G_$OY9)JLW6M6]-?SA&7TPEC$)=(>$(0_("H
M
M              +Y//Y?6 ,H-<             "'G#[X?/QAX?,$1WM39&%
MYI?>7)+7NJ]SC/<7[I;#\2;'QDA:W4F;PM6>G9PC7J2Y"TEMJL(35XPI]8]?
MV?"$8A+C]WE\/#I^CPZ
M                                            OD\_E]8 R@UP
M         5AYPZ?:",GVRI8S\:]Q/X-Q"2,.^KNDIW,L:-&,/13WN>;\*6,L
MLD8S_A322PJ31C/Z80@"37[_ #^/4
M                                                     %\GG\OK
M &4&N             "L(](P_MH0_/&$ 1E>V)^'0XQ[D9Y:?X\U;OJ[I9HP
MEZ230GCO72-2:>>>/KC"'AX=/+R!)K'SC]X*
M
MOD\_E]8 R@UP             /C#^VE_W4 1E^V+_DQ[C/Z<W=/_ (= DUCY
MQ^^/ZP4
M                              !?)Y_+ZP!E!K@             K&'3
MT?V4TO3\\(@C/]L.E&/&7<9]D.^/NEFCX_UV\]8=/ $F$?&,8_E!0
M
M                %\GG\OK &4&N             "Z?_>O[:7Z C/\ ;#GF
MAQEW%PCX>KOC[II8]8?"7>HPEZ?F!)?'SC]\04
M
M !?)Y_+ZP!E!K@             K#SA]\/TQA $:WMEP_%XT[BXP\/PN^/ND
M]77X]-YZ>'3J"2F/C&,?R@H
M                                              "^3S^7U@#*#7
M            ^,/[:7_=0!&M[8<T/\6/<?XPZS=\/=''SAXQCO,(QZ?.()*0
M
M                        7R>?R^L 90:X             *P\(P_MH?IC
M" (S/;%C_P"6/<5T^'?)W30_-O/3](),X^<?OC^L%
M
M     7R>?R^L 90:X             *QAT],8^$(S20AXP^,T.@(Q_;!J4ZO
M%_<9/2GDJ2_Z<W=/#U230FA_W[^V$8P^ ).(^<?OC^L%
M
M        7R>?R^L 90:X             ->YN9*7[K)-X1JW5&E+]_JAT_."
M*WVE:]*YX1Y_N*->:ZHUN^GNSC2N)X22S582<EWE.I#TTX>F$M*K+-)#X])0
M2MQ\X_?']8*
M                                   OD\_E]8 R@UP
M8KFE"I&UC^'+-&2O3GA&,(1C+&6,(^J'Y8 B&]F2-I-VT<RS6->%U:1[X^\*
M%*XED],M2>3F+.TKF$.G7K&G=23R1Z_UOV1!+_'SC]\?U@H
M
M          "^3S^7U@#*#7             !=-">,:48>GTPC",W7S^7CY@A
MK]DF'I[4>69(^$TO?3WJQC"$/3#I-SOM,81Z0\.L8>?V@F3CYQ^^/ZP4
M
M                   !?)Y_+ZP!E!K@             LK_ ,*U_P"%E_W(
M(<O9*FJ3]J7+4U6>-2>/?3WJP]4>G7TPYWVF$L.D(0AX0!,C'SC]\?U@H
M
M                    "^3S^7U@#*#7             !BJ1C&-'K#^#<20
ME^Z/6'S!#E[(\/\ VF\JQ^,W?/WK1C]_^/K;(?+P@"9./G'[X_K!0
M
M                %\GG\OK &4&N             "RO'I-:?\-+#\\.@(;O
M9%C";M.Y6],>O7OK[UY8PAYRQASQMG6$WV=/2"96/G'[X_K!0
M
M            %\GG\OK &4&N             #'<?PK3PC'^[2^7Y8=.OR!#
MK[)5>>IVF<G0C3HTXVW>_P!Z=O#\*G&2,_IYYV[K/6A&,WJJQ]7G]@)CX^$8
MP^R(*
M                             OD\_E]8 R@UP             8JLWJF
MM_["O++]_6$8 AR]D>'_ +3>58_UW?/WK3?=_P"?.UR_0$R<?./WQ_6"@
M
M                    +Y//Y?6 ,H-<             &.M#I-;0A"$/56E
MC'\L80Z@B2]F/"R8?M$W2K)7GN?X\[R.\[,1_$]$G[M-/W%[[CXT9(R2_M2Q
MAC_7UFZ1ZSQ!+C'\OG^?]/Q
M                                               !?)Y_+ZP!E!K@
M             QSQ]<U#X>BM"'V]?V8_=T\@17^SQ3GJ=G>8A)-&6$.ZOO,C
M-Z9HR1CT[G.3NDL8PA'K",/. )5(0Z>'3IT\.D/AT^'CX@
M
M          OD\_E]8 R@UP             65ND)K7IX=:T.O3PZQC+\>GGY
M@BJ]G"ZH5>S[8):<\8QM^[+O,MJT(R3R^BO_ *2_)-7T0]4L/5#\.K+'K#K#
MQ\_,$K
M                               +Y//Y?6 ,H-<             &.>/
MKFH]?ZBO"$.GY)8^?7K]@(K_ &=:,:G9WEX2S=(R=U?>7UC-",WJC#N<Y-Z?
M&$(>$ 2J>7A'SAY]
M                                         7R>?R^L 90:X
M      *5I8QC;1AY2U9>O_V8@BO]G3^9[FOZ5?>9_K-\F@E1
M
M            !?)Y_+ZP!E!K@             I5C&$;:$/*-67KX?V,?S B
MO]G3^9[FOZ5?>9_K-\F@E1
M                                              !?)Y_+ZP!E!K@
M            59H0_=X1Z]9JDO3Y2Q\_S@BN]G3^9[FOZ5?>9_K-\F@E1
M
M                     !?)Y_+ZP!E!K@             QU.LU6A#I&,L)
MH1ATAY1A+X^,/L!%I[.L(0[.\OT\_P#2I[S/5_;0[G>3X?+P@"4\
M
M                %\GG\OK &4&N             #2O)(RUL?7C5C3IT:\\
MU3K-)))-+4I^B'KC--#PEC'K\@18>S)<0NNRV\N(1]7XW=!WCSQJ=81_%C-W
M-<FQC4A&'ATF!*X
M                                       "^3S^7U@#*#7
M    !AOI81M9YO3)&>2G4GI33R23PDJ2T:DTL80GA&'\*6 (B_8ZNJ]]V"XB
M\N9Y9[FZ[AN[6O<3222R2QK5>Y#DJ>ITA+"$.D9H]02]
M
M         OD\_E]8 R@UP             8[G]NWJRQ\.E&KX_\ X,\OU!$)
M[&E+\#L"P]'KZOPNX;NUD]48=/5Z>Y#DF$(](=>G7H"7\
M
M         %\GG\OK &4&N             "RZZ2V]2/E"-&M",8?\#/'X>/P
M!$)[&D\)_;_P4T)HS=>X+NTC--'KUC-'N1Y*CUC&/C&/2()?@
M
M             7R>?R^L 90:X             ,=U#U6E;^QI5NG3\E">$.O
MYP0_^Q;_ +/S!?T@N[/_ %CN2 3"
M                                                     OD\_E]8
M R@UP             :][6A3MX])*D_62M"/X<.OI]-"I&/K\8=(?E!$A['U
M*%+L&PT):E.K"IW =UU>$:<M666$M?N*Y&K22_W6E2C&:62>'6,(1EZ^48P\
M02[@
M                            OD\_E]8 R@UP             :N2EE_<
MKF;]F6:%G=]*D8?P/^+5/VH_;"'Q!%C[+=:YK=@>AS7&&K86$G*'<+1MJ=>Y
MJ74V2LJ/.6^4[7.23U8QFI4LQ2EA7EIP\*<)ND 2L
M
M      OD\_E]8 R@UP             :>2CZL=?=80_9L;ST]/\ DU6$>OV>
M (UO9^_F"<2?^)>8O\\&[@DU
M                                                !?)Y_+ZP!E!K
M@             T\C_\ +\A_R&\_YO4!&M[/W\P3B3_Q+S'_ )X-X!)J
M                   "L.GCU\X^7Y(@MA&$.DD>L:D)>L9NG[,?'[8?L]>@
M*@
MOD\_E]8 R@U_S?./3[O/\H/F4,M:W%Y=V-.6Z_&LJM*E7GGM:TEM&:K1A7A&
MC<S2PHUI))8])HRQ_9F\(^(/I@           T\C_P#+[_\ Y#>?\WJ C7]G
M_I#L$XDZ1A-_VDYB\81ZP_RP;OX?($F@
M                                                        +Y//
MY?6 ,H-<&*6WMZ4)8R4X>F2$\LE.$8QA+"I'K4\(QCU]4?&/4&4
M  &EEYI:>)R-2:$8R28Z^FJ0E_A1EEM*LT80^/JCT\ 1E^S=-0J^WOPU<VM2
M:I;7N=Y;O*'KCUJ24[CEK=*D)*D/A/",8QC#\H)00
M
M     7R>?R^L 90:X             /C;-4FI:_EYI983SPQ.4GI]>O3UT\=
M<SR=80\8P]4( B[]D:ZFOO;0[=KZK1DM[N]AR-=9"G3FC&2%_6Y.V^:YC+",
M8^B'K_J?AT!*Z
M                                     "^3S^7U@#*#7
M  !\K/S4XX?)23P]49\7DX0EC)--",(6%?UPC"'2/C)U\.L.OEU!&5[,$ME+
M[<W!$,?+))9_OO*,:$DDLU.662/*NY>F66A/-//;RRR](0IQFFC+#IX@E*
M
M                      !?)Y_+ZP!E!K@             ^%M=.6;7,W/'
M\3K)@LU&$*<\9(S>K%W,(_P8PC&;IY1^$01;^QS++#VO^V6>6E5I1KV/(-Q/
M)7C-/5]=;D_<JD\9ZD\\\]3K--_"FCUB"64
M                                                           %
M\GG\OK &4&N             #XFRPZZWL,/MP67A_P#M]P"*SV+8QC[6G:Y-
M&/7UXK>YH=>O7I'DO;^G7J"6X
M                                                 %\GG\OK &4&
MN             #XNR?]W-@_ZCR_][[@$5/L5?[+#M6_ZEWC_.5MX)<
M
M                    7R>?R^L 90:X             /B[)_W=V#KY?Q'E
MO[WW (J_8ME]/M8]J\/#_P"2[Q'P^S_&5MX);@
M
M  7R>?R^L 90:X             /A[/&,-9V.:7SA@<Q&'AUAZH8ZYC#P^/C
M\ 1D^R7B(8;VN>TBE"[DN_W[2]@R\9Y)99849LKO>TWLUKTEFF\;6-7T>/CX
M>/B"5(
M                              %\GG\OK &4&N             #X&TR
M1CK>P3PZ>JG@\U-)/_54XQQEU+",LOC+-&'7XP!'-[,]I;V?MA]GTMO2DHRU
MN-KRZJPDEZ?B7-SM^RU:]>>/QJ59YNL02<
M                                                           O
MD\_E]8 R@UP             ?#V?_NUL7_4.8_O=<@CL]G'_ &8G9S_Z75?\
M*]C!)>
M                              "^3S^7U@#*#7             !\/9_
M^[6Q?]0YC^]UR".SV<?]F)V<_P#I=5_PKV,$EX
M
M  +Y//Y?6 ,H-<             '&-TNI+35MBNJ\].A8VNN;#<7]S5J0ITK
M>WH8>[J35JL8QA^Q)"6,8Q\>D/$$>?LUUJ5Q[8'9K6H5):M&KQ7/4I59(^J2
MI)-M6QQEGDF\II9H>,(_8"3,
M                                                %\GG\OK &4&N
M             #KGF*$LW$/*T)H=98\:[U":'6,.LL=8R<(PZP\8=8 C^]D[
M_92=C?3R_P 2F/Z?=_'>;Z0ZQ\8]( E'
M                                                        !?)Y
M_+ZP!E!K@             ZYYB_R0\K?^FN]?X,9,'@#V4?#VINQR'_\*8[^
M_>:!**
M                              "^3S^7U@#*#7             !U[RY
M)+5XFY1ISQFEDJ<<[M)-&6'6:$L^M9*6:,L(^$9H0CX0!X&]E^UC8^UCV1VG
M6M'\#A?'2PC7I?@UHPCFLU-#UTNO[$>D02=@
M
MOD\_E]8 R@UP             =7\X332<*<Q3RS3R32<5\A32SR1Z3R32ZEE
MHPFDCX=)Y8PZP_*#RW[74DM/V\.SZ662G)#_ !'ZA-Z:<OIEZSV]2>:;I"$(
M0C/&;K'\L8@]Z
M                                      OD\_E]8 R@UP
M   =/]PU_3Q7;_SKDZL.M+'<-\G7]2$/.-.TTK-7$\(?EC+3!YO]KZG-3]O'
MLXA-/"?\;@+0;R7IZ?"G?XN6\I0CZ?C+2K0EC^6$0>\
M
M        7R>?R^L 90:X             //_ '97$MKVK=S5U---++;]OG,U
M>::6'6:66EQUL=2,T(>/6,(2@\^^U+&$WML=D-3K/'\7MOXRJ>JIU]<T*FOV
MU26,WJ\?&$_7[@2!
M                                         OD\_E]8 R@UP
M      >=N[[I_HE=TO7R_P!'+F[K]W^+39NH.A?:CF]7MJ=C4>O7_P!LW%'C
M]VKV4/A]G0$@8
M                                     +Y//Y?6 ,H-<
M  'G;N__ )I/=+_1RYN_S:;,#H'VG?\ 9H=C']&;BK_!FS!(.
M
M             "^3S^7U@#*#7             !YU[P)O3VD=TTT?ZGMRYNC
MY=?+C39H^7AU!UA[;&%H:][?793B+:,)J%MVP<*5))H0C"$?WS0L)?3=(1\N
MD]S$'MD
M                               %\GG\OK &4&N             #SEW
MB?S1>ZC^CAS?_FSV8'#?;X_F'=F']%K@?_-EK0/7X
M
M     +Y//Y?6 ,H-<             'G+O$_FB]U']'#F_\ S9[,#AOM\?S#
MNS#^BUP/_FRUH'K\
M                                        %\GG\OK &4&N
M     #S=WE59:':!W5UIXR0ED[<.;NL:D\*<D.O&FS0AZIX^$L <1]OC^8=V
M8=/_ .K7 \8=?"/2/&6M1A^@'K\
M                                                   %\GG\OK &
M4&N             #Q[[A->K;=B7>+7HU)J56GVU<S1EJ2?PI>NA9R6/3K]L
ML8P!D]OJ'_L0[,8Q\X]K/ WEY=(\8ZU&'GX]?$'KX
M
M     %\GG\OK &4&N             #QM[B7\PKO)_HT<S?X!YL&Y[??\P_L
MP_HL<"?YL-9!Z]
M                                      !?)Y_+ZP!E!K@
M    \:>XI/2I]A/>3/6JTZ-*7MIYE]=6K-Z:<DL=$S4(QFF^$/$&Y[?$\)^P
M_LPC#X=K7 \L8>/A&3C/6Y)O.$(_PI8@]?@
M                                                           O
MD\_E]8 R@UP             >+/<<IR5>PCO!IU9):E.IV\\HR5))H=99Y)M
M6OX32S0^,LT(](@[6[4[:WM.U_MRMK2A2MK>AP5Q/2HT*,D)*5*E)HV$A)3I
MR2PA++)+#RA#P@#OT
M                                         %\GG\OK &4&N
M      #Q=[C4WI["N[^;IUZ=O?)\>GV_]F+_ .\';W:_+Z.VKMZDAY2<(\62
M=?+KZ=(PDO7I\.O0'>8
M                                           +Y//Y?6 ,H-<
M        $>ONR9.[PWMI=\&4L+RKC[NS[<>2:M&\HPEFJ4(_Q)6DFFEEFEGE
MFZR31A&'2/6$0>ENUZ,TW;1V]1J?_$CPCQ9&?KYQFCI&$]48^$O\*/CY0!WH
M
M                        "^3S^7U@#*#7             !&[[P?^RY[\
M/Z-/)7]YJGV@]8]L<8S=MO;]/'^%/PGQ9-'ITA#K_(?">4/L!WB
M
M               "^3S^7U@#*#7             !'#[OWIA[7W?9&?^##ML
MY(C-]T,//&(/7';C-2G[>.!IZ,OII3\,\83TX=.G22;2L)&2'3X=)?A\ =S
M
M                        OD\_E]8 R@UP             1P>[_)&I[7O
M?93EA&,U3MLY'DA"$(QC&,^(GEA"$(>,9HQCX0^,0>NNW.TFL.WS@JQG]?6S
MX=XSMNE22:E6A&CI>%EC"M2FAUI5(1\(R_", =R@
M
M    OD\_E]8 R@UP             1T>[I'I[9'?!_1YWS_F$H/;?%<?_*_C
M>'V:%IWZ=<Q@.>
M                                       OD\_E]8 R@UP
M    1R^[O-++[8_?#&:,)8?Z/.]PZQC"$(1C920A",8_&,8^ /;O%?\ DPXX
M_P# 6F_X-XP'/0
M                                      7R>?R^L 90:X
M   (P?>=N)+3VL^^*M-0DKPFX2S5'\.::,D(1N+W&6TM7U2PC-&:E&?U0AY1
M\H^ /?7$E&-'C'CR$:M2KZM#TV:$:D81C+#^3>,A"6$(0A"$(= =B
M
M                  OD\_E]8 R@UP             1:>];4ITO:K[WIJL\
MM.$>&[Z2$9H](1GJ9G$2TY?[:>::$(?;&()#N*X1AQEQU",.D8:%IL(_?#7,
M=U@#GH
M                              +Y//Y?6 ,H-<             $47OA
M_P"RF[V/_2B3_"'7P21\7_Y-.//_  +J'^#N-!SH
M
M    %\GG\OK &4&N             "*/WP81F]J7O9C"'6$.)X1^4FPX",WA
MY^'I!)!Q;-+-QIQY&6/7_L+I_P (P_A:YC)H><(?"(.>
M
M         OD\_E]8 R@UP             1B>\GBZ>>]M#NQP-2I+0HYK2L+
MB*]>I+-/+1IY3=-:M)ZOIEK6\9X4I:W6,/7+Y>8)#M!L_P!PT?3+*$TL\MIJ
M6M6LLTD.DDT+;"V5#U2^,T?3-Z.L.L8QA '+0
M
M 7R>?R^L 90:X             (U/=[FA0]NON8J5(_LSX#4I(=/VH]:N^ZK
M1DA&$/*$:D\/D"0S5(>G5=8EC#I&&N83KT\NL,;;P^?D#[X
M
M           +Y//Y?6 ,H-<             $4_O8;!-KWMK]P-[)0DN/WJ[
MXGPD].I4C2AZ<YS'H>'A4A/"$8RQHQNHS>7CT!)[K5*>CKN I3QA&-+!XBEU
MAY1_#QUM+-&'WS]0?;
M                                          !?)Y_+ZP!E!K@
M        B)]]+_9I<W?EV_MYA^?N"XT@"6/!^.!P<?\ ](QW_,Z /I@
M
M                   OD\_E]8 R@UP             1$^^E_LTN;O_ !AV
M\?ZP?&@)8\''_H'!P^,,1CH1A\8?\2H>?V ^F
M
M "^3S^7U@#*#7             !%%[V%G1R/MX\IX^XZ_@7W(W;/9UO3X3?A
M77<=Q=0J>G\OHGCT!*O;6LEG;6UM3C_<[:WI6M/SZ_AVTD*5/U1C&,8S>B$.
ML?R S
M                              OD\_E]8 R@UP             16>]#
M_L_^1O\ U1[7_P#64XK!*M-Y0^^;]8+
M                                                        7R>?
MR^L 90:X             (IO>FKTJ'8#ODM:>62-WRUVPVM*$9H0]57_ $C>
M,*U.27KYSSPI1AT!*[/X=/OF_3'J#&
M                                                      "^3S^7
MU@#*#7             !#][Y=2C#L&R<E2-+U5.X;M3ITOQ9_3-^-'N!X_C+
M"E"/\.K"$L>D/+IU!,+4^'S^@,8
M                                                   +Y//Y?6 ,
MH-<             $-/OO_L]A-*/2$?5W/\ :3#]J'7P_P ?^C>4?.'2()FI
M_A\_H#&
M                               "^3S^7U@#*#7             !$A[
MTVMR[?V<ZWJ_[]3QW\>]U_:?;1O:TL9Z5":ES9J5WUFE\/";]S]/WQ!+A'PC
M-_"\9HQCU\O&$L/V?"'AX H
M                                               "^3S^7U@#*#7
M  \(^4TLWQ\(]?"/E'[H@=8?;",>O2,(1\81A\(P^$? #K#[0 /#XQA"/V1C
MT^WQ_1'\P'6'PC"/Q\(]>L/A&'Y(@=8?:!UE^,\L/A&$8^4?LC^6(   (J_=
M]FFD[:N+J,T(3T[OO([3*$_A'K+3J<NX2I&,(_;"-*'B"56;IZYHPZ=8].OR
MAX=04
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M_($P,L(0C/Z8=)8SS0Z?V4(QA-'YQ!<
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M>:YI?C1EA+)4GGFI0A&,8S4HS1],\W62G&6::$/*,.L ;(
M
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MI?Y.6RH2RT;.6_NJ,]6%*2$):<)_3#PA 'W@7R>?R^L 90:X
M
M                    *]8_;^?Q_3Y@=?@!U\OR H    "^3S^7U@#*#7
M
M                                      !?)Y_+ZP!E!K@
M
A                               OD\_E]8 R@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tv526458_ex1-1img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-1img07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ +4  0  !P$! 0
M       ! @,&!P@)! 4* 0$                     $   !@(! P("!0<$
M!PX/!1D! @,$!08 !P@1$@DA$S$405&!(A5A<<$R%A<*D;$C&*'10E(WN'GP
M,Y,D5=6VM]=8>)@9.>'Q8K+B8S2T)34V5M9W*'*2<]1UE;66.!J"TD-3129V
M)Y>(*9FB@Z5'5\=9B1$!                     /_:  P# 0 "$0,1 #\
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M#X?2(!\<#T$'O(4X>I3% P#\0Z& !#U#T^G C@,!TZ_# CT'ZA_DP(=/H^G
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M,!@,!@,!@,!@,!@8]VV)@U1L\2'.F8->742J)*'25(8*U)B4Z:J9B*)J$'U
MQ1 P#Z@(#@:>>)V3DYOQC\ YF:DI"9F)7B-H:0E):6>N9*3DG[O7<$X=OI"0
M>JKNWKQRNH8ZBJAS'.8PB(B(X'07 8# 8%!<5 * I=W=UZ=  ! >OW0Z@/KT
M 1ZB(>H &!^=?EKR3Y?:EG?+M'+[N=QD?0*)P8=:"GX"IPU>C^/E,Y!;%OM(
MO5L:JRLA-$L$]6(5B#R1F'IFZ)7")!30322#N#?CQ_VBVPNR^:G'>Q[ZM'(*
MI<?-RT*!U==]BS;"T;%90NQ=.579<O1K9>&36/+=)2L3DNY%)51+YENS532.
M)BD*.!OQM&A);2UY;=>JVR]T="WPSB%4M^K[0YIFP(!-T8@'DJC:V2:SF!F$
M2 /MN4RF,0!'I\>N!^;BJP?);6VG4-HZEY7<BMA;KGO*D/%.IL.4V^KAL'3*
M>OZGR/NNOXUG/5*N@Q>*-)&KLRDE#)"D_D3(%'JCU(8H6S:_.SRT:66N476W
M&BI;2N.K:M.SW)=&GU?84W5[;,UOD1L+C[+UG4%F/8XE+5[1G(:V=.U)2SI3
M")'+QNS$G>/N"'3[GUS*Y5:'E*I"\;J3H^4<*\7^27)^[NM\NKLW",AN/;.B
M2!JA%1U'<-W99>SEMJC8RZYS),EDP,8#%*/4-"9?SG[/9;ZU]66-%T_,ZCO[
M@]55;P,9N1W;:+<W?%Y[R"CV=NVY-0D!I9>PQ,FQ_#I>LQ7XD^9QSE)Z9X0W
M]$(>^+\I_D-9JRDG:M6\07-9IF@N&_*FY(UN7VR-G>ZRY6V)I33:^JB:JSZ'
M<WNJRQUGJ<JJI^'O&P)M@;%5,9<H8TU]YN^<FTX?9MMI'$6H/Z]8=>;/NW'A
MO.)3E4)%EU]M&"U\S:WZVR=T5@-J2\]'R+IY^'U]&#=(RK9*(, +.DU\#HCK
M/R/VF8\9VR>7]WG]+-MN:ND;MKZSQKNM;DUO18/<%?M3&I1%(O%!L4'8MO4Z
MTFDIEDD]@T4Y5R+MPFDW<JE4*H :4ZZ\P/,W:X):CI.L>/C3>:6Z.7^M'%SV
M1![BU_K]6O<6M!ZJWLG8G.JW;UYLF"G+<WV<2+-'/'Z0M!0^;,;M_P!+F#&$
MOY8.3_*6+T!L#5G[K=%:C+S1X%Z@OD"6W6-OR!N,GN.KT_9-Y1B$! U:?:EE
M3V16*28J-C/)2,0,_!PF4HH8&X?D/\M&Q^'G*9AINEQ6L+'4*S :%L.PH:3I
M&X;1?7K?>&Y6NM2MD+M7?P?5.J5&$.J=[%'F%Y569=![)6R12&,(:5[$\K_+
M=A>M-\DV9-$16K+]HOFA+ZIT K;KG#V"-L=3W1I#3]*<\L2N%G$(Q?T24F%)
M1\ZC@8"Q;.GS,B?>D"QPRO0.?'._7W(>W:9MMFXR;.N=HY7[)@;C+U)SLFQ:
MEINI= <&-3<BK-6]*UK]J59VLW:YDDGQ!:2+MXU9RCD%U"J%.)1"S-7^:[GI
MM[4=MOE0XJT)5S:];::W#IV9<0LXUBJ_5=F;)1I<Q5I*LO\ :C*7WO<H6&<)
MO8\D"]@#RJY5FY&Z:Z::*H7N/FGW\RFN,%K?1&A7?'^X054CMZ[+8TC;R -=
MI2.U+=J>UTHL6YGU;QQVDH6PU]N@P0MU<E6D@^660&0332]_ MO7GF@YWVC3
M6R=I/.*] =)6"C5R]:#D%5F]#KD<6>W+7-?.*E/EMNX%)7<MB95"VMI-H,*2
MO!)R31:-33374(!0WM/Y)]@-O&JMRI8EU;:]ZM]KPG'5\@ZJFTM8ZBJVX[9O
MB)TA'N]@5.\!^\^I5JG.;*R?SC<[A0Y$B* @[,F)5@#2J@\I>7'*CR>\7]$W
MN]:SB:GQEV)RXB=RMM(RNR('6V];?JFDZ7L=5M,(Q+;5G3IC6X[<B,:XAIIW
M,QS>99/3JIG$402#X%SY1>00G-'8=+UKN35"KZ*\C>_=9:YJVSD+LMK=CJBG
M^/%/;S>G66"JMC@IB><IS,<C(,T&ZY2HR2CEV;O3)VE#ZFH/.-R9W?<-*RM&
MXSPZ^K;%-<+Z3LV-< W1G33O*:FUJS6.S5"_2VQX1A%1M(&U)#$Q2]=E'$^#
M19,CM,_7VPW7Y2\IN0VI.:K_ %%I$FN'<WL^-X=46M/=L3NQ)6HUEUMR[\BV
M5EM :Y@9F-BE'D/%:\0'W8\[-S)G.1)VL!$D#$#674OENY4;C9UD\<EPWU@K
MJ34LILKE!(;JD[_3H#8DC!<DMH\?9:O<=I5.RN K+(J^J'2Z3R83G5#/Y)FS
M,@4YA,8+%GO,[RTB==5RY,:CQBG)#D%IV VAI:+8%O::FB)>7Y7ZPXZKU'D<
MU-;G"TX5.*V<FZ(Z9&KZAIJ.79>T)1 Y0^U9?,5ROTU([:M&S:?QFV70-.\K
M^0?#U]K?52UZ@N0-ILND-"V;;Q-OA'3%BL4+7:'(R57,U>M!9O#LV#M-R#@1
M*!#A]1_Y2>;H6+7&@89;A]8]W;MLG#&3I^SJG$[$GM046A<M&NTG3ZN6F);W
M55Y/;%HA=8J*L54)5JVEF3Y!<[5 I@ZAK7N/S(<LKB.]-4ZSN&BFLC(:5W5L
MC5VVJC0]IUFNT&3X[<B-8ZTFV8VRZ3R)MN1UNA[2X2?23*(AF46];J))BZ2Z
MFP-MK[Y;^1- FKK:U83CQ.Z[C]O<LN-<)K&'<6F1W5";"XM:8N^PD]S6L[*R
MJL U)?)S7SD7,>+)JYAX>5BU/Q%=1P8PAYZ#Y,^;]1Y,<7].\DF/&R-I6V*]
MQV-L"YT.H7"9BFU\Y%1<Y8(R@,)"$VC99O5-BABJQ<?#C9H5Q&V<".7:3QN0
M2@F&4^6_DYWCH?GE4^.U'8ZOLNN&^S>'^OMA0;W7^S7=X8(<H[4[K"TR\VK^
M.0&L:FZBTR$<PT4W93[Z2%)8%P;$Z& --]O>8[R$U".URQH^G]&W>W[)HG)W
MD'#Q]9JLNO$QFGM [D>:CA*?:)R[;RH$;'6"PK,#OYFPME'+>)043!.,6*"B
MI0_0WH[8FQMDU&(NUE/1&C:VQ].M<75:@JK,3%$A;51JY8U:A?)I*8EXB7LD
M7)2BX ^CO8;NFHH*)(B4QCB&R >H /J'4.O0?00Z_0(?7@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@3D^/V
M?I# JX'GP& P& P& P& P& P& P&!CW;G^"C9_\ ZN[M_L9D\#2[Q$_\UIX\
M_P#@=<??]K6OX'1/ 8# 8# Q58=':AM;G9#RRZWI=@<;@JL/1]I?CE?82R&P
M:?7T)IO"5JW-7R2S>;AXI*QORH(+%$B?S2@AZC@67K+B?QXTM!5&LZDU%1]>
M0%#L\Y=:I&5>(".;Q5PLD0\@9NR@8BOOO9>2AGRC559R=8QD! @= *3M#*]^
MN]6U7KZY['NTPA7:7KNJ3]SMM@<HN'#6!JU7BG4U.S#ANS26=*-8F*9*K'(D
M0QQ(00* CT# U-HM\X3VI72M0UZYU3:&_(!>V<Q=)H5J-3EX6\243,1EOL>[
MZ_)-FCB,_:0LW=6[TSHZB;H7+DYB%[DS= ^Y:N$O#*]N*5,VKC=I.=>4>?L-
MMIKZ0IT$H2%L=KMHWFSOVJR:947HSU[5-+/$UP5;N)3_ $P8@K?>P,OW/5^I
M[U(EL-]I-3M$DVI%RUFO*V!FS<JH438I(UM>J<\46.9,D):T8QN#QJIZ+@B3
MT ?B&!C^/S@RUO#O:BG%C0R5[(@F@:W+4>%2?()MZJ-'(8'*Y 08*J5%S^&*
M'(4BBS4P)JB<H!T"[D]6<2TK0_T\WH.J#6Q33VLTY*CH0T<$F?1VLK0JWU2B
M[:$)T<TVGVI!0(PO>*2+H@B4.H!@6W'<$N$K"9VU)Q_&#0S:9W+&/XC;I6U!
MK*I[G%3DJ2:DF=ACDT1;H-I>9;I/7'M)-A7?I)KG$RI"G /)K^B<)96G[DX6
M42B:I#7NM$(2,W)I1C6V;6IM'.UXP+?$/+"5PDDUG)BU-DA>B\!PL],N4#+*
M%6 HX%SZYX;<2=/E(MK;0.F:*>O.K3)MW%>J,0P<1TA>:I$TJ[2#Q4QU%RR5
MOJ4 Q82:RQO<?-VY"K";M[Q#X!>"7!@+I0]B)<8= DOE+8T^/U]9S42N!-UQ
MGKD"FI'[,K@@)D%*F0?;9+MNJS=MT(50$O3 N7:?#OB+O>\QVT-O\>]-[-V5
M78V.CF=XNM,@;!889C$2)9Z#;N'[LAW*98210*\9*+&,+97N,D8@B;J%OQG!
MOA.WMFP=GQ_&70Z-MV]%6^+V3;VU"K:CN]PU^13"]Q\V^!L9-U%7$Y16DT2_
MT;Q?JNJ!EA,H(? X\Z0X'Z_E;)6^-FIM*4J3X_;"D(FQ$IU/80!J5LN]ZSJZ
M,NJ,NX;(IR-CM.K9*+0>O6Z[HZ[+L044$Q3$*'MC^ '!2#BMHT6'XNZ&BX/=
MSIE,;2K<?1J\S1NCN-E7,O$NY"-;)E,R(PF7BKIN+0C<J#Q4ZY *J)SX&(&>
MJ?&E+<FZIQ_8\>M2/]Z\1=5UFY5H$-,$_9C2E'MLQ(R-3;&MX0:=*AYJ3FV;
MF58,7+D[X7)U'B) .914 RO'\ N!$&EMN.;\6- ,6._$@:;59*4BN"RV*V/,
MJ61NTDV*B9VQT@L!SRB:+(B1".S X  6#OP/OL->\.J+5JGP884#5D-1]@4[
M8:U?X\MZNS=5&PU>L.(A[L 7L.5H[BBJM'MG9KK*/5?G%%G('(8YBB)0\])U
MIPLXT6'0]"UYKC3FJ['(K[$J.@8:I0$1&O57<G'MK1M&/KCV.2/WO)J*@D'L
MFLX6]YR1L03F,H !@9$)QTXX+;(FMP(:@ULYV7-V5O/S=]0@(A:==VY*FO\
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MJ*;1JDD'0B90 +VP& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P)R?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8# Q
M[MS_  4;/_\ 5W=O]C,G@:7>(G_FM/'G_P #KC[_ +6M?P.B> P& P& P&!K
M9S+HEMVCQ"Y3:TH$86:O>P>.VYZ52X8SEFS++6RT:[L4+78PSN1.G'M@?2[U
M%(3N# @0#=5![ ' _,OMGQ/\]*%8XRH<9FBC/00<*]K/Z?6X>ZL:C<-+[NVV
M_P!$N^0'&RI6%*812BZ5MU*DS:\"X8IIMX1Y,/4_F"(>P.!>43XW-^[GLB17
MO%"Q:-X?_C7)>QZ?XEV_:D>9;3LK)<1:W0:F^DXZGW9]%LU[_P C&CV?CD4I
M!XBQ7,+Y4&ZRN!:^TO%;O6(T+26%7T?N-ZZL.E.%MDWI T78E:N4M<>2M+0W
M/%;GL6S=9[0V/ 06Y6+B-LT028;)3,2Y>']ATU>"NR+@;4\L^'G.?=?BZX.:
ML>U%6.N6HIRASO*_CKKI[ 7AQL/75:JEE@HFE1<;MNW/*YL=]6Y)Q"S#Z!F;
M 9"0<,UD$WZJA$3G"YO&OPEWYQYY!<?[]NK7VR9TW]1>[Z?1V%>IFA35HT^^
M_K-V/8]?U/>#4ZS+0BL<.L9]BWATF#>31BB-5(\7($2*(!SUV'P"\D&QN3O)
MG8.O^.LGHM;8=)YNTBRV^NWFMQ8;7+=9*ORNGF)=MAMR7V3<6UQKD(_9QKR2
MAH1E1G,D5!BBD4I3IAFKCWXPMG6+D>ZNSOA7,\7>-5QY%5O;,9IVX;7J]Q_
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M[FU] 7UK57<FA-.H%&=;?,%C5Y9LU9(/U6WZIE"HI@8?[D,#8+ 8# 8# 8#
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MV]M"Q6.;XQ!5MH,4E>.41IKY^:=U T86K),V2#: 9-%8TZ3AM(&%82D ,$[
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M#"!$Q* ^O4>H .! CM%0ON%$W3UZ_ P@ !ZFZE$2F+T'X@(]>OY!Z!,1TDH
M]AA,!1 H]"CV@(_ .O3LZ]/J' &<I$.1,>_J(=2"!3=@= $>O7IT^ #\/J'
M\[R5CH],JSUTW:HG51;D5<K)MTU'+E8J#5L4ZZB93.72Z@%3('WCG'H =1Z8
M$Q)%J<%#)F4$J1A(<WLK%*!NI2]I3'(4%/O& /NB8!'X8'PX"[5"VIR:]4LD
M#:4H66=UZ97KLU%3:<1/,/;&0@992-=N0CYE@*Y/?:K"1=+W"]Q0ZA@?>.^1
M3 ._W"B83=" F8QS]GM@/:4O41$ .7[/7X!@?%9W.HR0-31UF@),K^0=13$6
M$U&N@>RL<JNB_C6HI.3 YD(]5HJ"R).JJ0I'[@#L-T#[I7*8B(E[Q]1ZB
M^A@)UZ"(&$HB/ZW02_E],"4[I(>Y/J8#G Q0(<##WB).I0'L PB!R^H>GJ7
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M$>@ /LE)W?>ZC@;8<LM$%Y+Z(N>EBW.0UV^M:M6?0UWBXF/G7M:L%)NM;O\
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MCMFJ946K<7#^7<^TU2)Z)MB"L)4R_$" 'J.!U:P& P& P& P& P'^;X?I^.
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MTNO).9VZ-#K-:B>1DFEHA_46FB"\A)JSJ[9E]-Q4^$_#U8Y(S\,1K[AH[EU
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M 1NBJ<!,5,H 4H"  &!U!P& P& P& P& P& P& P& P& P& P& P& P& P&
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M)^^J0/N*&*(:W[G\4?C?E&LE.;6HKJ#C+ALG8SYZ8^XMBT:$E;%RDFZNTO\
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M$P] ^'TX'.GPTJ)K>+[AFLE_G:VJ16)U*).I%;18E"CVB "'4#? ?7 Z:X#
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M*;ZUMP4T,RUDLQL]GU7;I69NNU]H(\A&QM;GNTE4+1R0B] IQK-B>>.^<LI
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M& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!36*!D%P'X"@J A]
M]2&#H/Y/7 Y,^"N!9U[Q0\.V[)1PH23IEMLBXN#$,8KVR[.N\V\22 A2E(V1
M<O3%2+ZB!  !$1P-B_)!R"3XK<)]^<@CZZJ^V5-75B)L;37UVE&L'3YY_P#M
M?6XR/7L\R[8R2,1!0#^12DG+KV%3-DV@J%+WE+T#5C@!Y&+QRYW5LS2ES8<6
M;2ZH&KZ5M5#;/##?LUR%U(P_:NP/:\GKR\6"<HE(+7MBD!H,DV9H&=@M& <Y
MA)Z=X:61/G*V>XVT^@CZYXBS%3;\S9+B<PTM3N3-FE>=D\R8[6_=<78L'H$V
ML?P=Y'-.U6?>(?C!4TX1JLJ*I1 !P/T=3D)%3D3(P<TP9S4+/1S^ F8>4;I/
MHN4AY1NJSD8R19*$41<Q[YHL=)9,Q3$,F8P" @.!RGD?*#HO0M8O*VU-=["I
M5)U5MG;6I*^TTUJV\[8CJSJSC[&5EI8=GW(E$KSF%U=0:TUF42+G<J)H-FX%
M*F4P H) V#Y0<\.-O&&H:JM&RTMC7AKO=M(3.J:]J+45QW-9[:QK%:C[])SD
M97*C$2CQNQK]:42E%'"Y4RH))"MW ).N!KYJCR.>/?D?N"FV.IL9V0VU%1NK
MJEJO8EZT3=ZC.S-+Y4RKII49/5=IN%>C)&5UW=)RIK(R#]@)6A3L1*H)B% 1
M#[M[\Q7"+6Y6II:S;0F3G5NYI9>FZ4V-<$:C7-<[?6T?=KM>7T!#/&%2I$!L
M)#Y5:1>*II"D<JQ0$# &!]*>\I^@:!/6^I71:YW"W06W-G4I.F:%U#MW;ML@
M*1K!_4HZ?V+L2$@*PX=5>O0KRXLQ>R@ >,[5B W55,!RE#$RGF.XJ5V*=QVU
MY2>FY TINQ_*N](Z;W/L.ET;2FL-IS>J9G:NU9Q2I1PT&K1"C(@3KQWVLV9C
MG%,YTNA\#ZUS\F'&K2U?V;HG0]3EF-WTUI3;=MT? 3.J;EK'C=L][I77*M_L
M%'U7M9U#L:;/(04$8%%PC3"F1+O]H5!#MP+4)YG=,4[;-4UUM4C%E"N>/^U=
M];8V52F=TG*MI,NK:YIN;7UI:C'KH?C%RDC;;3*/R2AD$%3L&X%.L^(4@;:<
M .<4#S@U79[2,"KKK95#N4E6]G:=F&<S'6S6:$FJ\G=<!9&D]'L%U7MQUTLP
ME!6;D.T]Q95-)0WM&Z!BG;'DTI&A=T\C=<[7U]LZ1KVHI'1\523Z>U7L+;=\
MNTAM+6]HV)8WJU7JD8^(PKE.95D3&DA529@!54S&]U,"F#-\WY .-,)Q5UAS
M&>6&VR6EMRN]?QNL_P!G:#;;%>;99MG2Q:_1:I'4"%8O+,M:YB?.#$C$B(J$
M=@)3^H@.!BB.\L/$*0C*'((R6VF[&XPFT[+/*26DMD,0TK :5FUZQM9YR 06
MA_F-+M:386X,WGXN1(17623*!S*E 0]>K?*KQ+VQ9J]16TOL[6]SM<P]B("L
M;NTS?]32K@J.MYK;<'9E&=RC8_VJE=:!5I-_!/Q'V9(K!<J7WTNT0M25\L''
M&M0#>_3DO.7"E;)-0QT)4M-ZQVIL;>]Z;6S4T]MYVM-:RB:PL\9E?U&KOI6,
M,T.LFI#MC+KG3.8I!"YXORO<-K%+:B85NT; ML9MR@:XV&A<:QJ+85AU_K&H
M;;;O7&L9'>UPAX)W Z?"Z"Q72:$EUDC =)05 2(7O$+[XE>1CBQS6L]PJ.C+
M=8'=AI<,SM+:.NM-GJ,ZNFNY)\\A(G:NMT[$@W/>=9R$JR.@C+LRF;>X=/KT
M]P@F"Q>47D4H/$#D77M7;?C1C=7S''V;V^I>(U&>LMW>W3][5-U73-7U&B0+
M![(6J9N4I:NYN"1O>!0H% H$$QBADVF^0;C1=^*EXYFQMML+'2^KD;D.RE)R
MB6F,OE!E=?R'R%RK-IUT$<YM<;9858R?>S*B8_:H53KV&[L#"Z?ENXK/-<3F
MP6]9Y,R#RO7E#7TYJ1IQ=W"KOB)DG=(/L]G8YO4IJS^TD31)#78#,-YIV1"/
M79]3%.8X&( 7=!>5'A1::DUN\'M%W)PK]31Z<<1*GV\TN_3Y#:^D=GZU?-H(
MT267>1KN@PDA(R#A-,Z48VC78K&*"!\#(_%CGGQ^YF:XN.W=0R%V9T"EMD7T
MA9ME:UMVKF,G5'\(M8XN]5E:WQ;1.T46;@VZCA&19'53!)$X' APZ&#3*:\X
M/$!QK&S; U@AM;9<A6+9H^+2I9-4WZ$M=UU_NO;D5J6N[CU= N8%S*;!U^>5
M=K&:.(]$1>JH$1 I!63$0V<Y,\\:UQ2V+46&QX11MJ23T]9-@3=P20FY'8"M
MQ3N],HVO-74O6L='KRMLMM_D+$N#9B0Q797#;L]L ]PQ O.A<_>+&P>,]MY<
M0&SDV&DM<JVICLB5GH":AI[7\_27[>+M%+MU1<LRV"(N,1*.T6HQXI'<'<+)
ME3 W>'4-<)WS$<08.NIV:>B^3$5*Q[ZV-;?KR1XL[M;[4UQ6Z+&0$O;-C[)U
MXM50GJ;JZ#B+;'/%9YT0&7M.R@!A,!RE"W]O>9#C?2MKZ9UIKXEFVBQV%OC7
M^HKOMMG4[K%:+U]%W'5T_M=]+)[H/75J!/6N!I4>PDEX!)W[YF4AW=Y3)F*
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MV0>C:]#PU'58<7[E/;]B-Y_M9&6F/:JK[I<HV[7595:_C(E0_"VIVQT^JQE
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MQP'[R_X@3_>Q>+O_ (Q?(#_<QP*A-D_Q 0D4,;C)XO"B0H"0H<B>0)O<$3%
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M S@Z1"7WDPS,N4Q1!)!+NKBB93&$I?OC\1'UZ>N!%"5_B 73L/G:?XGV<?\
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MB'J/3J%!VX_B)$DDP:QWB4>+J>^954LKR@1*@4IS))-Q(M%_TAU )[@& 1
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MH"43&<J2G*%R!![1$I!1;QAE1$QONAT].OY,#S"]_B,/]1?$G_\ -ODYZA]
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M!#I\0Z#T$0]!#H/P$/40P(]A?3TZ]/AU]?Y>OQP E*(  E+T P&    #N#T
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M.8R#_D$QT6K.NIMI0-93E"C(36FHJ^@NI\BT4F:G#D>//:(F5:1F%%%>A@$
M#A!H:NS;.2A] <1Y3D9LOBOLSC%RT5NW#SDQI'8C?9/C9M+K3EH<1$!I7D;,
MU>JS18RW[)=!64JTC)/?G&3HJS4YFP=0#[?$[1\Y;'_&.O:%4Y:49;4_AK@]
MFZQU[.VSD3J[69^:M$V9,,8U"]1=K<1L7,2A+<FX*O"/#FCG# R1BMS,O:'
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MWOVN[9U-R7G^2EHVFN2\;_\ W'-M=2K*P/W\4O(*5MF[69%CVTPZ7:@0WL&
M+^Y>Z\W?)3GD.X\6G4LLWY'>1)?QK3FAYS6-=N]VU\5_K9Q4H7:C[]Y#FOH1
M%6C./TG5'\LH:54C7 M'::R*9A5#J%3C%I_;43M3B!P^EZ'=IG<_%;RN\M.5
M.[=I3E.M,=6EM"7=CNBT43<S+8)HX:A8%]RH[1BH=NR3D'<D"Y7)%4DTFQC
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MP,%<D^.VN>4^F;7HO:3>P'HEQ<5MU,I5.QR-1G#+56T0MOBA9ST2HF_9 $S
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M#DCR5O?*GCQL#2[*BS3)U+[@C81I9]2;ED[/;*BM1G]9L<.=1"3>IGBE(98
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MA]'[P.1X=/R?UCMJ^GYL#J6)"#\2E_)]T.@? ?0.GIZA@1[$QZ=2%$2A]T1
M/N^@AZ>GIZ#@0!-/IVBF02B':)>PO02A\"_#]4.GP^&! $T@#M*FF4G]X!"@
M7X]0] #H/K@1]M(0 !3()2]>A>PO0.H=/NATZ%]/J^C H%9,R.E'Q&C4CU9!
M)LL\*W1*[6;('440;JN0("RB"*BIC$()A*43"(!ZC@5Q33$>X4R";X=PE 1Z
M=.G3U#ZL!VEZB/:7J(]1'H'41Z=.HC](],"'MH_$4DQ$0 ##VEZF*'P*/I\
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M4\$0 "R4:97V7!2]2E5*8 $0Z8'8O 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M /3H/QZ>N!U5P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P&!#J'4H"!1 QN@@8.OQ^KT'UP./7@NC7$/P)-$NTTTG4;RSYW,
M7*20B9)-=MS&W4DJ1,QA,)B <H]!Z^H8'8; 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# G)\?L_2&!5P//@,!@,!@,
M!@,!@,!@,!@,"8OZP?GP./7@BG4YOQKZN(0_>:"VQRFKZP?*_+ 1:/Y.;:.9
M,#>^N#OL!R >]_1]X^G8'3U#L'@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,"'0!$G7Z#E'[?H_D' Y->%II\APRLS+VB(_
M*<T?((W!%(0%-($N:>\" F02^G:0"] P.LV P& P& P& P& P& P& P& P&
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ME$?7IZ=P=?SX'*GPW%[.(EU)U$PDYN>0P@B81,(B'-C>?41$0#J(X'5C 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M-T#KZB =^!UXP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MW12YV^0]*-53<>^9^P+S-W(J9ZJ3L(#10'JZZ7MB)A$J(' >AN@!UHP& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P)R
M?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8# F)^L'V_S#@<K/#I_])[-?\*OF9_C
M-[-P.J. P& P& P& P& P& P& P& P& P& P& P& Z%$![NIOI* @ @40^ A
M]N P& P& P& P& P& P& P& P&!,7X_R?]<&!QT\*$RYE^+V[VI_:32K7D0\
MAL"D(*=YE41Y7[(F>XQ"& $S>[+J%Z&]>G0W3H.!V)P& P& P& P& P& P&
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MTY=_Y2'FO_MG&P.JN P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P&!.3X_9^D,"K@>? 8# 8# 8# 8# 8# 8# 8$0^(?G
M#^R/I@<J/$A_@DY:#]!O)KY#C%-Z]#%-R7N9@$.O0>GKT_.&!U6P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!.3X_9^D,#
ME)XEU$SZVY@$(<IS(^27FLDJ!# 84U/WEE4[#@'J4WMJE-T'UZ" _# ZL8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8$Y/C]GZ0P*N!Y\!@,!@,!@,!@,!@,!@,!@/3Z>O01 !Z!U'U$ Z?7ZX')/P
M_/T'FKN:"!$11=1WE"Y_MY$HF$W>Y<;VFGZ1^WH )]&;Q(G:'][W#ZC@=;,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@3D
M^/V?I# XO^%P3*U?R1"H=0WL^7#FJFD G,($3!QKU4$R@(] ("BAAZ!Z=1'Z
MQP.SN P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M[=-%9#RR<\DWRI"K@=TZ-LY%8%EA5.9(3%:J)I@"8%* $#J'=U' ['X# 8#
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MHT-U1 0#U!/XF^(AUQP& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P&!.3X_9^D,#E7XN?_'/DY_RJO)?_ &!:0P.J. P& P&
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MV<*9T44D5U?<U+J,YOFER$!5X!!]$_<$WMEZ@3M 1 0[38# 8# 8# 8# 8#
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MB_#_ $YY%3?W)_)MR;,0WT'+\G0R]Q?K#J40_.&!U,P& P& P& P& P& P&
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MF5$0$ -Y1ME]H_0/346HNO3\PX':7 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M?G#^? XP>(G_  D>7W_*R;S_ -J?1^!V>P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P&!,4H&'H/U#T$!$! ?AU 0]0'H.!Q
M8\28B;>GF6$1$>GE%V24.HB/0"ZAU$  '7X 'T!]&!VEP& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P)R?'[/TA@5<#
MSX# 8# 8# 8# 8# 8# 8# B'Q#\X?SX'&#Q$_P"$CR^_Y63>?^U/H_ [/8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# G)\
M?L_2&!Q6\27^'/S+_P"5&V5_M1:BP.TV P& P& P& P& P& P& P& P& P&
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M?1^!V>P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MJL*2GT=Y!Z8'9; 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M#C;XF6"L;M'R^-5C$.<?*SN)X!DQ$2>U):8T+(H$ZB ??31=% P?08!P.R.
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MS5<,WZ)A;KI$<ME""8H] .40^@<"Z/FD@.!!$Q1'N .\AB=PD+W&Z=X%$0*
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M P& P& P& P& P& P& P& P& P& P& P& P&!.3X_9^D,"K@>? 8# 8# 8#
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M15'L$.L8B #TZA\?K#U^/\_3 AW%$.H&#H( (#U#IT-Z /7ZA$?3 C@,!@,
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M&>TQLR>8Z^K]7VJ[TZXMVQ;/ 5-[6JS4WUQ30;HO5UP(*C@""'0AS8&3^/\
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MD#^W@.AO[PW\@?V\!T-_>&_D#^W@.AO[PW\@?V\!T-_>&_D#^W@0^'43="
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M>U^O_P"W=RX^Z(]O0.O[V^G</>'0/B(B&!.7P(>/\X=227,$P?6'._EL/_\
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MY"F'J)_;#T#9W7]<.F!*7^'\\41R H7C_;A3$1#N_K!\A0 !* F'NZ[.#M
M#XC@1_\ J?OQ2!U_]GZV]  PF'^L)R&$"@4.HB80V;T+^3K\?HP)A_A]_%.
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M3X&]P5$E)1%68=4&&MZ$$I))OW]=D*Y.JU%E)]SXCI6LSSIB[,Q 3D9NE45
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MR#--!B1-N];U8H1I%R@"I6101Z^U]W \&N=+:DU -D+JC5NO=9)V^=/9+4%
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MW)XDL<H(5YO(QZR2C@1[$S)CW=/3J'LI&P:ELFFUO85#ET+32KC",+'5;)%
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M'.%3I$1546A)IHY*=(RB9DG!1 P^O0+L,Z*0O<9%P =QBC_1"'0 Z=#B(B
MF/<'WNO0H?'I@>KZ 'Z_4,!@,!@,#DWY0%@)>?%XB*J*8K^3[18 0Y?Z=<$J
M'M9?L:&]LX%$H@!E/4!$A3=,#K*/Q'\X_P ^!# 8# 8$Y/C]GZ0P*N!Y\!@,
M!@,!@,!@,!@,!@,!@3$_6#[?YAP.4_C?_P .OEQ_RD4G_BF\6<#JM@,!@,"
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ML_7Z6Q;9.V"D1E(O,:&QIJZW1::"QV!.MUA=5[(.7KAV]0< 4QCG<I=V!I!
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MW'W96S;=LM[:-BZ$T8CHBZ2\^[OM=N,]J:.V4_MYT4G\F^CHJ<.HLY*LCV$
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M<A#" 30WF%X?6758;?KS;?T]6YB]U#7FN(B&X];3E+CN^>OD!)VNK+:-JK.
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M^L?J_L=,#R/&B+Y(B+A)!8A%4UR%702<$*N@<%6ZQ2*E,4%$%B@<IOUBF#J
M@/K@5D4P13!,H_ /O#Z_>'IT$P]3&'J/Y\"KU'ZQ_E'Z^O\ /@>9XU;OVCIB
M\;H.V;QLNT=M'21%VKILY3,BX;.4%2F36;KI'$IR& 2F*(@.!\Z @(:K1,?
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M1-T]<#$NQN0>AM0-5'NU-S:NUTW32,KTN5]K%>75(0QB#\LUDI%NZ=G%0HE
MB1#G,8.@ (^F!KDMY"M"S9TD=116Z^0KA=1PDF?1FD=AW*$ S<B9CJ*75]$U
M^@(MU!5!,BAY8$S*=>A@$IN@9GU9LS<E[L\DC;>.MBU%16\>9>,LEWV%196S
M3,@*Z14F2=(I4A94X9L#8PG.JXD .!P$GM_W8AL)Z?0'0/Y?[. P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P&!.3X_9^D,"K@>? 8# 8# 8# 8# 8# 8# 8$Q/U@^W^8<#E/XW_\
M#KY<?\I%)_XIO%G ZK8# 8# 8# 8# 8'PK18X2H5V8M5FF(VOURNL',Q8)V8
M=)LHN(A8],74G(/7:QB)-D&S-(YA,8>@=/I^&!^&S7WG*W26C\@GW"7C+9[K
MRQYX<I]J[$I]CFJ[-.Z4WK<-%PFF]2#I76ZBI;SO"Q*ZMUG%RTG(%2CJE$.G
M:AWSLI2'0 -T>%/\.G8-I[E4YN>83;UUY-;ZN++YD^B).W+RU#J3=90B[>#V
M!8888IG:!CQ33*G"P;:*KK3V02.5X'<)P_5Q6*95:37HBHTZO0M3JM?;(,8*
MM5F(C("!AV#4$RMF$;$13-K'LF;<B8%(1-,H%  Z?# ^U)R+.'8.Y22<MF$>
MP;JNWKY\Y08L6;5N0RB[EX]='3;-&Z*91,<ZA@*4H=1P.%7+;S]\5M$0]J#1
M$)+\MYJH/RP=FM&O9F-KG'ZJ6-P<S1I697?TX12I6J[.)$Q$$:Y4D['.N%#@
M4K<HC@<!./E1\BG\21R6VYKCR V2R<;>!/&&S5A_?>-VHHQ2G!9-AR2 SU1U
MK)6:2&4GI>TQE<= \FEY)0R\0*I"$9-79R>T'[5N-'%;C_Q"U36=+\;-8U?4
MVLJNCTCZW5X])#YUXH B[F;#++%6F;)8'RIA.X?/7"[A4X_>/TZ  ;#_ */A
M^3 8# 8# 8$>@].H (_4'U_;\,#!NVN2O'_0C):4W?O#3^GXQ$"&,\V=LBI4
M=/M,7N,(!8I5@H80#U* %^_] ^N!SWEO-WP8>R3F T;([NY?V9K]TT'Q(X];
M7W.@=<W:*21KE&5YCKYH0_N$ZK+RJ;<!,'53IU' K?UTO)#M)80T-XL)ZCU]
M4YBM+ES-Y&:XTO[9 ,D'NR&O-;--S7IJ(IG,<I?;$IS$[!.01Z@'HC=4>7W9
MLJHYV1RXXG<9JXLBHFI6>-W'BR[9MY#.B <!_;[>=N3AFTDS*( 5PC K-S]P
M]4 'U ,BM?&U6K>R(CR,Y3\R>2B@K X<QUNWC*ZMJ*RID&Z:I34KCRRU/ F;
M+&0 XH*E62#N$.WH8P&#/^K>$'$/2H ?5_'+4-3>>\@Y-,MZ1"2=E5=-AZI.
MW-JG6LK8G+H#?>%0[D3B<>X1[O7 V?(U021*@DF1-$@ ":1"@4B0=?O D4.@
M)@("(>GPP/1@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"<GQ^S](8%7 \^ P& P& P& P& P&
M P& P)B?K!]O\PX'*?QO_P"'7RX_Y2*3_P 4WBS@=5L!@,!@,!@,"B=PBF"A
ME%"IE1*8ZIS]2$3(4O><YU# !"D(7U$PCT#Z<#CYO+S&Z+B=CS7'WAQ0-F^0
MSE!"_.L)35/&)FRD:/2)1J"(?_E=WW,K,M6:]9(+'[5ND@[>)]IRBW$P=HA^
M6?R[;LYM<E74CQFWO;4=P;<OE^UUI-MQ XDV&=@>'O$G8^[G[V+H$3R4W6DZ
MCK3RCY)QS</GTJHT,V@X9%LH_>HBAV$,'ZZ/';XO>/WCVUQ7(RHLY38F\0H5
M8I5]Y ["?K6C9%DCJ['HLD:E 2KX5"4C6<(JD9*,K\41JP;-R%[R*J]R@AGC
ME)S[X8\*X$TYRCY):KTTDFB*S6(M%G:_MC*E(F8P$A*3&_B%PFEE0*(%!LR5
M$WT#Z".!R=C_ #=[>Y5N1BO%QXXN2?)Q@\$[*.Y#;P:AQHXO,#K H1*<7M5R
M27LEFC6H@14R#%LD[70[@3^\ @ <0>3]3\M')'D0[X];QWMQ[Y?\J)1"-F(?
M@#HNN[$LG$KC)7PFVA$+CRYGVUWUU0X>!<,W"AV[:RDML](G0(1LW]M10I@W
MEV!Q7F>/U\T?Q\I,AK'E%YB]MPOS>K)J)UBPJ_#OQ;:&%8D;;=[:FT#$-S4G
M5;2#'W4("2<H#9+=8_;.*A$R&3P/TL<-^)NNN%>AJ?H?6QW\FQ@DWTS;[O/G
M!U<]J[,LCI65ONU+[*F,HYFKC=YY=1VZ7644.0IB(E-[:1  -I,"43 '7KU]
M Z]?H]1Z?'X=<"D#E(>@=3=3=1 .TWP#L 1$0 0#U4#XCZX&.=C[IT_IV&<6
M+;6T=?:P@FK=T[7E[_<:]46!$&2?NNC@YG9!BF<44PZB4HB?Z.G7 Y0RG\01
MXNWLHYK6H]R7WDY;6TJE$%J?&+0VY]S2;UXJ7N(6.D:W3 K#M$WH'NDD!3#N
M >O;ZX'H_P"46YU;0/*,N,_B%Y+.$%4$3PEUY;[+UAQ=JZAU1,8[A[77LG<M
MB-VR10'^B&.3<&'IU*4! 1#WM*=YT=NIQSJQ[>X#\,8Q<B:K^(UKKK97*.^M
MRJE]M5H>P;!EM=4AL[:]QE .E'O4CJ 0!$2=P"$$O$O?-@@Z6Y3>37R";X4D
M' *25=I>U(CB]K=PV*)A_#T*CH>#KTNW9J>X/N%-+' _0 ^ " AFO4OA^\:V
MG7PS=<X?ZBL5L."1U[UMJ+>;OO+ETGT SP]IVV\N,LBY<&*!U1040*H?U$N!
MT5@H.'K46TA:_$Q4%$L4RI-(R$C641&MDRE I2-F$>B@T;D I0 "D*   8'U
M>G^;\^!#H'U!_(&!' 8# 8# !Z^F!1!=,3"4.X3 ;L[0*/4QP*8P@4!Z=W0I
M!'T^C J$,!_@!R^G7[Z9TQ_NOH.4H]?NX% 'C85")>Z4%%#'(F4_W!5.F!A4
M*CW=/=,F!!$P%ZB4/4>F!%9VV04!%58A51(*A4NO54R13 4ZA$P_I#D(80 P
M@ @7KZ].H8%8Q@*43=IC_D('4P_F#Z<"3WB" "7J<!'IU('> =!$IA,)>H%
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MAWB'G5X+^9LIU 9^<LJJ:B1"E!QX]^/3I1%03!_2%5:RK5/J82"':8HAT$<
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MH]?B X%-UP6\KWMG!EYO+H102_T1W7!KBRL4#]P!T532B43'*(CTZ%$! 1#
MW*X@:'Y>:8=7M7E'SBF.82,^G#%IS:2T-JW2R%$^25?#)'0/KMJBXGUYE)9$
M%?FS"5'V0]L [C8&[^ P& P& P)R?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8#
MF)^L'V_S#@<I_&__ (=?+C_E(I/_ !3>+.!U6P/&_9(R+1RQ=)D6:O&Z[-T@
MH)BD6:NDCHN4C&(8INBJ)Q+Z" @ B(#UZ8'#R(\#FF-;+_A'&OF7Y$>)NI%;
M#9+6OH?07*2?KVK4[!:W7XC-2$5'3$7.2\.9W)"*Y@1=AU,80$>WH !?]2\$
M'CO8S:%KV_0MB<O+D@^-)$LG,G<VR>0OLO56X(.U6U8N5A5HZ9'AP]TY!BQ
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M)K6CNF;8G*3L.'C";/IEC?R\8C>]&I7NK1\.+J,>%AY!2E#LN;2,0A5&YEI
MXB)Q3*)0QW=_%-P.O:.O&TWHM!&(UQ&3M=@H.O73855AIFIVJ_/MJS=+N\=
M6=BTV%4WFRIAS,EC)HKMJD]6.<B8 80P/A53QQ>.YU<-QMJ]KFM6&SJ'<5R\
MTDNPK5/QVH$+W*5W;,A5:3KUU9GD+HR,O,K$1L\X80[.,3DQ*58Q3D$,#Y=
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MJ(F.83#UP/M]A/3[A?01$/NAZ";U,(>GH)A^/UX$>TO02@4H%'XE H 4?S@
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M+K)H&.*9%5CG  ,8PB'U   ] #H'Y/3\F P& P& P& P)R?'[/TA@5<#SX#
M8# 8# 8# 8# 8# 8# F)^L'V_P PX'*?QO\ ^'7RX_Y2*3_Q3>+.!U6P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P)R?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8# F)^L'V_S#@<I_&__ (=?+C_E
M(I/_ !3>+.!U6P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P)R?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8# F)^L'V
M_P PX'*?QO\ ^'7RX_Y2*3_Q3>+.!U6P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P)R?'[/TA@5<#SX# 8# 8#
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M?CT_/TP("(!\1 /SCTP(_1U^CZ_HP)>\@" =Y.X?@7N #?8'TX$>H#\! ?4
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M1$/K2@R&OM92L%>;1&6?7+5]M*/W.WM-*L*4@9]!7Z%V3&(R#"83$7;8 ,@
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ME4WGY<1*!PZ>2.6 0.0Z8_T?%+BXB8Q0.4HF(*B8]HAU P!U 1# ZL8# 8#
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M *8/<5/W>ICJ&[U1-V@3N%0?7X%#T^'I@1!J4 , *K%[P %.TP!W]  !$0
M #' !ZB'TF$?C@/E2]! %5B@(@(]I^@CT$@^H@'T]G01^/0>F!(+(!#I\PYZ
MB4""I[O100 X']5"@!A$1#H/Y/3 J?*_TI%!65,*?NB0.X0+W+" G.(=1-UZ
M!T .O0 $>G3 J^W^L)3G*8W;U,4P@(]HA\?[[J =/KZ8%+Y8/@90QP^KH
M?WHE   0 1_)UP/EPU9@ZXV=,8",CX9@\D9&7<,(EBVCF:LI+NE'TM(*MVJ2
M2:CR3>KJ++J=.JJJAC&ZF$1$/K"@40Z=1*'<)NT@B4HF$>[J)0'H(]_0?R]/
M7 "W+VB0IA(!O4X@ =QQ .T!,80'T OIT^'3  @ $[/<.(=1$/O?J@("'0 $
M.@]>HB/7KUZ^N!$B($[NU10.[H!0ZAT(4.O0H=.G4H!Z!]10Z8$HM2"H97N
MIS!V]2D*!RAU,)NB@@)@ W=Z@'T_GP)P1[0 H*FZ_>ZG#X")@ .O9^J!0Z!]
MT Z=/3 B1(" !0.<2E  Z"8>AN@=H]WP$P"'UX$AFY#= $R@ ']R4W:7X]1Z
M  = ZC\>G3UP)?E2=XG[C]3  *  AT4Z 4H"?T$3'!,H%ZC] ?GP*GLEZB?J
M8%.HB"@#T$!,  /0 ^[TZ!\,"7Y<OW@[S"4X]3@ %+W>HB/<(% 3=1$1'KU#
MU] # D,T3,("!U"=H"! *<0* &_6 Q/U#@;J/4!#IZ_#T#H$PMP$.@J*]
M*'>(@3MZ]HD >O:(=?C\<"<J70  3F,!3=Q2B!>TOH( !0Z>@  _GP("@4>X
M!,<2F$!$O4  .@  =O:!>G:(>@CU$/A\,"/M!][[PB)_UA'UZAZ?=]?[CH'3
MI]0C@0!$ ]0.H'IT]#B ?K=P"(!\1 /3I\.GT8$ ;DZ=!'J7J(].TH=>HB(@
M/0/4@]?A]>!."10-WAZ#UZ_1Z&'XB ].H";Z<"!DS"/4JRA?CU#J40,(_ 3
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M638C)FR8,&B2+1FS:,TB))))D*FF0H 4  ,#W_+AU*/N*=Q [2"(E'M#H4!
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MY-B/YQ94'^U@=3<!@,!@,!@,!@,!@,!@,!@,!@,!@,!TZ?' 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8#I@,!@,!@,!@,!@,!@,!@,!@,!@,!@.F P& P&
M P& P& P& P& P& P'3Z?HP& P& P& P)R?'[/TA@5<#SX# 8# 8# 8# 8#
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M4O%/\BU9/ 252MO)ML,D\4 ZK-8IV=<D#M$VG8"1DS)]%>_O[B].F!X)Q?\
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M0_XI24HH]A1UO_57:;40C$8XC9_^T074^T@2<&?*.Q;?) S+[8)E4]P>HE#
MW*#KT#K\>@=>G7IU^GIU]<". P&! 3%*(=1^(] #Z_R &!S1Y%M_+PYVU.CQ
M+F?'PQTD#.(2K;;?[/?Z^S!D@CT%)Y>94H+12M?(FD?=!H")N\$ +[GWQP,*
MDB_X@<45_=M'B3*OT3^5*C%<KQ2-]_\ IOF%5&W<GT3_ %.TA^IOCT# IEC/
MX@SN#W+-XCP3ZAWBE&\LC* 7Z1+W,P*8W3Z.@=?R8%;\+_B!/> O[4>)?Y43
ME 50B^5@N2D].X00.U(D8?J 3A@><8S^('%T<4[CXDA9 9P5+W8;E@1P<"J
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MB#"G[G'*SQ>E0*FF)CAQEY!&'KWF!?[O[W$@'L+VB4>X -U$.GIW8$2ZZ_B
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MN45$DSAWM:N =) L0 ]LY2*)& 1'O24(0Z:GJ4.T% -U /B "'7H/4 #T8#
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MFVH7;6FY>ZZS;.==0&FYB%CK+-0UZ/-!3MHSDTWL+96%A(1=5[(K%60[DC)
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M5VM//J-)TY2/E=<33I](F<.IH:[9H1BX7!4?=<))'+W=Q^N!A:=\>7'B9V#
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M9AJ)4:O'WK<-GLR6H=;:[VQ5MTUW5FGPEC+)T37Y[_2XQ9VT2!91PW9)-C+
MDD0"AM=_5'T@WU=R?U A$34?3N7UDV_;MRHLIYX$G*V+>56:U38;Z!D%A7/
MJR$0P)\L"0"DW6 3D#UP-6-K>)7B'MQRXFYD=J5ZW&D=&S;>_4_9$C$6F*=<
M?M6S>G*(O&.G+%^P;$D->V!ZUDE/ES*N%%/F"&36("A0^K5_&GPHTA09*KLR
MV6I4V8J7&34YWMJVE*&'\&XZ[8G-EZ*C$;!8W@.E["OL:[."KF5557EC+D;"
M!Q$I3!\+<'BNX<66Y6C<]ELVTM.6ZY;!M]KO-_H^Z)#7:]J_>R_JR-DUK-R:
MYCLC4RRS-;CQ;L4Q1=(/3G^372.N<#!L5R1X1:;Y*UG5,)-R6R-93>BY121U
M/LC3%Z?4'96NP=5!YK^;B8BVH$?N1B+%3I ["0;."+%<H  B(*%*? M;1/CW
MXY<9>+U]XE:B5V=2=)7']M9)^@EM.V?M155[N@FI:I2FWM5ZG8*DX>OB+20K
M(K%]MZNJKZ%/VX&H=A\*W&%KI*]0>HF3RY[:M+7;-FK^SN0%ZN-XC[+?MOPN
MNHF8MEXD:3)5B3=N&<;JN""'D8KV'4([;%D&W<X XG#Z_!7Q5MM$UIY:N2-J
M4VAR&G-K;RVJM9(G9&S;C'54^_M:UW5-VJJ=RV"[3MNRUWE2K13?B<PU1527
M'JV00*F4,#[D#X4.$-5V!K&^5EKN.M.M4-.-YH."B]KSK:N2DSQ/CV,3I&SV
M^+^3.M9IF @F)62P+K@T=)"*ID!<@58H?7?>'7BLX:5Z-1LO)!O!QK6Q5JPU
MYAO"QQT/LS6%@V-,;5;:3V?') 1O;=65>V3C_P##&!_;7:,GRK8RZB"IB"&1
MKIXR>%>Q:=*:IM>OC2U/?;:W9O63IW[7S"HN;QR0@;/6-B2GM$7/(Q<*^;65
MR>,0;'0:Q[E)(Z  *!  ,4AXLN*S6@2.C7>].29+#;[:AL0;+(\D9 VUI*.I
M=9<Z^_ V[9\B,#*:VA*U8_DGD<I#N&8+KI+JC\X*:V!M74^"?'*G:1XU\=J_
M3Y1GJ[B3<->WG241^T\R=Y!V?5:CY:JRDQ*BZ,^L  XE'"KHCDQR/%E!$X '
M3H&HFR?!YP4VLA&-[%%;?BF3*KW2G.V-6VO8ZVK8*_==RO\ ?3YI./F?27]I
MALV47>-2MEVY11.""I54BE* ;'TWA#Q+,]I]CIL<,H75VS.2UTA5H6_2,W'0
M^Q^1E>F:+OI*4.@[5(9TM'33QL1FIVC%N53=I"&*  &*];^(GB-J"_4>]Z^4
MW150HC+2I1I\-N2UQ='MDYQ[KK"K:OMMXK[$6REEGHNL1C=D\!5P1G*)IIF=
MMUE"E4 /I\G/&=Q YM;I_>_M"0V$_N-8K]7UA>J]KS;,G58*P0=4L26S*95]
MB0L&J>114B9R23D2MP79'=(K%!P59N8I<"\[QXU.(>S(LT-;=?RC^.+,\HIP
M[+]KK$ GFN9:"Z.]WKE0CW^C6F%'!7$>).GX0NBF=KV=G3 ^WQJX.Z(X=QFW
MW,'9]H7U_O8]2;;;NO(O:\OM2=MC:JU@FNZG".9:TJI,VD>C6ETXY)JB1,BR
M8D 0,<WJ&$(;Q-\(]7UZTOK"\V;)U1C#T%I!CMC>=IE:]HK6FF]A-=P52@:U
MDYF3;$U]K&!ND*B_<LSKG(=NT(@JI\NF! #[UG\5O"R_Q3I*4JEK=M)<-W2S
M"0@]B61B[BIKD=N6!Y&W.VU*5A'2+V(L3':T0UEX%\U6$T:5,"I"*8@&!C%+
MPY\/74L_5BME<GOWP+M)DFX=GQ/*2ZDW3N&HWFP-+"-:W5.%D!7GJ6]DX 31
M;;Y5F1J0J_RIRB=41#<_CYQC>:GW%R8W;:):/FK9OFVT5A7FT8U4194+2FGJ
M@WJ>K:'[CH1<R$PW,ZE'\B\$3 JYD1(43%2 Q@W&P& P& P& P)R?'[/TA@5
M<#SX# 8# 8# 8# 8# 8# 8# B'Q#\X?SX'+'Q?\ _=OD7_RF_)O_ +RH6!U-
MP& P& P& P'7 8#K]'T8# 8# 8#K]'T8# 8# =?H^C 8# 8# 8# 8# 8# 8#
M 8# U*Y[Q<E,\(^7,9#,7DI,/N->[&<7&1S=P[?R+YUKNP(MF#-JS26=N7#M
M4X$(FD0RASF   1'I@?E I.J?(KQ$LO'+5.N:=M+957X_>+CE?L[AOO-]65K
MG=H.>WC2M#2L[QUNT [30B'-^T99("3&K,WAVPRL4=BU]E0S=4@!MYJBW\I]
MR7J%TMJCEKSGEN(5@O4Z-2Y+7"KOJKR,L+^$XAWC8&V->R=MO&JH*2B*;!;F
M90J4.^_"4UFK]T[C63LX-R 4-OO%3.\U4[I6"<@MB\@-HPFWO'_J??$^OO=B
MV;0E3Y%.-CV^L3-7K*L;6:\WIS63I"$:Y?P9RJ* 8/FC=#*'ZAR"-<N:,AL"
M:WO!7;FG=.:&J^#G,U#>K*VZOM9];<<MR*\B..,FGJGCH#_6D/3YAE+ZOJ\H
MI'(1[J;<3L=')/D!!=7MP.]VBMR73F5I?R86B(L>W$]5V*U7JA<:7DG0K+K&
M[1],+QHI)GTC1(VY5J+L;EE*;#EY$6*RS,ZGSB2@%+Z!@<:]!CR5XNO>*7'^
M*V+S*H]MIK7Q\0W%#1%;UZ>4T5N#2VSXV@R_-6R[]_ M=,:Z:UTJ=L5N:/',
M])1S^L(QT<X1(LX6.HJ%Y6JS>1G65>9VE;>O-J<K>]>-^P-F<AIUM6TK;8..
ML=3.;NO*HYG>/%3_ &/2+4KBQXSV:95",(F_>2+9A\^1-51N B&J6VMQ\@M1
M<=KNAQWM_D1G8[=/,OE[?M:[^5+M'5M]V77ZGI#243IE2^/J]Q]OVU-E/YN?
M4<$K;((FNQEH3BW1G[Q$$BA@4]A7WR"T9UM'8"%HY$ZBMG(N^<$+%R6MA8+:
M-,CZS6'/"PZC^PQ$KKS6%\MFM&LCNV#4C)XT3&.U6KI-!F[(W37+U#=A/FKS
MSH/&*GTRY6_>]QY([EXC\;WFA[+3^->TE3VG:37DO<:]M6:L)76NSGJ5K_<J
M:&5EAGT(T#-!!^1%(5#" =3M _UB&VDO(]M]]L[<]_V3([;Y;Q.AJ%?#H(5G
M7M?U:>UQ>IH?6$"G QSYLSFG!4UQ>'6<@_ZH"4 *F7J'%6:VQN*B:TXGUG2^
M[^7M!C#<$>&^P>&E4T-1[#>->\@N3EZV!,K<E(_D-8V%1GFDX[<KR*!IEC//
M8AI%(NW+\!.LF=,H=!>,O+CE+<^=&JN-VPG^X4%Z!NOR#_OWCY?5EBA*0?5R
M:[%_Q)+(;!6K+:G32"D4Z74A$V$DHLL@GU5 PE' U/YCV;>U]YWU&%5G^3T[
MN?5_D(ITYQYX\-:98E^*(<?*WQ^FY.B;DD)N/I2M.5L4QM>2=(NY>1FTG+!R
M)V9T!(B G#3#AA<O).^UQO9)KMO>C#9&XKQQ)D>0A*QKC:*>QZ)O#8?*36&N
M]UV"!FM@Z0J%=JTFEH\LHS?Q$0>:BXR+CDI1)8$B=3ANQO'8'++3E8?:TO?)
M7GW$:ZUK;^=U>TEN/7]&?;#V[MG>E$OM'#B1KK<ECKM"DG5FI4C79F6*@DY9
MQL-: 1[73U+V"%$+D8TOR7[JN&E[;N#D'S1T;:MD<N*-QYW1JG2RD/4]8T'3
M(\2:I>]D7*I&;TF83B7,GNXCMHUMAW;HC$Y%F;57N.;J&%*'.>1#:.Q.->N7
M>R^5-.J6RI/B[I_<_(&G45I!;8?4:I6/FVSN<K.[/?Z^=*QDQ*GI%73D)5PD
MF=H+U%4B2 O!*<,3\@N47D9HL1Q'HU%L/-^7W%K36-&LB]N73MB=5W28_+ZX
M4&QK[)H%%T7;4-J6AIJ*M,33)+%+UR*:,7:3Y QUENX0O. D>7.M-?[V;Z9?
M<FG-_K/(OR4SFQ)N4UO)WO9.K*O:=\\>7@3^BGMMKAU).>>Z+FIR6@46#ER,
MBZ*H*1%%$")$#8_7R_++D'2F6N]2\G?( QXP_O\ >5;S6_(*6:RU=Y+;#UKK
MSC55K+4*U;KA=->,K7&U)QR%DI)I!OG4>SD9=!J9F3[A4SF#.?+_ &YS&9>*
M/AEL!YL3;FK]WV-II17D5)U*E;*B-@S2KNDRCJP5R?LNJ*9=[MHMW/6E%L9Q
M,(UZ00*[*5NLB1)4PX&FK+D)S[N5WT3(3<MSYU-NN3I7!AQQDX\GK9IW6.XX
ME_/?)\P+5R]M\%K5I5S3!()HY=KK2PUUS#L3L546)'2YB%#V,MS<F;'0I>1_
M>-SXO?+=YMC2P\F>/M@T@[LO%_0\C%<W]9LI)KJ1&TZTC$8U9;59%T8@*\]F
M&*T2"\L[71.F#G U60W!S2W_ &'>52N\#R]LNM+";CAL1*B[V4V!:0HFV*7S
M\U^T? W='TCKFBT![7J"[*$U6ZLYFXIJT1!8SE44Q. ;Q>(S;7D0N7-^U5_E
M!L_<<VFG4-^.>1>J=@P&WUZ7KVYL=HHQVHC4%U9]<U34&O6AXDKI-BVK$S.H
M3,4)%S]GM@? P-N:U^2/9?-3FMIR6VYN^MUR4=<MJG5M,P\/N>1J]GXI(Z,L
M!]8RVMF4;K4-+P%DGI)9@HSMIK,I,!+F58*M 4/T*'3TM/V7(^,[Q5::U3MG
MD[0GMZM'#C7&Q]C4)Y/5W=D)K=*E2KS9["QS[B!%[3$6HQ@QR[I\R(+0Q4B_
MK@!L#E_L/<_D2K--I41LG;//:K[,IU V_6.($?KBBV!\XY.<C:+S)V/KVFQ?
M*16$UP_CI]N^T)#59Z"<PM$0TK$O'<I[P*"8P!L+7]>^0#:=M&5OO*#GKJ]+
M;6^?(_4KC7]?3L)7:O4->:!"?L?&='7?S=!EI&B,['-L03;RK)R=:QQ:0- 6
M,W.GT"_^8V].>*/B]\=-\@)G;M:OFQ%M7DYC;$J#78%-V14J^KJNQ.G<]8U=
M9ZYV!L*G1KZ^-&02R\=#&.FH8I% *FH<0"KXLTM^6/FQK?;')'8VX;M;-A^*
M_601T_-TZ^4&C7YQ7^4&YDG:EK@[56(,ZFP*I2I&"<"I( R?.BRAWA6WMNP(
M0.0.U-:\@6.GN1.LV-GYCO&=(N_/N7O4R_@+7-6ZG/4O(5I*UUIC5[7^PA)U
MY7[KIETG/J$CEG3.3,LN;M'V!3(&UW*RV>1VIU&Q;9K&[^7E;U3LCGYR+U[:
MKA*3FUX6+UQQFUG!/EN++R@PNKM96W85+IVTY6265D;(UC'@RCIJU17%)%8!
M .HFX;WRXC/%KPXL5]V3N&M6Z6L7'L.:N[-(5"Q16^*QH:0?/0O]UJ53=5A]
M>(6RRJ0Q"4HX0BS2L>W<NG1&A^TZ90Y+:)Y#[WXC:1N+AN]YCQFNMW:U\GK;
M0"LWIK95@V+;N3<ER,:RFDKY?("+IQ9^$OTW2I,T@W?RC-@S79I.C^AB*E .
MIGF-V=R1UMI'BO9]6;6W'19'V[.\V%5M41.V*_.[<N:.K8Y2GU-QM'5>O]I/
M=;S_ .U)UU8YC-P+F"GGP U=J$!#L4#0CD-R#YH-+9L"=W:OSEXD\>)F$F=B
M,YCCOKN/?[RA-RUG@QQRN57KU_E->TN9>6RA1=[=7!*Q/'+<L*,PS19NGC)N
M@5)(,LTV\\_+.CH+E1&;3Y:6)A6[OXJ*FSUA ^W(:=V]JO=6JZ6/*J]6FLHU
MHI;K,/)*QKK*RQI C: DDR*=4@!3J'-,MXYO\KJOR?K>Q['SPC=(D;:-W*_+
M<%MJW*QZ^V%JOGMK65O]1B5V^A=<P%(NU+THNZ<!6*E^-1B?R2"_S+M1$>H9
MLO/)?R$[#Y&\OX[6H\S)*ESFD/)177VGML5>[[$AZ_/T/7\N?C":'H9]"5S2
M-+=V2S0J?X"SCYBRR%F:.3)O3&54,D(9NY8J^0>KT.2VU$;?Y;:YI%_YD*:M
MW$LWD=FPU>T9QWH6G(:9UXYU34--Z[MEWH-/OFVWBC><LD.PD>X"(-5/;:>Z
M9(-\N$4OO!;E5P;E=BVV0V'MVZ^-_;Q^5-L>U.?HKN=I]5WG4U.+UJN51N,7
M'W&%N;D)^>;-E)!M&*RQ323@R:?ME0*'Z"2'$Y>X0$!ZB @/UE$0]!'XAZ?'
M FP& P& P& P)R?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8# @/3IZCT#TZCU .
M@"/J/41  Z!@<J_%HN5PKY$U2]O0WDXY/ ':JDN':5K0RE_I43&*(]H>H#ZE
M'J _# ZJX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#ZA
M^H>H?D' ?R?$!Z] Z]0^ ]?CU# B(]W4# !@'IU 0#H/0>H=?S#@0$"C_<%^
M/=\/[H?B/YQP(]1].OJ >H /P_)_)@!'J("/KT^'4 P(?0(= Z#\0$ $!Z_D
M'TP(]1]?R_'\OY_K# B!A >O7X_' =P]>OH'V!]/J/Q]?C@0ZB'7\OQ^&!3.
M!A$!#IU .G41Z?2'3H/0WKZ?2 @(!TP+,H&NZ5JVM,:7KNK0E+J,6\F'T97*
MZS3C8=@ZL$M(S\VJS8("5!O^(S,LX<J=I0**RQA H=?0+V'U#M, &+Z=0, "
M ]!ZA_(.!$!Z!VAT /J   /7X^G3 "(CTZ^O3X#T#J'T#T'X^H8 ![?@ ?#I
M\/3I]F!#\G0!#IT !^ !^3ZL /P$.@  _$  .@_1ZA]/PP(]>@B(  "/Q'IZ
MCZ 'J/Q^ 8 !Z=.@!T#X!TZ '\GK@!'K\>GT?0'T?#[0^CZL" = $1   1^(
M@ =1Z].O4?CZ],!] AZ=!'J/H'J(_$1^L1P(B/40$0 PEZ]HB'J'4.@]!]!#
MJ'QP(]W7IU !Z?6'U@(?#X=>@]/S8$!]0 H@ @'UA@0#H ="@!0#X 4   ^G
MT^KUP @ B(B4HB/TB =?SA^7 ?7^7X_R=/YL!]@?1\  /ATZ?1]'3 !T >[M
M+W#U]>GKZ_$.OU#TP ]/7[I0ZCW#T /4WI]X?R^@8$>X?K_S!@.H@/7Z<"'T
M]?I#Z?Y?[>!-W#UZ^G</0!-T#J(!UZ!U^H.N!*'IZ@  /H'7H'T=>G\G7T_/
M@:T\D>(/&_EO&5B&Y$:@J^U8^G/W<G6?QQ:98/(5V_(@G*(-9& E(>1_"9YN
MV(WDF1EC,Y%L'LN4EDA$@AL'"0\978:)@(2-CX6&A(UE#Q$/$M4647%1<<V3
M9L(V.9MTTF[1BR:HD323(4I"$*     8'U.HCT_)\/R?9@.X?3U^'P#X!Z?D
MP(?EZ%$>T2AU#TZ#Z]/3Z.N!9D70:E$W&Q;#9UZ(;WBVPT!7K):4FA0G)B#J
MBTJO7(E\_$3**Q\.M.O#H)!VE(9R<>@B/7 O/ 8# 8# 8# 8$Y/C]GZ0P*N!
MY\!@,!@,!@,!@,!@,!@,!@2G*!R"0P=Q3"7J'U]#!Z>HAZ#@<A?$(Y1=1'D0
M4;+E<H)^4SF&U*L4RAOZ=I/UYL\2$53&4 &[E,R8 /P*4 #J'0<#KY@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@3D^/V?I# JX'GP& P& P& P& P& P& P&!$/B'YP_GP.,7A>_\ )7R,_P"5
MNYW_ .V&QP.SF P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P&!.3X_9^D,"K@>? 8# 8# 8# 8# 8# 8# 8$0^(?G#
M\OTA^; XQ^%\>ZJ>1@1*0H_\K;SM*($ W3J78$>4QNIS&,(G-U'Z@Z^F!V;P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P)R?'[/TA@5<#SX# 8# 8# 8# 8# 8# 8# B'Q#\X?SX'&+PO?^2OD9
M_P K=SO_ -L-C@=G,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,"<GQ^S](8%7 \^ P& P& P& P& P& P& P(A\
M0_.'\^!QB\+W_DKY&?\ *W<[_P#;#8X'9S 8# 8# 8$.H!\1 /S^F!$ Z_#U
M_-@1Z#]0_P @X#H/U#_(. Z#]0_R#@0'T#J/H'UCZ!_*.!*!RB & P=H]>AN
MOH/3X^OPZX$/<)T$W>7H'3J/7T#N] Z_5UP(]Y/3[Y?7X?> /YQP(]Q?[\G_
M +\O]O "8@=1$Y.@ (C]\OH >HC\<"'<7U^\7T$0_6+\0]/KP'>3U^\7T^/J
M'IZ]/7ZOA@.\O0![@$!^'3Z>G_2P '(/P,4>GITZAUZ_>].GQZ_='^3 @*J8
M  B<H )@* B(  F$0*!0$?B(B8 ^W >X3^^ >H] Z#U^CK]'Y,![A/AW%Z]0
M#IU]>H_  #XB.!$#E'X& ?40Z@/4.H (B'7\@!@ ,4?I#Z/[(=0_L#@1[@]?
M4/N^@_DZ_#K^?  8H^O7^7T_G_/@0[R]O=U^[_?>O3X]/CTZ?' FP& P& P)
M/<()A)WE[P#J)>OWNG4 ^'T]!$.O3X8$>\OT& ?0!]!Z^AA$H>H?68,"; @(
M@'Q'\N!$?3X_FP)!43#T$Y0'H4>G7UZ&'M*/3X]!-Z8$^!*)R@/;W!W>GI]/
MKU$/3X^H%' CU#Z_\P?' =0'X" _:'T?' C@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@0$0#XCT_S?\ 1P(_YOY/3 8# 8# 8#KU_P WY '^8<!@2@8I
MO@8!'H ] 'UZ#\!Z?'H.!-@,!@,!@,"<GQ^S](8%7 \^ P& P& P& P& P&
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M?]&Y9_ZZ8#YW^(1_U$\1/^B\L_\ 7/ ?._Q"/^HGB)_T;EG_ *Z8$#/OXA$
M)T@_$0(B<0/U6Y9AVDZ=>\/_  H/=Z_1Z8$ ?_Q" _\ WD\1 >O0/Z;ED/7\
MO_C3Z<";YW^(1_U$\1/^B\L_]<\!\]_$(?ZB^(G_ $;EG_KI@2F?_P 0B4Q
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MF >H&$ $0$>O42]0^Z8?K^. $A!]#$*(#\0$ ^D.@_1Z#T^G CVE].A0]
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MHY476<!O%7.>?,"M'U3HO;NR+B3DQNG6?C3G]9IU70UT5K5L;VG?L[!<J+F
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MY;<H-45O=_+KDIH&XUK6FL-;(U72^K]1\?)O9=?L%#D+SIZ;G6$L_P!U4\T
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M1=QKALU=?*1K<RB10(3 [F@4A?0I"D#KW="E  [A$3";H'TB8>O7Z\"; 8#
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MTP*2D2Q6!0JJ7N L)!<=X%$'1DP)[1G1.WL<BB) $@' 0(/P ,"N+- RH+&
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M[@*',3VCG/V=HG,HG]TW7KW%]!P( Q1 Q#E,J44R 1,I1*!$R "10(0 #T(
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*GQ^S](8%7 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>tv526458_ex1-2img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-2img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ 0   0 " 04! 0$
M       &!P@! P0%"0(*"P$!  $% 0$!              (! P0%!@<("1
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MAM$.9 6T8+&/*\,#7ZUVF*G( !3!YMNO<VW1UQM.Y=&S36![?3>H;IL!^RW
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M"1/HO4IGS)BJ"S)JZ&@P'SD&JA2E*=ND?DI! ./$ XP+YP& P& P& P& P&
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MP8PAP A@>M^ P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MUTUTAD[E]YB8# 8# 8# 8# 8# 8&$7N6B8/;R[O"7T-_8K[T\1'G@#?NXL/
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M7UMT5'=A99.>WJTU31DMMS"2)$ ?W\M>8?M,LJFD!42NOS/Y@+?+ $Q6 PE
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M)N>9>.?L_4/QR/KZ)S,1ZOD52%#DQN _3Z?P>O&5[91OEQXNN28B/Q:_,+P
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MN^,<3.+!T_S7F([H^4*WZ&;7V8M);IZG;VN_[3[6T[)+FC+9^8$=3EAIDZB
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M,ZO2OKEUBTKH:+"=U/2F=5D+E 5X; LQ=NU4GY6[,'* BBX<+(D$%G1S"8@
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M=5D;).HQRK1NW7>B8& KG)^(P^/ <CE;<EQ]J5F*:]^DSKIZ:]-?XQT9&_\
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MYK-<_P!.:N;-;;X:5B+1$VB]+=U)_HTF?2>LHTSV_P!$;1INP;I! ZK#?6D
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MS6QXJTUTIDSQ_IQEO,:17MTB)_JETMJ]Q2S5FV/*(IK6OH6$FLEGCB3/:$Y
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M.^4R.N23;7CR(9 U3G95Q#0$,T8OTW$I-3,J[:*>*#5(YB%#UY'TP*0ZE?\
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MK'$.C$LEC-D6T=%PT0W/X-VC9(B9.1$?(P\Y1<>C6 P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MTT<@^K/</"-EBD[!ZP"3=L==JQIOV-4(WC9.(."5[:EY;*BJQL*)/F@<P?,
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M>LSUF=.OR=IA:,!@,!@,!@:<^O' _K^S"FO73\'D[W]56TUN_JSVX%@N\K-
MLTA0MAJMB"<T=6+6"B+>04]0*"97#@Y?40Y'@O/)@S4\E@FDTY+K/VKQ%O\
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M[SAYC6:CI19MJC=C!W,M*^@8ZBGT,#/LA^K0:B)@ H%!(2A\?+-;DVN7%_\
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MCFGK:WI$1TK6L>E:UCI$1I$?).@]?T9-I8G5KA4P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M*& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P&!QG3-N]15;.D4UVSA)1
M!PW63(HBX15*)%$EDS@8BB2A#"!BB @("(#DJV[?3U5K;)CRUS8[36])UB8^
M$_"8_&$<;4:H,$E$(^M0#!%1!!L=)I"QR"8MFQ@.W0$B;<I3)(*% Q"B'B0P
M (!R&1KVUG72-)]?Q9N3E.6OBC%7=9Z:6M:)K>T36UHTFT==(M,=)GUF.DN8
ME5:XB9N=."AB':D,FV4)%L2';E.<RB@(F*@ I HH<3#X\<F$1^(Y28B9UF(U
M5GE>5M2U,FZW-N^([M<EY[M(B(UZ]>D0YI(A@DFFBDT:II)?+^6D1J@"28)?
MY%\M," 0GROZG@/P_9QE=*_"(_E_:PJ9,U;3>^3)?);769M,S.OK\73A1J>!
M7I/V8KXDDETG4B086.\9!RB(F1</R_3^+Q9(P\E,H!C%^P<1I&OX^K8UYSFZ
M9*Y:[S<Q:E>VG^I?6E?2:TGNUK$Q\(TAVK:$BV?R_I635M\E 6J'T[=%O\AJ
M)@-],F"1" 5$#!R!0] R46[?1@;C/NMW3)CW>7)DIEMW6[IF9F?G,S,S,_BY
M9F:!C@<Z:9S 04P,=,AC F/K\L#"'/ASZ\97O_#JQIP8>^N7MTRTKI6T>L1^
M#Z.T;G.0YD4A.0 *4XI$$P% >2EYXY\2_8'V92M[5UTGU7XOEK$UI:8U]?Q?
M!&+=,ZBB:9"&5$QE!*F4#&,;^483<>0B/Z\E]R=-%JM;5G3NG[7_ $_#7YZ?
M,!B@ FX#@#CR8 ].3??S^C'W;:=/59G:8)K:-)[K^L]UM9_"9U^73\F^5$A2
M@0H !2_ ./A]W'ZLC-IM.LIX\-,-(QXHTI6.D>N@*13?'X<" AQZ" _8(<\<
M8BVBYI,QVVTFGQC3H$2*4?0"\!QP4"  %X#CTX_1B;3*%,5:=(B.R/2(B(BO
MY-W(KOKZM   ^  'Z@XPI$1'2(T@$.>?T^F"8UC1MBD @4/(>"\^GW^0<>N2
MBT1\(6OL5^F)F>R->GSU^;04$QY 0]!X].?0/'U#@/L]<1:8]%RE(QV[ZZQ;
M33U^#<\0Y 1]> X !_I_=D4M9!*!@X'[,(VK%O4\?4!^X../O#].#MZQUZ?)
MH8A1#C@ ^X> ]/U9*+3$ZJZ:5[:](_!\?)+^#D1,8GJ!A^//'']''=/6(Z1*
MU&&OT3?ZKT^,^K>R*\8#C 8&G ?'CUPII&NNG5\F)Y" \B E^ _T_3)1;3I\
M"W=->VLZ=7WD50<#Y$OW>GZ0#*PI:)F-(G1]914P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P&!ISZ@''H//K]W'']/ UP& P& P& P& P& P&!IS\?CZ?\WI@:X# 8#
M8# 8# 8# T$>./0?7[OL_7@!'@!'[L#Y _V^)@_@]?XL#[#U !]0Y^P?C_#^
MG 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&@CQQ^G UP& P& P& P& P&
MP,<.SVA+)V'UVA1:KV#W5ULDD)^/FOV_T1-PT#<UF[)-PFK!*O9R%G68Q#\R
MY3+$!$#B*9>#!@8 E]JG<OB ']V_W+CF!4IQ,&S]>D$R8 /*0@&N!#\7W_'
M[",]K+:S9=<\I[KON62J!SIBB@7;5$CA0(545%"?-;ZX.9454_P<F#\(>H>N
M!VC;VN]@I*NE'/NC^YB[34?.%VJ(;MI;<&C%1H*2# 3IZS$SD6SH?G?.-P<_
M'@(>.!RFWMA7=-JNBY]SOW,7+HZ)2(//WZ4Y &ZH  "M].GK,R:PF$!'Q-Z!
MS@<6:]KZ_NTR!#^Z+[F,&<$4TE#CNZERGFJ50#*N (ZUF4I!5( E\0Y O/(?
M# YC#VPKJ@^D%Y#W.?<PD&3@K8(V/+O:HLAC!23*1R8[M'69UI 72GXOYP
MG/ <X'RZ]L&[*$$K?W._<P:G%=R8J@[UJ*X BKQ],@)#:S+R+40'\?/*G/J&
M!UI?:XV0$41F/NG>YD,J10QSS([GI'@J0QQ,1(L=^[7Y!03+Z"//XOMP.2A[
M7FP4V**"_NC^Y>X?D14*M(#NRF)$76.KY$6!DGK0$D@21_ ! ,("/XA]<#B-
M_:WV21R*CGW4/<O<H"W=$^F+N:DM^%U2%*T<?.)K8Y_\R* )A)QXJ / \8',
MB/:\O[0ZHS'NB>Y?,D.1 J9$]W4Z+%(Z:(D74 [?6JPF^H6X/P/H0/PAZ8$$
MWG[>U^H&C=U7: ]RGW)AL=1U9L2UUQQ(;YK#QBTEJ_4I:6BOK(\FN&H2#8CU
MH05$Q4(*A.0\B_' H34G6YK5>@.MNW78;W0?<;J=<8=<*=N/:UE0[ 1*$+#H
MN*@QGI]VPBR:WDI#Y KN#%0;%.X7.82ID$YC &!UMP:]5*-TUKG?BP>[M[EC
M?JW;V%:D:UL=IND\JI+)VV6""@6S2KQ^GG%G/(.Y<10%M]*"Z:A3 8H<#@59
MK/:G2?;$)M63IWNU>[ ZEM,4LNR;S19>UW:O;-+0#236&-;:YKB:T$QMMO@D
M)-ZFB=:+:._EGY\O@(X$#USV<Z![3AMNV6F^[;[N3VNZ'I%TV'M><DI;84)#
M4^ UZFT4MK62E9CK\P8$L465XGY1?S!?F$_!4A'G L7?6S^CW7%6GL=E>\%[
MH 3=WUE![GCJS2]F3VP[+#ZLLT:C+P5YMT/2=&SCRFUZ18+@HFK) VY !]/0
M<"\-9T/KCM_8NH-6ZQ]W+W(KS:MZZ/>=C=7! []CW</9]0,I-O".;0E.?NE"
M-:?+E7((?3+*)N@4*<!3 2C@5YV;>]7.HFVH/1>Y_=)]V]#:M@HJNRHNH46V
M7'9\DM1V\FK#N;$L77NA+$FW8-9%$4U3*"7Y8B'/'D'(5[M?;G3/2^NM/;/O
M'NI^[RWCM\PEFL^L*9'SMRD-F3E6ICTC&UV=YKHFA2VZO0,*LH JNY!LU2\/
M4@G] $,X]+]4-:]B-+UCL'J#W6?<8N.F[O7E[/ 7EIV5KS6)7@T <$?N7)WV
MKVJT6,6HU6(Y(X*DHV.D<#@42C@>=5#[)^WW>-O0FEZU[OGNK$"P7,-8TO:$
MOL29C=$7.]I+C&I52L;GD=,$J,K*N'R?R$C&=%2<KB )J'\@Y";R>T^G#/:]
MZT>C[HGO$V:[Z\VHST;>3TM_LFUU>L[*D735BWKDG=ZSU^D*O'.CG>D,*BCT
MI")\G$0 HB 9>=H^LFI.GVD+?OCL?[JGN6Z_T_3$XM"PV)SV'8/3-S2T@UB(
MQJU:0NJ74Y(/'CQT0@$1*HJ8!$W' "(!0W9>,ZC='- ZFW]O#W<?<QJFCMNR
MM<A=:W&/WJI<FTT:WP#NVPC@H16J):6+&N(1N=<5E2C\LO &X^P(5-..D51[
M$UGJ4O[N7N>#N.ZZ56WRQKS#?#^2C4]4M*7*[-3LLE/EU@K'1BSJHQ2SM)'Y
MH.%" 4!)^(.0ISK[;.D79?9FJ:'IOW _?)F'VSB/+%KJ[2,UM>#U=*IL&S]\
M[DQO,WJ1M6SL$PC5@^<=0S(R@>!1$1 ,"2IROMY;(T3%=LB>[Q[H$UK::WY7
MNK:DDQ[#2\7-Q&Y+!-JUZ%J<Y48_7;)U"_4.$S+E=*(@W.T#YQ3F+@519+Y[
M:U.VELO6%L]S;WF:^&GMKN-([-V:\V3M1;2U,V2Q=LXY6!L>TH[6#VKPYE'3
MY/A5RJDB!1\Q,4@@80ND:'T(9]R[1T47]U'W46_8*K:N<[;E8U;LE.C4%*&E
M3$-@+R$=</V)5B9!9.GK%?@5$X\IB/B(C^' H"J[7]KJZZ19]@JG[J7O V;7
M\MO9/K5!(P.VMDR]NG=O*5LEL2K<%48S6[N=EBK0JI#D610,F)C@7GD<#O0M
M?MTL-0RF\+W[C_O6:AUQ$[CJFBWTUMZ_[8UVX1O=Q0<N8@B<?/ZR0=K0::;0
M_P!6^(0R+00_G?$.1 ,@-HZ1ZA:MO6WM9._<,]X^^7W26J-8[LN5/U'NF[;*
MGG.O-NV!Q7*7-5AA5Z"^<V87<@@)UR-@.+9MPJ;@H\X$8Z/ZYZ?>X3*V&.ZZ
M=[?>X6CZVRDGKVWW[9U_HE&<NH6<+6YJOQ5OFZ$2%D+/#R_DFZCTU1<H"0_F
M0/$<#T@#V;:T'_U0CW1A_7VX>#_^!N!K_>;JU_A!_=%_NN'G]9N _O-U:_P@
M_NB_W7#S^LW ?WFZM?X0?W1?[KAY_6;@:?WFVL_X0?W1O[KEZ']*G8#^\VUG
M_"#^Z-_=<O1_IT[ U_O-U:_P@_NB_P!UP\_K-P']YNK7^$']T7^ZX>?UFX#^
M\W5K_"#^Z+_=<//ZS<!_>;JU_A!_=%_NN'G]9N _O-U:_P (/[HO]UP\_K-P
M']YNK7^$']T7^ZX>?UFX#^\W5K_"#^Z+_=<//ZS<!_>;JU_A!_=%_NN'G]9N
M _O-U:_P@_NB_P!UP\_K-P']YNK7^$']T7^ZX>?UFX#^\W5K_"#^Z+_=<//Z
MS<!_>;JU_A!_=%_NN'G]9N _O-U:_P (/[HO]UP\_K-P']YNK7^$']T7^ZX>
M?UFX&G]YMK0__5!_=%_NN7H?TJ=@:_WFZM?X0?W1?[KAZ/\ 3IV _O-U:_P@
M_NB_W7#S^LW ?WF^M!\/<(]T7^ZX>?UFX'V/LXUG@H![@GNA@)0,!C!VYD.5
M!,("!CA^R/CR4 X#@ P/C^\W5K_"#^Z+_=<//ZS<#['V<*P*::?]\#]T(HD.
M<XJ!VX?^9P.4H 0P#4!3\2"7D."@/K@?1/9RJY4U4S>X![H*AE *!%#]N9#S
M1X'D13 M0 GXOMY ?A@;7]YNK7^$']T7^ZX>?UFX'S_>;*US_P"S"/=&'] ]
MN'G'\7[&X&Z'LX5<"'+_ 'P'W01,;P\5![<O_-,2CR82@%0 GX_@/(#Z8&U_
M>;*UZ_\ ^PCW1@Y'GT[<O/ZS<#0WLUUDW_U0CW1@'CCD.W#SD/\ Z#<#D+>S
ME5E3$$GN >Z W^6BDD8$NW$APH=,H 98_P VHJ&^8J/J;@0+S\ # VO[S=6O
M\(/[HO\ =<//ZS<#<5]G"K*)MTR>X![H" H$$JBB7;F2^8Y,)_+YJWS*F<@'
M !X_ !0XP-5_9QJZJQU">X![H#<AQ 2HI=N9$R:?!0 ? 5JBJ?\ $/KZB/J.
M!\A[.%8!,Y!]P/W0C&.)/%0>W+\#I@41$P$\:@!>%.?7D!^'IQ@;?]YMK/\
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M7+W^L[ ?WFVL_P"$']T;^ZY>_P!9V!K_ 'FZM?X0?W1?[KAY_6;@/[S=6O\
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MK]DEI-KU?O?8>BQ<!3=W2$?$_M $'$NX>9E'=<L4C!!]4A'R2+=94GH'XO3
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MU'7[9&Y*6Q>5'3G<FZ46!L86ZMNYFJ])J[I?9M-UK,QQ$70NR)NYB\E &)#
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M2@N9(WUQV;LB/ ?+.0P?NR*83"/(< 'P^\0^P>/TA@?> P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MV#:MNTU7+LQGK[0IBFP=VB8I5%<M9<WVH.KU4W,DX,NFE^72U::'7(LE\PG
M?'X\!81MYZ4+ KVDVX-7%K#5\M%N;&-_J@0+>3;HF<.(Y:7_ #;\O2?H-R&4
M.B90%"D 3"  '.!W$OL>IP[6HR*DH@\B;M*,8JOR\:JW?1#P\FR<R#%Z6327
M^B-&KM&IU"KD.8AB^H<AZX'W5]G:VO#4KVE;!I-P9'DW,*1Y5K5!6!H:99)
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M=8K9?8F*W,UNLCOC>=;O6O8AY6*Y!S,,QH=>CD=<6YY!+QS@[0[Y/P= 8/F
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MU-:TFG/I6+"&D=C1^E-2P%)G=O+QQ53@FUO5G4="U4\2_/:M4S@)BF#@/1#
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MIEB4TC&(<1 3"J)?A@2; 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M=QI*D:ZU<M='3=]:UZ94%X16=79_4"S&04:QA#J(,OJU?DI ())?,-X% !'
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M0%-5BL0P<?=XC@2"%1*VAXE @ !$(Q@B3C_&)-4B%#^  P.RX#[@_BP(72B
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M4$E/"J,#!\I3U&QI (#X#Z@'Y?ZCS^K K[54S?3ZXJ7YI12 ^"+("Z?[1QQ
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MA]N!D$,G= ]0JD;R <!_KB)_[#_A@4-N6T;#C+1H,K*J- ))[?91<B9*;*X
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M/(JE*<BC,I3%,'(#RX1X]/MX'U#].!+$?\A2^/\ D9/C\?Y(?'].!N8$-I?
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M"7C\!_4.!":L=(\Y>@3.4QR3[4JI0$HF3-^31YR@< 'DIC%-SP/ X$WP*GN
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M;D:I52.;>LFJG6X%-PW4A8U8R:Z<0T36**_X#J&^<41$> YYP),6'M!1*(W
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M"C?Y]9.+:@L<3<D. G-_%@3Q6(GU%3'3M;M @B(E1+%1!DRA]A0,=N=40_\
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M\> ((B  ;G^5ZX%MX%6VPHCLC50_+$Q2FN8B?CT3'\D0X$1^SG[,"TL"+74
M&K3 "/ ?3D'^)PB(?T0P),G_ )&G_P!(7_K0P/O BE2(4B$T!?@-DF3#\/B9
MQS]@!QZX$KP*W+'<[:5EQ#_(Z E'%'DW_HVP&<#Z?R>>2?'[L"R,""6XH&FJ
M (AR);0J8/T#^0RX?TAP)W@=18#"2#F#%$2B6->B!BE\C!_F=3U*7D/(0^S
MY4;Z1S#X_P#:37^4' _Y G\0^P<#FX$%IB1$WMX,0H%%6XO5%!#^J/\ E\:3
MD?T^) P)U@0IX<W[?P2?/X1K4Z80_2#Z)#^E@37 BMJ-XD@/@/\ KHA0]?\
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M_ BMV+YU69+SQRV)_0<(C_SL"3)>B28?_8R?]:&!N8$0IQO)M.#]O[3SG/\
M Y /Z08$OP(>3_9ZX_\ %-O_ *K+8$PP(3:_].*+_P",RG]"#EA_I!@3; Z:
MQ?Z0S/\ WL>_]SJ8',C?]+V/Z6;4?_@=/ YN!":?_P!N7/\ \;GO_<,?@3;
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M!7X+,_WIJ-PX^O\ V 36/^(>?I/VB4(3DO/B'\[SZ\<C@6!@0RZ+)(IUD55
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MFKVM2KEHN==)2[7<AA.02"FLWLD@V72#D $2D41'UP+4P(('^Z:I_P"(B/\
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M+1^<D <BJF ??YEX_IX$5M"B2A8 I%4C#^U$,;@%"<\ LH'PYY^.!*?G(EX
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M+ S"P& P& P& P*(<5EG*[[E7[_YRJ/[IXI@FB1TY;@7_76_<'. MEDC?B$
M#XX%EDI%;(D9$&;D4S&\Q*:6ES#Y<<>AA?>0!Q]@#Q@0:Z:[JRZ-53^C<%*W
MOE;DP#\RE#^:[-5P9,#B=Z)O#\0^@#\>,"?&IU>,(F%DMR(\CXR4H3X_H(]*
M&!'+C2*XXJ%I;&9K 1>NS21C"_DE1*!XYR'D!5'H@(A\0]0P./4-?5E&I5=
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M82[1DFX*FFY34$4)5@Z1-YM5DEA$BZ)1X WP# MU"@U$J2?,"R$WRD2&-PL
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MQ^/.!6VO-L4AO3X5J_DG3!\V072=-'$#/(*HJ$>NB&\DS1@<>9BB(#\!YY#
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MIBW1S2 M9YKZZ(.XV=L%5FG)Q<@T5=QX3RI&S]LF9L8RK-P3@R:GP.40$/3
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M& P& P& P& P& P& P*#[6?VKO9+_>#W#_P>6+ KGV]_[1/IY_Q:],_[0(+
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MDK:C,G5/I<+*2R P4%$+/':R9%D$&9?G*F2#TP+0V/[GO4RB);%B8G8+>[;
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M$_9;99=<4W8$++WUS/L45I.W6^4O-YN,W/;+L%E(=U)2;AT=%5$2I)(I%(0
M#T-P& P,4^TO7-UV)7ZWJ-;0E5OW"=IM5=C7 JQZDA^T;77+.TM%:LE\MPW^
MA6EAL0"#@WS")@D/)!\L#!SL;[4B'96,OL#8]J-8&)V+VZMW8Z==5^L&:3:=
M;L?6V;Z]M*>WDBR?FK-1:,LF_P#KSF^6<$A2!$H&Y .?T4]LR:ZIZIWW2+G<
M-<S]MW=0X#52UQUK4[O!.&]1J=)F:57I2P+;"O\ ?Y*:L)4)A1R=-%9I'MS_
M ,VW1(F.!6&UO:,ODKK'7U(T]V AJ0_U]I#K!I==:9H;LT-?HGKW=;5:I']J
M35&PUZW1#2W-[(1(HPTFR>-CM@#YYDU#E$*]TS[(4EK76LA0I_=-.O"QM7=9
M];0TE*ZK*LWB&V@.UEP[+N#BRD9Q^X?-;"E:PB" HX^<0S<JZQU3<A@0_</L
M+OK[L*3M\#NFFEAKW9-KL]B5BZ4BXO8U'76RM]K[S0+36E0V#4XX;M"/'2K+
MF90D8=4!*M](50@<AG/WH]O^\]E;=6+?J';]1U3(N>OFS.IFQT[S0%]ALW>C
M]LOJU*V![1&)9R$;P6RXYS5TDV3UV#MI\I8Y5$3&*00"4T7V\HRF:([O:2CM
MA.W45V\9V6)CI1W%@LZHD5-:'KFE([ZKS>&-/O6B,$$@JH84A645\?3XX&+2
M'LRA/ZJ8T2_;F:FG'N](/<MMGZ=2T8M-^6)Z@_V)BD)%HR4D^<HJ?E8_FK=9
M=10J*G\SX>(B; MGVV/;)>]&XG=#&W6[7MLDMHUJB:\:R^NZU>*^]7IFO8"6
M@8A];'M\O]]>O[6_3EU5E",3M(QJ81(W0(3@,"DX7VJ>TE1JFF6E9[6ZH+9.
MG;J%C^H*$EU_1-4&=9CFEH@GZV^D6UI)8[U9I.KVI1LD:,>1;!BY;E<HH?-6
M7$P0"T>T9L;1'5?8>N^OMX:[-VCL1?I-7TG=IK4,T@:Y(:+W@EL2WW]S%+/B
M)2\$N\F';S\H^<FHDT1!))43@4<#O9SV:]Q.V%LGXCLM0V&U^PC3LM7^U5D>
M:?=O:G,U/M!;:[:KBVTM6U+A]70YJ#"NE:,7#]W(D,DN910HJ%()0[C9_LN6
M.=Z_4SKWK7L@XK55C-W=E=DV].QUVPN8VQ5[L7&RD=^7"TJ-UJDF[LVLP?@I
M#N'+XS%P<5/JVZI3 3 (>R<M)+NX.X;_ #2=+=:JTO05/RJD)Q=M=R^KNM]P
MZVRDRX?*2[R+393,!8F\@@D1$54'3<Q14,13\(3/2?M.7*K=@=6=D]Z=A:_L
MW8FIFU3J44PJNJVM+JTIKV@:6MNH*JPD8ES/31BVQ<MI.^>R!3BF?P^0@DDE
MP4 RHE^AK1UUHZT];6&P00:]>K3!V,E@?5=@^+96D16KU6U6"]>6<?ER*+LM
MR,82'^8B*:'@8H@<0P*6ZM>U@YTCUM[5=;[_ +ND;E3>S$ ZJ;>!I$1)T^GZ
MIA'=%=TJ0=:_@9VT6YS#RE@.[^O?I)NR1X.$R$;H(I!X8&Y3?;@VTZGJ)9-Y
M]DH#8SO6FNK[JFD056TI7*/782K6W2R>G$)LHIRDG+N[B1N'USI=5R9H8>$&
MR+9(1 0P\G/8(?62YZNE;)VQGYNHZDK],AJ=!/Z:]/(Q2%7T--Z/<P$4"=V2
MJ,=6I,TR>:$1B5I/ZU0Z0NODB4H!+>T'MG;6UR]T9V"ZT2MJV)N/K]KWK5J.
MDUJ$B=>(H1#/2=/VQ2WVR!K5]EXRK6M]/1NS3HJQR[MJ+,J8+HJ*')X"%'==
M/85LS2 T==]Q7JEI7F7H>F6W9:C6.FFNPH6/6M^M&P%D=63\+9Z]7JTYFD[/
M]"\4482"391 %6?RS>HAZ"=-/;*N?53L#7=F2G8!CL75NHM*;.T-H?7A-;1E
M7L53I.SMNQVVY$+I=6,JO^V4C#OHQ-F@X%J@91(!44 RICF,%.W3VB]B/)C9
MSC5_:V+IK7=,YV6A;O'3^GX&VJK:5[.66NV^V52"<.YE$6-RK,Y$+FCIDI!3
M%)R!5D#_ "RX&3_:KI=9]FV/K8RU\\:FK%3T]O3J_?W,PZ9#,0.L]OZG;5)C
ML*'9N#MD9R9K-BK,>+AHF9,[E!T?Q,3Q' F^G.BSO2>B^P^G:CNFSL);><<1
M*)O;&$AV,MKF61TS4]2MYF#:%*X1?NDE:FG)#]0<W)U!('B!?(0\I:Q[/G:7
M0*>O1TIV3J4MLB>[6ZQW;==GRVKVJT%KE/5^C=CZV6DSTZUWF=F;ZYOKFP-2
MN !ZV5:KF452$J8@!0EVH_9NVO4]E3FLG&Y"0O3ZNK=7; [B5JI7Y:_;ZOVG
MBVJ^2UH2LK=RW?ZLAD=DVI5!2-*BZ*LQ3*"9R^IC!-:#[(]ET'+T?9/7'M4[
MI^[=?U^+I%>MUXU;!WFK$I0Z\=:\LC5Y3U)9B@[FG[=<CUHZ%8I6ZZ8IG342
M4,&!U5@]CVP7??-OV]M/N;:;P%EKFSH9E^>T..-:VG[T-,?NCF2$<ELJ-3CJ
M_7Q.I(Q\?&Q+0"&6,DJH<I2B <BX>QD3>5,:0W8GM!.7ZU,8)2CIV.G:WKNO
MX\NO(+1LWI'7,62OMG[XGYO#-I@\K(NS+F_,%^4"@FB!  ,UNE/2RT=$]1;U
M29352W!M>^NG5P;H5"E-=7QL^^J])+ 4N >"_G[&^=R,BHR*#E\]?*$2,N()
ME33*4@A8?0_K7L[KKU^U/K.^6J)58QFIB)W&AQ<.W.:.W%<K78[OL.;:7%)9
M%9]$_-LPQS=H1LDW3^E^<3^7X@& L'[:78:8ZZT/2:VTZ3K\FH9G?&I@I>T-
M<5SL'HW;NH+A?I:UZ]V8%"GG;)>I[9AXR73;H/TW97*/@NF<@D,3 Z*E^Q'6
M->[9T[>H#>AYZL4J*T,&P&>Q=?-+G=+58^O\4I#5E[49]Y821-*BY-A\HIT%
M&$@NP^G)],J7UP,N6/MPNVO2:G=3&VYE26O4.W2;JTYME.HLSD@+=6]M2FU:
M"%LIJT@K'6IA'N),S&13,JB#Q$14)\I3Q,4,;KS[-5\M]0L\5'=M7%9N6_J3
MNJE=OKDVU#6Y)':#;>%^B]CV!UKRON99!KK16'F(LK-D4%7Q08*'$X'7,*N!
MF-7.ALU':&[:=?)G<)W]6[&[%MEUJTJRIK!G-:WC+C'UA&4A'('D5VEI.63K
MZBY%U 0,!'(D$/P%-@;U)Z 05"V]U_VNQV$[<JZ.V?V\V8,0K7HYF6T27;1H
MBUDF"SM!R)VP5(R("DM_.*/ ]#^/ <!C+8/:/B9;=EYV1/[Y@6-2O/<AKW(=
M03/2="8[6C[''MX(&M(AM]O912UQM25<U](5R(M@.*"BJ("!%#8'*K'M=[(A
M=21^CI7O)+36M-7VN*V1UF9-]*:S@;3HW9E:V"ML&G61Y<6$DJ]V(QCU)!U'
MO6+Y)%*28NCE,)!XP.TGO;5OVV7-FVYV"[9$N?:=G*:EE]+[8IVN*Y5*/HM3
M1]JD[G4!AM8NYF796-.<L4RY5GC2+PYG*:H)HBB"9!P)*V]N>:W!-4N_]WNQ
M4?VJE:MLR7NR](DM=5F&T.TB76L[!K2-IM4H#J1FV]9.FWL*LH]DS+N9![(%
M((&3*F3@+++T(KK_ */6+I1==X7"Z4=&03+JS8TT2'_;/6,-7+E&W;4$$,F=
M99E<5M4S$.T2:+OP^8]:-DT5B<!R(4[:_;9W'V,:HQO>#N39-Z4=2\ZSFYC4
MM)HL;J;45KI^LY-]9(RMS<!#3CN04G+;;EF3Z4DTG9#&2CD6J!")"; Y=8]G
M[KG4-EU^:BY!=YI6M;RNW8*K=<+/#Q]OHD7<]DZM_=O>B).;.M*R3B(L+\0F
M5$5@5,5^93@W"@B 96FZ>:[8[V7W?47J%-:!U/FNJ,70*Q!PT53(.KRE]4OB
MECBVT<DW31?M'QA0!L4A4/#DP\&$1P,-X[V9>M4_6=45+><[8-YTK2?4-AU-
MUW 39UZQ'5J-=+O%;ILQL>M2K7Y]KN[,S-NL#CYS9%NP3 A3 (X':=?O;^VK
MUFW0G-ZV[[R:\+9H32*6Y=67#3^MK1:=GQ6D:,SU? OD[<XED;55"3%.B6C9
MPZ006,+E(RP'Y/X@%FV3IYM];M=N+<VJ>Z2NOJ7NQKK8-SZ#?:?H.P%9!G1Z
MJ[J"(1-SEYAO::8VL$(NH BDCXI*E$Z?(\X$*Z+>W3>NDTA"1X=DZ1L;5T'3
MYVI1E;2ZJ:>UG?'#&1>J/8IS.[EJ[DUQLWY2HKRH5WY@\-XG4'R !P+LBNC%
M)K71:2Z0CL*62J<K%66(/>G3**0F"A:+Z^OKA1"/45"-^<V<OS-TPY$/ H&^
M/I@8_P#9_P!O&6VUV@;]HZ-V@H&I+!/Z?I&C%:UL;K;IOL!#RK>B6:U6^-D:
MPXV8_35AIMVM95R.",">:B:)!$1\ $ W]D>UQHZ6B=NWVT7V,J^ZKGORE=FJ
M=V55J%0AK-I':%+KM2K<<_K#IZHFW-7WJ5=6*K'.W/TBB4DJD)?0AL"*SWMU
M7.:WU0]_VKM!$;0I6H-DO]^Z<AYV@41CN1Y<#Q,S^7:ZD>S(.C3CK3'YO+J_
M(C_IU 39'3:F4,BB3 S<Z.:OL^@^K] HVUIF!<;+12M=]VH[B))!U L+GL:W
MSNP+*U8OB_+0-$Q3VQ&;I+?A(JFB"@ !3!@9>J/F2355\J[;),D$CKKNU5TD
MVR*"9/F'657,<$DTB)_B$PB  'J.!T$)>:593.25RX5:P'9%3.\)"6")E3-"
M*F$B1W(,7:XMR*'#@HGX P^@>N!(5';5(3 JX03$A/,X**D3$I!'@#F YB^)
M!'TY'TYP-AI*1T@"HL7S1Z"!_EKBT<H.024$.0(H9!10I#B'KP(@.!]*R3!N
M?Y3EXU;*"03E(X721,8@?RCE!0Y1,4GVB'P^W WD'+=TF"K=9)=,0Y!1%0BJ
M8@/PX.F8Q!^'V#@;^ P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MLC?U[0[N1HV-C&S*=:5_\M&/)67CEU)NU'0* 9,Q" 0!\AP)@M(;A$# E2J
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M2(K],[0;*MEFSB+CSH&_S0!BF QP'X<!@3[ 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# H#M@<$NK/9500,8":!W$;Q(43F'C7EB]"E#@3#^@,"N_;V'G
MHET\'[^M6F!]0X_^8""^P?4,#,/ 8# 8# 8# JAL ?OME3?:&M(LOZP&R/AY
M_C# M? JK:1DRJZT Y!.!]J58A>!X\3@UF#D,/J'H4Y0P+5P(#M1%)SK/8+=
M=,JJ*],LJ2J9OY)TU(AV4Y1_0)1P.QH)"IT6EID "D3JE=(4H!P!2DB&92E
M/L  # EN!&:\4 <600_JK Y'XB(<@U9E'@!'T^'PP)-@4&W61'L](H"4OSR:
M/CE"FX#S^6>\/"F+Y 'EXB8H>@_:&!?F!2>_UCHT)KX& OS+OKU(_H B)#W*
M&\@+R ^)AX^/QP+LP-AR'+9P _ 4%0_C3-@<6'#B*C@ . !FW /U F7C ['
M@57^7^U>Q/ O!OS:$^8(_P!4?]GF/K^KC GN!4%O(F;;>G3&(0QR-=C>!C%
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M4-X@ "8YF$9Y',(!R8QA^T>1P)]@49;TR#OO3"HD 5"U7;!"GX_$4ATJ>8P
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MM)-6:H=GH#R.D",BQ]F7KSH\DBHR;O22,8ZKDU-,UV0_/%(?,Z:A54S )
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ME4ET#$4(82F# Z.*M,'3=?VZXV>00B:Y5'-[L$[)NCE(WCX>$?RDA(O%CF$
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M3U3$0.82!ZV2*$0,;\(@/'ZL"=8'2V14$*].K"8I2I0THJ8QP*)0!-BX.(F
MWX1*''(\^G&!Y67/0N^W6XNFG<_K>UH5XF*'I:UZ4VKK785DD*:SM6KM@K0E
MG96&FVIE#61&&M=9M,$F<R2[,R3IFN<@FY(0,#TTUPYV$]I,&\VK$U> OKIL
MNO8(.FRDA-UV(55=.#M(UC,RC*-=RIV; R1%W MT"*K@<Q"%()0P,6NQ6@V7
M;OK+VZZWEM!JP7;S6[:^"T,FZ,F>MRSZ$B?HWRS$RA"NB,)%-(RZ F*8Z7D4
M! 1# J>K]8^PNQ-V=&=Q;]D-<5\>G^L+^G*PU">2DVXON[=C4LFJY69:NI"*
MB4X"B,:<@=\DW 5W"CUY\HP 1N"APS6LQT_WT:M2^:0JI:MLI<$1$/-5(O[)
M)',0!X$03.J7GCX<A@>/$A[5.U(7N+8>[^O[=KY/;;3NA(;HJT%:U;*_I=BT
M+L#6=-UILJIV&+,T=MZ[M-@U@5G<#,1Z0@BH0$U3^"QA('L+O%O'N=4V-M)*
MD:QZRT FLJNH9%,A366'!+S/\2 *GB'W8&)?:7I2][0=E^K-XNAJC/=?]1TS
ML)7=KZSL!)$[R\N=L5>O5VN%8&9ID34C&)(YS]<FLX2\TU"@!3\B !G]7J_"
M5.!AJQ6XME!UZO1;"$@X:-0(UCHJ)C&J3*/CV+9, (@U:-42)ID . *4 P*A
MBG6RB0VL0H$?3)& <W"92V2YLTG+,I.-IOU-A,+RE(QC!ZTE+$$R1L3Y+P[=
MO].90WGYE*40O0HF$H"8.#>O(!^L?A\,"M(]@<-MV61!SRD:CUAE])^+^;42
MF)YQ\[U_#RJ53CT_QN!9N!#K(/$W20YX TZ\ ?T_Z!R8@'_5 &!,<",W,X)5
M2P*"'($BG8\<<\_S1O3C].!(4!Y01'[TDQ_C(&!NX$%HITC$MGRSE/XWJRE/
MXF WBH5PD!RFX$>#%'XA]F!.1^ _J' I=7Z0>PK P'1%X&G9$/$%2BM],-SC
MQ$WRO+R^5\TO'EQQSZ<X%TX$1M >3RI!P(@%G;&^WT$K"0X,/'W<X$N#]'PP
M(I>3 %.M'(@'^@4D/Q#X?2J!]OWCZ8'>Q8@,;'B @/+%H/(" @/+=,>0$/3U
MP.=@8_=>'A7<)L@_F4_R=W[7;^13%$/YBRJ$$.2CQR'(?IP,@!$  1$> #XC
M@50NY3'=L6W ">9M8RZP'!<!.8I+/%IB3Z?GD"E$>?/CXCQ@6Q@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@8J=ZTC+])^WR)6K]^97K%O9,K&+,8LDZ$
MVL;. (L#%50,5VISPF('*/EQZA@=%[=WIT*Z9AP8O'6+2(>)^?,O&NZ_^$_(
MB/F7X#]O.!F1@,!@,!@,!@8OR57N3OLI/SD%:F5<8K:<K$:1%Q#IS:KQRVN$
MZY=+$;+/&J:*2:"Y$Q.')O(P?9@6T-?V/Q^'8D< _>:DM!#^()<H_P!' H'>
M-;VD+C2YB[$9+\;YH8_+;TIDB1) K&R_/7<F-+G46(4!#\)1( \?IP+Z&O[,
MX_W18KG[_P!AFW]+\['C J#L#3]MRFB]Q1L7LYDVE'^M;DSC%FM%C_FHOG$"
M^2;' 5Y=8@_SI@_J?3XX$CU34=J1FL==1[_9#!1XRHM/:.S'I; QP<-J]'(N
M2B=.4(10?G$-^+@.<"P7-?V(=41:[$8H(B4H 12EL5CE, ?C,53\T3 0,/P
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M^&"A_P#S4WZ?$<U]"5.M?^DBCZBH@L/H \?' [PU3O1D_#]Z4B!N./F%JM9
MWZ_^U?OP,:]+:ZVA&;5[2/9+9\@#6P;*JLC"<04$Y^0P0UW7V"A2E.A\MN55
MRW,<4R@ %$?MYP,C@J%_ ?\ =8DQ#[AJ55_I_1\X&.MWUSLQ3LIU[GR[?>*1
MD5 [C1=Q2M)K1DW:C^%KZ;<YG)!262,D)1$/$/7U ?0<#*3\DN''^S@.?O\
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M_+9C8)/YZ(?U/\ZN4AOO_#@6A@4YM\0!?4O/V[CJ8!^O\NL'_.# N/ @VSE
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M[:'B \%'R2B?4P?;QQ@3W H;M!*!"]?]KRIDC+E95)ZJ*)%/DF4_G6Y0 %!
M0(/)OCQ@7;'#S'L1'XBS:B/ZQ03_ (L#F8&-74TJQ=.I_/'DX["V\8/CZ$':
M=O%,/7[B<8&2H^H"'WX$/;)F+>I500_ I68@"CZ<"*<C*@</C\0$0P)A@5/?
MUI).YZ?29* 5JO;Y<LF42%-\QL2I3:B10$?4@@Z*0>0]?L^W MC A6R'*;/7
M]U=*F*1-"K3BISG'@I2EC7 B)A'X &!(H4Q3P\28H@)31K P"'J @9JD(" _
M: @.!V>!0'6ES]7K)5;GG_S0-II?>'\QL6RHAQ_ G_'@7_@0U+_9^[_35&H_
M_+5<..,"98$<LRWR&34W)/QRT6F '()^1,\3_D\ /@8?O^S D>!$[Z(A1KH(
M?$*G8A#]80[SC KWK2/EUXT>;[3:IH8CZ<>HUJ.$?3[/7 N[ QEZV_\ ;?8?
M_C*;&_[@K.!DU@0.2_W1ZG_XKV__ +NJV!/," ;06!"DRJ@ASPXA2^GWGG(T
M@?Q>6!/\!@8_=6I-:9T529)=--)5RK;/)-(!!,H(W:QH%\0'U#DB0"/Z1P,@
M<""L#_\ FBV(GIP%7KIOT^K^:#^' G6!#[$/$[21\0'_ $:?AZ_9S!20<A^D
M,"8!Z@ _?@1BZJE1J=A5/_))%NC&_5\L?T#@2-$0%%(0^ I)B'ZA*&!N8%6:
MI8&CF-Q0.8QS'V5>G7D<WD8P.Y@7 <C^@%. _0&!:>!C:Y$W]EW% !N"CUUF
M!$O'Q']X\1QZ_HP,DL")6<P%=U,!#GSL[8H#_C1^@D3<A^G@O'\.!+<"';",
M)*+;CA\2UV6,'ZP9*\8'?PXB:)C!'[8]D/\ &U1'_GX'98&,/5HXFK^V@'D?
M#L3NE,!$1$1!.UJ 'Q_0.!D\/Z/C@4\X6']_42@( '.IYE8?_0;;$$_AY\\"
MX<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,##OW#O[0;NS_Q3>PW_  36
MS X_MT?V@O2[_BNZ,_X-Z[@9F8# 8# 8# 8%1,).*/O*RQ('0--(:TJSTY/(
MH.21JUBL:11^7SYF0,Y)_*XX WI]N!;G/Z_XA_I?' QU["37Y0YT&4/'_1;L
M50(?\?!0X=Q5J./B)^ $_P#,>@!ZC]F!D7_S?#G^E@5MN)\G&ZGV3(*F(1-E
M1[.Y,94!^6 (P[M3E3_H/P^OZ,#OZ*_-*TFGRAR)IGD:M7WYTTN!2(9Y$M'
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M0M4K48UJB148^OPS%, EI\Q?EM(]NB7CSE3#Z@3G[\"4%TOK(GEXU=$/+^4
MR4T(&_0(#)" A^C H;KGU8U%KF@2$''5=L=%]L+9EC.NG*SI_J5K%>9R64.8
MQY,3B*1G7RP 1_"!. ],"_ TWK8"B4*RD "'''YE,_#]?YCS@4PQZ[ZJ:=E9
MC8"-/9!,O--05?5>G=2*IC)-K?-KA_-JO#D*<4C$*)@#D2D /LP,A U_3B@
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M3>\W)6E-C53_  ->J"E_"K:XL@?T\"Y,#@R?^ELA_P"L+O\ [G4P.OJW^QJ
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M_'RN<#&7M-V(T_"ZZ@UUKW$&%?;&HHQ,B!UE%#.92_0C-N3Q^47T,HIZCSP
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MI?7-W"=>.P,V:\J%4.94H$$Y0'^4&!D$&SZ09,%@EW I"*8 <(2?$HBJ/"?
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M8D=/^SNL;;3-I2,<O<UB->Q6]8Q4CB@7D'!1C;NY0%3Y2D$*A6Y^0\/@(<"
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MIL"@AZ@E^>M5!* _8 F]1^_ G6 P& P& P& P& P& P& P& P& P& P& P&
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MF(+3GY$JW(4IWWF<P*QIBB8! H!ZCSZ8$V+;+J9=)/\ =A+%1.D4RC@UCK
MBJ/\I(4OK_,_C_C@]!P*%[++[CO.E=C4BDZ6E9:PV>ON(F)*M=*;'-0=*N&X
M@HY<.I$ 10!$IC<\"(B'''KS@6[&7/8X,62:^FIELH1FV(HFI<*><Z:I4RD.
MF84Y Y#"02^HE$0^[ W5[SLI/R^5I68<  ?A\;I32"<?3TX._#Q^/VX$1HMB
MVS!U=K&R.D)5%TU<RJ@IA?:2Y$Z;R6?ODS HD\(3GY;D \>.0P)4%\V</QTA
M,@'W_MO2Q_H _P"<#@)6K:"<P[D?W,/A0<Q[% H!=JB#DBJ*KDQR& S@"^
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MSL=IX_#[?] ><"+5>6WG!0C"*=:E@72C0BX&73V:S*!S+/'"X!XFKH<%(FJ
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MIJ:EA2J)(II"0-DM!  3(4G/G^0>O/CS@<C]J=Q 41#4T-Y?8 [(9^/\(_D
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MI8V[FRGLDE-J*JJ+#'@R( \ <"&# ZQ'WL*!&M['.VWK;NBN:]3B]_#JZ_\
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MU !^(<_IXP-<!@,!@. ^[ 8# 8# 8# 8# TX#X\!S\/A]GQXP-<!Q_BX# <
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M3%.4Q3\"4Q1 Q3 8.0$!#D! 0P/H!Y^'_-QZ8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# P[]P[^T&[L_\4WL-_P $ULP+$ZG  =6.M(
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M/7[0  '^/  4H?  #GX_I_7]^ \2\@/'J'''Z./L#]&!]8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MK.J?/R#Y0?V!^N1)X\CR)_\ 7B!O(0^[TYP-2=6?>/X-Y^ZQJ@3?U/AT/UT
M?^A -R$1_@P-O^Q8]Y01*']]:U, >8>8EZ'ZZ WA]O@!K@<//[N?3 [5;JM[
MNH"H+;W7*$8?E(%1!ST0U6!?F^'+D52HVP/05AX3$HAP3X@(^N! I#I%[P3^
M31E ]XM@P #>:T;']+=3(QAC% 1(5-L>84/\I10>#@)N?'X#S@<V,Z-^[,M*
M(R-A]Y!\BF>1<N7L?7>FNFTF!&H%349-F2$C*+<$^>!BK%.8>4A_"(&Y' E$
MITC]T&P.5WK_ -XJQ0"O(HM&=0Z6Z(8QA6Q#G%%5R@^EW:JCTY3 "ABG H\>
M@!@=4?H3[G7D8$O>CV*"?*'B*G3KK\*@!R'U7EP[ #"8H?@]0\1^.!RB="?<
MK*(^?O1;1. B(@']A]UZ+P'V!R#GUXP/L>A7N4C_ "?>@VB7_P#P_P"O)O\
MKG A_0P..AT*]S/Q4^I]Z#9/G\U3Y0H=/>OP%^3\$?F HZ-_/<?RN/P\_# ^
MB="/<N 0%3WI-GF_" "4O3OKT4/+[1*/U8CP/W8&[_8%>Y3_ (:#:/\ <?\
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MX#^P+]R?_#.[1_N0>O?^><#0>A7N4"(?_P"Y_:0  ^O'4#KUR(?< BX'C^+
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M*">L^MJ2S0GRQ*<BZXZY5(]$RGX@'Y:?'PX^W Y/][3[G_X:+NQ_^3OK-_\
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M<H2UC6E7[]W''5C5D^5$RK$50$#![*=^.TCR-ZRZSV]UN&.V+:I/L+6JYKV
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MK"H";EDX2=-E/EJ&2/\ *71,=)3Q.00'@1X, A\0P.9@:"(% 3"/   B(C\
M  Y$1P-AJ[;/42.6;A!TV4 12<-EDUT50 QB&%-5(QTS@4Y1 >!'U# Y& P-
MA)PBN=4J*R*HH*&16!)0J@I+%X$Z2G@8?EJ%*<!$H\&#D/OP-_ 8# ZQE,Q4
M@[DH]E)1[I_#K)(2K%J];.7D8JX1*X;)R39%0ZS!5RV,"A"*E*8Q! P (>N!
MV)SE(')C 4/O$> _A$?0.1P.*T?LWIG16CINY,R<&:.P;KI+&;.B%*91JY*D
M8XH.4RG 3)FX. & 1 .0P.9@,!@=6_FX:*<1C23E8V.=33S\OAF[]\V9KRTA
M\E1Q]!&).%4U'[WZ=$ZGRD@,?P()N. $<#L^0_3\>/@/]'T],#7 Z:P6* JD
M0]L%HFXBN04:D"TC-3TDSAXB/1$Y4P5>R4@L@T:I&4.!0,<X )A /MP-Y>:B
M&D0I/NY6-;0:3 91::7?-DHE*,!#ZH9%2254(S38 V_G/G&."?A^+GCUP-F(
ML4#/"\"%F8J6-'J(HORQD@SD#,E7+9)ZV3=@T66^G.Y9+IK)@?@3I'*<O)3
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M[.1,ZC%RTC 2:L1(-)%..G(=?Z:6AGIVBJQ6LI&./YM= XE52/Z&* X'=_\
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M*J@PU$P,M(1HI.) I3G6$2G,!L#D[(WI[K6]82PSNL]@=Q-.5$C;W3-K4_\
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M,L'&!^L-DZ!ZT:NP17;"Z;(N/IG)/EN6_P Y,JGR'*8"8$W"/EXG+R/B8!#
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MGL[L;KUC7!L<DJPOY-$-6KEJ_<RA:]]5#+6%1V")R(-G::"@>AC>H%#9Z_\
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MPVWM]^Y_76KG-46C]+1'8_=X7J6MB-RCT$Y&YO;?7(-B1Q%O3 @U3=.$A/\
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M/D(7/LKV7.NFSSVX\Q>-I,PN.^NQO8:139R<,=%&Y=EM-J:5MT>V(O%F_P!
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M& P& P& P& P& P& P& P& P& P& P& P& P&!AW[AP&'H/W8*4HG.;J=V%
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M&@F*'H(AS]WV\C\ X^/(X&O(>GK\<#X,LD7GR4(7@0 ?(P!P(CX@'J(>HF]
M^\<#[ P"'(" A\.0'[?AQ^OG <A]X??\0^ ?$<#87=M6J8K.7+=NB E**JZR
M:28&.(%(43J&*7DQA  #GU$<#Z,X0)X^:Z1/,0*3R4(7S$?@!?(0\A'CTXP/
ML%$S !BG()1#R 0,40$/O 0'@0P/KD!#GD./OY],#X!5(P%,50ABFY\1*8#
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M-UDN%$U#D$!P+R(<%"$. &*!R%. &*)3 !@ 0 Q1 !*8.?4!]0P/K 8# 8#
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MZH>S&Y+!3=5)[ G0:TZ6WDTA$[H_5M*NM5;#8C)2$6JJQ3<G%%!)<Q!*/ "
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M%-P@LF/FBL@J4#IJ)J%Y(8BA# (>OJ \X&[R <_9\.?L^(\?T1P-!, ?8/\
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MI-U=K'E7VKL6B:Q[=7%76].LFZJ-0[BMM.:LUX9TB^W;JR^3&)V%+(RMC?\
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M0#]?V P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MX,=NN9-=#@/(/Q!@9QX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M*@  <!ZM%H?N$@1/R[#]:#*IAXG,;KO=!*N'X0^8H!=SD%-3\(\^'!>1^
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MO5%UWI84=?$U;KZK6&Z6JZL%VLW#QU?JK)Q(33LCU@Y=I.5&:+8_\VF8QQ4
M" 'D(!@533W/178T%4NSJ-*H\?8G6E75Z@'%P@T8?<,3IB73+/N7:M0?.#VV
M,KTDFU(Y^7\D$U/P#\1# [[4^R.CVXH!_;*+(ZU/$--CS>I%'4Y\BKJO-B5U
M"/<2U7CFU@5CW$E)MT)1 X)H%4$Y5 $.?7 ODNOM#_*%T6$H0H)IKKF< XCQ
M232://R]RL94'/@5-L__ )@YN>"+?@'@WI@<!M#]<I=U-H,E=8R;RORK.$L:
M+.;A7CB"FW9BH,(B;30D%%(J4=*'*1%!<$U5#" %*(B&!,'&G]8.Q(9S1Z^N
M9,G@0RC(IC%(']3Y";D0P-@-+ZI HE"A5P"CZ"'T!>!_@YP'[EM4\<?L%7./
MN^@+Q_%SQ@<I/4FM$> 2I4"D ?#Y;(I./L]/$0P.4EK#7J)#)IU""*0QP.8H
MLDS 8X#R!A\O+D0$<"9M&C9BV09LT$FS5LF1%NW1(":2*1  I$TR% "E*4H<
M &!R,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#S_ /=5_P#9<7<__>!OG^IIL#+K3W^Y
M)JW_ 'N:1_M9C,"QL!@81^XEJ%YO;J1L_5S76%FW2WLCBDJ3&K*=L5IJJSW2
MOPM[K<W/1,)=WX?0Q;\(V/45(FL=)-V*?R!43^9Y@%;^V[2]]:ETVXH&X*)>
MZU%2&U-OV/6,+?=APFQK=JG33JPMAUCKR\6II)R;BPV0&0N7 *).7Y6Z*I$E
M' F+P >DF P&!@KV>TKLO9/9CV_=A4UBR=4O1>Y=K7':;E=XS:NHZ$L>A;W2
M*^Y8I+A]2]45LLX@DHF@(&^6H)C?A*.!XK=@O;%[A/X^\VWK!"GU3N/<&QO<
M>E-HVYOLH&SBSTO;;QI+:*@Y$"3(QY6%@<QHD;)H)IGAU7/S#BF85!$,KN@/
M63M!HKH3V\H\EK:]Q.UMBR&S9;5&K-OW^BMD1DI[6["$0C(=UIZ<?P6OJK+V
M=-<R H28OA,87*RB*A_PAA3TF]JWLG)SM;C.VNJG4'HB2W_#;=L6GWVPHEM$
M,6T/UA?T7Z-Q5:'<;)'N8D^TE4C@W&2<.'A$RNG0F5,<<#C4_P!NOMO2=2ZE
M:AUJ=2>J-2N-416S.F\+M^O0CO>M<UW:^QIY$86Q?M(WK;5HM)WJN61-B_>-
MDY(&WTRYB&(( %#[H]J'O=;(6;LU:TS(ZTUU<MJ!>%.K^G-PT.ZVNL0*W6"C
MZGI31]8-OOX^H3<S1K+!NDG#I1TNX8?-%RP.H)2#@9Z=;^BG<S4/N,Z<W<XJ
MT_,TYKJNE4[=FT=N;3K.P2R$/#Z*C*7(_L02"=0MGBMBOKK&H)R#5>.=P*Z*
M2CU%9-50"X'=;GZ)=F;[W@N5D1U<XE86V=A&.VV':)SLZ/1@X_K8CH67UM9N
MJ$G0#RQ)\XV.U/RJ D6/5BU$3'<*+E4#QP)WMGV\-E-O;S]N7KO6=3U:SW'J
MGM;05LNM(K5G39PD8>NP%HA[C-UV8GG;)*5;Q$W9Q?'34-Y+)%/\E,1\28&!
M]U]EKL74-&:=B=+U:'KC]AJWK>KV@UY2+M$DD=R7;5.V[5;;G%QJ%R6_8"<E
MI:JSR)"&E_EQ3I1$$E0$I2EP,^FW1CL2S]I2N=8T&=DG]A1>R(?85ATW=MD0
MWYI<M2L-YEV-,];I'8%:*RK,4WL6OR#$%(W.$:W,?Z<JGR \L##B^>VMVCN,
M[$2]0Z=ZVU96)B.H41UYIT5OI9=;H7+5/L,XV=;MI/!4=N&%AMVS*@\*5RUK
MJBR#1PT(S(;Z<YA ,<]R>VCMBG;0T+K)KU4A.PN\MO:L]R^S["LQMGRM0KD!
M<;]NR#>]?]Q6V_/3KM%K'K:IV5#\M8H</6P&5(T 3)'$ OB[^U7W@E+_ &%L
MVK-=G]@*_O5L4EW:=;B6B;7LFDW+JLKJ6N=;7]0;>,U$1,'L@[=V1SR$>1-F
M1R7A8QAP.[V![5?;+^RCZ>*:NU+JRJ]?= 1G4=67L$':ZY%S:Y**65<[[BYQ
M:82D[H]>RTQ.O%$D8E9FSF".CJ/U'"@$  V:Q[8G:NG:RH<63KIKF6I&J;-0
MAL?5.,VY$1=4["52D[<['3ZZ,G**,UH2)%W%;0@II-O(>9573 R"O(% !"8Z
MI]G[>,?&6*9V;5J1(;"@*#U";Z&E66QY.5-IY]K/LK=-L7^AU29?$0D6C>N4
M298119$2E++I-OI^ 2  $+L]VWI%W3[9[^U5(]?ZAKM>AUBG4!5'8LO8ZW7[
M;4KG6MZP-YLK)PZGF$M/LH"1ID07Z4]=(S?+O!.DY<?3_@$,7^V'M#]C+57*
M+,ZRIB5BE9C;?=.V;GJ%;V!2*U-V::WO=';W46TY"S[%@['"/G=0IA2QHE22
M)(0J"_,<)#@? S9]QOIGVOVWTRZF=>='UJK[5GM?N:[%[9D-B6JNO;"U+$Z>
MFJ8RL\/,WV)=5F?D&MGD@,Y>O&*SLK?^?;I?4^)BABOKSV9-CS;#0;_L1KZA
M7NX4JR]3:GL9_([%L<\VD=*ZFZP.]<[.K4>HFZC3O8Z=V&5NJ=J=(I9$Q"+K
M%,! P*99>T)W@3WKU=M%I7DK=3M>UGJ;&M9:/W;7&,UHA[U]V#:9RT1X3E@K
M,Y;['$6"O2;4R9(19L$LJ3Z9^(ID(<H3&P>T!V8JT)HJRTS5VI+:_J%>N,EV
M9U(AL=Q6&?9V4#N7';NKU4M5A5:?0S1Y;6I%D1<28':,W7+3Q^G, 8&/=U]D
M'N;9X/KNR&O14#5*X;>JR>G=<[FK%:A.N5EV?VHD]U5NP1-DE:=*+2S:,H+Y
M&-=.8!-K)HN69443"V4,&!Z,=/?;=[(:4]Q"(WO?J1J9S1:0S[7)+]D8V^OY
M7<F]2[]MT%9J='7>DKP;=*(&A-VBS/YQGK@#E* IE3(($ *"VY[8?>#:/>GL
M)O!U1-5HT2W0/:.L1,U"["BJ"?8E7VWJ>-IVMX63<0E9?[&0F&+UGXRC^0>J
M,V2X?,9LQ+Y&,&3G5[VZ>QM8]KWN9TQV= :VK,INF(VM :3J(R5=GR5N+N&N
MXZ$BU=F6>H0$+5YZ7&Z-U79GK.,04%L"1UB"X\QP*M8>UAV';[WC7(4W4S2,
MA-B1>R(7LVQM*;:\LM81O5^)TLAU%:5)"$3F/V#0N3%9\)C.AB!:K_.*@#G
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ML"@I-_PF ?QB7D!#[\".W+8U#U[39C8EXM]>JM$K[$LG-6Z;E&C&OQL>=5-
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M^'D8H7>6[5!1)^NG:*ZHC$G(G+*DG8DR<4H=442$DE >"1B<RH"4 5$HB8!
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MA<*ZM$R$O7FKMS)0#.5"1_+U9AN+(Y%$ 4%1(0'R   > Z/J_O>,[.Z U3V
MA*]*5.&VO4F=NC*[-.F+Z4BV;Y5<B"+MY&**Q[HRB:(*%.B8Q#$.' X%]8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8'G_[JO\ [+B[G_[P-\_U--@9=:>_W)-6_P"]S2/]K,9@6-@,!@,!@,!@
M1&_M'C^BW5C'-%7TB]J5C9L&2 I@N\>N8=ZBU:HF5,1(JKA<Y2%$YBE 1]1
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MIY%#D?(/3X^H>F!H!R#SP8H\!R(@(< 'Z1^& *<AR@8ARF*/P,4P&*/ZA 1
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M9L/679$%1VBU0=$N2[.?J[J2BUEEV!'3, *H":@@ A>6[O=N9Z*VCOS7EWU
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M2=DU#L>H:XWPUF]=US9QJW,/F=%3FVT79*AL6NIOI6H$MT.T2?L5A3,^8_.
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ML8X$P$$#"8C9X<2_]$ 8&>>H@ NI]8%#X!KRE '/W!6XP _H8%AX# 8# 8#
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MQKD <1\DW3< 1=!0 .DJ!B&]0' [K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MBJFLD8C@!% 2*IG!4 Y]4C$,)5 X#GTY],#DX# 8# 8# 8# 8# 8# 8# 8#
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M3>K:M>JVY/ H.9]S;=:3$_/*GE%WK=T1M]00A2HGY"@;%:_=AUE=]W*QMP[
MWOA.F:Y;[*E--IN$V.N*!N/?L*&PJO6Z;2I)A.7RWQS.N&D_H(I10T7(%<II
M@B!3D#T1TC*=[]CZT[@2N_)_8D'9XCJG4Z7KFFPVO8FG0DAM>Q:/>VFW7RE_
MYE>V*1N#:WOD8L6X/#LFCQ(Z1$04 > \R&$_[H776G06H=)O>RIYG7&DJM4]
M>4E[U\@K)I:1ULMUG):)C=%GV2\CW4^Z["1_8!ZJS4A3/P46%/Y'Y:8@F7P/
M3CN957,%4>B;[L[$[F[$Z"H!;&IV=3JM5G[/+6&_N-8M$J!>]EZYU;'1SZ=J
ML=; ?@JU18J,VCQRV.H@/@ @&".A(3W)HT(4NM;;V U!UTJUPK=XT9I2PZ]A
MYNR/]';6[3S]:;4K:\W?8N=N$<MK[2',HE&$?-G\6U4:BN(@F*>!CY6]]>[[
MK"\]:==TNJ=N[%6*5"52*O*]STZ26K5WB74IM%Q?YV;D4Z,LX).Q3L(IDS*[
MG&2@)IH'0;JH*'4P,K-S7GW/==:=U,R3MO;>7?6:H.;%9-CZGT1KJZ[>'>\W
MK&#MNN]7W6M?LLYA:[I]+84F^@Y-ZC'%58H-$TW3L@?,<8'HMO#<ZE^]N+:E
MEV+J;=6ZKO3*U&T?<>E.NJ5HK&QKQN"H+U@;W1:-(PAV4P6KO+.91L]>,CBD
MK%@Y*F)R_A,'BIKW06YVQNL4A':U[?6&PV-UK&Y=89-O![/I%5ZJ6-QVED[M
MV/UU?8FZ2C>5J52A-2&0BHYW94UOSR*;BDU OSRI 'JYVFZF[-ENNW;J#IUT
M[(RDS*;TH>WM=L879,TC8;"K'35/=S-3(]:+?5/]; H1TJ:&)].@*: $,!BA
MZAZ)6JA3EN[ T:YD7>-*YK+7MO"( !63C7UUN:K6,37<HHKD!\G"Q$>)@(<@
M@0Z_)?7 \:*#H?L2V[114FQU-N.M;:B]OL)NY=@7UU6)JF2U>=R=>PQ(5\RZ
MS"RM9Z/ Z;5(WDNDH<GD1(2 < J'>E!]RZ'D^[TMUZM/876:7]D5VRW)KPE/
MA(*=_>>_@];=9H[257:C;HJ?,WH4Y.DL?@U8?1D>*-ERB;@!Y"*7'87N<:^W
MU ]=ZYM#M[L.W1 W.ZZI=MJ1JN6@+BQ<;7UQ'0<GV5FW$%%G9ZA85^2GF2+A
M@+543H 40,H1+@.1 :W]UUY?58R4VMV8@S[.U]K^U[#VK&U771;)1YT\]V8D
M;!K*ER3JI.V,/66C"O4QL5#Y#EPW!\15,P*.#" 4[M5I[Z,'JS6C*J;>[0K(
MVRO:NOFR+>3657M^RJMLNQ:FFGDC08:MUF,KSAOKZ,V%&M"R#<3E^G76!-RH
M#=10 "U=L;(][F4=NM1U6L=@XN\0MTV%*V';53H]$CM=V#7=UK^C8RG-*5)2
M<C-MD+/47*]I> T,BJ5BX*?@Z@D(&!E/[LVMNW]B@=::#U.IVNOVH9?1_P"S
M+J9THYK#B>NVZHJ_41LC_9(6:0(RF(O7DGKIO(NW#R*!%8\B)Q OH4@A;G2-
M3W"U]H=DH3L\]O3FFKTBU)5B'F:=&L:K"7!"?EF%:8ZSN3*2 \U#N*6=N(D3
M:D(HH4%E!*L8Y0"JNN >XQ7NV?7>LS<'N:*Z[0=5K=8V%'SZ,([H#2NM='_/
M))*.032>)3JNT$BHF,91T_(8!!02)& ,#$II[?7<&![66_LRA5F2%8F/<E[!
M;"CHN!UA66^]FD4^A%T]&[%?;F&Q#/S?7.;LA2-Y^!%)([=@)/EIG)\P2!:5
M#/[R#KKWO!.6M6X%=ESOY<RI4G+Z^J$+9Z199-Q&Q]W>4X'SN71DJ_$F=JN&
M!3H U#Y(BB*B9?' W+1!^[G1[C2-<TN[=B['1Z3MG8,- ;,GH2HW&P;"C&>U
MH=Y .]F+)OJ\Q/4)#6BSE%HZ=D2;E_'P3YR:>!._<*V5[@CWNS,ZJZ23>ZW>
MQX#0FCKAK:N1B-71ZIQ5FL6QME,-B2_9)[*M5Y<&$E4J^@C')MSF/]0F3Y0%
M,)C"%>=?[K[I]58!<IJN]S[C4XT*]$7ZG[G@M;.-H2^[YC4.Q8RY/]71T2Z;
MQ9- PNVEH)PR,=PFFD0@F(!T/(!#*NNZN[C7+I][ACW=DMMZS[<V4VN-5U7J
M^>>PIJ_"5R*UW7&T+^[R$AT4$&JUAL;I\=RL=<_SUB<%\2E#D,8^T'6>DZKN
MVPH"X=*=S]@ZOLKJQ 4_JT_U[6IO9C+5_8BQSVP9W8I'STTDLKI*P35VM<7+
M_M.M\AHFW:B3YY ;E2$)*WZV>Y35M=.'.Q=K]@]DS;J*C*G::A4+G7W5:_9^
MHZWHCIDXJ,&+5J]0F)2^LI-NJ^27!T\]3*F B@& ,1G"/O;6GLOL9BRB.VU#
MT;LJ\1U8F%G%EJ9C:UJO[[Z82+F=8SAW"D?$_P#F2$>@NK&QX D190'2B[A/
MS$+3UQ7?=8IF[M6I7,G;[\KK=VH+^F/&MII4UH8F@82_WD^_6O9ELU^1+V?:
M<O3DHY6"6;-S+N5%6PMQ('U!0#.;W8G_ .^KK3II:G]1]R=DS;/GW<9$'A*K
M*RC?K]&VRO+QDAN>]:O)/5Y]9[34HYR8U=CU3@",OX+&51!/R$,4](=(=BI=
MIIJK3VHNP\1\N&W3#W[M]*70824VOUHMVD:?3M":Q+<HZREM2=]K=CBCK/8U
M-F0(5ZBY6!P85P,8,M.C'3W8.MM>^V_9;PWVO&WK2VL=CZ\O=9GKY,OH:%B7
MYIT]>5LU?<2CZ-E)WP41(#TPJ.3"("8WQX#VQP& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P&!Y#7[1>[=E=I]RW>O*OJG#T>?UC)56\OK-L(LP2
M/AX$\A9X*C4:*>1U"L;.8<(D05^O QRJ*&Y,(^/ >;=B]QKO%&S-@=WJ[3FC
M=%.;8S1C]OSG7M";L4 X1@[>X_8U&OGC8V.>$D[-"M&BY_!Z=HDJ(_/'R\RA
M:?3+N7[H.U_<'A-<[BB:_']?'L ]6<01]36N$+)T$=85ZU5G=$%>V-56K:3F
MQW:35C_I'$V)."';@U(<@*"'J?KRF;-K'N$[\FY*V;3M6KKQUZU?.P$?:'YW
M&MZ3;V=VN,1(537[1!DRCXU9:(9(/7I3F7=JG7 ZA_'P* ?G\M>Y_<4[(7&F
MU.Z7K?A=>P&]M=W_ 'W3H_K1.ZG::\LE*W!:?R;1%5M3!O&S>Q]=6.F0C%_)
MO2O7B9C%3.HJ9-Q\D C&_-M>YE6-PZ5U]!R.]%[G0=M:UW'KW1\#JJ?L-.V[
M6+9JS9-^NUZV)N%D51-)I0MCRB, -36>)(?*:HB= QC$, >HG4+:7=?=?0_L
M+,=[[!9HJ=&**M!S_7G7=NH&Y&<4\A&;RP5VOPTK5X4#V*.G2+,$5&C582(J
M?B5,( H 9M>VY7G$'H)P[)*[&/#66YS,_7Z9LY_=YBQ:RB':#(J%-4GMA^=G
MFS-S)&<+KG44;@Z74(@()%*&!Z#X# 8# 8# 8# 8# 8# 8'R)0$0YX'CGT$.
M?C_[3  4 $1]1$?O^P/NP-!(40'T#[./3X<" AP'Z!P-2E "@ ^O <?H^//P
M^&!P6D5&,',@\91[)H[EETG,HZ;-4$'$DY1;IM$7#]9(A%'BZ35$B13J"8Q4
MR 4!X  P.6=(#   (D /L+Z!QSR/  (  C@?92^/\'P]../C_BX#P 1$1]0$
M _"/J4!#GD0#[QYP.&$:Q"1-+?2-1DQ: P"0%LC]<5A\T7 L0>>'U'T8N!^9
M\KR\//\ %QSZX'.P& XY^/K@. #X!QR/(_K^_P#7@;9DRG#@?+T^ @8>0]0]
M0'X@/I@?0%  _A$1XY#XCS]@X&H@ _\ .$?7C^/ ^/EASSR;GCCT$0#CD1^
M?K_7@:@0  "_8'/(??R''KZ_'C ^?E!R4>1_#R'Z>/L#GG[,#4$^!_E'X^T
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M@I05511,J82E,(E*)A$ ]<#D@4 ]0#]'\&!H!>!$?L'[./N^ X&HAS\>>.!
M0Y$.>>/CQ@. XXX] ]./U8&AB 8?41]/N_7S\?NP/DR8&XY^'' @( (#Q\.>
M0Y].?OP/KQ#C@/P_]+Z?9QQ^K >/ >GZ?OXX']'(>OZ<#4 X#^/UXX^.!K@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#Y.7S#QYX]0_H>O]/
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>@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tv526458_ex1-2img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-2img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ )<  0 !! ,! 0$
M       )!08'" $#! (*"P$!                     !    8" @(! @0#
M!@,% @(;  $" P0%!@<1"!()(3$305$B%'$R%6&1(Q87"H&Q0J%2)!@9T>$S
M\,'Q8G*2)4-S1%4F)]>"4Y75-I97=[<XF+AY&A$!
M /_:  P# 0 "$0,1 #\ _?P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /-)EL1"0;RC
M+[CA--D23-2W#^B4E]3,P'U'DMRD?<:)PD\F7^*TXRKDOJ1MO)0XG_B1 .\
M
M
M             >23#:E()#BG$DE9K_0:2,U&1E\^25$9?/T 4G%\6I<.J&Z.
M@C.Q*UJ3-EH9>ERYR_W%C+>G3'#D37I#YD[*D+42?+Q1SXI(DD1$%P@
M
M
M
M
M
M
M
M  Q%M/=> :8J(N0[,R.DPJAL\JQG!J:YR2T165MKF69V3%+B6.,R3;>2U89#
M<R$18_F1(-U1$9ER RA$F?NB/EE;"DI;-:%J;7XJ6GE3?FTIQM2FS^#X4? #
MV@
M
M               "*#VZM0VM&]?%N(9\7?8)TA4]]XDK0I2MYXP@_(G/)/!D
M7T^G/]H"5Q#;:#6:$I2:U&M?B7'DM7\RC(OCR5^)_4P'V
M
M                                                           (
MBO<JI;/6S2\TE>)0>^_1F0D_X]A,,C&7//P1G)(!+<R9J4\HS^CJD$7Y>!$7
M/_$!W@
M
M                   "&GWB3W:/I?CF3$V:XF)]S.D>26K:_-3[M;#[):X:
M?*K3]PDG,6ZZC[:3X3SSR F"@/..2)R5-J0VA\OLFLEI4HEMMK<-25?!?K5P
M7\ %4
M
M                   $*?\ N"H<F3ZM]XKJWTQ+Z/GO6^7CT]:U$BKOXO87
M6BZ>Q/Q)1M_LY:R7SQQ\?/("9:F4^<"&4I9.2B@0/W+B5&MMR0<1G[RT*,B-
M1&X1GSP1_("K
M
M                         .#+DN#Y^?R^ $+'OJ<7$]9VYGFD,K<F;7ZP
ML2?W#A*04=[L=JR.9H09'XK2U\I+\3,!,E4'Y1VS^3+]I7F7/]L-H_\ M 58
M
M
M              0G?[@G[,7U@[;?5R2?]6^J[CIF?X([+ZJ_'\")) )G*<DE
M#8,CY,XD C__ !83']WPH@%5
M
M                                      $2/NUHZO)NB%CC=W$;GTU_
MV2Z7TUM!=-26YE;8]LM/19L9Q2#)24/QW%),R/G@P$L$-C]N;C:6VFV4FE#*
M6?))$V@O!!+2KGE9(21<\_)$ ]P
M
M                                         B7]UTAR'T4L)K*#6["[
M)]+Y:"+\#C=LM./>2OP))>)\F?P7X@)7VC/[S_Y%X%S\\^7"E<?]WX2HOH ]
M(
M
M               B8]V23_\ 3[V#)+_[ VYU<L3^OS^P[*:KDFDC+X)1DCCY
M^"_$!+"T9&ISY^5*)?CQ\D2D((N?_H?^T!W
M                                                    .%*)*349
MD1$7)F9DDB_B9_!$ ^4+)9>1$9?Q+C\"/DOS(^0'V
M                                   (G/=@7W?7-O#["B4]"RG1$TTH
M_6MIR-O;6\E"U)3R:30:4J+GX^A@)6XZ2)/G^*T-&?S^'VTD1<?AQP ]
M
M             "BY&S:/T=DS23(U?;N15IKITN"JRBQ)9\$U(?@(6VJ6VVKY
M-!*(U /55ID(@L(EK2[+0VVB4^VW]EJ1(2T@GY#+!N.G'9>=Y4ELSY01\?@
MJ                                                       AL]Z
M>3T^+>NW;9V46T6K)=E==,6@.U#+JU?UNWW7@:*U^S6E:$HJ6?VQI?5^HDDI
M/) )C6./!!?C]IHS+\N4?'_(!W
M                                            !QQ]
M                                            0^^\VAK;7UM[\N;B
M/9/1M?7VF=DQ6ZHS<D./X9MG#;9QQ48OB0PS'2ZIQ!\DI*?[ $KN+6D2\JJ^
MZ@&^N#=U-3=0ER#7]PX=K!9F1DFE;BR:4EMSDT$1$GG@!<H
M
M
M BG]TR4*]8W=)U9J4EC4R'S;Y,FB_:9)1/$I:$\&I?*?YN>2+X 2':A,E:SU
MTHOHO7>"J(_S+_+<'Y_[0&2@
M
M                                     !$C[RK)=/ZIN\MK&K'[&0SI
MLXRVX[B&7#8DY)1,NN>2FWR4F,AS[BB\24:4F1*+ZD$DFGS3_I=K?Q,_G7>"
MK)/'Z4H5C-<E'!\%S\H/^ #)0
M
M                                       B,][EE/IO4IWEL:U;#<Q6
MGT5Q+?0AU!1+++,;ASB-M9&C[BHKZR09_P JN#+Z )+-1M(;UCK@D<\%KO!F
MRY/G]+>.0B3_ ,>#^0&1P
M
M                                  !$M[S3?;]2W?=]EMA2V]%6)D3S
M+4HC)-S2FI?VI3;L?R0VM7B?CY)5^HC(R(!(OI8R/5&KU%]%:RP!1<_7@\7K
M>.?K\@,I
M
M                      "*[W:,JE>J/OK'-M2B<T!D*6B+CEQXI=<IM)?V
MF[XE\@)!-/Q),'6>MX<QM467#UO@L.97J,EJ@2XN.0&WV%.D7ZUH6?B?/_<Y
M+Z@,F@
M
M                   "+'W03'%>KKO;'C->4R+HFW6PVOR-MYYR?5*BI4;:
M34E"WB\5\<FE/R?U(!(?KHK9S&,:EW:&8MK*PW$EVE=#=7(@0K;^DM.63<&2
MM"3DQRE/&E*_Q0@O@!?X
M
M                                  C!]R[:?_2][QICG]F5*T5=LNO(
M6;*E-/3JV,HC>2:5)5]I9D1D?)$?P D&P.J8IZ#'X45Q91(>(XM71HREK>)E
MBMJF8[)E)=<=>?-;7!&I9FI1IY,S/Y 7P
M
M                                               (Q/<M7RK?U<=\
MH,5+*WVNNF9V*&WGE1D/,53#5K)8-])*4VIYF"M*5$7*5*(!NYHBVA9)J'5>
M60(1U\7*=5:WO8\-4EV6N)%L\2K)L6$I]XS6]^T8D$CS/@UGR9ER8#+X
M
M
M          CO]KS29'K=[V-K2DT'U4W22C5XFGR+#9RT>1G\)5^C]//Y? #8
M/J*M)]7^MK:"Y2WUXTEPOA1>1+UQCQI/Y(OJE)?W -C0
M
M                                                         !JE
MWFQJNRGIAVXHK:,FPK[CK5NZ%*@O?++[2M;9(M".$\*2I+R24E1'RE1? "W?
M7182+?H3TNM94EV7(E]6-$F](>6IQUU:=<8^@UK6K]2C_3QR?Y -SP
M
M
M       !K%W3R*EQ?J!VIO,@EJ@T]3UVW-+LI1,NOFS#3KO(4NNH::2IQTTD
MOZ)(S,!C3UF&V7KZZ3-QS=7$_P#*GHEQAU]*$NK^Y@%.:B62#-)*27'P7TY
M;T
M
M                #17V8I=1Z^>[KD9)JDKZN;G2VDE^)N++ [M*$$KDB0:S
M5QS]" 5'UR1/Z=T2Z;5QUCE$N'U;T:RJC<F%.55DC :5*(RI/CY2%H^>5F?S
M]. &[(
M
M                    TB]CR"3T/[DO.$2FCZS;=;4GGY-)X=;>?//P2?$_
MD^?H K70)]B3TMZE/14QSBGUFTHIAZ(^4B*XV[@U2:2C/(Y0\V26R/R+X^?@
M!N&
M
M                 -'_ &0S(=?T)[IS;+[ZJZ)UBW"]+3'2X;WVRP>[\R9-
MKETE^*?P^2YY >WUTLUK/1#IBFJ;-B 75?1O[&.2EFEN$K7M Y'+]:E*,R0K
MZG\@-TP
M
M                    !I[WYCE(Z2]Q&5+X0YUGW.1\H0X2#/7V0F:B;4DT
MK/@OQ^H#S>O'P7T4Z:/(4HB/JUHQ!-N-$TX2?].\?X6MOCEORX/]/T+@!N6
M
M
M             -1>^S+KW23N&ACR-Y76/=RD$DR2KR9UOD;G"3,CX,R3]?P
M=G1*^K<MZ;]4,MJV'X4'(>LNBIT*O>0VW^RB+US0$VR2&OT$KRYY(OI\ -M@
M
M
M             !J;WGF1H_3'N"X^XI#47J_O1Y\T-+=<0@M8Y.HS0T1$3O!<
M?!']3X 61ZS%H5Z]^D!MJ):%=4=&F2DD9I/QU_0$H^3X/Y,_@@&](
M
M
M       U0[W/*A])NX<]M'+L7JSOYY!D1>1J9U9E+J4_/YFC^ #''JY4ZKUT
M]&3=-2EJZHZ1-2E*Y/G_ "'1\%\GY?!'Q^7P WV
M
M                                                     &K/=B'_
M %[J!VRQI#R8[MQUHWG7)?-)O&RJ=J_*6$N&RAQM:_#SYXY3SQ]2 8%]1.2.
MY7ZR>@]^N*B#_4.IVF4_LDK-W[3L3$8$-9D\LB4I+A1"5P9<I,^#Y 20%_:7
M']@
M
M                 UU[>LDYU0[/I2A/F[UYW.V9^)>2B5KC)$\&?')_!@-9
M_4"RVQZP>A#))2E;7574*22E*222"Q:"7*33^GY,!)$
M
M                                                         , ]
MI#^]UP[#03(O"3H;;R%G_P!7Z\!OF^"^>.#)7Y -7?4+X_\ IC=#"2:E$GJO
MJ-/DK^8S1C,-)\_0OJ0"2
M
M                                    82[+(-?7+?Z"(C->DMJH+\S-
M6"WI$7(#3WTW13A^K+H&P<ER5]KJSJE).N'^I?GCT9S]7_S39&2?X$ DO
M
M
M           &&^P_"M![Q;4I*4*TYLTEFHR(DI/"[LC4I1_"4D1_)F TS].B
MU'ZN.A'B9&@NLNM&OCY_^#IFFT_/Y&EL!)@
M
M                                                 ,(]B&9LK1>]
MH56TN39RM*[-9KXJ(YRW),][#+IJ&RU$(E'*4X_PDFR+]9J\?Q :2>F"TA6?
MJVZ$.5[JY$9/7+$83CRF5Q_&QI?O5-K%<8<)"V7HEE$>;4@TEXF@R 2D@
M
M
M          "V<J36?T2^.Q^REA6/7*9CC[GVV40"@2#E&\M2DH0T3)J-1GQP
MGD^0$;?I;CP&O65U0*O2S^S:QC/$0#862V4PCVUGIQOL*2I2395'-)I,OJG@
M!*4
M
M                 + V=)758!GEZTU&E/5&#9;.:A36B=A2G(E!/DH8EMF?
M^)&=4T27$_\ 4@S(!&_Z/;!=IZK.G%JZQ&BN6V!Y39+C14$S&COSMFYM*=C1
M6B+_  XS3BS)!?@DB+\ $KX
M
M                                     QIN/]>J=H,DHTJ7K?.2(_G]
M/.,V:25_*HC,C/\ (_X (Y?1XI3GJDZ/F<=$?_[U,YTT(\/ C7F^5F2R)"4I
M(WB_Q/@B/]7R7/("60O_ ))_\_C_ + '(
M
M                                             #'>SZ@\DP;.<9^T
ME_\ K^"Y=3H94ZN.EQ=I0V$'P4^V9.-)<*1XFHCY1SR7R C;]'OA#]5O2VG6
MV3,R@UODN*R(Q+6X3,O$-BYACTV/]TR_Q/LR:Y1>1_J5QR?X@)9R/DB,!R
M
M
M           I=F[&_:V#3IH2HJV6XXM9$E*&?LN)6I3IEXI(BYY^?H BL]'[
MZ)7K0T LE-O$Q?[]88D(4EU+K3?8C:J$O-NI-25H>21&1D9D:># 2S@
M
M
M        "T,V2AO%LJD&HRXQ>_\ N%S^DT(J99\G\<_!$ B-_P!OS%GU/J/Z
M?1[5*$2;2DVG>1?%?W"76VNZ-A6M<YSR9EY0)B/CZ_ ": C,R(S <@
M
M
M      ++V$E?^2<S4GQ\"P_)O+Y/R\OZ+-)/!<<&7_$!%IZ(E$OU(]'#(OY-
M26R#^/\ J+,LD(^/[#X 2^H_E3_\Z7_(@'T
M
M                                                M'/^/\AYMS]"
MQ').?_S-,_\ D (HO0C(*5ZC>CJ^#(CUGD++G)&7'V<]RQGCY^GBELB/^T!,
M47!$1%]"+X_@ Y
M
M                           6_D49Z=5VL!I*'/WM+:Q2:6I"$NKD0GVF
MT*6X9-(2I2^#-7Z2(_GX 1/>BIAZ-ZO>ME3*CHA3,=F;SQ65#0ZR^W'E4&_-
MFT\A#;L92XSC2%P^$*;,VU(X-'*3 3 $7!$7Y$1?W$ Y
M
M                                                         4/(
M22=1;D9),SIK0OU?3@X3_P!>?C@P$2'H999A>KCK9%0MQ\W+/>TA3O!&E+KO
M8+9SKB#61?/@;G".3Y-' "8L
M
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M])&?!'^/U =AGP7/_M_^01@.$*\DD?!I^OP?')<'Q^!F7R ^@
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MCBXRU*;\U$DE&&Q8
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M['%+U]VOKY2(L:#<OPUG#=6DC,!Y(_O2Z8S(&0.;4U=VAU-6XO89Q0RYNW-
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M+$:,RE*&T(224H21$7! /4
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M./[DUS?:)CT<S)']M4N5U%K@35)7D?[Z>YD4"3(KTMQ%?I<3Y^:%F233Y&1
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M(O+^SZ\ .T
M %#NGU-QIB/$O'^EV+AF?S]PT17E?:1^2B)/)\\_ ",CTW1F4>O/KY:(EV$@
M\AE[BNV&K.0F2[5HMMT9ZXNJKW&F6VVZV"ICAILR+P(_CD!*D7P7S]0'(
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M[5RF7D>)Z1UWH#7D'!\,IL5Z^Z^[+'<UF/64.O[!T^/)H-@YSCF50&5:JD;
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MO)=I8VC-GCD6QJ;2$U(:L7VW_L(#]%
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M,V.ZTMQ#+QK;()JT^)ER1<$?/X<']?DC+^(#G@OIP7'\ #@OKP7/TYX+Z?D
M$1%]"(OX$0!P7Y%_<0!P7S\%\\\_'UY^O/\ $ ,B/ZD1_P 2 /$B+@B(B^O'
M!< '!?3@N/R <@ #@TD?/)$?/'/)%\\?3G^'(!P7UX+G^ !P7S\%\_7X^O\
M'\P#@OR+\P R(_J1'_$N?K]0'/'X_B X,B/ZD1\'R7)$?!_G_$ X(OP+^X X
M+GG@N?SX^0#Q3^1?W%_'_F Y,B/ZES_$!P22+Y(B(_I\$1?3Z .>"/ZESP?)
M?Q_/^(#C@OKP7)\<_'Y?3^[D X+\B <\?A^ #C@OR+^X!R X-*3^J2/G\R(
M(B+Z$1?A\%^1<%_V 'BG_NI_N( X+\B_N <\%^0#C@OR+^X@'6TRRPDT,M-M
M)-;CAI;0AM)N.K-QU9D@DD:W'%&I1_51GR?R [> ''!?D7UY^A?7\_X@'!%\
MD1<_3G@ X+X^"^/I\?3^ #D!QP7Q\%\?3X+X_@ >*?GX+Y^OP7S_ ! /%)GR
M:2,_CY,B_#Z .0
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MMI)K)1I(!E%*221$7)\?F?)_W@.0
M
M                '6?_ ,(G_P"=,!#IZ/&UQNDDEIY"VS>[6]TG(GFA24R8
MZ.RFQ2)]A7\KC)^)D2B^.2,OP 3'%]/X\G_>8#D   'F_=-\>7ZB1Y>'GQ^G
MDN>?GZ<<EP7YF9 .]"R67*>>.3+Y+@^2^I&1_)&0#A:R01'QSR?!$1ER9\&?
MP1_4_C^[Y <$YY?1*N."^>/Q_(OSX_$!REQ*S423(S29D?R7)*+CR(R^I&7)
M?W@/L  ?*E$DN3_,B(OCDS,^"(N3+DS,P'P3I'\DE1EP1\_''SSR7)&?\IE^
M')?D )=2I9H(E<EQSR1D7TY_Y&7]X#M ?"UD@BY(S\E$DB+CZF?U_@7X@.HY
M"2_ S_4A/P9<<K/@B(_@CY/X+CZF [5K\./TJ,C/C])<\'^']A<@/.J6E)F7
M@L_@N/H1J,R\B\>3)"D^/SR1\?\ $!V,OI?\C01^)<<*/Z*Y-1?!ER1_*?P,
M_@!V.+^VA2^#5XESP1D7/X?4_@@'RTZ3J?(B-/S\$?'/'X'_ &<@.T   '!F
M1%R?_M^GS]"^3 =3;Q.&:?!2?CR(SXX-/)$1ESPKGY_(!W          #X6L
MD$1F1GS]"(N3 ?1'R1'QP?XE]>#+X,N2^/@P'(#H*0DW?M$1FKDRY2:5$7B7
M)^?SRG^'U =QF1<<_C_:1?\ ,R =9.I-?@7//!F9_@1%_;]# =H#K==)I)*,
MC/E1)^#(N.>3Y/DR+@N/D 0X2V_N>*B_F_29?/*3,C+YX_$@'"'269D1&1E^
M!\<_A\?'/R7/S^1@.T!P9D7U_P#E?VG_ & .HGT&X39<^7U_#C@_CGZ_/S_Q
M^0'<   #Y4HD%Y*,B+DBY,^"^?[># <D?/\ 9^9?D8#D  ?*EDDR+\^?Q(OI
MP7X_FHR+_B Y(^2(_IR7(#Y6LD%]#/@N>"^O'/'_ #/_ ( .$.$K@N.#_$N2
M,R/Y,B^/Q,B,_P"! .5.)09>7P1\?J/X27SQ\F?!%^']X#Y)Y)_7XY/@O^KD
M^3+C]//ZOCZ?(#[2HE%RDR,N3+DC(R/@^#X,OR,@'T
M                                 #SN&LGV"2E1I/S\U<&:4D2%&7D?
M'QRKCCY 17^ETS?Z!8')?\527-R=MEO+^REDS=7VMW*AXR;2I1-\FV7)$8"5
MCZ?!     (&>[&";-S3VD=%<%T[VD[):R*YK,JWGV1USB.Y)U#I5WKYI5#4%
MAM_73-7*CJR;8N?9+7U\B8MUIAR%$?)1>1D9!-S@V:8AL3%:C-L!R>AS/#\C
M9=GT63XQ:0[JAMXO[AZ.N16VD!UZ),91)86V:D*,B6A1?4C 78:25]2YX_\
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MXMCFZ9>>W]U'R^74UU_U3Q;8]IV8AP%U<V18IBXS=Q,1CUYNQ5*?3;OF7WO
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M7K,4W'(N,D93VKWO'=UWN';SDG'\!?JET4765A68W%I$6K)-RV;&$KE7CY)
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M_P!P_62;M+^1%5(2TTU$6VAR6RX8?IN
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M^MU[-R*%B5AK:!+L(U[70T0$57FIQYM)J2 ]F6^Q_P!2^MJ_;%NE6'WC:+_
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M[7Q?&9T6SQG'-B8%C>746.6$%E,:'+HJN[@S(E4]%C-H:;4PELT-H))<)(B
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MW*69*8Z/W%_:Y;&;LWI3Y..G/;1((R>22P&U
M                            .LS,G$%\\&1_'X?F BJ],!G_ .03!#^2
M+_6OMT1_/Y]LMT<?]H"5D        !$GN+U]=;NQ_:?>V6,[]V=C]]G>L<)P
MGMKUTUGGM+48GL2J5B>84&ILBVO3M5LG)X<Z'07$O]@34F,Q-1%:-Y#J6DD
MP[AOI?P/4TC_ %>HMQ;<W)VFQ_"]P5%'LS<%M3,1LLD9SH%77S"\8RNKQJ@K
MH%=A6"X?&CLQ"A,)D$YYO.J=4LR,-<<6] ,2%I/ (#W<C>>.]D<?Q3"<3G;B
MBT^N,T>QC7%9HFZT?D.A\3Q^SQ*MQN7KH\:RJV1!L)<8[=*W4NJ=-:2(@O+<
M/HJZJ7?7NLTYL3LWN/7F$0>P]+LBMR=R\P"E;LK*SU-BG7/'=:SDY-13L?MV
MIN/4D=J&\ZP5A_591K843AI(!<+_ **>H6T,8<EX+O?<#F#6[16VMYN(91B5
M_28CE,#6.N-2-YK0W**.4QD,]E>G:2P=:?<=BN3X+C1MDTMQ "^<4]'.DZ%&
MUK#*=Y;NSW+MYX-%Q_<V:7BL1@6V;9D]O6IW[DNR'8-)00Z.NN,@R;'($%<1
MF,BOCP&#)"?(^2#,O='H#IG<FYZWM/MOL+L'36!5&$Z\P#<N&55OC>.:]VUC
MFO-IIV+JBNS')[2M>O*2%5;*N&W%,P9+)6BUML.<I3P89LZM= M/]2[O%+W7
M]YG5Q;8QH6#U]BJR6TC3(UAB$'9F4;5*[GQ8M?&COY'*R7*Y)+?3XI1'\4I0
M7ZC,-]U26T*X7RA!(-9N+2I*2XXY(_))<>)'\\_0!V&ZVDR)2O'DB,N4J+DC
M,B+CDOS,B_B9?F ILV^I*V95UUA;UL&PO)$B'2P)<V/'FW$N)$<GRHM5$=<1
M(L9$:"RMYQ#*5J0TDU&1)(S 5'[[7'/F7'CY\_/\A_\ 4?Q\)_M_,!Q^X9/R
MX<(_#CSX)1^//T,^"^A_G] %IPMA8/99O>ZU@9522\_Q>BH\FR+#X\YES(*7
M'\FDV$/'[BRK4J.1%@6\JIDH8<61)<4PLB_E,!V7&?83CV28AAU[E-'497G[
MMVQA&.6%C'BW.5O8W7';W[5#7/+3*LUT]67[B0325&TU^I7! .7<\PQG-(VN
M7<GID9[,QN7F,3#CG,_YCD8I LXM+-R)FH)1S7*>+;3F8ZY!(^VEYQ*3/DP'
MLK<MQ>XM\AQ^IR&FM+[$G:UC*J2OL8LVVQI^XA%95+-]71W7)E0[9UZB?83(
M0V;K/ZT\I^0'CR//,,Q"QQ.HRC)Z6@M,[OO\K897VT]B%,RC(_Z?-MCI:..^
MI#EE8E65S[YM-$I1-,J5]",!=!OM$?!JX/X^#2HC^3\2^I?4U?'\0'/WF_S/
MCY/GQ7X\%P1F2O'@^#,!1Y^38[53::ML[VHKK'(I3T''J^=8Q(DZ]G1HCT^1
M"IHC[K<BTEQX,=QY;;"7%H:0I1D22,P%6*0RHEF2^2;(E+_2K]*33YD9EX\\
M&GY+^P!X*N]I;N!&M:6VKKBJFDLX=G52V+"NE?;?<BN%'G1%O17C1):4V9)6
M9DM)I^I&0#KOLAHL5I+;)<EMZZ@QZAKI=O=W5Q+9KZRIJZ]A4F=8V,V4MIB'
M"AQT&MQQQ24(21F9D ]4*UK;*# LZ^=%G5UK%CSJR?$?;D0K"',81)B2H<II
M2F9,>5'<2MM:%&E:#(R,R >M3S:>/)7'D1FDS(^#(N.3YXXX^0%&R+)\=Q''
M[G+,INZS'<8QRLG75_D%U,8K:>EJ*R.N78V=K8RUM18$"#%:4XZZZI*$(2:C
M,B(!](R3'W*,LG1=5:L;.H3?E?E.CG3?T)<([)-S_4_N?LOZ6JN+[_W_ #^U
M]G]?EX_(#[I<AHLDIJK(L=N*V^Q^]@QK2DNZ>;'LJFWK)K*9,.QK;&&X]$FP
M94=9.-O-K4VM!DHC,C(P'9 NZ>T>L8U9:5]B_4355ELS EL3'*JR0RW(77V2
M8ZW#@3D,/(6;3O@X25I/CA1<A43<01&HU%XI^3/\"+^T_P  '!.MGX\*Y\_E
M'P?ZRX(^4?'ZRX/GXY^ &*RWMIH[.72_ZF885M!V5#TY+KSO8293.UK"G:R"
M#KQ31NDH\NE4KZ9*()<OJ9/R)/P? <N[UTZT_@T=.R<1E.;+RZZP+ CKK>-:
M,Y5F>-HM5Y#C=3)K52HS]I2?T.8F6V:R..Y&<0OQ6DT@,I??:,C42_(D\$KQ
M)2O$S^A'XD9D?]GU >65:5L)R&S-GPX;U@\J/7L2I#49^=(0RN0N/#9>4AR2
M^AAM2S0@E*)"3,RX(P'L^XWQSY%QY$CG\#4?T21_B?/_ &@.$NMJ(S)7)$7)
MGXJ(B+YX,S,B+@R+DOS+Y^@#Y.0R1$9N$1&1*(S(R(TJ-)$HC,N/$S67S]/D
M!]_<1^?R1\&7!D9?4_DN.?H7/\ % F9?BM?D-/B,[(Z.'E60Q;*=18W)M(;%
M[<P:9MIVWFUE2X\F=.B5;;[9R'6VU(9^XGS,O(N0]\2ZJ)\NRKX-G FSJ9YF
M-;PHDIF3+JI$F.B7&9LH[*UO079$5Q+B$NDDUH,E%R1\@/<I]E*5+4XDD),B
M4H^>$^1\)Y/CX(S_ !^@"V\4SC#L[I(N385E%#EN.37)[4*_QRTB7-+,<JYL
MJMLFXMI7NR(4A<"PA/,/$A9_;=:4E7!D9 *K.NZ>K."5G:0*X[2?&JZS]_+8
MAE8VDPG%1*V <A;93+"232OMLM^3J_$^$GP8#KM,AH:-DI-U<U=/'-$APG[6
M?&KF3;B1URY;A.S'64&W$B-J==41\-MI-2N$D9@/<B;%<:0\V\AQETDJ;=;Y
M6VXE:?-"VUI(TK;6CY2HC,E%\D9@.XGFS4:25RHB\C(B,^"X(^?IQ]# ?*I#
M*./)U!<DH_D_CA!&:S,_H1)X/D!PW)8=;0ZTZAQIPDJ0XA1*0LE?RFE1<I/D
M!3X]_1R[&SIXEO6RK>D_8_UFJC38\BRJ/ZFPN56_U2"RXN57E81FU.,_>2C[
MJ"-2>2(!4OOM$1*-?"3/@E&2B29F9D7"C(B/DR ><[* 3O[<Y3)2":^\<<U\
M2$M<J3]Q;!_XR$>2%%R9$7Z3_(^ 1;&!.BMSH4R--A/-$^S,B.HDQ7F3+R)U
MF0P;C3K:D_)&DS(R^@#V)42BY2?)'^(#D
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M>C4.7YQ>Y+M3-Z/K+67%Y4;6V[CF74FT\1QNGW'E-NQ^]L466/Q9"%0YL/\
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MO'GCG\R =X
M /*^\IMUA!(4:'%D2E)(S\3,^$D?'T3S]?[ $7OJ K'*7I308U(4B2_C6_\
MMY5+DM*(FO-':+;<]2C3S_B'_P".\>?G@R 2ED1$7!%P7Y?_ "@'(
M($>Z'M)[+:1[;Y/UWTKU_P!&YQC.)Y!UDU_:YGLS:^28C?\ ^>^T,'/)N(2(
MU!C^+W9KQ+'$X*Z<YTW"?7]Q)-D1_(#6;!O?ALW)9. 9O9];=>0]*G3Z.H]I
MLU^S9[V[(6R=W:MRS8L.1K/7$FK0C+M68VYCK<29/^Z4GP>6\E!E'<(@UI=]
MPG>[)<XV9973FM=;T%]UIC;+U!BVJ<AQC:.&8Y9Y+U+W#O?'Y^49-:8VF\GY
MA73<8K3G4Q.LLPWFC4HG8SJ4K#*75'VV=QJ+75;KK9L[1NYMGZ[K-A;9WMO3
ML;M'&.N6(1=14UW@F/X_CF$JUS@,VLM\]DW&32/%+M8V26&6FUD\XZE0#"V3
M^_[M)MW#HT76VO=6:DL[#<*<:B9M43<CR%%QJ2QZV;CW5676-1-H8SBCAVD]
M_ 8Z&ISE4B,\2U?:;/R3YAL1B7O<W?BN!T3V1=<L-S2M:P*VPB@S^WW9246?
M;([ :[T;K?8N1W.;:WJL7_;:[U?E<_+W6X=TR_)2ZXA"DL)2M) -C]P>QCL;
M<]$^TV?7&/8SH+L-UL[CZOZS9$6J,V9SO&EG-V'IM=Y,K+K-,5K4O1+C%LZ>
MB.-O0VU_532TFI)@,L^K?VF;6]A^R-OU>3=;4:>U5C% O*=;YPC*6Y]A>,1=
MC9'@#V/Y%4JE%+8LGV:#]\F0B+$C<FY'\5*;-PPG!^TW_P#DT?A_TE^'/'QQ
M^')@'VV_^XG^7Q_E+^7X+Q^GTX(@''V6N./M-\<<<>"?I^7T /M-<&7VT<']
M?TE\\<\<_'R9<F Y-MLR-)MHX5QY%XIX/CZ<EQ\F7'P Y\4_)^*?GZ_!?/X?
M/Y_ #C[;?S^A'S\'^DODN>>#^/GY( 4VVHO%2$*+DCX-)&7)?0_I]2 <)::3
MQXMH3XEPGA*2-)<<<$?'P7! /KP1]/%/X?\ 27X?)?A^!@./MM\<>"./R\4\
M?G]./S /MM_/^&CY/D_TI^3+YY/X^O(#K5%C*6VXJ.PIQGR^RM32#6UYI-"_
MM*-)FWYH49'QQR1\ .WQ3\_I3\_!_!?)?/P?Y_4!\_::^OVV_GZ_H3_87Y?D
M1?W !--%]&VRX^G"$E^?]G]H#[)*2^B4E_ B <>*>>?%//Y\%S\_7Y >*RJJ
MRY@3:JWKH-I5V45Z#8UMC$8FP)\*0V;3\.;#DMN1Y45]I1I6VXE2%)/@R,@'
MH9BQ8S33,>.PPRPTTPPTRTVTVRRPC[;++2$)2E#3+9>*4D1$DO@@';X(YY\4
M\_7GQ+G_ ) '@@OHE)<_7])?A]/P_  \$>)I\$^*OA2?$O$_XEQP8!X(/X-"
M3+Z<>)?^P )""^"0@N?KPDOG\?R_,!Q]MOGG[:.?S\4\_7GZ\?F ^O%///BG
MG\^"Y <>"/\ NI^O/\I?7\_I]?D!X+2GJ+ROE5%U5UUO53FC8FUEI!BV%?,8
M,R,V94*6T]&D-&:2/Q6DR^" ?!TE,=C&MSJ:P[:'!>K(EH<"(=C%K9+C+TBN
MCSC9_=,09#T=M:VDK)M:D),RY(@%2)"$GRE"2/CCDDD1\<$7')%SQP0#GQ+Z
M<%Q^7!?GS_S <>"/^ZGY/R/])?7\_I]0#P0?_0G\?^DOQ^OX?B >"../!/!\
M<EXEQ\?3XX_#\ '/!']2+Y^OP7R X\$<$GQ3XE\$G@N"+^POI^  :4F?)I29
MGP1F9$9F1'R1<_V& >*?^ZG^XOQ+@_[R^ '))27T21<%X_!%]/R_A\ ./!'!
MEXIX/ZEXEP?/Q\EQP?P0!X(XX\4\$?D1>)<$K\_I]0 DI(S,DI(SYY,B+D^?
MD^?XF8 :$&7B:4FG_NF1&7]WT <&VVHN#;09?D:4F7TX^AE^7P ^O$OCX+X^
MGP7Q_ !R1$7T+C^
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M)\@,\@
M                                                           #
MSK,B?;,_Q_1_Q/DR/^ "(STMN1D=7=M8_$==DHPKO%W4QAV6^TIC]T\UOC*;
M9;K#1D9MLF5N2>/^\DS 2]@
M
M                                    #R/-N+>CFASQ)MPUK2:3,E->
M/B:2/C@E>0"'KTNV4F?H_M-)>:F-?>]CW=)"#EH+Q=93M&2W]R*\E*&Y#)K:
M,O-)$1&7'U(P$R     #CDOIR7/U <>2?^\GY/CZE]?KQ_'@ \T?/ZT?'U_4
M7Q_'Y^ '/DG\R_O+\?DO^P (R/Z&1_/'P9?7\OX@')?F7Q]?D Y+\R <@
M
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MA],[#+G*L;K[FPQU\I*&Y)*K7Y:FTDZE+O@1>9$KD@&>0
M
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M ?,KW2=68*9JYFGN^\5-;^S*P-_H)VI;*$=AS^P*29ZT_P +]YXG]OG^;CX
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M).(>2?!ESQ]E9GQR1ESQ].?S 0Q^C=YHNCTMV# >BQ9/;KN"MAF3(2X3$?\
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M]3^2-1D7!G\?D ^OLK_!U7/)'R?)GR7U5P:O$E'\_AQ\_0!V?;_^;<_^B_\
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M_LX]?/ZYP_6JK6S.AP;"9&3MR(\Y11I,QPU)>:+[:%&$XR/Y4_A^DO@OP^"
M?0
M                                                         .IQ
M7BIKXY\G./G\.4*+X 1%>E*QKYW1V.S!;L4.4O9CN!46?[Z4[);7:P>R^SC>
M.M)U3AQ:DHS[*6F2/A"DK_,!+R7T_C\_W_(#D   $9VUO4=T?WML_;^S-T:O
M>V.>Z+K$,OR;#+F_N(&(5NPL2P^UU\>PL<C8]+IK:JRG)L'M"K+=93%QI\:.
MSYL^2/(PR*CUH='VJ'$L=:Z^86W#P3+(>;XC++^K.75%DD+(,4RA$V#>/V;U
MLAF1>X/4OOQS>.,^J$@EH-/)&%M,^J#U\,9$G+"ZQX _?IQC)\/.3-*\G07Z
M#,&LFCW\>;1R[AVBGRY$/,K.,U+>C+E18LM3++B&B)!!<>DO6WU(ZY3([VE<
M M,&K$X5FF!V>+Q,WS2SQ3):?/Y-:_DD_*J*ZOK&+D&3/1ZB/$CV<CRF18#2
M8S:TLI)!!3*?U:=!J'''<2J^MF#MXV]CF$XD]2RW\BL*U['M<T&6XMA58_%G
M7CZ'8]%C^=V\5OG]2FYJ_,U*)!I#'JO3)ZUG,,:UXYU@QI>&-M/,.U!Y=LLW
MI[4BQ.UD(M+D\V.[M#>F*,E+D2''/V_#'E]C_# 52]]7VH+C"Z?5I;"VFO4%
M9V2Q;L&O4]]:T^68/_2,,QF%C&/:'J*R]J)#F/Z8JX]<P^Q7QG"?0^@S-Y1*
M41A2('IA]:E?3X-0HZNXC(JM=YU:[(QN/,N\UFO%EENBI:D2+F?*R=ZPR*HC
M,4,%N-6SG9%=';B-(0R24D0#-^L^@V@=/[UQ[>NO*RWQJ;A&D[C0^O=?P)[:
M-<X!B&49^_LK,YV+TAQE38M_E^3O)7-D.RG4FTTA#:$$0#=<
M
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M#+_V& [>>?H
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M-,HKLQE9M57VNZK']96R7<1Q'%]JS+FCRZ'8[ 5$EPWI]G9_:91(:JU)4M"
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M.N-J6;2 E_
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M*H
M                                !F1?4^/GCY_,_H7\3 16>J0R+$^\
MG/P7_J>]VR3S\<D6P87TY^O!@)4P    $<G;3J#N+>&\M#]A-$]D8W7+9FC,
M8VGA<2=:::H]S4^1X[M96+E;ID4]YDF-M5DVO_RLU]IQ"W343I_! (W,0_V_
MN&XWG^_,\:[&V,>?N/'MVU34VMT+K@L@K,B["Y3C.:;'M\LM+MW(HNQ<>*YH
MW&:NHE0H\:#$FK:6IY2$.F&>=A>KS:&-= =-].]';TO<AS76W:S3FZHVZ-AP
M:1-IBU-C&[8VRKJ3CV-2(MMC[K.&5RG6Z6E<0J(:6D,*-*#Y(+"=]$.K)&I=
MX:VD[USF?=[QQ'57^8\\ML.QR5)_U:U7OW/>PKFU7\88.)06;.8YQGKZ)M":
M$06H;"2;/D_(@P^[_MVZ"RONO%G8=L\QJH.E"><R>)@.E=6:WN<DLI.S+?:L
MU_6N5XJQ M=-PK2VNWHE@W#.>N=#2@EK-PC4L+^ZP^A3#>L6>ZKR^AW<SD"=
M6;55GE6VK0^N<5N;3&X>L=H:XH\<RS*,>0B]S?)(#FSG)BKBV>?-28I-)8;4
MM3H"T[O_ &^])/U-+U-1]HKNB8=>TBF)FKVE<'R+-*=C46!YCA#MABLZXEH<
MP');=O+2D,VE2ZQ*A&QXG]Q+BB2&VW=/U/)[=[>ZJ[>C]B<ZUS:]8J"BQ>.Z
MC$*O+,LR:HJ<OQ'+;"UI\^.SH<AP[-\E5B2(EC.3^]9E0Y#R?VZ36:C#3?\
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MJVMW6GM7(PN5DM:W)L([DO\ J_+S9)82DN0R);?[=;6MQM"'L:5V;V;(8J=
MTFEJBFFX7C\Z3"G4W7VXT"F^:MY-@3C&.N4=RNT12-L-ML67EQ(4VLT *OMW
M_;^X1LO7>F,15V'MT7NH<CWM+7E69Z@Q?9,3(L0W^]CQY+C*<5N;F-7UMYC[
M>,,LU=JXJ839*/[D9PN" 3M:0P#)M9X@]B5]G!9M55MFW%P,CQ:HQ9[$L!K:
M.EIJ##I#=,91KF15'6.NJG*;86[^X\/MH2VD@&8P
M
M         !TN)\EM<F7"7"5P7U,R29ES_81D1@(=/3/:VM]IOMUD%SP<VZ]E
M_>"::FD$TRXVC9J().M-?K\&E*AG\<E\\F?R8"9 OH7\"_Y .0
M
M
M  '2[R2F3+Z_=+DB^?@TJY/^!$0"'?TO-FG1?9UM"3^VW['.\*5I^3)LO]6I
M:DI^>321FKG_ (@)C@
M
M                               !YW5<+:_^ND7_ -$DR 1%^FM37^C_
M &[993X-L>R+NJV2>>?D]F$M1E\?!&I1@)?
M
M                                                 !U+\?)'/'/W
M",O_ *$RY_O 0]^FJMMJ[3_;R781UQ8EW['>Y]M1+6\EPY=8>SE0%OI;Y-;"
M?W\-Y/BKY,TF?T,!,07T+^! .0
M
M                                      'ED*)*F#X<,U.H1^@N2+E1
M?*OR(N0$27J%J#8TAV$GHR.3<G>>P#N/<KB\\UU*N/MRWJWZ6J:<23D>$M4;
M]RLC4KA]U7!\ )=4_P J?DSX(BY/Z_'Q\_V@/H
M
M                                                  !U.OM,^)N+
M\?-Q#:?A1F:U_P J2(B,_G@!$QZA;BH;T5OR@BSHUC:8MWR[D4F1L0"<-53<
M3MPW.2,0I*'DM.?>73749TS(C(TN%P9@):RX,B,OH Y
M
M                                                        4JP)
M1N1#2M"4IF,?<);GV^242DEX\&7DODRX+\0$27JF=*=?^S)Y=@]:FGV7;R3^
M\=A-UO),XEK9M#"(K!(2A,0C^WY<$;A)\CY,S,PF!3]"_@0#D
M
M
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MO[0'V
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M<;_-;T>&[/3$>A$?^ 2@N#555T_SK;'KWQ#UGT=+/VN]UKW7A7?ZGP6'DO\
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M_O)_'_J+\.>?Q_#@!]$?/R7R1_)&7X@."4E7\JB5_ R/_D Y
M                                 =:S^A?DXW_VF0"&OU&K2>1^TUDB
MX4U[2NQQJ/Z)/[E7@:D\?P(OD!,N7T+^!?\ (!R   "(_P!A^?1L:O\ '7$^
MSZGZ'JKL&M'KO7]YJO3^VJG/X&0Y+68Q29%=X]LBFN+-IA-[)15168I(_>O2
M%-I2I?P0:H-,[RN=<Z]SF%[^WW-=[9R:'I[6E[A'4WJW'<R/8EE:*Q:3C>.1
M8N/R+%-A5W#9LEQ'2NK6DU2%I2DS 7]CO5OM+C^58]@7_KV;GR/,]AN9.SBF
M/6&FNI-Y<7KN"0H<_,6,=B(Q>2HY&,0+%EZ>VV1NLH<2I9<&0"]5]6.V-$]D
M$^![NM@HN\<-I-ZO*M(=0[FCQ]P^&/OY/3.X]"*!(-I!MM+?=CF1_I+GZ +J
M_P#*SWB*=,E0_<ODL)4Q-;(=B1^I_3T_O>45"X\R0@Z0E/N6+;R5DY\&ZR;1
M$:DI(S#VL=0._P"<.?!I_;YDSB3_ '"9$9CI1U D0?WTEM:WBLXD/&B+RE/'
MY/)5X..F9_)F8# &7Z0[VQ=CX'HW)_>E!Q^UW)$R9.O\)I.G/6BNV5ET'!JJ
M/89I_EA^/"F5B(M!%>0Y+,XYH:8=)"B\E?(7A6=".[S3JG6/=_O&W1!D/5$=
M<[KOU,MF:FV42HIQH+JL=,Z^Y:-)MH;2:'D_*?'CD!<%7U [G,Y5*N:CW"RX
MV03;O^BY04'IYTUAW]S>0&&%LX_<R*FBC6=C:PVG4+./*6Z^VTX7"$^7R&((
MWK;WKKC<&2=D<-]K-%A^YMATB]<YWMFWZJ]78UYET"LG_OXV/V/]/51X];V5
M4^UY)7+C2+*.KGQ=0A2D&%/_ -(=NX7D%%AD[W[9T]M_94NL37(@Z0ZIW9Y'
M7V=W)H:;]K15F)3DPVOZY#=@(L9$PVF7.65*2:BY#-M%T^[>7S6.VU![F<LR
M:EK7K./C/[/J]TUO:=ZW><43SAOQL:=@7-Q62$K)/B?W6#+@^#^5!:#^K^YU
MYL78&G<:]YU.]L?7D7!9^PL#N>G/4UW(,9J\[5+;ICRR"U65Y,GE\&+XU2'4
MF;O@KR2X@TD07-_Y+/9C#A1FZKVZXP<*HNT?Y0KY70_K(W1UT&(P_&*.W&K6
MHG[.]B/*,D.07(Z4$:D^!<@+?SK0W>G4Z*7:.P/;#H##[&S?I->M;-SCI%HF
MHG6V2Y9:.U.,8] RI.15TA3]O-?9BQ(1/+^ZY^DDF9_(<;$P'O/I6J:1N7W&
M::UI67TM2:Q$WIKI:CM93O[^.U*E8W"F9!*DV%A^YGM&M_\ ;2?LO+0M7'/R
M%/O^NW;&URG$=39E[P;"5DU['RNRPS$?_*AU.F.9- UT_5GEC^0PYU)80[F;
MCBK1@IR7394TI[^4OD!>VP]"=L-<8S2W&V?=/_E?#I^08UB]%*RSI[TQJ:.R
MR6]FL5.-8_CR['&517KNVF2$,0F8Q+<-2B)"3X >3,^D?<*'D=761?=WV(PB
M;?MRBI</MM0=59%O=2HG^)-7CT*;BE38S(L9)_#$9IQ+2#(N>"(!ZJCI-W9D
MS$Y-BON]WS.IZM]<=R-8Z&ZI9;3)G04$S9(M'_\ *R(CA'(4:OLNF@V2,D_/
M!&87*KJ1[!F(/[6A]R>3KF3%+FLO6'3WJ3,_?H4Z;TJ82F*2++E(2DE)0XE:
MD-D@B,S2DR(+)D=5?9A_5(DR+[N$'5V%O^VI8TWI[UF-=NM+A$W6-N0EQF+"
M<MU*T.-Q4\\$1$GZ@+(S'!.Y>J,@L,:V?[Y*'$,EQC6&3;3OL?N^I766':P-
M745A&9OMD6]3-_<2(V-X]*DH87/<:;9;+DC,^%& V$J>IGL;NZ*!<T_N1R>S
MA6]3'LZ2RK^E'5)RIGQ;&(F563VG6Z=TY4"2R\AQ*FUI\T&1D?R J</K1[7H
ML*)&=]G&LK"0PREI^PE](,!1(G+2DB.2^U!SR'$:></^8FFT(_(B^@#Q6?3_
M -H,Z"3\7VZ3ZR\?DI>DQHW2+KD[B\-I2E?<CU<6:U+N_MLM\?:.3->7Y<FM
M2BX(@ZXW1[V+L6$FR5[D=N//2UFX[%=ZA=55U;"C9;9\(->K&#9B,EX&HDES
M^H^>>0%1D]+_ &,R2X5[A=F,D?!'^UZ;=3XYDGGY\#1B_*5F7P1GSQ^1@+<J
MNB7L=:GO2+OW)[=L(K4M;D"+!ZG]9H!+B*;\29M/N4,MN2ZA?SY-I:3\?RE\
M@/=6=)?917<$7N+V%()QEHGU3NFW6"R63S+9,^40YE.HH[3S2$J<3PHS=Y41
MD1^)!Q:=-/:#]]A=%[A\B0U]I_\ =MW/1_K!)6X_PG]JIAR!602:82?/W$J2
MI1E]%$8"[I/6[V@I<44#V48$IAN"AJ.=CTNUXY(<FI6GS?F'#S**TMIYHOE+
M26O%7TY(!;]-UZ]O$*="<MO8AURO()3T*LFG^DC422JM:;2I+<!V!N*(VU.?
M?,R=6XEQ'VR+P))_(#NEZ9]R']1L'J_N_P!)FZUXR17PYG238#KL-IM;GB\M
MZ/V=CJ>ER4*3]WR,V^4EX)3\\A;SW4GVOYU*ERL^]IV&ZU1&B-L4E9UPZ:8)
M2U\J0M9JE6&3.[?S3:EG,?0@B0RB(_%:21F:DJ/Y >.5Z_O8:^U7J:]SF_6)
M;'^)/7_Y:>M"HLQ]#"282W$;Q9DF8I2B-3B%*<^ZV?CR1_J 7?%Z9^R%EIM#
M_N#SQU39<>2.E/4])_PY?QZ0HTE^'R I[_3#V9?;4<;W"Y;^Y_?-FE4GI)U:
M6Q_3?NMFZA3;%,PX<_[1*)"R439*,O)"BY(P[6>K'M7@R"3&]I.%64%B/(AL
MG>=(M6JG3DK?)R/96BJG*:V*=JVURA7[=#,4R^C1 /)3]</<#4T[QR_9#UYR
M?(74V1):O>CE?%QJ,<IQ7[#[+&/[?J;Q95K9D:?N2UDM9?K\D_I(.I_1OND6
MS&^SWPZ3MO1HKK:T-]'LU::L92F22U*F*>['SC8=0Z7E_@(0WR9\MF1$0"V9
M>B?><Y]K]IWZZ/QN6%$^2.EF8E]N225FW^V-_=$KR:-SQ)2EESX\F22^"(/1
MC?7/W9R))'F_LCZL0X/VC5X87T?2[-;E%\(2W(R/:KT8XQE\JY9\^?H9 +CM
M^K_MPM9L:-%]H6K,<I7&&CLK&CZ-8"]EJ9+;S9J36OWF>6^/MPWF"5Y$_"=6
M2SY)1%\ .YCJ9[4ZN;&FP_;!3WZ5Q7FY]9EG2#2?].;E*D+-A^L7C%MC\]I#
M,7Q+Q?>>Y<Y/Z<$0=EIUO]NI-M%1>R_2I.G(9.0=UT=Q=]!122K]P3!5VS(1
ME(4KCP-7*2_'D!9SO77W>?M7&4>R'J$Z_P#NV9+,I[H?9H=)ED_F M+6]SCE
M'DE_\(O[2G4J,S0I)? #NOM)>\POVA8YWKZ)/>2%E8.6G3'8%<MM:>/M*B(8
MWK>)D&YR?GYFT2>"X(^3X"A(T'[XW"2M_P!@W1QM25$9QV.EF6.,+3\I-*G'
M]OD\1)(_(N"(_(N.> 'R[H#WPGC,N,S["ND3631;!YZKF)Z69.;%M";028T:
MYE.;:=9JBE&M2WBC5[[B%)22'3(U$ K--JSWQ'80V[WM=ZVH]69I383ZOJSN
M^PM")+*B_<,P9&ZZ>))>4\22-)O,)\3/CCX(!?TG4ON817SU1.Y?1.3:I8YJ
MV9'3#:D*N=D?/+5C(;[06$IJ.LN/U--J4DR^A_0!9D?5WO:-J1^Y[8>M]I_[
M_$?]OU7W@ZTY'^R\LW)'W-XLK;D'*^VGQ3YI^WRKGRX284^1UV]WK<J)81?8
MIT^FJ>NF%6%//Z/VD6F@X^K[LF2BN=C[CEW<^S9E*2VV3LEA*V"Y4M+GZ@%5
MF]?O=@J(LX/L2ZBIGJ7$4E#_ $=M40VR-:/WZ266[I#ZB0V1_9Y3RHS_ %F7
MU(+=;ZX^])TS-_V7]08?)G^B)T.F24E\_7RD[J:5R9?F J]9U]]WM6<<G_8G
MTWR1HK6#(D-W'1B_KS*L8)XY4)I=+OJ.;G[Q1H)1J\72(N4.H/\ F"H2=7^\
MF+-D+A=IO7)=P6IZ$Q6K'JWNV@D3:Y4/]4F4N'O&^17SXTY7"&D??0XTGDW$
M*/Q(+>D8I[_ZJ <&OVCZK\OG2$R37D-KKKLGAQ5:G?%$9EC'J^_R9JT:BI)2
MU*7,CJ=4KQX21>0#R?Z9_P"X$7]EH^T'K$896;B9+K/7#?KDAAM/E]I<9#FU
M"CO..?'DE9)2@OH:@%/F:[_W"3,>#_3.PGJ]?EK57NV/[S2F_(C#!1X'[>?%
MBFQE<MR44^:1/?=431MD9H2DBX )6!_[AIR)(-C?OJL8D)85]AA6C^Q<II]T
MD\)0\ZYG\8FD*/ZF2#X_(!,_BL2\AT%.WD\JOFY+_2*A&12ZIAV-62[UFNCM
M6\JOCR''I#$"1/2XIEM:UJ0UXD9FKDS"X0
M                  'F?<0TGS<6E"?NLI)2S)*?)2TDE/)\%RI1D0"&?U%N
MM.YC[6OL+0XVCVD]@T<H42TDZFDP,GT>1<_J0\1DHOP/X 30%]"_@7_(!R
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M_47QQ]>?D!R;C9%R:T$7S\FI/'Q\'\\_@8#A3S*/A3K:3XYX-:2/CZ\_7\B
M&G6GVTNL.MO-++R0ZTM+C:R_-*T&:5%_ P'8
M
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M&9%L;:-SJ726R,UENY)I/#,AL=70([%GA%7#UA VFY<5DJV09/5:DI2I3Q\
M)@/4CG&9L85N+5UQ@6U86OZ_L5V2R+1^99/52$X;'U;$V@G'6L+KKJTLI-N4
MQC/D7TFMA.-K0BD2VMMTVB;(PF+
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MHODN3(O[@'RU$BL-I:8CLLM)_E;:;2AM)FM3AFE"2))*-:C,S^IF9F ]
M
M                           ZG%<?\%M_]ID B5]3ES#72>P*I0ZVY94/
MM![@HLZ]I1JDUYW>1X_=UZ9#1D1M?NJ^<AY'X*0OD@$MQ'R1'^?_ ,?[P'(
M
M
M           #I>4A*>5&1%YM\FKDB^5D1?J_M,^/^("&+U2SXLO=ON F1/-N
M.Y[+\XB);-KP4F7"U)J>!-7RA)<I>F1UJ(_R^?Q 31)^A?P(!R
M
M
M   Z'V4/(\7"\DFIOX^.",G$F1E\?4C(!!SZIY3J.[/O!QQM1II:KO;A5U @
MDI1LQ[/)-%8C+NY+:5&?BJ?*AMN+X^#47("<T
M
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MB9!VUZ<9Z[N?5F 1)<B+#*^V=@=FQ%SW%,::<>^Y)L$?=:9;(_\ #/Q,!/\
MX9FF*[$Q7'<XP>]K<HP_+J2MR3&,DII34VHOJ&XBMS:NVK)C*E-R84Z&ZAQM
M9?!I5^?)$%T
M
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M7'X -]@
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M867BM!+\DG\&1 +\
M
M  '0^9_:=)O]2^/E*5$2OP^"YY(E&0"(;UL4S=?OSVTY! 0_%3>>P*QC+AK6
M[)9*93:5U:4R8W*=:0W]JQ=G>:FTFK]N9>)F0"7Y/)I29_4R(SX^G)E\\?V
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M\B(E$9FG\^"/Z /H
M                                   '0\V:D<(5X*-:#-1%\_S%]#_
MP$6GKRC0U[[]JLB(].1]_O6_$D0'G6U0(LF)H73IOS*^.VVV3+EFY*-Q]1F:
MG%$7)_! )42+@B+\B(O[B <@   HCV/4\FX@9!)JZN1=U<6P@5MP_ C.VT"#
M:&PJPAPK%Q"I46--7%:-Y"%I2Z;:?(C\2 68[IG5+^8S-AO:VU^]GM@U&9FY
ML_AN//Y=*;AQU0HR'\E?KW;AQ#4%9L$DWN/M&:?I\ *_?XOC=DFED7%!2VJ\
M:M6+G'G+*N@R$XY:Q8S\:-<5:I#2TUL^%&><2B0T;:VVUJ(E$1\&'YW^S_=7
ML%[+-V7WK]]5F;'B6M,:>FT'=KV'U<!ZTP[4]>^:JZTU#H2X\XT'*-T33\VG
MI41U3=>:B-+A$E3A!,ATNZ.=>NA.G:[3'7K#VZ"E)\[C+<FLGG;?.=DYE+3Y
M7.;[!RJ<MVUR3(KF49NN+=7X-F9I;2E/P V^,S))GQY&1&?!?')_D7)_ "AW
M>24V,U<R\R2SK,?I*]I3TZWO+*#45L-A!<K?E3K-Z)#CLH+Y-2W$D1$ BMW9
M[T?5;HRVL<4R#N!KO,\]KBLT*U_I1F^WCF3\ZG1]V94HJM7U.2LQ;)2"/[:)
M3T=+A$9DK@C,!&Y=_P"XPS'M&=WB/J.]=_8WNEF= MB-D>:9U3LZBU!A,R:V
MTY7Q[RTG3GY4RR?2[]PX3DBN=2TGR,SY^ CCW[HK_<5=M;*=F/L2:T/IWI?4
MXS;7^;:EA=J6^MFE,>AQV%3(LW=&2ZR_S1LS*,=IEI+]Y!_J7$HD^"%I,_D+
MXZ9]6?9;WKZTY3I_0A]'?7CT&N'JVAJ]E=?NN6R*O*>V^)P+-E_(7Z61F^65
M&RUZZOU0G(;M[8O0Y=[&6I3239>-0#]#VF>FG>+4&NZ'6N+=V=,Z^Q+#H2*?
M#L0U;T>P''L0I*1A'+$1FKD;#=-IQ;YFIU:#(W3,UJY<4I1A?<35WM!IZ]HB
M[6=3\SL8*S5]W)NJV:TBKM@G%*.-8RL7WHTBN4MGA/W(L4_%1<^"OH _/![(
M<-]E66=N;&/W4T+WD[(=#E1*-_4^OO5!L5G"Z I#E,AO*X.\*G[=7M;+K!-W
MY%&6[:UC#4<C\5GY<&&1>K'>GTN])Z:.WA/JS[B=<-@P$K<R"7F?0C/L^VPL
MVC/[]G>[5<_SC/L7%N-K4X[_ %-2242C))<@))J+_<->O>SET%?,J.WV,R<C
M6DJMO)>FG8.(;L127%LV240\,L5NU\A+9FVMDG#47'"> &P='[I?6Y8*BM95
MV'8TW(FI4N*QV!U]L_1"939?R*B6&TL,Q>FF*>27DE#4E:_'@S(@&Z>N.TW6
MS<3L1C4N_M*[,DS8Y2HT/!=IX1E%@ZQR9&X5=474J>E*?CZMEQS\\ ,ZD]^M
M*#0HC7Y>)\&:3)*?(S-1$:4_W@.X    !'=NKU?]5=U]IM7=TY6/Y)KCLSJV
MWKIK6UM1919:^R'8-)6-,,Q\,VJNE6VSGF*DQ&0U^WFI6HF"^T2B1^D!(6RS
M]HU\*,R69&2?^E''/PDOPYY_L =P            #4OMYUGR_LSA%%08%V:W
MGU8S#$LA:RK'-@:.MZ6)-?M8\61&CUV9T&15-O29IB?+_F[6R$-H=47/F1\&
M01J'W<[P^O=TX'LHU#%WCUUJ)R(:?8#U:H7WXF-T,@VHL2Y[']=FES,KP4HS
MRB.?<4"K&J0DS=4TTE*N FPP'/,0VCAF-;#U_D=+E^#YE3PL@Q3*<=LX=Q1Y
M!163")-?:U=C!=>C28LIE9&DR5R1\DHB,C(@N\    !T/OI83Y*+]))4HU&9
M)0DD<&9K6?PA/!_4_@!UPYL6PCLRH;[$F/(:2\R_&>:D,/-*^CC+[*EM/-F?
M_4DS(P'K
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M,ULSK#N_ MSX>M*42I.'7L>=/I)2R0X<'(J)PVKJ@L&S7XJ:EL-+)1&GYXY
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MRE.F:DLMI(B 9M
M                    'ALDFJ&]PZ3*DH-:732:R;4DC,E&@OYB+\@$0WKX
MK6Z_O-[F#:L3FILNT6BK-YE"7&FZV6_UFP)IZ%X.&:5/):CMJ6XC]*^2_$@$
MPR?Y2_@0#D   &!IG:7K/6V$NKLNQ&B:ZQ@29$*= F[>U]%G0IT1UQB5#EPW
M\A;DQY4=YI25MK0E:%)42B(R ?">U?5U:O!'9'0:U&7/BG<.O%*,OI_*61&?
M'R _*-V,]F^IL)]OFT,T]:ECI;MOV5VOUDI-&;FM]I[6Q[5O7'KPSJ;,94RK
MRIO;]]/B5N4QYK]^3-Q2TZWEN/16E-/J6:T)#,^.=.>O?;G(*_//<#[=M2=M
M;8G7;N#U-T_V P?3G4#"_P!FEJ;(K#Q+'<K@91L%BI2@T'*LY+7WD$9J0KDN
M G,Z^9_ZT-%X#4X?UKV?TSU;KJ(P35;3ZNV!I[&ZEU#"UIYE'6734BPD-N*7
MRY(6XZ?D?*CY 9__ /-CU:(DH:[*: >=4:4MM(W+K@ENK6?"$I+_ #&1&I9G
M\?F8"M9+V(T=B-*_D>1[DU)1T,-K]U/N;G9.&UE9"A);-YR6],F73+'VTL(4
MLN%<J27QS] $ ^T/<MDO=#.+S1OJBV!H'&\?Q?(G,>V]WX[/99CF/Z7PAK[9
M%)@Z0US<9'1YAN;-4(>0Y%E'&:HVO$S4MQ*O-(;?=*M"= ^IEE8[*O>V&I>P
MW;[8J6V]I]M-P;HUED6XL]L9"TK<I,;7(R27'P'"&7B),&BI_LQFFB)"B69$
M8"2I?:+K:Q]M+W8/1C7W"?-HW-NX G[J(JU-R3;-60D:_P!N:?\ $/\ Z#^#
M^0%L5G=CI[=_N?Z+VMZUVA17G8KW[+>6LGE,2F#(GF7TIR?R0I!G\_ "X"[8
M]6#(S+LMU_,BX,S+<FNC(N?IR?\ F/@N0'MB]G.N5C(C0ZC?ND;:;,\BAPX&
MVL DR9:D'^LHS#60+<?-!?)^)'P1 *Y"WGIN=*L(3&VM6O2JMYN-.BQMAXE)
ME0Y#C9.H8G1V;9;D)Y2/DD.$2E)^2+@![7-QZF;2HU;0URDR(S_7G.+I+A/\
MQ\JM"X)/X@/@]S:G.0<1&SM<KEIBKG+C)SG%C?1!:1]V1-4P5K]U,2.P1K6X
M9>"4ER9\ ,8P>Z?4"S^[_3^U76V:J.^<9],7>>LW38?^X;*67"3DO*7%.I\>
M/KY? "L)[:=6C3Y*[*=?DGR9&7^L^N#+R3_,DE?YC+Y2KX/Z?("R;GOQTGQ_
M&,FS2W[:];(>+88<I.572MV:]>B4+D+@Y3-A^VO7W4/M$HO\-*5+,SX(C 0M
M;$_W%NE=S3KC6GKCTI9=SLT.QG8U:9?L7,\*ZY=9Z!MI]J*]9Y%L';%K4V60
M4LAE_P"X;<"M=-^.1^)\GXF$1>P_4AN[:%YMKN?@'?3HKU%[=91CBW:WJMT(
MV5$U-J'/X3,\[.XP39.U*K8=/?S,CS".HX*[>)6(CM2%(</Q27D032>G'*O4
MGD^D8>_=':JU1U\WE6Y5=:VW>YN;,,?RO?-#N'%4,LYM23-M["R2]R7+Z1R6
MXIR)8PYI19L<R,D(42T)";I?9'KM!4:Y6^M+1R<X)*I&U<"9)1D7/P;E\DU&
M?/Y@*S&WUI*:7G"W'J>6S]N.]]R-L?$)"39E+4W'=(VK=2?MON(-*%<\+,C(
MN3 5^OV=KZYF(@TN<X7<REMK=_:56645C--".#4M$2).>>6VE)\J41<%P \[
MFWM3LN.,N[/UVT\THVW67,VQI#C;B3\5-N(59DI"TJ^#(RY(P%IV/9GKE33'
MJV[W]I*FL(_C]V#9[7P*#,;):?))N19-^T^UR7T\DES^ #RN=H^MS;*9/_F%
MT3^W<>88:>5MW $M.NR7$M,-(=/(";-U]U1)0DCY4KX+Y >TNR77TON&O>NE
MR)MUQA?&U,%_0\TK[;K3AG?$2'6UD9*2?RD_@_D![*WL%HRY6X5-N?4MNB.9
M(E.5FRL*G%&<5\H;>*->.*;4LOH1E\@,JU\^)9PHUA!E1IL*8RB1$F0GFY,.
M5'=22V9$62TI;,AAYLR4E:#4E1'R1F0#V + S;:FM=:-0Y&QMA8+K^)927(=
M=+SC+J#$H]A*9;2Z]&@/7T^ W-D--*)2D-FI1)^3X 6 GM9UA=>;CL=CM!O/
M/+0TTTC<6O%NNNN&26VFVDY$:UN.*/A)$1F9@+4V%WAZ=ZE<@-;0[3]=< <M
M%+_IK65[EP&FD3DMD:G5QHTN\0ZM"/\ O?R@,;O>S?UU/PVI;?>GJHB),7+A
M19;>]=<K;7+BL+E2D-++(/'[\6.T:^/J1$ _+1VM[H;VW?TXW1Z\K',>F_:N
M/G64.*T!WKHN^FA\6K)='2[/B;%Q"ZVG@&=RY60P,FP=<5FIEI@NFAYEE+C"
MCY 2X>O^-AN'[KV'W@[V=[.EV==K]MZZQ'1F)8=J'=>#%J70VG<2D.VZ->X=
M9WF11[/*<ERK)F7+"YL7([*7I#)(;+[9%R&1^FW9/+<-[J>Q#%MW]D=-W_4^
MSV'KO8?4K.\M[$ZVN;5MC,<.AEL/7>+,GF,F1%PG$KZK6M++R&CC29)H;(T*
M^ U!ZM=4-'VG5/V"Z_[H;5Z<[#["]K-[=GLGH=KYSMS1^T+.7B>459XYH3)R
MLUV3\W%58O20X:FJ]I[[T$FB5Y)49I(++]9_:3'?7KHG NK\+UA9-4[>H,/I
MJ?:VVNL6<=2\BU5O"\Q>MDUM/MB?LF1NRCO)L;,S86\AVY:2[$4^XGDR3P ]
M,*W[DZZ]@W87O/K3K-UH[)67;'36F\'Q+%=A=U-(X7L3JNUA=;/B7FI+M34C
M*Z:YQK);)W^I27J)Q9R%N?;<^X:. $F6F:;)\DAW.T/93NOIRJ3D%!.PS7G7
MS!96MG=1Z"IKAF3"MOZ-M3/E%FV9;!R&M-,67+:57UR&&_M,0R3^H@AFU7ZO
MY/7:IZI[IZ^=S_6I2[^Z.Y!V&PK";S8%?C&1:OV/I';>43)^"EM.]QS+<=S&
M'MW!\<EN5[-B4B0VVR?BT?D7F82!8!U2Z@;7U?V?M.]?=?JQVB[(]QL./",[
MVS39?JBMPO5&OZJ-,_T[P?KQB-[E5ZO$*#7EO,7;L2GG5SYUSQ*?<-:4<!NK
MZ\M4=).B/76CT?ICL!J?.BQUIZYVAMVXV7K2?GFT,JFR9#T[/]G7E3=/.3[A
MQI9,,KDNJ1'BM(:09)2 WCJ^Q6@[UIYVCW=IVX;CIYD.5>T,(L&V%&7*4NKA
MW;R6^2^?U&7Q^8#VEO?2Q_<\-OZK<_;LKE2S3L/#_P#PL-HTD[*?_P#IU_A1
MFC41*6?Z2\BY &-\:6E'5E&V]JJ1_7$OKI?L;'P]T[9$0S*8JL)NV5^_**9'
M]PV?,D<?JX 54MO:H6:$M[/UXXMQ1);2C-<:4:S,^"))%:<J,S^/CDP'J_U.
MUUX+>//L'2PT3AO/'EE#]IO[)$;QK64_Q031*(U<F7'/R \?^L6HO_WIZX__
M &XQG_\ 2@#A6X]1)+R/:FN"+CGD\XQ@BX+Z_)VG "F?Z]Z/-I+Z=RZG-A7G
MXN_ZC8=]I7@HT*\7?ZUX'XK+@^.>#^ %.<[)]>6>2>WOI=HTGXJ)S:F"(X5S
MP9'YWQ<'R ^XO8W0<YZ&U"W?IN65@_(B03C;1P=]<R9$CE*E1(;;-XM4N3'C
M+0XXA'*FT*)2BX 5>)NS4,M+#C6U=9.-RF?OQS8S[%7_ +S/*2)YI35JI#S2
MC67ZD&I)<E\_("Z:C-,5R+[ZL<R7',@:BJ;1*<IKVILTQU.D:D$\J%,?)E1D
MGX)?CS^ "OG,CI(U&_'2E/RHS?;X)/XF9^7QP ^3GQ$)-3LJ*WXIY/RD,EQ\
M?/)J<(BX/\^ %.5D=*E1H_K%-YI^32JU@DHD$9>2E)^_RDDD?S]0':]>U4:/
M)ER;.KCQH)>4V0]816F(B20VXHY#SCJ6V2)#R#Y49%PHOS(!4F7B=\^"X\3(
MOQ^>2\BX/Z'\&7/Y'R [@
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M$_$U*5XD9\?4P%-B>@SU/P%?=C]2Z<WE-FRMQW8VV7UFVI236E1NYWPKR(N
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MW0GI7Z_XOL[&NQ7;79&VO8)VEQK_ ,75[8[/W+5YBN)69/$\Q-UII:&G_37
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MNR"TR_+\KN5-<M%99%DEY)E.I1^E'W227T ;+
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MH5J7 ZK%I^3G$.!_F2Z;-V;?WZ8"I$M4%NXO)LB0EDW7#:2X234KCD!LH
M  <$7X?7Z_V@
M                        .I\O)I1<E^'//T+Y+Y/^'U 1>]1I\6=W^]JS
M4>6W).#EO4R+)0VYY_M9!:1FJ5'<X/E*TH)*N/P\O[0$HQ?0OX%_R <@.#(E
M$:3^2/X,OS+\@'Q]LB(B)2RXX_ZS_#CZ_P!I\?(#Y-A!J)1FLU$DTD9K4?!&
M1D?!&9I(S(_KQR ^VVTMI\4EP1GR?TY,SX+DS(BY/X ?8
M
M                                                   \LIHW65H\
ME-^?!>;?PLOP_+_M_ !%=TQ>ERN^7MHLI?\ 3T)C;4ZPXS!C08:8LAYBHT!
ML43+%])<39\UV^4C[A_))9(C 2M)_E+\#X+DOR/CY+_@ Y
M
M                                                           >
M>6?$=T_U?"?+A'RH_'YX27)<JX+X+\P$2/3*X8;]CGMPP]4=Q-J>7=2LU0I+
MJEQEU5UHXZF,E;9F7[:>T_1.&X7C\I4GY/@!+JDN$D7]A?7_ -_R Y
M
M
M       >2>Y]F*ZYP1\$7U/@OE1%]>#X^H"&;IQ-;>]O7MS0UX'^WQKI2T\2
M5F:C<3K')#0:T^"?M&2'>"+YY(N0$TA?)$?Y@
M
M                                                  #SRTI7'<2H
MDFDR+DE?R_4N.?QXY 0I]4?ZJQ[DO:K$@MM-U$O4'32Q4DF8Z/NY&C'<UAFZ
MXXA*7G4HK6FD&:OCQ27 ";%OS\$?<X\_$O/Q_E\N/GC^SD!]@
M
M
M .A_]33J3^"(B^?[C_Y@(;>JO*/<E[16N>"5ISI?)27Y_>Q_/6U*_+ZL$ F9
M
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M>?S\MF7/P FX
M                                    /X^0'RE:5&9$?ZD\<I_$B/Z&
M9?D? #Z ?"G$(,B4?!G]/@SYXX_(OK\_Q ?1J(D^7X<<\_V?G_ !T%*9,N24
M9EQY$?@OY3\\*_E_E,R^H#N4M*"\E'P7)%R?Q\G]"_B8 A:5D9I/G@S2?P9&
M2B^#(R/@^2,!]  #PU]975,=,2K@Q:^(@W%(C0V&XT=*GGG)#JDLM)2VE3K[
MRUJ,BY4I1F?R9@/<                       #Y61FA1$7)FE1$1_')\'P
M7/)?B _*3O\ [-=U)W>#MKJZF[UW^@]/0]K9'H[&Z.DU1KG,LGT?$H^HM-V9
MQC;^(0KBE>NLJ=R>WQN_JY3%DMZ$\PXK["D.L\@-F>M7:+O[2:4]3[^QL^U;
MLV7W)QK9L7.\XV=C+N)9Q<9Y/U?G>SM!5SD7 D1<4Q_&;6FHH";1QEMVT=D.
MJ;;1R U!ROVB=_\ ',5Z0[*R&?CC6-Y-E&;X/O:ZU3J2)DVI\AVS@O;<]'Y_
MA>Q;S([F#9Z8U_C&M);-K4VL=QV1*L_B07!DE8;1=T^X?9?$JKV69/BW::HZ
MY5W5K:FB=9:HQ&ITU0;3SK-K'.=4PK^AQ:BCY&Y"0_E^]MFY?70H;K:9:8,"
MN=)#9*-:R#"VJ>_7LHR3*]AXHULC1=[NO*\%[=8ACVC<NUTYC^,=?]X=0:'6
M<V3=6>18M/E9/EN.9_&RF=(4S/\ LL(FO14,\QB4HPJF3>T[MY2ZWB2[S*-/
MU-KNSUU]5]_]<[S&L4<=MT[IV9M[7NG=NOY6U=VDJ@EPZJ_S=AZ%!C-M1V6'
M/$S4M!J 8#N_8=[0"UE-L,7VEA.UJ:35X;V6OLOUW0:<P3;.N]'%;;QH-K:D
MK*G9SB\"S/(</RG5S3;1I95>.UZGD?;0Z1&03X>M_MQ?]L<*W;)R^PQFTR+4
M^\+G"J^RQFMET[-UK7(\3Q#9NI+^RKI,B2VW=66"YK&3-<CJ.([+8<-GA'P
MD1F-?=CNHY,E*3P@RX_2ODO%1$9&GE)ES\EQ^8"&GK7$K<9]T_LNA(F2UVV9
M=<.DV9E"L92W5.0J^/L;%Y<RE8=\29I8\E#:'$H-2425*Y_4K@PF?0KR0E1_
M4R+GX,OG\>"/YXY ?0
M                                        H64*M$XSD2J1Z/'NDT5L
MJH?F(-R(Q:)@2#KWI3:2-3D=J62%+21&9I(R ?C^TC[<?:3J+J#8=M]X:[HM
MNZWS%[0>M]/7^ZV=9Z-@9AN'+,HV;1;*FX5<:XL;']WJATL9K4U<[*T4<AI<
MA;CIJ)'VW0ONO_W,&SLHU:6W\8Z;X?7X]EE9=6V 8OFV\',=V'58_AF>Z2P+
M*\^V+C[^&H@1M>6<[<J':&RJIDUJ>Q7NN.J83SXAF_M![<=MKZL^N?LUKO<>
MJNJ^7]M,I=PY_1VR\?PS,L?R/(:3.8%%L^XO=R9+EV/8YB.I=98Y07$HIL+R
MM;:3-KF8W*GC205OV?>X#L+UKV?OWKKI#'M&,YAC>J<4LM7.Y+DMRYM_+WMD
MZAV5G+6\<#Q"7!1AUWKC2%UKQU&21GG)1I9>8<4\C[GV3#75_P!R7:O&(N.1
M+',-(Q:+.-\XS0X/F&QZR12YIM+#\0W9I;0>U-:Z)Q2N@)ILGSR2[<6V3/R9
MBS_9,SG$1F39B)< ;:=7?;=N'N)T][T;7SC_ $6Z/6W5J?53"W;_ %ACL5@6
M,X+*8EY#;V.3X5'G4<U&PL?H*A^&NDE/-OKLGV3<C,J/]N DE]6N]]F]E>E&
MJ-S[:SK"]D99FLC,K"-F6$1,8JHMWAR<ON&]?3<CQO#[:\H,.SF7@Y5[UU3-
M2G5U5@XY'<,G&U$ D*                           !PHN4J+GCDC+G\N
M2XY :7; ]?/4/:V[I_8[8.C,1OMX6&OK;5DO92GKB)D4K!;JCM,:LJA]5?80
MX;CLC'[R7!*4MI<MJ*\I#;J2/@@R%8=4=&V>'Z&P"7@-<>(=9,GU]F&C*9J7
M/CLZ]R#5M4Y28/.K'F9"),DJ:J=6Q]M]3C;R%G]TE ,7Y9ZY>F.<P,%J\RZ^
MX+E<'66ULPWC@4>^*WF,8WM78&0EE&8Y7%:*Q0B0_=W:4R'(\@GHGFA/^%^D
M@%E[Q]7O4CLML39^P=\8!+V4UN#'=:TV=X)=9';,8%/NM02;M>NMB5U55.UM
MA4;(QN!D$F$U:1Y39G"4EM2#-"5$%ZZH]=O3S1^Q+;;>K-!X3B6R+_6D74EY
MF$95O-N[G XD.KKBH[:3:V-@B<<FNI8C$B4HBER6XR"=<622(@JJ^@'4%VJU
MA2/Z#U\]4Z6QJ#AFJZYZND/P\)Q*KS*AV#74-0P]*4VF%&S+&8%APOSY>C)+
M^3](#"]GZ>_6]=L[1C7/4K6=LSN;.V=F[%;LUY+*9O<UBVEO=1+-MO\ K[94
M[#-KD$Y\XT(H\9Q<MW[C:R<5R&S'6_JOKKK$YMMS7SEZZK<FR7]F9(F[G1)4
M>IF(QC&\+HL3Q2'!@5T6DPG$<4Q.%!K(1(6<=ELR-Q9F9@-E7VR>9=:5]'&U
MH/CZ_J29?']OR U&J^HN'U_;[*^ZQ6EVO:.5]?<?ZZNT+DQG_*-?B6.9E99G
M%M&([<=,UZ\E6%AX.*=6I"6T$2"(^3 ;=,H4VTVA2O-2$)0I?''FI*2(U\?A
MY&7(#L
M                            'RM)+0M!ER2T*29&1&1DHC(R,C(R/GG\
M2,@%C6^M, R#%4X->8+AESA*":2C#K;&J6SQ8D17_OQ$E03H#]42673-:?\
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M*6KY,S,!>(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
5                         /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>tv526458_ex1-3img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ ,,  0 !! ,! 0
M       (! 4&!P$""0,* 0$                     $   !@(" 0(#! 4%
M"@,+ 3D! @,$!08 !Q$($B$3,10)05$B%6%Q,A87@9%2(QBAL<%"8G*2,],D
MT9,*@J*RTD-3-$0EU28G*#CPX<)C<X/#MD=7&524U#55A94V5I:F=Y=8\;-T
MQ'5F=C>'M\?72&AXF+BC9(2T1;7%QM9GISEY$0$
M_]H # ,!  (1 Q$ /P#]_& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P*#YU+\
MQ^0\5?>^6^8Y]L?:]OR\/+W?V>?+\/'[7/V<>N!7X# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# M_LH_F'N^RE[WM_Z[VR^[^QX<>YQY^/CZ<<X%PP& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P&!1_\ ;O\ YK_P8%9@,!@,!@<<A\.0YP.<!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@4?(?.\<^OM<\?;Q\.>/NYP*S 8# 8# Z@7@W//VCZ
M<??@=L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6GG_NQ[?MA_V/[_ )<K>7P]GW/V/8\?
M\7Q\N>?Q<8%VP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M96634"88  <\?:/(_P!__#@<X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# ZG_9'_ ,C[<#SPJ>MVFYW7U-]2NY=Q!LMF[$0UZZG6
M*"+QU#)VSJ%I2$6D6S58Z:#ES'I20*E2.8I3B  (@ \X%NNWTY:?,;1O.W-?
M;&LNKK/<FVLYE%E'0\79JO7-J:TVO7-KEV9"5F=4-$LE[[*U=JE9HU B#>66
M)\\)TWIUUE@MFNOIP1E%1KQY#<4_<9:&ME9N4A-RU,KS%[/34%3.Q%8>.7#>
M+7;QT>I*278E])$^71(FS.P2233$%#G -$J?1DH")UVD5MM\Q@%]=-ZW^4N:
M UDU6M]2Z\1?7!6\1R[JUA&QL*I5HHK\D2BR(]3?*JHA*#'G^3 )@T#I62B[
M_/MU/9KR1ID9L7=FX*CK9:I,&\I#[+[!,63#8<A-;%_-7$A9:NBFDY&)C CV
M1V0N_%5RZ3;-"(!%^^?2;)?[0O+2N^SA6ZR\O$GJ"J#JMN52IOK_ -CZ]V:F
MFE_LT;>XF7V3 IW&'79()L_W:D$H]WY%>@Z3^8.&[4/I\1['KAJW0,)M%U6E
M]>6G=MT=76 IK5,\A8=WT7>]5FW,+6YZ>L3>&9PLKO!5ZT1>.I4ZJ,<1!PJJ
MHLHYP,)U9]-J5H>GNVVJ;%N]"Z*=I2U4BDT\H$^]BZ:UJ]%AJ(A$G@+_ +6V
M/.V2&<QT$B!B'G6KA%$YDVBS04FZB(8A%_2H<LZNI2'W85\_JMP8TN'VRB;6
MQG=GE8/7.\[AN^D1FJ;[9-@V6XZR/%.KHXBUGLD\M4DY122=_,)O"^[@6JS_
M $JK+?:FE4KIO2H_(5[5L7I^D?N;HMI2 0K%+G=-SM$EKP]@KXWM5MLBA]/H
M-YA1M+1:(-W0A#DB#D,=4+&;Z0[AI4:]$0.XX2$FH,86U =C3]CLX538=9WG
M?=R0J82C'=K;:RM#4:[/EHQRFO:%K 9X@QE$Y1-PBHDJ&][G].Y6Q]6.O^@X
MS9#..M'7RVKWZ#LRT+>6U2L=GE8?8,5--Y:'J^T:UL9C#>6QW:[,S:U@_26;
MHBX<.B&735"KZ^_3KB-!/=3.HNXPLNKJW9\#?DY(*0,;+RT=$=.D.K2]<(_7
ML$N]CF;J63//(D%=PBU;G*Q*003*XP,E>=0]K.;).T$=L4TW5.S;Y3[(2M./
M0I<=RI6TVTH[=DAKIC?D[<G52ZZE-JQOYF=T>%&938N58Y-0H D[(&CX[Z8#
M^N_P>D*??M;UVQZOUMK2CN9973+"8;S,W5:GV@I]HNY8I6<9LS3LDAV+3D&/
MSP/4BOH4H.R.4EA*0-3T#Z/]EKCV[25PVYKZY+6#4-OUG7HP=;6@(FM2$SI*
M3U!"65H6V;#NRS([#\U5<F;,/DVK5J;Y1HFBF 8$I-/=#;)K7L'7]HO[W0I.
METFW[&V57$H_6RK#<$Y<-MZ\CM?VB O&RW-A>)2>NZXBT4<1#-%B1R8A(]NL
MJ"44C[X>F& P& P&!H7M!P/73?G/Q#2.V@_D-KVR^7\XD#^; O&@4P3TEI<"
ME\2_P@UN'V_M)T^'( <C]I2?9@;BP& P& P& P& P*7\/S?'B/E[?/GZ>/W>
M''ESY<>OP^&!58# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# ZG_8-
M_FF_O#@1%ZUL!9[<[QJBJ"@..S%7*!0*)?#VNJ76PXCSY#SY?,<?R8$O,!@,
M!@,!@,!@=3&\>/3GG [!Z@ _?@,!@,!@,!@,!@,!@,#0/:4_M]<]^GXYXT;M
MX_'/'^JUY9!X^ _M>>!E>CD?9TMIY+R\O8U;0$O( X\_"IQ!/+CD>.?'X8&T
M\!@,!@,!@,!@,"EX'YSG@W'M<^7 >'QX\?+RY\OMXX^&!58# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# \??KB]E=J=7^BDO;-+VZ5H>PKOM#7VLXBVP1$@G89I.*
MRLY-*0SU<BB,5)/(>LKMR.A*)D@6'P$J@E.4(1:;^J;W6Z=;$U=UX^JEI%0L
M/=I:!C8SMW4C)&K",9;$!;UL]F;U&!=4VP2#.=#Y61,S6B9!LW RQV"X)BNL
M'N?HKMEH3LC9]SU#3%^:WF:T#<T:#L\(^-FD8V&LRP2 $:1LT^CVT396HKQ#
MM(7,<LY0!5N<!-^R)@D6@NBY12<-U4UVZZ9%D%T3E42624*!TU$E"")#IG*(
M" @(@(#@?7 CIN7M;HS06P=&ZMVI= JUT['VM[2=11ZL-.OFEBLK \0DK'.Y
M>-C7<7 >\ZGV:"*CY5NFLNX*0@B// 8=4>]O56];A2T'4-MQEDVJ:^;)UBO6
MXJ%M#A-E>]1UYE:-@5U[-FA"0+=>!A7Y%!6^9%LNH!T4E3K$,0 W$^WMJ&-V
M/0M2.]@5PNQ-H1%UG*!6$7AG;RT1FNB1REV<1KAHDO'B-<3EFYETU%B*^)Q$
MI3 0_B&3GV+0$KRSUBI=:J78\C6GER8T(9^+_?!W4F#]M%O+,A7 <_FZD"WD
MGB:!G8(^Q[QO#R\N0 ,Q$Y0$2B8 $  1 ?L 1X ?U".!9;)9J[3:]-VRVSD5
M6JO6HI_.V&Q3K]M%PL)"Q;91Y)2LK)O5$6;&/8-$3**JJ'*1,A1$1  P*B#G
M(:S0T38ZY+1L]7YZ-93,'.0SUM)1,Q$R39-Y'2<9(LU%FCZ/?-%B*HK)',FH
MF8#%$0$!P+I@,!@,!@,!R'WX''(?>'\^ Y#[P_G# YP& P&!QR _ 0P.<!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@=3?LF_S1_O8$5.NRA%-J]V_ P&\>SE?
M*/'V&)U1ZRD.'ZRG*(#@2MP& P& P..0]?CZ?'T'^YZ>N!P!RF ! >0'X??_
M #?' L*%LJSJ4/"-;+ .9I,ZZ1XAO,1RTH11L4QW*9H]-P9V4[<A!$X"3D@
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M:G_E%=NJ3*D=3"3^QV[F H78ZJ6_:^@J[;JXTV!;J0^9O58R[L:P].[DS?D
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MQ=KNPS&N6BQU*3M=CM[#4,=^65>=D'\%/6>2-(1RCNT"_.Z.9(?*&5Y5X]S
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MJ,X_N8&Q,!@,!@,!@,!@,"A_[>_YG_SG@5V P& P& P& P& P& P& P& P&
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MZ1>18TG2;:;VO):EUM-$K=G?(V"9>;+?M&K\(ALJ9>.;OTA\E0,8J89=)_\
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MU#J.3I (F @@)<"6W6?L5<]]MK0I<NMNZ.O;FNKL4FJ>UHV.9M+*5VK)(+!
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MUK>=J6TCY2N:^K$O:YA**:&?2BS*'9JNSMH]J42 J\=&(":?F=-(IC@*AR$
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MA?GO:\R^7M^7AY!Y?#X^///PP*W 8# 8# 8# 8# 8# 8# 8# 8# 8# ^1SD
M?$P /J7X@/ ";D"^O AZX'(DY^(\_K#G_#@/;^ <^@? ./0.! 0X#G@.!# [
M 7UY'U'T]?U#R']W I/RYC[2K?Y-I\LNJNNNW^51]A99TL+EPLJEX>"BKAP8
M5#F$!,<X^0B(^N!U>Q47),%XJ1C6#^,<H V<QSUFW=,'#8OCPW79KIJ-U4 \
M0X(8HE] ],"WL*I5HMT5]&5N CGI#+G(\80\<T=$.Z1;-G1BN&[9-4IG+=DB
MFH(#R<B)"CR!2@ 6ZL:]H=)&1&E4JHT\9=?YJ6&KUJ&@!E'7D<_S,B,2S:"]
M<>1Q'S5\C<B(\^N!85]*ZA=35KLCG5VO%[!?()>L7>;6IE>4E;?7'1Q.Z@K,
M_,P%S.1+HYN54')E$U!X\@'@. L%EZV:!N$%9:Q9=-:SEH&Y*UQ:U1CBF01$
M)]6G,D8RIJR0MV:*KA2LQK<C>/$3<M$"^VEXD$0$,%F.DG4V?;ZX:2V@=9.F
MFHS)?PZ;!7&[9"M((R:TT1BBDT.@20BS2[E1T=H\!RU4<JG4,F)CF$0N-9Z=
M=8Z;89JUUG2=!B;%8F]X:3DJC"E67DV6R3MC7I@Y3=*KMACK&#4I5FY2%1(F
M)R)E(110I@PJ_P#0'JCL?7&NM3SFKFL;1]3KOST*.JLW8:N\@6<PLLO8(=*;
MB)5O-.8:QJN#&?MUG"A7"G!Q_&4I@#)MQ]-.OV\Z#0M;76G+-:WJTK1+71ZA
M-S-/FJ:T9Q2<&6/@9V!>M)1I'.(A$B"Z/N&(N1,HG 3% 0#6#[Z:W4IW7[C5
MFU$DH>!O.K*CIZ>C8>SSC1O^YU'LC2VU\8\IW:_R$^C/LB.%I G+EP<3"<PB
M81P)OP4-'UR$AZ]$HF;Q4#%1\-&(&547,A'Q;1%BR1,LL<ZRQDVR!2B8YA,;
MCD1$<"ZX# UQM[6S'<&L+]JZ3G+!6XZ_U28JCZ<JSX(Z?C6DRS59KN(UV8BI
M"*>TJ)3D.4R:J9C)F 2F' \6E_H@L'2:C\.S=B@K/**6&-LLA2M75BF5R1J,
MU665=+"QM-@9II&1#]\#0QYAV!U22J:HD%!(X>Z8,GJ?TC;?5E8QXAV!JS1R
M:Z(2<^SJ>E(VDPJE/=ZNL^GK-%1$;"V@Q$+-+TVQG40D#C_N\FJY=*%<*KB?
M HUOI2;Q1=4RVL^U4 :_:N)HBLZS<DU.:+KD-1M#R+TU8_/8Y*U22EBL'R<@
MHX5*8J;5P] 0,8B2G*8;#ZK_ $R[KI*;WZE?-LP$K2=UZHL6JI2"U?#6:HKS
MKBQ2#Q5395B;RUADXF(N4?&/EV[=&*(1DD5RH5,")\E4"->A_HW;3U7MO7.Q
M)G8NL'K/5VU=9V2%3CFUP=2TW4Z1;'T_,2#T),GR%?LEB9E:)!',O<CT52F,
M"OX1%4.(GZ5_9 IK3 RLYK61C;Q!5QQ-V.=GYJ5282=1[<OMOE@8Y@>&7?D9
M6Z@/S+NB%(5J$J(IJ&-Y"J(?7?'TWNRUUV-O-I78J/M5/O>P-T[@IENGMT/(
MFMQLQ>->/XJKUG^#[:$10CKC%2SDD6$\+M=H:+10*=$A$\#-K[]/'?+6VZLF
M:A4M:V.IZX@.B4:^JP3,37E+/(Z)D[:?:3]ZW6@RQ;E51*P&4(LY445>(N%"
M% PA[8A<>X_0[L!M_MM.['K[&5N^L-FL-.0CHT5L.G4!*@Q5 GV+N;8VE&8@
M).UR\<U<(GFX@]>.D\%^H9-P82@4!"]]->A>VM%;RZ\[+L=%J$"O7]5]BHS=
MULB["QDK#<+M==G.7M#//.6ZXKV)RM2S-3E5*D*;7V%2K*BJ9,F!HZ5^GUV4
MA;>F>*9G-KG0W96JH]=FZEJ:'!CI"U;=/N_8ERFB.7RX@VJ,@C%LTD?:!\H9
MBN((*@FB8X15T_74;[?Z]+:LU/(3%FUIIO3FSMRR.JKA3]G6+L#/4GM90KU;
M+S'A%6(AT[5;635\Z:L)X6$PY(V!$6I/:3  W#=-'=EI5!*]SFEMT>Q;+MO^
MP:NIC?6J&P+5KB\;%W_)W2-NDH#785:-IVWA4UXM:-M!@ETFJ;)PV.A_JRG#
M(KA3>XCRG;/TW%5OM$38FJ)_N-;B;&AD)Y"E;$_BQ;*5*:Z-4[1$RC9U.3J,
M3*R#U!JW2(+;AP1(@',)$PF'VRTOLS7T?U,J/7B/NDA,ZEU/VXE:S-(J3-RE
M&^RU](J,J\ZD++8%)>4+,3\I890[ JRP>X\$B2)?P)IE"B^D_+;=";[ 5FW7
MRR[+UM"HZR7J-GEB;D7A$+HXC["TOT-"RF\6;*YJ2B!V+1689E!1BR?F%-#P
M !+@>SV P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P+1\D;\V^=^:6\?#P^5X3]K_4^'/EX^YQS^+CG]K N^
M P& P& P& P& P& P& P&!P(@'QP-8;I6VLAJB^K:,8UB2V\6N/AUXRNCA=I
M5%[.8I2QP3[AKPY3C"'$3*>'XA . ^.!F]=+-%@H<MD!B%B"+C_SX8LRIHH9
MH62 RHQ0N!^9"-^?%0$ 4 %/; /(.<"['4(F "<> $P% >!'U'G@/0!'[,#P
MWW3=;Y._7\Z;ZQ@[=86]"H'0_?>T[?3X^>F#UF4DKA:W=(CG%CK;1VG"M7[=
M>-8JM7KQ(YS@3VTQ*(%$0]PVJCA1$AW*'RZPA^-(#E.!1Y'X&*)@'T_3@5&!
MY^?5#[/;!Z=]*=L;]U8RKSZ_55Q28NN%M;5U(5]JZMUYKM67D)",9O(]:3!B
MSEE%$T/F$2G4 O)N/00\X^U_U=-WZ&^GMT0[9UJ@:]E-@=DI*G.=@0$M^?&J
M:$0%-E;);(RNE;R;:4BWDZ[8$(S<JJNPCTS&Y3<" <A,KZIWU#I[Z??5RG;L
MI]&KE[NE[O59J,#5K9-O8^)0:OZY-VR=D7*L2"<J^,PC8(6Z?LE*4J[E-13@
M@"0P1V^HM]82W=&G'364C-+UZ[U?L#2G&Q]BMWUEDVM@K]>9$HRSR&I2C9F1
M@ZFRM[4N9-P]***AT"$%(@',<H;O[Z_5<I73[2O5W>-'I2.[*MV:MU?2KY$+
M&K53$UU)5<EID+0P<J0LNBK,(-7[)))DX!N'NKF!0Y?;. !K[ZC?U6MF=,^Q
MFD.N&GNK[KL3=-NTA.[MXQC9Y:-GWX.K),P3*LU. @*I9WTK,BA6WCA4Y@!,
MA!3X*8"J" 8IH'ZMO9[9O9K5>B=M?3'W]HBN[+DE8-:\SH724+57IXN4EV<W
M+$D=456$&M$0C?%V<7R2K9,3+<' GMF#W;P& P/+KN)]6SK!TPV8WT]<HW:F
MSMEH025OME0TM3"W1]KJFN$BN$K->UW,K#L89DHS.#D$BJ*N"M3$6.0B:B1E
M G=H_=FM>QFJ:3NK4-D0M>O-@0R4W7)E%%=JHH@915LZ9/V+LB3R,EXI\W5;
M/&BQ2+-G*1TSE Q1P-6]J^Y6BNFU<I5BW78W,<.Q;[7=<TFO0;,LU;+)8+#)
M-8\RT9 $<MG2\+ $=E<2;P!]IF@)>>5%$4U E2'Z?C]O& P&!QP'W!_,&!I[
M978'2&G;+K>G;3VC2J#:=P6$U4UA!6B;9Q4C=[$4[)(8F ;N3E,\<@O)-DOL
M+[SA)/GS4(40O,KN#5$%L6L:BF]BTJ'VG=8N0FZ?KN4L<2PNEHB(KYG\SDH"
MN.G*4K+,V'R2WO*()'*F"1_+CQ'@**[[PT_K6ZZSUQ?]B5.H7G<LC+0^JZQ/
MRK>-E+Y+0:#-Q*1=;2<"0DA(-4Y%#^I*;W#F6(4@&,8 $,F/L"A)6V-H"]SJ
MC:^3,2\GH>D.9^);7"5@H]91L^FXVL+NDYM]$,W"1B*N4D#(IG*(&, @(8'Q
MBME:YGK?8->P=^I4S?:FW0=6FCQ5H@Y&WUEJY!N9LYL%99OEIJ&;N"NT13.Y
M03(<%2<"/D7D'\2M<%NY=9?O]2B[)/&'FR:]&TP87@\,F0JAY<M2^>_/S1A$
MSE,+@&_M 40'RX' S; <<?# <<_' 8&-5^ETZIJ2JM6J=:K2LZ^_,YM2OP47
M#*3$D*1$1D)4\<U;&D'PHIE)[JPG4\2@'/ !@9'XE#X%*'\@8'/B7T_"'IZ!
MZ!Z?J^[ X$I #U*7@. _9#^3[/OP'!3<#P \? 1#U#]7(?<.!VP& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M&!8N$_SSCWWGN^W[GL^3CY3Q]CV_'QY^7_RN./VO7XX%]P& P& P& P& P&
MP& P& P.!*!OCSZ8'/'IQ]W^# 8'R61*L4"F$Q0 Y3\EX >2\^GJ _?@>$VF
MZ\-T_P"4$]TKRXJKZ?8Z6Z1===9L+NZ>-R,M=6#8,M(7A>K1T:Z5([>*7J!$
M[H7#0BB306*Q%A(9R3R#W>P-;;BVI5M':HV/N.[JN4:CJ^D6:^6(S-,BST\3
M5XEU+O&[%%55!)9^Z3:^V@0QR%.J<H"8H#R ?F*[[_4:T]]0OZ.N]]CQ5/L&
ML)NJ[^U+KYK3+=*1\C)*6E.S5NX1[V,?P*P,Y%!_13R"QDU$R@@HS< ('!(B
MHA$+ZC\8]B.AWT,=)3CM)C'6&J05BG'LJ06,4T+(0FI6")YA@\ BA$(F+OSD
M55#K)D]H%.0 # )0GY_RE:7A9S4O3S2$/*,1L-VWNHX85ADHQ4=G@4:JO3VL
MH5OYE5:L4Y6Y-$$#^22*IE>/(0*/ :[^J)I:@=A?JH_3DZ16A[.M==-=$25?
ME4X9P#)U'MI%E>CQ3B*<J"X53>E#6+,RHG,H4Q$R%$3?CY#R.'9LL\IW5CZ7
M.W?GV5\ZT?4L>03RS2;$J\1$:XE[<QJ@P\6=,CQX7BYS,N[%HHW42,R<-!(8
MQ"F(4/4GZFLEV/N'UR>O]5ZA6NLPW86J]?(ICK][>VS)6I0#Y[';GL]G2?$E
MH"?8+$DZ6Y7\3?*K^*RI0(9-0/(@>E/2)#ZWJ/9EPT[N/-,R/6XT):5I5]6T
MJ 1V$T@#MM5$-?!4&K"U$(YE 277_/$3D_*^?Q$<CX8'N%@,#H81#@"\<C\.
M>>/L^[ _/#]+DL9L3ZD_UH;?;VS>7GD=N5K6"1)17\T(%!BIS9-:/"^T_!4Q
MH=PSJ+ BB/ ( 5(J?CXE*  ^@[(Q>HNG_;VZ35K,CI2D=J>P<G4F)3_F<74M
M=ZWAXE[8):(38@N[7:/6R1G!B$*8%3)@=,!%7U#Q,[=]NM2=S8A_W%V3MJJE
MV<GV5T16>MO6J-GW4]/]>^KU8MTE,[(NMJ91S)*/&\[/>U=!]+$(9RY9-B-$
M1X(Y:D('[HM>; IVUZ-4]E:\GV5JHMZ@(NTU&R1WO QG*]-,TG\7)M2N4D')
M$7;58I@*HF10O/!B@("&!F6 P+5-3</7(QS,S\K&0<0R AWLK,/FL9&LR**$
M13.[?O54&K8AUE"D 3G* F, !ZB 8'YF?K_UQE?MW_2NA8*=9,[5;=[3->@W
M3ML66A$8V>N&D4VM@<LTO;_-&#>6%MY)E7*5P@<0#T,!@"_=RZ<^O?\ RAGZ
M?,=&2J$<M7-+-KNY46]]0#L*>^WW8).+2*W.4R3B88M11*)OP#Y\G 2^@AT^
MM2V+8_J"?1]IK+SCIEYO,'R<\*RQDDFQMM:4*DT*U252.51-9F<WN%$HB"@!
MSP'&!<MRMW:G_*5NK:C1-TI\OU<E57AVX*C\O'&I?8)%87!D_1-B9VJB!@-^
M 5#%YY$0P/$W86]MO]8OK#]MNXM)K$W;JUH?L]98S=:L8S*=B35-WLQ]:E@9
MY5!/AJ278-R-HQPH0R9)5JU,H8#<"8/3<D_4]E_\H[Z\;:U%*)6&G[/ZZUS9
M2%IAG@F;6"J2?7?848VDSJ"J019*1\?'HK-@ /%9/@Z8*%/P'ZR0^ 8# 8'
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M+R ^H8!-,B)1 IC"'/(B<XFXX#[Q^ !@=Q.0..3%#R$"EY, >1A#D #D?41
M/3 >9/Z1?CQ^T'QYXX^/QY' X\B&]/(HC^UP!@YX ?'GT'X /I^O Y 2 /B
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M)M&N)+6>BWRQXW=CZ52;6A\U4=2,0N<-%I%3,)/EBSK<A"/?#E-(#"*@D,'
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M'!6Z)1Y @<\B/J)C>HF\A'\0B'(F]<#CY=/D1_K Y]OD 55*7^K$#$$"E.
M/(>O]+[><#J9 GEY 98##YCP594"B)O'RY*!^/\ %#]7KQ\1P-72UQH5.?.F
M-WV74XO]X;"C$PL-.3\%!J(/)1MX)0+9%1PV<NWK\#*'*4_DH;W.0P,Y3K-8
M,S69$AXE5BNW=M%VWRK=5NLS>KJ+NV2J8E,11FNX.8YDC<IB?UXYP/JX@8/Q
M]X\0Q.HFLT<%.5HE[P.&1 18K%.4@G]UDF/"0_%( #QXX# [PD9$1399&'B6
MD0BN[7>.4VC-)H#I\Z'W'3YQ[2:8N'CE0?)14_)U#>IA$<"\X# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M@,#'_%[^\?N>XY^1^3]OV>$OEO=X\_=_U7O>?^+Y>?C]G'.!D& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P,&V1=VNMJ!=]@2#-9^QI-7GK2Z
M9-#E!RZ:P$0ZEUT"&. $2563:&*41] $0$?3 _-KVC[<;N[5QO3C<-3T0KIR
MGP6PI[;FO[3N:Y5DFM;U8:Q1;#+Q;!0[=0QTI1FA"N7#%-XB5%=R4I.0$1$
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M48# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# X,'D''P]<
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M_P ZY]G_ '#VN/>]]/CR]GG_ %'G[GG[GI^SQQZX%[P& P& P& P& P& P&
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M126%,RR22QBBHFFJ9(HF* @!A*'/P# Z.V#-\W4:NVC9TW4+XG0<MT7")^!
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M]0J:O* X'<>V^ERD]PZ^RDB>/D87&C-VMA('_EPKC7R1DA_S@#C X3[=Z,.
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MBR]PV,+*]<5#T>P/OXGL+)(5^+A7K0T?3WIH!&1D;4P1*:7!AX*+\'\135\
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MY.^Q&OM7]9;G)ZMN3_7>QV5;H&N)5S1[[&-&3^0I]G1:PZAX>PLV,B@LHU5
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M]YH_+^[X^'ROAS[_ +WC^+X<<?;]F!D. P& P& P& P& P& P& P& P& P&
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ME[8!>M;)5IO5MEJ6U.M-7NXSIEGD>S?UJ/C8QRB<Q3,X]PDF8 !)1(0]KO\
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MWGV_JS=&OZ77J16KO;-462K1<;NZIHV6PPU;1K\[4GD^WBV5CC7\XD9TW&0
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M9=4B9>3!Y',!0]1 ,"M P&^'V?H$/[^!P8Q$RF4.(%*4!,8P_ I0#D3"/V
M?' L"=NJBH@"5FKZ@F(=0 3F8Y0132*)E5  CDPB1,I1$P_  #UP+_YE^_\
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M_@P'F7[_ .X/_!@<@(#\,#G 8' " _# "8 ]!'^_@<>9?O\ [@_\& \R_?\
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M*UW):S^HXATNF*\IJ"H6^*E*Q?.SFL-50,XE(3ZJ<@$U2*/L$%$E$Q(C(/B
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M^V")G(">B)6;C++$LI-@"::Z)78A[DX# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MV,P/!R=K35&NL),Z2*STIET?,/LS^IUU4B)E_5-GW^(I=S97;8E;7C(6,O\
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M( 9%<H^H /K^@> JU.S$PD0ZANK_ &B$"%,80)2Z&8P^)1,!2E#9G)C'$.
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M(*D*JF?RI$WR11-4#IJE4^ @8! >>,#<.NFS=MK^CI%Y3(2G59(A15.0 *C
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M@G@H=I^RK= SR(CG)D6R6V+""#9$RK8PIMFY/PID+P4A0      P)8FH]*.
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MO.*[,O\ 64$ZWU!1BT%#;256E_WGBH)TV!J]@8]S^8@W9P+\G!W#)-,K5PN
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MW&V&@KQEVK#==T9&&JI2N'9U**J*RQB< ;_%_"'I@2Q1ZY3: F%+LWV8Y,
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M++K==EYOLLRG8\)[52;AB.C:5'*KG7V[1$&ZQGC:74$AVKE4BP@4G!Q)X_A
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MX*41:(HM$S>TKN]-9,CINB5<GD'[*@!\<"[G[ ;,*V.L?I]V$ Q$3JBB66T
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MG\FY:NFY/9>BF)@$(04GZIV^&40H^I[":ONX>U^V-.S%7K[W66]M]4#0D/\
M^D\.K^_MP5Z@:GU$1ULFU02-EOBBD;'-GC),#2+R0>.P(W4!4/3B/^HZQI7T
M])?NYV"U=:M<RM0/9:K8=7'B[)!2T]L2&V&^U=6XVNL[I$1%EKL%L.QIM'#=
M:=9M%H5B\,:0*3Y58V!KOZ/O:RZ]H*GVT<;/WU1=Z7ZD]GW:15]:JMS4&E4.
MVZFUA/5JI4 $D4W+Z@P%H"P1<?)N1.ZF%XQR\5$#JF(0/8? 8# 8# Q'8!A+
M0[L8HB4Q:C9#%$!X$!"&>B @(? 0' UMU@231Z[:+323(FF73VM@(1,H$*4/
MW3C X* <  !Q@;WP&!"[32HJ=P.ZA/(1]D.M"0 (C^$!UG8U_$.?@7E7GCX<
MB.!-' A[OM,3[RZ:%('X4]Z7E=4H< 4..O>U"E4,'H!A!18/T\C^O F"'P#]
M08$7N[)@+U([$&,/ !JBW<CZC\8U4/L]?C@20APXBV'Z6+(0_P#4- /[X8'T
M?<"5 OIY&<H@7T^XW(^OP#T# A_U..'S'9@XCZ?VS-R%Y]?\2.K)!#[^ $@A
M_)@3.P(7MOQ?4.F@]1%'IE6!#G_$!QO&W\^(_9[@-0YX_HAS]F!-# B7W.**
MNIZ<F4/(P]FNGX 4> ]0[3:B-\3<!Z>.!*AB/*'Z1.<W\AS"8!_E <#%MDJD
M0UY>UU3>":%,M*RA^!'P(G!2!SFX !'\)0'X>N!J;IXG[74OK&3CQ .OVG>
M#CT =>UX?L],"1*H@ %Y]/ZQ,/YS!R'\H8$/^N)S*;:[L"8PF\>S[ @<B(\
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M^3*G:+9 5]97V]0")O;3EG[0ZI""Z*'( (<\A\0' DZGV&T$J BEO#3ZH%$
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M-H/;@%* ![@F-0IT@%* &$1/R;X8&S]:.V[;6^O4E!%,Q:+41\1((  ?N_'
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M5ML&G,NLSJOF[%]LS)&L;_:\9*$E![1;A&?#F/B91D\C33 JBS5(8@BW\0.
MG 1P)3).N])5"BYB>I8( (^?M6+<15..!X\14JHDYYP-4Z34V@KW:["+[60U
M\WL)>L?6<C$FN7]BD848<=D]FS)&>JV6.C7I),SXRW)2$,E[($'GR\@ /0S
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MU,[+"/\ Z(O:0?Z5,F"A_=' VKK+TH]6*/Q)6:J4?N_]I>&'T_1P.!G@@ ?
M #U#[ ^T0# AUT; /X,6?T#_ ,>+[5?_ (QNS<"8O !\ # AE5__ !_/> ?_
M ',_7?\ ^J5O3@?UA]F!,[ A_P!G"!^__3X1 /\ QZ*+'_\ P[N/C^4,"7_
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M3 &E=Q>@_AU;?Q']/_@G+CZ?S8%EZX)"AH?2R(F PHZ=U4B)@] ,*5%A"B8
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M14QP%18.."CR&!,!G)LU@<^TNDH";M8AA*LB;U\OB'B<WX1^P?3G ^[CR<H
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MXP)?,?Q&=!S_ *MTX+\ ]?)P=7^YSQ@5Z@\$,(_<(?S^G^' AYT1."W7I!T
M>)7&Y^U2@$$>1*!NU^\%>!$. '@%>/Y,"8HCQQ^D0#^? A[3C?\ C:_8M/U_
MJ]"=2@$?Z7-M[<F ?YC8$P2_LE_S0_O8'; 8# 8# 8# 8# LGR:GY]\[[Y/9
M^4]OY?VA]SW?A[OO>YX^'AZ>/ASS]N!>\!@,!@,!@,!@,!@,!@,!@,!@,!@,
M#3V_SJ%T?N<41'R+J79)C"7X@8M+F!2_E\O4,#C0)!2TQJ-(2^!DM3ZT(8@A
MP)!+3(<OB(?>'AQ_)@;BP&!#G01$S=@.[IO$O)=TZP*H)?3D2]=-6*$*< X
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M7+!C+]>T6#)6B5@[1G_XE+EVN5FV&,]IN)E7GN'\"E\C*<CR(X$MC=;NO:@
M"FC=1F_0.NZD(?IY_P"Y/K@1-V9U^T27MUU<B":;U>$4ZUEV?4=QI:-7 8+"
MV#2*3<ZC,(\&PBE\X<H#X\_U@X$GS=5>LYO4= Z?#_-U[5B<_K\(PO/\N!%'
MO'UNZ_5WJ7O*7@=):MBY=I3RBP?,:-76[Q!=29BDB_+KI1Y54CJ>?A^$0Y W
M'P$<"3A>IO6-VY?KN^O^H7"QW8B*KB@UM<YBBF0_EY*QYQ !6.?X<!R(X!;J
M%U>4526'0>JR*)'+X*(4^);'3XY\?$S9!'@.1XX^ X$1^E'5CKC<>L]&F;!I
MG7TL^=6#;:8O%H%L4ZK1IN;836.+_4>R44TF**9">G/@4,"6"/3CK W-YMM*
M4=HIP)?<:1Z[17Q'XD]UNZ24\!X]0YX' BKJKK!H)[VM[=1"NMX8S")ANN:3
M-JD\G$$VGYE3;BL^*4&\LD/^\>!#&YY^_P"W E6IT^ZXJ 4 UHT0$O/XFEAN
M#$X^G  91G8D#G*''P$1# BMO/K%HJ,WCTNA&5-50:3NW-F,7[8MPO0G<M&_
M7;;DJ"95#6<RR(D=-RJB8ABF_!\>.0P)0+=->NR_CYTF8+X<\>SLK:C?GGC]
MKY>[)>?''^-SQ@1R[@]4M$UWJEV*EXNMV1F]C=,;#<,UAVGMA8B*Z=9D!1,"
M+B\*H'X4XX Q1#G[,#>%9ZBZ/7@HI52"N15%(R,64+_&7=I2 LXC6BZ_MHDV
M,5) @K*"/B0"E#GX8%^/U%T><4^8B_\ ]6JD<@%W9O%("&(<.#D,&QN2^("/
MP'X8$7^GG6#5,YH]"372V"5=;;'9%$YF.[MU12"B;#LCMF-:&!I&WMNS!0K!
MDB4QP(!U!+Y'$QQ$PA)P>IFHE?P ?;1#!Z^1]][S$/3TX#W[VLF(^OW<X$7J
M7UJUJOVW[$UE1ULLL9':;ZQO&ZC7<.VD)0CZ4G.PZ3GYB>+;"2#TJ[>/*0B9
MUC%3(00*!.?4)-_V4-;CR"<QNM ?M.&_MS#YAS\.%KRJ0  0^P"C^G BIV!Z
MST".VUTY9-9O<!U)[L#*L7 J;IV@L\11BNOV\)#YUD\5MWS+1P@41'W2&\@X
M#G[,"4B?5&CI\^S:^PA.>//R[%[84\O'X?\ 9%N5^'^3Q@:KW?UDI<5I7<\@
MUN_8(KEIJO8ST$7F]]IO8U91K3YE<6[QJZL"K)XS<>WX*)G*8BA#"'VX%7I+
MK="2&FM1/S[-[%LE'FK-<KJMH?>NP&D<BJM2X-0Z;1H264(U;)"($32 ?%,@
M !0 ,#9:W6>*(F8Q]J]EO;)P8?\ Q>+@81\1 Q1$OS!S'$#  ^H#\/7 C%U=
MT$VG%.S('V9OZ+*R[:[AC45H7<]IBU'R3%G3T D)+VG)BNI)RL!P,J)0$2D#
MD/A@2<+UC3(/)=W]IA^S\6\9@X?'GX*MC?=\<"+)]#K#W9<59'<G81'QZE(2
MP39MHN%[(V4>;F<,R,4Y9Q&+@:-.+3W3(B41 X (#Q^' E67K0L41$=^=H_C
M\"[;*ISZ_#A2!$ #]7&!%OL_H56 ;Z#4'=O8&74E.VVA(]%*P[%;OTX[YFQ.
M!_,&(%K'X)-DBW4]GS,9,!'\?(<!@2R5ZYR*P !.P_9)'C[2WZ$ 3\_ 1_\
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M"-QW4OSSR'B/J 8$Q\"%O;=;V3==$P* E-W$T3^+GCQ_KYYT( ' A_VOX_\
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M>T@90 YX.CZ<\?M+)E_PX$-=>!Y=T^U2G''GJ'I^CQ]P)R79-R!@'XCR)O'
MFF'J #]^ P& P& P& P& P,?_+E/WC_,_G%_:^2^6^1\B?+^7[7S'CX>?N<?
MA_:XX^S R# 8# 8# 8# 8# 8# 8# 8# 8# 8# T'V?*4>O.]P-\#Z:V40/\
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MUG\ -[>A^UI@,/'*8GMO6 HB7GU#R#T'C EK@0Z[^E.?J/MQ)/D55TZ2V2*
M\"=5SL>GMTDP'X![BB@%]?3U]<"7R!RG!4Q3>0>\H7[> $@@0Q0Y^P#%P/L(
M@''/VB !Z<^OV8$1^B"?M=3]0D\?#_N=93" <?M'O%H.8?3[3";D?O$<"7.!
M#O4B0E[4]OU3$ "J3&@ *?T_&*>I'   A\?P"8>.?OP)B8$1-ZB =B.DA#?$
M^VMO*% ?7E,G67;)##]H< 8X!Q^G EW@1([ZJ>UTN[/J>1B>.E;Y^(O/(>4&
MZ+Q^'U]>>,"4\4F"$<R;>($,V:-4#IEXX3.F@0IR\E_"/!@'U#T' K5!X* B
M/'XTP_TE"E /Y1'C A[T*/[O62LK^0G^8V+V&<@H/Q4*Y[%[77*<>?7DX*<^
MOKZ^OK@3%P(<ZX.*O=;M8 &$X-]4=2TC /\ U(17[)*E*'/V"9R4P<>G)OUX
M$QL"'781%=;L%T6%,!,BGO;9*BP>0 4I4^JV^3^1BB( /B82B'Z>,"8N!H/M
M8H"/5[L@J8W@5/0VWCF-_1*77UA$1].1^&!DFAT3M])Z@14+X*IZMUV10GH/
MB9.G0J1B\EY*/B9,0]!' VHKZIF#[PX#]?V?W<"'O3CU9]F#\B/N=Q=_B!A^
M(@2<CD2_IX*5/Q#G[ ^[ F-@0W9 4_U ;2)N# ET[HI0 P<@05=T[".H!>?^
MN B01X^/B'W8$R,"%?<,%/F>K0 (@4_<S1HG !]#ID0MYP ?7X%43 W'WE#
MFI@6R;.*<-+J 82BG&/S@8.0$HE:JF P"'KR A@1@Z'$\.EW5KD.!'1.M1X#
MC_&J\><!]/O\N<"5ROJ3@?4!$ $/L$!^("'V@.!#_KZ0#;\[M'$H&,.W=/B8
MP\")N.K&E.!$1]1\?(?YQP)B8$.MJ!Y=T>I11#R+_"GMH;@?4 .!NOI"FX'T
M\@(H8.?N,/WC@3$#X!S\>,"&_>HXI]6=S&$P@<6M1*0>1Y$BE[J*:9.0^!3*
MF,''V<C]@X$O&W'OO@^T%R_S"W1$/YP$,"L'C[?O#^?D./[N!#;H.57^S)3U
MCB(IN;3N-R@(C^TFYWALMP"G'/("J"H&'D 'D?7UP)?OP$6BPA_B@0YOT%34
M(<X_R$*(X$--;*IJ=RNUOB/)D=>=3&ZOQY((L-]N$DN1 .2@+H#!QZ )A'X\
MX$TR (% #?$ +SZ\^H% !_NX'? 8# 8# 8# 8# L_N$_-_:]Q+S]KR]OW?ZS
M_5?'V_NX_N>N!>,!@,!@,!@,!@,!@,!@,!@,!@,!@,"/G:-82=>M^#XA_NVD
M]FNR?Y2B5/EP*4P?T1]S] X&PM8AQ2*6'_S"TSX_H@VP?X,#8. P(,P];[':
MXVSOR4HU5T_:ZIMO:C39,:YM%^ME2L4*++4.J-9*1DA$M:).LG2"[K73IRFY
M1<"7VW*("4?Q<!L<+9VW#_T$VAE?TI[KN10+^@W&G5?C@:DMM;[36'<>G-I?
MPTU$0NK8K:3 T&EMF?!67=;&CJXQ242?J:X,FBVBBP:IU!.D0QQ4(  7D<#<
M'[^]I40\5>OVN71A]2G:[Y413*7X>)RNM8@<3^G/(>G&!HOL/'=L=SZEL6N$
M]%ZUKJ\[)4YVVEG6^?F4$%:U=:]:O940+K= Z@O4X0R!?$P"!U 'U !P-V)[
M.[."3R-UHJ!S<J?A1[#0YO$"G.!2"8^O2@*H%  -\  W(?#UP/FEM;LJ<P_,
M]68U%(@>9E$M_4Y<P>(\_L#6TOL_3\<#2?7L.T6GJ%+U>1ZUQDRYD]F[=OI'
M#'>=-323:;%V39KNQCQ!>#3$7+!K.D04'T**B8B \#@;Q2VUV+#R^;ZI.4@X
M#P%MN_7+D3#Z\@<%4V8$  ^ @)N?T8&DZV_[%P_8?:.W'76J0/!W;7&I:6PC
MVVV-<JR*,E2)?9TA,JK>3])O[!D[2R!$PG*!O(_KZ8&\S[HW(WX^;ZMW1,3?
ML WV3J1QR ?M>0FM:'B("(??S@1XW9.;]V+):7>175G8!":ZW[4=HS!#7[2H
M*.JY78.YQ1TV(*[%2*=\N>=05 AA+_5 ?[> P)!H[IVBS Z/]E'<:A?(!(=&
MU:.< ) 33(0QA+M)+P$Q2 /' _X,#4>[]I[9V7I3<^N8/JCNIK.7?5&Q*?#K
MO['H+Y(LM9:E+0<>9Q\MN=9R5N5T_*8X@3T( _# SNB;IV%$TJJ13_J]O<KZ
M(KT3$O"LCZ8?MS+13%&/,LBY3W*F4Z+L&P+)>G/M*%$?4<"^NNP%R50.F3JU
MV)1$Q5!,=9AJ19, 3144*7Q9;><K^:BI"E#\ A^+ T%H2_;%U=';5+9NL/8!
M16]=@-Q;(C A(_64NBG7KG9Q?U]5PJELU(R;E2+(F=PEXB9!43$Y,(8$A"=D
M),>?<ZX=DR_#CVZ74G/K]P@VORPE_6( &!'-SLVW!VO8[;'KKV*+2VG7^2UX
MY6"A0KB3+:GFQXFSMFB;!K<EG*C<8<BBACE(;@2@'WX$AP[.!_C: [.)C]G_
M (D3M4!_XN6],".O9':<_?ZOK]M6= ]D7[J#W_H"\R34=2R*!T("B[3A;-87
M0B,@H)Q8Q;$Z@D(!CG\?$H>1@X#?C#LX@@B";C1G9@3%(W!,Z&C;3XJ)_+(B
M)A(903)&]XQP\!'R* !SZX%%;>Q[>1J=G8,M,=C0?OJ[,LH\CS2%Q;MUY%['
M.&D>U46*D?V_F7BY"<\<!SZB >N!K;K1NL-?==M%T6QZ<[&-+!3=0ZYK,ZT)
MHV].RM):%J$.Q?-_F&[ 451160$!$HB'(8&Z2=I*SR('U?V++Q]_7[9A?7]8
M0I\".6M=RM(#=79RWS^LM_1L#?KGK":I[D="[064DHZJ:CJ=<F5E2)5X_P I
M[$VP52X/XB8I0$O//H$BC=KJ((?U=)WN)OB('T)M8 X_7^[ !@: L^^JS(]G
M=*7I.J[?)7*KIKL# SCT^D-L>Y&SMRMG7UY78QTT3J:JX*2$=59%0IPY+_4_
MKP)$&[7:J+Q[K3:;7GX?-:.V^GY_YG--+SQ]N!&GMWO^@; Z^7FIUMAM"4F)
M)]0E6[)KI3;1%U$(O8]1EY!0AUJ>5( ;1S!54PB(?A(/ZL#?[7MYI- 72*LE
M?/,CQR(@CI/=CKQ$RQQ$AU$=?F2]PH_$"F,'Z<"N5[=Z/,5/VIJZB<541X6T
MMNY$@)@<!7,8YM> !3$0 PASZ<@&!&_J9V3U10>NVL:E:YBS0%BB8Z;3E(F4
MU3N!N[:+K6J==@4Z2M#24(0Z+@ABB8H<E,'Q^.!(W^V+H$0]+F^3_P I;7VT
MDB_J 5:.F'E^CG C)KSM!I:'WWV:L\I;'D=#V:<TFI7))[1]CMV,PA$Z[;PT
ML9DJ-/$RQV,@X.D8.  #E !$ Y$ DV7N=UI$?Q[09)!Z^J];NC8!$/L SBN)
ME,/Z ]<"+NX^T>CYOL#T_FHS8D&YKU4OFWI6QROR5B22@FSSK_?HA@K)BM"I
MIMDWK^70(3R$O/EZ<^F!*9OW&ZT.?/V]UT,?#CGS>NV_QY^'OMB^?P^SX8$8
M>[':3K[;>I/8RK5_;E)FI^;U+<8R)AHR3.XDI*0=1JJ*#)FV*@)U7*YS>)2@
M B)OL^.!(]/N+UM(9;C>FJ2@)Q$OS5J;,O,@<$]Q,'(E!<AC@;@Y!$HEX_E"
MM6[B=7S)!QV)TJ0P*(F,"E]@ *3Q5((@81DBCSY@ ?8/K@1@Z/\ 9OKQ6.MU
M2A;!O'4D/*(7#=+L\=(["K#1ZBQEMX;'F(=9=%60*8IGL+(-UP'@ $% $/0<
M"7']K#K+_K [$Z.^7'T _P#$ZF\^0^H )OSS@?0!^S B9KWLAH%CV[[1V(^Z
MM2IPUBU]U991$TXV+520TNM!FW068;1+TLD9%V\C%IIHFLF4QA(JZ2(/!C
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M90I1$@"4'/D!3'#UXY$ P(NZ%G81MO7NPM^<18HK;?U)\JJ,@T CA O5K21
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MHSN>0C(C678ZCVF7F;E&:]BHE%&Q1DH^NLPZ,QCJVWCYN$C'9I)P\3.F)1(
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M #P8!'DH\!Z& ?B&!W\"?T"_9_BA]@\A]GV"&!R  4  H 4 ]       ]
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M)66PM6T!0IQDM5M6/[;'WB9I=J<;#:Q,-:VZ*U;>3+%^BJZ;(-OF5 W+UO\
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MD/X'$OD' \&$/@(X'WP& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M)5EU&MF%K;![3UQ&-V+Y(OJV71-^+ DO@,!@,!@,!@,#CR+SX^1?+^CR'/\
M-\<#G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M8Y2!ZIX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M5MH<-#QR2SA1TLFQBHI\W9,TU72YU# FF4#*'$P^HB.!DP;IU";U#:VLN/\
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M^D!!3D/N_P 4/7 Y!41$"B0X&^ C[:@)\_YPA\,#OY@'[0A\>/P\F_GX#T'
MY W(_ 0#[QY#^X(!@=L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,"AY_P!^_3\./_-7/.!78# 8# 8# 8# 8# 8# 8# 8# 8# 8$4>Z_E_97[#A
MR/\ 6ZELS4H<_M&?,U&OM<?85<%!(;X!P(\^F!*[ 8# Q#8(R(4*[##JV)O+
M!4;(,6O4&<7(6U"1"'>"Q6JS"<.G"OK&DZ\3,47ABM570$*J()B8<#\QVC-G
M;SA;?HV"J&UMGA3$]_\ 4V+WON2KE['V^O65%9WLJ!?:\[ ZGWDC+7;16]+W
M;/RYK<"PUFEZVW9N&7Y@DS*V9G?!L!MWZ^I97]G==8F>JM>L+;9M#U'LES1C
MZ,N%:=[*7W$^L9[KKNE2$,-IEH!WU\BX9LBX</%TG23AU\Y+$!BNW\0N/5[N
MQWKWS?>NKC;]C@J'30[9ZT@[LK6=1WZ";2:&UNMO8*RRG76WFFAAFK(^M;W5
MX>/%=51X]:SDBT3E2$=-D4G(; M_;;;=0^K.VB)E[V =:=<V^N:!CM3036XG
MA:\\L,;K^N--U;-K1XHFKX?KA99_8BK^!NB#AY9G=HB1AUG+5BH#),';K>';
M75EA^H9L*IW39,AH^-M-'T6C#0J4H,IH2Y2VA]'66@[GU1*-HMO+DJLY=;D\
M@KRS2.Y:1SIZRF$5B)(RP8&S]@_4:WT^N[+2NHX75D?M]WM?96K[&6^4K:$G
M#ZW*S[YZXZTZKLT_#QUBK3F4;632-Y-:_:1?HIR#CY9=%5!@KP(0PV/]13NP
MYL_6VMVG8NG=2M939>KKS:]L1M$OT)J>J52N[>[3=<=DQF[FTALM%2;UE=Y'
M6<99R%&9KB<*X639JNG*217J@5-H^MWVNJ!WTA+=?M2-V<)H)[L-Q5I:;F*U
M<+%*,NLLYO1#:T!#3-R0OZNDIVQ1 Q;4K:JR+1!L547%A3>)E;*!Z4]PNX^[
M.L.M= *.[5UGK-SV-1]J6NX[6VW&WRKZ54LFL==L[Q%:MJ-<C[HO8&5OVRN]
M5;Q(.)R0=-F\8\608RBY2,Q# ;%VY[&;3Z<?40W.2'BM%H:EU'(L-.14;^=)
M[LI%_-UHIFX[*_OTK.^Y5FTO7)K93..CD6L:3Y9:+76=>8K%01"KZ(6S?-5O
M?;+56_=C[*2D:%$ZS=4'7?8':VNMR[4(]L=6O%BD-IU2_:_UCJR)EM0W5"/0
MC8R.4;OWK*;J\Q[PMO,$1#2?TX.P_:67V5K13M!LRXPM&OO22F;T4'>>QM%S
M\)L^P;!LFN8V O>D5-7ZAUPM2HZLR$TYCK'"6"9D7;52RP"2**HK?-J!G7>+
MN?NSK[O3M"M7))PTT3I7H_3K-=E6L#!/W6K-D[B?=DF>N.PK)ZJR4DG$+6+3
MK",AK)&N".VB,;((2H$*DP>E5#Y!]4^U,:[1Z37*/K6[[PEK-===/Z_8-FF@
M'4?+U7L%UBZ_U*VW2-B*Q*R\%%WX.PGYZ<2,@3(1H1)K[Q%P4(&CY/ZH7:>R
MQFMP>53KIJ&3LVZZU7JQ/CM:92H=FCJ1V;V=U*VQ#;6EK;KD'5(K%IV)4&\M
M#?E)9"1_+CE9*+E>'!3 N;KZU\PZLM+8L.J$1.PBM8JO\1[0ELRM T/<[E#;
M5<PLAJ K^.:OMEZF^9U>9RE-D106?1#E1=!#R9G35#>?;KM=V IG1[1&PJ[2
MJ-3.S6^E8RS,JKK9:IW>-@J##46=W1L$E5MN[*I7*6[MT3JNOG\4I&*<*O7W
MNH1S-XI[1P#MM_ND\/T<Z]=E]$J:XV#8-I4;<<JWL;"J(U;5][L>J^H_8G9,
MK-HQ-UJ4W=H[7R^P=1C)13<H,Y-PW0;(KK@@LX*8,%["=H]E=.#_ $]K+N*9
MI%LUU*Z)VS=.Z+]SKVAIR%JE8^NZ>@:58*Y*0=1K;&L#&[>V<R9 #1FP8O&\
M@!5$ 4]H"AJ;17U#[1$=4]A/>P]"TU;.QE$,U:.;'7X^E5:%D[%M#N+NCK77
MZ]%512M"5^YTPG0$UGPE QYGY-1,Y45 4<G#*^N'=V>LFR4X3?&L:4\IT&_B
MXI!WJ'3ZNR+C;$5.D'6#?DH^G==TG6UANCB5/<MQ.'B"==;E0;-G9T%R&;L/
MFE@SJ[;ANX_Q;["5I;1,/KK47;*A];H[J9:-#UEE;MA1LW=-=THZ\U?)G\ON
MU5VQLUCL4EAJ\>A%';M8XK%%TT<J+.C)!!S4W>'L-5+I$;([3ZJZ]NM+*:/M
MNXD=>ZLU_KE2TV!W8(#ME?J)"O)^:J[1.NP4#7.MQHQ(Q'B[A9VY(]>N!1,H
M@D$X]@]ZZ?K'8M-TWLKZ>=*?;!3FHEQNEGK28INX*EJVAVB_0&NJ7<6%GJ^J
ME2/)>>E["58T1:VM&5;-D>075,Y9%<AJ#O#NV^Z>[7;0K.F]1:O)JGKWJCK1
M>[S"ONJ.MKS0)IQNC8VQZ_8Y;;&V$[16KOI^FP-6JZ*Y'<1#6)<@-72YFQRI
M@BJ&>=B>Z.DZK4H'^&_6O64!<I^ [0V6&7F-;ZQM4$HIURG=Y:^2B;*P31AI
M-K"VVSZM+)$=,CF<IMBBU\0.919(+%?>U=57VAKJ)J/4_2\1J5W-WG7=BV7*
M:XU9/2=[VG0MF=<]76R+@J&<D7.4VO5VQ[8DTTGD@X%221: Y31!+Y8'@9M7
MNY>F[).1-+8_3:I1[]LB96#0T 9SH<D1LZG0]CW;#6ZV35F<U]JAKIQ6H[1$
MJ^_+';=VX>%>,DD3BH=Q\L&>W'M7U?CNNO7O?VO^AD'LQ3?^D;GV3;:X9530
MM2LU,TCK"I0%OV79IF:LKIG59*?K;:VQ39O$,GBJTDY=C[:A44550#"@[C]/
M:/7[/+[+ZT5)^JM.;*?:W3@=,ZSA%KG 4K?;;4TU3X-BI890\S;M7U^<CIV:
M<G,T*[AE#O$T$3$5;IA>=&=B^J'9K1W9K9%0Z6U77=KT1J<^X(FM;4UE64&%
MMJ%HI-TN&K;*5XQCV8BTGE*2[1DV:1A,P.F)4W*Q3D5P(XZ#[.Z]L3FRM=B]
M+M9[+DVL/UWKL- Z[ZHRG5^SH=@>PJQWE/T^:![#;+GX^TUV4IACV$EV0D(V
M":QK)5,P+N54D@#;3ON-T"3A)&V3'1.>:Z^JJ(Q&U[B;7.GU6NN-Q?NW>;$V
MTY(1#>Z&G+/8E1H#Q@,M$(O:^F^=L0%[[+A19 -F:/VCU'W%M^NZ;DOIV673
M<M89FPUQ*6V92]))QL;=8C4]8WQ%UA^QI6P[;+IR$YI2XL)D7":!VC)PO^7K
MJE=D.0H:CEM]=5Z#-W& VMU3T917,1V?L&O*;*! .GT7?>OM/V===<WO8D9\
MI&&<A?\ 7CG7[Y28B"@JDD1W&JD,8K],A G)HJG=/]]'M\4CU.7U;:J=&4>>
MEJ=LNF5V(G!J>S(E_,T.UL#T^U6F&-&3[:(>I"B#Q.08NV2[=VW05)XB%XT[
MH3KIL^1W(X1T#K^.JU%V_/:NJ$JFTFBNK.2CP\#'W>7<E/)&2*E'[*4F(A'V
MN"F)&"8>1-S@;D/TKZQF QATU5?(WJ/LN9Y'U^/X"DETP)R/W"'&!\"=,.MJ
M7((Z>A$@,/(@24LA.1^\?"S@ CQ@=R],.N9#>:>K8U(_ \&1GKFBH'/QX.G;
MB" ?JP._]C;K[\2Z^.F']$EOOI '](^W<BAZ_JP.W]CW00^A==NTO\HFRMF$
M']7);.7 X_L@Z))Z$H\R3U#_ %6SMKEX'X\E.E=D?$0^\"AP. 'J%HLW[=3N
M*? \@+?<^ZDC#^@YD[\03%_0/. _LAZ/ /%.NWT/L IMX[Q(F'ZP+L$.2_?Z
MX'7^Q]I<>/*$NR?'_IOO??://^=[>RB<_P O.!]B=1=/I&*=%AL1,R8CX"3L
M#V!*)?3CTXV=P'I@?17JAJXPAXCMA$/7D&G8WL W*8?L$Y1V,MYF#[^0P.O]
ME+6XAP23W8@/V'3[+[^$P?H #;#(7CC].!W+U3UXF''[P[Y-R//X>R>\A#[/
M^O;%,;GT^_C [?V5J /^KLF^43?TS=D=W<<?=Z7Q<>1'_)_EP.W]E6D#QQ>=
M_( '_4TNQ6XE"?'X\N+6H<1']>!V_LN51O\ B9[![ $./H?R[!;4, D^/'"]
MA7+SS]P /Z>,#XGZPPQC>X7:'8A/[?:3W_L,2AQ\ *"LB<H_\T(A@"]9V(<^
MSMCL4A_2]S>=R6\P^P"\.Q\>!P/D/6M YA2_C!V71 >0]U#>EJ "\!^TF18#
ME !X] $1^. #J^V#_P!#IVC_ )=WS9O^B0],#@W6%#@?'>G:,1^[^-LP7^Z+
M40P.H=8OZ.^>T:0?T?XSO5N?T^2T2N<!_1SQ@=O[,7W;^[1_^_A<?]Y!P./[
M,3CC^K[$=HT@'G\'\6&RH!^D#N:LNKR/W";@/LP. ZQNR<C_ &C>TOV?L[1B
MU1_F5J' 8';^S2]+^)/L7VC%0OJ3WMDPXI"</4ON%_=#Q$G/Q#CU# Y+USL0
M@(J=C.QY!X^#>]5<PB/Z1<440#U_H\8'1QUTL(%662['=EO=%D+1-+]]JF9,
MIC>) <^VG1_5R3U-Y\\\_$!#TP-WZZJ<A2*RUKDC<+C?%F)E!"T7U]$R%GD?
M=,)Q^><PD9#1QR(\@4G@U2$"AZ@(^N!G6 P& P& P& P& P& P,=]R0_>3VO
MEV_Y9\G[GS7N*?,?-^/C[/M>'M^/M^O/E_)]N!D6 P& P& P& P& P& P& P
M& P& P&!%?NF'EU=WF3_ *]2#M!$/00(Z?M4#G#_ "R%5$0^SD,"4X?X1_O^
MO]W YP&!9+-)+0U;L$PW336<1,)*R:"2W/LJK,&"[I--7Q,0WM*'2 #<&*/
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MR*;5XE(FJ,B(E045.@5L)E2D Q!,&9C(M"F(4SMJ4RAB$2**R8&5.J &3(D
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MZ)C*C*U.'<;(B59!?6$JSN#/8<V:^5ZUZB?3TI3[M!6AY\T\1M 25G?*/5'
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MM\=*1D:0TI/E4,=%+R.!?7U]<#-3Z:WH8/P=N+^4WIZGU=HY4!_D_<0!#^?
MT'V/8=C],:=O>RH#M/8I67J$?#JMV,IJ'3GRSI67L\/#%565;5= P"BW>* (
M   (" _$/4-ZHZ@WL0RZ+;M3/MTR*#XIDT[J/Q33,*JI4"B, 'DFE[WH(_B'
M[?C@?<=1=@2 !D^UDTJH42"!'.G-3^P< ,'F50&\*@MP8G/[)RB _;@:-ZSM
M^R&W-5(7J4['DCG2]]W/5 8Q^E=<HM2M=;[KV+KF,=@!0 ???0U5:G5#G@%
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M;&J$Y:NP2];CY.*HDV1@Q?&AUIB:^6=N#+*&4$JW!AX] ],"5> P& P& P&
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M<.TX& >O#E ."-VJAS"!2B.!D'D' #R' \  \AP//PX^_G YP& P& P& P&
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M+[V0UO=]=2MII5TJ]>NM=B.MVK:$YG:]+S\%%,I^%97>M.XYR9DJL9,Z)A$
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M6:O#_P"QJ-_]6<#[EL=?.!1).PQ@,')1+*,C 8/O*(+CR&!]RS,.?D22T:<
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MZ=%;N"(NP0BR 8!X$2AZ!F9(C^R !_G *G\WN&-Q_)Q@=?DD_M(B8/TI!_Y
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M#J\@_P"15VR?Z_4ARCP/W?# J4^F75I(H$)HK7)"@//!($A0 >1'D.%O0?7
M'Z8]6%0X4T90#!]@?E1PX_F<8%,;I5U:$>"Z1HZ9!_ZTU?HG)^E,R,@G[9@'
MX"7@0P.G]B3JO_Z)NN_^IUA_[\X';^Q5U@#T+J2&*4/0"EF+44H!]@ 4LZ!2
M@ ?8'I@/[%?6+_T4L/\ ^SFU_P#?[ I2]'>KB:OO(ZJ9MUOQ#[S:T7ILL'F
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M<)"X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M,!@,"U^:7YK[?I[_ +/G]GE[7CX_?SX>?]W NF P& P& P& P& P& P& P&
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MV91ZI7Y-OYKLT8&0EXI['LY)=RU.40O>JOJ<ZDVGM?5FE$-4;YJ6P]JT^K;
M9PULKVODE*?3=@LKM-:ZG;BW@=F3LI^7VZN4==Z9Q#MIAI""\:-9A:/?+@V
M,>W9]3K7/7+>VT=2[)@+3:U:\[T[$T*L:FISV=V!,R=]UQLS9=G/(#8IZO5>
M8_+:_KTRD=&Q3A6=D5C_ "C-D_>*)HX'HE5;LTMCZPLFL';8HE?<0B /[)6)
M2O,)TD[6(>THNZTO*(H'EV<>A,E9/3E(46DF@X:J "J)P ,TP& P& P& P-7
M[:W3JG1%73NVY-@U36E16EHZ 1L5QEVL+%+3DN*P1<0BZ=J$(M(R MS^TB7D
MY_ W >@X'SUCN[4^YV8R6JK[7+]&!$1L[^8UIZ$@Q-$S$I8X6,?D=$#V5$'D
MM49-N42B(^XR4 >. Y#:F!CU9ME9N<<YEJG.Q=AC6<Y8ZR[?1#Q!\V;6&H3T
MC5K3"+K-SG(G)UZR1#IB\1$?-!TW43. &*( &0X&,7&Y5?7]=DK==9^)JU7A
MDT59>P3KU".B8U)PZ09-U'KYR=-!N19XZ32*)A#DYP#XC@9, \@'V#]H#\0_
MOX&/VB5<PD'*RC0B*KAC&2+M%)R*A4#K-&2SE(%3HD.J5,3I<#X@(\#Z>N!#
M/45L[F[8U9KO9[2W]:89OL"F5ZX(1#G6&SY)2,3GXQO)$8K/$MK11WQFQ7 %
M%4K=OY"'/@7X &RDX_N<0.%KWUB.81]!+J?;"' <!Z>)MQ*<^OZ0P/D9KW4_
MQ+1U='[A4H&W$2C^GR'8IP+S]WK^L?C@<E_MG(E\5Y?JZY/SS[B5?VRR*!1^
M!/9&QR0B(<?M>X'^;@!7[E\?@<]8#CS_ .F>V0]/OX!T<?C@=?>[I_$!ZNF*
M'K^)/;27D ?$ $14\1_D']7V8&L]Q;:[A:;UK;]H2=:ZXV.*I42K-R4-#RNS
MVDK(,T5D&ZB$>YD8LK!)R N0. JF @E((<@(\@$Z6#DSMJBX.42BJ7SX$H$
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MGMV[2ZAOUB7^(A1 /YQP/L3L!M+PY5ZC;Q*H "8R9)S3*@_$?$"'_B:F4PF
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MO2@Z;2_SZL2X/\FX030DC*+22(G(&#4W1'U%(+3-+B[&YW?:EPBH?5TCII[
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M/@(B!0'X#Z (X$-M2ASVQ[BB'[05?JV7U]?4:O?Q]/CZ\*?'XX$SD^!3)Z?
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M]^6"^9A)"T%^$>+E$'PL06!L+WY03_,?* X,"?N>/AYCX\\^F!5")!#D1#@
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MU_,:/<--/FI0?[P"3);L=)6(69V?B=.Q LH;P7(4P!^D+6WY[_#RA_O/\_\
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M,!@,!@,"+';$O_@=KDO/ N>Q?7E'G^@!=HUU3R_2/I@2GP& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P @ _$.?UX# 8# 8# 8# 8# 8# 8# < & P& P& P& P& P& P&!:_
M$GYMY<H?]C<>/ >_\QS^W^QY>/R_ISY<?9Q@73 8# 8# 8# 8# 8# 8# 8#
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M05$U$U$RF(<BA Y*(#P8../B&!68# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)R!3%$!*< $/0Q1]0'[!P II'.104R&42\O:.8@"=/W \3^V80Y)Y@' \?'
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M8-?:S+=-I+M8BW0C.<8-91L@NZ00D6R#T$UBIJJ)@H4?$YB\&$/#^0^J]O\
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M 8%%R'SWCR'E[7EX\AY>/P\O'X^//IS\.<"MP& P& P& P& P& P& P& P&
MP& P(I]H>3.^M[4/VG?:C50D./[) 91MOE5 ,'Q'S2C#E+Q_C'#[ ' E9@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>:5I3%7ZONDE@$"@V^G;V+ Y1Y
MY/\ -=BNN!2>/V?@^5$1Y^_T^W O7:"\;P7[-:>TWK?L56^M]&E>OG8#;]\M
MDQ1J/<G[Z3UY<='UBL-VI[V=.)C(=@VV'(NI 0,0ZB:1.%" 4QL"#M?^L9?(
M_4,9LNV:!J\_%U^ETZ.O$A#[7_=6XV+;=LZT3_8Z!DZ)I^4I<Q(CHVSUZ':&
M"?7FCN&;:07<HM'S2-<KF#(K7]4S<S.-OM?L?7^!U9/5"W6+5<I;*MN-EL]*
M+VM4Z)IS=CR-BH2<U35D)FF2&J-LMT32B_L.D9U!=LFQ4;@C('"S;:^I]NYW
M3Z/9J+2J+JYGLF'L.QM4/1V/3]M2MSU<C#W)O&.MD4(8JLV35-D:2<,T='20
M/*QPJN 9_/JKMGR"02GZP?4K;=C]^;-U..C+K1:16([=TOK[:$R>P%0OC/KW
MMI/3NPDW<--T:KQ<<]6L"Y73!.'EK$5)J!DI,\<^#Y00@AK3ZQ&V[)(2FP[/
MJNQP.JWR&VNP])@INN*5US<>K\!U;VWL76U:@)V>@X0Q+RZN.G5G\U*-CV""
M$TF5LRD3I(G02#W-U/N:.VM/;O@V$.XC#:4W!_")\Z6?MGJ4^^#5^LMF'F69
M&Y"BR;$0V4FR%%03* LR4/SXF* !&'2_U!J7MN$WS/.]=7*G-NL- D+%O-L^
M592<C3=@5V=VW'7+3Z#) C167MU8A=4_FQU4_!LNQG(XR8_U_(!'>1^JI?H!
M!^6Q]++BPE*[IMQVKMK"/WQI692B.HS6&KDFXVPQ=H2R*DO=$'LXX8C5?9;^
MZO%.3MY)= S55R%WF?JJ/XRRR;=#J=LM]K]O;[U&P^Q!V%K%FE-4+3W8VL=9
M=P[#"K+3 S[ M>O5ZA5X>*.4SR<9.'!C"R,U$JH6R'^K.O8)VJU".ZF[9"U[
M1F?F-1QR-VU*_+9]6-F&[G,[MR;<#;V,?4F%>4T%.&4AG3C\S7149B0"JK*I
M-PVEUH^HU!;LW)0NO4O1+3%VVV:"H&Y&&R9-M7*74+PK;M5Z]VB_:4>FR%SL
M5F>MXMA?1;.2LG4R$<\CW*+E4"%2<+!JK7/U::\^VSK716PM:3!KCL#;UEU8
MK;ZA)U1"JPTA([RW=K'6"/[L3%O<WN0.X@]4(+SCHC8J+9=Z"J!%$1,5$)5R
M_=Z$BNQ\QU]_A)L=9E!7^%U.^VR=S2V]&7V5-]=[%V?1K47'GLQ[D];Q^KZ]
MY/'QHY)JA(.D4 ,<!,H4--:5^JWI/>F]M:Z,J5!VBB\V14J9+(VY['P1H*M6
M^Z:/9]A6E'L+-G-N9Q$L=KN1;D<32#9:%_.%TV)'!CF\P#2VV/K-4B$LF]->
M:@T9L_8UQU':%:A#2[DM6BJ1>)NG;JIVGMQ-FCQ>TM92N$I#VSJ'CEY=*/0L
M"S50C,YRE\A#>W9;ZD=+ZC;3OU3VO6Y:6@8Z%Z[(:YC*6$*-UM5SW$/8^4M3
M23<VRS5JFQE=I=2T.:04=JO6Q4R&5 QE#&1+@7Z__4YT52=-Z'W5&4[;^P8+
ML+J^^;JI=?I]8@4+1%ZNU138Z_;4M=I:W&UU.+CDZ-69(BBS1N[=OI!8/:CT
M79C%\@O-N^H_I"I5D+2:K;9L+9P;<",1%5FIQLC/S[_3G976_5*5C(>-<6%B
M"SZS[5VG%A$E542*I'"JNX,V,0$S!%#=WUH=;ZVUELF7'2VX=?;(B6-EK.KX
MS<\/1H6FW#<59OTQIZTU*0G:_LV2:QT'K3:$2LUFY-VZCHMZU;J*13YX4R9Q
M#;E+^JQK6^1]9_A[H_L3M)Y;:SJ)Q3EJO4=?U\E]O^V==S^UF^M(.,NFU8=U
M!6>MZ]IDY,RBLJJW@FC2,,FE*.EUV9'0;JL_U =416J=(;0IM$W/MUSV!B+'
M8:!K/6]&1=;-+"4*"7L&T'EDA+--5B)KCG6C=L9G),W#\'J\P9*/8I/':Z21
MPOVHN]>BMZ3E!A-<.+3+H;.G-EP=-L"L$5E"R7\+JC2;M.2IE'+PC]I&2,#?
MV!F(J-RKJ*^Z15-$2>H19J'U?.O;?:M1T'M0)6O;=N6X;AJA$E;8(25+KSW^
MT)M31^HRV20D)=G8DI/8A=>(.E@81\BTBU)!(7:S=!1,XAN[<OU*^O.BME;#
MUG=HK;"KK4\4^>[#N$!KYU*4*LRJ&B+AV0BZBM8#/VJTC:;)JFA2KQDBS;N6
MX+MP0<KMU%404"Q;$^J9UJUK-6"$EH+>$XK48I6T6Y[3M16&S1E8HL?0-*;)
ML=]EG; P\5NJ5SL'5ROBH%7D#/'BB#9JX.B?@-&W_P"M!UOJFP=#Z[=FG-?6
M38>U[!1MK5?;<0SKUUU'!U^US^K$7CZM1UC>JS$Q:-NM6<>R",6E2-HD'LFZ
M3(V;\F#>=8^J-U\M:M"58TOL R@+[^Y+].XS.H):*JU1J.U=C/M2Z;V#>GKE
MZ#NNTW<&P(IVQ@E105=BFV.[>MV;(2.3A7=F?J*ZTZ\;/K&JEH&RS,@%^UC7
M-JWI6 G6^IM1P5_2DYU4;9L!K'O8QC=4J%"NYQG%G*!7#-(@'6247;D5#%Z]
M]4G1NW>LF^.PV@F\O;G.B6\,M-T:WIIU"67;VI5H>FS2RS0UC2:U^V13A1VS
M4Y%V0&ZB#E!LX342($@=8]V=&[8WU=>M=9>7)IM&D-KR\=,K32)ZK1D^RUK;
MXJBWE]59*7:MB3+2OV6<9HF5 B9':3@CAJ*[<P*X$->E_P!5!'M_MZI:OBJ%
MK'_PHI-[N,\IJG=-BVI;=)'I\HPC8Z%[ U:3TIKV'H+NXK/%4(T[.:EB+2#)
M=N3S*F94 M.H/JUL-H]H$>N2&O\ 6JDLIV.W-U]=U.H;HL%N["5V.U'.W6 -
MNRWZ<-IB%K<+J.4<5%)5V_3MC@\6C*-?(JRA_:$/1#MIV 1ZL]=MG[^7JKJ[
MI:VAX^5-5&4HE"NIH7\_$01&R,HNSD$FAR'E04\A14Y GCQR/(!A6F.]?6KL
M!N78NAM5WEQ8[_K1*?<R@?N].LJU8V-/L+"G722H=N=1Z=<NL?3;C)(Q4FJP
M<*E;O5 *'F0?/ TX\6 ?JW4QGP/FV^G1L=R=3X%,1UV8UFB0H!\>2F:F$>?L
M$/TX&D]._6$UGL&W-(^YU>A46C*0>Z;-9K57NP%0V?:=,UG2K>SOI:T]B=:0
M->C9S3E7G&U2<MF3QTX=%4F%VD>4IUG)1*&UM2_5@ZI;#AM;(S-M=0.Q=EW2
MU4QAK. J6SKO8JVZ@K-5XJ/<W=..UVP>4YL^@-BUB1<N9)JUCFP312ING"")
MW0A](SZJ'79_-:/K1EWP2>TT7,A=9]M'VW^%.FX9CH6]]A9)W;-PR],A*"O,
MQ]&IJ+E6%,Z:32;&31>G:E;E,(A=([ZM70J6@26&/W1(/&WSLZW<QC75>X'=
MFBHVL5ZM6^Q6Z?JS2A+V"O4"&J%OCY9Q/O6Z$02.7%?YCQ25\ V!0N_^AKAI
M+:_8&7=6&C:XU)O79V@99[8:Y/+2UBN&N=CGUBR)2*]%1;V>NCF_V11LA!L(
MML\?O';HC,J0NRJHD"T//J;=+8Z4I<3)[9?1:][B'4M$.Y76FUHN&BE6J5N/
M^[5VGY"CMH37U\=+T.8;MJ]-N&$VY=,%$4FIE!(4X4I_JA=)R4AOL$VUY;]W
M%[(-;5 NJMP*3T8F%5K]\_?*>JB="/:*[JP:%:XR=_>U^S;5O\G?(N_G?94*
M80M,W]3/KRGO>"T12I9"]2KM,2V2U-7;Z J%>>COC4N@$V,;9)V#:UJ]G-;=
MFN$SJPC]Z@W>0CADL=-P<H%"\N/JC=$6\ I9R[]C'\*2Q)5@BT-2=GSSYX_<
MUFR7-A(1L-"4>0F9:IRU3IDQ(,IUJW6A'S6*=J-W:@-U? )QUNQ0UN@(2TUV
M0;2U?L<1&ST%+,E069RL+,LD)&*DV:H  *-7[!RFJF;T$2' > P+W@,!@,!@
M,!@,!@,"C]M#YWW_ &@^9]CY?W?\;V?+WO'C^CY_;]^!68# 8# 8# 8# 8#
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M*[50KB]WCHRAVB8GV6U+-0;]4XG6R5\:4:T-+-3KK6;72&L6QVO8&IY%HX9
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M @7R<^C-=)FA-:F;:^N49A6G62CR]G+3;.A*+UZ5Z_\ 4W6R4,WDHBPQ$\2
MF+MU>-^<,TWJ'S5;LCI%-0CHGFH$]>EG5[8_5G6EITPNA2DH>WO]J[0<VRE3
MM\=1M<V!?[,9")J$(UV!9;';GL="U1JV<N90RK4KN1]U0K=(YSF.$%M2_22W
M-KCM)UKW<.SM4&J>DHSK@,[&Q4/86=JF7^H.J;_KG;(>,=A$D*>*L$U(+SJ3
MUV^,*Z*_R:K% Y!=K!K.X_23V;V(VMVOL%UK>DZ)2]B]JMM7V,L$M6'Z^Y-H
MT&W1FBJB]HMKGXU-Y&K:;EZ_KM_),TE#JKC+@S*HR2*BHX4#;ML^D=;):_;)
MFZB[Z^:Z91\QNW86BMCU&H6*+W*M<;NO4K%HK7&TG+-NVA8W1W66Z4:&<0T?
M%+OO?;0$.1JUBOD5 >!KM?Z(*]EE[!8MF*Z,V+-7;5U]4NG[S0,U.PDAV1V;
MIW:D):-L1\)-PDBBT1;;DW'-24>X.8\BRAQ0 G#I @ %=M+Z0.U[Z;9#1%+J
MTZD[A/L;@[WA,,;^S[ ;"AD3:25<=9;Y8F$ ^@V.B4T-7KQR+M5&QE+&DC@)
M HN4GB[H/0#IQUTV;UWZ]V/JC)5&LQ%3@J)8Y.DVJ!OTO:JNI<=P7;<<[9M<
MPK6>A(>QQU8UM'NH,Y'IH^/9O%9=<C)@S0;%;E""W37Z3V\^O7<[7'9.^;#J
MMG85'7C"OR4S'7.37L2[%;KS2=/_ ,&T*BOJJ-5<4&CV*HIOHN1<V]=H=FU;
M"G!,WQW#D0CE6OI5=E+OKKL',UBA]?\ 5<_M6V]A22);.K9X^_\ 8^)N/?AO
MNB*9=@&DOK.T4J&8TC7E &/J#I_%W^,=QED4]^,3:JJMSA6ZC^EKOZM6I_UW
M?OFZ-*A- ;DOUIE&AKI :ID-ZV:R]G-:]1:W2=HU^ HTHU:T/2F]I;]Y6E=A
MFR4">OP0(-DT%&K7 D]6_I@[NA/IAW;I4PFM=5V;F]T,-B0U%AI6$CZ ]U@V
MOM+M=DTI<;77-&UZH/$-A-X&5,]>--<(Q'NRB:#J*>I$=*.@VA].KZ>%WZ;S
M>V[!/UO6:DELK1E&H\3)0-UD;%8JNZIE_P!Z3,7JYY*GU?0HN3I,#2KW7(]C
M(L8^+;(%B/E&T0U9MVI0#1O37Z5>_-"=LM2;ZV#::S._N11:=7Y:X5[:#U*2
M0JU=ZN4W2B6A6]$_@C&3%DH,)?X%S--'#VZIPYTP;._R-.53,X$*^_\ TV]N
MV*X[PEWNBM ;%3MNVY6_WBSV3>>SJ]-]Y-;RV\PV?3=";SKC"E/ZS4JKI>IG
M;P[->3+;4'1(1FR;-VT4[?(8&GGOTG.VY%]>!%R>H&6Q*K4I>'UYV52VA?YG
M8/5:JK:"WYJ6O=>]5LK'2%IBQ:U@+)LN&DR3*<C#N/%FLK^6BZ1:G$-OZWZ9
M]A.NWTRN^.J)BI1T9:]B52\R&J-1ZBLC"T-X=^&K(&HK.*R.KM/Z:9PTU?[=
M"+2_MQ,(>2]UR#MPX6DU5S8& ROTS>RS]W6G$#JO3U$BD;5.3>C:FP[&;,L4
M;]/6X/-KU"]R&[-6O9&FLS;!M5U9PDDZ=1[)&)10=O1BQ,:+D90^!BNO?I@]
MQZ5=K%?#1%&DIMMV9M^WZ:K,=A;X=XVM=YTYVAU]-;D5F:O7:J#E)"P[$HKM
M-)=@E;UV<.Y;+R"A&C$5 W'],?Z?G9_KCOT-D;MK-*@J5%U;:$=5X2(OI+B\
MA+3L:O=;26NRL61&AVL<_P!A7'7-A?R[PCE1[(*K)N7JBCARH! _0-@,!@,!
M@>:A1X^L 1+@/P_395/Y?H-VC)P !]G'C@0Z-U7[<S&K-1=6*YJ)'5UMZ\6;
MLKL1KW3/L:J)UZZV[8NLM^U&H6J@M:W)R&Y6.P]L6[=:,S<E)&*AFD(NS>BV
M4D@,R(<, ANNGU+-EWNVQ.XJQ>HC3FU*UJG2UNKMAWO3[G'P5%5K'2RN;QNK
M6$B[8_C'$A9FVMMB'1*1-1R+F:56.43NU"J!:(3Z?/>'6%2UA':3=P\!*7/9
M';?=VQ$YJR03$=#=BK-J_MK2M1[7J<@S&>";C=G1^VZXQGP02=N64G!M)<45
M%7<B"87!]T_[WV:*V,$>GV@U-3&>GM]3>BM6+]W9J\7RK]A66L-!M=<2%LV>
MQV0\<V>O77;4!8)2+B)&6DH=@=)TJ\38H281Y0_15'@X!@R!Y_V6#1M\U^Q_
MV3[)/?\ 1/E,/ZWG]GT^[TP*S 8# 8# 8# 8# 8# 8# 8# HN?\ ??\ F./^
M=YP*W 8# 8# 8# 8# 8# 8# 8# 8# 8# BQV*]O]^NIP&XY4[)-"B ASY"33
M>X7*0#Z>O@=N)P^XQ>?CQ@2F$ 'X_P#!\?3XA@:>D^O&@9I\^E)G1VGY:2DU
MUG4E(26LZ4_>R+EP83.'#YV[A%G#M=<QA$YU#&,81]1P+(MU2ZN.  J_6S02
MP!P)06T[KM4"B!BG 0 ]=, "!R%']8 /V8%(KU"ZGK(*-E>L?7T[=8#%51'3
M>NP3.!S>9P$I:Z ?B,/(_>.!9#=(.FIQY-U2ZZ?;\-,Z^+\?\V  ,#X*=&.F
M"I1(IU1Z[F((@/C_  >H8!R4P&*(<08<>)@ <"WN.@71YVH*SGJ/UT65$  3
MGU!1O(>/O$(7UP+,?Z<7090!\NG'6X>1Y'_Q(:4'KSS_ (L04<#X#]-GH"/_
M -IQUS ?T:HJ10_F+&AP.!\1^FMT##U#I_H GZ6VMJ^W./Z#'1;D,8OZ!].<
M"E4^FGT0.8?;ZHZ703'@ (A5"M#%].!$@LUT4TC<^H"4 $!]?C@4[KZ:/1E5
M--/^S'KWP3$PE(@:<;@41 .>?9G&HFYX^T1XP*0OTSNCX" $ZTU)#CT*JA+6
MM$4_\I,R%P353$/\D0$,#JM],KI*H)1/U_C#"4!X%O>MG1_'K_C VO"@*C^D
M>.,"@_\ 27W2%-3YA+1KYNL B8#MMQ[R;B03>@@E[&PTRIEX$0X* !QZ?# Y
M4^F1TO5$!'4=J3X#CAOO?L"F4?MY$I-E  F_3\>, 'TQ.G_/!-:W5 ./11#L
MEV92. ?T?P;>+P40^(!Z8'4WTQ.HO/):1LY$./V4.SG98I0'^D 'VJL;R']>
M!\2_3$ZI*<@G&;T8&^/NMNT_90AQ#G]@3*;1]2_;Q^C ^Q?ID]:$0\$'G8=,
MI?V?;[7=C $.?4?'SV>(<^7W@(8'(_33Z]\?U5B[-M1^T4>V/8 HG^X!\+^M
M^S_)@?8GTW-()%*"&P>UR $_U9$^W6_B G^@@#=3"&!\UOISZEX#V-H=P$^.
M1,#;MWNTP''D./,7]M.)1_S./TX'P_\ 2<FO #R3WOW4;E'@2II=P=QE,B4>
M.$R^,F?@"%_#Z&-Z?:.!R7Z=E&2 2I=@N\)2F'DP%[C[G !'X<CS)#ZX$'7'
M2JLNOJ4Q>ODM[=Q&B33HY/6L+*W[2;'1NI3+;YK\/^0HVL'1Y1*I*)HE75C2
MB#8STJ:PE$Y1-@3D)]/6#3]$^TG?I,O//B7N?M?QY^_@7 ^N!4'^G]&C_J^U
M_?E(>>?(G<#9!_3U_#PY^8+Q_P R _IP*<W0!'D2$[<=_P @"'B"A>VUO/X"
M8/VP]^)5$PD$>>#"(>GW>F!5!T(=E;)-2]S.]X B(F!P;LB_5=*\E\?%952J
MF\RA\>./C@<!T+E""'AW9[Z !?4"#OUBL7]7FXI)UC!_G"(X%07HM-%Y\>ZW
M>LGW^6\(5;G]0+413C^3C ZFZ,VCU!/O-WL2#_%XVQ1EO /N 7&LU!/Z>G)N
M1_EP.G]AZ[)>B/?#O6!1]3 ;8FJW!N?AZ'=ZH.<H<?8 \?;\<#X#TJVJ(>+?
MZA'=EL8/V#J2>CG'B0!_8,#K2ZJ:@B7T\A 1^WG [$Z7;H2+XI_41[DG#GGR
M7#KPJ;G] GT;Y<?R\8'/]C??9?4OU'.WI1^'K!=85?\ G3Z#X#]?.!V_L?=@
M2E$ ^HWVS$  ?52J]8C'^_U$FC4BCQ]GH&!2GZ?]CS<?)_4B[3(F 1\Q=T;K
M,[(8./P@4G\&V_B8!^WD0'[L"I)U*[,)(^)?J,]C%7!2\%67UMUS. G^PQTD
M]6IH& .?4.  <#HEU6[9)\^'U&-X'YXY^;T_UN5 /\SV==-Q#]//.!]!ZO=O
M/^I?47VL4P?L_-:*Z^KI>GP]PK>J,E5 X_HG(//\V!W3ZQ]R$^>?J*WI3G[3
M=>-(#Q^C_L,,#Z*=:^Z7B((?45M:9_3Q,MUHT<X(4/@/) 02,8W'V\X%,7KC
MWE3#Q3^HM+J /KY+]4]*G/S]P"$BWX#^3 ^I>NW>DH_@^HFXY_\ SCJ9II0@
M!\?0J,RB8#?R\?HP.?[._>T#>7_I11,>.!X_LB:D]>./0>+&'QXP/H?0/>\
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MX4;L*+;Q^\I2W<>#\_;R.!]"M?JBB0#!/=#E!$/B-9[ MN?C_P!3-97!D_\
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M*M];KUL@EU',':(.)L4,Y5;KM%7$5-L&\E'+J-72:3ELHJT<D,*:A2G((\&
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MD:B4/K'SX^0\H?30K)P^'XOS+M?>EU.?AP"9F@ 7X\@8>?AZAZ=X# 8# 8#
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M5L0FXK3L/&4F6&FBG?2-[NC#T6^SDU%1S>513=Q[-LFR_8;$ H>N& P& P&
MP& P& P& P& P/,^ ;F-]7N_.#  _)?3EU@T(81]?9?]E]KO$Q^_\1VYP$/L
M\0P)][$@;79J79(2C79SKBX2,4Y0K=X:0D'95*W,>(G8R*M>L;1[#33(BY0*
MX;*D**J)C FHDIX*D#QHU7VK[2[>U/'=5$=@K4CZDE,WJ_UMO>P.-=TB6JM%
MH-2DF]FL>]6]-6AFL(^U#=-8RL>C4CA[;Q_8I-HU.Y,5)XH4)Y7?O)H#3>Q*
M[IW85MGOSMQ=];Z=EK\I!ME*9%[:V=&&>T>GV^9C5&Z$#9;8@#9<2),@CV9I
M1H191 '"1<#.M.=L]8;PMP52C1U].WD*U;;A5+I+5%TPH-[KM%OX:SL[^IV<
MKARW<JQMK43)\JZ(T>*-5DW)$C-SE4$)08# 8# 8# 8# 8# 8# 8# 8# M?)
MOS7XCX>SX_I\_'RX^/C[/CZ\_M>?Z,"Z8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M$6.P'_T6>EW_ -\/:_\ \5SL3@2GP+!(U2KS$A$2TM7(&3E:^[7?P,G(0\<]
MD(1\Y3%%R]B'KELJYC';A$PE.HB8AS%'@1$,"YJ1[%8ZJJS-JLJNU.Q655;H
MJ**LE!$3LU%#D$QVIQ$1%,1$@B/PP+9"U6M5N)+ 5R AJ_!$]_VX2$BF$3$)
M@Y,8[H$XU@W;LR Z.<PJ<$_&)AYYYP.9*KUN9A#UF8@(26KBC=NT4K\G$Q[^
M#.U9BD+1L:)=-E6!D&HHD%,GM^)/ /$ X# QYYJC5\BLBXD=<T1^Y;0I*VV<
MO:A7G2[:N)M%X].O-U5XY0Z,&FP<JH T*(-P14.3P\3" A7I:]H:-77HZ-+J
M:5+=>[\S44ZW"DJZX+N?G5RK5\C$(A4J[W^N.!D1\U?QCR;UP/O%T>FP<"YJ
MT)4ZU#5EY\Y\Y7HJ!B8Z#=!(D%.1*YB&;-&.7+()F$JX'3'W2B(&Y <"&.\>
MFEGVM<]>PM7W@.I>IS- ";SZFT_3^M K.]U&L^C8V17E_&.;6ZC,95TS09SB
M$?YA*Q:8MP,W%990X2ML6FM16^WQ&P;9JW75GOM>9&C("[V&D5B:M\%&G^?
M\=#663BG4U%L#A*N@,B@N1,0<J\A_6'\@QN&ZT==*X]KDC7=":7@)"GK2;BI
M/H35E$BGE6<31ECS*]<<L8!!:#6ESN5#.C-3)&<"H85!-Y#R%E0ZB]5&J"C5
MMUHT"V:*Q#VOJLV^F]<HLE8*3FFUDDH91FG6RMCQ<C86:+YP@)?;6=I$6. J
M%*8 JIWJEUCM$QK*PV/KUI2=G-*_+_P>EI75]*>O]5@T=H/V9->N5X0ZE/29
MOVR:Z)& H%26(!R@!@YP-^%*!?@(C\/41Y'T^\?B(X'; 8# 8# 8# 8# 8#
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M>;=$#GZM/9$X!R4.AO5-/R /3S#>':902<_T@(H4>/N$,#TDP& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P/,K5?OG^K/W \O(R#?IO
MT]13-X_@3%;8?9-8J?E\/)44E#!SZCXCQ\,#TUP& P& P& P& P& P& P& P
M& P& P&!CON?^$GM^RU]OY'_ %_F?YOYKX^SX^SX>U\M^+]OG]&!D6 P& P&
M P& P& P& P& P& P& P&!$[<X\=D.H7W)S.[G(_8(_^)2Y8 0/_ %/\N?\
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M&!YGZ* #_5.^H2<P^9D.N70-N01X'VRG?]KUC$)Z<@4YS 80^'.!Z88# 8#
M8# 8# 8# 8# 8# 8# 8# 8# QWS>_O%X^RK\C[''N^;;V?<]GR\O#GYGSY_#
M\./Y,#(L!@,!@,!@,!@,!@,!@,!@,!@=?$.>?7GU_NX'; 8$3]K#SVLZFI\
M'%>[&K@;D>>4ZW040+Z!^R8'(B/^;^G EA@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@>;>DPY^IWWG^SY;KUTP;$ /\ '(9SOM43F#CT,!AX]/3C ]),
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#S+T"?W/J
MC?41.(<#_ 7H*AQ]G"2/9MUY?:(^1G@A]G[.!Z:8# 8# 8# 8# 8# 8# 8#
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M'5THG[[?4Z><\$5L/4%@!!_:!5IUT:NU%1]1+X')(%*'V\D'G[,#T?P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P/,[I\'EWC^JT8.
M !#=76AF8/M,<.IFM)+W.>/V13EB%X^/D0?LXP/3' 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8%G]P/S?V?7R]OW>?Q>/C[/M^'/'A[GEZ\<\^/K\,"\8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8$6)\A%>YVN?,OF9EUJVZLV#D0]I1WLG3[=8Y0#CD
M52)$+Z\AZ>F!*? 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# \XNJ@E4[Q
M?4^.40.">Q^KS8# /(%]CK'4^4N0$0 4C+" A\0YP/1W 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# <@/P'G 8# 8# 8# 8# 8# 8# 8'F7TV$YNZGU7UAY$3=D
M^OK;S^PS=OTIT68A ^S^K<*& 1#UY],#TTP& P& P& P& P& P& P& P& P&
M P'/'QP+#\N;\]]_Q0]OV^?+VDO=\_E_;\_=^9]SGP_#_JOV?3G OV P& P&
M P& P& P& P& P& P& P&!%266 W=JE-_$0%'JWLMSY<AP8%=MZE2\./B E]
MKGG[><"5> P& P& P& P& P& P& P& P& P& P& P& P&!YK].Q!7N9]4=R'
M!>=WZ$9B3CU 676NA@*@CZ /N^]SQ]G&!Z48# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# #Z@(??@=2E\>?7GG [8# 8# 8# 8# 8# 8# 8'F;TP/SW#^JX;C]CM+
MI%E^L2=+>O[WW/T>CWQX_P GG[<#TRP& P& P& P& P& P& P& P& P& P.A
M_A_+_@' QWWP_>+Y7^N_["^8Y^9)[/EX>WX_*>'GY>/KY>7'/V8&2X# 8# 8
M# 8# 8# 8# 8# 8# 8# 8$1Y(?\ QNZH%$P^/]DC8YO'_%Y#<FJOQ<<?' EQ
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>;_ $V]E7MC]4%P@)#@7LKJ
M1BJH3CD%&G5;3JJC<P_$116>";CX *@X'I!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@>8O2<Q1[=_5A<^0G2<]O-0-$A$>2D68])
M.N**X% >/$2G2, X'IU@,!@,!@,!@,!@,!@,!@,!@,!@,!@<#Q]OP_5S@6WV
M6WYC[WMD]SV^?=\E/<]WVO#P\.?;\/E_T?'].!<\!@,!@,!@,!@,!@,!@,!@
M,!@,!@,"(LK^'O+77/(^37J1>R%)]AP=[AUV8YC?:'M_)%X_SAP)=8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'F?T@7$_9KZI)^/AW(I;#CD>/%MU(T
M Z!0/C^(YEA 0^'IS@>F& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P&!Y?]#R>YV4^J@_5'U>=WH!NF'("!1A^IW7>/3* \<B*A ,(_
MT1#C ]0,!@,!@,!@,!@,!@,!@,!@,!@,!@,#H?X?R_X!P+%\TG^<_*<I^?A[
MG^L'W/+Y3GP]KV^./;]>?+^3 R# 8# 8# 8# 8# 8# 8# 8# 8# 8# BO(@4
MW<N.X*454^L4MR(AZ@FKMVM\EY^/B<4!Y /Z(<_9@2HP& P& P& P& P& P&
M P& P& P& P& P& P& P/-7HIXF[!_5(<  "1;O%#))*<!Y&,SZD]:FRQ/7\
M0 DLD< Y]./4/0<#TJP& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M>ITC?Z1RB/\ +@>B> P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P&!Y@_37)YR?U!%0$  OU-.T?)1^(\0>K$/3CT^).?U8'I]@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@<#\!_4/][ PCW$OSSV_F/Z[Y?\ [#\U/'V?=Y^;
M\/:]OWO<_J_V_P!C]/I@9Q@,!@,!@,#3%L[&]?J'8[#3KOO#4E0MM2IY]A6F
MKV78E3A+#7*&FN@V4N<Y"R,LWD8JK)KNDR&?KID:@90O)_Q!R%13NP6A]AUN
M-N-"W/JNZ5*9N">O8BS5:_5:>@92^K 04J3'2L9*.6+VVJ H7QCDSF=CS_J\
M"XP6[--6FTWJC5G;.M;#=-7I)+;*J,'>:S*V;7R*P+&26NT&QDUY.K)'!NIP
M9\D@'X#?<.!D)K]1B5*.OI[E5BT:8:P#Z)N)I^+"KRC*UKQ[6KNXZ>%U^5O6
MUC=2S5-@=)4Q7:CE(J0G%0@"&.K;NTNWBKM..-NZP0A-:RXU_8TPM?JHE%4"
M?!RFS&$NT@>6*TJLN#Q8B7RS\Z"WN& OCY" 8&=C-PH/8V,&7C D9EF\D(A@
M+]J#V5CX\&(R#Z,:BK[[]FQ"3;>\JD4Y$OF$O(0]PO(6HMXI1T*^Z);ZN=M;
M''RE5<%GXHR%F=^O^ZUY8'8IS3G\(_@;"J;T^&!0QFS=;S<PXKT-L&D2T^SF
MGE<=P<9:X%_,-;%'(23F0@7,8U?JO4)IBVAGBBS4Q 72(T6,8H D<2AF^ P&
M P&!%J%-X]RMJG,/CQUPT$@F<0X+R?9O8=19,IOV3G\0*(A\0 0^P<"48&*/
MP,4?40]!#XAZ#@<\A]X?SA@.0^\/YPP'(?>'\X8#D/O#^<,#GG[?LP..0^\/
MYPP'(?>'\X8#D/O#^<,!R'WA_.& Y#[P_G# <A]X?SA@.0^\/YPP'(?>'\X8
M'.!QR ?$0P'(?>'\X8'. YX^.!QR'WA_/@<X# <@/P'G 8# \U_ITO1>2_?E
M0ZQ3*?\ I1#L2EX^GD=./8T*-2, !P'BBBU(3D/CP'/KZB'I1@,#CD/AR'.!
MS@,!@,!@<<@/P$,#G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'F1]-
M5(2?V\''J<S[ZE_;E8YPX$ !K(4V+(0W'H4Q4XXI0#[?'GX\\AZ;X# 8# 8#
M XY#X<AS@<X# 8# 8# 8# 8# 8# ZG'@/UCQ_<' Q_Y5G^=>Y[1/F?D?'S\C
M>?L>]Y^'CS\?>_%Y\<<?AYYP,BP& P& P ^H"'WX'D-.=7>P\+VJLVR:WKW7
M5MJL+N#<G:JF[&FKFV:VRV6FZ]04.N=6ZZS%76KP/8Z)96E$KY28/*FC20S-
MFD"/O@8$ R64Z,.V^LNC (U.#M6Z-%[]UMN/9E\F'S$LJE8[5*J6SLU?6+I5
M46KNP7.SK* (M2F<G9&*S1,5J!B8&@]2]2-@[:V_V>_M,='J]J35EDH>X=>:
M=@Z?>].+ZSLE0N>W839LNZV-&Z_L [*N&U-WW*#96";<S/M5Z.;LQCDFWN.7
M[F1#?MIUQ<M5]7OIH5*]P+A>,T/L3J!![YKU?5"49LGM7UB\UW7))=S'"9B^
MK5"[!OJS*K+^T9JFE'E>"=%-#WB! ^I],M^.[2ENFU="(V"5JFV=6 AU1A+Y
MUT+JJR=;=;U[L'$T>HLI,FPY.-VANJM;'V^A=9V?NZ<2V=')\G%^)FA1=A*3
M2G0RX5G8O4+^)=)0E8JN?3IV7UJ[#7J)V19DWS*?D)7KRE4-3U=VVM3"=C*J
MVAZW/E!] HL2.A:BJY4 ZR11"(\IT#[&IZ\ZG4='2SJ1<Q?4[5'7VMR+&<UF
M1OTFVSK[LO4]I/=SJ*35@^=+&KZ_CT"D4J2<I)NG%8:QYB)).RN40K:AUOV]
MINW3\>IK.U4)WM+MGUKLFMQO3W2%XNLYV%#M1==V[[O.L=C:BKL+>)#KW$=;
M',][_P"_:8R?@Z=-R-$0,Z^;#])!>/$./0/L_5@=L!@,!@>2WU:[GM/76FZY
M8Z9<+5JO6TE:6L1O7;NN(=W([!J%1(W52@6;=[%K1\E7ZS*.Y60,YDTWK)1%
M\FS8%70+)JJE#274_=_8Q[T#[;7K3UEW#OYMK[7]MDNH.P]WUYLWV[>K(PUF
M_E)**5C2A,DO,/5K:1L>)745D5G[Q=Q&&5Y:_+(!J*D]Y*%J#8EH0Z]]N+EV
MBUQ5-%]=;OV,F-]76Q7J$UA.;*[)Z)H!=CQUIF&M=3K"<WI_9-ND;#%Q2@5Z
ML/JVV^;9QATG+9<+!._6@WFYW!48S6&L=5;'U._M%@1A_P JG63:[]D:A(=F
MMZZ9JDAUW2D]E,)N<=5>D:I:2DFK%5JU)/)%V)5BQ+%=NY$+=K;ZN_=/<$21
MI4M>=3H*Q*0]@V"ZEWT[-;%KL%5H3KGL?=[G6<O$ZQW%,O6.TH62I3*->JR4
MC$/$DI%11S ,56I47(;^N7U$]MZBLG3"23?4VRT[O=_#/=<C"WY=):VZ=J>Z
M5^OU'KVI]=QD#9*U.3U?KDI;9216GF43;W:4@Z21?1L?'K%D4PV9W;F>V-G[
M7GU3UJGMYIS,9U):WZGQVKMA:5HU%K.UI3:=JK=>O&Z6&VFSMW=*"48END^C
MXAO(.S,6[DI&QEE4A$-7VSO?VSB-AQ/A#Z9^;FMK;ZZ[:JKP3UT;4N6D]?\
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M <!]P?S!@. ^X/Y@P.AD4CF(<Z:9CIB84SB0HF3$Y?$_@;CDOF7T'CXA@?0
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M;$RLXK6*W(PCT]NAX>"M$NUJS2P-ZS#6>?CZY&?-RS%HVDUEXQFN9?WVR*A
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M!@,!@,!@,!@,#CD ^(A@<X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M/J4/A_3']/\ Y;' [\J?T2?\8;_9X'(";[0*'Q^!A'[N/B0/C@<<G^PI./\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>tv526458_ex1-3img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ ,   0 !! ,! 0
M       ( 04&!P(#! D* 0$                     $   !@(! @0"!00*
M!@T3"!L" P0%!@<  0@1$B$3% DQ%4%182(6<9$R%X&AL4)2(S.3TQC18G*2
M)"7PP;+"TD/5MC=7=R@X@E/#-%34-56%E28VEB>7UUAX&>%CHT1%M59'M\=(
M:)ADA)2D=:7%9G:&UK@*\:)SM$:F9X<I$0$                     _]H
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"U_^[/_ %/_ .3X%TP& P&
MP& P& P& P& P& P& P& P-977O0:;MK>_AJLIYO?3ZM15UWO L/'06AT93(
M]=>@Z?JX>NOQZ"@['TZ_;@;@6+T+<3I0X+4B$C8PEZ/6*"4I.S!:%L)>C#Q@
M!L8M!WO6NO7?3>!W$'D*B2U"8XI0G.!HPD\@P!Q)I8M=0C+-+V( P"U\-ZWO
M6\"BA0G2$F*51Y*9.2#8SCU!H"22@:^(S#3!!  &OKWO6L#@8M1E;3:-5IBM
MK1Z*1Z,/*!M68(&S EIM"'KSQB+UL6M Z[WKQP/3OP^O?Y,"FM]==<"N P&
MP& P& P& P..Q:UOIX_#K_E8'+ 8# 8# 8''8M:^OZ_# Y8# XZ%K?U_EW\/
MR?EP.6 P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P+9T_QQ_P!3NO\ ]D=,"YX# 8# 8# 8# 8#
M 8# 8# 8# 8# 8&LKKUK=-6WK?PW64\UO\FXJZ]<"Q<= A#15,A#\ 5!5H [
MZ]?NZ@S)T\?IP/G%[L<)KJUG'AW6]KW;QKIV#?KEG5AKTG+"M7>R:?L5RA=/
MRUF;8PO:U4NKJM3'IKU.C79$FD,@0C.,0;/0DJS$AQ80DO[<ELQJRN)=(Z:X
M;654*TD(6E-%6U8:F00@J QF=S"O(C958Q@P[;RU4O:B6'[>HN)0 7^+58"O
M..$6(P08![QR1N</;$YE-KQUVT.=2G-CJ$)HB!#;'&0L*)>6 X.PC*&8D/&'
M0@[T+6]^&];P/@C*+(FLFMC@= 'P]=+Y#[2O)>+\<Y,S@7+-/$ZO![67LQ5J
M0=HE&J,?%<CXR4(R.I)OEF* &S4 M%&F"WT"^.?.;F_>W&FVD,OMLR'Q^U.'
M0>2^IV)?P\T[5&H:;-I]K6-->L%'6_+9T73SZBG*YJ5&SQ$DD3:J0@\Y4(8U
MR9.$K3>07)[CQ9/*^WHC<Z"SZ]A?N*<;J/>*5!7T6&"\'"^./W$YCD<S+GB0
MQR?HJ]J%,H3K(VV1\M,UDJO,"H)< *0:("W_ /I#.6\!AU82LKDK0]]G<L.,
M#?=YZQ#73"V1/@@_OEV\>ZM<I"^!A[T3(9;1L#2W>YIS"Y2+3YM]B1_K%Q"8
M2PA&$H.%\WG=;7%[PK_)K7URTEE-O=*N 9#%V:/L3A+U\/XCLTA*AAD4A"A9
M%&B;[5$Z;U938G1EG*=@'M*4:(0<"#O)7E-RUGG"NQ(<]<EJML)XY)^WY7W*
M]$OJ:O%,1D=0$S2Z*9@4BJ1L!%K!6K9#!K%8+65-;.Y+513SLY@<@CVJT?LM
M&'T^YCVG9?$VK.*]!<>Y2WPZ5/#>Y18I+77'5PNF4[@E-P5J \.E?UK(K3A\
M(AD&8')>V?.7*3RL9+.U*0%%F*% ]*"P^>+;[FW.V>UF9?<:F/':(Q:K>,O
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M0LRU6"R;KW+'VNRJXK)AKYXT6Q1N"/4;D,G?YN.T&L20XMP)3H&XA6K,+4[
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M,!@,!@,!@,!@,!@,!@6_R]_,_.\W77TOE^3TUU\KO[N_KTZ]WF^'U=,"X8#
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M;-SK30:LA[^Q4W73IQQ<82\QQT/9(_65FL4#ECK7A)3XGTV/L=D30P,"DT9
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M# 8# 8# 8# MO7_&OE^6#M]'ZCS.X?F>9YGD=O;^AV>7]/QZX%RP& P& P&
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M$N1%]HZMM^F.3%O\?2+A=9;=U%5/!5,.B7()\C=>Q-Z+<')P9Q$C4?-7-O;
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M& P& P& P& P& P& P& P& P& P+7_[L_P#4_P#Y/@73 8# 8# 8# 8# 8#
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ME,-32$3Y&Z>G+NTUTAO"TEE*UB5;#BG;/10-=)[0:5[222I,$/1B \[?^#!
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M$8R^,K@D((9R&X<B(/1!==B)0C)5!.;C3QX5T ;R,V=(TTB)O'D]9_(1%HE
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MX -B<"@Y.&3V#/.5\];.+K!R#G?(G\3.#[[<+Q7\/A''J5M-;<@#]<J6]XY
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M42)(<&?P7E?R:=RZ]26IR*MBOX^:6M4\=)O3E$CNH7+:3H.1SW#EL'F;Q*J
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M.@T'</N,RYE@4RC+\\PU+6U:<2^&TX@4 =X0WV.QZ=F74@L !S>K&:F]$?\
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MAAO:2>Y9RUK=G<-(G_CCR;*_$-755%;%J2%2IEBDHO+EE14@DG'"#C2MUB6
M@3)(W>+&UMCV<0YG&JX[,FM1L",\L0E(?0?V\^8TJY?0R:6#,?PA&T!\Z<X)
M6421(ES+)G8VF(?7D4Y&R :1[=3G)Z98]R1>'UC(-(2E%HD:-($X1AB@)@P^
MCF@ZU\-8%<!@,!@,!@,!@,"U^/SCKTWT^7_'IOIU\_X=?AUP+I@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@:8Y#^%#7?OZZ@LH6O^)ASKK>OV=;P/?1^NE1U:'^#6
M=?\ C^6(,VM?YC>!MC 8# ?Y/C@4Z?E_/O\ LX%>GY?S[P& P& P&!;C'AH)
M=D;"<Z-Q3ZX(%[J@93%R8#LN:VH]O2NCDC;A&Z6*4#:J=TA:@X !%DF*B@CW
MK9@-"#W[&'7TZ^.]>&]>&]?'7Q^/C@6MM961F-=U+2U-K8>_NFWQ^.;T25&<
M\O1B) UB=G4Q.66)>YB;6Q,GV>;L9NR$Y1?=V@#K07+S0?7^WK^S@68R3QPI
MW1Q\U^92W]PTX[0,9CJ@ \+M,Z=N5N^T;8)1I:I^5I'=(:I[ "\@M42(?:$T
M&Q!>?,#_ )7T?V<"GG ^'7777COQU_9P/&L=VMO,0%+W!"A-=EX6MK*6*TZ8
MQR<QI52T#<W@.- ):O$B0G':)+T(S91(Q].T MZ#W:,!O]]K7Y=Z\?R>.!RU
MO6_AO6_R;ZX'@4J6PXX3,J/1&J5:%0>-K-.($H4-NAEI%1^T0A^::BT:I 4,
M?;L&A&:#O?46M;#SQY@88FP,D6B[0V1Z,QIH;6"/,#,B3-K.QL;.C);VEH:F
MY(64D0-S:@3EDD$E!"644 (0ZUK6M8'MVO0A6@;=K$FG$Q*:N+0;4$Z6F(B#
MB4YRP"78_/&E)/4%@$9H/8$8PZWOKO6MAZN[7UZ_/K ==:^.]:_9_+_8P,&@
M-;0"KFQQ9*[A\;A32\2.0R]W01IK1M*=VELM=#WJ3R9T D**VXO[^Z*!GJU9
MVQGG#WKN%O6M:T&;"UOK^EK7U>/3IX8%0[UKKU$'Z/WW]G Z!K4A83A&*4X
M)Q: H&(XH("![T 6@'"$/6BA[T,.^@NF_O:^O6!V&& " 9@QA**+"(9AA@M
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M-[=F!WV^'Q^&!Q"E3ZV/M**#L6_XW80A#LS>PZ!OSA!UU-V(&M:^]UZZU@5
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M336U(X>3ZM,WFF UL1(!A*%O6NH?# ]7RI!Y'I?0HO3>I$L]/Z<KR-K!*_F
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M7$1Y;\AYE9E32%ZLN;U)7,XH3CM#+ZY<GU-6 Y?%V)IN_G5''&<-,G!&Y#4
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MY7[BU"H6-=&8E"DO(=15;EQ+F<"?WAE:T;0RJ+ C45LQR\D;*F+Z-; H. 6
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MH$I<E46T_P L *5H-$-A:=-L"L,PY)\O>9NJAY;*R+@B41:I)6'NNL-:HXI
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MW2X9ZT0]324JOPRE*:F43F+Q1J-$UF6RW-;A(DZN7EQ5B;D9C2E5+PJG4 2
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MY!J-38+T:X-B%ZA4C,DIWI'HE62D6@4[WI6'6^N\# V/G!P*N#\2-B.[:6E
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M*JAXS3I\,'*-SQ^6+=/$+ ,V?:$#MZ$$"2*]*!$C!T$%Y:.8? F-1ENLMEY
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M=?\ ^-X_5T^CZ<"]8# 8# 8# 8# 8# 8# 8# 8# 8# 8&C.1XP%45>!PQ:
MNG;%WLS?P#K4*D_?O]@&_'[,#(J=#L%9UF#8>P8:U@^CP_#?>&--80Z%]>P^
M.L#:. P&!H;D/QPI;E%!TE>7C$0RR-MDA:IFQ&I'V1Q&31.7L CM,LOA<WAK
MO'YC"Y,V 6'%%KVQ<E4Z(4&E;'LLT8!!8:BXD\;:)D$:D]15+%H$^1"GFWC_
M !Q>P%.*<;;431*7*=(X6$DQ:<E5%"F3PK=5"LXLQQ5KE1IQYY@C!;V$E];U
MOX;Z_DP& P& P&! SE7[=]&<P)>DF5G.<]:W(-9/5/O (>YQQ$%^@+O(4DMT
MU^O?HM(WR(K$<E1 4"6QQ4RK'$C_  )P-5H>B;09'&>#U;16_2[]03:U3EJ"
MR+'MQAK=9(F4VLH]8=P08B!V;(6]M#&@2A2*4H$P5>DRQV5)&U:8>-"4F+4G
ME&!%UL]JUIF-@<F97?EUV=,HG<E^7+<%=5;$I"CC<.K!3:U$-= %S9 OW&?Q
MZ7;D>@I[PE1* /1K$ATL*.3H J"]F;#9M)^V)3%'RY#-66=VD^NR-_*DVTBC
M57P6/Z=":3E_'\L37'*<K.LV:+$:KN7"UL#.2@ZN:,E=U]28J&H"-*WV9:ZJ
M2OI&JXP2IR*NPILHUI@<CLT</8&UA0T%;:.TH.N2N]654V&I[00&"7IM31]:
M)>XN0EHQ/Z9]+$,H0;+H;VM&2,43+X'=UGSJ3V/;4(Y!0RT)5 I4I82PHN1%
M_27D!(3(\^C9FY^7O+.^R#2(:Y420B=DY9NE#8!.>)($-??^AY88;<U;3JF+
MCF59Q\MSY#R.XW&,,M1Q63NCY<=*5G2#.BK6'1FG$=.1&,I(U7X1+TP60HP*
ML!*Q.9I7LTP0;\<O:;XG.$26UZ!OG3;7J^P:MGYT+;)26E:"MU%Q@+XD1:)I
ME.FT3RGBYU5$A&LT%5Z\]TZJ-*0!WLK VEP[X)5[PV/FBR(RM\F"^6LL)B92
MMXA5-P?Y5$:^3NQ3 B-1TW6M;-TCDJ]0]J%#N^.1*IR<SM%=XP!)"' V _<3
MX.^AY>;_ !)-FI1S+CR&.V*N:G)N+61DA!42>F"5T",6-:PIF<=1=* _0CP*
MB@K]>=HO[P@B#3MY>W34EW?)4IDHF< 8C:<C7'"SH]#2HCILN#CY$7T$F8*P
MDH7R-/!T>(;'G:CR'%B$VKRT;DM3Z'VFE"(#5<X]K&E;P9.1\ OJ+1^91B?S
M^Z9C1,^*V=^L^F&[DTWQY\NJ/L:E2ETA0AW;3,I>T(M#4I5)"I.0H3]$F]&A
M)RG..R^)67R/G$M+9=Q^TFNJJ@@<&;CC')N9:(I2'/;)&TKXJ4HT U,@D\BG
MLC6*BNTT"5">E3:.-V4(>PA";[,M=+BD*>0<A;:F:&OX#3-8<?V.<0ZCY3$Z
M;A-$.4\-@K0JAR^L_P ,6[O4>LIW9UATK2N9IR-1HPL12LHI2 )K)N&4(2\?
M*JX]$2R3I&2K;#KRSDLG9V^'1=\>)3 [-2VP,[Y9$XTQ1*-)'N4$CUY+0W(2
MT"<P($FBME@WH-4<*/;<KOA1-IQ8$7L&3SJ2SVNX%63XK?(?5D2^8,U</$J=
MV*2R(ZN(3$UTVLIX.EZK;Y(WHY>YO!H2S31A$'?<'B1^WJ]?@*\*B?\ E-:,
MIJ:Z'ZWYKN'ND'J%,MB%@6M:BJXB9:W3!HAC?*'PR&3!5O2)&Y*%*0]"$"=0
M$P( ;"&PJ7X3IZTNM1R-FUM2FWKF?62>HY=(7MACT<8E[O.@U&U!5QR,L16B
M8JQ0^'4TVL[.W^>L,*(5+CU*I2J5G'##2L\]L@,VM*P[=UR$E2"72-2QKX4Y
M*Z\@;L[L1T<O>M>0D98[.D84[:_WS"(!+*S3M<6;'M04-@CBY6A*4F;&6>6&
M_>/G"R.T/.=62=9$WLF:FQRW&5R>I81'D.W9TNZ^':^;"E*MOC;4T-:=X=78
M;2U@ E(3I"6QB2@ 4'?=@1OY!>U# ;XDKQ-%=BID,LDTWN:0/SK,:7J6WTI$
M>NEKJ5C<6Z(L-BLCJQ1:;PEFI5D(8)+Z=6H( $X"M.M)& HL-R5=P-;JNY.
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M6*RHG,&^NJR?8U7IC%)>-0N/<,61ED?Y](W9KD#4)2I=G8TY8>4N <4C("F
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M,!@,"F]:W\<"NM=/#6 P/G_R4]RCC-Q4OJJ.-]FJ;%<;6MYN:W]B8X!73_.
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MHQ31\=$4:?)*%*%C7TPRQ]X-4-Z09HEA#RJ4CT$)1F]B#?> P& P& P& P&
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M@?J_;W_9P':'ZOV]X'+ IVZZ]>GC@5P./:'ZOV]X#L#]7[>_[. [ _5^WO\
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ME944:EJA6:M8_DD9DIBIK=BTOR!W.31N:-#B>F2JSE2="Z)%!I8"E!0Q!(7
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M2A4O=1U^V7!=U?&\KUE)T@XLK0YUV155JNT+B36-QF\+C(X+*U3"ZI'M$L(
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M5;#87+_D5:*OGA":2>KJ+JV*POEQP"15G0*=C9?G/(^"S=6X2^Q[93/Q:/\
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MO /U;ZZ^CZ-^.!TA3(@J#E84R8*I0420H4A(+TH/)3",$G)..T#S#2B!'#V
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MMA!W;Z:UUP/*2PL!)*1,0RM!)#>>0K0D%-J,LE$I3 $4F4I"@D! F/3ECV$
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MJ;16_.TH#0DI]RB\8+>W(!I#;U4RV/UO-.=<+>Z9;:O,?9M0,"XZ4>*WZTY
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M#Z.7)1S';M7MU5[<E,39&N9TO+D)S,C1F"3!I6TX+:+*RDI#P:2%-[FI@9"
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M/*8'A."X((I6V7P_MF])%$5#@[P&Q&>=M40LBMKV7I7,]$^Z?&60)2%J90L
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MJ"/3R5SEW<H18J")$1^JW]EBMGN,9FZN($P^?!KB22)$A?2V!<Y'-*I0$M4
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MJPUSAJTU[ GD[>4D(,-$<B$>6$L A;WK6M[T'K2WW1:Z#"LY%=%3JZU [FL
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M]GYJY'E60UK+]=&N+VHJY&J7^,2" E2]GBCIR"=8R\FSBN6U--(LSMEI0_\
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MF=OWNG=W=OCTZ>.!?,!@,!@,!@,!@,!@,!@,!@,!@,!@,",/,GIOBWR("/\
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M.<4J1E>9LI(I+,+$ ]*7LT7:6/6P![M]->.\"NFIN" !>D*+1984@"R])"-
M ! +N0  #0.T(4(O$G6O K?Z/3 H%H; DK$^F]!I.Y&*#7%/I$GT2X&JP:*5
M&+2M%^6K,5%!T$P1FA;&'73?76!T_AY@\EL3_(VCT[*8 YG(^6H_):32]="S
M6PKR>Q 87K]'96@;U]&!T@BL9*/?E14=82E4I$2*3J2V=O ?(Q)DH4*<3\:%
M/HQXV0A!HD&U&S.PK6@:Z!UTP/2!D:"R I2VQM E C"W 3 0)0IP-X-Z$!"
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M)+(,T(H 0Z#UN/$[C$[$ID[GQ]IQ>0DU)@D%+*ZBJ@&@S2"M%8R\ PFM@M'
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M^'_>"E&_W;JP./X/Y?A%KMN2A! U](J'EP!B_O+IV$/[>!V?A7F#_MQ4-O\
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M0T53WO%<H[1=&.7&0:F6F)O-?L90Z[52.!-DA*>EG"!/RJ7V<S >KK0W/)T
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MCXA #:78H0VR?BS*+, )Y<0[G$=OS@?R9Y&R*&"D)YCRW1M&R/%8)5+:JV
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M,!@,!@12YLBZ\5>18.F_&FIP1UU_]/,JI%W=/_6O4=WV].F!*W 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8%!:[M=/AXX%=>&M:^K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# Q_S"_P 2^7Y&_.^5]_J>Y+U\GSNWR.WN]5Y7F?>_1[>_Z<#(,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,")O. 00<3N1(M;Z"#54@V+>M>/EZ)WYFNNM=
M=Z[/H^W EE@,!@8//+#CU<,X7R0DR96C&O2-H2(C#)=/';U2[N]-H3'"61_>
M )Q=F^X[9&B0?OA:ZX&I!\K*M*Z><S7:3U^'G<;^0!?=K7AO8>ZMM==:W]6!
MU_ULZC_YAN+K]7]7>_.OY.GZM_HP.0>650[_ $R+9)^P^@+U)WO7UZT970=[
M#]OUX'#^MQ2__'[+U^6C+MU^[7V!Z"N5]-&@[PJK""'QZ^;2UR$BUV_'?:;
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M<E;T^J;[D#++JA.OB6--ZR9XC]>,R7CZ06EJ90A1R]TLIR>)0JV04L:$Z/O
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M>\OS_3=/+[P]_P"EU[NSKU[NSZ>G7M^S N6 P& P& P& P& P& P& P& P&
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M'.0L HJ_+6]&H>HT)T3/8X^Z'IBSUC08[HBB43D8@,,[!'$Z\HS>NH?# R?
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M9@ &<VM&!WZ+C#LG0M;WH2^VM&[#K]+6Q>G-#K>_HWVB_)@7'2KF5UZ;:.-
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M ,2OQP*;FW+4'0(>/]2F:Z^(OZPCQ\/J^_2^A8%?QQRU_P#)]J;_ .B$=?\
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M0XNI0U!?DZ4!)"$N,!@,!@,!@,!@,!@,!@,!@,!@,"&'%/\ V2^<'_G5F_\
MR#:6P-)>X_OEI#JDN2]:+Y0-U$M%)4RHG4*A*6HXE9)ELVS'G!S>!1"QE$K0
MN#P.(SA$G;8XT-<8VW.XW5S-4#5G=J=)L-=<\N8?(:KZ/K9OI1@CT=OEQ?\
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ME)7"Q).MH0WI.9+04JNRVVY793.P6<ZU4_UNIG)@ZP:+,21QC#/XC!3F9%L
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M_K\B>!+? 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8$.>*Q( SGFBHUU\P_ER^%C\?N]J:C*'"7VZZ>&_XS?7Z\"8V P& P& P& P
M& P& P& P& P& P*;UUUO7UZWK\^!"R:;V+G!Q[+W\!<>.4A@OHWW?C/C61^
M;MU^? F:EWO9!>]_'>M]?H_?;P._ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8%LZ[^;]O</IZ+S.WN^[_*]GP^KKX_EP+G@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@1&YP_P#!JM/_ .TS!_K]B.!+G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MZP*X# 8#KK7QWTP& ZZW\-]<!@.O7X8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8$,N(>]?B'F5X_I\R[!V'^VT765.%#WK^Y,!O6_MU@3-P& P& P& P& P& P
M& P& P& P&!Q%XA%K7QV'?[F!$5X\><=5[UXZWQ5Y$=.G^ZYQ:!_FRQ:_+K
MEWKX:_)K K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#'_ #U7XG]+_A'H
M_E'JNOE[]-Y_J/(\OSN[IW]OWNSM^WK]&!D& P& P& P& P& P& P& P& P&
M P&!$GFR#0^/,JW\.DTH\KX?'1EZ5GOKO\G3 EM@,!@-^&M[^K _/-RVY_\
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M%>>3L?W'H[-GTF247'%2!!(Y[&5+3&5B>2$1QQ<R$K@@0C4.J%4/R3TQ9H1
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M!Y"B=*&UN*5,2-P(WWK"D.S1%[[@$"WX8$-I'[>EU%\F>2UK1H",/'F\(/\
MU@V?CJ4Z1X*UE]PJ6U:_\?Y++%CDN4%,.X8@@SL&0K5!1NS%,E[%R<L:A(26
M:$=(GP2YBP&N>"JB6\98MR!*IWA&X<".0O'<CDR;5B Q"B7114@N>O)^U.*1
MAFT$G**.[;Y!'GQ"@7C1^1O28X1&@"#,+EX3\OH#%^6=6U)QTJVU8%RF]N2J
M>)\)_5G8,=KMKXWS>J(#9L#201OCMNO"-:OH=6?8^W5$H0+3W(I0G.\Y#WG
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MBC/-Y)'ZT'1(^7=\;ZZWO0A; LCZ;>Q!^G^-3"UU^K6L"9& P& P& P& P&
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M@,!@,!@,!@,!@,!@,!@,"''#<6MM?(4.NO4/+ODCO?Y S]0GUO\ 9$FWO]G
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M P& P&!;O//^8^1Z;?D=G=ZCN,[>OE]?AY7E]W=]WIW]>GC@7' 8# 8# 8#
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M2?H/Y#<9-"W].O+NZ(GZZ?1XB3:U^3>\"6V P& P& P& P& P& P& P& P&
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M@,!@,"*'+\6_P)6I>O@=R/X\E"^OM_6G'1[Z?4+[F!*_ 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8$0.%Z< :_M%1KN\P[E;R^V+
MKO[OAR2LL&N@>GATT# E_@,!@,!@,!@,!@,!@,!@,!@,!@,!@0N(U_\ ]#WC
M?_SF$:UO[/\ OY2KI^3KX_FP)HX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8'D],3ZOU/:+SNWM[O,,Z=O9T[>SN[.W[.G3KX_'QP/7@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@10Y9:WN*UAK_YYKC?T_P#"E'-[P)7X# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# B/PQ_V-[+_\ZSF!_P#I+V?@
M2XP& P& P& P& P& P& P& P& P&!07@$6_LW^Y@0S;-:W[@DIW]7#6ONGV;
M_7=9F]_GWK7YL"9N P& P& P& P& P& P& P& P& P& P& P& P&!U_Z9_D_
M@X'9@,!@,!@,!@,!@,!@,!@,!@,!@,!@13Y9=-1>J-:^(^3?''N#].]?K18.
MF]?3K6M Z_DUO E9@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,")/#0/97-EZWKIW<J^8(M:WUZ[UKDQ9X=[UU^.M"UTP);8#KK7Q
MWTP& P& P& P& P& P& P& P& P*"_1%U^'3?[F!#-LZ?^D#E/3X_P!3:OOS
M;NZS>[ F;@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@=7<'S>WKKNZ=>W
MKKKTZ?'I\>F!VX# 8# 8# 8# 8# 8# 8# 8# 8# 8$5.5P>K!4GC_P#-+<=-
M_FLIO^W[<"5> P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P(H</_O5[80OAV\H^8X>G]URCM/?Q_XG E?@<1![NGCTZ8'+7AK6OJP&
M P& P& P& P& P& P& P&!Q%XA%K^UW^Y@0R:M]?<&EVO^-<-*WWOZM^IO"U
M-!Z;^C8?3[_+UP)GX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%K\\SYM
MY'8?Y/I^[SNT/D^=\?([NWN_DOO_ !Z=?MP+I@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@13Y6[%\HI4 ?'1G*/CJ6:'IU[BM6"B,V$7U:UL/=^Q@2LP& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!%+A[_L<6!O\ A<HN
M88M_E_K16M@2MP& P& P& P& P& P& P& P& P&!3?PW^3>!"M@\P?/V8C'H
M0MAX85*$T6]?HG"NZY.X(NGP'W%"_9#O FK@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@>7L*]7YO7^.[/*Z>:/IY?3OZ>3W>7W=WCW=.O3 ]6 P& P&
MP& P& P& P& P& P& P&!$SE<=LELI'>@]WF<K..A'QZ=-&3I)K8OMZ:W\,"
M6> P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P(H</-
M_P#>YGVO_GH.8G[7*&U?[.!*_ 8# 8# 8# 8# 8# 8# 8# 8# 8# AI']?[_
M )L+7U<1*GWO?V_KSOC>]?GU@3+P& P& P& P& P& P& P& P& P& P& P&
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M^.:T'G=99>O@'B+1PNN_COONCD5X?L=N!,# 8# 8# 8# 8# 8# 8# 8# 8#
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M\[6WU\2^)-#$:U_: M[D0<'>_P"V[E OV.F!,; 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# Z_P#3/\G\' [,!@,!@,!@,!@,!@,!@,!@,!@,!@,"(_+7
M_E7CUO73_A94%U^W7XC7:P)<8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# AOP3_V!E0OH,O+E +7UZUOD;:'Q_O<"9& P& P& P&
M P& P& P& P& P& P&!#2*?\/NZ/C_P4N/OT[^FT>077]S F7@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@=?^F?Y/X.!V8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8$2N6G3T_'+73KHSEI1H1?D*=74\'Y.TP&MX$M<!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0VX)_P"P&+_=MY0?_I'VE@3)
MP& P& P& P& P& P& P& Z]?A@,!@,!@0VBNO]_W=.]?#7%3CYKK]'C:/(3?
M3\VL"9. P& P& P& P& P& P& P& P& P& P& P& P&!T]P?.[.X/?V]W9W:
M[^WIT[NSKW=O7PZ_#K@=V P& P& P& P& P& P& P& P& P&!$SEEKJ3QQ^S
MEG26_P S@[X$L\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@0[X,E;)H@PO>];V&ZN38^NM>&]&\B[.,UKQ^K0\"8F P& P& P& P
M& P& P&!3>NNNF #KMUT^/C@5P& P&!#:(!_W^5UF>'07%SC[KI]/W;,Y _'
M[/' F3@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6[TH/F7K>T/G>3Z;O
M[/O>GZ>;Y7?_  ?.^]^U@7' 8# 8# 8# 8# 8# 8# 8# 8# 8# BERJ#H97'
MC0@Z%H'*JE1A_M1?,'?6A?EU@2MP& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P&!#W@R9H=#"[A:V:*X^29GT:%LO?(:S.@^GQ[=ZZ=
M,"86 P& P& P& P& P& P& P& P& P.(][T >]>&]!%O7Y=:W@0WA0N[G;>^
MQ=/XGC/QS++WOIKM"=87((8]:^'Z0]:WX]<"96 P& P& P& P& P& P& P&
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M 8# 8# 8# 8# 8# 8# 8# 8$/N#@-ET*A+$'L%NR;X,V'Z]CO"?=1^'AUWO
MF#@,!@,!@,!@,!@,!@,!@,!@,!@,"F^FM;WOX:UX_DP(:P#KOG'?^A==]G'+
MC6'IOQ[=[E]\BWK7Y?COI@3+P& P& P& P& P& P& P& P& P& P& P& P&
MP.O_ $S_ "?P<#LP& P& P& P& P& P& P& P& P& P(I\G]=[GQF*WTT$?*
MBMC.[Z>I,9GZC6OAOXB2ZU^3>\"5F P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P(A\)-Z%0[2;\-GSV\C1!^@.QWE8FMAU]FO+U^?
M EY@,!@,!@,!@,!@,!@,!@,!@,!@,#B/] 7]R+]S>!#F!_\ #CY!?^;SQM_;
MEU[ZP)D8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'G[]^H[.GAU^/C_Q
MOK^3K@>C 8# 8# 8# 8# 8# 8# 8# 8# 8# BAR?\'KC!UW^GRGKK0?RAB%E
M;WU^KPP)7X# 8# 8# 8# X[%K6^F_#PZ]=^&OS_# Y8# 8# 8# 8# 8# 8#
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MB;MZ ^7_ "7KW>29W^M]9^CZCN\KL]/X]G3NZ^/7I@7[ 8# 8# 8# 8# 8#
M8# 8# 8# 8# BKR<UU?>+'V<I(9O_P#L6RL"56 P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P(;\$@;)XXQ<L?B+<XO3QUXZ\+VLK>
M_'?3?PW@3(P& P& P& P& P& P& P& P& P&!3?CK>OLP(AU\/1G-+D.(.M]
M 43QL)WUZ?I?B"\S_#IO?AV*-?LX$O<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,"U]3/F_3RP]OI/T_.W^AW]>OD]O3S/,\.O7]' NF P& P& P& P&
MP& P& P& P& P&!%7DYU^>\6.G_E20SK^3\"65@2JP& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P&!#C@Q][CS%Q!\0_CB]M]VO$/3=
MZ6/TWUUX>/7 F/@,!@,!@,!@,!@,!@,!@,!@,!@,!@0]KC_AH<C=?3JE.-VM
MZ^G6_FER^&_JW@3"P& P& P& P& P& P& P& P& P& P& P& P& P+3YY7SK
MR>\OS?1?R??_ !_;YG=YGE]?Y#Z.[I^GX8%VP& P& P& P& P& P& P& P&
MP& P(I\FS-:?^+!?3?47*2'^.O'IV0"R3-^'Q^&\"5F P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P(;\#-;#QIB&M[Z]\PNXWKXZ\
M#+PGXNG3?T^.!,C 8# 8# 8# 8# 8# 8# 8# 8# 8%-_#?Y,"&]8#T=S1Y*G
M!ZZT*E>,HNF_CKS5]T[U]G[S>!,G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# PWR1_CCSO.'U^3=OD^L#V>G\SI_RCW>?U]3X^9V^3]'7O\ # S+ 8#
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M_?+H3>N__I>G;>-[>GUB[>F!*C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8$-^!9FS^,D&,Z=O9(;?UO6O'KLZZ)^=OQ\.G;KP^W
M F1@,!@,!@,!@,!@,!@,!@,!@,!@,!@0ZK+7=S8Y5[Z:UHFI>+P-:^OS5%VC
MZ_9V^5@3%P& P& P& P& P& P& P& P& P& P& P& P& P/-Y>_5>;WBZ>7V
M>5TUV=?CYG7IW>9T\.OU8'IP& P& P& P& P& P& P& P& P& P(J<C1"#/N
M(VM;_E>2Q 0:Z_I;+HV\31A^S70&M[_)KZL"5> P& P& P& P& P& P& P&
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M[@B#_"#L/Y];U@0NIK?7FAS.UX:T&#\3M:_[G[9WU_;_ &L":> P& P& P&
MP& P& P& P& P& P& P& P& P&!XO/.];Y/EZ\CR^OF]3N[S>WN[>WR/)[>W
MZ?,Z]?#I@>W 8# 8# 8# 8# 8# 8# 8# 8# 8# BU?V]:MKA?U^&^0\K_/KB
MYR)Z?LZP)2X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# AOP#WW\2Z:,UOJ$QED1H-_6 Z=RHTO?V=0"UX?'6!,C 8# 8# 8# 8#
M8# 8# 8# 8# 8'$>M[ +6OCL(M:_+TWTP(<4Z'6N8G,H?37746XMD#W]/>7%
M[',[?R:T?KI]N]X$R<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"T>E4?
M-_5=QGI_)Z=/-/\ *[NSL[?(]3Y'F=?'O\KKT\.O7 N^ P& P& P& P& P&
MP& P& P& P&!%;D +_OM\+M?_/"S$7V_Q?%7D8;K7[.P],"5. P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P(:>W]O?]4.DM?_ (-.
MN_V?QC)\"9> P& P& P& P& P& P& P& P& P*;^&_R;_<P(<4[_ ,,+F=_:
ML7&'I_W&SOX_GP)D8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%F]:?\
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MEQ[_ -\9Q+,_XPYW:+8?X7F5D)-KI]&NW:KKX_5]N!*O 8# 8# 8# 8# 8#
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M?"<=R>XEDEZ&,H!7(!4H 'Q!K1-?,I!)QFM^'\6H6 "'Z=;'@2TP& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P+2_BT!B>A;WVZ"TN0
MMBW^]UI&=OK^QTP(T\(0:UQ(XU&;!K0S*0KXP(_AL11S"B.#O6OCVC 8$6OL
MWK E9@,!@,!@,!@,!@,!@,!@,!@,!@,!OX;Z?'Z,"&G', -<@N=@@!#_ +-U
M7EB%K73>Q%<9:9$,O?U^6:=O?Y1=<"9> P& P& P& P& P& P& P& P& P&
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M@,!@,!@,!@,!@,!@,!@,#&)H+>HA*^G3_M9?M^/V-:O?Y/HP-%\-0:*XH\9
M!Z] \=Z/!KKOK]W56Q0S7P^GN,W^Q@2;P& P& P& P& P& P& P& P& P& P
M(?\ & T1UF<Y-BUK7E<M2"@]/I"7Q<XS!Z[^/C@3 P& P& P& P& P& P& P
M& P& P& P& P& P& P+3U,^;]OE$^7Y/F>9VB\_KY?9W=W=V>3^]^'7K@7;
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MPUKKXX%CXP]"^/\ 0Y7Z =4=48"@"^/\5 &#0PZ^G>R]"#W?5UU@;^P& P&
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MU4UI3# Z\!;(#UZ^&!D6 P& P& P& P& P& P& P& P& P& P& P& P& P&
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M,=_BOQ+W>69Y_H/*\[^([?3]?-\KIU\_R_.^]W=/T_#X8&18# 8# 8# X[
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M_P KR>WN_2[>[S_L_1^W OF P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M?[O?^@P*=3/X(/YP7]'@.IG\$']^+^CP*]1_0$']_O7^<W@4ZF?P0?S@OZ/
M=3/X(/YP7]'@.IG\$'\X+^CP'4S^"#^<%_1X%>H_H"'^_P!_Z#>!3J9_!!_.
M"_H\!U,_@@_G!?T>!RUW?3K6OKZ;WO\ SNL"OC]'[O3_ "MX''>Q_0$.]?:/
M>O\ .;P*=3/X(/YP7]'@.IG\$'\X+^CP'4S^"#^<%_1X%=;'U^\$.M?8+>]_
MFV . WL7[W0=Z^T6]?N %@4ZF?P0?S@OZ/ =3/X(/YP7]'@.IG\$'\X+^CP.
M7WOIUKK_ '6]_P"=U@<>H_H"#^_W_1[P.7C]6OS[_L8%-]WT:#O\HMZ_<"+
MKOKT\-:WOZM[Z:_/TW@<>IG\$'\X+^CP*]1_2$']_O?^<U@.H^OZ(>GU]^^O
MYNS_ "\"N^O[W6M[^W>]?N!%@<>IG\$']_O^CP*]1_P0_P!]O_08%.IG\$']
M^+^CP'4S^"#^<%_1X%>H_H"'^_W_ *#>!3J9_!!_?B_H\#EKK].M:_)O>_\
M.ZP*;[NOAH/3Z]BWK?YNW?[N!7?7][K6]_;O>OW BP./4S^"#^<%_1X#J9_!
M!_."_H\!U,_@@_G!?T> ZF?P0?S@OZ/ KU'] 0_W^_\ 0;P*=3/X(/[\7]'@
M5ZC^@(?[_?\ H-X%.IG\$'\X+^CP'4S^"#^<%_1X#J9_!!_."_H\#EKN_?:U
MK\@MB_="' IO8_H"'>OM'O7[79O =1_2$/\ ?[_T&L#@/8^GB$/Q^@S?]'@8
AI_AGXNZ]7#T/R;]#H/Y5ZOS?CYO7M]3Y/T=G3[>N!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>tv526458_ex1-3img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ *4  0 !!0$! 0$
M       ( 00%!@<""0,* 0$                     $  ! P0! P("!08'
M" P)" L ! 4& 0(#!P@1$A,A%#$)05$B%19A<8$R4A>1H4*2,Y/3L<'1<B,D
MMACP@J+"TH,T1#=W*#AB0\.T)34F=B=38W-UM3:F1U?ALH1&5F9GIV@9$0$
M                    _]H # ,!  (1 Q$ /P#^_@
M
M                                        &%^\DOW]]T=UWO/N[[P\
M7COZ>#S>W\WEZ>/M[_L].O=U^CIZ@9H
M
M                             &,]JE^]/=>V3^Z\'9[GPX_<=G3IV>;M
M\G9T^CKT R8
M
M         ++K_GO^TZ?[GJ!>@
M
M                       L?^?=/I[.[I]/;V].O3ZNOI^<"^
M
M                                                !A_)3[Y\/BK_
M ,F]QY.Z_P"/3P^3]CLZ?8[?CW>H&8
M
M                            !@_"F^_^_MP>[]GY^O;E\WA_Y/W=W=XN
M[N].G[/Y?4#.
M
M           Q/N;OO?VOBIV>W\WGZ4_7Z=OM^GZ_=V_;[OU.GI^L!E@
M                 &,:WEJ?$B=>SN"1S0J\/G2K4.:Q2D4X>^['Y<"G%6[#
MFLIDLNMK6VM>EUM:?&E0,F
M                                          >*4N[OIZ=:_3_!Z >P
M            QG3#][?J8/=>TZ^3PW>X]IW]O9Y^G3L]QZ]O7I^3J!DP
M                  $*OEY(\:+AUH?%BNR76_A1VN[LU]<V6M<LN?L]];LU
M]*Y;^N7+==ZUKZW?5T FJ
M                                                       6';;]
MX^3I3O\ ;^#N_P#F^OFZ?G[P+\                      !#'Y>^6W/PZT
M3FLZ]F2*+JV]:=*_9DCW;=Z=:]/M4 F<
M
M      6?_/?^+_O 7@                      "$WR[ZW4X<Z#QTZ>.D'R
M9?A_XW/('G+FI6OY,EU?3Z/@!-D   =?X_@
M
M     "T[:>\Z]U>OC_5Z6]OPZ=.O7N[_ *?S 78
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MS&?7._V'033I/>>UEUC%!)1M6<:LBC7)8KI&-[5F;G =;/,U19'Y#,'[!(I
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MGX[9LE&J9[5;WC2X<JA$IR8[KTZ?+FL#Z%4KU]:>M*^M*T^D
M          !C>S)]Z=W3!X/;=>G97W'N.O;W]_P\?A^ST^L#)
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M*=:]U?2G_A>OYP%++*5ZTMI2O7KUIZ5ZU^-?T_2!6EEM/2EM*>O7]/IZ_G]
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M2O6EM<DO?\E;:?7TK?T F6
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MOPITZ=?I ]TNI7X5Z_P@5
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M7Z.Z;BDW6KT25*J1X4R9UL7X4/5)BLJ!]6
M
M%CYL7WA[?NKYO;>X[>E>GC[_ !=W=T[>O=]'7\H%\
M    AA\OJO\ V/M"_EB+G_I4]U]0)G@  #I_A =*?5_LK\?X0 "E*4^%.GY@
M
M                          "S_P">_P#%_5Z_#Z_B!>
M         (9_+\MI3A]HKT_4B:VEOK]%TD>K[OSU[J_H F8
M
M                     6?_ #S_ (O^\!>                       (8
M_+[KUX?Z'K]<1<Z_PRM[ F<
M                                                         8SW
M./[T]OX5'D\/3S>+/[?IT\O;Y.SP=>GT]W7KZ 9,
M  !"KY>WE_U0="TR4NI;= Z9K:UMZ4NN4OCMGR7VW=*=U,EU_=]7KZ>@$U0
M
M                                #'=4?WCV=<'OO%Y>G=@]QX.WQ]W9
MW>X\7=Z=>G;U R(                      "&_R_Z?]CGCO7Z];M_I_P#O
MJW_ !,@
M                                         POW?3[[^\NF+O\ ![?K
MTKY/%X^O;UZ=/Z3U_,!F@                      $.?E__P#<WX[?]6[?
M_P"?+0)C
M                                          %EY+??>+OM[O'W=G=3
MN^'Q[>O7X 7H                      "'7 &G3AOQV_ZN$'_GJRO]\"8H
M
M                                 !B/97?>WO?=9NWL[/:],?B_H>SK
MW=ODZ=?M=.OZP&7                       0Y^7[_ -S/CGUK6M:ZN8KJ
MUKZUK6[*NK=7\]:_$"8P
M                                                     !@NN/[]
M[?*L\OA[O%_EO:=OB[>G])X>O\KIV]>X#.@                      (;?
M+ZNK=PRXWUK_ "M3QG)7_&R56W7?HZ_ "9(
M
M        !8>"WW_G[;>OCZ=>E.O?V=._K\>OC^S]73Z.OJ!?@
M           (:_+WNI_J6\;[?Y5VKV7/3_Z)1G6WXJ=?KI;\:?0!,H
M
M                            UGQU_%'?UQ>/V7=T\W^5]QV=G;[?LZ]?
M!Z]_7IV^GQ V8                      !#'Y?/6WAEQFI6G3OT_&*W=:5
M^-+,UUO3\E?)6OY: 3.
M                                                     ,?_ )/[
MSZ]<?D]KTZ?8\G;W]?UNG=V_^#^D#(                       (A<!K>S
MACQCLKZU_<K!KJU^CI>U8[K:?7Z=0)>@
M
M     &M=%_XHZ^YM^[?8=/:=*=?<].OG[^_]CT[.WNZ>OP V4
M           !$3@5_P!S;C)_U)0+^)GQ=?X )=@
M
M            & \7_M'YNF/L]AV^/I;Y?<=W_+/Z3]3P?Y'N[>[Z/@!GP
M                   $0N!?V.&_&"VM>M;M(02_K\.G5E29.G3\GDZ?H EZ
M
M                                  8KQ5^]?/\ 8_H?%^I3N[.SO_6^
M/=Y/T=/0#*@                      (A\"NEW#/BY?\:_N,U[UN^/Z\=;
MKJ?SJ 2\
M                                          ->[%GXC\GD4>R]GX_%
MTQ>V\W3O\O\ 1>;OZ?9[N_M^CIU V$                      !#_@'7_L
M7<7?^HK6W^B[9_A F
M                                                    6G?7W?;T
M_D_'Z>G9UZ?P@78                     'X*:W43**VUK2ZF#+6VM*]*T
MN\=W2M*_16E0(A\ +[:\+.+-*W=;[M%:\RTIZ^N*]B2>*[\W;TI2G7K2@$PP
M
M                                 #"=%_WWU\/^8^+IY?/CZ=WA_P#D
M._R=_D].O;\ ,V                     !:K[ZXD*S)3I6N-(HOI2O7IUL
MPWW4Z]/7IZ 1*X#I[,/#+BO6VZ^M;= ZTP]+NG3I;'$-U:^E*?:[KJ_H E^
M
M                                 8[O4_>?C\=OM?!W>7ID\GF^'3KT
M\?C[?R]>H&1                      LG*M*-R^M?A1$JK7\W@R 15X'5I
M7AEQ9Z?_ *!M:T_32,MU*_Q@2W
M
M,=WJ/O'L\-?;^+N\_DQ=O=V]/'X>_P W=U]>[ITZ>@&1
M      L72M*-CC6M>E*(5=:UKZ4I2B?)UK6H$5N!U.G#/BW3ZM!ZON_3DBZ&
MZ_\ CI3\P$MP
M                                             # >[S?B#V7==XO;
M>XZ>*G;V]G9V^7L^/D]?UNOT? #/@                     8B0?\ J%[_
M /JAR_\ ,LP$9."E.G#?BY_U"ZS_ -%VT"60
M
M #Q6VO=U].G6G\0'L      &-Z5^\/CZ=_=TZU^'MNW^'J!D@
M          ,+)+JVQU_NI7I6UE=;J5]/2M$.>O7U]/0",7 RZZ_A?Q7R7UK6
MZ[0.KJW7=/C?=%&VZ[X=*4K7KUZ?0!+<
M
M      U[WN7\1^P]IG\'M/<^^[\/M_+V]GM>SKY_-V_:^'3I]/T ;"
M               !K\MO\<5DV3IW>./O-_2GIU[&U3=TZ_1UZ 1MX+8ZI>'G
M&)#6[OJFT1K"E<E*=M+O_8]GI2M+*]:V^O7Z:@2R
M
M              ,/Y*?>WB_)Y.[UZ=WM^WQ?#IW]OVNG7KV@9@
M           #69KU_!TM[>O=^&7[MZ?'K]U*NG3\O4".W!ZM:\2>-E+Z5IDM
MT'J3OI7]:V^Z&MWD[O\ PJW6^OY0)7@
M
M    &#]OD^^_<?8\79\/%B[^_P!OV=WD\GEZ]/3KV_#T S@
M        &M3.O;#Y7=\>V-/M?X&M54"/?":REO%3CQTKU_\ @?JS'_5Q!MK2
MOZ?)_$!*D
M                                           P/O<GXA]CX<?A]GY_
M/[C_ "ODZ=/'[?Q?T?;_ "N_KU^@#/                      :M..OX*F
M'3X_A:0=/S_=*L#A7#&VEO%?CS2E*4_^">L/2E*4_P#X-:*_1^<"3P
M
M                           !9>/%[WR=EOEZ=.[M^U_1].O7Z^WT_,!>
M@                     :K.[NV$3*[]F*R&[^!H65 X7PSNZ\6N.M.GZVB
M]4Y:_DNRPADOK2GY*5O D\
M                                                        8;W&
M;[[]KT3^/VWN.GFI[GMZ>/R^'X^'R?9Z_7](&9
MTG95],>N9_?7K2ED)E5]:T^-*6L2^M>GY?0#C?#C%DIQ9XX9;J4[;]#:HI3I
M]=(4R4K3I]'ZH$F@
M                                                 #'^;']X^#_*
M^;P>3KX<OB\?7IT\_C\/?W>O;W=>GKT R                      &B[1_
MZ,]B_P#N)+O]'W #E/#NE*<3^-5*?_H(U3_H2S 20
M
M               ,1UR_?'3Q8?%X.OD\&+S_ *OZWG]QY/%W?9Z>/KU^GH!E
MP                     -#VG=VZQV-=7X6P.7W5Z?DC[A4#EG#ZRN+BEQJ
MQ7=*W4T/JBM:T^'K"&2[Z>E?A>!(\
M
M   Q'OK/O?V/BR>7Q>3R=O\ D_%X^[KW_#]?[/3X]?R 9<
M       #0-L5Z:MV57KTZ0"95ZU^CI'7'U YIQ&ITXN<<*5ITNMT+J#I2OI6
MG=K^/77^E?7^DZ_FKZ 2*
M                                                       ,7[1/
M][>\[*^X]OX/)Y,O3Q_K=OB[_#W?E[>[I]/0#*
M<[V_=V:FVA?TZ]FNYM=T^'7MC3G7IU_+T Y[Q.I7_5DXXW=>O70FI/\ =05A
MR4I^BE_3] $A@
M                                              ##>]3??7L/<8O=
M^'W/MNMWF\/C[/+V]G;V=WI^L!F0                     .;[D_Z(=J]/
MC^[><_Z,.@&@\3:UKQAXWUZ=.N@=/5Z?'U_=]'.[U_.!(8
M
M                    POA0_?GF[,?WC[3M\G97R^UZ_J=_3M[._P!>G7]
M&:                      YON7TU!M6OU:WG/^C#H!H/$RO7C!QN_Z@=/U
M_G:^CM0)#
M                                           &M]:_B7L^[<?7V?E^
M\^ZWN\?;X_!X_-Y?+Y/Y?C[.ST[N[T V0                     #F&[:U
MMTQMRZE:TK36$^K2M/2M*TBCM7K2M/7K0#1^+%:4XZ<<[+:]N.O'_45V.RE.
MEO;; 8W3K2VG3ITZT D.
M                                                      83S)/O
MSVO?B]]X?>^+NIYO:>+VOG[/CX_-]CK]8&;                      Y;O
M*M;=*;@NI\;=6[ K3K\.M(F[UIU T_BWAMIQVX^]*W?YIH?4*6SKT^U9?K^.
M7UNO]/UJ5LI\.E )!
M                                                   &*]DG^]O>
M]MWN/;=G=WW].W]7IV]>G;T_D_#N]?CZ@94                     #E.]
MJ_\ P1W';]-=5;#_ -$7@#6.+=.G'/05*_&S1FGK;ORU_=\P>M*_2!WT
M
M                              Q_EP?>/B[:>X\77N[*]?'TZ_TG3MZ_
M1TZ]>@&0                      Y-OFM;=([BK3X_NIV+_%#WFM/XP-?X
MP4Z<=]#TZ=/_ ((:A_BU^PT_B [R
M
M  8OV"?[T]]US>?M[>GGO\/3P]G7P]>SKV_Q^OQ R@
M   ')=\W4LTCN.ZOPIJC8O\ N8>\W5_BH!AN-5O30.CJ]?\ \F=64Z?F@,:
M[F
M           "VL4TOR5Q^++3I6M.ZMM.WT]>O7K\*@7(
M      #"?YM]^]?'D]S[7Q^7M3^+L[?)X^_O\_=T]>G3I^CU S8
M            '&^05U]-%[NK;U_R>G=DY+/3KTR_@Y[I3Z/6O3Z*@6?&S_N_
MZ-]?_P FM6U__ 4;_P  '<
M                                                        #']R
M?[PZ>3#[CL\?9WV>7]3R?J?K=W9Z]?CV_D R                      '(
M-_?]!6[_ /JBV-_H:]@8GC3_ - .C/\ J6U7_H%&P.Z@
M
M                 &"]IE^_O>>:SP^U\7@\5>_R]O\ 2^;R]O;V>G;V=>OT
M_0!G0                     .1[][?W&;HZ].W]TVQO)_B_@UZ_6^GH!AN
M-/\ T!:-^K]R^J^GYOP#&P.Z@
M                                                          %A
MU_S[ITK\?CVW=.GAZ_K=O;\?R@7X                     '(]]6>31^Z<
M77M\VI=B6=W[/6'O5O7I]/3J!AN-/_0%HVGU:7U73_\  ,; [J
M
M                        8/[KO^_OO;WRCQ^S]K]W_9]OW_K>X_4[_)V^
MGZW3\@&<                      X]R R>/1>[Z]U:76:@V/DMKZ];:6PY
M[^U2M/A6E:?G QG&FG306C:5^/[E]5]?S_@*-@=T
M
M              ,1Y:?>WA\UG7Q]_A\OV_Z+IW>+IU^'\7J!EP
M           .,<B?LZ$WIEI^M;IC9O2E?A]F&/=U/JK\0++C7ZZ#T;7_ /LO
MJS_0*-@=T                                               #Q==
M6E>E.GP ]@                                            %C[7%[
M[W72[R]G;U[J]G3L[>G;\.O3Z?B!?                      <>Y!76X]#
M;QOO];+=/[)ONI\?LV0Q[K=Z>GQH!CN-5:?ZO^C:?3^YG5E?T?@&-4_O =R
M
M                                 ,%[91]_^Z_RWM_;>+IYZ^'KV=?)
MX/+V_K?9Z]G7K]/0#.@                     <1Y(Y;K./^].WIZZ9VIW
M=:=>G9!'S);^;[0'GC9;2F@-&5I\?W,ZMI^BD"C@'<
M
M                "R_Y]W=EO7Q>+O\ 7N[.GD[?J_7]0+T
M        #A?)7[''CD)=]%=)[4KZ?&G9 7WJ!^O&S_N_Z,_ZFM7?Z!1L#MX
M
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M!RFW3^2#XMG5:L](5DV5A?E$#L?.MGMKI3AB^=-(,K52WN[Z),EF:M>G2OQ
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MF?'6E.N2VD(=O2G7K3KZ>G4"XXZ8_'HW3-*UZULT[JS#^>N.$,U:W4]?A7N
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M4M8I=*(TUNT!Y&L/(6,0.QEDFQ'[83EKM@O8,$>27.$H7/-&W'9ERJ\F:E:
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M6]PQ5OO#F\M^8!R+X[<OFSB[I.?NNVHAJ!5/.-L?T'/V?6?XVDN+2O"5QV)
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MLO\ ZF=EF5O3953DSV^3-XVI;GONR)[>^_IBNI]JO7J!M(
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M+J5_=Y*ZTZ5^CU V_1E*4U%JVVE*4I36>OO2GI2E/P<QTM]*?13I7H!UH
M          %*5I7X 5                  "M*5ITKZTJ!2E*4^%*4_-0"H
M                                                         # ]
M73\0]GM</W1[+R>[\F3S>Z_4\/B[/%V]OKU[NOY/I SP
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MJ57*V5O;[&'(XYG!MPW7WX+VVR4-M5..M?*GHOP>2VWRV=0[>
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M&]/Q/:YOB2%*)&U;H8N0L)@<F4Q%DJFQ9VVVR_%?D5XT*:F/,')=;\2^5;+
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ME:_2'5
M Q7M<OWK[KRU\7B[/%W^G]'V_J>+X=WK^O\ '^ #*@
M   1QY9Y+L?&OD/?;TZV:*VSEIUIUI2ZS7\DI;U_\'[=0-XTM_T8ZZ_ZMM??
MP?A5M_OU ZL          4[:=>O3U 5I2OQ KT].GT? "E*4I\ *=MOU?QU
M=EOU?QU =MOU?QU_P@.VWZOXZ_X0*UI2OQ K2G3TH!2M*5^(%?AZ4  >>VWZ
MOXZ@5I2E/@ K2E?B!3LM^K^.O^$!V6_5_'7_  @.RWZOXZ_X0';;]7\=?\(#
MLM^K^.O^$!V6_5_'7Z?C_"!7I3IT^@"VS(\&?^DLI=6E*=M;J4OI;6EW=2ZE
ME]+L??2OPK6G6G7TZ 5QI,.*^W)92ZVMF/Q66TNNMQVX_L]*=EM:6WUIV^E;
MJ5NI3Z0+D
M   ,#[Q7^(/9]4WLO9=_ZM_NO<?'IW^7Q^/L^CLZ_E SP
M      $;>6U.O&CDG3Z^/6W_ .'\#O70#?=,4[-7ZQI7^7K" 4IT^CQ1EO[N
MOP^/DIT ZJ
M                                            :_Y*?B;Q=<'?]T]?
M'TM]QXO/_3=>[N\/D^QTZ?K ;                      !&WEMUIQJY(=*
M5KUX\[BZTI3KUK2#/=:4_/UZ?G W[3/7]V6M;;OY&M(%3%U]/2L8;?)6GP[O
M6E/S =4
M                                         ,']C[__ .47>3V/_)O!
M?_1]W])Y_P!7P]W\GX=_Y0,X                     !&_EI]GC5R/NZ]/
M^S_MRG\,*>*?']('0=1XZVZ\UO;UI7PZVA6/TIZ5ZQYLIUI]5/L?Q@=/
M
M                              ,']K[_ .[OKV?=_A\73#_2>3R^;N[O
M/^I]GMZ=/I_*!G                      (W\MJ5NXT\C+;:=:W:#VQ;2G
M3KUK6%N]*4_/6H'1M5VW6P2!6]*VVV:]AEM:>GV?_0*&E*5_+3MJ!TH
M
M                             USQ9_Q/[GQ*?%]W>R\G=;[;L[O=]WC\
MO7R>7[/?V]?H^'J!L8                     $;.6^;P<9^2&?M[O;:"VO
MFI3KTI=V0MXOK2OIZ?J@=2UC_P#<>%?^XD,_^PTX'00
M
M                #"_>%/OK[N^QW^'S_K5[_%XNG7ITZ=?)Z?5T^GKZ 9H
M                    "-W+:F.G&CD9?EZ>&W0VU:Y^M.MM<-(8\5O[Z=*U
MNLI92O6@'4=9?_<B%_\ N+#?_L1.!T
M
M     QWM\7WE[KPXO-XO#[CQV>;Q]O=XO+T\GC[O7MZ].OJ!D0
M           (R\P+^G%_DU;\?^SUMVO2O7_^1GFGYOY0'6=9>L(A=?\ ^A(;
M_P#8:<#H(
M                                          !A/O1/]^_='7)[GVGO
M.G@N\7AZ=G7W'?V]W?\ 1V]0,V                     !&#F)6F/BYR=S
M7UZ8[./FVK;J_&O6Z$._3I3Z>O0#L&M*5MA4-MK\;8-#J5_/1EP4_NT W\
M
M                                Q/?@^]_'VV>Y]OY>[LL\GAZ=GZ_]
M)V=_T?#J!E@                     (L\TK_'Q1Y/4Z=:7\>=OY*]>OZV&
M"/M]/IZ=*^.@':=<V](A%*]*^D/BV.GQ];<;.EI;\?IKU WT
M
M                      QWLL'WC[SOO\_;^IY;^SIX_%_1]>WM[?7ITZ=?
M7X@9$                     "*O-S)2SB/R@NKU]./6X;?3X]:0%^RU^FG
M\BVOZ0.ZP'K^$XKU^F*1ZOZ/NI%T_,!NH
M
M      !9]/\ /?\ B^O^YZ?W +P                     ")_.:O;P]Y0W
M4KTN_P!7S<M>OQ^&N))T]/S] .^P.E:12+VW4K2ZV*QZVM*^E:=&I'2ZE:5]
M:5I=0#<P
M                                         "UZ?YUUZ?R>G7_:]>@%
MT                     !$OG17_L?<IK?_ /7?<'7],#?:?W )%1'_ -1L
M7_NZS?\ F"<#:@
M                                               "Q\N3W_B\67Q>
M'KY__%^3X^'M[>O7M^UW=>G7T O@                     (C<[[JV\/.4
ME:5Z5_U>=N]:_3V_@=[MK_= DI&;>UK:J6V=N*QE:[,=?C;VVHD_2E*_DMK0
M#90
M                                    "Q[;??\ ?]KO\?C_ %Z]O9V]
M_3Q]>WN[OIZ=0+X                     "(//2ZN/AORGS].M,?'O;EG;
M\.O="'F_KU^-/U:T E(P8_"U(,'7KX4#=B[OAW>-O26]W3UZ=P&:
M
M                          ,7VV?>W=UP?\F_5]//[C]OIV=W;[?TZ]W3
MZ.@&4                      A_P ]_P#N9\IZ?7H/:M.GU]80\>GYJTJ!
M*YJI2Q BQU],EJ%%WTK^MU]O9;ZU^FO6SI^@#)
M
M            %AX\?WAY>RWR^'Q^3I3N\?ZWCZ_L]WK^<"_
M         B'SQLI?P[Y/XZUK2W)H;9U*UI\:>2*.2>O3KZ>EN2M:?E EFGQ4
MP]ME*UKX\.+#2M?C6F&G;2ZOI\;NOJ!<@
M
M      %EU_SW_:=/]QU O0                     (><^\EN'AIRARWW5M
MMLT1L>M:TZ]?6/+;;?A]%;KJ 3!I;6EU:_7U_N@>@
M
M              "R[J>]Z=:=>WLZ?3U[._\ _9 O0
M  (6?,*RW6\*^573I]G14ZMIU^K,U9L=U/RUK2[T_*!-,
M
M                    6'3_ #_KU_D=OY.WL[NG3X=>[Z?C] %^
M             !#7Y@EO7AAR:^'_ $1R#]-:6]?7ZZ>@$R@
M
M                     !9_\]_XO^\!>                      0[Y]T
MI?PZY'X[OU,VKW3!=3]JF?/BPW6TKZ>MU,G3Z_6@$Q
M
M                 !9=:>^[>M.[Q=W;UIW=OP[NWX]O7TZ_#J!>@  "OI2M
M?J \VW=W7TZ= /0               "''/RO_8]Y!TI]$"SUZ_E^]&GH!,<
M
M                                  6?CP>]\_BI[GP>W\O\KP]WF[>G
M[/?]/U@7@    =*4^%.@                !#GG[3IP\Y UKTIW0/-92M?I
MNO=6FVRW\]UU>E/R@3&
M                                                      %G_P ]
M_P"+_O 7@                     $,^?\ EZ\0M^I^VGI"T->ZM?CYY*U8
MNG3X?9[>OY>H$S/_ -8
M                                  4NKVTZ_'U 4KUIU J
M        6?\ SW_B_P"\!>                      0SYY]O\ JK[SMRTI
M6S/#&O#9;=ZVY,N26,V'%;T]>M:Y<]M*?EJ!,P
M                                                     '3K\0
M                 PONKOOSV??9T]IY^SV^3N[?U/\ E'?X_P!;U_5Z=/3K
MU] ,T                     !#;GM92[BMN*O7UJP,&/I^2Z=Q3K7X?$"9
M(
M                                    P_W?@^^_O7QV>[]E]W^?MKW^
MS[_<^#KUZ=ON/M_6!F                      (;<]O^ZIN'_ZFC?^GL2
MF2
M                                     ,?V9/O+R=?\GX>WI_*[OCT^
M/;X>G^V[_P @&0                      AUSRMI=Q9VY97X7LT>ZT_P 6
M>P_X5_-<!,2G]^O\5>@%0
M                                                      "P[[?O
M'Q>6SO\ ;^7P?^,[.[L\W7IT[>[[/3](%^                     !#+GU
MGL3<6-MYLG=VVM$:MKV6]UW7/L2%8;*]/3K3O^/Y )F4^'Z:_P!VH%0
M
M                            "TZU]Y\+OZ/L_7KV]O3OZ]G3IW=WIU^H
M"[                      A5\P"RW)Q7VYCN]:5:H?3I2OK6O[S856VGIZ
M]:UZ?G FI3X?IK_=J!4
M                                                     LO+A]_X
M/)B\_@\OB[_\OV=W;W^+K_0]?3NZ?K>@%Z                     !"?Y@
M%?:\6MJ++JUNLORZR3TLI\>Y3MZ I[;O7TZ6W7=:^GP FP
M
M                     -1\5?QCY_-E[ONWP^'W%?#[?IY/^3=.[O\ /Z]W
M]'^7O] -N                      A/\PNVZ_B9L^EM*W5JXZGI2E/6M:_
MOHU]Z4I]/P FP
M                                                ,#V9?Q#W^##[
M?V/_ "C[/N/<]W3Q=?'W^'P^OZ_ZWT?2!G@                     (;<^
M\7?Q6V-2E?6]XU/9^2G3<NOJ_P!\"9-/3^&O\=>H
M
M               L^[_/>G6_^B[.WNIX_P!OO[?CY/HZ_4!>
M          0QY_77TXK[&I9==2^][U!APTI7XY\^ZM=X<5MOT4NR9,E*?I F
M;3^_7^[4"H
M                                           !A.J[[\Z>')['P]/+
MY$WB[_%UZ^/K[GO[OL_5T]?@!FP                     (8<_:=>+LX_]
M[]&?I_\ CYJ_TK_ !,\
M                                                      8#[U_]
MH?N?Q7]WLO>>;Q*O'X_U.SS^#VOE[_Y'D[NWU_(!GP
M   (6\^J79N-$P3XO7+=-./UG;UI2E?<<BM78[*=:^E.O;7X@32
M
M                          &(]M?]\>Y[J]O@Z=O?G[?U>SM\?N/!W]?7
MN\?7IZ?E RX                     $,^>-E+>.LAN]:U4;!XZX;_R66<E
M-1V4K;Z>EW15=_ !,P
M                                                     :_]X9/Q
M']U]<79['WOZW^6[?Z'IV=/U>_U[NOY.GT@;       #\5&.[)BOLLK2EU:>
ME:_"E0/>*VMF/';=7K=;99;=6GPK6EM*5K3]('L            (?<YO7C^X
MV?3^]3C-7U^'2O)_3M.G\0$P0
M                                                           !
M8]?\^Z=/HZ=?I_H^O3K]7]\"^                      AOSIONLX_.5].
MO6NWN+6"ST_6IFY1Z;IDI3K3[5>VM:_72E*@3(
M
M             &N>_K^)?NWVRGI[/W?N^['[7]7Q^'M\/?Y/I_7 V,
M               "&O/"O30*?I\?WY\6_7\_)757^ "90
M
M                    Q7FM^]O!TKW>+R]?M]OZG;TZ]O9W]/HZ]>GJ!E0
M                    (7\\;JW:,9L-OK;GY!<5\.6VE.M;\=W)'5EU;*_3
M2E>O7T]?0":
M                                               USV^;\1>;MP^#
MQ]W=[>SR>7VWBZ^?W/D[NWT_HNG;Z=0-C                      ACSEI
MW:?C>'KT\W(GBG;2[Z+>O(K6V3UI\:]?:]/]L!,X
M
M               8+W__ *?^[?:4[?9^Y]WYK/U_U/'[?L\G7L_E=W;^3J!G
M0                     (:\W[+LFIXE993NONY'<5^VWK2G7IOZ 74]:UI
M\*VUK^@"90
M                                             QG@M^]?+X[>GM^_
MS>:_O\W]%XO!U[?'X?7K^T!DP                     (@<T:==90S\G(W
MBU7_ /SW!0)?@
M                                               #7_O+'^(/NW_)
M^3V_D_I*^3KXN_M\7CZ=O9Z]>[] &P                      0\YI9+?W
M<P5/2O7,HY(\6,>*WT^U?=OB&9+:5KUZ6TK8GOKUK]0$PP
M
M                    !C.Y/]Z^/MI[GP>3N\.3KV=.SIY_'X_]KW=?R 9,
M                     "&O-3[$&U5=3UNS\J.*R:__ .CMW7%<M.E/VNZ^
MOJ!,H
M                                        8CNS??';X<?B\']-X[O-
M^IUZ^3O[?%W?9^'Q] ,N                     !#?FODMMA&F:5Z^O+?B
MK9\/IOW1%.G7\@$R
M                                                   !B/=X_O?V
MGCR>7Q=>[IC[.SQ]_=U\G?V]?L_#KW?D]0,N                     !#+
MFE2F6-Z(37TZX5',#BQ3+2GI=6W%M=G56]MU/6VOE2V?HI6GT@3-
M
M                           &K],/XL\G6SO^[?;]OGR^3S=?/W>#KX>G
MM_3K^M^@#:                      (8\SLEMC+Q_I6E:UOYB<6L=.GT5O
MV<AZ7?EI3H!,X
M                                                :[Y,7XE[//\
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ML=M:]+K_  3U-GMK;3XUICR6]U>GPZ 3.
M                                                       "G6E/
MC6@%>O3X@4ZT^NG\(%0        &$\:?\0>;ML]U]W>+R>O?[?R]_B[>_P"/
ME^UW].G3[/Q S8      /B5\TJ&;/DFS]7JXS"-[317CU5+6OB^X:<PS-0S:
MUYJ+-BZ\SP?8.QU,/6HFN(LC=!TZ^OWY*:WQU,V8G--?7RJJ)U8:U'N!L>:8
M-\S2=ZPCNW^.SML5)L+3^KF?6<CE[9,W&!ZOCZIY<9/&%<B42A5]\;\VRN<J
MVN37AQ++8Y@;DS;F2YJ9,UP<_<8\KE7+/A,Q9&/ESKW8FO-;<5Y#-=X+H_R)
M<M5-R)'#U.%VXV:PC\4B[KJA([;.<5U+MG/LSR84#:V8L6"N7*MMP4;P[XD3
M;[X\_+^^8ZO8'C;$OVK#M@\P9)KF<[.6?^WKZV7-]JUJV WK:,S.S*$C2BO4
M+6JQM0)VNVQ%CP)<-F*RVV@0AWC%I1?NW9R3ANX\QHJX:NX[2Q-'=@8K.1,G
MCO(:Y1QJC<1A^F>.>?-'5''I#KN"0QEK*T,K6K;WY\V1DQX&?+E\V?/>$@H#
M ]B9==:^>M7/7+6&:-BWS2-7K=,:UG-=EH)%*=!.[QI9KDBK8:3:[:NWUAU7
M')UBFR]O0/*U"FN3JO<K,69'B0VX@UG=D<V#"HUM"/[LV-RIG_'1%\S?W?(R
M;L5=L7;:==#N_#6%R&(-$/3\=8\RRM#J%%R.<&AMS)(HAP),&+%XL]:THX9;
M@BU"6[=-FUH^]\AWC?RV7+>']&3;'[Q8QR4U^MT#I^-<-7N0Y^2+=N6-3]/Q
MCDLXKM*]$U.J!PCU\S32E2JRV9\7W?9=4/Z4.+THV!-^-7'R9;8:<K%M&6:3
MU;)-C,V>WLSMDX>X0R.4I1Y\7BP5P9\#VISVWXZV6UQW4K;6G6@'=0   !J\
MBBC1)JM57=O0.7W,_,\C;+5Z>JBB!W8LUZIL<4?V[/"N1JKN^R_UZ?5\ -H
M
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M1"\L#ZWI79F=D6:M*YDCBV+L6=&M2YNVG=CR6767?30#.
M
M           -34P:)K)NS['4L:+-.&"+R&%L\COMOJX-\6ECK&GN1LB>OD\-
MJ-X=H>UY\WV.^MZ+'TNI2E:5"*.U?EY<2]KN^P9DX:ABT:VIL6/[#8W3;\2:
M6QOG[<HVC!%^MYG(&Q2N1N3%D?7R).%Z57D5H%6)=9;915CS4MH!R+1'RD^&
M>G-9MFO)/K",[W6(]ER3;RN9;:AD$5.RN>2M/%D;NK2LL6C4;BC0PY4D':+*
M-2=#:AOO;\6;+9ESTKEJ$RIOQNT/LG9,'W%/-3065;2UK<BN@L]>8^B62:-5
M;%ZAV::('.^SS78V9W69EB*S+Y+42O-DS8*8\M]U]0P\\XG<;-H;(:MP;!TE
MKF7;/8VJQD:YR^1I"MD25KPIGI&D357WV=ZBK8GD:^U%DR]^5#[S-5/=CNON
MK4-&F7 ;ASL*"H=:3;CUKB209LE"N9((\XM.:Y,DD3C&TL.=%J?/B5XEV/ [
MQ)#@;%B6F7V:M!ALP9L5^.VEH&YP?B3QKUOLM=N2"Z3UW%-IN;>K;'">,T=1
MI9*K2N:=G2O%^1PMI6^U<^X(\AM<%=M**G"B7'[C)EK;0#,:YXT:%U%/MC;1
MUKJN(P[8&VE=BW8$I9T%V)S?LMJQ2Z9<-M^7-EPM"!:]+<[BJ2H;$J96YJ,R
MS-CR*LN3-<'<P      8;S(_OKVWEQ>^\/N/!W_Y;P>+Q>;LZ_J=WV?@!F0
M
M                                                         8;V
M7_IKWGGM[O;]/!VW_P!#V^/N[N[L[_-^3X>@&9
M
M                                    !C/<8_O/VWE_RWC[_%TNZ>/L
MZ]>[M[>O=]'7KT R8
M
M               ,%[#']^?>'D4>3Q^+Q]]OM^G@[>[L[._K_MNG7UZ 9T
M
M                                                        &$[,
M/W[Y.F;S^V\?=XL_@\7;W=GE[O;^3N]>G3NZ 9L
M
M                                     &)[<'WKW],7G[.SX8_)T\/=
MUZ]OD[NWTZ]?U?0#+
M
M                UKV^;\5>?NQ^W^Z^_M_RGD\_D\/[7BZ>/U_5Z_E V4
M               =:5^%>H
M
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M =<G[-G]9=_9@.N3]FS^LN_LP'7)^S9_67?V8"M<G2OV;>O2O3[5:^OT?R*
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1[GN_6\_D[/<>+Z/'^GJ!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>tv526458_ex1-3img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ *4  0 !!0$! 0$
M       ( 00%!@<# @D* 0$                     $  ! P0! P$$!08(
M" D&" \ ! 4& 0(#!P@1$A,4(3$5"4%185(6<9$B,I/3@;%"DB,S%QCPH6)R
MPM)#)<$D-(6W*#AH>%/#I*=8N-&"Q$4F-G:V=_&BLF.#975&-U>8J!DY$0$
M                    _]H # ,!  (1 Q$ /P#^_@
M
M                                        &%]79\?]'^GY/AGEZ>._
MM[?4?K^3IX^WK^CTZ]W7Z.GM S0
M
M                         ,5VX_C']5A[_1>3R^*WS=WD\?\ 6]._M[/9
MT]P&5
M
M   !C.G^^/\ F[K_ .D= ,F
M
M                     #&__.__ #;_ /*@,D
M
M                                    "U_I?5^ZST_AZ]>M?)ZCNZ=.
MGN[?$!=          'Q;2[K[>O3I]?4#[
M
M                    8[]+XMT]O;\/Z]/;V]WJ>G7ZN[I_B R(
M
M                                                  +#S7?$O3_H
M]GI//_E=_D\?OZ_J=OT?6!?@                     4K6EM*W75Z4MI6M
M:U]U*4IUK6OY* 8Y&[MZ_->G3**7YK,=^;QW69,5]^''GO2WY\=N6VR[)@HH
MQW6=]*5MK=3W@9(
M                                                 M.^SUGCZ6>7
MP^3KVU[_  =>S]?ITZ>7Z.H%V                     !2ZG=2MO6M.M*T
MZTKTK3K3IUI7Z*@0SP^2SY@=,-,^>J>SAKW6)KLM]<%N6[=UU+\_BZTLKGOL
MMMMK?6E;NVVE*=/;U"9H
M                                                     !C?_GC_
M )M_^5 9(                      !"U)7R_,$5*K/;ANX8M5+>OLN_3W<
M\WT_1]U.MMOM]H$T@
M                                                  #&=/\ ?'_-
MW7_TCH!DP                     %?=4"'+7AQ4YWNM:=>Y-Q#8$V+]+W8
M<FZY=2O=3^56OI+.E?LK]8$Q@
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M-B7I[DRQ0ENRIJYPV=7\R77;]+=;K-7(L\LTTNVOQWU3M'8ZU!F0MK2X<O\
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M_MRARU'KG8VT<,000UBD.Q4N"S,Q54Y$UKHE6H<]E+,:])7,'ZF4KUIU J
M       QO7_>OC\=G;Z/U'D[K_)Y/)X.WM_4[/']/OZ@9(
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M[IHD?6UH=\6?'=CK8BJH38\M[;:GNKUZ]U0[L
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MIA4IEZV:I,"^&HT:C"OOQ*E4M0JL69LQV5NO7X<EM^"F2VZE:AO/2E/=3H
M= '3Z/H \,ZA.DQ^53FPI\7?BQ^3-DLQ6>3/EL3X,?=?6VWOS9\EMEE/?=?=
M2E.M:T M<KJTIW-$S9G)OP/#DE7KFYJRK$V-R7HFK(AQ.BQ$AOR6JE25MRN:
M:U1DQVW68;E&*E]:5R6=0MWB11^/8;5#^^-#&GNR)<-JAX<D;;@NRKG!$THL
M5,RW-AQUR+'5R3I<5.O7(H48\=O6^^VVH9D"G2GU4_P]O\8&%>8Y')!>S9I
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ME>ON]H%+K[;?9=7I7W]/;6O3K2G7V4K[.M0%+[:]>EU*]*UI7V^ZM/?2OVT
M5OMI[[J?_CKTI^>H"E]MU.M+K:TZUI[*T]]*]*T_+2H%>M/KI^<"O7I[P/GO
MMK6M.ZG6GV@5ZT^NGYZ .M/KI^>@#K3ZZ?GH!3OMZ].ZG7\O\/\ %0#ZZ]?<
M                       QW=7XKV=?T?0>3M]G]9Y^SN^ON[/9^0#(@
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M:2JKI$IO=<$FB/X8=LS@@K''+P_H9P_<8                     #&=/\
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MN[UL#6$)V"OV)&VR,RAYK1?J^6H%\A>T/QA%8K\C<]9[;TUV?"DSIPBO*OE
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M^^*R/,_IT"BW,OR.V'&VVJ4U;;LN3'GQA(6GNH
M            #%]V'XST[Z^I^'?U?M[?3^HZ^3KV_K>7V=.ON R@
M             %*UI;2MU?=2E:U_)2G4"&K37OY]2/);^K3AW".O7V5_I-V[
M%K9^;QU F6                                         !T
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M6Y[2IEV*VV_*CSJ&U2JQ856.R^E;L=U:7TI6E:T]H&P@
M
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M 844#T7$X_!X@\1#3,:??-)=B)4^-->RI[;,>19=@R680_?8
M
M     #"^JM^.^B\5_D]%ZGS>GS^/Q=WC\?G[?!Y?)[??U[?8!F@
M             $.&J^[^_P#3+%3KX;.(&NKK/9^CW9-S;.NNZ7>^M:_E F.
M  ?/9;]7^.O_ ,(%>E.G3Z %*4I[@.(<A..6H>4^L7?3>\HXY2[6LA5-RI_C
M""93:%X'VC4HJK1(GA=!)%&G5S:+%=+<UZ+-GO29<V+'??CNOQ8ZVAK&Y>(>
MA^0.J8CI/;D<E$LUS!W2'/C U?VI[59';XWKZW#=#'EYE\=FK1,I,[1Y<FQ+
ML"ER7J\U'+!B6W77*L=F:T)&($6%N1(T">]5DPH4B='ARKERUS79,27#9@QW
MK7)R4*G!P5WV8Z5R9\^7)FRW];K[[KJUK4+L
M                                                           &
M([D_QWLZIO5?"N_I_0^K\7JNWKU_Y1X.[_XG=]H&7
M   I7W5_)7^("'C3_P!OB9?^$/6W_3#LX"8@
M                <4C,^ELKW3L.*M[,@3:OULQL+(YR19:LM>9!MI^P)),M
M9H_;2MK?=&(="%[?<M4U\EZAS=O3V>.J'/2\.U@
M                              &&^'U^._$^N+K\/]'[KO+X?+Y>G7W?
MUW\'3[0,R                       APQU[N>\[]O=X>)>M<=WUV=^W]HW
M8[:_5W4LKT_(!,<                                        /.S%C
MQUNNLLMMNOKW7UMI2E;[O93NNK3]:O2GOJ!Z
M                            &+]59\:]'Y[?)\+]1Z?N_2[?5>/S=GU=
M?9U R@                      "'$>I_U]ME5_[JFJ:?\ K9VY[0)C@
M
M                              &*^'U^+_$?5Y_^3>#T?;B]/T_\IW=O
MD[N[[?\ $!E0                     *7=>VO3W]*]/R]/8!#>-];N>VS;
MZ5ZV?W4-/]*^WWY-K;AR>RE?KLZ5J!,D
M
M      P'GL_$7I.JSO\ A_J^OD4>CZ=_I_%V=W@\G\OITZ]?;[P,^
M                AY%\=/[\VRLW6O=7BMIBRM/9V]*[,V_7ZNO7V 3#
M
M                              ,;Z+'\5]?W5\GHO3^/ML[>GE[O)W]O
ME[^GZ/3N[>GT=?:!D@                     *5KTI6M?=2G7\P$.HO7KS
MMV?;U_JN*FEZ7>_IUOV=N+IT^O\ JZ@3&
M
M       -;[%GXKZ]F/T'P7R>3SW>3U7JO%V^F\7;V^+^7W]?H[?I V0
M                #XR>RR^O^1=_%4"'L4MI7G3M;)_*KQ9T=2OU=*[,W;7W
M?EH!,4
M                                        M>S'ZWR]?Z3TWA_6I^KY
M/)T[??W?3^0"Z                      ^,GMLOI_D7?Q5 A]%+Z4YT[6Q
M?RK>+.C[JU^CV;,W93\H$Q
M                                                        #7/$
MO_%'D]53X;\*\GH^RO7U7F\7F\G?V_U?LZ=O\/T ;&
M   !2[]6[K[NE?X@(=Q*EM>=&V[KNGEIQ>T;;;UKTN\==E;NK=TM^FG?T]O0
M"8H
M                                    !@_^,?B+N[K?2_"O'X^M/)YO
M4>3S=.[KX.S]'KTZ]_V 9P                     "EU.M*T^NE:?GH!#R
M*65KSJVUFZ^RWB[H_%V]/;6M=E[MN[NOU?H] )B
M
M             &$])A_$'K.G]/\ "_#^K9T\?J.O7NZ>3KW>SW]O3Z.H&;
M                     1 B=*TYQ[<Z_P#LQZ._Z2=W@2_
M
M                     -?].M_$WJ_*H]!\(]+X.ZSTWJ/4^;R]GB[_ "=G
ML[N_I]'0#8                       $08G=UYQ;=I_P!V31U?_63N_P!@
M$O@
M                                    "R\]?B/I^VG;Z3R]W6O7KY>W
MIV].G3I](%Z                       B!$Z5ISCVY6O\ [,FCJ?\ K)W>
M!+\
M                                     P/@6_B+U?BN]%\.]+Y?4T[.
M_P OG_Y+Y/U^[V=_;UZ?3T SP                     %*^RE:_8!$:)V]
M>;FV<GMZW<9](4K3Z*=-C[MK[/I]]P$N@
M
M      #&^IR_$O!V4\7C[>_ID[NOC\O7W>/IU]GO R0
M     "'L+MK3F_N:M?\ V<=%6^_V4K2;[ANKT^S]("80
M
M                 !8]V?XAV>*SP>'O\W2WN[OU?'^OW]>OMZ]O3I[ +X
M                    !#^'?]M_<]/^[EHJO\-9MN"G\5 )@
M
M                       & ]?D_$OPSOKV?"O7=OA_1[?4>G[?/V].[O\
M;TZ]>GT?2!GP                      $.H57_ *\6[+/IQ<<=#4NK]%:W
MS;<E:5I_!:!,4
M                                               LO%7XCY^M.WT?
MC[?;U[O-W=WU=.GL O0                      $.852M.<>Z[ZTK_ $G'
M#0];JUIT]MDVW'2E*_12M*7?XP)C
M
M  & ^(Y_Q'\*]'F\/P[UOKN_%X?ZSQ>G[.OFZ]WMZ].G7Z?H SX
M             "(,+IW<U]RYJ5]EW'71E.WZ:?\ TTV_]/\  !+X
M
M                          P?G_\ I'X/'=T^$=_GZ7>/N]7_ %'=V]GD
M[?TNG=W=OMZ=/:!G                       $/(76^WG#NW'6M?%3CEH6
MN*W^32OXUW+2^MOM]]:].O\  !,,
M
M  PO8I^/=_?C])\.Z^/LQ]_G\O;W=WD\OZGT]G3I[.OT 9H
M         !#V&7=><6[;.G]5QST/[?IN\DUW'^:EO9_C F$
M
M                     :]ZI3^*/2>EL])\%\WK//\ I^?U?;X?3>+IV]GM
M[^_K]'3Z0-A                       0ZA5U*\YMY4I7VTXYZ"Z_PS3<U
M: 3%
M   ,36]SL5([<:7%F2YU2OU^>]15/D1)[$^6J2[$F_I[5=<JBEMEWZ6/MI7N
MZ?0!E@                                 LNJ;XAV=MGJO2^7KV_I^/
MR>+N[NG3W^SW]0+T                      !#F%6TMYS;SK[>M>.>@:5Z
M_P"3,]ST F,
M                                             :WZRS\5^D[\/7X/
MT[.M?/W^H\W7I^KX_'_#U V0                      !#*!678^<.[<=]
M>M^/C5Q[QW^WK^G;-MW77>WI3K3IDI[0)F@
M
M        %GZK'Z[TG3+Y/!Y>O@R>+IW>[S]OBZ_9UZ@7@
M       "'4*MI3G-O.M/IXYZ!ZU]]/\ ZY[G[?;[NG2@$Q0
M
M                    #%]V3XMV=N/Q^G[OZFSR]?=Y/-ZKN[.OZ/3Q=>OT
M]/:!E                       $-8!CNP<W][)[ZTNNP<<N.]MUUO7MK6^
M;;WK[.O2O3I;]-* 3*
M                                                    ,;ZVSXKZ
M#LN\OI//W];.WQ]_3NZ=>_\ 7]GY?HZ>T#)                      4K[
MJ]/?T AW!O;SHY"UK_)X[\;*?DK?,M_UK2OVU[/\0$Q0
M
M                 #">BP_B/XAX[O-\']'Y>[+V]GK/-V=G?X>[K[>O;W?;
MT S8                      "'<$_[<_(S_P /?&?_ .]_(0"8@
M
M                          !B_B*3XM\-\^+UOI?/Z;K=Y?3]?Z_IX^WL
M\GZ/ZP&4                      I=7I;=7ZJ5K_B AOK^M]_.GDC?2E:X
MK>/7&"RMU/;9;EOEG(;)6SK]ZN.M*_D F2
M
M        8'Q(_P 2^3MQ^N^#].[MKY?#ZOIU[NG3LZ^S\H&>
M          I6G6E:?72M/ST AQK2O=S;Y/4_\EHWBO93[>]YY!7]:_5TZ 3(
M
M                                  -?\F/\2^/P5\WPOO\ 4]R7KX?-
MV^#M[O5>+R?I?J]O?](&P                       (>:U[?[['**M.G7^
MQ+BK[>GMZ?%^0M??_"!,,
M                                                       P?K\'
MXB^&>:[U'PGUG@[,O;X_4^+R=_9X>[K[.G=W=/HZ 9P
M    "EU>EM:_52M?S4 AOK&^MW-SE-9TITQZ1XH]*_37O=>0U:]?R=H$R0
M
M                               #'>AQ?%/7];_/Z7T_ON[/#W]W9V]>
MWKY/;UZ=0,B                     !2ZM*4K6ONI2M:_DI3K4"&VJ\=].
M:_++)=T[*Z9XBV65Z];NM''DC=6G3Z*=MUH$R@
M
M           ##^HM^/>FZY.[X7YOU+_%T]3V]ODZ>/R_3V]>O3V@9@
M               "E:4NI6VONK2M*_DK3H!$;6..EO,KE3?3KW7ZAXG4N]OL
M_06\B*4Z4^CW@2Z
M                                                 ,9\.2?%/B73
M)ZSP>+KY;O%X_P!7KXNO;W_:!DP                      $1=97TKS*Y6
M6>WKBU-Q1Q7?56[U/(3+UI]G;?0"70
M
M   !A.VSXWUZ?I^+N[NW'TZ>+M\??_6>3^5T]_;]@&;
M      0_U==;=S/Y:UMNI=2FK^*%*UMK2M*5Z[]KTKT]U>EU*_P@3
M
M                            ,;W8/BG;WX_/Z;IX^^WO_6Z]W9UZ]W9]
M/3KV_8!D@                     *74ZTK3ZZ5I^>@$,M06]G-#F)CZ]:X
MM<\3K*W?17JBW;?[*?1T[P)G
M                                                          &O
M>G4?BGU/FL]+\$[/3^.O?ZCUG];Y>_M[/'[.WMZ]?;U^@#80
M         *7=>VO3W]*]/R]/8!#33]UF3F9S)OMK2Z^R$\5,&2ZE>M;;K6';
M"BW'7ZJTL54N_)>!,P
M                                                    MNW'ZOR=
M/Z3P^+NZ7>[N\G9UZ=ON]OO N0                      $+-+6=O,GFG?
MUZ^2-\5_9]WLANP:?P]0)I@
M                                                        &N>@
MO_%7K_5J/'\'\?H^MGIN_P!1V^7IV]_E[?I[NG3Z/I V,
M       !"_3'_;&YG?\ V;XM?_<W8($T
M
M      # >S\2]WJK.[X3XO0^2G=V>H\OJ^SW]>[]#I]7MZ_0!GP
M             $,M)V]_+KF@HNKTR6MG&-%VT_5[,&OI0KMOZ^_ONR.5]*_1
MTMI]H$S0
M                                         #%>+'\9\W9=Y?A_;Y.^
M_M\?G_5[.OC[N[Z>G=T^P#*@                     *^SV@0VTG;6G+;F
MM6ONNLXV74_)_9DZV^WZO;;4"9(
M
M!KGH[_Q3\2[<O;\*^'=>[+X^GF]7Y.SR>#IW?H]W;W=WLZ] -C
M            5]OL AKI.M:\MN:]*_R;>-EM/9]']F3K=[?MZW5 F4
M
M                            8[NK\4[/H]%Y/I_\MV=/?TZ 9$
M               "E:]*5K]5*U_,!#_2Z>^WE?S15UK3QJ;^.N.RGM[J5P:Q
M7UOK=[.G2OGIT]H$P0
M                                                   #!?#E/X@^
M*=R7T_H/2=OZ?J^WO\G3]3L\7E]OZP&=                      I=[:5I
M]=*_Q 1(TU=_UI>9-E.G2Q5Q^I2E/;6G75V:OZ7TT]G0"7
M
M                    !C>]1\2[>O\ 0=G9T[+??X_)U[_UNG<!D@
M               %?92M?J B%IBVMO*GF?=6O6F1;Q\K3[*4U7DM_CL EZ
M
M                                6713Z_\ K,?I?#U[/TO+Y/U>G]7V
M^/Z>O=UZ_8!>@                     ?-WZMW^;7^(")FFZ4_O/\ ,2[I
M^E<JT#W5^OIJ_)T_-UJ!+4
M                                                        UWSJ
MOQ3Z7M4^C^#^K\G7_BOF]3X/%^M_6=OZ73I]O4#8@
M  *5IUI6GUTK3\X$2=,W]>47,G'T_JEN@+*5^]UU96[KT^C]8"6X
M
M                         !9>'_>'J.[V^D\79T^CR]W7NZ^[K] %Z
M                  !2ONK^2H$1-+UZ\I^:'_[PX_5_/JB@$O
M
M                        #7?4./XG])Z?%\,^&>I]3WY?-ZCR^+Q=G9X?
M'T]O7NZ]?Y/T@;$                     !\WUZ675^JVZOYJ5 B!I&^N3
ME+S3K6E*=KIQ^LIT^JFH\-_6OV]<E0)@@
M
M      &"\N;\1^/Q?\6^%]//[/\ E7J._P 'Z_=_4?I=>WI_E=?8!G0
M                /F^E:V7TI[ZVW4IU^NM*TI_C A?Q\Z_WG.;U*UK6MDJT
M+97K6M>VM^CV!7;;3K_)IB56U^KK6H$T@
M
M      #">#)^(/4>HO\ %\,\?IN^[L[_ #]?)V>/MZ=/9^MUZ_0!FP
M                $+N/E*TY/<Y.M/\ ^+^/U/X:<?8=UI_ !-$
M
M                         UKU2C\6>G[L?H_@O3IX;O+ZSU7E[?4^7Q]O
MI_;X^SN^GKT]@&R@                      (;:#_[3W.C_P"W>B/_ '>8
M*!,D
M                                      Q7CM^+=?'C[O3^;O\ '3O[
MOZCN\GOZ]GZ/Y/I RH                      "'FA++:<D^;V3_:7SS1U
MN7V^ZZSCS *TMK3W6W4I?UZ=*>RM )A@
M
M     &N>HS_BCP]N;T_POQ]?37>'S>7S]WJ^G;W=GZ/9_"!L8
M           "'FA*]>2_.O[-F:4I_P#XW:RN_P!("88
M
M                !ANEWQO^JQ^+TO7R]+/+ZKW>_P G?V>G]G3LZ=?;U^@#
M,@                      (=:"Z_WF.=WU?VG:3Z?_ -M>L.H$Q0
M
M                           "R\__ !WT_CR?J>3O\&;Q=.WI_P H[?!W
M=?9V]>X"]                      I=7I2M?JI6OYJ 0UX\YO4\D.=N>E.
MWIM;36#MZ]?;BXTZIO[O=3W^;_$!,L
M
M    QGKLGQ/T'AM[/%YO-WTZ].SW=GOZ]WLZ^[I]/7V 9,
M       "EWZMW7W=*_Q 0PXWT_ZPW.SZ_P"U_4/7\M.,NH??]?M F@
M
M                            >/AQ^;S>+'Y.WM\O99Y.WI^KW]._MZ_1
MUZ >P                     %*TZTK3ZZ5I^<"&O'?%3#R+YVXZ5K=3^US
M3M_6OT5OXPZ=OK2GV=;P)E@
M                                                        &,^*
M8/BWP?\ 3]3Z/UO3Q7>/P]_CZ^7KV]W?]'3J!DP
M%?=4"'/'O_M'\]^O_P#6K3]*?93^ZCHRO3\G6M:_P@3&
M
M                  ,?ZA)\3]+^AZ[T?J/U+._TOE\?7O\ U^WR_1[@,@
M                     ASQ[_[1W/?_ /#5I_\ ]U'1@$Q@
M
M                     "V\&/U/GZ5\G3IW=]_3IV=O3M[NSIT^CI[_ &^\
M"Y                      5]GM AYQZOI_>&YY8J]>_'O#4]]UWT5MR\4M
M$764I7WUK3I7J!,,
M                                                  \_]I_A]T#T
M                       0ZX]TK3D=SWKTKTKNO4'2O2O2M:<4=%]>E?L
MF*
M                                    >?6GDZ=?;]7_ ,4#T
M                1"X^_I<@>=N2GNNWAJJSI]/]'Q2T-2M?X>X"7H
M                   I6O2G4!;7NIU]WM J
M                                          67FN];X/'D[/'W>;I_
M1^3I_5?J^[L]O=U]_L O0                      $1./MM;=^\Z>M.G=O
M'5MU/MMKQ3T)3K3[*UI4"78                          .G3W
M
M"T[L/J^G?_3=O9V=]WZO;W].SKV_;UZ=0+L                     "E?=
M7\E?X@(FZ$ITWUS?_P#PT:L_]UG15/\ @ EF
M
M          6/EI\0\??CZ>'IV=UWF[_U_P!7LZ>/L]OO]_V@7P
M           'QD_J[_\ ,N_BJ!$[0%*UWISANN]M?[<]8V>WV^RWB;Q[OZ4^
MJG=DK7I]=0):
M                                              %OX<7J?/X[/-V>
M+R]M._Q?K>/NZ=>WO]H%P                     !2ZG=;6W[U*T_/3H!$
MSC]=W;QYR5^[O[76&GY,7$WCK3K7[:UJ!+0
M
M         \_]I_A]T#T                       1+X^678MW<X:7^RN3D
M! <EGMZ];?[J/';V^P"6@
M                                                      !Y_P"T
M_P /N@>@                     %+O9;=7_)K_ ! 1+X^9*YMW<X;KJ=/#
MO^ 8;>GW:<4>.W7K]?6H$M0
M                                                        #S_V
MG^'W0/0                     #YO_ %+O\V[^*H$1>.M>N[N=%?\ O"P'
M_P!U'CN!+P
M                                            \_\ :?X?= ]
M                 /F_]6[_ #:_Q5 B)QSK2N[.<_\ XAH'3K]%>G%'CM2M
M*?76VOO EZ
M                                            >76GE[>ZG=T[NWK3
MN[>G3N[>O7MZ^SK[NH'J                     !2M>E*U^JE:_FIU AYQ
MKN\NY><67VV]>1L2Z6UKUK2G]U[CYC]ONZ=:XJUI^4"8@
M
M                  !:>#%ZSU79;Y_#Z?R=GZ?AZ^3Q]W7]7R>W\OL NP
M                   *5I2M*TK[JTK2OY*@0SXP777;BYTUK7K;;R4C&.RO
ML]E,7&;0=E;.M/ILNITK]H$S0
M                                                          #S
M_P!I_A]T#T                      5]U0(<\8T_@V[SEN[J7>;DRR9?93
MIV]W'+1->VOU].H$Q@
M                                                   #S_VG^'W0
M/0                     "EW7MNZ>_MKT_+T A_P 8<EF;9?-?+;6E]W]Z
M''@R7_3W)M":0PTLK6OM_HK;:6T^R@$P0
M
M      #S_P!I_A]T#T                       0SXI_\ \Q>;O_BP5_\
M09I$"9@
M                                        !Y_[3_#[H'H
M            !2ZO2VZM?=2E:_FH!#GBUCNIL3F=?[.V[E"J^G]:^W3&GL5]
M:_7=W8_?7V@3'
M                                               //_:?X?= ]
M                   *74I6VZE?=6VM*_DK0"(7%NVGXWYC9/Y5_*=YMN^J
ME,6IM2V6]/MZ>\"7P
M                                                  !8]^;XAX^Z
MSTWI^O;XK_)ZCN]_FZ^/Q>+Z.G7N O@                     %?9[0(A\
M6Z]9ES#I]7*E^_Z*=2@2\
M                                                       +?K=Z
MCW7=O;V_K?H=.G?U[>GZW=[.OU 7                      "OV^X"&_$_
M)=EF/,NZZM*UMY:R?%3IT_4PZMU-CMI[/9UIVU^T"9
M
M                !:>HQ>L]-Y</E\7D\/?_ ,8[?=Y/'[_#]'7[P%V
M                !\WW=MMUU:=:6VUNK3Z^E*UZ 0VXDXZV2GF+?6ZE:9.7
M,WNI3Z:=-?:OI[>OM^@"98
M                                                       !JWI*
M?BSUOJL_D^'^G]+Y;O!Z;IW]_B[?UO4?3U[>O^4!M(
M   %+J4K;=2OMI6VM*T^NE:>T"''$WK^).7->OZ_+;8'=[*>WLA.M;+:]?HZ
M6TZ?;0"9
M                                          !@OZ+X]U[,7?Z;M\G6
MWR^7L[O'T\?=_4>W];W 9T                     "EWZM?R5_B AQQ)_I
M'SEIF]W=RZV7C[?J]/%==IZUZ_Y?CZ_9U F0
M
M          >/;7S=W=7IV].WV=ONZ]WNZ]_T=>ON ]@
M    *5]M*T^NE0(;<0*T];RM[J];[^8FXJT^NMF-I@N*GY:6]G0"90
M
M                           !A?\ >/QO^IR_#O!_6^5-X._LZ]?'U]3Y
M>_\ 1]W3I[0,T                     !2OLI6OU4_P^H"&7#NG>IY49Z^
MRMW,7=V/MI[NF#%$,%M>OOZW4Q=?RU F<
M
M       6?GS>M\'@IX/'W>H[LO=W].O9V^G\73I]/D_@ O
M        *75Z6W5K[J6UK7^"@$.N'^.['7E!6ZG2F3F%O');]MM<D9MZ_P Z
MRH$Q@
M                                      #'^FS?$?4]]WA\/;V^7-X^
MO3M[?!Y_#Y.OM[^SKV^S[0,@                     !2M*74K;7W5I6E?
MR5IT AUP[S54)^362ZEM+K>8F^\'Z/7IVIW5G3V5KU_E5LPTK7[>H$Q@
M
M                             ##>NS_&O0=V/P^'S=OCKY.WQ^[O[NWI
MY/;[OL^T#,@                      (8<+[:T;^3%_7K;EYE\B\EGMK7]
M&LG1VT_QV@3/
M                                              //^7_A]T#T
M                  5]U0(:\,+>C+R)NZ5ZY.87)&O7ITI=3%.+D]M;?LI9
MAI3[:TJ!,H
M                                            PWQ')\<^%^D4>/T/
MJ_6?H^FZ]_C\/ZG=Y?I]_3H!F0                     *5IUI6E/?6E:
M0]X:74NC>^.G\GESR9L_9[,<[.O_ .2!,,
M
M        Q_JK/B?HO'D[_2>I\W2_P]/)XO#W=O9Y?Y73KU[?;T R
M               "&O"ZF3\*[KR5MKXU'+#D]FIDZ>S-6NV'S%2^VONK2GBZ
M=:>SK2OV@3*
M                                             ,3XE7Q?R]+/2>#W
M^''W>3MZ?UWJ/)W?_J^G3V=0,L                       B+PT_\ J)M/
MZ?\ K0<G?^F>5_Q 2Z
M                                                    ,9ZZOQ/T
M/A]GB\OF\V/[G7M\/3R?P^X#)@                      (E<.NVL#V5=9
MT[;N2W)NZZM/92MU=T2RO7W>_H!+4
M
M   Q_I<7K_4]E_?TZ^3S7]O?XO%V^+N[/'X_L_6]OV@9
M       !$3AA7NUSL._W5R\E.3=]:?56F[)A92E/LZ6@2[
M
M                    ,/\ $\?QCX9_1]_B[^OEKY>_Q^3M\/CZ=GC]O=W>
M\#,                       (=<([Z9M63M396MV+/R6Y478JU]E:VX]^S
MQ-=^C[[:6Y,%U*4K]%.ONJ!,4
M                                                           M
M?(F]7XNE/5^+NZ^"_KXNO_E_'V=.OT=W\ %T                       A
MGP5K6NFY=6M.E?[RW+>G\%G);:%E/X>EH$S
M
M         #%=;_BO;XL7C\7?Y.V[S=>SM[N[O[?%_)]W7N RH
M           "''!BM+M(.U]ON_M_Y74KU]_=_>7VE2M?M]MOY0)C@
M
M                          %CZ[%Z[T/CR^;M[O)TQ>/M[/)[_)Y/LZ=O
MO^SV@7P                      "&?!3R4T>Y6UMK2R[>_*[)W5MK3NR?W
MI=Q8?96M*4K3Q8+?=^4"9@
M                                                       !9^CP
M>M];V7>?Q^/O\F3M[.WW>/N\77[>WK]H%X                       B1P
MCIV:%I97V]=U\K,GL]E*4NY4[GZ4^VM.H$MP
M
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MKRGW+=2EW2M>E:VUI6GV5I4"7(
M                                            "G6E/?6@#K3ZZ?G
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M6ZOJ5SNX9\^6M*]+\F6M0-H
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MI2E* 9H
M                               #7)1#HE-VW SS.,L$L:4KTP2-,V2-
MH0/2!/((H](9'&'S"D<<"A/B=H](&Q,N1**6TRI5>#'EQW6Y++;J!SC;W&_C
M]R M9:;QTEJK;MT;]5^'<NQX%&9EGC]5V9$H67,BE^;EJAIO4J&U/ENN3W8Z
MURI\5_ZV.RM BUKOY8?%J";9Y%[:=H^Y[67<FZ+T^P(CM[#$9K!\#2ZS6W8K
MHSI6G+$T;A)DJJ:)TRW%GDRM_7M]$:? C4)TV*F("9:#4>KFC65VEV77L-8]
M271APA/]FC)'&EG@UD/=DBM Z1G%&&U*E9\+(X(E^?'E368K<5]N6_K3]*H&
M VIQYT3O&,L,-W%I_6VSXI%W1K>HY'9U#6*3M#$Z,U,=C:L:4+LB4X$&5/@Q
M4P_T5+;;\'7%?2[%==94,&KXJ\;7!LV<RN.C-6+VC="=4EVPVJX2PJ$.PL*U
M\=9,JI*TV5'?A=[\LC>U2_NR4K=:LS5S6UIDI;=0, DX5<1D"W4KBAXVZ62+
M]#KG-QTTK3:]C>'-K18\/"V1..6'WV(:59O42%RSN%+<72S&ORW*;*6YZ]X&
M\O\ QXT7*MP0_D!)-2Z_?-VZ_:5C%"=IND6:5DYC#.OL78U+<SR+,FN<4J>N
M-T5VXZ4OZX;5>>F.MM,V7O#LH      ++SH_7>G\F#UG9W^+K9ZCQ]OZW3^L
M[.G\ %Z
M
M     ##^FR?&/4^:SM\?3P]+N[Q>+MZ]>O;Y/-]'W0,P
M
M                                          "T]1@]9Z7OIY_'Y?'T
MNZ]G3M[N[IV]?LZ]0+L
M
M                 &-^&8?B7Q/RJ/-V=GB[[/3]/'X^O9X^_N[?\KIU R0
M
M                                                         ,3_
M $?Q?_;>7P]O7Q*/3]G9W=OE[_3>7N]ON[N@&6
M
M                                    !:=B3U?D[L/JNSL[>['Y/=W=
MW;_6=_C]G7[OV 78
M
M              ,1Z#)\7]?Y,?B\?;XNROD\GB\??Y.O;T[?9TZ=?M RX
M                                               "G6E/?6@%0
M
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MG_"!6O7^32E:_;6M/XK;@/GKD^[9_/K^[ KUO^[;_.K_ *@%.N3[MG\^[]V
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/7F]_EZ]OJ/#]'9_"!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>tv526458_ex1-3img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ *(  0 " @,! 0$
M       %" 8' 00) @,* 0$                     $   !@(! P(# P8(
M" 8/ PT  P0%!@<! @@1$A,4"2$Q%4%1%F%QD2(R4H%"DB,SD],7H;'!<B1$
M)1AB@L+2PR;PT>&B0X,T=#4G-W>W*#ACHU6X\5.S5+1%M39V1U@9$0$
M                _]H # ,!  (1 Q$ /P#^_@
M
M                                                     $9ZS'U;
MT/;OW>E\_7LV[/'W=O=Y/V?Z3X=/GU^SI\0$F
M
M                                                    #H>(GZAY
M?"3YO'_3>/7R_L]O3R=._IV_#IU^0#O@
M
M                                               Z?^N_^+_R .X
M                      #YUVUVQUUVUVQ\NNN<9Q_@ ?0
M
M                                     Z?7'K>G7X^+KT^WI\NO3[NH
M#N                        ZZ8CP%]F=N[];.>O3I\\YS\NN?O =@
M
M                                              1/7_;'C\>/_)_/
MW=3N[Y>'R?L>#M_B]O=UZ_K= $L
M
M                                          "%["/KO_@O4>D\_3H=
MY/%_Y/W]>[P]_=^K\OV?T@)H
M
M                                       $3ZG;ZOZ7Q8[/3^;S],?M
M].WT_3]ON[?U^[]CI\/V@$L                          (MO>FMU-5$M
MZPE6:A,\"XLG;OW0JNPLW*-9KCXI5NA1VF^Q._:9C3?7;..F<9R$H
M
M                                        ",Z$_5>O81ZGTG7R>#;S
M^E[^GC]1V]O;ZCX]O7\O0!)@                        /@S/0LS/3KTT
MVSTS]O37/P^'Q^("H'%/;!LLY@'YUSKOMRNEA.V/(;OKGTM<U<ETWUU-WWP7
MG8HC3KKKTTZXZXQCKD!<(
M
M        '4_UWK_]AV?P=W?^GJ [8                        !GY9 4V
MXDF:F2/E[V]?YKEO/R]NN/XV877&WP^?7 "Y(
M
M                        .G_KO_B_\@#N
M .,_+/YL@*;\0R]<._+<_P"/D4<P+/P9GK\.B:,U^F*[=?EKT*TQU^_("XNY
MQ)?](:67\>GZ^^NOQZ=>GZV<?'H _3KC/RSU_P"Z
M
M                          .IVX]9U[L]?'^STU[?ETZ=>O=W_;^8!VP
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M_FSB3# Q]V]U#BNQ2E<VN[A8J6')J9J6X4,\)IVX'!*\XN:Y9!140@*"+MT
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MQ=W0/K&N/9W18R.Q*1T;#U*)0:V/+<H2*-=-\Y)4D&%[=-]-L8#)P
M                  !&]AGU3NZ$>#TW7IV9]1ZCKV]_?\O'X?U>GW@)(
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MV,9SC&<ZZ].[;I]V.OQ <XSC.,9QG&<9QC.,XSUQG&?CC.,X^&<9P Y
M         '5_5]7T[<]WCZ]_P[?N[.G=U[NGQ^7R =H
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MC'R =D              =7IGUG7IMT\77NZ8[/GT[>[NZ]WV].GR =H
M                     4RX?=V5O*K?7KXMN8ET_K8S^KMOHBA16?A\^NNQ
M>=?X %S0   .F,_/'4      <=NOW8_0 8QC'PQCIC\@#GIC/SQU .F/N
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M3&,?#& 'V              .IW9]7V]?AX_E_  [8
M     #C/RS^;/^(!3;AWCIMRD_+S&O+/Z=XL N4   #\M3R=]LZZ&Z;;:[[%
M[:Z[8VSKOK^UIMC'7MVQ]V0#!VFV^-,;:9SMW=.W?&V<XUSG&<],=>F,9QG'
MYP'Z@    /C??73&,[9QCK\,=?MSTZ]/T8 <Z[=WQQ\OA]O7Y@/H!QUQGKC[
MOSX^_P"_\P!C.,YSCX_#Y_#./T9SCID!R
M
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M!.V'=*Y-JM4T-ZC7!^Z<XC0Y.9@!9X
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M^^P7#
M                                !T?,5]0]/W9\WIO4=O3/3Q]_B[N[
MIV]>[[.OY0'>                          %/N'^<93<D_O\ ][Z_L?H?
M&S "X(
M                                                     .G_ *[_
M .+^[X_+[_F [@                          IYP_S_H_)/&/_P#;Z_\
MK^?ZXU9^/Z0%PP
M
M =/_ %S_ ,7_ ) '<                          %-N&^?]%Y,Y^?DYC\
M@]L?DP4^MA.V,_ESMIG/Y@%R0
M
M            1GJ2_JGI_"H\GAZ>;Q'^GZ=/+V^3L\'7I]O=UZ_ !)@
M                    "F?#7/5'R4SC/7'^^-R,QUQ\OU90AUSC^#..F?RX
M 7,
M                                                  !']J;ZAU[D
MWJNSN[?YOU/B[.S[_)V=?X $@                         9^'Q 4RX7Z
M_P"RN1QG7^DYC\E=NWI\=?\ KQC3IG/7IGXE=?X0%S0
M
M                              0?T_;Z[]2[RNGI_3]O9GR>/L[NG=T^
M?D^/SZ= $X                         XV^6?S9_Q *;<+]-]6+D+MOKG
M&#>87)8PO.?X^GX_/+[L?D[],X_/@!<H
M
M                   '0\F/7^/OU[NSN[.['=T[.G7MZ]>@#O@
M               .,XZXSC[\9Q^D!3KAD9Y(W?&>F,=.7?)S3X?'^CLYST_3
MGH N,
M                                                    "(]%M]6]
M;ZH[M[.STO0OQ?T/9U[NWR=.OZW3K^T EP                         !
M37A3UQ"[CSM^V=RJY+;YVS\=C-M+1>"C=]L_/.WDTS\<_'("Y0
M
M                                     (+H7]<Z>=9Y?'Y/#W*/2=O@
M\?;V]?3_ /"Z=/VOC\P$Z                          *>\,"<:0BU]\9
MS^ORDY/[9QUQTZYN*2E_=]Q("X0
M
M              .AX-?7^?MUZ^/IUZ8Z]_9T[^OSZ^/]7[NGV=?B [X
M                     J+PTQ_U!L[;[#N3G)PW3_,VNB6=.OW9 6Z
M
M                                          !COIC?Q'ZCHF]/Z3NZ
M^;'J?4=GB_H?'U[?#]O=TZ ,B                          %1N&F<9KV
MQ>F<9_\ F4Y-8^&<9QUQ=,MQG'P^W&< +<@
M
M                      C^NGU+_P %W^FZ=.FGEZ=_7KW=.[I^3^$!(
M                       "G'"/&<5E8O7I^MR=Y4;X_P W-\3?IU_+CJ N
M.
M                                                #&>B_P#%/=ZK
M'T[T'3T?3'7U/3KY^_O_ '/AV]O=]OR 9,
M*:<&MLFU%,C]\]QIO)3ECDW?Y=VQ?(RQD^O7&/U<9U*(UU^&,?L_?U 7+
M
M                                            !COAW_$WFZ%^#Z;T
M[.F/+ZKOZ>IZ=?V?3_S?=T[OL^0#(@                         !37@N
M5XZ7DN_=U]7R-Y:+,8Z=.S!O)>T/YO/WYU^\!<H
M
M                          $3X?\ :WJ/U.OA\7['ZW9V=W[7S[N_^#I\
M $L                          *:<$=\[42X>7/51F^^5^YG=^WG'^]!;
MA6-MNGS_ *'M_P"* N6
M
M      #'NQ9^(_)Y%'HO1^/Q="O3>;IW^7^B\W?T_5[N_M^SIU 9"
M                   *=\&4F"J+5*._;;*B\>5NV=,XQC&G_P U-SYZ8SC/
MQ^/WX 7$
M                                                       !U._/
MJ^WI_%^?V].SKT_2 [8                          J1PG_\ 89^K\"\W
M/RKVQC'PQUSRKNC/7M^_.,@+;@
M
M             A.B_P"M]?#_ *#XNGE\Y?3N\/\ ^@[_ "=_D^'7M^0";
M   '6P=MYO'TU[>[..O3/7X?P] '9                  %2>$W_L)T_P#?
M-RI__*HN8!;8
M                                                           $
M=WJ?J?C\>OI?!W>7H9Y/-\NG7IX_'V_EZ]0$B      ..F/GTQU <@
M           "G?!?;!_'UM4:9SDL^V>4*K3N^&V2EO**XE!&=L?'IMXML=<?
M9D!<0
M                                                    $=WJ/J/9
MX<^G\7=Y_(5V]W;T\?A[_-W=?CW=.G3X )$
M 4UX%]?]V]BQG'3I8_(G/\&>2=O_ !_-G[ %R@
M
M                         0'JSOQ!Z+NV\7IO4=/%CM[>SL[?+V?/R?']
MKK]GR 3X                          ISP-_G>-,468^!:N97B=IKG]O7
M!W("U%.,;].NO=C11C&>F<_'&0%Q@
M
M                ='_7?R?+^'Q=>OZ '>
M%-^ F<YXL03K]LING./R_P#KSLKXX_@Z +D
M
M                       QSUIWXD^G^C/\'H_4>O\ (5Z?S=G9Z;Q]/+Y>
MS];[NGQ 9&                          *9<!M\:\7Z]3],]=G:VUO=]F
M,++JL$_!?Y<EXWZ9S]H"YH
M
M         (?R8^K^+X?+R=WQZ=WI^WQ?+IW]GZW3KU[?B F
M             !3?@07TXMUIOMIT-V46-G;;/[6=3+6FQNN<_DVSMG;\O4!<
M@
M                                                $'Z<SZWZC]3Q
M=GR\17?W^G[.[R>3R]>GPZ]OR^ "<                          %0>"N
M/'QDK8G'QQIB;[=WRSGNLV;8^./X %O@
M
M                   0?K<_7O0^,OIZ7S^7S_SG=V]/'Z?Q?+I\>[O_ ( $
MX                          *A\&,ZF<9:U.TSC)9I<TW+STSC.=-[+FV
M^F>F<8SCKKM\L@+>
M
M    Z/B)];Y>S3R].G?V_K?T?3KW??V_#\P#O
M   "G_ __P"EFJO_ #.6_P#Q%F0"X
M
M                 (?S*/K/I^TCP^G\_7RX]1T[?'W^+KU\7D_5Z].O7\@"
M8                          %/.!?_P!*U4?^92W_ .(LR 7#
M                                                     ?.VN=NG
M3[.H#G'PQC'Y '(                                           (_
MRE?4?!T,\W@\G7P&^+Q_L]/4>/Q=_=_%[NO3X] $@
M       *<\"-LYXK5/U__89=_@L>9X_Q8 7&
M
M                       !$=3?K'3Q$^+P=?)X"O/^S^UY_4>3Q=WZO3Q]
M>OV] $N                          *;\!_\ Z5JG_P#,9?\ _$B9@+D
M
M                                               B/7:?5_0^(SR^
M+R>3M_F_%X^[KW_+]O\ 5Z?/K^0!+@                         "F? '
M;OXFT^9G/78QMEN^<_O8S8DNVUV^'PZ;=^<XZ?/J N8
M
M                              ")]*1]7]9V9]1X/!Y/(;T\?;W]OB[_
M  ]W7X]>WNZ?;T 2P                          IA[??_P!(U*_E89%G
M],[E&?\ * N>
M                                                           "
M&]:F^M>@]05ZOP^I]-UV\WA\?9Y>WL[>SN^'[0"9
M      %,?;]QG'$>E,9QTS^'Y!G^#:<R?;&?X<9 7.
M
M                             !">)%]=\O87]0]+V^3LSY?2]/V/)V]/
M'Y/CTZ_,!-@                         "F7M^[=_$*C#<XZ9.BSN;G&/
MCC7R3"0&=,9^WIY/\ "YH
M
M        ,<[M/Q-X_0D^3T/F]=WZ^?Q?T7;X?+W]._\ 5[^SMZ?J]>H#(P
M                       !3'V^L9QP]H;K]D1<\9_/B5/8"YP
M
M                                      (7R)OK7I^\KUOA];XO)CS^
MD\?I?-X^O=XO/^KU^74!-                          "FOM\=#.&/'I3
M_&5P/1;MKC]G7=P>'-<9IK]O9H8=G&O7X],?'X@+E
M
M                             BO0$?5_7]=_/Z;LZ=VW3IU[>GSZ=O;_
M !?V>[X].OQ 2H                          IG[>NN=.%G''7;YXK1KW
M^&>N.TU8OWT^/W]OS^X!<P
M
M         $9Y$_U3Q]G^D^'KW]G\3IU_;_P= $F
M     *;>WOMG?A9QP,V_:VK-HU_XA:A;J7GI_FY^?V@+D@
M
M                                 B_0)_JGK^IWG[>WIYM_#_0^/KX>
MO9W=G_;^8"4                          %-?;](W+X8\8\[9US_ZFXGO
M\.OR4I<GZ?9\\:[?'\H"Y0
M
M         (7_ $;ZYW=F_J?3>+R=I'C[>GD\?=W>?NZ?'ITZ?XP$T
M                   *A\"<8UX:<9-<?#']R<#ST_+EH+SM_AR MX
M
M                                         #H=R?U_[97G[/'V=^GD
M_8\G['[7=V?;\^W\@#O@                         "H/ ;/=PQXP[_?2
M%?;],_/'G8DI^N/SZXWZ +?
M
M           @?0Y_$'K^\OM])X?'XMO+W]O7O\WE[>SM^'3LZ_EZ? !/
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M1N"6+]?D^B,]&M)=:MM2,2YM2FI]5&AY*QNR;C<PO8D/3H
M
M          !TOAZWY9_8Z=>W/3KV]>G=TZ=>@#N@
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M[
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M,D6RJG:"E\XXE<1'K=QE!Q3K5*JR'2]+$5N6))H0>_.T2E<O9X#JY8P<1L7
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M@
M                    (?R:?6/'Y"N_Q]WC\O\ .?T73N\?YO\ !\0$P
M                      Z3E_Z.7_\ F2K_ /4& *H\"<=.%_%?_P!PE:X_
M1&F\!;L          .F/N^?S      #I]OV@   =/M^T   'SG7&W3K]G7I_
M" YZ8QT_)_\ F <@
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M"=NW;./B S@
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M<DCI W%[;F=\51!;(V-9A&8H3:],:;%ZF'8+\NX6"
M
M        !U/]<Z]FO7Q=G?\ 'N[.O?V]?ET[OB [8
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M,02G\:-''8RND:TQ(G)*+U+]1G'QQC7&H;7
M
M  !"^G5_6_4^0CTOA\?9W&^;^B^79V^+IY/CUZ]>@":
M        8[+\](G*,]>G2.O>>OW=&U3GJ K7P:[\<1N+>,ZYQG/'BJ<G8SC.
M,X,S$FO.,;8S^QG/7/P^ "VP
M
M           (WM/^J=WDU]/Z?M\?:7W>7KU[^_R>3IV_#IV_E 20
M                #&YGCNA\KUZ].L:?<=?NZM:K'4!7GA)G_P"5'CGI\>I=
M$5+IU^S/;#T&OPQ]F/U0%J@
M
M          1_15]2_;U]+X>[MZ9[^[IV].OCZ=G=\?VNO4!(
M             ,6G&VVL*F&VN>FVL6D&VN<?/&V&E7G&<?FR T-PNTU+XK<<
M\:ZXU_\ 475>N_3'3];2'-7PS_+S^8!:(
M
M                    $#WK?Q!X_ K]%Z/R^I[L>D\G3L\'3KU[^OZW3I\_
MB G@                        &+S?'="Y=K^]%W_'Z6I7@!HWAQIXN+O'
MLKKU[*3K#];Y=?\ J:S_ & +-
M
M             _#K_/\ \'3_ +WJ _<                        !B<]V
M[(+--^O;V1.1[=V/L[6=9GK\/C\.@#1?#+.V_%CCF9MG.W=1%2[;;9SUSG<R
M",)W=M]^=]3,9Z_E 6@
M
M      !C_D<_Q'XO3$_2O1>3U7D-\WJNG;X?'X_%V]OQZ]W7\GV@,@
M                   879&^2Z\GN^.F<Z0N4[XQGY9SJQKLXZ_D^ #2?#+^
M:XL<;"L?'!G'ZH#\YS\\;:0-@3XUQ]G3.I>,_G 6@
M
M                            !#^IQ]8]/^KT\?;\L]WE\7E[?G\O%\>O
M3I]G4!,                         ,"M3;72L+'WVSG&ND"F&VV<?'.-=
M8\XYSG&,?'.<8P U3P]+P1Q5XU$:XQL7K0=3;EF=?UMM#(0R&Z8VQTQG'4HS
M7/Y,]< +)@
M                                                         A_#
MO]8\_FSV>+L\/?\ #^B_<\7RZ_']OY_H 3                         #
M7=O9[:FM#;'SQ7<USCK\OA&G//Q :XXE:X+XP<:RM<9QKIQ\I[IC/QSC_J#'
M]/CG\VF %BP
M                                                          8]
MZE5^(_2_Z/Z/T??\M_4^HZ=?VO)V>/L^SMZ_;U 9"
M      UA=QF"J7MTW;KVE5A/C-NGQSTTBCMMGI^7I@!A/%77.O''CYUZ?"@:
M9TST^776 ,6<]/R?K +"@
M
M        Q[RZ_B?Q=Q'D^D]WCZ:^I\7J/Z;KW=W@\GZG3I^T R$
M               !JF]NF:0N3'WU58?P^W/_ %1> &,<6=<:\<* ^'3.M%4]
MKG'QZX_]7L?^&<9_, WZ
M
M       #'OA^)/Z8WN^G]/!Z7/9V=W])ZKN_HN[X=.G;W_E 9"
M               U+?)F"J0N<[..N"*GL,S.,?/;&L/>MLXQ]V?@ @>,>OBX
M^445UQGMI.I=>N,=,9\5?Q[7KC'SZ9[OX &^
M
M                        0GZWU_N[_P!3Z?X?%_-?TGD\OFZ]WFZ=GZO3
MIT^W\H";                         :/Y('[$T%>>Q>^=-]*8M0W.<?#.
MOB@CWMIO\?W-P#C7C&./]&=,?'^YFK.OWXQF!1W&O7[NO;G] #>
M
M                                       ,9\:G\5>I_GO3_3O1=/%G
MP]O7U??W^?IW>7X=?'U_B]0&3                         - \H#.SCMR
M"ZX[,:T7:^?-UQ\>^!2+;;7IGI\<838QCX_: E>/)7AI*G"==NI9-05@3C3I
M]I<+9L8VZ_EU ;I
M
M  !">N_VY]/[=>OI_/U[]>[Q]G3KV=>_]OX?+I^7K\ $V
M          KIRRSTXT<C/GU_N(MGMSC.<9QM_=W*^G3\O4!E]%ZXTJ*K--=>
MW72L*]UQKCY:ZXAS'C37'Y,=N>@#;@
M
M                 (STY/U3U7A)]3X/!Y_$7Y_!T[_'YNWR>/R?Q>O3K\0$
MF                         KCRSVZ<:>1^.G[%!6V?C.>O3.2X%("\8ST
M^.,?S^?T ,XI;7PU75I6/CC-8P+KG/S_ )J+-1>/ETQ\<?,!M8
M
M                                     $%]33_B#Z5U-]5Z/U73P;>+
MP?L]WJ._M[N_X=.G4!.@                        *V<MOU>-')+;/RSQ
M]MW7'Y\PAXQ@!L*GM-M*SK$O;IC<FM(1H9CY]-OPVUZ],9^6?CID!M$
M
M                                          $5U)^J]O;IZCP=_=VZ
M>7Q=O;T[^GD[._[/EU 2H                        "M_+37&_&GD;KG/
MPS05LXST^?3,*=\9_P &0&QZMUP5!:]*TZ]F*]B>O7/SZ$L+5J7U^[.<;Y ;
M)
M                                                !%>G+^I^?]?O
MZ=W](9V=?!XOV.[LZ=GV=.G7X_/X@)4                        !6OE?
M_P#33R:Z_91%J=/R=:_>OE]P#:M:8Z0J&X^Z#0['Z&5. S\
M
M                                  '1_P!>_P"+_P!& [P
M               "M7+#;&O&GDWG;.-<8HBT]LYSG&,8QB /6,YSG/RQU ;7
MK7_^BX=__8\/_P#Y*0 SX
M
M        '3Z?Z9UZ9Z=GS^SKV_X^@#N                         *K\U
M-O!Q/Y/;EY[3C>/MN=N_[N"H*];[8Z8^.>[4OIC\N0&[:YTSB'1';KC./P=%
M2>GV]269)G.WSZ]NWD^ #.P
M
M          1_D-^H^/L,\/A[O+\/'Y.G]!TZ=?V?UNORZ_ !(
M              *J<W=M=.(_)\W;.NN2^/%Q9UVV^6NWX!?]L_HTQG/YL -Z
M5WC.(9$L9QTSB*QWKC/SQ_L5OQ_D 9N                      .KKE3ZG
MIVZ^E\6<YVVZX-\W=KTQC'[O;U =H
M                                                    '0[=?J'?
MUV\GC\?3OSV]G;W]/'U[>[N^WIU =\                        !4SG3_
M /1YRCQ\LZ\>[CVZ_;G&U>R$K_&9U_@ 6&A9?@C<<3]>[PQIBT[OO\;8D+ZX
MQ]F,]O4!EH
M                                                        _#<_
MM-U*Z=>[7;;KUZ?LXZ_X@'1[2_J?DZI^OI^GC^'J/-T_I>O9W=OI_AU[NG3X
M= $J                         J#SWWV+X9<J]],YUWQQXMC&NVN>FV.Z
M(.NFW3/V=VNV<?FR M#'=,%,S*7G7&FV&=NUZ8QCY:(4FO3X?#&-<]?@ G0
M
M                                            !\YTUSMW9UUSMTSC
MKG&.O3/SQU_* Z'C*^H^7QZ>7Q>+R=,=WBZ>3Q]?W>_X_G 2(
M             "H//;IGAIRGQGY;4!:I6<X^S'X-=3.OZ=0%JVPO!:5 7C.<
MX);DFFN?OQX=-.N?X"L?I 28
M
M           .C_KW_%_Z,!W@                        %0^>6<8X><GL
MY^6:'LK7./O[HVOU^7YL]/S +;DZ>,O77.,8Z8QCX?+&,8Z8Q^;& 'Z@
M
M                                           CO)I]3\/7^<\/EZ?\
M#IV?/[^H"1                         4_P">^<XX;\H,X^>*'LG/\.L;
M7[8_PX 7
M                                                          1O
MBU^J>HZ[=_IO3].N>WQ]?+^S\N_O^W[O@ D@
M%-N?:DHOAMRFSOW:ZDT78!.^V<8Z=ZQ@5$%=/CUSKC<_'7/V= %R0
M
M                                         '1_U[_B_P#1@.\
M                    I5[AFF#.%O*$G.,]A]-2K0W.OSSG<@HK&.['QQW:
M9SC^ !=4
M                                                        !T.N
M/7]O7'=X^_MZX[NSM[>[I\^WN^'7Y=0'?                         4S
M]PCKIPMY,&Y^.NU3/Q7P^?7/CQU_[_\ P +F
M
M                         (SQ%?5?4>/'G]/Z?S=OZW@_I?#W=/V?+^M^
M<!)@                        *7^X7@P[A=R32E[9TV-K%PTTVZ8SW;G+
M$I62\8VQTSMMC.,=/GGNQT 70_[H
M
M                #H_Z]_Q?^C =X                        !2WW 3N
MWB'R")QCKG:!DYQGK\LJG]H2XST_^SSIW +I
M
M                         .C_ *[U_P"+_P#==W4!W@
M          %*_<!US_NE7SC./B="FO0KY==^R6LNIFN/R8RHTZ_9^L NH
M
M                                              A?4;?7/2]VG;Z;
MS=OIS>[IV]O3U'?X^[N^/[/3M^'7K\ $T                         IC
MS\U\G%.Y2^O3K&&G7^ ^<1(O?[.GZN"\?I 7.
M
M                          1'H$_UOZIX]/6>A]!YOUN_TOD]1X>G=V?T
M_P"MUZ=?L 2X                        "G'/77.W%>W]<?M;LD>UU_-F
M>Q'&WQ^SY@+C@
M
M (_M,^I=_7^;\/;\M>_N^?;UZ_T73X_O=WY $@
M   IISV-V+XKW 9C&.I;5&-=>ORZ'3^'XVSG^3CH N5CY?PY_P >0'(
M
M                                          (7UG_6#Z?Y"?\ T5ZW
MP]NWG_\ *?3^7O\ V/%_%[?GU^(":                         4NY]]=
MN+5MXQ_^&PXO\G<99<+[?X/B NAC_+G_  YZ@.0
M
M                          =3K_IGRSU\?CZ]<=O3^EZ]O3KUZ_#Y@.V
M                        I9[@^<D\3+4.*QU-,4UJDV_C=2E5N0%.9KKC
M[-]BS<XUS]_Q 73
M
M    1WG+^I^GZE>3P>;M[\^?Y=GD\?R\';^KU_> 2(
M      "EON [].*]BZ9^.#GRG2<?+IC8^[JY3Z[9^W.-=C<9S^3 "Z./\N?\
M>0'(
M                                                   ,6[]_Q;V=
M=>SZ=U[>['=T_?[>OD[>[X?+Q=?XW?\  !E(
M"EW/_&,\7)QC..N-I;1Q>?\ -VORKM<X_-G&P"Z./A^G/^'/4
M
M                                     !BW=O\ BWL\2?P?3>[S==/5
M>KZ]/'_1=_A]-\>G?TZ_'H RD                        !2KG\9_\L<U
M)QKUSM-./Q?7K\,>MY#U>FZY^W^;[>[\OR 75
M
M                          1?_P#%>_O,Z>'P>+]7Q=W9Y_-T[>[R]/U>
MO7Y )0                        !3+GF7@WCF_P"G;C;!MB\=2S=?AT,Q
M_O*T]V:[8S\_U3-\8^[KD!<T
M
M            !CG<M_$?3P&^A\']+Y$WA\O@Z]WCZ^I[_P"+\NG\ #(P
M                    %/.<^O7CVZX^PVU.-!.WY-5/)RG2-ML8^W.FN.N/
MR@+A@
M                                                     ,;^H_\
M67Z7X]NOI?5^3PJ_'V>/Q]OG]/Z/R]_\3R=W;\?R ,D
M        4UYV=VO'U9CKTV47+Q7)(QU^&=M>4-.G;Z_DZED[9^/YOM 7*
M
M                                              0OI\_6_4]VW3P^
M/IW'^/KX_P!CQ^H\'E_C=_C_ &?U>O4!-                         *;
M<\/_ & )_P#WY\6__P I6J %R0
M
M              &-^L-_$OH>I7C]+ZK^-Y>WQ>+M[>WM[?)\>[K^3I]H#)
M                       %*^>&NQU)L16F>FW^\-Q3QGKG.,9QGDA5N>F>
MG7KCI\P%U
M                                                          $9
MTV^H?//3N^77/3IZ;I]_3Y@),                        !33G 7DVHXP
M5VYVP=R+XKZ[:XQG.V==.05=G8[.GQQG!A.N?M^&,X 7+
M
M                                  8W]0S^)OIGIE/3T7K/5]Q?I>O;
MXO!V^'R>3[?V_P#  R0                        !4#FD9C2M8"5G7.<J
MN27%XC3/PZ:[:WG#%'=MUZ]<=I&<?GR M^
M
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M3 0_).HJSY TU*>.MK2)5'XU=:+:%[X8WQJC\I=E)/63G(HD:[)7(I0[:)&
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M_6Y_$?T_P[=OHO5>H]07V]_3Q^/TW9Y.O;\>[NZ?D 9
M         ICS-+-,9N/Y9>NVWDYC<7MM]=>F>\DJQT)QV-_^!IH3G;/Y@%S@
M   >:7N$GJ(]//;^LPV'V3+HY4W+]PF4L+JRJYW;\E;&Q;QBY$PIN4YBU=L<
M@?R$*V22U$CW6[$83)]E&OEWUQMU ><]\6'SDM#G75=CTX]<@HA1SLMXCO\
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M5[2-HD$</,65W)V5'+H?LJ2-JY>N,/U4ZA2WBY[EG*!6<T22SK^2R>G=N0/
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M?\X#D              0OA+^L^;MSW=O7R>??^E]/X_'X/V?'X?CU_>^(":
M                        4]YAYSHW<=>F.N#N7_'0O;_@XTF!AO=^G7&
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M+*Z6E;#W'X@FKVW6F]XC'JY8'B;KF>MH<T6NQ(W;#,Q$M[6;NF+),(W3:X)
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M_<#L;Y^&O31.BVWQC/PSMKC&/CT 74
M
M                   8Y]00_B'T/B4>NZ=OE^G*?#V^C]1V_4/!Z?M\?_#Z
M=_ZO[7P 9&                         I1S%_G'CB,FVQ_-[\QJB4=<?#
M;!B1CGQVF,9SC..W;;3'7X=<X^[Y@+K@*"I><:Z3N'*YDK?CM<,WD?&N0U;$
MX]&=F]-%7RZW6TSLMZ%^BR"4:-RJ-ULQ.>AQBI_<"_":T(E3FF)/2:I]U(;K
MXL\A"^2M8+)[O$3H.[L%A6754MC?XB:)DUM\UJ:;/4"EN(W-&+!37+XP8],9
MN42_0A*:87UT/3IS]#"= A.8W*)#Q(ILVSLP20VO*7.41Z$5[4D.5($4QLR8
MOQQZK,<C*IUSJUE+VZ*M+H\&Y/VTTRD:SL=V-N@"<FW+.@*UH^(<BI]8K;&J
MDGK9"W*&R(U \.RV59L)K(>8@V1F,1U \R>3/SVV'^<E W)%2K8DLPS&G849
MMJ&(,'/CAO*IC7$ C7(VK7V7VXPQ"25RS-<@+6;R=IL!([KH-NF6$Z;-J)=+
MTS MRVHU1Q"U9LE-T**VWTSJ CZX]PSA3;KHB9*UY)U?+W9SE[+ FQ V/!NI
M[G+9&HEB)B9V["M,FU7&.CE!7=&4:5G9/LO0&I>_U&,%Y#;*_DS0393ZZ_EU
MLPI-3+<XNS.HL8UX)Q&MWADF*ZO'!H1*]>N[F[8G3<<T$I4VIQZIPUP01H9O
MMKC8*N;^YOQMD'(CB]QPJ.4LUQRGE%$IA8\=?X?(V4N,1NN8;NZH%<A<5[@H
M*R\/"^0,#B@*8T6-W4DQK6[*2B-2,]P8)GWB>$Z.T]ZXD5F-4,;$<XONLW>R
M)DZQ]A@C5/\ C]*:DB<@CAR\YY-6[?B9;;9)S4JR3J1ND:UAQV22M-=]@O4G
MY&4*JMW?C^GN.LS[Q+;OJYE2$S6/&6%HV_2R7S*O,4T<-GCLU8U!:[.,%9WP
MCWU/Z>+.-P'X2#DMQ\BMI-E'R.[*M8[C>DF%[35SK.(ZCG;BDV;7!X*-21@Y
MQT=S,GM#2J5%:>+O-3IC3-,;::;9P&MH3SYX262YQ=DK_EGQXF;S-I)I#8>U
M1NW(0[+Y1+#49;@3'6)(D>C#W1X4HS=3"B"<;&&XSTTQMGX (&0^X)Q60&:(
MX7;T(N%Y27M4G'>51VGY9%)Z_P "L*Y[!(K.)Z3AL:W[SQ]J32?<TM889U.+
MPF.U++,,TR6 V,FYA\3UB2?+4W)F@CTM4Y5:6>J*M^ ;IJ\W0O1,;68FAVL@
MSI&O!(U!;?GUF2?]-WU(QU,VQKD.QIRXXL[M]?NW^\G0A39;#<4[5:N46]7Z
M5/8[6>NPU%+X*8ID)6)4EV=,^E[T/GQJIQDK/0S&=0';WY4\9BXW&YD9R*HD
MN'S*0*HE$)9O;E?Z1F52M"=Z9;&(V_;2+#4^R%&HQXSD24TU25O\-M,9 8!$
M.<''^>VC.:FB4HV=WRK9=:\&M!YQEJ0Q:NY)3,<K>43--*G-S=T2E&B+06@A
M*(6%)SD>5:1<2::5NEVQD-B[<H>-ND:C\TVY!T=K#99NK*BLMVMF ZQB3FH'
MAOCR\N.R#:0X:7LQ$_NR1"=A,<;DI8J*)VZ&&::Y#9<MG<*@#06_3R7Q>$LI
MRLIO*=Y?(&F,M9C@HU-W3H=%[VL0I=EA^A&^="L;]^V--LXQ\,@.@Z6;7K(^
M,T8>IW#&>22--HMCT>=90QMSZ_HS-]BM%;(T+' AQ=DNYA>VN#$Y9FF=M<XQ
MGKC(#II[>JQ6<RIDMEUZI/DCN?'XZ2GFD:.-?G]*0C5*6-E*+=-C'5X3I7 @
MPQ,GP8=H6<7MG7&-]<Y"4_O#@V7.0,N)G$MGB)EHCI4TZR-FRY1DIRZ?33)"
MA]=ZID+<>['@V4Z%8.ZX[.O4!^3%94 E"DM'&9Q#I$L.:3G\E(PR=C>%1K$F
M<CF90]E)VYP4FFM!#PF,2;J=<9(T4E[%9VP9KG7 ?JWV%!75F22-LFL0<(^O
M/4I4+ZADK*L9EJE&?NF6)TCHF7FH5)Z527L6;IH9ML7OKG7;&,XS@!UHO9D&
MF4HL"&1F1H'B3U8[,C%8+0EP=ZB,.\DC#3-&)$NV,+T)-,<HN^)5FFQ.QFF-
M#>W;;!FN^FH9 ;)8^2F.6F/S(6B3K-VY0L,=$.B4AQ*Z^1 <HV4:E%+2^GZQ
M6V<&8^W #!+ENVL^/]=22UK;E*.(P6)M_P!3>G<\A8O.*295)$6NR-J;"%CJ
MYF[*UY.F"TQ)N_4S&>G3X@)Z&V)&)VW'NC"J7%IT\FE\2W(?F1YBKGN\P63/
MT2D.I#/)4+4Z*&\MXC2WTRO0G9*N2E84IS#4^^ANP91H[-AR5,N3N3><A6FE
MD)%A:Q,8E5''&^ DE,HU-R2>::?^IKKKG.=M_ACX@,<C%A0N9?7/PO)F=ZQ&
M9B\U\_Y1*M=OI<VCVVFKW&%'?G3_ &PV9,QY2M>[./LZ],@,RSG/P[<=>H##
MX[8,.EDCGT1CSZF<Y)5SVSQN?-1)2K0Z-OC_ !)AG30WJS#R"B#C5T3DZ!;K
ML1N;I@M3KKMMC?&VNH9D  ,*CUB0V52B>PQ@>R7&3U@XL31.V@LA66?'7*2Q
MMME[$D4FG$%IE!CC&W=,KTR1N;KKH;C7?.N^,ZX#'3+PJDN>(JPQ.&15/ULH
M/A68LVF'.KHURM/7V]K989)HV%*RHHX'USIAX(T<]DGJ4>Y>Q6=\F%Z[!M<
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M'HY(N,5.OK/%I$GEC,E=X:VN.Y<A3QR+Q'=Q7JU99JU[W<(U"69&M+7&*"G
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M,ED<:N0Q^QV-/VLZD9+QMG/RQCY@+D
M
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M^FI+N<8F3F*"/2J#"2S#TV#=#O3';Z8V-3^8O&-#O!OG.O=C&,;=.N '8
M  8F^PYBD+S%7MU:6YP<88\GR&-KEI&35;&\*&1TC1RYK,UWU\*@UB?5J?;N
MQMC):G;'V@,L
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M,,5,D^B\O3.BN,RB-K85,)?JUFKD[,<8I8GS#3)FHK=/NN;DV%)/<%R0
M   8YZ;7\4>LZ;^3Z9Z;R]2^WP>3R>G[>SO[?-_.=W=W=WP_9 9&       #
MXR67MGKMIKG/Y<8^_K^GJ Y[->F<=N.F?G\/G]_7[^H#GICITZ?#[OG_ (P$
M8\L;+(FM<QO[0VO;,Z$[)G)I=D*9Q;7!/OG&=R%J%64:F5%;9UQG.N^NV.N,
M9 26==<YQG..N=<]=<YZ_#/QQUQ]WPS^@!QDO3/7KIK\<]<_#'QSUZ]<_?\
M$!SV:_=\\=,_'/QQ]WY@$*]1F.R0EN32%C:GM.T/31)&M.[(4R\AOD# M+<F
M)[1E*BS2T[HS.).BA*?KC!A!^FIFF==]<9P$WC&,8QC&.F,?#& '(
M
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M^.QN$(8U2]5K9$X0..OC3"4[8TV%/$2F4*M5LM=2-W58GU*)TP1I@_!X7[
M     !">9-]:]-Y"O5]GJ/#Y,>;P>#Q>7LZ]WC[_ (?=U 38
M
M
M  ^=L],=<?> @?2F?7/6^8OIX.WP^/?N\/B[/V^[L\GJ?C\OV/@ R
M
M
M        ?&_R_A_R9 1/F+^I>G\F/+V>7Q=-NOC]/V]>O;V=>_[.O4!,@
M
M
M          #XW^7\/^3(" ] 5]<]?Y%'F\7B\?>7Z;IZ7Y]G9Y.[M_X73K]@
M#(@
M
M                !\;_ "_A_P F0$+_ #7UCK_/^?TW9U\!OI_'V=_;Y^O@
M\GY.G=_  G0
M
M                        !\;_ "_A_P F0$9XT_K_ "_S/J/'V=.A7F_H
M^[N^7DZ^+X?YOY $L
M
M                               /C?Y?P_Y,@,=\"G\1^;R%^D^G=WC\
M>?)Y^[P=?)^ST[/CTZ=0&2@                                   XZ
MXS\LX <@
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M=/ZS;^S .IG[NG]9M_9@.>N_V:Z_R\_\S(#CJ9^[I_+V_LP'/7?[-=?Y>?\
MF9 <=3/W=/ZS;^S .IG[NG]9M_9@'4S]W3^LV_LP'UCN_C8QC\VV=O\ 'KJ
MXSG?[-=<X_+OG'^#LR ==_MUU_EY_P"9@!QU,_=T_K-O[,!B'1;^-.[N<?1_
92.GB\?\ LGU'?^UZCR=WJ/']GBZ?E ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>tv526458_ex1-3img06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ )L  0  !P$! 0
M       ! P0%!@<( @D* 0$                     $   !@(" 0," P0%
M" 8% A<! @,$!08 !Q$($B$3"3$405$582(R%G&14B,7@;%"DC.3TQBAT7+2
M0R3PP6+")8)3PS1%)AGA\:)C1%2DQ#5EA:.$E#96-PH1 0
M      #_V@ , P$  A$#$0 _ /W\8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M L'OI_S-]OPI[GZ1[G^S4\?'[GCS]SQ]KP_T>/+R\OPX]<"_X# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M& P& P& P& P& P& P+/S_\ '_'_ /8_/'_\[Q@7C 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8%L_OOU;_1^U^T^O^G]WY?P_7GQ^W]?IQ_EP+G@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,"U<!^M<_C^F<?C_#]SS]/I_%_EP+K@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,"T>GZW[? _P#TA]SY>1N?/WOM_'CGQ\/#UXX^
MOK@7? 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%G\!_7O/Q)_^J_#R_>\^/N?
M+CZ^/U_9@7C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%JY_^-^/X?I?G^WG[
MKQ_JXP+K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"U__ %9__=__ -'P+I@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"W>V/ZI[ON%Y^U]OV> Y]KS\O<Y^OE
M[OI_1@7' 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MA!=(@?5/ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MJ2+#56^;5;(ZLKNU62,L\UBC2YZ9G8TR%LC&=@M*U:=-VRCUNA(/OTQQXKJ
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M17/5^SXC;%-N;*JP]T3:62$J]PK+)&1K<ZX:QTI&F2N"BJB9E""<42EY#D1
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M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"S_\
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MZ8#]?4"#P/'Y>F!,%XT*D*QE4P(4HG'GCD  .1_=^O/[,#S]\RY /?2Y$GN
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M_!3"41%)4.#!ZCZ"0!X_;],"'W;?^V/^[4_[F! 7K8/JH/\ NU?^Y@>P<$$
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M+XX-6B2G5_2)@,Z.4QB)1BIFY2.5/!,P@0/=,)2B/T 1P,&I.O.R>SZ[+2E
M^3]]:H>$MEZI$Q8H7K#I)VO&7&BRLK1[K69 PM?MVLA4;)%N45TSH%,1PB/(
MF3XY"@EZ'VECKC4-=K_*&E'W/8L%(S&KZ\;JQIMW(V^'UPUAW][DD$D5$TY%
M!B2<8"NHDLBF4CP@% 1.&!MQUI'ND<'I6O?9TT74374:@/5+52S=L+EX!F*A
MT_O0=.0(U(HDHD50%C*\*<D)^Z(8;8]9=@JI%W6T[ ^2^RUEC7JHI;9MP737
M7>LP--B*W&.9*VV:1CI^ E9A.M-(IH=P855B>P0ACBJ</H%7":4[+V&&C)>
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M7"_P>J?EAC+-)REDF>PDCOV+TI9HRS7^%V917W4^UU(G1O\ 1:A3M<Z]5M;
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MDGNZVCO3LUH^GU>Z;Q0>6)XR85:[O;R\E*G^DQZ(*L?9<?=O6[DQD YOW?\
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M/U4JZ[%VV$P:D@?E\W=*W)9G:>OT'JM/7.F.UFP;Q5KY8K#5XC8SS5U&ZO[
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M4Q^U7>E<_P!VBFW,*KGN7N\R@HD2$Q3-^2!X&']X2_7 ^EV P& P& P& P&
MP&!9_P#ZO_\ [G__ $W O& P& P& P& P& P& P& P& P& P& P& P& P& P
M/F+V>.V#Y(_C0*L10RJM0[QI-Q*!? BH:TUP^$ZG)@'Q]F/.4..1\C!^'/ ;
MOWAWKT9UYWYH+KAL8]M1V#V/FHFNZZ<1,(S?P!YF<E'L/$M)5T>7:RB?W+V/
M5]Q1HS>),DP*HZ,@11,QPP;OK\@%%Z1T69=N:E=-C;06U%MG;=4I%0KCV78M
MZQJEK -9RY;#F6ZB*-2UW%VFZ0;%^]**[PGZ@!T6ZH)J"0-,0?RLZRJ>YME:
M2WM!SM=MD/O[=VM-=!K.GWC9$<^UGHG4NC=I7?:.QWT5#K%H["%9;B$SU90G
MV#=!F/\ >F/X^X$(#YKNCEOH)KM1Y?:]]F5=DKZOBM14C4]FM&[+!.)ZVDMR
M(2D'KB)(YE7M<?ZHAG4Z@Y$Q#&0;J-13+($,S +Z/RM:ICK?V&K$]IWL"F;3
M>U-'Z?H+&N:RL=FN^_KMN_2T7N^-K>O-?ECHR=:VBK5%P\>2T<]%-1C&,1>+
MG2]TJ!0WQJ#Y ^MV^=B:RUEJB7O-NL.U=(H=@X)ZRUA?$JS :X7L=II@+;"L
M[F"1A=>64ETI4K#FAYA9I)?J;)5N"(G*( &.WKY->FVM=B6W6MUV7,P<K1I2
M]UFRV%?6FS%J"TOFM-;%W'=M9,;XUJ2]8GMDP>JA&>/#1[ET[.P(?P*94HIX
M&XY'M/HZ*T%#]GYF=L$+IVT(4U6#FIS7NP86QRR>P;1%4ZB(IZ^E*PTV"16T
M6&?9I,4EHQ,RJ;M-< ! X*8&IG/R)]/&]00O1ME+*UF1U.SW:R=A2KH1W(:Z
M?[79:/&92B', A+>^WV9*-8UTU41(Y0%PFJH0$1\P#E%M\T779G>8R!MU"VW
M2=?JRO<.N2^P)?7FPI7]$E>GNVM?ZKL4DI6JG1[ H;7D^%S7DU[&HZ;Q-<2C
M3M9%1)R)TT0[64[V=3([8MHU<OL]JTL]&D+M6YUZ>IW-.D,[/K;7X[7V!1(W
M9'\MAKZ6O%-UJB>;DH-C)+R;5@@J=1 !14*0.>I/Y1^J\3)[)O5L:6J(T=0-
M*:QV8XWNKJ7;\DY=U+9=KW1 N%IN@M=5J7^H:NB3::5=EM$FDE79()% $5/W
MD3N RMY\E?Q\1UD@-?3^VZY6'*E'BMH0JELU]=*S38:+;ZI/O6/9O+).T]A5
M:GL&%TRBE9_T!XX:3[2&606!L4%"%$,LZB]X*1V^VAV+K&O:Y-M:AI%#1"\+
M;K+!W.F6*UI[IUL;8OMRM!OM2JEDJYX9J*'LG.1=&0:NDG"9O 0$P:M@/E:Z
ML;0K#JXZ5FEKS P>^M4Z4V9)6&)G==LZI$[.DIQDVV"9[:(%%*:KL8PK<@X\
M $@BFU.54R'[OD%L>_)1\>N_=,V:9D9.]WG6D+<>O+!_6G?7S?#><FIO;E[)
M(=9IBGTQ2A,K1>(W8-KI[:0@'$*W>IN4BMUC "2I/(+6;Y<>O@6 ]A_2+Q+:
M4<Z0U'L^K7&O:\V+/[3F+[MGLELOJ^AJ FB6%-6V"UM45L'7QFBI"HBY*Y,J
MB= I4RJ'#8RGRK]*VD)JVQJ7"_%9;>@8"PUD&VE-MOG$$QMVY?\  &N-MDDC
M:<Z3U,]F]N-W4,@A8SQ@G>1[HGHH@<H!O/LQW,ZY]2"UM'>EIF(0;3%W"U-6
M-:U[?=E/8NE:[0C7VP=DVB*U[6;0^J^NJ,299&E9U^DA'LSO$0.J!CX' EH^
M51*2[&;*ZZUW1#>]4F'[ Z[ZVQMX=R%O<0-R7M'6>U]G-K6"339:QG*FW@8;
M7D*6-BFP2+S]1>.17DQC(P4W*H=%Z:^2'J3L:L:DBY.RQ5,MEGT'K[?DQ3&\
M#:++0]/04_I=??+*O6G;<736FL*W.UO6<,\E&[1X[C7ZL:R^Y1:E3,F A<*!
M\E72'>#*I)5*Z6"UK73=S;1M9K#C2>W%[*ZV8WJT-L^&7D*@YH:DY7:TK19=
MC8F=BE&S.(2C%B.A=)E 1*&]+KVXZ[4[>M5ZRV"X.7FZ+0E7G["G0=(O%S1@
MD[8M/HU!W>;)6*S-U36Q;2M5Y((Q2??1OWOV:HHB8"\X'!5C[<?$[NVX->S%
MN;'NNS.JNV(72<)+R6A]\O\ 9=0V/:OYAM-.C(76;.B'M5I+(JU>3DX9\$0^
M2:+M%G*"B"O[Y@[IE>WW66*ZU1W;V0V+%GZZ3L'5K!#[$0@[!(MYF/ND[&UB
MHH1U;;0KBV/Y:=LLNV8MH\C STSQ<$_: _.!RS.?(_U?2VM)56]1D'':5>]0
M:3V9B]S6J-D2K6^OWS=#_4,%J=CIV2I0; =65U=&*/V\:*!Y!Y).T&R$>=P;
MD V6Y^3OH#",-=R4EV(I\"QV4I--*8K+0-TAP!:K[!:Z?L3:?0?59NK05*]L
MEVC7WA9PL8+604(@?Q$Q0$-F=A^SG4'J,A2S=A;I1]7(3[JYVNDMY"M2,FJ9
MQ3& 3E_N$='5BOS+F)0K4;,@ZE9<R:"+9-R)UEP XB(4+SNWTVEMW0W79SN"
MDRVY9=:NQ,/4/TZ6E2*O-D4)YL"KPR=G2A7-/:2-YUPU6DV;,\@FXD8XAC$3
M.7TP-3[7[<=0^N_:F/Z[[@KM-UM+[/TE6+FAM68K,0A4;&S?[%0TM7]:VV<9
MPJQHHA'A&"#-:970B#)KH-"'*H":9@M&Y_D3Z,:@I6\;Q'W#7NPYG0]NK<%M
MVE4D8$]VBG.S]L5;2MHF1;R*#-*<8M+-)?;3;QNHNU5=QBC%=<'28)E#/:+W
M1^.MY4-7T:B;MZ\QU&VV1W3M8T*/7@:Y 3Y7-P6UR]J3:DK,(QK#*.[VZ4A%
M(UXT:G6E%#-13,L82"&D-/=YNK>V^Q-#Z::KT8BE(RM+[5IVUD^@-<UBLZVU
MUHK<DSU\LD4O5DUUE;'#[9OE&.1".C4#I!%MT'$@0@$*D0.H9GL-TEUEM'9,
M8YV!HVN[PI&NY&?V5'1 5D=IM*#KFH.;F[CY=*':J6643JE':'DDX?R5<MHW
MQ6*W*B8IA#FB.[_=3HWJWH/OEM[6C'6T5W1L^JM,P:Y*[6+E=))IM^TRM?H,
M;L*RQ;-D*]8:P#9:6EFSA59**; NW*FNX(":H6O3W=;XM+EKR;?H&Z^:J:]*
M7FQ%9;7-HJ^NXN=ZTQ^OMPS^I'%BKD!!LI%M3FEIN=915BBPOB^=F?L2BB5T
MN1+ [ECMK]86>D);LG#6S4[?0DE6I'8TUM>'4@"4J3KA&SM*5L;^78)%1D50
M2,NV6*H!W9EQ4;"051,F(<I4WLU\7M )!S-5VII-@W[H3CN?B'!S.9%I=UYA
MU5](.XZ:*^CG26O*NYL%785@T9,A$1I9INHP!('95D0"JN7?'XPM-2]B96/:
MNCZ[-Z5V$_UO.(0-,7F)"@[-<1\E+V*IL@J=3DEF-I81=%7<S*+(158H1Y#O
M?:*5(1#=G_-9TGU]L1AJP-K:9I][5U:C<HN-:.H:(8GUBWAIS8#9.-LC)NC6
MA11JC1_8TH=)Y][^C K*$;?:&,X$,(IO<OX\+M8Z8UHNW-%6*:[#O&,Q49:O
M,&+UEM.4J=CDH^O.U;4SAC0\S.,[9$O4X,KUW]VYD&3C]/!15!42!HW7_P B
M_07M3'5[:,M"UU_1:/I^3[)QNT]M56F.T-9,XG=$UIEHW9MY%69M,%?)RWT]
M9:,)&MC+.P123(?[LR2 AT!8N[WQXUAYJ>TVGL3UKAG^Z(<[O3MEEK;3T'5[
MA0NB3%T:KS:Z@*.&C78IRI.2>Z3[>: ?> CDH\!L'L(UZ\:$ZU[:V/>=-4*9
MU7IRKW3><O06-$I*K24G*I'R-M=/(2"E632M_P ]3DBW$K9VL**BC]<ICK%$
M1. :^[([IZZ1EGZ5T?L;4)EJ]WKNFLS6EW\LV K36N]:!!%OU%_FF5BI,KBN
MR;]^H:#;K)F68NWSP(YP8R+WQ4#66O=V?'YMJO2&IY*JZTU#8^Q^T.PE=EM,
M6*(K&O-A[&OM=V'LKKIL.\NDZBLWD"V;83ZE2S=A-'=MYI^V.*9% 7*HD0,.
MZB[(^)K2+:N:8ZV;NTZ_F[1MU\QJS6P[=DMC;!L^WG=3AZ2)8"S;%G)RR/9!
M[3(UI LE&3D&3INU,Q;F44373 -[3=8Z(ZX[=S%MO2VG$NW.^Z]!1D8M=TJS
M*[+5I\95WE*9UBEN9".6G*W5[5&0SQ-2-2732G7B;D"IKG R90A497X_]O:\
MU]\A 570R-45U,6O4[L'L2HTVM/JGJ5^\DZV:J+66TM&ZM1@C.Y5W&GCE%40
M(+Q9F) ]Y1(P:UC+]\7M55A=.Q-,ZQ0FII/K/9-J1=W:U;4#+K>XT;:=G4/4
M=B@37DYTJHLWN]Z:P*#AB8#M),\>U%4YUFZ!0#8"5Z^,&+F-&/4+1T:83\(J
M,-UH>-YC1*$O%JS5HG*D:,T<X0< \9C)W2.DH\4X,Q06E$G*(\K@H&!2[6[%
M?'%J>B[(N=QM769W7^OKW4=+V7&5\VK[))ZN?--F%)IRL6*!CUUE*F:K;)?K
MR$2V<E;%B'B3MVD")T5CE#-VCSH2RT>PT@>=ZV2O7R'KMJCV>O;#:*);-=%J
MVGV\;<+J1>-L<I*QCZ)UDSD&4G)'6]PL0BJ@X5%(HI&P+;K)3XXMF7.DN=/C
MTSO>P6>KU0UTIKP=,6.VM=-"WF*0N%/3KXNY9#7(LCOX<_VA0CQ0,X:C^X*A
M,"\5RC]#NO5JI6AZS =9]37BY0=YB*!IYH.O*Q;K=6KPK&26PHVM4599M-6*
M"LA:,S-(HHMEFZZ$,BF8!2:$(0-&T77?Q7O9&IZIUAK3K%.0B]+["W>+>Z^B
M:-.Z[B8!G#:XU3OF-L5GK[IW"QSB5J.R8*/>1SY3P4BTT@\"$9H@0$S4>AJU
M>C=&:84HVKVF_M+[^A8K=?7)M0&\9 :XK,SJV&W45SM5LWF:O&3<W,3L S44
M> \<N'2!1.(*-2"4,F::1Z',;YI:XR-SU-+141HR)ZH=:=;3^P:/+Z^CJG1;
MS!2\LSU3#RL@X>62]K6"FUJ/D7*#EXZ0"NL40*DK[PJAN2[Q74/NI45-=;9J
MFLMQ5:(VQ>*PUHNU8&->$/M'2E@FZ3;%J] 69!-S(OJO)I/$0?,DU$S-U1,1
M04E.1#"-UP70SK'J2LP&SM;Z+JFO$X*#T=K[77\G4DCF:K<Y>ZBLRUC0:>LB
MV=SD.:[J1,F[C61%$RKMTWJQ/)(J@!C\#J_J-MS=6I.R$-9FS&?T?>]X,Z/K
MMM8ZS7::?=.VK/=]=77:\Y1DVP2DYM"XGK5B:P<DJZX?1[ITLD@HH!5$0[5H
M>SM;[1CGLMK/8%(V)%1<BK#2<G1;9 6Z.CIANDDLXBG[VOR$BV:22*2Q#'04
M,54I3E$2\"&!G(F ! /7UP/FI\5R2Z76JQE<('04'MAWO4!,XE$WLJ=SMW'2
M5Y*(AXJIF*8 YYX$,#Z68# 8# 8# 8# 8# 8%@^X)_,OV_LJ>Y^D^?O^TX]O
MP^YY]OW/:^VY\O7^+R_#C O^ P& P& P& P& P& P& P& P& P& P& P& P&
M P/F/V4!NI\EWQI)N#$\B4GO NV(8_B(KCKC738XD#R 3F!JX4 0]0 !Y_(0
M#/=T]!NJ.X>T>M.SNQOYE9[RK*6O24]&*VG8:E%V%YH^VS6P*$^=U"-E&:-D
M=4J7M4B8Q"E%!5K(*INDU2"3P"W]K>JW4_NML-CKG<%BN(7/6^JYTUEK.O-E
MVS6;F?TAO*<"&E*QL.3JCB-5L% LUQTVFL,:9V4!>0H>\44%#$6#VYZB=0]8
M[(=VF:2=-K-V1V1OZOK0DW9I5Y%WJZ]GM<49?;-4:-$P%RQ1F*#UL;NVR!'"
M!&9&KQ0AO-<  .?C?&IU!IM-U'UV=;6[&I7(NU+AM_2.TVNV9XN[*;*U'6#C
M7T[ U;9\'7TXVH4.O:HGAB!8N4T2O"+^XJHYD%#+&#.7GQ^]196_WRJ06SMJ
M5/:S]'K1O [6H;L>M[QK1UHV@S/7O5&XJ6F_1EEZR_N-!K\A7)R26(NG96S5
M=)P!_$^!O;4W63J[TP0:WFKN"4IG7-/:DZTFG;9;SJLOY8K^Q;A-TY*77?JI
MHO;_ '[:&YWR[^16Y>S4K))\_OGX.&N[S\9_7+8VS[]LNR3FTG"=]6VI*O\
M7);VW6US6]F;HU OHG8>VJK$/H9[-PFRI;5CTT8B<9%2,8@<56S%)4YC&#>7
M93J;K'M)U\3ZZW:4GXVGI26LIF,DX!Q!O)5O(:DME<MM;.Y86B%L=1LS!1_6
MT4GS&5C'\>[04.55 1$HE#CV:^&[JY)4S3] 877?]7JFHM?M]2-XRO['BTBW
M_5#;=,=OXNO-@KR%0D%G\".PX9FH"L:,6_38M2-2."I&4 X7V4^)_23];=JI
M-K[]01W=6NX%7=L?YOK:K;7C#N]>Z'L?=#?6ARTU!W%,5+71@<1[=^I)$2_4
MW@*>Z4Z8)AK:'ZE]'-O]AMHP56[#WVPVE>U]G]D3?76%NE85I.O=K7ZB-NJ_
M8K:=>B5J&:SH6^*9W)5JHB[F7T5%S5A7<I,R"Y)XANW<GQ>Z)W/%1,<_O.YZ
M2X@HCJM ,YBCVBL)R2\3T[E=@V'445/DM=+M<3:X=6Q;$6D)F/E6KUA)O(]B
MH9$@HF]T,/MWQ&]>]B[VMN^=D6[8E^FK[JY[KW8$#/Q^I@97.>F-)NNOL_M*
M2GH_6+*W0%TFM9JH)G;03^'@49)HB]28$4 Q3!N+H5UFU=H_7MMNVN.P^R^T
MJ785Q2[A-[QV/<:A;']R3I.NJWJ.I.H&<U]6JG$!&,Z92V+<%$RJKJN$3KG6
M,JH<PAIC7_Q"=:=6LMMH15IVG:5]T;<UQN"\NMDR]/M*D[+ZRDKI(URKS!F]
M+@U;/791WL*43DUY4[^>DTERIK2)@22\ Y-^.KXF+3IF'O[?M/OR#W5.P&Q.
MD+*B2NMKE,NE*VGT&E'UDT_6;4:Q5B(&#37D; R05K8$?+-(PA$?U-P98JA
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M5(CV72:9[56&_P W*U Z]CFI_9=DD A&+,[EH0R;5H!2)J J+@._^K'9:O\
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M+B:_V+JE#J[HQKK/;ELC+ULRAL];5EG5KM;X5VQD(BP3T.U8(M7<A&/XY)=
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M^?\ Q/'CZ^N!D. P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P*9!JFW,H*8F %#BI[?)03(<?+R%-,A2E
M*)Q,(F_$1]1P*G 8# 8# 8# 8# 8# Q[V@_FGW.?_J'SX^)?XOO?#R\^//\
M@]..>/V<X&0X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# Q/V7G\Z>[X)?I_Z!
MY^?OF][[S[SVO_I;VO'P]G_3]S]GC^.!EF P& P& P& P& P& P& P& P& P
M& P& P& P& P& Y#\\!R'Y_CQ_E_+^G <A].?7\L!R'YX# AR'YA_7@1Y ?H
M/.!#D/S#^O <A^8?UX#D/S#^O >0?F']88#R ?Q#^L,!Y /T$!_RA@1Y /J/
M&!#D/S#^L,!Y!^8?UA@1P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P+;X%_5O=_P!/
M[/V/X@_@]SW>/'Z^7EZ_T8%RP& P& P& P& P& P& P& P& P& P& P& P&
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MR.(ZM1<4Z80K.*9QD=58%JS>-3,SMW9U'8G((+B !K[MIM/8>D-P]\%VF_\
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M1!LHX;).!,4AS)IF.4 $2E$> "MP& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!C?M/\
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M(]7>ZRQ!D#QIRAUQL*!TP^Y5;I27+R32\X\4T@4\P ?W#@80 1XP+D^[DQ+
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MT@ZA'4NE"]D52-E3 YC4^K>_23B29%/$KL\<6@_=M6BJ?]Z0#@4ZJ/[Q"F#
MKDN\.NGR(.HO77:V6B3BV!G*L>J^ZRM'I7+8CI-5$7=39OP3]LX<BNBEXC@2
M%.].M&;V/9/-=]JVCN2?O(R.;.NKVYO>?OH\CQ1\W9M25E5R^%JDP6.<42*!
M[9/(!$HE$0N"G>C5R(J_<47LXV!%^M&*?<=2^QB8E?(&4(LB4$=;+>::9DC
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M1 Y#B(#R @'T^G&!*2^2/I(<%3CV%K@D1(!U!4@+FW(F!E")%,90]7*'JHH
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M&Q^XX).%;L54GB!V9T/TUVH'U_\ MN2\**G4$.>##P0P!^7D3Q-X_F'/K^.
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M1#!WXF$.!,7WT3D*(E'C]T ],"TJ:UH"IA.>E4\PF_B\JK7C<AQP ")XTQA
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M<Y 4+XG IS (@!B^@_F& %DS$.!:MA#D!X]A/CDHD,41#QX$2F3*(?D)0_+
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M;X]?D+VGU+ZS]J;+V/L+[=.U^P!=9=X>H6NXYO8)6V;"G._EJV+4M8Z18IO
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M )R/(?G@7DKIL==5L1P@=R@5,R[<JJ9ET2JARD95(#"HF50/X1$ Y_# GX#
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MF$R943'Y*'3.]-8=FOD&US.Z=FJXKU$T-= CRV9_9WC:U]@[9"1;]&6;Q/\
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M+^54T-65FLJW_P 1UH#1.\-4RVG*^ZB$7_ZQ$T%#1%/5D#F.1&-5CTCO'!3
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MEU[KZE:II-6UOKBJP-'H5)@HVM5&GU>/0B:]78&);$:1\7$QK4B;=HT;($
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MR#]D-N0%][9:1H]TU!IN\LK_ *>ZM:WWK U#7UIL<6^9JU6S[OG9BFR-BO\
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MZ?E_1R.!Z,3R_'T]/3CT]!Y#^K ]"'(?E^0X& 6S5&L+]+U2P7O7-#NL_0Y
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MD2G557,5)(B93+KG,JNL8I  !565.8QS#^\8PB(CR.!.*7C]OT#Z<?3 ]8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# QC[YQ_-_Z?\
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MR#@_VB:3M#Q!452E$)[??&ZRZVM6T W]V!=-4>UECZ@:D@DZOU7(\W/>('8
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M80T@OMV_U+J]2G,-KY#=TXDQKSE2(==E6-NL\4T*@J$DO',%Q8I?WXIG*7C
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MQ!@>5=Y=P&:9U%.DS9UP_29))M>SVM3'.W,8"GD#"^K48D1),OJ) ,94W]G
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MM-\=2O7>4D']182$7J>5;2;8=U6C>]:92,K,:SD+5!+U6XVUVB1] 2$-(2+
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MN.4B#Q] XX+_ $>(?N\>F!Z%!$0 HID$"\>("'H7C\ #Z 'K@>0:MRJ>Z"1
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M H<^G(A^'X"(_P!>![P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP/!@-SZ<\<?GQ@>\"R?>I?S#^G^Z;WOTK[OV?!7P]O[GVO<]SQ]GSY]./+RX
M]>.,"]X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M=H&^H<A]%!^H8$])RW7Y]A=%;@1 ?:5(IP(  B ^!AX$ ' G8# 8# 8# 8#
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M/=>P^]I[K53]?R9V4B[=Q%C7OM=5(=5P4K8S5)RJF<Q6:XE#:=T[(_$?4%;
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M#@ !0H)C^\7@WK@0;=,.NS4OBEKI,I/N'+OP/;[ZH;[EP5%(Q_=&S^8I>TB
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M/'S*.:.G\@\:L6#%LN\>O7CA)JT9M&J1EW3ITY7.1%NV;($,=0YS 4A $1$
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ML4%4M=3?3O2E9I^LI&MLY8T+&3U<[.U.=D7<VP4/*I'=_?G?/056:G#1L/\
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M# 8# 8# 8# 8# 8# 8# 8# 8# < /U#G AP'Y!_4& X#\@_J# <!^0?U!@.
M_(/ZL!P'Y!_4& X#\@_J# <!^0?U!@. _(/Z@P' ?D']08#@/R#^H,!P'Y!_
M4& X#\@_J# <!^0?U!@. _(/Z@P' ?D']08$> #Z!Q@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@47!?U#SX]?M_;\O$?[?GX>7''/
M'K@5N P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P,;^R/\ S5]]]VX]K](\/L^2
M?;>[]QX^[X^'N>[X?CY<<?A@9)@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#'
MN0_F?G[M/R_2?:^Q]T//P^X]W[OPXY\O+]SC^SZ\_A@9#@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,"S^"7Z_Y>V/N_I7/N>1^/'[KQ\/#GV^?QYXY_;Q@7C
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MQR "&!> V=K@X>2=^I2I?IYIVROF+R'U#G]2#U# ]!LK7PF$@7>H"/IP(6B
M$#"(@  7B2YY'G JFM\IKT5OM+56W)$#&*LHWL$*N5,2_7S!%\<Q/K^(!@79
M"<C'2BB+9VV=+(F3(X2;.FC@[<ZI 43*L5)P84Q.F(&#GZA],"L2>HK"0"B
M>9#'#R,GR %,)! 2@<1^I<":==%/CS53+SSQR<@<\?7ZB'YX'G[DGU BI@_
M2IF$HA^8&_A$./7GGZ8 K@#AY$35,4?H8"EX'^@1.'(8$"N2F\.$E_WR^7JD
M)1+ZB  <#"!B&'CT ?K@>ON _>_NEN2@ ^/@'D8!'CDH>7KP/U_$,#RHY*F
M"*:YN1XX3145'Z"/(E2*<P!Z?7CC IQD2@'/VKSQ]?WC-SD+_2(G OB'/IR/
M !_1@3Q=<*%)["X@9/W/< I1('ISX!^_YG4]/H #Q@>BN/(GN"BN0/(2^*A
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M9Q+R(<CXAZA]?H8?3 J,!@0 P"/ >OISR'T]?V_G@1P& P& P& P& P& P&
MP& P& P& P& P&!+!4@J>US_ 'GA[GCZ<@3R\0,(?7@1P)F P& P& P& P&
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M+NZ*AV$TZ;U,Q(DIX]Y[T@HBD*9BJ 8H8G2]U=5)BR;+BE-9=V[.Q0O3FO\
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M2D9-4W<[7[J.7!T,:T<]5X(IV"IUR"S\UVVSV2SMF@V+XG*8I53JF,8#>(%
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M^=7VRADG5KOK4Z?O J"^A]]E!(R"OLJ%.<-9F( @H''H(@/X#@4I_D+ZFD$
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M< /T' J\!@,!@,!@,!@,!@63V#_S#]Q]PI[?Z9X?;>8^'E[_ #[GA[?CQ_\
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M*AA P?F;U_>,'Y_7 \@V %#'*HJ4#!ZD P>(G_\ G1'Q\Q/XAQZB)>/PY]<
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M91 H%#@ XP)RO7G0JQS*+:4U(JH<" 9176M)4.8$R FF G4@C&X(F4"A^0
M8%F/U6ZQJE\5>O&D%B\^0@MJJC*@)N1'GA2",'("/U^N!0K]0^J;@Z*JO6O0
MYE&RIUVYPU)0BF0741%L=9,2P(>*AVYA((_V1XP*$_3+J2HNW<GZT:*,LT4(
MHU,&JJ03V!32]HA2 G"$ Q"$^A3>0 /K]<"U+=%^FS@I2K=8='*>"3M IC:V
MJPG*B_= ]=I <8WR BSD/(0_#Z!P&!M'5^A=,:3_ %4-1ZQI.N"SI&*<R2FU
MV+@"R9(P7@QY7P1S9O\ <@S%^M[?GSX>X/'U' VW@,!@,# ]DZTIVVZF\I%\
MCWDI6I!PR<O&+"=GJXNLK'N4W;8/U2M2<1+))@LF F*1<I3AZ&Y# YU)T%ZK
MI@)4Z!84RCQP5/;NZ$@)P0J8>T5/89"I\%('' ?7UP.?NQ^A>K?7VI4RP*:[
MW%;YVY;2H^IZ!3*QV5V[7']EONR) \+ ,#R5AV]#Q#9F0P*+N%%51]ENDHH!
M#B7C Y[HTY\9[XU1K&Q[5LS0>[9Z>L=5D])['[3[Q_GNF7JKVQU49V"D96M[
M:G:BLW"RIE)%R2+\["507;J-E#>Z! #-ZW+?&-)P5+L-7[);/D(78*KIC4'K
M7L9V???K#>.<UM!>6%NXLSAS&5PKN]1"1)9RFVC%E)1H0BYS+I 8,4+</C@1
M:$N$]OS<-<HMAFJM&ZXNA^U'8MPTV 6SZSA-K(RS* A[<XGJQ#-:C.(O/N95
MJR;JQ_#TAQ:'(J8+M%7GHM-,U7\UN[LSKR"BWT">/=6CL=OB/E)%TX_Q(.[^
M_K36WRUEAX>LM=:R;]^_D6[:-08IINCN 1Y, ;GH.O\ J'LBV6W4VM.YFYKA
ML+4B**FP:M6>XUWG+55D8J2-$.7=L9$LKM1!$)=FHV=JJ$\"N"G(82F 0P-7
MU5UU5NFP-0:PT[VM[=;>F-NAL)TP?:X[+2ECB:9"4RN0-HG;1L5W+S;.4KT"
M[97&(0BC)(.EGYY-L9!$Z!CKE#5[SL/UTK\?LFR6;>WR74S7M#KNT+)4MHV&
MP*/*!OF/TV9^2_-=$O&S&PO[=*1OZ:J=JW?,8I:3;D.X9>^V2<+)!>]3]B^I
MNWQ[ 1#+O)V[U/$: N%>I%]V)N?9]%U76_YIEG5@CE(:IV*[5LJ+U:+L-1DH
MQV"R#?W';-7[85T0!80ZT@=3T^WV"S4FC_(5V%F;C6FC%S;:]"[HU%:K'5V3
MT&CYDZF(0FO7KJ!2=H+HG!91),#)+%#GQ4#D./[=L_5+6C:%NU3["?)CN,O9
M@VP)_6Q=16JA0TS+U2D3L;'S]SD8>\,->5N&J"*MDC@C_8$73YF\161;J%%1
M0H=!RM2T#"%NSB3^3[=\$363II#[,&2[5Z?;):]DUW:T<TC;L,G4Q)5Y1>3;
M*M@1="BH=PF=/Q$Y1  L&R+7HS116T?9OD<['2UAD6C%]&42$VEHFY[ >1TO
M5YRWP,JVK:.LEYTT+/0U?6,TD%@!FH)TS&6!(_N &7(?X>2C-H[9?);M^KNO
MY*@+]-UVU;.ZRLK-6ZQ:$(%Q#2EKA)G7"#^L(+&LS!#R<$(F+AXB0#"91/R#
M:;#KCL>QP;21KO>_LLY:R"#22C;*R4Z^S4)+Q;Y--TU6C#-=3JM7;==HH4R:
MY5!34*8#%$0'G WAJ?4ULUZZE36O>.T=QEDV\>DT)L9&BME(%RS^^(N\A I%
M2JA2)R2+WP7!Q[XB*1!*)>/4-^$*!"E( B(%*!0$1$1X   .1'U$> P/6 P&
M P& P& P&!BOW3G^<?M>4_LOT3_YD_N?>?<>YX_<>[[?^P]?#PYX]>?PP,JP
M& P& P& P& P& P& P& P& P& P& P& P& P& P&!@E+U=K36ZUB<Z\UY1J&
MXM\I^N6Q:F5* JZMHFQ(*7ZS8E(./8GFY;VA$OW+D55O$>/+C SO 8# 8&G]
ML]?=%[X"MEW7IS6&VR4Y\YDZH39-&K=T+7'[T&I7KJ%+88V0".5?%8H@O[7B
M"P(D X& A> VU["0( V!-,$2I B"/B7VO: H$]KVP#P]OP]/'CCCTXP/*C<B
MR8I*D353$2B*:A0.01(8#$$2F 0$2&* A^0@ X$E2.9KE5(Y:MW":_ KIKHI
MK)KB42F(*Q%"&*J)!*'CY<\<!Q],"NP& P& P& P& P& P& P.$.]';.F=0F
M77*XW_7#N_U2\]B([7LO*148:;GM4,5=4;6N,EMZ'A48R2>R*=+B*@Y-*?:^
MRZ;P*[Y=,QQ2%!8- 7;Y%NG%:L,G7-PTI>0&?EM@#>[G6=:DV/K:IU%G:-WZ
M2U//;;N*#(?M'._*QJR>C:^BF@_]Y!99FJ9)FL118-J=;>U_2_>NYK!1=1T2
M?JVX6U0?3DTM=>O%PU'+OXJ2K6FY2R5\EDM]2@0E9EO2)^@/).-3744)%KPY
ME"B1)($@YD@^XGQA;9V4^UBZT53W]+J.M8:WT_8%]ZO/VU.L,+K^L;V2=#KY
ME=-8MU7]'UYK#KA*'C9^-]Z&=MRDCV*@KE(DH&_M[=B^B6CI"G5^RU2IN[EL
M;6$_N_5L"76LU_+5DCJK-3FZ(Q_)V*/J,O TJ2F=C/7,HW=OTBN@F79W/B=<
MW!@U95^TGQ+ZOH-@Z_LJSJ:@U>[1:Q[WHZB=9;W*42\R$E,4#7ECK\?"U33A
MJ_N!XQMVQ(.OKIL&SY;[EVBW,BF9,Z:075;NY\87637"%=H5<AZWKBT]?Y_9
M%2KFJ>M5UC-<;&UY"4W9>V%M=UZ5C=>1FN'ES?5J,M,B%6>.V\@D87XN4$3B
MN&!SUNJ;^*K8^OY'K;KMK7]1R-CLVNX>VK:AUA5M8SE7BD9^N2,C-PMAV7J:
M<UCL ^MGMDCB33:&),245]VDB ME/  #=^A77Q#[JC:)UNU4IJW8$U9-,-WT
M!5I^NVJO[ O&OU-6:NH[BR23FRP-3F92ZN]3ZUISM94WM3R$0UB)1,B+99DY
M4#QL*-^%EE%[ USL2#ZONHFI3NNZC<J$]A!G&Z-G@[WL].C1,#5V#20&=L$9
ML2\6YDY&#0=.4I)\_9OS ?W$2A?KU,="ZCL7KAMP;M'T34]+IVT>\]3DJO\
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MHU2[42_5ZERFK:JNZ=SD=<M$W+:#:]6Q=ZO(7B O+KK_ !*,.P7001K";E8
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M,%%C)()$$XCP4,#:. P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MTGGE[W( F00$ $0'TP,F9=[=&O41]MENTKD&Y%E$ENM78!(S;W4_<2^[3'7
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M>X'8#11TP\1, ;6IHB!3B!"#^[*"(?OG+@3O^9;0? @??VCTSD*?S*7:5+,
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M\/+W%/X?#CCPY\/']GTY]?K@5F P& P& P& P& P& P& P& P& P& P& P&
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M"'TXX]1XP/1FB)N>?<$!!,!+[JOB()F,8O)?/@1$3?O#_I  <\\!@>%&#90
M*<IQ* @/B"JA0'@PF !\3 (E]1#CZ>(B'T'C F@@4#%,!E  I!(!/+]P0'\1
M#CU$ ] _+ F^!?R_Z1_Z\!X%_+_I'_KP'@7\O^D?^O >!?R_Z1_Z\"(  ?3
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M<\>/D'ESX>7''///CZ_T8$[ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M 8# 8# 8%KX#]7]SAS_]*>QSY#]KY>?O<>WX\>[X_P"GS]/W<"Z8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M4!# "8H?C]/7\_\ -@1Y#CGGT_/  (#],". P(<ASQ^/'/\ D^F!' 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8%'[2/WGO\ B3[CV_9]SQ'W/:X]SV_+GCQ\O7 K,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@:&WAJ*Z[4;0!*/OC8>B'\.]47?2FO(;7L
MJZL#,Z1B%BI;^>ZG9P+'IJF]SQ;^R83?41P/C_K/N#4]M+GKE*[T=MVSA7;N
MN=6U>SS/4O7];A]AAL>_6'6=4V!K^QS&KVD-<]0R5YJSR-<S[14R#9R1(BI2
M&<-P5#O@E(V$>+_6B?(>1S$(RTA7U)QYKOK:]9A/PSAPTEH9>6_0R-@F(QVT
M52<-O,%T%$CE,4IBCP%#L!#8VJ*C;KY?_D(:UBK46";66W2LIIG3JY8*"?+
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M&* \A]!Y#GDOUY*/X?LP/> P& P& P& P&!(\ ]_SY'G\OP_@XP)^ P& P&
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MS/87L*4+8+_JZG5J#F 76:@Z?3B[<P(J<HB'U'(7@H /'^?\ _ZL#T!2AZ
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M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"!@
MP"4?4!#@0P*4S!D=,J)VK<Z)&YV@)&13,E]JJ!"J-O;$HE^W4*F4#$X\1  Y
M#TP(F9-#"H8R"1Q5]%?(A3>Z'M"APJ @/N *(^ \\_N^GT],"2ZC&#Q5HLY8
MLW*K$PG9*N&R*RK-0P !CM%%$S';',4H )B"41  ]?0,"0G 0:+9PR2AXQ)D
M[$PNV2;!HFS="?@#"Y:IHE0<"8"ASYE'GC T)NKJ+UZ["RNM)?;FNF=J<:CE
MUIBE-BS5E@(E$[E2*7<1-AA*U,1$/=:LN\@F+@\1,H/XL[AD@H* F3 <#="5
M(J""8I(U6LI)"T)'BDG!1::0L$WKF238BD1H5/[-.2>K."I<> +K'4 /,YA$
M+([U%JU^J[7?:UU\]6?3$187JKNF5QRH\L%?C20T!.NCK1AS.)B#ATRM&;HX
MBNU; "21BD "X%++:6U#/P<O6)W56MINM6 T<>?KLO1JQ)P4X>'4,K$'F(A[
M%+QTF>+5.8S85TSB@8PB3Q$1P+W:M<:^O1ZNM=Z-3KBO2)]C;*8O:JS"6%:H
MVN, 0C;-6%I=B\4@+#'>0^P]:"BY1Y_<.&!8SZ5U&I7I:I#K#7Y:K/5V+J,S
M6DJC!(P,G581_,2L/7'L0BP(P<0D7)V%^X0:F3%%)=ZN<I0,J<1"U.>N^AGC
MVU23G2FIE9*]3C6S7>1'7E2+(7*QL64M&LI^V/4X<KJQS+..GGS=)T\.LN1!
MZN0# 590#!:%NK/6US5:_17.@]-N:55+3#7BLU%QK>HKUJOW.NQ[6)@;7#PB
ML.>.C[##Q+%!JW=I)E72;(D2*8"% H!G)=3:Q)%6F"3UU1$82\^^-UAT*E H
M1=P%T54KD;2P1CR-K 9P"Q_,795A-YFY^H\AB]KZW]?KW!2E8N^CM0V^N3B\
MZZF8.S:ZJ,Y%2KJT6EK>+.XD&4E#N$':]CNC%"6?F.4PO))$CE7S6(4X!2R_
M6+KI/V12YS&A]./[FLI455KBOK>H?S<L-!E:Y.4DBUG)#DG%4*I*U"*78)&7
M%-J:.;>V4H(I@4,;DNF'4>8CI"'E>L'7^1B978:^VY.->:BH;AB_VB[3:HO-
MA.VRL"9%>X/4&22:\@8!<K))@0YS%],#9E TOJ/5<M=Y[6NL:#09S94Z>S["
MF*?4X2NR=VL*BSQR>9M+Z*9-7,Y(BYD7"ON.#*&!5PJ<.#*'$P;-P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P&!+_P#$_P#3^S@3,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@2?(OO>'D7S\?+P\@\_'CCR\.?+QY].?
MIS@3L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@6[[4GZE][XE][V?MO/P_>^W
MX]WVO/\ L^]^]_T8%QP& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!+_P#$_P#3
M^S@3,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@2__ !/_ $_LX$S 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8$O_Q/_3^S@3,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@2_P#Q/_3^S@3,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:<
MVO4=JVI.-3UAM=34[INL@9_*!2X"_)2+?WCBJQ5A+$Y8M68>/ _=)*BMQ^Z!
M1X# ^*L=WMV-(S[ENIVX3JT=3=O]A=0[9;VCKY0W,E1HC1M?VI;6>YFD-#.B
M6&?J%ZA=6/DHA!JBL9X\:.&R9E'2*J) V,IW1AFD=071OD[IJQMA+&>5P6'2
MF>D'[M!Y*6:M1\!8X2+*^DJ-8U[71)QBVCYE..DWCN,<HIH&.B8 #(;-V_85
MI%U+2'RQ=:HF)B=6MMH2"LAU_AE&?\K/Z;';*CIPKIMLQ/[J3DM=R*$NV@T#
M'F',:Y3<)-3$,4V!LR6W9L*GZNI.Z;GW\T3 :WV:)$J+/3W5*R1;FT+&BI6;
M<D:5UYM=A:DQC8*"?2$@"C!/]-CF3ARY]INBHH4-4$[3=IU:INZ_0^Y=<VFJ
MZ>W=6^O5:7C.M97I]W[-F'53@E(F@ 3L'%!$1"URN\?&)R+TZK(Y@47(J9%,
MQ@"ZP7:3M FVBD=Q[PT;UMN;JV2M2=ZZW)U_FS2@NHUS7&(3]8M-&[ S]5LF
MO'DC<(YD6>!9.-!ZJ9 5A5(8H!-CNU6Z962ADX#N_P#'B\),IS2$>:6U1MR*
M4?MJZ_E(V<DV1O\ ')DR4;MG\,\1;NA_\JY5:+E2.?VC@ 70O;79SV/K\C!=
MV.A<G'SJ-F7CI"3UIN&/^X:4F(BYJU2*B;3=Y2MHN(B)Q@Y5=NBHMC-W[90B
MA@<(^88!#]Z-]V[8R= I>]ND-R;1\)"V.R7-E0]T0M.KD/8(/:TM$2SNRR6X
M!9N B'VI'Z$LT3,9:.$Y2N2)B/H&VVG;C;;L],:Q7:GXU9&2N\DZAJRV+([+
M]VV2;>780)VD(FC?UW#EPSEI5HV6 I3 "SI(IA#W">075_V+[,IZPM^[X[;7
M1:ZZWU_'6&3MLS0F>Y+.B#"KQ24S+Q,"M"V>12>61PS<("BWY546%R@4A.52
M<AI3;?R*]BM&;#6HUMH&K)QI7:'2-B[5M%,AMTSU7T?6=H3+J$HDGMYX1D]E
MZR5VM$.Q4;-F;D022.N8Q$DS#@9R7OUL0ZVSVZVT/CXA$-46*LUJ<L-EWO?H
MFK2$G::^YLC8D-)#7UC2'VK*-?E5)X@":T:\(8Q0:KG3#*9/M;NR,L%GK$SV
M&^-:'MM,KB=LMU:/?MEN)6LUI1W"L49"42;SK18J:CZS1J10,D"AE))H %Y<
MH>X&!1_?K8TH_:QL#OWXZ+P1Q(RC)]-5/8^R?T.E-(^C3%Y<S>P95:3=-*W!
MM8N"='4=+']HGVZJ0B55)0I O9>\6S64?7Y!7?/QGR:%OKMFMU6.TWQLU%2;
MK%(5E6MOD8IH-;E5GR42^@WC=0Q?;$CEFLB &53.4H6RJ=]]OVN5@(1O9.C$
M!-W"2:PE!K][W5M.@V.^3<O7(^RQ[*L5^:HA7TVJS++-&3I/Q(HF_5%N( OP
MD8-F0?:OL?.T.R;/@YWXY++KRF,R#<]@PO:^VK4FGS8M63U2-LED;ZWEH:)(
M#.3;+%,NX2$R3E(P%$JA#&"$?VVWW*!'(Q;_ ./*6E[31/\ $>J-6'<"Q#^O
MT<K.0>J7-FS6U:60=4])&(>'/)()';%39KF,< 14\0UDT[[[E=R#(5!Z'NZG
M(UVOR"&R(3M]8":N?R,S8K#66%:@MF&UPTJ\A9EIBLOTPC4W(O1*S7-[8E24
M\0VS1>XF\[Z=2.C-=]9DK I<KGKZ&A)/M-9*^_LMGH$ZXJ]H)4V$OIEL^ML5
M'S[-9J#N/3705514*4PF(8 #W/\ ;7L-6)V1HDI0.HY-EQE;L-IG*ZIW!E&B
M54@J]^EKO)VZ$<:A.[J<"SBYQDJJ\?$;)&.X("8F$Y>0S",[+=B7DI'5I/4/
M6V1N<O!)VJ!J\1W%CY&6L]*,P0>*7>OL3ZO&3<57W'*8%>F;^R)5$S>7!RB(
M6U]V3[5L E'"W5O6/NPTPE'R+?\ YPZ,DS9&/_XC^16U\F6*=#P;P;N4DUU!
M(/B0W&!XF.TG9^$;-G+[J?3U7#VQUFMFBH/M/ S\FTD[5)%BH)S(I,=9MSQ<
M.N IK*+K$!+VE?/R I3#@:MA>_\ N.U(2#RL=886P!'Q>SK![;#M#08EW(06
MG;6O2M@6&,AYZF,ID]<A;4@+0'8HBBL<Q?;,?R*(AM"$[/\ ;.58,7L;T<DY
M%&6;M7C!)'M'ILKXT.\:-G;67-'2T;#229#(NBF,F* F(4>1_$ #/?\ &_MJ
MF"XAT:MQS)L45VPH=B=#N"N7RB@%<-0/(2J*K<4DA$X'$OMF#T  ' NA-Y=A
MV":@2'2;:PJ>X!BC$[DT#)(&(9),PB)U-AQ"A%"K"8HE]D0_=Y P@/ !(:=D
M=ZN9!Q''Z-[\;&;%,87;F]]?DX]80$O[K5]_BU[+DQ@-Z>(C_P!&!-D^P6Z8
M]JJ_7Z3=@'(($ YFT/=NO4DZ4#S @ @U)MSWUS<CR(!] ]?I@8X7M7MGG^_Z
M(=M&X?@*;O0:XF'\A*EN(> #\\"L:=K=FN''V@]*.VC02M'CP3.6VAR)F28J
M(IJHI.E=W))*O%CN"@BEP!E?7Q#@.<"8CVJV$NW!^;I5V_(FBV1<J-W<9HU-
MZ5)V90@HECF^ZG3IP]0!'R41+P<A3D'_ $@P*YCVJM3MBF[0ZD]KF)E?O$T(
MV6H=,;NP4:*^**:J@[.,U9A((@91,ZAP2*( 03>1B\A>(;M#(2,>XD%NN':B
M).BFJLJPD]4-4'Q?9'P,BV1+:9$CQ53@1(5 X@</I@8_%]K9R:3:.&74?N"1
M!S'HRS523I&O(4_LO7+UN#5TTEMEM7L?*(F9F.JT733713.F8Y2^90P+T/92
MVA].J7:L@?B'\N:O5'^D!1V@H3Z?ASS^S LCGME,L9$L<IU)[I+*'(H8'+76
M]&=QP>V3W!*9^AL46Y#F ."@(AY&],"4KW!DT6;9X;J;W/,@[(90B:>HX-\]
M2(3GDSA&.V(<6YC!ZE*)?(0#Z"(X%W9=N6:)"*SW7KMM7B.D_?9HN]$VBQ+'
M3Y#CWCU%[9R,%Q+ZF07!(Y?Z?3 JT^Z%#.Z28CJ?M,DX4431 %NL6Y$TB'4$
M"E%5R-5%LF3UY$PG\0#ZC@3U>Y>O4%E$%]:]F"*)\<^'6G<CHH_T'95)R0..
M/Q$.?PYP*97NSJU ACK4'LFF4G\?EUCWAY%]>.!*%)$W/.!3-^\^GG!U$PI_
M8Q(Z::2IBK=8M\$Y(LN#<@E$*&8##[@^H?@ <CZ8'M[WGTI&C*?J%>[!-$H9
M)!>0<J]8.P8M447 J%34(NGKA1-<H"F/D)!-P'K]/7 GN^\_7Z,$#S#C:T&T
M!F9^YDIG0&\XZ.8-06?(^X_=N->E3: 88Y0P>7')!(;Z'+R&0P/<GKO9;,QI
ML-=)AU9Y%W'LFL.KK?9[%P9:7(JI%&74?TUJV9MI!- YDEECIHG H_O>F!TX
M11-3R\#E-XF$AN! 1*<O'D0W'T,7GU#\,#W@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,"7_ .)_Z?V<"9@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@?+_;WQ']3-SQ;="Q(;&AK"R@-^UMK<JM>%XJ</']AK_;]FV8TNS48.
MZS9U*G;KW+*UTDFP>(QK:0=-3$5;.W22P5W6SXL="]8CNWM/MFSK)-R4Y09^
M5F+2^H[/[UWKG:&WMMP:2,!1J'3JE",W-EW3+(N$8Z/:)%8HM44"H^V<5 U(
M^^$OJN[5F2)6[;3.*GM/1VI9"'*;44C[CJ*TS!Z$9[(+89[4<O<BVW_#6N-6
MBT<$E_*JZY#+GB!44.(AO-M\;&M8/1.B](TS;^\:4OU]'9J5+VG$RNO978#B
M)W(PMD9LJO23&V:YL.MT(&=8V]9)HV80#(D$DU:IQ?V::!2"&=)='Z'%Z LF
M@*W;[I78)_L.'VA5K:W<PSVXZ_M-7L-4LU2=P;R3AW3"35KTE3VHE7D472[D
M#',X.HJ85!#3FP/C9K6U%&TQL;L7OVR6&9(]B[_*GD*8JA>:6\VW3-QDUJE'
M.*C)LZ/K]E8:(S:(1\,=H'V"BY%5%%%A4 -=ROQ3U^S6BL1;[<]Y:Z#AM$:S
MU#/:YAFE;86"^2^J+I?;#5)R:MRD"N^B8=@PV$]159Q0,$G"Y ,<.!4 X9)7
M_B\JC0-JS,_O;<%EONWM52^F+!?F:5'KDA&TQS%ZQ@*XI5$*U6(YC%S]4K>G
MX=H#\A4UG:A%%%0$QDRIAA-9^(+4]882D1_C!LIW$V2#O#:UQ*D)1(=*8F;B
MEOAJ:Q@=A7T58Y>(;]B9M-NB85BK'!!5<5A3$1"[./BIHDW*7JRWG:MCG[ML
MYY%R=OF&M%H\*T>R%=V/JC9,(_9UR :J1R3F/=Z:B&#WR**+U %1$A!4 0#8
MVF/CBI^J]'7708;0L]IH]TW%5ME/(\L!#5B/A:U5W-.?--10D)'E>,82E2QZ
M:B#XC<J(&*Y7*4B(' "A?-V?'N;<>[MC[+'L'L*E:\WC6-%57>NG:Y6**JUV
M7%:$MD[9("&/?Y.(=6VJURU,;&[C9QI'"DJ^9K&*"Z93"3 UAIKXC=.Z8O![
MS$7VR2CU&?NLJP05INM(1PK%72@[OU^M7+3-U^KL)B[,(6/WD^78GD%3G06:
M)\  .'?OAEE(^,JL4.WUF:AMY[0-3*?>X;:%<UFZBM?N(2)OXW'45UODJE9'
M%77N[F'V%*:C0!:,7D56T623= R]H$V8-@P/87P_:AOD$UKQ-I;!A6+33-ET
ML4R<=5'RRT18'^\YHLXMY134AIEI.;T=KG]/:7)'I%\2'554P,9V/\,FNMD[
M L5PE.P>XVE>M6X[[N*8UJV;U3^4 D=CVJYVBRQ4;[<8WDV97*M]?)@Z.LLI
MYMH];Q\VAO?#*FOQ5?97%C<$>QUE<.9B>HTIM9K):QI,@383*A[!H6VHUK$F
M5< AKN6<;&I:KH\A'(J*%92 MP3]QL@Y -NP_P =-'B=([LT,-\GG=0W5H+2
M>BY!PK!0))&$#2FKBZLC[LT*5,T>ZG+#%L6+I<HHHJ-7#0!;KD'V3(!R+/?"
M%4[K ,:??.RVQ+)5'K37,G>6W\I02-DLVP--4B\435-CB+S)RL[::S5:]#W%
M,)"O*+R2,Z$>5)VY,B\D".@NN[_AL4[ 0EC;WOLV[;SUV2;DN;BGZ1J>OZC,
M*H?XWMO?;U.A6FL230QHS=[Q-4%9=U^HKH'5E/U CHZ) KZ/\-\)1]E=?K^G
MOZ?M!-*6N M4DRME.5<25H<TK>NVMZ5 8I_ 7>N0=<>_J>X'T?*+O(J;*Z;L
MVJC5-B<' +AD^Z_B>:;CVKL2Z/\ ;4"G2;M8)'8*%-D]5JKVT]\D]A:,V2XA
MKKMVL; I]MNFE2S>C6R"-9\&+IJRDUDD9(GV[(R >^O/Q<R/6S=^A]T0.YX.
M<4UAIR,U)?8P^J%V4OM!.&JEMK4(\&QO=@3[>KM812T LP4.R>2;9HU,P5D'
M#1P9,@:\M?Q:W)WL7:URA]DZG=5:\[H:;W;ZON>GI:RT.;MJ+;9D>_3V:@XN
M7\PV6+<LMA-U6K5%^#!H_C1<HMB ?V@##XSXB+C7HF$@8[<=0>SL.^C9M3=+
MRC6MOOU^HI78>LR]><7IG=XZ-_DB$;LW9H)BM'.OLD/M_(QC$4]X-?L_AYV-
M!P%HKU>VW0VTQ/5S^3I-X1'8+)22KT;9=)7EW''5;R?C#-=H26I7+*T%9(I(
MILWY%$ON'7W)5PZ(T)\>FX=,[ST-NM/<-#6;:ZUO9M<[/@FL+:9I2]1<J;8$
MM!-X=S894A*^ZK5@MK-<CD$TO>8MW"*C4ISH*)!]L&_'L(B < *20\<@/_AE
M_+T_JP/7M\J"?S/P)?$4^0]O^GCCGG_+@>"-DDP(5(H)E3*)$RD#@"$$>1*'
MU#@1P/!VI5%$U#*&$R9_(G[J8B "02&)Y"03>!N>1_;@1!HB'^B _P!)$_\
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M;RX]H_N?<>?U][GV_;]K\..><"OP& P& P& P& P& P& P& P& P& P& P&
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MK8$   #@   _(   P(\ 'T#C @  4.   #U]   #U]?H'&!' <<?3 @!0+]
MX]1'^O C@,!@,!@,!@,!@,!@!#GT'U ?00'\<"' >@?E]/\ )@1X ?J'.!#Q
M+Y>7 >7''/X\<\\#^8 .! I"%$1*4I1,(F$0  $3#]1$0^HC@>L!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@4'"_W_ )\_W/M^WQY^G\/N>7M\?Q>?ISS],"OP& P& P& P& P& P& P&
MP& P& P& P& P& P& P, V5JS7FXJR2F[0J,/>*H2?K%H&O3Z!G<2M.TRP1U
MJK#YVR\R(O1A[#$MG:::P'1%5$HF(8 XP,Y%N@*H+BDF*Y2'3*L)0]TJ:@IF
M43*I_$5-0R11, #P(E#GZ!@0*U;ID$B:*:9!446$J9?; 5E3F455$">/*BJA
MQ,8WU,81$?7 F F4!\@ >?3D1,8>>/ISR(\B&![P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P+;]X7]4^R\TO+[;W?:\P]_GG_:^W]?M^/W?
M+Z>?I@7+ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&%_;#_/7W/W"WE^B^/L?
M>D]G[;W../L/+W_+[G][W/'V?P\O/TP,TP& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MA\^''Z9]A[7'O-_M??\ +S]WV.?N?N>?W.?X?' ON P& P& P& P& P& P&
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M 8# 8%%[ZWWOL^V'L>WS[O*WE[OCY>/C['L^/C^/N<\^G&!6X# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M'U'G ]8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8%F^]7_6_L>4?9^V]_P"A_>_AXXYX\.//UY^O'I@7G 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8$OG^\\?7\_V?3C^O F8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# LGZB;]>_2_M5_'[#[O[OT^VY\_;]GGPY]W\>/+Z8%[P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P&!Y.<J91,<P%*'U,8> #^D1] P/0#SZAZ@/J A^.!;
M?O"?JOZ?[:OG]G]W[W!_8\?<]GVN?'V_>Y_>XYY\?7C N6 P& P& P& P& P
M&!I"]]ENNVL7MKC-C;XT[0I.AUV.N%XCKALFGUQ_3JE,2L;!15FM+*7F&KF
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MM).+E(UT@^CY*-?MTW;&08/6RBK=VR>-5B*)*IF,11,P&*(@(#@5^ P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P'/'UP& P(<A].0YP'(!]1# <A^8?U
MX$<!@,!@,!@,!@,"E=MR.DC(*E\TCA^\7DP<_7\2&*;_ *<"I*4"E H>@% "
M@'[ #@/^C M'L+_K/O\ @E]O]O\ Q_;I>Y[OCX_[?W_=\O'_ /!\>/IS@7C
M8# 8# 8# 8# 8$!#D!#\P$/_ $^F!\6;QT:['*[\WIM>G_X1KH.$>TFQ-1VJ
M3DE5+Q?;_P!@=&:JUG4-6[0A7]'6CH&DZCM>LT9%M-(R\DH[8LXQJ$>W]A8Y
M@V./Q[5W5MFZ:2VGM84"U(]:.M>_=!SSJYR@PTG>X6^T.+_2JY994L1/.'L3
ML7:"#R2L#LS9RHFX?KNC)+F.8A@YFTK\?>\4*!KJP;%TUK#76]JOWKZ];PDX
M/5VQ$*]HBCZLUBCK.E3;'1E-I\+%$7@HC4>O&\,T96Q)W-R:IG#M5PW.JFW3
M#8O<#3N]K[N?M/'ZZT%1=VW.[:RZC.](RFZV+-SJ.I5ZAVS=,3L=]#.K%!S=
M!D=LZSG+X-DBZU-)ILY5T^9N%3J(-U 0# =*_&A<ZEV&IBDYJ"@1>GJS 5M*
M0W2MLY9;?MGUF;H%4>H\QU;L 4ZL0,P,.PV%!&M)I!K.I0A!0348-47)P]H(
MN_C9W?'=?M;TNK_RZSV[7OB=WITEG;.-Q<$A"7>9?:3>:PIT>U48KQC.F/&E
M6L#%[,M8Q-V+=9-1T"ROM"0,.@?C\[&ZPVMJ;=<70*I6A1W;>-CVZIZOW(H]
MU5H'1.S-G5Z];IZ_M-,2>HF$-N^$M-'HZ@QTA"LX&22NU@,H5H5JV*]P/K!T
M"HENUETVZZT6\QTG!V&O:UBFYZQ-*BM,TJ%=+.I&J4&74$ZH#*4&J/&4,X #
MG*59B8H&,  (AV%@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#E+O!N>
MV=>.JFY]U4A.*/9M?5EM,L%9N*=3\<P16GH>,E)=2M,92$?VMS"0[]P\;1#=
MXT<2SE C1)9-18IP#Y0-/E?WIUM4I]9[7ZH4M<OMW>5K::P>R, MUEVHKUQ8
MV/3= 8[%D>N3]YN.58NR;&V!+HL6TM/0SA]#1B#ES]HX<IHG"OMGSNP=6@HN
M33ZMV:S2=G;5*\5*OU'<%*LKYUINR4[;%Y>6&TK0T.]0H^T8&$U*X*XJ;WEN
M@X?M@=2[5$CI9N'3]][T;"KW>S3FD8^)8PND;;$Z;C;0>QT!R_NTE<^P$%NR
M:I7Z1,,]H1,I5V%?=:K:L7RA:G8(HJ[QPD[D&"I6X&#5.^?E3G&E\F](:DUZ
MC3+(_P!XGT)5]Q['FJW+0T9/4+L!HC5&[K%-Z?C91O=V4#!U?<8R5;>/%$&\
MV9!-02)MEFZC@-+(_,ILY@YH=AM.EZXRU>F^V/<K[8X6XQ2=WF->%ZE[([A:
MHJ<!J:9DOU^%G7VIW](/(6-1ZXBU9C]59IMT"?;*G#IR\_)?=YKJ?5MS:;T=
M.QNU+KVPC>H3&CWB*=VA"MWX+/*5N?GUX2+GM=R]I@FCR%7;LVZSVNN73E1(
M%!0 >#!]!^K6XE.P?6[1&\G#1E'O=MZDH.PI2,C1?#'1,S::U&RLU#L!DTTI
M 6D5+.5FZ8K![@E3#R$1]1#?6 P& P& P& P&!;/OB_JOZ?X!Y?;_<>Y[J?/
M'\/A[7/N?MYXXP+G@,!@,!@,!@,!@,!@0X#\@_J# <!^0?U!@. _(/Z@P//M
MD_LA]?+Z?Z7Y_P!/K@>N _(/Z@P' ?D']08#Q*/^B'H("'H'U#U ?Z0'  4
M^@ ']  '^; C@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#'[34ZM>(%
M_5KI6X*W5F5!N63KUFB6$["2(-';>0: ^BI-!TQ= V?-$ED_<(;P53*<.#%
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M'[CV_;^O^CY<_LP*W 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MS\^>/+Z^S[O^3G NN P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P,=Y)_,O/M*>
M]]A[7O<MO#[?GW?:\/+[CP][U\N/XO3GC R+ 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8%%]RS^^^U]YO][[?N^QYD^X]KQX\_'^/V_\ HP*W 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8%E^W5_6_N/>3\/8X]CA3R]GV_#S\O+V_<]_\./X?
MVX%ZP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P&!0_>-OU#[#R'[O[?[KP]L_'L
M>7M>?N^/M^7GZ>//EQZ\<8%=@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"P?I
MJ_\ ,/ZGY#]O]G]OX>?^GQ_%X>'/'_RL"_X# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# QC]19?S9^D\/OU'])_4.?L7OZ=]E[OV_'ZAQ^G_=>_P#^'S[OCZ\<
M8&3X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# H/9;_?\ O^X'W'M>U[7NEX\>
M//R]G^+SX_'Z^/[,"OP& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M4_LD_P!X;_AX#E3^R3_>&_X> Y4_LD_WAO\ AX#E3^R3_>&_X> Y/^)2<?\
M;$?_ *&&![_]/_3TP(>OY!_6/_5@0$3\^A2\?M.(#_5X#@1'R_T0 ?Z1$O\
MF*; AR?T_=+^//[P_P"3C]SUYP')_P 2D_UQ'_W P(<G_LDX_P"V/_#P(\G_
M  *3_7$/_<' ARI_9)_O#?\ #P'*G]DG^\-_P\"("?GU*4 _8<1'^KP# ?O?
M@!>/^T(?^Z.!#D_XE)_KC_PPP BI^!2#^7*A@_\ H8X$1$_IP4H_GR80]?V<
M$'G ARI_9)_O#?\ #P'*G]DG^\-_P\!RI_9)_O#?\/ <J?V2?[PW_#P'*G]D
MG^\-_P / CR?^R7_ %Q_[F!#D_XE)_KC_P ,,"/)^?X2<?\ ;'G^KPP(CS^
M /\ 2/'_ *AP(^O^7^G_ -?&!Y$3\^A2B'[3B _U> X$.5/[)/\ 7'_AX$>3
M_P!DO^L/_<P(<J?V2?[PW_#P(@)OQ H?7Z&$?RX^I ^N!#D_X%)Q_P!L0_\
MH8X$>3_V2\_]L?\ N8$.5/[)/]X;_AX#E3^R3_7-_P / CR?\"D_UQ#_ -P<
M"'*G]DG^\-_P\!RI_9)_O#?\/ <J?V2?[PW_  \!RI_9)_O#?\/ CR?\"E_U
MQ_[@X$.5/[)/]<W_  \"/)_P*3_7$/\ W!P(ASQZ\ /[!Y#^O@,"/K^'^?C_
M -0X'D1/^!2B'[3B'_N#@0Y4_LD_WAO^'@.5/[)/]X;_ (> Y4_LD_WAO^'@
M1 3\_O%* ?L,(C_4)"X 1-_H@40_:80_S$-@0Y4_LD_WAO\ AX#E3^R3_>&_
MX>!'D_XE)_KB/_N!@1_>_(/ZQ_[N!YY/^!2?ZX_\,<#UZ_B ?U\_^H," ^7^
MB!1_I,(?YBFP(CSQZ  C^0CP']? X'GE3^R3_>&_X>!'D_XE)_KB/_N!@.3?
MD7_6'_N8$1Y_T0 1_:(A_F*; \\J?V2?ZX_\/ CR?^R7_6'_ +F!#E3^R3_7
M-_P\!RI_9)_O#?\ #P(\G_ I?]<?^X.!#E3^R3_7-_P\#T'/X@ ?T"(_^Z&!
M ?+GT O'YB80'^KQ'_/@1'G_ $0 1_:(A_F*; \\J?V2?[PW_#P'*G]DG^\-
M_P / <J?V2?[PW_#P'*G]DG^\-_P\"/)_P "E_UQ_P"X.!#E3^R3_7-_P\"/
M)_P*7_7'_N#@0Y4_LD_WAO\ AX#E3^R3_>&_X> Y4_LD_P!X;_AX'H/+_2
M_H,)O\Y2X$!$_P"!2B'[3B'_ $> X#D_XE+_ *X_]P,"'*G]DG^\-_P\##__
A #W\Z\\R/V/Z1_!P?])^[\_K[O/_ -,>S^'AQ^WG __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>tv526458_ex1-3img07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex1-3img07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$)0,T P$1  (1 0,1 ?_$ ,   0  !P$! 0
M       ! @0%!@<( PD* 0$                     $   !@(! @,#!@4*
M"PT0"!<" P0%!@<  0@1$B$3"3$4%4%182(6%W&1,E(8@:&QT4*2(S.3T\%B
M<E,D5-35EE>7\(*RPM(T1)0E5B?76*)#@\/$194F1M8WARB8&7EC<S5UM<4V
M1W?'.$CA\:-DA:6&IL9GN J$I+1EMK>($0$                     _]H
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M!@,!@,!@2BUUUTP,;]^W\2[?=1=/;YOF[Z=.WW?OZ=O9T[OJ=GMZ_6P,FP&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P)![Z:\/G_;P++\-*^(^]^[$].SN\WM,[
M^_R_*Z]>_L\WY.O3IV?3@7W 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M_LGN\/R/*^GV>9@7' 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MCTQZ*89&]/,?GM[1YAD+4[DN,%C=AH8ZQZE3[40:3=[&;I.QQEOM5IEJF(
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MY]GQR&39B8T=U@B]GRRV8FDG3PCBI<H:$K1(9JY(%/V=7,ICU'3@M3D)6E+
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M'*=@!']NE21-UBL6,4P!@9=-KXX3%[+1!4 ^,[T6G'L-_P!L>D73MGS15/\
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M@4GA[WU[M=>WIT\/S.O9^5U[NGUO9[,"KP& P& P& P& P& P& P& P& P&
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M,$88(0Q;WL+EVA_-U^+7T_MX$.T.NFNGL]GM\/HUOV]/' ET25KV%@UX=-]
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M]Z6!=-3:[2J'1*6"NK4-IR9Q(CA!)]6G'IJ7# 65Y3Q6:FKR)8SLFZU,"_\
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M@;A,QRCB6!*CB9CQ/G6IV9+;ZY17!2.D5SS:[$NBZ0F7#9C%$@1*$)>A*"3
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M6I&$C L/P3T6%Z%MEL?XZ\/'2 I5]BE6%+W.G&R*J*\;JZI)SO\ 5R!=&))
MT$B>6)YK9MTZH%A! $J]I. N1&*R-ZZA6&H_0IU#Q3HRG^(6HZ5+E<'%L?'M
M2!^T^(86ELE8H##ONX^V0HHFKA83(AO^D'P$+ 8%QVL]SWH[ W5)>*GI%Q6E
MFWD4_P#&_B6FIE^8XC)&"=H:C8WEKDK78)S2G@>XLWL;(M>I(OFBM^1$-*)
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M-.=<O5[<84A:7*:JN:=AL4^.,7J6QY"V,[A"3F891XTJ/29S,4"&40A+"$G
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MJ-C>DS(O;9$LET=;.WS$ CS"3#UH=\MWIGDI8K)XJOM-&ZHY*R^I$QJ/>8&
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MYL]Y YH7 A8F+"(.^N)5"6WQVKV#UG,;H(MB-16+R9,>>\L,K42T,HD%BO\
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M:J@[DY2;U;M@BKOFZGC5I61<8Q;>J^>Y1<\ND;WZ=/$YCHJ5VLSU.T*&M5)
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MLF)5N(P#"'VWX=7PLY T#4LRFB^O"K@?*FK:<6?$:]E;7)FMA5SUC,<F5Y1
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MH\EN1T%2,S87!H:GG+6V<$Q68WN-OQBG[EMRM!I:V>9PL<E9"&2F@+;637O
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M9CS&&MLE"M.QC5B,"QNZIP94\B9#W%"C)>VM.\MJMK6JFX:@I YIS4"H1*H
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M. P& P& P&!C_N8OM![_ -Q?\1[MV]O\)Y?E>9^5T_KOT^S R# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# ^'OKF]=4GPW%^Z(]4[@4,@7RE".L]428,'S"
M&4<,._H%O [5YM\-8-S3AL8KZ<V0[P9(@>9>6B:R6.N)FQ2@<EB[@Q*A*H1:
M,9E<>62V*$'_ !.//"5.6[1]Q(]X3&Z"(X!@:??_ $I*GE1BJ*22X[U>J#7.
M4BF:ZB7&3LZQL=;:EE*JJ+?;2>+,6,2BW')Z5QYP5/.D@GH*#[4JSG(10Q"T
M3H+;+?3<AMM09R(Y <N;LO)."/32+?;.7N-5I$,;;G)FKU@2&-+2RPI%!&U9
M'7BL4CJX^<A.3/CP<I$Z$GDC]V &NW+TEJ5E\%BE7S>]E#Z:1.;V<9TWQ2 T
MO5S/,XYR$HU/3TMKY@K^LHY&VB!#:(*WMSHUKD8%"TMS)-6*-*2%.R !N#C;
MP1=N("5G::GNV*D+Y=<\-D5G[2431E3H9E2]>P*61M#5K#$*GA47;"G\QS>$
MCLX/NM^]FK=*#@>[D';2"#)N7?IQU_RTL=JMJ02=&W32)-%9I(.AEE=1*U*\
M;G*NGBX%1RF55]+=!:9NSRU@NIT;EB%080(C9"54E/(4%=P@V,CX4Q-MX0N?
M"9LEZY#'7>O)/"%LY01*%,"[WV8N3D^2"0HX9#F>+PAJ\]Y>%!I2)(D((*+$
M$&]C%H1@PTO<'INE6!;%KW3!K_E536%=">PH9-7-L@T.EI"FF;2JJCZWF%=H
MD<C :6F=DBZBF]\9WK>Q;;UZQ26<D5IQ:+P,DK3TY*[JET1*87-Y"BCS5?+A
M=C#'#F]"I2M",WA2EX3,\%*<#5&W!6W,\.0E/'OIXC%2A>'98M!*WUP,B*X1
M(6?AO0'%.*6DZ-$BXRMU%*:IMU7&&QT4D3GCXI85L2DDE@_OR1K>F1],9!IW
M=L+5IA'(EAP$ZI,?HI06'$,B]&242*+3MN4<PG;4MO1BY$13D-,SZ/C)FIE&
M>15U,5\/R:OXZEF2!LK=T89:TFH4JH_;X$QG5B+$3I466LT'T#YM\11<P:QC
M%? ET5C HQ*PR@H<XJQIMB-KS_LM(HP0HVV#?X5+XU)8X<_A=F5X8) T+D+H
MB)\T2E((]*:'RFY >EUR?KP5@O'%.U)58THO&EK+I.RI=.G:!ZFYK+)..?&N
MCV,J1JY\F4M3\*1/= ;D#Q*4IP7IN5+MD$M+D68(PH.J$?I7N(X0V-2CDE+6
M*<I[KF]]FSN*15"@>&J;SK@?KA6I^SBH3P U";'E>]RM$NZ!/VH"%)L!>OX<
M(85!?1\=(2G5KF[D,TL,L/O*@;T1N< IH^,M+0_TK5=C4VX$H4LDM6>2=<ZR
MV*V$8Y%N[H\N*]%(DP5)NUB/86\L,?JOT6/L!(7"3/G([4D?'>'PF'OCFBJ]
MY1NTG'"JSY)UJ&:RI\EUPV _/L]E:?D2-Q=50U0$/O34$I$D1)#@$)@S*1^C
M\QNDLI9\2V)#79+#:-XN4791EA4^3.'-W:>*:PM9&)34R19-4T1@$AG*=0L0
MO 7MLE:=.2:G4(@DJD@3#0WGSQ]/%'S#DL)G;7(X2P2^-5U9U-K@V97[M9L0
M' +:61A>^/S-&6F=0+R++B3A%R3V92N/7,Y@3U!"U"> P R@W!QQXMK>.TVY
M%&,\N;W6MKM>ZPED;8A1X2.60R1PBBX!1,B(7NXW)9&'Y@=F2K6=:@3$-2+W
M)0:J*-]X)$5H ?/:)^D7;$-@C[#V?DA#&UH/LFL94VUM%:^M^O*.>FR"1VSH
MX_O4E@-?\BH\Z1.<V4HL=([.Z>".<1B@UL90DA:O(.4]0[9JK@R.N/3I,X"F
M684[!'25D4R&TD,)TRDDD3[4K+(?4\#.E+OY?P,B3!#I()V'H_W?^-!W] AR
M+=?I%R*WH]:%6CY"(&>E'F2<G[;J6.ZK16KG,,N_E=#Y9%)LY3:;?;@DF=5O
M$CK!D2]G:"4+:M,,=RB%BT\EN3Z-#=TQ]/ZR6^^9_P G:1OF/1NVYO(I02D1
MV=6+G/Z]C%=V#1W'^H)HQ(8PV6%& K99\;X[LTD1NAXMIACV8VJ4AJ<>S]!K
MR<^F!-IG(9VX*N1*,DAPDDLG\ ?C:O;CY0RV+)V_BDZ)7R;H$CVUP63,K;8W
M%5$O-:VYL9$JML>%"(&DWE%'8$[WZ9$_GT@M&R[)O:-*K2NRGN9E>V";$*O6
ML<";'GE+5?'VGXTOA3$XS9U>TK!6,4X_HQJ2G!>L7/RY<<=M0E#H)6@ZCN&A
M9L347$AKKX8)7(>*EM\?IFI;M$)&TV;Q&$Q]?4]B%M)3@N+1HGK[OYFZ.C<0
M8J" Q:C*3B-UHS8L#D#@YP3Y/T]&(+.YQ8%8Q>RZHINQ:#HV'$5DZ*&:'5U8
M7(=OM23KK7"P6L4W3V7.49AS2B:OA(F1 TBV8<,@XPP9(0Z3YW<'WWE@\TM.
MX5-V.'3ZET=LL341,TUG*H<_1NY&"/L\D(=]4_:M/34EQ:ED3;5:;0'82%4
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M&ZK&L.#/DCJN9)-OQ# [\@I@?,J^CG&.Y*$CI 7R\+9L%?''94_V^J=RVQO
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M.N!-@?'/UK>W]'/CL(WIVE^I%Z=YA.Q>P!NN3T!Z"#\PM;W@?8O7L_5W^SO
MC@,!@,!@,!@6CS0_%O)\P'F=/-\KS >9Y7N_;W^7W=_9W^'7ITZX%WP& P&
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M9.60A0C*!H.R2@@+V'6M=.FL#W"QLH24"<+.UA3M1P5#60%O2:);5 =B$$]
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M,!@,!@,!@,!@,!@,!@6WRP?$O,Z![NWM_)\>OE?QG=[>[M^KT]G3Y.OC@7+
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MS1JP$S3!(!00>.S)4&H4%2$$,)<&)[0K=SH^3;<OBR!XC:3R][1")VCT82,
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M51K./TDN%^K@)\-IRC%;2[,8*NI*JD$T;ED?CB,E]5N.Q.,B<U;@_# M6G*
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M]=;UX;UO7?UUO6\#U >29KN+,"8'V=P-]X>OS=0]==<#Q^((/[>1_P"V2?\
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M P& P)>[77IX]?#]? CO?3Y]_@P)?,#]/ZW[>!-H77V=<". P& P& P& P&
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M*G-Y<E3F,]P>WA1K1R^52^1NAQBE[D"T6^\U:M,&/8>T.MZ+" (0X8Y@\R8
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M4'7#(YK$Z^4+V8<NGKHDWH0'>>S<X4EEJL\01&=YI3HM\H.Q"$(("]!Z[UK
MS:R+Q@]>%J4(GA'()LH)$1':[8U!+C*WYZ-*.$WMR9K2",5)PJS2MZ$:=H!9
M8=;%O?ATV&O^'E12"E*6:HM+U:!1-)!)[!LN;EM>Q#:TDOL^:.\Z>FMK.'XG
M(6(Y[]ST/?B,16Q?+@:2]1AX;8_!:'E;JYIFLF#<Q.-$K H4K"46B4R2:?#W
M!08,W?=M 6F=Q:/WK6PZ+Z]WAK>!L%;S1@\B/-:Z8A-I7VY$*CT1JJMH8N!#
M25Q !C"G4V3+ 1Z&IP#-+T7L8#E'=YFNW7RX'"?!%HY*6;7%TI"):QT-'%W+
M+D:LDIC4G06)<I,@<;"=%;G&SUKB-9 8TE:R"2""EH=+1FA!O6@!ZZW@?3NG
M>-U65 H6/\=:75VG;V65]I;+FKZOF=@R41?G:U\2E+R>K4$IM><+M2(O=D98
M=]H2]:Z:P.@PAT (0Z]@=:UKV?)^#6M?BP)L!@,!@>1AY!0BP&G%%C.$(!(#
M#  $:,(-F""6$6];&()8=BWK77>M:Z^S ] B"+6A!%H0=ZT+6P[UO6];UUUO
M6]>&];U[,". P& P&!*$01ZT( @B#OKT$'>A:WTWTWTWKKK?3>L"; 8# 8#
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M%K7C[=?-[=8'IYA?]<!^^#^W@0\TK73J87KKOIKZX?'?3>^FO'QWTUO F",
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M;%K>MX$OOB/^VTW\N5_JL#WT,&]!WH8=Z'KJ#>A:Z"UO776P[Z]!:WKYL";
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M.<@ZZKQD[/$(6S-BV'3ZM.2K3F)E!)9Y!X!DG$G%@.),*- (LP!Y)G\&<2,
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M'KH+776MZ%K\(=]=;_#K>!+HDK77?E@WO>]BWO8="WO8M[WO?477?MW@2C)
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MI$M8%Z%PD'E-2IK-LDQJ-2MI[R<TA^$EV_)"$@=D;"D2.@DY/804G+)#&_T
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M0N18NOREJ:,,UK\/2Y_#>!$7(6Q@![M\0N1&]=.O0"RBQC\?9U!JY^NM_/\
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M^Y^;\3[@]WE]OE^1Y?G>;YOF?N_+[.SP[N[PP,DP& P& P& P& P& P& P&
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M;2@$?AC"@CK3M5[DF1I!+#$+< 9PBBBP"-$+>@AUOI@;'P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MG76Z^B?3?3?7Y&G7S8$"Z(I K6] IRJPZWOKOI7L3UU]GMZM._FP(?<-1O\
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M9GB"BQ-I$TPI^;Z.=)20Y+#WNDKYLGD?#=''B9B^K>HL:UW7:\H 0:4-^R2
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M^1YW\+T[.G?Y73YOU.GC@7K 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# EV#0M]=^WIT^3V=
M>O3V>SK@38# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# M?D%?%/>.S?G>5Y??W;[>WLZ_D=>WN^3KTZ]/HP+I@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"P>YG?:#W[J=Y7NWD]GG"\G\CKW^1
MW]GY7AUZ=W7Z,"_X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M1=2['OJQN;SG%:8O>%"%N:MN#@Y/"UQ=G!00SLZ-"1L\\SW9 C3IBNP@@HL
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MY,_PUBKYU^TDO)^U"V/*(9'$+<UQX$,^+A9BB-$A/T2@")1L1XC!B#H_ 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M 8# QWR5'VF]ZZ'>1[A[I_%#\GIU]X[N_P [L[O,\.O9U^3 R+ 8# 8# 8#
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MA\G:WU0_R2THP;:M.QBU5+,VK*Z75ZI2HT%E^Y+6YOD1LI9C E^\ID8UJ,\
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M=&IXAC2"&(IHP0")L\J1Q%J1E-S9%TC^WM*=T31]O;B"TY*,LT)!1!82PAT
M.@Z"L4TI4*PI:0KK& *27(#V6O*/AT=-+6@DTN+L"1A5@,;1!4!?YX4%[6Z'
MK>E+L'2LS0C]>9@8P'B]QM @G+4"@J8"UV?)6^9V2VAJ^$:03^7M+B)X:Y3,
MT?P/W>32%M=QB5$+%@3CRE A&!%H8M[V'FZ\6.-#ZVM#,]\?*3>&:/OK-)V!
MG=*L@Z]J8Y''8\V1%@?6AO5,9J1N>&6*,J-L2J"0 -(;TA*<&]%%  $/1XXO
M<;9 IL18^T%3#PJM[;=NUE+G6$(7GV5\(5EN#7]NSU3&:;*]MS@2!01M<([9
M2@ 30]#-:%@;B9&1FC3.UQZ.M+8PL+(@2M3,R,R!*UM#2V(20)D+<V-J(HA&
MA0HTY82RBB@!++ '6@ZUK73 NF P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P&!8_BJ?X]\'ZF>]>Z>^=/(%Y?D=.SN\_O[>[O\ #ITZX%\P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P&!0>:F^(>3VE^]^1W=W8#S?)^;O_C.
MSN^3V=<"OP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P&!;/=BOB?G_PGF=O=_&#
M[.OD^3^1W=G3L^3ITZ^/M\<"YX# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# HN
MO]F_YSI_S/7 K<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4G;KWONZ?N?;X_
MF_B]F!5X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# H?-,]_\ *\HSRO)Z^?X>
M7YGM\GITZ]>WZW=UZ=?#VX%=@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"V=N
M_B7?W;Z]GE].[?3L\KO_ ".[M_+^7IU^G N> P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P+7V@^+=>I'^M^O9TUY_O'L[_ ,CN[?=O#KW=/DZ8%TP& P& P& P
M& P& P& P& P& P& P& P& P-3V6KMEL):5E5Q>-S-?MUU\3:97.54#;$[9[
ML,.U!;BAADU5JS]'=.A.B"P^/7NP.4TG+NQEY<H.11SC(J+A-NL]!3#:;DW*
M#]QFZ9"YQME8ZT>RP<>_,02EU=9@UD$E#UY8QKR=]_:+KH-P!GG+<6Q!#Q]I
MPS8!; (0.1SYO7<'?06O"B.H=Z^76^F]=?' D%.N78MZ[>/-1^SKT#R1>"_#
MY]A,H00O#K[<"7<]Y7>'_DWUV+K\NN3)G:+I[=AZT=K>]?J:P,&G'(J\ZS#%
MQ3^F*>B)4VF#)7L/&^<I_<Q2:<R3WH3%$V0K=';.7OCF6B/&42 /7RR#!BV$
M !"T&!2CF[*H9;;)1<FA?'YCMB3#;$\=@+IS$9T,K=ESYHP3"VDM*VI"]D.D
M@T09\.2FC I</+W[L6;TP-Z:L7E5H.MCXR1((^F]]FN2#</KV_-O=5EZ%^KL
M/X=>W IS;0Y8D:#LKBG&5O?OV Y',!.P:UK\KJ?7V]"UOK\GS8$A=K<LS!A"
M/B3'2BQ;Z"-UR2C1G8'Y1: "OPB%TW\FMZP,0*Y(W.X2S<$;J3@:Z9EAD(C8
MLT\F(8X/2;[* B)TF*6HM1<HQ&I82)\QF*2C.TTHMW2#V'M.!O89J*U>482^
MW7$X@8@ZUK8P7[!@[%O73J+7>S=-=?;XZ]F!,"UN2P"3CUW%H* LG0S!C,ON
MOS2@DE@[S#S#=LP-%  '6][Z^&M:Z[W@<_SOGZ?6#?$'>R(G45?M%A- Y# '
M2:\R>.L6;YQ'BRF]0-_B:IZ4)2WYF"G=D@]J4VS"= 4E;V+6C ]0V9KDE>PG
MI@CA'&=.M?I4P.,LC34EY&T\>M?HNSFLI#M(6HDE/K:QE;SY(W@,5!_@-#7$
M!T/>S ZV&2_?!R=^7AU(];^;5]4]O]E;K>!5!MODKLKN%Q"D 3.@M^7N]JFV
M+>]=>FNH5WE>/A]'SX%%'[QOV1-A3RV<6'1<TKDA2QH<VR^J<=V]U(-Z]AJ-
M6D<]D&$##XZ,T+8=_)O H7OD1<L5(*42OC>9&]G@"806]\@*3;-'Z$Z-+(#9
M.UC\3HX(WE_0).H=[U[RM(*Z]YQ81!D&K>Y(;U]?B#)>O_L=VU!K\/7J]Z_6
MP/3[V>1&@['KB5*!#]OE??747R].NNOQG6OJ]?G^3 I3;>Y)]=>7Q E6]=/'
MI>--A\>OS#=Q[]GTX%"EO^\%CRZ1M+Q;=%4C8T+0Y/;"1?-)'/#.W/XW,IB7
MNC<3(!*T*-Y-9%@4AIH @4"2':!O?ECZ!1-'(2\9.%P41?B\X2),SO3M&G8]
MDOVD7,ELDD?6FMK\P. T<I[4CRR.!(R%:8S03DYP=@'K0M;UH/-_Y!WA'0-.
MI-QA=H^%^?&^-,6W&]Z':!/4D=MFA:H^V"<9H3IP>',10])TI/<>=L.^T.^F
M\"[@MKD:'81"XA3[?;O6]ZU<]&#ZZUOKTZ"F -"ZZ^38M?AU@5^[GY![\1\.
M+&W\VB;<H(&^OR]>MDAUTP)M7-?WA_Y&UE_Y7: W_P#3+\<##D_*Z=*!L12?
MCD]*#92_R.*Q@LCD!QI4#D4GAWQO[71UD"5:XA.;Y%OLTY?$4I.AG(MH%'G!
M!Y)G:%6EY.68O7L#8@XQ29>YRU@6RN*MR.^>-RE9)8LVC9RW&2L*<BU!FNS
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M.BDS;(UJ-03L*S29M,4C;TX?1' ATUOVZU@.FM>S6L". P& P& P& P& P&
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M!=>V:1+_  C9_P"[,#S^\2OM>V=0[7R?_*=D_N[ A]XU>_[^X;_A.R?W=@2
MLJN3-]"Y_"A[UKKO0)4Q"WK7S]-+]^&!=&N711\/-2LDGCSPI3@":>G:WIM<
M#R2Q[[0&&E)%)QA8!"\-;WK6M[P,AP& P& P&!1_[-_Z'_0P*S 8# 8# 8#
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MMSTIHLHL-$_I^-;(NJF.&2FP$JBGD Q,S6D7QAH>0I#"88,J1ND7>YHU('A
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MABI*4<,0P@%O>M#%U^C V;@,!@,!@,"C_P!F_P#0_P"A@5F P& P& P& P&
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M))J0;]N+FET2[/.ERP2Q0:+:;:8+S7GILUU IO5<Z.M:VYBX47IJC5,().;
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M[>G[KN]O3V]OD]/\]W_1@7# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%#W:]
M_P#+\PON\CO\GQ\SMZ]OG=?9V]WU>GZO7Y,"NP& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P&!2==^^>P7\7V?E[[>WIW]>SIT[N[PZ_-@5> P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P*+S"O?O*[RO.\CS/+[_X?MZ]O?Y?7^)^3NZ?E>&!6X#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# P_R/\ MS]Y]X4]_P -\GW?WG^QO(Z=
M_7W3KW]_G^/?T\O_ #V!F& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P+#V&_:
M'O\ ))]W]Q_UQ]3WCWGKT\O^+[_)\GQ_*Z=WR?+@7[ 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8%'W;]]Z?7Z>5V=O=KR_P _O[>G7S/DZ_-@5F P& P& P&
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M)ND+;WO>]\N+E'U^0V$\=OJ[U[-AV13:??7K\^]X$/N-MGKUWRUN76_G##J
MUT^D(15&,O\ ?!%KZ,!]QUN;UO7Z7MTZ^G<(XW[_ /I);P/,ZC+?&4(!?+VX
M0&;UK6C=P#C@(6O'77>]AI8H>][UKY!:P/45)W$()8?TN+;T(&N@A_8+C[U,
MW\^]?=+O6OU,"45(W'O6]:Y=6SKQ_P!X''[_ $M3@W^O@>?W'W)_RN;9_P
MJ%_XK\";[D+D_P"5Q:_^ -"?\5^!(.C;C'K_ .J\MP&_F# >/^P]?9K>N^IQ
MB_YK\6!G5;UK/H:ZKUTNO6<6HB5H I$K/*(U6K(D:U(5)9^W),?"8?&UQR@1
M1>RNPXTTG01;WH'=T%H-T:\/# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# L'Q7_MA^#^4/N]T]\\WR57E>7V]G9Y_D>Z>9YG[GS.[IX],"_X# 8# 8#
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M/\@H&BD2)*1T+[]@$:,TP8= 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M7=[E[]T[_P"&\O\ B>GE]/R?,\>[K]'3Y<"_X# 8# 8# 8# 8# 8# 8# 8#
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M,!@,#'/?]_:7X;[LIZ>Y^]^]]Q?NOY/E^3V^3W^9\OY>!D> P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P+5YP?BWD=-]WE>;U^OV_D=O3KV]G?T^3KUZ>.!=<!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#S\TKJ(.C ;$'P$'0P[$'?S;UUZZ
MWX8$=&%[\.\/7\.M?LX#S"_SP?O@_MX$>\&_8,/[[7[>!+YQ6O::7K_/A_;P
M)?>$^M]-GD]?F\T'7\7=@>@Q@!KJ,00ZWOIK8MZUX_-XX (P"UH01!WK?LWK
M>MZ\/#]G CW!U\O]']C :%K?AK?[.!'KK7MWTP& P& P& P& P& P& P& P&
M P& P&!#KK7MWK C@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,"P^0+X]YW:1V>7UZ^27YOF>[]G?YWO'F=
MW9]7^+_)\.N!?L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#2MFCN%.:U[JA
M-62WS3G 3^*S'*4(TY =!![D% &+HE?>'KU[O.!O>M>SKO?7 TDFG')0PQV*
M*=N&@CF)6G0/92"PK#+,9URI3M&E1/)9;+W-RU0LULHLH[0#!F:V#6MB\,#(
MQ.7+\/Y+)QE-WUUKPFMK [O'IO>NZ*[UKP\<"<2WF%OMVGC_ !G4:WKZ^PSR
MWBO+'[>S8282J#O>M=/'>];\?9@4H7'F7H0M;A_%@?;L01:^]BV];T(.^@M"
M".L#.T01:Z;UO776_# ]].W,,'31D'XL[W[=B^]RT0=-?0$=2#WX?AP([DO+
MTO8M;@_%XS8A["2#5R6@ 1Q6M==F!\JFU@NNOEUV_+[?DP*;4SY5;5J$&X1Q
M=&YHTI"]8WEWW9H%B1$I&86E6JD8J.T>C1J1E"" XT(2QB#OH+?3>!<");RX
M"'8]5AQO/"8$.P")OZ?[UTWK>]"T(ZC30BT+6_#I@>@IERZ"'?;4?'<W>M>&
M@\@YJ 8_P;W08@AW^I@1%->6P %[!2=$+A"UL0]$<B)F'1'3>@ZT+>^/0M"[
MM]?9X>& #.^7776MT%2>]?,#D5+N[V?)YG'D ?Q[U@>GVZY;_P"("FO_ #B9
M-_Q X$ 3[EIL707'VFPZ\?$/))Z%O][NAP[P(&3_ );@WT+XY50JUTU_"$<C
MW (.N_W/0^DBA]=?+X=,")5@<M!"WI1QPJ\@'3P'KD:J-ZB^0/;]S)?3P^7K
M@>@K Y5:"(6N/%8;Z:WO_P"J(4ZUOIKKTZ_<]OI^+>!X)K(Y5G]W7CC6NNW6
MMZV3R+..Z]=[]NAT\1V].GT]<"([,Y1EC$6+C;7^]A\-[_2-2@UO?]095FAA
MZ?3K E^]#E#_ ,FVO_\ SCT7_%9@>GWH<FNWKOCE ]"U[0_I%(-^/AUZ;^[+
M6]ZU^# A]Z/)KY>.,$_\XE#_ ,66L"0VT>3P ;V3QO@)QG770O?(Y 5H7S_7
MW6(NF]?@P-Y0!\F$@8 KYQ$6Z$OOO1Y)K(U2LJ9I $%A*V4>%[)9V, S#!"%
MH1?D?4[=;[M]? ,Q-,\H&Q]@S-:WKJ$&NX7;^Z%H/M%VZ\>FO' YO=)MRC*<
M70#)25/.3.4O6%LBU??DI;'!S:P&"TWK5K:30SD0UJUI.M"&G]Y.T0+?;LP7
MMP*(,YY<B+"+[@:5"9O>^XLSD?) ]NODWW:H 6][W^# @*<\N@Z\>/U,;%\F
M@\C)+O6]_0+= !P)RIQRW%W>;0%,D[UT[=;Y&2+?=\__ ,P>NG3 ;G?++7A]
MP%.B\=^.N1SUK7A\W=177Q_4P/ R><M.OU>/E-B\/W7))Z#\_P U$[\,"JU/
M^5/37=Q[J_KTUUZ<AU>P]?E[=[IT.]AZ^S?37A\FL";4]Y4;UU_1[K+?C\G(
M15O]?[G^F!(*Q.41 ?,.X\5N,._ (2.1&P"$+^J55*07VZ^7IO>_HP*8BT>3
MHQ""?QM@A&]>.NSD8WG=VODUK_@R+WW;UO7MZ:^G ]!6AR9UT_\ )MAGCU_^
MN%:OD_\ %Y\N!Y[M/DYK?37&.*CU^>#D.P]HOI#H<# /I^'6MX'F9:_)PL0.
MO&&*]F^O</?(EA#V:UT\=!# 3.[V_1@0+MKDQL"@1O&.+ $#8O= E<B&$_2D
M&NG01@_L 7[OO8>N^G0?3 F*MGDN/0MCXP1O6];Z:\KD/&S-;U].S80GWK?Z
MF\";5L<F.\O6^+L?T 1@ F#UR&BV]EE[WT&9H&X=KOV#7CV]==?GP/'5M\G.
MT.Q\78P4/?F=Q9G(N.[V'031!!O0BH&:#?F%ZT+VZV'>^GR=<";=M<F/DXQQ
M3?\ _P!%,6O_ *7^!#[VN3/AK]&**==[Z:_\HIAWX[_\7^!Z"M;DV'Q%QBBV
MM?/OD0P=/UH$+?[&!YCMKDWH Q%\78V:/01;#K7(9A"6,6M;Z:V<* Z  .]_
M+OPU@>15O<G3!"[^+L4+!H(-Z'^DA&S>X8M?7!VDP(SMT#?AUWTZX&80>QKO
M?)*C;)I1#/"HX<!4%7)D-P,\M-2J0 ")"24R)XJT'K"E@NX(C G!\K8?R1=?
M .@L!@,!@2BWO01;#KNWH.]ZUUZ==ZUUUKKX].N\#45BS2THZ)KU7=/EV9I2
M)>!V\VP62$;9QIMI])>FWEM5EN(5OFB_BQ!$7V>.MZWUT&N-6OR:[.N^)Z?0
M^GY'W^07>NOS=WP7^A@>/WM<H/\ DDI?_.!@O]XL"H#:W)C>M=W% @(MZ\0Z
MOJ#"Z;Z>.M;TS:Z]," [8Y+ Z:%Q2(UU^>^H('_1- <"3[W.2?\ R4T_^7R!
M?WJP/ VW^3H!:\CB()4#>NNS"K]KD(0[_-WYR$L6]]/HZ8$VK@Y+"2Z-_1'.
M"I\S0=IC+YK30- ^MU'M062;KKK6M= ]OCU]NNF!Z%V]R2V7W&\4 E&]=]2O
MOZKP?36O9OO]R"'QP/(NX>2H][UOB:6#6M==;%?U=B^7ITWHM />L#S'<7)P
M)@@@XC%F UO6@FZY!5V$(NNO'>@B;=#UK7TZP&K@Y/?NN(Y =;UU#O?(.OMZ
M%KKO7771I]GA@>OWM\G^G77$E-O6^F]?^4#!>O3?X&/>OU]X'J"V>38BQB%Q
M-( 9K8= +^_R#""/6];Z[V9\$UV=.GS;ZX$P;7Y,[UKNXGD!W\O_  ]P473P
M^?3-KKXX$H[8Y.!WK1?$U,/73QWN_H*#IOQZZZ?!!8$16OR<T'J'B81L7YHK
M\@H?^:^"BU@>/WN<G-"[1<2T^M_1R @6_P!;;.'>!4[M?DOKLWOB@5K0A@T+
M?W\07?8#?78A_P#N/KNV'IX:U[?GP-_0]V?GV-M#K)XR*'/JU($YSC0W=$_;
M:%6QC"-)\7;@%I%V@A#H6A@"'KH73>M;UO6@R; 8# 8# 8%C^(;^/_#?=Q=O
MN7O'O/O .WOZ]OE^[=GF?D?NN[I]&!?,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,#S,#W %K6M==]-^W8>HM;UTZB#]8/C\NO'7MP/Q60W@=S @PK9C=7\,
M)TD9%>ZV2O\ (K@@G'\5KIW)KY\TS:3NP-%IP>4BC7-./?9!H>W]-,IA%&R5
MQU*C+ E5^8H$0,-T1OD9STNGD3;U#UQR0N>46DGDEM)+/057(J0?(%6L7COJ
M74;7++(*7:T[:XRF $1;B<[2%*M!,B"7!:M2KC$Y"HU*,W W!/%7K+1A\I"&
ML)'*)_8HW?\ 9K6Z6>U'U2]*Y/10>;IL9CIUKLA42)-72Q'Q12#=D3L8-,WJ
M&]61Y"$;L P6@YTI:-^K9QVIQBI2"1'FRN4*(U(8NC/<F&!OZ*(78D]1-EF]
MCS0Z8.)24PVOIKQ+=SC&]V4*'$+JM<'0M('S">B8-Y6HE]:^-0V&2&'37D>J
MD%A\C^8RE]:RX77TZ,KM-'[9*CO"V.)HE'8TE4)*"EE;$*W=V/=G4A"<8(L+
MDY-X1)P;#[?N4%LF8\Z*;D\GCJTFO*(XL3UQ(E;>#::'/5ZWA-(K&'-K;B3U
MIRU2IAT!K1P,T49HSW=-(B=B,[C.@@_.I8O'_D8W\@.:=U4_PLOQ1<,UCW*%
MS;)G9==*1RV!VE:ZV/TC$X?$+GATQ<()S7XN3*(2Y=(VN)/+">77:=J >8>'
MW<1(@IW'E9S[5WQ..,_#.Y+ ?)?527D77C%4]>0NB)U0,%IFH#*VXW<89;&W
M)''W>:[D[3.I8JD,VTY*TX2C6LYO]S+);Q%C#=5O67ZT59QM5 :P'RNL1]-Y
M#\A2*]N9VIJM'TV40MDM2GJNK9)9\<9*=6)(O7S@V!F$Y;E M1A.HCQQ!!:U
M0,HL.!*URSU:*?D/*99&([S"GDBM26\[5<"6O];0V615ALO[U*BHGB6Z(#%C
M$2GCE+P>F].,^1D( [:W46AD@(6#3JR]AL"^IGZS,9:Y?9%>/G(%[897R3O6
MH&*O&*HJM4RRNZ:J6'KF*E[28FYNIZ>2-8IY%VO&C'-4\N38Y,Z1E7ID^MM1
M"H;H6'Z):836(5457%W(-J56V"NH0&T5+0F3IFA18@8RV!FQ[6F3C.(3-YTE
MTI$266,98 ;UH(MAUK>!LW8 BUTWUZ?-W"U^QO AHL&M=-:\/P[W^SO CH(0
M^.M:UO CO6MZV'>M;#O6];UO6MZWK?MUO7LWK>!XZ3)P_D$% Z^WL $'7\/;
MK77 G\DK^M%[_" .]_J[WK>]X#R2=>PHK7_0P_M8$V@AUX:"'6OFUK6L"/37
MS:_%K AL =].H=;Z;UO7AKPWKV;U\V]8$W3]?QP)1!"/706NNNNM_JZ]F\"'
MEE_F!]N]]=ZUO?7>^OMWUW@8Y+MC31:3*D01%+R8^]'HSDI.AJP*B6U28G,3
MAT$0AG@-#K8->.]BZ8'Y[Z0K_G]7%.<8;;8YV9!G&\XOQ3K:8)W^RN2/,60O
M3M<,HKYWFMWSR!7WN/1JDY1"H@6[I]MK!HQM+7/AVUIXT[>D+V$R#D)SW/B2
M(R'O?P*.M46J>)*8BX4A,9G-W^97];G*F".\V:K!E,N5R%L5UJWP6..2% ,E
M>F":8$*C84AY)>@W_/.1/+9CXD\+'*H)LP.=B3SB)/[;L^R)A3<BG+E(Y?2_
M'>.V ECA<4!+& ,8D=B3<PY$XZ6"4K Z"H+3D@5:T(H.<A>I;S)D=KW]$89'
M&YI11R*+2HD@DU)28(:\G3;:'&F%,Y#NB*D@7^1D2V.VR^NP4[@I0*')O1IE
MJ E*D"(P\,HL?FCZ@=2UTN?')_K:=Z=[%G]9J9NGI==!4%,12G.6$FX^/5W2
MK3A.'YB<$\_CZ5 L'[YI(QL2M84J&,3< X0@Z!EO,CDT@X><1[2F:J'4)*KI
M"_BNJY4U2V%:<,JW31#IG(( 6UU28)HEP%-W/;$UH40%PA:3'.&T*?2A<J;]
MC#&N-UV<J">*G/[E%9*94GO@B3N4C@]5SMCM15#:C41SC=4TD8X!N%(GN1.2
M6)QZ3RI8-U-:&YN7'; H-<!#.+$(@.98+ZE/)-Q9YI/Y6XPJJ&X^1PN(R:[Y
ME7$]FE/19A:HCRSD\<>HW"8U="^)/*&U'F!1]G1REB=BVER&IV8;H9YK8E+#
M+V;U*^98JJ+NYT9JP7Q61QJ0-K!&8U2%D.[PP21JX1TSR41V(M=2;0+(D,//
ML";N[<I0#*:DJ-G)*..=2MI59NPTY#?4JYBR:3GSV02*!1>,,[19E5!6+*>D
M;I6Y2=OY'<4FU=RHD4<A5Q2=#*&ZMZ=N%0::E8Y*K;]I$BIP^( 0&*#$H=,H
M/4$Y7EL$MN-0BK-YHGCW5;?<=J*V:C;&;Y-R"J-)RDNJJY3;M.%N-EZ,KUJU
M0=5;FS8U*$LF/<#1@**.$E5IS\#MXF=WE/HQP.C$RV;7]IW)+FZY;A:8*F=4
M#=%JTK>,.-END%<%HUAYP"C)2\0^+.W<=H#F)6JZ%>08(H(?0LU&F.V'9I01
M[#KIK>][UOI_G=AU@2^X)-ZV'R ]-^W747C_ ,U@>X"2B]=H"PZUUZ^SKX]-
M:]N^N_9K G[ ?FA_>Z_:P'8#\P/[W7[6!*$DH/782BP[W[=A '77\/36!'99
M>_: /XM?L>S E 047UT L =;WUWK6OEW[=^/7 B HL'Y  AZ[$+PU\HA;%O>
MOFZBWO ],!@,!@,"7L#W;%VZ[A=.[?3QWV]>G7\'7 AY1?=W=@>[KUZ]-=>N
M!P/ZC\S+@M!1)S<+3?:5BCKR3XPQ*P[(CDY45FOCU<R^[X9'IL,Z?)%;>?$V
MU8PN!Q"I;I01HH@P6]F!UUWH/DO:?J)W;Q93/$<HZ0I;\H)1:5J@I?DKR"E3
M9*T<W1UU5=335\HECM"13NIB+"/>['E\C;8_("ULC>S$;(I1MJ*0J40@%!L@
MKU/>0BJT;WK&0FT+6Z&*VJPQ4BUGZ+.LFK3C! %\ZFT462F]'-);;.YOCV <
M=;&P:*0HZT 6ZO92Y*:X,80+#0Q=X]1?DDE@\MO]:YTZ_L4!+Y,FP)CB,/N:
M#PJ0[I;@JPWD9)9L"2R=)*)=#99/)3LYK2+&)N7-;4D*,+$I4GZ- %N-Y\<B
MI??<*9$]LU?.JB$[P&.Q.1T8Q2Z&1+DN['\M.%Z!_D]4/ILVD1JXJ!1BY7*%
MOR *QU;E9R-?M0 'GB3(PVU6'J/<F;>W6L:A+AQI=93<$@XXMSC*V>'62\17
MC)([E0W0OL#C_9L?W8S8Y3*\:I:JI(5>48NC9AART9;@VH"!(CE ;1M'U [:
MCW%;AO<0G6A*8>^0M<R^8SNS[;CTW?:>C$OA56*9RS5FT-31*XZ_)GNXY"C-
M0M&CW-8M(3IU!:1(YN&TY PUY6MT\JI%PJYX7W+)+-HW9+M=NT[:SM+<[.DH
MXKTW\ IT%A A$,>ED@9CY=1T E3Z\ *2-Y)CJ[-NS5"<U0/1 0T;;-QV*7,3
MJ_X,\SIE:]%+9_Q;'*;1D\]D-^IH]8R]CN=X=ZF@EO,TK9I&]I9TQ5W'WV6L
M0'E06V['[MK:0E\-3!"@X^<K>1=#TK$8M,+N@X);*I.HETWY#<N2KBFK')YC
MKB1PRNXNEV9I!.!.4-D]FR"\'Q RML?TJ"D"P&A;(XM6&J !#MWA5S^N*_\
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M6(H99 DY.R2QD#"82,!6R]E@&48'0@[UK6PBUUUXX'J!.27W]A8 >88(TSL
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M_P KI]'C@7W 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MR?;^K@7# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M_-X#J9^:#^4%_-X#J9^:#^4%_-X$WUOEUKK_ %6]_P"EU@2]1_($'[_?\WO
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&I]/7 __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>tv526458_ex2-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex2-1img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@">@,T P$1  (1 0,1 ?_$ .$    %!0$!
M      ,$!08'  $"" D*"P$  @,! 0$! 0            (! P0%!@<("1
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M@)*@)#!TB.NH#[AXNN?+WS!::+W3]ZF$XV;@PYXKEVU0;]G+6OK'WT>;[B,
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MN%H66IT"Y=K2L3DN%Q>Y4M3B!M4M&UU@I-SJ3DJAEU#>1*8YBE5%)%7B[O\
M:OYFL6^H7O\ 2O8Z;:#WF#L,#9:]"!D4L0HB('B/*2%O=6V]M[*/J!W'N8?S
M:,<3&-=@./EU;Z!,F(AI[!Y:A[/M_#B08,T'&H[RF98<79-(F<6QDZ!<RD6%
M(%0*J-;DA(L"8E."H)CSZ=!ZM--!XZ71 J=8VS9D[NT>7XUK-N__  MS@/+;
M_E-?+W+#U VP79U"2;F"R(9[O!W7)MYRJK66-B'4Q/8?P H>D.I*5;1BBMBD
MY=VDDHV:0RPD:D<'%RFF105/Z+_,=S<-\]]4W)U6W/3]FI#:"T)?W8#@#5X
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M"9RI\XFQUA"G6R)>PN:\K8[N4BTJII;<SB\):AP=&L,)Y=W#L'^+C.9&W3>
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MT&*$@_@\&;L@DJY-#*1,FQ*]V_6B(<(2U8-'.)-V8Y'O0FFHW%,.OS*9C%2
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M8LQ,  +VG[!]]$Y1E=F[0SJ:RG"5AN(=L7+"L1;) BQP'3MN;-*RZ6O+4H"
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M\)9NLA#%+'B'FK.+:G;4[%0Y74P!PK9U/9N_6]IT^RH3S+ N,H8$:F,>$QE
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MC':R\2[":?DT'\>J(M^D4U [!HA0W:**HE+SZ=#:" :\(_Q:+J;^X#',AL^
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MX]1P]9(+&.(E*=-VPB454 ;R\58\R2:2S!<5A;/]$5""=,2#Q5<W1N[@60)
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MU@[DIO:7M0;Q,<DH^=OI; F(F,?&-VR>JCUW)O:PDS:(-T2:F4.8@%*',=.
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M/+ZC26ZILE3E%7N+9!NU!'H<OJ#-NW2]1?H+]XQ4H@XBY?T]XZ.F;MJM>ZS
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MY@\>QFW3F"N"*$*E/L8F:+(Q;Q] &E6\DW5$O816:E4U$$3J!^O]\WG[6X,
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M?1P]AJ W=!K#N7DIK%E.R!<;V5Z9T2P2D[4G4VVDW K$ZW-L28KJ5=N1(ZA
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M6B:2Q,0I5#@\:E5)(6@B)RB(FDUE&P@ "5LEX<9!NS9PV":(PUD N>&>2?Y
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MHXCT9CU<:DB,E&,S',I6,<IO(Z29MI"/>)#U).V3Q!-PU=)B(%'H714 P:@
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M\P'S.E[^Y\001\$[E+949+90G3/*V&9VDP2?#70M[6W8'B3"<7B?2Q&/^:
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M&#I][2L]4R8M+F[+L\@QEBA2P,K)5#'E8IT!%,<H4&O2#>&^:G;H3$H1V<3
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MU?H[Y["N:E:,G9GO\]0K(O(-QEH=&%CYK(#Z%O"4FQ1.Z(U(B_0<M .H=,R
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M*'<;Y5J[;[(TB\=TI./3A(*2DFLF^+(3\ZZ2:_!HNN<$TNLYP*/4WC1LMNJ
MFVJ-)X%FN,8[](7+TU6H\;9:B1[ /XT7W)[B<&P&";1;9G,F,6-7)<0QU.3@
MWRM(Q;6>KEQ8M<B59S(G?*-&]@I<3$R:LTR/HYCF[)R=<B8(G,6[H(#=0#VP
MS! S8"8(1HGEC'II;H_2(XD?3V4J+;Z=GDC4'=UK6YK!UUKB5QJ>/6S^CY.I
M=M1D<BWJ0"+I6/H]:#G'+=>XVV3U09,NX514_48="D.8,NTVM^ZZJB-DTF,
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M??QTA'.Y<CIO)M'4D9!8IPZA53-]G%/5?->^Q FVH5%.<A%"@CL,2.PUE_\
MS:_/2L9Z/U'S 3J"V',8XY ^BEZ?WO;.IR\8_2:[L=MSJNU96QW*R/S9IH H
ML)!K"C7J\R.<)\A"NG"MA<N")FU-TM3&Z>11X7:,4V%]@#YCJMH&,,P[8\X
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M6+"1)F)@0*Q_/2J?G3K"(('Q^X X_P#5?B>T2?3V5L)6;7,9S@H::JT@[JM
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MEEYR_9MV][EL@8(B+U-5O$&XA'#F/,:X.N.16EF84Z,RICFXUV3@T+I LBN
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M?,R]?A)F%J<Z]A+]E-E#/H<Q[$K6(V5)7&1R*O.D ,4N^UN-Q;2;;&/35_\
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M&)[:C:GA\WN^1+44>XU(\BJ)&J@8PD%M3T';J7.F7J$H"2TV!ZU/H ")V?M
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M-("86E?$SB9\)'MQ/HK#+"2-M<4B#BDVC'%U#RC1HNT.FP*M&$R\%PM5U:=
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MPX@L!4P:7Y>P5RN$;KSUC@X)LZ$0:.)J781B+PQ2@H8&JKYP@FN)$QU'I$1
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M-K/R8W0[YR.U9>TW"H/4W*AQ%P>/:K',(*.DCFZO3]73>M'>;IBUR[>:W8;
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M)%ADCFUH 9TMNXRJ+^9)\OOT^%?^('UU*,"+O;^A_*^,7)/N;RS5FL5$?*K
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M/=]G',8@99TY/KK(AM0$!#V:?W?CJ'%??4JT&*S( " ^S0P>'M$-!U_7^[@
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M0Y?E_P#M=IFEE>O/\N23?+$.H:)<T%=ZE@P[Q)5L5YU@+.T3<^AS<'K>0VZ
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M0/4<64.N/LG3-(?IY"A&;IY9I-0CIXI*ID.EHD(SS$'WA.$*9YY XX4P1C$
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M>DA[9NZV\MZZ0CQBK&%6HV4JBM<Y-ZBX<FEDWKKYY$M&BZ:)TW!$ERJJE41
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MJS./Y=/9Q(_Q'(\@.-) /UKC>&6!,@I%FR4& +>I][)=A1+)E;,N>&H:SEL
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MQ^J.T^RI]1CV,<UC8Z-029L8QL@T8-6I"HMFS-JF1%NV22( $33123 I0
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M@F)1^A%&("@-7ULF#M -).C%,5, (T1T3(8ZV6^479M:VN*HPU-Q=L=1'\@
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MG$BK$$F:,%< 8Y0U\1Y?V:<3)IG]VM<MX!FRVU3<R@OT'.; .9.GJ4*D!/\
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M]H .@\9,ZBK&$$@$X#R]_P!PZ?@'%BJ",<Z *+D%7O\ ?6#1#IZ0$-3&ZC"
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MJ'Z7O*#]H]H'"<:DG-=D/5V5<N%9CWEBR) +/5ZW28E<"RM[KZS9,UM@3*'
MZ+2-)&I$>>>7#LM7C5#41.<$U,72;"WKC[7=,+>RN@:W(PMM/@>,R9\.D8LK
M-WAG=E4,!JN#(<2.(_CPITTFOQ\DW7MLLZC;C8KQ#M1D)Q HK0"=;=$\ZQK%
M:17 QV]6227 P@<H+OU3"NYU.)2)T;J\ULBQ:U6MO:8POXM8P+O&!?AA@HP7
M#$W(H(U&"S<>$<AV>T\:8$--SS*9FL(P#A07E>[:Z-U[R"QH+'\B7IB&2)UT
M5D9*YU]R(QA&IRJ 1JDU=N_]<A5=M^S:O;=.KW( N8&W!\5T>\>$6V7QZOS%
MD3W21"EE<V1,C(\E_P#>&4=Q.=.6P5I#&["$NM9;.CC1VCMO:F!#KOGUCI$J
M\*^L2[]9951>2L4.\ 9A-<PG4443<HE  =&TRV=Q\?<?9WR/UB-!P 2X,%@9
M!&'Z9'(JQ]VI91; 9?PC'F0<_3./KJ8D3-GZ"3R/736:+(HKMUD3@=%9NX13
M7051.7D9-5%0IBB'B \<TZK9T7!#S!'(@QCZ:MS$C*AD4Q$-=1Y<O;S'[^$N
M8X5!HYIR /=I^L.*:B@%2]>H#X>SW<O^/!4D$59JL10I1(H11,Y0.FHF<IR*
M$, "4Q#E$2F*8!U 0'00X,C%$$'&F\A>*6^M<O1F-MK;RZ5^+B)J>J36:CG%
MDAH>P+RS:#E).$2<&D6+&7<03TC=51,I%C-50*(]!M'# 84Q$=U$X;(%,L[Z
MQQE4M->LTA39\]7N#*"EV$JZK%B3C8R84@IUNQ775C)9.+FFC@R"P$4!)PF8
M0T,'#J0U14*1V\G:/99C)%>K&Z/;S89[#$;)3688:$S-CN4D\60L*?MSDQD%
MFQL*Z]0BX57X'CA^5!)J?X53$-RXL0,V0)QC^%3I-5#[T=F=DI5IR! ;M=ML
MU0Z2$:E=KQ"9TQE(5>F*SKKY?#%M%B969:+K2TL_-V&@/%43+KZ$3 Q^7%6L
MME$4VGUT'%[U-GTWCVX99A-U6W69Q/CUPT8WO*$7FG',C0*8_?HD<L&-JN+6
MQ*P$&_?-U2'11<N$U52F 2E'4.+#X1)PFETM2Q%;K=KD["TJRQ.XO"$O7,E1
M%IG\=ST;E*D/8>^05%C#S5WFJ?(MYL[2QQ=*ADC.Y==H=5.,;%%1R*9 $>">
M S)H(C$THMMS.V9VWQV[99_PP\:Y?++J8H<M,H4IPAE!. 3<+SZN.U49LZ=T
M2@4FBIGIXX7)6H)F[HDZ1X@ZP2",:CA/"F)7M]FQNV.9]G4-X>V"SO*M6YBY
MVAO 9ZQ;,JURGUY)%>?MDZ2/M#@T16H-!P0[M\OVVK8IRBH<H"&L%F5BKB"*
MDB!(FISC<G8XFYQA6(:^4Z6LLG3FF18RNQEGA'\[*X]?NTH]C?8N(:/EI"0I
M3Q\X(@C*I)G8*K'*0JHF$ %3<Y40V<84=@;_ $:WO;5$5:UU^?DZ+,_3UT81
M,LP?NZI/?*(N>^2V%!JNJI$R?R6:9NNRL!#]ARF?30P<&IAB:"I FA*)D&@Y
M)A5Y_'MRJ]X@VDO-0#F9J<Y&6"+1FZW*NX.P12DA%N734'T-,L%VKE/JZDET
MCE'F4>%+$XU'?G2;+Y"@(J_5K'#A.6&PVV&FYV)50BG2\*#.!%$'I'TLF06S
M)T<JNJ1#Z ?334#&(![58%9Y52]T!Q;CQ$2.6%/(H"/B'/W!X\2#--K$8QJH
M7X^D-/\ 'B%DF>%,LQCG0Y5DQ_+/\!C!IJ/+77V /L$=>(*GWAB*:H4,JTR1
M>I)B<A7-)Q.\,P?HK)$69V+(SR,0<"V7(J51%XQIL-)$,<ABB09)V77XFG'2
M#ML-KKQ&YW(P/Y;08B1R+L(G/0IX/59AVC-%/K;^ ]O=3&M5N>[>*ZNU?L59
M^C/3L8/'A7#T4GE>LTVX)%5NB6.56 YVU,DIIRBFREC@J>*;]23L!1336XZ%
MK:K\Q7==LA-Z 6NX8.JB6N*/^XJ@EDP\PP5\1(-5RX-LDM_3D =A. !["<CP
MXX8T_P!EB:#"B(UN65._L?S4]LD[3&KIQ\P7)2XB\?7!@]2(91C((N5130(8
M#) P*1H8AF^J8X/[E<&\\ZW"V=.@*9(\H8!",B",3QU$M,XT,@5-#8MG/&>?
MTX85$=7NSVX9:9TC()FFF,GBR=<D6*!F]>RQ=F[-NZ6D8ILKW 9R&,H5ZB:0
MB3&,=M+O151,HDT(<G2WFSM;?IAWNPG7?7%3BUE)(\1XBZP(2YA*+# ,V-0N
M$W &QTY<B>SNXCGW4^LU)R-;9$R/CXL:.5%A84JJP\HX.C 7V2D'ZJ,/3K*#
M;53Y>V>N%79'R>KJ)3274(!DA714Q]$\O<O\)ORPV,%[C+[UM0):XG\T"-)P
M<D P8(+I8#6H_5R .1[#]_"G%AE[&EJJ<"R1>-)^$<JFOL-/$(C:R6N7$\C,
MRLRB"BJ+I*>DW"SAL[1.=FNW,4$#="?06GJZ7'W0W$CX9_<8>YH7!54P(*
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M@9Y!6.<I"'5WFAA, @)1'Y3U/:'IN\;:EE<*QA@/"ZG%'6<U=8=3R-=>TX9
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ME[(2)EJLS@G4?C]!9%1J,<9E52)C,%*#1/F5J590.Z3'O+:V=MMKW4(.ZTW
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M=H9\Y.FW?F2!9,2@W>)*H@4$NEU+<+:ZG>V755(MI>(0QXK0!@%8]^VP&*#
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MBHU1U:9R)OD@LW4*F4U<BW$:B<BAC%!V'G-P]U=JNPV))O,#>O[BZ2C!KL0
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MVRI2.))) Z#ULXN,P9(PI)M(Y7RZ:@?G.D--!SG:6-H[?W ,H61H&#MR,$>
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M@?Q$K#+J/&LM BUD"Q[.29G68.F[8IDS\C)EW==1;>^)L@?"J1;MLIE2+0"
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M3VQ;8QS.5>J'^DV@6+#$.^.9:3%4FUIC<)5$W;FF2)W\(W,C4YB7)&@)F;(
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M\6GA^@\$%LJOLH_NQC2"ZF5B+D RHE J@ 8/#0-?<.@Z:<7*-(CC6IK9420
M*AC=5+Z;6=SC@'0-@)M[RX5(Q@ Y3*.:/,-T5@(8BA5#@90=- 'F <:MLOZR
M YZ@?0#C7?\ E&!\X='T@$-U+;!@8@@WDU3Z)HWL,K$8[V9;=:DDYE*]?,98
M0Q UJEF8)HLI@M5M-$A[;3P(*I7+6;K LWRD8Y9.BK-5'$<N'014I5"];>[B
M=Z^X33<Z??=I!Q4LITMVJV3!A! 88Q(K@?.EI4^<.JVU)&CJFZ41F +]R!W
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MI#120!QFII4GG<XW9-SP#9HZ="^;E<D>!J0C 1,9RJ0/-LP%4H !0#J$?BU
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MA:)LDH[<!@O-;]L!3/YR/=6JKY @8]%LU^13384&%J=62N1@@W45=,))%]$
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M#!VH\:P;99:<<-FS1B86*0D9F\<MT=1ZFV[M6A>OV%!(4 [?;VT@*EL0%).
MU$"VI9G\1EA>UPK: )TAC'\S$XDGD ,8S,1AE3UF;?,0>-&2"D6EB#$]=KMD
MK5,JKU\,).W#Z?$L'CYG;) CYC]%Q4DZ(D1]'-UB22HG,9== AE$..;9M?%=
M09E<;KJ5QPSNH+JDF7*B"'*R8:"OY08!JUB$2?=M@0.$\AV=O&I/Q?\ /TJ!
M1*+57$)1,<0=1CF+B\H,#1$W:)$J2'S%]CRL22!TX& E9%PLJ22DD@5."FK9
MJ8#$<EIWPL-O+NZO%K_4'>?+F0@X"ZP@LP  T*<,F81%66I\M;:0$ SY]PX
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MLDYG'IF[$[M:.R!/L>T4B2R9>DL1'*]I8IR^876 XMRXK0M;:XFWV8\S>NX
MN,,%), VUYS^-LOPJ/>JTL;@)<P@&0^T\NP>NDJAV:P1-5K.+L;4]M)V"'@&
M?U18W1$&&+Z3.29EW\S%N'D>?JL$S%22ZY31$2!SIF I7"K0I@.$[RQ;:^V\
MW=PBPS> #&XZKX5(!]T, #K: <U#'"IMA@@MHHU 8\A..//$G >RN<N]]VVK
M&[?TX:VXGYNV7M3<2M9+C87H@W:.XX<>W9O!UJ(8L3?+:XS173=/$F*26O91
M!59=98>Z;*US58?2H2PY@#M$$DDXL<I/J RKZ]^V]M6^3OFV_<:"G2%499O>
M4D\_"$ _S<:Z#(VAVHNN5PB H"L((G,?4QD#% P&,7Q VIA*/W<<XI&(RKP/
MPQ90)$D3ZZ523+, Z^T00\-1 -?NUUX6#RJOX,A\2*.H3S54.H&_3TZ\P(8=
M/V<N(Q%,]B!G4)[A<2U_<3CB3QQ.6BZTMH[?Q$PA8L>SC:"LD?(P3TCYD44Y
M*-G*W8X5V8ID7\/,QTE#R;50R3IJJ40T-1%4-:4X36DK3TZJG$T^!Q14,U9=
MHV*J'%4ZRXQBX1Y5UKO0]S%:RY;\L2NZ)"SS=;DXF:OUQ<6Q2.D6#Z*7AUV(
MJ) V(F8A2/\ I. I42&G'&#P/>*ET"+(IEI>E;@N'E:ZO&Y3S:SA7:E,?Y^K
M@V"K2*&["QX^S!-Y[J=LS+)NZJ>9CK TRK9G[YRI65H--ZS7*P4)Y5%(A6^&
M0VX8D@B/;,]](BM[P,&L*?L'LN"9!&RX%W+Y.;S,"VH&+L8Q.4(>B6>LXAVQ
M1^:&.5,GX5JZ+&GM)>S&O#'S,:C,S:[N3:-RMDRN"@B*AJ20IQGWF:1G+$MZ
MIY<,*KP4Z2!$&F\T])NIM6T41EN+RH0^(F=?C=GBSRM49Z&UB!KF9(W.,=#(
M)%9-OYR(*6:':1KA6P&*NK7FR;,#E.4S@V9FM.-)7$SJ,XF65_1XE!%:7=C9
M-O\ Z19#':@*J?4322^]*/NQLC#QNZ>WD3S#$SD)O$D)#&U1D)?<2VL.X&8W
M&RCV#40DV#+#\BXM5DD802MD9=J%9= T*D"J15S6$V'6XK6P;=S5(R'C 5O6
M *J+FX98$MI4#L"S'JGZJ[/HRP)I@DF*2:94^R1N0/RD6X"';;$3_A*@F  !
M2^  '&NVTJ($"*22F/&LQD!5U$[9N8-2&$QFZ)M#)]';. B01 Z8I%Z3>(=)
M=/ -(+$-$5?;.K$UB27;1#<@1[=NW. :),HYFDB4XB":1NELU33*(@D0I1'3
MD4H!X '% 5WO@ 9FKD6;GA'BFOG->MW+JN/5/W.6"1B49B,!CC6M-)@'$H!*
MU(M,=-$U7[(T<=ND]?,5G95!:&ZA,9+0-0$VOZK_ &7-_P" O[9B1<6]J0"/
M$FE2RX@_BG'#//"O1?.ZJW1.A.GB4]-O&<H_UFX!P'+VTQ_2/F( GJ);746\
M>:*&JER7+3]ECTI&Q#;%6&++U,L59#YA,3K:*".09B83L2-S*I('4 A]"<>]
M^=[=U?E7?*S%[MQK&A3I6!\1:#1 !DB<"208$BO";"Y; :ZW@N6[5S2<3J)1
MA''#229'Y:]4G]*#&04?M"W*3$#8!M+6>W&(/!GE(&Q5Q9^J;&U4<NBC'V'0
MW892KQRV(JV#RZPHF4 0,8Q"?-/_ %.[N[O/FGIIO+H*]/,KJ5H_6N#-9X &
M#CC';7F_E*VEK8O;4 +YG"?RKS]?*9KU3]PW8[F@=71U:>S7C\S>'5GX9KU6
M$]E7)H F /:81\?'BA6\1%%-ZUJH(5FS.7)P310@IA150W6)"(DC7)E3&!,I
MSB4J8"(Z (Z!R 1XZ&TU'=653$FZGI\0JC<A5LEV_*?J-?**R33$\(;)]NC2
M0R-A_)-/D=ZVX:[.9_$E@FK.G5SO,$;?E!83K]U68F*83M*-***/$5F[MR+L
MR*34P$.Y O\ 2+K&Z3>_->]8[?=V=Q;Z=8MZ;R*DJ=QN3K6'8Z7@P9$C$C5I
MKP/RRP:T'N$:&9H()..E8.(X<HJ+,"R-SVLR5ELJ0K+[D,39,@19XZLT 0*"
MV+0I>HY8^83)65J>R-P=/UY9TXA2)HIEE86(>*E4[@I]7R#YF^7[WSCMUV.R
M:VNPNL&%R#F3 PC(9,<#+ $9U]Z_;?YML_(K[X]1VK;A]SMWL.FLIJM.!J =
M0Q#1BA"G(FNUN&_Z@3U%<BM+K+/,;[:J3"XWJSRS7"2-C6>F&X6]Q,N82 I:
M#8UZ0[\[:I)FJ)3-!<(MVH%7.;03=/S;JO[+6NBW[-KXX77OG#\," 68R,E'
M,"3@*Z&UZA^WO4K3WMOT?J=IES#[I&!X!4BRID\SD,Z=%7_J ?4:O1I<[3'V
MUQO\F>M6CXYZ%.-2)M':IVRJD7)2MP0:KOFBIDQ!,P  I&%3K  (*E5W]H-M
M:MJXW9;4#PDX=@QQ^O"K.F;CY O7&2_T7>)I/O'<+CZDK>S*^^_UC*':ZU6:
M%";(<TT/(JYX^J98CJT^IU205^CF]L:*W!>UY&BVE80?-Q5,DY3<O&BR )BF
ML+A4K8WDMC\H=#W6WN7]QN;]B_:]ZT;3,_O:"%"!@2#F(D8R !-=K>]/^3_B
M$V]CI6Y:TV17>(%]W5XBUH:<,LQ_,28HKC+U%/5WFJSEZ[9+I^SS#E%Q']>M
M$+%;*]+R2%^D:(R55;LJ0-<R)-0ZS.T2/9:%D7;A%LU6=-Q(#@JA@*;WY+Z)
M8W-C8[2_N=SOMR$*JELC3K/XRRB"!)TXG S$5=;Z7\E7]K<O?V_?;:U8U:S<
MWEEE;3F$"VM78"3&(SFM&GO]0'ZB%=ET&4MCO;2Q>3J2#XC%:D655=8>HB+D
M&KH;PT8.UH]$3"N8AB(@*1@ZQ$Z7<]7M_P!HKC)X7;3,3(PPPGE/##&N'=ZI
M^V2W%MV>D]3%PQ_^.V0>W'X8]_TQMF+^H-]0_&.05,?QV(ML=Z9.&%?G(J[,
M*9:&:-FJ-IB#3<+.PT.UN\D<JCE IFIV97!W:;X ;B J"/3JV'[,W-[M3N5=
METLRL&(&AE)# R!WSB",9C&J^M=;^0^F;L;>QTOJ3VV(*GXU'+(?=( VN9&8
M&,@B*,2W]0-OC0>FAXND[7'+NM8W?Y*O82%#L;"*HM>K-B85JTRS^3:Y!DE)
M2(-)RB:44HW;BK)+(JE2(8@)J*9-G^SERZT/<8+<<!>9+"0,L#&)F(&)B"!.
M[ZS^WPL?Z?IV_>Z%U'7O$4!00"04L-J )@2%G@#72OTU-]7J.^IM%%F(EQM6
MPRP3DK]"()3V);[8WOS*AQF-Y=4#$97:,3(WD@O8"@<BP@JV;=PH""@@7S'S
MA\C[+Y.+6K[77NA+;8%8_4-P#'C'EF>\56-]^W%S;IN[^PZD]J\UU=*;L @6
MQ:T^(VE )+F868T]M=97N.O4KA9R)A+%F?9<W3G$"M8*P_R%R<$8YGR&<J*U
ME1!;*0*I2R[0A5F0G,4KL"J$(8%$P(I\^2W8O6V>V')7%AA(7\W<#[W*03AB
M*KF__9^VH"],ZWJ&!_UZ#E'_ $2"?H)I2D<&^J#\L<JM,R[*9&0:H.%&2:F'
M,Q1*D@Y2_-:MG2Q<EJHM"N0#H,<4U")".O, UX1/A-8%P.$)Q@C+G_"F3JG[
M06SK/3>LZ?R_&6\XRDVB?IPI$KN*/47M[3YLRS1LG.8KQ5O)M)K"N8"3,#,)
M !Y"'EXLV3$#-Y-BHH&A#'!(Z0D43 Z1R',EZWY-[0X8J<1'%3D0<00?O!@S
M5AZW^U;"+NPZN$[-WMSZ,=N>'I[:C#+.W7U&;)7;#AV\9BV61]*RG4K!30O;
M3"V8&@MGED:NH=S7SNS9->LZY+.6;LJL:X<IJ,W*A3(@ K F17J[=NG^'<6D
MOF];!E97(C$C"2!QXC/*:V=,^9?VIZ9U#;]1VO3>KK<V]Y+@'QEEE+(P99'P
MZD"1B V/ CATEQWA*V8GQ-@F"@7D7)W["6**+BV1$IE8ZOY*A*O 143,12BB
MP**Q!W+F,%Y#N%0,9DY,)% ["[@!P[/<6%LW-A?U?!7'+SF;;8PP'$8PXXKE
MBJU\^^9MY9ZW\P;SK>T4VK.YW5V\$;W@+EPOI)'$3$\^RGD:RTC,U=F:E.PB
M$E6+,G8*+=ZG/D5:RL8Z,!&#F$GX9VDFO'/GPK'[9@,8A@(FLU55*8BG$V[.
MZZ3NEW.V<K?0AT=3A@9#*W$#T',$#$5Q;A6XI#"5(@CV1]/14"5^\9+P6NPJ
MTN@^M=0:O4(N,/:I[\Z/8G<.FK>.->';7RL78&;1NF"#2=40B)D#E,SDVBI3
M,2]6Y8V?6IW"J+6\(+$(,">)T XJ<R4ED_$C>]6(/=M0)E1AB?M^PP#P(RI=
MLA(J6MUTR1B@Z<=D'Z=8GO\ 7T'3:%LDTC&QROE"6"M3+(T8[?-H1F1!NXDR
MG8RC(I2-'38R*;D2W?>SM+73>J>/9:F-HF2JR9.EE,@$F2%\2MBRF2M-.IV=
M,'(Q'$X>K+GGPIL3-[QWE&M5JBY2AV-#L$5.1TA2IM%)[&,*S:V2(LH9ZBUL
M#:%L]*D%F;Q=NJE(D;,W"1C)LI%P*J"PZ=KL^I=)OW.H=,9KVU>V0Z8'5;,%
M@=)*NL@'PRP(!:VL$4C-;=0MR%;5AV'TP0><X<C4C2]TL] AI.N9<K#^\4-W
M'#"N7R\2ZL2<A'2Z*D8NU4?MT'K>TPCYJH(*-91-E,$*8Q!-)F$JI\2;3;;Z
MZNZZ2ZVM^&U*)TD$'4,,"C C!DU)Q_3RJSS'MK%X%K?WX9\1WP>^H/@,KUK"
MK&"E\:WS'5SP^#-W%1L1(WJ%3LM:3;/3&+42-9-=&T1HL#D.4ADB/CB)2D<1
MB2O=>GZEWIVXZS?:UU*S?L]8<R6%LE&)CQRH*$' XD<U<B%I$=+*AK9!MY#'
M$#ES'TPK7P^]3".,GSQGMQ?VW(YK*SL5F>[2(/'MGFY>+,DN\)9WE7:J1I(1
MK69614Z0+&OED4W#@5$6KY$XMT/7M\G]8ZG;0_,BV=N]LJJ]0:XBJ^ T*Y!U
M%U'YE!($,R'Q-SOCK-DD;>6F3Y84DCF1(CU'T'*N=MVW'9[FW=TQM5J3+X#Q
M4%@82\)@'([B](9OHLO(D=.FKS!DTTJ@9&AVKA^19PT@ZTT1+'( LBD^:-U#
MID]KL_ESHVR6UU.[=3?;X6RK;FSY9VUT# C<(6\IL,#<NL=1AC;9@#7,N;K<
M,6LJOEVM6"M.L=J&)'<L1S$TRJ+GG*FV!"3 (JKW6M5:6/-2ERW)U9KCJQXA
MD':,8U3NE8VZ.W#!I#7E-9R<A)@KJ3C9PXI@K(1/4N4>KO\ H_2OF9%N!WL[
MBXFD6MHYN)?62?+?=J"6MX ^6%5K8F$NX159OW=J3@K*,9< %>T)P/;B#S6N
MP6WO<CB?+(M[%M]92FZ;-\A!)EELLY%(VAG[$K/RZJ2;V!:,NQBZN)/I,Y$F
M[5G#QC@2&%NYD5P.J?Y!\P= ZETLBQUS3TWHBN=-FUXACR<F;S0 269W'%4$
M =O:[BU=\6W!OWX]YL_2/PCE$ \S6P#\*97[6-ASS8%LP9%?011GH:HMG*N+
M*$RAEUY$M;85$%UVT;&B\5 YWEJ>J'?N4B*G,CTH(I<!7WMZR-MT*V-KT[48
M>X0+UPD :B\8MP"V0- )&.+'5*AM5\ZG(QCW1V1_[QQ.-.O3*.6G->N;J!?8
MMQG6Y#KJ%:;L(B;R-8EE$"LVV0'Z3X356D1,2Q<+DC&PMY-TGUB^ZDS"@4F&
M\W3.C*^U1CO.HW/?8$BTF)E!CJN$X%S*#\$'Q38!=N%;GNVQB!F3_-R4#AGS
MI'F\E5F"E;5C3!]>FLAYBFH!5TI;(55Q/$9,%%",'TS9LG3#AQ&(G@S+BHBQ
M!VJH9^)4T&8B!R%:WL-[N+2[_K3)8Z2K@!3X)F85+2B3,06"X+B6R-27Q*6\
M;L9C&.\GE]=2Q6:;//(:.B;7/EJ%6KC)K!EH=!5D(U@H5@Q: *<W?WZ#"PS;
M=%F8O</'MX5,3 KWN[H?3%<WEE;S/M;9N;EB6-VY!S_+;$J,<M1<Y1&%.%(&
MEC $0!]9)Q]45#6*\LP4P_M]HQ!4&=L@W<ZRQGC9"JD+&4QE7JY.R$3+6>Q7
M$Z!8)(UFN#AXN7R)Y.0<L&C50R(F/KQNZALMQ92W8ZG=*;C2;ES7)?4R@J@3
MWI5('B"J&8@&!46[J,2R $' 1@,^>6)[S1_*<1:KY#HT*_6!.0#(LA7ZH>DT
MY_)QM;8,YHSJ1MSAV\!@WLERBH6F14@JJJ[69QYU2ID.Q^/FG3MY8VNZ^(V*
M &RI?6X!<E<$TC%$+.5&&IA)A\*L=3<72_XL(&6.?:8'H[*F*8RI#Q18RLX;
MKK*\R:#I6)0:0*R,7C^O(QS15T\:3%Q13-7H,[1JV, -&I7CQ,Q=/*^/'.7:
M76#7NI7#:4C5XA+M)S"^\T_F, _FJTN!A:$GLR'><OK/94,0T9]:2N<[[EB5
MB[?4VDBE2V5&A$7[6B+$QU%MOG32Q1CA):5NQ6MOL;]LLH\,+0_EA$&!#"!1
MW[G>6]IM]M8Z8KV[X1G-QH\R;A\.DC!!H52(\0GWR*A$-QSJ@@F(&6&<\_IA
M4K9;E15QI]%'B$$7URG8W%R*==1%W#12TM88R%(8151:&;1Z44Z44,0$A*D*
M9R:@!!-QS^G%EWB[DDDVP;D_X5+9\3(%-<74A3"#A]/13S7R'(M8S(\FCCRX
M+JTZ3*RC6;%FW<+WPQQ312<58G?+YA 5S]M05>T"8E,(_ '4.((&*JQ&(S/#
MOJ=6;0<#Z^ZF[09A>6RMD-Z%>EVOG(VA1[R4.W8$1CGD-"NIE2O3#@JH._/-
MR7(IDTRE42 O6/40XB4VG<@+LK"3C-QHG@Q"R!E^#'B<.%0IDG"#A0.3K7(N
ML.VQZE0[ PD))PZJT="NPCF4DX7?R"4&PE03([[0QKM98AR@)@5.AS$@> 4[
M :]W;5C":I,\AB<IX"F?PH3G4H*6A\WL%AADJA/*,X2 ;2K:PD0;C&3;KI4%
M>"CSE6%VK*())D#0R8$$QP !'0=,^B0,<34DYU'=<LCN2R<\EOI6Q,'<O0:,
MR>Q,@FS0<UX"S-^D"C-F1<.&R#PZ3LHE3*J<W2)O: AQL=C\ EHQH\YV!Y^&
MV".[ >NJQ_4)QR'VT\LOR2D/B?(TBVBG,ZX:46U+HPK/I*[DS!"NR^51Z_A*
M903@ B;D4.8\N$V<G>VL=)\U,<X\0Q]'\*E\$)SP/U4\H$ZHPD2HN@HW7-#Q
MRB[573NMEO)HBJW/TZ_F)'U*.FO,.*;V-QO\1].-,OV5'C7(-A4J_P!1J8PN
M2<@:R_)B58H1IIH8H\CY5*T"11XBBG%"P,#HQ#&*Y*34O;[GP<5/G3Z:<1K!
M.C/V*(3J4AY**AT)"(GA7;C'V"06!3KB&I.LBR+AJ<I14$_202G#I,(@;I6!
M&-,)XTH04VK)H+E?)(LGK68DX4Q"*""#Y>-4.!UX[O""JR!D0ZA\3%,0X#R*
M/"Z .ZB:37D^_2<+LFQ(P[HY&[B/.<) [4$59D(@49 R1-4W8J"/1T&T$Y3
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M^.,?Y@4'_-1?0JK+Q ^K&I?EKJ:+BI&98P4I909N&)4V$ F1PZ<-)0 6:2!
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MYQ=^Q35>$'0AI^H.F"O6@Y3E&Z;))8@I><4,4VEF\Z4B[E[>PNAV5R-#0MP
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MXW(43G?G.4R1L9V#7[GQG6;SB1J?4VIO\[$G22<-&-TY!(,U;YJJ--H89"!
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M,SCG5IQM=&#:M2P-FAZM:;[2:[CY4K=RJU780:<79[O-4&46ZB)B@W0,T:G
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M"#3B;SL*N2(40E&"Q+ )RPATG":@2O;:JOE/)"01%<J;5N<YA#D4"\]!T#B
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M;:EQNMHF$$(DL1WBW)_WAV'.D8*3I"N5GB>/=,>RI!AHFWLF LJM0,>4)(X
M"JBLHK(')T)!Y<5XFJP\*DZ6*<QBC_U H 4!T-SXP7CM'?5NKEZ[R@:?4SDP
M./NU?:!TG0%4>OZJ19((-H5PED?,1'Q3@H12M5!1&GI*@ @H+?R%<?R5W?G
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M5,ZQ9[%\95F22YB"!@3\UVA/\8$ZN8=6UU+K>P7R["6-O:)G3<\IO^&\7GO
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M(-8T60+*:])C'D  #  ZAKH%5W=>+2U_=H.5U ^'K]FGZIJ!:2)"H2>*F/\
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M=(*HK>9%)_8E'509&9(S*IE6R#JS*@V1%3I PG4,,G?7&4-?L6+*G-ITW#A
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M,T&14@F[L[J3.](M*P(HKUB06,W*F13OL51$>H -SUXUCJ6ZN#RMP1>M ?\
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M>T??1:*/C&"9MF45N#LT#Y=8")(2^0FTV9,3@<4T!+DMG8'X 8%0TZSZZ@
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M?J*W00H,0FR**8)]MD:+HZ"_3U !P,J=0X&#QZ?AX&W=G\-BW(XG69[Y>/0
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M$,.A\T35265;=3P>EN-LN[N+=LM:V<$_JL-3A?$N8P4ZM(&IS(F1(BN>-]Y
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M:^_]O# F*5N5#F3 .0"( /V_9P!CF:2@3M0-H.HC^(^'[]>#43E%&-9@84@
M +KH'^/V<^(DD>(8=E%&2+@(!J A]OLX4H0>RI!K!5;0/A#7Q_0.#20>$U!S
MI'61%PJ0QRCH0WB(^'ZA#B6#GB**7>X!2% .>@ &@?=PL-Z:F<*2E 5.H(@
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MEKJ!C:C[N$GIQG];</Z%'UL:B&F?#]/51DS+)3@"&<6^KQQ0_C)$TV2<*FU
M- !>6M*B0=)M>?9'4/9PB':&0B.?\3 ?4OVT$.3.KZ>NB@TNPOBF&6R7<W*(
MN3J@WATZY6$B)&3*3R@*Q<$I)&0(8!.4PN 6 P_QZ  <7^?93PI9MAX&)U-Z
M<6 Q[H[* C<6,=D"@QQ10US=R:AW%J5ZE#BI<):8M@"*H 4Y :3KQXP32$H:
M 4J0%#V!P-O=PON.$'\H">U0"3VS1Y:<1/?)^NGK&QT7#-RM(F+81#%(FA6D
M<U0CVB9"!H  @V321*4H?9RXQO>+F7+,W,XGVU!0'+ 4N$$IB!R'00\ UTT'
MW?KXJU29IB%.<Q1-8B9= ]Y@-J81,(:#X (CKISXO4G,U(51D*%7,4Z %\>0
M<O?R\-.%4%7FFX10")#$T'I_=R^T>+&:<Z*"4+JMU&Y:CX\_#7@#$".%10IB
M)*=)BF 1#P#PYZ:\ 9@(HHP03)ARYAS]G+A&AL\ZFB:2@(+F4.&@".FOW\M?
MNX9SJ330,#-'#/$CART$/:.O]G%82,9J29JDW20 (  ?=R#7_APCQG,U$Q0P
M*";40*'A[]/U\AXK+",\:@F:#/U^TA>?W#]W/EQ,F(X4L"9XU<IQ -#<O<'^
M/#A)$\::*S[A=->(\LT100JAS^_E^FFH\,BG.@47.8!$!#VCI^/LXL9Q;&-2
M3-#HE!3D/,I0$#%]_@(:Z<_9QF1R3/&I7!IKY^7KBWI_4]Q^$;F#)FC(K-=V
M41#V%RT5/Y,[S=+?XUO(@\;3)VTB%>>/TG2!C,V[J.74[C9X45#E)^OODK:K
M?^6KEA&U+.R9EG\*[.V""(D:@","00""N&-7R]>3;[Q[SX2+@4\0Q<QZL"/7
M-<9L4W:8PSB=S5,E,[%?<+Y AX"S5,8F,@+[ .YNFV=NGD]Q"&R!>JG--7DS
M2'$=45FY0:+MOF3-=-(3H%54[/4MO\=U'XO91;WEHE6Q*$JZDJ&*JP(\R7!@
MXA@3!@>IM7VVFR^'W(+V;@!4P&Q5AJB2#[OA/(,IC":$N,3<L$S\)N P1*-)
MS%L@UM!:39(YO'O/IPDW(LJ7*8MR#2X)JC5SJ,[BM\F08)M9MA+M*ZFX1>&!
M=0P'Q5CJED],ZDFG?C2",0&XJZ,3(\.I]0T,FK21@*6U9N].<;O;M.S:2(X9
M HP&$ZL($A@L@U-N)]QD5D-PPFZ5M8>/<FLWA8M\Z2LL-7]NT#8; \1;Q^4+
M%*9$D9/Y9' SG42M(,RQF2,LF0%5D@U:CR-UTA=B(ZQO7M;1S A2UXJ!.A0D
M3,'Q"25R'$=?;]:;=>'I&T\W<#,E@J _F))R[.><95"DYC6P9/N"Z&9]QX6G
M,LFVAY*QSL-,5[);Q_)*A&QELC(IDSF7%IN61IZ.IX)LV-:8"@Z,9-1L_ G6
M4N^R^WV.W!Z5M2O2P84E?+,9@D$:422=37""!,I,&N/N=JV_ND;S>NW4,V&#
M8@08@XG# *(/.*?>'Z-F+$V1X9YM?S&M.Y/BRL4U(Z'DJQ'L[TG,3]:8/$AA
MCSCB&GY=_5&THF[C+0SA743)*NRE6=.#=):-_N=AU#;,G5]O&S,DDACI@$F2
M!,!@"K6R^I8P K7L-IONEWA>V5_]8<B!()'"<9$R& @SC2]D3<+M\I$E,V%S
MA;*E1R<I'JO6.$LA,7U-B*)-/'Z2*[B8MZ+)Z]LV)XM8J",>NT2;+26B2!GR
M )G4%NG])ZGN[*J+UE]N3!NIXBZQ@ DP+IG$$D#$P<J?>]9VFV<W/*<7."&0
M%/,G,H.!B3E/&H@0HUDW9V^\Y1RDFRHV'H!A5G&6;UY-W7F%-I==;QEIJM5H
M"=?":?H2*]9*U6A>Y#64'KJ*=F7<@0ZZYM^X-KY?VR;/9ZGWMPG0L@LSDPS-
MJA8#8-B@57A1,5S$VY^9-S\9>(LV+>-VYBIT :E49G'#3@TE232#D^\5N(8X
MBK^ (6+9SF'8V-N-\N%"7=Y"EVUBF;)<ZG9:BWD6Y,7P[*IU*KG Q73J(;-W
MC635;@NHT3;'"WI/3[S7;][J#DVKG@6V\(-("M.F;AULX ,,8TA@H8FJ][U-
M&N;6WMT56VZR[++2Q)4B?"-(&(.D23$P*VAP<Q07QAZH.2L0M9^*6>[9XF2@
M&=039$=P,A;MS6)K ]*M-1JC"P231FZ1.UC2-F2+*/BFZ!2=\P',;L=&MBW\
MR]"VNZ*.@W[:BW$C:WU!(,B3,DDDECD*\]\T!;O1-_N+8('F65 X$7&+&<LB
ML+@(617OH]%XLV'I;[+E+(PFXZ>=XF(_FV5F!X-C+*R-JLKYTO,G??[HS]TN
MX,JH)Q$PF.(B(Z@/'Y3_ 'DNV;G[E]9:SI\L;L :2-( 1! TX81&&&&0RJKH
MB^5TJPAS"9\\3Z<<ZZC]/P=/4;_S:_%XZ^/[./G$^*8%=*>-4 Z^'&9F/F&,
MJ!E3(R6828[OXE#^&DVDXCTBH/*"D? @'3ZA ?9U!J'+4/'CJ='"GJ6U)R&Y
M3_F'TRK/NY&UNQGY;?4:^69\JB)WTR-O2>;7V28.%2WF[DD%)$N,HNP]DJ.'
M]M3BJ+FD7UNQQ(L"/HD6WR]--PNU<-044U S=(#?T$^;7=?GO>)M?AVO#IFV
M)ARH_P#$;HMD+@P/O8 AL.)KS'RM;VYV*B\6TZ^61TK(X<:U:K<Y=H2,@U*\
M]M<-))3S(K"29U]L'DH91F'2\K4VTGC2#A?YH*B!E@*4[)$A5$5U0#4WFKJ)
M=ND7@I0@@CWBQXRI'I$Y\1R]Y;O;ZS;";*=&$QE',&?J]=$W<I&NK >R7>XW
MBM94BJ3'.J<Q2C!9K729DV5V5!=5\]7QP[50LD<X,YL$LL#QY$KJ$531<'75
M31AP5"6K:(=L7QEH$ C 0'!9?PI@#&8@$WJ+ <W79AN@LY9G&<XSXG,=LUL_
M5IW($/6IMMB& JK"A%0:2M<GL=W^>RO3[!<)V&E4[FO)YJE(*'N9YI4HQ;67
M;F<.D8\KQTD51)(QR%Y3)8O7%??R7$^%U57"AO#%J2L>\01!8@9FMZ[S<&SY
M6WM6UM0(="6#$C&7(!GW9SS.(J,)&8RC&W"$>U)LG,V*1@Y9*?458-G,H]2<
M,Q&VQ#EHHO,-C,G:2WE5$18=I4$&Z)RI$6,FMOU]--CR;C?IAP4$D*"/<(B"
M#Q][ DF<)&(V-_K\RWC<((/$Y8CNX98X95:(LF6S3MWN"DHY;9(-,$=QC=O,
M DZ?/XD[-)^R=JF>)/!B&\+J4CCL]\J;9%02F X.U$N6-B^W2T% VH!DZ<1/
M+AB>$QB<LA8MOJ*W3=4_JS@.<?9_#.9ITY4G[M9(OSU]K=?7&%:O9G&%KNEZ
MF,56=*>E)APK;/H.4AXMLMF*=?PCABY=P\C(MR.%7@F,D<QS]&#96MG8NBWT
MQW9BP%Q -8"Z<-6?EK.H!@IP$:JW[H[RY:U;Y$  E3.@S.,0/&8@Z21,U#<7
M,1D&A*.=N^0,F3D>W/%&M,^^BBQ-JB G?J(DNL*K=U;D:X_F9/2-D8M&802;
M,^P"BVCU82]JV+EY5&\2T'+' '4IB, 6"EHS!*X8P/"*Y+,J$G:,VG"3$'TY
MQ/$3EWTW7RZ"KU(MULEI95F;4\E9@8P,>_58P[E5RFR5B1<V*" TC(-$2K*-
MSKL$@Z3%,82ID.6]R_DEMNH-Q9TR2)(B03!R.4!HX9Q6:$4EKQ/EG/L[L1]8
M^VO8W_3,1U-B(1JWIDA-2S%>;W(/GSR?K\76I%!5*-VS-V158N+G;2W00=I.
M55.X5X4RRGPG3_)*/'PS]VC?^%NF^J(B_! :6+ AOC2QDJN.H#AQYDT;VTEK
M;;3$DSN2L@#!CMSD"<QCPXUZ_/B[:!_ 144U^[J'GS'[./@%P!7@]E9' P H
MP<^I="CIJ/O#QY>[A*K8GC0?9$P:CS^W]!X*6L@;IE'70-?>'^/MY<7*V&%,
M#A0H!IQ.=%8"41$1UXF1%%"!R^WA",(%$580 ?'_ (<,)%% F*/,.?WAPV!H
MJBD'3PU]XC[>(@ R<ZB*$Z0TT]NG[?V\1.,U- Z#KKJ.GNX:!,\:*$*8 \0
M>(99RSJ*$[G+PY_LXSD$&#44$(?IKIPA!U2,J*OI[.+ 2#A16!D"F\?V<7ZJ
M:LBHE#0/\>#510VF@:<4LTF35BXBLO@'_('X\^ .>!J:",!2\@(4-===-/\
MB/%JDMQJHQ.% =HH^!0 1]NG%NLCC458K< '7I 1\/#ES_6'%;.!G1E1PI0
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M=QY*PKZTEQ,=-W5S6%E%TPK]2ZQ*YJ:+Z:<PT ^?RZ3IRV3.""H<<[;)TI+
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M#@AN<;BO->&)VXYJG*#D9W&Y%C7>>?Y 5JN1+.*IS6T3*Z:3,B:[L\B/D7(
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M4.RRB#RSJM$R2[IRX TH_0@JW((%*D8B"(*-N]P>G[>UT_IBPS8(8E5 $L[
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M);/+)C&]0;FZRI;2TJF/VM#)6;96Z\FK/O)\<50CA\R>)*5<0DW;2-=-5>\
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M[>$7$G"I-9IG J(*@H=0^@AJ=0PZ:Z"( (^P1#G]W$QC$85&.=)JY7KI1/H
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M/#BX)QJ9HR4- TY^P?U@&@_</#*VJBLPY" _CPV=36?7]GV?IRX7316.O%+
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MBC*FHXHYD)"N3J5KM/=JM1E:N,6>5*$59OF;1JW)*SJ+@Y"+V CQFDHDX%0
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M\D6+=PTFJ_(WKDV@@'8=LT6[WN !#!VG!0Z3&3#I,Q:2>,@"3G/,44,&-_\
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M+Y<LYX?NJ4(EEO93<L2U.VME\26V;DXAE.Y#E6T6OY4BL@DW$SH4RIIAQN0
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M)1Z$T@3G*H=V<ZFSK8VQ5YE9& L'RS]L3K35(O'.U6;E,R2J:P "B?(Z:@I
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M%T!I+=*-A%XZ2C7;EO 0<7$N3E;1;%-R5%0B2O' \[;[/HJV[X#;F];"+;?
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M#E(U"(QBIK^4/-U<'!TQ]>,>5[</C>$N$3,M;>WGJ=D:RUZD2+2!C(VTR+Z
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MTPZHOLI3;DC0L!2!Q8B2/%FN1"P(G+B;]55&LSJNXZB#/# 28R&!S]5>P?\
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M1./934CV:>7A/E7:\JF20>+-G+UV8 18ID:*J)* 3K3ZU%G70F77X-3:#IJ
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M*2H4Y]GT[:COJ1FCF0>1:#XK0K9^XCTW18YRKU%0=JH H#)==,":@FL;MF.
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M(HBGK25M@MRC#OP_C5E.<;@^-*,&BTW",O-N7+9O"NH1^:6F6*-55F"S9?\
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MI*BKZ]?3%/C4Z78S1=G9VL7MH0(W7@ZW+U=\1BG%3 E5!\B$\*3@[-P*143
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M) D8U,4]"+&,W*Z(@<%3MBJE05T16 3)]XC94Q@U2.!QT'7D4VO+A: 2#27
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M2 ;P 1'0!7RQ,\*(H25EX^#9*24HN+9FB9,AU2H+N! ZQP32("+9-98YE%!
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M("(9]# QA)%$&E9*QTOZ\?P*$>[5MLW3X^7F%%8F2[/TO'G?$CF<BY<-18-
M25DUNEH8Q3B=<XF)J/,T-HU$C3-&,9TFT^(QA=JI"OZY66H5=C+/G4"R>P+Z
M$3CY2-?+L7+YC%2+=JJW,#IN<"*E)T*%YD$2#Q&IAD<ZB36:A<=6>T9 J+5@
M12U)PC*-O+A"+>M%U(F>8F\HV-.^73:N%73)<=025,J'3\7-,.F1J6'[:,<^
M%*4N_HL),8\KTVT24G7KAVTHA"Q"SU5H>+9("Y[3AFU,C%MF[7M!U*=M+4I!
M_B* @A,F>)J1J.5-MS9,3M8;+CP\24T75WCL^3B-ZK*G*]?-FWFW1RII,?\
MKJJ12B<QFO<!-03*&$IC"874.Q &?"IAC$TY&5SA4U:Q&1D0]0@I6,KQXN53
M0:Q\&R;3:+].O1B**ZK=THX6"+[?ET$3'; HF*A2$'J""IQ).-1I)QXTZ)F;
M)!H-U3M'#U1RY\NFV:G;$7Z2(+NG#C_=+H)BDV00,)@ >H1$ #QX503AQI:
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M&FIATN_CSR-<A/EMA*Y6:D9LXYP '44E6Y=$!.N@U FJP"!42]L@  G#A6!
M&&#94IU$X1 J[*NU^5C:^\C9%9_&L3A)P[]!PV= Z26= \*";\J G&-54(0
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MHI$5IT68S,R*KM L>T*T9MRBT4:-P*LLOYINBHT$S9[W7!A R1B$#D'1TE*
M01AAG12?$8ZAX9%F5I(S_F&!FPM7RCYJ+I,C9)VW,D $CR-A*^;NQ*Y-V^XL
M":>I@[9.FEF/  >BHFG))P+>8\TF^>29V3Q)LDI&IN44F)#-'*;M)=$A6PKD
M<"ND43&[@@(!IIIPJD@1QYT32$%"B$Y3YH@^F6O05TFVCF;E@WBV"+P(P'",
M:V)&=U@0Y8E(-4E"G !. &^(>+T,K&% I<C8%C%N%G;<SI1PNB#=55TN58QT
MBN%'"8&Z4D^HR1E!*4PZF[8 41$ #AZFEKW_ &Z:^\=-=-1\= UX**MRU =
M$2CJ41 !$HZ"'4&O@.@CS^W@HJED/,ME$!670!4HD%9LH"2Y UY]M02G HB'
M+P'D/!108L4P;IMD%G35--4%BF;K?FB/=,L=,YUBK=2*JAQZBZ::<@T  #@H
MHNK!H.FJ#5R]DG!$723LAUW2:BIEV[I5TB*AS-Q Y"'4 O2(:=!"AIR'6MN,
M110J42T3AU(0YW3AFLU=,UE'2XN7:J3P%@7%5=4!ZS&!<VFH=)0T  T#3BHF
M3-1.-)K6K,&!WAXYU)1Y7QF9U4F2[=! AVAG*ISH(%:"BB=^Y>*+.1*'YRIQ
M,.GAQ!,Q/"B:;;O%U>?NK&Y>O+ N6T)ODI-I\V[3/ID&3./<"U1;MD11-Y-B
M0A1$3B7F(?$.O#!HB ,*BG4S@$V*2:*,M.G L@YD5SN9 KI1XHZ7*L=LZ,NW
M/HQ3 H)IHI D4B?(/?P:L<AE4S2"UQW7T#($37ENTV<)J)(&?]:/DT#NE&\.
M9,4.D\6@+P_24=5@ "@*@@&G%Y+!>'T^VIGC3X2239-D&Y3J'(W020(=8_<5
M,5(A4RF4/H G4$"\QTYCPB^+$T36*1DA A" 4I"% A"% "D*0@=)2D*4 *4I
M0    #0 X>(&%%,>:HE?D5)0\DYF7))=LLR,V7DS+M&#-[)LI>3:QS5RDL@D
MVEGL<@+E-0JI#I)@F %3$2B+(QPJ9HI!XXK4&^\_'N9<J2:RCB/B3O&Y8:%4
M5D!DS!$1[=D@1F0'"BA0#J-^4LH7_.(\29.=$^NKDQK7%URGD42O&3:3:R;"
M/4.9=L@+5235(S<I.P51>,Q<2RRHD.41[I]=0Z"Z5,2N51]=&HB@5^%=*.F[
MZQ+/55890SUW//%'':@BJI,F0'2%$HQIT%Q37;" H+E O641*40K))J)IY1C
M!*/; U\Z^D-#J*>8DW(.G0BH83B4RP)I )2CX!IQ%!,TFFK$4E).Y@AWR3]V
MU=LRG2D'*:+-.14:K2"S!F4X-$'CUPR1446%,RHF3#00#4!F:)D0:N$(5)[$
MR!I:96+$L9-FFT7D%#MWIY-9HH9Y)D+T%?NF2;3MMS* /9(H?3F;7BY"8(PC
M"IF:/2$<G(,^V9U(,]%4U@6C'BC!R(IFZ@(*Z7Q&1/\ YR#J4P>/$R=444EA
M5X5TX\X\;F?+B405!T?K1<G-&&AC+O&R94F[UR:+5.CUJE.8I%# 70!  &&$
M<**Q)5XMM'%BR*2(M >'>*@,BY[[HQ]2 W<."&*N+--+I2*D0Q"]H@$'4.H#
M4XJ9%+2JJH4!YA^&@:#S]W@ <"KJ/91G5*"(@4_4/3TFZBB74PJ=0"!^OJU
M"E 0$-.>NNH:<: ($#*FH\FF04BFT#X?B+RYE'43:ASY#U"(Z^.O"DPT<#12
M K L5Y9";/YL'S9,Y$.ARJ5L0YTQ2%P+4![*KD$Q$H&.!M $= YCJW".%%)Z
ME/A%(%G O0>R;=DP^7B]DGJ[B7>MU%6SEZ#^3$2N' 2CEHF=T4!*1;I HAT
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ME QU  YP #' %%#& !]IA'Q$>)-L\#1%8"BD4$R]I$ 1$#(@":>B(@4R8&1
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M39WMX]U+)&M+?F 8@NH(E03QTDF>0BG])1ZM^QO1K_09N$GL146#BX>9JO\
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MZIUUN]>KP^.KCC5\R@*:A>8&/;(5"LY*JD.=2F-:^H9Z#UL_9$2\ZKW%5A5
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MP%SK\Y:;$^ND285V,Q<AIT JL^=H,R>43:R JG339AH7W/5=\J]6Z-T^S?\
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M*\N5N-9L[6Z#-HDALP0P!SXQWP.'*O9Y_2F';)MGC91PFDZ6L.?7[=CU-SJ
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MF#LT&_6H)<:ZPD1J^JB1--BW;&O4MR=;-O4WNLV@63<(QPG2-D6+L^4B$O\
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MW(/P]_#JLB>VF!-$DCI2!SCW#"1,Q@43%4.HG-5+I4*D<Q#$4* F IM=.0B
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M  >SAP9J:L(:\AXFBK 4 _QX**P*!B"!  YR#W#BH=3J,4QC]8$$#?$)1ZQ
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MX'(**]=W]+&[BW5<?N$P;*RZ]BW#E<BB+H&S)1-O@0S)1DFN@5,C5S$E215
M@I")FZ8F3UTZ?DW[RAQT^XBD>5&V/#''<88&9!YCB:JW5Q;O3=E<75_7W2G"
M/^PQ'<<([J]F!!#KT3_T@$=/_/K\?VZ=7AQ\!4?HCG%<EC(GA-'S !@$/$!#
M^[A1($TZB5[**]GIU#P]P>SB4;2:S.I([:HI=/'QXT4ZS&-9\O'3PX@J&SJ'
M,"15^H \>7%#+I/94*=0FK@ &#WA^@<*!)BFH%4H$#7]/ ?[N+T$"IHN0X]7
M^'[/NX>IHX4_(--/N'^SPUX4E9@YU$T)KK[ XJUD5$F@QXM1M0DYU(H,X'$4
M^@$Q#N!W>YU:]KI-U=OI\5.K337X=->&J:R$=-- U^[V<!RHH4HZ!IIQ2S$-
M435Q$0]G[^(#2<<!1-!&,/CIK]@<7@14UB4PB/AI]H<OPX**S$1^T>%9@M1-
M7*)A\0'^T??]O%):3(SJ*N<GP^'C^H/'3BU&+9U(I//U%.&@?IH'AP]31Q$!
M$ U#[?W?LUX@Y44;  ]O%)8SA431-QUZ:D\?;]O%H,#&IH!(5/ P<_U:Z>'W
M\5,Y)D94LT;T]W#+<P\5$T$9(XZ]'X<A_L >+)%36F6_?9;5M_>W":VWWNUS
M5*K\S>L37M2?@8N)FGZ;W$N2*WD>.CE(R<(>-=1\T[KA6CHIPU\NL?IYZ<*P
MU*54P2(_C3HVE@W(S06_/9/2M]NSS,&SFPV64Q14<O-:NVD;10H:"6FH,M7N
MU:NR)XJ-DVHQ)EGKBM$;G.<H'(FJ)BB!BE$&D(I.8*D>L12MXL^8/JK7?(_I
M.84N>Z:Q;F8BWW&I,\V;=I?;'N^PA#M8P^+=UN/'-:>5>!E+\UU:R=>R)58Y
MV4C.=C5"O"I-TDN1>[W<TMJ# P14$R(-:MXQ]!^/KT]@&F92WV[L\][/]IF1
MZIE?;KL]R6% ;4JGVJ@.G#K&[6YY&K]?C[KE&K8[%<"1,8]%!%!)(B7^CUIF
ME25!"X B#W<J<N7][$UTXV4[,JQLKKN;ZQ5;Q9[REG#=#G3=).R%G18MW<79
M\[6!K89BN,RQP%;N(B"5:%3;KJ%!=4HB*@:\,[FY<-QO>,3Z  /8!58D5RWN
MO]/]5Y)#+&&,>[ZMU.(-@^?\D2^2LR['*<%">4Z7DK+.-;-;ZQ1LH3<&[R!C
M7']OFVICR,4R.N59)4R7< HZ\.]W6=3 :SF>?;WGC3@A5"BI(W)>BM"9%RG=
M<D;7]X>;=D##-> J)MCW#X_Q#6\?W"F97Q#C6J/*!2V)&M\CGKRF6J!H+SY,
MWEVBJJR3), (0IC+&57RQ!@ -S^GTQJ9PBI0KWHV;986:IC8[RR3N(:=Z<$C
MZ99\*V0(R2@[+AJ6ML=;Y"XSEF!DC/?S"</V!NE=N"*":JGF"$(J4G2Z)H<.
M/>'MJ)SYF/9/WUJ%2?Z>R%PYA[9]C7 &^;.^%;=LCR+N5O\ AK,$/C[$]BN0
M$W-)1C.TP$_$6:(DJG()1,9&>6(X\KU.2.51$B8]L2#+.( F9^G.K#<)GM ]
ME=/]BNQ"I[&ZYEDT=D3)&<\P[@LGN\PY^S[EYY#KWW*EY68MHF/4=L*U'0];
MK=<KL,S(TCHQ@V3;M4A/IJ)^4+;"DL<6(S^SN%5"0(F1,USH@_Z=K:_'7W!&
M2I'*>19FW8)3WII13U:#J3-Q8B;PI[)%G;K3BS9F"GS#"5@RG*O*^ND).\L<
MG?+TEZ>),FZMS(*Y;OP]WNFC"%YA L]@F/KH_ ^AC:L56K#=WVQ^HIN(VSW#
M%&S+$.R5],TC&>$;.C?L<X<FIV>A)R>C,@5BR,8^>DY.<%5R+4A *HF(D.4J
MAR"FB% Y3[233%@23$33YOOHY9;NF7\4;D67J?;I*-N7Q[MO?;8[3G&H8[P"
MWLF5*(_RC/9-6=V>&DJ%)5F*EBK2K5B0\<T;@5**;*A^:9<57+EK0M #!F,\
M?%&'<(P[S2X3/&C]#]#K F+W^PMO3;S;).H;*W6ZZ4ML%D2+C+M-;JK#O%HR
MU,R]8LNVA9S$@S?RHO%UU2-6"R"Z)RM2IHI)E-PX=EQF'+ZB>.J(GOCC1.$<
M/XS3.Q-Z'A\473"T4EOTW96C:9M?R(;*^V79]+N*BQI&,;C'.9=_2&=@R+!L
MH[(64Z+C>0G%31,),+"W!$A&ZJAT15*I'O&"%TR,!33AVU')_P"F<V!2NVRV
MXQM"%AL^Z2YSUHOLIOY?1S-CN&2RC9<CO,E!?6:$4]9U%!U%R3OR:+8J'3Y(
M#%%3N'%3B"& >("O,C,1R'=PXU.OEE4J%]'#<%5,\Y]SU@SU4MQN IO<W.8]
MMN9(2F8:V^V&/M=PQ_CR'QZA8Q=WNL61U'KR[>.6=JH-P3136>&+H<$TS K7
M&945CJ"+'#'V?7/V4L^WZ<ZWOWM;$:)O=Q3CN@W"\7_'&4<+WRH9>P3N'QHZ
MCV&2L0YBI*9R1-]@O.LW$)(%D$EED).-=-SL7K9<Q!*0Q4E"53ZJ@'&*TB9>
MAECZ^X8W<8_WA[I]Q.[W)^\K^7),AYUMLG"X^FZ*EA=ZWF,/CAR@TMJ6@4%S
M2[$V(^4.BT5"15U37#L&,D(=,R!A4DD'&L\/^D)>:WGS&&X[=YOQW ;\LA;>
M*9>J+M?99$IN.,?5_#J62H *K:;Q*1U,1 ^2<D+5S5L:8EE^ZN4"F6(JJ1(R
M<X$X8#MJ"W"FS5?0IQUCO;[L-QCC3/UYH&X#T\[?9K1AO=U5Z14V5XL$)=;?
M8K3<<:Y!J)G2D/9\=VI&>*R>L%W9@,BVU*)077(<N,'.7A!'L^_C1JY95N_L
M0]/>B;'$=QRT98VF29[<1NQS5NL5LLI1("OSE'D<TNXYX_H43+M7,G*RD'7C
ML#%:N5ETU3D6, ID\!>[=\R,(A8]4T:L/16R&&\:Y>HELSK-90S_ ".9Z[D7
M)ZEOQ#47M#KE.;X$Q^:#C8U#%D;*P2RKR\M&\DS5>?-)$"/#G7$I@T#7BLE2
M,!4$S4]G)U?=R#[N(J*MV.7A^_\ 6/NXBBKE3Z1]FGWCPRF#AG10X:"'OXL4
MF.VF&58F*  (\^'!)HH(2]7+]_$7(CMJ#6((:#U:<O?S_NXHJ*L/B/WCP457
M3U?AS\->++6= K$WP#KX^[]O]W#W"-,5)JDBD3*0I"@4A0T*4-="@/WB(^WB
MC/$YU%#B8 ^W@HHLN=3HU2ZA4*=,W244@%0I5"B=+J6 2%!0FH"/(0#P$!T'
MC0N64"IH,NBRJ+DBRH)E(H7M=(D34 X?"<Z:A04(=,0Y>'(>&J:-F'I#@HK#
MK'W!P45<IQ$=!_9P449 =0UX0B#109S?8/+P#3AAE11<QQ^W[@#7B:*!$XA[
M-/OU_P ."BC:(B.G+_A_AQ!RHK-773D&O^/$+11(!-U::<M?=[/OX:HJYQ$"
M_"&H\0Q@34-.8B:#(<XFT !UXS2:@ #*C12B4_7IJ.@C^KW\:I\$58@EA6N&
M\$Z3K:_G1HZ.LBV<8YL31V=NR^9+)M'34472J<<*B/GS(MS&,"/67NZ=.H:\
M=WY46/F#97% +#<(0"8$J9S@QWP8HWJ+\'<@PV@GG$=G&OF ^HQ;V\GOUWG5
M5Z[5DZA%;J\@RTLX@UEC%3/%S;ENDRC1E5IAXLX9/F*)5&JRHM06:]QKV"E(
M)?U7TX7O['T[=65(8[*TF,8B),P (/,#5&<FM71;OG;=]C?QM"X6'KP GC]7
M946,[BMC"4@<,9$J<'D?%X-'%8B)8\)8(1]:*+><A,Y.H6>J2UQM3RI*G:92
M7<R:9SPC\A7$4= Z)DEG!>*GV%@*=]LW-K?&)$@@,,-+<<5,9@E2 "#%>H\U
M[ESX'?('V M^4IQ$J6E""9$HTMD>^)I"O.-<W;<,DURV8YE\CLBD6NSFH6J=
MA9['9HJLU6=5K,*RM$=9$(F/" <*5PKJ25<]FOOCR)P8H+@;H'+:W6VZE9>W
MNQ:.0*@AA)$QA.,%0/Q<35EZUO=C=6ZE^ZUK$*I!4:5.D9B(PQ. )/AD4J6_
M*],N$+#06X7+*#V)KTNQNC'$>WRB-6D%&V=U.67'<_-W_)TO( 1]-IQ*XB@+
M0CEL@S>IM4R-2J&[5=GH_4VW#[OIZKKP56NN) (&"@8Z=1AO=,B23%4[K>[#
M=!#U?<OX"&%NU;"A<QXR)UD D:CP/;@R$[KML>,E[!*4 \6M7QC(@!DZY,P[
MD):.8HH]Z,IAIR;:7.JN).26:6!65L+%V@F\;E: !M"\:7M];M_I[MAIDF9G
M,\P!I@&1"D:LYQK&-]\NNKB_J:YJ5I%HI[H, +J:0TG7+8^&!R<=%R!1J_+2
M]LPC<J37K-;XX*5?\#9BK5MC:#<8(I;-=IN'C;NF27>51W%2HQQV1)&2>.4)
ML$B^?%,0;\9]QL]S<1!?1KA1PRNL:P0 ,L),%B2JQID%9QK?M>HJ+S[OH82V
M[HB&W>\*$*#B)XDYR<3&--V_9=SQE1-KBQ>/@\>T]G7G%A1HC88.*IRR<$=[
M.DEK_:U3D3N)WH5MP15^_<24>V44!(WE#D  J&WVMJXU[%[PXF9 .$*#[@[
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M:/)06Z2J/(?(CI-"K2A*KDHD2YCW$U$5IA:Y>6<4M"/JE"E;+.M8UI8Y91E
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MC.75^QOE#'56@;!'X[5R[*8XMEWN]-@:=3\NQ&*VZEA>5*3?-;$TB4SK+,R
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MB!@&5]I2T[:8PDW68%M;*^ZF;)!*LQD4IVOQK>1.\FH=2.*+@KELFJ@9 !4
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MLE2YQ$_E50?$5!B6( .&DY5IV'3;-[;K>ZF&>V<=.1QXDP"),G#,&2:V(K^
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M2R)1L5S2\*EAO!E>L$A2FMO=1;=M5+5(9#,0CZQQ,15$$D4C+RKI-S8T7Q3
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M+1;^5BKF\AV,,23?2)W)7S)NMW \XL(IE[]JY8L)\+;5M+KK $@!-0 [5!)
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M==LW-OU N+ME SJY!)72"&('!@9!((PQX"N=\Q]$VW0[OG[!5%NXQ4%/S Y
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MHHL"102[@$ #@'+D/ZP]NO#SC%362*JJ@& P!IX>(>']O 0,Z*#*@5 PBD0
M$PZF_'Q\ \!UXFBAG!1[0:!S#3]?"J9)%%"=8J(Z'#V!K^GMX@#0TBCA%63*
M4-!Z2@8H>( &O P#>(YFHHF^[HJ)'*8P= &T* B!!$VGQ&  'J$-.7NU'AE
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MKHHD5$"E$H".@ZZ<^0:_9X!Q;10S8I4@'4 U$?;IK^OA6!(PHK)7H'W!S]G
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M\L8-6 2,P^[?GI9_Y5)+SDF]%(O><*=2JO2'48= XL$,*!C2@8=3:Z_CQ:!
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M0!,(@.G/7E^@^S@U"BBZH"D&NHCI[-=?NTY<311HJNC<5!(H?0/X4R]1QU$
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M0JIEBZ#H&OVC[AX**,.@,3HZA\?P_ ??P SE11H@*"F40'0=/T^SB"1.-%6
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MXFW"]A(FNW40[8G\WU.T+=M %+EG)!D8EI\"G@?$2N4:>'#U_0IO7MS.#^4
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M3X?L#EI^@<6>;V431LJ@"3K/R*(:@.@#]^G$>9R%$T&X_+2%0W\(&)H/WF
M\-??PZO.'&C'T4. $63#00'E]_\ ?P25;'(T4463$J9Q((D'I, ' H&Z!T$
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M'(YKK-@W--.39JL<RJZL2J*JDB^E&2DFHV16<%3*"1#H)&."!NW\P_><#_\
M--\H8O%RRK+K),*=N@A9$ 8 D*3FI:"V/G>FLESYHZK<M1I-]LNQR/;VUZX4
MA(*8= ZE'JTU'7F(CKJ.H^ \?E&VWA@YS7J2(K#B[51A/90Y@U#3[OW\5ME4
M45<@4J*P".G4FIS -0#5,0$1Y&  #[>7#VY0@YXCZZINP<^5?)KO3R&D=A#L
M&])J%'22]1S*K=R6,F969>S3N-P? ,E)APVLEE>/(QJ]-+N5UDFZ96Q54TB@
M4"@ !_2;K+7+/S/Y>IFM_P!EMQ@NG'</^10"9$03J!U&O"?+K*R L23KG&9P
M4#"2<!AB,#6N%1/#W&FRN+[Q/+55P#N:>XNN?D!7AZ\_MY8Z&L,%9F\='NKA
M,4R5B4ES%;1Q&[IN^<*N$BJ HJ4_S[=C<C=C<V0'LGWQ,:@)*E<0H<&,3A&$
MC"/JED6OAS:)B_'@,8 G S^(CNXXT_J],XL81%BVT[BY*T++P"5VD*E>:).0
M-^JK2Q3<HED>#=1F,%XNP7)Q'6NJ4QBQ*_-)%1:LWH&?1ZZY2)*3N#N3?M[W
MH@M%FTZU=61M,%2-0;2-!.J/Q%8!$T;5MOY;[7K!>5#%64AA/O#PD3# :9G"
M9()%,.HK7^I0K.Q82ME;V^UZSF0@I3)\P^G(7+#JP4UK&R=7DY 5F\MD'Z =
M3#1+R3F(A85'S3LJ2P @B4A;]Q;VETFWOMM<W=TJ94+*B97$8(S*-0AF;PR1
MGCC*7 ->QN6["$YL88QC_BB<H Q[,*0Y&_W.%D GH3,>3;_=(&7DYIJE;G%?
M3QY-,G1UI K-2!N$O8 L*C&[R3Q91)V"A9QB=))5)-8O0+W-A;O*2]E+6W81
MH"D.. &I=, *% *P5.$D0:5-W=M& [/=4S,^$QV&0<<<<".ZAF>2<C1ST'M:
MSGD>CY)C15L2LLM)A)TZHOU0DHVMLF,_2Y=*48$I<.\<%76;1CMLJ?LM$4!3
M:',;%>Z=M-S:.WW-BV^T*D*(AB(DAIG,XP2"<R9.%Z]0WB'58N'S3CCBHY>H
M=G=E6$TP:SCN.DL]258LT;9Y-A3(S+^.D366UO(*K2, L*6086OQQTW9)=FD
MFXA@FZPF]DP<CYIXD)>^3.-LFU0_V5;J7 N*7/=QG $]I,E7@08Y5;YS77%[
MJ91IPU*. /$ <<Q(Q[*>5E-4\OR#K$F$YV5K^(\2.K1,SN0<D6XAV<@V6K-;
MQJ-H4QQ3*^SN-67LMNJ3-^5@\"P.TW#Q(BJP(I]0V=--SIZOO.JJC[ZZ H6V
M/$)9B5#,T$H#&N%4Z3 DX5;U_P"XW!:Z.2EBV26DX' "8 D Q,23/M8>47<!
M,F:T"H%DYBLTM:P*MW<ZA!&L5CL4XNYE+=9Y%6&CHU$J;IXH+9HDY3*K',_+
MHE.8045#I]-V^X5FOWCXKIQTR0 !"*),'#,C DDGA5._N[<V!MQ)=1B3F3Q^
MAQB*]?O]+$W3"#4<K1ZC-=S9-R+9LN;R*#9ZD1AMU776;MD4UW G9'<^4* +
M%(DD@!=#Z@;CXQ^\S,BW;2G]-5V9([2=WZ!E/;-0/%T_:-D0^Y]..W^KV?7[
M203Z"=/N#QTTUT /9^''YR!PK,T22<YJ/LBXVIN6Z7:L;Y'K<5<L>WN"DJM<
MZC.-Q=0MDKDPW,UDX>4;%.07#%\V.)%":AU%'3@@$%3D:$XU']ZVTX%R2YMB
M^0L3TZX&OF,8K#%R-.QH/BV3%4%-R%EA:#*(J* BXKL98)9R\22Z0$%EC#U<
MQX.,TLXU'$AL#V83UOK%^F-L^)9&WTRU6"[5V>=59NJ];6>T7I]E":E7X";L
M3IU\DR;BP(I/R.F[.96.\;II+F$_%B $8U8N5.[<-LVVN;L35Q3</@O'N6GE
M21DFE=DK;#=Z6BHR:\N,Y!-YEBNQE35N?\FE\PC#K'CWP)E!=%0"AQ( 0AC[
MP.%2<1'"DVR[&-H5KNU%R/8-MN')*YXUKT%5:3-'I,2W^GZ]5&KQE3XAE',T
M6T2=G26L@N2"!5NH,)WCBQ%N8PCP>%R-6,&1AD<Y[P<>^DQ$CB<_IW43FMB.
MT6S*XG=3F L?/G&"JC6:!B)4\8X34H=(I5CJEPJ%3AC-WB(F@:Q;*-$23%NO
MWDVSZ/25( ' 1$8("N D'#LG.HDQIX4#.;#]H%HK$M2IO;[CIW69FM,J>_CP
MBEFYPKL9DN=S+$LH^0:NT)2&7ALJV>0L#)TS70>,I5V==!5,^@@Y  ^G'_8#
MW@44QGWI?^G_ "+FDN5=J&(DOY=Q58AZDDR@W,8UCD*3//+33Y!=G&/V;.:L
ME9L\DYDF,N_3=2K5\Y573<E454,8X>+&CNPI8L'IK[$+6]CY&?VL8AEWT7=+
M=D%J>0K"2[4]KO\ 8F=PNSU_'@L6/EHZTW"/1EWL8[26BEI5,'8MO,"9007&
M7"?">52#A%3%F#:[M]S\9LKFS$=-R:Y94VUX^9N;1%E?+LJA=Y.JS=FAH];N
M)JL"2$U1H=Z59$2.6SR-;KH*)*IE-P!CFI@4 D94B0NT+;=7,*.MN,-AZGH8
M0DGR\K8<>OFKJ9BK5*.YUK:'TU:GLP[?S=JL,A9&*#YS(R+IR]<N4B'55.)0
MXGMXT29FD++6QK:1GEK86.7\ 8]OC:UW]/*L^>9BU D'^0TZ=#X[4M0R[)RT
MEFTB^Q_7V4([!%9-%]%(%:N"*I"8HP0(J)J5J)@'"F,KA/Y!QUBNCT2XVJH4
M>@3T[4X!A .9.E8S8.(O'E8=I1B39F:'I44Y.UC403 K1L())]*8 4%,9<J)
M]=1Y.;(]I%FI<UCF>V[8HE*98\LSF>9J!6J4<FQ?9GLSE5U8\G* W(BNC=)]
M1PJ5X^2,FJX1542.(I',05D9U(-56-D6TBCJP2U,VZ8FJXU<S(U>;PE1C(^/
MB"1L-DBNL&C&+;I$CDHYI 9AM#--MVO+E;SKL@$Z5! )5HXF*"32E@':+MJV
MJL[,PVY80Q_AMK=?DY;:2E0J<<>Q$KP2Q*\C++&%59ZVK[><=(L4CF%-HV5[
M*12)%(0KR&]XR:"2:C&G>G%L7QO./+-C_:OANG6!_8:O:W$M7ZJA'.OGU'NS
M;)%,=MNPH5-BVJ5]:)RT<U1*1HS>%$Z29>HP&(!S^RB:=LWL<VF6>9@K)8-O
MF,)B<K-@O=J@9)_ $5>QEAR?=662<AR:#D50444N&08UM-O2*"=)2403<@0%
M2@?BAE@X@4L\Z>,GM;V\3.%9?;G+8AH[K!\Z\G9&5QBM#)'JKF1LUPD,@S4D
M1GU JSE7-YE%Y<CI!1)PWD#]]$Z:A2F""7)F:)J(#^F[L.=GQ*=WM0PBN.!C
M%/B<5:8R4+6U0L 6_NN4SB<EE5"YE^=]<MY\_P Z$9#7S@BMPR7;MM3;5CH(
M/=C@?9AW5(/'C0DGZ;>PZ;NV1\DRVU7"[Z]Y=;V5KDJT+5%J,K;FMS78/+@U
MDEP4 J;6U244V>2*:)4BO7J)7*P'7U4X"[E0I. R^H^L8=U <C(P1'LQ'MQ[
MZDNT;2-M%PM!KO:L)XYL=O/DB"S :QS-98/Y<,I5JDHXU@[X1TNF8Q+$QQX@
M2$%4  %HHOEE2J)")1@$@1.%+--S&>Q+9UA\(H<7[;L0T=2"O,-DJ%5K].C6
MCF)O-;@+#5:Q88UX*:CQDO5JQ;I6.BD4SE;1K*0<(MDDDU3E&6=FQ8SA'JRI
M@S 0#A]^=%H[81LVAK1:[?![;L20=KO5F@[O:;'$4^,CY61MU8N;'(\%8$7+
M9),8F189$C&\_P!3,&Y5II(KU4JCCX^!V:X(N&1$8\L,.[ >JA"!A6HVV#T=
M=O&W')M^RC8Y0^=YZX1->@HXMYQEAJKMHIG5,M-\XP5@GTL;46I$OV2VF38U
MA*!8I(HNDW#!)1%--4ZZBJ1!!7!@&$XS#1J'<8J\,=!3\+,">\2 ?1)K=/(6
MR+:#E5D#7)NVW#=Z;C>;-DTR%HHD#,)*WV[F9*76QKE>-%1<NKD>-;?-TU!,
MA)@W3!RFH!"Z,LBEH9+9]MD2S:UW'ML!XI1SVT%J9++R%+A$+T@=E77-/:N&
MTZBU(Y;O"U)T:+,L3I64C@(W.8R2:92VJ3'BRI"3,<**VW9-M(OF5_YZW7;=
MAJUYH!6NN4\H3U!KTE=$G]1525J\LA..61W:$Y  @FFU?E$'B2"9$04[1"D"
M80^*HDQ'"E.8V;;5;+1E<;6';SB*5H*V,Z[AE2HNZ/!*P1,4T^8-8JA0&K$6
M@)LZS5+$;YA&MTN@K%\ .$>A4 /Q6T<,J@9R9COIR5?;-MWI.*OY$U/">,J]
MA;SYY8,61=.@VE"^:K6)*W*2/TP1F$2+\]J;IR8J]KK\^0KC7N@!^$P]%$B<
M<J2;9M1VYVS*89XE,,X[_GRC!JP,9G!M4X%'*T$W&)D(-F_AKH:/5EF4W#Q,
MHX;L7O49PT15,FF8$C&(,X33@C*M/]I'I*;:MJLY<KDND&9;M;AQZE]07S'.
M%*PE#M\5R%UE*3(MZ_B;&N/Z_*7E&2R%*K2%CD&SJ7D#N *94B)02X,-6H"#
M4Q6T55V4;1:3!EK-4VP8$KE>2R! Y5;0\)BVG1T>TR35%%5*I>6C=M$D*SM-
M7%=0L:\2Z%8])4Z;<4TSF*(<3)S%32K2MF^U+&ZDDOCS;?@ZBKS%UA<D2:U1
MQA3H!9Y?:V]>25;MBJT;$-U/G=<D9%RNP6*("S6<K'2Z!54$S%V.)/"**S>[
M/]K3J\7W)[C;C@][D?*5=F*GD6\/L95!S9[Q7;'')1%CA;5,JQ)WTQ&V2);I
MM9%-8YO/H)$37[A2% %X1PHF,Z/8QVH[;\/8\MN*\9X*Q30,>Y"1>HW^E5&F
M0T16KL22@DJQ(_5D:@U*E8U']<0(Q7.\[QUFA"I&$2%  (C+"@XX5K3D?TQ=
ML%HQ'-8#QM3*_MSP_D&^5*W9TI6#:-CVKL\[5RHN$GC;&MY</ZM+.&-2?.&3
M4AU(H6,BV:HF;M7""2RI3$XXYU7J(/;6X^2,/8QS) Q-5RG0*C?ZM!6&N6Z(
M@+5!,)B-B+;4)!&5J=FB6SU%0D;-UN10(LR<H]"S<X? 8-1U98XTH)XTQ9S:
M5MJL]><5&S8*Q5/5=WC%IA0U>E*1 OH8F)(^70L##':<>Z9JMDJHRGFB+U%H
M4I4T7:":Q *HF0Q; \8COJ:?..\/XRPG1HG&F'*#4\9T2&!R6)J5(@8VMU]@
M=^Y5>/W*,9%MV[87DB^<'6<+F RSA8YCJ&,81'A'N,YDFH81A236-OF&*>TQ
M<TKF,*-#-\)(V%#$K2)KD:Q;XW1ML>ZBK,A2TD$"E@$9Z,>JMW1$.@JZ*ABF
M 0'3A6=W)9R2QS[:E=7#*HTK>Q?9E3Y!W*5/:C@6LR;^?C;2[D8/%].BGZ\_
M"7**R'"2!GC*)0<@>#O,&SEF) ."3)\U261*F<@" '<9$X CT'/U\:EF:<9]
M=*-UV4;1LCRD%.7W;;ANW3%:NEDR+"O[!0X"2=,[I<IEO8K=/&5<LSB[<V>P
MLT7\@1?NH.WR"2ZI#*ID.6=1)&HY?='U #N%1J/&B5XV2[2LDPD=5[[MHPM;
MJW$WRWY.C82P4* DH]I?LA3#J?O]H1;+LA($A>YIZJYF@'5*54.(NB*\6DZA
MB9J02,JF)GAS%4=6K]38_'U285;*SR>D<DP#.%9-X>[/;5!,ZS97-CCT4DVT
MBK.UZ.09.A.7\UND4@\@X0L2=1,@8"I+DC'AA4897VD8/RIB*OX@>4V$K<+C
MFO2$)A25J\!6VTU@APYH$UC&.G,1A*0TM#5:4@:5/NHYJGY19D9FH9NL@J@8
MR8LCE6! \,CNPI<,N%:C;??2)VH8>QWDW'EWIU6SK%9<NE#O5M:WC%&'ZA66
MDMB^KHU&@?2=#Q/1Z/4ZLXKT6"ZGGD$!D7#EZX,=?MG!(K^?<#%M1U8C/G4Z
MC6YR6U;;:WA):K-L&8H;UN?KN.*C,P;6B5MI#2%7P]+NK!B:ON8IK'HL#Q..
M)UZJ\A4.WT1[E05$@*<=>*C;1E\2C*(],_71J;GC1H-L6WP*/D_&9<,XV_EY
MFFS62ZY;I)ZC#J53(]PN1VBULLUO@#MAC)B=LCMBDX>NCI]Y=RF"YC"L'7PX
M,8\:-1PQRIF8YV4;3\5.(U;'^WS$E(/!#:C0GTM2H>%^6K7NL0]*NSQJ=HW(
MI\PN%3KK"/E'!C&7?MF:(+F.) '@:8PQHDG.BB&Q'9\WOF/,EM=LN$4K]B2O
M4FK8QO/T#"#:Z1 XW0(UQ\PK\R+87;/Z(9) WBE>H5F3;5),Y4S&*(7A8)/=
M0"<A6PR>.J8A;97("58A!O,]5HRC3EI4CVYYB6ID-)3,O%5A^\$@JNX6-D[$
M_<(-S]2::SQ8P!^8;5-<^$^[3B8QSK7TFQ?9HSL.+K0SVSX59V3"T>QB<2S3
M?']>;N<=QT0\>24"SJP(LB(Q;>L2$BX7B2D)I$K+G.S[!C"/#A[A4B3I/"CL
MK5#;GZ0>W?!65;KF&T3+[.EJM#%E&1IKU0L.P 1249EN'SC'6"><XWQ_37N1
M,B,\DUB)D$[!-G<O$E8U,Z8$64<*K5#6#F?31@*V4C-@&S*(97^)8;8,+L(7
M*,E$2U]BVE&B$65B?U^S?6E?750*ET1Q8*Y",NR19>60:R9C.DDRKF$XR Y(
M/*@,5.I<#$4IWW87LQRG6J!2\@[:\56NGXLBYN!H-8E*TV-!UZN68-;#5DHQ
M$R+5_4YM8I%G44[*XCEG"**QD1512.1AYBAE!@/GVSB3],<:0,001PR[(RJ:
M\=87Q5B*'E:_C&@5>BP4[*%FYN*K<4VCFDO,%K\'4QE9-)$NCZ04K5:CV1U5
M>I11!HF!A'37A'UW7+N9><_1'U 5!+-F<O\ ;4"5+T\=D%#++$I.U[#]52F[
M[0<G2)(.JM8X#W;%=E6N6-)=GY84QBT*%;'*TC%,6O9CV3Q=55) IU#B9".'
MTPQH)-2/F+:IMTSU9ZK=<OX;HV1;926"L75[#98OS<K"1BUEK=Q4C6;I-5$X
ML#6RGQ<CV3B9('K!!8"]:8#PP4%@2*G4>%,/)^PO9_FEG+M,E[?<?6?Y]?Y_
M*4T[.S?1$M*7ZW52'HMQL#V<K[^*F5CW.F5UC%3+87'DY9@T20=HK)E O%C(
MA'BH#$4_LH;6\"YGQ4E@[*&*:1<,2,D8!&%HC^%;,X.K_21$4Z<K3R0Q8QU4
M'U.3;D+%/(Q5J\CRE $52<2"I$5$SC4$2'IB["'^+Z?AE7;%CE#'E%L=IMT!
M#12,Y!RC:TWQF:.OT\[N$--L+M-2&0(TXM; 9]).BSK4"I/P<)D(4H!GR.-%
M-G/?II[7,Q5)A36]#:4BMGSSA#/EWK=":C M,E2FW^GM:!1*B^*RDXA.LQ3*
ME1,;&M5HM1BJP3C&QTM#I]0FD<*,*=-B],;8=:J[BVK6+;10)*LX<:.X^C09
M@L"#$D9)69"[2T/;0;3:"V2H.=O#5.;?LK,:7;/ID@/5R*.1,H,!5'A ''EQ
MS]?&I!@R,Z7+[Z>VT7)C*/C[=A:#>M(K)&2LMQIHRP7:JR#2^YF554R[*)R]
M2L\'+#%Y-*N=*=B!7&&DT#=I=J=, *$Z44R!!FF:[<>-9G2H [ .%%*YZ<FR
MRGOJ;(U[ %3C'&/J[1*C5"-W=B68L:OC"'O5=QY /HM[..8N>BZA7\F3S!FG
M((NNEE)*MS"9$"$*\\!$=WTBDDY4D8H]-;9GA%^U?8WP=%P*T3=\?9%AY-S<
MLA6*<86'%4?98G&47'2EFLTQ(1-#QK&VN0;P=;17^GV"3U7M,B"!1XIN%7T@
M@'2(RX R/;)HU',5.>+-KN%\.S+"PXZJC^L2<?%9'B&C=*WW!_!(,LN96E,W
MY _^FW\XM7%Y*9R9-.GQ'YV8OFR*HM4%4VGY'$,[,9J"9[P(K8@I"IAX\+J)
M$&HFK+@ IC]WW^SA[>=-1 AM2]/W?L_OXM)@3168!TZAX?=Q4SM/*EFK=H#>
M'Z_9Q&LDR9HK+H5#4"@/+37\>+-2M X5$&9X^RKZN-=1#E]HCX?KXA5 I@#/
M90@?%R-[0Y_V_OX9SI&&=+FX(.%8"7H63$"\NL=?_*'M^WC/!;.KXBM.-[[@
MX8HJPI. ;&3S1BY4[@PJ=M)!"S-UW:KCMCU^4:-"'77$-=$$CZ@)>KCV_P C
M(!U&^S"5&SNR,)Q$83^(DP(XD5S>J!6M)/O:S'^XU?)>JB4%9[8K#WI\=.JR
M+B[Q+2UM$A+(UHTVV722F"Q\:ZC$I!M&"^!3Y>Y!!,J9SI%[8=.G[,ZD+MMK
MB[<1<8+*S@8&*G/$XB8)GQ8U=TJ'M6GNY)[I'">-3S1KM8W5SL6WS-U1C)AO
M8X*"%ZI5X+&M,NU=LU&QV22I5AI]MKQB+6%"5K+1C!AYRPLBRL:NJV=+$'I6
M1\IU&RB;5-[T]F1[=[%FU%2I8:P5S$-GX<" 0")!]+L(O;B[9WJAE:WAD#J"
M^$@\<,,\1@:AZ0QGE#!-NG8PSD,9(*-XP)B[Y&7/78VUPZ[Q@9]\VB@&QP5K
M9'6=JK@@Q;6<S1Z;I\[J5,QNE<WFTWP%S;@7&7$*D&")QF!I,2<=)/*N6+>^
MV!\N]JMKQ+83]?LU8\:D,<G8,>RL ]L]BS1N+RTV6>Q:+.8Q="P^.2U])&GS
ME!AZ-B^%N;=1NV*,2\;E2?-FD<BU$RHQO>,/3S;>RWJ>Z+-FPP)4ARUQM6HL
M7;1"R "#BVH1JBK?[AM9 :U<W+01,".'X9[\"!APSIUKV/;(M"5R1B,;HS4O
M:#3\<2$0Q_(6&61>V%CWYN9ME7:?1U.0@_*-A<5A" <M91!@P,5X8!,&EEO;
M]2=V!ND68$$-I!!F K'4^O#QEPRG5X!A5S?V&\BW+EE68_AX@\9& C\NG'#'
M.@&MZQQ$UV;C]O6:(DL-;H^5EI3 V<:8Z2I\C9FZJ$=CJ2I.2WTDS9L+VYA6
MSM4SB1=1@$:$%@*SDBY4%+O)W]V]:O;W9Q=MB!?0PQ!G4I!P@F,(;41J !$B
M;>]VNT1K71MV 6_Z+*2 1D0WYH)QPC*2#!C6)IF5]Q.46\%EZT6J(&#>8[CY
M24GHQ_8X*HU606;4V.6IE:K4)+0["+,YM$?\N.BR7:2 HFUD4"@*O&F=KT^R
MUW9@$MJ&8!+P6\1<C'#&8(Y<*@+O-SN/.ZF^J")D2 ,!@!(XCACSJ4FV0V]T
M<?\ ;[@"J2U7HCR$CJ(C/6B_W"O+2S)C.#>+]?I>M2@7*B1B$JZJLF@Y69R:
M[9G""U9HFZ4U##AM;>YMG&^Z@0]P-K(50=(@A%5B S''B-3,-1$0*>_=M;Y?
M*Z6A2SJ626..EM3R,0 X!!@X*0*B';^G%2&X;"N.B(.Y6$D-PE/<-+*S:L(]
MQ.@]LL=&H2K&!50FV[%DSKY16!)V58X%#013Z2 GW-];<;&Z[$)<&V<CD&T,
M<8(F.8XB1V\O9'_ZOL[6>O>* >_4..0_V5[B?0@LMSM?J>^LLXG23 P,'E-6
M+KKE_ LX5FNT<YERRH5))1.(CWD@[9"R42.HLJ[-T%+H<B?;+Q\I_>VSM=O^
MV_R@EG1K.U&33@MBP,I(&)DP%$GB9->2^73/4M\3)87#,X8ZWRPR@#.:]829
M2DUZ1T+J(](?PZCXZ:?;Q^544@%CG->OU8P:R^'JUUY>/M\?^/%VL1-+J$Q0
M@\0Y@>FFH)4="*<Q#0AQUTUU^ 1Y<M>+!G55P\#R-?)7L][,XV<*V)O&5LLG
M$>H_FN+AX>,QS69B/"/##51*M-66%F&CJ&F9,Z9"G. MUQ$ZASBFD<0[G]*O
MFC;_ /[2#;WRS*W1K)+"X0?ZK1I((($DS!' 8XQX/Y;"IINVP)U#@",5G(\,
M< :@W&E7DK8,H+-2)CJ51O+6BQSD_ ,THNM0JCV/CC+3LJE&/7:99%=8A"1[
M9JLLX<K)@T0,?0I?#;]K=I0HU->8Z% F6(DX+/ "9)P$R1G7TRQ;UOYAA;2X
ML2/=$\3''D!W"IAA*IE7,4XNO@VF0=EQ#7*[\L:Y(N&/8JDU%1A1OYD.I!!I
M?7B\O!1MOL%WGS,X9-BP;SS@CQDV2%LY+^=R[/4ND]'8)U.Z4WUUY\M&+L"Q
M0#PB)50)>25$,<1ET;VTW_5F_P#IJ!]NBGQ, H\,DXGB2?#&)P&%:RN$J8T>
M$@;5<)&A9,AT)55^%H-;+53(JCUJ*=.(.7^K&(25LAWLVYE7*/RM>):"U<+-
M#]*.FA?4?%;JR3N+=N=I<$J5(#%BT-*M"0%@^\21J&,8^:O;6U<?RKY87USD
M$K '/,<<(' T#,5&2JD$O97;F/E*'&+J$B[)75JO;64I*+1)9%-LE'H3"2"S
MJ+@GC=S*$=-B_+4%CG6*!E#MU*GW27F!:?.(Q!D0)[1WP<)C P)J1:\E?_AC
ME0#Z)>3;1]-3$O$UR ?^9L!++*23>N)LW#*03:2T0YKBCQ_8DGD&\>)B]C8Y
MJN4A%DW)0.9P*H8]$'1;!++ A03V@S !!YDP,0:UIM=TR^;JMBS_ (@#ZL_9
M]=+U"BH.?EVU=Q8]>7J\I6E-I8T7CZ=I%(A&T=).EHBP)K(F)-W&!M$G,N3,
MR+1;1O$,RH'<JHZB<N-KKV=37DBQ!,R&:>(@X+ B!J(8SV"K+:*Y LRUR<09
MTY^L@XQA@,S4P6%&[XP5LV']Q%7@,6PEB739TK)08K9,,8SMFQ^6SOHJ0K-L
MCX:7@):ISU3FC.DG==BTFJKERT5/JF8RJG/1MOO]&ZV):ZX,%&<Z@#$@JS Z
MU*B0QP 8".&T[F[M-5C=VTLHP@%5\)(R,C\)&,C.14.6> LF-[JC&6J(;13V
MID2LL>:4J\)+QDW\R!B\KRZK*6C9AC:820(Z*X8N72!DEFB@"(%)\(]_97;.
MYLE;3$JV!AB"",#!!!4B(8 B#(Q.7+WEHVSYI YY#'CZ0>!KV&_TN,LK(0ZB
MYV3B-^<VS<W+E3\W%+QRAQCMM .VL>PB&R3:#(V573U:%[)4SE4 2&-S#X=^
M\EO4MRZ""H7:KQG [J"22=78<<Z<,7Z;ML(TW-QZ9\B8 R@QA7LUZA! 3F_B
MTY_?RUX_/")^&J!BIFDY%V F!,>L!'K-J!#B0H)](CUG !(GKU<NH0ZO9KH/
M%@MX8YU*84.FH1?7H,!N@?B /L /'A&$'LJLYXT.*J10'X@Y>(>W7[?9KQ"U
M8IPCC6(N$B:#U!S'V!KXA[=.+-).=23&6=6!R141 IO;X@'(?NUX8)%)0@_#
MR P@ _=P9F2,:*!Y$,/QF#7V@&H?=X?9PV8HK!4PAJ &/J :\@'0?L >>NG
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M#YXGL!5A/KC#MKY1@LX(64>@G)?+@.B_>6DY*=&Q[NG3BC]<WR=J#6V219U
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M<BYFUZX*@A#'/ E \'D<8[8GG04 QD3CACP<I]FKV9T@[B_6^GJ4MN8QEBG
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MV6*50*'DRM'N>.E222%2NE<QA $<1YYH&Y'L>D[0[#K5;C4]O<%5LMM[.W4
M>*X1JPG'Q$&1.)"Y#NI90R99L?PY?=[:EK+NRK#.<,8T?&,G@"_$A,8/JS/8
MKN4EGBRT_)&,[#3XX8NNSE-O;*UW.[14FPB%U62IUU%"NFJRR+DBR:AP-18O
M':2GQ*@%=)5$+ KEF0H)X@S/;4E5N*!H,#C,??6NJWI.;:$:C%P,=#,\43R<
MADN8M&6ZGN3S"RW Y&<9I8Q47F6(REF"/?U6Q7R"R#%UZ+;/FKM51%JE'-08
M@T%LB8J#R5;]/XA_'JQ49P!JQ+F3$'G J!: ' >DR9P,FKY-]-O%]THV/,7X
M[S'1L%TBG[J<4;H))IBR0LE?E64KB;$*6$*A!8[L\?EUK,T9Q#5*OP(-E4-$
MN]&"*I5O,K%$W"K="(;-[4@@802 9Q 0<SCCA B!4:,!#* &!SY8<Z7'WI![
M;I^+A8^-DCJQ;2JNJ5<65=N>8HI/<%4I7(4_EJQUW=,YB,TNW6?&-DR5;9::
M>K2ROFU7<J](*PM'2[8]1?;^[=MW5;$&6'ND01BG*?6<*O4.I!5L1_MX&GW<
M_38QM;&543E*7W)''^2\\97I-CQCG7,F%[S!6'=++2,SN'A&%BA3RCMO3\C.
MI15-:.*[2*W; 1)!1$"@/$AMDKE[1N6V8R20K"1@IP9<8[/14LSL #'A$",/
M732@_31V55EY35;=MUR?'0] I6+Z.QKLK=K3EC%$M7\(T.]8IQNXN-:BYF>;
M624@L97^2AE'DG' X7CE4TW!U!13.45';P[>[;;5AIDH8./XX7/+$TNN/>#1
MZ_JIW88]*[8O1#URU8L+DM]8:19\>SM-MKS<!E#(LI1&&(PL1\88XAD[I9[#
M&L,;T,UPDE&->=-%&Z2KU0ZA3J=)BK?O[S2+%]0MO@"NF<<YP)RS!@TZN =2
MXF")P.8CC[.(J5W>SJI06(UL(O*<ED_#2F:T-P1H-K89.IY%:Y-#.R6XY2R)
MRPRB,'8TDLM$&2+'E6AT>P -.E5'\LR,NTOJ;9FTQ$'BAXY :UQS(U3V4J/=
ML$/;Q93(YX]^!S.&%19=O3.V"[F9JXV6VTNY.IBTS665LEQK3)>5*)*3"><A
MK#C*="O\-&6.'>*TNRR=+BWI8E4I8XCIF55K\"BG<;1NNGN&6):2""&1I4)J
M4@E3X0!S!S$S3->\]-#&0%"Y00 2T<QBQ/\ "G)3/3KPI@'+E7SMC"'R)>IF
MBGF'M+QSD;-62+57J%/V"EQ^/+;=L3P]OMC^GUZ]VNDQA6#Y5XV,+XBBW0Z:
M&77,LA9-X47=0IM(%5P,  -(U*HQ &!(!('!JKTE<5D]A/V\^_.A;'Z=VQ3<
MQ-Y(R':L:3-H'*+JW$R909>_9/AJ2VO]MHJ.,+[;'^'4;6RI]5S',8_33B7<
M^A'HRIVNBR3@3*]]2+Z7MLZI="RL,C"""((#*PP803]1@B!8MPE?"3]M&">E
MCLP*Q>MW-,RE+3\K<(J_S.097<7N!=90F+C$XVDL-FEY') Y+)<3$FL32SBN
M2+1-XFQ?1!BMU41*DET5HURW!$>H'U_QJ2Q-#0'I7[(*Z[QD:,Q#**5O$<#2
MH&FXTF,C9'F\1";&M4<T3'5CLV*I>UO:)<+I1Z4^7BXZ7DV+E\FR4 IU%#II
M'(H+*JK."F1S!F<#GGC43@0,B(/:#F*5(GTQ=GD+5Y"I-J'>G#-4U"+5YF2S
MGFV7NF*&F*5YM?%\7A.\R60'-LPW%8_&S2*<8C7'D<";9ZJW4%1N;M G:I@Z
M=.&&$S';C4EBQ+',U)Y=C>V<VUY?9H:A/S[>'*3PJE+=WF_/99)P^NRV2%)5
MI?W-G5R$SGV]]6&70D$Y4KUN^*51-0HE#A<%$9U$R9%)-C]/K:C;*1!XZL6-
M%)BJUU3,JT6V?7*\K22+C<'-KV3,3M6=&R?.G;R[3C@[E959=0Z"AOR!2#EP
M!^)&-!SBE+'&QW;/A[,-@S[C_'AXG)]A:6Z."7>6Z\6")JL=D&QM+AD*.QQ4
M;'99:H8PC[_;6*,G-(5]C')R+U,%%@,/%FJ<#PJ*9DKZ;VT.Q9<?9LE<;RZE
MEF,D169K#34<EY/;X3MF9()2/7A,NVW :%O3PW8LD1;R):NTI5U"*.!?MD79
MQ,Z3(L%09 3 P.?.@'"BK+TP]ED>-N(VQ7*!$W%0ZCBIN,GY7>T2JIN<H0>:
MI1GC&AOKNXJ&*6$YE2ML9I\A7&48FZ=-R@<!2$4Q;S2,,(IX,2,Z<MR]/;:?
M?LAY!RK:<<NY"Z908W9C<G87G(#:(D/YD8F3P9>I!M5VMI1K$1-6?%#="&=O
MF;-NZ50:MU#'[R"2A85P@8*!XHGMC*B68*9Q68[),_725>/3?V?9)<S$C:L:
M2@R5BMEPM\_)U_(^3J;*S3G(E+H6/,C5R6EJ=<(&2DL?9 I^,(%G,UQ=52$D
M/EJ2JC85NI00764R(F ,@<A .(SC"<Z88"/ISIG*^DYL(5EIR66PFL=I.,<N
MQ@U;^9N6RX\@HS/U;D:GFR,IN,D[R2@4=ED^)E5S2X1,<T,X>&(Z 2.$DE2*
MS,^+8D45(%,]/C:Q2LF0&6H&J71.W5M[6YYL@_S'F&5J,M>:E2$<:5_*EOH<
MG>75+O67F-!;)19K1,,7TVX023.LX.N0BH+C4DDY_3C17*WI];6<X9$NF3<B
MTJR/+M>&V,OF\[7\G9*ICIA8,,N)I3%V0*B:GVJ#4HN3Z<SL;]@WL4.=E*JQ
M3U9BNLJU4,D,ABO&H)@8TK6389M'LNVJ"V?2>)6Z6WVM3=?M,%28>U76 D(^
MW5>Z)Y&B+@G=X6R,+XO<"WX@S+B55DU'[V1.==PJJ=0XF@G4?%518S432/I.
M[(9*NU>"_E]?(TD %^0FK' YRS77K[E*'RM8VUNR?7,XY!AKZRNF:*W?[2Q1
M?R+*Q/I!(ZZ1>@$RZE%D"QI&=1@:G7/VS[;]NB@*Y6,J5^TGC*C%V"MQ/T'D
MC(6+GJM+M\0TK]SQ_,2..K/6'D]0+E L$6DG#O3KL72*1-4P.4I@M8$H4!\)
MS[:8&#JXBN>FZ_T?J'FZ*-4< RM0V]5^58Y=@\A-E:=DF5<2,?F.AXZQS+.*
M'/X\S7B*8AHZ'J6,XUN%4D59:CR2C9!=Y%'50344M5])U/C*@=T(+8SG$( )
MSPI_,;'5C,^UBQ];,3Z:WFI^Q7;93JK6JNG0AE@K-]KV4TW$S.3ST)/(]>P0
MUVV$M$E'*29XLR,IA]L,4[BB)%B%2JG4%MW#"?C.EI4MK;'NHH [@('LI"2<
MZ8L-Z7&S>$I\A48Z@79-J=]0']3F7><,URMQQ"&*',B]Q=&8)NLO?7]IPK!8
M^=33XT6QKCJ/:HD>KI'(H@H*?#&/=X5'&:=LAL!VSO\ :5+[&3TZRL]NMB>2
M<A*P+7)605+7\SF<E&S!*32629"QO;\69?Y'4/**.AD!6%90X 8"CIQ MJ$T
MKE3*Y5M0SK5;+/I9X<.A@6(3L\6PP'BG=BUWQY[D\SKV_,6<\V9OID2V88\E
MI'-=\NSIU%P[,[5JSETWC*35>PS%I&LO*D W77\,UYTMH"6#3 !))X1],JE[
MK>\QA8CEA_MK9;-NU6@;TI"/ELKTI=G1H_'V6<6,7<J_G(^[6B@YPAHNNY.C
MTH5N^91M.B[3$P3,C=Z\0>3C<B?=:DCEC=TW3MW%V@**5:\2"0 "JD",_P 1
MC @0L8$M51&L8^[[:0L;^GQLUVY9,C=RC"NVQ"_TY*;4@;ADW,^6\BLZ_-6J
MM(4BTVZ,BKY<9V,)?;U7BBS?R*:!G\@+A?0>MRMW*W-[<W!:26<X:5'L &0'
M= '90"MM9)@<R:;$WL<P3DC,CO/,7A%_%3<C:+!>W+[(U^RBUQ[*WVVX^DL1
MVW)C/:W'VQA2I"X6W&<HK$/I.7:Q3URTZ3'344'NC<;%FV--ZYJ?\MN"!_BN
M&5GL4/WBEU%\8@=N'LS]<4V\?>DGM+PLF:[5T;_*W2M+T6S5*>RAF'+MCJ51
MG,-5/(%3PPE\E<7YI($H&,(+),LR80_S,J",:[.B4X"5,Y*1?<,+=E54'"
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MIT"R+GE6O,=6T@ZID:,?$QQ8R"I@09@5[3I+=/Z2$ZAU!_*M7+NE2 3WDX8
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M4R_\"*@+ Y P"H90Y7+MC1W"H 8H@;XNL>L1]G,:[NYM,X\^]O-,8X1CV W
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M *)).2KD6:.^ ,R2 ,2*=FTK.9. ',\OIEG214J>\<OBVV\O4+#;B*J^2:(
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MXK'+!K'D;E,!P(4;'8VDW*N3I$$/S&S>.,8X=0E -  \_;6Q^E;U <;AF?\
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M9RE$ %,>YC%0RA.H!U IM1 ?=P)MWF!L;!9A&-QAZ?ZHQH+ ?]0X?R__ &:
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MT.N+(+G>2LD<$5S@83>3$3MM_1=F_7=Y=^8=[9M;:^Z*LK(+$*H+%@Q]X@J
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M&]62]4JF/YS<]D+)4@M?<0Y)M$;/QZ]+PD[K6!7<.+Z+:SAPDI^2,X[/;3%
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M&XW$@$0B'5<2<\"G ZC@:2XM@/I;5./'2N?$X ^FN4%U]0G?/ .]Q-=Q5O\
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M,%W46I7-0KD ]=KI-8V413APBI22'N"2/A+Q4WRL>O)Z"84X]9RVDP#4?*E
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M4X[78UJE#&\JD5Y-S+UI"U:.4,)2R5CEE!1C6SDP&(HDR1T,Y=J%$#),T%5
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MI]ILFH)>V._9CJ>ZME]JRV;3,02%Q8YD*8:X[1F 3&9@8U4ZVUP&+#U =N0
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M<1W3KFI&R*"3R/<S\8JBQE'S11(2*-SOF[AOU !TAU #<9;C=6Z-=T/(M*Q
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MWR@L9R;UN",8)QR!CGEAP[-MAOKMZS!:WM+['B-*I)[CQ![^=>N7^E*%@XV
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MK+D8NF:7YC:S9#0:MW:Z#LH!VWL'2 <)&*B/4167.;N  LP*;4EWX#: 6_\
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M5]+L$UN['HVULV9OJ@2SQH+,%1D$F':\P0R:RIR%$,G2E-G<SLKS/M[HTW%
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MM8.>=@(J"(")G\HL;X?A 1T\=>-6\B+#<3MD]A9?J I$_$/YS[8-&LKB8&]
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M&+J0L/;.,M99M)PO*&6,D9=\Z.5---(A2)[>E:]GN3NKS220SN1G& ,"0 !
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M,D3.%96R&*H&+93!P[._OK?'TZ:99ZIDQ+(.)L<;FZ[CO$FQNGP>Z:;W*O\
M)#J0E=\D$BSGYLU$H&7I!>Q3F2ZKCV9G&;M6./'U,ZD\S W=70 #8K%J]M;*
MVMX"OGQX (U+J !#9A&8-K826T@#C"#R%N,=OJTJ"),\)/',QZ,:Y?MJCZF]
M]C:[5).6RO3LC;YLK8LW.8/OL%DRSY"MM5EFU@F8G+;6US43"01L/X%2C+)4
M5$:TJT<P\U#UV1;I.&S5VN)_86TM6KUQ=PRILK8 NZ!"V]/B6V"1B^D*#!D.
MSSJ:*J0!XSU/)$Y\IK8S#>T/<'3VF0;ONOVP;M+!N-M^-]WT!4'NWBSY:",J
MV=VN<:TIAM;&5DH=K@JAB_',XW8&G:_(RAF,*=@)E7I!4!='CRG4NO;GJ%Y@
MY VYO%D6)55\JVISG,@Z9\0QR)-:$VZC0K >8+4$CGJ8X^CV171/?EL]W@[E
MD=LL0\J^/\HVR@;",MNLC)9*7R63%#K=I'/MNPPLS59+%60\;_2N9'CEO9E:
ME.N$WC9D@#OI22*H*A.=LM_=VK.-L[I;:<C!/Y09GPS[PXU-VRKP1$A>//GW
MUR6883W-X+R?EA]8Z_NC;1$ZZITWMYW29CQ-G-;,V(;Y([0Z16\8OK_D>'R-
M_P!MT57*SGB2>1TVR?UJ>.P6+(&03,DX;B'LMK?O=1LK8VU^V[^60U@J"'Q!
M<*P;43I&O( GP]M9#Y>TQN!YD>+'T2<@*EK%,1N=DE*HZH&!\R[>LI1\QM,/
MDO(]FR)G"=@LD[CX?<5A]K>+#DL;3<7M%R8[R;CM:TOU[)$^53^FC*13A\[3
M,#1ODW6V&VNJM\W;UC ,/"I%I6EA;&)"I@<NT@2*A+B$X*P,CG$DX8_7PIP8
MKV]Y*R9AC=C3\N8%W($L5MVOW:?QAEC(KS,V)<I3F[2&?3D[BVFO;:3,4U0,
MCYJ2FY4Z<?;:PO7HE8&"$>JW=]3<J&&[9?XT_#O9N6Q<4LHQ&C#Q$8$I$%M.
M4DF*O4@XZ2#'&<Y^NM@(3%^0\<;L\/V27P_D>X;5_P"0NTR1KTLI@C<SG!:G
MVEO.Y)L^3$W$IC[.414*?:FSB7:ELDC*PTX15P5H<8X6[=0HX71?/_2.C=*K
M(1KS)<@:9P XR9,1C II422I(,0>&6,]LUH+0=G>_6K8(>S]7@[?*QE_V]R5
M1^18@_GY=(N=NU WC4&T6&M;H:$GF5S(-[&?#<<HO 2>-D:^K+QYYR(<)D<'
M8)KZ>K;?RM[<V>\NJY:W(?W?$ZJX:?Q094SCF9Q%.NDJ&53CR[_94\K8^K%H
MOM>@,F;0MU#ZU--I6X(^+Z+AG$.ZO;\\AMPZ68J:XQO<J,VO>:+7-0$\QCW2
MZ["X/Y]!G'(F5,9O'AYA)2M1O[.Q)VSVVZ?Y]W7<!B=26H4JV(U!6X1(SXU6
MS*K:65M9& @Y\*V>WIQ/J18;-LHG*W)YSRS=HO:"-!R<VH=/@,A4V>W8KY%V
MEN(6LYAL\I%KPL;CVVV6&GUBV#L1,NW:HK E+%%0K=:KI[VKQ.A5MW=+S!./
MA)D"<,)U$81P%6NX&@.#!(D_EQQGN]M;N>G_ )1S1N\G]QLIFJPP5BINV[)$
MMMJQID^ALX:O3V3+]1[7<+#=,T1TK MFLG6&:E)L]1KCN!#ICD;+!SA56Y@T
M(7#_ *G8[AK> 0Q*M!5L 3(Q!B8!&(.1%6S;=!(.O4<03@/H)]-;O4*S6NER
MF4UK8S4M]0<9+D6H7NO193S,=\FJE1AE5+M68M QW3=)6/.161C4S 4Y1[C1
M%,.YQU=[8V^Y3:_#'RMQ\.#Y;,2IU.YBVS981"L>YB3%46F=2^OQ)KB>.  Q
M ^L4J9;J=>O3O%,K"22C&>D[[7W4)?ZB_:)O"Q%=CIBW+F66!!Y#V:&[<(4@
M-7J3M 15$Q"E,7K+7T_<W-H;]IUE!8<-;<&)8JG,%6\6:E3AG&!:ZH?00<2P
M@CD,?2,,L:?B=WE*<=%GE(D<FT4=I-(Z_1"*C:LNUEC DS3LS5PHHXILF[,(
M%!1516+44$ *Y3.8J/&0[5;ZZMB6U1)MMBPYZ2,' [(<#-2!-6DE?ZF7/AZ>
M7U4:P^4CF#L4Z043I63(-]F6RJ ]2;AD6R/(:.= H!SD6*XCH=$Y3%'IZ!#3
MA>IDK<MV<9MV+:GOTAB.S%C46L02<BS'VQ65\61?VO$]?%(5%7-OD+&H!B',
M5LSJ58F%C.#B4.DAOFTHQ*43:!J?WZ<)M0;=F_='"T%SSULHCU!O54OXF4=L
M^H5*)@(F34X@4 )U',(@4I0  ZS"8>0% .8C[.,.HYTY&-1;B P.Z@:?[0HF
MM]IN%L*7H,7J93-DE#PQQ$XF,<%(-%L/5R WB4 +H ;^H@^>+1/]*TB>E5&H
M?[Q-56Q*:OS$GUG#V15[OTR%RQ77>V"A"V.8N3P!*J8$V=6@'C5NL<R9R)%*
M2QV-@ =SJ 3Z=(:AJ$;5@EC<7B8)MA!EF[#_ -A6RCOH>"RJ?S3ZA]Y%24L'
MQ''_ )NGE]P<82\* *F3)Y4&9,QD_ 1U#_AS'W<5U-,_)5";9*QCD''#F2?0
MR&0:);:.YF(P2_,HA"V0$A +R<?UF3)YY@E("JEJ8H=P@<PXE3I(;B#5JK&)
MSKC='[%-[\YCS"%9N'_9'6939C7MOK';VG5(&_3B&8+/@"T0D@V=91L;^KP,
MWB#&5HJT$FFA6(5"S!#V0Z4QYEV,>W;*H->KQ0;>DX=L@J9X1'IFFI7;;*=Z
MU7S%:=Y=3)M@>;@\HV++!+I@F8MV3X_"56J>1L68(Q?!R-;RBRQ\^MUCOL";
M ,=)SRRU9BV=@)(KM4@9F:MG*EUM_+6[;\12Z;9Q/N^6'$+_ (M9/H%,[:Q;
M!@>6& CCJ(8SW1AZ:BBB>C7D;&4[CBW53,5+C[E!9JV72F3Y%&"G&\=G';]M
MBQQMBCI&A6EBDFH,/<H#,& W-DI+PIW:<:SE73%=0I)%T9/,%OBTJ!R2-,R!
MC (,<IF>^M.XW%N^[-H@$L0)RU-/L&%31GGT^,TV^K'7I$E6W%F9>H[D'>2P
M81V=,H[=)=[2[IB*YXU:PC7,&,J;:+?4KFT=V5%18&K)=JZ8I*-S+:*CQH0G
M0R.3#1EV$$#V5ED2",P(]>=1EDOTI<T9<4L^1IF_)U^]NH[9BO\ R6F]PV;L
MMX+S.;;'9[--V>B[II>?KM<L.7XBXLG['R%B<QIY5C(M4EE6ZJ*2S=ZND:]6
M1('J'#VFB:0)+TQMV\K*76,;S6"*=CU[8H>Q1]4K5]RK9J=8;"[WBX@W&6&Y
MT3'&0*G+?]I4BK6:'*EEX:IV*6@+39)))TLV:$03.2;PUV]-MB'.?9!!$=AQ
MGT4I$B*O:?3"WAVC',+MQ->\',<&8NQ/GS%%5>N)V>L 9LB,IM;D6GRF3\52
MV'%T<?71J_LJ#BWS<5;9<+$+(Y/)=MXL0DJ1;96MYJY;'',$0>S'V59=?S'+
MP!,8#L$4PKGZ.6Y*IYD/=L09+KULQ71,D?-<"8Y-N%SOM0R+CG#2^%KYC^,P
MXTSKA&IW"W-H7&UBNZC>$!(NCJIMVT>Z.4S0G<I25&@3&H'/E,_6/54AETP?
MRD9<R"/5!QX36STQLDW?WI2\XZL2> JCB[-68]G>;\A7U/+>5\H9AI;_ &V4
M_;XSL%2IAK-C*N*WNQV*R8&11:W.:G&;WRLDL\<1YW(=HQH)9FD^(B.R,^/&
MH9@45(Q69/.3(J,=XGIMY-R=NAW$;A3D:QF*KY U:P6&[8=N&6!W4NJEC?;5
M?L5S&#*=BBLQ<?3[D6\6JRLYE@[4F"NF[I@!2-E'(,U$+E: 125T*].'&6;<
M:;7*2_W,R<C+;D,KN93-.>UY)9431^2,@"V<JU=FQ%[(M(1A2*NQC(8C)JJ9
ML@=@?H$PB)C0Q75X<J4D#/.M\BKICKH.GZ>'$32:JN)@-J #[.(I3C0)D_;X
M_LTXB<8HHJ8=#%+X@ CJ'O\ 9Q;;:#!RH!J-X4IHS,-W9*&-V+34J?96  70
MGF8%U,5B<3UZ0U.FDK&&UU'DH :!ISWN?,Z=;8>];N.I[F"LOM#THPNG^90?
M5@?K%*N6H=>;QG?8UH43O5JM,KQY2B &"48LS/XM0HZ"(&3D&R9@^[A.GWA8
MWMBZWN+<6?\ #,-[)HNJ6M,HS*FGA"2K:>A(F::& [.;B6,NV4(8#%,VDFJ3
MQ$2G 1*8!27 0$!$!#C+>MM9NM8?WT8J>\&*8-J 89,)J,HEO\NS/=D#*E[%
MJH=%G&Z/0!# ^KLK9H&76!0"ZK +)['%-J/P!T_\W'08FYT>T>%N]<4]SJC*
M/6KFD!_58<U!]1(/UBEC,,4I+XOR"R102654J<LY;)J$!0BKN-9JR+5,Z8F(
M!RF<-2AH)@U]X<5])O#;=0L71AINKV8$P<>ZFNKJML ,"M8/\A)/_)1]&C%[
M;.OF:;S\EQY2O5U-VT2>ME[A.IE63C>\FX()&B!',@L4W41#M]2A4&S9"6W+
M"W:5H_F:#!T+QRQ)(4<3.%,7!C1BWL''$U%]4I+=3-%_DKXZ+;9YU6L<6>)3
M.V50K,+VAN,,L:#KRAE6Q7$>NT "O'9W3\ 5#0Z9="CU-S?<]%V]JR EI;MY
M#^8SY;>)N1DX"%P.=5A!YS,V)*J>SCPJLSWEQ/TR?C<>1)+&>->03F9M[H[D
M*17"0=JAY!Z95ZT$KNRR<<5H*BC&/'X0()5UV_(1CI&W6UN[;[HPK:@ML1YC
MED91 ."B3@S=X#476E"$Q.&/#,5*#"GP<(X5N%UG!L<XP(+E6Q68[9G$5\A>
MDX_3D0*@0U9:)_\ XI.MVH&G><*CSXYER^]V+.V0):. "XLTX>)LV)Y8#DHJ
MT !I8R>9J)L=2]NN<AE@*B92'B'.4I!R6[ST7JX,W^EZ>W:M:K7'2C=602&-
M3(JD_D2D:_F !$7! ZN.KU&S9V=O:B^5:[\-BBM/_4N$EFQ"G5@563AFLU4L
ML6TY:L_0,AQ^JL+DVI^.LB8F<.!DIFS3DG<7QY-Z=Q8+K9'T139%JA',&Z:1
MU2LBC-'4!JR(SC6YR 82I@&O";:Y?W>SW"D!;*(@  "HH9UDGM\(&IB6.6-0
MP5;B_F)/?E],L*.93)?YC'MVE7$@[QPT2KDRG!PU<DD$[>\>O&YF,6M8;2EY
MAO!@=^X34%I&@=8- U>:ZDX7IR67W]BPL77:X)+#P"!J("'%O"#BV'\O&INA
M]#'*%,0<3Z?NI1K 0]$K$;1,)UJ,6B*O'MXQQ.F0&-HD:>,;(L73F3F&Q%W]
MJF"E;"=5-D5PJ8^I7#E =3<5W1NMUNFW?6;C"[<);3'ZAU8PJD@*.6H@90#5
M*H%4+;@JN'9Z3Q^OM%1/0F5:AXYO>[^K)9+RM?GCG)8U0&[7R=>8/FR#*N/D
M*PZD$ZS18B'J<>P0/+3"ZBB0IF KH1'I'I[VY>9CM=D!MNFV5%LL3BQ&+R\:
MG8N6.A  1'AI;:K :YC<;&(RY89"!Q-<XXO-&2=Q$SE.Y&E+/5*58K2HS9)U
M-,%,@S6,!5;1]"K.$HV2CV;FQQ^098 74N%A&+IB;QV9!DTFEVQ%$.C:V2JE
MK:[-4UKBUU_=#1+NPD@:%& 4/<B3*@FJE8W0S28/+..$=_,X=AIX%Q>XOE1R
M)M8P6C3DK[:8M.)R8^A8X\WB/ 59LKI55]&6.ROS._YZY46;@=R^(X,>*<S"
MRCQTV7%%JUX[#MLME8L=5ZAYGP"AO)UF;V[=1&O3_P!&U)\)/ZA4:5906(K2
MT6+;=(\PY_E4'@2?>;GPG/A4K;7_ $Y=N$UM^I[[*,6ZW$Y4D,?V:DO,QYB<
M/[2Y=,G*LO67LK5ZH^?*U2JP=B.R!^*+%JFL][I572[A4>[QXOJ_7]]O[URU
M+)L&8?I@E@(R!)Q) PGAPK=;VME% B7YUE*;/,'YFQ6$+BNEX@Q[N7P8VA:7
M>8V&HE*B&LC/UY&.F&<#D:"A6Z@MHNWG;)3U9EBJ"[BU7";ENL(>=;+;OE[K
MZ](OFQO%\[I-R-0,%TB0'ML02(F'3)U,$3I95N[=;J>"!= C^!^P\#2/CZR*
MNW$1E:^5I[1+_79%AA?+MF2B8Y[;<>N2R8Q].E,BL4&8-KGC8\@M^5-.2$0/
M%.UTWOEWL:5V;TO4MAM5+;#;&U?VK6S?M+J\%P1+K;:92Z!G;$D.%9)2X5K)
M;-P /<!5AX6R)' $\U[>4@XB:6<[UN@?S8;TBQ5&NPNXC,L%(I8[C:LBH8;;
MD6EP"B;6SMIB$%A;8BC+U 3.Y5[YB/EJTI#"HV<F4<D.YX=L@]..[L.;G3;3
M@'7[Z(\R(Q74C0%(E7#8@1 V&1*,(<C(9$\^&%%-W361JV+7,K8%TH;.[C%]
M6J%BL3'\P]OL>/)VOW* N<,LHV2"Z5)<(*84=1ZX><;&<($.1!005-BV]R\^
MP:QMSYFSM.URV#FLC2X99E3XE.H8$*T$Y"MO"P9OZA6"><8@@\>.&8FMNLPK
MLI&+@DLGPS:#M=%M;.[U^PQKARSA+#%,"+1UQ>T^R@Y2DJO.!3Y%THLQ762=
MI&3 R)W29.[Q5T^[<M77&Q<G;W;1M,K1J$^) RGPN X$$ C@0":>Y$C6/$&D
M<CS@\#'#/C3)7A)[*RC]_GF1DK%MCER+0U(AHC2.C;C"/SE:H7#/80ITWLO#
MSW> L6V0[4*#$$UY1L*J@&2QD+;N*-@0N[ U'')ACIMD\1QQG5(68 IV\7O@
ME?H)/T[ZA6@8'>V"$LR>-5&85[#4:AAJD0K10J#>LWS&]_"S+W3%BWS%&'C&
MT:\@(%5>)-VF,@X2=-RK,@%3JZ'4MU8:\&OR+MX!Y(_,HP?"3)+"1X@ ,&I;
M8=5(7AAZIQ'W=]2]C7(U0S'E45HZ0)CO.A*4O"9/J;$IVMJI]_IBC%>*+.PK
M\$#V2E66O3KL[07J*S9P@S(1-5%XW-VJ[R;C:=.%J^/,V(NZD)]THX(?2>#!
ME7$$$2200:A&MW+QTX7H@CB",N\$3]5;%6V6G9>MS%.MC)O7KN+<\I1IZ*$7
M5=L%@KH_/8!_ .'A%%6$VWDHY,RT4Z 5P3ZNT=RD!E YFU"V]PM^P2VV!AU.
M!"MX6#0<5*D^(<\0IPJ]@SKI;!XP/:,CW]E2U7)-O9H*%L;0X&86&%CY=)+3
MI%-M),D'A$3% 1Z3$*MTB \P'4!XRWD^%W#V''ZZ,5GGI,33#Q"1Q%,2M-AK
MN2+E6VVI8>PQD5D"(1+KVVT@N=6NVMLGJ(@FFX=,&#P"A\/><*CIJ(Z[+Q\_
M9)=<#S$<VSW1J0GN\8[@.5*,'(X$3]A^RC&58UXK4W$VP 3R]+>L+M$D P)F
M.M6U3NWK RO28"H34.9RR5'33L.#\5=-N"W>"73%JY-MNY\)S_"88=H%47 <
M0!+ R/1C]XJ4FYB+IIN43B9!5%)5$=.8D4(11,W/QZBB \<R"ET@Y@P:VI$8
M95PQ]4]LYK&$,W0;)%\C#U?#.ZC(M?9L#^0*_C+WA69BEH!A(-A*I&&;9"D'
M;DQND2HME] #0 $OV3Y 9;^ZLW#I-UMQM+;3CC:NE@T8R#;"+&9*FN'NK+7=
MR%7 (K-ZRICTE2?37S\,/QC&<D9B,L$@QD(63AIJ CK("Z+>4KEJ._>2U&FC
M3L,Y5F$X.M7$K5S(MDCKMW2!"!VS+"4Y?TYU!7-GS;(BZ((&8*B RP<)*2%.
M!4\<P>OL2HO:7QMXB>(.8,C@&Q(X]]3S7E;U6'ERP#N9FH.8Q_>Z]*62/G,Q
MVW("];0G8BVML85S)F-<FJ,+W;8%R\IJUE?_ #*'A42.C2(MY 1**16WF[]I
M-P;?4.F(PW%M@"+80-I@NUJY;)56((M@JS0(E.9[^IT5]KN2IM."98M (.D.
MK8D8:L0,9@]D&7+%L3M\RI*O92ZWIY4E;-).(9/"\C+P\C8J3+"PD6*8W9!.
M,85:KR-.DF_0^C@DSM3D*L[<MSD.R/LVU\=6VBE5MK= \7F08>2I_3DDE6!$
M- .(60-5<TVGV.Y,M<-N<-$X@XCQ# 2(QQ[8.%2TQD\U5VI0T9A_:=5L--&2
ML@Q5FY>W7..N6073"6MS&,:O+%;+16)ZVKVJKWQ$S'RARM'Y551.F<X ">$6
M=H]YCN=V;[1D%4JF4X*K!8*2=4LN.7'IZ[XMCRK*VQ/$D,<^)()D-W&E>(SA
MGC(4:T=PF%X6?A:TJY:S%3>O%Z\61FHKMOS8BC*7\LJ=>M>*XJ=(Q>PL!)QU
MC?1S 7BKA;N'*01>G;"QJ-VZREL=6< X>:6EBKD8-=5K88:0 *IN;O<7\%08
M8$998Z0( *@P54AB,<<:8L_=8N%>7&@XYF<P;3;C;)@T,_QD2Y6*S8BNT/4X
M> JDM(0\<_C&-VJ<]/R8O&:)DV[UD6,0<IH(B4HHAJ2PEQUW.Z%G>V@LJY0!
MUDR,5)0K$'&"3#$\:SW#=*&PCW;!F"H8E2 ,<" P,R.(B8Y4J8VV^M<-8Z'<
M=E6KM+JWCF61[#2J7%W2GQ%*M2U)C8RSPZUCCHNWKV*RU:0GE)>).RK<9),)
M-FDZ3D"M3]929-WU>YN]T>D[)C::YY:O<*.2H=BIB4TJP4A@7(T^$KJ&>G9;
M(;2Q\?N_U"H8JNH0=(G&#)$@X*#.(,4C3<I=\NU6XW7*!6,'1X6SVY1NVH]'
MI=21R/DR;BH['TJU+8<>R<.0XEQ9)12RZ[R%6:L B@0(4@KJ%'>FPVW1KJ6=
MEX]V]I0=;NY6V&+:B&G.Z&@:@QU3P%8WW-SJBL=R--E7)D*JZF@")6/P1.$"
M(K97T[;[829IOMCB?-)/J!M+W0V> ?/Y'YH>.D&. +NW0EYUD^1D&=@=(S]B
M:FUD63H52OC%*3M@8.*NM]+.Y.PV[ $W^I[,$9!E^)0LJF5"^!6B"/=$&36&
M]= Z?OP#X4V=[CP-ME]9)C+C7M._IW[A.W[TTZ5D2W'A/J:]93RG/38P-0IM
M%C@>C.-XI--.O4.)@ZXW42:QJ1!,DV(8W2 &UT#CX#^^^WL;+]P[VTV^KR+=
MBTJR]RX<B3XKK.^)).+&N/\ +>H])MEO>,\ .7Y0!7<T T  X^.5WJOP458>
M7/W<^",:*2WI2(1LD9RH!D0;/'!S"&H$2*B<YN6AM>D U\!^[@LVSYRYR7!]
MM5WW*V'89A#]1KY83;*$K6-A3&?QFYD,6S#KU&,KQ*4EC:QW"/+,IQN!Z"X:
M2-CCAL$O,IO9$I3O&HIJLFK4 =IMR?F%(G_1'YIZ?:O_ #5Y>]B]9'1[1 N*
MC8&_>!TD(JP(A@98G3)P,^(^6;AM].!L2KF\?=)_(N!QGNCMJ(:/C-A+UB7L
MUDR _KE+KYT[-8+0_E))U'P4LKI"M1K\.V7<S$Y;'+:1.F5F1-21<D[RQU$T
M04,EY7?W-PUU;5I%:\WA4 "6 $F3DH$3C"C+$Q/NMFNI2[$Z!B3R/8.?M[:=
MV-<2Y7O+VV(80GY&B;?T*ODBI92F+=-UBFMUXVCN;-7+1&OXF$FX:X.ELB3*
M\05_#IP[E91*08-E5$B(D5'"V[V>S*?W%%O;]G0VT"M<DM$,#!4: &(>8A6(
MDX5T/*W&X5A98K9A@Q) P&!&!DZL)$<13/A[/@>E YJ64ZB;$TW+1SQ_.N\;
M8V=P>&W5)KD,LY@9>8JLQ/-+L\NDZ6UF3D6[=S,$$)-N[14*BV*)M]S;;J^Z
MMT]Q>3$KK:7#%H?2X7RPH@,)">Z0023$VK^SVJE=R!;'&%A8 D&"9),]HQF:
M<-HA\(PTNK/6V[U^UUVJP#TL>K4I1I-W5_(5^,AAC:DI3'Q'#F-^0L7:#B36
M6B2!%(QRIQU.BLQ72U8ZIY8M6;;V[KL)5A"@$F6UC R9T@,=4CGJ%EV[L;OB
MMLK(.6> &$9B,)PP@\HHRA!X'@6TR8V2(6#QI.QKI^XBG:KMQ>)& C6T5-V*
MDS6-HEV_FT)JIN% 4?1:C=,I"-S+)*JD,=WQ8MOJES0I1GW"&.2*3(5Q<,+#
M#!6!S,, ?#64V-J 7N;A;:'\)S(S((SPXC_;2.[;XER9.3=:QE QEPE6)QKE
MBR3G"CNI!I585B^._CK7AYM591TG6U'"MJ6=NWTHZ*G#(R"")V?FBD!:4LW]
MK%[>G1I(9;=IH8N5TE;FH -"@*H4'5!\<9 N6[K&W; )RUL)$#BL99G$Q$Y3
M1[)=,R-6;_\ 3V\:^68K20DK(_HV5(=M7<EH+DQY3Y*S&OR:\5*VW(-B=6&C
MNH]-Y)&;L%$4G,<Y,W3["8#DVV[V-RPK])52F$VS-LR[!= # *"K:L),D, 3
M-6O;NJ^G>,9X-[WNB9P))D1C'*0*1LFQ5UQ#8(-BSN4O"VBIMXR3HCZ*L#9X
M'9E>[/A,0DFQ52445EI24.X#MJ@X1-WB+!UE[2>FP+&\M.C6@UBY*W!IB0#$
M-/ 1&49$=N?<ZMM%T-#IXE,S!SD<_IQKUL?TW5QMEII;)[>;/,6R8-.[CT&\
MI-*+J2G8B4]N[.69.RR+CSZ;1I*]94 !,2&.0XATDZ-?BW[P6;"*]JPBHI&V
MD 0)/Q40 -,D9XS$9XU7<>X^TVMQR2&-TK,F%_3PQQP(PKUC. Z2IAK\!ER@
M<-?$IS"&G+GR,8!Y<?!;1#3S"X>BLMSPE<<S6@V;[QFS%VP6T95V[N\9Q>0\
M18?G<AE8YAKD_<ZK*1V,:Q,SEGJRK6H6^G2+.9F1@SMF[X'BJ+)4XG4;K '1
MQU.J$W.JW@QEVN'$2 =1D'&(&-5;?5Y2G)8^KA7.*U[_ '=1B+..V5QG./VW
M-JC;<%XUDLG95J56RTXJAK5GW+-60:XM;(P%HR#9L"VEA36L:X@9&X-7,#=I
ME<S)!6/ @G1G:VWO[%[%X,MK4&U3"ZE#+&.!B<2#(U<Y%6F,3()(J6MK^Z'-
M>_.\[K\69$@<1U]':G#6S%MEJ$)-O9Z&R/G5W*VJ.J]_BXMK,O!E<.1\- F:
M/F[U=X1K<T9**355<0B[E2;&ZVVSNI:VNH;P7 6N?E0GPA<)#0#J(@B(P!BJ
MPMUL7C3!P[>$]G94 X^]47=!3:9(ESA0Z3DF"8Y6RE@:)G-J= D8A_6B[:L0
M2F8,N9#DQSSFA&JSK1K1*Z]!%JT.)8Z29F24!\X528</=VMJSOKR;DJ&2^54
M$F7)\4F!J"G'D3I.(SJ5-QE)D8<OXX5*TQZL.W7;SN=E<'0&(LW7&WY3B<%+
MLIINE18BM2=GR#0(6Z0#JXY-OEZ@HPLS-HY9K[)4%E1=@IW@:MUDVZ9%=.YM
MOU'I^WN.Z@K=O(($!0 A"P(@1.G.>.,U4&%NXPC$@2)QR.?;C2=>-XN5K91O
M32OK#'M/KN>=ZDI)91BS9FEI:6Q-MOJ5#HJ-BE*]"1E%<-K!>K59W%SC&4>5
MHX:RTTDJX77%-%J$<6SIA?=?$;+8,PLFRRX#Q78!8ZV."@!&(!\*D<Y:H!)5
M'_$6] CD,ZO:?5LJ,)5W4WNMQ?D&LUW',*:OY4/@61IV5<$.]PR.&+7G<F'7
M-Z6L=9NEMDY7&]64D&4<E#)PK!ZZ0C9M_P"?ZVR'-L^3M=XUK:LKW@0#<,^$
M$@0O)L?>QP]R)DVLT++CP=G'O^G?17&'JW8[N=2QQCZ*V][HJ9!*1++&D"SC
MX'%:=WRED^NY&PWA"<Q;0',;E8(*KQS"?S=67CNPNG+!BM&R"WDG"9VKA0E_
M5 =KU*Y?W 5MPU]L&DA22""P.9 8"#AQ,C"GM:;EH1@ ([::4?ZQ>V2C I2I
M"H9CQS39MUGZ_P!U<UZ!QZ-ICW^*V669JQXIC(6!R0K-(N6$#@F5:N[.S0=0
M[Z023:LI!0ZZCQ#9U"W<.X6^WZMQ+=M 6Q4/DVKF=9;2APQ$B/":=:J"@P62
M3&?</5G3#_\ NL8-FL6IUF5QUE7"DSD[(#FLXKP]=:K 5E[>;C:[?BEPH[LC
MF+G9F(+%8MP?F>MW,60F%,M?;+R#Q4R[3RB77VB.>HBW?&K>6 %<$ZF4HOAM
MH 3X[]QH)F1J(4 !C61GMZ=)\()X=I&)_P ((-=D-KV!EH*4M.=KBH5_>,AM
MHB&I7?9)M3X^PO -$T:?5X]D8-(L9Q,3R3IH0"@R(Z28#U"V456Y_P R=8LW
MUM](V(C:V)-P_P#=OL9=B>(0^!2?>*FYAJ"K=M;3B;KGQDC#DHR'><^R8X5N
MCWE2'  *'3J'6?0 ZC ',?#V\>-),P:V# X5@JZ.)A( : 80$!Y"(=(ZA[.?
M,.(#09J23QI/FX:&LT-)5VRQL=8H"?8NXJ<@YIFV?Q,E%OD%&[UA(1SI)1J^
M9NT%#$424*8ABFT$.-EB[=L7%W&V9K=^V0RLI(8$8@@C$$<Q53,I4I<&I&P(
M(D1R[:YLVVO(;8LGUN":0:<EC>_M&U(296*05>56]U(SY1)K0;$K+.%F<9EG
M'SU\W4KLP\,9&?KR[QJ]-YUHF[-]#V][_P U=.N77>.IV";ATB'MO$FZ@42U
MFZ 1>MK#6KHMNG@8H.:X^#O!(FPP QQ!'(SDRGW6/O"0<1-35C:6-5C7ZHL&
M[N[8>8SIG_TL\:.Y6]8VC+F5Q)SD'-1+_P \_LD7&6HDJ5:/7 \E'MN@43.D
M.@J7"Z@BWA8W)"VNJZ(+@A;5TVX"NK" C,A2&'A<SJTM).FVQ74DS:'#BH.8
M(S,$&1F.$BEW$#.8H=-%2A+N\@8OB;;>6T?5&SOSTU!0C>X2JT4>@S#IW_UV
M$CHM<A"13I05 33 &:VI2MCT]1?;[O<GXJ+'4&M6Y<CPLQ0:O-4#PL3/C41)
M\8Q+!K0<("IUVPQ@#//@>/=ZC1G&->:2XY(OV*;.VCY2<RM<GKI,[>2^DIYX
MDA#LG,1:ZZJ=!U&S*;YF<BSQ!-O(MU!,54JH%[0IU&^Z_#[7J%N4M[6V!B-8
M66.I6Q!$'!3*$01&=-; <,]LXECSCA@1G]HHTP=0&2\LVJMWRL$CYJOX[IA7
M=0F%F[E5N[=6>U/362H3+55LM(-FOD6YV\BS[#AL<Q>X5NN(D"MUN[7IMM]G
M<#V&W#D. >"( KJ9 )DC29#8P67&HU:KQ6X((02/2<0?0,J+93D;)4 H\+++
MR%UI$GD.INEI)O'*R=ZK\75':MT>#-QD>FHXMD,R+7TRJ/V:17[9,VKA)P'4
MX*VQM[7>>=<MZ;.\2R_AF+;,P"#23[C'5.ECI)'A*X+2W&(*@2R%AC^(1CCS
MRSSYSG4CN*/1G,+'V^D/&%&*R9.IB+L]%1C&4>:/77<33\S^.CR%A;) /GCE
M9RZ;NTU-555%4S).#"IQS[5^[8<[2^GF(#!MO(Q.&!.*-E!$<)D859!P:8&<
MB,N[*.=,_!ERDXZN0L1DB,-!6JYN9BXL)AHDY^F;42Y2SJR-4HURJ)EH.=8L
M)1!NI$OC \*"6J2CLI3JANZSM+;[AKFQ8-MK6FW!(UJ;8"&1^)25)#KX<<0L
M@4FV9E UCQF3V8XX<CB,#Z)HI-TN4',K>:QNHUB5*C69&4L55D5G 4JP3]Q<
MA'QRYV#/K+6K(> BI YY5@GWC%<$*Y0<E-H!M]W8'3&V^]&IKMQ0CCWU5 20
M"??344\#88>%E-6,I-X.F&D8C@2?J, XCT@T^IG([!6HW-S\N>-;;7X91FYI
M,P@C\Q<2TSU1<"W2T%5G-0\]*.$T6[UN*K5<#:<C@=,N--H?/MVY!V]Q_?4F
M !BQYJ5&)!Q'J-7%_"29U#AQG^-)=7HL[A2 AXRCBO9:?!0T;'OZ"LX(>50<
M,VQ2OI/'TA(+E(W%ZL4RIX9TJ#,XC_M%&@ZIJ/NMXG5+K7=YX-P[$BX!AB<!
M< &,9:P-0_%KS"JAM !,4'#[ON]44JTZ8C<CW^P6^&>F<0=6@VM'9]Q(S=RT
ML\DJC8;BS>L'**+V-E8UFE$-UT5BD43."A#% 0XKW%I^G[1+-X#SKC^9_D$J
MAG(AB7((S$&I5A<N%E/A CTG$^K"G'D]W),*9(,HA8#SEB.VJ$&!S@F(RME7
M)$IN1'H./;BVKE5Z?0!T3;&'30!XS[1;=W<!K@_23QM_A7$^N-/>13."%('O
M9#O-/&(B&M>BHF&8E,1A$L&42Q3_ (C),8QJFR:%$0  $WET"Z\@Y\9KMYKS
ML[XW'8D]Y,GVFI@* !E%,*N+#/W^X6LQ!&/@46V/(4W(Q'#F/<?-K:]1'I'\
MH9ARV9B(&YJ1QP$ $NHW[D#;[.W;_P"HY+MW'PH/5J;N:E!)<GEA]I]M2@<!
M.'@(#S_9K^X..>&U":FA"'*4N@@'+].7Z^)J5,4U<B/K5'8_NTE1(QI-7=A4
M;&^ID*_7%JPE[8UAGKBN13YR!TQ09R,RF@BJ?J+TD.(ZAPPB1JRFKJ\P$5O+
MW)4=M44:)==V6;<AS>-MO-HSDC97<5),:UG&Q;BMO\1D_%[K%<KAZOR>WB24
M966?JL6P82;Z,?Q*QW0MNZS"259R-1  B:*>UU]3?>>\D\3WF+?T*M5^MI6R
M:MAF^!\_'QM:;O9\ 6&ZQ6T2YP+AR:YAF;'F0(%M!I3K-\U8N9&9;@>,!X4(
MQ9@JD5:J@X4\D?5TWS#:-QD7_P!G4::>Q:U:N:3@P8VY/LJ2L^3+=(HD+B^5
MDJ[)SI2V;+U2L[^8A9EU#Q,8P^5'4!&28 X=(2MM#&HP#QJ?+6 9SK<W<NAD
M;/&"]D67:CGS->-YS)&4=M]5O[G;C.6[&57FJGF"PP#;(*SBGVB,D[3$GC2=
M;=BM+ F_ARG.*Y0/W"<*  YG(3G2" 2(K2K-WJB;S-NK"G -&QO9XZP9UW"X
MSI\"\H639>X3&-]M698C#8N+C?GV18&*7R?D.(7/8$QC8MZ\7*(J(12S5-PY
M3O"6V]51 ]E89<]4W?AB6@-;C.8EQ"LI<&$#>81O'8NS*[>T*E/KYN)I[FJ3
MD:YO<5&WG(3EOB."<E$TK5B]<XLW9M'SGR"#E"@8Z08I>.%-*)]2??/BW-*<
M/)XZ<YAK^<=S5E0K<;-UBTUT8&D,<BX\Q QPMC5BK+1+JO3U&JTFZN,NX=,9
M]ZZ%41<MFS=%TZ170A7$Y45TRH&X_-&1=B65[-=+/2X+> GM)MF?4*3C&HV>
MLNL7-;Y3<@.L,E4@KK+VF1DIME,U!PD9RJH0KM\Q5#R:) *!ZP@5O#[LT5K1
M2_4OQ8OD/T][!9-ST.MB2V;5LM0^=I<Z[E2NN-R+6O[8)JK1EW>-(?IB+PBS
MD[*HU;+"W^)9R4"=?24!A#111;9/FB;M^X^K,,I;A]WC_=?-9+W-Q^>-LCBK
M2C[;CCG&U=GKN7$J[Z,D:JPJ6+Z4E5&%;7JMIAI%Q)6]Z^%-PH\(NY!FQ4 &
M,L*BN\:X+*<B@'2!N0@.IA#WZ!IIQ60:J,FJZ$REU,( .GMT\=/#GQ%160'3
M -"G*(CX?:/]_!15"8? ?W<^(BB@5$N8#^T/MXL3WL*!477]5"$DJ=?5EA;(
MU:87B; N *"F%5N/EH=VHN!#%*#:/L2<6]5.<!!)%J<_@ CQT=MJN)<VB@$W
M%! P]Y)81/$KK4 9E@*5\"KG(''N.'UP:E,#]Q17J#0H%$IDS@&H_P 0!J',
M.DP?LXQ1X0.=6\:BG%X?+(B3Q\53H<8YFW,"BB8!*<:TN/S:H+$*/_YO]/.R
M-BB B4QVA]--!*&O>_K.-V__ %E!G^<>%_26&H_XA5*G2- &"_5P]GU45R3*
M0E4EZEDJ7E&\;%U]TZJ-E?+J(MFK"O7U>*8-W<BZ643309LK7'1IC'-\)2G,
M/+QXNV=F_N;5S865+/<&I0))+6@S0H ,DH6 'UY4KE!INDX# ]Q@8^F*.A]0
MY,9.&[=>9IE'=!VRORZ1USLS(X?F>2052,O4H9T3D190"R2Y#"8I&P=!SY;?
ME]/N#S EV^.!Q53VQ@Q&< E0<"3B*N67&$@>W^'UTS<>2U2Q;C-E6'!TX<,?
MS[W&Z,9'-%'DQ.24<KW8))C&L4%'\U/6"MK,WINE,ZJHKF44,( 8_&WJ5G=]
M2WWQ*DL;RBZ3D #@TDX*JN&7@!$#@*JME431EI.F/J[\"#2':JS*3U_Q_8KP
M*L!3K<UEJ(_I<8J"3J2<.DR6BKHWZ;:*]3IN<89\W5C6?0T.L[ BR[@NA37;
M;<A=E?VUD!]S;9;BN<=($H^A2(DZE;49("D@ X@<#6K,80B(YG,2?0:DG)<M
M%$K,UCFOL1EK)8:I*14/5X0B")8UJ]CUV+65F%^WY"K0+==4I2N7(%*8X=*)
M%E/RQQ[!77<IN[ATVK=Q6+'B09TCBQ@9#&.0QIW( *#&1D/MY4G4.))?*S3[
MSD%^TL,LYBHR31AT413J$!+%;%!Z+2*<%$\C)QK\JJ9GKT#J)&)JD1OS+Q.\
M*[7<W=KLY%D.P!_$5G#'& 1& ./$FA8N*KM[T>WCZJ0JS9)67O\ DF HY42,
M'SZ!LSR]/"E<PX \A25E1I6F!A)]1R)'M44%9P4Q&"'63XEC")!?<[4V=E8O
M7R"890OXA#:Y:/=P? 'Q&#@(H#0[*.P^R,/56-P0K6-[KC&QO._)V&P3-FK7
MG5"#)VNPOI"HOY%I&,"J'(9)N=6"#5! J#)N(E,<J9?C"=L+V]VM^U;)%JW;
M5XG  .H),?XLSC0Q4,I.<QZQ13+\*[L6-IIYDI1E$UL\C5%WM90=D&.+%I7"
M 6=(6Z6,=)M+MQ9$-YA "$CR)@;K,L4!-PW3-[<V6]5]MA?&K2W$$HR^'D9.
M!&,U%V&MD/[O\12?E*QV>R8YM1,?&1KE,&LNXEO:#)@S<2YID_R%HWJ$2NBC
MY*' SL-)14@@8H!Y--0!!8+>G6+2;JU\:2V\\U25@D"/$=33F1^',?B@X52[
M.RDK[L'VX8=G;ZJ@+/F*,?7BGQN.F*TFSQC(S4%3[Q+24\LUIEL;-F0/)^8G
M6W3UY,EJS3J\Z6[\P[6K;<Z) .U>'3!(G1V?G[FZ;NY"O?\ +=U0 $XM"KPT
MJ[L!I UF<P,:KOHC)IQ%N0"9P[2><#GAV&M>\GTL,V9GK=%P,[L.,[33HL5(
MJ=3$99O?8Q%NS7?V;<9%N/+2Q<6T9-ZT:UB(%RTF7TM)]#$8]DV=E#T6V+=$
MZ4V\ZAY=U+C8KD$X+;L$2#<<JQN, 45$\6IF64)%R[HM2(&?/M;L&$#,D]E;
M3XIK6<<<4F-PI0< P>.'+GS2MIS>\RK6[O6$W\DX*I-7=NP;Q4'?+?<)(JZY
MVL<ZBHB.9'*D@59-FDFF/S[J_4-QU;?-N;[%@8"X:0JC *JB0,,R,2?$222:
MVV45$TQ![Y],UN_5H&-I%8@:E$@",368F/A8X# &J<7%-4F30%.D  RO82+U
MB  !CB(Z<^.<6DXYU9,=],F[X;QYDB29V61CWT;;HE)5K%7VH3,M3[M&I KU
M*L$K+ .V$BM'D5((&9N17::F.!DAZC ,JY0SF(XU$29XUSVW(;*)P5 S;5<R
M[BI6>AXEQ4LJ03J_Q#1'(.#I4Z2%L@) *Q2XF1F%H=@D5X34POUFJ"J2#@CD
M4#AZSY?ZA;NL.G;E]%MSJL\%M;@3Y;8S&ICIG)20Q! (K+NK5QAYMHM(B0#F
MO'AP&/;V4W<<U6D8NV]3T=7J86*JV)KI"O[/->>EIW(E4L= <PMF@+/-Y >.
M)"R9 I5OQP[:+1D\9=0[)NZ)_$SU*UZM[:&YU6VBW=>YW%LZ9C3>5]2.ND^Y
M=2Z&#6VST_FC56A"6C"P%./$X8@SQ!''[*V/W/4FNY/Q<KB/-J"TK6YFV8V?
MU[(<6<88CULC?:^";!*99D<.*QD)6+<G!,4BIHR93F!#0QCHAPM@7&X.ZV(T
ML+=Q7M9E9MF3C *:AB/P0)X&K+X5U*'W21]!Q!BI,RTZ;J8XR'BW+Z#"5B[;
M3;K$U^TNF2*%=L0GAW0-8R5(<AV-;N2"B^B/4)6[Q1'NMQ*H/ER9]A;9MU8W
M/3I&YMW$)7\0QQ8'BD9\1.,C&F<Z49'Q$&#PG[ZB&C,]S&*Z34,9SM@QQ+8P
M;UVNU^,W /UK+)7RLUU*!9Q,6UO&/2L6T2M.+-.A).Q#,J,DW!.\^:B4W%=Y
M;!W!%E6#JQ&C  D,?=/*1[L3P!IK2LJ ,03 Q] S[:?^",>!@>O72,QLU?SE
M#C<@6M4]!3.U>R")3MXE5[/5.0751$\E-/>Z^?LG"G:>/'*BB HF-TJ6=0=M
MZ]I]T52\UE8?$#-H##L& (& $8U9; 0$ 3!/V4S\\XSI&?;A@O(^-KPZQCF"
M'>7M.DYJI<6T5N$,E%U9\=[3[C#R;$R-HI99Q5N6:K$R1--3I,!#-G($6*^R
M>]L[5^QND\S:!5)ML3H.I@-2F?"T3I=?:)%5W$2XZ7!A<$PPS&&7:.8IVUW,
M>16@AC#<IB5:0M:+5$[^QXABWUNH-M8 X%N%EC*X]6"]5YFDL*1W $3DDHQ8
MY06=$U3$W/%A7<W-FP"$D#40".PG*>'":M+D'2P)[ONSIUXCGY7'F)J"ZL*D
MI.4=2K,7X6!QW74W3HEX .6)+&W*!W4K!,&BI2F?E R[- @"Y Y .N&SJ%I=
MYU2\EK2NY-P@)@ T#&"< 9X9,3 Q@4EMM-M29*D9_3Z"I)=K%?Y;ICQ@[:G;
M*8QNCDY4=%3/F:]EH!V+IJY3(9(S0@E$W\8 <%2B7J !$*K8%KIU]+@/F?$6
MQ/(A+L@C.?J@S3-BZG^4_6*?4R)1AIP'&O9&*?=[3Q! 6BX*^_D">OL'D'@/
M'/M$:P?YJI8%3@:3,;K&=XXH:XK.%SKTRK*BX> ;S:XGA&)Q7= 8I# X6UZC
MZ@ ]0CJ <-OUC>WE@"+SX#+!C@.RM&W;])3_ "CORKDOZS9(YO@F:EWRL@4K
M';]NV3,WAID*S+NV[C%L>E)#'VA9G),:\Y:PXN0*NZ;+HF[HI%**JJ93?2_V
MS:_\2]FU )WFR:2-2B+K 2H(9@21@I!$2<!61PJ7A<,@Z;F1@GP\#D/:,:^>
M,Q4KJCQH>D05PK< 2&8-1CYR>J\Y*HV@8]VBC-2<BRI569.HY6;13,;5DJZ[
M1%-''<5**OZIU7DL$;MK;W),$*RC3A @LQF)QD#+"!A?8-M[@-H,%@9D''G(
M ]4>G&C$FI.IP+B/SM%9'C<8N)Z,.@U:#+OT6XKJ&46E77TT_4=2=)4B6A46
MPMD (6=[!U!,1%4>,#W+;W-6R\H[D*>4Y& )R:>_PS&!%==0P73N WER.>?/
M#,?;4CX#+.%DRK8-@ZW]51*LJE+MJZ$O(;FXW#Z=68L6I[8C')AB)S5W$@Z9
M$.YK*R:OS!80?@"!UP'D]2MV_-U=7GR-"Z"2!MC>UDL 3^MJC$*_AC%#,5?M
M'OJ-.S*KCB,WTP,3^&,L1QSK'*,ODLL<]?.F;M_/HRYDF#:0*A)D)&+235*.
M&,;S#M-\]>AW'!U.ZFJF+L4BE!8QU4N+-K9LK"VO#8TXQ@9XY".0PX$Y0#3W
M[%^/,<ZFGZ12I:K#FJ7R15&&4HI:)CPCW,F7N+)+.(X[\(^1L]F12?/:R91Z
MX?))B?K(LY>@9,552]0&7+=C:VK+-M""<%PXQ[J\8$<L!P'+GWKURW<!OSIY
M\>T\./II_+W[*5G@G$!<J4RND*_DE:39V=H?1U0:,,?L3.EC/#9=EV,XVQ,#
M*4:Q9DW2Q2H-EY$Y5%2^7$Y>6VS2W=6]8;0_O@K)\<8#0(\P$3X>.G >**V6
MMXVX325E2=)G#P\?$?=C#U]E:U/6=3E+)'.I6[3$_:8Q_9ZM&X8MTY#Y>CI+
M'T8&2Y&,@HN_3*GT_>FMX?N>\WFX(L:P14.=,Z7G%45![]FW=7;LJ6E76BL7
M4>7XO "Q4>*V5'X7)+0(\(-8KLBZ"[DL"1I/C$>+ ,<&!.16 #VD5:Q9<N%V
M:LI:YSC5P\:(0$=7$)B/E 9+)R*KZ+=Q[!LS:G@HV.J,=&D73!)RV:%)H*2I
MCB'%FPV2[:[I53H;4S01F,9))U$L3R)D\J;>;@W+8:0&  ]D=P@=L5MYL0K8
MKV+<E+5Z_P 9/V6/V);H;.C7ZFSR/'7V&M,ABIU$)P+1K-4:HQ*OTU)//SDF
MCM=1=<0.W%4.L4WZMNA<W72+-RP4M_WO:+K9K8ME5O*VLD/<(!"R-0& TF./
M"WJM9Z-U*^&#GX:-(U:I=E6,@,"V..>(KVK_ -/-'V-MZ6N%%;LVLB%PD[CF
M24LQ;6UE64P:;4R=8$GAEV<VBA(MR$.V A"G(4H@01( )B4 _-W[^/;_ /SF
M[M;;(UE;=@*4*E2!:3&5\.)).'.J/EHD]'MF",\#,C$X&<<*[>B.@@&@\_;[
M.?'QUS)BN[5:\6:?JI-57,'4 A[PX 8--2-()@#&23%303Q[PNHAU 0HH& ?
MA$P:@ >S4 X-N[#=!R<K@P]-57EFVP(P*'ZJ^77&-XO)&Q9#&;B4KD2[L7J3
M9-C81G 0E>ISI^5KA:M5U%\D=G$M(Z1DFK!\<KA^]>H-R"\'NG*=5N4W]#_F
MK7MOG#XH:V1>CVY.IV@>?<,8DD8B(58,88 QX;Y54W=BMD8%KQ RSTK]^$FH
M.QQCRPY:I.1*Y-,92DXFPB:XR]@1&'I[MA/Y"G'<?C]O&.K'EZ%@J^M9IS'\
MJ^.U%.02;L/DBIVS<%D@*?@?,F]VG2[EEMHWF[_<Z%B3A;4&X2%MECY8?3.!
MU:@&,$U]'Z=MS>LN(*VK<S_BRS8#&)PRP.%*5S77M+BO;?\ ;% GFXM*,LL4
MGD4M>9J9&S=;[$,:_F+/"6I-]-FK-$E;_7H.781<+.)PBT;*B,@U6.98$^59
M?18/5^KW0+A*MHU?IVD!;2I$+J<HS*Q9"VI80A8FF]>OO=&UV*R@D:OQ,3F9
MQPD @ Q!Q!-3EBG:KE"%:P=3#+&&[9*R2,*$EMGR]7PON,I"%A7T!..Z"TM=
M;72?4/)5B"D(ODQA&2+558J;,SA)0_0ISM[UNQ?FZR7[-@,9OV_#<,@KKTF
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M(]?49P;+L/FKI\ZGV]^U:<D^=<)?.6/F1)0$$L!)51@8@"IW71MU;41=MW'
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MB06Z_=:/RR,PB0QDU3MGK4_40RS=0HFIV%B]M>I6ED>0Y#$YH]H&6.(RA3F
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MBX0)<'\.'IPP]=/RNQZ$)$1T"S*0&T-&Q\6S!,@))^7CF:+)$B:9?A(F1-
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MRIF)2>=.;4PE".A7B3/U&2[@QY8Z[;0-TUO;6>J[K5<O,AMH"0?%::XRW'G
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M4MD0#3&T;A5Q@1[>0/<<171?#&YO"6\7;!";CJLQR!#XMM$8-@C"WVJR6/\
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M@1,Q)PW3 _2=_=6ZZW.EV[*EF'OIY4XD>.=88%\CK$"3KK)O].ZL(P##=.Q
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M@V6UMW[2[#K>V!8"(9D4,YMD#^JUHBW*D %=>)$'C].W)_M>ZW^DM>Z9<&@
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M*&7/(3:H'[#5'NIE6T;IJ*G#J'X9^]]DC<WK"#]=;FS"F< NC>,TF,@<2QX
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M.3KEC868+W/6B1*HA"UIL)$E.ZH(A:NU3IEZWU<Z6LOK;;AH(<H 2SC^6Y*
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M?1]7=1I[1)ZN*-<A1!$K!E9@!75O*W241;VVM'U5D:##=T0\I'P:92*UTI]
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M+IG0F(:)GOT)(OG@ 7XFK9,%!_W(B;J[2_<VU[9?,C$MNF?RL9+%D8>8\_\
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M[I?RIII_VT8J'B$U 3-*M;<X<I_*EA*4CE)< /T*$6*GC^!/GH-N9L79*.V
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M]7=Q$#+*'$#2+^1+'L5#BLJ^'S&ZWN^9WWEE6L[R^BI9'B6XJ2Z2PR!8ZW4
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M4:NH0DH>.A[MCRTHIF.Y0C'M38+D>"7N"@9))\AW!21.;;TN_<VO56N;X%[
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M4<OSS"HJ J:FSLRY5626$#!$N%S)'$K,R7EGZC<N=>=KT!>HD9+E<40%@?\
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M6H36-QA9Y'YI/@1[*,[@Z22;&R:Y5,:2L4RN*9SII6]%VX,J]:\A%'I70#L
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MNUB'M:LT:MYFKWR7@T<H(1I"/6+R@UI(EE6O1.R4X+!&M6B,:_.7J%S$/AT
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M%V>E[=_;M.DV2P'\UOQC_AUB>VBY@5?B&CT'#ZX-20Y#J.B!=0*?773D/+F
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MV*G)-BKI%E(,E;BE2.F2@:*)20G3,FN5-4G3VFZ?9=.9+@UV-T^ET. 9+<'
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MS:MIM2/;B3L\DT?*L2%*4?C "_%SUXV;C![>(TK90<>(U'VD]G*D7(_XC]=
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M&A?1XP?LCU5XN,,0=)L<(^Q9D!RSC(6?0A;-7[38X2US[6GVQ@*FB\E"PDW
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MH9EZ5:0>-8T%#G(MYZ_N=YTYEZ9T^Q\3O]:EW<HBPX\QRV/FXHA5%@J"$5W
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MB/707_W%=BX](?\ =-AL#G$?B-:T>WH42E$!.*)2)G 3AJ!AU !UXCSEG$T
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MH"V[3^$W2TZ1B69B]P*<--M"PU ":?9W>J7[I^!#(Z&6<20NF))P &E9SEB
M8DUKG=\(XIOT[.,X_.^0YVY),X2D0.5-Q2+V]P^8A1?)-W#B[DC$5+;CV 4?
M :2K:[LE@9L8X6HKH',8ZB7J.C[KJ?3-LMZ[M[ M:M;VK$*;:YZ4#0MRX%\-
MR"DMJTR(!Y6Y3;W+I47&-S(,\D-VF)*@YJ<<,Z(5+)C7'3J_;9=Q:,&-48'L
MS*,B;/89,[S$>7%G3:8J*U1M>)V-FOJ5+F%:_"1DO%1#N!BW-29O5BL@=)D5
MXOW>T3J-VSUWH;%+OA$+ \ZV 94K<*IK ULI<.RN5&K3A5-N^;9?9[L#R\<_
MP-A!!63&0(! TSA-89<I*E;R;C^@U(\9:=N>4+-6;K#-(>V+Y#FX4UCIU<A[
MD\7>VJT3F5JS.15M>2BDUWX=LHE_LEW;4_?3#ANF;X7=G=O.C6M_;UVVU)HD
MHS,F(\#(RZ2"K$8LH;"3&YLA+@4$&VT$09S&.>(,S,B<I%>J;^F,>U]&@1:$
M"P>,FY[/NI>*%46*Z</DEF^U-VSDCKL)>1:3B;]G+-Q(J@BD1N)#)'1;JIJE
M-\,_?,.PNEB"@.R .$8_&SP&G$',XSQG#1L5G;V/S3?!]=K/F1[.';ZO<3@7
MZ9D#@8#*+7[**CH05[NKG^8UH35#JZ2Z 42:=.GP:::CIKQ^<.K'_6BUFHL6
M8[O)MD?76VPNA,3CJ;_F-$K8BF6[8L665[0'L%N(B4#]/=<GHM@,4I"_YU2-
M2+F*'/0 -Q?MF;X3<*F(%NW/8/,7[8]E0X!99XD_4:E 42G(DW5 %B%Z#G[P
M <JADC$,41 P"'44Y0,'N$-?'CD&Y%S"K%F O"M6,14 H8[@INH*1,=+K#-I
MV" D8E!_2I^89V>89R:J\:F@BO R9Y%JJ)G,>*)3*")UT' @ <>AZW=MCJ=R
MW<4G;C3I(]\*44K!,R(. :<,B,ZHL)%H,L:\9Y'$BK23RF/\MTFO9"H<'6WT
M]1,BU%"&LL3"R5:L2SN1I,NXCX*95:%BIY-W'1:QO*&*DZ,F!^XV*!1$53;7
M&Z7>O6&-VU;N6V8K.I 1<7Q+^'$B3BLP QFI\Q1=",-+$'/(Y9'C]=*MRPHO
M%42T5_&\-5I.&D:O8(5/'EJ;%-%$2D8QVU*SK%@,W?2%<2ZU *#18CM@!1$J
M9&X#U!GV^XV=[<(N_P!:J'4ZTB1XA)9<FPG$:6[\J'1S;/E@'#(_8>%%ZN3#
M67J]6HVRT*LQ$ZK'1=C8U.RU>'BY^)D%XXAR357D6I00<KMTUS$!_#.E2D 1
M)W"ZB7B[<[/==,NN;6I[*.5UJ=2F#$,",#V. >,54K^8@#  D9$0?1_"D"N4
MN0QOD2]5U&M5K(=?G&E<O#)DYAZU%7KM&B4*9-E1>^180%J&./5V1E =?+UQ
M!VF)UUU!$!NW%W9;[8VKQ)L;E2Z$B3;..M21BR2&;+4/"851E #I=*GQ" 1E
M/(]A@CC&>=(V2:;AVU+Q^4*Q7HRNY(QU)M)6QN6=2@X/(+:HD;.X6SLK!7YJ
M#76GXF/@Y95VB1RW<-51:!Y58O6!QLV/Q6SG9[Q!=VFX4JIG4FO VRKJ?"25
MTF"" TLN$5-QQBR^\N? @<<.['C-,7-63MOM!L^,=N.Y&&QP_EMW!+K1L32=
M6IC>7>7Y>!K!IJQGE:DE"R2T.2-AG"2Y':3IXU6<K(I)@511,IZ=HA5OC^F,
M;=ZRRLR7"!&.2M(#<B"%(&?&G)"L$N '5@"!V<1P[YQJ$*7NKVQ?RLI-[J5F
MK>426L<CPT;CM+$%QR#*W$^'U"0^0'>/(VIX^L.2X)@NT(F]08R,>^1*U7$B
M22::1Q+LW2?K%KJFQ9(#+=1L8),!@ITNRMX25TMA)F14!@%!B3RCVCB.>-13
MMIW/[,,LQK^GX]D0QDUL%-L^3:*EE_ EHI5+S/AN%\I'6ATC7KY6JFQN;BN?
M.4&8S57=-G4TP71<=3A9-\BE:X-Q1O0!?M2 Q1H97GWD(!(5O>BXC*K2,!!J
MM75I48<I&!'W]QQJ%[+D79E>!;X?N4A4J0U;1^.K#C/<$3'MBLVV:/E,ZQ<)
M9<<U+)^0V=6J33 >8KQ#V&(>-VSV1K[R69/6+A4#21T3GZVTZW;VNY&ZZ=^N
M+@_4M%0+BZ>*SK2XIQ.E@T&0/"8K,R!QY;^$\#FN//(@_0XB:;U,]8O;7A2L
MQE6R-9X*Y2$NW21QE:Y[&=JB%+DS6E6E=C+!3KO*8WIS+<'67$DX0%)..8L;
MPY(NG_L9,AS2YNHWRKL.MENI;(/L]LH+7 0RH0IA@%8GR7U& "[6.*L@BW5'
MQ5RT#;<:B!RQ]<>(>IN$'.H]J.\G9<ME[),G9Y&W9LW)R5@J=2'#W_:SFI5Q
M7)*V6YS0:9+9W:Q^,>^WIZ5Y>*1L12JN@](1(%2%&>?.WLCQ/4-RNVL6^BV[
M:[3:6 2UXD:B"?=VK&-;.!XK[DEFR%JVJ)4+>++YC^)R8 @Y_P XS'"%'",2
M:W"EM\&U/"C&+A$IRQ7G/]MKK^[W3*][VNY<I^-MN%<MUBDJ;+9>R[#/\?)E
MPY2#VJ"5;),I-PE(22;%)!T\0CT"N6_E=V+5S=>?U-?A>E6U!6VC:[EU5$J@
M<8%F$S<("KBP4F0=-NZ$'@\5X\2L!9S)' >TX214OYDW,;/MA:M3H<VW=YQW
M'V"HRTG'0-6QM+WF?CZ1#$)(7+(%M/CJGW%CAO$#&2<%>SDDH@=14ZP+K^<6
M+W"TI8O]4#[NX1L^BE@<)(DY +*FZX& )A1P*BKM:6("RUWN]/"0!W338C-X
M.Q3 HW"2RG?;!F&YXZB+5E^ZY#H^VC)UVP_"F?8YC,U6!_CVYTS'TWC%KW<:
M6J-72>FF%GAX]XT;"X2*J1L%%WS^J;A;'2[?D[.["*"^8& \QS .(D@0)D@$
MXU=;4 @DZG!,X9GL%80&[';'9$[5GC<P6P;>:@\QU>K-6\09GP=D'%W<PMA>
M4JKJS7BT/;9CVO/KDC9Y7*=?.2(C2J,W2[QI'D"4<H*%3ONJUA$Z=TT"[N03
MKN@ZB6;"+:B8"JI&HRQ)8C3-1X@S.^"\N&',CB>7#+&FG=_4?VIY3G:/CC'E
M.R\@P<R3F:M98/9?FNR96:?RQC*/?PHC;!3'%[J^0H*Q-U@9=:5FHYO$)1RS
M<A$GAG92E-OMMITW;MO]ZZ/O+H*6[6HYL#JN7"1@%7 */$6:=2Z:1KB\)B<3
M'L ^W+*IC1W^;%*%=I[$E3JM]M&7?KVMXY?1[C;ODAB>XYYMM;@YJJXUM^7+
M=18VDPV3):,L+(/*RDFU.U$3MTTRF0,W)BV_3]YO[GG&[;M;-3#,6TK;&9(5
M<6 &,*"3A.<U8C ,8!U<HS[R<JW$QSMX*C'LI;+D;5+3:E9Z5NS^"CX5B./X
MNTSTA\V._;-'+8KRU3%<#MLV#^0 "MFS5+RS= Q0.*=2WVSN;ADZ<K)MM(16
M;^H541XB,%#>\RB223J8T]NV0)N06DG#+''T\A3^3A(&\9 :F;Q$2K6<;NG#
MIU(!%LB-IO(#^-=1:3%L)4>VZ0I\'(N!=";J*5\\2( ]UJH!,VD['8Q= ^(O
MQI'Y;8,ENPNP 7^52<F!-BD%_P"59]?+T?7W4Y[PM 5>*4>,X*'<SKE1*&JT
M0+)BF$Y9GY3A#1:8BC^6519,3KJAIY9JFJL80*F(\5]/VQW-T@G3: +.WY47
MWF[>0'XF(48FAV"@GCD.T\!],LZ#I-(94FLPT&NDQ?RZ;99S,R16#9,LK8Y9
MVZE[+,@EV0*0LI-/EEM!Y@02@(CIKPMZ];O;AO+739)\(Y*/=$\P/6:%72(.
M?V\::#2+:WG)J,V=DT4K.)?F\?&O")IJ(2N0I]M\MFU68= D<(5"MN%V)C\R
M^<D5TP #-SAQ==5-KLP6!\^]#1^6V,C_ )VQ'\J@Y,*CWGG\*_7Q]0^OLJ1+
MI/(TZO*OXJ.0<S;XZ436HM)--N,U99/K0A(TQDB$_*,Z#N+F_A0:IJJF$"D,
M/&7:6#O+D$Z;0&IC^51BQ] R'$D#,U+M"R,^7,\*,4:I%IU0@*T+T[][',BJ
M2DHH ]V6F7BJK^=EE-0 W=EYETNY, \P,J/#[C=>?N7NP C' <E$!1_E4 >B
MH1="A)G#UGCZZ9K10]VR>M()G[E<QBT?PS-RD8IF\C?IY!)*;,@;7J,>I5O1
MJ)@#H[\HNGKUHG*&MD&SV($?K7R&@\+:GPS_ (WQ[D!R:E!UW#'NKA_F.?J&
M'I[*>5VLAJ;6WLBB@60F'*C6*K44 FZY>RRRY&$'&B!3%-VEWZY#+G#_ $FQ
M%%3?"0PADL6QNKZI.FWB6;\J@2Q] !CF8'&K&E%GCP';0U1K)*;58*ND<"]4
MCF1@?2"H#WI*6=JJ/IB44U\%966=+.#A_P RG!?O_%;A[T0"<!R48*/0H ]%
M"IH4+R'^VETA]2B(B?EK\("( /+[.7%?UU-9I+F4$/RP Q $"F$/B*40#4"C
MX@ Z!KI[N%TC/A11DO4&O3TDZA$1#4^FHB)C#T@;I 3"(B/O'QX4Z1G1,5<0
M5'Q. ?\ EZ@__:X4,@X34:JHPKB @!BA[A .?[QXD>73:NVB_2]*.OF"" ?Y
M!3#4?LUU >)\!, 5$FJ!5PJ/0=$"%_YM>8B'+4!#P'B0%7&I)-,_(=TJN*J%
M=LG7F9-!T[']6GKG:YE87*Z,57*U%NIB:D!;-B+N%O*1K-4_0D0RJFG24!,(
M )J![JCMK7&E;Z=LN3:I6[95+M(2D!:-N%DW71@JURQ,7:>':7+,X*VRLJR=
M,D7T79*U8'@,'D(X*G)-WB2J1T0.D< $Q@K&)BIX=E08]]5S;!%3.38JP0VY
M*N)8?Q[!94NMAF]M^5&-098YM[J59TBVL[1\A4AY*&OKR >(PJA%1&25:J$2
M 3D$H3'@%R!H;+T4>FIBRAOQV[XDMMOQG,N+[;,J4^PTVI(XMQEC.V9%R!<+
M/>:/+Y,B8C'U<KD4_=VA:.H4 [E955$2MH=HD"CM1$%$NLAFQ&7;4@5%$SZL
M.SB$:$F%Y/*TO6HV@*9,R!<H3!>4)^L81J[6X6S'LJ;.\I%U9T?$4O7KG1)N
M/DF$NFW=QRD6Y,NF1-,Q^(90&9&9 RK)&H3&.(&9&&8H4$L%7%B0!WG 5E>/
M5(VIXZZGK^+SA-P2F;7>WA_=:1MZR;=*0CFMID5#%9:*K9H&ON(XTY(W1TDB
MS HG%Z@H5REU(#W AI 9C^%HB<<@9@28(.%2UMD(!$$B?1B/7AEG2DP]27;D
M]J4UD*/QYN9>TAE-1U8C+8AM;R_\DOMIFLFQN((2L8U>C52(Y"FIJ]RJ;9JA
M%^9!5$BBW5VDCF"$<7$U(1IQGL@Q]>%+I SJ5X7>QMO?81R7N"E[%*X_QWA:
M4D*YEYEDK'USH-^QO:(]M#/?I*T8VL< RNS.S2;.S1:L8S19+*2Y)1H9EY@'
M*74[8'2<XFH@^BH#F?53VQQK*%9MJ)N2ELB3.06N-0V_M-KV4PW&Q\M)T:RY
M-A9N3PQ-0L-=&=$L%(I\E(,9SL'CEP9+(E4[Z*R2=09F4OI;#LX3$]TX=]-'
M"1_&)COC&*RG_4$VW76,R_2IK'&YJ&B:+2I]QF>U2^U'+R=,Q2:/PNPS;*Q%
M^O05MU4Z]=JU1IABX4CEG8O$9!9%J!?,'(4;]O<9;JN@\2D&#A,<(XCGV4I
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M;0[U&7I5]KZL@S=0CGLQETI<TR7&.ESQZ@E71?Q7G&XD*X2!Q'OD.V*A1UZ
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M!W V=SS?[#?9E34Y>TC/$6W#^Z'(NM)9@Y,,%) K5=N7.H6_/E/C[8$@#2[
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M-=]O^*[:9!'YA#*/2R@#M-6W?" PR!!]&1]AFI33'0H ?^),I2GUT'00 /:
M!J B&O'-99N2,C4S!J+\?G+$3E[HZA?+##V-S:H;40Z7E>O+AS-^83UY:-;0
M>3:F*'\ )$$?XPUZ74&\ZW8W69:T$;L:T D>E-!]/92V\&9!P,CN./UR*"RY
M#-9"OQ\^O ,[$>FSS:?7BWD<C)$>P@-GD3:$2-5B'*LY+5Y1VJW*!3"+E-,
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MLLRP.?F%B?O:,YE7DW-S-FFI!Y-+E\C'$;MAXQMMMELF+]0N6K^Y# PFEPL
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M',4OL/3-SW4]P%:S77=S>&)V&KF6LR9V@\89,VSV"SUJGYBS];EYO)&3::M
M9ZJJJ5W1JCI6NP$A*)R7R&-<NS-T^Z]<F.B6V!8DDDF>[ "/95ERX78'\*J
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MN[13-QWMK\U]'W]D6;]L7$?4J_&Z?,15/NV1:U(R(QA02CH3"OB16=]L]L^
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M$+DB3NUEDUG5Q1L<+<YYM$(LXYC7823EXE9RC"J+5UHT?&C4@;IM_. 7M%
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MZ2[55V]CRL9)JLS.+9T N%&IA.LDB=1,HD_07[%6KS/9,CRYWD<88+M5;#'
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MGD >^DBRP]..U^I<PY,Q!$>4[SES6I2C6O"'G543/3+-IBW1[JKVV\NTTE#
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M;LXJ/$Y)QQ,Z5[V,SP-/KD0HD<\A].Z@#04%450R7D:XLY679I"FE.S:B,1
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MGJ^V6]MUP6]?W <C#)2I )XZ+B''"!2V])PL,5/Y57[_ *P:TDSYZ<]>RKN
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MM1)8&^2A<QEE+A!M3+"I*'QX3LQ1I9!,Y7B27<3/R=Q>NW-PQ4!7:(5<5P!
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MI=*J9#L"<3:7CLA51.820[=4>O05N>O%EVYN+)_^IWSL[3<+;>?9/$?HH3:
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MHML8Y,VGQN6%<GQ;Y\UIPUR7INX5Z@W?M7G;9)1POCF,F<WE7MW[JH6%UO"
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M&P%.WBS> P*K;+8@8ARNI3W&1A3"R6GS#(DYS'J!Q](J([=ZSLEMPH+>Q_\
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M0$VPD\Q2H=VD(I'%4 F3!J!2M!T4%B+&T(G1=W(&6)1?3,.P..'@YELJRN[
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MOB)G'2-VAXEQ$(-;3?8"V5%O]28WDG: I6VQ5>=EYC&V+8N+J#&1G/E58F+
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M^8-RFWVY%OI=O2[,VA_-<7'10MLR"GFVS+3:N,KE!;B35BVEV-MKEX:]PP(
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M<?;G]="A;+9&"LG9<=2ZB0Z@:3I;]A;(Q4AC"41.P6^0V4@F*.HD+'JZ /\
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MBW*R9URD-W#IMCFI G7[9B <2AR#0!XD]/W*9J,>T??5-S]B/W63W>F3/_\
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MN1V7;!]&%VEI/UH_2_2+HENBIYET71D 3-2<EBY1=*=2*W2E]#]XAA VAS
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MGS=9N$>8[H%%P.@M+=@N2Q\!D:=6W;W$;<WSN0#:N:M!G3I"^Z 22(.HK[L
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M*%)_U;MFI?2(P)"LV,$2@KS/6K#:^GS!M^;=&9)G5:[8F,<) [<:^F=H;N"
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MX@L3API@.= J$Z1Y>'M_?PM-1<RPI@0.RNIWEDT?R4P4%(%-0[RP=1>A!/\
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M")3<AZOP$P#_ /*(<%%4'2.H!U_>)C"'X#U<N"BKCR+RU^SF(C^_4>"BKE\
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M^\D^C7#M^@BH=QYQTDX>.G[E1=PJJ8Q0)UK'[Y?-X4>=8VEUQ/O(8Q.HX:L
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M^,2:N<.>OL'B:F@O\W_P_P!O!11D?#QT^W@HK "%_P";7[M/\>"BL^10U$=
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M#@HTCG1A&V9#5)U)T1(H"(AJM+.P'E__ *!3:?AQ%1I7G0Q;+?A$0&D 8_\
MREE'A"!_^44;$(/!2D0:.$LM[ NAZ()] Y]N71)I]@"J'4I]_!44,%BNQ^84
M=8FG(2FF6.@^W74R8B/!10@V2X@'Q4-R<?>2=8A[_<B \%%"A/W,0 ?H0P".
M@\[(Q#0!]X=C74 \0X**R^=W,W(U'3$HAJ !8V6NH!KS$[8I Y_;P45035O#
MD%",'O'ZFB#!^'\)AT^W3@HH9.6M@@!CTLA==="A88X5"_?JF*?_ ,W!10R<
MK9C" 'JKHG4.@B::A!(37EJ(I]1Q*'W"/V<%%&RR$[U  UL=/ 1&6CQ /MT!
M,##P44H(N)%3DI&%;!U  ZODCCI[3!VTC:Z>[EKP44I_?X\%%5P457!15<%%
M5P45;G[- #[O^'!15:>_01]^G]XCP45B<IC?PFZ=/#X0-H/O\0]G"E2>-%8]
M"GM5U^XFG]H\1I;F:F1RK+I-K_'J'NT#@T'F:*R$!]^G#0>=*:H T]NO$T 1
M5]."@ #*K" #X_K]O!4U6G+3]/V<%%8]!?M_7Q,U,FL^(J*K@HJN"B@E_P#2
M/]W]H<%%(2OM_P!/^'V?>/!11 _\7^3]/=P44I-/X/\ T?P^\?V<%%* >/\
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B"BJX**K@HJN"BJX**K@HJN"BJX**K@HJN"BJX**K@HK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>tv526458_ex2-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex2-1img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@">@,T P$1  (1 0,1 ?_$ ,@  0 !! ,! 0$
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MI_</]V!4! ?(<"N P& P& P& P*<A](?M# KSSY8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%. ^@/V8
M#@/H#]F!7@!\PYP(&*'F'@/\<"!/Y@_7@7L!@,!@,!@," DY\0' CZ!^K]_]
MV!4""'QX^S^_ N8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8$!. >'C^GZ\"0" AR&!7 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8$/7X\<?'CS^O[,"> P& P& P& P& P& P& P& P& P& P&
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M# 8# 8# 8# 8# 8# 8# 8# 8# "'/@.!#T!]?Z?JP*>KT_='Q^O_ (?;@2$
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M Y\/AY<^7B&!4.2 (G.''TC]?E^_ IZ5.>?6'V>/Z>&!=^WSP& P& P& P&
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M2*:[>&1U[L-[TO8VDJ;PT\EI;7VIMJ:PISQL[V6ML,]AJ,-L>O:XI&ZI.;)
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M"ZIL#N@_ZQH6:L6*/WKJ_6^TM6(AL1IKY@\82SYGLQI&/VK>!D%2R:!R,"R
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MMY=U,US$NBNM4W#UT.WNYAU7OI]8*=WNU'R$/24Q!_"MD]JE;M_60W!N"^/
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MDI^9E*%2Y.7M5=&HVB6D:M"/I.RU,2F*-8L$@Y9*.IFO"4XA^"<G4;<"(>C
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MRMVKM=VG6S86)D=>6*EUN9I")HIP5W%F0JTC&NH1 \8[3*JW$B!114 #$X'
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M,D'_ .(5JM.2EYP8Y/\ $E0,"K<JT'"-[EFMHZSH/K-J[9]3ZW2FV;=H6O\
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M@,!@,!@,!@," DY'D!_Z<"GJ]/AQY?I]&!4#A\?#]^!/ 8#@ \@XP'GX#@4
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MRW\O]?9.OLN)ZQ]R3Y;L7';GJFJL=9$67RNEE_2200* ?/(M\SM\X.JHL(>
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MN[7XS:2?:UG'Y\^S/RW>+I4V("KCM_U<03,!A!1;L!J=(@@4 $P@<]M*40*
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MA+E=;B_(-[JW18JQ4/\ 5NT&4,0J@?+T%V-5+Z#>7*B6HSI%-SX" F 0'P$
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M_D#(-7A$C)D,<2 *A> YXR=!Z7EYX#G E@1-_A_[08&@OMLR:$OUWMSY%%-
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M2Y$!YX !XXY](<\?1SQSQ@2 3F^/A\1P+N #P^D?MP*<>//(^?/GX?9@5P&
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M+F0QBMWLH8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8% ,4P<E$#!R(<@("')1$I@Y#XE, @/T#@5P& P
M& P& P& P& P& P& P& P&!'U%^G^W^& ]9?KP)<@/D/. P*"8 ^.  0'RP
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M(Z+15OJSN6Z%XL=$J2'1?MR"R'H*)A6=@OIQ(C= >. ,8?$?VY!P%O<"UJ1
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M*LFGL8RY%.2^  01$! 0Y#QPN/>+R?>5=91R4>EO>\H-U$4_FJZ'BDR.!53
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M/AXYGQZ[Z>+33R3&T\>G#_IF/LDW_<NV_KOM_P#E6]&:4P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M@H !0\> #P .1$1X^ <C@3P*" _ >/U /V8%H.1  5#XA]10$H\D$ #P 0$
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M;^Y&S 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8%!'@!' L8'(P& P& P& P& P& P& P& P& P*#SP/'G@ YX
M#GSP*X# 8# 8# 8# 8%!$ \\"GK+]/[A_NP'J+].!7P#Z Y_?@5Y ?(><!@,
M (<AQ@4 H!\/'Z<"N P& P(&+SX@/C^G[,"/H'RY#G[?^&!,I>/B(_P_9@2P
M& P& P& P& P-#_;.5.XZ5:C<'!,!<RVX7("D"@)G(XWCLE9)4GS2)J<+)J
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M/2%N7T$>C]>3;"U6[']VWGJ=D>&<+=KMIHN1.02"5$%F$FS%-IZ2<"D3TIF
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MH %<E&D;'.5X _BP4[*=G%0<B)@.!U_F;B-\U0AB@)3#R8G'W1#'=3-<?_\
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MS4N_ ;+EY*'@<H@.,TRO&]O/KE\TJJ$AV19B42B!6?<WMT@G]TXJ%#TANP?
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M- ?:W.53H9U[.1JJS 82W\H+?+!7U!LJZ =90$A,F4SDX"IP41 OKX^&>?\
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MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M5Z?$?4 \CEF]O**Y(=#HM-(J)>UO>\Q"*%.0QNU-V.KR!3!Z!6.@9=5,>>1
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M*& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MP )A$W!#*B7CD>..,>*77P>/6S%GBTGTTU@WHS88# 8# 8# 8# 8# 8# 8#
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M)MD^MVHCHOVR@*MW15Z7$./F)* 8_J)ZE1#Q$1\/$1'-[;_N7OX<1NIF0P&
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M(XD^6H019]D=E+T15!5%9;N9WS<BDU,T%,W89)NDL!SJ'!RLDPI+,AG:?S.
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MJ;R2Z^S%<3NE8<MJY#MY.+>.:_\ A%U?P;2-$+W3.9TXSARIG#H;;VC.^,3
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MK/=N3G1# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M$)/MH4]A-KHLD&Z*SY-0YR&_$.06#X3SH/UD;ZE[ Z?I>O&.OZ_V2U[9M:[
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MZ%->PKV!:%1E&S$@5YI4V4-&2K%K)(L[%7&2=$AE BI%-W&G<Q;9<Z!ET2*
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M@B04T@ZI=>?ED$OI])/])*CP''I*(!Q]09TUF-).DD_!=_U7XMLLTR8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%@?,?M' O!Y
M!]@?PP(B?CD \_W8$"_>$1-^KR\?V8&,-J;EU/H^N$MVY-BT[6-86EHV!:SM
MUGHZOQSR:F71&D5$LEY!=$'LB]6-]U%(#J 0ICB $*8P),\AD9L)7!1.8ABB
M!ON^H0^\7@! Y>.0$ABF#C Y?B40\_2/AX_IX8%S CZ@ >!_;@2P& P& P&
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ML7G?BVJRH8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MZ=KF]:SIR35-3*NX6.'@=5=4!,8?B(YO2VZ2[?JQ"<FT&:# 8# 8# 8# 8#
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MZZ;=L%CJFL=Y:KO]CJ<FSAK!#5"]5V>?1LH^9F?M&1T8Z0<?B%EFJ1S "/S
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M+&91)HR0?"FHR5;NV+H>UQTY'#H]@ ^Z  /)A^(\9 $W'P,/V%' IZ_^J?\
M]D<!Z_\ JG_]D<"0CQX^8?0 >/\ ' K@4Y^W]@_W8#D!^G]@_P!WC@4^[_R_
M_1'^[ @)>1^Z \?L_9S@7 X\@Y_8/]N Y^W]@X#C[?VC_#RP(F$>/ !_5_#
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MX"!P^@3>7V!XCXX%0\?'DX"'/@/GX?5] X 3^'T&Y\O,?U!YC@2 >?CS]?Z
M 8%> \OT\/+]F!AVBZ TAK&Z778>O=5T>FWG8:Z[FZ6BOU]A&S%@5>2*\T_%
MV[;I%.1.3FW2K]X1/Y9';]0SE8#KF%3,7?A?567^3?5ZOB'T!^W,R[6\!4.1
M_F^'EQ_'SS6MMN*/@6NL5^[5F?I]LBV\W6;-$OH.?AW0J@VDXF3;G:OF*XH*
M)+ DY;JF(/I,4W ^ ACON>,X#3EO[:O1QH_6E6W7^NMWJY%"KJI6"\IE5*H0
M$SBJW+:0;G,5,."F$G) _E$,W+F'LMA[:O1@C4K7_;S52M14.J)#S%R$QE5
M/R90YK**B@\''T^H1]//AQA.2XX]M;HNX/&G6Z[4\#1BB)X[Y4E;$ 040-\Q
M(2E0L*95 ]7(F X& _(^KGD>1E<>>V[T>>/S2SOK_5U7_ @9T,W<BGY$GH 1
M EE*3UE+_*/'J*/B @/C@<-K[9?15FS>,F77BKH,Y(# ]03G;N5-R10?4<BG
M%HY%,YO$2\^D1\>,2XXP6C^V/T=-'?E?^A34C 3 ?\(A?]JMT@,!A$#$%&\I
MF()/4/' ^ > >'AEMMYG-1;VQ>C2Z2*"FC$ (@E\E+Y6PMKH* D'/W160O::
MRG//B)C"(_'&>@(^V1TD0]!DM-/$E4D_E).$]K[I(Z22#C_+3>!L7\4D0>.1
M IPY'Q'QR=?845]LWI4LH#H^I94C@52+&4;[BWFV(JJGP!#JD;;,1(L(%( #
MZP, @' ^&9N]D5;<^V3TJ>" .-33YB_-%;T);LWXW;BH)O4(G00VBFD<HF\?
M28HE]7CQSFI>"/HJ>V]T_,04?].K>5$P  I([Y["H(\AX 844-JD3]10\C<<
MA\,N;C'0RXI_;4Z>J(BW&A7P43& XE+V-[+E. E 2@)5";@*H7T\_ 0\\6VD
MX<8OC[;?4<4 ;#4MHB@4PG*0W9_M,82G$@$]13CNGUAP0. \?#GP\QQW6<5S
M<YZK7_X.#J<9VBY- ;G!RW*=-!1/MQVY3*BD82&%%--/>94RH^M,# 00](&\
M0\<Y3R=!RC^W/U=,98PH=@"_.X$2D[F=QR%2$IBF S?T;Z 6X@)0_DX#.EWG
M+@+!/;AZR)E.5)QV.3 Y/1X=T^XJOH#GU"9(7&]5O0<P@ B(>/ACNSSYF;S7
M"^W9UX(4A26+M,D8@  *)=X.Y*1A]/J OJ*GO0J0B4#"'/IY'X\C@[JO']O;
M0AUTG/\ 5_; JB*8)E$G>;N2!!3*/)2G3_US%,X%'Z0P9"^WSH]-8'*5\[;I
MK "A?67O!V[,!BJBH8Y3%4W.<H@*JHGYXY]7CES49;U/UIH6F)]]8JI:MY33
MV0BUXEPSV9V)WCMV"3;KNFCPR[.O;-OUJA&,F11D0I':*";DB1CIE.!%#E-;
MM;Z?0;"$#Q^S,B[@,#5WO"J5#I7V_6-_*CU=W^J;QX^ZGJ>VG'QY#CP#,>23
M;Q[:[?ILL^PRKI5-)+3>I4D/1\A/65#31^6/*?RB56**GZ!#P$GH .!^C._E
MF/+M/_-?Q&3<YA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,")PY+]GC^GZL"A/(?MP,7[G;2C[4^U6,),+5Z8>ZVO;2+G$"22BL-
M).*O*(L)E!.%:OIA5Q%O#$6*5J@LY$2<)$.IZ2C9S'YH_9TAZ[7.V3N(DHS2
MK>SN]:H/*V"]V[E1NS8;^E]?4^FWAWKVA=@]0Z]H<NCL6P,E[%9U&"ZC]H]E
MUC@44A$V=M_T]?LMY\>;]"/<HMR/UAV]_09$36H:PD+3\1/+51HDQ"7C#6)=
MY:V[IFXJ[)M7 =J+22:@'8)%,N4#"F!3<M<=TRC#O1'^@W4?LN8H+FD/(UW)
MU]@]=4GM)<NR[;\='-Y50J+]6XU>LNZ:H#9\51'TE5&324!41 J:8F;9SQYC
M?X1\ 'X>H Y^'GY_9SF1X [O1C5>W]V8L;E>5H@^Z*I_J)2TDM:(.FD--VWJ
M1*D<PI9"//;E26^]42M-H)F"GXR29Q5@<M# 1#@WI\=_+>6<</I?[.G":\GO
MV4_)C>'I*7D! ? 3" C]X/'R-\/ISS.:Z'CXX# 8# 8# 8# 8&CG>;L3MKK;
M3=06G3FNX7;-@N/8*EZ^L="?R"\?8)S7CBL7FXWM#6QDW35L]VH6OTQ48!DY
M];9^^]+8X%^:"J=DRLF7E76_=FV_M2KK;-H]YT76HR,E-6I:YTE:];VUMMSM
MQ7MT;FLVN8^SZH836PX:>@E*7"MVR*3-O#S*J]CBI)*4_+VID_DVS!9A]"X^
MX%W-T]"6E[/WO2FV7Y=V=I]),EHO2=@I</0&G6Z2A*[)[6L[2-VG<I:8BX!E
M83VR=BDE$#EB89=%%=,JAG*+''")6OW#-TL=\ZDU%1^XG6S:M!F?SK^H=STF
MLZ2HL/87,?LJ@PZT)%2.ZNQ]8I5MF(*!MJK5Q_0[RP*G<)>+0CLBC8';PZY.
M#UPVW==AV'J7L/8^M-B5.AWJ'H]PND#<*,2#WA54#4C\UE#1S$\O'Q$9:&\N
MV@C,W!P005;J*J%3'YB13CF<QY9J]U.]>M*\M#RD0AO-TWUA[>^S+7MIG4:/
M066M/]SVY9^#V)7GNNDI4LS>EE*M&?EL7^4)*K1RI".7?WE!$;9(U9,^SM_4
MWN;OO9?2;L;N2P[RU]<]Q4W2<1=X%$S6B6V,U9<Y6C3DJH2[:]T#6GNPH.$B
M[(@4KAC+L7DNB@Q6Y3/\E<#1,5@"$]P?M3)T;7;=KMMW)PK^T[(K6X=[P6IM
M;;12UO2839O5>-=[8K=HU(WD]0;2A]?5C:DRT4FF,.QCFIG@*R\,1>"D$U/)
MOY_+/Y6OA\>N?'=;;?3\TG^:.,W[^]]XRHSVSJC$W_<FE:YK:<K"SM_I^BEW
M/(7.P]CK-1M6=BZQ*:T3?:FV5JEC48]NQG2Q31K\^.5)/(L6Y47**O;3;?R[
M[^#673R8\79M<769VW_<[O7\LULQUN!V2S]UN]MYK';ITW:;GZZM&CYMNOI/
M<V.BM=33*]:.CMEM]%S=.GV]HA]FN)9T]0E:_?RG=QT#8D4K*9J0BC.-4,IV
M\>^GDT\>^+KM?U2\Y.Z_?$SPR<.CNV_>WW:W4,1NO3U6N>P[EOO56Y=F/*\=
MSI5D_G[+U=@NE4A=*7L![(5_6B&MW3>6[#':-?S)FU*)Y<QHP&QP24;!P\U\
ML_C[;>+$\V>'7EM,\.?Z,X]QA*X=M.]]*NT/KS:>SK_IE&#V?MN$LI;,\U7^
M:?THUJ77F9UE(/-^USI%?=77J.MZMHM3V"0AJG#.2()+,9%]^.C3I9Z?R<;/
ME]?\?Y.#T"[B&[40>[*#9.NFU-Y6)%YUD[,[:@-'145K\-17S<^CZYK!;2M'
ML]G<ZJ7MT-$[:E[M($E&"D^S4DOPY19':?AU1R3&.),.E]']F[FW59]G:]'L
M1V)V5KR6ZXZQLUJW+>]/UG4UXTCVJMLU;(S86M=;I2^FZK72DA(-DU?J0$E$
M6'^F%TTDUG*I7GRL7&,SGF?3K]"X:EP6]?<LI^DPGZ7.;/W=9K;T\WEMRPRF
MZ8:NT>Q:LV=5-Q(4J#6H%5JO7S\%>)Y"GLC+1]1?ILB/53&= Y,FX(">OR9X
M\.,^DSGZG!V&)[5=OY#LCUP3M.PMN,J].[=M%'<ZGK^J%*^O;8E/N1O'7$A.
MR!9;24S6-GTFO::A($LJLUN5/F*:R9A.$2FBOP*KC;MS^7]/Q][P^4P<,>[O
MG8_L[[@,+V/[-NJ)1=Q5/JTKK:Z]<]'[)8:>C;_'T7LK3=?+;(3[!KT"!B[+
MNNR4>5F33%5%^,&_KACQ4>NT(Z6<';N(<,>[7"'[6=PU8[KE+I;D[#24 WVK
M<:\E&1FOVUEFM_E3VKJ]O$_T/LDW4NM5/>=/B*5*SD:,;/1>GII9(RKXCUPK
M&?B%-^/67R2;8[+9+FXDSUMY\/@CM]6[,=[YB?U%8+I)]FTK@IL71L+0-:4_
M6,?":^VYJ:=N\S#;RV)?'!]"7-E8+)713%F]A'4Y03P$ @VF&S@ZBWK=_/\
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ME&<I_-;_ .U?L"#A/UE2]:!M46PJQ 4.=,I!,F(@ B8 #XC@9QU.*0ZLUH*
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MHK<6Y#1*<TMJC4E_V::!%RHQ3ECT:G2]I&),[_#N%69) T5\GYORCF3 _J]
MB'I'&LS<>J/-SJ_[JC3L1V&J_6RQ:@<:BV!8)OLF^CXN>LIID]SU!I6QI5>H
M;JH+EE!-8^5K%RL;.5BY1JNJB[K\O$G;J@J5=LJKU[<? ]V-=8^[!L5;4FN>
MR/8C2L#K#K;=;'!Q]IV%&(;QC5M90EQI6P['1;%(N]F:@H],O\+-VRI1E<5?
M5J6D6*$C8&0_-,5='US:<."XXND%]V/M&O5.REQ?]5*U4&_7:@R\],5>?2[
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M +<\)F_#,GXV3XT=4IGN*]0-A.ZPTH^T9BTFMT;$3<*O$:DW6[9&K]@?R4;
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MJBD J)(E,JH1,!574*DBD!CF* JK*G I"^9C" !XCD97$QY+^OR'SP+F P&
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M"TU'MX#;;VIFO%;@U8*KMW)8Y-4([YOSR%3^2J8@6[\.'1;Q^#8+6GM^]?\
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M,(V.>QARE=LNICKT?=NW97W.;)L;_3>.K]FU]./]V7"NO:IK)E29QK Z_:;
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MB(_=YX^&+KQS+1=]/I+]T/(H%#[ \OMXQ-<<@*;GP'Z/VY<?01-P43?=Y]?
M&\@\ #CS\_ ,S->8CZ@'@/28 +Q\1X$/HX\A\OCFL<!> 0'Q#**X$#% 0#Q$
M/3Y"'G]8>'GS@2X#D!X\0YX^KGSP*_I^G.!$0-Z> .(#]/ >/ZN.,")"B'J$
M1$3"/B/T\>7A@2$!$ \?'GGR_OSG=+TJG' >8?:/E_'+-;)P$1#U (<@/(A\
M1^GGZ1X\LQ^:BI0'S,  ;CC[OEP'/'/T\<YN3;G42X\Q#S'@/$1XX^SRS8H
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MV?#-,)8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8 ?$!#Z<"A@]0"'TX&HG?9K9G/2OL\SID.UL5G<:6O2,'"/XV&F(^3=GA'(
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M/0X=('^4!2F,667'&)BX>I"8@8A1* @42AP ^(\?0//.91/ 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8&B'N<FC@Z&=E2R[H6<0K1FK>5=  F%&,<V> ;OS^@"*"I_P"D4/\
M= HB;RX\<<UG-O?A# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8%!'@!' U![]6T:+TU[%VXK.4?&@]93;Q!"'N-JU^^!R(MV[
M5<+G1WD=<*ZT9N%RK.7$:NB\!LFH5,Y3#S@>6OLW6Z!O6R]X32^PM-;&N%8B
M'>MRSL!OKLAO;9DM4:G<@:Q]PAU]\6&=:TO2]Y?>I^T9QYU7#AV*1W"YP3(
M=+;^S.>,_+_)RX/6KMI/Z2A-7Q[;L#3$[WK:V7^C4Q[$+0*MC38R\]-II0-C
M+&,T7$R#BO2B1'*3B.3-(-E2%50X,7U!B9Z#628DM=T+JZ2I]7[CL064IN"
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M7EKZ?N:?3OUS?E.)&^&= P& P& P& P& P& P& P& P& P& P& P& P& P&
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M<%'/CXW#,SG@UVN=/7H/3!Q>;S0:?J>LZVW=([]H6KVFZH/3B;VG1.MI0(^
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M>U/&[%-9)NH\7:P4H_72:$<+D(*AB@0#G*7GD0#(,E8# 8# 8# 8# 8# 8#
M8&B'N4 4>HMJ*=,52'VSU7(=,!,7UE4[6Z3(8HF)P8H<&\1#X9R\LVO;-?\
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M P& P& P& P& P& P& P& P& P& P&!8$>1Y' I@72#R''T?PP)X# 8# 8#
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M34D':(12'C'T7>SZPJRMH:R]&=K-JJI+3<H9:$<&.@"G(+A+GJ/4@A@-Z>1
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MDMVF%5$H 4?+R'Q'^.7;68RB*0^HOZQ\/H_NQ)/D*G _(>D0X^/CQCMHJ8P
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M'76\0E#N)UJ17$Y2:EY[KQ9.S;1:H, NYBR[#_3BKN $RIVJ@O3)E*0R!_Q
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MR_\ E+/V55KCM5!#Q,X4*"9/OF+G/R:3?;3/Z==Y;\CAU;3YT# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8%HX>//T_V8$,!@,"1/Y@_7_ <"]@,!@,
M!@," %X-S\/A]N!(1X^S@1_9Q@>8ONJQ\Q,:"U?'P]9IET:NNS^D1L%/V;8_
MZ0UC::TVEI9[+P>Q;*=G)-H>G/BMB@Z67;.4BB!.4E#>D@V8RLX-A>IENN]G
MI\L:XZ[Z\:Z0AW["+K\;URVHVVE5'$6G&ICZGCIG1:*W@7#0P%20:%17 R
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M.;R]9P=JZJ^TAO[4+75G]2[_ .C2)=S=1M\Z'T[,5GL8PE!W)<;O":=8U\M
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MU2=+=1VO1O675&KKPC'M[?4HJ9;S2<4^3D8\KF4MU@GQ^2]1(FFY$Z$J43G
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M>:W7:;=M_4["!2@'  ' _1\<,K8)!ZBG QO /+U"(#Y^?CX^><[I<JN&'CQ
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MDZH>N*L86D6E*-)%YUW:JN =$82T:=ZD?\ZDCM%S2>_W/S=]XRWC/7GP^_\
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M<^/[1_9@5#@0^K]/# H!2ASX?M^&!;#Q-X?3X?9_T8%[ 8%D0'GQ#X_1_#
M01^K[<!Z#?1^\,!Z#?1^_ >@WT?O#^_ KZ#?4'Z?5@5 G \B/E]&!,0Y#C M
MB0?MP*>@WT?O#^_ KZ#?4'Z?5@5 G' B/D.!<P& P& P& P& P&!$?$!#,=_
M'V%!Y](@4?'C]_\ 9SFNZ3F./\L2^8CZO'QY#^S'/XBZGR'@'EYCS_'GZ1RB
MZ "'F//T8 0 ?MXXYP*_#Z<<^8MB;@>//.?8N50'G)=,<A/.DY<4,HH7CCP\
ML"N P+9C\^ ?MP+>!,I>?/P#^.!=P& P& P& P&!00 ?,,"GH+]'[Q_OP'H+
M]'[Q_OP)  !Y8# 8$3%Y#Z_T\,"S@7BAP'U_']/JP)8# 8# H(@'G@4]9?I_
M<.!7U%'X_P!G\<"N P& P&#)@S# 8# 8# @<0XX#@?' B4HCXB(\?\OAP/''
MGX?5@7<"'RR"<%!(43@ @!N/$"C\.<!Z"\\E^Z(>'/'/F'T?9@1X-ZAX$/5Q
MXCQ\/L^&!$R0&$H&X$>. $  ../AQ]&!,J1"^0?;]>!<P*?3]0_V .!7 !X^
M. P.&Z;J.$'"1512,J  0X>(EX\?WX'POR^:&992)91VTCFT<Z8N:^DC&+QT
MDY65;':RZKP[+\W:O&)$E"%327*@H58?F$,8A#!<\,+GACJ^JX:&44:*D\T#
M&4]7/_F'(4AA^/\ A#C(CXDRI</SRN(PT9 O*TO^9!:WDE*OF,Q&^E-J,2>!
M9-XYXTDS*J"L"Y%U&X% ">DW(CFIVXN;>[HU)IVWNM[^G#\79 3-P #R(!]7
M[<RRNG2 2@/^(GWBCQSP;X"( (")0^CD,#J;-"R/2J(VEE7ER-YT5XYS$.)(
MO$<S0;.(V16;.DOF-I7\R!0JB!%E$@0](_,/ZC$S69/TYY?\73.LXZ6_IXY]
M;SGPQ]WP[127LP^I%H24:+VB@R,[)1C19=1E$RPSU<E*Z[CGCP&,D[8(G2?D
M4!9-%0Y#)<>DQ3"&=?#YKX]-_%?_ (_))+ZS&TVEGT=OX_\ (_:\?D\&W_Q>
M626XS9V[3:6<9GEC%O5]*#UU4*Q8+[<:W QL';]G/8F4O%@:-C&>V68K]=95
M.OR4MZU?0Z6AZ]&MVB0 ! ^2B #].8V\ODWUUTWMNFF9)Z2W-Q\;<N6WF\F^
MNGCWMOCTEFL]);FR?&VUT'_2^RW>"+$;EF&$J^B73]O$6/7DM;Z,\?Q[QLU2
M-*/8^/ED4XB77^6=,[<KB0;)E^^F<HG$I=7R:Z[9\/#6]+B_?K]([[>?Q^/R
M=_\ #EUTLF==YKMB^F<<9[XE]8SJ4GI3 A1]0!X /AX '' #R(B/ ?KSB\:1
M $O(#X!X<8$C!R A@0*40'D0'ZO$/[\"Y@,"@CQ\!'[ P(^L/H']/UX#UA]?
M[O[\"OK+]GZ?5@4^83_F# J!BCY#YX$3\@/F/'PX' B!A#XC^OQP)^L/B X$
M@$!\AP \_#C]>  3?$ #]?\ PP*X# 8# 8# 8# H//'@/ X%L?7Y>/Z?6&2R
M7F*^@?B/]O\ =E^ >@0\A_LR>PB;D/,<F=8!# '//Z>>3NEY"[Z@'R'G'?PX
M!SC7?-P*YL6CAX\^/Z>&!(@<!S]/]F2V3F)<Y.[/*44'Q#C,=]RJ'H^O]W_'
M+^X87   #@,W+*BH^(<91:] _2&8[X)@ !Y?M^.7OU$LO=K>H8[IZAC(8S/4
M,N8&,P,F8&4,!@,!@,!@,!@. \^/'Z<!@," G#ZQP*@8H_'C[?TXP)8# IP'
MT!^P,"N P& P&$Q$?27Z,*>@OT?OP'H+^@X0](!_TC_?A5> ^O\ :/\ ?@4]
M(?2/[1\,)A3T!\1']N%4^7]?[L"H%$/(W[O^. $IA\/5^[ IZ1#R-@5 HASP
M///TA^_SP'!N>?N_OP(F P^8?LP "?Z_U_\ '"?BF(FX\@_;_P!&%"\\#SY\
M_P!V!+ H'D'V!@5P&!0W/'AYX H< '[1^T<"A1$0\?/G[,"6!:66203,JL<J
M:9?$QS#P4/M'X8'RE;'!(<F7EXY$I2B8YU7:*92%#GD3&.8 *4/I$0 ,#AC<
MJD4.1LL)P/CS^9M!+QY\\_.$ # XQ[_2"CZ36^N$-]!I=CS]/@ KX%I2\5'C
MD+9"E+])GB @/E_*/S.#?5Q@53OU) ?3_54()Q\P_'(EY^P!-@5/L*CIB 'M
M4(41\O4_1 /MY]7'&!'_ %$HHC_^EL%SSX>F2;F_:!3F /UX%#;"HP<<VZ$+
MSX 'YBV#[/#GXX%HVQJ,F/WK?"$#XB=^C]/'Q "_OP(_ZF4#GTA<(01 0 ?_
M %:8A]O(!QQ]?E@7B[$I)PY):8E3R#A-<IQ\>/(I $1#QP+X7FJ&X]-@8#SX
M@("8_/ZBE$0_7@2&\50@\'L,=R(<AR8P?7SSQ@!O52#_ /6",-SY>E?GG]A1
M#G^&!4;U4"  J6*+(!AX+ZG)2B(_1P8 'G MC?:: B 6&+]7B/'S_$>/CX%'
M ?U[4/(;#$!S\#/" (_8'I$1_9@4_KVF_&PQ ?0'XD.1^'@'H 1P+I;M4#AR
M6P11@_ZKDHF_47T\CP.!="WU0/'\_C X#G@SI,H\?8/ \X%?ZQK @ A.1P@;
MGT_YH<CQ^L,")[A6B )AGXPI?#S6+X /AX\<CYX%"W2K#Q_]\$4;G_E=)@/Z
MP$<"X%OK)@^[.Q?ZWB9?_P!H2X%?ZLK!C<?U!%@/(\!^.0 /#P^)@# N#:JV
M7C_X_$<#\32#4/V??\<"A;761'@+!$#]L@T#]?\ X@?1@2"U5GCD;!"!_P#[
M1G_:L X$PLU<'RGX8?+RDV0^?EX MS@1-:*V7D1GH4/I_P#BC$!^@.1,N7C)
M;)S$0M%<.( 6PP@#\2#)L1-^YP//ZLG?J+@6>N"/I"=B!'Z D&H_7\%<LLO(
M2&P0H@(EFX@ +QR8S]KZ0^GU#\[[OZ\HD6=AA !&:B!^LL@TX$?J_P [C,V=
M<B[^;Q9OY9&/4_[+UL/U_!0?HSG;TO%40DXT?_MQH/P#TNT#<_9PKXYD7 ?,
M#?RNVW/_ %7*!A^S@%1''QY"X#ML7Q%RF(?4(&_>43?3FIB7.1=!PF/DHD)?
M/U HF/AY@/\ .&=-;F<43!9,?)5(?L,7_P#*'- "B?/ "7_VB\?N$?HR62\Q
M4?28 $?+Z^0#S_9G.]MX2\%5#@/ .?/Z!'C]V9Q/45Y#Z>/M 0']@\#E[9ZP
M4$P!QR)0Y\N3 '/V?3DDMY"H"(_ !^P>?[@SI+O["GJ-\"<_88,G=;T%L5%
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MA^O OEJL:3^1NW\_#U) /'Z_/ Y(5Z/X#EN@' \\%2* <_3Y#@1&"0+X)(-
M((\F*9/^;QY 1$"CY?5@5&":G*8IVK3@P<&X+R(^(#YB3ZL#CC6V1?\ PV;7
MGS\2E\1'[4\"(UJ//_XD>T-X<?\ AIB/CY\>HHX$#5EAX@$<T$OT?*1_X8$
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M'TE)].8[O2\4<<U(K@C_ .YI@/P R"?@'ZBAC:RZYZ>RK(T2N#YM2?\ V/@
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M[8E_7-A,'W:>/J^@TOZ2_7XC'<^'V9.[CG!VT"]3_B T\Q?K"92.(?#P+^"
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=%?\ NO\ @_\ $/\ R>7D7]^=M/TL;<WTLVR__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>tv526458_ex4-11img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex4-11img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *P"X P$1  (1 0,1 ?_$ ,<   (" P$! 0
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MHQ"?ASBD"@_M$BIG,&O%/X6XYL=O<W:ULO788+ZVL[&3MF6-7#*TD#1R96!
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M-UWC;C3F_9LV\.+8EL=S0 EH%41AI ,Q@FB!*([C\*:/X6/C45RX&W^5.5.
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M9C;\][*EX[].&WMJ7+*][;:DAE*]5[LD5S(X4^U59L@/M"@^W'EPQYQ[/A'
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M-15NR5)F!- :A:+,<08JI@_HM[Z3G*!@_.(F8Q0 "@(>],;")0 H 4H:?0
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4Y>YTK[Z=:?9BP]PH6'1P<3$Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>tv526458_ex4-12img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex4-12img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *0"5 P$1  (1 0,1 ?_$ *,   $#!0$!
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M/8JN*IE8U26G_EZ*GG6P6S8O#-%RK2<*6R]P\)E'([91Y2J@Z!T,G8&Z2CA
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M8'TVA=ZMT*^OF&Z9AE1?S$K88S]^*I.+#-2L=#Q\;!/5DHQ:6=E9G<.W+GN
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MVE,<$R%[A*7X (_(.NDLCYP&S.+VCP'%?\=<V00Q@MC8UK25* !3]2GK]NO
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M%6Q%R\$8H>23_5OIEQ*APZSNMM5-@F0?W%3& NG$4Q;^89Q69'3!O'FKT+
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0ZKUC6VCI:6CI:6CI:6O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>tv526458_ex4-13img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex4-13img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *0"= P$1  (1 0,1 ?_$ ,    $$ @,!
M      @ !0<) P8! @0* 0 ! P4!               &  4' 0(#! @)$
M!@$# P(" PT$"P$    ! @,$!08' !$($A,)(3$B%$$5%E%A<9$R4K.T-76U
M-A>!='8W0G*"(S,TE2:V=S@9$0 " 0,# P$% P4. PD    ! @,1! 4 !@<A
M,1(305%A(A1Q,@B!0G,5-9&AL<%B<K(C,[,D-'064G4V\-'Q0U-$5!<W_]H
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MI:V]+2TM:]+F$&SDGJ/<;OR>X[!NS6#U#Z0#?6"%O!BYZ@7*_P#AK1R()AE
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M701DYIV/2XE'7=44,H[.0.GJWV OH  &P:<\SN+,9X1C+L\IA0(C.5)5% 4
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M\#K2\-\->,6"9<LWB;"=%IDR0@HA-,8E1S+@AT["FG(RBCQRW,8=MS)G(8P
M #N&B'<W+'*F\('LMS9F6[Q;,&,8;P1BH !:-*(:4H*U]_?0WM?BKC#:MU]3
MMW%+!?\ M=E))-:U):OY/:/8="AY%L\<:L%7SBZXY!X20R6UF;G8I."NAED"
M+XB3@#5@C^U,XTZ9G$\N+R7:*G;%.CTHMCJ%,94")G..#]C;XW;C=P3;(RBV
M4T%K&A@<,?JC+ZI$+-6D:D1M1B&^9E% M6 5SGO/9&ULE@8MZXV2[BN)Y/\
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'+2TM+7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>tv526458_ex4-14img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex4-14img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ (P"5 P$1  (1 0,1 ?_$ *L   (" @,!
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MG %KSE-I/H>Y85KE-B\B2(&;1PVPM.>TE66?K.A[9@#^?34355,<11!\43B
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M+625:EJ,(:4A2E0, <\$7,5N<?5:3H4G=4ZU2Z>U.I3*H6DA#CR8!*8!)2F
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@Y_@QU)Z:NSQH_P"[MV^N6/5%Q\^,?0O$XF)B<3$Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>tv526458_ex4-15img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_ex4-15img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ )0"5 P$1  (1 0,1 ?_$ *T   $#!0$!
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M6MEK@HK&?PT->8<P&<M!4'R[MN[1(84B$XW83LS@^#=_[;!7D+\AQ3)6\UQ
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MFXO_ /8R^%HZT#-WN,$;X9&AGB9"PLF8$5[20Q7. +_$W<';SN_?V^;6+&Y
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M,JK05'S3?7@  0;!5U3I+^'27_0.$]**CITMZ:JB!%\53P\=]*4JJ[ZJ
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MN#G" RU5A,"P&.:VICZOQ\HFSG)"62IDHO(S2$\^DF)/%<M4DF:B $(<XKB
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2>E$V1$1-DUE^-&MNEQFLU__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tv526458_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_img01.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X ; # 2(  A$! Q$!_\0
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MH'ID9Q7'CL*J,E*.S.O!XAU4U+='S=?^+_$D>HW*)KNHJJRL !<O@#/UJO\
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MT!YCF;S$/X-G]*^AG\*>'G@$#:)I_E@8Q]G7^>*XKQ1\(=-O8)+C0?\ 0[H
MD0,Q,;^W/*G]*F./H5'RSB5+!5J:YH,M^#/BE9>()4L-21+*_;A#G]W*?09Z
M'V/YUZ%7R-<VUQ87DEM<Q/#<0L5=&&"I%>]?"[QB_B'2GT^^DW:A9J/G)YEC
MZ!OJ.A_#UKGQF#4%[2GL;83%N;]G4W.TU5WCTB]DC8JZV[LK X((4\U\S_\
M"9>)=W_(>U+K_P _3_XU]+:Q_P @2_\ ^O:3_P!!-?)O\7XUIED8RC*Z[$9C
M*2<;,^K?#TLD_AO2YIG:21[2)G=CDL2HR2?6M*LKPS_R*ND?]><7_H K5KRI
M_$STH?"@KRSXQ:SJ>DOI']G:A<VGF"7?Y$I3=C9C./J:]3KQ[XY??T3Z3?\
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M+&+6;9IRVT#)"D^@;&#^==#7R!SGWKV;4O\ A8WV+1O['^U;?[.B\_\ U?\
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M/N_F23],5V?B'_D6M5_Z\YO_ $ UCBZBGB=.ED;86#A0UZGRE_%^-?6>E?\
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M\=]XC*;5(9;-&W;O]\CC'L/SHHKGQF+J1?)'0VPF&IR7-+4]@50JA5 "@8
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%7$=A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tv526458_img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_img02.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  %4# 2(  A$! Q$!_\0
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tv526458_img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv526458_img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!+0'U P$1  (1 0,1 ?_$ -H  0 " P$! 0$!
M       &!P0%" D# @$* 0$  @(# 0$             !P@%!@$#! D"$
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MV!['CO5$?,P#2*P<.%C8MPBV(('A)58Z0-DNK,JF^AB)J&)T>B)TR*F !^4
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@&@6_-,?^ 3/]Q@L QZ7^5('\.0_<. 2? &
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M(1YG*)7RS5(P$4<I-!."ZB"9QX&.!1* ^01P#,P!@# & , 8 P!@# & , 8
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MW9@#K+5]TK_>$C[LP!UEJ^Z5_O"1]V8 ZRU?=*_WA(^[, =9:ONE?[PD?=F
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M#.8FF#'/[21C4D^B'5BQ=.ESB?CY0.5PT;E*7H_. B/'YL V6 :!;\TQ_P"
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M=Q/U$R@#P0NE8?(+Q3TQ>@#AE-5P9Q..<I#Y.L,=(! .!P$HB ZWG>XO;'W
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MOA:ZHM\%WIT5]JJ6(^&9O&*5B\G1R)[CVK^$U53UDIXA](?MSL.!Q#Z0_:&
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M.J;)45$#?ITJLJ47U],3G2)\K$.I86Q5^R-"OZ[.P\^P/P$KV%DV4JT, AQ
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M:TDOABN]B1GJ:/F9E#$CPQ7>Q(SU-'S, >&*[V)&>IH^9@#PQ7>Q(SU-'S,
M>&*[V)&>IH^9@#PQ7>Q(SU-'S, >&*[V)&>IH^9@#PQ7>Q(SU-'S, B=KE=3
M41D,C=92C5)B!#'!S8Y"&ADCE+QX]4:060ZTWD^0O$1'Y S#WC(;#C\'Q-]K
M:6C@TUZII61HNGHZW)K\FIFK+C>0Y'/\+C]#5UM1KITP122JGMZ&KI[5T0XR
MO7/_ ,G]15.Q@E7>RI?B)$6%$JIW:"R_'HD3+*RX1$8J4YO(!D5%O\ '(+R;
MNEVCQV.1T%9+<'QM57?#QKY:(G-733+%$C4\7(Y40GK'.U'=Z^-2>X4M-:J/
MQ?5S-:Y$]/E1>;(GL<UOR%>0W-7L[:$JC&:XY?J[6@>!_P &TGP4MML62'A_
MQ3F,BTH>&KR!0\ICNG#@$P_F /ERD&5_YC.:9MD'\/NV;%/MW,)M6MD=YE3%
M'X+)TQ>2Q6LUU=(^1*=G-TJMU-]J.W#;W#Z!URS?())X8_G.A:VF@1?P6R2+
M++,Y?!L;&.7P)!,\H6^=H2 R-TV97*6FYXF65C(Q6T3+$AP#BTAXT#0E7@RD
M >B!R&=^4./#CY1\ML[!]Y]Z\@CW![L<L2MO#N+*"%7314S%77R41BP4\34T
M1%BI4\I535TDO%5Z+=OQM9@%"MLP>QSU+&K]-S::.14^G*_26HF5>?O^6OAP
M3@DPI?Z:/+A .2RMQ1MVU9LX]8Z>W2PN$V:ZXCQ,I[,@"Q"9R"/_ #%SKEX>
M3RAEV,1[2=H,5I8:5]--6Q0M1&LD?Y4+?4V&G2)J)ZG=6OBJFIY#W:[K76-:
M6ROHK/0\D;2PHKT3T>9,LJZ^MJ,4[ JNG-3T=NFVI^MZ36DDR 0IH6M1+!P8
MI0  %5VW:D=+&$ \ICG,8?G')_L6*XUC$20X[04=$Q$T^IA9&J^US6HY5]:J
MJD!7_+<IRJ99\EN-;72*NOU\TDB)[&N<K6IZD1$):-9KQA$1A8T1'Y1%HB(C
M_M$2YGE55XKS-=1$1-$Y'\\,5WL2,]31\S!R/#%=[$C/4T?,P!X8KO8D9ZFC
MYF /#%=[$C/4T?,P!X8KO8D9ZFCYF /#%=[$C/4T?,P!X8KO8D9ZFCYF /#%
M=[$C/4T?,P!X8KO8D9ZFCYF /#%=[$C/4T?,P!X8KO8D9ZFCYF /#%=[$C/4
MT?,P!X8KO8D9ZFCYF /#%=[$C/4T?,P!X8KO8D9ZFCYF /#%=[$C/4T?,P"K
M=G:!H.S(WJ7,<C!3K<O&,LL.W20D6BA0_P LCDI>K)(LRFX<4E!XE_[,R9OX
MLK%W&]J.V7<C:47)(EH,VIV:4EVIFHE5"K>+&2?-2IIT7CY,BZMXK#)"]5>2
M/M_N=D>WU4OV>Y)[/([66ED55B?KS5O/RWJGTVIQ^FUZ<#FN.MMBT@_;47?]
M68VZC.E!:0=_3BDI<@HAY")R)7"*@R!4D_*=)4 ?)%XB7KR='*8XSW#;W]H-
MZIMJ>[JFGOVUDKO)MV1Q-?4JD;>#&U"N175",8FKXI=*Z%J.5OQ4?EDO5V"8
M?NC3297M-*VWY2Q.N>@5R1+U<U6-6JGEJJ\GL7R7+HB^4[4MZ:Y6.4_;L6A-
M*ZHU[*,I-#KFLY5&:=>77(H AUI)&JJQ2YE2&_F YA$IP$#!Q 0SZ 4V [%[
MKV.#*;/0VBXV6MB1\571]+$D:OBDE,K%ZD7@YKEZFN16O1'(J$>4&[N]& UC
MK4V\72GJ('=+H*ERS(U4\/+J$D1$7P5$T5-%1=-%.:Y_]+?4::YW^K]B[1U9
M)"<5$S1LTG,,4C<>)>BFJ2.F#%*/TO\ C_CFAUW:AB$,WQ>(72[V>LUU18Y?
M,:B_H2_SI*MO[O\ ,YH?@\TM-FO=%IHJ2P^6Y4]?ZR+^9(D/+'SYZO Q]<[]
MIFT8QN/^1"['B"F>+)E_E3ZR=C;%T1$OD\DDC_@(9X_X?]RV*)__ )G*:>[4
MC>45:U>I4]&LK)OO3M]I[?XC=K>8*B95B539ZQ_SI:%R=*+Z=(7P?^0[V'4O
M+<OS V(;7'<R>FJ#2UH7V4G7)VK+QRZ%F47!Z,ITXYK,SQ$4V94T!*J!T2G%
M42@GQ*(A+.U]YW9N7QE+NA:Z.A?!Y:0RP2-5)U7JZ]6-EE1$;HU4=JU%ZE3I
MX*I#NZUDV>M:455M1=JVOCJ/,6>&HC<BTZ)T^7H]T4*JKM7HK='*G2B]7%$.
MI/#%=[$C/4T?,R6B'1X8KO8D9ZFCYF /#%=[$C/4T?,P!X8KO8D9ZFCYF 9C
M*(BXXYU&$>T9J*% BAVZ":1CD >D!3"0H")0-Y>& ;' - M^:8_\ F?[C!8!
MCTO\J0/X<A^X< D^ , 8 P!@# & , 8 P!@# /BX;MW;==H[01=-72*K=RV<
M)$6;N&ZQ#)K(+HJ%,FJBJF82F*8!*8HB APS],>^-Z21JK9&JBHJ+HJ*G%%1
M4Y*G@I^7L9(Q8Y$1T;D5%14U147@J*B\%14YH> /-#^F9MOERV1)<X?Z7$KX
M$O222[S8W+8EU9J'L>(ZPSR4CJS!.ED8E=N^$#'/7G IH=8/61:S-P5)(]K\
M,WGQK.;!_#/?J%M=8Y4Z(:]R:RPJJ=*><[1571%T\]$55;[L[9&*YR5+S?93
M(\)OB[D[#RK1WAGOSV]OZF=$7J<D3=4;HNG&!=$UT6!S'M8U;&Y0.9WE3_4%
M0>4R=JJW+GS9U<CI*[ZJ*L>O2:TK$B*4Q+5%E)-FR$\P9NDC&=-%6J4Q&B!B
MN"] "N%/G5W9_P"4ULG73.RBWV[[/H:EW73WBR*RG1%>J.C^*IF(^C5ZKHJ2
MMB;YVNK)FN56MM+V^]\&09%']@5LW3DE.U6SVVOZGJO1JCUIY'],RM314=&K
ME=%HJ/8K41[NW75$YEM7(J(UN>C=S4U,O1/6[2B5Q)>AD#@"!4))P*Y@*F/
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MX=(R2$7,-%P,</D#V3\OR!G'[U]T^+)_\Q8K;>J9O-].YK7JGJ2.1JZ_\/\
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M7YTJI^.O2B_-:WD7;EK2,1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M:.\_ 'M.=^&E>]H[S\ >TYWX:5[VCO/P![3G?AI7O:.\_ 'M.=^&E>]H[S\
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MW'HBJGK3@3_:+[9<@I4KK%5TU91KR?#*R5O'UL541?4O$G.8LRHP!@# & ,
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MS6FUPRW!O'SZE$J)M?PD61%9&O\ LF,3U'=GAUGP  >3@  <  )^8  #Y@
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MQ  !Z7$A':ZQ"&X_.  (A@&QP#0+?FF/_ )G^XP6 8]+_*D#^'(?N' )/@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M&.7?)/G;=1-1)(Y54Q,!<6 , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M> /94G\2RGJD)[KP![*D_B64]4A/=> /94G\2RGJD)[KP![*D_B64]4A/=>
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , T"WYIC_P  F?[C
M!8!CTO\ *D#^'(?N' )/@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MC[' 'BNO]I)?5N/L< >*Z_VDE]6X^QP!XKK_ &DE]6X^QP!XKK_:27U;C['
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , T"WYIC_ , F?[C!8!CTO\J0/X<A^X< D^ , 8 P!@# & ,
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M^K6>6N.PZ4H9K(!6J[+S%-V/;:6U0K;:SR[F165>M*^FH")EU5C&,(\ X]$
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M&R@N%2-S+]2<Y0.WL 8 P#0+?FF/_ )G^XP6 8]+_*D#^'(?N' )/@# & ,
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M(*B,J VARV1JVF&"$LZ0L%'L+@YBQT\[1%!-5-L8%>F*8JE*< ,ISI-"7V'
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & :!;\TQ_X!,_W&"P#'I?Y4@?PY#]
MPX!)\ 8 P!@# & , 8!7.P-N:TU6$0.P[G!U0T^LY0AT91R)7+_T$B*D@X0:
MHD6<^SXPCA,SIR)0;M04(*IR <O$#62N]-2PE\C]92EVC&MUDW$.R;1/4R"R
M"<E8F[EW78E_--V:L%$S5A:LU%(]DZ=(NGI"@*"9P$O$#]S.\M05V^--8SVQ
M:K#WU^,01I69*419R"RU@.NG M0%?H-R/9Q1JH5F@8X+.CE$J93#Y, U%_YB
MM/:LL+JN;!N+6JNF%>CK/(/Y-L]+"1T9+O)MG%^T)=%NJS9.7PUJ05(FH8H]
M0S54'@4O$0,,O-!R_GCZ]*AM6J@PM3YY'U]<[EPF,DK'+,&T@X214;%72BV+
MB4;)K/5"D9IG<)E,J G* @3Q':.NW'H?47*OK'?WJ2UDS23D$3KK[!AQDO:E
M/(W*(K^WH].(=*JMQ*!R(('5'_+#I8!JK_NW4FJWT5&;$V#6*C(S:*KJ.8S$
MDF@[5CVZR;=S++(%Z:C&$:N%2IK/EP39I',!3J%$0# +0(<BA"J)F*=,Y2G(
M<A@,0Y# !BF*8HB4Q3%'B AY!# /U@# & 1J6N%8@I)*)FIIC%/58"=M/!^H
M+5JC7JR>/)/2[N06*2/9,HL95 53K*DX%/TO*4IA*!) $! ! 0$! ! 0'B @
M/E 0$/(("& :9Y8X&/G(6M/99BUG[&VEWD%$++D(_EFL 5B::78H"/372C"R
M;<5A#^3KB<?EP#=8!&JW<*Y;QL!:[)DDAJMEDZ?/@1!TA[.L<.1LI)1A_2D$
M.N.V(\2$3I]-(W3_ (3#Y> $EP!@# & , 8 P!@# & 0^\7^EZU@3V:]V.,K
M$&5VTCR/I-84_2I%^IU3&-8-TRJ.Y&2>' 02;MTU%E.B(E*( / " V7F0T=4
M(ZKR]@V-!M(RY0Q[+ /D"2$FV7K"*S%NYM+]6*9/2P569N9-NFO)/_1F*"BI
M2**E,/# -YL'=NI=4.X5CLC8%9I;FPH/WD02?D4V)'3&*48HR<B990.H:QL<
MK)MRKN5C)H)"L3I'#I!@'YO^Z=;ZQ5K"=SL*<6E;4IAW$O$FKR09!&P+%L^D
MI=XXCT')6D4B+]H@"YOX#N7K=(O$RI< A[#FNY=)2NO+9&[<J3ZNL9&.AU)-
MJY<K).):6+(J1\;&)D:BXF'ZZ4.[/U30BZA$VRIC 4J9A ";_P"L^J/9<]-#
ML"K!%5B+JLW/OAE6X(Q<1>6J3NF2+@1,!O1+4BL7V><H&!VIQ33Z1P$H 2_Q
M170LX4L9E@%L- C:"U\7! E#UTL@6)/,IM1X'48)21RH'4#B!%#E >'2+Q _
M==LL!;8PLU69=A.Q!GTM&DDHQP1TS4?0,L]@IALFX3$4U%(^8C5VZG1$0!5(
MP<?)@&[P#"CI*.F&+64B7[*4C7R)'#*1CG2#UB\;J!Q37:NVRBK=PB</D,0P
ME'Z< S< 8!5=<WAJ*WW&3U_6-B5:=N,0:13?04;*(N7)5H9<C6;;-E2"+60=
MP;I0J3Y)NHJHR4'HKE3-Y, M3 & , 8!&(FZ56<<*,XN=CW+Q.5L4(#(RWHS
MU:3J3TD=96[1FZ!!R]+"O%2$741*=(HG*/2X&*(@2? -)"66 L8S!8&78RPU
M^<>UJ;!BN1<8N?C2-U'\0\Z CU+YH1TF*B8^4H'#Z< QK?;J[0JO.W.VR1(>
MM5J.<2TW**(.G*;".:%Z;AR=!D@Y=JE3+Y1!-,YA^8, DF , 8 P!@# - M^
M:8_\ F?[C!8!CTO\J0/X<A^X< D^ , 8 P#G#F/UWO38<'6V>C-PM]1R<=*N
MG4\Y7B"2 3K!5IU+5J5T"#E=EZ$XXGZ)2=%;I_Q"'0+QC+<W&L_R2@I8,!O3
M;-513.=,Y8^OS6*W1K>K1RMZ7<=$31VO%4Z4)5VJRC;K%[A5S[B6)U[I)86M
MA:DG1Y+T=JYW3JU'=;=$U5=6Z<$7J73D?_TS?J"__F='=Q+>YLAO^%G<;_?B
M+]DO]$3;_%OME_N%+^U3^E'_ *9OU!?_ ,SH[N);W-C^%G<;_?B+]DO]$/XM
M]LO]PI?VJ?TH_P#3-^H+_P#F='=Q+>YL?PL[C?[[Q?LE_HA_%OMD_N%+^U3^
ME)EMNH[7IE)UA*H3.W[MS3T:AW.)JVU-:42+G:9<).:?1#U;7.TX!\?V6A4;
M&^B(L5'KHL89#V>+I*0:K <A['8C;K[:<;I+=DU:EQOL46DU0C$8DKM577I3
MT-5&Z\%=T]2HBJJ%9,SN>/WC**RYXK0K;<?FEZH*97K(L3>E$5.I?2Y%=IJJ
M-ZNE%5$12@-LU?F/;[BO.SH+4UFL>QO3X<M>U]%0AG6EU30NLV#.G\P\?;'4
MFVKD]M[5]B>2;8(><Z(R4>BV:M$$G*#1^?8S6#I-QHVU[@VWM&3M,S8ZIIZU
M1O+/9Y*(>5!A%S&P)'7Q7UM+'KS$DN=_3BP\^R8EE6J+0CLGE2(NB81, 'UC
M8*8VARW\V6THB-=3-EYD*IMD]!CFJ)@D']"B*--:^TU$L$E3E*);+&,/;2).
M(!Z3/J#Q_B' ,3>D+=(%'6]NU57=OL^8>O:G:5JJR%8J<?:=8V\'2\2LOJK<
M@2;GV?!01YJ/3<*RAE8MS&(J*+-7BAP4:G P*[KR_L>;AQS O-<225!M5HGM
M7I59(BRCRL6!E5XR$4YI%8DST[5NGL#PP>JK*D13>$KJ,8\-P(X>$ "PI)S8
MM2<QVW[S-:OV%L:N;;I&K8NF3FO:XVMJT2O14[8QG-?3S<[]FM6FCU]/DE&C
MMT*42N9XX!9PDHCP,!5]:K.U!W/!/%:WN%ALAOS!7Z6O5TDI>=/IY]RUN&ER
M\'5>)(2:6HSQ((1[7VS6,:-/:K.=:KNU1(4%EU@*HB^7C:G^GT6J^#?9[6]Y
M*9JQ39'&U=A"]4YI81.'5I"RR9+40B=QA3N723)L3HL13(4JJ:G5)"4#?(DO
MUHWA<21$9NY_LNN\Q>@RL+0TL%@)J&G4-OJS2$_NROS4>A84:G&^U()Y+E=L
M'+(7$@]D6AFG3.0QT /A6*9N)<J*3ACS&U"^FU_O>+YE;VF]GYAI8)>99NF5
M$DM11[R;5K5CG8V>41D*X$ DV]FPZ*C14R"JI$1 _,SK;<&Q=/6*CN-=6R-A
M'G+MS?5&,@T)*]P,3<;6YG=8N=1S[RM76VRMIJ$K:SLI$S.(E7[D6J1')!4]
M&<&(<#(M]'V3-6ZIDK)=S:[UM_IIK)'3KEI0=KVZS:_N3&VV9Q?RV".0VC6R
M5J?>HJQ0*+VQI+L'44!D2G!,BZ"H'27-%4M@3MEK4S0H:>?/(?0_-;$M92!$
M4G4;;+/3:<WI35LZ(LBLVEI:4CE"LS$$!ZU$1XEX . 4/9=6[2IK&9AH&/W3
M-:WEH3E,LFSHUI<[G9;?9%4;9L1GO]M6G[FP+V4M@D(%I7E9UE%+MU'K AR-
MR&55$AP*N#6&UV<:V0:53<%6U!+[BYBYYW#2<-LB^79!2P-M>#IRR3D+0=HU
M78KM@VC6$X1@LM(O/9;D[8'J!5B)JM@+TB:AO*/WGJ=^[7V[9]/1D/JB&VL[
MDG3B%D;EN5C0))&"VEX61E7JD90X@%6B%O8MW(-7-@49KBFL2,?J. /2' &
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MIN<C!79-,$';:X.P1!64ES^F@LJW7;%1 [5P!@# & :!;\TQ_P" 3/\ <8+
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M.4Q#D,)3 ("(8!]T44FZ22""2:"""9$4442%32123*!$TDDR 4B::9"@!2@
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M!@# & , 8 P!@# & , 8!H%OS3'_ (!,_P!Q@L QZ7^5('\.0_<. 2? & ,
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MJ($%%-3JS >@N , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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I$Q$64(#D(65 B82;\43("^AA5.=48@#E5*H! *4""!@$PB8.  8#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
